Table of Contents

As filed with the Securities and Exchange Commission on April 16, 2010

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

Amyris Biotechnologies, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   8731   55-0856151

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

 

5885 Hollis Street, Suite 100

Emeryville, CA 94608

(510) 450-0761

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

 

John G. Melo

President and Chief Executive Officer

Amyris Biotechnologies, Inc.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

(510) 450-0761

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

 

Gordon K. Davidson, Esq.

Daniel J. Winnike, Esq.

Sayre E. Stevick, Esq.

Fenwick & West LLP

801 California Street

Mountain View, California 94041

(650) 988-8500

 

Jeffrey D. Saper, Esq.

Allison B. Spinner, Esq.

Wilson Sonsini Goodrich & Rosati, P.C.

650 Page Mill Road

Palo Alto, California 84304

(650) 493-9300

 

 

 

Approximate date of commencement of proposed sale to the public: as soon as practicable after this registration statement is declared effective.

 

 

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.   ¨

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.   ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.   ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.   ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer      ¨    Accelerated filer      ¨
Non-accelerated filer      x     (Do not check if a smaller reporting company)    Smaller reporting company      ¨

 

 

 

CALCULATION OF REGISTRATION FEE

 

          

Title of Each Class of

Securities To Be Registered

   Proposed Maximum
Aggregate  Offering
Price (1)(2)
  Amount of
Registration Fee

Common Stock, $0.001 par value per share

   $100,000,000   $7,130
          
  (1)   Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.
  (2)   Includes shares which may be purchased by the underwriters pursuant to their option to purchase additional shares.

 

 

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.

 

 


Table of Contents

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.

 

PROSPECTUS (Subject to Completion)

Issued April 16, 2010

 

             Shares

 

LOGO

 

COMMON STOCK

 

 

 

Amyris Biotechnologies, Inc. is offering              shares of its common stock. This is our initial public offering and no public market currently exists for our shares. We anticipate that the initial public offering price of our common stock will be between $              and $              per share.

 

 

 

We have applied to list our common stock on                      under the symbol “AMRS”.

 

 

 

Investing in our common stock involves substantial risks. See “ Risk Factors ” beginning on page 10.

 

 

 

PRICE $              A SHARE

 

 

 

      

Price to

Public

    

Underwriting

Discounts and
Commissions

    

Proceeds to

Amyris

Per Share

     $               $               $         

Total

     $                          $                          $                    

 

We have granted the underwriters the right to purchase up to an additional              shares of common stock.

 

The Securities and Exchange Commission and state securities regulators have not approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The underwriters expect to deliver the shares of common stock to purchasers on                     , 2010.

 

 

 

MORGAN STANLEY     GOLDMAN, SACHS & CO.
  J.P. MORGAN  

 

 

 

BANCO ITAÚ     THOMAS WEISEL PARTNERS LLC

 

                    , 2010


Table of Contents

LOGO


Table of Contents

TABLE OF CONTENTS

 


 

 

 

You should rely only on the information contained in this prospectus or in any free-writing prospectus we may specifically authorize to be delivered or made available to you. We have not and the underwriters have not authorized anyone to provide you with additional or different information. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information in this prospectus or a free-writing prospectus is accurate only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.

 

Until                          , 2010 (25 days after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

 

For investors outside the U.S.: We have not and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the U.S. Persons outside the U.S. who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the U.S.

 

 

 

i


Table of Contents

PROSPECTUS SUMMARY

 

This summary highlights information appearing elsewhere in this prospectus and does not contain all of the information you should consider in making your investment decision. You should read this entire prospectus carefully, especially the “Risk Factors” section beginning on page  10 and our consolidated financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision.

 

AMYRIS BIOTECHNOLOGIES, INC.

 

Business Overview

 

Our Company

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. We genetically modify microorganisms, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of target molecules. Our first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications such as detergents, cosmetics, perfumes and industrial lubricants, to transportation fuels such as diesel. We call these No Compromise ® products because we design them to perform comparably to or better than currently available products. While our platform is able to utilize a wide variety of feedstocks, we have focused our initial research and development, business development and production operations on the use of Brazilian sugarcane as our primary feedstock because of its abundance, low cost and relative price stability. We intend to secure access to this feedstock and expand our production capacity in a “capital light” manner. Under this approach, we expect to work with Brazilian sugar and ethanol producers to build new, “bolt-on” facilities adjacent to their existing mills instead of building entirely new “greenfield” facilities, thereby reducing the capital required to establish and scale our production. Our first such arrangement is our joint venture with Usina São Martinho, a subsidiary of São Martinho S.A., one of the largest sugar and ethanol producers in Brazil.

 

Technology

 

We have developed genetic engineering and screening technologies that enable us to modify the way microorganisms, or microbes, process sugar. By controlling these metabolic pathways, we design microbes to serve as living factories, or biorefineries, to produce target molecules that we seek to commercialize. Our platform utilizes proprietary high-throughput processes to create and test as many as 1,000 yeast strains a day in order to select those yeast strains which are most efficient. We first developed and applied our technology to create microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial therapeutic. This work was funded by a five year grant awarded by the Bill & Melinda Gates Foundation to the Institute for OneWorld Health. We have granted a royalty-free license to this technology to sanofi-aventis for the commercialization of artemisinin-based drugs.

 

Feedstock

 

We are focusing on Brazilian sugarcane as our primary feedstock. Brazil is the world’s largest producer of sugarcane, crushing over 600 million tons of sugarcane annually to provide feedstock to approximately 400 sugar and ethanol mills. According to UNICA, the Brazilian Sugarcane Industry Association, sugarcane is the lowest cost feedstock to produce renewable products at scale and using it enables us to leverage the established Brazilian infrastructure. Common to both our process and the sugarcane-to-ethanol process is the use of fermentation, a well-established process that combines a sugar source and yeast to produce beer, wine and, more recently, ethanol fuels. We plan to establish production capacity taking as input the same sugar source that is routinely processed by existing sugar and ethanol mills and directing it to customized fermentors, where it will be combined with our genetically engineered yeast.

 

 

1


Table of Contents

Scale-Up

 

We operate research and development laboratories in Emeryville, California, and have built an adjacent pilot facility that tests our yeast strains in 300 liter scale fermentors. We have an identical pilot plant in Campinas, Brazil, to facilitate the adaptation of our technology to the Brazilian production environment. We established a 5,000 liter demonstration facility in Brazil in September 2009 to further validate our processes and equipment as we move toward commercialization of our products. We have also completed production runs using our strains to produce farnesene in a 60,000 liter fermentor at a contract manufacturing facility in the U.S.

 

Commercial Production

 

We expect to access feedstock and expand our production through our capital light strategy. Our first such arrangement is our joint venture with Usina São Martinho, SMA Indústria Quimica S.A. This facility is located at Usina São Martinho, the world’s largest sugarcane processing facility, which crushed 8.1 million tons of sugarcane during the 2009-2010 harvest. We have also provided Usina São Martinho with an option to produce our products at a second production facility. We have non-binding letters of intent in place with three leading Brazilian sugar and ethanol producers, Bunge Limited, Cosan and Açúcar Guarani, a subsidiary of Tereos, to build new, bolt-on facilities adjacent to specified existing mills to produce our products. We expect that these mill owners will make a substantial capital or operating contribution to fund these facilities in return for a share of the higher gross margin we believe we will realize from the sale of our renewable products. In addition, we expect these arrangements to provide us with access to over ten million tons of sugarcane crush capacity annually, which we intend to expand over time with these and other mills. This capacity represents approximately 9.8% of the total crush capacity of these sugar and ethanol producers.

 

Commercialization

 

We plan to commence commercialization of our products starting in 2011 using contract manufacturers, and to have our first capital light production facility, our joint venture with Usina São Martinho, operational in the second quarter of 2012. As we commence commercial production of our initial molecule, farnesene, we expect to target specialty chemical markets. Further, we are seeking to improve our strain performance to expand our addressable markets, including additional specialty chemical applications and renewable diesel. For most specialty chemical applications, we intend to sell directly to industrial customers. For distribution of our diesel in the U.S., we expect to sell directly, primarily to corporations with large trucking fleets. For distribution of our diesel in other geographies, we expect to sell indirectly through third parties. To build the capabilities we will need to import and distribute our renewable fuels products in the U.S., we have established our subsidiary Amyris Fuels, LLC. Amyris Fuels currently generates revenues through the sale of third party ethanol to wholesale customers through a network of terminals in the southeastern U.S.

 

Our Industry

 

Petroleum is a fundamental building block for products, such as consumer products, chemicals, plastics and transportation fuels, that are essential to modern economies. According to the U.S. Energy Information Administration (“EIA”), in 2008 the total worldwide demand for petroleum was over $3 trillion, or 5% of worldwide gross domestic product. Recently, however, the increased demand for petroleum in the face of limited supply, supply chain uncertainty and negative environmental impacts has created challenges to the current petroleum infrastructure. As a result, there have been many attempts to create products comparable to petroleum derivatives without these drawbacks. However, initial approaches have faced a number of challenges that have limited their success, including:

 

   

Exposure to volatile feedstock pricing. Many U.S. renewable fuels companies have focused on the conversion of commodity feedstocks, such as corn or vegetable oil, into ethanol or biodiesel. These companies were exposed to swings in the market prices for their feedstocks, which at times made production unprofitable for a number of producers in these industries.

 

 

2


Table of Contents
   

Limited product portfolio . Companies engaging in early attempts to create renewable fuels typically focused on one end product, such as ethanol or biodiesel. These companies generally lacked product diversity and, therefore, were vulnerable to variability of market prices and the degree of government support for their primary product. Further, the products these companies made were imperfect substitutes for the products they were intended to replace, as neither ethanol nor biodiesel can be stored or transported conventionally and both are subject to blend limits.

 

   

Capital intensity . Many initial U.S. ethanol companies utilized a vertically integrated business model that required hundreds of millions of dollars to construct and own mills. This left them with limited ability to enter new geographies and to access new feedstock, as they were tied to their existing facilities.

 

   

Dependence on policy . The economic viability of many alternative fuels is based on government regulations and support, making it difficult to build a business with long term sustainability.

 

Other efforts to develop alternatives to petroleum-sourced products include the use of non-food-based feedstocks, such as cellulosic sugars sourced from wood chips, corn stalks and sugarcane bagasse. Some of these approaches have shown promise and may not be influenced by commodity markets and food versus fuel concerns. However, they are not complete solutions to the challenges above, and to date, these approaches have been limited by cost and technical considerations, among others.

 

Our Solution

 

Our proprietary technology enables us to engineer microbes, such as yeast, to produce target molecules, and our business model is designed to produce these products and bring them to market in a capital light manner. Our industrial synthetic biology platform is designed to produce competitive products from widely available plant-derived feedstocks using genetically modified yeast strains in a well-established fermentation process. We are focusing our initial production efforts in Brazil, positioning us to access sugarcane feedstock and to leverage the substantial infrastructure of existing sugar and ethanol mills.

 

Competitive Strengths

 

Our key competitive strengths are:

 

   

Abundant, low-cost and relatively price stable feedstock. Brazilian sugar and ethanol mills typically grow much of their own sugarcane, and sugarcane in Brazil does not compete as a food source. As a result, this industry enjoys a low production cost structure and is insulated from feedstock price volatility.

 

   

Broad range of potential products . Our initial molecule, farnesene, can serve as the basis for a wide range of products, enabling us to optimize our product mix and reduce our exposure to any one end market. Our technology platform gives us the ability to produce potentially thousands of additional target molecules.

 

   

Scalable, capital light approach. Our technology platform enables us to leverage the large existing sugar and ethanol industry infrastructure in Brazil.

 

   

Not policy dependent. While we benefit from regulations, such as the Renewable Fuels Standard provided for by the U.S. Energy Policy Act of 2005, that encourage the use of renewable products, we expect our products to be offered on a cost-competitive basis with existing products without reliance on subsidies.

 

Our Solution for our Customers

 

The key benefits we intend to provide to our customers include:

 

   

No Compromise product offerings. We refer to our products as No Compromise because we design them to perform comparably to or better than currently available products. For example, we expect that our diesel will not require engine or distribution infrastructure modifications, will have better performance at low temperatures and will generally have a higher cetane number than biodiesel.

 

 

 

3


Table of Contents
   

Greater pricing stability . We believe that our use of Brazilian sugarcane, and our ability over time to utilize a wide variety of other plant-based feedstocks, will enable us to offer our specialty chemical customers greater pricing protection from the level of price volatility generally associated with exposure to petroleum-sourced products.

 

   

“Green” alternative. Our products are derived from renewable sources, enabling our customers to reduce the environmental impact of their products and, in some cases, increase the loyalty consumers have for these products.

 

Our Value Proposition to Sugar and Ethanol Producers

 

The key benefits we intend to provide to sugar and ethanol producers that will work with us to produce our products include:

 

   

Product diversification. By producing our products, sugar and ethanol mills would be able to diversify their business beyond their current sugar or ethanol production and potentially mitigate volatility in their financial performance caused by changes in the market prices for sugar or ethanol.

 

   

Opportunity for growth. By diversifying their product base to address additional market opportunities, producers may be able to expand the amount of sugarcane grown and processed at their mills.

 

   

Potential for improved margins. We intend to offer these producers a share of the higher gross margin we believe we will realize from the sale of our renewable products relative to their existing products, potentially improving their gross margins and the return they realize on their feedstock.

 

Our Strategy

 

Our objective is to become the leading provider of renewable specialty chemicals and transportation fuels worldwide. Key elements of our strategy include:

 

   

Pursuing market opportunities that maximize our returns. We intend to commercialize initially in select specialty chemical markets and then as we lower our production costs, to expand into broader specialty chemical markets and transportation fuels. We also intend to enter into collaborative research, development and commercialization agreements to accelerate our entry into select new product opportunities.

 

   

Leveraging our technology platform to improve efficiency. We intend to continually apply our technology platform to lower the cost of production of our products through yield improvements and other efficiencies.

 

   

Focusing on Brazilian sugarcane. We are focusing on Brazilian sugarcane as our primary feedstock because of its abundance, low cost and relative price stability.

 

   

Advancing capital light production. We expect to partner with existing sugar and ethanol mills to establish and scale production at a lower cost than the cost of greenfield mill construction.

 

   

Continuing to develop our fuels distribution network. We will continue to expand the size and geographic scope of our Amyris Fuels distribution network in the U.S. and establish arrangements with third parties for distribution in other countries.

 

OUR RISKS

 

Our business is subject to numerous risks and uncertainties that you should understand before making an investment decision. These risks are discussed more fully in the section entitled “Risk Factors” beginning on page 10 of this prospectus. These include:

 

   

we have a limited operating history and have not generated revenues from the sale of any of our renewable products, and our business may fail if we are not able to successfully commercialize these products;

 

 

4


Table of Contents
   

we have incurred losses to date, anticipate continuing to incur losses in the future and may never achieve or sustain profitability;

 

   

if we are unable to decrease our production costs, we may not be able produce our products at competitive prices and our business will not succeed;

 

   

we have no experience producing our products at the commercial scale needed for the development of our business, and we will not succeed if we cannot effectively scale our technology and processes;

 

   

our ability to commence commercial sales of our products in 2011 is subject to a number of risks, any of which could delay our sales and adversely impact our customer relationships, business and results of operations;

 

   

if our joint venture production facility with Usina São Martinho in Brazil does not successfully commence operations in the second quarter of 2012, our customer relationships, business and results of operations may be adversely affected;

 

   

our joint venture with Usina São Martinho contemplates that we will make significant capital expenditures and subjects us to certain legal and financial terms that could adversely affect us;

 

   

we plan to enter into arrangements with Brazilian sugar and ethanol producers to produce our products, and if we are not able to complete these arrangements in a timely manner and on terms favorable to us, our business will be adversely affected;

 

   

building new bolt-on facilities adjacent to existing sugar and ethanol mills for production of our products requires significant capital, and if mill owners are unwilling to contribute, or do not have or have access to this capital, production of our products would be more limited or expensive than expected and our business would be harmed;

 

   

our strategy of relying on existing Brazilian sugar and ethanol producers to produce our products will make us substantially dependent on these owners, and they may not perform their obligations under agreements with us or otherwise perform to our standards;

 

   

our reliance on contract manufacturers to produce our products during construction of our Usina São Martinho joint venture production facility and periodically for additional short-term production capacity exposes us to risks relating to the price and availability of that contract manufacturing and could adversely affect our growth;

 

   

the production of our products will require sugar feedstock, and the inability to obtain such feedstock in sufficient quantities or in a timely manner may limit our ability to produce our products;

 

   

an increase in the price and profitability of ethanol and sugar relative to our products could adversely affect our arrangements with sugar and ethanol producers;

 

   

the price of sugarcane feedstock can be volatile as a result of changes in industry policy and may increase the cost of production of our products;

 

   

most of our planned initial production capacity will be in Brazil, and our business will be adversely affected if we do not operate effectively in that country;

 

   

we may face risks relating to the use of our genetically modified yeast strains and if we are not able to secure regulatory approval for the use of our yeast strains or if we face public objection to our use of them, our business could be adversely affected;

 

   

we may not be able to obtain regulatory approval for the sale of our renewable products; and

 

   

we cannot assure you that our products will be approved or accepted by customers in specialty chemical markets.

 

 

5


Table of Contents

Company Information

 

We were originally incorporated in the State of California in July 2003, and we plan to reincorporate in the State of Delaware prior to the completion of this offering. Our corporate headquarters are located at 5885 Hollis Street, Suite 100, Emeryville, CA 94608, and our telephone number is (510) 450-0761. Our website address is www.amyris.com. The information contained on our website or that can be accessed through our website is not part of this prospectus, and investors should not rely on any such information in deciding whether to purchase our common stock.

 

Except where the context requires otherwise, in this prospectus, “Amyris,” “our company,” “the Company,” “we,” “us” and “our” refer to Amyris Biotechnologies, Inc. and its subsidiaries. These subsidiaries include Amyris Brasil S.A., a majority-owned Brazilian company through which we conduct our Brazilian operations, and Amyris Fuels, LLC, a wholly-owned subsidiary through which we are building our U.S. fuels distribution capabilities. In connection with the completion of this offering, Amyris Brasil S.A. will become a wholly-owned subsidiary through the conversion of third-party held stock in that subsidiary into our common stock. Amyris Brasil holds our equity interest in our joint venture with Usina São Martinho, SMA Indústria Química S.A.

 

Amyris ® , No Compromise ® and our logo are our trademarks. This prospectus also contains trademarks and trade names of other businesses that are the property of their respective holders.

 

 

6


Table of Contents

THE OFFERING

 

Common stock offered by us

  

             shares

Common stock to be outstanding after this offering

  

             shares

Use of proceeds

   We intend to use the net proceeds from this offering for capital expenditures, working capital and other general corporate purposes, including for building engineering services capabilities and growing our chemistry capabilities. We may also use a portion of our proceeds to expand our current business through acquisitions of other companies, assets or technologies. See “Use of Proceeds.”

Risk factors

   You should read the “Risk Factors” section of this prospectus beginning on page  10 for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.

Proposed stock exchange trading symbol

  

“AMRS”

 

 

 

The number of shares of our common stock to be outstanding after this offering is based on 24,215,560 shares of our common stock outstanding as of December 31, 2009, after giving effect to the conversion of our outstanding convertible preferred stock into 18,790,244 shares of common stock and the conversion of shares of Amyris Brasil held by third party investors in this subsidiary into 311,111 shares of our common stock and excludes:

 

   

4,446,894 shares of common stock issuable upon the exercise of stock options outstanding as of December 31, 2009, at a weighted average exercise price of $2.87 per share;

 

   

144,158 shares of common stock issuable upon the exercise of outstanding warrants as of December 31, 2009, that will remain outstanding after the completion of this offering through various dates from one year from the effective date of this offering to March 2016, with a weighted average price of $21.20 per share;

 

   

50,000 shares of common stock subject to restricted stock units outstanding as of December 31, 2009;

 

   

             shares of common stock reserved for future issuance under our 2010 Equity Incentive Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Employee Benefit Plans;” and

 

   

             shares of common stock reserved for future issuance under our 2010 Employee Stock Purchase Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Employee Benefit Plans.”

 

Unless otherwise indicated, the information in this prospectus assumes:

 

   

our reincorporation into Delaware and the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws immediately prior to the completion of this offering; and

 

   

no exercise by the underwriters of their option to purchase additional shares.

 

All references in this prospectus to “U.S. dollars,” “dollars,” “US$” or “$” are to U.S. dollars. All references to the “real”, “reais” or “BRL$” are to the Brazilian real, the official currency of Brazil. All conversions of Brazilian reais into U.S. dollars in this document are based on the BRL$/US$ exchange rate as of April 2, 2010, reported by The Wall Street Journal of BRL$1.7649: US$1.0000.

 

 

7


Table of Contents

SUMMARY CONSOLIDATED FINANCIAL DATA

 

The following table summarizes our consolidated financial data. We have derived the following consolidated statement of operations data for the fiscal years ended December 31, 2007, 2008 and 2009 and the consolidated balance sheet data as of December 31, 2009 from our audited consolidated financial statements appearing elsewhere in this prospectus. You should read the summary of our consolidated financial data set forth below together with the more detailed information contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the related notes appearing elsewhere in this prospectus. Our historical results presented below are not necessarily indicative of financial results to be achieved in the future.

 

     Years Ended December 31,  
              2007                        2008                        2009            
     (in thousands, except share and per share amounts)  

Consolidated Statement of Operations Data:

      

Total revenues

   $ 6,184      $ 13,892      $ 64,608   
                        

Cost and operating expenses

      

Cost of product sales

            10,364        60,428   

Research and development (1)

     8,662        30,306        38,263   

Sales, general and administrative (1)

     10,522        16,622        23,558   

Restructuring and asset impairment charges

                   5,768   
                        

Total cost and operating expenses

     19,184        57,292        128,017   
                        

Loss from operations

     (13,000     (43,400     (63,409

Total other income (expense)

     1,226        857        (1,391
                        

Loss before income taxes

     (11,774     (42,543     (64,800

Benefit from income taxes

            (207       
                        

Net loss

     (11,774     (42,336     (64,800

Loss attributable to noncontrolling interest

            (472     (341
                        

Net loss attributable to Amyris Biotechnologies, Inc. stockholders

   $ (11,774   $ (41,864   $ (64,459
                        

Net loss per share of common stock attributable to Amyris Biotechnologies, Inc. stockholders, basic and diluted (2)

   $ (3.28   $ (9.91   $ (13.56
                        

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (2)

     3,592,932        4,223,533        4,753,085   
                        

Pro forma net loss per share of common stock attributable to Amyris Biotechnologies, Inc. stockholders, basic and diluted (unaudited) (2)

       $ (3.16
            

Weighted-average shares of common stock outstanding used in computing pro forma net loss per share of common stock, basic and diluted (unaudited) (2)

         20,279,433   
            

 

 

8


Table of Contents

 

 

     As of December 31, 2009
     Actual     Pro Forma (3)    Pro Forma as
Adjusted (4)
           (in thousands)     
           (Unaudited)    (Unaudited)

Consolidated Balance Sheet Data:

       

Cash, cash equivalents, short term investments and restricted cash

   $ 71,716      $ 71,716    $             

Working capital

     51,062        51,062   

Total assets

     122,159        122,159   

Total indebtedness (5)

     20,608        20,608   

Convertible preferred stock warrant liability

     2,740          

Convertible preferred stock

     179,651          

Redeemable noncontrolling interest

     5,506          

Total equity (deficit)

   $ (113,745   $ 74,152    $  

 

  (1)   Includes stock-based compensation expense as follows:

 

     Years Ended December 31,
     2007    2008    2009
     (in thousands)

Research and development

   $ 117    $ 632    $ 773

Sales, general and administrative

     429      1,395      2,526
                    

Total stock-based compensation expense

   $ 546    $ 2,027    $ 3,299
                    

 

  (2)   See Note 2 to our Consolidated Financial Statements appearing elsewhere in this prospectus for an explanation of the method used to calculate basic and diluted net loss per share of common stock, the pro forma basic and diluted net loss per share of common stock and the weighted-average number of shares used in computation of the per share amounts.
  (3)   On a pro forma basis to reflect the conversion of all outstanding shares of our convertible preferred stock into common stock, the conversion of shares of Amyris Brasil held by investors in that subsidiary into shares of our common stock and the reclassification of the convertible preferred stock warrant liability to common stock immediately prior to the completion of this offering.
  (4)   On a pro forma as adjusted basis to reflect the sale of              shares of our common stock by us in this offering at an assumed initial public offering price of $             per share (which is the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us in connection with the offering. A $1.00 increase (decrease) in the assumed initial public offering price of $             per share of common stock would increase (decrease) cash, cash equivalents and short-term investments by $ million, working capital by $             million, total assets by $             million and total stockholders’ equity (deficit) by $             million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us in connection with the offering. The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.
  (5)   Total indebtedness includes an $8.3 million credit facility associated with our student loan auction rate securities holdings, $7.2 million in capital lease obligations, a $4.0 million note payable and a $1.0 million loan payable (See Note 5 and Note 6 to our Consolidated Financial Statements).

 

 

9


Table of Contents

RISK FACTORS

 

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this prospectus, including the consolidated financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely harmed. The trading price of our common stock could decline due to any of these risks, and, as a result, you may lose all or part of your investment.

 

Risks Related to Our Business

 

We have a limited operating history and have not generated revenues from the sale of any of our renewable products, and our business may fail if we are not able to successfully commercialize these products.

 

We are an early stage company with a limited operating history, and we have not yet commercialized any of our renewable products. To date, our revenues have consisted of sales of ethanol produced by third parties, funding from third party collaborative research services and government grants. We are subject to the substantial risk of failure facing businesses seeking to develop products based on a new technology. Certain factors that could, alone or in combination, prevent us from successfully commercializing our renewable products include:

 

   

technical challenges with our production processes that we are not able to overcome;

 

   

our ability to achieve commercial scale production of our specialty chemical and fuel products on a cost effective basis;

 

   

our ability to secure access to low-cost feedstock;

 

   

our ability to establish and maintain successful relationships for the production of our products with the owners of sugar and ethanol mills;

 

   

our ability to secure and maintain all necessary regulatory approvals for the production, distribution and sale of our products and to comply with applicable laws and regulations;

 

   

our ability to develop customer relationships and build a cost-effective distribution network for our products;

 

   

actions of direct and indirect competitors that may seek to enter the renewable products markets in competition with us or that may seek to impose barriers to one or more aspects of the renewable products businesses that we intend to pursue; and

 

   

public concerns about the ethical, legal, environmental and social ramifications of genetically engineered products and processes, use of land and renewable carbon sources for the production of renewable products and diversion of resources from food production.

 

We have incurred losses to date, anticipate continuing to incur losses in the future and may never achieve or sustain profitability.

 

We have incurred substantial net losses since our inception, including a net loss of $64.8 million in 2009, a net loss of $42.3 million in 2008 and a net loss of $11.8 million in 2007. We expect these losses to continue. As of December 31, 2009, we had an accumulated deficit of $120.4 million. We expect to incur additional costs and expenses related to the continued development and expansion of our business, including our research and development operations, continued operation of our pilot plants and demonstration facility and engineering and design work. Further, we expect to incur costs related to the facility that we are developing with Usina São Martinho and adoption of our technology at other sugar and ethanol mills. There can be no assurance that we will ever achieve or sustain profitability on a quarterly or annual basis.

 

10


Table of Contents

If we are unable to decrease our production costs, we may not be able to produce our products at competitive prices and our business will not succeed.

 

We have developed the ability to create yeast strains that are capable of converting feedstocks into desired target molecules that form the basis of our products. The successful development of our business depends on our ability to increase the efficiency with which we produce these target molecules from feedstock. Our production costs are primarily driven by our ability to increase the yield from our yeast strains and other production factors.

 

Yield refers to the amount of the desired molecule that can be produced from a fixed amount of feedstock. We believe that we will be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. While we believe that we will be able to attain this level of yield of farnesene in commercial production, we cannot assure you that we will do so on the timeline we have planned or at all. If we cannot, it is likely that we will not be able to commercialize farnesene in a timely manner, and in that event, our business would be materially and adversely affected.

 

In order to successfully enter transportation fuels and certain other specialty chemical markets, our yeast strains must produce those products at substantially higher yields than we have achieved to date. We have produced and screened several hundred thousand yeast strains to reach our current farnesene yield levels and anticipate having to produce and screen hundreds of thousands of additional strains as we seek to achieve the requisite yield levels to enter these larger markets. We may never achieve the yields needed for us to profitably enter these markets. Further, yield improvement is generally not achieved on a linear basis over time, which makes it difficult for us to predict with a high level of specificity when, if ever, new yield levels will be attained. If we are delayed, or are not successful, in improving the yield of farnesene with our yeast strains, our ability to enter a number of the markets that we are currently targeting will similarly be delayed or precluded and our ability to grow our business will be impaired.

 

Additional factors that impact our production cost include productivity, separation efficiency and chemical process efficiency. Productivity represents the rate at which our product is produced by a given yeast strain. Separation efficiency refers to the amount of desired product produced in the fermentation process that we are able to extract and the time that it takes to do so. Chemical process efficiency refers to the cost and yield for the chemical finishing steps that convert our target molecule into a desired product. Our ability to lower our production costs to enter and successfully compete in our target markets over time is contingent on efficiency gains of yield and these additional factors.

 

We have no experience producing our products at the commercial scale needed for the development of our business, and we will not succeed if we cannot effectively scale our technology and processes.

 

In addition to further developing our yeast strains to achieve acceptable production costs, we must demonstrate the ability to utilize our yeast strains to produce the desired products at commercial scale on an economically viable basis. Such production will require that our technology and processes be scalable from laboratory, pilot and demonstration projects to commercial scale production. Our technology may not perform as expected when applied at a commercial production level, or we may encounter operational challenges for which we are unable to devise a workable solution. For example, contamination in the production process could decrease process efficiency, create delays or increase our costs. We may not be able to scale up our production in a timely manner, if at all, even if we successfully complete product development in our laboratories and pilot and demonstration facilities. If this occurs, our ability to commercialize our technology will be adversely affected, and with respect to any products that we do bring to market, we may not be able to lower the cost of production, which would adversely affect our ability to increase the future profitability of our business.

 

Our ability to commence commercial sales of our products in 2011 is subject to a number of risks, any of which could delay our sales and adversely impact our customer relationships, business and results of operations.

 

We are seeking to commence commercial sales of our initial products for specialty chemical applications in 2011. We do not currently have definitive agreements with customers and may not be able to enter into supply

 

11


Table of Contents

agreements on terms acceptable to us or at all. We are focusing our sales and marketing efforts on working with a small number of target customers and will need to convince them that our products are comparable to or better than the specialty chemicals they currently use and that we seek to replace. In addition, these customers will need to complete product qualification procedures which may not be achieved in a timely manner or at all.

 

In order to commence sales in 2011, we must secure production capacity with contract manufacturers. Such capacity may not be available to us at prices or on terms acceptable to us, or at all. While we are in active discussions with several contract manufacturers, we do not currently have definitive agreements with contract manufacturers that would provide the production capacity required to achieve commercialization of our products in 2011 at the volumes we intend, or at all. In addition, certain contract manufacturers may not have the equipment required for the production of our products and we cannot be assured that such equipment can be ordered or installed on a timely basis or at all. In addition, we will need to transfer our yeast strains and production processes to each of our contract manufacturing facilities, and we may face technical or operational challenges that delay the start-up of production or increase our costs. The failure of our contract manufacturers to produce our initial products on a timely basis or at all, or to produce our products in accordance with quality specifications or in volumes sufficient to meet our customer demand, could harm our relationships with our customers. Additionally, we have not tested our current yeast strains at commercial scale production levels, and our production costs will be impacted by the progress we make in improving the yield, productivity, separation efficiency and chemical process efficiency of our production process before we commence 2011 production. If we are unable to make the necessary progress, we may nonetheless decide to commence sales of our products at a loss in order to establish demand for our products and develop customer relationships, which could adversely affect our results of operations.

 

If our joint venture production facility with Usina São Martinho in Brazil does not successfully commence operations in the second quarter of 2012, our customer relationships, business and results of operations may be adversely affected.

 

We have selected Brazil as the optimal geography for the initial commercial production of our products, largely because of the availability of sugarcane as a feedstock and the existing infrastructure for producing, gathering and processing this sugarcane. Our business plan envisions that we will develop our production capacity in Brazil by demonstrating to existing sugar and ethanol producers the economic advantages of producing our products in addition to, or in lieu of, their current products. In order to have control over the development of our first commercial production facility in Brazil, we entered into an agreement with Usina São Martinho, one of the largest sugar and ethanol producers in Brazil, for the joint ownership and development of a production facility at the Usina São Martinho mill.

 

In order for our production facility at Usina São Martinho to meet our goal of commencing production in the second quarter of 2012, we must successfully complete the designs and other plans needed for the construction of this facility and secure in a timely manner the requisite permits, licenses and other governmental approvals in Brazil for doing so. Issuance of permits is subject to government review and may require, among other conditions, modification of plans or remediation of environmental impacts at the Usina São Martinho site. Construction of the facility must also be completed on a timely basis and within the budget. Once the facility is operational, it must perform as we have designed it. If we encounter significant delays, cost overruns, engineering problems, equipment supply constraints or other serious challenges in bringing this facility online, we may be unable to produce our initial renewable products in the time frame we have planned, or we may continue to use contract manufacturing sources, which would reduce our expected gross margins. Further, if our efforts to complete, and commence production at, this facility are not successful, other mill owners in Brazil may decide not to work with us to develop additional production facilities, demand more favorable terms or delay their commitment to invest capital in our production.

 

12


Table of Contents

Our joint venture with Usina São Martinho contemplates that we will make significant capital expenditures and subjects us to certain legal and financial terms that could adversely affect us.

 

In April 2010, we entered into a joint venture with Usina São Martinho to build a new production facility for the production of our products at the Usina São Martinho sugar and ethanol mill located in São Paulo state. The terms of this joint venture are complex and are set forth in agreements that include several schedules that the parties anticipate will be converted into definitive agreements. If we and Usina São Martinho are unable to complete the agreements contemplated by these schedules, our ability to commence operations under the joint venture will be delayed and may never occur. Further, if we and Usina São Martinho disagree over the interpretation of the joint venture documents, the future success of the joint venture may be impaired and any amount that we have invested in it may be at risk.

 

The construction of the facility at Usina São Martinho will be the first project of this nature which we will design and manage. We expect the construction costs of the new facility to total between $80 million to $100 million. Under the terms of our joint venture agreement, construction of the production facility will take place in two phases. Phase I is designed to construct a facility capable of producing farnesene from up to one million tons of crushed sugarcane and Phase II will add capacities of up to a second million tons. Within one year of the commencement of Phase I commercial operations, Usina São Martinho will be required to reimburse us for half of the cost of Phase I, up to a cap of 30.9 million reais ($17.5 million based on exchange rate at April 2, 2010). Thereafter, Usina São Martinho will co-fund the construction of Phase II and, as necessary, make a final payment at completion such that their total contribution will be 61.8 million reais ($35.0 million based on exchange rate at April 2, 2010).

 

The difference in the amounts and timing of our capital contributions relative to Usina São Martinho’s could leave us vulnerable in the event we encounter challenges in building the facility or bringing it online, delays in achieving commercial viability with our farnesene production process, disputes with Usina São Martinho or other unanticipated events that may occur prior to the time Usina São Martinho makes its capital contribution. In addition, because Usina São Martinho’s contribution is capped, we will bear the responsibility for construction costs in excess of those anticipated.

 

The joint venture will be managed by a three member executive committee, of which we appoint two members, including the plant director who is the most senior executive. The executive committee will be responsible for managing the construction and operation of the production facility. The joint venture will be governed by a four member board of directors, of which we and Usina São Martinho will each appoint two members. The board of directors has certain protective rights which include final approval of the engineering designs and project work plan developed and recommended by the executive committee. If our directors and the Usina São Martinho directors fail to reach agreement on approval of the engineering designs or project work plans, construction of the facility could be delayed or terminated. Further, Usina São Martinho has the right to terminate the joint venture under certain circumstances. If the joint venture is terminated, we would be required to buy the joint venture’s assets at fair value and transfer them to another location. In that event, we could incur significant unexpected costs and be required to find alternative locations for our facility, which would substantially delay the commencement of production.

 

Under the terms of the joint venture agreements, if Amyris Brasil becomes controlled, directly or indirectly, by a competitor of Usina São Martinho, then Usina São Martinho has the right to acquire our interest in the joint venture. If Usina São Martinho becomes controlled, directly or indirectly, by a competitor of ours, then we have the right to sell our interest in the joint venture to Usina São Martinho. In either case, the purchase price shall be determined in accordance with the joint venture agreements, and we would continue to have the obligation to acquire products produced by the joint venture for the remainder of the term of the supply agreement then in effect even though we would no longer be involved in the joint venture’s management.

 

The joint venture has agreed to purchase, and Usina São Martinho has agreed to provide, feedstock for a price that is based on the average return that Usina São Martinho could receive from the production of its current

 

13


Table of Contents

products, sugar and ethanol. If the cost of these products increases relative to the price at which we can sell the output that we are required to purchase from the joint venture, our return on sales of products produced by the joint venture would be adversely affected. We are required to purchase the output of the joint venture for the first four years at a price that guarantees the return of Usina São Martinho’s investment plus a fixed interest rate. We may not be able to sell the output at a price that allows us to achieve anticipated, or any, level of profitability on the product we acquire under these terms. Similarly, the return that we are required to provide the joint venture for products after the first four years may have an adverse effect on the profitability we achieve from acquiring the mill’s output. Finally, our purchase obligation with the mill requires us to purchase the output regardless of whether we have a customer for such output, and our results of operations and financial condition would be adversely affected if we are unable to sell the output that we are required to purchase.

 

We plan to enter into arrangements with Brazilian sugar and ethanol producers to produce our products, and if we are not able to complete these arrangements in a timely manner and on terms favorable to us, our business will be adversely affected.

 

To expand our production in Brazil beyond that of our initial production facility with Usina São Martinho, we intend to enter into agreements with sugar and ethanol producers in Brazil that require them to make a substantial capital or operating contribution to produce our renewable products. In return, we expect to provide them with a share of the higher gross margin we believe we will realize from the sale of these products relative to their existing products. There can be no assurance that a sufficient number of Brazilian sugar and ethanol mill owners will accept the opportunity to partner with us for the production of our products, whether on those terms or at all. Reluctance on the part of mill owners may be caused, for example, by their failure to understand our technology or product opportunities or agree with the greater economic benefits that we believe they can achieve from partnering with us. Mill owners may also be reluctant or unable to obtain needed capital, or they may be limited by existing contractual obligations with other third parties, liability, health and safety concerns, and additional maintenance, training, operating and other ongoing expenses. We have entered into letters of intent with three Brazilian sugar and ethanol producers to produce our products and Usina São Martinho has the option for production at a second mill, but these do not bind either the mill owner or us to enter into and proceed with a formal relationship. There are numerous issues regarding these mill relationships that must be successfully negotiated with each of the mill owners and we may not be successful in completing these negotiations. Even if sugar and ethanol producers are willing to build new facilities and produce our products, they may do so only on economic terms that place more of the cost, or confer less of the economic return, on us than we currently anticipate. If we are not successful in negotiations with sugar and ethanol mill owners, our cost of gaining this production capacity may be higher than we anticipate in terms of up-front costs, capital expenditure or lost future returns, and we may not gain the production base that we need in Brazil to allow us to grow our business.

 

Building new, bolt-on facilities adjacent to existing sugar and ethanol mills for production of our products requires significant capital, and if mill owners are unwilling to contribute, or do not have or have access to this capital, production of our products would be more limited or more expensive than expected and our business would be harmed.

 

We expect to expand our production capacity using a capital light approach, through which mill owners would invest a substantial portion or all of the capital needed to build our bolt-on production facilities, in exchange for a share of the higher gross margin from the sale of our renewable chemicals and fuels, as compared to their current products. Mill owners may perceive this construction as a costly process requiring substantial capital or operating contribution. Mill owners may not have sufficient capital of their own for this purpose or may not be willing or able to secure financing. As a result, they may choose not to contribute the amount of capital that we anticipate or may need to seek external sources of financing, which may not be available. If the mill owner needs to obtain financing through debt, we may be required to provide a guarantee.

 

Even if sugar and ethanol producers are attracted to the opportunity, they may not attract the credit that they need or want to do so. In the past, Brazil has experienced very high rates of inflation, and the government’s

 

14


Table of Contents

measures to control inflation have often included maintaining a tight monetary policy with high interest rates, restricting the availability of credit. Limitations in the credit markets that would impede or prevent this kind of financing could adversely affect our ability to develop the production capacity needed to allow us to grow our business.

 

Our strategy of relying on existing Brazilian sugar and ethanol producers to produce our products will make us substantially dependent on these owners, and they may not perform their obligations under agreements with us or otherwise perform to our standards.

 

Even if we reach agreements with Brazilian sugar and ethanol producers to produce our products, initially the mill owners will be unfamiliar with our technology and production processes. We cannot be sure that the owners will have or develop the operational expertise needed to run the additional equipment and processes required to produce our products. Further, we may have limited control over the application of our specifications and quality requirements and the amount or timing of resources that any mill owner is able or willing to devote to production of our products. Mill owners may fail to perform their obligations as expected or may breach or terminate key terms of their agreements with us, such as the obligation to provide the agreed-upon amount of sugarcane feedstock for the production of our products. Moreover, disagreements with one or more mill owners could develop, and any conflict with a mill owner could negatively impact our relationship, and reduce our ability to enter into future agreements, with other sugar and ethanol mill owners. Furthermore, the sugar and ethanol mills may be subject to unanticipated disruptions to operations such as unscheduled down times, operational hazards, equipment failures, labor disruptions, land reform movements, political disruptions and natural disasters, thus preventing or delaying the production of our products. If our sugar and ethanol mill partners in Brazil fail to successfully operate the production facilities for our products, or terminate their relationships with us, such operational difficulties could adversely impact the timely and efficient production of our products. As a result, our business, results of operations and financial condition could be harmed.

 

Our reliance on contract manufacturers to produce our products during construction of our Usina São Martinho joint venture production facility and periodically for additional short-term production capacity exposes us to risks relating to the price and availability of that contract manufacturing and could adversely affect our growth.

 

We anticipate commencing production of certain of our products in 2011 through the use of contract manufacturers prior to the time that our joint venture facility in Brazil is ready to commence production. Similarly, as we grow and look to bring new facilities on line, it is possible that there will be periods when the demand for our products exceeds our production capacity. We intend to seek to enter relationships with contract manufacturers for these purposes. We cannot be sure that contract manufacturers with this capacity will be available when we need their services, that they will be willing to dedicate a portion of their production capacity to our products or that we will be able to reach acceptable price and other terms with them for the provision of their production services. If we are unable to secure the services of such third parties when and as needed, we may lose customer opportunities and the growth of our business may be impaired. In addition, we expect that our costs to produce products using contract manufacturers will be higher than the costs to produce our products in sugar and ethanol mills with which we have entered into long term relationships.

 

The production of our products will require sugar feedstock, and the inability to obtain such feedstock in sufficient quantities or in a timely manner may limit our ability to produce our products.

 

We anticipate that the production of our products will require large volumes of feedstock, initially Brazilian sugarcane. We cannot predict the future availability of such feedstock or be sure that our mill partners, which we expect to supply the sugarcane necessary to produce our products, will be able to supply it in sufficient quantities or in a timely manner. Crop yields and sugar content depend on weather conditions, such as rainfall and temperature, that vary. Weather conditions have historically caused volatility in the ethanol and sugar industries

 

15


Table of Contents

by causing crop failures or reduced harvests. Excessive rainfall can adversely affect the supply of sugarcane available for the production of our products by reducing the sucrose content and limiting growers’ ability to harvest. Crop disease and pestilence can also occur from time to time and can adversely affect sugarcane growth, potentially rendering useless or unusable all or a substantial portion of affected harvests. The limited amount of time during which sugarcane keeps its sugar content after harvest and the fact that sugarcane is not itself a traded commodity increases these risks and limits our ability to substitute supply in the event of such an occurrence. If Brazilian sugarcane production is adversely affected by these or other conditions, our ability to produce our products will be impaired, and our business will be adversely affected.

 

An increase in the price and profitability of ethanol and sugar relative to our products could adversely affect our arrangements with sugar and ethanol producers.

 

In order to induce owners of sugar and ethanol facilities to produce our products, we plan to compensate them for the feedstock consumed in the production of our products in an amount equal to the revenue they would have realized had they instead produced their traditional products, plus any incremental costs incurred in the production of our products over their usual production costs. Finally, as we sell our products, we expect to share a portion of the realized gross margin with these mill owners. An increase in the price of ethanol or sugar relative to the price at which we can sell our products could result in the cost of our products increasing without a corresponding increase in the price at which we can sell our products. In this event our results of operations would be adversely affected. If ethanol prices are sufficiently high so that the return from converting a given amount of sugarcane to ethanol exceeds the return from converting that amount of sugarcane into our products, then we will have to compensate the mill owner for that loss or risk the mill owner reverting to the production of ethanol and not produce our products at all.

 

Many factors could cause this unfavorable price dislocation. If sugar prices increase over a sustained period of time, this may encourage sugar production at the expense of ethanol in mills with flexibility to produce both products, which in turn could cause domestic prices in Brazilian reais for ethanol to increase. In addition, the Brazilian government currently requires the use of anhydrous ethanol as a gasoline additive. Any change in these government policies could affect ethanol demand in a way that discourages mill owners from producing our products.

 

The price of sugarcane feedstock can be volatile as a result of changes in industry policy and may increase the cost of production of our products.

 

In Brazil, sugarcane prices may increase due, among other things, to changes in the criteria set by the Conselho dos Produtores de Cana, Açúcar e Álcool (Council of Sugarcane, Sugar and Ethanol Producers), or Consecana. Consecana is an industry association of producers of sugarcane, sugar and ethanol that sets market terms and prices for general supply, lease and partnership agreements and may change such prices and terms. Such changes could result in higher sugarcane prices and/or a significant decrease in the volume of sugarcane available for the production of our products, which could adversely our business and results of operations.

 

Most of our planned initial production capacity will be in Brazil, and our business will be adversely affected if we do not operate effectively in that country.

 

For the foreseeable future, we will be subject to risks associated with the concentration of essential product sourcing and operations in Brazil. In the past, the Brazilian economy was characterized by frequent and occasionally extensive intervention by the Brazilian government and unstable economic cycles. The Brazilian government has changed in the past, and may change in the future, monetary, taxation, credit, tariff and other policies to influence the course of Brazil’s economy. For example, the government’s actions to control inflation have at times involved setting wage and price controls, adjusting interest rates, imposing taxes and exchange controls and limiting imports into Brazil. We have no control over, and cannot predict, what policies or actions the Brazilian government may take in the future. For example, the Brazilian government may take actions to

 

16


Table of Contents

support state-controlled entities in our industry that could adversely affect us. Our business, financial performance and prospects may be adversely affected by, among others, the following factors:

 

   

delays or failures in securing licenses, permits or other governmental approvals necessary to build and operate facilities and use our yeast strains to produce products;

 

   

rapid consolidation in the sugar and ethanol industries in Brazil, which could result in a decrease in competition;

 

   

political, economic, diplomatic or social instability in or affecting Brazil;

 

   

changing interest rates;

 

   

tax burden and policies;

 

   

effects of changes in currency exchange rates;

 

   

exchange controls and restrictions on remittances abroad;

 

   

inflation;

 

   

land reform movements;

 

   

export or import restrictions that limit our ability to move our products out of Brazil or interfere with the import of essential materials into Brazil;

 

   

changes in or interpretations of foreign regulations that may adversely affect our ability to sell our products or repatriate profits to the U.S.;

 

   

tariffs, trade protection measures and other regulatory requirements;

 

   

successful compliance with U.S. and foreign laws that regulate the conduct of business abroad;

 

   

an inability, or reduced ability, to protect our intellectual property in Brazil including any effect of compulsory licensing imposed by government action; and

 

   

difficulties and costs of staffing and managing foreign operations.

 

Such factors could have a material adverse impact on our results of operations and financial condition.

 

In addition, Brazilian presidential and parliamentary elections will take place in October 2010. The Brazilian president has significant power to determine public policies and introduce measures affecting the Brazilian economy and companies such as ours. The new government, whether or not controlled by the current president’s political party, may seek to implement changes to existing public policies. For example, the current or future government may face pressure to reduce public investments (including investments in infrastructure), due to increasing inflation and public debt. This could have a material adverse impact on our operations.

 

We cannot predict whether the current or future Brazilian government will implement changes to existing policies on taxation, exchange controls, monetary strategy and social security, among others. We cannot estimate the impact of any such changes on the Brazilian economy or our operations.

 

We may face risks relating to the use of our genetically modified yeast strains and if we are not able to secure regulatory approval for the use of our yeast strains or if we face public objection to our use of them, our business could be adversely affected.

 

The use of genetically modified microorganisms (“GMMs”), such as our yeast strains, is subject to laws and regulations in many countries, some of which are new and some of which are still evolving. Public attitudes about the safety and environmental hazards of, and ethical concerns over, genetic research and GMMs could influence public acceptance of our technology and products. In the U.S., the Environmental Protection Agency

 

17


Table of Contents

(“EPA”) regulates the commercial use of GMMs as well as potential products from the GMMs. While the strain of genetically modified yeast that we currently use for the development and anticipate using for the commercial production of our target molecules, S. cerevisiae , is eligible for exemption from EPA review because it is recognized as posing a low risk, we must satisfy certain criteria to achieve this exemption, including but not limited to use of compliant containment structures and safety procedures, and we cannot be sure that we will meet such criteria in a timely manner, or at all. If exemption of S. cerevisiae is not obtained, our business may be substantially harmed.

 

In addition to S. cerevisiae , we may seek to use different GMMs in the future that will require EPA approval. If approval of different GMMs is not secured, our ability to grow our business could be adversely affected.

 

In Brazil, GMMs are regulated by the National Biosafety Technical Commission, or CTNBio. We have obtained approval from CTNBio to use GMMs in a contained environment in our Campinas facilities for research and development purposes. In addition, we have obtained initial commercial approval from CTNBio for one of our current yeast strains. As we continue to develop new yeast strains, we will be required to obtain further approvals from CTNBio in order to use these strains in commercial production in Brazil. We may not be able to obtain approvals from relevant Brazilian authorities on a timely basis, or at all, and if we do not, our ability to produce our products in Brazil would be impaired, which would adversely affect our results of operations and financial condition.

 

We expect to encounter GMM regulations in most if not all of the countries in which we may seek to establish production capabilities, and the scope and nature of these regulations will likely be different from country to country. If we cannot meet the applicable requirements in other countries in which we intend to produce products using our yeast strains, or if it takes longer than anticipated to obtain such approvals, our business could be adversely affected.

 

We may not be able to obtain regulatory approval for the sale of our renewable products.

 

Our renewable chemical products may be subject to government regulation in our target markets. In the U.S., the EPA administers the Toxic Substances Control Act, or TSCA, which regulates the commercial registration, distribution, and use of chemicals. Before an entity can manufacture or distribute significant volumes of a chemical, it needs to determine whether that chemical is listed in the TSCA inventory. If the substance is listed, then manufacture or distribution can commence immediately. If not, then a pre-manufacture notice must be filed with the EPA for a review period of up to 180 days including extensions. Some of the products we produce or plan to produce, such as farnesene and squalane, are already in the TSCA inventory. Others, such as our lubricant s, diesel and jet fuel, are not yet listed. We may not be able to expediently receive approval from the EPA to list the molecules we would like to make on the TSCA registry, resulting in delays or significant increases in testing requirements. A similar program exists in the European Union, called REACH (Registration, Evaluation, Authorization, and Restriction of Chemical Substances). We similarly need to register our products with the European Commission, and this process could cause delays or significant costs. To the extent that other geographies, such as Brazil, may rely on TSCA or REACH for chemical registration in their geographies, delays with the U.S. or European authorities may subsequently delay entry into these markets as well.

 

Our diesel fuel is subject to regulation by various government agencies, including the EPA and the California Air Resources Board in the U.S. and Agencia Nacional do Petroleo, or ANP, in Brazil. To date, we have obtained registration with the EPA for the use of our diesel in the U.S. at a 20% blend rate with petroleum diesel. We are currently seeking supplemental EPA registration for a 35% blend rate and working to secure ANP approval for use of our diesel in Brazil at a 10% blend rate. We are currently in process of registration of our fuel with the California Air Resources Board and the European Commission. Registration with each of these bodies is required for the sale and use of our fuels within their respective jurisdictions.

 

18


Table of Contents

We expect to encounter regulations in most if not all of the countries in which we may seek to sell our renewable chemical and fuel products, and we cannot assure you that we will be able to obtain necessary approvals in a timely manner or at all. If our chemical and fuel products do not meet applicable regulatory requirements in a particular country or at all, then we may not be able to commercialize our products and our business will be adversely affected.

 

We cannot assure you that our products will be approved or accepted by customers in specialty chemical markets.

 

The markets we intend to enter first are those for specialty chemical products used by large consumer products or specialty chemical companies. In entering these markets, we intend to sell our products as alternatives to chemicals currently in use, and in some cases the chemicals that we seek to replace have been used for many years. The potential customers for our molecules generally have well developed manufacturing processes and arrangements with suppliers of the chemical components of their products and may have a resistance to changing these processes and components. These potential customers frequently impose lengthy and complex product qualification procedures on their suppliers, influenced by consumer preference, manufacturing considerations such as process changes and capital and other costs associated with transitioning to alternative components, supplier operating history, regulatory issues, product liability and other factors, many of which are unknown to, or not well understood by, us. Satisfying these processes may take many months or years. If we are unable to convince these potential customers that our products are comparable to the chemicals that they currently use or that the use of our products is otherwise to their benefits, we will not be successful in entering these markets and our business will be adversely affected.

 

If we are unable to satisfy the significant product certification requirements of equipment manufacturers, we may not be able to successfully enter markets for transportation fuels, and our business would be adversely affected.

 

In order for our diesel fuel product to be accepted in various countries around the world, diesel engine manufacturers must certify that the use of our fuels in their equipment will not invalidate product warranties and that they otherwise regard our diesel as an acceptable fuel. In addition, we must successfully demonstrate to these manufacturers that our fuel does do not degrade the performance or reduce the lifecycle of their engines or cause them to fail to meet emissions standards. Meeting these suitability standards can be a time consuming and expensive process, and we may invest substantial time and resources into such qualification efforts without ultimately securing approval. To date, our diesel fuel products have achieved limited approvals from certain engine manufacturers, but we cannot be assured that other engine or vehicle manufacturers or fleet operators, will approve usage of our fuels. Although our diesel fuel satisfies existing pipeline operator and fuel distributor requirements, such fuel has not been reviewed nor transported by such operators as of this date. If these operators impose volume limitations on the transport of our fuels, our ability to sell our fuels may be impaired.

 

Our ability to sell a jet fuel product will be subject to the same types of qualification requirements as our diesel fuel, although we believe the qualification process will take longer and will be more expensive than the process for diesel.

 

We expect our international operations to expose us to the risk of fluctuation in currency exchange rates and rates of foreign inflation, which could adversely affect our results of operations.

 

We currently incur some costs and expenses in Brazilian reais and may in the future incur additional expenses in foreign currencies and derive a portion of our revenues in the local currencies of customers throughout the world. As a result, our revenues and results of operations are subject to foreign exchange fluctuations, which we may not be able to manage successfully. During the past few decades, the Brazilian currency in particular faced frequent and substantial exchange rate fluctuations in relation to the U.S. dollar and other foreign currencies. For example, the real appreciated 12.3%, 8.7% and 17.0% against the U.S. dollar in

 

19


Table of Contents

2005, 2006, and 2007 respectively. As a result of the global financial crisis in mid-2008, the real depreciated 31.9% against the U.S. dollar. In 2009, due in part to the recovery of the Brazilian economy at a faster rate than the global economy, the real once again appreciated 25% against the U.S. dollar. There can be no assurance that the real will not significantly appreciate or depreciate against the U.S. dollar in the future.

 

We bear the risk that the rate of inflation in the foreign countries where we incur costs and expenses or the decline in value of the U.S. dollar compared to those foreign currencies will increase our costs as expressed in U.S. dollars. Future measures by the Central Bank of Brazil to control inflation, including interest rate adjustments, intervention in the foreign exchange market and changes to the fixed the value of the real, may trigger increases in inflation. Whether in Brazil or otherwise, we may not be able to adjust the prices of our products to offset the effects of inflation on our cost structure, which could increase our costs and reduce our net operating margins. If we do not successfully manage these risks through hedging or other mechanisms, our revenues and results of operations could be adversely affected.

 

We expect to face competition for our specialty chemical and transportation fuels products from providers of petroleum-based products and from other companies seeking to provide alternatives to these products, and if we cannot compete effectively against these companies or products we may not be successful in bringing our products to market or further growing our business after we do so.

 

We expect that our renewable products will compete with both the traditional, largely petroleum-based specialty chemical and fuels products that are currently being used in our target markets and with the alternatives to these existing products that established enterprises and new companies are seeking to produce. Amyris Fuels competes with other ethanol distributors in buying and selling third party ethanol.

 

In the specialty chemical markets that we will seek to enter initially, and in other chemical markets that we may seek to enter in the future, we will compete with the established providers of chemicals currently used in these products. Producers of these incumbent products include global oil companies, large international chemical companies and other companies specializing in specific products, such as squalane or essential oils. We may also compete in one or more of these markets with products that are offered as alternatives to the traditional petroleum-based or other traditional products being offered in these markets.

 

In the transportation fuels market, we expect to compete with independent and integrated oil refiners, advanced biofuels companies and biodiesel companies. These refiners compete with us by selling traditional fuel products and some are also pursuing hydrocarbon fuel production using non-renewable feedstocks, such as natural gas and coal, as well as processes using renewable feedstocks, such as vegetable oil and biomass. We also expect to compete with companies which are developing the capacity to produce diesel and other transportation fuels from renewable resources in other ways. These include advanced biofuels companies using specific enzymes that they have developed to convert cellulosic biomass, which is non-food plant material such as wood chips, corn stalks and sugarcane bagasse, into fermentable sugars. Similar to us, some companies are seeking to use engineered enzymes to convert sugars, in some cases from cellulosic biomass and in others from natural sugar sources, into renewable diesel and other fuels. Biodiesel companies convert vegetable oils and animal oils into diesel fuel and some are seeking to produce diesel and other transportation fuels using thermochemical methods to convert biomass into renewable fuels.

 

We believe the primary competitive factors in both the chemicals and fuels markets are:

 

   

product price;

 

   

product performance and other measures of quality;

 

   

infrastructure compatibility of products;

 

   

sustainability; and

 

   

dependability of supply.

 

20


Table of Contents

The oil companies, large chemical companies and well-established agricultural products companies with whom we compete are much larger than we are, have, in many cases, well developed distribution systems and networks for their products, have valuable historical relationships with the potential customers we are seeking to serve and have much more extensive sales and marketing programs in place to promote their products. In order to be successful, we must convince customers that our products are at least as effective as the traditional products they are seeking to replace and must provide our products on a cost-competitive basis with these traditional products and other available alternatives. Some of our competitors may use their influence to impede the development and acceptance of renewable products of the type that we are seeking to produce.

 

We believe that for our chemical products to succeed in the market, we must demonstrate that our products are comparable alternatives to existing products and to any alternative products that are being developed for the same markets based on some combination of product cost, availability, performance and consumer preference characteristics. With respect to our diesel and other transportation fuels products, we believe that our product must perform as effectively as petroleum-based fuel, or alternative fuels, and be available on a cost-competitive basis. In addition, with the wide range of renewable fuels products under development, we must be successful in reaching potential customers and convincing them that ours are effective and reliable alternatives.

 

Amyris Fuels currently competes with regional ethanol distributors in its purchase, distribution and sale of third party ethanol in the southeastern U.S. and competes with other suppliers based on price, convenience and reliability of supply.

 

We have limited experience in structuring arrangements with customers for the purchase of our renewable products, and we may not be successful in this essential aspect of our business.

 

We expect that the customers for our products will be large companies currently selling chemical products for various consumer and other applications and large users of diesel fuel. As a company that has not yet completed the development of our products, we have limited experience operating in the industries or interacting with the customers we intend to target. The development of expertise in these markets may take a longer period of time than we expect and will require that we expand our sales and marketing infrastructure. These events could delay our ability to capitalize on the opportunities presented to us by our technology and products, including preventing us from achieving commercialization of our initial products in 2011. Further, we expect to sell large amounts of our products to specific customers, and this will require that we effectively negotiate contracts for these purchase and sale relationships. The companies with which we expect to have customer arrangements are, in general, much larger and have substantially greater operating histories and experience in target industries than we have. As a result, we may not be effective in negotiating the terms of our relationships with these companies, which could adversely affect our future results of operations.

 

A decline in the price of petroleum and petroleum-based products may reduce demand for many of our renewable products and may otherwise adversely affect our business.

 

We anticipate that most of our renewable products, and in particular our fuels, will be marketed as alternatives to corresponding petroleum-based products. If the price of oil falls, we may be unable to produce products that are a cost-effective alternatives to their petroleum-based products. Declining oil prices, or the perception of a future decline in oil prices, may adversely affect the prices we can obtain from our potential customers or prevent potential customers from entering into agreements with us to buy our products. During sustained periods of lower oil prices we may be unable to sell our products, which could materially and adversely affect our operating results.

 

Our pursuit of new product opportunities may not be technically feasible, which would limit our ability to expand our product line and sources of revenues.

 

Our technology provides us with the capability to genetically engineer microbes to produce potentially thousands of molecules. In order to grow our business over time we will need to, and we intend to, commit

 

21


Table of Contents

substantial resources to the development and analysis of these new molecules and the new pathways, or microbial strains, required to produce them. There is no guarantee that we will be successful in creating microbial strains that are capable of producing each target molecule. For example, some target molecules may be “toxic” to the microbe, which means that the production of the molecule kills the microbe. Other molecules may be biologically producible in small amounts but cannot be produced in quantities adequate for commercial production. In addition, some of our microbes may have longer production cycles that may make production of the target molecules more costly. If we are unable to resolve issues of this nature, we may not be able to expand our product line to introduce new sources of revenues.

 

Changes in government regulations, including subsidies and economic incentives, could have a material adverse effect upon our business and results of operations.

 

The market for renewable fuels is heavily influenced by foreign, federal, state and local government regulations and policies. Changes to existing or adoption of new domestic or foreign federal, state and local legislative initiatives that impact the production, distribution or sale of renewable fuels may harm our business. For example, in 2007, the U.S. Congress passed an alternative fuels mandate that currently calls for 13 billion gallons of liquid transportation fuels sold in 2010 to come from alternative sources, including renewable fuels, a mandate that grows to 36 billion gallons by 2022. Of this amount, a minimum of 21 billion gallons must be advanced biofuels. In the U.S. and in a number of other countries, these regulations and policies have been modified in the past and may be modified again in the future. Any reduction in mandated requirements for fuel alternatives and additives to gasoline may cause demand for biofuels to decline and deter investment in the research and development of renewable fuels. In addition, the U.S. Congress has passed legislation that extends tax credits to blenders of certain renewable fuel products. However, there is no assurance that this or any other favorable legislation will remain in place. For example, the biodiesel tax credit expired in December 2009, and its extension was not approved until March 2010. Any reduction in, or phasing out or elimination of existing tax credits, subsidies and other incentives in the U.S. and foreign markets for renewable fuels, or any inability of our customers to access such credits, subsidies and incentives, may adversely affect demand for our products and increase the overall cost of commercialization of our renewable fuels, which would adversely affect our business. In addition, market uncertainty regarding future policies may also affect our ability to develop new renewable products or to license our technologies to third parties and to sell products to our end customers. Any inability to address these requirements and any regulatory or policy changes could have a material adverse effect on our business, financial condition and results of operations.

 

Concerns associated with renewable fuels, including land usage, national security interests and food crop usage, are receiving legislative industry and public attention. This could result in future legislation, regulation and/or administrative action that could adversely affect our business. Any inability to address these requirements and any regulatory or policy changes could have a material adverse effect on our business or the business of our partners or customers, financial condition and results of operations.

 

Furthermore, the production of our products will depend on the availability of feedstock, especially sugarcane. Agricultural production and trade flows are subject to government policies and regulations. Governmental policies affecting the agricultural industry, such as taxes, tariffs, duties, subsidies, incentives and import and export restrictions on agricultural commodities and commodity products, can influence the planting of certain crops, the location and size of crop production, whether unprocessed or processed commodity products are traded, the volume and types of imports and exports, and the availability and competitiveness of feedstocks as raw materials. Future government policies may adversely affect the supply of sugarcane, restrict our ability to use sugarcane to produce our products, and negatively impact our revenues and results of operations.

 

We may incur significant costs complying with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.

 

We use hazardous chemicals and radioactive and biological materials in our business and are subject to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage,

 

22


Table of Contents

handling and disposal of these materials both in the U.S. and overseas. Although we have implemented safety procedures for handling and disposing of these materials and waste products in an effort to comply with these laws and regulations, we cannot be sure that our safety measures are compliant or capable of eliminating the risk of accidental injury or contamination from the use, storage, handling or disposal of hazardous materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our insurance coverage. There can be no assurance that violations of environmental, health and safety laws will not occur in the future as a result of human error, accident, equipment failure or other causes. Compliance with applicable environmental laws and regulations may be expensive, and the failure to comply with past, present, or future laws could result in the imposition of fines, third party property damage, product liability and personal injury claims, investigation and remediation costs, the suspension of production, or a cessation of operations, and our liability may exceed our total assets. Liability under environmental laws can be joint and several and without regard to comparative fault. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could impair our research, development or production efforts and harm our business.

 

Our financial results could vary significantly from quarter to quarter and are difficult to predict.

 

Our revenues and results of operations could vary significantly from quarter to quarter because of a variety of factors, many of which are outside of our control. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Factors that could cause our quarterly results of operations to fluctuate include:

 

   

achievement, or failure to achieve, technology or product development milestones needed to allow us to enter identified markets on a cost effective basis;

 

   

delays or greater than anticipated expenses associated with the completion of new production facilities, and the time to complete scale-up of production following completion of a new production facility;

 

   

disruptions in the production process at any facility where we produce our products;

 

   

the timing, size and mix of sales to customers for our products;

 

   

increases in price or decreases in availability of our feedstocks;

 

   

the unavailability of contract manufacturing capacity altogether or at anticipated cost;

 

   

fluctuations in foreign currency exchange rates;

 

   

gains or losses associated with our hedging activities, especially in Amyris Fuels;

 

   

fluctuations in the price of and demand for sugar, ethanol, and petroleum-based and other products for which our products are alternatives;

 

   

seasonal production and sale of our products;

 

   

the effects of competitive pricing pressures, including decreases in average selling prices of our products;

 

   

unanticipated expenses associated with changes in governmental regulations and environmental, health and safety requirements;

 

   

reductions or changes to existing fuel and chemical regulations and policies;

 

   

departure of executives or other key management employees;

 

   

our ability to use our net operating loss carry forwards to offset future taxable income;

 

   

business interruptions such as earthquakes and other natural disasters;

 

   

our ability to integrate businesses that we may acquire;

 

23


Table of Contents
   

risks associated with the international aspects of our business; and

 

   

changes in general economic, industry and market conditions, both domestically and in our foreign markets.

 

Due to these factors and others the results of any quarterly or annual period may not meet our expectations or the expectations of our investors and may not be meaningful indications of our future performance.

 

Disruption of transportation and logistics services or insufficient investment in public infrastructure could adversely affect our business.

 

We initially intend to manufacture most of our renewable products in Brazil, where existing transportation infrastructure is underdeveloped. Substantial investments required for infrastructure changes and expansions may not be made on a timely basis or at all. Any delay or failure in making the changes to or expansion of infrastructure could harm demand or prices for our renewable products and impose additional costs that would hinder their commercialization.

 

In Brazil, a substantial portion of commercial transportation is by truck, which is significantly more expensive than the rail transportation available to U.S. and other international producers. Our dependence on truck transport may affect our production cost and, consequently, impair our ability to compete with petroleum-sourced products in local and world markets.

 

We may require additional financing in the future and may not be able to obtain such financing on favorable terms, if at all.

 

We will continue to fund our research and development and related activities and to provide working capital to fund production, storage, distribution and other aspects of our business. In addition, we plan to make significant capital expenditures in connection with our joint venture with Usina São Martinho and other potential mill arrangements. While we plan to enter into relationships with sugar and ethanol producers for them to provide some portion or all of the capital needed to build the new, adjacent bolt-on production facility, we may determine that it is more advantageous for us to provide some portion or all of the financing that we currently expect to be provided by these owners.

 

If our capital resources are insufficient to meet our capital requirements, we will have to raise additional funds. If future financings involve the issuance of equity securities, our existing stockholders would suffer dilution. If we are able to raise additional debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop and commercialize products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research and development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.

 

Our fuels marketing and distribution business depends, and will depend for the foreseeable future, on purchasing and reselling ethanol produced by third parties, which may not be available to us on favorable terms or at all and which we may be unable to resell.

 

Amyris Fuels currently purchases and sells ethanol under short-term agreements and in spot transactions. In the future, we plan to continue the purchase and sale of ethanol and to hedge the price volatility of ethanol using futures contracts. We cannot predict the future market price of ethanol or the price or other terms of any supply

 

24


Table of Contents

contracts that Amyris Fuels may enter into. We cannot assure you that Amyris Fuels will be able to purchase ethanol at favorable prices, allowing our ethanol marketing activities to be profitable. In addition, there can be no guarantee that futures contracts to hedge the risks from the purchase and sale of ethanol will effectively mitigate risk as intended, that such hedging instruments will always be available, or that counterparties to such hedging contracts will honor their obligations. As a result of these pricing and hedging uncertainties, Amyris Fuels may incur operating losses, harming our results of operations and financial condition. If Amyris Fuels is unable to conduct sales of ethanol on favorable volume, price and other terms, our results of operations and financial condition will be harmed.

 

The success of our fuels marketing and distribution business depends on our ability to expand our access to financial and infrastructure assets.

 

In June 2008, we began to distribute ethanol produced by third parties in the U.S. through our wholly-owned subsidiary, Amyris Fuels. Amyris Fuels currently has secured access to certain terminal and other storage capacity for ethanol, and it engages providers of transportation and transloading services for the movement of ethanol. If Amyris Fuels is unable to access sufficient terminal and other storage capacity and/or to obtain transportation and transloading services on favorable terms, its business will be substantially harmed, which will reduce our revenues and adversely affect our results of operations and financial condition.

 

Growth may place significant demands on our management and our infrastructure.

 

We have experienced, and may continue to experience, expansion of our business as we continue to make efforts to develop and bring our products to market. We have grown from approximately 18 employees at the end of 2005 to approximately 221 employees at the end of 2009. We work simultaneously on multiple projects to develop, produce and commercialize several types of renewable chemicals and fuels. Our growth and diversified operations have placed, and may continue to place, significant demands on our management and our operational and financial infrastructure. In particular, continued growth could strain our ability to:

 

   

develop and improve our operational, financial and management controls;

 

   

enhance our reporting systems and procedures;

 

   

recruit, train and retain highly skilled personnel;

 

   

develop and maintain our relationships with existing and potential business partners;

 

   

maintain our quality standards; and

 

   

maintain customer satisfaction.

 

Managing our growth will require significant expenditures and allocation of valuable management resources. If we fail to achieve the necessary level of efficiency in our organization as it grows, our business, results of operations and financial condition would be harmed.

 

If we fail to maintain an effective system of internal controls, we might not be able to report our financial results accurately or prevent fraud; in that case, our stockholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our stock.

 

Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. In addition, Section 404 of the Sarbanes-Oxley Act of 2002 will require us and our independent registered public accounting firm to evaluate and report on our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ending December 31, 2011. The process of implementing our internal controls and complying with Section 404 will be expensive and time consuming, and will require significant attention of management. We cannot be certain that these measures will ensure that we implement and maintain adequate controls over our financial processes and reporting in the future. Even if we conclude, and our independent

 

25


Table of Contents

registered public accounting firm concurs, that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our reporting obligations. If we or our independent registered public accounting firm discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market’s confidence in our financial statements and harm our stock price. In addition, a delay in compliance with Section 404 could subject us to a variety of administrative sanctions, including SEC action, ineligibility for short form resale registration, the suspension or delisting of our common stock from the stock exchange on which it is listed and the inability of registered broker-dealers to make a market in our common stock, which would further reduce our stock price and could harm our business.

 

Our proprietary rights may not adequately protect our technologies and product candidates.

 

Our commercial success will depend substantially on our ability to obtain patents and maintain adequate legal protection for our technologies and product candidates in the U.S. and other countries. To date, we have 22 issued U.S. and foreign patents and 195 pending U.S. and foreign patent applications that are owned by or licensed to us. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies and future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.

 

We apply for patents covering both our technologies and product candidates, as we deem appropriate. However, we may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all. Our existing and future patents may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products or technologies. In addition, the patent positions of companies like ours are highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of patent claims has emerged to date in the U.S. and the landscape is expected to become even more uncertain in view of recent rule changes by the Patent and Trademark Office, the introduction of patent reform legislation in Congress and recent decisions in patent law cases by the U.S. Supreme Court. In addition, certain key U.S. patents were obtained using a procedure for accelerated examination recently implemented by the U.S. Patent and Trademark Office (“USPTO”) which requires special activities and disclosures that may create additional risks related to the validity or enforceability of the U.S. patents so obtained. The patent situation outside of the U.S. is even less predictable. As a result, the validity and enforceability of patents cannot be predicted with certainty. Moreover, we cannot be certain whether:

 

   

we or our licensors were the first to make the inventions covered by each of our issued patents and pending patent applications;

 

   

we or our licensors were the first to file patent applications for these inventions;

 

   

others will independently develop similar or alternative technologies or duplicate any of our technologies;

 

   

any of our or our licensors’ patents will be valid or enforceable;

 

   

any patents issued to us or our licensors will provide us with any competitive advantages, or will be challenged by third parties;

 

   

we will develop additional proprietary products or technologies that are patentable; or

 

   

the patents of others will have an adverse effect on our business.

 

We do not know whether any of our patent applications or those patent applications that we license will result in the issuance of any patents. Even if patents are issued, they may not be sufficient to protect our

 

26


Table of Contents

technology or product candidates. The patents we own or license and those that may be issued in the future may be challenged, invalidated, rendered unenforceable, or circumvented, and the rights granted under any issued patents may not provide us with proprietary protection or competitive advantages. In particular, U.S. patents we obtained using the USPTO accelerated examination program may introduce additional risks to the validity or enforceability of some or all of these specially-obtained U.S. patents if validity or enforceability are challenged. Moreover, third parties could practice our inventions in territories where we do not have patent protection or in territories where they could obtain a compulsory license to our technology where patented. Such third parties may then try to import products made using our inventions into the U.S. or other territories. Additional uncertainty may result from potential passage of patent reform legislation by the U.S. Congress, legal precedent by the U.S. Federal Circuit and Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. Accordingly, we cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth, validity and enforceability of the claims upheld in our and other companies’ patents.

 

Unauthorized parties may attempt to copy or otherwise obtain and use our products or technology. Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technology, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the U.S. or may provide, today or in the future, for compulsory licenses. If competitors are able to use our technology, our ability to compete effectively could be harmed. Moreover, others may independently develop and obtain patents for technologies that are similar to, or superior to, our technologies. If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could cause harm to our business.

 

We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

 

We rely on trade secrets to protect some of our technology, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to maintain and protect. Our strategy for scale-up of production would require us to share confidential information with our Brazilian business partners and other parties. While we use reasonable efforts to protect our trade secrets, our or our business partners’ employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. In addition, foreign courts are sometimes less willing than U.S. courts to protect trade secrets. If our competitors independently develop equivalent knowledge, methods and know-how, we would not be able to assert our trade secrets against them. We require new employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, our proprietary information may be disclosed, or these agreements may be unenforceable or difficult to enforce. Additionally, trade secret law in Brazil differs from that in the U.S. which requires us to take a different approach to protecting our trade secrets in Brazil. We may employ approaches to trade secret protection that are novel and untested under Brazilian law and we cannot guarantee that we would prevail if our trade secrets are contested in Brazil. If any of the above risks materializes our failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

 

Third parties may misappropriate our yeast strains.

 

Third parties, including sugar and ethanol mill owners, contract manufacturers, other contractors and shipping agents, often have custody or control of our yeast strains. If our yeast strains were stolen, misappropriated or reverse engineered, they could be used by other parties who may be able to reproduce the

 

27


Table of Contents

yeast strains for their own commercial gain. If this were to occur, it would be difficult for us to challenge and prevent this type of use, especially in countries with limited intellectual property protection.

 

If we are sued for infringing intellectual property rights or other proprietary rights of third parties, litigation could be costly and time consuming and could prevent us from developing or commercializing our future products.

 

Our commercial success depends on our ability to operate without infringing the patents and proprietary rights of other parties and without breaching any agreements we have entered into with regard to our technologies and product candidates. We cannot determine with certainty whether patents or patent applications of other parties may materially affect our ability to conduct our business. Our industry spans several sectors, including biotechnology, renewable fuels, renewable specialty chemicals and other renewable compounds, and is characterized by the existence of a significant number of patents and disputes regarding patent and other intellectual property rights. Because patent applications can take several years to issue, there may currently be pending applications, unknown to us, that may result in issued patents that cover our technologies or product candidates. We are aware of a significant number of patents and patent applications relating to aspects of our technologies filed by, and issued to, third parties. The existence of third-party patent applications and patents could significantly reduce the coverage of patents owned by or licensed to us and limit our ability to obtain meaningful patent protection. If we wish to make, use, sell, offer to sell, or import the technology or compound claimed in issued and unexpired patents owned by others, we will need to obtain a license from the owner, enter into litigation to challenge the validity of the patents or incur the risk of litigation in the event that the owner asserts that we infringe its patents. If patents containing competitive or conflicting claims are issued to third parties and these claims are ultimately determined to be valid, we may be enjoined from pursing research, development, or commercialization of products, or be required to obtain licenses to these patents, or to develop or obtain alternative technology.

 

If a third-party asserts that we infringe upon its patents or other proprietary rights, we could face a number of issues that could seriously harm our competitive position, including:

 

   

infringement and other intellectual property claims, which could be costly and time consuming to litigate, whether or not the claims have merit, and which could delay getting our products to market and divert management attention from our business;

 

   

substantial damages for past infringement, which we may have to pay if a court determines that our product candidates or technologies infringe a competitor’s patent or other proprietary rights;

 

   

a court prohibiting us from selling or licensing our technologies or future products unless the holder licenses the patent or other proprietary rights to us, which it is not required to do; and

 

   

if a license is available from a third party, we may have to pay substantial royalties or grant cross licenses to our patents or proprietary rights.

 

The industries in which we operate, and the biotechnology industry in particular, are characterized by frequent and extensive litigation regarding patents and other intellectual property rights. Many biotechnology companies have employed intellectual property litigation as a way to gain a competitive advantage. If any of our competitors have filed patent applications or obtained patents that claim inventions also claimed by us, we may have to participate in interference proceedings declared by the relevant patent regulatory agency to determine priority of invention and, thus, the right to the patents for these inventions in the U.S. These proceedings could result in substantial cost to us even if the outcome is favorable. Even if successful, an interference may result in loss of certain claims. Our involvement in litigation, interferences, opposition proceedings or other intellectual property proceedings inside and outside of the U.S., to defend our intellectual property rights or as a result of alleged infringement of the rights of others, may divert management time from focusing on business operations and could cause us to spend significant resources, all of which could harm our business and results of operations.

 

28


Table of Contents

Many of our employees were previously employed at universities, biotechnology, specialty chemical or oil companies, including our competitors or potential competitors. We may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel and be enjoined from certain activities. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and demand on management resources.

 

We may need to commence litigation to enforce our intellectual property rights, which would divert resources and management’s time and attention and the results of which would be uncertain.

 

Enforcement of claims that a third party is using our proprietary rights without permission is expensive, time consuming and uncertain. Litigation would result in substantial costs, even if the eventual outcome is favorable to us and would divert management’s attention from our business objectives. In addition, an adverse outcome in litigation could result in a substantial loss of our proprietary rights and we may lose our ability to exclude others from practicing our technology or producing our product candidates.

 

The laws of some foreign countries do not protect intellectual property rights to the same extent as do the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology and/or bioindustrial technologies. This could make it difficult for us to stop the infringement of our patents or misappropriation of our other intellectual property rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Moreover, our efforts to protect our intellectual property rights in such countries may be inadequate.

 

Loss of key personnel, including key management personnel, and/or failure to attract and retain additional personnel could delay our product development programs and harm our research and development efforts and our ability to meet our business objectives.

 

Our business involves complex, global operations across a variety of markets and requires a management team and employee workforce that is knowledgeable in the many areas in which we operate. The loss of any key member of our management or key technical and operational employees, or the failure to attract or retain such employees could prevent us from developing and commercializing our products for our target markets and executing our business strategy. We may not be able to attract or retain qualified employees in the future due to the intense competition for qualified personnel among biotechnology and other technology-based businesses, particularly in the renewable fuels area, or due to the availability of personnel with the qualifications or experience necessary for our business. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience staffing constraints that will adversely affect our ability to meet the demands of our collaborators and customers in a timely fashion or to support our internal research and development programs. In particular, our product and process development programs are dependent on our ability to attract and retain highly skilled technical and operational personnel. Competition for such personnel from numerous companies and academic and other research institutions may limit our ability to do so on acceptable terms. All of our employees are at-will employees, which means that either the employee or we may terminate their employment at any time.

 

As we expand our operations, we will need to hire additional qualified research and development and management personnel to succeed. The process of hiring, training and successfully integrating qualified personnel into our operation is a lengthy and expensive one. The market for qualified personnel is very

 

29


Table of Contents

competitive because of the limited number of people available with the necessary technical skills and understanding of our technology and anticipated products. Our failure to hire and retain qualified personnel could impair our ability to meet our research and development and business objectives and adversely affect our results of operations and financial condition.

 

We may be sued for product liability.

 

The design, development, production and sale of our products involve an inherent risk of product liability claims and the associated adverse publicity. We may be named directly in product liability suits relating to our products, even for defects resulting from errors of our commercial partners, contract manufacturers or chemical finishers. These claims could be brought by various parties, including customers who are purchasing products directly from us or other users who purchase products from our customers. We could also be named as co-parties in product liability suits that are brought against the sugar and ethanol mills who produce our products in Brazil. Insurance coverage is expensive, may be difficult to obtain and may not be available in the future on acceptable terms. We cannot assure you that our contract manufacturers or the sugar and ethanol producers who produce our products will have adequate insurance coverage to cover against potential claims. This insurance may not provide adequate coverage against potential losses, and if claims or losses exceed our liability insurance coverage, we may go out of business. In addition, insurance coverage may become more expensive, which would harm our results of operations.

 

During the ordinary course of business, we may become subject to lawsuits or indemnity claims, which could materially and adversely affect our business and results of operations.

 

From time to time, we may in the ordinary course of business be named as a defendant in lawsuits, claims and other legal proceedings. These actions may seek, among other things, compensation for alleged personal injury, worker’s compensation, employment discrimination, breach of contract, property damages, civil penalties and other losses of injunctive or declaratory relief. In the event that such actions or indemnities are ultimately resolved unfavorably at amounts exceeding our accrued liability, or at material amounts, the outcome could materially and adversely affect our reputation, business and results of operations. In addition, payments of significant amounts, even if reserved, could adversely affect our liquidity position.

 

Our ability to use our net operating loss carry forwards to offset future taxable income may be subject to certain limitations.

 

In general, under Section 382 of the Internal Revenue Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating loss carry forwards, or NOLs, to offset future taxable income. If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, or if we undergo an ownership change in connection with or after this public offering, our ability to utilize NOLs could be limited by Section 382 of the Internal Revenue Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Internal Revenue Code. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. For these reasons, we may not be able to utilize a material portion of the NOLs reflected on our balance sheet, even if we attain profitability.

 

Loss of our government grant funding could impair our research and development efforts.

 

We have been awarded a $24.3 million “Integrated Bio-Refinery” grant from the U.S. Department of Energy (“DOE”). The terms of this grant require us to use the funds to leverage and expand our existing Emeryville, California, pilot plant and support laboratories to develop U.S.-based production capabilities for renewable fuels and chemicals derived from sweet sorghum. Under this grant, we would be required to fund an additional $10.5 million in cost sharing expenses. Generally, government grant agreements have fixed terms and

 

30


Table of Contents

may be terminated, modified or recovered by the granting agency under certain conditions. If the DOE later terminates its grant agreement with us, our U.S.-based research and development activities could be impaired, which could harm our business.

 

Our headquarters and other facilities are located in an active earthquake zone, and an earthquake or other types of natural disasters affecting us or our suppliers could cause resource shortages and disrupt and harm our results of operations.

 

We conduct our primary research and development operations in the San Francisco Bay Area in an active earthquake zone, and certain of our suppliers conduct their operations in the same region or in other locations that are susceptible to natural disasters. In addition, California and some of the locations where certain of our suppliers are located have experienced shortages of water, electric power and natural gas from time to time. The occurrence of a natural disaster, such as an earthquake, drought or flood, or localized extended outages of critical utilities or transportation systems, or any critical resource shortages, affecting us or our suppliers could cause a significant interruption in our business, damage or destroy our facilities, production equipment or inventory or those of our suppliers and cause us to incur significant costs or result in limitations on the availability of our raw materials, any of which could harm our business, financial condition and results of operations. The insurance we maintain against fires, earthquakes and other natural disasters may not be adequate to cover our losses in any particular case.

 

Risks Related to this Offering and Ownership of Our Common Stock

 

An active trading market for our common stock may not develop, and you may not be able to resell your shares at or above the initial public offering price.

 

Prior to this offering, there has been no public market for shares of our common stock. Although we will apply to have our common stock approved for quotation on a stock exchange, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock will be determined through negotiations between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after the offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell.

 

Our stock price may be volatile, and the market price of our common stock after this offering may drop below the price you pay.

 

The market price of our common stock could be subject to significant fluctuations after this offering and it may decline below the initial public offering price. Market prices for securities of early stage companies have historically been particularly volatile. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price. Such fluctuations could be in response to, among other things, the factors described in this “Risk Factors” section or elsewhere in this registration statement, or other factors, some of which are beyond our control, such as:

 

   

fluctuations in our financial results or outlook or those of companies perceived to be similar to us;

 

   

changes in estimates of our financial results or recommendations by securities analysts;

 

   

changes in market valuations of similar companies;

 

   

changes in the prices of commodities associated with our business such as sugar, ethanol and petroleum;

 

   

changes in our capital structure, such as future issuances of securities or the incurrence of debt;

 

   

announcements by us or our competitors of significant contracts, acquisitions or strategic alliances;

 

31


Table of Contents
   

regulatory developments in the U.S., Brazil, and/or other foreign countries;

 

   

litigation involving us, our general industry or both;

 

   

additions or departures of key personnel;

 

   

investors’ general perception of us; and

 

   

changes in general economic, industry and market conditions.

 

Furthermore, the stock markets have experienced price and volume fluctuations that have affected, and continue to affect, the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, political and market conditions, such as recessions, interest rate changes and international currency fluctuations, may negatively affect the market price of our common stock.

 

In the past, many companies that have experienced volatility in the market price of their stock have become subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

 

We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our results of operations.

 

As a public company, we will incur significant additional accounting, legal and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We also have incurred and will incur costs associated with corporate governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act, as well as rules implemented by the Securities and Exchange Commission and the exchange on which we list our common stock. The expenses incurred by public companies for reporting and corporate governance purposes have increased dramatically in recent years. We expect these rules and regulations to substantially increase our financial and legal compliance costs. We also expect that as we become a public company it will be more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage previously available. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers.

 

The concentration of our capital stock ownership with insiders upon the completion of this offering will limit your ability to influence corporate matters.

 

We anticipate that our executive officers, directors, current five percent or greater stockholders and entities affiliated with them will together beneficially own approximately     % of our common stock outstanding after this offering. This significant concentration of share ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with controlling stockholders. Also, these stockholders, acting together, will be able to control our management and affairs and matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may have the effect of delaying or preventing a change of control, including a merger, consolidation or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control, even if that change of control would benefit our other stockholders.

 

32


Table of Contents

A significant portion of our total outstanding shares may be sold into the public market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.

 

Sales of a substantial number of shares of our common stock in the public market could occur at any time after the expiration of the lock-up agreements described in the “Underwriters” and “Shares Eligible for Future Sale—Lock-Up Agreements” sections of this prospectus. These sales, or the market perception that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have              shares of common stock outstanding based on the number of shares outstanding as of December 31, 2009, and assuming the conversion of shares of Amyris Brasil held by investors into shares of our common stock and no exercise of outstanding options or warrants after December 31, 2009. This includes the              shares that we are selling in this offering, which may be resold in the public market immediately. The remaining 24,215,560 shares, or     % of our outstanding shares after this offering, are currently restricted as a result of securities laws or lock-up agreements but will be able to be sold, subject to any applicable volume limitations under federal securities laws, in the near future as set forth below:

 

   

         shares will be eligible for sale immediately upon completion of this offering; and

 

   

         shares will be eligible for sale upon the expiration of lock-up agreements, subject in some cases to volume and other restrictions of Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act.

 

The lock-up agreements expire 180 days after the date of this prospectus, except that the 180-day period may be extended in certain cases for up to 34 additional days under certain circumstances where we announce or pre-announce earnings or a material event occurs within approximately 17 days prior to, or approximately 16 days after, the termination of the 180-day period. The representatives of the underwriters may, in their sole discretion and at any time without notice, release all or any portion of the securities subject to lock-up agreements.

 

Following this offering, holders of              of the shares of our common stock not sold in this offering and holders of warrants to purchase an aggregate of              shares of common stock not sold in this offering will be entitled to rights with respect to the registration of these shares under the Securities Act. See “Description of Capital Stock—Registration Rights.” If we register their shares of common stock following the expiration of the lock-up agreements, these stockholders could sell those shares in the public market without being subject to the volume and other restrictions of Rule 144 and Rule 701.

 

After the closing of this offering, we intend to register approximately              shares of common stock that have been reserved for future issuance under our stock incentive plans. Of these shares,              shares will be eligible for sale upon the exercise of outstanding options that will be vested after the expiration of the lock-up agreements.

 

Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment.

 

The assumed initial public offering price of our common stock is substantially higher than the net tangible book value per share of our outstanding common stock immediately after this offering. Therefore, if you purchase our common stock in this offering, you will incur immediate dilution of approximately $              in net tangible book value per share from the price you paid. In addition, investors purchasing common stock in this offering will own only approximately     % of our shares outstanding after the offering even though they will have contributed     % of the total consideration received by us in connection with our sales of common stock. Moreover, we issued options and warrants in the past to acquire our stock at prices significantly below the assumed initial public offering price. As of December 31, 2009, 4,446,894 shares of common stock were issuable upon exercise of outstanding stock options with a weighted average exercise price of $2.87 per share. As of December 31, 2009, warrants to purchase 144,158 shares of common stock (assuming conversion of all shares of

 

33


Table of Contents

preferred stock into common stock as of December 31, 2009) were issuable upon exercise of outstanding warrants with a weighted average exercise price of $21.20 per share. To the extent that these outstanding options and warrants are ultimately exercised, you will incur further dilution. For a further description of the dilution that you will experience immediately after this offering, see the “Dilution” section of this prospectus.

 

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

 

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

 

Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that increase the value of your investment.

 

Our management will have broad discretion in the application of the net proceeds from this offering, and you will be relying on the judgment of our management regarding the application of these proceeds. Our management might not apply our net proceeds of this offering in ways that increase the value of your investment. We expect to use the net proceeds to us from this offering for working capital, and other general corporate purposes, which may in the future include expansion of production facilities, investments in, or acquisitions of, complementary businesses, joint ventures, partnerships, services or technologies. Our management might not be able to yield a significant return, if any, on any investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering.

 

After the completion of this offering, we do not expect to declare any dividends in the foreseeable future.

 

After the completion of this offering, we do not anticipate declaring any cash dividends to holders of our common stock in the foreseeable future. In addition, our equipment lease with TriplePoint Capital LLC and our letter of credit facility currently restrict our ability to pay dividends. Consequently, investors may need to rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment. Investors seeking cash dividends should not purchase our common stock.

 

Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.

 

Our amended and restated certificate of incorporation and our amended and restated bylaws to be effective upon the completion of this offering will contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:

 

   

staggered board of directors;

 

   

authorizing the board to issue, without stockholder approval, preferred stock with rights senior to those of our common stock;

 

   

authorizing the board to amend our bylaws and to fill board vacancies until the next annual meeting of the stockholders;

 

   

prohibiting stockholder action by written consent;

 

34


Table of Contents
   

limiting the liability of, and providing indemnification to, our directors and officers;

 

   

not authorizing our stockholders to call a special stockholder meeting;

 

   

eliminating the ability of our stockholders to call special meetings; and

 

   

requiring advance notification of stockholder nominations and proposals.

 

As a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law, which, subject to some exceptions, prohibits “business combinations” between a Delaware corporation and an “interested stockholder,” which is generally defined as a stockholder who becomes a beneficial owner of 15% or more of a Delaware corporation’s voting stock, for a three-year period following the date that the stockholder became an interested stockholder.

 

These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws to be effective upon the completion of this offering and under Delaware law could discourage potential takeover attempts, reduce the price that investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions. See “Description of Capital Stock—Preferred Stock” and “Description of Capital Stock—Antitakeover Provisions.”

 

35


Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains forward-looking statements. All statements, other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “continue” or other similar words.

 

These forward-looking statements are only predictions. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to materially differ from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We have described in the “Risk Factors” section and elsewhere in this prospectus the principal risks and uncertainties that we believe could cause actual results to differ from these forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as guarantees of future events.

 

In particular, forward looking statements in this prospectus include statements about:

 

   

achievement of advances in our technology platform, including yield;

 

   

target molecules we intend to produce from our synthetic biology platform;

 

   

the expected applications of our molecules and addressable markets;

 

   

the expected cost-competitiveness and relative performance attributes of our products;

 

   

timing of commercial sales of our products;

 

   

the acceptance and success of our capital light model for production of our products at sugar and ethanol mills;

 

   

the timing and capacity of manufacturing available to us, including from contract manufacturing partners, our joint venture with Usina São Martinho and sugar and ethanol mill owners;

 

   

government regulatory and industry certification approval and acceptance of our products and genetically modified microorganisms;

 

   

the availability of suitable and cost-competitive feedstock;

 

   

the commercial scale-up of our production;

 

   

our access to distribution infrastructure and services and chemical processing;

 

   

government policymaking and incentives relating to renewable fuels;

 

   

the future price and volatility of petroleum; and

 

   

our ability to manage operations in Brazil.

 

The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future or to conform these statements to actual results or revised expectations, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus.

 

This prospectus also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the statistical and other industry data generated by independent parties and contained in this prospectus and, accordingly, we cannot guarantee their accuracy or completeness. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors.”

 

36


Table of Contents

USE OF PROCEEDS

 

We estimate that our net proceeds from the sale of the common stock that we are offering will be approximately $             million, assuming an initial public offering price of $             per share, which is the midpoint of the price range listed on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A $1.00 increase (decrease) in the assumed initial public offering price of $             per share would increase (decrease) our net proceeds from this offering by approximately $             million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we estimate that our net proceeds will be approximately $              million after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

We expect to use the net proceeds from this offering for capital expenditures related to the establishment of production facilities, including capital expenditures related to the establishment of our joint venture production facility, working capital and general corporate purposes, including building engineering services capabilities to support sugar and ethanol mill adoption of our technology and growing our chemistry capabilities to accelerate customer use of our chemical products. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” for additional information about our anticipated use of cash resources. We may also use a portion of the net proceeds to expand our business through acquisitions of other companies, assets or technologies. However, at this time, we do not have any commitment to any specific acquisitions.

 

Some of the other principal purposes of this offering are to create a public market for our common stock, increase our visibility in the marketplace and provide liquidity to existing stockholders. A public market for our common stock will facilitate future access to public equity markets and enhance our ability to sell our common stock as a means of attracting and retaining key employees and as consideration for acquisitions.

 

We will have broad discretion in the way that we use the net proceeds of this offering. The amounts that we actually spend for the purposes described above may vary significantly and will depend, in part, on the timing and amount of our future revenues, our future expenses and any potential acquisitions that we may propose. Pending the uses of the net proceeds of this offering, as described above, we intend to invest the net proceeds in investment-grade, interest-bearing securities. See “Risk Factors-Risks Related to This Offering and Ownership of our Common Stock—Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that increase the value of your investment.”

 

DIVIDEND POLICY

 

We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings and do not expect to declare or pay any dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our Board of Directors and will depend on our financial condition, results of operations, capital requirements and other factors that our Board of Directors considers relevant. In addition, our equipment lease with TriplePoint Capital LLC and our letter of credit facility currently restrict our ability to pay dividends.

 

37


Table of Contents

CAPITALIZATION

 

The following table sets forth our cash and cash equivalents and capitalization as of December 31, 2009:

 

   

on an actual basis;

 

   

on a pro forma basis to reflect:

 

   

the conversion of all of our outstanding shares of convertible preferred stock into 18,790,244 shares of common stock upon the completion of this offering;

 

   

the conversion of 1,111,111 shares of Amyris Brasil held by third party investors in this subsidiary into 311,111 shares of our common stock at the completion of this offering;

 

   

the reclassification of the preferred stock warrant liability to common stock immediately prior to the completion of this offering; and

 

   

the reclassification of redeemable noncontrolling interest to common stock immediately prior to the completion of this offering;

 

   

on a pro forma basis as adjusted to reflect the pro forma adjustments described above and the sale by us of              shares of our common stock that we are offering at an assumed initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

Our capitalization following the closing of this offering will be adjusted based upon the actual initial public offering price and other terms of the offering determined at pricing. You should read the following table together with our Consolidated Financial Statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this prospectus.

 

     As of December 31, 2009
     Actual     Pro Forma     Pro Forma as
Adjusted
     (in thousands, except share and
per share data)

Cash, cash equivalents, short term investments and restricted cash

   $ 71,716      $ 71,716      $             
                      

Total indebtedness (1)

   $ 20,608      $ 20,608      $  
                      

Convertible preferred stock warrant liability

   $ 2,740      $      $  
                      

Convertible preferred stock—no par value: 21,080,641 shares authorized, 18,365,222 shares issued and outstanding, actual; shares authorized, issued and outstanding pro forma and pro forma as adjusted

     179,651            

Redeemable noncontrolling interest

     5,506            
                      

Stockholders’ Equity (Deficit):

      

Common stock—no par value: 33,000,000 shares authorized, 5,114,205 shares issued and outstanding actual; 33,000,000 authorized, 24,215,560 shares issued and outstanding pro forma;              authorized,              shares issued and outstanding pro forma as adjusted

     858        188,755     

Additional paid-in capital

     4,509        4,509     

Accumulated other comprehensive income

     1,336        1,336     

Accumulated deficit

     (120,448     (120,448  
                      

Total equity (deficit)

     (113,745     74,152     
                      

Total capitalization

   $ 94,760      $ 94,760      $  
                      

 

38


Table of Contents

 

  (1)   Total indebtedness includes an $8.3 million credit facility associated with our student loan auction rate securities holdings, $7.2 million in capital lease obligations, a $4.0 million note payable and a $1.0 million loan payable (See Note 5 and Note 6 to our Consolidated Financial Statements).

 

A $1.00 increase (decrease) in the assumed initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, working capital, total assets and total stockholders’ deficit by $             million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase of 1.0 million shares in the number of shares of common stock offered by us would increase each of cash and cash equivalents, working capital, total assets and total stockholders’ equity (deficit) by approximately $             million. Similarly, each decrease of 1.0 million shares in the number of shares offered by us would decrease each of cash and cash equivalents, working capital, total assets and total stockholders’ equity by approximately $             million. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering.

 

If the underwriters’ option to purchase additional shares were exercised in full, pro forma as adjusted cash, cash equivalents, common stock and additional paid-in capital, stockholders’ equity (deficit) and shares issued and outstanding as of December 31, 2009, would be $             million, $             million, $             million and $             million.

 

The table above does not include:

 

   

4,446,894 shares of common stock issuable upon the exercise of stock options outstanding as of December 31, 2009, at a weighted average exercise price of $2.87 per share;

 

   

144,158 shares of common stock issuable upon the exercise of outstanding warrants as of December 31, 2009, that will remain outstanding after the completion of this offering through various dates from one year from the effective date of this offering to March 2016, with a weighted average price of $21.20 per share;

 

   

50,000 shares of common stock subject to restricted stock units outstanding as of December 31, 2009;

 

   

             shares of common stock reserved for future issuance under our 2010 Equity Incentive Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Employee Benefit Plans”; and

 

   

             shares of common stock reserved for future issuance under our 2010 Employee Stock Purchase Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Employee Benefit Plans.”

 

39


Table of Contents

DILUTION

 

If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the net tangible book value per share of our common stock after this offering. As of December 31, 2009, our net tangible book value was $             million, or $             per share of common stock, and our pro forma net tangible book value was $             million, or $             per share of our common stock. Pro forma net tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by the total number of shares of our common stock outstanding, after giving effect to the conversion at the completion of this offering of shares of Amyris Brasil held by investors in that subsidiary, the automatic conversion of all of our outstanding convertible preferred stock into shares of common stock upon the completion of this offering and the reclassification of preferred stock warrant liability to common stock immediately prior to the completion of this offering.

 

After giving effect to the sale by us of              shares of our common stock in this offering at an assumed initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value as of December 31, 2009, would have been approximately $             million, or $             per share of our common stock. This amount represents an immediate increase in our pro forma net tangible book value of $             per share to our existing stockholders and an immediate dilution in our pro forma net tangible book value of $             per share to new investors purchasing shares of our common stock in this offering at the initial public offering price.

 

The following table illustrates this dilution on a per share basis:

 

Assumed initial public offering price per share

      $             

Pro forma net tangible book value per share as of December 31, 2009, before giving effect to this offering

      $  

Increase in pro forma net tangible book value per share attributable to new investors

      $  
       

Pro forma as adjusted net tangible book value per share after this offering

      $  
         

Dilution per share to investors in this offering

      $  
         

 

A $1.00 increase (decrease) in the initial public offering price of $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma net tangible book value per share after this offering by approximately $             and would increase (decrease) dilution per share to new investors by approximately $            , assuming that the number of shares offered by us, as listed on the cover page of this prospectus, remains the same. In addition, to the extent any outstanding options or warrants are exercised, new investors will experience further dilution.

 

If the underwriters exercise their over-allotment option in full, the pro forma as adjusted net tangible book value will increase to $             per share, representing an immediate increase to existing stockholders of $             per share and an immediate dilution of $             per share to new investors.

 

The following table summarizes, as of December 31, 2009, the number of shares purchased or to be purchased from us, the total consideration paid or to be paid to us, and the average price per share paid or to be paid to us by existing stockholders and new investors purchasing shares of our common stock in this offering at an assumed initial public offering price of $             per share before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows, new investors purchasing shares of our common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid.

 

40


Table of Contents
     Shares Purchased     Total Consideration     Average
Price

Per  Share
       Number    Percent     Amount    Percent    
     (In thousands other than percentages and
per share data)

Existing stockholders

             $                        $             

New investors

            
                              

Total

      100   $      100  
                          

 

A $1.00 increase (decrease) in the assumed initial public offering price of $             per share would increase (decrease) the total consideration paid to us by new investors by $             million and increase (decrease) the percent of total consideration paid to us by new investors by     % assuming that the number of shares offered by us, as listed on the cover page of this prospectus, remains the same.

 

The number of shares purchased from us by existing stockholders is based on our common stock outstanding as of December 31, 2009, after giving effect to the conversion of all of our outstanding convertible preferred stock into common stock and the conversion of shares of Amyris Brasil held by third party investors in this subsidiary into shares of our common stock upon the completion of this offering. This number excludes:

 

   

4,446,894 shares of common stock issuable upon the exercise of stock options outstanding as of December 31, 2009, at a weighted average exercise price of $2.87 per share;

 

   

144,158 shares of common stock issuable upon the exercise of outstanding warrants as of December 31, 2009, that will remain outstanding after the completion of this offering through various dates from one year from the effective date of this offering to March 2016, with a weighted average price of $21.20 per share;

 

   

50,000 shares of common stock subject to restricted stock units outstanding as of December 31, 2009;

 

   

             shares of common stock reserved for future issuance under our 2010 Equity Incentive Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management— Employee Benefit Plans;” and

 

   

             shares of common stock reserved for future issuance under our 2010 Employee Stock Purchase Plan, which will become effective upon the completion of this offering and will contain provisions that will automatically increase its share reserve each year, as more fully described in “Management—Employee Benefit Plans.”

 

If all our outstanding stock options and outstanding warrants had been exercised as of December 31, 2009, our pro forma net tangible book value as of December 31, 2009, would have been approximately $             million or $             per share of our common stock, and the pro forma net tangible book value after giving effect to this offering would have been $             per share, representing dilution in our pro forma net tangible book value per share to new investors of $            .

 

41


Table of Contents

SELECTED CONSOLIDATED FINANCIAL DATA

 

The selected consolidated statement of operations data for the years ended December 31, 2007, 2008 and 2009 and the selected consolidated balance sheet data as of December 31, 2008 and 2009 are derived from our audited Consolidated Financial Statements, appearing elsewhere in this prospectus. The selected consolidated statement of operations data for 2005 and 2006 and the selected consolidated balance sheet data as of December 31, 2005, 2006 and 2007 have been derived from our audited consolidated financial statements, which are not included in this prospectus. The historical results presented below are not necessarily indicative of financial results to be achieved in future periods. You should read the following selected consolidated financial data in conjunction with “Management’s Discussion Analysis of Financial Condition and Results of Operations” and our Consolidated Financial Statements appearing elsewhere in this prospectus.

 

    Years Ended December 31,  
    2005     2006     2007     2008     2009  
    (in thousands, except share and per share amounts)  

Consolidated Statement of Operations Data:

         

Revenues

         

Product sales

  $      $      $      $ 10,680      $ 61,689   

Collaborative research services

    2,235        3,804        6,046        3,008        2,919   

Government grants

    255        198        138        204          
                                       

Total revenues

    2,490        4,002        6,184        13,892        64,608   
                                       

Cost and operating expenses

         

Cost of product sales

                         10,364        60,428   

Research and development (1)

    1,866        3,633        8,662        30,306        38,263   

Sales, general and administrative (1)

    610        2,787        10,522        16,622        23,558   

Restructuring and asset impairment charges

                                5,768   
                                       

Total cost and operating expenses

    2,476        6,420        19,184        57,292        128,017   
                                       

Income (loss) from operations

    14        (2,418     (13,000     (43,400     (63,409

Other income (expense)

         

Interest income

    50        213        1,178        1,378        448   

Interest expense

                  (28     (377     (1,218

Other income (expense), net

           36        76        (144     (621
                                       

Total other income (expense)

    50        249        1,226        857        (1,391
                                       

Income (loss) before income taxes

    64        (2,169     (11,774     (42,543     (64,800

Provision for (benefit from) income taxes

    556        (354            (207       
                                       

Net loss

    (492     (1,815     (11,774     (42,336     (64,800

Loss attributable to noncontrolling interest

                         (472     (341
                                       

Net loss attributable to Amyris Biotechnologies, Inc. stockholders

  $ (492   $ (1,815   $ (11,774   $ (41,864   $ (64,459
                                       

Net loss per share of common stock attributable to Amyris Biotechnologies, Inc. stockholders, basic and diluted (2)

  $ (0.25   $ (0.60   $ (3.28   $ (9.91   $ (13.56
                                       

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted (2)

    1,954,900        3,049,761        3,592,932        4,223,533        4,753,085   
                                       

Pro forma net loss per share of common stock attributable to Amyris Biotechnologies, Inc. stockholders, basic and diluted (unaudited) (2)

          $ (3.16
               

Weighted-average shares of common stock outstanding used in computing pro forma net loss per share of common stock, basic and diluted (unaudited) (2)

            20,279,433   
               

 

42


Table of Contents

 

     As of December 31,  
     2005     2006     2007     2008     2009  
     (in thousands)  

Consolidated Balance Sheet Data:

          

Cash, cash equivalents, investments and restricted cash

   $ 3,767      $ 6,706      $ 45,862      $ 52,888      $ 71,716   

Working capital (deficit)

     (1,222     2,287        31,045        32,356        51,062   

Total assets

     4,678        8,580        50,889        98,823        122,159   

Total indebtedness (3)

                   655        6,747        20,608   

Convertible preferred stock warrant liability

                          2,132        2,740   

Convertible preferred stock

            6,397        58,126        121,436        179,651   

Redeemable noncontrolling interest

                                 5,506   

Total deficit

   $ (521   $ (2,301   $ (13,301   $ (52,143   $ (113,745

 

  (1)   Includes stock-based compensation expense.
  (2)   See Note 2 to our Consolidated Financial Statements for an explanation of the method used to calculate basic and diluted net loss per share of common stock, the pro forma basic and diluted net loss per share of common stock and the weighted-average number of shares used in computation of the per share amounts.
  (3)   Total indebtedness includes an $8.3 million credit facility associated with our student loan auction rate securities holdings, $7.2 million in capital lease obligations, a $4.0 million note payable and a $1.0 million loan payable (See Note 5 and Note 6 to our Consolidated Financial Statements).

 

43


Table of Contents

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the other financial information appearing elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors, including those discussed below and those discussed in the section entitled “Risk Factors” included elsewhere in this prospectus.

 

Overview

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. We genetically modify microorganisms, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of molecules. Our first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications such as detergents, cosmetics, perfumes and industrial lubricants, to transportation fuels such as diesel. We have focused our research and development, business development and production operations on the use of Brazilian sugarcane as our primary feedstock for the foreseeable future, because it is abundant, low cost and relatively price stable. We intend to secure access to this feedstock and expand our production capacity in a “capital light” manner. Under this approach, we expect to work with Brazilian sugar and ethanol producers to build a new, “bolt-on” facility adjacent to their existing mills instead of building new “greenfield” facilities, thereby reducing the capital required to establish and scale our production. Our first such arrangement is our joint venture with Usina São Martinho, one of the largest sugar and ethanol producers in Brazil.

 

We commenced research activities in January 2005 to build our platform, focusing on development of microbial strains to provide an alternative, lower cost source of artemisinic acid, a precursor of artemisinin, an anti-malarial therapeutic. This work was funded by a five-year grant awarded by the Bill & Melinda Gates Foundation to the Institute for OneWorld Health to support a research collaboration with Amyris and the University of California, Berkeley. In 2008, we entered into an agreement to license our artemisinic acid-producing yeast strains to sanofi-aventis on a royalty free basis for the purpose of manufacturing and commercializing artemisinin-based drugs for the treatment of malaria.

 

As we embark on new research programs, we first identify the molecule that we want to produce based on its market opportunity, and then engineer yeast strains capable of producing the target molecule. Thereafter, we focus on improving the yeast strains so they can produce the desired end product at commercially viable levels. We gauge our production efficiency by measuring a number of production metrics, of which “yield” is the primary metric. Yield quantifies the amount of target molecule produced from a given amount of sugar. To improve yield, our strain development and screening technology utilizes proprietary high-throughput processes to create and test as many as 1,000 yeast strains a day in order to select those yeast strains which are most efficient.

 

In 2006, leveraging our research on artemisinin, we launched formal research programs to produce farnesene, a molecule which can be used as a renewable chemical ingredient for consumer and industrial products and as a fuel. We believe that we will be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. We will continue to seek to improve our yield of farnesene and other molecules in order to enter additional markets profitably and improve our production economics.

 

One of our priorities is to evolve our production processes to transition from laboratory to commercial scale. To do this, we expect to initiate commercial production through the use of contract manufacturing as we complete our joint venture facility with Usina São Martinho which will be located in Brazil. While our yeast

 

44


Table of Contents

strains can use a wide variety of feedstocks, we are focusing on the use of sugarcane as our predominant feedstock and seeking to leverage Brazil’s existing ethanol infrastructure. In 2008, we established a base of operations in Brazil to move our strains from the laboratory toward commercial production and to oversee Brazilian commercialization of our products. Key milestones to date include:

 

   

In March 2008, we established our subsidiary Amyris Brasil S.A. in Campinas, Brazil, and opened laboratories at this site in August 2008.

 

   

In November 2008, we began operation of our first 300 liter scale pilot plant, in Emeryville, California. This facility enables us to test our strains at a significantly larger volume than the two liter scale we use in our laboratories, which is the first step in our scale-up process.

 

   

In June 2009, we began operation of our second 300 liter scale pilot plant in Campinas, Brazil. This pilot plant is a replica of our plant in Emeryville, which enables us to control transfer of our strains and processes to Brazil, where we can test them with commercial production feedstock.

 

   

In June 2009, through the use of a contract manufacturer, we completed our first initial production runs in 60,000 liter scale fermentors to evaluate results at a larger scale and to produce renewable diesel fuel to support our certification efforts.

 

   

In September 2009, we began operation of our 5,000 liter scale demonstration facility in Campinas, Brazil. We refine large scale equipment design and processes at this scale, the final step before transitioning to a full commercial facility.

 

   

In January 2010, we ordered four 600,000 liter commercial plant fermentors for the purpose of commencing commercial production in the second quarter of 2012 in our Usina São Martinho joint venture facility.

 

   

In February 2010, we received approval from the Brazilian government to use one of our current yeast strains in broad commercial production and we will seek to amend this approval from time to time as we develop new strains.

 

   

In April 2010, we signed a definitive agreement with Usina São Martinho to establish a joint venture for our first production facility in Brazil.

 

We expect to commercialize our products through the use of contract manufacturing in 2011. Starting in the second quarter of 2012, we intend to transition this production to our joint venture with Usina São Martinho. We have also provided Usina São Martinho with an option to produce our products at a second production facility, and we have non-binding letters of intent in place with three leading Brazilian sugar and ethanol producers, Bunge Limited, Cosan and Açúcar Guarani, a subsidiary of Tereos, to establish production at certain of their existing mills.

 

We intend to work with Brazilian sugar and ethanol producers to increase our production on a capital light basis as follows:

 

   

We would provide mill owners with design and engineering services to build the facility and with access to our yeast strains and processes;

 

   

The mill owners would make a substantial contribution of capital to enable construction of our bolt-on facility or make other substantial operating contributions;

 

   

We would enter into agreements to purchase the products produced and retain exclusive distribution and sales rights; and

 

   

We plan to compensate the mill owner for the feedstock consumed in the production of our products in an amount equal to the revenue they would have realized had they instead produced their traditional products, plus any incremental costs incurred in the production of our products over their usual production costs. Further, as we sell our products, we expect to share a portion of the higher gross margin we expect to realize from the sale of our renewable products with these mill owners.

 

45


Table of Contents

We believe that our capital light approach should enable us to increase production capacity without needing to invest the amount of upfront capital that would be required for the construction of new greenfield facilities.

 

To build the capabilities we will need to distribute our renewable fuels products in the U.S., we have established our subsidiary Amyris Fuels, LLC. Amyris Fuels currently generates revenues by selling third party ethanol to wholesale customers through a network of 13 storage terminals in the southeastern U.S., including in Georgia, North Carolina, South Carolina, Virginia and Tennessee.

 

To date we have not generated any revenues from the commercialization of our own products. Our revenues have come from ethanol sales by Amyris Fuels, which accounted for 77% and 95% of our total revenues in 2008 and 2009, respectively, and from collaborative research services and grants.

 

We continue to experience significant losses as we invest in research and development, commercial facility design, sales and marketing and administrative infrastructure. As of December 31, 2009, we had an accumulated deficit of $120.4 million . We incurred net losses attributable to Amyris shareholders of $11.8 million, $41.9 million and $64.5 million in 2007, 2008 and 2009, respectively.

 

Recent Developments

 

On April 14, 2010, we entered into a joint venture with Usina São Martinho to build a new production facility for the production of our products at the Usina São Martinho sugar and ethanol mill located in São Paulo state. The joint venture, SMA Indústria Química S.A., was created to build the first facility in Brazil fully dedicated to the production of Amyris renewable products. The new company will be located at Usina São Martinho in Pradópolis, São Paulo state.

 

The joint venture will be managed by a three-member executive committee, of which we appoint two members, including the plant director who is the most senior executive. The executive committee will be responsible for managing the construction and operation of the production facility. The joint venture will be governed by a four-member board of directors, of which we and Usina São Martinho will each appoint two members. The board of directors has certain protective rights which include final approval of the engineering designs and project work plan developed and recommended by the executive committee.

 

The construction of the facility at Usina São Martinho will be the first project of this nature that we will design and manage. We expect the construction costs of the new facility to total between $80 million to $100 million. Under the terms of our joint venture agreement, construction of the production facility will take place in two phases. Phase I is designed to construct a facility capable of producing farnesene from one million tons of crushed sugarcane, and Phase II will expand that capacity to two million tons. Within one year of the commencement of Phase I commercial operations, Usina São Martinho will be required to reimburse us for half of the cost of Phase I, up to a cap of 30.9 million reais ($17.5 million based on exchange rate at April 2, 2010). Thereafter, Usina São Martinho will co-fund the construction of Phase II and, as necessary, make a final payment at completion such that their total contribution will be 61.8 million reais ($35.0 million based on exchange rate at April 2, 2010).

 

Post commercialization, Amyris will market and distribute the Amyris renewable products. São Martinho will sell feedstock and provide certain other services to the joint venture. The cost of the feedstock to the joint venture is a price that is based on the average return that Usina São Martinho could receive from the production of its current products, sugar and ethanol. We are required to purchase the output of the joint venture for the first four years at a price that guarantees the return of Usina São Martinho’s investment plus a fixed interest rate.

 

Under the terms of the joint venture agreements, if Amyris Brasil becomes controlled, directly or indirectly, by a competitor of Usina São Martinho, then Usina São Martinho has the right to acquire our interest in the joint venture. If Usina São Martinho becomes controlled, directly or indirectly, by a competitor of ours, then we have the right to sell our interest in the joint venture to Usina São Martinho. In either case, the purchase price shall be

 

46


Table of Contents

determined in accordance with the joint venture agreements, and we would continue to have the obligation to acquire products produced by the joint venture for the remainder of the term of the supply agreement then in effect even though we would no longer be involved in the joint venture’s management.

 

Financial Operations Overview

 

Revenues

 

To date, our revenues have consisted of sales of ethanol, collaborative research services and government grants.

 

   

Product sales.  Product sales are derived from sales of ethanol purchased from third parties under short-term agreements at prevailing market prices.

 

   

Collaborative research services . Collaborative research service revenues generally consist of payments for research and development activities for specific projects. These payments may include a combination of cost plus reimbursement, up-front payments or milestone payments.

 

   

Government grants. Government grant revenues consist of payments from government entities. The terms of these grants generally provide us with reimbursement for research and development services and certain types of capital expenditures over a contractually defined period.

 

Ethanol sales by Amyris Fuels accounted for 77% and 95% of our total revenues in 2008 and 2009, respectively. The balance of our revenues has come from collaborative research services and grants. Prior to commercialization of our products, we expect to increase revenues from grants and collaborations. We expect to receive approximately $24.3 million in funding for 2010 through 2012 under a grant from the DOE. Under this grant, we would be required to fund an additional $10.5 million in cost sharing expenses. We expect revenues from the sale of our renewable products to comprise an increasing portion of our total revenues.

 

We expect to commercialize our renewable products starting in 2011. We anticipate that our revenues from sales of our renewable products may be significantly lower in the first quarter of each year, as we expect to produce and sell the majority of our products during the sugarcane harvesting period, which typically begins in April or May and ends in November or December in the region of Brazil where we intend to locate the majority of our production capacity.

 

Cost and Operating Expenses

 

Cost and operating expenses consist of cost of product sales, research and development expenses, sales, general and administrative expenses and restructuring and asset impairment charges. Cost of product sales and personnel-related expenses comprise the most significant components of these expenses. We expect to continue to hire new employees, particularly in process development and manufacturing and general and administration in order to support our anticipated growth.

 

Cost of Product Sales. Our cost of product sales consists primarily of cost of purchased ethanol products, terminal fees paid for storage and handling, transportation costs between terminals, product losses and changes in the fair value of the derivative contracts used for hedging the price volatility of ethanol. To date gross margins on product sales have been nominal given the relatively high cost of ethanol compared to the price at which ethanol is sold. We expect gross margins to improve once we are producing through the joint venture with Usina São Martinho and additional sugar and ethanol mills. We expect lower margins on products produced by contract manufacturers than on products produced by our joint venture or by sugar and ethanol mills with whom we are partnering. In the future, gross margins may vary depending on the mix of specialty chemicals and renewable fuels that we produce. We expect that the cost of our products will be comprised primarily of the cost of the products paid to the mill owners or the contract manufacturer and, if applicable, chemical finishing and distribution costs.

 

47


Table of Contents

Research and Development.  Research and development expenses consist primarily of expenses for personnel engaged in the development of new products, the expansion of product applications and the improvement in yield. These expenses also consist of facilities costs and other related overhead and lab materials. We expense all of our research and development costs as they are incurred. In the near term, we expect to hire additional employees, as well as incur contract-related expenses as we continue to invest in the development of our products. Accordingly, we expect that our research and development expenses will continue to increase.

 

Sales, General and Administrative. Sales, general and administrative expenses consist primarily of personnel-related expenses related to our executive, legal, finance, human resource and information technology functions, as well as fees for professional services and allocated facility overhead expenses. These expenses also include costs related to our sales function, including marketing programs and other allocated costs. Professional services consist principally of external legal, accounting, tax, audit and other consulting services. We expect sales, general and administrative expenses to increase as we incur additional costs related to operating as a publicly-traded company, including increased legal fees, accounting, costs of compliance with securities, corporate governance and other regulations, investor relations expenses and higher insurance premiums, particularly those related to director and officer insurance. In addition, we expect to incur additional costs as we hire personnel and enhance our infrastructure to support the anticipated growth of our business.

 

Restructuring and Asset Impairment Charges. Restructuring and asset impairment charges consist primarily of non-cash charges relating to the consolidation of our headquarters in a single facility in Emeryville, California, and asset impairment charges related to the vacated facility.

 

Other Income (Expense), Net

 

Interest Income.  Interest income consists primarily of interest income earned on investments and cash balances. Our interest income will vary each reporting period depending on our average investment balances during the period and market interest rates. We expect interest income to fluctuate in the future with changes in average investment balances and market interest rates.

 

Interest Expense.  We recognize interest expense on all of our capital leases, loans payable and debt obligations. We expect interest expense to fluctuate in the future with changes in our debt obligations.

 

Other Income (Expense), Net.  Other income (expense), net consists primarily of the change in the fair value of our convertible preferred stock warrants, change in the fair value of our auction rate securities (“ARS”) and our rights to sell our ARS. Our outstanding convertible preferred stock warrants are classified as a liability and the change in the fair value of these warrants will vary based on multiple factors, but will generally increase if the fair value of underlying stock increases. We will continue to record adjustments to the fair value of the warrants until they are exercised, converted into warrants to purchase common stock or expire, at which time the warrants will no longer be remeasured at each balance sheet date and the then-current aggregate fair value of these warrants will be reclassified from liabilities to common stock and we will cease to record any related periodic fair value adjustments.

 

Income Taxes

 

Provision for (Benefit from) Income Taxes.  Since inception, we have incurred net losses and have not recorded any U.S. federal and state and non-U.S. income tax provisions, with limited exceptions in several years, since the tax benefits of our net losses have been offset by valuation allowances.

 

48


Table of Contents

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates and assumptions on historical experience and on various other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The results of our analysis form the basis for making assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

 

We believe the following critical accounting policies involve significant areas of management’s judgments and estimates in the preparation of our financial statements.

 

Revenue Recognition

 

We currently recognize revenues from the sale of ethanol, the delivery of collaborative research services and from government grants. Revenues are recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable and collectability is reasonably assured.

 

If sales arrangements contain multiple elements, we evaluate whether the components of each arrangement represent separate units of accounting. We have determined that all of our revenue arrangements should be accounted for as a single unit of accounting. Application of the standard requires subjective determination and requires management to make judgments about the fair values of each individual element and whether it is separable from other aspects of the contractual relationship.

 

For each source of revenues, we apply the above revenue recognition criteria in the following manner:

 

Product Sales

 

We sell ethanol under short-term agreements and in spot transactions at prevailing market prices. Revenues are recognized, net of discounts and allowances, once passage of title and risk of loss have occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met.

 

Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of product revenues. Such charges were not significant in any of the periods presented.

 

Collaborative Research Services

 

Revenues from collaborative research services are recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, we recognize revenues using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenues are recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenues are recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenues are recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured.

 

49


Table of Contents

Government Grants

 

Government grants are made pursuant to agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding.

 

Impairment of Long-Lived Assets

 

We assess impairment of long-lived assets, which include property and equipment, on at least an annual basis and test long-lived assets for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to, significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; or expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

 

Recoverability is assessed based on the fair value of the asset, which is calculated as the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized in the consolidated statements of operations when the carrying amount is determined to be not recoverable and exceeds fair value, which is determined on a discounted cash flow basis.

 

We make estimates and judgments about future undiscounted cash flows and fair values. Although our cash flow forecasts are based on assumptions that are consistent with our plans, there is significant exercise of judgment involved in determining the cash flow attributable to a long-lived asset over its estimated remaining useful life. Our estimates of anticipated cash flows could be reduced significantly in the future. As a result, the carrying amounts of our long-lived assets could be reduced through impairment charges in the future.

 

Convertible Preferred Stock Warrants

 

Freestanding warrants to purchase shares of our convertible preferred stock are classified as liabilities on our consolidated balance sheets at fair value because the warrants may conditionally obligate us to redeem the underlying convertible preferred stock at some point in the future. The warrants are subject to remeasurement at each balance sheet date, and any change in fair value is recognized as a component of other income (expense), net in the consolidated statements of operations. We estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option pricing model. We use a number of assumptions to estimate the fair value including the remaining contractual terms of the warrant, risk-free interest rates and expected dividend yield and expected volatility of the price of the underlying common stock. These assumptions are highly judgmental and could differ significantly in the future.

 

For 2007, 2008 and 2009, we recorded charges of $0, $0.1 million and $0.4 million through other income (expense), net to reflect the change in the fair value of the warrants.

 

We will continue to record adjustments to the fair value of the warrants until they are exercised, converted into warrants to purchase common stock or expire, at which time the warrants will no longer be remeasured at each balance sheet date. At that time, the then-current aggregate fair value of these warrants will be reclassified from liabilities to common stock and we will cease to record any related periodic fair value adjustments.

 

50


Table of Contents

Stock-Based Compensation

 

Our stock-based compensation expense is as follows:

 

     Years Ended December 31,
     2007    2008    2009
     (Dollars in thousands)

Research and development

   $ 117    $ 632    $ 773

Sales, general and administrative

     429      1,395      2,526
                    

Total stock-based compensation expense

   $ 546    $ 2,027    $ 3,299
                    

 

We recognize compensation expense related to share-based transactions, including the awarding of employee stock options, based on the grant date estimated fair value. We amortize the fair value of the employee stock options on a straight-line basis over the requisite service period of the award, which is generally the vesting period.

 

In future periods, our stock-based compensation expense is expected to increase as a result of our existing unrecognized stock-based compensation still to be recognized and as we issue additional stock-based awards in order to attract and retain employees and nonemployee consultants.

 

Significant Factors, Assumptions and Methodologies Used In Determining Fair Value

 

We utilize the Black-Scholes option pricing model to estimate the fair value of our share-based payment awards. The Black-Scholes option pricing model requires inputs such as the expected term of the grant, expected volatility and risk-free interest rate. Further, the forfeiture rate also affects the amount of aggregate compensation that we are required to record as an expense. These inputs are subjective and generally require significant judgment.

 

The fair value of employee stock options was estimated for 2007, 2008 and 2009 using the following weighted-average assumptions:

 

     Years Ended December 31,
     2007   2008      2009

Expected dividend yield

   0%   0%      0%

Risk-free interest rate

  

3.9%-4.7%

  3.2%      2.8%

Expected term (in years)

   6.0   6.0      6.0

Expected volatility

   70%   70%      97%

 

Our expected term is derived from a comparable group of publicly listed companies that has a similar industry, life cycle, revenue and market capitalization profile.

 

Our expected volatility is derived from the historical volatilities of several unrelated public companies within our industry over a period equal to the expected term of our options because we do not have any trading history to use for calculating the volatility of our own common stock. We based our analysis of expected volatility on reported data for comparable companies that issued options with substantially similar terms using an average of the historical volatility measures of this group of comparable companies.

 

Our risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to each option’s expected term.

 

Our expected dividend yield was assumed to be zero as we have not paid, and do not anticipate paying, cash dividends on our shares of common stock.

 

51


Table of Contents

We estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover and other factors. Quarterly changes in the estimated forfeiture rate can have a significant effect on reported stock-based compensation expense, as the cumulative effect of adjusting the rate for all expense amortization is recognized in the period the forfeiture estimate is changed. If a revised forfeiture rate is higher than the previously estimated forfeiture rate, an adjustment is made that will result in a decrease to the stock-based compensation expense recognized in the consolidated financial statements. If a revised forfeiture rate is lower than the previously estimated forfeiture rate, an adjustment is made that will result in an increase to the stock-based compensation expense recognized in the consolidated financial statements.

 

We will continue to use judgment in evaluating the expected term, volatility and forfeiture rate related to our own stock-based compensation on a prospective basis and incorporating these factors into the Black-Scholes option pricing model.

 

Each of these inputs is subjective and generally requires significant management and director judgment to determine. If, in the future, we determine that another method for calculating the fair value of our stock options is more reasonable, or if another method for calculating these input assumptions is prescribed by authoritative guidance, and, therefore, should be used to estimate expected volatility or expected term, the fair value calculated for our employee stock options could change significantly. Higher volatility and longer expected terms generally result in an increase to stock-based compensation expense determined at the date of grant.

 

The following table summarizes the options granted from January 1, 2008, through the date of this prospectus:

 

Grant Date

   Number of Options
Granted
   Exercise Price
Per Share
   Estimated Fair Value
Per Share
    Intrinsic Value
Per Share

January 2, 2008

   51,700    $ 3.93    $ 4.26   $ 0.33

February 1, 2008

   103,900      3.93      4.35     0.42

February 27, 2008

   210,000      3.93      4.43     0.50

March 7, 2008

   49,000      3.93      4.58     0.65

April 1, 2008

   285,970      3.93      5.08     1.15

May 7, 2008

   113,500      3.93      5.80     1.87

June 2, 2008

   135,500      3.93      6.33     2.40

August 25, 2008

   279,979      3.93      7.95     4.02

September 15, 2008

   60,000      3.93      8.36     4.43

September 14, 2009

   965,153      4.31      4.31       

October 27, 2009

   144,400      4.31      4.31       

January 7, 2010

   1,178,810      9.32      9.32       

March 19, 2010

   236,500      14.28      14.28       

 

  *   We reassessed the fair value of our common stock subsequent to the grant date

 

All options granted by our board of directors on the dates noted above were intended to be exercisable at the fair value of our stock based on information known at that time. For the purposes of recording stock-based compensation expense, we reviewed the historical pattern of our common stock, and subsequently reassessed the fair value of our stock for the options granted from January 2, 2008, through September 15, 2008.

 

52


Table of Contents

The fair values of the common stock underlying our stock options have historically been determined by our Board of Directors with input from management. In the absence of a public trading market for our common stock, our Board has determined the fair value of the common stock utilizing methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation , (referred to herein as the “AICPA Practice Guide”). In addition, our Board of Directors considered numerous objective and subjective factors including:

 

   

the prices for our convertible preferred stock sold to outside investors in arm’s-length transactions;

 

   

the prices of our common stock sold to investors in arm’s-length transactions;

 

   

rights, preferences and privileges of that convertible preferred stock relative to those of our common stock;

 

   

valuations using the methodologies described below;

 

   

actual operating and financial performance based on management’s estimates;

 

   

the execution of strategic and development agreements;

 

   

the hiring of key personnel;

 

   

status of product development;

 

   

the risks inherent in the development and expansion of our products and services;

 

   

our stage of development and revenue growth;

 

   

achievement of various product certifications;

 

   

the lack of an active public market for our common and convertible preferred stock;

 

   

the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given prevailing market conditions and the nature and history of our business;

 

   

the performance of similarly-situated companies in our industry;

 

   

trends in the renewable chemicals and fuels industries;

 

   

industry information such as market growth and volume; and

 

   

macro-economic events.

 

Our Board of Directors considered common stock valuations performed as of September 16, 2008, August 7, 2009, December 29, 2009, and March 9, 2010, in determining the grant date fair value of common stock. Using these valuations, and the other factors described above, our Board of Directors made the following estimates of fair value of our common stock.

 

Valuation Date

   Fair Value Per Share

September 16, 2008

   $ 8.38

August 7, 2009

     4.31

December 29, 2009

     9.32

March 9, 2010

     14.28

 

The valuations that our Board of Directors considered in determining the fair value of our common stock from September 2008 through October 2009 were based on the estimated aggregate enterprise value at the valuation date using the implied equity value from our convertible preferred stock financings, as the probability of a sale or merger occurring in the foreseeable future were deemed to be highly uncertain. In order to arrive at the fair value of our common stock, the indicated enterprise value of our company calculated at the valuation date was allocated to the shares of convertible preferred stock and the warrants to purchase convertible preferred

 

53


Table of Contents

stock, and shares of common stock and the options to purchase common stock using an option pricing methodology. The option pricing method treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under this method, the common stock has value only if the funds available for distribution to shareholders exceed the value of the liquidation preference at the time of a liquidity event, such as a strategic sale, merger or initial public offering, assuming the enterprise has funds available to make a liquidation preference meaningful and collectible by the holders of preferred stock. The common stock is modeled as a call option on the underlying equity value at a predetermined exercise price. In the model, the exercise price is based on a comparison with the total equity value rather than, as in the case of a regular call option, a comparison with a per share stock price. Thus, common stock is considered to be a call option with a claim on the enterprise at an exercise price equal to the remaining value immediately after the preferred stock is liquidated. The option pricing method uses the Black-Scholes option pricing model to price the call options. This model defines the securities’ fair values as functions of the current fair value of a company and uses assumptions such as the anticipated timing of a potential liquidity event and the estimated volatility of the equity securities. The anticipated timing of a liquidity event utilized in these valuations was based on then-current plans and estimates of our Board of Directors and management regarding a liquidity event. The aggregate value of the common stock derived from the option pricing method was then divided by the number of shares of common stock outstanding to arrive at the per share value. A discount for lack of marketability was applied to reflect the increased risk arising from the inability to readily sell the shares. This approach is consistent with the methods outlined in the AICPA Practice Guide.

 

The common stock valuation as of September 16, 2008, was performed following the commencement of sale of shares of our Series B-1 preferred stock sold during the period from February 2008 to January 2009 at a price of $25.26 per share to several venture capital and private equity firms. The price per share for the Series B-1 shares and the terms of the transactions were the result of negotiations between us and the Series B-1 investors.

 

The common stock valuation as of August 7, 2009, was performed following the commencement of our sale of shares of our Series C preferred stock in July 2009 at a price of $12.46 per share to several venture capital and private equity firms. The price per share for the Series C shares and the terms of the transactions were the result of negotiations between us and the Series C investors.

 

Commencing in December 2009, the valuations that our Board of Directors considered in determining the fair value of our common stock were based on the market approach and the income approach to estimate our aggregate enterprise value at each valuation date. The market approach measures the value of a company through the analysis of recent sales of comparable companies. Consideration is given to the financial condition and operating performance of the company being valued relative to those of publicly traded companies operating in the same or similar lines of business. When choosing the comparable companies to be used for the market approach, we focused on companies in our industry. Some of the specific criteria used to select comparable companies within this industry include the business description, business size, projected growth, financial condition and historical earnings. The income approach measures the value of a company as the present value of its future economic benefits by applying an appropriate risk-adjusted discount rate to expected cash flows, based on forecasted revenues and costs. We prepared a financial forecast for each valuation to be used in the computation of the enterprise value for both the market approach and the income approach. The financial forecasts took into account our past experience and future expectations. The risks associated with achieving these forecasts were assessed in selecting the appropriate discount rate.

 

These contemporaneous valuations used two equity allocation scenarios to derive our common stock fair value as follows: (i) a sale or merger scenario and (ii) an initial public offering scenario. Under both scenarios, we used an options-based methodology for allocating the estimated aggregate value to each of our securities using the Black-Scholes option-pricing model. We also considered the price per share of common stock established in recent transactions among our shareholders. Each of the aggregate values of the common stock derived from the two option pricing models was then divided by the number of shares of common stock

 

54


Table of Contents

outstanding to arrive at a per share value. A discount for lack of marketability was applied to reflect the increased risk arising from the inability to readily sell the shares.

 

There is inherent uncertainty in these estimates and if we had made different assumptions than those described above, the amount of our stock-based compensation expense, net loss and net loss per share amounts could have been significantly different.

 

Discussion of Specific Valuation Inputs

 

We granted stock options in 2008, 2009 and 2010 with exercise prices between $3.93 and $14.28 per share. No single event caused the valuation of our common stock to increase or decrease from January 2008 to April 2010; rather, it has been a combination of the following factors that led to the changes in the fair value of the underlying common stock:

 

January to March 2008: In January 2008, we appointed a Chief Financial Officer. In February 2008, we closed the first round of our Series B-1 convertible preferred stock financing, at a price of $25.26 per share. In March 2008, we announced a development agreement for artemisinin with One World Health and sanofi-aventis. In March 2008 we also established our subsidiary Amyris Brasil S.A. in Campinas, Brazil. For option grants from January to March 2008, the Board of Directors deemed the fair market value of the common stock to be $3.93. However, for purposes of computing the related stock compensation expense the fair value of our common stock was subsequently reassessed at $4.26-$4.58 per share for options granted from January 2008 to March 2008.

 

April to September 2008: During this period, we completed subsequent rounds of our Series B-1 convertible preferred stock financing at a price of $25.26 per share. In June 2008, we began generating revenues through our Amyris Fuels, LLC subsidiary. For option grants from April to September 2008, the board deemed the fair market value of the option grants to be $3.93. However, for purpose of computing the related stock compensation expense the fair value of our common stock was subsequently reassessed at $5.08-$8.36 per share for options granted from April 2008 to September 2008.

 

October 2008 to June 2009: In November 2008, we completed our first test runs at our pilot plant in Emeryville, California, to produce renewable products. In November 2008, we appointed a Senior Vice President of Research Programs and Operations. In December 2008, we determined market conditions had deteriorated and reduced our workforce by 12%. In January 2009, we closed the final round of our Series B-1 convertible preferred stock financing at a price of $25.26 per share. In April 2009, we received EPA registration for our renewable diesel fuel. In June 2009, we completed our initial production runs at our 300 liter scale fermentors in our pilot plant in Campinas, Brazil, to transition our yeast and processes into Brazil. Additionally in June 2009, through the use of a contract manufacturer, we completed our first initial production runs in 60,000 liter scale fermentors to evaluate results at a larger scale and to produce renewable diesel fuel to support our certification efforts. No options were granted during the period from October 2008 to August 2009.

 

July to October 2009: In July 2009, we closed the first round of our Series C convertible preferred stock financing at a price of $12.46 per share, which was 51% lower than the price per share we received from our Series B-1 convertible preferred stock financing in 2008 resulting from unfavorable market conditions related to the availability of private funding at the time. In September 2009, we began operations of our 5,000 liter scale demonstration facility in Campinas, Brazil. As a result of these transactions, and applying the Common Stock valuation methodology described above, we estimated the fair value of our common stock to be $4.31 per share as of August 7, 2009, and it remained at that price through the end of October 2009 because there were no significant developments in our business.

 

November to December 2009: In November 2009, we secured a patent covering our second potential jet fuel product and another patent covering our lubricant products. We also signed a memorandum of understanding

 

55


Table of Contents

with two international corporations to evaluate the technical and sustainability aspects of our renewable jet fuel. In addition, we signed a binding letter of intent related to the construction and launch of our first commercial facility at an ethanol mill owned by Usina São Martinho in Brazil. In December 2009, we received a notice of selection from the DOE, authorizing a grant for $24.3 million. Further, we announced letters of intent with Bunge Limited, Cosan and Açúcar Guarani for the purpose of partnering for the production of renewable chemicals and fuels. We also appointed a Chief Commercial Officer and a Chief Operating Officer. In December, three of our founders and our CEO sold to four existing investors shares of common stock representing in each case less than 10% of their overall common stock and options holdings at a price of $7.00 per share. Due to the change in the equity markets, in December we also deemed the probability of completing an initial public offering to be probable in the next eighteen months. As a result of these transactions, and applying the Common Stock valuation methodology described above, we estimated the fair value of our common stock to be $9.32 per share as of December 31, 2009. No options were granted during the period from November to December 2009.

 

January 2010 to February 2010: From December 29, 2009, to January 10, 2010, our valuation remained at $9.32 per share because there were no significant developments in our business. In January 2010, we ordered four 600,000 liter commercial fermentors for the purpose of commencing commercial production in our Usina São Martinho joint venture facility. Also in January 2010, we commenced negotiations to receive $3.9 million from a DOE grant, which is being made to the NREL, and under which we would be a subcontractor. Additionally, in January we closed the final round of our Series C convertible preferred stock financing at a price of $12.46 per share. In February 2010, we received approval from the Brazilian government to use our current yeast strain in commercial production. During this period we began discussions with investment banks regarding an IPO.

 

March 2010 to April 2010: In March 2010, we received an additional $1.7 million investment from an investor in Amyris Brasil and we completed our $47.8 million Series C-1 preferred stock financing at a price of $17.56 per share. In April 2010, we entered into a joint venture with Usina São Martinho.

 

Nonemployee Stock-Based Compensation

 

We account for stock options issued to nonemployees based on the estimated fair value of the awards using the Black-Scholes option pricing model. We account for restricted stock units (“RSUs”) issued to nonemployees based on the estimated fair value of our common stock. The measurement of stock based compensation is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in our consolidated statement of operations during the period the related services are rendered.

 

Stock-based compensation expense for options and RSUs granted to nonemployees for 2007, 2008 and 2009 was $0.2 million, $0.7 million and $0.7 million.

 

There is inherent uncertainty in these estimates and if different assumptions had been used, the fair value of the equity instruments issued to nonemployee consultants could have been significantly different.

 

Income Taxes

 

We are subject to income taxes in both the U.S. and foreign jurisdictions, and we use estimates in determining our provisions for income taxes. We use the liability method of accounting for income taxes, whereby deferred tax assets or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income.

 

Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. We recognize a valuation allowance against our net deferred tax assets if it is more likely than not that some portion of the deferred tax assets will not be fully realizable. This assessment requires judgment as to the likelihood and amounts of future taxable income by tax jurisdiction. At December 31, 2009, we had a full valuation allowance against all of our deferred tax assets.

 

56


Table of Contents

Effective January 1, 2007, we adopted ASC 740-10 to account for uncertain tax positions. As of December 31, 2007, 2008 and 2009, our total unrecognized tax benefits were $0.1, $0.6 and $1.0 million, of which none of the tax benefits, if recognized, would affect the effective income tax rate due to the valuation allowance that currently offsets deferred tax assets. We do not anticipate the total amounts of unrecognized income tax benefits will significantly increase or decrease in the next 12 months.

 

We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.

 

Results of Operations

 

The following table sets forth our consolidated results of operations for the periods shown:

 

     Years Ended December 31,  
     2007     2008     2009  
     (Dollars in thousands)  

Consolidated Statements of Operations Data:

      

Revenues

      

Product sales

   $      $ 10,680      $ 61,689   

Collaborative research services

     6,046        3,008        2,919   

Government grants

     138        204          
                        

Total revenues

     6,184        13,892        64,608   
                        

Cost and operating expenses

      

Cost of product sales

            10,364        60,428   

Research and development

     8,662        30,306        38,263   

Sales, general and administrative

     10,522        16,622        23,558   

Restructuring and asset impairment charges

                   5,768   
                        

Total cost and operating expenses

     19,184        57,292        128,017   
                        

Loss from operations

     (13,000     (43,400     (63,409

Other income (expense)

      

Interest income

     1,178        1,378        448   

Interest expense

     (28     (377     (1,218

Other income (expense), net

     76        (144     (621
                        

Total other income (expense)

     1,226        857        (1,391
                        

Loss before income taxes

     (11,774     (42,543     (64,800

Benefit from income taxes

            (207       
                        

Net loss

     (11,774     (42,336     (64,800

Net loss attributable to noncontrolling interest

            (472     (341
                        

Net loss attributable to Amyris Biotechnologies, Inc. shareholders

   $ (11,774   $ (41,864   $ (64,459
                        

 

57


Table of Contents

Comparison of Years Ended December 31, 2008 and 2009

 

Revenues

 

     Years Ended December 31,    Change in 2009  
         2008            2009        $  
     (Dollars in thousands)  

Revenues

        

Product sales

   $ 10,680    $ 61,689    $ 51,009   

Collaborative research services

     3,008      2,919      (89

Government grants

     204           (204
                      

Total revenues

   $ 13,892    $ 64,608    $ 50,716   
                      

 

Our total revenues increased by $50.7 million to $64.6 million in 2009 from $13.9 million in 2008. The increase was primarily the result of the $51.0 million increase in sales of ethanol purchased from third parties to $61.7 million in 2009 from $10.7 million in 2008, as we commenced our ethanol trading business in the second half of 2008. We sold 29.9 million gallons of ethanol in 2009 compared to 4.7 million gallons in 2008, as we had an increase in the number of customers and accessed additional terminal space in 2009.

 

Revenues from collaborative research services were relatively flat in 2009 compared to 2008. Collaborative research service revenues in 2009 included $1.6 million for contracted research services focused on strain improvement performed on behalf of Sanofi Chimie. Additionally, 2009 collaborative research services included $1.3 million related to the completion of our work under an agreement with One World Health and sanofi-aventis related to the anti-malaria product. Collaborative research service revenues in 2008 included $3.0 million associated with the same agreement.

 

Cost and Operating Expenses

 

     Years Ended December 31,    Change in 2009
          2008              2009         $
     (Dollars in thousands)

Cost and operating expenses

        

Cost of product sales

   $ 10,364    $ 60,428    $ 50,064

Research and development

     30,306      38,263      7,957

Sales, general and administrative

     16,622      23,558      6,936

Restructuring and asset impairment charges

          5,768      5,768
                    

Total cost and operating expenses

   $ 57,292    $ 128,017    $ 70,725
                    

 

Cost of Product Sales

 

Our cost of product sales increased by $50.1 million in 2009, primarily due to higher volumes of ethanol sales.

 

Research and Development Expenses

 

Our research and development expenses increased by $8.0 million in 2009 over 2008, primarily the result of $5.0 million in additional expenses from a full year of facility-related expenses and depreciation costs for our headquarters, that includes lab and office space, and our pilot plant in Emeryville, California, both of which we occupied in the second and third quarter of 2008, respectively, and the growth of our operations in Brazil. Our 2009 research and development expenses also included facility-related expenses and depreciation costs relating to our pilot plant and demonstration facility in Campinas, Brazil, that opened in 2009. The increase was also

 

58


Table of Contents

attributable to increased personnel-related expenses of $4.3 million, due in part to an increase in research and development personnel in Brazil associated with the expansion of the Brazil operations. These increases were offset in part by lower professional services fees of $1.5 million incurred in 2009 compared to 2008 when we used consultants to facilitate our research efforts. Research and development expenses included stock-based compensation expense of $0.6 million and $0.8 million during 2008 and 2009.

 

Sales, General and Administrative Expenses

 

Our sales, general and administrative expenses increased by $6.9 million in 2009 primarily as a result of increased personnel-related expenses of $3.0 million, and higher consulting and professional fees of $3.1 million. The increase in consulting and professional fees was due to the expansion of our Brazilian operations and the use of consultants to negotiate other contracts during the year in addition to consulting costs associated with the initial design work for a commercial production facility in Brazil. To a lesser extent, the increase was due to an increase in depreciation costs due to leasehold improvements associated with a full year of depreciation for our headquarters in Emeryville, California. Sales, general and administrative expenses included stock-based compensation expense of $1.4 million and $2.5 million during 2008 and 2009.

 

Restructuring and Asset Impairment Charges

 

Restructuring and asset impairment charges were $5.8 million and consisted primarily of non-cash charges related to consolidation of our headquarters in a single facility in Emeryville, California, and asset impairment charges related to the vacated facility in 2009. These costs represent future rent expense, write off of leasehold improvements and the reversal of deferred rent associated with the leased facility.

 

Other Income (Expense)

 

     Years Ended December 31,     Change in 2009  
         2008             2009         $  
     (Dollars in thousands)  

Other income (expense)

      

Interest income

   $ 1,378      $ 448      $ (930

Interest expense

     (377     (1,218     (841

Other income (expense), net

     (144     (621     (477
                        

Total other income (expense)

   $ 857      $ (1,391   $ (2,248
                        

 

Interest Income

 

Interest income decreased by $0.9 million in 2009. The decrease was a result of lower interest rates, partially offset by higher average investment balances.

 

Interest Expense

 

Interest expense increased by $0.8 million in 2009. The increase resulted primarily from higher outstanding principal balances on our capital leases in 2009 compared to 2008.

 

Other Income (Expense), Net

 

Other income (expense), net increased by $0.5 million in 2009 primarily due to higher expense related to the increase in the fair value of our convertible preferred stock warrants.

 

59


Table of Contents

Comparison of Years Ended December 31, 2007 and 2008

 

Revenues

 

     Years Ended December 31,    Change in 2008  
         2007            2008        $  
     (Dollars in thousands)  

Revenues

        

Product sales

   $    $ 10,680    $ 10,680   

Collaborative research services

     6,046      3,008      (3,038

Government grants

     138      204      66   
                      

Total revenues

   $ 6,184    $ 13,892    $ 7,708   
                      

 

Our total revenues increased $7.7 million to $13.9 million in 2008 from $6.2 million in 2007. The increase was primarily the result of the $10.7 million in sales of third party ethanol in 2008 for 4.7 million gallons of ethanol sold compared to zero in 2007.

 

Revenues from government grants increased by $0.1 million in 2008 primarily as a result of a professional services contract with a research institution compared to a lower level of grant funding from Small Business Innovation Research in 2007.

 

Revenues from collaborative research services decreased by $3.0 million in 2008 primarily as a result of the substantial completion of the anti-malaria product development, which was completed in 2009.

 

Cost and Operating Expenses

 

     Years Ended December 31,    Change in 2008
         2007            2008        $
     (Dollars in thousands)

Cost and operating expenses

        

Cost of product sales

   $    $ 10,364    $ 10,364

Research and development

     8,662      30,306      21,644

Sales, general and administrative

     10,522      16,622      6,100
                    

Total cost and operating expenses

   $ 19,184    $ 57,292    $ 38,108
                    

 

Cost of Product Sales

 

Our cost of product sales increased to $10.4 million in 2008 from zero in 2007 as a result of the commencement of ethanol sales in 2008.

 

Research and Development Expenses

 

Our research and development expenses increased by $21.6 million in 2008, primarily as a result of higher facility-related expenses and depreciation costs of $9.4 million. In May 2008, we entered into an operating lease for our facility in Campinas, Brazil. Also contributing to this increase was higher facility-related expenses and depreciation costs for our new headquarters in Emeryville, California, which includes lab and office space, and costs associated with the pilot plant also in located in Emeryville. Additionally, we incurred higher personnel-related expenses of $6.8 million attributable to a 91% increase in employee headcount in our research and development functions over the prior year. We also incurred higher professional fees of $3.0 million as we leveraged consultants during this expansion phase as well as $1.9 million in higher expenses associated with lab supplies. Research and development expenses included stock-based compensation expense of $0.1 million and $0.6 million during 2007 and 2008.

 

60


Table of Contents

Sales, General and Administrative Expenses

 

Our sales, general and administrative expenses increased by $6.1 million in 2008 primarily as a result of $5.4 million in increased personnel-related expenses attributable to higher sales and general and administrative headcount, which increased 48% over the prior year. We increased our headcount in Emeryville and in Chicago, where we established Amyris Fuels, LLC. We also had an increase of $1.8 million in higher professional and consulting fees. Sales, general and administrative expenses included stock-based compensation expense of $0.4 million and $1.4 million during 2007 and 2008.

 

Other Income (Expense)

 

     Years Ended December 31,     Change in 2008  
         2007             2008         $  
     (Dollars in thousands)  

Other income (expense)

      

Interest income

   $ 1,178      $ 1,378      $ 200   

Interest expense

     (28     (377     (349

Other income (expense), net

     76        (144     (220
                        

Total other income (expense)

   $ 1,226      $ 857      $ (369
                        

 

Interest Income

 

Interest income increased by $0.2 million in 2008. The increase resulted from our higher average investment balances and higher interest rates in 2008 compared to 2007.

 

Interest Expense

 

Interest expense increased by $0.3 million in 2008 due primarily to higher outstanding principal balances on our capital leases in 2008 compared to 2007.

 

Other Income (Expense), Net

 

Other income (expense), net decreased by $0.2 million. Other income (expense), net in 2008 included $0.1 million expense related to the increase in the fair value of our convertible preferred stock warrants.

 

Liquidity and Capital Resources

 

     December 31,
     2008    2009
     (Dollars in thousands)

Working capital

   $ 32,356    $ 51,062

Cash and cash equivalents and short-term investments

   $ 37,190    $ 67,210

 

     Years Ended December 31,  
     2007     2008     2009  
     (Dollars in thousands)  

Net cash used in operating activities

   $ (9,526   $ (38,879   $ (45,718

Net cash used in investing activities

   $ (41,643   $ (14,660   $ (25,422

Net cash provided by financing activities

   $ 51,539      $ 67,979      $ 71,473   

 

Since our inception, we have financed our operations primarily through an aggregate of $244.3 million from private placements of equity securities, $19.6 million of collaborative research services revenues and $14.4 million of equipment financing.

 

61


Table of Contents

As of December 31, 2009, we had cash, cash equivalents and marketable securities of $67.2 million compared to $37.2 million as of December 31, 2008. As of December 31, 2009, we had total debt, including capital lease obligations of $20.6 million. In addition, we had total borrowing capacity of $2.8 million under our Credit Agreement, which we currently utilize in connection with our Amyris Fuels business. In 2010, we closed private placements of equity securities with net proceeds to us of $51.5 million and we received an additional $1.7 million investment in Amyris Brasil.

 

During the years ended December 31, 2007, 2008 and 2009, we used $2.5 million, $22.0 million and $7.6 million in cash, respectively, to fund capital expenditures. We currently anticipate making aggregate capital expenditures of between 140 million Brazilian reais and 180 million Brazilian reais for the Usina São Martinho joint venture facility, of which we expect São Martinho to reimburse us for 61.8 million Brazilian reais. Of this expenditure, we expect to incur approximately 50 to 60 million Brazilian reais in 2010 (approximately $28 million to $34 million), approximately 80 to 110 million Brazilian reais in 2011 (approximately $45 million to $62 million) and approximately 10 million Brazilian reais in 2012 (approximately $6 million). During 2010 and 2011 we expect to incur $15 million to $20 million in fees associated with engineering design plans that we expect to use for our joint venture and other capital light mill construction. Additionally, we anticipate making approximately $6.0 million in capital expenditures for research and scale-up equipment and tenant improvements in 2010.

 

Beyond our investment in Usina São Martinho, we expect to invest capital in additional production arrangements, the timing and amount of which will depend on our business and financial outlook and the specifics of the opportunity. We may also consider additional strategic investments or acquisitions. This may require us to access additional capital through equity or debt offerings. If we are unable to access additional capital, our growth will be limited due to the inability to invest in additional production facilities.

 

We believe that our existing cash, cash equivalents, and short term investments, the net proceeds of this offering and funding under the two grants from the DOE will be sufficient to fund our operations and other capital expenditures for at least the next 12 months.

 

Credit Agreement. In November 2008, we entered into an uncommitted facility letter (the “Credit Agreement”) with a financial institution to secure letters of credit and to finance short term advances for the purchase of ethanol and associated margin requirements as needed. In October 2009, the agreement was amended to decrease the maximum amount that we may borrow under such facility. The Credit Agreement, as amended, provides an aggregate maximum availability up to the lower of $20.0 million or the borrowing base as defined in the agreement. We may use this line to secure letters of credit for product purchases in an aggregate amount up to $5.7 million. In addition, we may borrow cash for the purchase of product, which is determined by our borrowing base. As of year-end we had sufficient borrowing base levels to draw up to a total of $2.8 million in short term cash advances and had $4.6 million available for letters of credit in addition to those outstanding at year end. As of December 31, 2008 and 2009, we had no outstanding advances and had $0.7 million and $1.1 million in outstanding letters of credit under the Credit Agreement which are guaranteed by Amyris Biotechnologies, Inc. and payable on demand. The Credit Agreement is collateralized by a first priority security interest in certain of our present and future assets. (See Note 6 to the Consolidated Financial Statements).

 

Auction Rate Securities. Our investment portfolio includes auction rate securities (“ARS”), which are issued principally by student loan entities and rated AAA by a major credit rating agency. In February 2008, auctions failed for $12.95 million in par value of ARS that we held because sell orders exceeded buy orders. During the year ended December 31, 2009, a total of $250,000 of the ARS held by us were called at par by the issuer. As of December 31, 2009, we owned $12.7 million par value of these securities.

 

In October 2008, UBS AG (“UBS”) offered to repurchase all of the ARS that we purchased from them. We formally accepted the settlement offer and entered into a repurchase agreement with UBS in November 2008. By accepting the agreement, we received the right (“Put Option”) to sell our ARS at par value to UBS between June 30, 2010, and July 2, 2012. We expect to sell the ARS under the Put Option. However, if the Put Option is

 

62


Table of Contents

not exercised before July 2, 2012, it will expire and UBS will have no further rights or obligation to buy the ARS. (See Note 3 to the Consolidated Financial Statements.)

 

Cash Flows from Operating Activities

 

Our primary uses of cash from operating activities are for cost of product sales and personnel-related expenditures offset by cash received from product sales. Cash used in operating activities was $9.5 million, $38.9 million and $45.7 million for the years ended December 31, 2007, 2008 and 2009.

 

Cash used in operating activities of $45.7 million in 2009 reflected a net loss of $64.8 million, partially offset by aggregate non-cash charges of $10.4 million and a net change of $8.7 million in our net operating assets and liabilities. Non-cash charges primarily included $5.8 million of depreciation and amortization and $3.3 million of stock-based compensation. The net change in our operating assets and liabilities was primarily a result of our restructuring activity of $5.1 million, the increase in accrued and other liabilities of $4.5 million and the decrease in prepaid and other assets of $1.0 million, partially offset by the increase in inventory of $0.9 million and the decrease in accounts payable of $1.0 million.

 

Cash used in operating activities of $38.9 million in 2008 reflected a net loss of $42.3 million, partially offset by aggregate non-cash charges of $4.8 million, and net change of $1.3 million in our net operating assets and liabilities. Non-cash charges primarily included $2.6 million of depreciation and amortization and $2.0 million of stock-based compensation. The net change in our operating assets and liabilities was primarily a result of the increase in prepaid expenses and other assets of $1.9 million, the increase in inventory of $1.4 million and the decrease in deferred revenue of $1.4 million, partially offset by the increase in accrued and other liabilities of $2.1 million and the increase in accounts payable of $1.3 million.

 

Cash used in operating activities of $9.5 million in 2007 reflected a net loss of $11.8 million, partially offset by aggregate non-cash charges of $1.8 million and a net change of $0.4 million in our net operating assets and liabilities. Non-cash charges primarily included $0.6 million of depreciation and amortization and $0.5 million of stock-based compensation. The net change in our operating assets and liabilities was primarily a result of the increase in accrued and other liabilities of $2.3 million, partially offset by the decrease in deferred revenue of $1.9 million.

 

Cash Flows from Investing Activities

 

Our investing activities consist primarily of net investment purchases, maturities and sales and capital expenditures.

 

In 2009, cash used in investing activities was $25.4 million as a result of $16.0 million in net investment purchases and $7.6 million of capital expenditures, and a $1.8 million increase in restricted cash.

 

In 2008, cash used in investing activities was $14.7 million as a result of $22.0 million of capital expenditures and $2.0 million increase in restricted cash, partially offset by $9.3 million in net investment sales and maturities.

 

In 2007, cash used in investing activities was $41.6 million as a result of $38.4 million in net investment purchases, $2.5 million of capital expenditures and $0.7 million increase in restricted cash.

 

Cash Flows from Financing Activities

 

In 2009, cash provided by financing activities was $71.5 million, primarily as a result of the net receipt of $56.5 million from our sale of Series C convertible preferred stock, the net receipt of $1.8 million from our sale of Series B-1 convertible preferred stock, the receipt of $9.6 million from debt, primarily from an advance on

 

63


Table of Contents

student loan auction rate securities held at UBS, $4.8 million in proceeds from equipment financing and the receipt of $3.1 million from investors for their noncontrolling interest in Amyris Brasil, partially offset by our purchase of the noncontrolling interest in Amyris Brasil for $2.3 million, our principal payments on our equipment financing facilities of $1.1 million and principal repayments on our debt of $1.0 million.

 

In 2008, cash provided by financing activities was $68.0 million, primarily as a result of the receipt of $61.4 million from our sale of Series B-1 convertible preferred stock, the receipt of $3.7 million from our sale of Series B convertible preferred stock, the receipt of $1.6 million from the sale of the noncontrolling interest in Amyris Brasil and $1.2 million in proceeds from equipment financing.

 

In 2007, cash provided by financing activities was $51.5 million, primarily as a result of the receipt of $13.9 million from our sale of Series A convertible preferred stock and the receipt of $37.6 million from our sale of Series B convertible preferred stock.

 

Contractual Obligations

 

The following is a summary of our contractual obligations as of December 31, 2009:

 

    Total   2010   2011   2012   2013   2014 and
beyond
    (Dollars in thousands)

Principal payments on long term debt

  $ 13,380   $ 9,018   $ 1,348   $ 655   $ 533   $ 1,826

Interest payments on long-term debt, fixed rate (1)

    1,618     442     381     251     193     351

Interest payments on long-term debt, variable rate (2)

    55     55                

Operating leases

    34,747     3,161     4,021     4,669     4,328     18,568

Principal payments on capital leases

    7,228     2,251     2,469     2,241     267    

Interest payments and executor costs on capital leases

    1,303     710     436     153     4    

Terminal storage costs

    2,059     934     805     320        
                                   

Total

  $ 60,390   $ 16,571   $ 9,460   $ 8,289   $ 5,325   $ 20,745

 

  (1)   For fixed rate facilities, the interest rates are more fully described in Note 6 of our consolidated financial statements.
  (2)   For variable rate facilities, amounts are based on weighted average interest rate which was 1.32% as of December 31, 2009.

 

Amyris Brasil S.A. Transactions

 

Between December 2009 and April 2010, we entered into agreements with certain investors to sell a noncontrolling equity interest in Amyris Brasil S.A. (See Notes 16 and 19 to our Consolidated Financial Statements included elsewhere in this prospectus for a description of these transactions.) Under the terms of these agreements, we have the right to require the investors to convert their shares of Amyris Brasil into shares of our common stock. We intend to exercise this right prior to the completion of this offering, and as a result we will issue 550,044 shares of our common stock to these investors.

 

Off-Balance Sheet Arrangements

 

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our consolidated balance sheets.

 

64


Table of Contents

Quantitative and Qualitative Disclosures about Market Risk

 

We are exposed to financial market risks, primarily changes in interest rates, currency exchange rates and commodity prices. On a limited basis we use derivative financial instruments primarily to manage commodity price risk. All of the potential changes noted below are based on sensitivity analyses performed on our financial positions as of December 31, 2009. Actual results may differ materially.

 

Interest Rate Risk

 

Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our outstanding debt obligations. We generally invest our cash in investments with short maturities or with frequent interest reset terms. Accordingly, our interest income fluctuates with short-term market conditions. As of December 31, 2009, our investment portfolio consisted primarily of money market funds, government bonds and notes and ARS. With the exception of our ARS, these were highly liquid investments. Due to the short-term nature of our investment portfolio, our exposure to interest rate risk is minimal.

 

Interest rate risk is present with both fixed- and variable-rate debt. As of December 31, 2009, approximately 60 percent of our debt portfolio was comprised of variable-rate debt and 40 percent was fixed-rate debt. If interest rates had increased by 100 basis points related to the outstanding amounts as of December 31, 2009, our interest expense would have changed by $42,000 on an annual basis.

 

Foreign Currency Risk

 

Most of our sales contracts are principally denominated in U.S. dollars and, therefore, our revenues are not currently subject to significant foreign currency risk. We do incur certain operating expenses in currencies other than the U.S. dollar in relation to Amyris Brasil and, therefore, are subject to volatility in cash flows due to fluctuations in foreign currency exchange rates, particularly changes in the Brazilian reais. To date, we have not entered into any hedging contracts since exchange rate fluctuations have had minimal impact on our results of operations and cash flows.

 

Commodity Price Risk

 

Our exposure to market risk for changes in commodity prices currently relates primarily to our purchases of ethanol. When possible, we manage our exposure to this risk primarily through the use of supplier pricing agreements. We also, at times, use standard derivative commodity instruments to hedge the price volatility of ethanol, principally through ethanol futures contracts. The changes in fair value of these contracts are recorded on the balance sheet and recognized immediately in cost of product sales. We recognized (losses) gains of $0, $752,000 and ($1,910,000) as the change in fair value for the years ended December 31, 2007, 2008 and 2009, respectively. (See Note 3 to the Consolidated Financial Statements).

 

Recent Accounting Pronouncements

 

In June 2009, the FASB issued a new accounting standard that requires a qualitative approach to identifying a controlling financial interest in a variable interest entity (“VIE”), and requires ongoing assessment of whether an interest in a VIE makes the holder the primary beneficiary of the VIE. The new accounting standard became effective for us on January 1, 2010. We are evaluating the impact of the pending adoption on our consolidated financial statements.

 

In October 2009, the FASB issued a new accounting standard that changes the accounting for arrangements with multiple deliverables. Specifically, the new accounting standard requires an entity to allocate arrangement consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices. In addition, the new standard eliminates the use of the residual method of allocation and requires the relative-

 

65


Table of Contents

selling-price method in all circumstances in which an entity recognizes revenue for an arrangement with multiple deliverables. In October 2009, the FASB also issued new accounting standard that changes revenue recognition for tangible products containing software and hardware elements. Specifically, if certain requirements are met, revenue arrangements that contain tangible products with software elements that are essential to the functionality of the products are scoped out of the existing software revenue recognition accounting guidance and will be accounted for under these new accounting standards. Both standards will be effective for us in the first quarter of 2011. Early adoption is permitted. We are currently assessing the impact that the adoption of these standards will have on our consolidated financial statements.

 

In January 2010, the FASB issued an amendment to an accounting standard which requires new disclosures for fair value measures and provides clarification for existing disclosure requirements. Specifically, this amendment requires an entity to disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and to describe the reasons for the transfers; and to disclose separately information about purchases, sales, issuances and settlements in the reconciliation for fair value measurements using significant unobservable inputs, or Level 3 inputs. This amendment clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and requires disclosure about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level 2 and Level 3 inputs. The adoption of this amendment will not impact the Company’s consolidated financial statements.

 

66


Table of Contents

BUSINESS

 

Business Overview

 

Our Company

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. We genetically modify microorganisms, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of target molecules. Our first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications such as detergents, cosmetics, perfumes, and industrial lubricants, to transportation fuels such as diesel. We call these No Compromise products because we design them to perform comparably to or better than currently available products. While our platform is able to utilize a wide variety of feedstocks, we have focused our initial research and development, business development and production operations on the use of Brazilian sugarcane as our primary feedstock, because it is abundant, low cost and relatively price stable. We intend to secure access to this feedstock and expand our production capacity in a “capital light” manner. Under this approach, we expect to work with Brazilian sugar and ethanol producers to build new, “bolt-on” facilities adjacent to their existing mills instead of building new “greenfield” facilities, thereby reducing the capital required to establish and scale our production. Our first such arrangement is our joint venture with Usina São Martinho, a subsidiary of São Martinho S.A., one of the largest sugar and ethanol producers in Brazil.

 

Technology

 

We have developed genetic engineering and screening technologies which enable us to modify the way microbes process sugar. By controlling these metabolic pathways, we design microbes to serve as living factories, or biorefineries, to produce target molecules that we seek to commercialize. Our platform utilizes proprietary high-throughput processes to create and test as many as 1,000 yeast strains a day in order to select those yeast strains which are most efficient. We first developed and applied our technology to create microbial strains that produce artemisinic acid, a precursor of artemisinin, an anti-malarial therapeutic. We have granted a royalty-free license to this technology to sanofi-aventis for the commercialization of artemisinin-based drugs.

 

Feedstock

 

We are focusing on Brazilian sugarcane as our primary feedstock given its abundance, low cost and relative price stability. Brazil is the world’s largest producer of sugarcane, crushing over 600 million tons of sugarcane annually to provide feedstock to approximately 400 sugar and ethanol mills. According to UNICA, the Brazilian Sugarcane Industry Association, sugarcane is the lowest cost feedstock to produce renewable products at scale and using it enables us to leverage the established Brazilian infrastructure. Common to both our process and the sugarcane-to-ethanol process is the use of fermentation, a well-established process that combines a sugar source and yeast to produce beer and wine and, more recently, ethanol fuels. We plan to establish production capacity by partnering with sugar and ethanol producers, and then taking as input the same sugar source that is routinely processed by these mills and directing it to customized fermentors, where it would be combined with our genetically engineered yeast.

 

Scale-Up

 

We operate research and development laboratories in Emeryville, California, and have built an adjacent pilot facility that tests our yeast strains in 300 liter scale fermentors. We have an identical pilot plant in Campinas, Brazil, to facilitate the adaptation of our technology to the Brazilian production environment. We established a 5,000 liter demonstration facility in Brazil in September 2009 to further validate our processes and equipment as we move toward commercialization of our products. We have also completed production runs using our strains to produce farnesene at a contract manufacturing facility in a 60,000 liter fermentor in the U.S.

 

67


Table of Contents

Commercial Production

 

We expect to access feedstock and scale our production through our capital light strategy. Our first such arrangement is our joint venture with Usina São Martinho, SMA Industrio Quimico S.A. This facility is located at Usina São Martinho, the world’s largest sugarcane processing facility, which crushed 8.1 million tons of sugarcane in the 2009/2010 harvest. We have also provided Usina São Martinho with an option to produce our products at a second production facility. We have non-binding letters of intent in place with three leading Brazilian sugar and ethanol producers, Bunge Limited, Cosan and Açúcar Guarani, a subsidiary of Tereos, to build new, bolt-on facilities adjacent to specified existing mills to produce our products. We expect that these mill owners will make a substantial contribution of capital or operating contribution to fund these facilities in return for a share of the higher gross margin we believe we will realize from the sale of our renewable products. In addition, we expect these arrangements to provide us with access to over ten million tons of sugarcane crush capacity annually, which we intend to expand over time with these and other mills. This capacity represents approximately 9.8% of the total crush capacity of these producers.

 

Products and Distribution

 

As we commence commercial production of our initial molecule, farnesene, we expect to target specialty chemical markets. Further, we are seeking to improve our strain performance to expand our addressable markets, including additional chemical applications and renewable diesel. For most specialty chemical applications, we intend to sell directly to industrial customers. For distribution of our fuel products in the U.S., we expect to sell directly, primarily to corporations with large trucking fleets. For distribution of our fuel products in other geographies, we expect to sell indirectly through third parties. To build the capabilities we will need to import and distribute our products into the U.S., we have established our subsidiary Amyris Fuels, LLC. Amyris Fuels currently generates revenues through the sale of ethanol to wholesale customers through a network of terminals in the southeastern U.S.

 

68


Table of Contents

Industry Background

 

Petroleum is a fundamental building block for products, such as consumer products, chemicals, plastics, and transportation fuels, that are essential to modern economies. According to EIA, in 2008 the total worldwide demand for petroleum was over $3 trillion, or 5% of worldwide gross domestic product. The graphic below outlines some of the markets that currently rely on petroleum as a precursor:

 

LOGO

 

Historically, the abundance of petroleum has made it a convenient and inexpensive source of many chemicals and transportation fuels. Recently, however, changes in the economics of petroleum production and consumer preferences have created challenges for the current infrastructure, such as:

 

   

Increased demand for petroleum but limited supply. Petroleum is a finite resource, and locating and extracting new petroleum resources is becoming more challenging and expensive. At the same time, population growth, economic development and urbanization in emerging countries such as Brazil, Russia, India and China are significantly increasing the demand for petroleum.

 

   

Volatility of petroleum prices. Petroleum prices are highly volatile, which reduces petroleum’s attractiveness as a building block for products. For instance, the price per barrel of petroleum ranged from $145.66 in July 2008 to $30.81 in December 2008. This variability adds a level of price uncertainty to providers and customers of goods that rely on petroleum.

 

   

Supply chain uncertainty and inconsistency . Secure and stable access to petroleum is increasingly threatened by a variety of factors, including the political instability of several large oil producing countries, competition over energy sources and attacks on supply infrastructure, as well as accidents and natural disasters. Concerns with dependence on current petroleum producing countries are spurring private and public initiatives to reduce petroleum use and develop effective alternatives.

 

 

69


Table of Contents
   

Negative environmental impact and changing consumer sentiment . The production of petroleum and its use as a fossil fuel create emissions that are harmful to the environment. This has led to changes in consumer attitudes towards consumption and raised the likelihood of regulatory frameworks that will continue to challenge the economics of petroleum-based products.

 

To address the foregoing challenges, countries have taken various actions to promote environmentally-friendly alternatives to petroleum. The U.S. Energy Policy Act of 2005 mandated that 7.5 billion gallons of renewable fuels be produced in the U.S. by 2012 as part of the Renewable Fuels Standard (“RFS”). The RFS was amended by the Energy Independence and Security Act of 2007, which calls for 36 billion gallons of renewable fuels—including 21 billion gallons from cellulosic ethanol and other advanced biofuels—by 2022. According to EIA, this is approximately 11% of the 2022 forecast for total U.S. petroleum demand. Similar mandates have been enacted in Europe, where the Renewable Energy Directive calls for 20% of energy to come from renewable sources by 2020. These and other policies, such as tariffs on petroleum inputs and subsidies for renewable energy research, provide meaningful incentives for the development and acceptance of alternative sources for petroleum and petroleum derivatives.

 

Petroleum Alternatives

 

There have been many attempts to create equivalent products to petroleum-based products that avoid the difficulties listed above. However, these initial approaches have faced challenges that have limited, or may limit, their success:

 

   

Exposure to volatile feedstock pricing. Many U.S. renewable fuels companies have focused on the conversion of commodity feedstocks, such as corn or vegetable oil, into ethanol or biodiesel. These companies were exposed to potential swings in the market prices for their feedstocks. According to The World Bank, the price of maize rose over 60% from 2005 to 2007, due largely to the U.S. ethanol program combined with reduced stocks in major exporting countries. In addition to significantly impacting food prices and availability, such increases reduced or eliminated the profitability of these businesses, and at various times have made production unprofitable for a number of producers in these industries.

 

   

Limited product portfolio . Companies engaging in early attempts to create renewable fuels typically focused on one end product, such as ethanol or biodiesel. These companies generally lacked product diversity and therefore were vulnerable to variability of market prices and the degree of government support for their primary products. Further, these companies’ products were imperfect substitutes for the transportation fuels they were intended to replace. For example, neither ethanol nor biodiesel can be transported in conventional petroleum pipelines or stored in blended form with petroleum-sourced fuels for any significant time due to their corrosive and viscous properties. In addition, ethanol has a lower energy content than petroleum-sourced fuels, resulting in reduced fuel economy. In many countries, ethanol and biodiesel can be blended with petroleum-based fuels only in limited quantities without requiring engine modifications or risking invalidation of engine or vehicle warranties. In the U.S., current blend limits set by the EPA restrict ethanol blending to 10% or less of gasoline.

 

   

Capital intensity . Many initial U.S. ethanol companies utilized a business model that included the construction and ownership of mills to control their production process. A new ethanol mill requires capital outlays of hundreds of millions of dollars. Given these significant capital outlays, ethanol producers were limited in their ability to opportunistically and rapidly enter new geographies with access to new feedstock, as they were tied to their existing facilities and construction plans.

 

   

Dependence on policy . The economic viability of many alternative fuel and energy resources is based on government regulations and support. For instance, corn based ethanol and biodiesel are both heavily dependent on government subsidies to blenders and refineries. For example, in response to the U.S. Senate’s delay in extending a biodiesel tax credit beyond its expiration in December 2009, many biodiesel producers laid off workers and suspended operations until the extension was approved in March 2010.

 

 

70


Table of Contents

As a result of these challenges, many corn ethanol and biodiesel solutions have not been successful. Other efforts to develop alternatives to petroleum-sourced products include the use of non-food-based feedstocks, such as cellulosic sugars sourced from wood chips, corn stalks and sugarcane bagasse. Some of these approaches have shown promise and may not be influenced by commodity markets and food versus fuel concerns. However, they are not complete solutions to the challenges above, and to date, these approaches have been limited by cost and technical considerations, among others.

 

The Amyris Solution

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-based products used in specialty chemical and transportation fuel markets worldwide. Our proprietary technology enables us to engineer microbes, such as yeast, to produce target molecules, and our business model is designed to produce these products and bring them to market in a capital light manner. Our technology platform is designed to produce competitive products from widely available plant-derived feedstocks, using genetically modified yeast strains in a well-established fermentation process. We are focusing our initial production efforts in Brazil, positioning us to access abundant, low-cost and relatively price stable sugarcane feedstock sources and to leverage the substantial infrastructure of existing sugar and ethanol mills.

 

Competitive Strengths

 

Our key competitive strengths are:

 

   

Abundant, low-cost and relatively price stable feedstock. The Brazilian sugarcane industry enjoys a low production cost structure and is insulated from feedstock price volatility. The sugar and ethanol industries are vertically integrated with most mills growing much or all of their own sugarcane. Hence, they are generally exposed only to these agricultural production costs, rather than the market price of a volatile, traded commodity feedstock. Even when cane is procured from third-party growers the contract price is a formula derived from the selling price of the resultant sugar or ethanol production, insulating the mill from any substantial disconnect between its feedstock price and ultimate product selling price. Furthermore, Brazilian sugarcane does not compete for use as a food source. According to the U.S. Department of Agriculture, roughly 50% of Brazilian sugarcane is used for sugar production, and the production of cane is expected to substantially increase over the next 10 years.

 

   

Broad range of potential products . Our technology platform gives us the ability to produce potentially thousands of target molecules. This capability enables us to focus on the development of promising, high-value products, optimizing our overall mix of products and mitigating our exposure to any one end market. Our farnesene molecule, on which we are initially focusing, forms the basis for a wide range of chemical and fuels applications.

 

   

Scalable, capital light approach. We are developing production capacity by entering into agreements with sugar and ethanol producers to build new, bolt-on facilities adjacent to their existing mills to produce our products at a lower cost than the cost of building a new greenfield facility, under which they will make a substantial capital or operating contribution in return for a share in the higher gross margin that we believe we will realize from the sale of our products. With approximately 400 sugar and ethanol mills operating in Brazil, we believe that this capital light model will allow us to take advantage of the large infrastructure that is already in place.

 

   

Not policy dependent. We do not intend to rely on subsidies, mandates or tariffs to make our products commercially viable. While we benefit from policies such as the Renewable Fuels Standard that encourage the use of renewable products, and while we will seek to access incentives available for the production of our products, we expect our products to be offered on a cost-competitive basis with existing products without reliance on subsidies.

 

71


Table of Contents

Our Solution for our Customers

 

The key benefits we intend to provide to our customers include:

 

   

No Compromise product offerings . We refer to our products as No Compromise because we design them to perform comparably to or better than currently available products. For example, in initial testing our squalane, a natural emollient used in high-end cosmetics, has exhibited characteristics comparable to currently available squalane. In addition, our diesel will not require engine or distribution infrastructure modifications, will have better performance at low temperatures and generally will have a higher cetane number than biodiesel.

 

   

Greater pricing stability . We expect that our use of Brazilian sugarcane will make our products less susceptible to price volatility than petroleum-sourced, corn-based ethanol and biodiesel products. Our yeast strains are designed to utilize a wide variety of feedstocks, which will allow us to seek other low-cost sugar sources for our process over time. We believe that this will help protect our customers from the level of volatility generally associated with exposure to petroleum and other commodities.

 

   

“Green” alternative. Our products are derived from renewable sources, enabling our customers to reduce the environmental impact of their products. For example, we believe we can provide our prospective customers in the specialty chemical market with a competitive advantage by offering “greener” products than those that are based on petroleum. We also believe that our diesel offers a number of environmental benefits, including the elimination of sulfur and greatly reduced nitrogen oxides, particulate matter, carbon monoxide and hydrocarbon exhaust emissions.

 

Our Value Proposition to Sugar and Ethanol Producers

 

The key benefits we intend to provide to sugar and ethanol producers that will work with us to produce our products include:

 

   

Product diversification. By producing our products, sugar and ethanol mills would be able to diversify their business beyond their current sugar or ethanol production and potentially mitigate volatility in their financial performance caused by changes in the market prices for sugar or ethanol.

 

   

Opportunity for growth. By diversifying their product base to address expanded market opportunities, producers may be able to expand the amount of sugarcane grown and processed at their mills.

 

   

Potential for improved margins. We intend to offer these producers a share of the higher gross margin we believe we will realize from the sale of our renewable products relative to their existing products, potentially improving their gross margins and the return they realize on their feedstock.

 

Our Strategy

 

Our objective is to become the leading provider of renewable specialty chemicals and transportation fuels worldwide. These specialty chemical and transportation fuels markets are some of the largest addressable markets in the world, aggregating to well above $1 trillion annually. However, for decades there has been little success in developing alternatives to the petroleum-sourced products that serve these markets. We believe this to be the case because incumbents have significant advantages in the form of established production processes, access to historically low cost and plentiful petroleum feedstock and significant financial resources, which together form high barriers to entry. As a result, we believe that in order for a new company to offer products that effectively compete with petroleum-based products for these end markets, it is important to build a company that can fundamentally innovate and differentiate to achieve a long-term sustainable competitive advantage.

 

Since inception we focused our company on achieving a sustainable competitive advantage by abiding by three strategic principles. First, we select target markets where we can deliver products that perform comparably to existing offerings on a cost-competitive basis. Second, we will continue to advance our technology such that we can

 

72


Table of Contents

scale our business using a wide variety of feedstocks in a capital light fashion. Finally, we intend to participate in the distribution and sale of our products, either directly or with partners, to maximize the value we can capture from sales of our products. By selectively participating in the supply chain for each of our end markets, we intend to position our company to capture the greatest value across each end market.

 

Activities that we are pursuing to support these elements of our strategy include:

 

   

Pursuing market opportunities that maximize our returns. We expect to be able to produce numerous specialty chemicals as well as renewable diesel from our farnesene molecule and other molecules that we can produce. We intend to expand our chemistry capabilities in order to expand market applications and support customer adoption of our products. We are currently in active discussions with various consumer products and oil companies for their purchase of our products. We will focus our initial sales and marketing efforts on a small number of high value applications for which there exists an attractive business case for our products. As we further lower our production costs and increase our production capacity, we believe our ability to address a wide range of target markets will provide us with significant flexibility in adjusting product mix in order to maximize our returns. We also intend to enter into collaborative research, development and commercialization agreements to accelerate our entry into select new product opportunities.

 

   

Leveraging our technology platform to improve efficiency. We intend to continually leverage our technology platform to lower the cost of production of our products through continued strain improvement and gains in other production process efficiencies. For example, since we first engineered a yeast strain capable of producing farnesene in 2006, we have substantially increased our yield and have achieved a 15% yield at two liter scale which we believe, if replicated at commercial production scale, will enable us to enter certain specialty chemical markets. We intend to further develop our strains to enable us to address transportation fuels markets.

 

   

Focusing on Brazilian sugarcane . We are focusing on Brazilian sugarcane as our primary feedstock given its abundance, low cost and relative price stability. We formed Amyris Brasil in March 2008 to establish local visibility to enhance our ability to access sugarcane. We have entered into non-binding letters of intent for production relationships with three sugar and ethanol producers in Brazil, Bunge Limited, Cosan and Açúcar Guarani. If successfully consummated, we believe these production relationships, together with the Usina São Martinho mill, would provide us with access to over ten million tons of annual crushing capacity. We will continue to develop relationships to secure additional feedstock sources.

 

   

Advancing capital light production. We expect to partner with existing sugar and ethanol mills to establish and scale production at a lower cost than the cost of greenfield mill construction. While we are constructing our first capital light facility in Brazil, our joint venture with Usina São Martinho, we expect to initiate commercial production starting in 2011 through the use of contract manufacturing. We then expect to begin to operate the joint venture facility starting in the second quarter of 2012. We also intend to build engineering services capabilities to support sugar and ethanol mill adoption of our technology.

 

   

Continuing to develop our fuels distribution network. We will continue to invest in our Amyris Fuels distribution network, expanding our footprint in the U.S. We believe this strategy builds capabilities for future distribution and sales of our renewable products in the U.S. We will seek to establish arrangements with large oil companies for distribution of our renewable fuels in other countries.

 

73


Table of Contents

Technology

 

We believe that our technology enables us to genetically engineer microorganisms that will perform as effectively in commercial manufacturing conditions as they perform in the laboratory. We accomplish this by maintaining a constant feedback loop between our laboratory, where strains are initially created and modified, and our two pilot plants, where we expose those strains to conditions that simulate a commercial production environment. This allows us to focus our microbe development resources on those strains that demonstrate the potential to scale effectively. The key components of our industrial synthetic biology platform are strain engineering, process development and scale-up and chemical finishing.

 

Strain Engineering

 

The process by which a living organism converts sugar to molecules is comprised of many individual steps that together form a pathway. We focus on engineering microorganisms to build pathways that are specifically designed to produce target molecules for which we believe there may be significant market opportunities. The primary biological pathway within the microbe that we currently use to produce our target molecules is the isoprenoid pathway. Isoprenoids constitute a large, diverse class of molecules with current product applications in a wide range of industries, including specialty chemicals and fuels. The microorganisms we currently use are strains of yeast, although we have demonstrated that our technology can be applied in E. coli bacteria and we believe it can also be used in other microbes.

 

The following chart illustrates the use of our engineered yeast cells to produce target molecules in a variety of applications:

 

LOGO

 

74


Table of Contents

The key steps in our strain engineering process are:

 

Identifying target molecules. We start our process by identifying the commercial application that we want to pursue. We identify the key molecular properties that are essential to product performance in a specific commercial application and then analyze the chemical structures that drive those key performance characteristics. Finally, we identify target molecules or simple derivatives of molecules that are comprised of these key chemical structures and that may be produced by our yeast strains.

 

Developing initial strains. Once we have chosen a target molecule, we identify the steps required for its production in a biological pathway. We then seek to design a pathway to produce the target, either directly or by producing a molecule that can, through simple chemical steps, be synthesized, or converted, into the target. Once this pathway is identified, we undertake to engineer it into our yeast strains by employing the processes discussed below.

 

Improving strain performance to achieve commercial viability. After we have established a pathway and verified that it can produce the target molecule, the yeast strain must be improved to increase the level of efficiency of production. The two key measures of yeast strain efficiency are yield and productivity. Our focus to date has been on maximizing yield, which is the measurement of the amount of a specified molecule that is produced by our yeast from a given amount of sugar. Yield is measured both at laboratory scale, where production occurs in a controlled environment with highly uniform feedstock, and at commercial scale where products are produced on-site using commercially available feedstock, such as sugarcane juice. Yield is expressed as a percentage, with, for example, a yield of 10% indicating that of one gram of product is produced from ten grams of sugar input. Yeast strain productivity represents the rate at which our product is produced by a given yeast strain. The higher productivity a strain has, the more product can be produced in the same size fermentor in a given period of time.

 

We seek to achieve yield gains primarily by means of two different scientific approaches—random mutagenesis and rational design. In random mutagenesis, a mutagen, such as ultraviolet light, is applied to a strain that already produces some amount of a target molecule. The goal is to mutagenize, or genetically change, the strain so it will produce a greater amount of that target molecule. In order to identify strains that are more productive than the parent, or starting strain, large numbers of mutagenized strains must be screened. We have developed assays for screening tens of thousands of strains per week, and we frequently evolve the assays we use for this rapid, or high-throughput, analysis of production.

 

We augment our efforts to identify improved yeast strains via random mutagenesis by employing a process we refer to as rational design, in which we specifically design strains to achieve a desired effect. Through the use of techniques like genomics, which is the analysis of nucleic acids within the cell, metabolomics, which is the analysis of reaction intermediates inside the cell, and proteomics, which is the analysis of enzymes inside the cell, we can identify potential bottlenecks in the flow of the sugar feedstock to the target molecules. We can then explore solutions to those bottlenecks and test them by making targeted, or rational, genetic changes to the pathway. In order to increase the efficiency of these rational design efforts, we have developed and implemented a series of automated processes:

 

   

Rapid strain engineering . This is a method of engineering strains in which we break the strain engineering process into a series of modular steps, which allows for more rapid construction of strains than do conventional methods.

 

   

Automated strain engineering . We are able to take the strain engineering processes normally undertaken by people and implement them on standard molecular biology and liquid handling robotics equipment.

 

   

High-throughput assays . We implement the previous two steps in conjunction with the same high-throughput assays used to screen mutagenized strains in order to identify those strains with improved production capabilities.

 

75


Table of Contents

Our two primary strain engineering approaches, random mutagenesis and rational design, also intersect in a way that enables us to leverage both. In addition to using random mutagenesis to generate strains, we also use it to identify hypotheses about further improvements that can be implemented through rational design techniques. By comparing the DNA sequence of a newly identified, improved microorganism to the DNA sequence of its parent strain, we can identify the specific mutations in the improved strain that we believe led to the improvements, and then rationally design them into other strains. Additionally, we can use these identified mutations to generate new hypotheses for rational design.

 

Our progress to date with farnesene demonstrates results obtained from the application of our technology platform. After identifying farnesene as a molecule with commercial potential, we developed a farnesene producing yeast strain and began to apply our strain improvement processes. We increased the peak yield for farnesene from approximately 6% to 15% in 2009 at the two liter laboratory scale.

 

We have selectively transitioned from our laboratories to our pilot plants several strains that we believe have the potential to scale effectively. In doing so, we have demonstrated the ability of certain strains to achieve farnesene yields at the 300 liter pilot scale that are comparable to those achieved at the two liter laboratory scale. Similarly, we have selectively transitioned two of these strains to the 5,000 liter demonstration scale, and these strains have demonstrated yields comparable to those achieved at the two liter and 300 liter scales. We plan to continue to transition our most promising strains to demonstration scale, with the goal of achieving no, or minimal, drop-off in yield levels.

 

The two graphs below show, on the left, our progress in improving farnesene yield at laboratory scale with our increasingly productive yeast strains over the course of 2009 and, on the right, the yields obtained at each of the two liter and 300 liter scales in Emeryville for three of our strains and also at the 300 liter and 5,000 liter scales in Campinas for the two strains that have been further tested there.

 

LOGO

 

We believe that we will be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. Based on our success in matching at the 5,000 liter scale the yields achieved by earlier generation strains at the two liter and 300 liter scales, we believe we can achieve the 15% yield at commercial scale, although we cannot be assured that we will do so until we have fully transitioned to that scale. In order to enter substantially larger markets such as those for diesel and certain specialty chemical products, we must achieve substantially higher farnesene yields than we have achieved to date. We may never achieve the yields needed to address these larger markets.

 

76


Table of Contents

Process Development and Scale-up

 

The basis of our production process is a well established fermentation process that uses our genetically engineered yeast strains to convert the sugar source into target molecules like farnesene. We employ a multi-stage scale-up approach, to progress from laboratory scale to commercial production scale. This approach is depicted in the diagram below.

 

LOGO

 

   

Laboratory scale. This first stage of scale-up evaluates the performance of promising new strains in a fermentation process under conditions approximating our pilot plant conditions. A limited number of strains are selected for further scale-up, and the fermentation process is further optimized to improve performance of each selected strain.

 

   

U.S. pilot plant. Our 300 liter U.S. pilot plant is located in Emeryville, California, adjacent to our laboratories. At this facility, we develop and test complete production processes that will eventually form the basis of processes used for commercial production. The activities we conduct at this pilot plant include feedstock preparation, fermentation runs and product separation. At the Emeryville pilot plant, we use commercially available sucrose as the feedstock.

 

   

Brazil pilot plant. We have a second 300 liter pilot plant located in Campinas, Brazil, which is substantially identical to our pilot plant in Emeryville. Using an identical design and process between the Emeryville and Campinas pilot plants allows us to replicate our processes while incorporating Brazilian sugarcane as our feedstock.

 

   

Brazil demonstration plant . In addition to our two pilot facilities, we have a demonstration facility in Campinas, Brazil, which contains two 5,000 liter fermentors. Here, the production process we developed at the 300 liter scale is further adapted to perform at the 5,000 liter scale, allowing for additional validation of production processes and equipment as we move toward full scale commercial

 

77


Table of Contents
 

production. This facility will provide technology support for development and continuous improvement of our commercial facilities.

 

   

Contract manufacturing . We have also run certain of our strains for farnesene production at contract manufacturing facilities in 60,000 liter fermentors. Thus far, the primary purpose of these operations has been the production of sufficient volumes for product testing. To date, we have produced approximately 50 barrels (or approximately 10,000 liters) of our renewable diesel for testing and certification purposes. However, production at this scale also serves as an indication of the performance of our strains at scales that are larger than that of our demonstration plant, and we anticipate using contract manufacturers for this purpose in the future. We intend to use larger fermentors on a contract manufacturing basis to initiate commercial production and in the future as needed to meet demand.

 

Chemical Finishing Steps

 

Although our product development process starts with identification and development of a target molecule for a specific product application, we also enhance the value of our biologically-derived molecules by finding multiple uses for them. In certain cases, the biologically-derived molecule will itself be the end product and in others it serves as an intermediary molecule that can then be converted into other products by means of simple chemistry steps such as hydrogenation and polymerization. For example, our diesel molecule farnesane is derived by hydrogenating the biologically derived farnesene. However, farnesene can also be converted into other applications such as lubricants, surfactants and squalane by one or more other simple chemistry steps.

 

Production

 

Commercial Production

 

We expect to initiate commercial production through the use of contract manufacturing as we complete our facility at our planned joint venture facility with Usina São Martinho. Following completion of the facility, we will seek to expand our production capacity by entering into agreements with owners of additional sugar and ethanol mills in Brazil. We may also use alternative production resources in other geographies. We anticipate that for many applications chemical finishing processes will be applied to the molecules that we produce in order to create desired products.

 

We are currently developing the engineering designs and technical capabilities to build out facilities at existing sugar and ethanol mills to produce our products. Because the bulk of our production process leverages the same equipment and process steps used to produce ethanol, we will be able to utilize much of the existing infrastructure. We expect this capital light approach will allow us to scale production at a lower cost than the cost of greenfield mill construction. The mill operator will retain the ability to direct the crushed sugarcane to produce either their current products or our products.

 

The manner in which we intend to develop our manufacturing capacity is as follows:

 

Contract manufacturing. To date, we have used contract manufacturing facilities to produce quantities of farnesene needed for certification and fleet testing. We are currently seeking to enter relationships with additional contract manufacturers that will enable us to commercialize our products beginning in 2011. In addition, we may use contract manufacturing to supplement our production capacity as new facilities are coming online and as otherwise needed to help us meet demand for our products.

 

First production in Brazil through joint venture with Usina São Martinho. We have formed a joint venture with Usina São Martinho, a subsidiary of a leading sugar and ethanol company in Brazil, São Martinho S.A., to establish our first commercial-scale production facility at Usina São Martinho, located in São Paulo state, Brazil, which crushed 8.1 million tons of sugarcane in the 2009/2010 harvest season. We expect that production of our products will commence at the facility in the second quarter of 2012.

 

78


Table of Contents

Increasing production in Brazil through arrangements with sugar and ethanol mill owners. We anticipate increasing our commercial production through arrangements with other ethanol and sugar producers in Brazil. We have entered into non-binding letters of intent for production relationships with three sugar and ethanol producers in Brazil, Bunge Limited, Cosan and Açúcar Guarani. If successfully consummated, we believe these production relationships together with the Usina São Martinho mill would provide us with access to over ten million tons of annual crushing capacity, which we expect to expand over time with these and other mills. This capacity represents approximately 9.8% of the total crush capacity of these producers.

 

Alternative geographies for production. Although we have identified the use of new bolt-on facilities adjacent to existing sugar and ethanol mills in Brazil as the optimal source for our primary production efforts, we may use facilities in alternative geographies for certain products. We are also exploring production options in the U.S. Through our “Integrated Biorefinery Grant” from the DOE, which we were awarded in early April 2010, we are evaluating the potential for the production of our renewable products from sweet sorghum grown in Florida, Louisiana, Alabama, Texas and Hawaii.

 

Chemical finishing steps. For each product requiring additional chemical finishing steps, we will evaluate the optimal geographies and facilities for the completion of these steps. These chemical finishing steps may be performed either by our customers or outsourced by us.

 

Cost of Production

 

The primary focus of our research and development efforts at this time is on the refinement of our production processes, particularly the yield level of our farnesene strains, so that we are able to produce our products economically at commercial scale. Other important measures of production efficiency include yeast strain productivity, separation efficiency and chemical process efficiency. Productivity represents the rate at which our product is produced by a given yeast strain. The higher productivity a strain has, the more product can be produced in the same size fermentor in a given period of time. Separation yield refers to the amount of desired product produced in the fermentation process that we are able to extract and the time that it takes to do so. Chemical process efficiency refers to the cost and yield for the chemical finishing steps that convert our target molecule into a desired product.

 

Our Products

 

We are focused on bringing a broad range of products to market, including specialty chemicals and renewable transportation fuels. Our current product development efforts focus on the development and production of a limited number of chemical products and on diesel as our initial transportation fuel. Over time we plan to develop additional chemical and fuel products, and have already begun initial product development and testing efforts with regard to several of these products.

 

For the foreseeable future, the products that we develop will seek to replace petroleum-sourced, or other biological or chemical-derived, components of existing consumer and commercial products in target markets. Our No Compromise commitment is based on the premise that while our customers will value products made from renewable resources, each product must be economically viable and competitive in terms of product quality relative to the existing product that it is seeking to replace. We believe that this philosophy of targeting existing attractive markets with a “green” alternative that is cost-competitive with the current product components and provides comparable or better performance will position our products to achieve acceptance as they become available.

 

A common characteristic of many of the products on which we are initially concentrating is that they are derived from farnesene, which is a 15-carbon molecule produced in our fermentation process. We have the ability to perform finishing processes to chemically convert farnesene into a variety of products, providing significant end market flexibility to our process. Since we first produced farnesene in a microbial system we have been concentrating on decreasing the production costs primarily by increasing the yield. We believe that we will

 

79


Table of Contents

be able to enter certain specialty chemical markets with farnesene if we can attain at commercial production scale the 15% yield that we have achieved at two liter scale. Our ability to enter other specialty chemical markets and the diesel market will depend on our continuing to reduce the production cost of the farnesene molecule.

 

Chemical Products

 

Our first commercialization efforts have been focused on the molecule farnesene, which forms the basis for a wide range of products varying from specialty chemical applications such as emollients, flavors and fragrances, surfactants for various consumer and commercial purposes, isoprene, industrial and automotive oils and lubricants. We continue to seek to identify additional uses of farnesene and to select those uses that enhance our ability to optimize the return on our technology and our production capacity.

 

In addition to farnesene-derived chemicals, we are seeking to develop additional chemical products through modifications to our engineered yeast strains to produce different molecules. These include flavors and fragrances chemicals, such as patchouli oil and sandalwood oil, used widely in perfumery and household products. We are also investigating the production of molecules such as isoprene, which is used extensively for the production of tires, among other uses.

 

While we currently expect to initially pursue the markets described above in the order that we have indicated, we may slow or accelerate the development of one or more of our products based on a variety of factors. Among these will be our ability to continue to lower the production costs of our products. Other contributing factors may include our ability to complete product qualification processes required by our customers and to satisfy any applicable regulatory requirements. We may also elect to change or redirect the pace of development of our chemical products as we continue to evaluate opportunities available to us in the chemical and fuels markets.

 

Transportation Fuels

 

We have selected diesel as our primary area of focus within the transportation fuels market because of its projected global demand growth, the lack of a scalable, competitive renewable product and our belief that our fuel product has properties superior to those of existing renewable alternatives. Testing to date indicates that our diesel will not require engine or distribution infrastructure modifications. An independent third party that we engaged has tested our fuel and determined that it performs as well or better than both petroleum-sourced diesel and biodiesel on many critical ASTM certification metrics, as shown in the following chart:

 

LOGO

 

80


Table of Contents

We will produce our renewable diesel by the simple chemical step of hydrogenating our farnesene. Hydrogenation is a common chemical process currently used in the production of liquid transportation fuels, margarine and numerous other products. We plan to complete this process in one or more locations to be determined based on a variety of factors, including cost, reliability and proximity to the production site and end customer.

 

We have completed significant steps to validate our ability to produce a market-accepted diesel product. By design, our product is a hydrocarbon of similar size to many of the hydrocarbons in petroleum-sourced diesel fuel. Due to the similarity of its chemical composition to that of existing petroleum-sourced diesel, our product has the properties required of diesel fuel and thereby satisfies the American Society for Testing and Materials, or ASTM, D975 Table 1 specifications for petroleum-derived diesel fuel oils. The EPA has registered our diesel for use as a 20% blend with petroleum diesel in standard engines and we are working to obtain registration for a higher blend with petroleum diesel. Our blend ratio compares, by way of example, with the typical 3-5% blend of other bio-diesel products with petroleum diesel. We have completed successful engine testing of our diesel fuel with Cummins and Mercedes-Benz Brasil at a blend of up to 10%, and we continue to work with other diesel engine manufacturers to qualify our product for use in their engines.

 

The prices at which we expect to be able to sell our diesel fuel are lower than those of many of the chemical products that we may sell. Consequently, our ability to successfully enter the diesel fuels market is particularly dependent upon our ability to continue to lower our production costs. Our ability to enter the diesel market is also dependent on our continuing to achieve the required regulatory approvals in the global markets in which we will seek to sell our diesel products. These approvals primarily involve clearance by the relevant environmental agencies in the particular jurisdiction. We must also be certified by a sufficient number of diesel engine manufacturers, vehicle manufacturers or operators of large trucking fleets so that our diesel will have an appropriately large and accessible addressable market. Our experience with Cummins and Mercedes-Benz Brasil supports our belief that because our fuel is substantially similar to petroleum diesel fuel, OEMs are receptive to investing the time and resources needed for the certification process.

 

We believe that we will also have the capacity to produce a jet fuel that is competitive with existing petroleum-sourced jet fuel. Through a different combination of fermentation and chemical finishing steps, we have produced fuels that have the chemical properties required of jet fuel. We have agreements with and/or have begun testing a series of jet fuels through this process with major engine and aircraft manufacturers.

 

Ethanol Sales and Collaborative Research Services

 

Since the second quarter of 2008 we have generated revenues from the purchase and sale of third party ethanol in the U.S. We expect to continue to engage in these purchases and sales to further develop our fuel distribution capabilities in the U.S. We have also derived revenues from providing collaborative research services under agreements with the Bill and Melinda Gates Foundation and sanofi-aventis.

 

Product Distribution and Sales

 

We intend to distribute and sell our products either directly or with partners, depending on the market. For most chemical applications, we intend to sell directly to specialty chemical and consumer products companies. We have entered into discussions with several of these companies, based on our ability to offer an attractive alternative to petroleum-based products by reducing their exposure to commodity price volatility and by providing the benefits of using a renewable ingredient.

 

Our approach to the diesel market will vary by the different regions in which we intend to market our renewable diesel. For Brazil and other markets outside the U.S., we intend to sell indirectly through third parties. In the U.S., we plan to vertically integrate our commercialization efforts to the point of blending our renewable diesel with petroleum-sourced diesel, which may make us eligible to receive certain blend credits. We expect that our customers in the U.S. will be large purchasers of diesel transportation fuels, including corporations with large trucking fleets.

 

81


Table of Contents

Since 2008, we have been developing a fuels distribution network and capabilities in the U.S. through Amyris Fuels, through which we currently purchase ethanol produced by third parties and sell it to wholesale customers. For 2009, Murphy Oil USA, Inc. and The Pantry, Inc. each accounted for more than 10% of our reported revenues by virtue of their purchases of ethanol from Amyris Fuels. Our customers purchase ethanol from us under short term agreements and spot transactions, and we currently do not have any contractual commitments from customers to purchase ethanol from us over a period of time.

 

Intellectual Property

 

Our success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to operate without infringing the proprietary rights of others. We seek to avoid the latter by monitoring patents and publications in our product areas and technologies to be aware of developments that may affect our business, and to the extent we identify such developments, evaluate and take appropriate courses of action. With respect to the former, our policy is to protect our proprietary position by, among other methods, filing for patent applications on inventions that are important to the development and conduct of our business with the U.S. Patent and Trademark Office (“USPTO”) and its foreign counterparts.

 

To date, we have 22 issued U.S. and foreign patents and 195 pending U.S. and foreign patent applications that are owned by or licensed to us. We also use other forms of protection (such as trademarks, copyrights, and trade secrets) to protect our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable. We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach provides us with a strong proprietary position.

 

Notwithstanding the increasing backlog and patent pendency at the USPTO, we have obtained U.S. patents for many of our potential products through the use of a recently introduced accelerated examination program by the USPTO. Using this procedure, we have obtained patents for various fuel products: U.S. Patent No. 7,399,323 covering Amyris Renewable Diesel; U.S. Patent No. 7,540,888 covering Amyris Renewable Gasoline; and U.S. Patents No. 7,589,243 and No. 7,671,245, covering Amyris Renewable Jet Products. Since obtaining our fuels patents, we have expanded the use of this program to our chemicals portfolio and have recently obtained U.S. Patent Nos. 7,592,295 and 7,691,792 for lubricant products, and U.S. Patent No. 7,655,739, which covers adhesive products.

 

We also protect our proprietary information by requiring our employees, consultants, contractors and other advisers to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement. Agreements with our employees also prevent them from bringing the proprietary rights of third parties to us. In addition, we also require confidentiality or material transfer agreements from third parties that receive our confidential data or materials.

 

Competition

 

We expect that our renewable products will compete with both the traditional, largely petroleum-based specialty chemical and fuels products that are currently being used in our target markets and with the alternatives to these existing products that established enterprises and new companies are seeking to produce. Amyris Fuels competes with other ethanol distributors.

 

Chemical Products

 

The chemical products that we initially plan to produce include emollients, flavors and fragrances, surfactants, for various consumer and commercial purposes, isoprene, industrial and automotive oils and lubricants. In these markets, and other chemical markets that we may seek to enter in the future, we will compete with the established providers of components currently used in these products. Producers of these incumbent products include global oil companies, large international chemical companies and other companies specializing in specific products, such as squalane or essential oils. We may also compete in one or more of these markets with products that are offered as alternatives to the traditional petroleum-based or other traditional products being offered in these markets.

 

82


Table of Contents

Transportation Fuel Products

 

Independent and Integrated oil refiners . Our competitors with respect to traditional fuel products are independent and integrated oil refiners. These companies are also our primary competitors with respect to fuels, including jet fuel currently in use in other transportation markets. We compete with these companies because an increasing penetration of renewable fuels reduces the need for fuels derived from traditional petroleum sources.

 

Many of these companies are seeking to provide alternative transportation fuel products through investing in internal research and development programs or in emerging technology companies. These efforts include processes that use non-renewable feedstocks, such as natural gas and coal, and renewable feedstocks, such as vegetable oil and biomass. These technologies are in varying states of development, the most advanced of which are those using non-renewable feedstocks, such as coal. The application of refining technologies to renewable feedstocks is less developed, with demonstration units in operation using vegetable oil or animal fats at a number of oil companies and active research on refining of biomass at other companies.

 

Advanced biofuels . Many other companies are exploring options for the production of diesel and other transportation fuels from renewable resources in other ways. These include companies using enzymes to convert cellulosic biomass, which is non-food plant material such as wood chips, corn stalks and sugarcane bagasse, into fermentable sugars to be converted into renewable fuels.

 

Biodiesel . Another source of renewable fuels products is the biodiesel industry, which is served by large, well-established agricultural products companies that convert vegetable oils, and in some cases animal oils, into diesel fuel. Other companies are seeking to produce diesel and other transportation fuels using thermochemical methods to convert biomass into renewable fuels.

 

We believe the primary competitive factors in both the chemical and fuel markets are:

 

   

product price;

 

   

product performance and other measures of quality;

 

   

infrastructure compatibility of products;

 

   

sustainability; and

 

   

dependability of supply.

 

The oil companies, large chemical companies and well-established agricultural products companies with which we compete are much larger than we are, in many cases have well developed distribution systems and networks for their products, have historical relationships with the potential customers we are seeking to serve and have sales and marketing programs in place to promote their products. In order to be successful, we must convince customers that our products are at least as effective as the products we are seeking to replace and we must provide our products on a cost-competitive basis. Some of our competitors may use their influence to impede the development and acceptance of renewable products of the type that we are seeking to produce

 

We believe that for our chemical products to succeed in the market, we must demonstrate that they are comparable to both existing products and other alternative products that are being developed for the same markets based on some combination of product cost, availability, performance and consumer preference characteristics. With respect to our diesel and other transportation fuels products, we believe that our product must perform as effectively as the petroleum-sourced fuel and be available on a cost-competitive basis. Given the size of the traditional transportation fuels markets and the developing stage of alternatives fuels markets, we do not believe that our success will necessarily prevent other renewable diesel or other fuels products from achieving commercial success, or that the success of other renewable products will prevent our fuels products from being successful. However, with the wide range of renewable fuels products under development, we must be successful in reaching potential customers and convincing them that ours are effective and reliable alternatives.

 

83


Table of Contents

Amyris Fuels

 

Amyris Fuels competes with regional ethanol distributors in the southeastern U.S. The primary competitive factors in the Amyris Fuels business are price, convenience, and reliability of supply.

 

Environmental and Other Regulatory Matters

 

Our development and production processes involve the use, generation, handling, storage, transportation and disposal of hazardous chemicals and radioactive and biological materials. We are subject to a variety of federal, state, local and international laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the U.S., Brazil and other countries where we operate or may operate or sell our products in the future. These laws, regulations and permits can require expensive fees, pollution control equipment or operational changes to limit actual or potential impact of our technology on the environment and violation of these laws could result in significant fines, civil sanctions, permit revocation or costs from environmental remediation. We believe we are currently in substantial compliance with applicable environmental regulations and permitting. However, future developments including our commencement of commercial manufacturing of one or more of our products, requiring more stringent environmental regulation, policies and enforcement, the implementation of new laws and regulations or the discovery of unknown environmental conditions may require expenditures that could have a material adverse effect on our business, results of operations or financial condition. See “Risk Factors—Risks Relating to Our Business—We may incur significant costs complying with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.”

 

The use of GMMs like our yeast strains, is subject to laws and regulations in many countries. In the U.S., the EPA regulates the commercial use of GMMs as well as potential products from the GMMs. The strain of genetically modified yeast that we use, S. cerevisiae , is eligible for exemption from EPA review because the EPA recognizes it as posing a low risk given its long history of safe use and will qualify for such exemption provided that it meets certain criteria, including but not limited to use of compliant containment structures and safety procedures. In Brazil, GMMs are regulated by CTNBio under its Biosafety law No 11.105-2005. We have obtained approval from CTNBio to use GMMs in our Campinas facilities for research and development purposes. In addition, we have obtained initial commercial approval from CTNBio for one of our current yeast strains. We expect to encounter GMM regulations in most if not all of the countries in which we may seek to make our products, however, the scope and nature of these regulations will likely be different from country to country. If we cannot meet the applicable requirements in countries in which we intend to use produce our products using our yeast strains, then our business will be adversely affected. See “Risk Factors—Risks Relating to Our Business—We may not be able to obtain regulatory approval for the use of our genetically modified yeast strains.”

 

Our renewable chemical products may subject to regulation by government agencies in our target markets. The EPA administers the requirements of the TSCA, which regulates the commercial use of chemicals. Before an entity can manufacture a chemical, it needs to determine whether that chemical is listed in the TSCA inventory. If the substance is listed, then manufacture can commence immediately. If not, then a pre-manufacture notice must be filed with the EPA which has 90 days to review.

 

Our diesel fuel is subject to regulation by various government agencies. In the U.S., this includes the EPA and the California Air Resources Board. In Brazil, this includes Agencia Nacional do Petroleo, or ANP. To date we have obtained registration with the EPA for the use of our diesel in the U.S. at a 20% blend rate. We are currently seeking supplemental EPA registration for a 35% blend rate and working to secure ANP approval for use of our diesel in Brazil at a 10% blend rate. We are currently exploring registration of our fuel with the California Air Resources Board and the European Commission. Registration with each of these bodies is required for the sale and use of our fuels within their respective jurisdictions. “Risk Factors—Risks Relating to Our Business—We may not be able to obtain regulatory approval for our renewable products.”

 

84


Table of Contents

Amyris Fuels is subject to various U.S. federal regulations relating to its marketing and distribution of ethanol, and it is registered with the EPA in connection with its use of ethanol as a fuel additive. In addition, Amyris Fuels is subject to various state regulations, including regulations regarding excise tax payments and the posting of surety bonds in connection with ethanol sales.

 

Research and Development

 

We devote substantial resources to our research and development efforts. Our research and development organization is comprised of approximately 190 employees, 60 of whom hold Ph.D.s. Our technology development is currently focused primarily on improving the performance of our production strains and on developing strains that produce new molecules. To facilitate the transfer of our fermentation technology to production, we operate pilot-scale fermentation facilities in both Emeryville, California, and Campinas, Brazil, and transfer strains on a regular basis through this process. Our process consists of a number of discrete steps including:

 

   

identifying new target molecules

 

   

creating new microbial strains capable of producing the target molecule

 

   

increasing product yield and productivity from microbial strains through strain modification or fermentation improvements

 

   

increasing efficiency of product separation and purification

 

   

continuous translation of these steps from lab to commercial scale production.

 

Our research and development expenditures were approximately $8.7 million, $30.3 million and $38.3 million for the fiscal years ended December 31, 2007, 2008 and 2009, respectively.

 

Employees

 

As of April 1, 2010, we had 248 full-time employees. Of these employees, 184 were in the U.S. and 64 were in Brazil. None of our employees is represented by a labor union or is covered by a collective bargaining agreement. We have never experienced any employment-related work stoppages and consider relations with our employees to be good.

 

Facilities

 

We lease approximately 125,000 square feet of space in two adjacent buildings in Emeryville, California, pursuant to two leases. Of this, we use approximately 82,000 square feet for general office purposes and lab space, and approximately 23,000 square feet comprise our pilot plant. Approximately 20,000 square feet of office space was vacated in the restructuring that we completed in August 2009. The leases expire in May 2018. We have an option to extend these leases for five years.

 

Amyris Brasil leases approximately 13,000 square feet of space in Campinas, Brazil, pursuant to a lease that will expire in May 2013. Of this, approximately 9,000 square feet comprise a pilot plant and demonstration facility, and the remainder is general office and lab space. Amyris Brasil has a right of first refusal to purchase the space if the landlord elects to sell it and an option to extend the lease for five additional years.

 

Amyris Fuels has secured the use of ethanol storage tanks with an aggregate capacity of 32,500 barrels at various locations in Virginia, North Carolina, South Carolina, Georgia and Tennessee. The agreements have initial terms of approximately three years, which begin expiring in 2011. Upon expiration of the respective initial term, each agreement will continue for successive one-year terms until terminated by one of the parties.

 

We also use a small amount of office space in Oakbrook Terrace, Illinois.

 

We believe that our current facilities are suitable and adequate to meet our needs and that suitable additional space will be available to accommodate the foreseeable expansion of our operations.

 

85


Table of Contents

MANAGEMENT

 

Executive Officers and Directors

 

The following table sets forth information regarding our executive officers, directors and key employees as of March 31, 2010.

 

Name

   Age   

Position

Directors:

     

John Melo

   44    Director, President and Chief Executive Officer

Ralph Alexander (1)

   55    Director

John Doerr (2)

   58    Director

Geoffrey Duyk, M.D., Ph.D. (1) (2)

   51    Director

Samir Kaul (2)

   36    Director

Patrick Pichette (1)

   47    Director

Carole Piwnica

   52    Director

Keith Kinkead Reiling, Ph.D.

   36   

Director and Senior Vice President of Corporate Development

Fernando de Castro Reinach, Ph.D.

   53    Director

Other Executive Officers:

     

Jeryl Hilleman

   52    Chief Financial Officer

Peter Boynton

   55    Chief Commercial Officer

Joel Cherry, Ph.D.

   49    Senior Vice President, Research Programs and Operations

Jefferson Lievense, Ph.D.

   55   

Senior Vice President, Process Development and Manufacturing

Mario Portela

   48    Chief Operating Officer

Neil Renninger, Ph.D.

   35    Chief Technical Officer

Tamara Tompkins

   45    Senior Vice President, General Counsel and Secretary

Key Employees:

     

Jack Newman, Ph.D.

   43    Senior Vice President, Research

 

  (1)   Member of Audit Committee
  (2)   Member of Compensation Committee

 

Directors

 

John Melo

 

John Melo has served as our President and Chief Executive Officer and a director since January 2007 and our President since January 2008. Before joining Amyris, Mr. Melo served in various senior management positions at BP Plc (formerly British Petroleum), one of the world’s largest energy firms, from 1997 to 2006, most recently as President of U.S. Fuels Operations from 2004 until December 2006, and previously as Chief Information Officer of the refining and marketing segment from 2001 to 2003, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, from 2000 to 2001, and Director of Global Brand Development from 1999 to 2000. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, from 1996 to 1997, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of U.S. Oil Company. Mr. Melo’s experience as a senior executive at one of the world’s largest energy companies provides critical leadership in designing the fuels value chain, shaping strategic direction and business transactions, and in building teams to drive innovation.

 

86


Table of Contents

Ralph Alexander

 

Ralph Alexander has been a member of our Board of Directors since May 2007. Mr. Alexander has been a Managing Director at Riverstone Holdings, LLC, an energy and power-focused private equity firm, since September 2007. Previously, he served in various senior management positions with affiliates and subsidiaries of BP Plc (formerly British Petroleum), most recently as Chief Executive Officer of Innovene, BP’s olefins and derivatives subsidiary, from 2004 to December 2005, as Chief Executive Officer of BP’s Gas, Power and Renewables and Solar segment from 2001 to 2004, and as a Group Vice President in BP’s Exploration and Production segment and BP’s Refinery and Marketing segment. Mr. Alexander has served on the board of directors of Stein Mart Inc. since August 2007. Mr. Alexander previously served on the boards of directors Anglo-American Plc from April 2005 to October 2007 and of Foster Wheeler from May 2006 to February 2007. He is currently deputy-chairman of the board of Polytechnic University. Mr. Alexander holds a Bachelor of Science degree and a Master of Science degree in Nuclear Engineering from Brooklyn Polytech (now Polytechnic University), and a Master of Science degree in Management Science from Stanford University. Mr. Alexander’s extensive experience with the energy industry generally and renewable fuels in particular enables him to provide important insight and guidance to our management team and Board of Directors.

 

John Doerr

 

John Doerr has been a member of our Board of Directors since May 2006. Mr. Doerr has been a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, since 1980. Mr. Doerr currently serves on the board of directors of Google Inc., as well as on the boards of directors of several private companies. Previously, Mr. Doerr served on the boards of directors of Amazon.com, Inc., Move, Inc., drugstore.com, Inc., Homestore.com, Inc., palmOne, Inc. and Sun Microsystems, Inc. Mr. Doerr holds a Bachelor of Science and a Master of Science in Electrical Engineering and Computer Science degrees from Rice University and a Master of Business Administration degree from Harvard University. Mr. Doerr’s global business leadership as general partner of Kleiner Perkins Caufield & Byers, as well as his outside board experience as director of several public companies enable him to provide valuable insight and guidance to our management team and Board of Directors.

 

Geoffrey Duyk, M.D., Ph.D.

 

Dr. Geoffrey Duyk has been a member of our Board of Directors since May 2006. Dr. Duyk is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P. Previously, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of several private companies and the non-profit Wesleyan University Board of Trustees. He served on the board of directors of Agria Corporation from August 2007   to May 2009, Cardiovascular Systems, Inc. (formerly Replidyne, Inc.) from 2004 to February 2009, Exelixis, Inc. from 1996 to 2003, and several private companies. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and Doctor of Philosophy and medical degrees from Case Western Reserve University. Mr. Duyk’s experience with the biotechnology industry enables him to provide insight and guidance to our management team and Board of Directors.

 

Samir Kaul

 

Samir Kaul has been a member of our Board of Directors since May 2006. Mr. Kaul has been a General Partner at Khosla Ventures, a venture capital firm focusing on clean technologies, since February 2006. Previously, Mr. Kaul was a member of Flagship Ventures, a venture capital firm, from 2002 to May 2006. Prior to Flagship, Mr. Kaul worked at The Institute for Genomic Research (TIGR). Mr. Kaul currently serves on the boards of directors of several private companies. Mr. Kaul holds a Bachelor of Science degree in Biology from the University of Michigan, a Master of Science degree in Biochemistry from the University of Maryland and a

 

87


Table of Contents

Master of Business Administration degree from Harvard University. Mr. Kaul provides our Board of Directors with wide-ranging experience in synthetic biology and high throughput system development and insight in the management of startup companies.

 

Patrick Pichette

 

Patrick Pichette has been a member of our Board of Directors since March 2010. Mr. Pichette has been a Senior Vice President and the Chief Financial Officer of Google Inc., an internet search company, since August 2008. Previously, he served in various senior financial management positions at Bell Canada, a telecommunications firm, from 2001 to July 2008, most recently as President, Operations from 2004 to July 2008 and, from 2002 to 2003, as Chief Financial Officer. Mr. Pichette was a partner at McKinsey & Company, a consulting firm, from 1996 to 2000, and served as Vice President and Chief Financial Officer of Call-Net Enterprises, a Canadian telecommunications company, from 1994 to 1996. Mr. Pichette served on the board of directors of Alaska Communication Systems, Inc. from 2004 to August 2008 and Aliant Communications Systems Group, Inc. from 2006 to August 2008. He currently serves on the boards of the non-profit organizations Engineers Without Borders and the Trudeau Foundation. Mr. Pichette holds a Bachelor of Arts degree in Business Administration from Université du Québec à Montréal and a Master of Arts degree in Philosophy, Politics and Economics from Oxford University, where he attended as a Rhodes Scholar. Mr. Pichette’s expertise in accounting, finance, international financial operations and management enables him to provide important insight and guidance to our management team and Board of Directors and to serve as a member of our Audit Committee.

 

Carole Piwnica

 

Carole Piwnica has been a member of our Board of Directors since September 2009. Ms. Piwnica has been Director of NAXOS UK, a consulting firm advising private equity, since January 2008. Previously, Ms. Piwnica served as a director, from 1996 to July 2006, and Vice-Chairman of Governmental Affairs, from 2000 to 2006, of Tate & Lyle Plc, a European food and agricultural ingredients company. She was a director of S.A. Spadel N.V., a European soft drink company, from 1998 to 2004, and a chairman of Amylum Group, a European food ingredient company and subsidiary of Tate & Lyle Plc, from 1996 to 2000. From 1992 to 1996, Ms. Piwnica held general management positions and board memberships in various other European food companies, including Cacao Barry and Vital Sogéviandes. Ms. Piwnica currently serves on the boards of directors of Toepfer International GmbH, Dairy Crest Group Plc and Aviva Plc. She was a member of the Biotech Advisory Council of Monsanto from May 2006 to October 2009. Ms. Piwnica holds a Law degree from the Université Libre de Bruxelles and a Master of Laws degree from New York University. Ms. Piwnica provides the Board of Directors and management with significant experience in corporate leadership in multinational firms.

 

Keith Kinkead Reiling, Ph.D.

 

Dr. Reiling is a co-founder of Amyris and has been a member of our Board of Directors since July 2008 and from 2003 to May 2006. Dr. Reiling has served as our Senior Vice President, Corporate Development since January 2008 and also served as our President from 2003 to January 2008. He holds a Bachelor of Science degree in Physics from the University of California, Los Angeles, a Master of Science degree in Applied Physics from Columbia University and a Doctor of Philosophy degree in Biophysics from the University of California, San Francisco. Dr. Reiling provides our Board of Directors with insight into the fundamental science behind Amyris’ technology and the application of that technology in the chemicals and fuels sectors.

 

Fernando de Castro Reinach, Ph.D.

 

Dr. Fernando de Castro Reinach has been a member of our Board of Directors since September 2008. Dr. Reinach has been a General Partner at Votorantim Novos Negócios Ltda., the private equity arm of Votorantim Group, a large Brazilian industrial group, since 2001. Before joining Votorantim, he was involved in

 

88


Table of Contents

the creation of two companies, Genomic Engenharia Molecular Ltda., a molecular diagnostic laboratory, and .ComDominio S/A, a datacenter company. Dr. Reinach currently serves on the board of directors of Tivit Terceirização de Processos, Serviços e Tecnologia S/A, a Brazilian IT company which is publicly traded in Brazil. Dr. Reinach holds Bachelor of Science degree in biology from the University of São Paulo and a Doctor of Philosophy degree in Cell and Molecular Biology from Cornell University Medical College. Dr. Reinach’s experience with Brazilian business practices and startup companies enable him to provide important insight and guidance to our management team and Board of Directors and to assist management with establishing and developing operations in Brazil.

 

Other Executive Officers

 

Jeryl Hilleman

 

Jeryl Hilleman has served as our Chief Financial Officer since January 2008. Before joining Amyris, from 1997 to June 2007, she was Executive Vice President and Chief Financial Officer of Symyx Technologies, Inc., a research and development infrastructure company providing scientific software and research services to technology companies. Before Symyx, Ms. Hilleman worked with two biotechnology companies, Geron Corporation, a biopharmaceutical company, as Vice President, Finance from 1992 to 1997, and Cytel Corporation, a provider of clinical trial design tools, services and statistics applications, as Chief Financial Officer from 1987 to 1992. Ms. Hilleman holds a Bachelor of Arts degree in History from Brown University and a Master of Business Administration degree from the Wharton Graduate School of Business.

 

Peter Boynton

 

Peter P. Boynton has served as our Chief Commercial Officer since December 2009. Mr. Boynton joined Amyris from Tate & Lyle Plc, a global food and agricultural ingredients company, where he served in various positions from 1999 to December 2009, most recently as Senior Vice President, Bio-products and Fermentation. Previously, he held multiple positions at Cargill, Inc., a privately held food and agriculture company, from 1980 to 1998, lastly as Vice President NACM. Mr. Boynton holds a Bachelor of Science degree in Economics from the University of Georgia.

 

Joel Cherry, Ph.D.

 

Dr. Joel Cherry has served as our Senior Vice President of Research Programs and Operations since November 2008. Before joining Amyris, Dr. Cherry was Senior Director of Bioenergy Biotechnology at Novozymes, a biotechnology company focusing on development and manufacture of industrial enzymes from 1992 to November 2008. At Novozymes, he served in a variety of R&D scientific and management positions, including membership in Novozymes’ International R&D Management team, and as Principal Investigator and Director of the BioEnergy Project, a U.S. Department of Energy-funded $18 million effort initiated in 2000. Dr. Cherry holds a Bachelor of Arts degree in Chemistry from Carleton College and a Doctor of Philosophy degree in Biochemistry from the University of New Hampshire.

 

Jefferson Lievense, Ph.D.

 

Dr. Jefferson Lievense has served as our Senior Vice President of Process Development and Manufacturing since December 2007. Before joining Amyris, he was the Vice President of Technology and Process Development and served in other technology management positions for the Research and Development organization of Tate & Lyle Plc, a European food and agricultural ingredients company, from 1994 to November 2007. Prior to that, he was Vice President of Research and Operations and President of the Bio-Business Incubator of Michigan for Michigan Biotechnology Institute from 1993 to 1994, Director of Chemical Programs and Pathway Engineering for Genencor International from 1990 to 1993, and held various process engineering, research scientist and product management positions at Eastman Kodak Company from 1982 to 1989.

 

89


Table of Contents

Dr. Lievense holds a Bachelor of Science degree in Chemical Engineering from The University of Michigan and a Doctor of Philosophy degree in Chemical Engineering from Purdue University.

 

Mario Portela

 

Mario Portela joined us as our Chief Operating Officer in December 2009. He also serves as Chair of the Board of Directors of Amyris Brasil. He has also worked since December 2008 as an advisor to TPG Capital on strategy, mergers and acquisitions. From December 2007 to December 2008, Mr. Portela was Vice President and Officer, Corporate Development, with LyondellBasell Industries, a leading manufacturer of polymers, petrochemicals, fuels and technology licensing. He held a similar position with Lyondell Chemical Company from 2003 until its merger with Basell in December 2007. Mr. Portela holds a degree in Mechanical Engineering from the IMPE Institute in Lisbon, Portugal.

 

Neil Renninger, Ph.D.

 

Dr. Neil Renninger is a co-founder of Amyris and has served as our Chief Technical Officer since January 2008, and has also served as our Vice President of Development from 2003 to March 2007 and as our Senior Vice President of Development from March 2007 to January 2008. Dr. Renninger holds a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology, a Master of Science degree in Environmental Engineering and a Doctor of Philosophy degree in Chemical Engineering from the University of California, Berkeley.

 

Tamara Tompkins

 

Tamara Tompkins has served as our General Counsel since February 2005, Secretary since November 2005 and Senior Vice President since July 2007. Before joining Amyris, she practiced as an attorney at Morgan, Lewis & Bockius LLP, a law firm, from 2003 to February 2005. Previously, Ms. Tompkins worked as an attorney at Brobeck, Phleger & Harrison LLP, a law firm, from 1996 to 1999 and from 2000 to 2003, and Shearman & Stearling LLP, a law firm, from 1994 to 1996. From 1999 to 2000, she was the Director of the Berkeley Center for Law and Technology at the Boalt Hall School of Law. Ms. Tompkins holds a Bachelor of Arts degree in History from Middlebury College and a Juris Doctor degree from Georgetown University Law Center.

 

Key Employee

 

Jack Newman, Ph.D.

 

Dr. Jack Newman is a co-founder of Amyris and has served as our Senior Vice President of Research since July 2007, and also served as our Director, Biology from 2004 to June 2007. Dr. Newman holds a Bachelor of Arts degree in Molecular and Cell Biology from the University of California, Berkeley and a Doctor of Philosophy degree from the University of Wisconsin-Madison in the field of microbial physiology and gene regulation.

 

Our executive officers are elected by, and serve at the discretion of, our Board of Directors. There are no family relationships among any of our directors and executive officers.

 

Board of Directors

 

Under our amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering, our Board of Directors may set the authorized number of directors. Each director currently serves until our next annual meeting or until his or her successor is duly elected and qualified. Upon the completion of this offering, our common stock will be listed on                                 . The rules of                                  require that a majority of the members of our Board of Directors be independent within specified periods following the closing of this offering. We believe that seven of our directors are independent as determined under these rules: Ralph Alexander, John Doerr, Dr. Geoffrey Duyk, Samir Kaul, Patrick Pichette, Carole Piwnica and Dr. Fernando de Castro Reinach.

 

90


Table of Contents

Pursuant to a voting agreement as most recently amended and restated on March 12, 2010, Messrs. Kaul and Doerr and Dr. Duyk were appointed to our Board of Directors by certain of our investors. As of the date of this prospectus, Messrs. Kaul and Doerr and Dr. Duyk continue to serve on our Board of Directors and will continue to serve as directors until their resignation or until their successors are duly elected by the holders of our common stock, despite the fact that the voting agreement will terminate upon the completion of this offering.

 

Immediately prior to the completion of this offering, we will file our amended and restated certificate of incorporation. We anticipate that the amended and restated certificate of incorporation will divide our Board of Directors into three classes, with staggered three-year terms:

 

   

Class I directors, whose initial term will expire at the annual meeting of stockholders to be held in 2011;

 

   

Class II directors, whose initial term will expire at the annual meeting of stockholders to be held in 2012; and

 

   

Class III directors, whose initial term will expire at the annual meeting of stockholders to be held in 2013.

 

At each annual meeting of stockholders after the initial classification, the successors to directors whose terms have expired will be elected to serve from the time of election and qualification until the third annual meeting following such election. Upon the completion of this offering, the Class I directors will consist of             ,              and             ; the Class II directors will consist of             ,              and             ; and the Class III directors will consist of             ,              and             . As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.

 

In addition, we intend to amend and restate our certificate of incorporation and bylaws immediately prior to the completion of this offering to provide that only our Board of Directors may fill vacancies on our Board of Directors until the next annual meeting of stockholders. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the total number of directors.

 

The classification of our Board of Directors and provisions described above may have the effect of delaying or preventing changes in our control or management. See “Description of Capital Stock—Anti-Takeover Provisions—Restated Certificate of Incorporation and Restated Bylaw Provisions.”

 

Board Committees

 

Our Board of Directors has an Audit Committee and a Compensation Committee and will have a Nominating and Governance Committee, each of which has the composition and responsibilities described below as of the closing of this offering. Members serve on these committees until their resignations or until otherwise determined by our Board of Directors.

 

Audit Committee

 

Our Audit Committee is comprised of Mr. Alexander, Dr. Duyk and Mr. Pichette, who is the chair of the Audit Committee. The composition of our Audit Committee meets the requirements for independence under the current stock exchange and SEC rules and regulations. Each member of our Audit Committee is financially literate. In addition, we believe that Mr. Pichette is an “audit committee financial expert” as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act of 1933, as amended, or the Securities Act. Being an “audit committee financial expert” does not impose on Mr. Pichette any duties, obligations or liabilities that are greater than are generally imposed on him as a member of our Audit Committee and our Board of Directors. Our Board of Directors adopted a charter for our Audit Committee. Our Audit Committee, among other things, will:

 

   

oversee our accounting and financial reporting processes and audits of our consolidated financial statements;

 

91


Table of Contents
   

oversee our relationship with our independent auditors, including appointing and changing our independent auditors and ensuring their independence;

 

   

review and approve the audit and permissible non-audit services to be provided to us by our independent auditors;

 

   

facilitate communication among the independent auditors, our financial and senior management and the Board of Directors; and

 

   

monitor the periodic reviews of the adequacy of the accounting and financial reporting processes and systems of internal control.

 

Compensation Committee

 

Our Compensation Committee is comprised of Messrs. Doerr and Kaul and Dr. Duyk. The composition of our Compensation Committee meets the requirements for independence under the current stock exchange and SEC rules and regulations. The purpose of our Compensation Committee is to provide guidance and periodic monitoring for all of our compensation, benefit, perquisite and employee equity programs. We anticipate that our Compensation Committee will recommend, and our Board of Directors will adopt, a new charter for our Compensation Committee. Our Compensation Committee will discharge the responsibilities of our Board of Directors relating to compensation of our executive officers, and will, among other things:

 

   

review and approve, or recommend that our Board of Directors approve, the compensation of our executive officers;

 

   

review and recommend to our Board of Directors the compensation of our directors;

 

   

review and approve the terms of any material agreements with our executive officers;

 

   

administer our stock and equity incentive plans;

 

   

review and make recommendations to our Board of Directors with respect to incentive compensation and equity plans; and

 

   

establish and review our overall compensation philosophy.

 

Nominating and Governance Committee

 

We intend to establish a Nominating and Governance Committee by the time we complete this offering.

 

We intend to post the charters of our audit, compensation, and nominating and governance committees, and any amendments that may be adopted from time to time, on our website.

 

Compensation Committee Interlocks and Insider Participation

 

During fiscal 2009, our Compensation Committee consisted of Messrs. Doerr and Kaul and Dr. Duyk. None of them has at any time in the last fiscal year been one of our officers or employees, and none has had any relationships with our company of the type that is required to be disclosed under Item 404 of Regulation S-K. None of our executive officers has served as a member of the Board of Directors, or as a member of the compensation or similar committee, of any entity that has one or more executive officers who served on our Board of Directors or Compensation Committee during fiscal 2009. Messrs. Doerr and Kaul have pecuniary interests in their respective affiliated venture funds and may be deemed to have an interest in certain transactions with us, as more fully described in “Certain Relationships and Related Party Transactions” below.

 

92


Table of Contents

Code of Business Ethics and Conduct

 

Our Board of Directors will adopt a code of business conduct by the time we complete this offering. The code of business conduct will apply to all of our employees, officers and directors. The full text of our code of business conduct will be posted on our website. We intend to disclose future amendments to certain provisions of our code of business conduct, or waivers of these provisions, on our website and also in public filings.

 

Director Compensation

 

Our employee directors, Messrs. Melo and Reiling, have not received any compensation in connection with their service as directors. The compensation that we pay to Mr. Melo is discussed in the “Executive Compensation” section of this prospectus. As described under “Management—Executive Officers and Directors,” Mr. Reiling is employed in the capacity of Senior Vice President of Corporate Development and receives cash compensation and equity awards in such capacity, as determined by our Compensation Committee.

 

We pay our non-employee directors who are not affiliated with any of our stockholders a $5,000 fee for each meeting attended by them. This policy currently applies to Mr. Ralph Alexander and Ms. Carole Piwnica. In fiscal year 2009, pursuant to this policy, Mr. Alexander and Ms. Piwnica earned the fees described in the table below.

 

Name

   Fees Earned or Paid in Cash ($)

Ralph Alexander

   $ 10,000

Carole Piwnica

   $ 5,000

 

Except for meeting attendance fees in accordance with the policy described above, since our incorporation we have not paid any cash compensation to any of our directors for their service on the Board of Directors or on committees of the Board of Directors.

 

Certain of our non-employee directors were granted options to purchase shares of our common stock, as follows:

 

Name

   Date of Grant    Number of  Shares
Underlying
Unexercised
Option (1)
    Exercise Price
Per Share($)
   Vesting Start
Date
    Grant Date Fair
Value of Option
Awards ($) (2)

Ralph Alexander

   9/27/2007    45,000 (3)     3.93    7/20/2007 (4)     116,649

Patrick Pichette

   3/19/2010    100,000 (3)     14.28    3/4/2010 (5)     1,126,040
Dr. Fernando de Castro Reinach (6)    9/15/2008    60,000 (7)     3.93    9/15/2008 (8)     387,906

 

  (1)   None of the options reported in this table have been exercised as of the date of this prospectus.
  (2)   The amount in this column reflects the aggregate grant date fair value computed in accordance with ASC Topic 718. The assumptions used by us in determining the grant date fair value of option awards are set forth in Note 13 to our Consolidated Financial Statements included elsewhere in this prospectus. These amounts do not correspond to the actual value that will be recognized by the directors. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our Consolidated Financial Statements.
  (3)   These options are immediately exercisable without regard to vesting schedule. We retain a right of repurchase of unvested shares resulting from exercise of such options.
  (4)   This option vested over two years from the vesting start date.
  (5)   This option will vest in quarterly increments over three years from the vesting start date at a rate of 1/12 per quarter.
  (6)   This option was granted in consideration for Dr. Reinach’s service on the Board of Directors and was issued in the name of Lit Tele, Inc., whose parent is an affiliate of Dr. Reinach, as more fully described in the “Certain Relationships and Related Party Transactions” section below.

 

93


Table of Contents
  (7)   These options are not immediately exercisable and can be exercised only with respect to vested underlying shares.
  (8)   This option will vest in equal quarterly increments over three years from the vesting start date at a rate of 1/12th per quarter.

 

John Doerr, Dr. Geoffrey Duyk, Samir Kaul and Carole Piwnica have not to date received any options to purchase shares of our common stock or other equity awards in connection with their service on our Board of Directors.

 

Executive Compensation

 

Compensation Discussion and Analysis

 

The following discussion describes and analyzes our compensation for our named executive officers for 2009, which include our President and Chief Executive Officer (“CEO”), our Chief Financial Officer (“CFO”) and the three most highly compensated executive officers other than the CEO and CFO as set forth in the “ Summary Compensation Table ” below (our “named executive officers”).

 

We are building an integrated renewable products company by applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. Since our formation we have conducted substantial efforts to, and we continue to, further develop our technology platform. We have also engaged in extensive discussions and negotiations with third parties that we expect will provide facilities and feedstock for the production of our products and other third parties that we expect will purchase products that we produce. We have raised a substantial amount of capital from investors to support our growth as we seek to bring our products to market as well as from research institutions and other entities for the provision of collaborative research services and from government grants. Our success depends, among other things, on attracting and retaining executive officers with experience and skills in a number of different areas as we continue to further develop our products and seek to commercialize them.

 

We were formed in 2003. While our founders continue to serve us in key capacities, we have added a number of executive officers since our formation, including our CEO, CFO and other executives. These additional officers have joined us at various times from 2005 through December 2009.

 

Compensation Philosophy and Objectives and Elements of Compensation

 

Our intent and philosophy in designing compensation packages at the time of hiring new executives has been based in part on providing compensation that we thought was sufficient to enable us to attract the talent necessary to further develop our business while at the same time being prudent in the management of our cash and equity in light of the early stage of the development of our company. Compensation of our executive officers after the initial period following their hiring has been influenced by the amounts of compensation that we initially agreed to pay them as well as by our evaluation of their subsequent performance, changes in their levels of responsibility, prevailing market conditions, the financial condition and prospects of our company and our attempt to maintain some level of internal equity in the compensation of existing executives relative to the compensation paid to more recently hired executives.

 

We have compensated our executives with a combination of salaries, cash bonuses and stock option awards. We think this combination of cash and equity is largely consistent with the forms of compensation provided by other companies with which we compete for executive talent, and as such is a package that matches the expectations of our executives and of the market for executive talent. We also believe that it provides an appropriate blend of compensation to retain our executives, reward them for performance in the short term and induce them to contribute to the creation of value in the Company over the long term.

 

94


Table of Contents

We view the different components of our executive compensation as distinct. We believe we must maintain a salary that is sufficiently competitive to position us to attract the executives that we need and that it is important that our executives perceive that over time they will continue to have the opportunity to earn a salary that they regard as competitive.

 

The ability to earn cash bonuses should incentivize executives to effectively pursue goals established by our Board of Directors and should be regarded by executives as appropriately rewarding effective performance against these goals. We have in the past sought to establish target bonus levels and performance goals for executives at the beginning of the year to help ensure that our performance goals, and the bonus attainable for achieving these goals, were well understood by executives.

 

Our equity awards are also designed to be sufficiently competitive to allow us to attract executives. We have used stock options as the form of equity award for executives. Because our executive officers are awarded stock options with an exercise price equal to the fair market value of our common stock on the date of grant, these options will have value to our named executive officers only if the market price of our common stock increases after the date of grant. Typically, since November 2007 our stock option awards to executive officers vested and became exercisable at a rate of 20% upon the one-year anniversary of grant and then monthly over the following four years. Our Board of Directors believes that these stock option awards align the interests of our named executive officers with those of the stockholders, because they create the incentive to build stockholder value over the long-term. In addition, our Board of Directors believes the five-year vesting provision of our equity awards improves our ability to retain our executives. We have also determined that in order to attract qualified executives in our market it is highly desirable to provide equity compensation that is regarded as competitive relative to the compensation provided by other privately held, venture-backed companies.

 

We grant stock options to executive officers in connection with their hiring. The size of the initial stock option award is determined based on the executive’s position with us and takes into consideration the executive’s base salary and other compensation as well as an analysis of the grant and compensation practices of the companies that participate in the survey that we have reviewed in the past in connection with establishing our overall compensation policies. The initial stock option awards are intended to provide the executive with an incentive to build value in the organization over an extended period of time, while remaining consistent with our overall compensation philosophy. Insofar as we have to date incurred operating losses and consumed substantial amounts of cash in our operations, we have sought to attract executives to join us by compensating for cash salaries and cash bonus opportunities that were, in certain cases, lower than the salaries and bonuses they earned in their prior positions with stock options having the potential to provide significant value if we were successful.

 

We may also grant additional stock option grants in recognition of a commendable performance and in connection with a significant change in responsibilities. Typically, our Board of Directors determines to make equity awards upon the recommendation of the Compensation Committee. In making its recommendation or determination, the Committee or Board takes into account various factors. These factors include the responsibilities, past performance and anticipated future contribution of the executive officer, the executive’s overall compensation package and the executive’s existing equity holdings.

 

Stock options are granted with an exercise price equal to the fair value of our stock on the applicable date of grant. Upon completion of this offering, we expect to determine fair value for purposes of stock option pricing based on the most recent closing price of our common stock on the stock exchange on which our common stock is listed.

 

As further discussed below, our compensation philosophy for 2009 was significantly influenced by the deteriorating global economic circumstances that began to materialize in late 2008.

 

95


Table of Contents

Compensation Decision Process

 

Historic. Since our formation, our Board of Directors has overseen the compensation of our executive officers and our executive compensation programs and initiatives. While we have had a Compensation Committee of the Board, this committee has acted in an advisory role, assisting the Board of Directors in compensation matters. The Board of Directors has also sought, and received, significant input from our CEO with regard to the performance and compensation of executives other than himself.

 

In making compensation decisions for executive officers, we have referred to compensation survey data of competitive conditions in our market. With regard to annual base salaries and annual cash incentive bonus opportunity targets for fiscal year 2009, our Board of Directors reviewed comprehensive compensation data from the Radford Global Life Sciences Survey, which aggregated survey results from 130 biotechnology, pharmaceutical and medical device companies in Northern California with revenues of less than $1 billion. In addition, certain of our directors have significant experience with privately held venture-backed companies such as our and the executive compensation practices of such companies, and have applied this knowledge and experience to their judgments regarding our compensation decisions.

 

Post-offering . Prior to the completion of this offering, we anticipate that our Compensation Committee will recommend, and our Board of Directors will adopt, a new charter for our Compensation Committee which will expand the committee’s responsibilities. Currently, our Compensation Committee is comprised of Messrs. Doerr and Kaul and Dr. Duyk. In accordance with the amended charter, the Committee will determine the annual compensation of our CEO and other executive officers and will regularly report its compensation decisions to the full Board of Directors. The Committee will also administer our equity compensation plans, including our 2010 Equity Incentive Plan and 2010 Employee Stock Purchase Plan, which will become effective on or shortly after the date of this prospectus.

 

The Committee has not yet made significant decisions about the process that it will employ in performing these functions. All of our named executive officers continue to be paid the same salary that was in place at the end of 2009. We have retained Compensia, a compensation advisory firm, to support the Compensation Committee in developing our compensation structure as a publicly-held company. We expect that the Compensation Committee, with assistance from Compensia, will develop a peer group of companies to which it will refer in making compensation decisions regarding executive compensation.

 

2009 Compensation

 

In the final months of 2008, our Board of Directors recognized that the dramatically deteriorating condition of the global economy was likely to have an adverse affect on our business and prospects, at least in the near term. In the face of the challenging conditions of the financial markets at that time, our ability to continue to fund our operations through private placements of equity securities was uncertain.

 

In light of these conditions, in late 2008 our Board of Directors elected to forego our customary year-end process of considering changes in salaries for executive officers. Instead, the Board of Directors froze salaries at the time for all executive officers, as salaries were frozen for virtually all our employees. As a result, Mr. Melo’s and Ms. Tompkins’ salaries remained at the same level as had been in place since January 2008, the last previous time that their salaries were increased. The salaries of Ms. Hilleman and Messrs. Cherry and Lievense remained at the same levels as had been established at the times that they were hired by us, between December 2007 and November 2008.

 

The Board of Directors also elected at this time not to put in place a cash bonus program for executives as it had in 2007-2008. In addition, the Board of Directors determined not to pay any cash bonuses to executives for services rendered in 2008.

 

96


Table of Contents

Later in 2009, it appeared that the deterioration in global economic conditions had slowed, if not ceased. Activity in the public equity markets in the U.S. and in venture capital financings began to suggest that the ability for privately held companies to raise capital, while still challenging, was improving from the conditions existing in late 2008 and most of 2009. Recognizing this improvement, the Board approved an increase in the annual salary of our CEO by $100,000, to $500,000, effective December 1, 2009. This salary increase was made in recognition of raising private equity through the sale of our Series C convertible preferred stock, progress that was made with sugar and ethanol producers for securing production capacity in Brazil and expansion of the management team through the hiring of a chief operating officer and chief commercial officer. In addition, the Board of Directors approved, also effective December 1, 2009, an increase in the annual salary of our General Counsel of $29,500, to $300,000, recognizing that Ms. Tompkins’ responsibilities had increased substantially as we continued to increase the size and scope of our operations and that her salary was lower than that of the other named executive officers by approximately this amount. The Board of Directors also took into account that each of these officers last received a salary increase effective January 1, 2008.

 

In the second half of 2009, the Board of Directors also approved a bonus payment to Mr. Melo of $200,000 in recognition of the factors described above that were considered in approving Mr. Melo’s salary increase. Mr. Melo and the Board of Directors approved the amounts of cash bonus payments to each of the other named executive officers as are set forth in the Summary Compensation Table appearing below. The bonuses were made in recognition of the support of these executives in the achievement of the factors considered by the Board in approving Mr. Melo’s salary increase. In awarding these bonuses, the Board of Directors also took account of the fact that, other than Ms. Tompkins, none of these executive officers had received a salary increase or bonus since joining us.

 

In 2009, we granted stock options to three of our named executive officers. In September 2009, we granted options for the purchase of 210,000 shares to Mr. Cherry pursuant to the commitment we made at the time of hiring Mr. Cherry to grant him this number of stock options. Options for the purchase of 50,000 shares were granted to Mr. Leivense in recognition of the substantial and effective efforts made to oversee the development of our pilot and demonstration facilities in Brazil in 2009. Options for the purchase of 10,000 shares were granted to Ms. Tompkins in order to bring her aggregate option position closer in line with the option holdings of more recently hired executives and in recognition of efforts made in connection with the further development of Amyris Brasil and the joint venture with Usina São Martinho.

 

Severance and Change of Control Agreements

 

We have entered into offer letters, or amendments to offer letters, with each of our named executive officers providing for certain payments upon termination of their employment with us without cause and upon termination without cause following a change of control. These payments, and the definition for this purpose of change of control, are described in detail below under Potential Severance Payments upon Termination and upon Termination Following a Change in Control .

 

We believe that these agreements appropriately balance our needs to offer a competitive level of severance protection to our executives and to induce our executives to remain in our employ through the potentially disruptive conditions that may exist around the time of a change in control, while not unduly rewarding executives for a termination of their employment. We note that our change in control terms include so-called “double trigger” provisions, so that the executive is not entitled to the severance payment by the mere occurrence of the change in control. We believe this feature, will be an incentive to the executive to remain in the employ of the company if such continuation is required by our partner in a change in control transaction. We also believe that it is appropriate that our executives’ equity awards be treated, in the event of a change of control, like those of other employees and not accelerated if the executive’s employment continues following the change in control event.

 

97


Table of Contents

Other Executive Benefits and Perquisites

 

We provide the following benefits to our executive officers on the same basis as other eligible employees:

 

   

health insurance;

 

   

vacation, personal holidays and sick days;

 

   

life insurance and supplemental life insurance;

 

   

short-term and long-term disability; and

 

   

a 401(k) plan.

 

We believe these benefits are generally consistent with those offered by other companies with which we compete for executive talent.

 

Some of the executives whom we have hired, including Mr. Melo, held positions in locations outside of Northern California at the time that they agreed to join us. We have agreed in these instances to pay relocation expenses to these executives, including costs associated with commuting from our facilities to their family’s home outside of Northern California. The amounts paid in 2009 to named executive officers are included in the “All Other Compensation” column in the Summary Compensation Table below. Given the cost of living in the San Francisco Bay Area relative to most other metropolitan areas in the U.S., we believe that in order for us not to be limited to hiring executives located near our headquarters in Emeryville, California, that we must be willing to offer to pay an agreed upon amount of relocation costs.

 

Other Compensation Practices and Policies

 

Tax Considerations.  Section 162(m) of the Internal Revenue Code disallows a tax deduction for any publicly held corporation for individual compensation exceeding $1.0 million in any taxable year for our president and chief executive officer and each of the other named executive officers (other than our chief financial officer), unless compensation is performance based. As we are not currently publicly-traded, our board of directors has not previously taken the deductibility limit imposed by Section 162(m) into consideration in setting compensation. We expect that our compensation committee will adopt a policy at some point in the future that, where reasonably practicable, we will seek to qualify the variable compensation paid to our executive officers for an exemption from the deductibility limitations of Section 162(m). Until such policy is implemented, our Compensation Committee may, in its judgment, authorize compensation payments that do not consider the deductibility limit imposed by Section 162(m) when it believes that such payments are appropriate to attract and retain executive talent.

 

Policy regarding the timing of equity awards.  As a privately-owned company, there has been no market for our common stock. Accordingly, in fiscal 2009, we had no program, plan or practice pertaining to the timing of stock option grants to executive officers coinciding with the release of material non-public information. We do not, as of yet, have any plans to implement such a program, plan or practice after becoming a public company. However, we intend to implement policies to ensure that equity awards are granted at fair market value on the date that the grant action occurs.

 

Policy regarding restatements.  We do not have a formal policy regarding adjustment or recovery of awards or payments if the relevant performance measures upon which they are based are restated or otherwise adjusted in a manner that would reduce the size of the award or payment. Under those circumstances, our Board of Directors or the Compensation Committee would evaluate whether adjustments or recoveries of awards were appropriate based upon the facts and circumstances surrounding the restatement.

 

Stock Ownership Policies . We have not established stock ownership or similar guidelines with regards to our executive officers. All of our executive officers currently have a direct or indirect, through their stock option holdings, equity interest in our company, and we believe that they regard the potential returns from these interests as a significant element of their potential compensation for services to us.

 

98


Table of Contents

Summary Compensation Table

 

The following table sets forth information regarding compensation earned by our chief executive officer, our chief financial officer and each of our three other most highly compensated executive officers during 2009. We refer to these executive officers as our “named executive officers” elsewhere in this prospectus:

 

Name and Principal Position

   Year    Salary($)    Bonus($) (1)    Option
Awards($) (2)
   All Other
Compensation($)
    Total($)

John Melo

   2009    408,333    200,000       $ 221,617 (3)     829,950

President and Chief Executive Officer

                

Joel Cherry, Ph.D.

   2009    310,000    74,683    709,737           1,094,420

Senior Vice President, Research Programs and Operations

                

Jeryl Hilleman

   2009    300,000    149,365         18,833 (4)     468,198

Chief Financial Officer

                

Jefferson Lievense, Ph.D.

   2009    300,000    44,810    168,985      76,048 (5)     589,843

Senior Vice President, Process Development and Manufacturing

                

Tamara Tompkins

   2009    272,867    37,341    33,797      18,743 (6)     362,748

Senior Vice President and General Counsel

                

 

  (1)   The amounts reported in this column represent discretionary bonuses determined by the Board of Directors.
  (2)   The amounts in the “Option Awards” column reflect the aggregate grant date fair value computed in accordance with ASC Topic 718. The assumptions used by us in determining the grant date fair value of option awards are set forth in Note 13 to our Consolidated Financial Statements included elsewhere in this prospectus. See the “Grants of Plan-Based Awards” table for information on stock option grants made in fiscal 2009. These amounts do not correspond to the actual value that may be recognized by the named executive officers.
  (3)   Includes $145,907 for reimbursement for temporary housing and relocation expenses, $56,877 gross-up to pay associated taxes and $18,833 of health and life insurance premiums paid on behalf of Mr. Melo.
  (4)   Represents health and life insurance premiums paid on behalf of Ms. Hilleman.
  (5)   Includes $38,390 for reimbursement for temporary housing and relocation expenses, $18,825 gross-up to pay associated taxes and $18,833 of health and life insurance premiums paid on behalf of Mr. Lievense.
  (6)   Represents health and life insurance premiums paid on behalf of Ms. Tompkins.

 

99


Table of Contents

Grants of Plan-Based Awards

 

The following table sets forth information regarding grants of compensation in the form of plan-based awards made during 2009 to our named executive officers.

 

Name

   Grant Date    All Other
Option  Awards:
Number of  Securities
Underlying
Options (#) (1)
   Exercise or
Base Price
of Option
Awards

($/Sh) (2)
   Grant Date
Fair Value
of Option
Awards ($) (3)

John Melo

           

Joel Cherry, Ph.D.

   09/14/2009    210,000    4.31    709,737

Jeryl Hilleman

           

Jefferson Lievense, Ph.D.

   09/14/2009    50,000    4.31    168,985

Tamara Tompkins

   09/14/2009    10,000    4.31    33,797

 

  (1)   Grants vest as to 20% of the original number of shares on the first anniversary of the vesting commencement date, which is a date fixed by our Board of Directors when granting options, and as to an additional 1/60th of the original number of shares each month thereafter until the fifth anniversary of the vesting commencement date, subject to continued service through each relevant vesting date. Notwithstanding, grants are subject to certain rights to acceleration of vesting upon a change in control of our company and termination of employment following a change in control, as further described below in “Executive Compensation—Potential Payments upon Termination and upon Termination Following a Change in Control.” All options were granted under our 2005 Stock Option/Stock Issuance Plan, which is described below under “Executive Compensation—Stock Option and Other Compensation Plans.”
  (2)   Represents the fair market value of a share of our common stock, as determined by our Board of Directors, on the respective option grant date. For a discussion of our methodology for determining the fair value of our common stock, see the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” section of this prospectus.
  (3)   Reflects the grant date fair value of each award computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named executive officers. Our assumptions with respect to the calculation of stock-based compensation expenses are set forth above in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates—Stock-Based Compensation”. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our Consolidated Financial Statements included elsewhere in this prospectus.

 

100


Table of Contents

Outstanding Equity Awards at Fiscal Year End

 

The following table sets forth information regarding outstanding equity awards held as of December 31, 2009 by our named executive officers.

 

Name

   Number of
Securities
Underlying
Unexercised
Options that are
Exercisable  (#) (1) (2)
    Number of
Securities
Underlying
Unexercised
Options that are
Unexercisable (#)
   Option
Exercise
Price ($/Sh)
   Option
Expiration
Date

John Melo

   279,979 (3)        3.93    8/26/2018
   925,000 (4)        0.28    1/18/2017

Joel Cherry, Ph.D.

   210,000 (5)        4.31    9/13/2019

Jeryl Hilleman

   184,555 (6)        3.93    2/26/2018

Jefferson Lievense, Ph.D.

   50,000 (7)        4.31    9/13/2019
   200,000 (8)        3.93    12/12/2017

Tamara Tompkins

   10,000 (9)        4.31    9/13/2019
   100,000 (10)        0.28    5/8/2017

 

  (1)   All options granted to our named executive officers are immediately exercisable, regardless of vesting schedule.
  (2)   All options vest as to 20% of the original number of shares on the first anniversary of the vesting commencement date, which is a date fixed by our Board of Directors when granting options, and as to an additional 1/60th of the original number of shares each month thereafter until the fifth anniversary of the vesting commencement date.
  (3)   The vesting commencement date of this grant is 6/3/2008.
  (4)   The vesting commencement date of this grant is 10/23/2006.
  (5)   The vesting commencement date of this grant is 11/3/2008.
  (6)   The vesting commencement date of this grant is 1/28/2008.
  (7)   The vesting commencement date of this grant is 10/1/2008.
  (8)   The vesting commencement date of this grant is 12/12/2007.
  (9)   The vesting commencement date of this grant is 10/1/2008.
  (10)   The vesting commencement date of this grant is 11/6/2006.

 

Stock Option Exercises During Fiscal Year 2009

 

The following table shows information regarding option exercises by our named executive officers during fiscal year 2009.

 

     Option Awards

Name

   Number of
Shares Acquired
on Exercise (#)
   Value Realized
on Exercise
($) (1)

John Melo

   75,000    302,250

 

  (1)   The aggregate dollar value realized upon exercise of an option represents the difference between the aggregate fair market value of our common stock underlying the option on the date of exercise, which was determined by our Board of Directors to be approximately $4.31 per share, and the aggregate exercise price of the option, which was $21,000, based on a $0.28 exercise price per share.

 

101


Table of Contents

Pension Benefits

 

None of our named executive officers participates in, or has an account balance in, a qualified or non-qualified defined benefit plan sponsored by us.

 

Non-Qualified Deferred Compensation

 

None of our named executive officers participates in, or has account balances in, a traditional non-qualified deferred compensation plan or other deferred compensation plans maintained by us.

 

Potential Severance Payments upon Termination and upon Termination Following a Change in Control

 

The initial offer letters and amendments of the offer letters of Messrs. Melo, Cherry and Lievense, Ms. Hilleman and Ms. Tompkins provide that, if we terminate the employment of the respective named executive officer for any reason other than for cause, he or she will receive severance equal to 12 months of base salary, payable in accordance with our regular payroll practices. These payments will be terminated as of the date of commencement of employment with another employer. In addition, in the event of such termination, the respective named executive officer will receive COBRA benefits until the earlier of (i) 12 months from termination and (ii) commencement of employment with another employer.

 

We have also agreed that in the event we terminate any of our named executive officers without cause or constructively terminate the employment of any of our named executive officers, in either case within six months of a change of control of Amyris, the terminated individual will receive the benefits described in the preceding paragraph and accelerated vesting of 50% of any of his or her unvested options as of the date of termination.

 

As a condition to receipt of any of the benefits set forth in the preceding two paragraphs, the respective named executive officer must execute a release of claims in our favor and return to us any of our property and confidential information in his or her possession. In addition, to receive his severance and change of control benefits, Mr. Melo must resign from our Board of Directors.

 

For purposes of the above benefits, a change of control includes (i) any transaction after which our then current stockholders own less than 50% of the voting power of the surviving entity or its parent; (ii) a merger, reorganization or consolidation or other acquisition of Amyris after which our then-current stockholders transfer more than a majority of the voting power of the Company; and (iii) a sale of all or substantially all of our assets. Constructive termination means resignation of employment within 120 days after any of the following events, each of which must occur within five months of our change of control with respect to Jeryl Hilleman and John Melo and within six months of our change of control with respect to Joel Cherry, Tamara Tompkins and Jeff Lievense: a material reduction in responsibilities or base salary (unless the reduction is comparable to and part of a reduction of all executive officers) or a relocation of principal office more than 50 miles from the location of the named executive officer’s office immediately before a change of control. If an event constituting grounds for constructive termination occurs, the respective named executive officer must give us notice of it within 90 days and we have 30 days to remedy the condition caused by that event. Cause is determined by our Board of Directors and includes any of the following: (i) failure or refusal to comply in any material respect with any of our policies; (ii) a violation of law or regulation applicable to our business; (iii) conviction or plea of no contest to a felony and in addition, in some instances a misdemeanor involving moral turpitude under the laws of the United States or any state; (iv) fraud or misappropriation of our property; (v) non-performance, non-compliance or interference with the other party’s performance under the terms of any confidentiality, invention assignment or proprietary information agreement with us or with a former employer, (vi) failure to satisfactorily perform duties after having received written notice of such failure and at least 30 days to cure such failure, or (vii) misconduct or gross negligence in connection with the performance of employment duties to us.

 

To the extent any severance benefits to a named executive officer constitute deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended, and that officer is deemed a “specified employee” under Section 409A, then we will defer payment of these benefits to the extent necessary to avoid adverse tax treatment.

 

102


Table of Contents

The following table summarizes the potential payments and benefits payable to each of our named executive officers upon (i) termination of employment other than for cause and (ii) termination without cause or constructive termination following a change in our control, modeling, in each situation, that termination and change of control, where applicable, occurred on December 31, 2009.

 

     Qualifying Termination Other Than for
Cause not in Connection with a Change
of Control
   Qualifying Change of Control and Termination
Without Cause or Constructive Termination
Within 6 Months Following a Change of
Control

Name

   Base
Salary($) (1)
   COBRA
Benefits($) (1)
   Value of
Accelerated
Options or
Shares($)
   Base
Salary($) (1)
   COBRA
Benefits($) (1)
   Value of
Accelerated
Options or
Shares($) (2)

John Melo

   408,333    24,608       408,333    24,608    4,371,034

Joel Cherry, Ph.D.

   310,000    275       310,000    275    824,145

Jeryl Hilleman

   300,000    24,608       300,000    24,608    613,431

Jefferson Lievense, Ph.D.

   300,000    24,608       300,000    24,608    838,853

Tamara Tompkins

   272,867    24,608       272,867    24,608    384,951

 

  (1)   The amounts in this column assume that the respective named executive officer has not started employment with another company before the expiration of 12 months from termination of his or her employment with us.
  (2)   With respect to outstanding options as of December 31, 2009, this amount is equal to (a) the number of shares underlying unexercised options that would vest as a direct result of employment termination without cause or constructive termination following a change of control, assuming a December 31, 2009, change of control and employment termination, multiplied by (b) the excess of $9.32, which represents our Board of Directors’ determination of the fair market value of our common stock as of December 31, 2009, over the exercise price of the option. With respect to unvested shares held by the named executive officer, this amount is equal to (a) the number of unvested shares that would vest as a direct result of employment termination without cause or constructive termination following a change of control, assuming a December 31, 2009, change of control and employment termination, multiplied by (b) $9.32.

 

Agreements with Executives

 

We do not have formal employment agreements with any of our named executive officers. The initial compensation of each named executive officer was set forth in an offer letter that we executed with him or her at the time his or her employment with us commenced and that was later amended. Each offer letter provides that the named executive officer’s employment is at will.

 

As a condition to their employment, our named executive officers entered into non-competition, non-solicitation and proprietary information and inventions assignment agreements. Under these agreements, each named executive officer has agreed (i) not to solicit our employees during his or her employment and for a period of 12 months after the termination of his or her employment, (ii) not to compete with us or assist any other person to compete with us during the officer’s employment with us and (iii) to protect our confidential and proprietary information and to assign to us intellectual property developed during the course of his or her employment.

 

See above “Executive Compensation—Potential Payments upon Termination and upon Termination Following a Change in Control” for a description of potential payments to our named executive officers on a change of control.

 

103


Table of Contents

Stock Option and Other Compensation Plans

 

2005 Stock Option/Stock Issuance Plan

 

Background . Our Board of Directors adopted, and our stockholders approved, our 2005 Stock Option/Stock Issuance Plan in September 2005. We reserved a pool of shares of our common stock for issuance to employees and other service providers pursuant to awards granted under our 2005 Stock Option/Stock Issuance Plan, as amended. It provides for awards under two separate equity programs: (i) the Option Grant Program, under which eligible persons may be granted options, and (ii) the Stock Issuance Program, under which eligible persons may be granted stock purchase rights, awards of shares as a bonus for services rendered, or restricted stock units or other share awards which vest upon completion of a service period or performance milestones. The 2005 Stock Option/Stock Issuance Plan is administered by our Board of Directors, which may delegate administrative responsibilities to a committee.

 

Option Grant Program . Our 2005 Stock Option/Stock Issuance Plan provides for the grant of both incentive stock options, or ISOs, that qualify for favorable tax treatment under Section 422 of the Internal Revenue Code for their recipients and nonqualified stock options, or NSOs. ISOs may be granted only to our employees or employees of any of our subsidiaries. NSOs may be granted to employees, officers, non-employee directors, consultants and other independent advisors who provide services to us or any of our subsidiaries. The options’ exercise price must be at least equal to the fair market value of our common stock on the date of grant. The exercise price of options granted to 10% stockholders must be at least equal to 110% of the fair market value of our common stock on the date of grant. Payment of the option exercise price may be made in cash (including by check), with a full-recourse promissory note if authorized by the plan administrator, or following the registration of our common stock under the Securities Exchange Act, by surrender of shares or through a broker-assisted cashless exercise program. The maximum permitted term of options granted under our 2005 Stock Option/Stock Issuance Plan is ten years from the date of grant (five years for incentive stock options granted to 10% stockholders). The plan administrator may grant options subject to vesting restrictions but options granted to individuals who are not officers, non-employee directors or independent contractors cannot vest less than 20% per year. In the event of a change in control, the 2005 Stock Option/Stock Issuance Plan provides that unvested options that are not assumed or replaced by the successor corporation will vest in full immediately prior to such change in control and all options will expire on the consummation of the change in control or subject to other treatment imposed by the Board of Directors or the committee administering the 2005 Stock Option/Stock Issuance Plan in connection with a change in control. Our Board of Directors or Compensation Committee has authority to grant additional acceleration rights upon change of control to holders of options issued pursuant to the 2005 Stock Option/Stock Issuance Plan.

 

As of December 31, 2009, options to purchase 4,386,894 shares of our common stock granted from the 2005 Stock Option/Stock Issuance Plan remained outstanding and 579,518 shares of our common stock remained available for issuance upon the exercise of awards that may be granted from the 2005 Stock Option/Stock Issuance Plan. The options outstanding as of December 31, 2009, had a weighted-average exercise price of approximately $2.86 per share.

 

Stock Issuance Program . Our 2005 Stock Option/Stock Issuance Plan provides for direct issuances of shares of our common stock and issuances of share right awards or restricted stock units which entitle the recipients to receive the underlying shares upon completion of specified service periods or performance goals. We may issue stock, share right awards and restricted stock units to employees, officers, directors, consultants and other independent advisors who provide services to us or any of our subsidiaries. The issue price per share must be equal to at least the fair market value per share of our common stock on the issue date. The recipient may pay the purchase price of the shares in cash (including by check), in past services rendered to us or any of our subsidiaries, or by tendering any other valid consideration under the California Corporations Code. The shares that we issue pursuant to the Stock Issuance Program may be subject to vesting restrictions based on length of service or attainment of specified performance goals, as determined by our Board of Directors or Compensation Committee, but no awards made to individuals who are not officers, non-employee directors, or independent consultants may vest less than 20% per year. In the event of a change in control, the 2005 Stock Option/Stock

 

104


Table of Contents

Issuance Plan provides that unvested shares issued pursuant to the plan will vest in full immediately prior to such change in control unless the repurchase rights underlying such awards are assigned to the successor corporation, continued, or unless accelerated vesting is precluded by the documents evidencing the award. As of December 31, 2009, we had issued 1,027,297 shares of our common stock pursuant to the Stock Issuance Program of our 2005 Stock Option/Stock Issuance Plan.

 

Our 2010 Equity Incentive Plan will be effective upon the completion of this offering. As a result, no awards will be granted from the 2005 Stock Option/Stock Issuance Plan after the date of this prospectus and the 2005 Stock Option/Stock Issuance Plan will terminate. However, any outstanding awards granted from the 2005 Stock Option/Stock Issuance Plan will remain outstanding, subject to the terms of our 2005 Stock Option/Stock Issuance Plan and the applicable award agreements, until the awards are exercised or until they terminate or expire by their terms.

 

2010 Equity Incentive Plan

 

Background. We anticipate that we will adopt a 2010 Equity Incentive Plan that will become effective on the date of this prospectus and will serve as the successor equity compensation plan to our 2005 Stock Option/Stock Issuance Plan. We anticipate that we will reserve              shares of our common stock to be issued under our 2010 Equity Incentive Plan. Our 2010 Equity Incentive Plan will become effective on the date of our initial public offering and will terminate in 2020. Our 2010 Equity Incentive Plan will provide for the grant of incentive stock options, nonqualified stock options, restricted stock awards, stock bonuses, stock appreciation rights, restricted stock units and awards of performance shares.

 

Administration. Our 2010 Equity Incentive Plan will be administered by our Compensation Committee, all of the members of which are non-employee directors under applicable federal securities laws and outside directors as defined under applicable federal tax laws. This Compensation Committee will act as the plan administrator and will have the authority to construe and interpret the plan, grant awards, determine the terms and conditions of awards and make all other determinations necessary or advisable for the administration of the plan (subject to the limitations set forth in our 2010 Equity Incentive Plan).

 

Share Reserve. We anticipate that we will reserve              shares of our common stock for issuance under our 2010 Equity Incentive Plan plus:

 

   

all shares of our common stock reserved under our 2005 Stock Option/Stock Issuance Plan that are not issued or subject to outstanding grants as of the completion of this offering;

 

   

any shares issuable upon exercise of options granted under our 2005 Stock Option/Stock Issuance Plan that cease to be subject to such stock options; and

 

   

any shares of our common stock issued under our 2005 Stock Option/Stock Issuance Plan that are forfeited or repurchased by us at the original purchase price.

 

The number of shares available for grant and issuance under the 2010 Equity Incentive Plan will be increased on January 1 of each of 2011 through              by an amount equal to the lesser of (1)     % of our shares outstanding on the immediately preceding December 31 and (2) a number of shares as may be determined by our Board of Directors in its discretion. In addition, shares will again be available for grant and issuance under our 2010 Equity Incentive Plan that are:

 

   

subject to issuance upon exercise of an option or stock appreciation right granted under our 2010 Equity Incentive Plan and that cease to be subject to such award for any reason other than the award’s exercise;

 

   

subject to an award granted under our 2006 Equity Incentive Plan and that are subsequently forfeited or repurchased by us at the original issue price;

 

   

surrendered pursuant to an exchange program; or

 

105


Table of Contents
   

subject to an award granted under our 2010 Equity Incentive Plan that otherwise terminates without shares being issued.

 

Equity Awards. Our 2010 Equity Incentive Plan will permit us to grant the following types of awards:

 

Stock Options. Our 2010 Equity Incentive Plan will provide for the grant of incentive stock options, or ISOs, to employees, and nonqualified stock options, or NSOs, to employees, non-employee directors and consultants. We will be able to issue no more than              shares pursuant to the grant of ISOs under the 2010 Equity Incentive Plan. The Compensation Committee will determine the terms of each option award, provided that ISOs will be subject to statutory limitations. The Compensation Committee will determine the exercise price for a stock option, provided that the exercise price of an option may not be less than 100% (or 110% in the case of recipients of ISOs who hold more than 10% of our stock on the option grant date) of the fair market value of our common stock on the date of grant. Options granted under our 2010 Equity Incentive Plan will vest at the rate specified by the Compensation Committee and such vesting schedule will be set forth in the stock option agreement to which such stock option grant relates. Generally, the Compensation Committee will determine the term of stock options granted under our 2010 Equity Incentive Plan, up to a term of ten years (or five years in the case of ISOs granted to 10% stockholders).

 

After termination of an optionee, he or she will be able to exercise his or her vested option for the period of time stated in the stock option agreement to which such option relates, up to a maximum of five years from the date of termination. Generally, if termination is due to death or disability, the vested option will remain exercisable for 12 months. If an optionee is terminated for cause (as defined in our 2010 Equity Incentive Plan), then the optionee’s options will expire on the optionee’s termination date or at such later time and on such conditions as determined by our Compensation Committee. In all other cases, the vested option will generally remain exercisable for three months. However, an option may not be exercised later than its expiration date.

 

Restricted Stock Awards. A restricted stock award is an offer by us to sell shares of our common stock subject to restrictions that the Compensation Committee may impose. These restrictions may be based on completion of a specified period of service with us or upon the completion of performance goals during a performance period. The Compensation Committee will determine the price of a restricted stock award. Unless otherwise set forth in the award agreement, vesting will cease on the date the participant no longer provides services to us, and at that time unvested shares are forfeited to us or subject to repurchase by us.

 

Stock Bonus Awards. A stock bonus is an award of shares of our stock for past or future services to us. Stock bonuses will be granted as additional compensation for performance and, therefore, will not be issued in exchange for cash. The Compensation Committee will determine the number of shares to be issued as stock bonus and any restrictions on those shares. These restrictions may be based on completion of a specified period of service with us or upon the completion of performance goals during a performance period. Unless otherwise set forth in the award agreement, vesting will cease on the date the participant no longer provides services to us, and at that time unvested shares will be forfeited to us or will be subject to repurchase by us.

 

Stock Appreciation Rights. Stock appreciation rights provide for a payment, or payments, in cash or shares of our common stock to the holder based upon the difference between the fair market value of our common stock on the date of exercise and the stated exercise price. Stock appreciation rights may vest based on time or achievement of performance conditions.

 

Restricted Stock Units. Restricted stock units represent the right to receive shares of our common stock at a specified date in the future, subject to forfeiture of such right due to termination of employment or failure to achieve specified performance conditions. If the restricted stock unit has not been forfeited, then on the date specified in the restricted stock unit agreement we will deliver to the holder of the restricted stock unit shares of our common stock, cash or a combination of our common stock and cash.

 

Performance Shares . A performance share award is an award denominated in shares that are subject to performance factors. The award may be settled in cash or by issuance of those shares (which may consist of restricted stock).

 

106


Table of Contents

Change in Control. If we undergo a corporate transaction (as defined in our 2010 Equity Incentive Plan), we expect that our 2010 Equity Incentive Plan will provide that the successor company (if any) may assume, convert, replace or substitute outstanding awards. Outstanding awards that are not so assumed, converted, replaced or substituted will have their vesting accelerate and become exercisable in full.

 

Transferability of Awards. Unless the Compensation Committee provides otherwise, our 2010 Equity Incentive Plan does not allow for the transfer of awards, other than by will or the laws of descent and distribution, and generally only the recipient of an award may exercise it during his or her lifetime. The Compensation Committee will have discretion to determine and implement award transfer programs to give participants the opportunity to transfer any outstanding awards to a financial institution or other person or entity approved by the Compensation Committee. As part of such a program, the Compensation Committee will have the authority to amend any terms of awards included in the program, including expiration date, post-expiration exercise period, vesting and forfeiture conditions, permitted payment methods, and adjustments in the event of capitalization changes and other similar events.

 

Eligibility. The individuals eligible to participate in our 2010 Equity Incentive Plan will include our employees, officers, directors, consultants, independent contractors and advisors or any parent or subsidiary of ours, provided the consultants, independent contractors and advisors render services not in connection with the offer and sale of securities in a capital-raising transaction.

 

Payment for Purchase of Shares of our Common Stock. Payment for shares of our common stock purchased pursuant to our 2010 Equity Incentive Plan may be made by any of the following methods (provided such method is permitted in the applicable award agreement to which such shares relate): (1) cash (including by check); (2) cancellation of indebtedness; (3) surrender of shares; (4) waiver of compensation due or accrued for services rendered; (5) through a broker-assisted sale or other cashless exercise program, or (6) by any other method approved by our Board of Directors.

 

Limit on Awards. Under our 2010 Equity Incentive Plan, during any calendar year, no person will be eligible to receive more than              shares of our common stock, and in the case of new employees during their first fiscal year of employment with us,              shares of our common stock.

 

Amendment and Termination. Our Board of Directors will be able to amend or terminate our 2010 Equity Incentive Plan at any time, subject to stockholder approval where required. In addition, we cannot make an amendment that is detrimental to an outstanding award without the consent of the affected participant.

 

2010 Employee Stock Purchase Plan

 

Background. We expect that we will adopt a 2010 employee stock purchase plan designed to enable eligible employees to periodically purchase shares of our common stock at a discount. Purchases will be accomplished through participation in discrete offering periods. Our 2010 employee stock purchase plan will be intended to qualify as an employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended.

 

Share Reserve. We expect that we will initially reserve              shares of our common stock for issuance under our 2010 Employee Stock Purchase Plan. During the first eight years of the life of the plan, the number of shares reserved for issuance will increase automatically on the first day of each January, starting with January 1, 2011, by the number of shares equal to     % of our total outstanding shares as of the immediately preceding December 31st. Our Board of Directors or Compensation Committee will be able to reduce the amount of the increase in any particular year. No more than              shares of our common stock may be issued under our 2010 Employee Stock Purchase Plan and no other shares may be added to this plan without the approval of our stockholders.

 

107


Table of Contents

Administration. Our Compensation Committee will administer our 2010 Employee Stock Purchase Plan. Employees who are five percent stockholders, or would become five percent stockholders as a result of their participation in our 2010 Employee Stock Purchase Plan, are ineligible to participate in our 2010 Employee Stock Purchase Plan. We may impose additional restrictions on eligibility as well. Under our 2010 Employee Stock Purchase Plan, eligible employees will be able to acquire shares of our common stock by accumulating funds through payroll deductions. Our eligible employees will be able to select a rate of payroll deduction between one percent and 15% of their cash compensation. We will also have the right to amend or terminate our 2010 Employee Stock Purchase Plan, except that, subject to certain exceptions, no such action may adversely affect any outstanding rights to purchase stock under the plan. Our 2010 Employee Stock Purchase Plan will terminate on the tenth anniversary of the first offering date, unless it is terminated earlier by our Board of Directors.

 

Purchase Rights. When an offering period commences, our employees who meet the eligibility requirements for participation in that offering period will be automatically granted a non-transferable option to purchase shares in that offering period. Each offering period may run for no more than 24 months and consist of no more than five purchase periods. An employee’s participation will automatically end upon termination of employment for any reason.

 

No participant will have the right to purchase our shares at a rate which, when aggregated with purchase rights under all our employee stock purchase plans that are also outstanding in the same calendar year(s), have a fair market value of more than $25,000, determined as of the first day of the applicable offering period, for each calendar year in which such right is outstanding. The purchase price for shares of our common stock purchased under our 2010 Employee Stock Purchase Plan will be 85% of the lesser of the fair market value of our common stock on (1) the first trading day of the applicable offering period and (2) the last trading day of each purchase period in the applicable offering period.

 

Change in Control. In the event of a corporate transaction (as defined in our 2010 Employee Stock Purchase Plan), the successor company may assume or substitute the outstanding rights to purchase shares under our 2010 Employee Stock Purchase Plan. If the successor company refuses to assume or substitute the outstanding rights, the offering period for such purchase rights will be shortened and end on a new purchase date on or prior to the consummation of the corporate transaction and no new offering period will commence.

 

401(k) Plan

 

We maintain a deferred savings retirement plan for our U.S. employees. The deferred savings retirement plan is intended to qualify as a tax-qualified plan under Section 401 of the Internal Revenue Code. Contributions to the deferred savings retirement plan are not taxable to employees until withdrawn from the plan. The deferred savings retirement plan provides that each participant may contribute his or her pre-tax compensation (up to a statutory limit, which is $16,500 in 2010). For employees 50 years of age or older, an additional catch-up contribution of $5,500 is allowable. Under the plan, each employee is fully vested in his or her deferred salary contributions. The deferred savings retirement plan also permits us to make additional discretionary contributions, subject to established limits and a vesting schedule.

 

Limitation of Liability and Indemnification

 

Our certificate of incorporation, which will become effective immediately prior to the completion of this offering, limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the Delaware General Corporation Law and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of our directors:

 

   

for any breach of the director’s duty of loyalty to us or our stockholders;

 

   

for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

 

108


Table of Contents
   

for voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or

 

   

for any transaction from which the director derived an improper personal benefit.

 

Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law.

 

In addition, our amended and restated bylaws, which will become effective immediately prior to the completion of this offering, provide that we must indemnify our directors and officers and we must advance expenses, including attorneys’ fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions.

 

We maintain an insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

 

Certain of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of our Board of Directors.

 

Prior to completion of this offering, we intend to enter into indemnification agreements with each of our directors and executive officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements may require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements may also require us to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

 

At present, we are not aware of any pending litigation or proceeding involving any person who is or was one of our directors, officers, employees or other agents or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification.

 

The underwriting agreement provides for indemnification by the underwriters of us and our officers, directors and employees for certain liabilities arising under the Securities Act or otherwise.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

Rule 10b5-1 Sales Plans

 

Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend or terminate the plan in some circumstances. Our directors and executive officers may also buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.

 

109


Table of Contents

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

In addition to the compensation arrangements, including employment, termination of employment and change-in-control and indemnification arrangements, discussed, when required, above under “Management,” and the registration rights described below under “Description of Capital Stock – Registration Rights,” the following is a description of each transaction since January 1, 2007, and each currently proposed transaction in which:

 

   

we have been or are to be a participant;

 

   

the amount involved exceeds $120,000; and

 

   

any of our directors, executive officers or holders of more than 5% of any class of our capital stock at the time of the transactions in issue, or any immediate family member of or person sharing the household with any of these individuals, had or will have a direct or indirect material interest.

 

Warrants

 

From March 2008 through March 2009, we issued warrants to purchase an aggregate of 104,558 shares of our Series B-1 preferred stock at an exercise price of $25.26 per share.

 

In January 2010, we issued warrants to purchase an aggregate of 49,157 shares of our Series C preferred stock at an exercise price of $12.46 per share.

 

The holders of our warrants are entitled to specified registration rights. The following table summarizes the warrants issued in connection with the transactions described in this section, all of which were issued to holders of more than 5% of any class of our capital stock at the time of the transactions in issue.

 

Investor

   Warrants to Purchase Shares
of Series B-1 Preferred Stock
(#)
   Warrants to Purchase Shares
of Series C Preferred Stock
(#)
Entities associated with Advanced Equities Financial Corp.    104,558    49,157

 

Preferred Stock Financings

 

In April and May 2007, we sold an aggregate of 6,482,824 shares of our Series A preferred stock at $2.174 per share for an aggregate purchase price of approximately $14.1 million. In September 2007 and April 2008, we sold an aggregate of 1,667,817 shares of our Series B preferred stock at $24.88 per share for an aggregate purchase price of approximately $41.5 million. In February 2008, April 2008, May 2008, July 2008, September 2008, November 2008, December 2008 and January 2009, we sold an aggregate of 2,615,721 shares of our Series B-1 preferred stock at $25.26 per share for an aggregate purchase price of approximately $66.1 million. In July 2009, September 2009, October 2009, November 2009, December 2009 and January 2010, we sold an aggregate of 4,902,665 shares of our Series C preferred stock at $12.46 per share for an aggregate purchase price of approximately $61.1 million. In March 2010, we sold an aggregate of 2,724,766 shares of our Series C-1 preferred stock at $17.56 per share for an aggregate purchase price of approximately $47.8 million.

 

Although none of our executive officers or directors purchased Series A, B, B-1, C or C-1 preferred stock, pursuant to a voting agreement last amended and restated on March 12, 2010, (i) KPCB Holdings, Inc., as nominee, TPG Biotechnology Partners II, L.P. and entities affiliated with Khosla Ventures had representatives serving on our Board of Directors at the time the Series B, B-1 or C preferred stock were purchased, and these directors may have been considered to beneficially own any Series B, B-1 or C preferred stock purchased by the entities with which they were affiliated, and (ii) Lit Tele LLC had a representative serving on our Board of Directors at the time the Series C preferred stock was purchased, and this director may have been considered to beneficially own any Series C preferred stock purchased by the entity with which he is affiliated. These directors disclaim beneficial ownership of these securities. The terms of these purchases were the same as those made available to unaffiliated purchasers.

 

110


Table of Contents

The purchasers of these shares of our preferred stock are entitled to specified registration rights. See “Description of Capital Stock—Registration Rights.” The following table summarizes the Series A, B, B-1, C and C-1 preferred stock, reflected on an as-issued and as-converted to common stock basis, assuming conversion occurred on March 31, 2010, purchased by our executive officers, directors and holders of more than 5% of any class of our capital stock at the time of the transactions in issue, since January 1, 2007, in connection with the transactions described above in this section. The terms of these purchases were the same as those made available to unaffiliated purchasers.

 

Name

  Shares of
Series A
Preferred
Stock (#)
  Shares of
Series A
Preferred
Stock (on

an as-
converted
basis) (#)
  Shares of
Series B
Preferred
Stock (#)
  Shares of
Series B
Preferred
Stock (on
an as-

converted
basis) (#)
  Shares of
Series

B-1
Preferred
Stock (#)
  Shares of
Series
B-1
Preferred
Stock (on

an as-
converted
basis) (#)
  Shares of
Series C
Preferred
Stock (#)
  Shares of
Series C
Preferred
Stock (on

an as-
converted
basis) (#)
  Shares of
Series

C-1
Preferred
Stock (#)
  Shares of
Series

C-1
Preferred
Stock (on

an as-
converted
basis) (#)
KPCB Holdings, Inc., as nominee (1) (5)   3,449,861   3,449,861   150,723   171,523       419,688   419,688    
TPG Biotechnology Partners II, L.P. (2) (5)   2,299,907   2,299,907   401,929   457,395       419,687   419,687    
Entities affiliated with Khosla Ventures II, L.P. (3) (5)   3,449,861   3,449,861   150,723   171,523       419,687   419,687    
Entities associated with Advanced Equities Financial Corp.           1,301,312   1,484,794   174,675   174,675    
Lit Tele LLC (4) (5)           395,883   451,703   802,568   802,568    
Maxwell (Mauritius) Pte Ltd.                   2,724,766   2,724,766
Entities associated with DAG Ventures II, L.P.       803,859   914,791       220,707   220,707    

 

  (1)   John Doerr, one of our directors, is a manager of the general partners of entities affiliated with KPCB Holdings, Inc.
  (2)   Dr. Geoffrey Duyk, one of our directors, is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P.
  (3)   Samir Kaul, one of our directors, is a member of Khosla Ventures II, L.P.
  (4)   Dr. Fernando de Castro Reinach, one of our directors, is an affiliate of the parent company of Lit Tele LLC.
  (5)   The directors listed in the notes above disclaim beneficial ownership of these securities.

 

Stockholder Agreements

 

In connection with the sale of our Series A, B, B-1, C and C-1 preferred stock, we entered into agreements that grant customary preferred stock rights to all of our major preferred stock investors, including holders of more than 5% of our preferred stock at the time of the transactions in issue. The rights include registration rights, rights of first refusal, co-sale rights with respect to stock transfers, a voting agreement providing for the election of investor designees to our Board of Directors, information rights and other similar rights. The Amended and Restated Investors Rights Agreement dated March 12, 2010, which contains the registration rights and many of the other rights described above, is filed as an exhibit to the registration statement of which this prospectus is a part. All of these rights, other than the registration rights, will terminate upon the completion of this offering.

 

Upon the completion of this offering, holders of              shares of our common stock, or their permitted transferees, will be entitled to rights with respect to the registration of these shares under the Securities Act. For more detailed description of these registration rights, see “Description of Capital Stock—Registration Rights.”

 

Other Transactions

 

On September 15, 2008, we entered into a Stock Option Agreement with Lit Tele LLC, whereby Lit Tele LLC received an option to purchase up to 60,000 shares of our common stock at an exercise price of $3.93 per share, outside the terms of our 2005 Stock Option/Stock Issuance Plan.

 

On April 9, 2008 and November 25, 2008, we entered into Placement Agent Agreements with Advanced Equities, Inc., pursuant to which Advanced Equities acted as our exclusive placement agent in obtaining financing through a

 

111


Table of Contents

private placement of our Series B-1 preferred stock. Under the terms of these agreements, as compensation for its placement services, Advanced Equities received: (i) $2,641,149 in cash, and (ii) warrants to purchase 104,558 shares of our Series B-1 preferred stock as discussed in “Warrants” above. In addition, under the terms of these agreements, we are required to indemnify Advanced Equities and its affiliates for (a) any misrepresentations or untrue statements made by us to Advanced Equities, (b) any breach or alleged breach of any representation, warranty or covenant made by us in these agreements, and (c) any misrepresentations or untrue statements made by us in any document furnished to the investors placed by Advanced Equities. Furthermore, Advanced Equities is required to indemnify us for (a) any misrepresentations or untrue statements made by Advanced Equities to the investors it placed with us (except to the extent such misrepresentations or untrue statements are based on information provided to Advanced Equities by us), (b) any breach or alleged breach of any representation, warranty or covenant made by Advanced Equities in these agreements, and (c) Advanced Equities’ bad faith, gross negligence or willful misconduct in performing its services.

 

On September 28, 2009, we entered into a Placement Agent Agreement with Advanced Equities pursuant to which Advanced Equities acted as our exclusive placement agent in obtaining financing through a private placement of our Series C preferred stock. Under the terms of this agreement, as compensation for its placement services Advanced Equities received: (i) $619,965 in cash, and (ii) a warrant to purchase 49,157 shares of our Series C preferred stock as discussed in “Warrants” above. This agreement contains mutual indemnification obligations similar to the indemnification obligations contained in our Series B-1 placement agent agreements with Advanced Equities described above.

 

On July 31, 2009, we entered into an Amended and Restated Restricted Stock Issuance Agreement with Lit Tele LLC, which amended and restated the Restricted Stock Issuance Agreement between the parties dated September 15, 2008. Pursuant to this agreement, Lit Tele LLC was awarded 50,000 restricted stock units outside the terms of our 2005 Stock Option/Stock Issuance Plan, and each unit entitles Lit Tele LLC to receive one share of our common stock. These restricted stock units granted to Lit Tele LLC were in exchange for advisory services provided to us pursuant to the Amended and Restated Advisory Services Agreement dated July 31, 2009, between us and Lit Tele LLC, as amended by Amendment No. 1 dated February 11, 2010. Under the terms of Amendment No. 1, we issued to Lit Tele LLC additional 126,272 restricted stock units outside the terms of our 2005 Stock Option/Stock Issuance Plan, and each unit entitles Lit Tele LLC to receive one share of our common stock.

 

Dr. Fernando de Castro Reinach, one of our directors, is an affiliate of the parent company of Lit Tele LLC.

 

Indemnification Arrangements

 

Please see “Management—Limitation of Liability and Indemnification” for information on our indemnification arrangements with our directors and executive officers.

 

Executive Compensation and Employment Arrangements

 

Please see “Management—Executive Compensation” and “Management—Agreements with Executives” for information on compensation arrangements with our executive officers, including option grants and agreements with executive officers.

 

Related Person Transaction Policy

 

We anticipate that our policy, the charter of our Audit Committee and the charter of our Nominating and Governance Committee to be adopted by our Board of Directors will require that any transaction with a related party that must be reported under applicable SEC rules, other than compensation related matters, must be reviewed and approved or ratified by our Nominating and Governance Committee. The Audit Committee must provide such approval or ratification if the related party is, or is associated with, a member of the Nominating and Governance committee. These committees have not adopted policies or procedures for review of, or standards for approval of, these transactions.

 

112


Table of Contents

PRINCIPAL STOCKHOLDERS

 

The following table sets forth information with respect to the beneficial ownership of our common stock, as of March 31, 2010, by:

 

   

each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our voting securities;

 

   

each of our directors;

 

   

each of our named executive officers; and

 

   

all of our directors and executive officers as a group.

 

Beneficial ownership is determined in accordance with the rules of the SEC and generally includes any shares over which the individual or entity has sole or shared voting power or investment power. The information does not necessarily indicate beneficial ownership for any other purpose. Except as indicated in the footnotes to this table and pursuant to applicable community property laws, to our knowledge the persons named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned. The number of shares beneficially owned by each person or group as of March 31, 2010, includes shares of common stock that such person or group had the right to acquire on or within 60 days after March 31, 2010, upon the exercise of options and warrants or the settling of restricted stock units. References to options and warrants in the footnotes of the table below include only options and warrants outstanding as of March 31, 2010, that were exercisable on or within 60 days after March 31, 2010, and references to restricted stock units in the footnotes of the table below include only restricted stock units outstanding as of March 31, 2010, that would vest and could settle on or within 60 days after March 31, 2010. For the purposes of calculating each person’s or group’s percentage ownership, stock options and warrants exercisable and restricted stock units that would vest within 60 days after March 31, 2010, are included for that person or group but not the stock options, warrants or restricted stock units of any other person or group.

 

Percentage ownership of our common stock in the table before the offering is based on 27,105,654 shares of our common stock outstanding on March 31, 2010. This number and the numbers of beneficially owned shares reported in the table below assume the automatic conversion of all outstanding shares of our preferred stock into 21,984,942 shares of common stock in connection with the completion of this offering. Percentage ownership of our common stock after this offering also assumes our sale of the              shares in this offering. Except as otherwise set forth below, the address of the beneficial owner is c/o Amyris Biotechnologies, Inc., 5885 Hollis Street, Suite 100, Emeryville, CA 94608.

 

     Shares beneficially
owned prior to offering
   Shares beneficially
owned after offering

Name and address of beneficial owner

   Number (#)    Percentage
(%)
   Number (#)    Percentage
(%)

5% Stockholders

           

Entities affiliated with Advanced Equities Financial Corp. (1)

   1,827,927    6.7      

Entities affiliated with Khosla Ventures (2)

   4,161,237    15.4      

Entities affiliated with Kleiner Perkins Caufield & Byers (3)

   4,161,239    15.4      

Lit Tele LLC (4)

   1,429,200    5.2      

TPG Biotechnology Partners II, L.P. (5)

   3,270,488    12.1      

Maxwell (Mauritius) Pte Ltd (6)

   2,724,766    10.1      

Directors and Named Executive Officers

           

John Melo (7)

   1,204,979    4.3      

Ralph Alexander (8)

   45,000    *      

John Doerr (3) (9)

   3,916,526    14.4      

Geoffrey Duyk, MD, Ph.D. (5)(10)

           

 

113


Table of Contents
     Shares beneficially owned
prior to offering
   Shares beneficially
owned after offering

Name and address of beneficial owner

   Number (#)    Percentage
(%)
   Number (#)    Percentage
(%)

Samir Kaul (2)

   4,161,237    15.4      

Patrick Pichette (11)

   100,000    *      

Carole Piwnica

           

Kinkead Reiling (12)

   985,000    3.6      

Fernando de Castro Reinach, Ph.D. (4)

   1,429,200    5.2      

Jeryl Hilleman (13)

   250,000    *      

Joel Cherry, Ph.D. (14)

   230,000    *      

Jefferson Lievense, Ph.D. (15)

   280,000    1.0      

Tamara Tompkins (16)

   240,000    *      

All directors and executive officers as a group
(16 persons) (17)

   14,286,942    47.5      

 

   *   Represents beneficial ownership of less than 1%.
  (1)   Entities affiliated with Advanced Equities Financial Corp. (“AEFC”) beneficially own the following numbers of shares of common stock and shares of common stock issuable upon the exercise of warrants.

 

Entity

   Common Stock    Warrants

Advanced Equities Amyris Investments I, LLC

   293,603   

Advanced Equities Amyris Investments II, LLC

   857,339   

Advanced Equities Amyris Investments III, LLC

   39,399   

Advanced Equities Amyris Investments IV, LLC

   82,730   

AEI 2008 CleanTech Investments I, LLC

   122,301   

AEI 2008 CleanTech Investments II, LLC

   264,097   

Advanced Equities Financial Corp.

      168,458

 

All of the above entities other than AEFC (collectively, the “AEI Funds”) are controlled by managing members that are wholly-owned subsidiaries of AEFC. AEFC exercises voting and dispositive control over all of the AEI Funds. AEFC disclaims beneficial ownership of all of these shares, except to the extent of its pecuniary interest therein. The business address for AEFC and all of the AEI Funds is 311 S. Wacker Drive, Suite 1650, Chicago, IL 60606.

  (2)   Includes 3,621,384 shares of common stock held by Khosla Ventures II, L.P. and 539,853 shares of common stock held by Khosla Ventures III, L.P. Mr. Kaul, one of our directors, is the general partner of the general partners of these entities and as such may be deemed to have voting and investment power with respect to shares held by these entities. Mr. Kaul disclaims beneficial ownership of these shares except to the extent of his individual pecuniary interest in these entities. The address for Mr. Kaul and these entities is 3000 Sand Hill Road, Building 3, Suite 170, Menlo Park, CA 94025.
  (3)   Includes 3,704,859 shares of common stock held by KPCB XII, LLC and 67,718 shares held by KPCB XII Founders Fund, LLC, 143,949 shares beneficially held by Clarus, LLC, whose manager is L. John Doerr, and 244,713 shares held by other individual managers. Mr. Doerr is a manager of the general partners of these entities and has shared voting and investment authority over these shares. Mr. Doerr disclaims beneficial ownership of these shares except to the extent of his pecuniary interest arising therein. The shares are held for convenience in the name of “KPCB Holdings, Inc. as nominee” for the account of entities affiliated with Kleiner Perkins Caufield & Byers and others. KPCB Holdings, Inc. has no voting, dispositive or pecuniary interest in any such shares. The address for Mr. Doerr and these entities is 2750 Sand Hill Road, Menlo Park, CA 94025.

 

114


Table of Contents
  (4)   Includes (i) 1,295,439 shares of common stock (ii) 30,000 shares issuable upon exercise of options exercisable within 60 days of March 31, 2010, and (iii) 103,761 restricted stock units that would settle within 60 days of March 31, 2010, assuming no acceleration of the settlement of the restricted stock units. Lit Tele LLC’s sole indirect member is Votorantim Novos Negocios. Dr. Reinach, one of our directors, is a General Partner of Votorantim Novos Negocios and in such capacity has shared voting power with respect to such shares. Dr. Reinach disclaims beneficial ownership with respect to such shares except to the extent of his pecuniary interest therein. The address for Dr. Reinach and these entities is Rua Jeronimo da Veiga, 384-12° andar, São Paulo, Brazil.
  (5)   Includes 3,270,488 shares of common stock (the “TPG Stock”) held by TPG Biotechnology Partners II, L.P. (“Partners II”), a Delaware limited partnership, whose general partner is TPG Biotechnology GenPar II, L.P., a Delaware limited partnership (“GenPar II”), whose general partner is TPG Biotech Advisors II, LLC, a Delaware limited liability company (“Advisors II”), whose sole member is TPG Ventures Holdings, LLC, a Delaware limited liability company (“Venture Holdings II”), whose managing member is TPG Ventures Partners, L.P., a Delaware limited partnership (“Venture Partners II” and, together with Partners II, GenPar II, Advisors II and Venture Holdings II, the “TPG Funds”), whose general partner is Tarrant Advisors, Inc., a Texas corporation (“Tarrant”), whose sole shareholder is Tarrant Capital Advisors, Inc., a Delaware corporation (“TCA”). Messrs. David Bonderman and James G. Coulter are directors, officers and sole shareholders of TCA, and may therefore be deemed to be the beneficial owners of the TPG Stock. The address of each of the TPG Funds, Tarrant, TCA, and Messrs. Bonderman and Coulter is c/o TPG Capital, L.P., 301 Commerce Street, Suite 3300, Fort Worth, TX 76102.
  (6)   The address of Maxwell (Mauritius) Pte Ltd is 60B Orchard Road, #06-18 Tower 2, The Atrium @ Orchard, Singapore 238891.
  (7)   Represents 1,204,979 shares of common stock issuable upon exercise of options that are exercisable within 60 days of March 31, 2010. If these options were exercised in full, 455,988 of these shares would be subject to vesting and a right of repurchase in our favor upon Mr. Melo’s cessation of service prior to vesting.
  (8)   Represents 45,000 shares of common stock issuable upon exercise of vested options that are exercisable within 60 days of March 31, 2010.
  (9)   Represents shares held by entities affiliated with Kleiner Perkins Caufield & Byers of which Mr. Doerr is an affiliate but excludes 244,713 of these shares over which Mr. Doerr has no voting or investment power.
  (10)   Dr. Duyk, who is one of our directors, is a partner of TPG Growth, LLC, which is an affiliate of Partners II. Dr. Duyk has no voting or investment power over and disclaims beneficial ownership of the TPG Stock. The address of Dr. Duyk is c/o TPG Capital, L.P., 301 Commerce Street, Suite 3300, Fort Worth, TX 76102.
  (11)   Represents 100,000 shares of common stock issuable upon exercise of options that are exercisable within 60 days of March 31, 2010. If these options were exercised in full, all of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Mr. Pichette’s cessation of service prior to vesting.
  (12)   Includes (i) 863,000 shares of common stock held by Dr. Reiling, (ii) an aggregate of 37,000 shares of common stock held by transferees of Dr. Renninger, over which shares be retains shared voting power and (iii) 85,000 shares issuable upon exercise of options of Dr. Reiling that are exercisable within 60 days of March 31, 2010. If these options were exercised in full, 41,084 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Dr. Reiling’s cessation of service prior to vesting.
  (13)   Includes (i) 25,445 shares of common stock, of which 13,571 are unvested as of March 31, 2010, and subject to a lapsing right of repurchase in our favor and (ii) 224,555 shares issuable upon exercise of options that are exercisable within 60 days of March 31, 2010. If these options were exercised in full, 137,097 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Ms. Hilleman’s cessation of service prior to vesting.

 

115


Table of Contents
  (14)   Represents 230,000 shares of common stock issuable upon exercise of options that are exercisable within 60 days of March 31, 2010. If these options were exercised in full, 164,667 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Dr. Cherry’s cessation of service prior to vesting.
  (15)   Represents 280,000 shares of common stock issuable upon exercise of options that are exercisable within 60 days of March 31, 2010. If these options were exercised in full, 164,001 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Dr. Lievense’s cessation of service prior to vesting.
  (16)   Includes (i) 100,000 shares of common stock and (ii) 140,000 shares issuable upon exercise of options that are exercisable within 60 days of March 31, 2010. If these options were exercised in full, 63,334 of the shares resulting from such exercise would be subject to vesting and a right of repurchase in our favor upon Ms. Tompkins’ cessation of service prior to vesting.
  (17)   Includes the shares described in footnotes (2) through (5) and (7) through (16) above. Also includes (i) 900,000 shares of common stock held by executive officers and (ii) 545,000 shares issuable upon exercise of options held by executive officers within 60 days after March 19, 2010, of which 501,084 shares, if these options were exercised in full, would be subject to vesting and a right of repurchase in our favor upon the executive officer’s cessation of service prior to vesting.

 

116


Table of Contents

DESCRIPTION OF CAPITAL STOCK

 

Upon the completion of this offering, our authorized capital stock will consist of              shares of common stock, par value $0.001 per share, and              shares of preferred stock, par value $0.001 per share. A description of the material terms and provisions of our restated certificate of incorporation and restated bylaws affecting the rights of holders of our capital stock is set forth below. The description is intended as a summary, and is qualified in its entirety by reference to the form of our restated certificate of incorporation and the form of our restated bylaws to be adopted prior to the completion of this offering that will be filed with the registration statement relating to this prospectus. The descriptions of our common stock and preferred stock reflect changes to our capital structure that will occur upon the completion of this offering.

 

Common Stock

 

Dividend Rights

 

Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our Board of Directors, in its discretion, determines to issue dividends, and only then at the times and in the amounts that our Board of Directors may determine.

 

Voting Rights

 

Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Our restated certificate of incorporation eliminates the right of stockholders to cumulate votes for the election of directors. Our restated certificate of incorporation establishes a classified Board of Directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.

 

No Preemptive or Similar Rights

 

Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.

 

Right to Receive Liquidation Distributions

 

Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

 

Preferred Stock

 

Immediately upon the completion of this offering, each outstanding share of preferred stock will be converted into common stock.

 

Following this offering, we will be authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. Our Board of Directors also can increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our Board of Directors may authorize the issuance of preferred stock with voting

 

117


Table of Contents

or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock. We have no current plan to issue any shares of preferred stock.

 

Options

 

As of December 31, 2009, we had options to purchase 4,386,894 shares of our common stock outstanding pursuant to our 2005 Stock Option/Stock Issuance Plan. In addition, as of December 31, 2009, we had granted an option to purchase up to 60,000 shares of our common stock outside of our 2005 Stock Option/Stock Issuance Plan.

 

Warrants

 

As of December 31, 2009, we had one warrant to purchase 2,580 shares of our Series B preferred stock with an exercise price of $24.88 per share. The warrant has a net exercise provision under which the holder in lieu of payment of the exercise price in cash can surrender the warrant and receive a net number of shares of Series B preferred stock based on the fair market value of such stock at the time of exercise of the warrant after deduction of the aggregate exercise price. Unless earlier exercised, this warrant will expire on the first anniversary of the closing of this offering. After the closing of this offering, this warrant will become exercisable for a number of shares of common stock determined by multiplying 2,580 by the conversion ratio of the Series B Preferred Stock in effect at the closing of this offering.

 

As of December 31, 2009, we had six warrants to purchase an aggregate of 106,567 shares of our Series B-1 preferred stock with an exercise price of $25.26 per share. Each of these warrants has a net exercise provision under which the holder in lieu of payment of the exercise price in cash can surrender the warrant and receive a net number of shares of Series B-1 preferred stock based on the fair market value of such stock at the time of exercise of the warrant after deduction of the aggregate exercise price. Unless earlier exercised, one warrant to purchase 2,009 shares of Series B-1 Preferred Stock will expire on the first anniversary of the closing of this offering and five warrants to purchase an aggregate of 104,558 shares of our Series B-1 preferred stock will expire on various dates from March 2015 to March 2016. After the closing of this offering, these warrants will become exercisable for an aggregate number of shares of common stock determined by multiplying 106,567 by the conversion ratio of the Series B-1 preferred stock in effect at the closing of this offering.

 

As of December 31, 2009, we had two warrants to purchase an aggregate of 24,101 shares of our Series C preferred stock with an exercise price of $12.46 per share. Each of these warrants has a net exercise provision under which the holder in lieu of payment of the exercise price in cash can surrender the warrant and receive a net number of shares of Series C preferred stock based on the fair market value of such stock at the time of exercise of the warrant after deduction of the aggregate exercise price. Unless earlier exercised, these warrants will expire on the first anniversary of the closing of this offering. After the closing of this offering, these warrants will become exercisable for an aggregate number of shares of common stock determined by multiplying 24,101 by the conversion ratio of the Series C preferred stock in effect at the closing of this offering.

 

Restricted Stock Units

 

As of December 31, 2009, we had granted 50,000 restricted stock units outside our 2005 Stock Option/Stock Issuance Plan. Each restricted stock unit represents the right to receive one share of our common stock.

 

118


Table of Contents

Registration Rights

 

Demand Registration Rights

 

At any time beginning 180 days after the completion of this offering and ending on March 12, 2013, the holders of at least 30% of the shares having registration rights under our investors’ rights agreement may request that we file a registration statement under the Securities Act covering the shares of the requesting holders. We will be obligated to use our commercially reasonable efforts to register such shares if they represent at least 20% of the shares resulting from conversion of our preferred stock and if the anticipated aggregate price to the public is at least $5,000,000. We are required to effect no more than two registration statements upon exercise of these demand registration rights. We may postpone the filing of a registration statement for up to 90 days once in a 12-month period if we determine that the filing would be seriously detrimental to us and our stockholders.

 

Piggyback Registration Rights

 

If we register any of our securities for public sale, the stockholders with registration rights will have the right to include their shares in the registration statement. However, this right does not apply to a registration relating to any of our employee benefit plans, the offer and sale of debt securities, or a registration on any registration form that does not include the information required for registration of the shares having piggyback registration rights. The managing underwriter of any underwritten offering will have the right to limit, due to marketing reasons, the number of shares registered by these holders to 25% of the total shares covered by the registration statement.

 

Form S-3 Registration Rights

 

The holders of shares having registration rights can request that we register all or a portion of their shares on Form S-3 if we are eligible to file a registration statement on Form S-3 and the aggregate price to the public of the shares offered is at least $2,000,000. We are required to file no more than one registration statement on Form S-3 upon exercise of these rights in any 12-month period. We may postpone the filing of a registration statement on Form S-3 for up to 90 days once in a 12-month period if we determine that the filing would be seriously detrimental to us and our stockholders.

 

Registration Expenses

 

We will pay all expenses incurred in connection with exercise of demand and piggyback registration rights, except for underwriting discounts and commissions. However, we will not pay for any expenses of any demand registration if the request is subsequently withdrawn by the holders of a majority of the shares requested to be included in such a registration statement, subject to limited exceptions. The expenses associated with exercise of Form S-3 registration rights will be borne pro rata by the holders of the shares registered on such Form S-3.

 

Expiration of Registration Rights

 

The registration rights described above will expire five years after this offering is completed.

 

Holders of              of our shares with these registration rights have signed agreements with the underwriters prohibiting the exercise of their registration rights for 180 days, subject to a possible extension of up to 34 additional days beyond the end of such 180-day period, following the date of this prospectus. These agreements are described below under “Underwriting.”

 

Anti-Takeover Provisions

 

The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws may have the effect of delaying, deferring or discouraging another person from acquiring control of our company.

 

119


Table of Contents

Delaware Law

 

Upon completion of our reincorporation in the State of Delaware, we will be governed by the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. This section prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least 10% of the corporation’s assets with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of the corporation’s outstanding voting stock, unless:

 

   

the transaction is approved by the Board of Directors prior to the time that the interested stockholder became an interested stockholder;

 

   

upon consummation of the transaction which resulted in the stockholder’s becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or

 

   

at or subsequent to such time that the stockholder became an interested stockholder the business combination is approved by the Board of Directors and authorized at an annual or special meeting of stockholders by at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

 

A Delaware corporation may “opt out” of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate or incorporation or bylaws resulting from a stockholders’ amendment approved by at least a majority of the outstanding voting shares. We do not plan to “opt out” of these provisions. This statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us.

 

Restated Certificate of Incorporation and Restated Bylaw Provisions

 

Our restated certificate of incorporation and our restated bylaws will include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management team, including the following:

 

   

Board of Directors Vacancies.  Our restated certificate of incorporation and restated bylaws will authorize only our Board of Directors to fill vacant directorships. In addition, the number of directors constituting our Board of Directors will be set only by resolution adopted by a majority vote of our entire Board of Directors. These provisions prevent a stockholder from increasing the size of our Board of Directors and gaining control of our Board of Directors by filling the resulting vacancies with its own nominees.

 

   

Classified Board.  Our restated certificate of incorporation and restated bylaws will provide that our Board of Directors is classified into three classes of directors. The existence of a classified board could delay a successful tender offeror from obtaining majority control of our Board of Directors, and the prospect of that delay might deter a potential offeror. Pursuant to Delaware law, the directors of a corporation having a classified board may be removed by the stockholders only for cause. In addition, stockholders will not be permitted to cumulate their votes for the election of directors.

 

   

Stockholder Action; Special Meeting of Stockholders.  Our restated certificate of incorporation will provide that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. Our restated bylaws will further provide that special meetings of our stockholders may be called only by a majority of our Board of Directors, the chairman of our Board of Directors, our chief executive officer or our president.

 

   

Advance Notice Requirements for Stockholder Proposals and Director Nominations.  Our restated bylaws will provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also will specify certain requirements regarding the form

 

120


Table of Contents
 

and content of a stockholder’s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.

 

   

Issuance of Undesignated Preferred Stock.  After the filing of our restated certificate of incorporation, our Board of Directors will have the authority, without further action by the stockholders, to issue up to              shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by the Board of Directors. The existence of authorized but unissued shares of preferred stock enables our Board of Directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock will be                     .                      

 

Stock Exchange Listing

 

We will apply to have our common stock listed on the                                                   under the symbol “AMRS.”

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Prior to this offering, there has been no public market for our common stock, and we cannot assure you that a significant market for our common stock will develop or be sustained after this offering. Future public market sales or the possibility of such future sales, of substantial amounts of our common stock, including shares issued upon exercise of our options and warrants, could adversely affect the trading price of our common stock or could impair our ability to raise capital in the future. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of the contractual and legal restrictions on resale described below, sales of substantial amounts of our common stock in the public market after those restrictions lapse could also adversely affect the trading price of our common stock.

 

Sales of Restricted Securities

 

Upon the completion of this offering, a total of              shares of our common stock will be outstanding, based on the number of shares outstanding at December 31, 2009, and assuming no exercises of options or warrants after December 31, 2009, and the issuance of              shares of common stock in this offering.

 

Of the shares to be outstanding after the closing of this offering, all shares sold in this offering will be freely tradable without restriction under the Securities Act, except that any shares purchased in this offering by our “affiliates,” as that term is defined in Rule 144 under the Securities Act generally may be sold in the public market only in compliance with Rule 144.

 

The remaining 24,215,560 shares of common stock will be “restricted securities,” as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, which are summarized below. In addition, substantially all of these restricted securities will be subject to the lock-up agreements described below.

 

As a result of the lock-up agreements and the provisions of our Amended and Restated Investors Rights Agreement described below, and subject to the provisions of Rules 144 and 701 under the Securities Act, these restricted securities will be available for sale in the public market as follows:

 

   

on the date of this prospectus,              of the shares will be available for sale in the public market without restriction; and

 

121


Table of Contents
   

beginning 181 days after the date of this prospectus, subject to extension as described in “Underwriters,”              shares will become eligible for sale in the public market, of which              shares will be freely tradable under Rule 144, and              shares will be freely tradable, subject to the limitations under Rules 144 and 701, of which              shares will be unvested and subject to our right of repurchase.

 

In addition, of the              shares of our common stock that were subject to stock options and warrants outstanding as of December 31, 2009, options and warrants to purchase              shares of common stock will be exercisable 181 days following the effective date of this prospectus and the shares resulting from any such exercises will be eligible for sale 181 days following the effective date of this prospectus, subject to extension as described in “Underwriters.”

 

As of December 31, 2009, 50,000 shares of common stock were subject to outstanding restricted stock units, of which              units will have settled 181 days after the effective date of this prospectus and will be freely tradable, subject to the limitations under Rule 144.

 

Rule 144

 

In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person is entitled to sell those shares without complying with any of the requirements of Rule 144.

 

In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon the expiration of the lock-up agreements described below, within any three-month period beginning 90 days after the date of this prospectus, a number of shares that does not exceed the greater of:

 

   

1% of the number of shares of common stock then outstanding, which will equal approximately              shares immediately after the offering; or

 

   

the average weekly trading volume of the common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.

 

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.

 

Rule 701

 

Any of our employees, officers, directors or consultants who purchased shares under a written compensatory plan or contract may be entitled to sell them in reliance on Rule 701. Rule 701 permits affiliates to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. Rule 701 further provides that non-affiliates may sell these shares in reliance on Rule 144 without complying with the holding period, public information, volume limitation or notice provisions of Rule 144. All holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling those shares. However, all shares issued under Rule 701 are subject to lock-up agreements described below and/or to a 180-day market stand-off contractual restriction in our favor and will only become eligible for sale when the lock-up and/or market standoff period expires.

 

122


Table of Contents

Investors’ Rights Agreement

 

Under our Amended and Restated Investors’ Rights Agreement, the holders of our capital stock that are party to that agreement have agreed to not sell any of our securities owned by them for a period of 180 days after the date of effectiveness of the registration statement to which this prospectus is a part, and in specific circumstances, up to an additional 34 days. Such “market stand-off” rights are contingent upon all directors, officers and holders of at least one percent of our voting capital stock entering into a similar agreement.

 

Other Market Stand-off Provisions

 

In addition to the market-standoff restrictions described above, the stock purchase agreements entered into by all optionees who have exercised options under our 2005 Stock Option/Stock Issuance Plan contain a market stand-off restriction of 180 days, which is contingent upon all of our directors and officers being subject to a similar restriction.

 

Lock-Up Agreements

 

We and each of our directors, officers and a substantial majority of our other stockholders have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus:

 

   

offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned by us or such persons or any securities convertible into or exercisable or exchangeable for shares of common stock; or

 

   

enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock.

 

The terms of the lock-up agreements, including exceptions to the prohibitions described above, as more fully described in “Underwriting” below.

 

Registration Rights

 

Upon the completion of this offering, the holders of an aggregate of              shares of our common stock and the holders of warrants to purchase an aggregate of              shares of our common stock, or their permitted transferees, will be entitled to rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See “Description of Capital Stock—Registration Rights” for additional information.

 

Registration Statements

 

We intend to file a registration statement on Form S-8 under the Securities Act covering all of the shares of common stock subject to options outstanding and reserved for issuance under our stock plans. We expect to file this registration statement as soon as practicable after this offering. However, none of the shares registered on Form S-8 will be eligible for resale until the expiration of the lock-up agreements to which they are subject.

 

123


Table of Contents

MATERIAL U.S. FEDERAL TAX CONSIDERATIONS

FOR NON-U.S. HOLDERS OF COMMON STOCK

 

This section summarizes certain material U.S. federal income tax considerations relating to the ownership and disposition of common stock by non-U.S. holders. This summary does not provide a complete analysis of all potential tax considerations. The information provided below is based upon provisions of the Internal Revenue Code of 1986, as amended, or the Code, and Treasury regulations promulgated thereunder, administrative rulings and judicial decisions currently in effect. These authorities may change at any time, possibly on a retroactive basis, or the Internal Revenue Service, or IRS, might interpret the existing authorities differently. In either case, the tax considerations of owning or disposing of common stock could differ from those described below. For purposes of this summary, a “non-U.S. holder” is any holder other than:

 

   

an individual who is a citizen or resident of the U.S.;

 

   

a corporation created or organized under the laws of the U.S., any state or the District of Columbia;

 

   

a trust that is (1) subject to the primary supervision of a U.S. court and one of more U.S. persons have authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person; or

 

   

an estate whose income is subject to U.S. income tax regardless of source.

 

If you are a non-U.S. holder that is an individual, you may, in many cases, be deemed to be a resident alien, as opposed to a nonresident alien, by virtue of being present in the U.S. for at least 31 days in the calendar year and for an aggregate of at least 183 days during a three-year period ending in the current calendar year. For these purposes, all the days present in the current year, one-third of the days present in the immediately preceding year, and one-sixth of the days present in the second preceding year are counted. Resident aliens are subject to U.S. federal income tax as if they were U.S. citizens. Such an individual is urged to consult his or her own tax advisor regarding the U.S. federal income tax consequences of the sale, exchange of other disposition of common stock. If a partnership or other pass-through entity is a beneficial owner of common stock, the tax treatment of a partner in the partnership or an owner of the entity will depend upon the status of the partner or other owner and the activities of the partnership or other entity. Any partner in a partnership or member in a pass-through entity holding shares of our common stock should consult its own tax advisor.

 

This discussion assumes that a non-U.S. holder will hold our common stock as a capital asset (generally, property held for investment). The summary generally does not address tax considerations that may be relevant to particular investors because of their specific circumstances, or because they are subject to special rules, including if the investor is a U.S. expatriate, “controlled foreign corporation,” “passive foreign investment company,” corporation that accumulates earnings to avoid U.S. federal income tax, dealer in securities or currencies, financial institution, regulated investment company, real estate investment trust, tax-exempt entity, insurance company, person holding our common stock as part of a hedging, integrated, conversion or constructive sale transaction or a straddle, trader in securities that elects to use a mark-to-market method of accounting, person liable for the alternative minimum tax, and partner or beneficial owner in a pass-through entity. Finally, the summary does not describe the effects of any applicable foreign, state or local laws, or, except to the extent discussed below, the effects of any applicable gift or estate tax laws.

 

INVESTORS CONSIDERING THE PURCHASE OF COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF FOREIGN, STATE OR LOCAL LAWS, AND TAX TREATIES.

 

124


Table of Contents

Dividends

 

We do not expect to declare or pay any dividends on our common stock in the foreseeable future. If we do pay dividends on shares of our common stock, however, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a non-U.S. holder’s adjusted tax basis in shares of our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of our common stock. See “—Sale of Common Stock.”

 

Any dividend paid to a non-U.S. holder on our common stock will generally be subject to U.S. withholding tax at a 30% rate. The withholding tax might not apply, however, or might apply at a reduced rate, under the terms of an applicable income tax treaty between the U.S. and the non-U.S. holder’s country of residence. You should consult your tax advisors regarding your entitlement to benefits under a relevant income tax treaty. Generally, in order for us or our paying agent to withhold tax at a lower treaty rate, a non-U.S. holder must certify its entitlement to treaty benefits. A non-U.S. holder generally can meet this certification requirement by providing a Form W-8BEN (or any successor form) or appropriate substitute form to us or our paying agent. If the holder holds the stock through a financial institution or other agent acting on the holder’s behalf, the holder will be required to provide appropriate documentation to the agent. The holder’s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. For payments made to a foreign partnership or other pass-through entity, the certification requirements generally apply to the partners or other owners rather than to the partnership or other entity, and the partnership or other entity must provide the partners’ or other owners’ documentation to us or our paying agent. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS in a timely manner.

 

Dividends received by a non-U.S. holder that are effectively connected with a U.S. trade or business conducted by the non-U.S. holder, or, if an income tax treaty between the U.S. and the non-U.S. holder’s country of residence apply, are attributable to a permanent establishment you maintain in the U.S., are not subject to such withholding tax. To obtain this exemption, a non-U.S. holder must provide us with an IRS Form W-8ECI properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits, subject to any applicable tax treaty providing otherwise. In addition to the graduated tax described above, dividends received by corporate non-U.S. holders that are effectively connected with a U.S. trade or business of the corporate non-U.S. holder may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable tax treaty.

 

Sale of Common Stock

 

Non-U.S. holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other disposition of common stock unless:

 

   

the gain (1) is effectively connected with the conduct by the non-U.S. holder of a U.S. trade or business and (2) if an income tax treaty applies between the U.S. and the non-U.S. holder’s country of residence, the gain is attributable to a permanent establishment (or, in the case of an individual, a fixed base) maintained by the non-U.S. holder in the U.S. (in which case the special rules described below apply);

 

   

the non-U.S. holder is an individual who is present in the U.S. for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock, and certain other requirements are met (in which case the gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the individual is not considered a resident of the U.S.); or

 

125


Table of Contents
   

the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA, treat the gain as effectively connected with a U.S. trade or business.

 

The FIRPTA rules may apply to a sale, exchange or other disposition of common stock if we are, or were within the shorter of the five-year period preceding the disposition and the non-U.S. holder’s holding period, a “U.S. real property holding corporation,” or USRPHC. In general, we would be a USRPHC if interests in U.S. real estate comprised at least half of our assets. We do not believe that we are a USRPHC and we do not anticipate becoming one in the future. Even if we become a USRPHC, as long as our common stock is regularly traded on an established securities market, such common stock will be treated as U.S. real property interests only if a non-U.S. holder actually owns or constructively holds more than 5% of our outstanding common stock.

 

If any gain from the sale, exchange or other disposition of common stock, (1) is effectively connected with a U.S. trade or business conducted by a non-U.S. holder and (2) if an income tax treaty between the U.S. and the non-U.S. holder’s country of residence applies, is attributable to a permanent establishment (or, in the case of an individual, a fixed base) maintained by such non-U.S. holder in the U.S., then the gain generally will be subject to U.S. federal income tax at the regular graduated rates. If the non-U.S. holder is a corporation, under certain circumstances, that portion of its earnings and profits that is effectively connected with its U.S. trade or business, subject to certain adjustments, generally would be subject to a “branch profits tax.” The branch profits tax rate is generally 30%, although an applicable income tax treaty between the U.S. and the non-U.S. holder’s country of residence might provide for a lower rate.

 

U.S. Federal Estate Tax

 

The estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S. corporation, our common stock will be U.S. situs property and, therefore, will be included in the taxable estate of a nonresident alien decedent, unless an applicable estate tax treaty between the U.S. and the decedent’s country of residence provides otherwise.

 

Backup Withholding and Information Reporting

 

The Code and the Treasury regulations require those who make specified payments to report the payments to the IRS. Among the specified payments are dividends and proceeds paid by brokers to their customers. The required information returns enable the IRS to determine whether the recipient properly included the payments in income. This reporting regime is reinforced by “backup withholding” rules. These rules require the payors to withhold tax from payments subject to information reporting if the recipient fails to cooperate with the reporting regime by failing to provide his taxpayer identification number to the payor, furnishing an incorrect identification number, or failing to report interest or dividends on his returns. The backup withholding tax rate is currently 28%. The backup withholding rules do not apply to payments to corporations, whether domestic or foreign.

 

Payments to non-U.S. holders of dividends on common stock generally will not be subject to backup withholding, and payments of proceeds made to non-U.S. holders by a broker upon a sale of common stock will not be subject to information reporting or backup withholding, in each case so long as the non-U.S. holder certifies its nonresident status (and we or our paying agent do not have actual knowledge or reason to know the holder is a U.S. person or that the conditions of any other exemption are not, in fact, satisfied) or otherwise establishes an exemption. The certification procedures to claim treaty benefits described under “—Dividends” will satisfy the certification requirements necessary to avoid the backup withholding tax as well. We must report annually to the IRS any dividends paid to each non-U.S. holder and the tax withheld, if any, with respect to these dividends. Copies of these reports may be made available to tax authorities in the country where the non-U.S. holder resides.

 

Under the Treasury regulations, the payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or through a U.S. office of a broker generally will be subject to information reporting and backup withholding unless the beneficial owner certifies, under penalties of perjury, among other

 

126


Table of Contents

things, its status as a non-U.S. holder (and we or our paying agent do not have actual knowledge or reason to know the holder is a U.S. person) or otherwise establishes an exemption. The payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or through a non-U.S. office of a broker generally will not be subject to backup withholding and information reporting, except as noted below. Information reporting, but not backup withholding, will apply to a payment of proceeds, even if that payment is made outside of the U.S., if you sell our common stock through a non-U.S. office of a broker that is:

 

   

a U.S. person (including a foreign branch or office of such person);

 

   

a “controlled foreign corporation” for U.S. federal income tax purposes;

 

   

a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or

 

   

a foreign partnership if at any time during its tax year (a) one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or (b) the foreign partnership is engaged in a U.S. trade or business;

 

unless the broker has documentary evidence that the beneficial owner is a non-U.S. holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no actual knowledge or reason to know to the contrary).

 

Backup withholding is not an additional tax. Any amounts withheld from a payment to a holder of common stock under the backup withholding rules can be credited against any U.S. federal income tax liability of the holder and may entitle the holder to a refund, provided that the required information is furnished to the IRS in a timely manner.

 

THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.

 

127


Table of Contents

UNDERWRITERS

 

Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co. and J.P. Morgan Securities Inc. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below:

 

Name

         Number of
Shares

Morgan Stanley & Co. Incorporated

  

Goldman, Sachs & Co.

  

J.P. Morgan Securities Inc.

  

Itaú USA Securities Inc.

  

Thomas Weisel Partners LLC

  
      

Total:

  
    

 

The underwriters and the representatives are collectively referred to as the “underwriters” and the “representatives,” respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters’ over-allotment option described below.

 

The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $             a share under the public offering price. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part.

 

We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to              additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter’s name in the preceding table bears to the total number of shares of common stock listed next to the names of all underwriters in the preceding table.

 

The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase up to an additional              shares of common stock.

 

     Total
     Per Share    No Exercise    Full Exercise

Public offering price

   $                 $                 $             

Underwriting discounts and commissions to be paid by us

   $      $      $  

Proceeds, before expenses, to us

   $      $      $  

 

The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $            .

 

The underwriters have informed us that they do not intend sales to discretionary accounts to exceed five percent of the total number of shares of common stock offered by them.

 

128


Table of Contents

Our common stock has been approved for listing on                                                   under the trading symbol “AMRS”.

 

We and all of our directors and officers, and the holders of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus:

 

   

offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned by us or such persons or any securities convertible into or exercisable or exchangeable for shares of common stock, or

 

   

enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock;

 

whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we will not, during the period ending 180 days after the date of this prospectus, file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, except for the filing of a registration statement on Form S-8 relating to the offering of securities in accordance with the terms of a plan in effect on the date hereof.

 

The restrictions described in the immediately preceding paragraph to do not apply to, among other things:

 

   

transactions relating to shares of our common stock or other securities acquired in open market transactions after the completion of this offering, provided that no filing under the Securities Exchange Act of 1934, or the Exchange Act (other than a filing on a Form 5, Schedule 13D or Schedule 13G (or 13D/A or 13G/A) made after the expiration of the restricted period), shall be required or shall be voluntarily made in connection with subsequent sales of common stock or other securities acquired in such open market transactions;

 

   

transfers of shares of our common stock or any security convertible into or exercisable for common stock as a bona fide gift;

 

   

transfers of shares of our common stock or any security convertible into or exercisable or exchangeable for common stock to us, pursuant to agreements under which we have the option to repurchase such shares or a right of first refusal with respect to transfers of such shares, provided that such transfers after the date of this prospectus shall be for less than market value of our common stock at the time of transfer;

 

   

the sale of shares of common stock to the underwriters;

 

   

the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that such plan does not provide for any transaction, including any sale, until the termination of the restricted period; or

 

   

the exercise of options, warrants or rights to acquire shares of our common stock or any security convertible into common stock, in accordance with their terms, provided that the acquired common stock is subject to the restricted period.

 

In addition, we, all of our directors and officers, and the holders of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock.

 

129


Table of Contents

The 180 day restricted period described in the preceding paragraphs will be extended if:

 

   

during the last 17 days of the 180 day restricted period we issue an earnings release or material news or a material event relating to us occurs; or

 

   

prior to the expiration of the 180 day restricted period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 180 day period;

 

in which case the restrictions described in the preceding paragraph will continue to apply until the expiration of the 18 day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

 

In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time.

 

We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the other may be required to make because of any of these liabilities.

 

A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations.

 

The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for the issuer, for which they received or will receive customary fees and expenses.

 

In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve securities and instruments of the issuer.

 

130


Table of Contents

Pricing of the Offering

 

Prior to this offering, there has been no public market for our common stock. The initial public offering price was determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. We cannot assure you that the prices at which our shares will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our common stock will develop and continue after this offering.

 

European Economic Area

 

In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member State), each underwriter has represented and agreed that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the Relevant Implementation Date) it has not made and will not make an offer of shares to the public in that Relevant Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that it may, with effect from and including the Relevant Implementation Date, make an offer of shares to the public in that Relevant Member State at any time:

 

   

to legal entities which are authorised or regulated to operate in the financial markets or, if not so authorised or regulated, whose corporate purpose is solely to invest in securities;

 

   

to any legal entity which has two or more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000 and (3) an annual net turnover of more than €50,000,000, as shown in its last annual or consolidated accounts;

 

   

to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus Directive) subject to obtaining the prior consent of the representatives for any such offer; or

 

   

in any other circumstances which do not require the publication by the Issuer of a prospectus pursuant to Article 3 of the Prospectus Directive.

 

For the purposes of this provision, the expression an “offer of shares to the public” in relation to any shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression Prospectus Directive means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.

 

United Kingdom

 

Each underwriter has represented and agreed that:

 

   

it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of the shares in circumstances in which Section 21(1) of the FSMA does not apply to us; and

 

   

it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares in, from or otherwise involving the United Kingdom.

 

131


Table of Contents

Hong Kong

 

The shares may not be offered or sold by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii) to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a “prospectus” within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder.

 

Singapore

 

This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”), (ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

 

Where the shares are subscribed or purchased under Section 275 by a relevant person which is: (a) a corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries’ rights and interest in that trust shall not be transferable for 6 months after that corporation or that trust has acquired the shares under Section 275 except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA; (2) where no consideration is given for the transfer; or (3) by operation of law.

 

Japan

 

The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (the Financial Instruments and Exchange Law) and each underwriter has agreed that it will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan.

 

132


Table of Contents

LEGAL MATTERS

 

The validity of the shares of common stock offered hereby will be passed upon for us by Fenwick & West LLP, Mountain View, California. Wilson Sonsini Goodrich & Rosati, P.C., Palo Alto, California, is acting as counsel for the underwriters in connection with certain legal matters related to this offering.

 

Certain investment partnerships comprised of members of, and persons associated with, Wilson Sonsini Goodrich & Rosati, P.C. beneficially hold an aggregate of 23,000 shares of our common stock, which represents less than 0.1% of our outstanding shares of common stock.

 

EXPERTS

 

The consolidated financial statements as of December 31, 2008 and 2009 and for each of the three years in the period ended December 31, 2009, included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

 

WHERE YOU CAN FIND ADDITIONAL INFORMATION

 

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedule filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. We currently do not file periodic reports with the SEC. Upon completion of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Securities Exchange Act of 1934. A copy of the registration statement and the exhibits filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains an Internet website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov.

 

133


Table of Contents

CONSOLIDATED FINANCIAL STATEMENTS

 

Index

 

Amyris Biotechnologies, Inc.

 

     Page(s)

Report of Independent Registered Public Accounting Firm

   F-2

Consolidated Financial Statements

  

Consolidated Balance Sheets as of December 31, 2008 and 2009

   F-3

Consolidated Statements of Operations for the years ended December 31, 2007, 2008 and 2009

   F-4
Consolidated Statements of Convertible Preferred Stock, Redeemable Noncontrolling Interest and Deficit for the years ended December  31, 2007, 2008 and 2009    F-5

Consolidated Statements of Cash Flows for the years ended December 31, 2007, 2008 and 2009

   F-6

Notes to Consolidated Financial Statements

   F-8

 

F-1


Table of Contents

Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Shareholders of

Amyris Biotechnologies, Inc.

 

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, of convertible preferred stock, redeemable noncontrolling interest and deficit, and of cash flows present fairly, in all material respects, the financial position of Amyris Biotechnologies, Inc. and its subsidiaries at December 31, 2009 and December 31, 2008, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2009 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for noncontrolling interest in 2009.

 

/s/ PricewaterhouseCoopers LLP

 

San Jose, California

April 16, 2010

 

F-2


Table of Contents

Amyris Biotechnologies, Inc.

 

Consolidated Balance Sheets

In Thousands, Except Share and Per Share Amounts

 

    December 31,
2008
    December 31,
2009
    Pro Forma
Shareholders’ Equity
as of
December 31,

2009
 
                (Unaudited)  

Assets

     

Current assets:

     

Cash and cash equivalents

  $ 17,899      $ 19,188     

Short-term investments

    19,291        48,022     

Accounts receivable

    787        1,372     

Inventories

    1,420        2,298     

Prepaid expenses and other current assets

    1,556        3,983     
                 

Total current assets

    40,953        74,863     

Property and equipment, net

    41,565        42,560     

Restricted cash

    2,748        4,506     

Long-term investments

    12,950            

Other assets

    607        230     
                 

Total assets

  $ 98,823      $ 122,159     
                 

Liabilities, Convertible Preferred Stock, Redeemable Noncontrolling Interest and Equity (Deficit)

     

Current liabilities:

     

Accounts payable

  $ 2,617      $ 1,709     

Deferred revenue

           378     

Accrued and other current liabilities

    5,083        10,445     

Capital lease obligation, current portion

    557        2,251     

Debt, current portion

    340        9,018     
                 

Total current liabilities

    8,597        23,801     

Capital lease obligation, net of current portion

    3,041        4,977     

Long-term debt, net of current portion

    2,809        4,362     

Convertible preferred stock warrant liability

    2,132        2,740        

Deferred rent, net of current portion

    12,154        8,828     

Restructuring liability

           4,486     

Other liabilities

    797        1,553     
                 

Total liabilities

    29,530        50,747     
                 

Commitments and contingencies (Note 5)

     

Convertible preferred stock—no par value, 16,104,641 and 21,080,641

shares authorized as of December 31, 2008 and 2009; 13,681,658 and

18,365,222 shares issued and outstanding as of December 31, 2008 and

2009 (aggregate liquidation value $126,225 and $185,566 as of

December 31, 2008 and 2009); no shares issued and outstanding, pro

forma (unaudited)

    121,436        179,651        

Redeemable noncontrolling interest

           5,506        

Shareholders’ Equity (Deficit):

     

Common stock—no par value; 28,000,000 and 33,000,000 shares authorized as of December 31, 2008 and 2009; 5,015,576 and 5,114,205 shares issued and shares outstanding as of December 31, 2008 and 2009; 33,000,000 shares authorized, 24,215,560 shares issued and outstanding, pro forma (unaudited)

    583        858      188,755   

Additional paid-in capital

    2,582        4,509      4,509   

Accumulated other comprehensive income (loss)

    (468     1,336      1,336   

Accumulated deficit

    (55,989     (120,448   (120,448
                     

Total Amyris Biotechnologies, Inc. shareholders’ equity (deficit)

    (53,292     (113,745   74,152   
                     

Noncontrolling interest

    1,149               
                     

Total equity (deficit)

    (52,143     (113,745   74,152   
                     

Total liabilities, convertible preferred stock, redeemable noncontrolling interest and equity (deficit)

  $ 98,823      $ 122,159     
                 

 

See accompanying notes to the consolidated financial statements.

 

F-3


Table of Contents

Amyris Biotechnologies, Inc.

 

Consolidated Statements of Operations

In Thousands, Except Share and Per Share Amounts

 

       Years Ended December 31,  
     2007     2008     2009  

Revenues

      

Product sales

   $      $ 10,680      $ 61,689   

Collaborative research services

     6,046        3,008        2,919   

Government grants

     138        204          
                        

Total revenues

     6,184        13,892        64,608   

Cost and operating expenses

      

Cost of product sales

            10,364        60,428   

Research and development

     8,662        30,306        38,263   

Sales, general and administrative

     10,522        16,622        23,558   

Restructuring and asset impairment charges

                   5,768   
                        

Total cost and operating expenses

     19,184        57,292        128,017   
                        

Loss from operations

     (13,000     (43,400     (63,409

Other income (expense):

      

Interest income

     1,178        1,378        448   

Interest expense

     (28     (377     (1,218

Other income (expense), net

     76        (144     (621
                        

Total other income (expense)

     1,226        857        (1,391
                        

Loss before income taxes

     (11,774     (42,543     (64,800

Benefit from income taxes

            (207       
                        

Net loss

   $ (11,774   $ (42,336   $ (64,800

Loss attributable to noncontrolling interest

            (472     (341
                        

Net loss attributable to Amyris Biotechnologies, Inc. shareholders

   $ (11,774   $ (41,864   $ (64,459
                        

Net loss per share of common stock attributable to Amyris Biotechnologies, Inc. shareholders, basic and diluted

   $ (3.28   $ (9.91   $ (13.56
                        

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted

     3,592,932        4,223,533        4,753,085   
                        

Pro forma net loss per share of common stock attributable to Amyris Biotechnologies, Inc. shareholders, basic and diluted (unaudited)

       $ (3.16
            

Weighted-average shares of common stock outstanding used in computing pro forma net loss per share of common stock, basic and diluted (unaudited)

         20,279,433   
            

 

See accompanying notes to the consolidated financial statements.

 

F-4


Table of Contents

Amyris Biotechnologies, Inc.

 

Consolidated Statements of Convertible Preferred Stock, Redeemable Noncontrolling Interest and Deficit

for the years ended December 31, 2007, 2008 and 2009

    Convertible
Preferred Stock
    Redeemable
Noncontrolling
Interest
          Common Stock     Additional
Paid-in
Capital
    Accumulated
Deficit
    Accumulated
Other
Comprehensive
Income (Loss)
    Noncontrolling
Interest
    Total
Deficit
 
(In Thousands, Except Per Share Amounts)   Shares   Amount         Shares     Amount            

January 1, 2007

  2,992,176   $ 6,397      $          4,503,917      $ 42      $ 9      $ (2,351   $      $      $ (2,300

Issuance of Series A convertible preferred stock at $2.174 per share for cash and services, net of issuance costs of $21

  6,482,824     14,073                                                             

Issuance of Series B convertible preferred stock at $24.88 per share for cash and services, net of issuance costs of $89

  1,517,093     37,656                                                             

Issuance of common stock upon exercise of stock options, net of restricted stocks

                      361,723        219                                    219   

Repurchase of common stock

                      (20,625     (2                                 (2

Stock-based compensation

                                    546                             546   

Components of other comprehensive income (loss)

                       

Change in unrealized gain on investments

                                                  10               10   

Net loss

                                           (11,774                   (11,774
                             

Total comprehensive loss

                          (11,764
                                                                             

December 31, 2007

  10,992,093     58,126                 4,845,015        259        555        (14,125     10               (13,301

Issuance of Series B convertible preferred stock at $24.88 per share for cash, net of issuance costs of $80

  150,724     3,670                                                             

Issuance of Series B-1 convertible preferred stock at $25.26 per share for cash, net of issuance costs of $2,746

  2,538,841     61,385                                                             

Issuance of warrants in connection with issuance of Series B-1 convertible preferred stock

      (1,745                                                          

Issuance of common stock upon exercise of stock options, net of restricted stocks

                      172,059        326                                    326   

Repurchase of common stock

                      (1,498     (2                                 (2

Stock-based compensation

                                    2,027                             2,027   

Sale of noncontrolling interest

                                                         1,621        1,621   

Components of other comprehensive income (loss)

                       

Change in unrealized gain on investments

                                                  77               77   

Foreign currency translation adjustment

                                                  (555            (555

Net loss.

                                           (41,864            (472     (42,336
                             

Total comprehensive loss.

                          (42,814
                                                                             

December 31, 2008

  13,681,658     121,436                 5,015,576        583        2,582        (55,989     (468     1,149        (52,143

Issuance of Series B-1 convertible preferred stock at $25.26 per share for cash, net of issuance costs of $103

  76,880     1,840                                                             

Issuance of Series C convertible preferred stock at $12.46 per share for cash, net of issuance costs of $956

  4,606,684     56,443                                                             

Issuance of warrants in connection with issuance of Series B-1 convertible preferred stock

      (68                                                          

Issuance of common stock upon exercise of stock options, net of restricted stock

                      127,515        284                                    284   

Repurchase of common stock

                      (28,886     (9                                 (9

Stock-based compensation

                                    3,299                             3,299   

Proceeds from redeemable noncontrolling interest

             5,626                                                      

Purchase of noncontrolling interest

                                    (1,372                   (928     (2,300

Components of other comprehensive income (loss)

                       

Change in unrealized loss on investments

                                                  (84            (84

Foreign currency translation adjustment

                                                  1,888               1,888   

Net loss.

             (120                            (64,459            (221     (64,680
                             

Total comprehensive loss.

                          (62,876
                                                                             

December 31, 2009

  18,365,222   $ 179,651      $ 5,506          5,114,205      $ 858      $ 4,509      $ (120,448   $ 1,336      $      $ (113,745
                                                                             

 

See accompanying notes to the consolidated financial statements.

 

F-5


Table of Contents

Amyris Biotechnologies, Inc.

 

Consolidated Statements of Cash Flows

In Thousands

 

    Years Ended December 31,  
    2007     2008     2009  

Operating activities

     

Net loss.

  $ (11,774   $ (42,336   $ (64,800

Adjustments to reconcile net loss to net cash used in operating activities:

     

Convertible preferred stock issued for services

    255                 

Convertible preferred stock warrants

           274        62   

Depreciation and amortization

    634        2,627        5,775   

Loss on disposal of property and equipment

           144        12   

Stock-based compensation

    546        2,027        3,299   

Amortization of premium (discount) on investments

    402        (400     191   

Change in fair value of convertible preferred stock warrant liability

           114        445   

Restructuring and asset impairment charges

                  356   

Other noncash expenses

                  219   

Changes in assets and liabilities:

     

Accounts receivable, net

           (787     (585

Inventories

           (1,420     (878

Prepaid expenses and other assets

    (103     (1,943     972   

Accounts payable

    114        1,278        (997

Restructuring

                  5,078   

Accrued and other long-term liabilities

    2,303        2,114        4,470   

Deferred revenue

    (1,903     (1,355     378   

Deferred rent

           784        285   
                       

Net cash used in operating activities

    (9,526     (38,879     (45,718
                       

Investing activities

     

Purchase of short-term investments

    (120,901     (48,153     (47,996

Maturities of short-term investments

    88,258        52,746        31,690   

Sales of short-term investments

   
2,950
  
    8,905        250   

Purchases of long-term investments

    (8,750     (6,200       

Sales and maturities of long-term investments

           2,000          

Change in restricted cash

    (736     (1,962     (1,758

Purchase of property and equipment, net of disposals

    (2,464     (21,996     (7,608
                       

Net cash used in investing activities

    (41,643     (14,660     (25,422
                       

Financing activities

     

Proceeds from issuance of convertible preferred stock, net of issuance costs

    51,474        65,055        58,283   

Proceeds from issuance of common stock, net of repurchases

    217        586        113   

Purchase of noncontrolling interest

                  (2,300

Proceeds from equipment financing

           1,220        4,763   

Principal payments on capital leases

    (152     (378     (1,134

Proceeds from debt

                  9,643   

Principal payments on debt

           (125     (985

Proceeds from sale of noncontrolling interest

           1,621        3,090   
                       

Net cash provided by financing activities

    51,539        67,979        71,473   
                       

Effect of exchange rate changes on cash and cash equivalents

           (555     956   
                       

Net increase in cash and cash equivalents

    370        13,885        1,289   

Cash and cash equivalents at beginning of period

    3,644        4,014        17,899   
                       

Cash and cash equivalents at end of period

  $ 4,014      $ 17,899      $ 19,188   
                       

 

See accompanying notes to the consolidated financial statements.

 

F-6


Table of Contents

Amyris Biotechnologies, Inc.

 

Consolidated Statements of Cash Flows—(Continued)

In Thousands

 

     Years Ended December 31,  
     2007    2008    2009  

Supplemental disclosures of cash flow information:

        

Cash paid for interest

   $ 18    $ 320    $ 1,204   
                      

Cash paid for income taxes, net of refunds

   $    $    $ 27   
                      

Supplemental disclosure of noncash investing and financing activities:

        

Convertible preferred stock issued for services

   $      255    $    $   
                      

Stock receivable for noncontrolling interest

   $    $    $   2,536   
                      

Additions to property and equipment under capital lease obligations

   $ 807    $ 2,101    $   
                      

Additions to property and equipment under notes payable

   $    $ 3,274    $ 1,038   
                      

Additions to property and equipment under tenant improvement allowances

   $    $ 11,370    $   
                      

Acquisitions of assets under accounts payable

   $ 411    $ 731    $ 20   
                      

Financing of insurance premium under notes payable

   $    $    $ 378   
                      

Change in unrealized gain (loss) on investments

   $ 10    $ 77    $ (84
                      

Asset retirement obligation

   $    $ 470    $   
                      

Warrants issued in connection with the issuance of convertible preferred stock

   $    $ 1,745    $ 68   
                      

 

See accompanying notes to the consolidated financial statements.

 

F-7


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements

 

1. The Company and Basis of Presentation

 

Amyris Biotechnologies, Inc. (the “Company”) was incorporated in the State of California on July 17, 2003 for the purpose of leveraging breakthroughs in synthetic biology to develop and provide renewable compounds for a variety of markets. The Company is currently building and applying our industrial synthetic biology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. Our first commercialization efforts have been focused on a molecule called farnesene, which forms the basis for a wide range of products varying from specialty chemical applications to transportation fuels, such as diesel. While our platform is able to use a wide variety of feedstocks, the Company has focused initially on Brazilian sugarcane. The Company intends to secure access to this feedstock and to expand our production capacity by working with existing sugar and ethanol mill owners to build new, adjacent bolt-on facilities at their existing mills in return for a share of the higher gross margin the Company believes it will realize from the sale of our renewable products. Our first such arrangement is our joint venture with Usina São Martinho.

 

In February 2008, the Company incorporated a wholly owned subsidiary, Amyris Fuels, Inc., a Delaware corporation, which is engaged in marketing and distribution of certain fuels. In September 2008, the Company established a wholly owned subsidiary, Amyris Fuels, LLC, a Delaware limited liability company. In March 2008, the Company established a majority-owned subsidiary Amyris-Crystalsev Pesquisa e Desenvolvimento de Biocombustiveis Ltda, which was re-named to Amyris Brasil S.A. (“Amyris Brasil”) in 2009, for the purpose of manufacturing and trading transportation fuels from sugarcane feedstock in Brazil and abroad (See Note 16). In April 2009, Amyris Brasil became a wholly-owned subsidiary and in December 2009 Amyris Brasil became a majority-owned subsidiary of the Company.

 

In April 2009, the Company purchased the remaining outstanding shares in Amyris Brasil for $2.3 million resulting in Amyris Brasil becoming a wholly-owned subsidiary. The purchase of the noncontrolling interest was treated as an equity transaction and the fair value of the consideration paid of $2.3 million was recorded as a reduction of the carrying value of the noncontrolling interest and additional paid-in capital.

 

On December 22, 2009, the Company sold a 4.8% interest in Amyris Brasil for BRL$10.0 million. The redeemable noncontrolling interest is reported in the mezzanine equity section of the consolidated balance sheet because the Company is subject to a contingent put option under which it may be required to repurchase an interest in Amyris Brasil from the noncontrolling interest holder.

 

During December 2009, the Company has been awarded a grant from the Department of Energy (“DOE”), pursuant to the Recovery Act-Demonstration of Integrated Biorefinery Operations Funding Opportunity Announcement, authorizing a grant from the DOE for $24.3 million. Under this grant, we are required to fund an additional $10.5 million in cost sharing expenses. As of December 31, 2009, no amounts have been provided from the DOE.

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation and Use of Estimates

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. The consolidated financial statements include the accounts of the Company, wholly-owned subsidiaries and one majority-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. In preparing the consolidated financial statements, management must make estimates

 

F-8


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Unaudited Pro Forma Information

 

The December 31, 2009 unaudited pro forma shareholders’ equity has been prepared assuming that upon the completion of a qualifying initial public offering (i) all of the Company’s convertible preferred stock outstanding will automatically convert into shares of common stock, (ii) the Company’s convertible preferred stock warrants will become warrants for common stock (see Note 10), and (iii) shares of Amyris Brasil held by third parties will convert into shares of the Company’s common stock (see Note 16). The December 31, 2009 unaudited pro forma shareholders’ equity reflects the (i) the conversion of all 18,365,222 outstanding shares of preferred stock into 18,790,244 shares of common stock, the reclassification of the preferred stock warrant liability to common stock and reclassification of redeemable noncontrolling interest to common stock immediately prior to the completion of the public offering.

 

Significant Risks and Uncertainties

 

The Company is subject to certain risks and uncertainties that could have a material and adverse effect on the Company’s future financial position or results of operations. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, limited operating history, delays or greater than anticipated expenses associated with the completion of new production facilities and the time to complete scale up of production following completion of a new production facility, disruptions in the production process at any facility where we produce our products, the timing, size and mix of sales to customers for our products, fluctuations in foreign currency exchange rates, gains or losses associated with our hedging activities, especially in Amyris Fuels, fluctuations in the price of and demand for ethanol, as well as petroleum-based and other products for which our products are alternatives, seasonal production and sale of our products, the effects of competitive pricing pressures, including decreases in average selling prices of our products, unanticipated expenses associated with changes in governmental regulations and environmental, health and safety requirements, reductions or changes to existing fuel and chemical regulations and policies, departure of executives or other key management employees, our ability to use our net operating loss carry forwards to offset future taxable income, our ability to integrate businesses that we may acquire and risks associated with the international aspects of our business.

 

Certain products developed by the Company may require approvals from the Environmental Protection Agency or other United States or international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary approvals. If the Company was denied approval or approval was delayed, it may have a material adverse impact on the Company.

 

To achieve profitable operations, the Company must successfully develop, manufacture and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s future financial results.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments, accounts receivable, derivatives and

 

F-9


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

financial instruments. The Company places its cash equivalents and investments with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

 

The Company’s accounts receivable are derived from customers located in the United States. The Company performs ongoing credit evaluation of its customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary. To date, there have been no such losses and the Company has not recorded an allowance for doubtful accounts.

 

As of December 31, 2008 and 2009, customers representing greater than 10% of accounts receivable were as follows (in percentages):

 

     December 31,

Customers

   2008    2009

Customer A

   10    *

Customer B

   15    *

Customer C

   *    51

Customer D

   12    *

Customer E

   *    17

Customer F

   14    *

Customer G

   20    *

Customer H

   26    *

 

  *   Less than 10%

 

For the years ended December 31, 2007, 2008 and 2009, customers representing greater than 10% of revenues were as follows (in percentages):

 

     Years Ended December 31,

Customers

   2007    2008    2009

Customer A

   *    33    33

Customer B

   *    30    *

Customer C

   *    *    22

Customer D

   *    21    *

 

  *   Less than 10%

 

The Company is exposed to counterparty credit risk on all of its derivative commodity instruments. The Company has established and maintains strict counterparty credit guidelines and enters into agreements only with counterparties that are investment grade or better. The Company does not require collateral under these agreements.

 

Fair Value of Financial Instruments

 

The Company measures certain financial assets and liabilities at fair value based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Financial instruments are primarily comprised of commercial paper, government bonds and notes, auction rate securities (“ARS”), rights to

 

F-10


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

sell its ARS (“Put Option”), derivatives and convertible preferred stock warrants. Where available, fair value is based on or derived from observable market prices or other observable inputs. Where observable prices or inputs are not available valuation models are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments’ complexity.

 

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities, and market interest rates if applicable. Based on the borrowing rates currently available to the Company for debt with similar terms, the carrying value of the notes payable and credit facility approximates its fair value. The carrying amount of the convertible preferred stock warrant liability represents its estimated fair value.

 

Cash and Cash Equivalents

 

All highly liquid investments purchased with an original maturity date of three months or less at the date of purchase are considered to be cash equivalents. Cash and cash equivalents consist of money market funds, commercial paper and various deposit accounts.

 

Investments

 

Investments with original maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short-term investments. The Company classifies investments as short-term or long-term based upon whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. The Company invests its excess cash balances primarily in short-term investment grade commercial paper, government bonds and notes and ARS. The Company classifies all of its investments, other than ARS, as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in shareholders’ deficit. Debt securities are adjusted for amortization of premiums and accretion of discounts and such amortization and accretion are reported as a component of interest income. Realized gains and losses and declines in value that are considered to be other than temporary are recognized in the statements of operations. The cost of securities sold is determined on the specific identification method. There were no significant realized gains or losses from sales of debt securities during the years ended December 31, 2007, 2008 and 2009. As of December 31, 2008 and 2009, the Company did not have any other-than-temporary declines in the fair value of its debt securities.

 

The Company classifies the ARS as trading securities and records all changes in fair value as component of other income (expense), net. The underlying securities have stated or contractual maturities that are generally greater than one year. The Company estimates the fair value of the ARS using a discounted cash flow model incorporating assumptions that market participants would use in their estimates of fair value. The Company has a Put Option to sell its ARS at par value. The Company has accounted for the Put Option as a freestanding financial instrument and elected to record it at fair value with changes in fair value recorded as a component of other income (expense), net (See Note 3).

 

Restricted Cash

 

Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. As of December 31, 2008 and 2009, the Company had $2.7 million and $4.5 million of restricted cash held by a bank in certificate of deposits as collateral for certain of its facility and capital lease agreements.

 

F-11


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Inventories

 

Inventories, which consist of ethanol, are stated at the lower of cost or market. Cost is computed on a first-in, first-out basis. Inventory costs include costs such as transportation and storage costs incurred in bringing the inventory to its existing location.

 

Derivative Instruments

 

The Company is exposed to market risks related to price volatility of ethanol. The Company makes limited use of derivative instruments, which include futures positions on the New York Mercantile Exchange and the CME/Chicago Board of Trade. The Company does not engage in speculative derivative activities, and the majority of the Company’s activity in derivative commodity instruments is intended to manage the financial risk posed by physical transactions and inventory. Changes in the fair value of the derivative contracts are recognized currently in the consolidated statements of operations as specific hedge accounting criteria are not met.

 

Asset Retirement Obligations

 

The fair value of the asset retirement obligation is recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. In addition, the associated asset retirement cost is added to the carrying amount of the associated asset and this additional carrying amount is amortized over the life of the asset. The Company’s asset retirement obligations are associated with its commitment to return property subject to the operating lease in Brazil to its original condition upon lease termination.

 

As of December 31, 2008 and 2009, the Company has recorded asset retirement obligations of $499,000 and $746,000. The related leasehold improvements are being amortized to depreciation expense over the term of the lease or the useful life of the assets, whichever is shorter. Related amortization expense was $0, $106,000 and $175,000 for the years ended December 31, 2007, 2008 and 2009.

 

Property and equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the related assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.

 

Leasehold improvements are amortized on a straight-line basis over the terms of the lease, or the useful life of the assets, whichever is shorter. Depreciation and amortization periods for the Company’s property and equipment are as follows:

 

Furniture and office equipment

   5 years

Computers and software

   3-5 years

Research and laboratory equipment

   7 years

 

Computers and software includes internal-use software that is acquired, internally developed or modified to meet the Company’s internal needs. Amortization commences when the software is ready for its intended use and the amortization period is the estimated useful life of the software, generally three to five years. Capitalized costs primarily include contract labor and payroll costs of the individuals dedicated to the development of internal-use software. Capitalized software totaled approximately $0, $0.6, and $1.1 million as of December 31, 2007, 2008 and 2009 related to software development costs pertaining to the installation of a new financial reporting system.

 

F-12


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Impairment of Long-Lived Assets

 

The Company periodically reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset are impaired or the estimated useful lives are no longer appropriate. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to their estimated fair values. Fair value is estimated based on discounted future cash flows. Impairment charges of $0, $0 and $3,075,000 were recorded during the years ended December 31, 2007, 2008 and 2009.

 

Convertible Preferred Stock Warrant Liability

 

The Company accounts for its freestanding warrants for shares of the Company’s convertible preferred stock that are contingently redeemable as liabilities at fair value on the consolidated balance sheets. The warrants are subject to re-measurement at each balance sheet date and the change in fair value, if any, is recognized as other income (expense), net. The Company will continue to adjust the liability for changes in fair value until the earlier of (i) exercise of the warrants, (ii) conversion into warrants to purchase common stock, or (iii) expiration of the warrants. Upon conversion, the convertible preferred stock warrant liability will be reclassified to common stock.

 

Convertible Preferred Stock

 

The holders of the Company’s outstanding convertible preferred stock, voting or consenting together as a separate class, control the vote of the Company’s shareholders. As a result, the holders of all series of the Company’s convertible preferred stock can force a change in control that would trigger liquidation. As redemption of the convertible preferred stock through liquidation is outside the control of the Company, all shares of convertible preferred stock have been presented outside of shareholders’ deficit in the Company’s consolidated balance sheets. All series of convertible preferred stock are collectively referred to in the consolidated financial statements as convertible preferred stock.

 

Noncontrolling Interest and Redeemable Noncontrolling Interest

 

As of January 1, 2009, the Company adopted the new accounting standard which establishes accounting and reporting standards for noncontrolling interests in consolidated financial statements. These provisions require that the carrying value of noncontrolling interests to be removed from the mezzanine equity section of the consolidated balance sheet and reclassified as equity, and that consolidated net income be recast to include net income attributable to the noncontrolling interests. The standard requires retrospective presentation and disclosure of existing noncontrolling interests. Accordingly, the Company presented noncontrolling interests as a separate component of equity (deficit) and has also presented net loss attributable to the noncontrolling interest in the consolidated statement of operations. Upon adoption, the noncontrolling interest of $1.1 million as of December 31, 2008 was reclassified to a component of total equity (deficit) in the consolidated balance sheet from the mezzanine equity section.

 

In accordance with accounting and reporting standards for redeemable equity instruments, a noncontrolling interest with redemption features (“redeemable noncontrolling interest”), such as a put option, that is not solely within the control of the Company, is required to be reported in the mezzanine equity section of the consolidated balance sheet.

 

Changes in noncontrolling interest ownership that do not result in a change of control and where there is a difference between fair value and carrying value are accounted for as equity transactions.

 

F-13


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Revenue Recognition

 

The Company recognizes revenue from the sale of ethanol and delivery of research and development services and governmental grants. Ethanol sales consists of sales to customers through purchase from third-party suppliers in which the Company takes physical control of the ethanol and accepts risk of loss. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable and collectability is reasonably assured.

 

If sales arrangements contain multiple elements, the Company evaluates whether the components of each arrangement represent separate units of accounting. The Company has determined that, as of December 31, 2009, all revenue arrangements should be accounted for as a single unit of accounting.

 

Product Sales

 

The Company sells ethanol under short-term agreements at prevailing market prices. Revenues are recognized, net of discounts and allowances, once passage of title and risk of loss has occurred and contractually specified acceptance criteria have been met, provided all other revenue recognition criteria have also been met.

 

Collaborative Research Services

 

Revenue from collaborative research services is recognized as the services are performed consistent with the performance requirements of the contract. In cases where the planned levels of research services fluctuate over the research term, the Company recognizes revenue using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by the Company. When up-front payments are received and the planned levels of research services do not fluctuate over the research term, revenue is recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research services fluctuate over the research term, revenue is recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenue is recognized upon achievement of the milestone and is limited to those amounts whereby collectability is reasonably assured.

 

Government grants

 

Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met and only perfunctory obligations are outstanding.

 

Cost of Product Sales

 

Cost of product sales consists primarily of cost of purchased ethanol, terminal fees paid for storage and handling, transportation costs between terminals and changes in the fair value of the derivative commodity instruments.

 

Shipping and handling costs charged to customers are recorded as revenues. Shipping costs are included in cost of product revenues. Such charges were not significant in any of the periods presented.

 

F-14


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Costs of Start-Up Activities

 

Start-up activities are defined as those one-time activities related to opening a new facility, introducing a new product or service, conducting business in a new territory, conducting business with a new class of customer or beneficiary, initiating a new process in an existing facility, commencing some new operation or activities related to organizing a new entity All the costs associated with a potential site are expensed, until the site is considered viable by management, at which time costs would be considered for capitalization based on authoritative accounting literature.

 

Research and Development

 

Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on the Company’s behalf.

 

Income taxes

 

The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.

 

Effective January 1, 2007, the Company adopted the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken in a tax return, in the consolidated financial statements. Additionally, the guidance also prescribes new treatment for the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.

 

Currency Translation

 

The functional currency of the Company’s majority-owned subsidiary in Brazil is the Brazilian real. Accordingly, asset and liability accounts of those operations are translated into United States dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into United States dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income (loss) in the consolidated balance sheets.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) represents all changes in shareholders’ deficit except those resulting from investments or contributions by shareholders. The Company’s unrealized gains and losses on available-for-sale securities and foreign currency translation adjustments represent the components of comprehensive income (loss) excluded from the Company’s net loss and have been disclosed in the consolidated statements of convertible preferred stock, redeemable noncontrolling interest and deficit for all periods presented.

 

F-15


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The components of accumulated other comprehensive income (loss) are as follows (in thousands):

 

     December 31,
     2008     2009

Foreign currency translation adjustment

   $ (555   $ 1,333
              

Accumulated unrealized gain on investment

     87        3
              

Total accumulated other comprehensive income (loss)

   $ (468   $ 1,336
              

 

Stock-Based compensation

 

The Company accounts for stock-based compensation arrangements with employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using the Black-Scholes option pricing model. The fair value of options granted are being expensed on a straight-line basis over the vesting period.

 

The Company accounts for stock options issued to nonemployees based on the estimated fair value of the awards also using the Black-Scholes option pricing model. The Company accounts for restricted stock units (“RSUs”), issued to nonemployees based on the estimated fair value of the Company’s common stock. The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in the Company’s consolidated statements of operations during the period the related services are rendered.

 

Net Loss per Share and Unaudited Pro Forma Net Loss per Share of Common Stock

 

Basic net loss per share of common stock is computed by dividing the Company’s net loss attributable to Amyris Biotechnologies, Inc. shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed by giving effect to all potentially dilutive securities, including stock options, restricted stock units, warrants and convertible preferred stock. Basic and diluted net loss per share of common stock attributable to Amyris Biotechnologies, Inc. shareholders was the same for all periods presented as the inclusion of all potentially dilutive securities outstanding was anti-dilutive. As such, the numerator and the denominator used in computing both basic and diluted net loss are the same for each period presented.

 

The calculations for the unaudited pro forma basic and diluted net loss per share of common stock attributable to Amyris Biotechnologies, Inc. shareholders assume the conversion of all outstanding shares of convertible preferred stock into shares of common stock, as if the conversions had occurred at the beginning of the period or the issuance date for Series B-1 and Series C convertible preferred stock issued during the year ended December 31, 2009, and the conversion of Amyris Brasil shares held by third parties. Also, the numerator in the pro forma basic and diluted net loss per share calculation has been adjusted to remove gains and losses resulting from re-measurements of the convertible preferred stock warrant liability as these measurements would no longer be required when the convertible preferred stock warrants become warrants to purchase shares of the Company’s common stock.

 

F-16


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following table presents the calculation of historical and pro forma basic and diluted net loss per share of common stock attributable to Amyris Biotechnologies, Inc. shareholders (in thousands, except share and per share amounts):

 

     Years Ended December 31,  
     2007     2008     2009  

Actual:

      

Numerator:

      

Net loss attributable to Amyris Biotechnologies, Inc. shareholders

   $ (11,774   $ (41,864   $ (64,459
                        

Denominator:

      

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted

     3,592,932        4,223,533        4,753,085   
                        

Net loss per share of common stock attributable to Amyris Biotechnologies, Inc. shareholders, basic and diluted

   $ (3.28   $ (9.91   $ (13.56
                        

Pro Forma:

      

Numerator:

      

Net loss attributable to Amyris Biotechnologies, Inc. shareholders

       $ (64,459

Less: Change in fair value of convertible preferred stock warrant liability (unaudited)

         (445
            

Net loss used in computing pro forma net loss per share of common stock attributable to Amyris Biotechnologies, Inc. shareholders, basic and diluted (unaudited)

       $ (64,014
            

Denominator:

      

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted

         4,753,085   

Add: Pro forma adjustment to reflect weighted-average effect of assumed conversion of convertible preferred stock (unaudited)

         15,517,824   

Add: Pro forma adjustment to reflect weighted-average effect of conversion of Amyris Brasil shares (unaudited)

         8,524   
            

Weighted-average shares of common stock used in computing pro forma net loss per share of common stock, basic and diluted (unaudited)

         20,279,433   
            

Pro forma net loss per share of common stock attributable to Amyris Biotechnologies, Inc shareholders, basic and diluted (unaudited)

       $ (3.16
            

 

F-17


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:

 

     December 31,
2007
   December 31,
2008
   December 31,
2009

Convertible preferred stock (as converted basis)

   11,140,768    14,098,988    18,790,244

Period-end stock options to purchase common stock

   2,628,910    3,628,169    4,446,894

Period-end common stock subject to repurchase

   964,525    505,035    132,038

Convertible preferred stock warrants (as converted basis)

      126,862    144,158

Period-end restricted stock units

      50,000    50,000
              

Total

   14,734,203    18,409,054    23,563,334
              

 

Recent accounting pronouncements

 

In June 2009, the FASB issued a new accounting standard that requires a qualitative approach to identifying a controlling financial interest in a variable interest entity (“VIE”) and requires ongoing assessment of whether an interest in a VIE makes the holder the primary beneficiary of the VIE. The new accounting standard is effective for the Company on January 1, 2010. The Company is evaluating the impact of the pending adoption on its consolidated financial statements.

 

In October 2009, the FASB issued a new accounting standard that changes the accounting for arrangements with multiple deliverables. Specifically, the new accounting standard requires an entity to allocate arrangement consideration at the inception of an arrangement to all of its deliverables based on their relative selling prices. In addition, the new standard eliminates the use of the residual method of allocation and requires the relative-selling-price method in all circumstances in which an entity recognizes revenue for an arrangement with multiple deliverables. In October 2009, the FASB also issued a new accounting standard that changes revenue recognition for tangible products containing software and hardware elements. Specifically, if certain requirements are met, revenue arrangements that contain tangible products with software elements that are essential to the functionality of the products are scoped out of the existing software revenue recognition accounting guidance and will be accounted for under these new accounting standards. Both standards will be effective for the Company in the first quarter of 2011. Early adoption is permitted. The Company is currently assessing the impact that the adoption of these standards will have on its consolidated financial statements.

 

In January 2010, the FASB issued an amendment to an accounting standard which requires new disclosures for fair value measures and provides clarification for existing disclosure requirements. Specifically, this amendment require an entity to disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and to describe the reasons for the transfers; and to disclose separately information about purchases, sales, issuances and settlements in the reconciliation for fair value measurements using significant unobservable inputs, or Level 3 inputs. This amendment clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and requires disclosure about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level 2 and Level 3 inputs. The adoption of this amendment will not impact the Company’s consolidated financial statements.

 

F-18


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

3. Fair Value of Financial Instruments

 

Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:

 

   

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

 

   

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

   

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis as of December 31, 2008 and 2009 by level within the fair value hierarchy. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. As of December 31, 2008, the Company’s fair value hierarchy for its financial assets and financial liabilities that are carried at fair value was as follows (in thousands):

 

     Quoted Prices
in Active
Markets for
Identical Assets

(Level 1)
   Other
Observable

Inputs
(Level 2)
   Significant
Unobservable

Inputs
(Level 3)
   Balance as of
December 31,

2008

Financial Assets

           

Money market funds

   $ 7,784    $    $    $ 7,784

Commercial paper

          2,850           2,850

US Government agency securities

          16,441           16,441

Auction rate securities

               10,907      10,907

Put Option

               2,043      2,043
                           

Total financial assets

   $ 7,784    $ 19,291    $ 12,950    $ 40,025
                           

Financial Liabilities

           

Derivative liabilities

   $    $ 45    $    $ 45

Convertible preferred stock warrant liability

               2,132      2,132
                           

Total financial liabilities

   $    $ 45    $ 2,132    $ 2,177
                           

 

F-19


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

As of December 31, 2009, the Company’s fair value hierarchy for its financial assets and financial liabilities that are carried at fair value was as follows (in thousands):

 

     Quoted Prices
in Active
Markets for
Identical
Assets

(Level 1)
   Other
Observable
Inputs

(Level 2)
   Significant
Unobservable
Inputs

(Level 3)
   Balance as of
December 31,
2009

Financial Assets

           

Money market funds

   $ 12,479    $    $    $ 12,479

US Government agency securities

          35,322           35,322

Auction rate securities

               11,235      11,235

Put Option

               1,465      1,465

Derivative assets

          13           13
                           

Total financial assets

   $ 12,479    $ 35,335    $ 12,700    $ 60,514
                           

Financial Liabilities

           

Convertible preferred stock warrant liability

   $    $    $ 2,740    $ 2,740
                           

Total financial liabilities

   $    $    $ 2,740    $ 2,740
                           

 

The change in the fair value of the Level 3 investments is summarized below (in thousands):

 

     Auction Rate
Securities
    Put Option  

Fair value as of December 31, 2007

   $ 18,750      $   

Unrealized loss recorded in other income (expense), net

     (2,043       

Recognition of the Put Option

            2,043   

Net purchases and sales/ maturities

     (5,800       
                

Fair value as of December 31, 2008

   $ 10,907      $ 2,043   

Redemption at par

     (250       

Change in fair value recorded in other income (expense), net

     578        (578
                

Fair value as of December 31, 2009

   $ 11,235      $ 1,465   
                

 

The change in the fair value of the convertible preferred stock warrant liability is summarized below:

 

Fair value as of December 31, 2007

   $   

Fair value of warrants issued

     2,018   

Change in fair value recorded in other income (expense), net

     114   
        

Fair value as of December 31, 2008

     2,132   

Fair value of warrants issued

     336   

Fair value of cancelled award

     (173

Change in fair value recorded in other income (expense), net

     445   
        

Fair value as of December 31, 2009

   $ 2,740   
        

 

The Company’s investment portfolio includes ARS, which are issued principally by student loan entities and rated AAA by a major credit rating agency. ARS are structured to provide liquidity via an auction process that

 

F-20


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

resets the applicable interest rate at predetermined calendar intervals, usually every 28 days. The underlying securities have stated or contractual maturities that are generally greater than one year. Typically, the carrying value of ARS approximates fair value due to the frequent resetting of the interest rates. In February 2008, auctions failed for $12.95 million in par value of ARS that the Company held because sell orders exceeded buy orders. These failures are not believed to be a credit issue, but rather caused by a lack of liquidity. The funds associated with these failed auctions may not be accessible until the issuer calls the security, a successful auction occurs, a buyer is found outside of the auction process, or the security matures. During the year ended December 31, 2009, a total of $250,000 of the ARS held by the Company were called at par by the issuer; therefore no realized losses were recognized on these securities.

 

The Company received notification from UBS AG (“UBS”), issued in connection with a settlement entered into between UBS and certain regulatory agencies, offering to repurchase all of the Company’s auction rate security holdings at par value. The Company formally accepted the settlement offer and entered into a repurchase agreement with UBS in November 2008. By accepting the agreement, the Company (1) received the right (“Put Option”) to sell its ARS at par value to UBS between June 30, 2010 and July 2, 2012 and (2) gave UBS the right to purchase the ARS from the Company any time after the acceptance date as long as the Company receives the full par value. The agreement with UBS covers $12.7 million par value (fair value of $11.2 million) of the ARS held by the Company as of December 31, 2009.

 

The Company expects to sell the ARS under the Put Option. However, if the Put Option is not exercised before July 2, 2012, it will expire and UBS will have no further rights or obligation to buy the ARS. UBS’s obligations under the Put Option are not secured by its assets and do not require UBS to obtain any financing to support its performance obligations under the Put Option. UBS has disclaimed any assurance that it will have sufficient financial resources to satisfy its obligations under the Put Option.

 

During the year ended December 31, 2008, the Company made an election to transfer the ARS from available-for-sale to trading securities. The transfer to trading securities reflects the Company’s intent to exercise the Put Option during the period from June 30, 2010 to June 30, 2012. Prior to entering into the agreement, the Company’s intent was to hold the ARS until the market recovered. At the time of transfer, the unrealized loss on the auction rate securities was $2.0 million. Prior to the transfer, this unrealized loss was included in accumulated other comprehensive income (loss). Upon transfer of the ARS from available-for-sale to trading securities, the Company immediately recognized an unrealized loss of $2.0 million, included in other income (expense), net, for the amount of the unrealized loss not previously recognized in earnings. The Company accounted for the Put Option as a freestanding financial instrument and recorded it at fair value. This allowed any changes in the fair value of the Put Option to be offset with changes in the fair value of the related ARS in the Company’s consolidated statements of operations. As a result, $2.0 million was initially recorded as a credit to other income (expense), net for the fair value of the Put Option.

 

The Company estimates the fair value of the ARS using a discounted cash flow model incorporating assumptions that market participants would use in their estimates of fair value. Some of these assumptions include estimates for interest rates, timing and amount of cash flows and expected holding periods of the ARS. The Company estimates the fair value of the Put Option using the expected value that the Company will receive from UBS which was calculated as the difference between the fair value and the par value of the ARS as of the option exercise date. This value is discounted by using UBS’s credit default swap rate to account for the credit considerations of the counterparty risk. The Company will reassess the fair values in future reporting periods based on several factors, including continued failure of auctions, failure of investments to be redeemed, deterioration of credit ratings of investments, market risk and other factors.

 

F-21


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

As of December 31, 2009, the Company has classified its ARS as short-term investments and they were classified as long-term investments as of December 31, 2008 based on its intention to liquidate the investments on June 30, 2010.

 

Derivative Instruments

 

The Company utilizes derivative financial instruments to mitigate its exposure to certain market risks associated with its ongoing operations. The primary objective for holding derivative financial instruments is to manage commodity price risk. The Company’s derivative instruments principally include ethanol futures. All derivative commodity instruments are recorded at fair value on the consolidated balance sheets. None of the Company’s derivative instruments are designated as a hedging instrument. Changes in the fair value of these non-designated hedging instruments are recognized in cost of product sales in the consolidated statements of operations.

 

Derivative instruments measured at fair value as of December 31, 2008 and 2009, and their classification on the consolidated balance sheets and consolidated statements of operations, are presented in the following tables (in thousands) except contract amounts:

 

     Asset/Liability as of December 31,
     2008    2009

Type of Derivative Contract

   Quantity of Short
Contracts
   Fair Value    Quantity of Short
Contracts
   Fair Value

Regulated fixed price futures contracts, included in prepaid expenses and other current assets

      $    57    $ 13

Regulated fixed price futures contracts, included in accrued and other current liabilities

   35    $ 45       $

 

Type of Derivative Contract

  

Income
Statement Classification

   Years Ended December 31,  
      2008    2009  
          Gains (Losses) Recognized  

Regulated fixed price futures contracts

   Cost of Product Sales    $ 752    $ (1,910

 

4. Balance Sheet Components

 

Investments

 

The following table summarizes the Company’s investments as of December 31, 2008 (in thousands):

 

     December 31, 2008
     Amortized
Cost
   Unrealized Gain
(Loss)
    Fair Value

Short-term investments

       

Commercial paper

   $ 2,841    $ 9      $ 2,850

US Government agency securities

     16,363      78        16,441
                     

Total short-term investments

   $ 19,204    $ 87      $ 19,291
                     

Long-term investments

       

Auction rate securities

   $ 12,950    $ (2,043   $ 10,907

Put Option

          2,043        2,043
                     

Total long-term investments

   $ 12,950    $      $ 12,950
                     

 

F-22


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following table summarizes the Company’s investments as of December 31, 2009 (in thousands):

 

     December 31, 2009
     Amortized
Cost
   Unrealized Gain
(Loss)
    Fair Value

Short-term investments

       

US Government agency securities

   $ 35,319    $ 3      $ 35,322

Auction rate securities

     12,700      (1,465     11,235

Put Option

          1,465        1,465
                     

Total short-term investments

   $ 48,019    $ 3      $ 48,022
                     

 

Property and Equipment

 

Property and equipment, net is comprised of the following as of December 31, 2008 and 2009 (in thousands):

 

     December 31,  
     2008     2009  

Leasehold improvements

   $ 31,182      $ 29,575   

Research and laboratory equipment

     9,422        16,904   

Computers and software

     1,159        1,472   

Furniture and office equipment

     1,355        1,468   

Construction in progress

     1,998        2,158   
                
     45,116        51,577   

Less: accumulated depreciation and amortization

     (3,551     (9,017
                

Property and equipment, net

   $ 41,565      $ 42,560   
                

 

Depreciation and amortization expense was $634,000, $2.6 million and $5.8 million for the years ended December 31, 2007, 2008 and 2009.

 

Property and equipment includes $4.1 million and $8.9 million of research and laboratory equipment and furniture and office equipment under capital leases as of December 31, 2008 and 2009. Accumulated amortization of assets under capital leases totaled $626,000 and $2.1 million as of December 31, 2008 and 2009.

 

F-23


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Accrued and Other Current Liabilities

 

Accrued and other current liabilities are comprised of the following as of December 31, 2008 and 2009 (in thousands):

 

     December 31,
     2008    2009

Professional services

   $ 1,635    $ 2,411

Property and equipment

     731     

Accrued vacation

     636      1,471

Payroll and related expenses

     604      1,573

Tax-related liabilities

     431      330

Deferred rent, current portion

     100      893

Refundable exercise price on early exercise of stock options

     262      101

Refundable deposits

          2,177

Restructuring charge, current portion

          592

Other

     684      897
             

Total accrued and other current liabilities

   $ 5,083    $ 10,445
             

 

5. Commitments and Contingencies

 

Capital Leases

 

In March 2008, the Company executed an equipment financing agreement intended to cover certain qualifying research and laboratory hardware and software. In January 2009, the agreement was amended to increase the financing amount. During the years ended December 31, 2008 and 2009, the Company financed certain purchases of hardware equipment and software of approximately $3.3 million and $4.8 million, respectively. Pursuant to the equipment financing agreement, the Company financed the equipment with the transactions representing capital leases. Accordingly, fixed assets and capital lease liabilities were recorded at the present values of the future lease payments of $3.1 million and $6.9 million during the years ended December 31, 2008 and December 31, 2009. The incremental borrowing rates used to determine the present values of the future lease payments was 9.5%.

 

The Company has entered into various capital leases for research and laboratory equipment, furniture and office equipment. Capital lease obligations expire at various dates, with the latest maturity in April 2013.

 

In connection with the capital lease entered into in 2008, the Company issued a warrant to purchase shares of the Company’s convertible preferred stock (See Note 10).

 

F-24


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The recorded balance of capital lease obligations as of December 31, 2008 and 2009 was $3.6 million and $7.2 million. The Company recorded interest expense in connection with its capital leases of $18,000, $175,000 and $751,000 for the years ended December 31, 2007, 2008 and 2009. Future minimum payments under capital leases as of December 31, 2009, are as follows (in thousands):

 

     Capital Leases  

Years ending December 31:

  

2010

   $ 2,961   

2011

     2,905   

2012

     2,394   

2013

     271   

2014

       

Thereafter

       
        

Total future minimum lease payments

     8,531   

Less: executory costs

     (19
        

Net minimum lease payments

     8,512   

Less: amount representing interest

     (1,284
        

Present value of minimum lease payments

     7,228   

Less: current maturities

     (2,251
        

Long-term portion

   $ 4,977   
        

 

Operating Leases

 

The Company has noncancelable operating lease agreements for office, research and development and manufacturing space in the United States and Brazil.

 

In August 2007, the Company entered into an operating lease for its new headquarters in Emeryville, California, with a term of ten years commencing in May 2008. As part of the operating lease agreement, the Company was entitled to a tenant improvements allowance of $11.4 million and the Company recorded the allowance as deferred rent and associated expenditures as leasehold improvements. In connection with the operating lease, the Company elected to defer a portion of the monthly base rent due under the lease and entered into notes payable agreements with the lessor for the purchase of certain tenant improvements (see Note 6).

 

In addition, the Company leases a facility in Brazil pursuant to a noncancelable operating lease that expires in May 2013 and the Company leases office space in the United States under noncancelable operating leases that expire at various dates, with the latest expiration in May 2018.

 

The Company recognizes rent expense on a straight-line basis over the noncancelable lease term and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Where leases contain escalation clauses, rent abatements, and/or concession, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them in the determination of straight-line rent expense over the lease term. Rent expense for the years ended December 31, 2007, 2008 and 2009 was $1.0 million, $2.9 million and $3.6 million.

 

F-25


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

As of December 31, 2009, future minimum rental payments under the operating leases are as follows (in thousands):

 

     Operating Leases

Years ending December 31:

  

2010

   $ 3,161

2011

     4,021

2012

     4,669

2013

     4,328

2014

     4,051

Thereafter

     14,517
      

Total future minimum lease payments

   $ 34,747
      

 

Amyris Brasil S.A. Transactions

 

On December 22, 2009, the Company entered into an investment and shareholders’ agreement with third-party investors (“Investors”) to sell a 4.8% equity interest in Amyris Brasil. Under the terms of the agreements, the Company is required to make additional capital investments in Amyris Brasil worth at least BRL $50.0 million by May 21, 2010. (See Note 16).

 

Guarantor Arrangements

 

The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification period is for the officer or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of December 31, 2008 and 2009.

 

Other Matters

 

The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

 

F-26


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

6. Debt

 

Debt is comprised of the following as of December 31, 2008 and 2009 (in thousands):

 

     December 31,  
     2008     2009  

Credit facility

   $      $ 8,343   

Notes payable

            4,038   

Loans payable

     3,149        999   
                

Total debt

     3,149        13,380   

Less: current portion

     (340     (9,018
                

Long-term debt

   $ 2,809      $ 4,362   
                

 

Credit Facility

 

In January 2009, the Company entered into a credit facility with UBS associated with our student loan auction rate securities holdings. In March and April 2009, the Company drew down $8.1 million and $0.5 million on the credit facility. The credit facility is collateralized by the auction rate securities held with the bank. The credit facility bears a variable interest rate of LIBOR plus 1.25% and the weighted average borrowing rate under the credit facility was 1.32% as of December 31, 2009. As of December 31, 2009, the total amount outstanding under the credit facility was $8.3 million.

 

Notes Payable

 

During the period between May 2008 and October 2008, the Company entered into notes payable agreements with the lessor of its headquarters under which the total amount of $3.3 million was borrowed for the purchase of tenant improvements, bearing an interest rate of 9.5% per annum and to be repaid over a period of 55 to 120 months. As of December 31, 2008 and 2009, a principal amount of $3.1 million and $2.8 million was outstanding under these notes payable.

 

During the period between January 2009 and December 2009, the Company entered into notes payable agreements with a service provider in connection with its software implementation under which the total amount of $1.2 million was borrowed for the payment of implementation services and software licenses, bearing an interest rate of 8.53% per annum and to be repaid over a period of 72 to 83 months. As of December 31, 2009, a principal amount of $1.1 million was outstanding under these notes payable.

 

In July 2009, the Company entered into a notes payable agreement of $378,000 with its insurance provider. The notes payable are payable in monthly principal and interest installments of $45,300 through March 2010. The note payable accrues interest at 6%. As of December 31, 2009, a principal amount of $125,000 was outstanding under the notes payable.

 

Loans Payable

 

In August 2009, the Company entered into a loans payable agreement with the lessor of its headquarters under which $750,000 was borrowed. The loan is payable in monthly installments of interest only and unpaid interest and principle is payable in December 2011. Interest accrues at an interest rate of 10.5%. As of December 31, 2009, a principal amount of $750,000 was outstanding under the loan. The notes payable agreement is secured by a $750,000 letter of credit.

 

F-27


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

In December 2009, the Company entered into a loan payable agreement with the lessor of its Emeryville, pilot plant under which the total amount of $250,000 was borrowed, bearing an interest rate of 10% per annum and to be repaid over a period of 96 months. As of December 31, 2009, a principal amount of $249,000 was outstanding under the loan.

 

Future minimum payments under the debt agreements as of December 31, 2009 are as follows (in thousands):

 

       Credit Line     Notes Payable     Loans Payable  

Years ending December 31:

      

2010

   $ 8,398      $ 993      $ 123   

2011

            863        866   

2012

            861        45   

2013

            682        45   

2014

            592        45   

Thereafter

            1,406        134   
                        

Total minimum payments

     8,398        5,397        1,258   

Less: interest

     (55     (1,359     (259
                        

Present value of future minimum payments

     8,343        4,038        999   

Less: current portion

     (8,343     (653     (22
                        

Noncurrent portion of debt

   $      $ 3,385      $ 977   
                        

 

Letters of Credit

 

In November 2008, the Company entered into an uncommitted facility letter (the “Credit Agreement”) with a financial institution to finance the purchase and sale of fuel and for working capital requirements, as needed. In October 2009, the agreement was amended to decrease the maximum amount that the Company may borrow under such facility. The Credit Agreement, as amended, provides an aggregate maximum availability up to the lower of $20.0 million and the borrowing base as defined in the agreement, and is subject to a sub-limit of $5.7 million for the issuance of letters of credit and a sub-limit of $20 million for short-term cash advances for product purchases. Amyris has a parent guarantor for the payment of the outstanding balance under the Credit Agreement. Outstanding advances bear an interest rate at the Company’s option of the bank’s prime rate plus 1.0% or the bank’s cost of funds plus 3.5%. As of year-end, the Company had sufficient borrowing base levels to draw down up to a total of $2.8 million in short term cash advances and $4.6 million available for letters of credit in addition to those outstanding at year end. As of December 31, 2008 and 2009, the Company had no outstanding advances and had $0.7 million and $1.1 million in outstanding letters of credit under the Credit Agreement.

 

To the extent that amounts under the Credit Agreement remain unused, while the Credit Agreement is in effect and for so long thereafter as any of the obligations under the Credit Agreement are outstanding, the Company will pay an annual commitment fee of $300,000. The Credit Agreement requires compliance with certain customary covenants that require maintenance of certain specified financial ratios and conditions. As of December 31, 2009, the Company was in compliance with its financial covenants under the Credit Agreement. The Credit Agreement is collateralized by a first priority security interest in certain of the Company’s present and future assets.

 

In November 2009, the Company entered into an irrevocable standby letter of credit agreement for up to $4.5 million. As of December 31, 2009 four letters of credit had been issued totaling $3.8 million as security for

 

F-28


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

certain facility and capital leases, each of which expires on November 9, 2010 and will be automatically extended for two one-year periods. As of December 31, 2009, the Company was in compliance with all financial covenants in the letter of credit agreements. In connection with the letter of credit agreements, the Company maintained a deposit balance with the financial institution, which amounted to $4.5 million as of December 31, 2009. The availability of the letter of credit is dependent upon maintaining the cash deposits.

 

7. Income Taxes

 

The components of the provision for (benefit from) income taxes are as follows for the years ended December 31, 2007, 2008 and 2009 (in thousands):

 

     2007    2008     2009

Current:

       

Federal

   $    $      $

State

          (207    

Foreign

                
                     

Total current provision (benefit)

          (207    
                     

Deferred:

       

Federal

                

State

                

Foreign

                
                     

Total deferred provision (benefit)

                
                     

Total provision for (benefit from) income taxes

   $    $ (207   $
                     

 

A reconciliation between the statutory federal income tax and the Company’s effective tax rates as a percentage of loss before income taxes is as follows:

 

     Years Ended December 31,  
       2007         2008         2009    

Statutory tax rate

   34.0   34.0   34.0

State tax rate, net of federal benefit

   6.8      3.5      5.5   

Incentive stock option stock compensation

   (0.6   (0.5   (0.4

Federal R&D credit

   1.5      0.1      1.0   

Other

   (3.4   1.1      1.2   

Change in valuation allowance

   (38.3   (37.8   (41.3
                  

Effective income tax rate

   0   0.4   0
                  

 

F-29


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Temporary differences and carryforwards that gave rise to significant portions of deferred taxes are as follows (in thousands):

 

     December 31,
2008
    December 31,
2009
 

Net operating loss carry forwards

   $ 19,879      $ 37,118   

Fixed assets

            108   

Research and development credits

     208        2,409   

Accruals and reserves

     552        1,240   

Stock compensation

     719        1,602   

Other

            5,322   
                

Total deferred tax assets

     21,358        47,799   

Fixed assets

     (296       

Other

     (43       
                

Total deferred tax liabilities

     (339       
                

Net deferred tax asset prior to valuation allowance

     21,019        47,799   

Less: Valuation allowance

     (21,019     (47,799

Net deferred tax assets (liabilities)

   $      $   
                

 

Due to uncertainties surrounding the realization of deferred tax assets through future taxable income, the Company has provided a full valuation allowance and, therefore, has not recognized any benefits from the net operating losses and other deferred tax assets. The valuation allowance increased $4.5 million, $16.1 million and $26.8 million during the years ended December 31, 2007, 2008 and 2009, respectively.

 

Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, the Company believes it is not yet more likely than not that the net deferred tax assets will be fully realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets as of December 31, 2009.

 

As of December 31, 2009, the Company had federal and California net operating loss carryforwards of approximately $95.8 million and $67.4 million available to reduce future taxable income, if any, respectively.

 

The federal net operating loss carryforward begins expiring in 2025, and the California net operating loss carryforward begins expiring in 2015. The Company also had federal and California state research and development credit carryforwards of approximately $2.0 million and $2.1 million at December 31, 2009. The federal credits will expire starting 2024 if not utilized. The California tax credits can be carried forward indefinitely.

 

The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event the Company should experience an ownership change, as defined, utilization of its United States net operating loss carryforwards and tax credits could be limited.

 

F-30


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Effective January 1, 2007, the Company adopted the accounting guidance on uncertainties in income taxes. A reconciliation of the beginning and ending amounts of unrecognized tax benefits since the adoption of accounting guidance on uncertainty in income taxes is as follows:

 

January 1, 2007

   $ 41

Increases in balances related to tax provisions taken during current period

     108
      

December 31, 2007

     149

Increases in balances related to tax provisions taken during current period

     423
      

December 31, 2008

     572

Increases in balances related to tax provisions taken during current period

     460
      

December 31, 2009

   $ 1,032
      

 

The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. Management determined that no accrual for interest and penalties was required as of December 31, 2009.

 

As of December 31, 2009, the Company’s total unrecognized tax benefits were $1 million, of which none of the tax benefits, if recognized, would affect the effective income tax rate due to the valuation allowance that currently offsets deferred tax assets. The Company does not anticipate the total amounts of unrecognized income tax benefits will significantly increase or decrease in the next 12 months.

 

The Company’s primary tax jurisdiction is the United States. For United States federal and state tax purposes, tax years 2003 through 2009 remain open and subject to tax examination by the appropriate federal or state taxing authorities. Brazil tax years 2008 and 2009 remain open and subject to examination.

 

8. Research and Development Activities

 

Research and Collaboration Agreement

 

In November 2004, the Company entered into a research and collaboration agreement (the “Agreement”) with the Institute for One World Health (“IOWH”), a California nonprofit corporation and the Regents of the University of California, Berkeley (“UC Berkeley”). Per the agreement, IOWH agreed to work in partnership with UC Berkeley and the Company. UC Berkeley agreed to conduct basic research to aid in the engineering of a microbe to make a biosynthetic precursor of artemisinin, currently the most effective treatment for malaria. The Company will optimize the strain for industrial fermentation and develop a follow-on chemical synthesis for artemisinin using the precursor. IOWH agreed to perform the drug development and regulatory work to demonstrate the bioequivalence of microbially produced artemisinin derivative to the drug’s natural form. The Company will receive no payments from the eventual use of the technology towards the production of antimalarial drugs for use in the developing world. The Agreement, however, allows the Company to develop and maintain ownership rights over a platform technology that is applicable towards the production of many other compounds.

 

During the year ended December 31, 2007, the Company received $4.1 million under this agreement. The Company recorded deferred revenue of $1.4 million and $0 million as of December 31, 2007 and 2008.

 

F-31


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Exclusive Development and Commercialization Agreement

 

In November 2004, the Company entered into an exclusive development and commercialization agreement, as amended in January 2008, with IOWH and sanofi-aventis (the “Parties”) under which the Parties agreed to develop and commercialize specific products (“anti-malarias’) in the IOWH field and territory (countries in the developing world). Under this amended agreement, the Company will grant IOWH and its affiliates a worldwide, exclusive, royalty-free license to develop and commercialize such anti-malaria products in those developing world countries.

 

During the year ended December 31, 2007, 2008 and 2009, the Company received $0, $1.7 million and $1.3 million related to these agreements.

 

Professional Services Contract

 

During the year ended December 31, 2008, the Company entered into a professional services contract (the “Contract”) with Auburn University. Per the contract, the Company will provide a portion of the activities required to plant, grow, harvest, and analyze a sugarcane nursery in Alabama. During the years ended December 31, 2008 and 2009, the Company recognized revenue of $204,000 and $0 related to this arrangement.

 

Development Services Agreement

 

In June 2009, the Company entered into a development services agreement with Sanofi Chimie, under which the Company agreed to perform molecular biology development services related to strain improvement on behalf of Sanofi Chimie. Under the terms of the agreement, Sanofi Chimie provided the Company with an up-front payment of $1.5 million which is being recognized on a ratable basis over the research period under the arrangement. The Company is also eligible to receive milestone payments totaling $1.5 million and a bonus payment of $0.3 million if a specified target is met. Milestones to be earned under the agreement have been determined to be at risk and substantive at the inception of the arrangement and are expected to be recognized upon achievement of the milestone and when collectability is reasonably assured. Research and development revenue of $1.6 million, including milestone revenue was recognized under the agreement during the year ended December 31, 2009. The Company recorded deferred revenue of $378,000 as of December 31, 2009.

 

9. Convertible Preferred Stock

 

Under the Company’s amended and restated articles of incorporation, the Company’s convertible preferred stock is issuable in series.

 

A summary of convertible preferred stock issued and outstanding as of December 31, 2008 is as follows (in thousands, except share data):

 

     December 31, 2008
     Shares
Authorized
   Shares
Issued and
Outstanding
   Liquidation
Preference per
Share
   Liquidation
Amount
   Carrying
Value

Series A

   9,475,000    9,475,000    $ 2.174    $ 20,599    $ 20,470

Series B

   1,929,641    1,667,817      24.88      41,495      41,326

Series B-1

   4,700,000    2,538,841      25.26      64,131      59,640
                          

Total

   16,104,641    13,681,658       $ 126,225    $ 121,436
                          

 

F-32


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

A summary of convertible preferred stock issued and outstanding as of December 31, 2009 is as follows (in thousands, except share data):

 

     December 31, 2009
     Shares
Authorized
   Shares
Issued and
Outstanding
   Liquidation
Preference per
Share
   Liquidation
Amount
   Carrying
Value

Series A

   9,475,000    9,475,000    $ 2.174    $ 20,599    $ 20,470

Series B

   1,929,641    1,667,817      24.88      41,495      41,326

Series B-1

   4,700,000    2,615,721      25.26      66,073      61,412

Series C

   4,976,000    4,606,684      12.46      57,399      56,443
                          

Total

   21,080,641    18,365,222       $ 185,566    $ 179,651
                          

 

The convertible preferred stock is recorded at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is classified outside of shareholders’ equity (deficit) because the shares contain liquidation features that are not solely within the control of the Company.

 

The rights, preferences and privileges of the convertible preferred stock are as follows:

 

Voting

 

Except as required by applicable law, each share of convertible preferred stock has voting rights equal to an equivalent number of shares of common stock into which it is convertible and votes together as one class with the common stock.

 

As long as at least 20% of the originally issued shares of the convertible preferred stock remain outstanding, consent of the holders of at least the majority of the convertible preferred stock are required for any action that includes among others (i) alters or changes the rights, preferences or privileges of the common stock and convertible preferred stock; (ii) results in the redemption of any shares of convertible preferred stock or common stock; (iii) results in a liquidation or other corporate reorganization; (iv) amends or waives any provision of the Company’s amended and restated articles of incorporation; (v) increases or decreases the authorized size of the Board of Directors; and (vi) results in the payment or declaration of any dividend on any shares of common or convertible preferred stock.

 

Dividends

 

The holders of the convertible preferred stock are entitled to receive, in preference to any dividend on the common stock, noncumulative dividends, on a pari passu basis, at the rate of 8% of the original issue price per annum on each outstanding share of Series A, B, B-1 and C convertible preferred stock. Such dividends are payable when, as and if declared by the Board of Directors. No dividends have been declared to date.

 

Conversion Rights

 

Each share of preferred stock is convertible, at the option of the holder, at any time, into shares of common stock determined by dividing the issuance price per share by the conversion price in effect at the time of the conversion. The per share conversion prices of Series A, B, B-1 and C convertible preferred stock are $2.174, $22.65, $22.96 and $12.46. Accordingly, the conversion ratios for the Series A, B, B-1 and C convertible preferred stock to common stock are 1:1, 1:1.098, 1:1.10 and 1:1, respectively.

 

F-33


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Each share of Series A, B, B-1 and C convertible preferred stock shall automatically be converted into a number of shares of common stock upon the earlier to occur of (i) the date specified by the written consent or agreement of the holders of a majority of the then outstanding shares of Series A, B, B-1 and C convertible preferred stock, each such series voting together as a single class, or (ii) immediately upon the completion of the sale of the Company’s common stock in a firm commitment, underwritten public offering registered under the Securities Act of 1933, which results in aggregate proceeds to the Company equal to at least $30.0 million.

 

Liquidation Rights

 

In the event of any liquidation, dissolution, or winding up of the Company, the holders of the Series A, B, B-1 and C convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of the common stock, an amount equal to $2.174, $24.88, $25.26 and $12.46 per share plus any declared but unpaid dividends on such share (the “Liquidation Preference”). After the payment of the Liquidation Preference, all remaining assets available for distribution, if any, shall be distributed ratably among the holders of the common stock. If available assets are insufficient to pay the full Liquidation Preference, the available assets will be distributed to the holders of Series A, B, B-1 and C convertible preferred stock, in proportion to the preferential amount each such holder is otherwise entitled to receive.

 

A merger, consolidation, sale or lease of all or substantially all of the assets of the Company which will result in the Company’s shareholders immediately prior to such transaction not holding at least 50% of the voting power of the surviving entity, shall be deemed to be a liquidation, dissolution or winding up. Upon this event, holders of all shares of Series A, B, B-1 and C convertible preferred stock shall receive the greater of (i) their liquidation preference including any declared but unpaid dividends as of the liquidation date or (ii) the amount that would have been payable had all shares of each such series been converted into common stock immediately prior to this event.

 

Redemption Rights

 

The convertible preferred stock is not redeemable.

 

10. Warrants for Convertible Preferred Stock

 

The Company had the following unexercised convertible preferred stock warrants (in thousands, except for share data):

 

     Exercise
Price per
Share
   Shares as of    Fair Value as of

Underlying Stock

      December 31,    December 31,
      2008    2009    2008    2009

Series B Convertible Preferred Stock

   $ 24.88    12,628    2,580    $ 237    $ 48

Series B-1 Convertible Preferred Stock

   $ 25.26    102,724    106,567      1,895      2,267

Series C Convertible Preferred Stock

   $ 12.46       24,101           425
                          

Total

      115,352    133,248    $ 2,132    $ 2,740
                          

 

Series B

 

In 2008, in connection with consulting services, the Company issued a warrant to purchase 2,580 shares of the Company’s Series B convertible preferred stock at an exercise price of $24.88 per share. The warrant is

 

F-34


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

immediately exercisable and expires upon the earlier of (i) five years from the effective date; (ii) one year from the effective date of a public offering; or (iii) upon a change of control. The Company estimated the initial fair value of the warrant as of the date of issuance to be $39,000 and was recorded as consulting expense. The fair value was based on the contractual term of the warrants of five years, risk-free interest rate of 3.5%, expected volatility of 70% and 0% expected dividend yield.

 

In 2008, in connection with a capital lease agreement, the Company issued a warrant to purchase 10,048 shares of the Company’s Series B convertible preferred at an exercise price of $24.88 per share. The warrant was immediately exercisable and was due to expire upon the earlier of (i) ten years from the effective date; (ii) one year from the effective date of a public offering; or (iii) a merger event. The Company estimated the initial fair value of the warrant to be $196,000 and was recorded as other assets. The fair value was based on the contractual term of the warrants of ten years, risk-free interest rate of 4.04%, expected volatility of 70% and 0% annual dividend rate. In September 2009, the Company cancelled the warrant and issued a warrant to purchase 10,048 shares of the Company’s Series C convertible preferred stock.

 

Series B-1

 

In 2008, in connection with the Company’s issuance of Series B-1 convertible preferred stock, the Company issued warrants to purchase 100,715 shares of the Company’s Series B-1 convertible preferred stock at an exercise price of $25.26 per share to the placement agent. The warrants are immediately exercisable and expire seven years from the effective date. The Company estimated the initial fair value of these warrants as of the issuance dates to be $1.7 million and was recorded as a reduction to the carrying value of the Series B-1 convertible preferred stock. The fair value was based on the contractual term of the warrants of seven years, risk-free interest rates from 2.9% to 3.7%, expected volatility from 70% to 75%, and 0% expected dividend yield.

 

In 2008, in connection with an operating lease, the Company issued a warrant to purchase 2,009 shares of the Company’s Series B-1 convertible preferred stock at an exercise price of $25.26 per share. The warrant is exercisable immediately and expires upon the earlier of (i) ten years from the effective date; (ii) an underwritten public offering; or (iii) upon a change of control. The Company estimated the initial fair value of the warrant as of the date of issuance to be $40,000 and was recorded as rent expense. The fair value was based on the contractual term of the warrants of ten years, risk-free interest rate of 4.0%, expected volatility of 70% and 0% expected dividend yield.

 

In 2009, in connection with the Company’s issuance of Series B-1 convertible preferred stock, the Company issued a warrant to purchase 3,843 shares of the Company’s Series B-1 convertible preferred stock at an exercise price of $25.26 to the placement agent. The warrants are exercisable immediately and expire seven years from the effective date. The Company estimated the fair value of the warrant as of the date of issuance to be $68,000 and was recorded as a reduction to the carrying value of the Series B-1 convertible preferred stock. The fair value was based on the contractual term of the warrants of seven years, risk-free interest rate of 2.3%, expected volatility of 90%, and 0% expected dividend yield.

 

Series C

 

In September 2009, the Company cancelled the warrant to purchase 10,048 shares of the Company’s Series B convertible preferred stock and issued a warrant to purchase 16,075 shares of the Company’s Series C convertible preferred stock with an exercise price of $12.46 per share. In connection with a capital lease arrangement, the Company issued a warrant to purchase 8,026 shares of the Company’s Series C convertible preferred stock at an exercise price of $12.46 per share. The warrants are exercisable immediately and expire

 

F-35


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

upon the earlier of (i) September 2019; (ii) one year from the effective date of a public offering; or (iii) a merger event. The Company estimated the initial fair value of warrants as of the date of issuance to be $269,000 and was recorded as other assets and amortized over the capital lease draw-down period. The fair value was based on the contractual term of the warrants of ten years, risk-free interest rate of 3.3%, expected volatility of 97%, and 0% expected dividend yield.

 

The change in the fair value of convertible preferred stock warrants resulted in a charge to other expense in the amount of $114,000 and $445,000 during the years ended December 31, 2008 and 2009. The Company determined the fair value of the warrants as of December 31, 2008 and 2009 using the Black-Scholes option pricing model with the following assumptions:

 

     December 31,  
     2008     2009  

Expected dividend yield

   0   0

Risk-free interest rate

   1.6%-2.3   1.7%-3.9

Contractual term (in years)

   4-9.5      3-9.8   

Expected volatility

   80   98%-111

 

Each of these warrants includes a cashless exercise provision which permits the holder of the warrant to elect to exercise the warrant without paying the cash exercise price, and receive a number of shares determined by multiplying (i) the number of shares for which the warrant is being exercised by (ii) the difference between the fair market value of the stock on the date of exercise and the warrant exercise price, and dividing such by (iii) the fair market value of the stock on the date of exercise. At December 31, 2009, these warrants were outstanding and exercisable.

 

11. Common Stock

 

The Articles of Incorporation authorize the Company to issue 33,000,000 shares of common stock as of December 31, 2009. Holders of the Company’s common stock are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.

 

12. Restricted stock

 

Pursuant to restricted stock agreements with the Company’s founders, the Company has the right, but not the obligation, to repurchase all or any portion of the unvested shares of common stock upon termination of employment at the original purchase price per share. The repurchase rights with respect to founders stock lapse over the vesting period, which ranges from 68 to 100 months. As of December 31, 2008 and 2009, 267,711 and 52,084 restricted shares of common stock held by the Company’s founders were subject to repurchase by the Company.

 

13. Stock Based Compensation

 

Employee Equity Plan

 

In 2005, the Company established its 2005 Stock Option Plan (the “Plan”) which provides for the granting of common stock options, RSUs, restricted stock and stock purchase rights awards to employees and consultants of the Company. The Plan allows for time-based or performance-based vesting for the awards. Options granted

 

F-36


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

under the Plan may be either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants.

 

Options under the Plan may be granted for periods of up to ten years. All options issued to date have had a ten year life. The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. The exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the underlying stock on the date of grant as determined by the Board of Directors. The Company’s options generally vest over four to five years.

 

In December 2009, the Company issued 10,000 shares of restricted stock to an employee with performance-based vesting conditions. The performance based vesting conditions require the achievement of certain operational performance criteria as a condition of vesting for such award within six months following the date of grant. As of December 31, 2009, the Company assessed the probability of achieving the performance conditions and determined it was not probable that the performance condition will be satisfied. No compensation cost was recorded during the year ended December 31, 2009.

 

No income tax benefit has been recognized relating to stock-based compensation expense and no tax benefits have been realized from exercised stock options.

 

F-37


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Stock Option Activity

 

The Company’s stock option, RSU and restricted stock grant activity and related information for the years ended December 31, 2007, 2008 and 2009 was as follows:

 

    Shares
Available
for Grant
    Number
of Stock

Options
Outstanding
    Weighted-
Average
Exercise
Price
  Weighted-
Average
Remaining
Contractual
Life (Years)
  Aggregate
Intrinsic
Value
                        (in thousands)

Outstanding—January 1, 2007

  386,800      247,200      $ 0.22   6.96   $ 0

Additional shares authorized

  3,662,700                

Options granted

  (2,792,060   2,792,060        1.65    

Options exercised

       (361,723     0.60    

Options cancelled

  48,627      (48,627     0.20    

Shares repurchased

  20,625             0.10    
                           

Outstanding—December 31, 2007

  1,326,692      2,628,910        1.69   8.81     5,891

Additional shares authorized

  1,390,000              

Options granted

  (1,289,549   1,289,549        3.93    

Restricted stock units granted

  (50,000             

Options exercised

       (172,059     3.42    

Options cancelled

  118,231      (118,231     2.37    

Shares repurchased

  1,498             1.16    
                           

Outstanding—December 31, 2008

  1,496,872      3,628,169        2.38   8.22     21,764

Additional shares authorized

                 

Options granted

  (1,109,553   1,109,553        4.31    

Restricted stock granted

  (10,000             

Options exercised

       (117,515     1.04    

Options cancelled

  173,313      (173,313     2.98    

Shares repurchased

  28,886             0.32    
                           

Outstanding—December 31, 2009

  579,518      4,446,894      $ 2.87   8.19   $ 28,661
                 

Vested and expected to vest—December 31, 2009

    4,291,908      $ 2.85   8.17   $ 27,776

Exercisable—December 31, 2009

    1,897,783      $ 2.30   7.78   $ 13,319

 

The aggregate intrinsic value of options exercised under the Plan was $73,000, $26,000 and $308,000 for the years ended December 31, 2007, 2008 and 2009, determined as of the date of option exercise.

 

F-38


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following table summarizes information about stock options outstanding as of December 31, 2009:

 

     Options Outstanding    Options Vested

Exercise Price

     Number of Options      Weighted-Average
Remaining
Contractual Life
(Years)
     Number of Options  

$0.10

   36,700        5.96    35,574

$0.28

   1,180,400    7.10    706,686

$1.50

   273,660    7.57    186,633

$3.93

   1,846,591    8.11    760,537

$4.31

   1,109,543    9.69    208,353
            
   4,446,894    8.19    1,897,783
            

 

At December 31, 2008, 930,152 options were vested and exercisable under the plan with a weighted average exercise price of $1.27 per share.

 

Common Stock Subject to Repurchase

 

Historically, the Company allowed employees to exercise options prior to vesting. The Company has the right to repurchase at the original purchase price any unvested (but issued) common shares upon termination of service of an employee. The consideration received for an exercise of an option is considered to be a deposit of the exercise price and the related dollar amount is recorded as a liability. The shares and liability are reclassified into equity on a ratable basis as the award vests. The Company recorded a liability in accrued expenses of $262,000 and $101,000 relating to 237,324 and 69,954 options that were exercised and unvested as of December 31, 2008 and 2009. These shares were subject to a repurchase right held by the Company and are included in issued and outstanding shares as of December 31, 2008 and 2009.

 

Stock-Based Compensation

 

Stock-based compensation expense related to options and restricted stock units granted to employees and nonemployees was allocated to research and development expense and sales, general and administrative expense for the years ended December 31, 2007, 2008 and 2009 as follows (in thousands):

 

     Years Ended December 31,
     2007    2008    2009

Research and development

   $ 117    $ 632    $ 773

Sales, general and administrative

     429      1,395      2,526
                    

Total stock-based compensation expense

   $ 546    $ 2,027    $ 3,299
                    

 

Employee Stock–Based Compensation

 

During the years ended December 31, 2007, 2008 and 2009, the Company granted 2,531,360, 1,289,549 and 1,089,053 stock options to employees with a weighted average grant date fair value of $1.65, $5.83 and $4.31 per share. As of December 31, 2009, there was unrecognized compensation costs of $6.7 million related to these stock options. The Company expects to recognize those costs over a weighted average period of 3.1 years. Future option grants will increase the amount of compensation expense to be recorded in these periods.

 

F-39


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Compensation expense of $306,000, $1.4 million and $2.6 million was recorded during the years ended December 31, 2007, 2008 and 2009 for stock-based awards granted to employees based on the grant date estimated fair value. Of the compensation expense recorded, $38,000, $501,000 and $765,000 was allocated to research and development expenses during the years ended December 31, 2007, 2008 and 2009 and $268,000, $849,000 and $1.8 million was allocated to sales, general and administrative expenses during the years ended December 31, 2007, 2008 and 2009.

 

The Company estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated for the years ended December 31, 2007, 2008 and 2009 using the following weighted-average assumptions:

 

       Years Ended December 31,
       2007   2008   2009

Expected dividend yield

     0%   0%   0%

Risk-free interest rate

    

3.9%-4.7%

  3.2%   2.8%

Expected term (in years)

     6.0   6.0   6.0

Expected volatility

     70%   70%   97%

 

Expected Dividend Yield —The Company has never paid dividends and does not expect to pay dividends.

 

Risk-Free Interest Rate —The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of grant for zero coupon United States Treasury notes with maturities approximately equal to the option’s expected term.

 

Expected Term —Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s assumptions about the expected term have been based on that of companies that have similar industry, life cycle, revenue and market capitalization.

 

Expected Volatility —The expected volatility was based on the historical stock volatilities of several of the Company’s publicly listed comparable companies over a period equal to the expected terms of the options, as the Company does not have any trading history to use the volatility of its own common stock.

 

Fair Value of Common Stock —The fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there has been no public market for the Company’s common stock, the Board of Directors has determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and general and industry specific economic outlook, amongst other factors. The fair value of the underlying common stock shall be determined by the Board of Directors until such time as the Company’s common stock is listed on an established stock exchange or national market system.

 

F-40


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Information regarding the Company’s stock option grants during the year ended December 31, 2009, including the grant date; the number of stock options issued with each grant; the exercise price, which equals the grant date fair value of the underlying common stock for each grant of stock options, is summarized as follows:

 

Grant Date

   Number of Options
Granted
   Exercise Price and Fair
Value of Underlying
Common Stock

September 14, 2009

   965,153    $ 4.31

October 27, 2009

   144,400    $ 4.31

 

Forfeiture Rate —The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior, and other factors. The impact from a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual number of future forfeitures differs from that estimated by the Company, the Company may be required to record adjustments to stock-based compensation expense in future periods.

 

Each of the inputs discussed above is subjective and generally requires significant management and director judgment to determine.

 

Nonemployee Stock–Based Compensation

 

During the years ended December 31, 2007, 2008 and 2009, the Company granted options to purchase 260,700, 0 and 20,500 shares of common stock to nonemployees in exchange for services. Compensation expense of $240,000, $636,000 and $238,000 was recorded during the years ended December 31, 2007, 2008 and 2009 for stock-based awards granted to nonemployees. The nonemployee options were valued using the Black-Scholes option pricing model with the following weighted-average assumptions for the years ended December 31, 2007, 2008 and 2009:

 

       Years Ended December 31,
       2007   2008   2009

Expected dividend yield

     0%   0%   0%

Risk-free interest rate

    

3.9%-4.8%

 

1.52%-4.1%

 

1.82%-3.59%

Contractual term (in years)

     9.7   7.0-9.2   6.0-10.0

Expected volatility

     70%  

70%-75%

 

90%-98%

 

During 2008, the Company entered into a related party transaction with a venture capital group to provide strategic advisory services to Amyris and its majority owned subsidiary Amyris Brasil. One of its directors is also a member of the Company’s Board of Directors. As compensation for the advisory services to be rendered, the Company granted 50,000 RSUs with a grant date fair value of $8.38 during the year ended December 31, 2008. No additional RSUs were granted during the year ended December 31, 2009. The RSUs vest quarterly and become fully vested in July 2010. Compensation expense of $41,000 and $466,000 was recorded for the years ended December 31, 2008 and 2009.

 

F-41


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

Shares Reserved for Future Issuance

 

As of December 31, 2009, the Company had reserved shares of common stock for issuance as follows:

 

     December 31, 2009

Issuance of stock options

   5,026,412

Restricted stock units

   50,000

Conversion of convertible preferred stock

   18,790,244

Issuance upon exercise of convertible preferred stock warrants

   144,158
    
   24,010,814
    

 

14. Employee Benefit Plan

 

The Company established a 401(k) Plan to provide tax deferred salary deductions for all eligible employees. Participants may make voluntary contributions to the 401(k) Plan up to 90% of their eligible compensation, limited by certain Internal Revenue Service restrictions. The Company does not match employee contributions.

 

15. Related Party Transactions

 

The Company has entered into a license agreement with University of California, Berkeley. A co-founder and advisor to the Company is a professor at the University of California, Berkeley. The Company paid the advisor $15,000, $30,000 and $34,000 during the years ended December 31, 2007, 2008 and 2009.

 

Crystalsev Comercio E Representacao Ltda. (“Crystalsev”) was issued 40,193 shares of Series B convertible preferred stock by contributing $1.0 million during the Series B convertible preferred stock financing in March 2008 (see Note 16).

 

During 2008, the Company entered into an agreement with a venture capital group to provide strategic advisory services to Amyris and its majority owned subsidiary Amyris Brasil. One of its directors is also a member of the Company’s Board of Directors. (See Note 13).

 

16. Noncontrolling Interest

 

In March 2008, the Company and Crystalsev established the Company’s majority owned subsidiary, or Amyris-Crystalsev Pesquisa E Desenvolvimento de Biocombustiveis Ltda., which was re-named to be Amyris Brasil S.A. in 2009, for the manufacturing of transportation fuels from sugarcane feedstock in Brazil and trading such transportation fuels within Brazil and abroad. The Company invested $3.8 million of cash for 70% interest in Amyris Brasil and Crystalsev contributed $1.6 million of cash for the remaining 30% interest.

 

In April 2009, the Company purchased the remaining outstanding shares in Amyris Brasil for $2.3 million resulting in Amyris Brasil becoming a wholly-owned subsidiary. The purchase of the noncontrolling interest was treated as an equity transaction and the fair value of the consideration paid of $2.3 million was recorded as a reduction of the carrying value of the noncontrolling interest and additional paid-in capital.

 

On December 22, 2009, the Company sold a 4.8% interest in Amyris Brasil for BRL$10.0 million. The redeemable noncontrolling interest is reported in the mezzanine equity section of the consolidated balance sheet because the Company is subject to a contingent put option under which it may be required to repurchase an interest in Amyris Brasil from the noncontrolling interest holder. The Company has recognized a noncontrolling

 

F-42


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

interest for December 22, 2009 to December 31, 2009 in the consolidated balance sheets and statements of operations. The Company has also recognized a receivable of $2.5 million for which payment was received in January 2010.

 

Under the terms of the agreements, the Company is required to make additional capital investments in Amyris Brasil worth at least $30.0 million in the form of (i) a cash contribution of $10.0 million in the form of convertible loans to Amyris Brasil and (ii) an ownership interest in Usina Boa Vista S.A. (“Boa Vista”) equal to BRL$50.0 million. Under the terms of the agreements, the Investors are required to make capital contributions of BRL$10.0 million in Amyris Brasil and have the right to make additional capital contributions in Amyris Brasil equal to the lesser of (i) $32.5 million and (ii) an amount equal to 20% of Amyris Brasil’s post-valuation, as defined in the agreement, raised from qualified third party investors by February 20, 2010. The Company and the Investors intend that BRL$40.0 million of the proceeds raised shall be used to purchase 40% of Boa Vista by March 22, 2010. The Company also entered into a contingent put option with the Investors in the event that Amyris Brasil receives a binding offer from one or more third parties willing to acquire control of Amyris Brasil through a change of control event that will entitle the Investors to sell their shares to the Company. Under the terms of the put option, the Investors will have the right to receive from the Company its pro rate share of the total put option price. The put option price is defined as being the lower of (i) the amount invested by the Investors in Amyris Brasil plus 8% per year; and (ii) the total amount of proceeds actually received by the Company from a third party acquirer or from Amyris Brasil, in connection with a change of control event relating to the Company.

 

The following table provides a rollforward of the redeemable noncontrolling interest recorded as mezzanine equity:

 

       Year Ended
December 31, 2009
 

Beginning balance as of December 31, 2008

   $   

Proceeds from redeemable noncontrolling interest

     5,626   

Net loss

     (120
        

Ending balance as of December 31, 2009

   $ 5,506   
        

 

17. Restructuring

 

In June 2009, the Company initiated a restructuring plan to reduce its cost structure. The restructuring plan resulted in the consolidation of the Company’s headquarter facility located in Emeryville, California, which is under an operating lease. The Company ceased using a certain part of its headquarter facility in August 2009. The Company recorded approximately $5.4 million of restructuring charges associated with the facility lease costs after the operations ceased. In addition, as a result of the consolidation of the headquarter facility, the Company recorded approximately $3.1 million related to asset impairments and reversed $2.7 million related to deferred rent associated with the leased facility.

 

F-43


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

The following table summarizes the liability and utilization by cost type associated with the restructuring (in thousands):

 

     Exit Costs     Asset
Impairments
    Deferred Rent
Write-Off
    Total  

Accrued restructuring as of December 31, 2008

   $      $      $      $   

Additional accruals

     5,412        3,075        (2,719     5,768   

Cash payments

     (534                   (534

Accretion expense

     200                      200   

Non-cash settlements

            (3,075     2,719        (356
                                

Accrued restructuring as of December 31, 2009

     5,078                      5,078   

Less current portion

     (592                   (592
                                

Long-term portion as of December 31, 2009

   $ 4,486      $      $      $ 4,486   
                                

 

The restructuring accrual as of December 31, 2009, for facility-related leases (net of estimated sublease proceeds) will be paid over the respective facility lease term through May 2018.

 

18. Reporting Segments

 

The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reporting segment and operating unit structure.

 

Revenues by geography are based on the billing address of the customer. The following tables set forth revenue and long-lived assets by geographic area (in thousands):

 

Revenues

 

     Years Ended December 31,
     2007    2008    2009

United States

   $ 6,184    $ 13,892    $ 64,608
                    

Total

   $ 6,184    $ 13,892    $ 64,608
                    

 

Long-Lived Assets

 

     December 31,
2008
   December 31,
2009

United States

   $ 39,995    $ 34,868

Brazil

     1,570      7,692
             

Total

   $ 41,565    $ 42,560
             

 

F-44


Table of Contents

Amyris Biotechnologies, Inc.

 

Notes to Consolidated Financial Statements—(Continued)

 

19. Subsequent Events

 

The Company has evaluated subsequent events through April 16, 2010, the date on which the consolidated financial statements were issued for inclusion in the Company’s registration statement on Form S-1.

 

In January 2010, the Company raised $3.7 million before issuance costs, by issuing 295,981 shares of Series C convertible preferred stock at $12.46 per share.

 

In March 2010, the Company raised $47.8 million before issuance costs, by issuing 2,724,766 shares of Series C-1 convertible preferred stock at $17.56 per share.

 

In March 2010, the Company received an additional $1.7 million investment in Amyris Brasil.

 

On April 13, 2010, the board of directors of the Company approved the filing of a registration statement with the Securities and Exchange Commission for an initial public offering of the Company’s common stock.

 

On April 14, 2010 we entered into a joint venture with Usina São Martinho, to produce Amyris renewable products. The joint venture, SMA Indústria Química S.A., was created to build the first facility in Brazil fully dedicated to the production of Amyris renewable products. The new company will be located at the Usina São Martinho mill in Pradópolis, São Paulo state. The joint venture has a 20 year initial term.

 

Amyris plans to provide genetically engineered yeast to enable the joint venture to produce farnesene, a molecule which may be used as an ingredient in a wide range of consumer and industrial products, including detergents, cosmetics, perfumes and industrial lubricants.

 

The joint venture will be governed by a four member board of directors, of which the Company and São Martinho will each appoint two members. A three member executive committee, of which we appoint two members one of which will be the plant manager who is the most senior executive, will be responsible for managing construction and operation of the facility.

 

Under the joint venture agreement, Amyris will grant royalty-free license to the JV. Amyris will fund the construction costs of the new facility, which is estimated to total between $80 million to $100 million, of which São Martinho will reimburse up to 61.8 million Brazilian reais ($35 million) after we commence production. Post commercialization, Amyris will market and distribute the Amyris renewable products. São Martinho will sell feedstock and provide certain other services to the joint venture. The cost of the feedstock to the joint venture is a price that is based on the average return that Usina São Martinho could receive from the production of its current products, sugar and ethanol. We are required to purchase the output of the joint venture for the first four years at a price that guarantees the return of Usina São Martinho’s investment plus a fixed interest rate. After this four year period, the price is set to guarantee a break-even price to the joint venture plus an agreed upon return.

 

F-45


Table of Contents

LOGO


Table of Contents

 

 

LOGO


Table of Contents

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

 

The following table sets forth all expenses to be paid by the Registrant, other than estimated underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates except for the SEC registration fee, the FINRA filing fee and the stock exchange listing fee:

 

SEC registration fee

   $ 7,130

FINRA filing fee

     10,500

Stock exchange listing fee

     *

Printing and engraving

     *

Legal fees and expenses

     *

Accounting fees and expenses

     *

Blue sky fees and expenses (including legal fees)

     *

Transfer agent and registrar fees

     *

Director and officer insurance

     *

Miscellaneous

     *
      

Total

   $ *
      

 

  *   To be completed by amendment.

 

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s Board of Directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended (the “Securities Act”).

 

As permitted by the Delaware General Corporation Law, the Registrant’s restated certificate of incorporation to be effective upon the completion of the offering contains provisions that eliminate the personal liability of its directors for monetary damages for any breach of fiduciary duties as a director, except liability for the following:

 

   

any breach of the director’s duty of loyalty to the Registrant or its stockholders;

 

   

acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

 

   

under Section 174 of the Delaware General Corporation Law (regarding unlawful dividends and stock purchases); or

 

   

any transaction from which the director derived an improper personal benefit.

 

As permitted by the Delaware General Corporation Law, the Registrant’s restated bylaws to be effective upon the completion of this offering, provide that:

 

   

the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law, subject to very limited exceptions;

 

   

the Registrant may indemnify its other employees and agents as set forth in the Delaware General Corporation Law;

 

II-1


Table of Contents
   

the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to very limited exceptions; and

 

   

the rights conferred in the bylaws are not exclusive.

 

Prior to the completion of this offering, the Registrant intends to enter into indemnification agreements with each of its current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant’s restated certificate of incorporation and restated bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought. Reference is also made to Section        of the underwriting agreement filed as Exhibit 1.1 to this registration statement, which provides for the indemnification of executive officers, directors and controlling persons of the Registrant against certain liabilities. The indemnification provisions in the Registrant’s restated certificate of incorporation, restated bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the Registrant’s directors and executive officers for liabilities arising under the Securities Act.

 

The Registrant currently carries liability insurance for its directors and officers.

 

Three of Registrant’s directors (Mr. Doerr, Dr. Duyk and Mr. Kaul) are also indemnified by their employers with regard to their service on the Registrant’s Board of Directors.

 

Reference is made to the following documents filed as exhibits to this Registration Statement regarding relevant indemnification provisions described above and elsewhere herein:

 

Exhibit Title

  

Exhibit

Number

Form of Underwriting Agreement   

Form of Restated Certificate of Incorporation of the Registrant, to be in effect upon the completion of this offering

  
Form of Restated Bylaws of the Registrant, to be in effect upon the completion of this offering   

Amended and Restated Investors’ Rights Agreement, dated March 12, 2010, by and among the Registrant and certain security holders of the Registrant

  
Form of Indemnification Agreement   

 

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES

 

Since March 31, 2007, we have issued and sold the following securities:

 

  1.   As of March 31, 2010, we have issued 564,704 shares of our Common Stock to employees, directors, consultants and other service providers upon the exercise of options and stock purchase rights granted by us under our 2005 Stock Option/Stock Issuance Plan, with exercise prices ranging from $0.10 to $4.31 per share.

 

  2.   In April 2007 and May 2007, we sold an aggregate of 6,482,824 shares of our Series A Preferred Stock at $2.17 per share for an aggregate purchase price of approximately $14.1 million to 23 accredited investors.

 

  3.   In September 2007 and April 2008, we sold an aggregate of 1,667,817 shares of our Series B Preferred Stock at $24.88 per share for an aggregate purchase price of approximately $41.5 million to 11 accredited investors.

 

  4.   In February 2008, April 2008, May 2008, July 2008, September 2008, November 2008, December 2008 and January 2009, we sold an aggregate of 2,615,721 shares of our Series B-1 Preferred Stock at $25.26 per share for an aggregate purchase price of approximately $66.1 million to 26 accredited investors.

 

II-2


Table of Contents
  5.   From March 2008 through March 2009, we issued warrants to purchase an aggregate of 104,558 shares of our Series B-1 Preferred Stock at an exercise price of $25.26 per share to Advanced Equities Financial Corp.

 

  6.   In March 2008, we issued warrants to purchase 10,048 shares of our Series B Preferred Stock at an exercise price of $24.88 per share to TriplePoint Capital LLC. This warrant was cancelled before it was exercised, in exchange for the Series C Preferred Stock warrant issued to TriplePoint Capital LLC, referred to below.

 

  7.   In March 2008, we issued warrants to purchase 2,580 shares of our Series B Preferred Stock at an exercise price of $24.88 per share to Starfish, LLC.

 

  8.   In September 2008, we issued warrants to purchase 2,009 shares of our Series B-1 Preferred Stock at an exercise price of $25.26 per share to ES East Associates.

 

  9.   In September 2008, we issued options to purchase up to 60,000 shares of our Common Stock at an exercise price of $3.93 per share to Lit Tele LLC, outside the terms of our 2005 Stock Option/Stock Issuance Plan.

 

  10.   In September 2008, September 2009, October 2009, November 2009, December 2009 and January 2010, we sold an aggregate of 4,902,665 shares of our Series C Preferred Stock at $12.46 per share for an aggregate purchase price of approximately $61.1 million to 34 accredited investors.

 

  11.   In September 2008, July 2009 and February 2010, we issued an aggregate of 176,272 restricted stock units to Lit Tele LLC, outside the terms of our 2005 Stock Option/Stock Issuance Plan.

 

  12.   In September 2009, we issued warrants to purchase an aggregate of 24,101 shares of our Series C Preferred Stock at an exercise price of $12.46 per share to TriplePoint Capital LLC.

 

  13.   In October 2009, we approved the issuance of 10,000 shares of restricted stock to a service provider under our 2005 Stock Option/Stock Issuance Plan at a price of $4.31 per share.

 

  14.   In January 2010, we issued warrants to purchase 49,157 shares of our Series C Preferred Stock at an exercise price of $12.46 per share to Advanced Equities Financial Corp.

 

  15.   In March 2010, we sold 2,724,766 shares of our Series C-1 Preferred Stock at $17.56 per share for an aggregate purchase price of approximately $47.8 million to Maxwell (Mauritius) Pte Ltd.

 

  16.   In March 2010, we recorded an additional $1.7 million investment in Amyris Brasil.

 

Unless otherwise stated, the sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(2) of the Securities Act or Regulation D or Regulation S promulgated thereunder, or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us.

 

II-3


Table of Contents
ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)  Exhibits.  The following exhibits are included herein or incorporated herein by reference:

 

Exhibit
Number

 

Description

  1.01*

  Form of Underwriting Agreement

  3.01*

  Restated Certificate of Incorporation of the Registrant

  3.02*

  Bylaws of the Registrant

  3.03*

  Form of Restated Certificate of Incorporation of the Registrant, to be effective upon the consummation of this offering

  3.04*

  Form of Restated Bylaws of the Registrant, to be effective upon closing of this offering

  4.01*

  Form of the Registrant’s common stock certificate

  4.02

  Amended and Restated Investors’ Rights Agreement dated March 12, 2010 among the Registrant and the Registrant’s securityholders listed therein

  4.03*

  Shareholders’ Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and Stratus Investimendos Ltda. dated December 22, 2009

  4.04*

  Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and Stratus Investimentos Ltda. dated March 3, 2010

  4.05

  Form of Warrant to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp. and a schedule of issued Warrants to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp.

  4.06

  Warrant to Purchase Series C Preferred Stock dated January 7, 2010 issued by the Registrant to Advanced Equities Financial Corp.

  4.07

  Letter Agreement dated April 8, 2010 between the Registrant and Advanced Equities, Inc.

  4.08

  Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates LLC

  4.09

  Amendment No. 1 dated April 8, 2010 between ES East Associates LLC and the Registrant to Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates LLC

  4.10

  Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish LLC

  4.11

  Amendment No. 1 dated April 8, 2010 between Starfish LLC and the Registrant to Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish LLC

  4.12

  Amended and Restated Plain English Warrant Agreement dated March 14, 2008, as amended through September 18, 2009 between the Registrant and TriplePoint Capital LLC

  4.13

  Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Amended and Restated Plain English Warrant Agreement originally dated March 14, 2008, as amended, on September 18, 2009 between the Registrant and TriplePoint Capital LLC

  4.14

  Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC

  4.15

  Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC

  5.01*

  Opinion of Fenwick & West LLP regarding the legality of the securities being registered

10.01*

  Form of Indemnity Agreement between the Registrant and its directors and officers

10.02*

  Uncommitted Facility Letter dated November 25, 2008 between BNP Paribas and Amyris Fuels, Inc.

 

II-4


Table of Contents

Exhibit
Number

 

Description

10.03*   Amendment to Uncommitted Facility Letter dated October 7, 2009 between BNP Paribas, Amyris Fuels, LLC, and the Registrant

10.04

  Plain English Master Lease Agreement dated March 14, 2008 between the Registrant and TriplePoint Capital LLC

10.05

  First Amendment to Plain English Master Lease Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC

10.06

  Reimbursement and Security Agreement dated November 5, 2009 between the Registrant and Bank of the West

10.07

  First Amendment to Reimbursement and Security Agreement dated December 3, 2009 between the Registrant and Bank of the West

10.08

  Registrant’s acceptance dated November 10, 2008 of offer by UBS Financial Services Inc. relating to auction rate securities

10.09

  Assistance Agreement dated December 30, 2009, as modified by Assistance Agreement dated March 26, 2010, between the Registrant and U.S. Department of Energy, together with schedules and supplements thereto

10.10

  Amended and Restated Strategic Advisory Services Agreement dated July 31, 2009 between the Registrant and Lit Tele LLC

10.11

  Amendment No. 1 dated February 11, 2010 to Amended and Restated Strategic Advisory Services Agreement between the Registrant and Lit Tele LLC

10.12*

  Joint Venture Agreement dated April 14, 2010 among Usina São Martinho S.A., Amyris Brasil S.A. and the Registrant

10.13*

  Shareholders’ Agreement dated April 14, 2010 among SMA Indústria Química S.A., Usina São Martinho S.A. and Amyris Brasil S.A.

10.14*

  Amended and Restated Patent and Non-Exclusive Know-How License for Regents’ Project Patents Arising Under Regents’ Research Agreement Number 018896 dated January 11, 2008 between the Registrant and UC Regents

10.15*

  Amendment A to Exclusive Patent and Non-Exclusive Know-How License dated November 1, 2009 between The Regents of the University of California and Amyris Biotechnologies, Inc.

10.16*

  License Agreement dated August 21, 2006 between the Registrant and Arkion Life Sciences LLC

10.17

  Lease dated August 22, 2007 between ES East Associates LLC and Amyris Biotechnologies, Inc.

10.18

  First Amendment to Lease dated March 10, 2008 between the Registrant and ES East Associates LLC

10.19

  Second Amendment to Lease dated April 25, 2008 between the Registrant and ES East Associates LLC

10.20

  Third Amendment to Lease dated July 31, 2008 between the Registrant and ES East Associates LLC

10.21

  Fourth Amendment to Lease dated November 14, 2009 between the Registrant and ES East Associates LLC

10.22

  Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle LLC

10.23

  Letter amending Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle, LLC

10.24

  Second Amendment to Lease dated February 5, 2010 between the Registrant and EmeryStation Triangle, LLC

10.25

  Pilot Plant Expansion Right Letter dated December 22, 2008 between the Registrant and EmeryStation Triangle, LLC

10.26

  Private Instrument of Non-Residential Real Estate Lease Agreement between Lucio Tomasiello and Amyris Brasil S.A. dated March 31, 2008

 

II-5


Table of Contents

Exhibit
Number

 

Description

10.27

  Offer Letter dated September 27, 2006 between the Registrant and John Melo

10.28

  Amendment dated December 18, 2008 to Offer Letter between the Registrant and John Melo

10.29

  Offer Letter dated September 30, 2008 between the Registrant and Joel Cherry

10.30

  Amendment dated December 19, 2008 to Offer Letter between the Registrant and Joel Cherry

10.31

  Offer Letter dated January 17, 2008 between the Registrant and Jeryl Hilleman

10.32

  Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeryl Hilleman

10.33

  Offer Letter dated October 22, 2007 between the Registrant and Jeff Lievense

10.34

  Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeff Lievense

10.35

  Offer Letter dated January 24, 2005 between the Registrant and Tamara Tompkins

10.36

  Amendment to Offer Letter dated January 15, 2009 between the Registrant and Tamara Tompkins

10.37

  2005 Stock Option/Stock Issuance Plan of the Registrant

10.38

  Form of Notice of Grant of Stock Option under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.39

  Form of Notice of Grant of Stock Option (non-Exempt) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.40

  Form of Notice of Grant of Stock Option (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.41

  Form of Stock Option Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.42

  Form of Stock Option Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.43

  Form of Stock Purchase Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.44

  Form of Stock Purchase Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.45*

  2010 Equity Incentive Plan of the Registrant and forms of award agreements thereunder

10.46*

  2010 Employee Stock Purchase Plan of the Registrant

21.01

  List of subsidiaries of the Registrant

23.01

  Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm

23.02*

  Consent of Fenwick & West LLP (included in Exhibit 5.01)

24.01

  Power of Attorney (see page II-8 to this registration statement on Form S-1)

 

  *   To be filed by amendment.

 

(b)  Financial Statement Schedules.  All financial statement schedules are omitted because they are not applicable or the information is included in the Registrant’s consolidated financial statements or related notes.

 

ITEM 17. UNDERTAKINGS

 

The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the

 

II-6


Table of Contents

Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

The undersigned Registrant hereby undertakes that:

 

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-7


Table of Contents

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on this 16 th day of April, 2010.

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

  / S /  J OHN M ELO
  John G. Melo, President and Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints John G. Melo, Jeryl L. Hilleman and Tamara L. Tompkins, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

 

Date

/ S /  J OHN M ELO        

John Melo

  

Director, President and Chief Executive Officer

(Principal Executive Officer)

 

April 14, 2010

/ S /  J ERYL H ILLEMAN        

Jeryl Hilleman

  

Chief Financial Officer

(Principal Accounting and Financial Officer)

 

April 15, 2010

/ S /  R ALPH A LEXANDER        

Ralph Alexander

   Director  

April 15, 2010

/ S /  J OHN D OERR        

John Doerr

   Director  

April 14, 2010

/ S /  G EOFFREY D UYK        

Geoffrey Duyk, M.D., Ph.D.

   Director  

April 14, 2010

/ S /  S AMIR K AUL        

Samir Kaul

   Director  

April 14, 2010

/ S /  P ATRICK P ICHETTE        

Patrick Pichette

   Director  

April 14, 2010

 

Carole Piwnica

   Director  

April     , 2010

/ S /  K INKEAD R EILING        

Kinkead Reiling, Ph.D.

   Director  

April 14, 2010

/ S /  F ERNANDO R EINACH        

Fernando Reinach, Ph.D.

   Director  

April 14, 2010

 

II-8


Table of Contents

EXHIBIT INDEX

 

Exhibit
Number

 

Description

  1.01*

  Form of Underwriting Agreement

  3.01*

  Restated Certificate of Incorporation of the Registrant

  3.02*

  Bylaws of the Registrant

  3.03*

  Form of Restated Certificate of Incorporation of the Registrant, to be effective upon the consummation of this offering

  3.04*

  Form of Restated Bylaws of the Registrant, to be effective upon closing of this offering

  4.01*

  Form of the Registrant’s common stock certificate

  4.02

  Amended and Restated Investors’ Rights Agreement dated March 12, 2010 among the Registrant and the Registrant’s securityholders listed therein

  4.03*

  Shareholders’ Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and Stratus Investimendos Ltda. dated December 22, 2009

  4.04*

  Agreement by Fundo Mútuo de Investimento em Empresas Emergentes Inovadoras Stratus GC III, Amyris Biotechnologies, Inc., Amyris Brasil S.A. and Stratus Investimentos Ltda. dated March 3, 2010

  4.05

  Form of Warrant to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp. and a schedule of issued Warrants to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities Financial Corp.

  4.06

  Warrant to Purchase Series C Preferred Stock dated January 7, 2010 issued by the Registrant to Advanced Equities Financial Corp.

  4.07

  Letter Agreement dated April 8, 2010 between the Registrant and Advanced Equities, Inc.

  4.08

  Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates LLC

  4.09

  Amendment No. 1 dated April 8, 2010 between ES East Associates LLC and the Registrant to Stock Purchase Warrant dated September 23, 2008 issued by the Registrant to ES East Associates LLC

  4.10

  Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish LLC

  4.11

  Amendment No. 1 dated April 8, 2010 between Starfish LLC and the Registrant to Stock Purchase Warrant dated March 6, 2008 issued by the Registrant to Starfish LLC

  4.12

  Amended and Restated Plain English Warrant Agreement dated March 14, 2008, as amended through September 18, 2009 between the Registrant and TriplePoint Capital LLC

  4.13

  Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Amended and Restated Plain English Warrant Agreement originally dated March 14, 2008, as amended on September 18, 2009 between the Registrant and TriplePoint Capital LLC

  4.14

  Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC

  4.15

  Amendment No. 1 dated April 8, 2010 between the Registrant and TriplePoint Capital LLC to Plain English Warrant Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC

  5.01*

  Opinion of Fenwick & West LLP regarding the legality of the securities being registered

10.01*

  Form of Indemnity Agreement between the Registrant and its directors and officers

10.02*

  Uncommitted Facility Letter dated November 25, 2008 between BNP Paribas and Amyris Fuels, Inc.
10.03*   Amendment to Uncommitted Facility Letter dated October 7, 2009 between BNP Paribas, Amyris Fuels, LLC, and the Registrant

10.04

  Plain English Master Lease Agreement dated March 14, 2008 between the Registrant and TriplePoint Capital LLC


Table of Contents

Exhibit
Number

 

Description

10.05

  First Amendment to Plain English Master Lease Agreement dated September 18, 2009 between the Registrant and TriplePoint Capital LLC

10.06

  Reimbursement and Security Agreement dated November 5, 2009 between the Registrant and Bank of the West

10.07

  First Amendment to Reimbursement and Security Agreement dated December 3, 2009 between the Registrant and Bank of the West

10.08

  Registrant’s acceptance dated November 10, 2008 of offer by UBS Financial Services Inc. relating to auction rate securities

10.09

  Assistance Agreement dated December 30, 2009, as modified by Assistance Agreement dated March 26, 2010, between the Registrant and U.S. Department of Energy, together with schedules and supplements thereto

10.10

  Amended and Restated Strategic Advisory Services Agreement dated July 31, 2009 between the Registrant and Lit Tele LLC

10.11

  Amendment No. 1 dated February 11, 2010 to Amended and Restated Strategic Advisory Services Agreement between the Registrant and Lit Tele LLC

10.12*

  Joint Venture Agreement dated April 14, 2010 among Usina São Martinho S.A., Amyris Brasil S.A. and the Registrant

10.13*

  Shareholders’ Agreement dated April 14, 2010 among SMA Indústria Química S.A., Usina São Martinho S.A. and Amyris Brasil S.A.

10.14*

  Amended and Restated Patent and Non-Exclusive Know-How License for Regents’ Project Patents Arising Under Regents’ Research Agreement Number 018896 dated January 11, 2008 between the Registrant and UC Regents

10.15*

  Amendment A to Exclusive Patent and Non-Exclusive Know-How License dated November 1, 2009 between The Regents of the University of California and Amyris Biotechnologies, Inc.

10.16*

  License Agreement dated August 21, 2006 between the Registrant and Arkion Life Sciences LLC

10.17

  Lease dated August 22, 2007 between ES East Associates LLC and Amyris Biotechnologies, Inc.

10.18

  First Amendment to Lease dated March 10, 2008 between the Registrant and ES East Associates LLC

10.19

  Second Amendment to Lease dated April 25, 2008 between the Registrant and ES East Associates LLC

10.20

  Third Amendment to Lease dated July 31, 2008 between the Registrant and ES East Associates LLC

10.21

  Fourth Amendment to Lease dated November 14, 2009 between the Registrant and ES East Associates LLC

10.22

  Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle LLC

10.23

  Letter amending Lease dated April 25, 2008 between the Registrant and EmeryStation Triangle, LLC

10.24

  Second Amendment to Lease dated February 5, 2010 between the Registrant and EmeryStation Triangle, LLC

10.25

  Pilot Plant Expansion Right Letter dated December 22, 2008 between the Registrant and EmeryStation Triangle, LLC

10.26

  Private Instrument of Non-Residential Real Estate Lease Agreement between Lucio Tomasiello and Amyris Brasil S.A. dated March 31, 2008

10.27

  Offer Letter dated September 27, 2006 between the Registrant and John Melo

10.28

  Amendment dated December 18, 2008 to Offer Letter between the Registrant and John Melo

10.29

  Offer Letter dated September 30, 2008 between the Registrant and Joel Cherry

10.30

  Amendment dated December 19, 2008 to Offer Letter between the Registrant and Joel Cherry

10.31

  Offer Letter dated January 17, 2008 between the Registrant and Jeryl Hilleman


Table of Contents

Exhibit
Number

 

Description

10.32

  Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeryl Hilleman

10.33

  Offer Letter dated October 22, 2007 between the Registrant and Jeff Lievense

10.34

  Amendment dated December 18, 2008 to Offer Letter between the Registrant and Jeff Lievense

10.35

  Offer Letter dated January 24, 2005 between the Registrant and Tamara Tompkins

10.36

  Amendment to Offer Letter dated January 15, 2009 between the Registrant and Tamara Tompkins

10.37

  2005 Stock Option/Stock Issuance Plan of the Registrant

10.38

  Form of Notice of Grant of Stock Option under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.39

  Form of Notice of Grant of Stock Option (non-Exempt) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.40

  Form of Notice of Grant of Stock Option (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.41

  Form of Stock Option Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.42

  Form of Stock Option Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.43

  Form of Stock Purchase Agreement under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.44

  Form of Stock Purchase Agreement (non-US) under the Registrant’s 2005 Stock Option/Stock Issuance Plan

10.45*

  2010 Equity Incentive Plan of the Registrant and forms of award agreements thereunder

10.46*

  2010 Employee Stock Purchase Plan of the Registrant

21.01

  List of subsidiaries of the Registrant

23.01

  Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm

23.02*

  Consent of Fenwick & West LLP (included in Exhibit 5.01)

24.01

  Power of Attorney (see page II-8 to this registration statement on Form S-1)

 

 

  *   To be filed by amendment.

Exhibit 4.02

AMYRIS BIOTECHNOLOGIES, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “ Agreement ”) is made as of March 12, 2010, by and among Amyris Biotechnologies, Inc., a California corporation (the “ Company ”), and the holders of Series A Preferred Stock listed on Exhibit A attached hereto (the “ Series A Preferred Stock ”), the Series B Preferred Stock listed on Exhibit B attached hereto (the “ Series B Preferred Stock ”), the Series B-1 Preferred Stock listed on Exhibit C attached hereto (the “ Series B-1 Preferred Stock ”), the Series C Preferred Stock listed on Exhibit D attached hereto (the “ Series C Preferred Stock ”), and the Series C-1 Preferred Stock listed on Exhibit E attached hereto (the “ Series C-1 Preferred Stock ”, and together with the Series A Preferred Stock, the Series B Preferred Stock, the Series B-1 Preferred Stock, and the Series C Preferred Stock, the “ Preferred Stock ”) (each, an “Investor” and collectively, the “ Investors ”) and the individuals listed on Exhibit F hereto (each, a “ Common Holder ” and, together, the “ Common Holders ”).

RECITALS

WHEREAS, the Company and certain of the Investors are parties to that certain Amended and Restated Investors’ Rights Agreement made and entered into as of July 31, 2009, as subsequently amended by Amendment No. 1 thereto (the “ Previous Agreement ”);

WHEREAS, concurrently herewith, certain of the Investors and the Company are entering into a Series C-1 Preferred Stock Purchase Agreement of even date herewith (the “ Series C-1 Agreement ”), pursuant to which such Investors are purchasing from the Company shares of its Series C-1 Preferred Stock;

WHEREAS, in order to induce the Company to enter into the Series C-1 Agreement and to induce certain of the Investors to purchase shares of Series C-1 Preferred Stock pursuant to the Series C-1 Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors and certain other matters as set forth herein; and

WHEREAS, this Agreement has been signed and delivered by the Company and by the requisite holders as set forth in Section 3.7 of the Previous Agreement.

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

1.           Registration Rights . The Company covenants and agrees as follows:

1.1         Definitions . For purposes of this Section 1:

(a)        The term “ Act ” means the Securities Act of 1933, as amended.

(b)        The term “ Form S-3 ” means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that


permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC.

(c)        The term “ Holder ” means any Investor having purchased more than 5% of the Preferred Stock sold by the Company and, except with respect to Sections 1.2, 1.12, 1.13 and Section 2 hereof, the Common Holders owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.13 hereof.

(d)        The term “ 1934 Act ” shall mean the Securities Exchange Act of 1934, as amended.

(e)        The terms “ register ,” “ registered ” and “ registration ” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document.

(f)        The term “ Registrable Securities ” means: (i) any Common Stock issued or issuable upon conversion of the Preferred Stock of the Company, (ii) other than with respect to Sections 1.2, 1.12, 1.13 and Section 2 hereof, any Common Stock of the Company held by the Common Holders, (iii) the Common Shares, as defined in that certain Stock Transfer Agreement, dated December 24, 2009, by and among the Company, certain holders of the Company’s Preferred Stock and certain holders of the Company’s Common Stock, and (iv) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or in replacement of, the securities set forth in subsection (i), (ii) or (iii) hereof, excluding, however, any Registrable Securities which (A) have previously been registered or which have been sold to the public either pursuant to a registration statement or Rule 144, (B) which have been sold in a private transaction in which the transferor’s rights under this Agreement are not assigned, (C) held by a Holder (together with its affiliates) if, as reflected on the Company’s list of shareholders, such Holder (together with its affiliates) holds less than 1% of the Company’s outstanding Common Stock (treating all shares of Preferred Stock on an as converted basis) or (D) held by a Holder (together with its affiliates) if the Company has completed its IPO and all shares of Common Stock of the Company issuable or issued upon conversion of the shares held by and issuable to such Holder (and its affiliates) may be sold pursuant to Rule 144 during a ninety (90) day period.

(g)        The number of shares of “ Registrable Securities then outstanding ” shall mean the number of shares of Common Stock that are Registrable Securities and (i) are then issued and outstanding or (ii) are then issuable pursuant to the exercise or conversion of then outstanding and then exercisable options, warrants or convertible securities.

(h)        The term “ SEC ” shall mean the Securities and Exchange Commission.

1.2         Request for Registration .

(a) If the Company shall receive at any time after the earlier of (i) three (3) years after the date hereof and (ii) one-hundred eighty (180) days after the effective

 

2


date of the first registration statement for an underwritten public offering of the Company’s Common Stock, a written request from the Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company use its commercially reasonable efforts to file a registration statement under the Act covering the registration of at least twenty percent (20%) of the Preferred Stock of the Company having an aggregate offering price to the public of not less than $5,000,000 (net of any underwriters’ discounts or commissions), then the Company shall:

(i)        within thirty (30) days of the receipt thereof, give written notice of such request to all Holders; and

(ii)        use its commercially reasonable efforts to effect, as soon as practicable, but no later than ninety (90) days except in connection with the Company’s first registered public offering of its Securities, the registration under the Act of all Registrable Securities that the Holders request to be registered, subject to the limitations of subsection 1.2(b).

(b)        If the Holders initiating the registration request hereunder (the “ Initiating Holders ”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to subsection 1.2(a) and the Company shall include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by a majority in interest of the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in subsection 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten (including Registrable Securities), then the Initiating Holders shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder; provided , however , that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all securities other than Registrable Securities are first entirely excluded from the underwriting.

(c)        Notwithstanding the foregoing, if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 1.2 a certificate signed by the President or Chief Executive Officer of the Company stating that, in the good-faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its shareholders for such registration statement to be filed, the Company shall have the right to defer taking action with respect to such filing for a period not to exceed ninety (90) days after receipt of the request of the Initiating Holders, provided such right may not be exercised more than once

 

3


in any twelve (12) month period.

(d)        In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2:

(i)        After the Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective;

(ii)        During the period starting with the date ninety (90) days prior to the Company’s good-faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of the first registration statement for an underwritten public offering of the Company’s Common Stock (the “ IPO ”); provided that the Company delivers notice to the Initiating Holders within thirty (30) days of any such registration request and the Company is actively employing in good faith all commercially reasonable efforts to cause such registration statement to become effective; or

(iii)        If the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.12 below.

1.3         Company Registration . If (but without any obligation to do so) the Company proposes to register for its own account, or the account of others, any of its capital stock or other securities under the Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of securities to participants in a Company stock plan, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered or an SEC Rule 145 transaction), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within thirty (30) days after mailing of such notice by the Company in accordance with Section 3.5, the Company shall, subject to the provisions of Section 1.8, use its commercially reasonable efforts to cause to be registered under the Act all of the Registrable Securities that each such Holder has requested to be registered. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein.

1.4         Obligations of the Company . Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

(a)        Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a

 

4


period that is the shorter of one hundred twenty (120) days or until the distribution contemplated in the Registration Statement has been completed; provided , however , that (i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company; and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, such 120-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment that (x) includes any prospectus required by Section 10(a)(3) of the Act or (y) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (x) and (y) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the 1934 Act in the registration statement.

(b)        Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement.

(c)        Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them.

(d)        Use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, except as may be required by the Act.

(e)        In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement.

(f)        Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing. The Company will use its commercially reasonable efforts to amend or supplement such prospectus to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light

 

5


of the circumstances then existing.

(g)        Cause all such Registrable Securities registered hereunder to be listed on a national exchange or trading system and each securities exchange on which similar securities issued by the Company are then listed.

(h)        Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereto and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration.

(i)        Furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities.

(j)        Furnish on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters.

1.5         Furnish Information . It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities.

1.6         Expenses of Demand Registration . All expenses (other than underwriting discounts and commissions) incurred in connection with registrations, filings or qualifications pursuant to Section 1.2, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, and fees and expenses of counsel to the Company and one (1) counsel to the Holders (such expenses of counsel to the Holders shall not exceed $25,000) shall be borne by the Company; provided , however , that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2 (in which event such right shall be forfeited by all Holders); provided , further , however , that if at the time of such withdrawal, the Holders have

 

6


learned of material adverse information or a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request based upon such information with reasonable promptness following disclosure by the Company of such material adverse information or material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2.

1.7         Expenses of Company Registration . The Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to the registrations pursuant to Section 1.3 for each Holder (which right may be assigned as provided in Section 1.13), including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, and fees and expenses of counsel to the Company and one (1) counsel to the Holders (such expenses of counsel to the Holders shall not exceed $25,000), but excluding underwriting discounts and commissions relating to Registrable Securities.

1.8         Underwriting Requirements . If a registration statement for which the Company gives notice pursuant to Section 1.3 is for an underwritten offering, then the Company shall so advise the Holders of Registrable Securities. In such event, the right of any Holder’s Registrable Securities to be included in a registration pursuant to Section 1.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Agreement, if the managing underwriter(s) determine(s) in good faith that marketing factors require a limitation of the number of shares to be underwritten, then the managing underwriter(s) may exclude shares (including Registrable Securities) from the registration and the underwriting, and the number of shares that may be included in the registration and the underwriting shall be allocated first , to the Company, second , to each of the Holders (other than any Holder who is also a Common Holder) requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis based upon the total number of Registrable Securities then held by each such Holder, third , to each Holder who is also a Common Holder requesting inclusion of his Registrable Securities in such registration statement on a pro rata basis based upon the total number of Registrable Securities then held by each Holder who is also a Common Holder, and fourth , to any other securityholder; provided , however , that the right of the underwriters to exclude shares (including Registrable Securities) from the registration and underwriting as described above in this Section 1.8 shall be restricted so that: (i) the number of Registrable Securities then held by the Investors included in any such registration is not reduced below twenty-five percent (25%) of all the shares included in the registration, except for a registration relating to the Company’s initial public offering of its Common Stock, from which all Registrable Securities may be excluded and (ii) all shares held by securityholders that are not Registrable Securities shall first be excluded from such registration and underwriting before any Registrable Securities are so excluded, unless holders of two-thirds (2/3) of the Registrable Securities then outstanding approve the inclusion of such shares held by securityholders that are not Registrable Securities. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least twenty (20) business days prior to

 

7


the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder that is a venture capital fund, partnership or corporation, the affiliated venture capital funds, partners, retired partners and shareholders of such Holder, or the estates and family members of any such partners, shareholders and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence.

1.9           Delay of Registration . No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1.

1.10         Indemnification . In the event any Registrable Securities are included in a registration statement under this Section 1:

(a)        To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Act) for such Holder, the partners, members, officers and directors of such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a “ Violation ”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities law or any rule or regulation promulgated under the Act, the 1934 Act or any state securities law; and the Company will pay to each such Holder, the partners, members, officers and directors of such Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided , however , that the indemnity agreement contained in this subsection 1.10(a) shall not apply (i) to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, the partners, members, officers and directors of such Holder, underwriter or controlling person, (ii) if such untrue statement (or alleged untrue statement) or omission (or alleged omission) was contained in a preliminary prospectus and corrected in a final or amended prospectus or supplement thereto, copies of which were delivered to such Holder on a timely basis, and such Holder failed to deliver a copy of the final or amended prospectus at or prior to the confirmation for the sale of the Registrable

 

8


Securities to the persons asserting any such loss, claim, damage, or liability in any case where such delivery is required by the Securities Act, or (iii) to the extent that the loss, claim, damage or liability as to which indemnification is sought is in connection with an offer or sale made by such Holder in breach of the terms of this Agreement.

(b)        To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling securities in such registration statement and any partners, members, officers and directors of such Holder and any controlling person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability or action; provided , however , that the indemnity agreement contained in this subsection 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided that in no event shall any indemnity under this subsection 1.10(b) exceed the net proceeds from the offering received by such Holder.

(c)        Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided , however , that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to the indemnifying party’s ability to defend such action, shall relieve such indemnifying party of liability to the indemnified party under this Section 1.10 to the extent of such prejudice, but the omission to deliver written notice to the indemnifying party will not relieve the indemnifying party of any liability that it may have to any indemnified party otherwise than under this Section 1.10.

(d)        If the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss,

 

9


liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided , however , that in no event shall any contribution by a Holder hereunder, when taken together with any indemnification by such Holder pursuant to Section 1.10(b), exceed the net proceeds from the offering received by such Holder.

(e)        Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided , however , that to the extent the underwriting agreement does not address a matter addressed by this Agreement, the failure to address such matter shall not be deemed a conflict between the provisions of this Agreement and the underwriting agreement.

(f)        The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise.

1.11         Reports Under the 1934 Act . With a view to making available to the Holders the benefits of Rule 144 promulgated under the Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to use all commercially reasonable efforts to:

(a)        make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public;

(b)        take such action, including the voluntary registration of its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities;

(c)        file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and

(d)        furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the

 

10


effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents filed under the 1934 Act by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form.

1.12         Form S-3 Registration . If the Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form S-3 or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will:

(a)        promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and

(b)        use its commercially reasonable efforts to effect, as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided , however , that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.12: (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than two million dollars ($2,000,000); (iii) if the Company shall furnish to the Holders a certificate signed by the President or Chief Executive Officer of the Company stating that, in the good-faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its shareholders for such Form S-3 registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period not to exceed ninety (90) days after receipt of the request of the Holder or Holders under this Section 1.12 provided that such right may not be exercised more than once in any twelve (12) month period; (iv) if the Company has, within the twelve (12) month period preceding the date of such request, already effected one (1) registration on Form S-3 for the Holders pursuant to this Section 1.12; or (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.

Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. All expenses incurred in connection with registrations requested pursuant to this Section 1.12, including (without limitation) all registration, filing, qualification, printers’ and accounting fees and the fees and expenses of counsel to the Company and fees and expenses of counsel to the Holders, but excluding any

 

11


underwriters’ discounts or commissions, associated with Registrable Securities, shall be borne pro rata by the participating Holders. Registrations effected pursuant to this Section 1.12 shall not be counted as demands for registration or registrations effected pursuant to Section 1.2 or Section 1.3.

The Company shall not be obligated to effect any registration pursuant to this Section 1.12 if the Company delivers to the Holders requesting registration under this Section 1.12 an opinion, in form and substance reasonably acceptable to such Holders, of counsel reasonably satisfactory to such Holders, that all Registrable Securities so requested to be registered may be sold or transferred pursuant to Rule 144 under the Act.

1.13         Assignment of Registration Rights . The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities provided: (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section 1.14 below; (c) the transfer involves a transfer of at least one percent (1%) of then outstanding shares of Registrable Securities (as adjusted for dividends, splits, recapitalizations and the like); provided , however , that transfers or assignments to partners, limited partners, retired partners, members, former members, shareholders, parents, children, spouses, trusts or affiliates of a Holder shall be without restriction as to the minimum number of shares to be transferred; and (d) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act.

1.14         “Market Stand-Off” Agreement . Each Holder hereby agrees that, during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company, following the effective date of a registration statement of the Company filed under the Act pertaining to the IPO, it shall not, to the extent requested by the Company or such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any option to purchase or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included in such registration; provided , however , that:

(a)        such agreement shall be applicable only to the first such registration statement of the Company pertaining to the IPO;

(b)        all executive officers, directors and holders of one percent (1%) or more of the outstanding common stock (on an as converted to common stock basis) of the Company enter into similar agreements or arrangements;

(c)        such agreement shall provide that any discretionary releases (other than discretionary financial hardship waivers not exceeding $25,000 for any holder) from the lock-up be allocated to holders of Registrable Securities on a pro rata basis; and

 

12


(d)        such market stand-off time period shall not exceed one hundred eighty (180) days; provided , however , that, if during the last 17 days of the restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or prior to the expiration of the restricted period the Company announces that it will release earnings results during the 16-day period beginning on the last day of the restricted period, and if the Company’s securities are listed on the Nasdaq Stock Market and Rule 2711 of thereof applies, then the restrictions imposed by this Section 1.14 shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Investor (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period.

Notwithstanding the foregoing, the obligations described in this Section 1.14 shall not apply to a registration relating solely to employee benefit plans on Form S-4 or Form S-8 or similar forms that may be promulgated in the future, or to a registration relating solely to an SEC Rule 145 transaction.

1.15         Termination of Registration Rights . No Holder shall be entitled to exercise any right provided for in this Section 1 after five (5) years following the consummation of the IPO.

2.             Covenants of the Company .

2.1           Delivery of Financial Statements . The Company shall deliver to each Investor, for so long as such Investor holds (together with its affiliates) at least 5% of the Registrable Securities or 39,589 shares of Series B-1 Preferred (each as adjusted for dividends, splits, recapitalizations and the like) (each, a “ Significant Investor ”):

(a)        as soon as practicable, but in any event within forty-five (45) days after the end of each fiscal year of the Company, the Company’s annual operating plan, an income statement for such fiscal year, a balance sheet of the Company as of the end of such year, a statement of shareholder’s equity as of the end of such year and a statement of cash flows for such fiscal year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with generally accepted accounting principles), and such financial statements will be accompanied by a report and opinion thereon by independent public accountants selected by the Company’s Board of Directors within one hundred twenty (120) days after the end of each fiscal year;

(b)        as soon as practicable but in no event more than forty-five (45) days after the end of each of the first three quarters of each fiscal year of the Company, an unaudited income statement, balance sheet and statement of cash flows for and as of the end of each such quarter, such unaudited financial statements to be in reasonable detail; and

(c)        as soon as practicable after the end of each month, and in any event

 

13


within thirty (30) days after the end of each month, an unaudited consolidated balance sheet of the Company as of the end of such monthly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with generally accepted accounting principles.

2.2         Inspection Rights . The Company will maintain true books and records of account in which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied (except as noted therein, and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently applied. The Company shall permit each Significant Investor, at such Significant Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all upon reasonable notice and at such reasonable times as may be requested by such Significant Investor; provided , however , that the Company shall not be obligated under this Section 2.2 to provide information that it deems in good faith to be a trade secret or similar confidential or proprietary information if it believes in good faith that such disclosure would be detrimental to the Company. The rights set forth in this Section 2.2 shall be exercised solely in furtherance of the proper interests of such Significant Shareholder as an investor in the Company, and any Significant Shareholder exercising its rights of inspection hereunder agrees to maintain the confidentiality of all financial and other confidential information of the Company disclosed to it. At the request of the Company, each Significant Shareholder shall, as a condition of the exercise of its rights of inspection thereunder, execute a confidentiality agreement with the Company in form and substance satisfactory to the Company.

2.3         Option/Common Stock Vesting .

(a)        Unless otherwise unanimously approved by the Board of Directors or as otherwise contemplated herein, the Company hereby covenants that all stock, stock equivalents and options issued after the date hereof to employees, directors, consultants and other service providers of the Company shall vest in accordance with the following vesting schedule: twenty (20%) of the shares to vest at the expiration of one (1) year from (i) the date of the grant if the grantee is then in the service of the Company or (ii) the date service commences if the grantee is not then in service of the Company, and the remaining eighty percent (80%) of the shares to vest in a series of forty-eight (48) successive and equal monthly installments thereafter upon the completion by the employee, director, consultant or service provider of each month of service to the Company. Unless otherwise unanimously approved by the Board of Directors, the Company’s repurchase option shall provide that upon termination of the service of the employee, director, consultant or other service provider, with or without cause, the Company or its assignee (to the extent permissible under applicable securities laws) retains the option to repurchase at cost any unvested shares held by such shareholder.

(b)        The shares of Common Stock held by Jay D. Keasling shall accelerate in full in the event there is a Change of Control of the Company (as defined in the applicable stock restriction agreement) followed by a termination of such person’s services to the Company without cause.

 

14


2.4         Right of First Offer . Subject to applicable securities laws and the terms and conditions specified in this Section 2.4, the Company hereby grants to each Significant Investor and to each Investor for so long as such Investor holds (together with its affiliates) at least 401,284 shares of Series C Preferred Stock and/or Series C-1 Preferred Stock (as adjusted for dividends, splits, recapitalizations and the like) (together with the Significant Investors, the “ First Offer Rights Holders ”) a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). A First Offer Rights Holder shall be entitled to apportion the right of first offer hereby granted it among itself and its partners and affiliates in such proportions as it deems appropriate. Each time the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable for any shares of, any class or series of its capital stock (“ Shares ”), the Company shall first make an offering of such Shares to each First Offer Rights Holder in accordance with the following provisions:

(a)        The Company shall deliver a notice by certified mail (“ Notice ”) to the First Offer Rights Holders stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares.

(b)        Within ten (10) business days after giving of the Notice, each First Offer Rights Holder may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of common stock issued and held, or issuable upon conversion of the Registrable Securities then held, by such First Offer Rights Holder bears to the total number of shares of common stock of the Company then outstanding (assuming full conversion and exercise of all then outstanding convertible and exercisable securities of the Company). The Company shall promptly, in writing, inform each First Offer Rights Holder that elects to purchase all the shares available to it (“ Fully Exercising Investor ”) of any other First Offer Rights Holder’s failure to do likewise. During the five (5) business day period commencing after such information is given, each Fully Exercising Investor shall be entitled to elect to purchase up to that portion of the Shares not subscribed for by the First Offer Rights Holders that is equal to the proportion that the number of shares of common stock issued and held, or issuable upon conversion of Registrable Securities then held, by such Fully Exercising Investor bears to the total number of shares of common stock issued and held, or issuable upon conversion of the Registrable Securities then held, by all Fully Exercising Investors who wish to purchase some of the unsubscribed shares.

(c)        If all Shares that First Offer Rights Holders are entitled to obtain pursuant to subsection 2.4(b) are not elected to be purchased as provided in subsection 2.4(b) hereof, the Company may, during the ninety (90) day period following the expiration of the period provided in subsection 2.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Notice. If the Company does not consummate the sale of the Shares within such period, or if such agreement is not consummated within forty-five (45) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the First Offer Rights Holders in accordance herewith.

(d)        The right of first offer in this Section 2.4 shall not be applicable to

 

15


issuances of securities of the Company that are not “Additional Stock” (as defined in Article III, Section B(4)(d)(i) of the Company’s Amended and Restated Articles of Incorporation, as such Amended and Restated Articles of Incorporation may be amended from time to time).

(e)        The right of first offer set forth in this Section 2.4 may not be assigned or transferred, except that (i) such right is assignable by each First Offer Rights Holder to any wholly owned subsidiary or parent of, or to any corporation or entity that is, within the meaning of the Act, controlling, controlled by or under common control with, any such First Offer Rights Holder and (ii) such right is assignable between and among any of the First Offer Rights Holders or between and among any such First Offer Rights Holder and any affiliated partnerships, venture capital funds or other entities of such First Offer Rights Holder.

2.5         Proprietary Information Agreements . The Company shall require each employee hired by the Company to execute a proprietary information and inventions agreement and each consultant or contractor engaged by the Company to execute a consulting agreement, each in a form as recommended by the Company’s legal counsel.

2.6         Assignment of Information and Inspection Rights . The information rights set forth in Section 2.1 and inspection rights in Section 2.2 may be assigned (but only with all related obligations) by a Significant Investor to a transferee or assignee of such securities that (a) is a subsidiary, parent, general partner, limited partner, retired partner, member or retired member or stockholder of a Significant Investor that is a corporation, partnership or limited liability company or an entity affiliated by common control (or other related entity) with such Significant Investor or (b) is a Significant Investor’s family member or trust for the benefit of an individual Holder or (c) qualifies as a Significant Investor after such assignment or transfer.

2.7         Right of First Refusal . Any shares of Common Stock of the Company issued after the date hereof (other than shares of Common Stock issued upon conversion of Preferred Stock) shall be subject to a right of first refusal in favor of the Company upon transfer.

2.8         Assignment of Right of First Refusal . In the event the Company elects not to exercise any right of first refusal or right of first offer the Company may have on a proposed transfer of any of the Company’s outstanding capital stock pursuant to the Company’s charter documents, by contract or otherwise, the Company shall, to the extent it may do so, assign such right of first refusal or right of first offer to each Significant Investor. In the event of such assignment, each Significant Investor shall have a right to purchase its pro rata portion of the capital stock proposed to be transferred. Each Significant Investor’s pro rata portion shall be equal to the product obtained by multiplying (i) the aggregate number of shares proposed to be transferred by (ii) a fraction, the numerator of which is the number of shares of Registrable Securities held by such Significant Investor at the time of the proposed transfer and the denominator of which is the total number of Registrable Securities owned by all Significant Investors at the time of such proposed transfer.

2.9         Insurance . The Company shall continue to bind and maintain director & officer insurance with a carrier or carriers and on such terms and in such amount as is satisfactory to the Board, unless the Board determines that procuring such insurance would not be in the best interest of the Company and its stockholders.

 

16


2.10         Key Man Insurance . As soon as practicable after the Initial Closing, the Company will bind and maintain a key-man life insurance policy on the life of John G. Melo with a carrier or carriers and on such terms and in such amount as is satisfactory to the Board, unless the Board determines that procuring such insurance would not be in the best interest of the Company and its stockholders.

2.11         Director Indemnification . The Company will use its best efforts to maintain indemnification agreements with directors that will indemnify board members to the broadest extent permitted by applicable law. In the event the Company merges with another entity and is not the surviving corporation, or transfers all of its assets, proper provisions shall be made so that successors of the Company assume the Company’s obligations with respect to the indemnification of directors.

2.12         Amended and Restated Right of First Refusal and Co-Sale Agreement . The Company shall use commercially reasonable efforts to cause all officers and holders of at least 5% of the Company’s Common Stock to become a party to the Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of the date hereof.

2.13         Amended and Restated Voting Agreement . The Company shall use commercially reasonable efforts to cause all officers and holders of at least 1% of the Company’s Common Stock to become a party to the Amended and Restated Voting Agreement, dated as of the date hereof.

2.14         Reservation of Common Stock . The Company will at all times reserve and keep available, solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion.

2.15         Termination of Covenants . The covenants set forth in Section 2 hereof shall terminate as to Investors and be of no further force or effect upon (i) the consummation of a firm commitment underwritten public offering of the Company’s securities pursuant to which all outstanding shares of Preferred Stock automatically convert into Common Stock, (ii) a Liquidation Event (as defined in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time) or (iii) with respect to Sections 2.1 and 2.2, when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or Section 15(d) of the 1934 Act, whichever event shall first occur.

3.           Miscellaneous .

3.1         Successors and Assigns . Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

3.2         Governing Law . This Agreement shall be governed by and construed under the laws of the State of California without regard for conflicts of laws principles.

 

17


3.3         Counterparts . This Agreement may be executed in two or more counterparts, including counterparts transmitted by facsimile, other electronic transmission or otherwise, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

3.4         Titles and Subtitles . The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

3.5         Notices . All notices required or permitted under this Agreement shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

3.6         Attorneys’ Fees . If any dispute among the parties to this Agreement results in litigation, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including, without limitation, such reasonable fees and expenses of attorneys and accountants, that shall include, without limitation, all fees, costs and expenses of appeals.

3.7         Amendments and Waivers . Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding, provided that such amendment does not disproportionately impact any Holders; provided , however , that any Registrable Securities that are held by the Common Holders shall only be taken into account for the purposes of the foregoing sentence in the event that an amendment or waiver of any term of this Agreement would materially and adversely affect the rights of the Common Holders hereunder; provided further , that any amendment of a provision relating to the termination of any rights of the Investors shall require a majority of the then-effected Investors. Notwithstanding the above, Sections 2.1, 2.2 and 2.4 may be amended and the observance of any terms in such sections may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority in interest of the First Offer Rights Holders based on the number of shares of Registrable Securities then held by the First Offer Rights Holders; provided , further , that for any amendment or waiver of any provision herein that would have a material, adverse and disproportionate effect on a series of Preferred Stock relative to any other series of Preferred Stock, consent of the holders of at least the majority of such series of Preferred Stock voting as a separate class shall be required. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities then outstanding, each future holder of all such Registrable Securities and the Company.

 

18


3.8         Severability . If any of the provisions of this Agreement should, for any reason, be held by a court or other tribunal of competent jurisdiction to be illegal, invalid or unenforceable in any respect, such provisions shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect.

3.9         Aggregation of Stock . All shares of Registrable Securities held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

3.10         Entire Agreement . This Agreement and the Exhibits hereto, along with the Series B Agreement and the other documents delivered pursuant thereto, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants or agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.

3.11         Delays or Omissions . It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative.

3.12         Additional Investors . Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of its Preferred Stock, any purchaser of such shares of Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed, as applicable, an “ Investor ” or a “ Holder , ” and a party hereunder.

3.13         Previous Agreement . The Previous Agreement is hereby amended and superseded in its entirety and restated herein. Such amendment and restatement is effective upon execution and delivery of this Agreement by the Company and by the requisite holders as set forth in Section 3.7 of the Previous Agreement. Upon such execution, all provisions of, rights granted and covenants made in the Previous Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect.

[Signature Pages Follow]

 

19


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

COMPANY:
AMYRIS BIOTECHNOLOGIES, INC.
By:   /s/ John G. Melo
  John G. Melo
  Chief Executive Officer
Address:  

5885 Hollis Street, Ste. 100

Emeryville, CA 94608

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

COMMON HOLDERS:  
/s/ Jack D. Newman    
Jack D. Newman  
Address:      
   
/s/ K. Kinkead Reiling    
K. Kinkead Reiling  
Address:      
   
       
Jay D. Keasling  
Address:      
   
/s/ Neil Renninger    
Neil Renninger  
Address:      
   

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

COMMON HOLDER:  
/s/ John G. Melo    
John G. Melo  
Address:      
   

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTORS:
DAG Ventures III-QP, L.P.
By:   DAG Ventures Management III, LLC, its General Partner
By:   /s/ Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:  

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

 

DAG Ventures III, L.P.
By:   DAG Ventures Management III, LLC, its General Partner
By:   /s/ Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:  

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

 

DAG Ventures GP Fund III, LLC
By:   DAG Ventures Management III, LLC, its Managing Member
By:   /s/ Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:  

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

 

DAG Ventures I-N, LLC
By:   DAG Ventures Management, LLC, its Managing Member
By:   /s/ Thomas Goodrich
  R. Thomas Goodrich, Managing Director
Address:  

251 Lytton Ave., Suite 200

Palo Alto, CA 94301

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTORS:
KHOSLA VENTURES III, L.P.
By:   /s/ Samir Kaul

Name: Samir Kaul

Title: Partner

Address:   3000 Sand Hill Road, Bldg. 3, Ste. 170 Menlo Park, CA 94025
TPG BIOTECHNOLOGY PARTNERS II, L.P.
By:   TPG Biotechnology Genpar II, L.P.
By:   TPG Biotech Advisors II, LLC
By:   /s/ Jeffery D. Ekberg

Name: Jeffery D. Ekberg

Title: Vice President

Address:  

301 Commerce Street, Suite 3300

Fort Worth, Texas 76102

KPCB HOLDINGS, INC., AS NOMINEE
By:   /s/ John Doerr

Name: John Doerr

Title: Partner

Address:  

2750 Sand Hill Road

Menlo Park, CA 94025

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTOR:
NAXOS CAPITAL PARTNERS
By:    
Name:    
Title:    
Address:    

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTOR:
GROBER BUSINESS CORP
By:    
Name:    
Title:    
Address:  

Engenho São João, s/nº

Várzea, Recife - PE

Brasil

CEP – 50.741-520

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

INVESTOR:
MAXWELL (MAURITIUS) LTE LTD
By:   /s/ Fidah Alsagoff
Name:   Fidah Alsagoff
Title:   Authorized Signatory
Address:   c/o 60B Orchard Road
  #06-18 Tower 2
  The Atrium @ Orchard
  Singapore 238891
  Singapore

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the undersigned has duly executed this Amended and Restated Investors’ Rights Agreement as of the date set forth below.

 

Date:______________     INVESTOR:
     
    [Please print exact name of Investor as it should appear on stock certificate.]
    By:    
    Name:    
    Title:    
    [Please include title if Investor is an entity.]
    Address:    
       
     

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SIGNATURE PAGE


EXHIBIT A

SCHEDULE OF SERIES A INVESTORS

 

S ERIES A I NVESTOR

  N UMBER   OF
S HARES   OF  S ERIES
A S TOCK

Khosla Ventures II, L.P.

  3,449,861

KPCB Holdings, Inc., as nominee

  3,449,861

TPG Biotechnology Partners II, L.P.

  2,299,907

Total

  9,199,629


EXHIBIT B

SCHEDULE OF SERIES B INVESTORS

 

S ERIES B I NVESTOR

  N UMBER   OF
   S HARES   OF  S ERIES  
B S TOCK

DAG Ventures III, L.P.

  44,883            

DAG Ventures III-QP, L.P.

  477,134            

DAG Ventures GP Fund III, LLC

  491            

DAG Ventures I-N, LLC

  281,351            

Khosla Ventures II, L.P.

  150,723            

KPCB Holdings, Inc., as nominee

  150,723            

TPG Biotechnology Partners II, L.P.

  401,929            

ES East Associates, LLC

  9,859            

BB Trust Dated 2/21/03 (Richard Rock, Trustee)

  70,338            

Crystalsesv Comércio E Representação Ltda.

  40,193            

Santelisa Vale Bioenergia S.A.

  40,193            

Total

  1,667,817            


EXHIBIT C

SCHEDULE OF SERIES B-1 INVESTORS

 

S ERIES B-1 I NVESTOR

  N UMBER   OF
   S HARES   OF  S ERIES  
B-1 S TOCK

AEI 2008 CleanTech Investments I, LLC

  134,639        

AEI 2008 CleanTech Investments II, LLC

  180,127        

Advanced Equities Amyris Investments I, LLC

  226,465        

Advanced Equities Amyris Investments II, LLC

  661,403        

Advanced Equities Amyris Investments III, LLC

  32,258        

Advanced Equities Amyris Investments IV, LLC

  66,240        

Ameri Private Equity IV, LLC

  80,563        

Aspire Business LTD

  98,970        

Christopher Lenzo

  118,765        

Counter Point Venture Fund II, LP

  19,800        

Erasmus Louisiana Growth Fund II, LP

  39,589        

Exccess Venture Fund I, LLC

  79,178        

Gaenger Family Living Trust of 1995

  395        

GB Sears Family Trust

  3,365        

HS Partners Holdings III, LP

  158,353        

Innovative Financial Private Equity Fund II, LLC

  45,527        

Invest Biotech, LLC

  51,275        

James A. Goddard

  989        

Lit Tele, LLC

  395,883        

Millenium Trust Company

  39,589        

Northport Investments, LLC

  53,852        

TCM2, LLC

  39,589        

Technology Ventures, LLC

  39,588        

The Barlow Family Trust

  989        

Third Amended and Restated Robbins Trust of 1986

  4,159        

Toronto Angel Group Amyris Holdings LP

  43,991        

Total

  2,615,721        


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS

 

S ERIES C I NVESTOR

  N UMBER   OF
  S HARES   OF   S ERIES  
C S TOCK

Khosla Ventures III, L.P.

  321,027            

KPCB Holdings, Inc., as nominee

  321,027            

TPG Biotechnology Partners II, L.P.

  321,027            

Lit Tele, LLC

  802,568            

DAG Ventures II, L.P.

  146,582            

DAG Ventures III-QP, L.P.

  13,788            

DAG Ventures GP Fund III, LLC

  144            

DAG Ventures I-N, LLC

  60,193            

Grober Business Corp.

  802,568            

Amyris SA (an affiliate of NAXOS Capital Partners)

  561,797            

Advanced Equities Amyris Investments I, LLC

  22,685            

Advanced Equities Amyris Investments II, LLC

  65,672            

Advanced Equities Amyris Investments III, LLC

  2,184            

Advanced Equities Amyris Investments IV, LLC

  3,249            

AEI 2008 CleanTech Investments I, LLC

  5,003            

AEI 2008 CleanTech Investments II, LLC

  14,483            

Third Amended and Restated Robbins Trust of 1986 (Richard K. Robbins, Trustee)

  1,213            

James A. Goddard

  288            

Invest Biotech, LLC

  2,648            

Kevin Kaster

  1,271            

Millenium Trust Company LLP Cust FBO WNA Private Equity Fund B - Amyris LLC

  7,945            

Northern Rivers Silicon Valley Access Fund LP

  8,025            

Michael P. Waldbillig and Louise A. Waldbillig Trust, dated September 16, 2008

  1,324            

Advanced Equities Amyris Investments I, LLC

  10,139            

Advanced Equities Amyris Investments II, LLC

  30,724            


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS (cont.)

 

S ERIES C I NVESTOR

  N UMBER   OF
  S HARES   OF   S ERIES  
C S TOCK

Advanced Equities Amyris Investments III, LLC

  312            

Advanced Equities Amyris Investments IV, LLC

  3,593            

AEI 2008 CleanTech Investments I, LLC

  2,644            

AEI 2008 CleanTech Investments II, LLC

  3,818            

Northport Investments LLC

  3,815            

Innovative Financial Private Equity

  19,662            

Orgone Capital IV, LLC

  61,810            

HS Partners Holdings III, LP

  80,256            

Phyllis Gardner

  264            

Jeffrey and Andrea Tobias

  1,002            

BCP Investment, L.P.

  128,410            

Richard C. Blum Rollover IRA

  240,770            

Magoo 1, LLC

  6,621            

Advanced Equities Amyris Investments I, LLC

  394            

Advanced Equities Amyris Investments II, LLC

  1,249            

Advanced Equities Amyris Investments III, LLC

  96            

Advanced Equities Amyris Investments IV, LLC

  104            

AEI 2008 CleanTech Investments I, LLC

  491            

AEI 2008 CleanTech Investments II, LLC

  812            

Orgone Capital IV, LLC

  12,199            

Excess Venture Fund I, LLC

  8,026            

Westly Group

  381,219            

Northport Investments

  21,207            

Orgone Capital

  81,274            

Innovative Financial Private Equity

  12,039            

Advanced Equities Amyris Investments I, LLC

  1,989            


EXHIBIT D

SCHEDULE OF SERIES C INVESTORS (cont.)

 

S ERIES C I NVESTOR

  N UMBER   OF
  S HARES   OF   S ERIES  
C S TOCK

Advanced Equities Amyris Investments II, LLC

  5,034        

Khosla Ventures III, L.P.

  98,661        

KPCB Holdings, Inc., as nominee

  98,660        

TPG Biotechnology Partners II, L.P.

  98,660        

Total

  4,902,665        


EXHIBIT E

SCHEDULE OF SERIES C-1 INVESTORS

 

S ERIES C-1 I NVESTOR

  N UMBER   OF
S HARES   OF  S ERIES
C-1 S TOCK

Maxwell (Mauritius) Pte Ltd

  2,724,766        

Total

  2,724,766        


EXHIBIT F

SCHEDULE OF COMMON HOLDERS

 

N AME OF K EY E MPLOYEE

  N UMBER   OF
S HARES   OF
  C OMMON   S TOCK  

Jack D. Newman

  900,000        

K. Kinkead Reiling

  863,000        

Jay D. Keasling

  1,000,000        

Neil Renninger

  900,000        

John G. Melo 1

  1,204,979        

Total

  4,867,979        

 

1 Mr. Melo has options outstanding to purchase 1,204,979 shares of common stock.

Exhibit 4.05

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION THEREUNDER OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

WARRANT TO PURCHASE SERIES B-1 PREFERRED STOCK

OF

AMYRIS BIOTECHNOLOGIES, INC.

 

Number of Shares:    [          ] shares
Class of Stock:    Series B-1 Preferred Stock
Initial Exercise Price:    $25.26 per share
Issue Date:    [March 31,             ]/[June 30,             ]/[September 30,             ]/[December 31,             ]
Expiration Date:    [March 31,             ]/[June 30,             ]/[September 30,             ]/[December 31,             ]

This W ARRANT (this “ Warrant ”) certifies that, for good and valuable consideration, Advanced Equities Financial Corp. or its permitted registered assigns (“ Holder ”) is entitled to purchase from Amyris Biotechnologies, Inc., a California corporation (the “ Company ”), at any time until 5:00 p.m. (Pacific Time) on the Expiration Date set forth above, the number of fully paid and nonassessable shares of the class of stock (the “ Shares ”) of the Company at the Initial Exercise Price per Share (the “ Warrant Price ”), all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.

 

  1.

EXERCISE .

1.1         Method of Exercise . Holder may exercise this Warrant by delivering a duly executed Notice of Exercise in substantially the form attached as Exhibit A to the principal


office of the Company. This Warrant may be exercised in whole or in part and Holder shall also deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased.

1.2         Net Exercise Election . Holder may elect to convert this Warrant, without the payment by Holder of any additional consideration, by the surrender of this Warrant to the Company, with the net exercise election selected in the Notice of Exercise attached hereto as Exhibit A duly executed by Holder, into the number of Shares that is obtained under the following formula:

 

X =  

Y  (A-B)

 

  A

 

Where:

    

X =

   the number of Shares to be issued to Holder pursuant to this Section 1.2.
    

Y =

   the number of Shares then subject to this Warrant.
    

A =

   the fair market value of one Share, as determined in good faith by the Company’s Board of Directors, as at the time the net exercise election is made pursuant to this Section 1.2.
    

B =

   the Warrant Price.

For purposes of the above calculation, fair market value of one Share shall be determined by the Company’s Board of Directors in good faith; provided, however, that where there exists a public market for the Company’s Common Stock at the time of such exercise, the fair market value per share shall be the product of (i) the average of the closing bid and asked prices of the Common Stock quoted in the Over-The-Counter Market Summary or the last reported sale price of the Common Stock or the closing price quoted on any exchange on which the Common Stock is listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal for the five (5) trading days prior to the date of determination of fair market value and (ii) the number of shares of Common Stock into which each Share is convertible, if applicable, at the time of such exercise. Notwithstanding the foregoing, in the event this Warrant is exercised in connection with the Company’s initial public offering of Common Stock, the fair market value per share shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and (ii) the number of shares of Common Stock into which each Share is convertible, if applicable, at the time of such exercise. The Company will promptly respond in writing to an inquiry by Holder as to the then current fair market value of one Share.

1.3         Delivery of Certificate and New Warrant . Promptly after Holder exercises this Warrant, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, this Warrant shall automatically be reduced by the number of Shares issued and remain exercisable for such remaining Shares not so acquired, and all other terms of the Warrant shall otherwise remain in full force and effect as so adjusted. Upon final exercise of this Warrant for any such remaining number of Shares, this Warrant shall be surrendered by Holder to the Company for cancellation.

1.4         Replacement of Warrants . On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in

 

2


the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, or surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

1.5         Acquisition, Asset Sale, Liquidation of the Company . In the event the Company proposes to effect (i) an Acquisition (as such term is defined in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time (the “ Articles of Incorporation ”)); (ii) an Asset Sale (as defined in the Articles of Incorporation); or (iii) a Liquidation (as defined in the Articles of Incorporation), the Company shall give Holder at least ten (10) days advance written notice of such event (the “ Company Notice ”), which notice shall include the Company’s best estimate of the value of the Shares receivable upon exercise or conversion of this Warrant and the proposed date upon which such event is expected to occur. During such notice period, Holder may exercise this Warrant in accordance with its terms, whether or not exercise is contingent upon the happening of such event and/or existence of a minimum value of the Shares receivable upon exercise as provided on Holder’s exercise notice. Subject to prior exercise as provided in the preceding sentence, this Warrant will terminate immediately prior to the happening or consummation of the event described in the Company Notice.

 

  2.

ADJUSTMENTS TO THE SHARES .

2.1         Stock Dividends, Splits, Etc . If the Company declares or pays a dividend on the outstanding shares of the Company’s Common Stock payable in shares of the Company’s Common Stock or other securities of the Company or subdivides or combines the outstanding shares of the Company’s Common Stock, then upon exercise or conversion of this Warrant, unless, in case this Warrant is exercisable into shares of the Company’s Preferred Stock and the conversion ratio of such Preferred Stock already reflects such event for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend, subdivision or combination occurred.

2.2         Reclassification, Exchange or Substitution . Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant (other than a merger, consolidation or recapitalization described in Section 1.5 above or a stock dividend, split, etc. described in Section 2.1 above), Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution or other event. By way of example, such an event shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class or series as the Shares to Common Stock pursuant to the terms of the Company’s Articles of Incorporation upon the closing of a registered public offering of the Company’s Common Stock. The Company or its successor shall promptly issue to Holder a new Warrant for such new securities or other property. The new Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 2

 

3


including, without limitation, appropriate adjustments to the Warrant Price and to the number of securities or property issuable upon exercise or conversion of the new Warrant.

2.3         Adjustments of Warrant Price . If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are divided by reclassification or otherwise, into a greater number of shares, the Warrant Price shall be proportionately decreased.

2.4         Conversion of Warrant Stock . If all the outstanding shares of that particular series of preferred stock defined herein as the “Shares” and specifically identified in the preamble of this Warrant (the “ Series ”) of the Company are converted into Common Stock pursuant to the Company’s Articles of Incorporation (subject to the provisions of Section 1.5) or otherwise, or such Series otherwise ceases to exist, then, from and after the date on which such Series is so converted or ceases to exist (the “ Conversion Date ”): (i) this Warrant will be exercisable for Common Stock of the Company and the term “Shares” (wherever used in this Warrant) will thereafter mean the Company’s Common Stock; and (ii) the Warrant Price will be the price obtained by dividing (a) the Purchase Price in effect immediately prior to the Conversion Date by (b) the number of shares of Common Stock (including fractional shares) into which each share of such Series was convertible immediately prior to the Conversion Date (subject to subsequent adjustment as provided herein).

2.5         Adjustment is Cumulative . The provisions of this Section 2 shall similarly apply to successive stock dividends, stock splits or combinations, reclassifications, exchanges, substitutions, or other events.

2.6         Fractional Shares . No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of this Warrant, the Company shall eliminate such fractional Share interest by paying Holder an amount by check computed by multiplying the fractional interest by the fair market value of a full Share.

2.7         Certificate as to Adjustments . Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price.

 

4


3.        REPRESENTATIONS AND COVENANTS OF THE COMPANY . The Company hereby represents and warrants to Holder that all Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

 

  4.

REPRESENTATIONS AND AGREEMENTS OF HOLDER .

4.1         Representations . Holder hereby represents and warrants to the Company as follows. Holder is a sophisticated investor having such knowledge and experience in business and investment matters that Holder is capable of protecting Holder’s own interests in connection with the acquisition, exercise or disposition of this Warrant. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act. Holder is aware that this Warrant and the Shares are being, or will be, issued to Holder in reliance upon Holder’s representation in this Section 4 and that such securities are restricted securities that cannot be publicly sold except in certain prescribed situations. Holder is aware of the provisions of Rule 144 promulgated under the Act and of the conditions under which sales may be made thereunder. Holder has received such information about the Company as Holder deems reasonable, has had the opportunity to ask questions and receive answers from the Company with respect to its business, assets, prospects and financial condition and has verified any answers Holder has received from the Company with independent third parties to the extent Holder deems necessary. Holder, by acceptance hereof, acknowledges this Warrant and the Shares to be issued upon exercise hereof or conversion thereof are being acquired solely for Holder’s own account and not as a nominee for any other party, and for investment, and that Holder will not offer, sell or otherwise dispose of this Warrant or any Shares to be issued upon exercise hereof or conversion thereof except under circumstances that will not result in a violation of the Act or any state securities laws.

4.2         Legends . This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form:

 

   THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR LAW OR PURSUANT TO RULE 144 AND ANY STATE EXEMPTION FROM REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.   

4.3         Compliance with Securities Laws on Transfer . This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part

 

5


without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions satisfactory to the Company, as reasonably requested by the Company).

4.4         Transfer Procedure . Subject to the provisions of Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company a written notice of the portion of the Warrant being transferred, such notice setting forth the name, address and taxpayer identification number of the transferee, and surrendering this Warrant to the Company for reissuance to the transferee(s) (and to the new Warrant Holder for any remaining Shares, if applicable); provided that this Warrant may only be transferred to an “affiliate” (within the meaning of Rule 405 of Regulation C promulgated under the Act) of Holder.

If a transfer of all or part of this Warrant is permitted by the preceding paragraph, then this Warrant and all rights hereunder may be transferred, in whole or in part, on the books of the Company maintained for such purpose at the principal office of the Company referred to above, by Holder hereof in person, or by duly authorized attorney, upon surrender of this Warrant properly endorsed and upon payment of any necessary transfer tax or other governmental charge imposed upon such transfer together with a notice of assignment in the form attached as Exhibit B hereto. Upon any permitted partial transfer, the Company will issue and deliver to Holder a new Warrant or Warrants with respect to the Shares not so transferred. Each taker and holder of this Warrant, by taking or holding the same, consents and agrees that when this Warrant shall have been so endorsed, the person in possession of this Warrant may be treated by the Company, and all other persons dealing with this Warrant, as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented hereby and subject to the restrictions contained herein, any notice to the contrary notwithstanding; provided , however that until a transfer of this Warrant is duly registered on the books of the Company, the Company may treat Holder hereof as the owner of this Warrant for all purposes.

4.5         Market Standoff . Holder agrees, in connection with the Company’s initial public offering of the Company’s securities, upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities: (i) not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Shares (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days) from the effective date of such registration as may be requested by the underwriters and (ii) to execute any agreement reflecting clause (i) above as may be requested by the underwriters at the time of the initial public offering. The foregoing obligations shall apply only if all executive officers, directors and one-percent securityholders of the Company enter into similar agreements, it being understood that any such agreement shall not cover any equity securities of the Company Holder acquires in the Company’s initial public offering or otherwise in the public market. Any discretionary waiver or termination of the restrictions of such agreements by the Company or the managing underwriter shall apply to all persons subject to such agreements on a pro rata basis, based upon the number of shares held by each subject to such agreements. The foregoing obligations shall not apply to a registration

 

6


relating solely to employee benefit plans, or to a registration relating solely to a transaction pursuant to Rule 145 under the Securities Act.

 

  5.

GENERAL PROVISIONS .

5.1         Notices . All notices required or permitted under this Warrant shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

5.2         Attorneys Fees . In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

5.3         Governing Law . This Warrant will be governed by and construed in accordance with the laws of the State of California, without giving effect to that body of laws pertaining to conflict of laws.

5.4         Further Assurances . The parties agree to execute such further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Warrant.

5.5         Titles and Headings . The titles, captions and headings of this Warrant are included for ease of reference only and will be disregarded in interpreting or construing this Warrant. Unless otherwise specifically stated, all references herein to “sections” and “exhibits” will mean “sections” and “exhibits” to this Warrant.

5.6         Counterparts . This Warrant may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement.

5.7         Severability . If any provision of this Warrant is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Warrant and the remainder of this Warrant shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Warrant. Notwithstanding the forgoing, if the value of this Warrant based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations.

 

7


5.8         Facsimile Signatures . This Warrant may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. The original signature copy shall be delivered to the other party by express overnight delivery. The failure to deliver the original signature copy and/or the nonreceipt of the original signature copy shall have no effect upon the binding and enforceable nature of this Warrant.

5.9         Amendment and Waivers . This Warrant may be amended only by a written agreement executed by each of the parties hereto. No amendment of or waiver of, or modification of any obligation under this Warrant will be enforceable unless set forth in a writing signed by the party against which enforcement is sought. Any amendment effected in accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of this Warrant shall constitute a waiver of that provision as to that or any other instance. No waiver granted under this Warrant as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any performance other than the actual performance specifically waived.

5.10         Entire Agreement . This Warrant and the documents referred to herein constitute the entire agreement and understanding of the parties with respect to the subject matter of this Warrant, and supersede all prior understandings and agreements, whether oral or written, between or among the parties hereto with respect to the specific subject matter hereof.

[Signature Page Follows]

 

8


IN WITNESS WHEREOF, the parties hereto have executed this Warrant to Purchase Series B-1 Preferred Stock of Amyris Biotechnologies, Inc. as of the date first written above.

 

WARRANT HOLDER:      COMPANY:
A DVANCED E QUITIES F INANCIAL C ORP .      A MYRIS B IOTECHNOLOGIES , I NC .

By:

  

 

    

By:

 

/s/ John Melo

Name:

  

 

    

Name:

 

John Melo

Title:

  

 

    

Title:

 

Chief Executive Officer

Address:

  

 

    

Address:

 

5885 Hollis Street, Suite 100

 

    

Emeryville, CA 94608

 

    

 

Attention to:

  

 

    

Attention to:

 

Chief Executive Officer

Facsimile:

  

 

    

Facsimile:

 

(510) 225-8645

[Signature Page to Warrant to Purchase Series B-1 Preferred Stock of Amyris Biotechnologies, Inc.]


EXHIBIT A

NOTICE OF EXERCISE

(TO BE SIGNED ONLY UPON EXERCISE OF WARRANT)

1.          The undersigned hereby elects to purchase                      shares of the Series B-1 Preferred Stock (the “ Shares ”) of Amyris Biotechnologies, Inc., a California corporation, pursuant to the terms of the attached Warrant to Purchase Series B-1 Preferred Stock with an Issue Date of [March 31,             ]/[June 30,             ]/[September 30,             ]/[December 31,             ] (the “ Warrant ”), as follows:

(Initial applicable method:)

 

 

  

a.

     The undersigned tenders herewith payment of the total purchase price of such Shares in full, pursuant to a check or wire transfer, in the amount of $            .

 

  

b.

     This exercise or conversion              [is]              [is not] contingent upon the closing of the Acquisition, Asset Sale or other event specified in the Company Notice to Holder in accordance with Section 1.5 of the Warrant received by Holder on                      and              [is]              [is not] contingent upon a sale price or fair market value for the Company’s                      Series B-1 Preferred Stock in the Acquisition, Asset Sale or other event of no less than the lesser of (a) $             per share or (b) the per share price set forth in the Company Notice.

         

  

c.

     The undersigned hereby elects to convert the Warrant into Shares by the net exercise election pursuant to Section 1.2 of the Warrant. This conversion is exercised with respect to all of the shares of Series B-1 Preferred Stock covered by the Warrant resulting in a net total of              Shares being issued to the undersigned.

2.          Please issue a certificate or certificates representing said Shares in the name of the undersigned. The undersigned represents that it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws and hereby repeats the representations and warranties of the undersigned that are set forth in Section 4.1 of the attached Warrant.

 

Advanced Equities Financial Corp.

By:

  

 

Name:

  

 

Title:

  

 


EXHIBIT B

FORM OF ASSIGNMENT

FOR VALUE RECEIVED the undersigned Holder of this Warrant hereby sells, assigns and transfers unto the Assignee named below all of the rights of the undersigned under the within Warrant, with respect to the number of shares of the Shares set forth below:

 

Name of Assignee

   Address    No. of Shares
     
     

and does hereby irrevocably constitute and appoint                                               Attorney to make such transfer on the books of Amyris Biotechnologies, Inc., a California corporation, maintained for the purpose, with full power of substitution in the premises.

 

Dated:

 

 

     

Advanced Equities Financial Corp.

        By:  

 

       

  Name:

 

 

       

   Title:

 

 


Schedule

of

Warrants to Purchase Shares of Series B-1 Preferred Stock Issued by the Registrant to Advanced

Equities Financial Corp.

on the

Form of Warrant to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities

Financial Corp.

 

Issue Date

  

Number of Warrant Shares

  

Expiration Date

3/31/08    8,991    3/31/15
6/30/08    53,916    6/30/15
9/30/08    32,330    9/30/15
12/31/08    5,478    12/31/15
3/31/09    3,843    3/31/16

Exhibit 4.06

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION THEREUNDER OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

WARRANT TO PURCHASE SERIES C PREFERRED STOCK

OF

AMYRIS BIOTECHNOLOGIES, INC.

 

Number of Shares:

 

49,157 shares

Class of Stock:

 

Series C Preferred Stock

Initial Exercise Price:

 

$12.46 per share

Issue Date:

 

January 7, 2010

Expiration Date:

 

January 7, 2017

This W ARRANT (this “ Warrant ”) certifies that, for good and valuable consideration, Advanced Equities Financial Corp. or its permitted registered assigns (“ Holder ”) is entitled to purchase from Amyris Biotechnologies, Inc., a California corporation (the “ Company ”), at any time until 5:00 p.m. (Pacific Time) on the Expiration Date set forth above, the number of fully paid and nonassessable shares of the class of stock (the “ Shares ”) of the Company at the Initial Exercise Price per Share (the “ Warrant Price ”), all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.

 

  1.

EXERCISE .

1.1         Method of Exercise . Holder may exercise this Warrant by delivering a duly executed Notice of Exercise in substantially the form attached as Exhibit A to the principal office of the Company. This Warrant may be exercised in whole or in part and Holder shall also deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased.


1.2         Net Exercise Election . Holder may elect to convert this Warrant, without the payment by Holder of any additional consideration, by the surrender of this Warrant to the Company, with the net exercise election selected in the Notice of Exercise attached hereto as Exhibit A duly executed by Holder, into the number of Shares that is obtained under the following formula:

 

X =  

Y  (A-B)

 

  A

 

Where:

    

X =

  

the number of Shares to be issued to Holder pursuant to this Section 1.2.

    

Y =

  

the number of Shares then subject to this Warrant.

    

A =

  

the fair market value of one Share, as determined in good faith by the Company’s Board of Directors, as at the time the net exercise election is made pursuant to this Section 1.2.

    

B =

  

the Warrant Price.

For purposes of the above calculation, fair market value of one Share shall be determined by the Company’s Board of Directors in good faith; provided, however, that where there exists a public market for the Company’s Common Stock at the time of such exercise, the fair market value per share shall be the product of (i) the average of the closing bid and asked prices of the Common Stock quoted in the Over-The-Counter Market Summary or the last reported sale price of the Common Stock or the closing price quoted on any exchange on which the Common Stock is listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal for the five (5) trading days prior to the date of determination of fair market value and (ii) the number of shares of Common Stock into which each Share is convertible, if applicable, at the time of such exercise. Notwithstanding the foregoing, in the event this Warrant is exercised in connection with the Company’s initial public offering of Common Stock, the fair market value per share shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and (ii) the number of shares of Common Stock into which each Share is convertible, if applicable, at the time of such exercise. The Company will promptly respond in writing to an inquiry by Holder as to the then current fair market value of one Share.

1.3         Delivery of Certificate and New Warrant . Promptly after Holder exercises this Warrant, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, this Warrant shall automatically be reduced by the number of Shares issued and remain exercisable for such remaining Shares not so acquired, and all other terms of the Warrant shall otherwise remain in full force and effect as so adjusted. Upon final exercise of this Warrant for any such remaining number of Shares, this Warrant shall be surrendered by Holder to the Company for cancellation.

1.4         Replacement of Warrants . On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, or surrender and

 

2


cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

1.5         Acquisition, Asset Sale, Liquidation of the Company . In the event the Company proposes to effect (i) an Acquisition (as such term is defined in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time (the “ Articles of Incorporation ”)); (ii) an Asset Sale (as defined in the Articles of Incorporation); or (iv) a Liquidation (as defined in the Articles of Incorporation), the Company shall give Holder at least ten (10) days advance written notice of such event (the “ Company Notice ”), which notice shall include the Company’s best estimate of the value of the Shares receivable upon exercise or conversion of this Warrant and the proposed date upon which such event is expected to occur. During such notice period, Holder may exercise this Warrant in accordance with its terms, whether or not exercise is contingent upon the happening of such event and/or existence of a minimum value of the Shares receivable upon exercise as provided on Holder’s exercise notice. Subject to prior exercise as provided in the preceding sentence, this Warrant will terminate immediately prior to the happening or consummation of the event described in the Company Notice.

 

  2.

ADJUSTMENTS TO THE SHARES .

2.1         Stock Dividends, Splits, Etc . If the Company declares or pays a dividend on the outstanding shares of the Company’s Common Stock payable in shares of the Company’s Common Stock or other securities of the Company or subdivides or combines the outstanding shares of the Company’s Common Stock, then upon exercise or conversion of this Warrant, unless, in case this Warrant is exercisable into shares of the Company’s Preferred Stock and the conversion ratio of such Preferred Stock already reflects such event for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend, subdivision or combination occurred.

2.2         Reclassification, Exchange or Substitution . Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant (other than a merger, consolidation or recapitalization described in Section 1.5 above or a stock dividend, split, etc. described in Section 2.1 above), Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution or other event. By way of example, such an event shall include any automatic conversion of the outstanding or issuable securities of the Company of the same class or series as the Shares to Common Stock pursuant to the terms of the Company’s Articles of Incorporation upon the closing of a registered public offering of the Company’s Common Stock. The Company or its successor shall promptly issue to Holder a new Warrant for such new securities or other property. The new Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 2 including, without limitation, appropriate adjustments to the Warrant Price and to the number of securities or property issuable upon exercise or conversion of the new Warrant.

 

3


2.3         Adjustments of Warrant Price . If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are divided by reclassification or otherwise, into a greater number of shares, the Warrant Price shall be proportionately decreased.

2.4         Conversion of Warrant Stock . If all the outstanding shares of that particular series of preferred stock defined herein as the “Shares” and specifically identified in the preamble of this Warrant (the “ Series ”) of the Company are converted into Common Stock pursuant to the Company’s Articles of Incorporation (subject to the provisions of Section 1.5) or otherwise, or such Series otherwise ceases to exist, then, from and after the date on which such Series is so converted or ceases to exist (the “ Conversion Date ”): (i) this Warrant will be exercisable for Common Stock of the Company and the term “Shares” (wherever used in this Warrant) will thereafter mean the Company’s Common Stock; and (ii) the Warrant Price will be the price obtained by dividing (a) the Purchase Price in effect immediately prior to the Conversion Date by (b) the number of shares of Common Stock (including fractional shares) into which each share of such Series was convertible immediately prior to the Conversion Date (subject to subsequent adjustment as provided herein).

2.5         Adjustment is Cumulative . The provisions of this Section 2 shall similarly apply to successive stock dividends, stock splits or combinations, reclassifications, exchanges, substitutions, or other events.

2.6         Fractional Shares . No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of this Warrant, the Company shall eliminate such fractional Share interest by paying Holder an amount by check computed by multiplying the fractional interest by the fair market value of a full Share.

2.7         Certificate as to Adjustments . Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price.

 

4


3.        REPRESENTATIONS AND COVENANTS OF THE COMPANY . The Company hereby represents and warrants to Holder that all Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

 

  4.

REPRESENTATIONS AND AGREEMENTS OF HOLDER .

4.1         Representations . Holder hereby represents and warrants to the Company as follows. Holder is a sophisticated investor having such knowledge and experience in business and investment matters that Holder is capable of protecting Holder’s own interests in connection with the acquisition, exercise or disposition of this Warrant. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act. Holder is aware that this Warrant and the Shares are being, or will be, issued to Holder in reliance upon Holder’s representation in this Section 4 and that such securities are restricted securities that cannot be publicly sold except in certain prescribed situations. Holder is aware of the provisions of Rule 144 promulgated under the Act and of the conditions under which sales may be made thereunder. Holder has received such information about the Company as Holder deems reasonable, has had the opportunity to ask questions and receive answers from the Company with respect to its business, assets, prospects and financial condition and has verified any answers Holder has received from the Company with independent third parties to the extent Holder deems necessary. Holder, by acceptance hereof, acknowledges this Warrant and the Shares to be issued upon exercise hereof or conversion thereof are being acquired solely for Holder’s own account and not as a nominee for any other party, and for investment, and that Holder will not offer, sell or otherwise dispose of this Warrant or any Shares to be issued upon exercise hereof or conversion thereof except under circumstances that will not result in a violation of the Act or any state securities laws.

4.2         Legends . This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form:

 

  

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR LAW OR PURSUANT TO RULE 144 AND ANY STATE EXEMPTION FROM REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

  

4.3         Compliance with Securities Laws on Transfer . This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the

 

5


transferee (including, without limitation, the delivery of investment representation letters and legal opinions satisfactory to the Company, as reasonably requested by the Company).

4.4         Transfer Procedure . Subject to the provisions of Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company a written notice of the portion of the Warrant being transferred, such notice setting forth the name, address and taxpayer identification number of the transferee, and surrendering this Warrant to the Company for reissuance to the transferee(s) (and to the new Warrant Holder for any remaining Shares, if applicable); provided that this Warrant may only be transferred to an “affiliate” (within the meaning of Rule 405 of Regulation C promulgated under the Act) of Holder.

If a transfer of all or part of this Warrant is permitted by the preceding paragraph, then this Warrant and all rights hereunder may be transferred, in whole or in part, on the books of the Company maintained for such purpose at the principal office of the Company referred to above, by Holder hereof in person, or by duly authorized attorney, upon surrender of this Warrant properly endorsed and upon payment of any necessary transfer tax or other governmental charge imposed upon such transfer together with a notice of assignment in the form attached as Exhibit B hereto. Upon any permitted partial transfer, the Company will issue and deliver to Holder a new Warrant or Warrants with respect to the Shares not so transferred. Each taker and holder of this Warrant, by taking or holding the same, consents and agrees that when this Warrant shall have been so endorsed, the person in possession of this Warrant may be treated by the Company, and all other persons dealing with this Warrant, as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented hereby and subject to the restrictions contained herein, any notice to the contrary notwithstanding; provided , however that until a transfer of this Warrant is duly registered on the books of the Company, the Company may treat Holder hereof as the owner of this Warrant for all purposes.

4.5          Market Standoff . Holder agrees, in connection with the Company’s initial public offering of the Company’s securities, upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities: (i) not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Shares (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days) from the effective date of such registration as may be requested by the underwriters and (ii) to execute any agreement reflecting clause (i) above as may be requested by the underwriters at the time of the initial public offering. The foregoing obligations shall apply only if all executive officers, directors and one-percent securityholders of the Company enter into similar agreements, it being understood that any such agreement shall not cover any equity securities of the Company Holder acquires in the Company’s initial public offering or otherwise in the public market. Any discretionary waiver or termination of the restrictions of such agreements by the Company or the managing underwriter shall apply to all persons subject to such agreements on a pro rata basis, based upon the number of shares held by each subject to such agreements. The foregoing obligations shall not apply to a registration relating solely to employee benefit plans, or to a registration relating solely to a transaction pursuant to Rule 145 under the Securities Act.

 

6


  5. GENERAL PROVISIONS .

5.1         Notices . All notices required or permitted under this Warrant shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.

5.2         Attorneys Fees . In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

5.3         Governing Law . This Warrant will be governed by and construed in accordance with the laws of the State of California, without giving effect to that body of laws pertaining to conflict of laws.

5.4         Further Assurances . The parties agree to execute such further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Warrant.

5.5         Titles and Headings . The titles, captions and headings of this Warrant are included for ease of reference only and will be disregarded in interpreting or construing this Warrant. Unless otherwise specifically stated, all references herein to “sections” and “exhibits” will mean “sections” and “exhibits” to this Warrant.

5.6         Counterparts . This Warrant may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement.

5.7         Severability . If any provision of this Warrant is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Warrant and the remainder of this Warrant shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Warrant. Notwithstanding the forgoing, if the value of this Warrant based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations.

5.8         Facsimile Signatures . This Warrant may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. The original signature copy

 

7


shall be delivered to the other party by express overnight delivery. The failure to deliver the original signature copy and/or the nonreceipt of the original signature copy shall have no effect upon the binding and enforceable nature of this Warrant.

5.9         Amendment and Waivers . This Warrant may be amended only by a written agreement executed by each of the parties hereto. No amendment of or waiver of, or modification of any obligation under this Warrant will be enforceable unless set forth in a writing signed by the party against which enforcement is sought. Any amendment effected in accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of this Warrant shall constitute a waiver of that provision as to that or any other instance. No waiver granted under this Warrant as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any performance other than the actual performance specifically waived.

5.10         Entire Agreement . This Warrant and the documents referred to herein constitute the entire agreement and understanding of the parties with respect to the subject matter of this Warrant, and supersede all prior understandings and agreements, whether oral or written, between or among the parties hereto with respect to the specific subject matter hereof.

[Signature Page Follows]

 

8


IN WITNESS WHEREOF, the parties hereto have executed this Warrant to Purchase Series C Preferred Stock of Amyris Biotechnologies, Inc. as of the date first written above.

 

WARRANT HOLDER:      COMPANY:
A DVANCED E QUITIES F INANCIAL C ORP .      A MYRIS B IOTECHNOLOGIES , I NC .
By:  

/s/ Keith Daubenspeck

     By:  

/s/ John Melo

Name:  

Keith Daubenspeck

     Name:  

John Melo

Title:  

Chairman of the Board

     Title:  

Chief Executive Officer

Address:  

311 S. Wacker Dr., Suite 1650

     Address:  

5885 Hollis Street, Suite 100

Chicago, IL 60606

    

Emeryville, CA 94608

 

    

 

Attention to:  

 

     Attention to:  

Chief Executive Officer

Facsimile:  

 

     Facsimile:  

(510) 225-8645

[Signature Page to Warrant to Purchase Series C Preferred Stock of Amyris Biotechnologies, Inc.]


EXHIBIT A

NOTICE OF EXERCISE

(TO BE SIGNED ONLY UPON EXERCISE OF WARRANT)

1.         The undersigned hereby elects to purchase                                  shares of the Series C Preferred Stock (the “ Shares ”) of Amyris Biotechnologies, Inc., a California corporation, pursuant to the terms of the attached Warrant to Purchase Series C Preferred Stock with an Issue Date of January 7, 2010 (the “ Warrant ”), as follows:

(Initial applicable method:)

 

         

    

a.

   

The undersigned tenders herewith payment of the total purchase price of such Shares in full, pursuant to a check or wire transfer, in the amount of $            .

         

    

b.

   

This exercise or conversion              [is]              [is not] contingent upon the closing of the Acquisition, Asset Sale or other event specified in the Company Notice to Holder in accordance with Section 1.5 of the Warrant received by Holder on                              and              [is]              [is not] contingent upon a sale price or fair market value for the Company’s             Series C Preferred Stock in the Acquisition, Asset Sale or other event of no less than the lesser of (a) $             per share or (b) the per share price set forth in the Company Notice.

         

    

c.

   

The undersigned hereby elects to convert the Warrant into Shares by the net exercise election pursuant to Section 1.2 of the Warrant. This conversion is exercised with respect to all of the shares of Series C Preferred Stock covered by the Warrant resulting in a net total of              Shares being issued to the undersigned.

2.         Please issue a certificate or certificates representing said Shares in the name of the undersigned. The undersigned represents that it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws and hereby repeats the representations and warranties of the undersigned that are set forth in Section 4.1 of the attached Warrant.

 

Advanced Equities Financial Corp.

By:

  

 

Name:

  

 

Title:

  

 


EXHIBIT B

FORM OF ASSIGNMENT

FOR VALUE RECEIVED the undersigned Holder of this Warrant hereby sells, assigns and transfers unto the Assignee named below all of the rights of the undersigned under the within Warrant, with respect to the number of shares of the Shares set forth below:

 

Name of Assignee

   Address    No. of Shares
     
     

and does hereby irrevocably constitute and appoint                                               Attorney to make such transfer on the books of Amyris Biotechnologies, Inc., a California corporation, maintained for the purpose, with full power of substitution in the premises.

 

Dated:

 

 

   

Advanced Equities Financial Corp.

     

By:

 

 

     

                   Name:

 

 

     

                 Title:

 

 

Exhibit 4.07

[Insert Amyris Letterhead]

April 8, 2010

Advanced Equities, Inc.

311 S. Wacker Drive, Suite 1650

Chicago, IL 60606

Attention: David Schmidt

Dear David:

Reference is hereby made to the following warrants (each an “ AEI Warrant ” and collectively, the “ AEI Warrants ”):

 

  (A)

Warrant to Purchase Series B-1 Preferred Stock for 8,991 shares of Series B-1 Preferred Stock with an issue date of March 31, 2008;

 

  (B)

Warrant to Purchase Series B-1 Preferred Stock for 53,916 shares of Series B-1 Preferred Stock with an issue date of June 30, 2008;

 

  (C)

Warrant to Purchase Series B-1 Preferred Stock for 32,330 shares of Series B-1 Preferred Stock with an issue date of September 30, 2008;

 

  (D)

Warrant to Purchase Series B-1 Preferred Stock for 5,478 shares of Series B-1 Preferred Stock with an issue date of December 31, 2008;

 

  (E)

Warrant to Purchase Series B-1 Preferred Stock for 3,843 shares of Series B-1 Preferred Stock with an issue date of March 31, 2009; and

 

  (F)

Warrant to Purchase Series C Preferred Stock for [            ] shares of Series C Preferred Stock with an issue date of January     , 2010.

This Letter Agreement is made by and between Amyris Biotechnologies, Inc. (the “ Company ”) and Advanced Equities, Inc. and certain of its affiliated investment funds (collectively, “ AEI ”). The Company and AEI agree to the following:

 

  1.

AEI hereby acknowledges and agrees the following with respect to each of the AEI Warrants:

 

  (a)

The settlement of each AEI Warrant is to be made in Shares (as defined in each AEI Warrant) and, for the elimination of doubt, the fact that the Shares delivered on exercise of each AEI Warrant are not registered under the Securities Act of 1933 will not in any way require the Company to settle any AEI Warrant otherwise than in Shares, including,


  without limitation, that there is no circumstance that would require the Company to net cash settle any AEI Warrant.

 

  (b)

In case all the authorized Series B-1 Preferred Stock and/or Series C Preferred Stock of the Company is/are converted, pursuant to the Company’s Articles of Incorporation, as may be amended from time to time, into Common Stock or other securities or property, or the Series B-1 Preferred Stock and/or Series C Preferred Stock otherwise cease(s) to exist, then, Holder (as defined in each AEI Warrant), upon exercise of each AEI Warrant at any time after such time (the “Conversion Date” ), shall receive, in lieu of the number of Shares that would have been issuable upon such exercise immediately prior to the Conversion Date (the “Former Number of Shares” ), the stock and other securities and property which Holder would have been entitled to receive upon the Conversion Date if Holder had exercised such AEI Warrant with respect to the Former Number of Shares immediately prior to the Conversion Date (all subject to further adjustment as provided in each AEI Warrant).

 

  2.

This Letter Agreement, including each of the AEI Warrants, constitute the entire and exclusive agreement between the parties pertaining to the subject matter hereof, and supersedes any and all written or oral agreements previously existing between the parties with respect to such subject matter. Any modifications of this Letter Agreement must be in writing and signed by both parties hereto. This Letter Agreement may be executed in counterparts, and each of which will be considered an original.

[R EMAINDER OF P AGE I NTENTIONALLY L EFT B LANK ]


The parties have executed this Letter Agreement as of the first date set forth above.

 

Amyris Biotechnologies, Inc.

   

Advanced Equities, Inc.

By:

 

/s/ John G. Melo

   

By:

 

/s/ Keith Daubenspeck

Name:

 

John G. Melo

   

    Name:

 

Keith Daubenspeck

Title:

 

Chief Executive Officer

   

      Title:

 

Chairman of AEFC

[S IGNATURE P AGE TO L ETTER A GREEMENT BETWEEN A MYRIS B IOTECHNOLOGIES , I NC .

AND A DVANCED E QUITIES , I NC .]

Exhibit 4.08

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.

 

Warrant Issue Date: September 23, 2008

   Warrant No. B1-1

STOCK PURCHASE WARRANT

For value received, Amyris Biotechnologies, Inc. (the “ Company ”), a California corporation, hereby certifies that ES East Associates, LLC, a California limited liability company (the “ Holder ”) or its permitted assign(s) is entitled to purchase from the Company at the Exercise Price (as defined below), at any time or from time to time during the Exercise Period (as defined below), in whole or in part, 2,009 shares of Warrant Stock of the Company at the Exercise Price. This Warrant is subject the following terms and conditions.

1.       Certain Definitions .

(a)        “ Change in Control ” means any consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the shareholders of the Company immediately prior to such consolidation, merger or reorganization, do not hold at least a majority of the resulting or surviving corporation’s voting power immediately after such consolidation, merger or reorganization, or the sale, lease, or other disposition of all or substantially all of the assets of the Company.

(b)        “ Exercise Period ” means the period commencing on the Warrant Issue Date and ending on the date that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office of the Company) on the date 10 years from issuance, (y) a Change in Control, or (z) the closing of an initial public offering of the Company’s common stock pursuant to a registration statement Under the Securities Act of 1933, as amended (the “Securities Act”).

(c)        “ Exercise Price ” means $25.26.

(d)        “ Warrant Stock ” means shares of the Company’s Series B-1 Preferred Stock.

2.       Exercise of Warrant .

(a)        The purchase rights represented by this Warrant are exercisable by the Holder, in whole or in part, during the Exercise Period by the surrender of this Warrant, with the form of Subscription Agreement attached hereto as Annex A duly completed and executed by the Holder, to the Company at its principal executive office, accompanied by payment in cash, in lawful money of the United States of America, including by certified or official bank check made payable to the order of the Company or by wire transfer of immediately available funds to an account designated by the Company, of an amount equal to the Exercise Price multiplied by the number of shares of Warrant Stock being purchased pursuant to such exercise of the Warrant.

(b)        If the fair market value of one share of Warrant Stock is greater than the Exercise Price (at the date of calculation as set forth below), then in lieu of exercising this Warrant for cash, the Holder may elect to receive shares of Warrant Stock equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant during the Exercise Period at the principal office of the Company together with the properly completed Subscription Agreement and notice of such election in which event the Company shall issue to the Holder a number of shares of Warrant Stock computed using the following formula:

 

X = Y (A-B)

            A

 

1


Where

 

X =

    

the number of shares of Warrant Stock to be issued to the Holder

 

Y =

    

the number of shares of Warrant Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)

 

A =

    

The fair market value of one share of the Company’s Warrant Stock (at the date of such calculation)

 

B =

    

Exercise Price (as adjusted to the date of such calculation)

For purposes of the above calculation, the fair market value of one share of Warrant Stock shall be the fair value as determined in good faith by the Company’s Board of Directors or a duly appointed committee of the Board; provided , however , that in the event that the Warrant is being exercised in connection with the Company’s initial public offering, the fair market value per share shall be the per share offering price of the Company’s initial public offering.

(c)        This Warrant may be exercised for less than the full number of shares of Warrant Stock first shown above, provided that this Warrant may not be exercised in part for less than a whole number of shares of Warrant Stock. Upon any such partial exercise, the Company at its expense will forthwith issue to the Holder a new Warrant or Warrants of like tenor exercisable for the number of shares of Warrant Stock as to which rights have not been exercised (subject to adjustment as herein provided).

(d)        As soon as practicable after the exercise of this Warrant and payment of the aggregate Exercise Price, and in any event within 20 business days thereafter, the Company, at its expense, will cause to be issued in the name of and delivered to the Holder a certificate or certificates for the number of duly authorized, validly issued, fully paid and non-assessable shares of Warrant Stock to which the Holder shall be entitled upon such exercise, plus, in lieu of any fractional share to which the Holder would otherwise be entitled, cash in an amount determined in accordance with Section 3(d) hereof. The Company agrees that the shares so purchased shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been exercised.

(e)        Prior to the exercise of this Warrant, the Holder shall not be entitled to any rights of a shareholder of the Company with respect to shares for which this Warrant shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive rights, and shall not be entitled to receive any notice of any proceedings of the Company.

3.       Adjustments .

(a)         Adjustments Generally . In order to prevent dilution of the rights granted hereunder in the specific circumstances contemplated by this Section 3, the number of shares of Warrant Stock underlying this Warrant and the Exercise Price shall be subject to adjustment from time to time in accordance herewith. Upon each adjustment of the Exercise Price pursuant to this Section 3, the Holder shall thereafter be entitled to acquire upon exercise, at the Exercise Price resulting from such adjustment, the number of shares of the Company’s Warrant Stock determined by (i) multiplying (A) the Exercise Price in effect immediately prior to such adjustment by (B) the number of shares of Warrant Stock issuable upon exercise hereof immediately prior to such adjustment, and (ii) dividing the product thereof by the Exercise Price resulting from such adjustment.

(b)         Subdivisions and Combinations . In case the Company shall at any time subdivide its outstanding shares of Warrant Stock into a greater number of shares (including, without limitation, through any stock split effected by means of a dividend on the Warrant Stock which is payable in Warrant Stock), the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and, conversely, in case the outstanding shares of Warrant Stock of the Company shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased.

 

2


(c)         Reorganization, Reclassification, Consolidation, Merger or Sale of Assets . If any capital reorganization or reclassification of the capital stock of the Company, or consolidation or merger of the Company with another corporation, or the sale of a significant amount of assets to another corporation shall be effected in such a way that (i) does not constitute a Change in Control, and (ii) holders of Warrant Stock shall be entitled to receive stock, securities, cash or other property with respect to or in exchange for Warrant Stock, then, as a condition of such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision shall be made whereby the Holder shall have the right to acquire and receive upon exercise of this Warrant in accordance with the terms hereof such shares of stock, securities, cash or other property of the successor corporation that a holder of the shares deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, reclassification, consolidation, merger or sale if this Warrant had been exercised immediately before such reorganization, reclassification, consolidation, merger or sale. The foregoing provisions shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers or sales and to the stock or securities of any other corporation that are at the time receivable upon the exercise of this Warrant. In all events, appropriate adjustments (as determined by the Board of Directors of the Company) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant.

(d)         Fractional Shares . The Company shall not issue fractions of shares of Warrant Stock upon exercise of this Warrant or scrip in lieu thereof. If any fraction of a share of Warrant Stock would, except for the provisions of this Section 3(d), be issuable upon exercise of this Warrant, then the Company shall in lieu thereof pay to the person entitled thereto an amount in cash equal to the current value of such fraction, calculated to the nearest one-hundredth (1/100) of a share, to be computed on the basis of the fair market value per share as determined by the Board of Directors of the Company in accordance with the provisions of Section 2(b).

(e)         Certificate as to Adjustments . Whenever the Exercise Price shall be adjusted as provided in Section 3 hereof, the Company shall promptly compute such adjustment and furnish to the Holder a certificate setting forth such adjustment and showing in reasonable detail the facts requiring such adjustment, the Exercise Price that will be effective after such adjustment and the number of shares and the amount, if any, of other property that at the time would be received upon the exercise of this Warrant.

4.       Reservation of Stock Issuable on Exercise of Warrant . The Company shall at all times reserve and keep available out of its authorized but unissued stock, solely for the issuance and delivery upon the exercise of this Warrant, such number of its duly authorized shares of Warrant Stock as from time to time shall be issuable upon the exercise of this Warrant. All of the shares of Warrant Stock issuable upon exercise of this Warrant, when issued and delivered in accordance with the terms hereof and thereof, will be duly authorized, validly issued, fully paid and non-assessable, subject to no lien or other encumbrance other than restrictions on transfer arising under applicable securities laws and restrictions imposed by Section 6(a) hereof and the Agreements to which reference is made in Section 6(b) hereof.

5.       Replacement of Warrant . Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement reasonably satisfactory to the Company (with surety if reasonably required), or (in the case of mutilation) upon surrender and cancellation thereof, the Company will issue, in lieu thereof, a new Warrant of like tenor and amount.

6.       Negotiability . This Warrant is issued upon the following terms:

(a)         Transfer . By acceptance hereof, the Holder acknowledges and agrees that, except upon the prior written consent of the Company, this Warrant may not be transferred, and this Warrant may be exercised only by the Holder. Holder is acquiring the Warrant and the shares of Warrant Stock issuable upon exercise hereof for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof, and Holder has no present intention of selling, granting any participation in, or otherwise distributing the same.

 

3


(b)         Agreements . As a condition to the Company’s obligation to issue shares of capital stock upon exercise hereof, the Holder shall execute the Subscription Agreement attached hereto as Annex A and such stock transfer restriction and voting agreements as may reasonably be requested by the Company.

(c)         Transfer Taxes . The Company shall not be required to pay any federal or state transfer tax or charge that may be payable in respect of any transfer involved in the transfer or delivery of this Warrant or the issuance or delivery of certificates for Warrant Stock in a name other than that of the Holder or to issue or deliver any certificates for Warrant Stock upon the exercise of this Warrant until any and all such taxes and charges shall have been paid by the Holder or until it has been established to the Company’s reasonable satisfaction that no such tax or charge is due.

(d)         Compliance with Securities Laws . The Holder, by acceptance hereof, acknowledges that this Warrant and the shares of Warrant Stock to be issued upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other patty, and for investment, and that the Holder will not offer, sell or otherwise dispose of this Warrant or any shares of Warrant Stock to be issued upon exercise hereof except under circumstances that will not result in a violation of applicable federal and state securities laws.

7.       Subdivision of Rights . Subject to Section 6, this Warrant (as well as any new Warrants issued pursuant to the provisions of this Section 7) is exchangeable, upon the surrender hereof by the Holder, at the principal executive office of the Company for any number of new Warrants of like tenor and date representing in the aggregate the right to subscribe for and purchase the number of shares of Warrant Stock of the Company which may be subscribed for and purchased hereunder.

8.       Miscellaneous .

(a)         Notices . Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) the next business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company and to the Holder at the address or facsimile number set forth on such party’s signature page hereof or at such other address as the Company or the Holder may designate by 10 days’ advance written notice to the other parties hereto.

(b)         Books of the Company . The Company may treat the holder hereof as appearing on the Company’s books at any time as the holder for all purposes.

(c)         Headings . The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect the meaning hereof.

(d)         Amendment: Waiver . This Warrant and any term hereof may be amended, waived, discharged or terminated only by an instrument in writing signed by the party against whom enforcement of such amendment, waiver, discharge or termination is sought. No waivers of any term, condition or provision of this Warrant, in anyone or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision.

(e)         Benefits of this Warrant . Nothing in this Warrant shall be construed to give any person or corporation other than the Company and the Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and the Holder and any other permitted holder or holders of the Warrant.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

4


IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed and delivered by its authorized officer, as of the date first above written.

 

     

AMYRIS BIOTECHNOLOGIES, INC.

 
     

By:

 

/s/ Tamara L. Tompkins

 
     

        Name:

 

Tamara L. Tompkins

 
     

Title:

 

General Counsel & Corporate Secretary

 

AGREED TO AND ACCEPTED:

     

HOLDER

ES EAST ASSOCIATES, LLC

     

By:

 

/s/ Richard K. Robbins

     

Name:

 

Richard K. Robbins

     

Title:

 

Managing Editor

     

 

5


ANNEX A

SUBSCRIPTION AGREEMENT

 

Date:

   

 

  

To:

   

 

  
   

 

  
   

 

  

The undersigned (the “ Purchaser ”), pursuant to the provisions set forth in the attached Warrant, hereby irrevocably elects (check and complete appropriate box);

¨ to purchase              shares of Warrant Stock (the “ Warrant Shares ”) covered by such Warrant and herewith makes payment of $            , representing the full purchase price for such shares at the price per share provided for in such Warrant.

¨ to exercise the Warrant with respect to              shares of Warrant Stock, pursuant to Section 2(b) of the Warrant.

Purchaser represents and warrants to the Company as follows:

1.             Investment Representations . Purchaser understands that the Warrant Shares have not been registered under the Securities Act. Purchaser also understands that the Warrant Shares are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon Purchaser’s representations contained herein.

2.             Experience; Risk . Purchaser has such knowledge and experience in financial and business matters that Purchaser is capable of evaluating the merits and risks of the purchase of the Warrant Shares and of protecting Purchaser’s interests in connection therewith. Purchaser is able to fend for itself in the transactions contemplated by this Agreement and has the ability to bear the economic risk of the investment, including complete loss of the investment.

3.             Investment . Purchaser is acquiring the Warrant Shares for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof, and Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. Purchaser understands that the Warrant Shares have not been registered under the Securities Act and applicable state securities laws (collectively, the “Acts”) by reason of a specific exemption from the registration provisions of the Acts which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Purchaser’s representations as expressed herein.

4.             Information . Purchaser has been furnished with all information which it deems necessary to evaluate the merits and risks of purchasing the Warrant Shares and has had the opportunity to ask questions concerning the Warrant Shares and the Company and all questions posed have been answered to its satisfaction. Purchaser has been given the opportunity to obtain any additional information it deems necessary to verify the accuracy of any information obtained concerning the Warrant Shares and the Company. Purchaser has such knowledge and experience in financial and business matters that it is able to evaluate the merits and risks of purchasing the Warrant Shares and to make an informed decision relating thereto.

5.             Restricted Securities; Restrictions on Transfer . Purchaser understands that the Warrant Shares will be “restricted securities” under applicable securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations the Warrant Shares may be resold without registration under the Acts only in certain limited circumstances. Purchaser acknowledges that the Warrant Shares must be held indefinitely unless subsequently registered under the Acts or an exemption from such registration is available. Purchaser agrees to execute and deliver a counterpart signature page,


and become a party, to such agreements as other purchasers of Warrant Stock are a party to and such other stock transfer restriction, voting and other agreements as may be requested by the Company.

6.             No Public Market . Purchaser understands that no public market now exists for any of the securities issued by the Company and that there is no assurance that a public market will ever exist for such securities.

7.             Accredited Investor . Purchaser is an “accredited investor” within the meaning of Rule 501 promulgated under the Securities Act. The Purchaser has considered the Federal and state income tax implications of the exercise of the Warrant and the purchase and subsequent sale of the Warrant Shares.

8.             Residence . If Purchaser is an individual, then Purchaser resides in the state or province identified in the address of Purchaser set forth below; if Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of Purchaser in which its investment decision was made is located at the address or addresses of Purchaser set forth below.

9.             Further Limitations on Disposition . Without in any way limiting the representations set forth above, Purchaser further agrees not to make any disposition of any Shares unless and until:

(i)            there is then in effect a registration statement under the Acts covering such proposed disposition and such disposition is made in accordance with such registration statement; or

(ii)            Purchaser shall have notified the Company of the proposed disposition, and shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition, and, at the expense of Purchaser or its transferee, with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not requite registration of such securities under any of the Acts.

10.             Legends . Purchaser understands and agrees that any certificate or other instrument representing the Shares will bear a legend substantially similar to the legend set forth below:

THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NEITHER THIS SECURITY NOR THE SECURITIES ISSUABLE UPON CONVERSION [EXERCISE] HEREOF MAYBE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.

 

2


The legend set forth above shall be removed by the Company from any certificate or other instrument representing the Shares upon delivery to the Company of an opinion of counsel reasonably satisfactory to the Company that a registration statement under the Securities Act is at that time in effect with respect to the legended security or that such security can be freely transferred in a public sale without such a registration statement being in effect and that such transfer will not jeopardize the exemption or exemptions from registration pursuant to which the Company issued the Shares.

 

 

 

Signature

 

Print Name:

 

 

 

Address:

 

 

 

 

 

 

 

 

3


NOTICE OF TRANSFER

[To be signed only upon transfer of Warrant]

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto the Assignee named below the rights and obligations represented by the within Warrant with respect to the number of shares of Warrant Stock of Amyris Biotechnologies, Inc. set forth below:

 

Name of Assignee

    

Address

     

No. of Shares

  

 

    

 

     

 

  

and appoints                                      attorney to transfer said right on the warrant register of                      with full power of substitution in the premises.

 

Dated:

 

 

   

 

   
      (Signature must conform in all respects to name of Holder as specified on the face of the Warrant)  
     

Address:

   
     

 

   
     

 

   
     

 

   

Exhibit 4.09

AMENDMENT NO. 1 TO STOCK PURCHASE WARRANT

This Amendment No. 1 to Stock Purchase Warrant (this “ Amendment ”) is made and entered into as of April 8, 2010 (the “ Amendment Date ”), by and among ES East Associates, LLC, a California limited liability company (“ ES East Associates ”) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ”).

R E C I T A L S

WHEREAS, the Company and ES East Associates are parties to that certain Stock Purchase Warrant dated September 23, 2008 (the “ Warrant ”).

WHEREAS, the Company and ES East Associates desire to amend the Warrant.

NOW, THEREFORE, in consideration of the matters described in the recitals above and the mutual promises, covenants and undertakings contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

A M E N D M E N T

1.         AMENDMENT TO SECTION 1(B) OF WARRANT . The definition of “Exercise Period” set forth in Section 1(b) of the Warrant shall be deleted in its entirety and replaced with the following:

“(b)     “Exercise Period” means the period commencing on the Warrant Issue Date and ending on the date that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office o the Company) on the date 10 years from issuance, (y) a Change in Control, or (z) one (1) year from the effective date of an initial public offering of the Company’s securities. The settlement of the Warrant is to be made in Warrant Stock and, for the elimination of doubt, the fact that the Warrant Stock delivered on exercise of the this Warrant is not registered under the Securities Act of 1933 will not in any way require you to settle the Warrant otherwise than in Warrant Stock, including, without limitation, that there is no circumstance that would require the Company to net cash settle the Warrant.”

2.         AMENDMENT TO WARRANT: NEW SECTION 3(f) . A new Section 3(f) shall be added to the Warrant to read in its entirety as follows:

“(f)     In case all the authorized Series B-1 Preferred Stock of the Company is converted, pursuant to the Articles of Incorporation, as amended from time to time, into Common Stock or other securities or property, or the Series B-1 Preferred Stock otherwise ceases to exist, then, the Holder, upon exercise of this Warrant at any time after such time (the “Conversion Date” ), shall receive, in lieu of the number of shares of Warrant Stock that would have been issuable upon such exercise immediately prior to the Conversion Date (the “Former Number of Shares of Warrant Stock” ), the stock and other securities and property which the Holder would have been entitled to receive upon the Conversion Date if the Holder had exercised this Warrant with respect to the Former Number of Shares of Warrant Stock immediately prior to the Conversion Date (all subject to further adjustment as provided in this Warrant).”


3.         NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Warrant remain in full force and effect.

4.         GOVERNING LAW . This Amendment shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

5.         COUNTERPARTS; FASCIMILE . This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, or by email in portable document format (.pdf) and delivery of the signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties.

[Remainder of page left blank]

IN WITNESS WHEREOF , each of the Company and ES East Associates has caused this Amendment No. 1 to Stock Purchase Warrant to be executed by its duly authorized representative, each as of the Amendment Date.

 

AMYRIS BIOTECHNOLOGIES, INC.

  ES EAST ASSOCIATES, LLC

/s/ John Melo

   

/s/ Richard K. Robbins

By:

 

John Melo

     

  By:

 

Richard K. Robbins

 

Its:

 

Chief Executive Officer

     

  Its:

 

Managing Member

 

Exhibit 4.10

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.

 

Warrant Issue Date: March 6, 2008

  

                             Warrant No. 1-1

STOCK PURCHASE WARRANT

For value received, Amyris Biotechnologies, Inc. (the “ Company ”), a California corporation, hereby certifies that Starfish, LLC (the “ Holder ”) or its permitted assign(s) is entitled to purchase from the Company, at any time or from time to time during the Exercise Period (as defined below), in whole or in part, 2,580 shares of Warrant Stock (as defined below) of the Company at the Exercise Price (as defined below). This Warrant is subject to the following terms and conditions.

1.       Certain Definitions .

(a)        “ Change in Control ” means (i) any sale, lease, or other disposition of all or substantially all of the assets of the Company or (ii) any consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the shareholders of the Company immediately prior to such consolidation, merger or reorganization, do not hold at least a majority of the resulting or surviving entity’s voting power immediately after such consolidation, merger or reorganization.

(b)        “ Exercise Period ” means the period commencing on the Warrant Issue Date and ending on the date that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office of the Company) on the fifth (5th) anniversary of the Warrant Issue Date, (y) a Change in Control, or (z) the closing of an initial public offering of the Company’s common stock pursuant to a registration statement under the Securities Act of 1933, as amended (the “ Securities Act ”); provided , however , that the Company shall provide written notice to the Holder of a Change in Control or such initial public offering not less than ten (10) business days prior to the occurrence of such event.

(c)        “ Exercise Price ” means $24.88 per share of Warrant Stock, subject to adjustment as provided herein.

(d)        “ Warrant Stock ” means the Company’s Series B Preferred Stock.

 

1


2.       Exercise of Warrant .

(a)        The purchase rights represented by this Warrant are exercisable by the Holder, in whole or in part, during the Exercise Period by the surrender of this Warrant, with the form of Subscription Agreement attached hereto as Annex A duly completed and executed by the Holder, to the Company at its principal executive office, accompanied by payment in cash, in lawful money of the United States of America, including by certified or official bank check made payable to the order of the Company or by wire transfer of immediately available funds to an account designated by the Company, of an amount equal to the Exercise Price multiplied by the number of shares of Warrant Stock being purchased pursuant to such exercise of the Warrant.

(b)        If the fair market value of one share of Warrant Stock is greater than the Exercise Price (at the date of calculation as set forth below), then in lieu of exercising this Warrant for cash, the Holder may elect to receive shares of Warrant Stock equal to the value of this Warrant (or any portion hereof) by surrender of this Warrant (or such portion) during the Exercise Period at the principal office of the Company together with the properly completed Subscription Agreement and notice of such election in which event the Company shall issue to the Holder such number of shares of Warrant Stock computed using the following formula:

X = Y (A-B)

    A

Where X =      the number of shares of Warrant Stock to be issued to the Holder

Y =      the number of shares of Warrant Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised

A =      The fair market value of one share of the Company’s Warrant Stock (at the date of such exercise)

B =      Exercise Price (as adjusted to the date of such exercise)

For purposes of the above calculation, the fair market value of one share of Warrant Stock shall be the fair value as determined in good faith by the Company’s Board of Directors or a duly appointed committee of the Board; provided , however , that in the event that the Warrant is being exercised in connection with the Company’s initial public offering, the fair market value per share shall be the per share offering price of the Company’s initial public offering.

(c)        This Warrant may be exercised for less than the full number of shares of Warrant Stock first shown above, provided that this Warrant may not be exercised in part for less than a whole number of shares of Warrant Stock. Upon any such partial exercise, the Company at its expense will forthwith issue to the Holder a new Warrant or Warrants of like tenor exercisable for the number of shares of Warrant Stock as to which rights have not been exercised (subject to adjustment as herein provided).

(d)        As soon as practicable after the exercise of this Warrant and payment of the aggregate Exercise Price, and in any event within 20 business days thereafter, the Company, at its expense, will cause to be issued in the name of and delivered to the Holder a certificate or

 

2


certificates for the number of duly authorized, validly issued, fully paid and non-assessable shares of Warrant Stock to which the Holder shall be entitled upon such exercise, plus, in lieu of any fractional share to which the Holder would otherwise be entitled, cash in an amount determined in accordance with Section 3(d) hereof. The Company agrees that the shares so purchased shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been exercised.

(e)        Prior to the exercise of this Warrant, the Holder shall not be entitled to any rights of a shareholder of the Company with respect to shares for which this Warrant shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive rights, and shall not be entitled to receive any notice of any proceedings of the Company.

3.       Adjustments .

(a)         Adjustments Generally . In order to prevent dilution of the rights granted hereunder in the specific circumstances contemplated by this Section 3, the number of shares of Warrant Stock underlying this Warrant and the Exercise Price shall be subject to adjustment from time to time in accordance herewith. Upon each adjustment of the Exercise Price pursuant to this Section 3, the Holder shall thereafter be entitled to acquire upon exercise, at the Exercise Price resulting from such adjustment, the number of shares of the Company’s Warrant Stock determined by (i) multiplying (A) the Exercise Price in effect immediately prior to such adjustment by (B) the number of shares of Warrant Stock issuable upon exercise hereof immediately prior to such adjustment, and (ii) dividing the product thereof by the Exercise Price resulting from such adjustment.

(b)         Subdivisions and Combinations . In case the Company shall at any time subdivide its outstanding shares of Warrant Stock into a greater number of shares (including, without limitation, through any stock split effected by means of a dividend on the Warrant Stock which is payable in Warrant Stock), the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and, conversely, in case the outstanding shares of Warrant Stock of the Company shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased.

(c)         Reorganization, Reclassification, Consolidation, Merger or Sale of Assets . If, at any time prior to the exercise of this Warrant in full, the Company shall (i) effect any capital reorganization or reclassification of the capital stock of the Company, or consolidate or merge the Company with another entity, or sell, lease, or otherwise dispose of a significant amount of assets, in any such case in such a way that does not constitute a Change in Control, (ii) declare a dividend or make a distribution on the Warrant Stock payable in shares of its capital stock of any class, securities, cash or other property; or (iii) issue any shares of its capital stock by reclassification of its Warrant Shares (including any such reclassification in connection with a consolidation or a merger in which the Company is the continuing corporation), then, as a condition of such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision shall be made whereby the Holder shall have the right to acquire and receive upon exercise of this Warrant in accordance with the terms hereof such shares of stock, securities, cash or other property of the successor entity that a holder of the shares deliverable

 

3


upon exercise of this Warrant would have been entitled to receive in such reorganization, reclassification, consolidation, merger or sale if this Warrant had been exercised immediately before such reorganization, reclassification, consolidation, merger or sale. The foregoing provisions shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers or sales and to the stock or securities of any other corporation that are at the time receivable upon the exercise of this Warrant. In all events, appropriate adjustments (as determined by the Board of Directors of the Company) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant.

(d)         Fractional Shares . The Company shall not issue fractions of shares of Warrant Stock upon exercise of this Warrant or scrip in lieu thereof. If any fraction of a share of Warrant Stock would, except for the provisions of this Section 3(d), be issuable upon exercise of this Warrant, then the Company shall in lieu thereof pay to the person entitled thereto an amount in cash equal to the current value of such fraction, calculated to the nearest one-hundredth (1/100) of a share, to be computed on the basis of the fair market value per share as determined by the Board of Directors of the Company in accordance with the provisions of Section 2(b).

(e)         Certificate as to Adjustments . Whenever the Exercise Price shall be adjusted as provided in Section 3 hereof the Company shall promptly compute such adjustment and furnish to the Holder a certificate setting forth such adjustment and showing in reasonable detail the facts requiring such adjustment, the Exercise Price that will be effective after such adjustment and the number of shares and the amount, if any, of other property that at the time would be received upon the exercise of this Warrant.

4.       Reservation of Stock Issuable on Exercise of Warrant . The Company shall at all times reserve and keep available out of its authorized but unissued stock, solely for the issuance and delivery upon the exercise of this Warrant, such number of its duly authorized shares of Warrant Stock as from time to time shall be issuable upon the exercise of this Warrant. All of the shares of Warrant Stock issuable upon exercise of this Warrant, when issued and delivered in accordance with the terms hereof and thereof, will be duly authorized, validly issued, fully paid and non-assessable, subject to no lien or other encumbrance other than restrictions on transfer arising under applicable securities laws and restrictions imposed by Section 6(a) hereof and the Agreements to which reference is made in Section 6(b) hereof.

5.       Replacement of Warrant . Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement reasonably satisfactory to the Company (with surety if reasonably required), or (ill the case of mutilation) upon surrender and cancellation thereof, the Company will issue, in lieu thereof, a new Warrant of like tenor and amount.

6.       Negotiability . This Warrant is issued upon the following terms:

(a)         Transfer . By acceptance hereof, the Holder acknowledges and agrees that, except upon the prior written consent of the Company, this Warrant may not be transferred, and

 

4


this Warrant may be exercised only by the Holder. Holder is acquiring the Warrant and the shares of Warrant Stock issuable upon exercise hereof for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof, and Holder has no present intention of selling, granting any participation in, or otherwise distributing the same.

(b)         Agreements . As a condition to the Company’s obligation to issue shares of capital stock upon exercise hereof the Holder shall execute the Subscription Agreement attached hereto as Annex A and such stock transfer restriction and voting agreements as may reasonably be requested by the Company.

(c)         Transfer Taxes . The Company shall not be required to pay any federal or state transfer tax or charge that may be payable in respect of any transfer involved in the transfer or delivery of this Warrant or the issuance or delivery of certificates for Warrant Stock in a name other than that of the Holder or to issue or deliver any certificates for Warrant Stock upon the exercise of this Warrant until any and all such taxes and charges shall have been paid by the Holder or until it has been established to the Company’s reasonable satisfaction that no such tax or charge is due.

(d)         Compliance with Securities Laws . The Holder, by acceptance hereof, acknowledges that this Warrant and the shares of Warrant Stock to be issued upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other party, and for investment, and that the Holder will not offer, sell or otherwise dispose of this Warrant or any shares of Warrant Stock to be issued upon exercise hereof except under circumstances that will not result in a violation of applicable federal and state securities laws.

7.       Subdivision of Rights . Subject to Section 6, this Warrant (as well as any new Warrants issued pursuant to the provisions of this Section 7) is exchangeable, upon the surrender hereof by the Holder, at the principal executive office of the Company for any number of new Warrants of like tenor and date representing in the aggregate the right to subscribe for and purchase the number of shares of Warrant Stock of the Company which may be subscribed for mid purchased hereunder.

8.       No Impairment . The Company shall not by any action including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such commercially reasonable actions as may be necessary or appropriate to protect the rights of Holder against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares receivable upon the exercise of this Warrant above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such commercially reasonable action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use its commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

 

5


9.       Miscellaneous .

(a)         Notices . Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) the next business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company and to the Holder at the address or facsimile number set forth on such party’s signature page hereof or at such other address as the Company or the Holder may designate by 10 days’ advance written notice to the other parties hereto.

(b)         Books of the Company . The Company may treat the holder hereof as appearing on the Company’s books at any time as the holder for all purposes.

(c)         Headings . The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect the meaning hereof.

(d)         Amendment Waiver . This Warrant and any term hereof may be amended, waived, discharged or terminated only by an instrument in writing signed by the party against whom enforcement of such amendment, waiver, discharge or termination is sought. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision.

(e)         Benefits of this Warrant . Nothing in this Warrant shall be construed to give any person or corporation other than the Company and the Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and the Holder and any other permitted holder or holders of the Warrant.

(f)         Successor and Assigns . Subject to compliance with the provisions of Section 6(a), this Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder.

(g)         Severability . Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid tinder applicable law, but if any provision of this Warrant shall be prohibited by or invalid tinder applicable law, such provision shall be modified to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Warrant.

(h)         Headings . The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

6


(i)         Governing Law . This Warrant and the transactions contemplated hereby shall be governed by and interpreted in accordance with the local laws of the State of California without regard to the provisions thereof relating to conflicts of laws.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

7


IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed and delivered by its authorized officer, as of the date first above written.

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

 

/s/ Tamara L. Tompkins

Name:

 

 Tamara L. Tompkins

Title:

 

 General Counsel

 

AGREED TO AND ACCEPTED:

HOLDER

STARFISH, LLC

 /s/ [signature illegible]

 

8


ANNEX A

SUBSCRIPTION AGREEMENT

Date:                                                  

 

To:

Amyris Biotechnologies, Inc.

5980 Horton Street, Suite 350

Emeryville, CA 94608

The undersigned (the “ Purchaser ”), pursuant to the provisions set forth in the attached Warrant, hereby irrevocably elects (check and complete appropriate box):

¨ to purchase              shares of Warrant Stock (the “ Warrant Shares ”) covered by such Warrant and herewith makes payment of $            , representing the full purchase price for such shares at the price per share provided for in such Warrant.

¨ to exercise the Warrant with respect to              shares of Warrant Stock, pursuant to Section 2(b) of the Warrant.

Purchaser represents and warrants to the Company as follows:

1.       Investment Representations . Purchaser understands that the Warrant Shares have not been registered under the Securities Act. Purchaser also understands that the Warrant Shares are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon Purchaser’s representations contained herein.

2.       Experience; Risk . Purchaser has such knowledge and experience in financial and business matters that Purchaser is capable of evaluating the merits and risks of the purchase of the Warrant Shares and of protecting Purchaser’s interests in connection therewith. Purchaser is able to fend for itself in the transactions contemplated by this Agreement and has the ability to bear the economic risk of the investment, including complete loss of the investment.

3.       Investment . Purchaser is acquiring the Warrant Shares for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof, and Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. Purchaser understands that the Warrant Shares have not been registered under the Securities Act and applicable state securities laws (collectively, the “Acts”) by reason of a specific exemption from the registration provisions of the Acts which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Purchaser’s representations as expressed herein.

4.       Information . Purchaser has been furnished with all information which it deems necessary to evaluate the merits and risks of purchasing the Warrant Shares and has had the opportunity to ask questions concerning the Warrant Shares and the Company and all questions posed have been answered to its satisfaction. Purchaser has been given the opportunity to obtain any additional information it deems necessary to verify the accuracy of any information obtained


concerning the Warrant Shares and the Company. Purchaser has such knowledge and experience in financial and business matters that it is able to evaluate the merits and risks of purchasing the Warrant Shares and to make an informed decision relating thereto.

5.       Restricted Securities; Restrictions on Transfer . Purchaser understands that the Warrant Shares will be “restricted securities” under applicable securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations the Warrant Shares may be resold without registration under the Acts only in certain limited circumstances. Purchaser acknowledges that the Warrant Shares must be held indefinitely unless subsequently registered under the Acts or an exemption from such registration is available. Purchaser agrees to execute and deliver a counterpart signature page, and become a party, to such agreements as other purchasers of Warrant Stock are a party to and such other stock transfer restriction, voting and other agreements as may be requested by the Company.

6.       No Public Market . Purchaser understands that no public market now exists for any of the securities issued by the Company and that there is no assurance that a public market will ever exist for such securities.

7.       Accredited Investor . Purchaser is an “accredited investor” within the meaning of Rule 501 promulgated under the Securities Act. The Purchaser has considered the Federal and state income tax implications of the exercise of the Warrant and the purchase and subsequent sale of the Warrant Shares.

8.       Residence . If Purchaser is an individual, then Purchaser resides in the state or province identified in the address of Purchaser set forth below; if Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of Purchaser in which its investment decision was made is located at the address or addresses of Purchaser set forth below.

9.       Further Limitations on Disposition . Without in any way limiting the representations set forth above, Purchaser further agrees not to make any disposition of any Shares unless and until:

(i)      there is then in effect a registration statement under the Acts covering such proposed disposition and such disposition is made in accordance with such registration statement; or

(ii)      Purchaser shall have notified the Company of the proposed disposition, and shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition, and, at the expense of Purchaser or its transferee, with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such securities under any of the Acts.

10.       Legends . Purchaser understands and agrees that any certificate or other instrument representing the Shares will bear a legend substantially similar to the legend set forth below:

THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NEITHER THIS SECURITY NOR THE

 

2


SECURITIES ISSUABLE UPON CONVERSION [EXERCISE] HEREOF MAY BE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION UNDER TILE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.

The legend set forth above shall be removed by the Company from any certificate or other instrument representing the Shares upon delivery to the Company of an opinion of counsel reasonably satisfactory to the Company that a registration statement under the Securities Act is at that time in effect with respect to the legended security or that such security can be freely transferred in a public sale without such a registration statement being in effect and that such transfer will not jeopardize the exemption or exemptions from registration pursuant to which the Company issued the Shares.

 

 

Signature

 

Print name:

Address:

 

 

 

 

3


NOTICE OF TRANSFER

[To be signed only upon transfer of Warrant]

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto the Assignee named below the rights and obligations represented by the within Warrant with respect to the number of shares of Warrant Stock of              set forth below:

 

Name of Assignee

  Address   No. of Shares
   
   
   
   
   
   
   

and appoints                                  attorney to transfer said right on the warrant register of                  with full power of substitution in the premises.

 

Dated:

 

 

   

 

      (Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
     

Address:

     

 

     

 

     

 


Attachment B

Form of Warrant


NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.

 

Warrant Issue Date: January 2008   Warrant No. 1-1            

STOCK PURCHASE WARRANT

For value received, Amyris Biotechnologies, Inc. (the “ Company ”), a California corporation, hereby certifies that Starfish, LLC (the “ Holder ”) or its permitted assign(s) is entitled to purchase from the Company, at any time or from time to time during the Exercise Period (as defined below), in whole or in part, 2,580 shares of Warrant Stock (as defined below) of the Company at the Exercise Price (as defined below). This Warrant is subject to the following terms and conditions.

 

  1.

Certain Definitions .

(a)        “ Change in Control ” means (i) any sale, lease, or other disposition of all or substantially all of the assets of the Company or (ii) any consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the shareholders or the Company immediately prior to such consolidation, merger or reorganization, do not hold at least a majority of the resulting or surviving entity’s voting power immediately after such consolidation, merger or reorganization.

(b)        “ Exercise Period ” means the period commencing on the Warrant Issue Date and ending on the date that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office of the Company) on the fifth (5th) anniversary of the Warrant Issue Date, (y) a Change in Control, or (z) the closing of an initial public offering of the Company’s common stock pursuant to a registration statement under the Securities Act of 1933, as amended (the “ Securities Act ”); provided , however , that the Company shall provide written notice to the Holder of a Change in Control or such initial public offering not less than ten (10) business days prior to the occurrence or such event.

(c)        “ Exercise Price ” means $24.88 per share of Warrant Stock, subject to adjustment as provided herein.

(d)        “ Warrant Stock ” means the Company’s Series B Preferred Stock.

 

  2.

Exercise of Warrant .

(a)          The purchase rights represented by this Warrant are exercisable by the Holder, in whole or in part, during the Exercise Period by the surrender of this Warrant, with the


form of Subscription Agreement attached hereto as Annex A duly completed and executed by the Holder, to the Company at its principal executive office, accompanied by payment in cash, in lawful money of the United States of America, including by certified or official bank check made payable to the order of the Company or by wire transfer of immediately available funds to an account designated by the Company, of an amount equal to the Exercise Price multiplied by the number of shares of Warrant Stock being purchased pursuant to such exercise of the Warrant.

(b)        If the fair market value of one share of Warrant Stock is greater than the Exercise Price (at the date of calculation as set forth below), then in lieu of exercising this Warrant for cash, the Holder may elect to receive shares of Warrant Stock equal to the value of this Warrant (or any portion hereof) by surrender of this Warrant (or such portion) during the Exercise Period at the principal office of the Company together with the properly completed Subscription Agreement and notice of such election in which event the Company shall issue to the Holder such number of shares of Warrant Stock computed using the following formula:

X = Y (A-B)

  A

Where X =      the number of shares of Warrant Stock to be issued to the Holder

Y =      the number of shares of Warrant Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised

A =      The fair market value of one share of the Company’s Warrant Stock (at the date of such exercise)

B = Exercise Price (as adjusted to the date of such exercise)

For purposes of the above calculation, the fair market value of one share of Warrant Stock shall be the fair value as determined in good faith by the Company’s Board of Directors or a duly appointed committee of the Board; provided , however , that in the event that the Warrant is being exercised in connection with the Company’s initial public offering, the fair market value per share shall be the per share offering price of the Company’s initial public offering.

(c)        This Warrant may be exercised for less than the full number of shares of Warrant Stock first shown above, provided that this Warrant may not be exercised in part for less than a whole number of shares of Warrant Stock. Upon any such partial exercise, the Company at its expense will forthwith issue to the Holder a new Warrant or Warrants of like tenor exercisable for the number of shares of Warrant Stock as to which rights have not been exercised (subject to adjustment as herein provided).

(d)        As soon as practicable after the exercise of this Warrant and payment of the aggregate Exercise Price, and in any event within 20 business days thereafter, the Company, at its expense, will cause to be issued in the name of and delivered to the Holder a certificate or certificates for the number of duly authorized, validly issued, fully paid and non-assessable shares of Warrant Stock to which the Holder shall be entitled upon such exercise, plus, in lieu of any fractional share to which the Holder would otherwise be entitled, cash in an amount determined in accordance with Section 3(d) hereof. The Company agrees that the shares so

 

2


purchased shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been exercised.

(e)        Prior to the exercise of this Warrant, the Holder shall not be entitled to any rights of a shareholder of the Company with respect to shares for which this Warrant shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive rights, and shall not be entitled to receive any notice of any proceedings of the Company.

 

  3.

Adjustments .

(a)         Adjustments Generally . In order to prevent dilution of the rights granted hereunder in the specific circumstances contemplated by this Section 3, the number of shares of Warrant Stock underlying this Warrant and the Exercise Price shall be subject to adjustment from time to time in accordance herewith. Upon each adjustment of the Exercise Price pursuant to this Section 3, the Holder shall thereafter be entitled to acquire upon exercise, at the Exercise Price resulting from such adjustment, the number of shares of the Company’s Warrant Stock determined by (i) multiplying (A) the Exercise Price in effect immediately prior to such adjustment by (B) the number of shares of Warrant Stock issuable upon exercise hereof immediately prior to such adjustment, and (ii) dividing the product thereof by the Exercise Price resulting from such adjustment.

(b)         Subdivisions and Combinations . In case the Company shall at any time subdivide its outstanding shares of Warrant Stock into a greater number of shares (including, without limitation, through any stock split effected by means of a dividend on the Warrant Stock which is payable in Warrant Stock), the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and, conversely, in case the outstanding shares of Warrant Stock of the Company shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased.

(c)         Reorganization, Reclassification, Consolidation, Merger or Sale of Assets . If, at any time prior to the exercise of this Warrant in full, the Company shall (i) effect any capital reorganization or reclassification of the capital stock of the Company, or consolidate or merge the Company with another entity, or sell, lease, or otherwise dispose of a significant amount of assets, in any such case in such a way that does not constitute a Change in Control, (ii) declare a dividend or make a distribution on the Warrant Stock payable in shares of its capital stock of any class, securities, cash or other property; or (iii) issue any shares of its capital stock by reclassification of its Warrant Shares (including any such reclassification in connection with a consolidation or a merger in which the Company is the continuing corporation), then, as a condition of such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision shall be made whereby the Holder shall have the right to acquire and receive upon exercise of this Warrant in accordance with the terms hereof such shares of stock, securities, cash or other property of the successor entity that a holder of the shares deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, reclassification, consolidation, merger or sale if this Warrant had been exercised immediately before such reorganization, reclassification, consolidation, merger or sale. The foregoing provisions shall similarly apply to successive reorganizations, reclassifications, consolidations,

 

3


mergers or sales and to the stock or securities of any other corporation that are at the time receivable upon the exercise of this Warrant. In all events, appropriate adjustments (as determined by the Board of Directors of the Company) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant.

(d)         Fractional Shares . The Company shall not issue fractions of shares of Warrant Stock upon exercise of this Warrant or scrip in lieu thereof. If any fraction of a share of Warrant Stock would, except for the provisions of this Section 3(d), be issuable upon exercise of this Warrant, then the Company shall in lieu thereof pay to the person entitled thereto an amount in cash equal to the current value of such fraction, calculated to the nearest one-hundredth (1/100) of a share, to be computed on the basis of the fair market value per share as determined by the Board of Directors of the Company in accordance with the provisions of Section 2(b).

(e)         Certificate as to Adjustments . Whenever the Exercise Price shall be adjusted as provided in Section 3 hereof, the Company shall promptly compute such adjustment and furnish to the Holder a certificate setting forth such adjustment and showing in reasonable detail the facts requiring such adjustment, the Exercise Price that will be effective after such adjustment and the number of shares and the amount, if any, of other property that at the time would be received upon the exercise of this Warrant.

4.       Reservation of Stock Issuable on Exercise of Warrant . The Company shall at all times reserve and keep available out of its authorized but unissued stock, solely for the issuance and delivery upon the exercise of this Warrant, such number of its duly authorized shares of Warrant Stock as from time to time shall be issuable upon the exercise of this Warrant. All of the shares of Warrant Stock issuable upon exercise of this Warrant, when issued and delivered in accordance with the terms hereof and thereof, will be duly authorized, validly issued, fully paid and non-assessable, subject to no lien or other encumbrance other than restrictions on transfer arising under applicable securities laws and restrictions imposed by Section 6(a) hereof and the Agreements to which reference is made in Section 6(b) hereof.

5.       Replacement of Warrant . Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement reasonably satisfactory to the Company (with surety if reasonably required), or (in the case of mutilation) upon surrender and cancellation thereof, the Company will issue, in lieu thereof, a new Warrant of like tenor and amount.

6.       Negotiability . This Warrant is issued upon the following terms:

(a)         Transfer . By acceptance hereof, the Holder acknowledges and agrees that, except upon the prior written consent of the Company, this Warrant may not be transferred, and this Warrant may be exercised only by the Holder. Holder is acquiring the Warrant and the shares of Warrant Stock issuable upon exercise hereof for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution

 

4


thereof, and Holder has no present intention of selling, granting any participation in, or otherwise distributing the same.

(b)         Agreements . As a condition to the Company’s obligation to issue shares of capital stock upon exercise hereof, the Holder shall execute the Subscription Agreement attached hereto as Annex A and such stock transfer restriction and voting agreements as may reasonably be requested by the Company.

(c)         Transfer Taxes .  The Company shall not be required to pay any federal or state transfer tax or charge that may be payable in respect of any transfer involved in the transfer or delivery of this Warrant or the issuance or delivery of certificates for Warrant Stock in a name other than that of the Holder or to issue or deliver any certificates for Warrant Stock upon the exercise of this Warrant until any and all such taxes and charges shall have been paid by the Holder or until it has been established to the Company’s reasonable satisfaction that no such tax or charge is due.

(d)         Compliance with Securities Laws . The Holder, by acceptance hereof, acknowledges that this Warrant and the shares of Warrant Stock to be issued upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other party, and for investment, and that the Holder will not offer, sell or otherwise dispose of this Warrant or any shares of Warrant Stock to be issued upon exercise hereof except under circumstances that will not result in a violation of applicable federal and state securities laws.

7.       Subdivision of Rights . Subject to Section 6, this Warrant (as well as any new Warrants issued pursuant to the provisions of this Section 7) is exchangeable, upon the surrender hereof by the Holder, at the principal executive office of the Company for any number of new Warrants of like tenor and date representing in the aggregate the right to subscribe for and purchase the number of shares of Warrant Stock of the Company which may be subscribed for and purchased hereunder.

8.       No Impairment . The Company shall not by any action including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such commercially reasonable actions as may be necessary or appropriate to protect the rights of Holder against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares receivable upon the exercise of this Warrant above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such commercially reasonable action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use its commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

 

5


  9.

Miscellaneous .

(a)         Notices . Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) the next business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company and to the Holder at the address or facsimile number set forth on such party’s signature page hereof or at such other address as the Company or the Holder may designate by 10 days’ advance written notice to the other parties hereto.

(b)         Books of the Company . The Company may treat the holder hereof as appearing on the Company’s books at any time as the holder for all purposes.

(c)         Headings . The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect the meaning hereof.

(d)         Amendment; Waiver . This Warrant and any term hereof may be amended, waived, discharged or terminated only by an instrument in writing signed by the party against whom enforcement of such amendment, waiver, discharge or termination is sought. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision.

(e)         Benefits of this Warrant . Nothing in this Warrant shall be construed to give any person or corporation other than the Company and the Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and the Holder and any other permitted holder or holders of the Warrant.

(f)         Successor and Assigns . Subject to compliance with the provisions of Section 6(a), this Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder.

(g)         Severability . Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be modified to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Warrant.

(h)         Headings . The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

6


(i)         Governing Law . This Warrant and the transactions contemplated hereby shall be governed by and interpreted in accordance with the local laws of the State of California without regard to the provisions thereof relating to conflicts of laws.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

7


IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed and delivered by its authorized officer, as of the date first above written.

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

 

 

Name:

 

 

Title:

 

 

 

AGREED TO AND ACCEPTED:

HOLDER

STARFISH, LLC

 

 

8


LOGO

Statement of Work #1

This Statement of Work #1 is entered into by and between Amyris Biotechnologies, Inc., (“Amyris”) and Starfish, LLC (“Service Provider”) effective as of July 26, 2007 as a supplement to the Master Services Agreement dated July 26, 2007 by and between the parties (the “Services Agreement”). Pursuant to Section 1 of the Services Agreement, this Statement of Work #1 shall set forth the terms and conditions under which Service Provider shall perform certain services for Amyris. All capitalized terms used herein and not otherwise defined shall have the meaning set forth in the Services Agreement.

 

1.

General Scope/Nature of Work

Brand development.

 

2.

Description of Services

As set forth on Attachment A.

 

3.

Term of SOW

As set forth on Attachment A.

 

4.

Deliverables

As set forth on Attachment A.

 

5.

Fees

Fees in the amount of $192,500 plus a warrant in the form attached hereto as Attachment B.

 

6.

Payments

Service Provider shall submit to Amyris reasonably detailed invoices for all services rendered and expenses incurred at the end of each month in which Service Provider provided Services. Within thirty (30) days of receipt of Service Provider’s invoice, payment will be made by Amyris for each hour in which Service Provider has satisfactorily provided Services.

 

7.

Expenses

Amyris shall reimburse Service Provider for all travel expenses incurred in connection with this Agreement upon submission and verification of customary receipts and vouchers. Unless otherwise agreed by Amyris in advance, all air travel shall be economy class.


IN WITNESS WHEREOF, and intending to be bound by the provisions hereof, the parties hereto have caused this Statement of Work #1 to be executed personally or by their duly authorized representatives, to be effective as of the day and year set forth above.

 

STARFISH, LLC

   

AMYRIS BIOTECHNOLOGIES, INC.

By:

 

/s/ David Kassler

   

By:

 

/s/ Tamara L. Tompkins

Name:

 

  David Kassler

   

Name:

 

Tamara L. Tompkins

Title:

 

  President

   

Title:

 

General Counsel

 

2


Attachment A

Phase One:

Audit and Diagnosis

A full and rich articulation of the brand is critical to all future brand development. Starfish must determine what the brand stands for going forward, how it will be differentiated and how it will be presented to the marketplace. In order to create the brand in an effective manner, a fair amount of homework will be required.

Process

 

I. Kick-off meeting.

Starfish will meet with Amyris to refine the details of the process and specific deliverables. The parties will also, as a group, begin to share preliminary thoughts and insights that will guide us in our investigations moving forward.

 

II. Brand Dig

a. Desk Research (Category & Consumer analysis)

In this first working step, Starfish will review all relevant marketplace, competitive and consumer information/ data in order to insure that Starfish can offer a comprehensive overview of the barriers and opportunities.

b. Insight Gathering:

For insight in how the brand will be perceived by the community at large Starfish will utilize a Multi-Constituent Perception Analysis and conduct a thorough set of internal and external interviews.

Internally, Starfish will conduct executive interviews with members of Amyris, senior management team, board members and key investors to gain a solid footing in core values, existing beliefs and attitudes about the company and brand.

Clearly the distribution channel is a critically important part of Amyris’ business and therefore Starfish will spend a fair amount of time analyzing this sector’s understanding of the biofuel category including their motivations and needs. Starfish believes this type of research should be accomplished in person and recommend visiting 10-15 different locations across the country to gain a perspective on their attitudes and beliefs as well as their unique needs in terms of required support and training. This analysis will help us to understand the competitive dynamics and if there are any geographic variations in behaviors.

Externally, Starfish will meet with 8-10 industry opinion leaders, magazine/newspaper editors, analysts or industry insiders.

Also, Starfish will survey 30-50 customers across the different segments once they’re defined. These will take the form of one-on-one interviews. The purpose of these interviews will be to elicit information, insight and guidance in establishing a 360o perspective of the brand and uncovering inconsistencies in stakeholder perceptions.

Starfish will submit a questionnaire for Amyris’ approval before any research is conducted.


c. Competitive Analysis:

Our competitive analysis can be divided into three sections: Positioning Analysis, Competitive Activity/Spending and Marketing Communications Analysis and Marketplace Analysis.

In Positioning Starfish will outline Amyris’ key competitors’ brand positioning as expressed in their marketing communications, and map the results in order to uncover potential gaps that Starfish might exploit. To accomplish this Starfish will review as much of Amyris’ key competitors’ Marketing Communications materials as Starfish can gain access to. This includes advertising, direct marketing, collateral, websites, industry events etc.

Also, Starfish will utilize syndicated sources to read Competitive Activity/Spending to assess Amyris’ position in share of voice and recommend directionally where Amyris should be. Please understand that these sources may not show real insight since Amyris’ category does not spend much in formal advertising, but Starfish will at least gain some idea for spending levels, SOV (share of voice) and overall activity.

The Marketplace analysis is driven by a review of trade journals, industry reports and any sources Amyris would recommend that will educate us on the state of the emerging business that Amyris plans on serving.

 

III. Hypothesis Refinement

a. At the conclusion of the Brand Dig, Starfish will explore positioning hypotheses that emerge from our findings. These will be refined into two or three possible brand strategies to be evaluated by the team.

b. If needed, the final 1-2 strategic directions will be exposed to consumers via some form of qualitative research with the goal of checking/refining our language and our thinking.

In the end, only Amyris can determine what kind of company Amyris want to be. Our role will be to craft a positioning that brings that vision to life.

 

IV. Touch Point Mapping

Starfish’s Touch Point Mapping Process will examine thoroughly every one of Amyris’s potential brand interactions or touch points whether these interactions are with the distribution channel or with the customer themselves. This analysis will identify ways in which to create a unique and meaningful brand experience.

With this understanding, Starfish will present tactics at the highest level (i.e. initial thinking, not fully developed) that address the ideal program. The final deliverable will include the completed map along with a thorough analysis of how the brand is perceived at each touch point.

 

2


Phase Two:

Brand Development (Brand Strategy and Positioning)

The output from Phase Two will consist of an actionable Brand Strategy and Positioning recommendation that includes:

Brand Point of View: the driving passions and beliefs that exist within the Amyris organization

Brand Idea: the brand intent boiled down to the simplest language possible (e.g. for Apple it’s “Simplicity”).

Brand Mantra: a theme line or succinct rallying cry fit for public consumption. Likely will include a longer format description of the brand idea that Starfish call a Brand Manifesto

The Proposition: How will the products/services affect people’s lives?

The Support Points: The key reasons to believe the proposition.

The Primary Target: Based in part on the outcome of the business analysis and agreement of the long-term growth plan

Personality: the key attributes and characteristics of the brand that will inform the look, feel, tone and manner of all communications and activities

A Creative Brief: to provide direction for development of all future brand expression

Touch Point Map: that will provide an overview of the ideal touch point map that Starfish feel will create to improve the brand experience

Brand Architecture and names: to provide specifics on corporate parent name, business names, product names, etc.

Timing

Starfish believe that the scope of work outlined in this proposal will require approximately 8 to 12 weeks to get us to the point where creative development can begin with core identity elements (logo, tagline, etc.).

The following provides a rough timeline. A more detailed one will be built after our Kick-off meeting, but for now Starfish believe that following guidelines will be give Amyris a sense of the time required for each of the phases:

Phase I — 5 to 7 weeks

Phase II — 3 to 5 weeks

Please note that creative development can begin at the end of phase 2 for any core brand identity and collateral elements.

 

3

Exhibit 4.11

AMENDMENT NO. 1 TO STOCK PURCHASE WARRANT

This Amendment No. 1 to Stock Purchase Warrant (this “ Amendment ”) is made and entered into as of April 8, 2010 (the “ Amendment Date ”), by and among Starfish, LLC (“ Starfish ”) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ”).

RECITALS

WHEREAS, the Company and Starfish are parties to that certain Stock Purchase Warrant dated March 6, 2008 (the “ Warrant ”).

WHEREAS, the Company and Starfish desire to amend the Warrant.

NOW, THEREFORE, in consideration of the matters described in the recitals above and the mutual promises, covenants and undertakings contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

AMENDMENT

1.       AMENDMENT TO SECTION 1(B) OF WARRANT . The definition of “Exercise Period” set forth in Section 1(b) of the Warrant shall be deleted in its entirety and replaced with the following:

“(b)    “Exercise Period” means the period commencing on the Warrant Issue Date and ending on the date that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office o the Company) on the fifth (5 th ) anniversary of the Warrant Issue Date, (y) a Change in Control, or (z) one (1) year from the effective date of an initial public offering of the Company’s securities. The settlement of the Warrant is to be made in Warrant Stock and, for the elimination of doubt, the fact that the Warrant Stock delivered on exercise of the this Warrant is not registered under the Securities Act of 1933 will not in any way require you to settle the Warrant otherwise than in Warrant Stock, including, without limitation, that there is no circumstance that would require the Company to net cash settle the Warrant.”

2.       AMENDMENT TO WARRANT: NEW SECTION 3(f) . A new Section 3(f) shall be added to the Warrant to read in its entirety as follows:

“(f)    In case all the authorized Series B Preferred Stock of the Company is converted, pursuant to the Articles of Incorporation, as amended from time to time, into Common Stock or other securities or property, or the Series B Preferred Stock otherwise ceases to exist, then, the Holder, upon exercise of this Warrant at any time after such time (the “Conversion Date” ), shall receive, in lieu of the number of shares of Warrant Stock that would have been issuable upon such exercise immediately prior to the Conversion Date (the “Former Number of Shares of Warrant Stock” ), the stock and other securities and property which the Holder would have been entitled to receive upon the Conversion Date if the Holder had exercised this Warrant with respect to the Former Number of Shares of Warrant Stock immediately prior to the Conversion Date (all subject to further adjustment as provided in this Warrant).”


3.       NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Warrant remain in full force and effect.

4.       GOVERNING LAW . This Amendment shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

5.       COUNTERPARTS; FASCIMILE . This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, or by email in portable document format (.pdf) and delivery of the signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties.

[Remainder of page left blank]


IN WITNESS WHEREOF , each of the Company and Starfish has caused this Amendment No. 1 to Stock Purchase Warrant to be executed by its duly authorized representative, each as of the Amendment Date.

 

AMYRIS BIOTECHNOLOGIES, INC.           STARFISH, LLC

/s/ John Melo

     

/s/ David Kessler

  By:  

John Melo

          By:  

David Kessler

  Its:  

Chief Executive Officer

          Its:  

President

Exhibit 4.12

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (“the 1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.

AMENDED AND RESTATED PLAIN ENGLISH WARRANT AGREEMENT

This is an AMENDED AND RESTATED PLAIN ENGLISH WARRANT AGREEMENT dated March 14, 2008, as amended through September 18, 2009 by and between AMYRIS BIOTECHNOLOGIES, INC., a California corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company.

The words “We”, “Us”, or “Our” refer to the warrant holder, which is TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the issuer, which is AMYRIS BIOTECHNOLOGIES, INC., and not to any individual. The words “The Parties” refers to both TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES. This Amended and Restated Plain English Warrant Agreement may be referred to as the “Warrant Agreement”.

On March 14, 2008, the Parties entered into a Plain English Warrant Agreement (the “Original Warrant Agreement”).

In connection with the First Amendment to the Plain English Master Lease Agreement dated September 18, 2009, (the “Lease Amendment”) the Parties have agreed to change the Price Per Share of the Warrant Stock We have the right to purchase under this Warrant Agreement and replace the Original Warrant Agreement with this Warrant Agreement.

The Parties have entered into a Plain English Master Lease Agreement dated as of March 14, 2008, the Lease Amendment and related Hardware or Software Facility Schedules and Summary Schedules which are collectively referred to in this Warrant Agreement as the “Lease Agreement”.

In consideration of such Lease Agreement, the Parties agree to the following mutual agreements and conditions set forth below are entering into this Warrant Agreement and agree as follows:

 

WARRANT INFORMATION

Effective Date

 

    March 14, 2008, as amended through     September 18, 2009

  

Warrant Number

 

0534-W-01

  

Lease Facility Schedules

 

0534-LE-01H; 0539-LE-01S

     

Warrant Coverage

 

$250,000 (5% of $5,000,000); up to an

additional $250,000 (5% of any amounts

advanced under the Lease Agreement in

excess of $5,000,000 and earned based

upon increments of $1,000,000 advanced)

  

Number of Shares

 

10,048; up to an additional 10,048 (subject to adjustment per the terms of this Warrant Agreement. The Number of Shares is equal to the quotient of the Warrant Coverage and $24.88, the Series B Preferred Stock price per share).

  

Price

Per

Share

 

$12.46

  

Type of Stock

 

Series C Preferred Stock

 

1


OUR CONTACT INFORMATION

Name

 

TriplePoint Capital LLC

  

Address For Notices

 

2755 Sand Hill Road, Ste. 150
Menlo Park, CA 94025
Tel: (650) 854-2090
Fax: (650) 854-1850

  

Contact Person

 

Sajal Srivastava, COO
Tel: (650) 233-2102
Fax: (650) 854-1850
email:legal@triplepointcapital.com

YOUR CONTACT INFORMATION

Customer Name

 

Amyris Biotechnologies,

Inc.

  

Address For Notices

 

5980 Horton St., Suite 450
Emeryville, CA 94608

  

Contact Person

 

Name: Jeryl Hilleman, CFO
Tel: (510) 450-0761 x734
Fax: (510) 450-0794
Email: hilleman@amyris.com

 

1.

WHAT YOU AGREE TO GRANT US

Grant. You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, that number of fully paid and non-assessable shares of Your Warrant Stock equal to Two Hundred Fifty Thousand Dollars ($250,000), divided by $24.88.

In addition, You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, an additional number of fully paid and non-assessable shares of Your Warrant Stock equal to five percent (5%) of any amounts advanced under the Loan Agreement in excess of $5,000,000, divided by the $24.88 (up to an additional $250,000 in the aggregate of warrant coverage), the additional Warrant Coverage will be earned as follows: (i) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is over $5,000,000 but less than $6,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; (ii) immediately upon any Advance in which the total amount advanced under part 1 of the Loan Agreement is $6,000,000 or more but less than $7,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; (iii) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is $7,000,000 or more but less than $8,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; (iv) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is $8,000,000 or more but less than $9,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; and (v) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is $9,000,000 or more but not greater than $10,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000.

In no event shall the total Warrant Coverage exceed $500,000.

 

2


Number of Shares.   Subject to other adjustments per the terms of this Warrant Agreement, the Number of Shares is equal to the quotient of the Warrant Coverage divided by $24.88 (the Series B Preferred Stock price per share).

The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are subject to adjustment as provided in Section 4 hereof.

For purposes of this Warrant Agreement, the following capitalized terms have the meanings given below:

“Exercise Price” means $12.46.

“Warrant Stock” means Your Series C Preferred Stock.

The Parties agree that this Warrant Agreement to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price is included as part of the leased value and will be allocable to the Warrant Agreement and the original issue discount on the Lease Agreement shall be considered to be zero.

 

2.

WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK.

The term of this Warrant Agreement and our right to purchase Warrant Stock will begin the Effective Date, and shall be available until the earlier of (i) 10 years from the Effective Date or (ii) the effective date of Your initial public offering.

Notwithstanding the foregoing, Our right to purchase the Warrant Stock shall be automatically and fully exercised via the net issuance method described below (without surrender of the Warrant Agreement) upon the occurrence of a Merger Event, as defined below, with a Person that is not one of Your affiliates, in which Your common stock is exchanged for cash and/or stock that is traded on a recognized public exchange or on the NASDAQ National Market, provided that, upon consummation of the Merger Event, the consideration payable to Us pursuant to such exercise and on account of the Warrant Stock consists of (i) cash or (ii) stock that is traded on a recognized public exchange or on the NASDAQ National Market and the total per share consideration is equal to or greater than five (5) times the aggregate Exercise Price (as adjusted). No less than ten (10) business days prior to any Merger Event, You shall provide Us with written notice of the proposed Merger Event together with a copy of the executed merger agreement, or other definitive documentation (and all schedules and exhibits thereto) and information concerning Your expected capitalization immediately prior to the Merger Event. Upon consummation of the Merger Event, You shall promptly provide Us with (a) a copy of any modifications or amendments to the executed merger agreement, (b) any other documents in connection therewith, (c) updated information, if any, concerning Your capitalization immediately prior to the Merger Event, and, (d) upon request, by Us any other information reasonably necessary to an informed evaluation of Our rights under this Agreement.

 

3.

HOW WE MAY PURCHASE YOUR WARRANT STOCK.

We may exercise Our purchase rights, in Whole or in part, at any time, or from time to time, prior to the expiration of the term of this Warrant Agreement, by giving You a completed and

 

3


executed Notice of Exercise in the form attached as Exhibit I . Promptly upon receipt of the Notice of Exercise and in any event no later than twenty-one (21) days after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Warrant Stock that We have purchased and You will execute the Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any.

We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as determined below. If We elect the Net Issuance method, You will issue Warrant Stock using the following formula:

X = Y(A-B)

            A

    Where X =   the number of shares of Warrant Stock to be issued to Us.

                Y =   the number of shares of Warrant Stock We request to be exercised under

                          this Warrant Agreement.

                A =   the fair market value of one share of Warrant Stock.

                B =   the Exercise Price.

For purposes of the above calculation, current fair market value of Warrant Stock shall mean with respect to each share of Warrant Stock:

If the exercise is in connection with the initial public offering of Your Common Stock , and if Your registration statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” specified in the final prospectus of the offering and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise;

If this Warrant Agreement is exercised after, and not in connection with the Your initial public offering, and:

 

Þ

if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; or

 

Þ

if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise.

 

4


If this Warrant Agreement is exercised prior to or after Your initial public offering, and:

 

Þ

Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the current fair market value of Warrant Stock shall be the product of (x) the fair market value of a share of Your Common Stock (the highest price per share which You could obtain from a willing buyer (not a current employee or director) for shares of Common Stock sold, from authorized but unissued shares), as determined in good faith by Your Board of Directors and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise, unless You shall become subject to a merger, acquisition or other consolidation pursuant to which You are not the surviving party, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of the Your Warrant Stock on a common equivalent basis pursuant to such merger or acquisition or other consolidation.

During the term of this Warrant Agreement, You will at all times from and after the Effective Date have authorized and reserved a sufficient number of shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and (b) Common Stock to provide for the conversion of the Warrant Stock.

If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an amended Warrant Agreement stating the remaining number of shares that are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement.

If at the end of the term of this Warrant Agreement, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date, then this Warrant Agreement shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of Warrant Stock (or such other securities) for which it shall not previously have been exercised or converted, and You shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion to Us.

 

4.

WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE.

 

Þ

If You are Acquired.   If at any time: (i) there is a reorganization of Your stock (other than a reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity; (iii) You sell or convey, or grant an exclusive license with respect to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of the outstanding voting power of the capita] stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall be made so that We shall thereafter be entitled to receive, upon exercise of Our rights under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that which would have been issuable if We had exercised Our rights under this

 

5


  Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Your Board of Directors) shall be made in the application of the provisions of this Warrant Agreement with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable) shall be applicable to the greatest extent possible.

 

Þ

If You Reclassify Your Stock.   If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change any of the securities as to which purchase rights under this Warrant Agreement exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change.

 

Þ

If You Subdivide or Combine Your Shares.   If at any time You combine or subdivide Your Warrant Stock, the Exercise Price will be proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination.

 

Þ

If You Pay Stock Dividends.   If at any time You pay a dividend payable in, or make any other distribution (except any distribution specifically provided for in the above paragraphs) of Your Warrant Stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of Your Warrant Stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of which shall be the total number of all shares of Your Warrant Stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares of Warrant Stock (calculated to the nearest whole share) obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.

 

Þ

If You Change the Antidilution Rights of the Warrant Stock or Issue New Preferred or Convertible Stock.   All antidilution rights applicable to the Warrant Stock purchasable under this Warrant Agreement are as set forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement, amendment, modification of or waiver of any right under Your Certificate of Incorporation. You will provide Us with any written notices relating to such antidilution rights provided to other holders of the Warrant Stock.

 

5.

WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT.

Subject to the terms and conditions contained in Section 7, We (or any successor transferee) may transfer in whole or in part this Warrant Agreement and all its rights. You will record the transfer

 

6


on Your books when You receive Our Notice of Transfer in the form attached hereto as Exhibit III, and Our payment of all transfer taxes and other governmental charges involved in such transfer.

 

6.

REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU.

 

Þ

Reservation of Warrant Stock.   The Warrant Stock issuable upon exercise of Our rights under this Warrant Agreement will be duly and validly reserved and when issued in accordance with the provisions of this Warrant Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, however, that the Warrant Stock issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer under state and/or Federal securities laws, this Warrant Agreement and any other agreement between Us and You. Upon Our exercise, You will issue to Us certificates for shares of Warrant Stock without charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of shares of Warrant Stock. You will not be required to pay any tax, which may be payable in respect of any transfer involved and the issuance and delivery of any certificate in a name other than TriplePoint Capital LLC.

 

Þ

Due Authority.   Your execution and delivery of this Warrant Agreement and the performance of Your obligations hereunder, including the issuance to Us of the right to acquire the shares of Warrant Stock, have been duly authorized by all necessary corporate action on Your part and this Warrant Agreement is not inconsistent with the Your Certificate of Incorporation or Bylaws, subject to the accuracy of Our representations in Section 7 hereof, does not contravene any law or governmental rule, regulation or order applicable to it, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which You are a party or by which You are bound, and this Warrant Agreement constitutes a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies.

 

Þ

Consents and Approvals.   No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required notices pursuant to Federal and state securities laws, which filings will be effective by the times required thereby.

 

Þ

Issued Securities.   All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other securities have been duly authorized and validly issued and are fully paid and nonassessable. To the extent applicable all outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the Effective Date:

 

7


Your authorized capital consists of (A) 33,000,000 shares of Common Stock, of which 5,029,830 shares of Common Stock are issued and outstanding, and (B) 21,080,641 shares of preferred stock, of which 16,547,462 shares are issued and outstanding.

You have reserved 5,942,700 shares of Common Stock for issuance under Your Stock Incentive Plan, under which 3,405,762 options have been granted. Except as otherwise provided in this Warrant Agreement and as noted above, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Your capital stock or other of Your securities.

Except as set forth in Your Investor’s Rights Agreement, a true, correct and complete copy of which has been delivered to Us prior to the issuance of this Warrant, and the Lease Agreement, Your stockholders do not have preemptive rights to purchase new issuances of Your capital stock.

 

Þ

Other Commitments to Register Securities.   As of the Effective Date, except as set forth in this Warrant Agreement and the Investors’ Rights’ Agreement, You are not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued.

 

Þ

Exempt Transaction.   Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Warrant Stock upon exercise of this Warrant Agreement will constitute a transaction exempt front (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws.

 

Þ

Compliance with Rule 144.   We may sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and Exchange Commission. Upon exercise of this warrant, we will be obligated to become a party to the Investors’ Rights Agreement and, pursuant thereto, shall be entitled to the benefit of Your covenants with respect to Your compliance with the filing requirements of the Securities and Exchange Commission as set forth in such Rule 144, as may be amended.

 

Þ

No Impairment.   You agree not to, by amendment of Your Articles of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by You, but shall at all times in good faith assist in carrying out all the provisions of this Warrant and in taking all such action as may be necessary or appropriate to protect Our rights under this Warrant against impairment. However, You shall not be deemed to have impaired Our rights if You amend Your Articles of Incorporation or Your Investor’s Rights Agreement or similar agreements, or the holders of Your equity securities waive their rights thereunder, in a manner that does not (individually or when considered in the context of any other actions being taken in connection with such amendments or waivers) affect Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock.

 

8


7.

OUR REPRESENTATIONS AND COVENANTS TO YOU.

 

Þ

Investment Purpose.   The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of Our rights contained herein and the Common Stock issuable upon conversion will be acquired for investment purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any public distribution of the same in violation of the 1933 Act.

 

Þ

Private Issue.   We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon exercise of this Warrant Agreement and the Common Stock issuable upon conversion of the Warrant Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth in this Section 7.

 

Þ

Disposition of Our Rights.   In no event will We make a disposition of any of Our rights to acquire Warrant Stock or Warrant Stock issuable upon exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to be bound in writing to the applicable terms and conditions of this Warrant Agreement, and (iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of Our rights to acquire Warrant Stock or Warrant Stock issuable on the exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Warrant Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You at Our request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to the You at Our request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the holder of a share of Warrant Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without expense to such holder, one or more new certificates for the Warrant or for such shares of Warrant Stock not bearing any restrictive legend referring to 1933 Act registration or exemption.

 

Þ

Financial Risk.   We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and financial condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment.

 

9


Þ

Risk of No Registration.   We understand that if You do not register with the Securities and Exchange Commission pursuant to Section 12 of the 1934 Act (the “1934 Act”), or file reports pursuant to Section 15(d), of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to purchase Warrant Stock pursuant to this Warrant Agreement, or (ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Warrant Stock, We may be required to hold such securities for an indefinite period. We also understand that any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant Stock, which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule.

 

Þ

Accredited Investor.   We are an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D of the 1933 Act, as presently in effect.

 

8.

NOTICES YOU AGREE TO PROVIDE US.

You agree to give Us at least twenty (20) days prior written notice of the following events:

 

Þ

if You Pay a Dividend or distribution declaration upon your stock.

 

Þ

If You offer for subscription pro-rata to the existing shareholders additional stock or other rights.

 

Þ

If You consummate a Merger Event.

 

Þ

If You have an IPO.

 

Þ

If You dissolve or liquidate.

All notices in this Section must set forth details of the event, and if applicable, how the event adjusts either Our number of shares or Our Exercise Price and the method used for such adjustment.

 

9.

DOCUMENTS YOU WILL PROVIDE US.

Upon the Effective Date, copies of

 

Þ

Certified Resolutions

 

Þ

Articles of Incorporation

 

Þ

Investor’s Rights Agreement

 

Þ

Bylaws

 

Þ

Any other documents and other information that We may reasonably request and are necessary to implement the provisions and purposes of this Agreement.

 

10


10.

REGISTRATION RIGHTS UNDER THE 1933 ACT.

The shares of Your common stock into which the Warrant Stock is convertible shall have registration rights as set forth in the Investors’ Rights Agreement, dated as of February 29, 2008, (as amended, restated or otherwise modified in accordance with its terms from time to time, the Investor Rights Agreement”) to the same extent and on the same terms and conditions as possessed by the other Holders thereunder. The provisions set forth in Your Investors’ Right s Agreement relating to such registration rights shall not be amended or modified in a manner that treats Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock. By its receipt of this Warrant, the Holder agrees to be bound by the Investor Rights Agreement in so far as it relates to such registration rights as a Holder pursuant thereto.

 

11.

OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY.

Effective Date.   This Warrant Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties.

Attorney’s Fees.   In any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant Agreement.

Governing Law.   This Warrant Agreement shall be governed by and construed for all purposes under and in accordance with the laws of the State of California without giving effect to that body of law pertaining to conflicts of laws.

Consent to Jurisdiction and Venue.   All judicial proceedings arising in or under or related to this Warrant Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Plain English Warrant Agreement. Service of process on any party hereto in any action arising out of or relating to this agreement shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

Mutual Waiver of Jury Trial; Judicial Reference.   Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and The Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM,

 

11


CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “ CLAIMS ”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Warrant Agreement.

Counterparts.   This Warrant Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Notices.   Any notice required or permitted under this Warrant Agreement shall be given in writing and shall be deemed effectively given upon the earlier of (1) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is sent by overnight mail via nationally recognized courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending party.

Remedies.   In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement and that in the event of any breach of this Agreement, the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this Agreement.

 

12


Survival.   The representations, warranties, covenants, and conditions of the Parties contained herein or made pursuant to this Warrant Agreement shall survive the execution and delivery of this Warrant Agreement.

Severability.   In the event any one or more of the provisions of this Warrant Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision.

Entire Agreement.   This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter. This Warrant Agreement amends, restates and supersedes the Original Warrant Agreement.

Amendments.   Any provision of this Warrant Agreement may only be amended by a written instrument signed by the Parties.

Lost Warrants or Stock Certificates.   You covenant to Us that, upon receipt of evidence reasonably satisfactory to Us of the loss, theft, destruction or mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to You, or in the case of any such mutilation upon surrender and cancellation of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Agreement or stock certificate.

Rights as Stockholders.   We shall not, as a party to this Warrant Agreement, be entitled to vote or receive dividends or be deemed the holder of Warrant Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon Us any of the rights of one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until this Warrant Agreement is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.

Facsimile Signatures.   This Warrant Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party.

(Signature Page to Follow)

 

13


IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its officers who are duly authorized as of the Effective Date.

 

You:

 

AMYRIS BIOTECHNOLOGIES, INC.

Signature:

 

/s/ John G. Melo

Print Name:

 

John G. Melo

Title:

 

CEO

Us:

 

TRIPLEPOINT CAPITAL LLC

Signature:

 

/s/ Sajal Srivastava

Print Name:

 

Sajal Srivastava

Title:

 

Chief Operating Officer

[SIGNATURE PAGE TO AMENDED AND RESTATED PLAIN ENGLISH WARRANT

AGREEMENT 0534-W-01]

 

 

 

14


EXHIBIT I

NOTICE OF EXERCISE

 

To:

[                                               ]

 

1.

We hereby elect to purchase [                          ] shares of the Series [                          ] Preferred Stock of [                          ], pursuant to the terms of the Plain English Warrant Agreement dated the [                          ] day of [                          ], [200__] (the “Plain English Warrant Agreement”) between You and Us. We hereby tender here payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any.

 

2.

Method of Exercise (Please initial the applicable blank)

 

 

a.

                     The undersigned elects to exercise the Plain English Warrant Agreement by means of a cash payment, and gives You full payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any.

 

 

b.

                     The undersigned elects to exercise the Plain English Warrant Agreement by means of the Net Issuance Exercise method of Section 3 of the Plain English Warrant Agreement.

 

3.

In exercising Our rights to purchase the Series [                          ] Preferred Stock of [                          ], We hereby confirm and acknowledge the investment representations, warranties and covenants made in Section 7 of the Plain English Warrant Agreement.

Please issue a certificate or certificates representing these purchased shares of Series [                      ] Preferred Stock in Our name or in such other name as is specified below.

 

     
 

(Name)

 
     
 

(Address)

 
 

US:

 

TRIPLEPOINT CAPITAL LLC

 

By:

     
 

Title:

     
 

Date:

     

 

15


EXHIBIT II

ACKNOWLEDGMENT OF EXERCISE

[                                                       ], hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase [                          ] shares of the Series [                          ] Preferred Stock of [                          ], pursuant to the terms of the Plain English Warrant Agreement, and further acknowledges that [                          ] shares remain subject to purchase under the terms of the Plain English Warrant Agreement.

YOU:

 

By:

   

Title:

   

Date:

   
 

 

16


EXHIBIT III

TRANSFER NOTICE

FOR VALUE RECEIVED, the foregoing Plain English Warrant Agreement and all rights evidenced thereby are hereby transferred and assigned to

 

________________________________________________

(Please Print)

Whose address is ___________________________________________

________________________________________________________________

 

Dated:

       

Holder’s Signature:

       

Holder’s Address:

       

Transferee’s Signature:

       

Transferee’s Address:

       

Signature Guaranteed:

       

NOTE:   The signature to this Transfer Notice must correspond with the name as it appears on the face of the Plain English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Plain English Warrant Agreement.

 

17

Exhibit 4.13

AMENDMENT NO.1 TO AMENDED AND RESTATED PLAIN ENGLISH WARRANT AGREEMENT

This Amendment No.1 to Amended and Restated Plain English Warrant Agreement (this “ Amendment ) is made and entered into as of April 8, 2010 (the “ Amendment Date ), by and among TriplePoint Capital LLC, a Delaware limited liability company ( TriplePoint ) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ).

RECITALS

WHEREAS, the Company and TriplePoint are parties to that certain Amended and Restated Plain English Warrant Agreement, originally dated March 14, 2008 as amended September 18, 2009 (the “ Agreement ”).

WHEREAS, the Company and TriplePoint desire to amend the Agreement.

NOW, THEREFORE, in consideration of the matters described in the recitals above and the mutual promises, covenants and undertakings contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

AMENDMENT

1.       AMENDMENT TO AGREEMENT . The first paragraph of Section 2 shall be deleted in its entirety and replaced with the following:

“(a) The term of this Warrant Agreement and our right to purchase Warrant Stock will begin on the Effective Date, and shall be available until the earlier of (i) 10 years from the Effective Date or (ii) one (1) year from the effective date of an initial public offering of Your securities.

(b) The settlement of the Warrant pursuant to this Warrant Agreement is to be made in Warrant Stock and, for the elimination of doubt, the fact that the Warrant Stock delivered on exercise of the this Warrant Agreement is not registered under the Securities Act of 1933 will not in any way require you to settle the Warrant otherwise than in Warrant Stock, including, without limitation, that there is no circumstance that would require You to net cash settle the Warrant.

(c) In case all the authorized Series C Preferred Stock of the Company is converted, pursuant to the Company’s Articles of Incorporation, as may be amended from time to time, into Common Stock or other securities or property, or the Series C Preferred Stock otherwise ceases to exist, then, We, upon exercise of the Warrant pursuant to this Warrant Agreement at any time after such time (the “ Conversion Date ), shall receive, in lieu of the number of shares of Warrant Stock that would have been issuable upon such exercise immediately prior to the Conversion Date (the “ Former Number of Shares ), the stock and other securities and property which We would have been entitled to receive upon the Conversion Date if We had exercised the Warrant pursuant to this Warrant


Agreement with respect to the Former Number of Shares immediately prior to the Conversion Date (all subject to further adjustment as provided in this Warrant Agreement).”

2.       NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Agreement remain in full force and effect. Notwithstanding anything else in this Amendment, if there is any conflict between subsections (b) and (c) in Section 1 above and the Agreement, the terms of the Agreement shall prevail.

3.       GOVERNING LAW . This Amendment shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

4.       COUNTERPARTS; FASCIMILE . This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, or by email in portable document format (.pdf) and delivery of the signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties.

[Remainder of page left blank]

 

2


IN WITNESS WHEREOF, each of the Company and TriplePoint has caused this Amendment No. 1 to Amended and Restated Plain English Warrant Agreement to be executed by its duly authorized representative, each as of the Amendment Date.

 

AMYRIS BIOTECHNOLOGIES, INC.       TRIPLEPOINT CAPITAL, LLC

LOGO

     

LOGO

  By:  

Tamara L. Tompkins

          By:  

 

  Its:  

General Counsel

          Its:  

 

 

3

Exhibit 4.14

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (“the 1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.

PLAIN ENGLISH WARRANT AGREEMENT

This is a PLAIN ENGLISH WARRANT AGREEMENT dated September 18, 2009 by and between AMYRIS BIOTECHNOLOGIES, INC., a California corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company.

The words “We”, “Us”, or “Our” refer to the warrant holder, which is TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the issuer, which is AMYRIS BIOTECHNOLOGIES, INC., and not to any individual. The words “The Parties” refers to both TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES. This Plain English Warrant Agreement may be referred to as the “Warrant Agreement”.

The Parties have entered into a Plain English Master Lease Agreement dated as of March 14, 2008, as amended September 18, 2009 and related Hardware or Software Facility Schedules and Summary Schedules which are collectively referred to in this Warrant Agreement as the “Lease Agreement”.

In consideration of such Lease Agreement, the Parties agree to the following mutual agreements and conditions set forth below:

 

WARRANT INFORMATION

Effective Date

September 18, 2009

  

Warrant Number

0534-W-02

  

Lease Facility Schedules

0534-LE-02H; 0539-LE-02S

Warrant Coverage

$100,000 (5% of $2,000,000);

  

Number of Shares

8,026, subject to
adjustment per the
terms of
this Warrant
Agreement

  

Price Per Share

$12.46, subject to
adjustment
per the terms of this
Warrant
Agreement

  

Type of Stock

Series C Preferred Stock, subject to adjustment per the terms of this Warrant Agreement

 

OUR CONTACT INFORMATION

Name

TriplePoint Capital LLC

  

Address For Notices

2755 Sand Hill Road, Ste. 150
Menlo Park, CA 94025
Tel: (650) 854-2090
Fax: (650) 854-1850

  

Contact Person

Sajal Srivastava, COO
Tel: (650) 233-2102
Fax: (650) 854-1850
email:legal@triplepointcapital.com

 

1


YOUR CONTACT INFORMATION

Customer Name

Amyris Biotechnologies, Inc.

  

Address For Notices

5980 Horton St., Suite 450
Emeryville, CA 94608

  

Contact Person

Name: Jeryl Hilleman, CFO
Tel: (510) 450-0761 x734
Fax: (510) 450-0794
Email: hilleman@amyris.com

 

1.

WHAT YOU AGREE TO GRANT US

You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, that number of fully paid and non-assessable shares of Your Warrant Stock equal to One Hundred Thousand Dollars ($100,000), divided by the Exercise Price.

The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are subject to adjustment as provided in Section 4 hereof.

For purposes of this Warrant Agreement, the following capitalized terms have the meanings given below:

“Exercise Price” means the lower of (a) the lowest per share price for which Your preferred stock is sold in the Next Round or (b) $12.46.

“Next Round’ means the next bona fide round of equity financing in which You issue and sell shares of your preferred stock for aggregate gross cash proceeds of at least $1,000,000 (excluding any amounts received upon conversion or cancellation of indebtedness) subsequent to the Effective Date (anticipated to be Your Series D Preferred).

“Warrant Stock” means (a) the class and series of Your preferred stock issued in the Next Round, if the lowest per share price for which such preferred stock is sold in the Next Round is less than $12.46 per share, or (b) in all other cases, Your Series C Preferred Stock.

Notwithstanding the above, if this Warrant Agreement is exercised prior to the Next Round then this Warrant Agreement shall be exercisable for Your Series C Preferred Stock and the Exercise Price shall be $12.46 per share.

The Parties agree that this Warrant Agreement to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price is included as part of the leased value and will be allocable to the Warrant Agreement and the original issue discount on the Lease Agreement shall be considered to be zero.

 

2


2.

WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK.

The term of this Warrant Agreement and our right to purchase Warrant Stock will begin the Effective Date, and shall be available until the earlier of (i) 10 years from the Effective Date or (ii) the effective date of Your initial public offering.

Notwithstanding the foregoing, Our right to purchase the Warrant Stock shall be automatically and fully exercised via the net issuance method described below (without surrender of the Warrant Agreement) upon the occurrence of a Merger Event, as defined below, with a Person that is not one of Your affiliates, in which Your common stock is exchanged for cash and/or stock that is traded on a recognized public exchange or on the NASDAQ National Market, provided that, upon consummation of the Merger Event, the consideration payable to Us pursuant to such exercise and on account of the Warrant Stock consists of (i) cash or (ii) stock that is traded on a recognized public exchange or on the NASDAQ National Market and the total per share consideration is equal to or greater than five (5) times the aggregate Exercise Price (as adjusted). No less than ten (10) business days prior to any Merger Event, You shall provide Us with written notice of the proposed Merger Event together with a copy of the executed merger agreement, or other definitive documentation (and all schedules and exhibits thereto) and information concerning Your expected capitalization immediately prior to the Merger Event. Upon consummation of the Merger Event, You shall promptly provide Us with (a) a copy of any modifications or amendments to the executed merger agreement, (b) any other documents in connection therewith, (c) updated information, if any, concerning Your capitalization immediately prior to the Merger Event, and, (d) upon request, by Us any other information reasonably necessary to an informed evaluation of Our rights under this Agreement.

 

3.

HOW WE MAY PURCHASE YOUR WARRANT STOCK.

We may exercise Our purchase rights, in Whole or in part, at any time, or from time to time, prior to the expiration of the term of this Warrant Agreement, by giving You a completed and executed Notice of Exercise in the form attached as Exhibit I . Promptly upon receipt of the Notice of Exercise and in any event no later than twenty-one (21) days after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Warrant Stock that We have purchased and You will execute the Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any.

We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as determined below. If We elect the Net Issuance method, You will issue Warrant Stock using the following formula:

X = Y(A-B)

    A

 

Where X =

  

the number of shares of Warrant Stock to be issued to Us.

Y =   

the number of shares of Warrant Stock We request to be exercised under this Warrant Agreement.

 

3


A =         the fair market value of one share of Warrant Stock.

B =         the Exercise Price.

For purposes of the above calculation, current fair market value of Warrant Stock shall mean with respect to each share of Warrant Stock:

If the exercise is in connection with the initial public offering of Your Common Stock , and if Your registration statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” specified in the final prospectus of the offering and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise;

If this Warrant Agreement is exercised after, and not in connection with the Your initial public offering, and:

 

Þ

if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; or

 

Þ

if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise.

If this Warrant Agreement is exercised prior to or after Your initial public offering, and:

 

Þ

Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the current fair market value of Warrant Stock shall be the product of (x) the fair market value of a share of Your Common Stock (the highest price per share which You could obtain from a willing buyer (not a current employee or director) for shares of Common Stock sold, from authorized but unissued shares), as determined in good faith by Your Board of Directors and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the lime of such exercise, unless You shall become subject to a merger, acquisition or other consolidation pursuant to which You are not the surviving party, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of the Your Warrant Stock on a common equivalent basis pursuant to such merger or acquisition or other consolidation.

During the term of this Warrant Agreement, You will at all times from and after the Effective Date have authorized and reserved a sufficient number of shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and (b) Common Stock to provide for the conversion of the Warrant Stock.

 

4


If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an amended Warrant Agreement stating the remaining number of shares that are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement.

If at the end of the term of this Warrant Agreement, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date, then this Warrant Agreement shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of Warrant Stock (or such other securities) for which it shall not previously have been exercised or converted, and You shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion to Us.

 

4.

WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE.

 

Þ

If You are Acquired. If at any time: (i) there is a reorganization of Your stock (other than a reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity: (iii) You sell or convey, or grant an exclusive license with respect to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of the outstanding voting power of the capita] stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall he made so that We shall thereafter he entitled to receive, upon exercise of Our rights under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that which would have been issuable if We had exercised Our rights under this Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Your Board of Directors) shall be made in the application of the provisions of this Warrant Agreement with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable) shall be applicable to the greatest extent possible.

 

Þ

If You Reclassify Your Stock. If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change any of the securities as to which purchase rights under this Warrant Agreement exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change.

 

Þ

If You Subdivide or Combine Your Shares. If at any time You combine or subdivide Your Warrant Stock, the Exercise Price will be proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination.

 

5


Þ

If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution (except any distribution specifically provided for in the above paragraphs) of Your Warrant Stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of Your Warrant Stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of which shall be the total number of all shares of Your Warrant Stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares of Warrant Stock (calculated to the nearest whole share) obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.

 

Þ

If You Change the Antidilution Rights of the Warrant Stock or Issue New Preferred or Convertible Stock. All antidilution rights applicable to the Warrant Stock purchasable under this Warrant Agreement are as set forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement, amendment, modification of or waiver of any right under Your Certificate of Incorporation. You will provide Us with any written notices relating to such antidilution rights provided to other holders of the Warrant Stock.

 

5.

WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT.

Subject to the terms and conditions contained in Section 7, We (or any successor transferee) may transfer in whole or in part this Warrant Agreement and all its rights. You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached hereto as Exhibit III, and Our payment of all transfer taxes and other governmental charges involved in such transfer.

 

6.

REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU.

 

Þ

Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of Our rights under this Warrant Agreement will be duly and validly reserved and when issued in accordance with the provisions of this Warrant Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, however, that the Warrant Stock issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer under state and/or Federal securities laws, this Warrant Agreement and any other agreement between Us and You. Upon Our exercise, You will issue to Us certificates for shares of Warrant Stock without charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of shares of Warrant Stock. You will not be required to pay any tax, which may be payable in respect of any transfer involved and the issuance and delivery of any certificate in a name other than TriplePoint Capital LLC.

 

6


Þ

Due Authority. Your execution and delivery of this Warrant Agreement and the performance of Your obligations hereunder, including the issuance to Us of the right to acquire the shares of Warrant Stock, have been duly authorized by all necessary corporate action on Your part, other than any amendment of the Company’s articles of incorporation necessary to authorize the Next Round, and this Warrant Agreement is not inconsistent with the Your Certificate of Incorporation or Bylaws, subject to the accuracy of Our representations in Section 7 hereof, does not contravene any law or governmental rule, regulation or order applicable to it, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which You are a party or by which You are bound, and this Warrant Agreement constitutes a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies.

 

Þ

Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required notices pursuant to Federal and state securities laws, which filings will be effective by the times required thereby and for the filing of any amendment to Your articles of incorporation authorizing Your Next Round.

 

Þ

Issued Securities. All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other securities have been duly authorized and validly issued and are fully paid and nonassessable. To the extent applicable all outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the Effective Date:

Your authorized capital consists of (A) 33,000,000 shares of Common Stock, of which 5,029,830 shares of Common Stock are issued and outstanding, and (B) 21,080,641 shares of preferred stock, of which 16,547,462 shares are issued and outstanding.

You have reserved 5,942,700 shares of Common Stock for issuance under Your Stock Incentive Plan, under which 3,405,762 options have been granted. Except as otherwise provided in this Warrant Agreement and as noted above, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Your capital stock or other of Your securities.

Except as set forth in Your Investor’s Rights Agreement, a true, correct and complete copy of which has been delivered to Us prior to the issuance of this Warrant, and the Lease Agreement, Your stockholders do not have preemptive rights to purchase new issuances of Your capital stock.

 

Þ

Other Commitments to Register Securities. As of the Effective Date, except as set forth in this Warrant Agreement and the Investors’ Rights’ Agreement, You are not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under

 

7


  the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued.

 

Þ

Exempt Transaction. Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Warrant Stock upon exercise of this Warrant Agreement will constitute a transaction exempt front (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws.

 

Þ

Compliance with Rule 144. We may sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and Exchange Commission. Upon exercise of this warrant, we will be obligated to become a party to the Investors’ Rights Agreement and, pursuant thereto, shall be entitled to the benefit of Your covenants with respect to Your compliance with the filing requirements of the Securities and Exchange Commission as set forth in such Rule 144, as may be amended.

 

Þ

No Impairment. You agree not to, by amendment of Your Articles of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by You, but shall at all times in good faith assist in carrying out all the provisions of this Warrant and in taking all such action as may be necessary or appropriate to protect Our rights under this Warrant against impairment, However, You shall not be deemed to have impaired Our rights if You amend Your Articles of Incorporation or Your Investor’s Rights Agreement or similar agreements, or the holders of Your equity securities waive their rights thereunder, in a manner that does not (individually or when considered in the context of any other actions being taken in connection with such amendments or waivers) affect Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock.

 

7.

OUR REPRESENTATIONS AND COVENANTS TO YOU.

 

Þ

Investment Purpose. The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of Our rights contained herein and the Common Stock issuable upon conversion will be acquired for investment purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any public distribution of the same in violation of the 1933 Act.

 

Þ

Private Issue. We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon exercise of this Warrant Agreement and the Common Stock issuable upon conversion of the Warrant Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth in this Section 7.

 

Þ

Disposition of Our Rights. In no event will We make a disposition of any of Our rights to acquire Warrant Stock or Warrant Stock issuable upon exercise of such rights or the

 

8


  Common Stock issuable upon conversion of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to be bound in writing to the applicable terms and conditions of this Warrant Agreement, and (iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of Our rights to acquire Warrant Stock or Warrant Stock issuable on the exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Warrant Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You at Our request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to the You at Our request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the holder of a share of Warrant Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without expense to such holder, one or more new certificates for the Warrant or for such shares of Warrant Stock not bearing any restrictive legend referring to 1933 Act registration or exemption.

 

Þ

Financial Risk. We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and financial condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment.

 

Þ

Risk of No Registration. We understand that if You do not register with the Securities and Exchange Commission pursuant to Section 12 of the 1934 Act (the “1934 Act”), or file reports pursuant to Section 15(d), of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to purchase Warrant Stock pursuant to this Warrant Agreement, or (ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Warrant Stock, We may be required to hold such securities for an indefinite period. We also understand that any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant Stock, which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule.

 

Þ

Accredited Investor. We are an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D of the 1933 Act, as presently in effect.

 

9


8.

NOTICES YOU AGREE TO PROVIDE US.

You agree to give Us at least twenty (20) days prior written notice of the following events:

Þ if You Pay a Dividend or distribution declaration upon your stock.

Þ If You offer for subscription pro-rata to the existing shareholders additional stock or other rights.

Þ If You consummate a Merger Event.

Þ If You have an IPO.

Þ If You dissolve or liquidate.

All notices in this Section must set forth details of the event, and if applicable, how the event adjusts either Our number of shares or Our Exercise Price and the method used for such adjustment.

 

9.

DOCUMENTS YOU WILL PROVIDE US.

Upon the Effective Date, copies of

Þ Certified Resolutions

Þ Articles of Incorporation

Þ Investor’s Rights Agreement

Þ Bylaws

Þ Any other documents and other information that We may reasonably request and are necessary to implement the provisions and purposes of this Agreement.

 

10.

REGISTRATION RIGHTS UNDER THE 1933 ACT.

The shares of Your common stock into which the Warrant Stock is convertible shall have registration rights as set forth in the Investors’ Rights Agreement, dated as of February 29, 2008, (as amended, restated or otherwise modified in accordance with its terms from time to time, the Investors’ Rights Agreement”) to the same extent and on the same terms and conditions as possessed by the other Holders thereunder. The provisions set forth in Your Investors’ Right s Agreement relating to such registration rights shall not be amended or modified in a manner that treats Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock. By its receipt of this Warrant, the Holder agrees to be bound by the Investor Rights Agreement in so far as it relates to such registration rights as a Holder pursuant thereto.

 

10


11.

OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY.

Effective Date. This Warrant Agreement shall he construed and shall be given effect in all respects as if it had been executed and delivered by the Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties.

Attorney’s Fees. In any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant Agreement.

Governing Law. This Warrant Agreement shall be governed by and construed for all purposes under and in accordance with the laws of the State of California without giving effect to that body of law pertaining to conflicts of laws.

Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Warrant Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Plain English Warrant Agreement. Service of process on any party hereto in any action arising out of or relating to this agreement shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

Mutual Waiver of Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and The Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “ CLAIMS ”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES,

 

11


FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Warrant Agreement.

Counterparts. This Warrant Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Notices. Any notice required or permitted under this Warrant Agreement shall be given in writing and shall be deemed effectively given upon the earlier of (1) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is sent by overnight mail via nationally recognized courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending party.

Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement and that in the event of any breach of this Agreement, the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this Agreement.

Survival. The representations, warranties, covenants, and conditions of the Parties contained herein or made pursuant to this Warrant Agreement shall survive the execution and delivery of this Warrant Agreement.

Severability. In the event any one or more of the provisions of this Warrant Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision.

Entire Agreement. This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter.

 

12


Amendments. Any provision of this Warrant Agreement may only be amended by a written instrument signed by the Parties.

Lost Warrants or Stock Certificates. You covenant to Us that, upon receipt of evidence reasonably satisfactory to Us of the loss, theft, destruction or mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to You, or in the case of any such mutilation upon surrender and cancellation of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Agreement or stock certificate.

Rights as Stockholders. We shall not, as a party to this Warrant Agreement, be entitled to vote or receive dividends or be deemed the holder of Warrant Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein he construed to confer upon Us any of the rights of one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until this Warrant Agreement is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.

Facsimile Signatures. This Warrant Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party.

(Signature Page to Follow)

 

13


IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its officers who are duly authorized as of the Effective Date.

 

You:

 

AMYRIS BIOTECHNOLOGIES, INC.

Signature:

 

/s/ John G. Melo

Print Name:

 

John G. Melo

Title:

 

CEO

Us:

 

TRIPLEPOINT CAPITAL LLC

Signature:

 

/s/ Sajal Srivastava

Print Name:    

 

Sajal Srivastava

Title:

 

Chief Operating Officer

[SIGNATURE PAGE TO PLAIN ENGLISH WARRANT AGREEMENT 0534-W-02]

 

14


EXHIBIT I

NOTICE OF EXERCISE

To: [                                      ]

 

1.

We hereby elect to purchase [                      ] shares of the Series [                      ] Preferred Stock of [                      ], pursuant to the terms of the Plain English Warrant Agreement dated the [                      ] day of [                      ], [200      ] (the “Plain English Warrant Agreement”) between You and Us. We hereby tender here payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any.

 

2.

Method of Exercise (Please initial the applicable blank)

 

 

a.

                     The undersigned elects to exercise the Plain English Warrant Agreement by means of a cash payment, and gives You full payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any.

 

 

b.

                     The undersigned elects to exercise the Plain English Warrant Agreement by means of the Net Issuance Exercise method of Section 3 of the Plain English Warrant Agreement.

 

3.

In exercising Our rights to purchase the Series [                      ] Preferred Stock of [                      ], We hereby confirm and acknowledge the investment representations, warranties and covenants made in Section 7 of the Plain English Warrant Agreement.

Please issue a certificate or certificates representing these purchased shares of Series [                      ] Preferred Stock in Our name or in such other name as is specified below.

 

       
 

(Name)

       
 

(Address)

 

US:

 

TRIPLEPOINT CAPITAL LLC

 

By:

   
 

Title:  

   
 

Date:

   

 

15


EXHIBIT II

ACKNOWLEDGMENT OF EXERCISE

[                                               ], hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase [                      ] shares of the Series [                      ] Preferred Stock of [                      ], pursuant to the terms of the Plain English Warrant Agreement, and further acknowledges that [                      ] shares remain subject to purchase under the terms of the Plain English Warrant Agreement.

YOU:

     

By:

   

Title:

   

Date:  

   

 

16


EXHIBIT III

TRANSFER NOTICE

FOR VALUE RECEIVED, the foregoing Plain English Warrant Agreement and all rights evidenced thereby are hereby transferred and assigned to

 

   
 

(Please Print)

Whose address is                                                                                               

 

 

 

Dated:

   

Holder’s Signature:

   

Holder’s Address:

   

Transferee’s Signature:

   

Transferee’s Address:

   

Signature Guaranteed:

   

NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Plain English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Plain English Warrant Agreement.

 

17

Exhibit 4.15

AMENDMENT NO. 1 TO PLAIN ENGLISH WARRANT AGREEMENT

This Amendment No. 1 to Plain English Warrant Agreement (this “ Amendment ”) is made and entered into as of April 8, 2010 (the “ Amendment Date ”), by and among TriplePoint Capital LLC, a Delaware limited liability company (“ TriplePoint ”) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ”).

RECITALS

WHEREAS, the Company and TriplePoint are parties to that certain Plain English Warrant Agreement dated September 18, 2009 (the “ Agreement ”).

WHEREAS, the Company and TriplePoint desire to amend the Agreement.

NOW, THEREFORE, in consideration of the matters described in the recitals above and the mutual promises, covenants and undertakings contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

AMENDMENT

1.       AMENDMENT TO AGREEMENT . The first paragraph of Section 2 shall be deleted in its entirety and replaced with the following:

“(a) The term of this Warrant Agreement and our right to purchase Warrant Stock will begin on the Effective Date, and shall be available until the earlier of (i) 10 years from the Effective Date or (ii) one (l) year from the effective date of an initial public offering of Your securities.

(b) The settlement of the Warrant pursuant to this Warrant Agreement is to be made in Warrant Stock and, for the elimination of doubt, the fact that the Warrant Stock delivered on exercise of the this Warrant Agreement is not registered under the Securities Act of 1933 will not in any way require you to settle the Warrant otherwise than in Warrant Stock, including, without limitation, that there is no circumstance that would require You to net cash settle the Warrant.

(c) In case all the authorized Series C Preferred Stock of the Company is converted, pursuant to the Company’s Articles of Incorporation, as may be amended from time to time, into Common Stock or other securities or property, or the Series C Preferred Stock otherwise ceases to exist, then, We, upon exercise of the Warrant pursuant to this Warrant Agreement at any time after such time (the “ Conversion Date ”), shall receive, in lieu of the number of shares of Warrant Stock that would have been issuable upon such exercise immediately prior to the Conversion Date (the “ Former Number of Shares ”), the stock and other securities and property which We would have been entitled to receive upon the Conversion Date if We had exercised the Warrant pursuant to this Warrant Agreement with respect to the Former Number of Shares immediately prior to


the Conversion Date (all subject to further adjustment as provided in this Warrant Agreement).”

2.       NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Agreement remain in full force and effect. Notwithstanding anything else in this Amendment, if there is any conflict between subsections (b) and (c) in Section 1 above and the Agreement, the terms of the Agreement shall prevail.

3.       GOVERNING LAW . This Amendment shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

4.       COUNTERPARTS; FASCIMILE . This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, or by email in portable document format (.pdf) and delivery of the signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties.

[Remainder of page left blank]

 

2


IN WITNESS WHEREOF , each of the Company and TriplePoint has caused this Amendment No. 1 to Plain English Warrant Agreement to be executed by its duly authorized representative, each as of the Amendment Date.

 

AMYRIS BIOTECHNOLOGIES, INC.       TRIPLEPOINT CAPITAL, LLC

LOGO

     

LOGO

  By:  

Tamara L. Tompkins

          By:  

 

  Its:  

General Counsel

          Its:  

 

 

3

Exhibit 10.04

LOGO

Via Fed Ex

March 27, 2008

Jeryl Hilleman, CFO

Amyris Biotechnologies, Inc.

5980 Horton St., Suite 450

Emeryville, CA 94608

(510) 450-0761 x734

RE: Amyris Biotechnologies  |  TriplePoint Capital — Executed Documents

Dear Jeryl:

Enclosed, please find the following documents for your files:

 

  1. Master Lease Agreement (Original)

 

  2. Warrant Agreement (Copy)

 

  3. Hardware Facility Schedule - 0534-LE-01H & 02H (Original)

 

  4. Software Facility Schedule — 0534-LE-01S & 02S (Original)

 

  5. Extra Signature Page for Warrant Agreement — TriplePoint Capital does not execute more than one original warrant agreement

Should you have any questions or concerns, please do not hesitate to contact me at (650) 233-2158.

Sincerely,

Nisha K. Pandit

Legal Assistant

Enclosures


LOGO

PLAIN ENGLISH MASTER LEASE AGREEMENT

This is a PLAIN ENGLISH MASTER LEASE AGREEMENT dated March 14, 2008 by and between TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company, as lessor and AMYRIS BIOTECHNOLOGIES, INC. a California corporation as lessee.

The words “We”, “Us”, or “Our”, refer to TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the AMYRIS BIOTECHNOLOGIES, INC., not to any individual. The words “the Parties” refers to both TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES, INC. This Plain English Master Lease Agreement may be referred to as the “Agreement”.

The Parties agree to the following mutual agreements and conditions listed below:

 

 

  1. WHAT EQUIPMENT THE PARTIES AGREE TO LEASE

 

You agree to lease from Us and We agree to lease to You all of the Equipment that We approve at the rates, terms and conditions that are set forth in this Agreement and that are specifically referenced in the accompanying one- page Hardware and Software Facility Schedule(s).

“Equipment” will consist of all personal property (together with all parts, replacements, repairs, additions, accessions and accessories incorporated therein and/or affixed thereto, and all related operating manuals, maintenance records and similar information) leased pursuant to this Agreement and as listed on an outstanding Summary Schedule prepared pursuant to this Agreement. Without limiting the generality of the forgoing, Equipment may include present and future existing standard, third party off-the-shelf resalable equipment, as such term is defined in the UCC, consisting of personal computers, laptops, workstations, routers, switches, phone systems, fermenters (of any size), office equipment, electronic test equipment, manufacturing equipment, analytical equipment, lab equipment, non-customer production equipment, office furniture and other equipment that We approve in writing in Our sole reasonable discretion. For the avoidance of doubt, nothing herein shall confer on Us any interest in or title to any of Your Intellectual Property.

Equipment WILL NOT (unless otherwise noted in a Hardware and/or Software Facility Schedule) include rolling stock, custom or specialized equipment, installation costs, delivery costs, freight, leasehold improvements, special tooling and molds, software, handheld items (collectively “Soft Costs”), taxes and other fungible items.

 

 

  2. WHAT IS THE DIFFERENCE BETWEEN A MASTER LEASE AGREEMENT AND THE FACILITY SCHEDULES

 

This Agreement states legal terms and conditions that will govern ALL the lease transactions You may enter into with Us. You will not have to review and negotiate this Agreement again should The Parties execute additional lease transactions in the future.

A Hardware and/or Software Facility Schedule, in substantially the form as attached Exhibit A, is the document that the Parties will enter into each time a new lease transaction has been agreed to by the Parties. The respective Hardware and/or Software Facility Schedule will contain the specific financial terms of the specific lease transaction to which it applies (i.e. Commitment Amounts, Availability Periods, Lease Term, Lease Rate Factor, Interim Rent, Advance Rent, and so forth). The Hardware or Software Facility Schedule incorporates by reference, and is governed by, all of the terms and conditions of this Agreement. There may be multiple Hardware or Software Facility Schedule(s) associated with this Agreement, representing separate lease transactions, and there may be a


separate Hardware and/or Software Facility Schedule(s) for one or more specific lease transactions. Each Hardware and/or Software Facility Schedule shall constitute a separate instrument of lease.

 

 

3.        YOUR LEASE FACILITY COMMITMENT AMOUNT MAY BE DIVIDED INTO PARTS

 

The Commitment Amount and/or its corresponding parts (if any) will be noted on the respective Hardware or Software Facility Schedules (“Parts”). For purposes of this Agreement, references to the Commitment Amount shall mean the Part or Parts which are then available and in effect. Any terms or conditions associated with the availability of such Part are on the respective Hardware or Software Facility Schedule. As to any Part that is available “Upon Request and Additional Approval”, You are required to make a request to utilize that additional Part in writing to Us (the “Commitment Increase Request Notice”). After Our receipt of the Commitment Increase Request Notice, We will review the information available to Us and conduct any legal and business due diligence deemed necessary by Us in connection with Our attempt to obtain Our requisite credit approvals. Our agreement to consider providing the additional Part is not, and is not to be construed as, a commitment, offer, or agreement to provide such additional Part.

 

 

4.        ORDERING EQUIPMENT

 

You may order Equipment from any vendor, manufacturer or third party of Your choice. You will select all of Your Equipment, prepare all purchase orders and will not rely on Us at all when selecting Your Equipment. We may offer services to assist You in ordering Equipment, including obtaining price quotes and, if satisfactory to You, procuring equipment at any time during the Availability Period through our Preferred Pricing, arranged through partnerships with leading equipment manufacturers and equipment value-added resalers. You are under no obligation to use these services. Not all of the Equipment that You order may be eligible for placement under the lease — only Equipment which meets the terms and conditions in this Agreement may be placed on the lease, as determined in Our sole reasonable discretion.

You are responsible for all ordering, delivery, and transportation expenses as well as in-transit insurance to Your premises and installation and set-up costs of the Equipment. These expenses are not covered under this Agreement.

 

 

5.        PAVING FOR EQUIPMENT

 

At Your option, You can choose to pay for the Equipment and have Us reimburse You OR You can have Us pay the vendor, manufacturer, or other third party directly for the Equipment.

In either case, Our obligation to make payment is subject to the satisfaction of conditions set forth in this Agreement, including satisfaction of the following conditions:

 

  ð

The Equipment meets the definition of Equipment and We approve it in Our sole reasonable discretion.

 

  ð

You submit the invoice for the Equipment to Us during the Availability Period as listed on any Hardware or Software Facility Schedule(s).

 

  ð

The price of the Equipment plus the aggregate amount of all the Equipment We have already placed on lease for You does not exceed the Commitment Amount currently available.

 

  ð

The price of the Equipment does not include any additional expenses or costs that You are responsible for.

 

  ð

You and/or the vendor, manufacturer, or other third party accepts Our payment methods and terms.

 

 

6.        PROCEDURES TO FOLLOW WHEN WE PURCHASE THE EQUIPMENT DIRECTLY

 

Provided the conditions of Sections 5 and 8 are met and You elect to have Us purchase the Equipment directly for You, You agree to follow the procedures listed below to have Us pay the vendor, manufacturer, or other third party for the Equipment:

 

2


  ð

You accept the Equipment (even though You may not have received or installed the Equipment).

 

  ð

You will indicate Your acceptance of the Equipment by stamping and signing the invoice and faxing or mailing it to Us.

 

  ð

You will submit serial numbers and inventory numbers (We will provide You with inventory tags) of the Equipment to Us.

It should be noted that by accepting the Equipment, You have specifically authorized Us to pay for it, and that You accept the risk and responsibility with the vendor or manufacturer should any problems arise after the Equipment is received. You agree that We shall not, by virtue of entering into this Agreement, be required or obligated to pay any vendor, manufacturer, or third party until You have indicated to Us that You have accepted the Equipment for purposes of lease under this Agreement.

For the avoidance of doubt, no such acceptance by You shall be deemed to be an acceptance of the Equipment under any manufacturing, purchase supply or other agreement from any Supplier.

Upon satisfaction of these conditions, We will then pay the vendor, manufacturer or third party 100% of the price of the actual Equipment. The price We pay the vendor, manufacturer or third party for the Equipment is what We will use to calculate the Rent you owe Us.

 

 

7.        PROCEDURES TO FOLLOW WHEN YOU PURCHASE THE EQUIPMENT AND WE REIMBURSE YOU

 

Provided all of the conditions of Sections 5 and 8 are met and You elect to purchase the Equipment and have Us reimburse You, You agree to follow the procedures listed below in order to have Us reimburse You for new Equipment that You have already purchased:

 

  ð

You fax or mail the invoice to Us.

 

  ð

You submit proof that You have clear title and ownership of the Equipment.

 

  ð

You submit an Excel spreadsheet listing invoice information and Our inventory tag numbers (We will provide You with the inventory tags) for all the Equipment.

 

  ð

You sign a separate Plain English Purchase-Leaseback Agreement (the “Purchase-Leaseback Agreement”), in substantially the form as Exhibit B.

Upon satisfaction of these conditions, and receipt of the signed Plain English Purchase-Leaseback Agreement. We will then make payment to You based on the following:

Initial Purchase-Leaseback

 

  ð

For Equipment purchased before the date of execution of the applicable Purchase-Lease Agreement, and submitted to Us within the first thirty (30) days of the Availability Period of the respective Hardware and or Software Facility Schedule: At the original net equipment cost less the pre-determined depreciation amount as provided in the chart below.

 

Equipment Age    Percentage of Original Cost We will Pay

0-90 days old

   100%

91-150 days old

   80%

 

3


151-180 days old

   60%

over 180 days old

  

                                        Case by Case basis

Additional Purchase-Leasebacks

 

  ð

For Equipment purchased after the date of execution of the applicable Hardware or Software Facility Schedule, and submitted to Us within thirty (30) days of the invoice date: 100% of original net Equipment cost.

The price We pay You for the Equipment is what We will use to calculate the Rent you owe Us.

 

 

8.        CONDITIONS FOR US TO LEASE ADDITIONAL EQUIPMENT

 

Our obligation to lease Equipment that You request under this Agreement is subject to satisfaction of each of the applicable conditions set forth in Sections 6, 7 and 25 and each of the following conditions:

 

  ð

The representations and warranties in this Agreement, in the Warrant Agreement and any other Lease Documents shall be true, complete and correct in all material respects on and as of the date(s) We lease the Equipment to You with the same effect as though they were made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case they shall remain true, complete and correct in all material respects as of such date; provided , however , that such materiality qualifiers shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof.

 

  ð

You shall be in compliance with all the terns and provisions set forth in this Agreement and no Default or Event of Default shall have occurred and be continuing under this Agreement, any Hardware and/or Software Facility Schedule, or any Summary Schedule; or,

 

  ð

You are not in default under any other agreement with Us or any other lessor or lender, the result of which would allow the lessor, lender or any secured party to demand immediate payment.

 

  ð

No event or circumstance shall exist or have occurred that has had or could reasonably be expected to have a Material Adverse Effect.

 

  ð

You shall submit to Us any other documents and other information that We may reasonably request and are necessary to implement the provisions and purposes of this Agreement.

 

 

9.        WHEN THE LEASE BEGINS AND HOW YOU WILL KNOW WHAT IS ON THE LEASE

 

For Equipment that We paid for or will pay the manufacturer, vendor or other third party directly, the lease begins on the date(s) of Your written acceptance of that Equipment. You agree to provide Us with your acceptance date by hand writing such on the applicable invoice. For Equipment that You purchased and that We reimbursed You for, the lease begins on the date(s) that We made payment to You.

These date(s) will be known as the Lease Start Date(s). Subject to any agreement between Us with respect to any Advance Rent payments as referenced in any Hardware or Software Facility Schedule, beginning on the Lease Start Date(s) You are obligated to pay Rent for each item of Equipment for the term of the lease and are bound to the obligations associated with the lease as listed in this Agreement. Notwithstanding the forgoing, Your indemnity obligations under this Agreement begin immediately with Your execution hereof.

For each month during the Availability Period, We will prepare and send to You an associated Summary Schedule(s), in substantially the form as the attached Exhibit C. This Summary Schedule will list all of the Equipment that We approved, You accepted, and We paid for during that particular month and will reference and incorporate all of the terms and conditions of this Agreement. Each Summary Schedule will also contain the

 

4


Monthly Rent amount, Interim Rent amount, Use Tax amount, Equipment location, description, serial number(s), Our inventory tag number and the amount that We paid for the Equipment.

Each Summary Schedule(s) will represent a separate lease for the Equipment listed on it. The Lease Term (as indicated in the applicable Hardware or Software Facility Schedule) for all the Equipment on a Summary Schedule(s) will begin on the first day of the month following the Lease Start Dates for all the Equipment on that Summary Schedule. This date will be known as the Lease Commencement Date.

This means that while all of the Equipment purchased during a particular month on a Summary Schedule will have different Lease Start Dates during a particular month, they all will have the same Lease Commencement Date, which will be the first day of the next month.

During the Availability Period, if You have not accepted any Equipment or We have not paid for any Equipment during a particular month, there will be no Summary Schedule for that month.

 

 

10.      HOW AND WHEN YOU PAY US RENT

 

Rent is payable in advance and due on the first day of each month (unless that date falls on a weekend or national holiday in which event such payment shall be due on the previous business day). Rent amounts are indicated on each Summary Schedule that We will send to You via electronic mail on or around the 25 th of each month during the Availability Period; provided , however , Our failure to deliver such invoices shall not relieve You of your obligation to make such scheduled payment as and when due. The Monthly Rent amount is calculated by summing the costs or amounts We paid for all of the Equipment listed on the Summary Schedule and multiplying that aggregate amount by the Lease Rate Factor indicated on the applicable Hardware and/or Software Summary Schedule. On the first of each month We will email You a statement listing the Rent amounts for each Summary Schedule then in place. If the Lease Start Dates and Lease Commencement Dates for Equipment on a Summary Schedule are not the same, You will be obligated to also pay Us Rent for the period from the Lease Start Dates through, but not including, the Lease Commencement Date. This is called Interim Rent and it will be calculated for each piece of Equipment by multiplying the cost or amount We paid for that piece of Equipment by the Interim Rent Rate listed on the Hardware and/or Software Facility Schedule. Interim Rent will also be listed on each Summary Schedule.

Advance Rent shall be due on the date of purchase on any Purchase Leaseback Agreement and for all other leases on the Lease Commencement Date as listed on the applicable Summary Schedule.

Rent payments are due electronically by automatic debit through Automated Clearing House (ACH) payment on or before the first day of each month. You agree to fill out an Electronic Funds Transfer/Automatic Debit Authorization form that We provide.

If We do not receive any payments from You within two (2) business days after they are due You will pay a late charge on the overdue amount (which such late charge shall begin to accrue from the original due date). This late charge will be equal to the lesser of 5% of the amount due for each month not paid when due and until such time as payment is received or the maximum rate permitted by applicable law.

 

 

11.      YOU CANNOT TERMINATE THE LEASE

 

You understand that Your obligation to pay Us is absolute and unconditional and is not subject to any reduction, set-off, abatement, interruption, deferment, recoupment, defense or counterclaim for any reason whatsoever except payment in full. You promise to pay Us and abide by Your obligations from the Lease Start Date all the way through until all such obligations have been paid and satisfied in full.

You understand that You cannot terminate a lease during its term. Only after the term has finished will You be able to terminate a lease, and only by giving Us at least ninety (90) days prior written notice. We can terminate a lease after the term has finished by giving You sixty (60) days prior written notice.

 

5


Notwithstanding the foregoing, with sixty (60) days prior notice to Us (such notice to occur prior to the last ninety (90) days in any Summary Schedule Lease Term), You may prepay all rental payments and terminate the Lease Agreement without any termination or prepayment penalty, and purchase the Equipment in accordance with the terms of section 16 (the “Early Termination”).

 

 

12.      WE OWN THE EQUIPMENT

 

The Parties intend and agree that: (a) The lease constitutes a true “lease” and a “finance lease” as such terms are defined in UCC-2A and not a sale or retention of security interest and (b) You understand that You are not the owner of the Equipment and that You do not have title to it. You understand that You hold the Equipment subject to and subordinate to Our and any of Our assignees’ rights. Title to the Equipment shall at all times remain in Us. In order to secure the prompt payment of the rent and all of the other amounts from time to time outstanding with respect hereto and to each lease, and the performance and observance by You of all of the provisions hereof and thereof and of all of the other documents and instruments executed in connection with this Agreement, You hereby collaterally assign and grant to Us, a security interest in and lien on all of Your right, title and interest in and to all of the following: (1) (if contrary to the parties’ intentions a court determines that such lease is not a true “lease” under the UCC) the Equipment described in such Hardware and/or Software Facility Schedule and related Summary Schedules or otherwise covered thereby (including all inventory, fixtures or other property, related software (embedded therein or otherwise) and general intangibles, additions, attachments, accessories and accessions whether or not furnished by the supplier comprising the Equipment); (2) all subleases, chattel paper, accounts, security deposits, and general intangibles comprising the Equipment, and any and all substitutions, replacements or exchanges for any such item of Equipment or other collateral, in each such case in which You shall from time to time acquire an interest; and (3) any and all insurance and/or other proceeds of the Equipment. The collateral assignment, security interest and lien granted herein shall survive the termination, cancellation or expiration of each lease until such time as Your obligations (other than inchoate indemnity obligations) thereunder are fully and indefeasibly discharged.

Software and any licensed products will at all times remain the property of the owner of the software or licensed products. A license from the owner may be required and it is Your responsibility to obtain any required license before using any software or licensed products. You agree to treat software and licensed products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell them. You agree not to utilize any unlicensed or improperly licensed software on Our Equipment. You agree to cooperate with Us in obtaining any necessary transfer (or sublicense) of the any applicable software upon Our repossession and/or sale of the related Equipment.

 

 

13.      SALES, USE, AND PROPERTY TAXES

 

Each Summary Schedule is a net lease, which means You will pay when due, or reimburse Us, for all taxes, fees or any other charges such as maintaining, repairing and insuring the Equipment in each case, to the extent required by this Agreement (together with any related interest or penalties not arising from Our negligence) accrued for or arising during the term of each lease against Us, You or the Equipment, but without prejudice to and subject to the limitations in to Section 15.

If You intend for Us to pay Your vendor directly, You must notify Your vendor that We are in the business of purchasing tangible personal property for resale and that the transaction is not subject to sales tax. We will then provide them with Our resale certificate, if necessary. We will provide you a copy of Our resale certificate after You sign this Agreement. You will then be subject to a use tax on the Rent amount for the entire term of the lease. Use tax amounts will be indicated on each Summary Schedule. Use tax amounts are payable in advance and are due on the first day of each month by the same payment methods as Rent payments. Use tax amounts are based upon the location of the Equipment and are determined by each state tax authority. These tax amounts may change every year, depending on the local tax code and the location of the Equipment. You understand that the use and property tax rates may change as a result of relocating the Equipment.

If You purchase Equipment directly from a vendor, pay sales tax, and submit the Equipment to Us for a sale-leaseback transaction, then You represent that You have paid all state sales tax due on the cost of that portion of the

 

6


Equipment to be installed in that state and agree to provide evidence of such payment, if specifically requested. As a result, We will not charge You for use tax on the Rent. You understand that this is an irrevocable election to measure the tax by the Equipment cost and cannot be changed except prior to installation of the Equipment.

You also agree that We have the right each year to estimate the yearly personal property taxes that will be due for the Equipment and that You will pay Us the estimated taxes when We request payment either electronically or by check. At the end of every year, We will reimburse You for any excess tax payment, or We will apply it to the next year’s estimate. You also agree to sign any document We provide which is necessary for the purpose of such filing, so long as the filing does not interfere with Your right to use the Equipment.

 

 

14.      INSURANCE, RISK OF LOSS, AND DAMAGE TO THE EQUIPMENT

 

 

  ð

You agree that upon delivery and until the Equipment is returned to Our facilities in the condition required by this Agreement, You relieve Us of responsibility for all risks of physical damage to or loss or destruction of the Equipment.

 

  ð

You agree to keep the Equipment insured against loss until You have met all of Your obligations (other than inchoate indemnity obligations) under this lease. You agree to obtain, as of the date each Summary) Schedule begins, casualty insurance for each item of Equipment, from an insurance provider who is acceptable to Us.

 

  ð

You agree to insure the Equipment for either (i) its full replacement value or (ii) the greater of the fair market value of the Equipment or the lump sum of the unpaid balance of the remaining Rent monthly payments under this lease plus ten percent (10%) of the Equipment’s original purchase price.

 

  ð

You will ensure that the policy includes Us as the loss payee and additional insured and that We will be provided at least thirty (30) days prior written notice before cancellation. You will endeavor to give us notice of non-renewal, reduction in policy limits, or expiration. You will insure Our interests regardless of any breach or violation by You of any representation, warranty or condition contained in such policies and will be primary without right of contribution front any insurance effected by Us. You agree to provide Us with certificates or other evidence of insurance reasonably acceptable to Us promptly following the issuance of each Summary Schedule. In the event that You do not provide Us with proof of insurance within thirty (30) days of the starting date of a Summary Schedule. We will obtain this insurance on Your behalf and charge You for this insurance, plus a ten percent (10%) administrative surcharge.

 

  ð

You will maintain the Equipment as required by the terms of this Agreement, unless such Equipment is either lost, totally destroyed or subject to condemnation proceedings. Within fifteen (15) days of the loss of the Equipment, You must provide written notice of that loss to Us. You will have the option to either: (a) replace the item of Equipment with the same or better model, type, manufacturer and configuration which shall be free and clear of all liens and encumbrances, or (b) pay Us in a lump sure the unpaid balance of the remaining monthly payments under the Lease and the percentage of the Equipment’s original purchase price as stated on the respective Hardware and/or Software Facility Schedule, discounted to present value at the rate of 5% per annum.

 

  ð

If any insurance proceeds are paid as a result of any such loss or damage to the Equipment, You agree that such insurance proceeds shall be paid to Us (unless used to replace the equipment in accordance with Subsection (a) above) and We will apply it towards Your payment obligations under this lease.

 

  ð

You agree to carry bodily injury and property damage liability insurance during the term of any Hardware and/or Software Facility Schedule and all Summary Schedules in an amount of not less than $1,000,000.00 combined single limit per occurrence, and against risks customarily insured against. Your insurance certificate shall state that We are an additional insured for commercial general liability.

 

7


 

15.      YOU AGREE TO INDEMNIFY AND PROTECT US

 

GENERAL: You shall, but without prejudice to and subject to the limitations in the following paragraph, indemnify, defend and save Us, Our agents, employees, successors and assigns harmless from any and all liability, Claims, allegations, damages, or losses, except any liability for taxes on net income (any of the foregoing, a “ Claim ”), including reasonable counsel fees and other legal expenses, arising out of this Agreement, any lease hereunder and the Equipment, including without limitation, (a) the acquisition, rejection, ownership, selection, possession, leasing, operation (regardless of where, how and by whom operated), control, use, condition (including but not limited to latent and other defects, whether or not discoverable by You or any purchaser or other user of the Equipment) maintenance, delivery and return of the Equipment, (b) any claim in tort for negligence or strict liability, and any claim for patent, trademark or copyright infringement, or any environmental damage, or any criminal or terrorist act, (c) all matters relating to the waiver and disclaimer in Section 18 and (d) the return of the Equipment with any confidential or proprietary information left on the applicable hard drives. We are not responsible for any injuries, damages or losses to You, or any property, except to the extent of Our, Our agents, employees, successors and assigned, gross negligence or willful misconduct. We agree to give you prompt notice of any Claim or liability hereby indemnified against and You shall be entitled to control the defense thereof.

INCOME TAX: If (a) We, in computing Our taxable income or liability for tax, shall lose, or shall not have, or shall lose the right to claim or there shall be disallowed or recaptured for Federal and/or state income tax purposes, in whole or in part, the benefit of MACRS Deductions due solely to Your use of the Equipment (other than in the ordinary course or intended use) that alters the tax treatment of such Equipment; or (b) We shall become liable for additional tax as a result of You having added an attachment or made an alteration to the Equipment, including (without limitation) any such attachment or alteration which would increase the productivity or capability of the Equipment so as to violate the provisions of Rev. Proc. 2001-28, 2001-1 C.B. 1156 (as it may hereafter be modified or superseded): hereinafter referred to as a “Loss”; then You shall pay Us the Tax Indemnification Payment as additional rent. “MACRS Deductions” shall mean the deductions under Section 167 of the Internal Revenue Code of 1986, as now or hereafter amended (the “ Code ”), determined in accordance with the modified Accelerated Cost Recovery System with respect to the cost of any item of the Equipment using the accelerated method set forth in Section 168(b)(1) or 168(b)(2) of the Code as in effect on the date of the lease for property assigned to the 3-year class of property. For purposes hereof, “We”, “Us” and “Our” shall be deemed to include the consolidated Federal taxpayer group of which We are a member; and “Tax Indemnification Payment” shall mean such amount as, after consideration of (i) all taxes required to be paid by Us in respect of the receipt thereof under the laws of any governmental or taxing authority in the United States, and (ii) the amount of any interest or penalty (due solely to Your acts or omissions) which may be payable by Us in connection with the Loss, shall be required to cause Our after-tax net return (the “ Net Return ”) to be equal to, but no greater than, the Net Return computed consistently with current tax laws (and with the assumption that We are taxed at the highest marginal Federal and state tax rates) as of the date of the lease that would have been available to Us had the Loss not occurred. If we obtain any refund, rebate or other payment on account of any taxes paid by You pursuant hereto. We shall, to the extent we can identify such rebate, refund or payment as attributable to Your Equipment, promptly pay such amount to You.

The indemnities provided for under this Section 15 shall continue even after the term of this lease has expired.

 

 

16.      YOUR END OF TERM OPTIONS

 

You May Extend the Term of the Lease

As long as a Default does not exist and You have provided to Us written notice no earlier than twelve (12) months and no later than [ninety (90) days] prior to the expiration of the term of a Summary Schedule, You will have the right to extend the term of such Summary Schedule for a period of one (1) year. In such event, the monthly Rent to be paid during this extended period shall be its then fair market rental value as shall be mutually agreed upon and if The Parties cannot mutually agree, then the Summary Schedule shall continue in full force and effect pursuant to the existing terms and conditions until terminated in accordance with its terms. The Summary Schedule will continue in effect following the extended period until terminated by either Party upon not less than ninety (90) days prior written notice, which notice shall be effective as of the date of receipt.

 

8


You May Purchase the Equipment

Hardware - As long as a Default does not exist and You have provided to Us written notice no earlier than twelve (12) months and no later than [ninety (90) days] prior to the expiration of the term or the extended term of the applicable Summary Schedule (or in the case of Early Termination, You shall give notice in accordance with that provision), You will have the option at the expiration of the term to purchase all, but not less than all, of the Equipment listed in that schedule for a fair market value purchase price agreed upon by The Parties but not to exceed the percentage of original Equipment cost as listed on the applicable Hardware Facility Schedule and upon terms and conditions to be mutually agreed upon by The Parties following Your written notice, plus any taxes applicable at time of purchase.

Software — For each Software Facility Schedule(s), You agree that in addition to Your last monthly Rent payment You will remit to Us an amount equal to a percentage of the software’s original cost as indicated on the Software Facility Schedule, plus any applicable taxes.

You will pay the agreed upon purchase price to Us on the expiration date of the term or extended term. Title to the Equipment shall automatically pass to You, without representation or warranty by Us with respect to the status of title conveyed (except as to any Lien created by Us), upon payment in full of the purchase price but in no event earlier than the expiration of the fixed term or extended term, if applicable. If The Parties are unable to agree on the purchase price or the terms and conditions with respect to said purchase, then the Summary Schedule with respect to this Equipment shall remain in full force and effect.

You May Return the Equipment

When each Summary Schedule terminates, either at the end of its term or otherwise, You may return the Equipment to Us. You agree to provide Us written notice of Your decision to return the Equipment no later than [ninety (90) days] prior to the expiration of the term of a Summary Schedule. You will follow Our reasonable instructions and at Your expense (including, transportation expenses and in-transit insurance), return the Equipment to Us in the condition required by the maintenance obligations under this Agreement, normal wear and tear excluded. You shall return the Equipment to Us at the address listed on the Hardware and/or Software Facility Schedule or at such other address within the continental United States as directed by Us, provided, however, that Your expense shall be limited to the cost of retuning the Equipment to that address listed on the Hardware and/or Software Facility Schedule.

 

 

17.      TECHNOLOGY EXCHANGE OPTION

 

As long as a default does not exist, then on or after the expiration of the 12th month of any Plain English Summary Schedule, You shall have the option to replace any of the Equipment subject to such Plain English Summary Schedule with new technology equipment (“New Technology Equipment”) under the following guidelines:

 

  ð

The Equipment being replaced with New Technology Equipment shall have a minimum aggregate original cost equal to or greater than 52,500 and be comprised of full configurations of equipment (i.e. keyboard, mouse, monitor, system unit, etc.).

 

  ð

This Technology Exchange Option shall be limited to a maximum in the aggregate of fifty percent (50%) of the total original equipment cost funded under the respective lease and shall not apply to software or any soft costs financed, including but not limited to tenant improvements and custom equipment.

 

  ð

The cost of the New Technology Equipment must be equal to or greater than the original equipment cost of the replaced equipment, but in no event shall exceed one hundred fifty percent (150%) of the original equipment cost.

 

  ð

In connection with the Technology Exchange, the aggregate outstanding purchase price paid by its for the Equipment that would be in effect after the consummation of the Technology Exchange Option shall not exceed the original Commitment Amount set forth in the respective Hardware Facility Schedule.

 

9


  ð

The remaining lease payments applicable to the Equipment being replaced by the New Technology Equipment will be discounted to present value at five percent (5%).

The wholesale market value of the Equipment being replaced will be established by Us based upon then current market conditions. Upon the return of the replaced Equipment, the wholesale price will be deducted from the present value of the remaining rentals and the differential will be added to the cost of the New Technology Equipment in calculating the new rental. The lease for the New Technology Equipment will contain terms and conditions substantially similar to those for the replaced equipment and will have a Lease Term not less than the balance of the remaining Lease Term for the replaced equipment, provided that any extension of the term shall require your consent.

 

 

18.      WARRANTIES

 

WE ARE NOT A SELLER, SUPPLIER OR MANUFACTURER (AS SUCH TERMS ARE DEFINED OR USED IN THE UCC), OR DEALER, NOR A SELLER’S OR DEALER’S AGENT. THE EQUIPMENT IS LEASED HEREUNDER “AS IS”, AND WE HAVE NOT MADE, AND HEREBY DISCLAIM LIABILITY FOR, AND YOU HEREBY WAIVE ALL RIGHTS AGAINST US RELATING TO, ANY AND ALL WARRANTIES, REPRESENTATIONS OR OTHER OBLIGATIONS OF ANY KIND WITH RESPECT TO THE EQUIPMENT, EITHER EXPRESS OR IMPLIED, ARISING BY APPLICABLE LAW OR OTHERWISE, INCLUDING (i)  MERCHANTABILITY OR FITNESS FOR PARTICULAR USE OR PURPOSE, (ii) COURSE OF DEALING OR USAGE OR TRADE OR (iii) COMPLIANCE WITH APPLICABLE LAW, TITLE OR FREEDOM FROM LIENS (OTHER THAN LIENS CREATED BY US), TRADEMARK, PATENT OR COPYRIGHT INFRINGEMENT, AND LATENT DEFECTS (WHETHER OR NOT DISCOVERABLE); it being agreed that all such risks, are to be borne by You; and Our agreement to enter into this Agreement is in reliance upon the freedom from and complete negation of liability or responsibility for the matters waived and disclaimed herein . You hereby waive any claim against Us for any indirect, incidental or consequential damages to or losses resulting from any matter whatsoever.

So long as no Event of Default has occurred and is continuing, We will not disturb Your quiet and peaceful possession, and use of the Equipment. In addition, so long as no Event of Default has occurred and is continuing, We hereby transfer to You any warranties made to Us by the manufacturer, vendor or supplier, with respect to the Equipment, during the term of Your Summary Schedule and We shall take all actions and execute all documents reasonably requested by You to effect such transfer and to confer upon You all benefits of such warranties.

We are not responsible for any liability, claim, loss, damage or expense of any kind (including strict liability in tort) caused by the Equipment except for any loss or damage caused by Our willful misconduct or grossly negligent acts. In no event are We responsible for special, incidental or consequential damages.

 

 

19.      REPRESENTATIONS AND WARRANTIES FROM YOU

 

You represent and warrant that with respect to this Agreement, the Hardware and/or Software Facility Schedule(s), and the Summary Schedules that You execute that:

 

  ð

No Other Liens. The Equipment is personal property and when subjected to Your Use will not be or become fixtures under applicable law. The Equipment is not subject to any Liens. No other Lien has been created by You or is known by You to exist with respect to any Equipment. You have not created and do not know of any other existing Liens that involve the Equipment, other than those created by Us.

 

  ð

Due Organization. You are a corporation duly organized, legally existing and in good standing under the laws of the State of California with corporate organization number 2544865 and are duly qualified as a foreign corporation in all jurisdictions in which the nature of Your business or location of Your properties requires such qualifications and where the failure to be qualified would result in an event which individually or together with any other event, could reasonably be expected to have a Material Adverse Effect.

 

10


  ð

Authorization, Validity and Enforceability. Your execution, delivery and performance of this Agreement, all financing statements, and all other Lease Documents (i) have been, or will when executed and delivered be, duly authorized by all necessary corporate action, and (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than the Liens created by this Agreement and the other related Lease Documents. The person or people executing this Agreement and other Lease Documents are, or when such documents are executed and delivered be, duly authorized to do so, and the Lease Documents and each term and provision thereof are Your legal, valid and binding obligations, enforceable in accordance with their respective terms, subject to applicable bankruptcy, insolvency, reorganization or other similar laws generally affecting the enforcement of the rights of creditors and equitable principles (regardless of whether enforcement is sought in equity or at law).

 

  ð

Litigation. There are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to Your knowledge, threatened against You or any of Your business, property or rights (i) which involve any Lease Document or (ii) as to which there is a reasonable possibility of an adverse determination and which, if adversely determined, could, individually or in the aggregate result in an event which individually or together with any other event, would have a Material Adverse Effect.

 

  ð

Compliance with Applicable Laws. You are not in violation of any law, rule or regulation or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default could result in a Material Adverse Effect.

 

  ð

Conflict. Neither this Agreement nor any other Lease Document violates any provisions of Your articles or certificate of incorporation, bylaws or any contract, agreement, law, regulation, order, injunction, judgment, decree or writ to which You are subject.

 

  ð

Further Consent. The execution, delivery and performance of this Agreement and the other Lease Documents does not, or when such documents are executed and delivered will not, require the consent or approval of any other person, including any regulatory authority, or governmental body of the United States or any state or any political subdivision or the United States or any state.

 

  ð

Material Adverse Effect. As of the Closing Date, no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred or is continuing:

 

  ð

Other Defaults. You are not in default in any manner under any provision of any indenture or other agreement or instrument evidencing indebtedness, or any other material agreement or instrument to which You are a party or by which You or any of Your properties or assets are or may be bound, in each case where such default could result in an event which, individually or together with any other event, would have a Material Adverse Effect.

 

  ð

Information Correct. No information, report, financial statement, exhibit or schedule furnished by or on behalf of You to Us in connection with the negotiation of any Lease Document at the time such statement was made contained any material misstatement of fact or omitted to state any material fact necessary to make the statements, in the light of circumstances under which they were, not misleading; it being understood by Us that projections and forecasts provided by You that have been prepared in good faith and that are based on reasonable assumptions, are not to be viewed as facts, and that actual results during the periods covered by such projections and forecasts may differ from the projected and forecasted results.

 

  ð

Filing of Taxes. You have filed all required federal, state and local tax returns. Subject to Section 20, Paragraph “Taxes”, You have fully paid or You have reserved for and are contesting in good faith all taxes or installments (including any interest or penalties). You have fully paid or reserved for and are contesting in good faith all tax assessments that You have received for the 3 years preceding the Closing Date.

 

  ð

ERISA Compliance. You have met the minimum finding requirements of ERISA with respect to any employee benefit plans subject to ERISA. No event has occurred resulting from Your failure to comply with ERISA that is reasonably likely to result in Your incurring any liability that could reasonably be expected to have a Material Adverse Effect.

 

11


  ð

Hazardous Waste. None of Your properties or assets has ever been used by You or, to Your knowledge, by previous owners or operators, in the disposal of, or to produce, store, handle, treat, release, or transport, any hazardous waste or hazardous substance other than in accordance with applicable law; to Your knowledge, none of Your properties or assets has ever been designated or identified in any manner pursuant to any environmental protection statute as a hazardous waste or hazardous substance disposal site, or a candidate for closure pursuant to any environmental protection statute: no Lien arising under any environmental protection statute has attached to any revenues or to any real or personal property owned by You; and You have not received a summons, citation, notice, or directive from the Environmental Protection Agency or any other federal, state or other governmental agency concerning any action or omission by You resulting in the releasing, or otherwise disposing of hazardous waste or hazardous substances into the environment.

 

  ð

Your Information. Your present name, former names (if any), locations, and other information are correctly stated on the attached Exhibit D.

 

  ð

Operation of Business. To the best of Your knowledge, You own, possess, have access to, or can become licensed on reasonable terms under all patents, patent applications, trademarks, trade names, inventions, franchises, licenses, permits, computer software and copyrights necessary for the operation of Your business as now conducted, with no known infringement of, or conflict with, the rights of others. You have taken commercially reasonable measures to avoid liability from infringement by third parties using your facilities; in particular You have complied with the requirements of the Digital Millennium Copyright Act for notice and takedown.

 

 

20.      YOUR COVENANTS TO US

 

You covenant to the following:

 

  ð

Legal Existence and Qualification. You will maintain Your, and each of Your subsidiaries’, legal existence and good standing in Your and their respective jurisdictions of formation or organization, and maintain qualifications to do business in all jurisdictions in which the nature of Your business or location of Your properties require such qualifications and where the failure to be qualified would result in an event which, individually or together with any other event, would have a Material Adverse Effect.

 

  ð

Compliance with Laws. You will comply with all laws (including, without limitation, environmental laws) rules, regulations applicable to, and all orders and directives of any governmental or regulatory authority having jurisdiction over, You or Your business, and with all material agreements to which You are a party, except where the failure to so comply would not have a Material Adverse Effect. You shall not become an “investment company” or controlled by an “investment company,” within the meaning of the Investment Company Act of 1940, or become principally engaged in, or undertake as one of Your important activities, the business of extending credit for the purpose of purchasing or carrying margin stock, or use the proceeds of any loan for such purpose. You shall not fail to meet the minimum funding requirements of ERISA, permit a reportable event or prohibited transaction, as defined in ERISA, to occur, or fail to comply with the Federal Fair Labor Standards Act, except where the failure to so comply would not have a Material Adverse Effect You shall (1) ensure that no person who owns a controlling interest in or otherwise controls You is or shall be (A) listed on the Specially Designated Nationals and Blocked Person List maintained by the Office of Foreign Assets Control (“ OFAC ”), Department of the Treasury, and/or any other similar lists maintained by OFAC pursuant to any authorizing statute, Executive Order or regulation, or (B) a person designated under Sections 1(b), (c) or (d) of Executive Order No. 13224 (September 23, 2001), any related enabling legislation or any other similar Executive Orders, and (2) remain in compliance with all applicable Bank Secrecy Act (“ BSA ”) laws, regulations and government guidance on BSA compliance and on the prevention and detection of money laundering violations.

 

  ð

Mergers. You will notify Us of any proposed Merger Event at least twenty (20) days prior to the closing date, and You will provide all information, documents, and schedules that We reasonably request in connection with any such proposed event (collectively, the “Event Notice & Documents”). Upon Our receipt of the Event Notice & Documents We may choose, in Our sole discretion, either to: (i) allow this Agreement, all relevant Lease

 

12


  Documents to continue subject to the requirements below, or (ii) terminate the Lease Documents. We will let You know Our decision within ten (10) days of receiving the Event Notice & Documents. In the event We do not provide You with Our decision within ten (10) days, the Lease Documents will be considered terminated effective as of the close of the Merger Event. If the Lease Documents are terminated, then You will pay Us all the remaining rent for the balance of the term(s) of all Summary Schedules discounted to present value at five percent (5%), and at Your option return or purchase the Equipment in accordance with the terms of Section 16.

If We do not elect to terminate the Lease Documents, then (a) You, and any surviving or successor entity (collectively the “Surviving Entity”) will execute all agreements as provided by Us, including without limitation an agreement containing an assumption by the Surviving Entity of the due and punctual payment and performance of all of Your obligations and performance and observance of each of Your covenants and agreements under the Lease Documents, and (b) any person or entity that directly or indirectly owns or controls more than 50% of the voting stock of the Surviving Entity will execute and unconditional guaranty of the Lease Documents.

 

  ð

Acquisitions. You will not acquire all or substantially all of the capital stock or property of another Person (the “Target”), without Our prior written consent provided, that one of Your subsidiaries may merge or consolidate into another of Your subsidiaries or into You. Notwithstanding the foregoing, You may acquire a Target subject to the satisfaction of each of the following conditions (such acquisition of a Target being a “Permitted Acquisition”):

 

  a)

We shall receive al least 20 days prior written notice of such proposed Permitted Acquisition, which notice shall include a reasonably detailed description thereof; and

 

  b)

such Permitted Acquisition does not result in a right by any Person, whether or not exercised, to accelerate the maturity of any of Your Indebtedness; and

 

  c)

such Permitted Acquisition shall be consensual and shall have received any approval required by Target’s governing documents; and

 

  d)

the consideration paid by You consists solely of (1) Your capital stock or (2) the aggregate consideration paid by You (including all transaction costs, liabilities, Indebtedness and contingent obligations incurred or assumed by You in connection therewith) does not exceed $5,000,000 in the aggregate during any calendar year period following the Closing Date ; and

 

  e)

no other lender to You has a consent right and has not provided consent; and

 

  f)

immediately before and after giving effect to such Permitted Acquisition, no Default or Event of Default shall have occurred and be continuing; and

 

  g)

the prospects of payment and collection of the Obligations by Us and the ownership, perfection and priority of Our Liens in the Equipment, in Our sole, reasonable discretion, shall not be materially impaired; and

 

  h)

on or prior to the date of such Permitted Acquisition, We shall have received copies of the acquisition agreement and related agreements and instruments, and all opinions, certificates, lien search results and other documents reasonably requested by Us.

 

  ð

Additional Documents and Assurances. You will from time to time obtain any instruments or documents as We may reasonably request, and take all further action that may be reasonably necessary to give effect to the provisions and purpose of this Agreement or any other Lease Document. In addition, You authorize Us to file at any time precautionary financing statements, continuation statements, and amendments thereto that (i) either specifically describe the Equipment, and (ii) contain any other information required by the UCC for the sufficiency of filing office acceptance of any financing statement, continuation statement, or amendment, including whether, You are an organization, the type of organization and any organizational identification

 

13


  number issued to You, if applicable. You hereby appoint Us as Your lawful attorney-in-fact to sign Your name on any documents necessary to perfect or continue the perfection of any precautionary Lien regardless of whether an Event of Default has occurred. Our foregoing appointment as Your attorney in fact, and all of Our rights and powers, coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Our obligation to lease additional Equipment terminates.

 

  ð

Protection of Our Ownership. You will, at Your expense, protect and defend Our title to the Equipment against any Person attempting to claim ownership of the Equipment by asserting a claim against You or through You. You shall at all times keep the Equipment free and clear from any legal process or Liens whatsoever (except for Liens caused by Us) and shall give Us immediate written notice of any legal process affecting the Equipment. You will indemnify and hold Us and Our assignees harmless from and against any loss caused by Your failure to do so, except where such loss is caused by Us.

 

  ð

Dispositions, Liens and Encumbrances. You will not transfer, sell, assign, grant a security interest in, hypothecate, permit or suffer to exist any Lien, or otherwise transfer any interest in or encumber any portion of the Equipment.

 

  ð

Indebtedness. You will not incur any Indebtedness without the prior written consent of Us other than Indebtedness evidenced by this Agreement and Permitted Indebtedness.

 

  ð

Financial Statements. You will provide monthly and yearly financial statements in accordance with Section 25 of this Agreement.

 

  ð

Dividends and Distributions. You will not, without Our prior written consent, declare or pay any cash dividend or make a distribution on, or repurchase or redeem, any class of stock, other than pursuant to repurchase plans upon an employee director, officer or consultant’s death or termination of employment and other than dividends and distributions paid solely in Your capital stock.

 

  ð

Audits and Inspections. Upon Our request, You will, during normal business hours, make the Equipment, and books and records concerning the Equipment (including software used in Your business) available to Us for inspection at the place where it is located and shall make Your log and maintenance records pertaining to the Equipment available to Us for inspection. You will take all action necessary to correctly and completely, maintain in all material respects such books, records, logs, and maintenance records. If there is Equipment that is located off-site or at another location. You will obtain access for Us to those locations. You authorize Us to insert serial numbers or other inventory data physically on the Equipment. You will mark the Equipment with tags We provide to You in order to indicate Our ownership of the Equipment. You will keep all Equipment free from any other marking or tags that might be interpreted as a claim of ownership.

 

  ð

Taxes. You will pay when due all taxes fees or other charges of any nature whatsoever (together with any related interest or penalties) imposed or assessed against You, Us or the Equipment or upon Your ownership, possession, use, operation or disposition thereof or upon Your rents, receipts or earnings arising therefrom (excluding taxes imposed on Us based on Our net income) but without prejudice to and subject to the limitations in Section 15. Subject to Section 13, You shall file on or before the due date all federal, state and local tax returns including personal property tax returns in respect to the Equipment. Notwithstanding the foregoing, You may contest, in good faith and by appropriate proceedings, taxes for which You maintain adequate reserves in accordance with GAAP.

 

  ð

Intellectual Property. You will: (a) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of Your Intellectual Property to the extent material to Your business: (b) promptly advise Us in writing of material infringements of Your Intellectual Property: and (c) not allow any Intellectual Property material to Your business to be abandoned, forfeited or dedicated to the public without Our written consent.

 

  ð

Collateral Locations; Name Changes. You will not relocate Your chief executive office or Your principal place of business or any item of the Equipment unless: (i) You have given Us no less than thirty (30) days prior

 

14


  written notice, (ii) such relocation shall be within the continental United Slates: and (iii) all additional costs (including any administrative fees, additional taxes and insurance coverage) are reconciled and promptly paid by You. In addition, You will obtain and maintain such acknowledgments, consents, waivers and agreements from: (i) the owner, Lien holder, mortgagee and landlord with respect to any real property on which Equipment is located and (ii) from any Person in possession of Equipment, as We may require, all in form and substance reasonably satisfactory to Us. Without limiting the foregoing, where the Collateral is covered by a negotiable document (such as a warehouse receipt), You shall deliver to Us possession of such document.

 

  ð

Care, Use, and Maintenance of the Equipment. You will install and maintain the Equipment in good working condition (taking into consideration ordinary wear and tear) and make all necessary and proper repairs, renewals and replacements in accordance with prudent industry standards. You will, in accordance with prudent industry standards, protect the Equipment from damage and any other kind of loss while You have the Equipment or while it is being delivered to You. Except as provided in Section 14, even if the Equipment is damaged or lost, You will continue to pay the Monthly Rent amounts. You will only use the Equipment for business purposes and in compliance with all applicable laws. The Equipment will not be used by an entity exempt from federal income tax. You will not make any material alterations to the Equipment without Our prior written consent (which We will not unreasonably withhold) nor will You permanently attach the Equipment to any real estate If any Equipment requires maintenance contracts with the manufacturer of the Equipment, You will maintain one with the manufacturer or another party reasonably acceptable to Us and will provide Us a copy of the maintenance contract.

 

  ð

Change of Jurisdiction. You will not change Your state of organization unless You give Us no less than thirty (30) days prior written notice prior to changing Your state of organization.

 

 

21.      WHAT IS AN EVENT OF DEFAULT

 

The occurrence and continuation of any one or more of the following events shall constitute an “Event of Default” under this Agreement and the related Lease Documents:

 

  ð

Payment. You do not pay any Rent payments, fees, costs or other Obligations under this Agreement, or any of the other related Lease Documents within three (3) days of when such payment is due; or

 

  ð

Insurance. You do not maintain the insurance required by this Agreement;

 

  ð

Covenant. You fail to perform any covenant or Obligations under this Agreement, or any of the other related Lease Documents, and You fail to cure such breach (to the extent that such breach is capable of being cured) within twenty (20) days after the earlier of (i) We give You written notice or (ii) Your actual knowledge of such default; or

 

  ð

Misrepresentations. You or any Person acting for You makes any representation, warranty, or other statement now or later in this Agreement, any Lease Document or in any writing delivered to Us to induce Us to enter this Agreement, or any other Lease Document, and such representation, warranty, or other statement is incorrect in any material respect when made, provided , however , that such materiality qualifier shall not be applicable to any representation, warranty or statement that already is qualified or modified by materiality in the text thereof; or

ð Bankruptcy; Attachment; Other.

 

  ð

You (i) assign Your assets for the benefit of Your creditors, (ii) become unable to pay Your debts as they become due, or You become unable to pay or perform Your obligations under the Lease Documents, (iii) file a voluntary petition in bankruptcy, (iv) file any petition, answer, or document seeking for Yourself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances, (v) seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Yours or of all or any substantial part of Your assets or property, (vi) cease operation of

 

15


  Your business as Your business has normally been conducted, or terminate substantially all of Your employees, or (vii) You or Your directors or majority shareholders shall take any action initiating any of the foregoing actions described in this paragraph; or

 

  ð

Either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against You seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation without such action being dismissed or all orders or proceedings there under affecting Your operations or the business being stayed; or (ii) a stay of any such order or proceeding shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) You shall file any answer admitting or not contesting the material allegations of a petition filed against You in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or

 

  ð

Forty-five (45) days shall have expired after the appointment, without Your consent or acquiescence, of any trustee, receiver or liquidator of Yours or of all or any substantial part of Your properties without such appointment being vacated; or

 

  ð

Agreements with Us. The occurrence of any default under any other Lease Document, or any other agreement between You and Us (other than any default embodied in or covered by any clause of this Section 21) and such default continues for more than thirty (30) days after the earlier or (i) We have given notice of such default to You, or (ii) You have actual knowledge of such default; or

 

  ð

Other Agreements. The occurrence of any default (other than any default embodied in or covered by any other clause of this Section 21) under any lease, loan, or other agreement or obligation of Yours involving any indebtedness for borrowed money which aggregates more than $200,000 which permits the acceleration, or which default would have a Material Adverse Effect; or

 

  ð

Judgments. The entry of any judgment or arbitration award against You (i) involving an award in excess of $200,000 that is not covered by insurance by a solvent insurance carrier that has confirmed coverage in writing or (ii) in which You are enjoined, restrained or in any way prevented from conducting all or any material part of Your business or affairs.

 

 

22.      WHAT HAPPENS UPON AN EVENT OF DEFAULT

 

If an Event of Default has occurred and is continuing, We can at Our option, and without notice to You exercise any one or more of the following remedies: (a) proceed to enforce performance of the applicable covenants and terms of this Agreement or to recover damages for the breach thereof; (b) stop delivery of, or require You to assemble and return (in the condition and manner required by this Agreement) or make available for repossession by Us, any or all items of Equipment; (c) use Your premises for storage without liability; (d) sell, lease or otherwise dispose of any items of Equipment with or without notice at one or more public or private dispositions (ten (10) days advance notice shall be sufficient for all purposes); (e) regardless of whether We have recovered the Equipment, or if so recovered, have elected to retain any or all of the Equipment, or dispose of the Equipment by sale, lease or otherwise, recover as liquidated damages for the loss of a bargain due to Your default and not as a penalty (1) the rent due on that date plus (2) all unpaid rental as may be allocated to such item for the balance of the Lease Term (including any renewals or extension thereof, if applicable), discounted to present value at the rate of 5% per annum, plus (3) the residual value of such item of Equipment expected at the end of the Lease Term (as determined by Us in Our sole reasonable discretion), plus (4) all fees, costs and other amounts due and payable hereunder with respect thereto: and upon an Event of Default, all of the foregoing amounts shall become immediately due and payable to Us, to the extent permitted by UCC-2A, any other provision of the UCC or other applicable law and taking into account all applicable discounting (at the rate of 5% per annum) and credits (You will in all cases being liable for liable for any deficiencies) required thereby and upon satisfaction in full of all these obligations title to the Equipment, that has not otherwise been sold pursuant to this Section, shall automatically pass to You, without representation or warranty by Us; (f) recover from You all reasonable costs and expenses, including without limitation any incidental expenses and legal fees and expenses incurred by Us as a result of Your default hereunder,

 

16


less any credits due You pursuant to applicable law; and (g) with or without notice to You, cancel this Lease without prejudice to Our rights in respect of obligations then accrued and remaining unsatisfied. In addition to, and not in limitation of, the foregoing, We may also avail Ourselves of any other remedy or remedies provided for by any statute or otherwise available at law, in equity (including specific performance), or in bankruptcy or insolvency proceedings, including, without limitation, under UCC-2A, or any other provision of the UCC, You hereby waive notice of, or hearing with respect to, Our retaking the Equipment. All remedies of Us hereunder are cumulative and may, to the extent permitted by law, be exercised concurrently or separately. The exercise of any one remedy shall not be deemed to be an election of such remedy or to preclude the exercise of any other remedy. No failure on the part of Us to exercise and no delay in exercising any right or remedy shall operate as a waiver thereof or modify the terms of this Agreement.

In addition to the power of attorney granted in Section 20, effective only upon the occurrence and during the continuance of an Event of Default and solely for the purpose of exercising Our remedies hereunder, You hereby irrevocably appoint Us (and any of Our designated officers, agents, attorneys or employees) as Your true and lawful attorney to (a) dispose of any Equipment; and (b) make, settle, and adjust all claims under and decisions with respect to Your policies of insurance as they relate to the Equipment. Our appointment as Your attorney in fact, and each and every one of Our rights and powers, being coupled with an interest, is irrevocable until all of the Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Our obligation to lease Equipment hereunder is terminated.

 

 

23.      WHAT HAPPENS IF THERE IS AN EVENT OF DEFAULT AND YOU RETURN OUR EQUIPMENT OR WE REPOSSESS OUR EQUIPMENT

 

If an Event of Default has occurred pursuant to Section 21 and We require You to return Our Equipment, or We repossess Our Equipment, We will Use Our best efforts in accordance with Our normal business procedures to reduce Your damages to Us by selling, leasing, or otherwise disposing of all or any part of the Equipment at a public or private sale for cash or credit.

If We are able to sell or dispose of the Equipment for cash then We will subtract from this amount what the fair market value of the Equipment would have been at the expiration of the term of the lease and any default related costs and fees. Fair market value shall be defined as the amount that would be obtainable in an arms-length transaction between an informed and willing buyer and an informed and willing seller under no compulsion to buy. If there is left over cash, these proceeds will be applied against damages and any other sums due to Us from You.

If We lease the Equipment, We will take the present value (discounted at the rate of the new lease) of the rent for a term not to exceed Your original term of the lease and subtract default related costs and fees. If there is any remaining value, it will be applied against damages and any other sums due to Us from You.

However, You are still liable to Us for, and We may still recover from You, the amount by which these proceeds are less than the damages and other sums due to Us.

EXCEPT AS SET FORTH IN THIS SECTION, YOU WAIVE ANY RIGHTS NOW OR HEREAFTER CONFERRED BY STATUTE OR OTHERWISE WHICH MAY REQUIRE US TO MITIGATE OUR DAMAGES OR MODIFY ANY OF OUR RIGHTS OR REMEDIES STATED HEREIN.

 

 

24.      [INTENTIONALLY REMOVED]

 

This section intentionally removed.

 

 

25.      DOCUMENTS YOU WILL PROVIDE US

 

Secretary’s Certificate. Upon execution of this Plain English Master Lease Agreement, You will provide Us with a secretary’s certificate of incumbency and authority. This document identifies and authorizes individuals to execute binding documents on Your behalf.

 

17


Landlord/Mortgagee Waiver. You agree to provide Us with a Landlord/Mortgagee Waiver with respect to the Equipment so that Your landlord or mortgagee does not restrict Our access to Our Equipment or claim any interest in Our Equipment. Such waiver shall be in a form reasonably satisfactory to Us.

Financial Statements. Within thirty (30) days after the end of each month, You will provide to Us a monthly unaudited income statement; balance sheet and statement of cash flows prepared in accordance with generally accepted accounting principles (except for the absence of notes and year end adjustments). Within one hundred and eighty (180) days of every fiscal year end, You will provide Us audited financial statements accompanied by an audit report and opinion of the independent certified public accountants. You will provide Us any additional information (including, but not limited to, tax returns, income statements, balance sheets and names of principal creditors) as We reasonably believe are necessary to evaluate Your continuing ability to meet financial obligations under this Agreement. These statements should be emailed to Us at financials@tpcp.com, or upon Our prior approval, facsimiled or mailed to Us at the address listed on the Hardware and/or Software Facility Schedule.

Certificate of Compliance. On an annual basis We will provided You with a Certificate of Compliance, attached as Exhibit E and a list of all Equipment subject to this Agreement and the Lease Documents. Upon receipt You will have thirty (30) days to provide Us with the completed Certificate of Compliance.

 

 

26.      OTHER LEGAL PROVISIONS YOU WILL ABIDE BY

 

Entire Agreement. This Agreement, the associated Hardware and/or Software Facility Schedule(s), and the associated Summary Schedules supersede all other oral or written agreements or understandings between The Parties concerning the Equipment including, for example, purchase orders. ANY AMENDMENT OF THESE AGREEMENTS MAY ONLY BE ACCOMPLISHED THROUGH A DOCUMENT WITH SIGNATURES FROM THE PARTIES.

No Waiver. No action taken by You or Us will be deemed to constitute a waiver of compliance with any representation, warranty or covenant contained in this Agreement, Hardware and/or Software Facility Schedule or Summary Schedule. The waiver by Us of a breach of any provision this Agreement or the Lease Documents will not operate or be construed as a waiver of any subsequent breach.

Successors and Assigns. The provisions of this Agreement and the other Lease Documents shall inure to the benefit of and be binding on You and Your permitted assigns (if any). You shall not assign Your obligations under this Agreement, the Hardware or Software Facility Schedules, Summary Schedules or any of the other Lease Documents without Our express prior written consent, and any such attempted assignment shall be void and of no effect, You shall not sublease the Equipment without our prior written consent. You acknowledge and understand that We may sell and assign all or part of Our interest hereunder and all other related Lease Documents to any person or entity to be known as assignee. After such assignment the term “We” “Us” and “Our” as used in the Lease Documents will mean and include such assignee, and such assignee will be vested with all Our rights, powers and remedies hereunder and shall have Our duties with respect to the interest that You have granted Us; but with respect to any such interest not so transferred. We shall retain all rights, powers and remedies. No such assignment will relieve You of any of Your obligations. You will, if requested to do so, acknowledge such assignment in a writing. YOU WILL NOT ASSERT, AS AGAINST OUR ASSIGNEE, ANY DEFENSE, SETOFF, RECOUPMENT, CLAIM OR COUNTERCLAIM, WHETHER ARISING UNDER THIS AGREEMENT OR OTHERWISE.

Survival of Obligations. The obligations, representations and warranties contained in this Agreement and any Lease Documents are for the benefit of the Parties and survive the execution and delivery of this Agreement (provided that this Section shall not be deemed to make any such obligations, representations or warranties extend beyond the time provided for in this Agreement). The indemnification contained in this Agreement, or any other Lease Documents are for the benefit of the Parties and survive the execution, delivery, expiration or termination of this Agreement.

Notices. Any notice, request or other communication to either party by the other will be given in writing and deemed received upon the earlier of (1) actual receipt or (2) three (3) days after mailing if mailed postage prepaid by regular or airmail to Us or You, at the address set out in any Hardware and/or Software Facility Schedule, (3) one

 

18


(1) day after it is sent by courier or (4) on the same day as sent via facsimile transmission, with delivery , confirmation and provided that the original is sent by personal delivery or mail by the sending party.

Applicable Law. THIS AGREEMENT HAS BEEN, AND EACH HARDWARE AND/OR SOFTWARE FACILITY SCHEDULE AND SUMMARY SCHEDULE WILL HAVE BEEN MADE, EXECUTED AND DELIVERED IN THE STATE OF CALIFORNIA AND WILL BE GOVERNED AND CONSTRUED FOR ALL PURPOSES IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA WITHOUT GIVING EFFECT TO CONFLICT OF LAW PROVISIONS. NO RIGHTS OR REMEDIES REFERRED TO IN ARTICLE 2A OF THE UNIFORM COMMERCIAL CODE WILL BE CONFERRED ON YOU UNLESS EXPRESSLY GRANTED IN THIS AGREEMENT, HARDWARE AND/OR SOFTWARE FACILITY SCHEDULE(S) AGREEMENT OR SUMMARY SCHEDULE.

Consent To Jurisdiction And Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California: (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this agreement shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

Mutual Waiver Of Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and The Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT (COLLECTIVELY, “ CLAIMS ”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement.

Professional Fees. Your promise to pay any and all reasonable professional fees and expenses incurred by Us after the execution of this Agreement in connection with or related to: the Obligations, the administration, collection, or enforcement of the Obligations; amendment or modification of the Lease Documents; any waiver, consent, release, or termination under the Lease Documents; the protection, preservation, sale, lease, liquidation, disposition of or other action related to the Equipment or the exercise of remedies with respect to the Equipment; or any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to You or the Equipment, and any appeal or review thereof; and any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to You, the Equipment, the Lease Documents,

 

19


including representing Us in any adversary proceeding or contested matter commenced or continued by or on behalf of Your estate, and any appeal or review thereof. Our professional fees and expenses shall include the reasonable fees or expenses for Our attorneys, accountants, auctioneers, liquidators, appraisers, investment advisors, environmental and management consultants, or experts engaged by Us in connection with the foregoing. Your promise to pay all of Our reasonable professional fees and expenses is part of the Obligations under this Agreement.

Severability. If any one or more of the provisions of this Agreement, any Hardware and/or Software Facility Schedule, or any Summary Schedule is for any reason held invalid, illegal or unenforceable, the remaining provisions of this Agreement, any such Hardware and/or Software Facility Schedule, and any such Summary Schedule will be unimpaired, and the invalid, illegal or unenforceable provision replaced by a mutually acceptable valid, legal and enforceable provision that is closest to the original intention of The Parties.

Counterparts. This Agreement, any Hardware and/or Software Facility Schedule, and any Summary Schedule may be executed in any number of counterparts, each of which will be considered an original, but all such counterparts together constitute one and the same instrument.

Facsimile Signatures. This Agreement, any Hardware and/or Software Facility Schedule, and any Summary Schedule may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party.

Confidentiality. All information (other than any such information contained in periodic reports filed by You with the Securities and Exchange Commission) disclosed by You to Us shall be considered confidential for purposes of this Agreement. In handling any confidential information. We will exercise the same degree of care that We exercise for Our own proprietary information and at least reasonable care, but disclosure of information may be made (i) to Our subsidiaries or affiliates in connection with their business with You provided that they agree to assume and abide by the provisions hereof, (ii) to prospective transferees or purchasers of any interest in the loans (provided, however, such prospective transferee agrees to of the terms of this provision and any purchaser, shall be agreeing to assume the obligations hereunder shall therefore agree to abide by the provisions hereof, including, without limitation, the provisions of this Section), (iii) as We deem necessary or appropriate to any bank, financial institution or other similar entity with a need to know such information, provided, however, that such bank, financial institution or other similar entity agrees in writing to maintain the confidentiality of such information, (iv) to S&P, Moody’s, Fitch and/or other ratings agency, as We deem necessary in connection with rating Us, provided, however, that the confidentiality provisions in this Agreement shall apply, (v) as required by law, regulation, subpoena, or other order, provided We shall use Our best efforts to first give You notice of ay such required disclosure so as to permit You to seek to obtain protective orders (vi) as required in connection with Our examination or audit (provided that confidentiality provisions in this agreement shall apply) and (vii) as We consider appropriate for the exercise of remedies under this Agreement. Confidential information does not include information that either: (a) is in the public domain when disclosed to Us, or becomes part of the public domain after disclosure to Us; or (b) is disclosed to Us by a third party, if we do not know that the third party is prohibited from disclosing the information. Notwithstanding the above, You hereby consent to the use by Us of Your company name and logo for advertising, promotional and marketing purposes only. Such use may reference the type of credit facility but will not indicate the amount or financial terms of the credit facility without Your prior written approval.

 

 

27.      DEFINITIONS

 

Capitalized terms used in this Agreement shall have the following meanings:

Advance Rent ” has the meaning given to it in Section 10.

Closing Date ” means March 14, 2008.

“Commitment Increase Request Notice” has the meaning given to it in Section 3.

“Default” means any event that, with the passage of time or notice or both would, unless cured or waived, become an Event of Default.

 

20


“Equipment” has the meaning given to it in Section 1.

“Event of Default” has the meaning given to it in Section 21.

“GAAP” means United States generally accepted accounting principles, consistently applied, as in effect from time to time.

Indebtedness ” means, of any Person, at any date, without duplication and without regard to whether matured or unmatured, absolute or contingent: (i) all obligations of such Person for borrowed money; (ii) all obligations of such Person evidenced by bonds, debentures, notes, or other similar instruments; (iii) all obligations of such Person to pay the deferred purchase price of property or services; (iv) all obligations of such Person as lessee under capital leases; (v) all obligations of such Person to reimburse or prepay any bank or other Person in respect of amounts paid under a letter of credit, banker’s acceptance, or similar instrument, whether drawn or undrawn; (vi) all obligations of such Person to purchase securities which arise out of or in connection with the sale of the same or substantially similar securities; (vii) all obligations of such Person to purchase, redeem, exchange, convert or otherwise acquire for value any capital stock of such Person or any warrants, rights or options to acquire such capital stock, now or hereafter outstanding, except to the extent that such obligations remain performable solely at the option of such Person; (viii) all obligations to repurchase assets previously sold (including any obligation to repurchase any accounts or chattel paper under any factoring, receivables purchase, or similar arrangement); (ix) obligations of such Person under interest rate swap, cap, collar or similar hedging arrangements; and (x) all obligations of others of any type described in clause (i) through clause (ix) above guaranteed by such Person.

“Lease Commencement Date” has the meaning given to it in Section 9.

“Lease Start Date” has the meaning given to it in Section 9.

“Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily inclined or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, any lease in the nature of a security interest, and the filing of any financing statement (other than a precautionary financing statement with respect to a lease that is not in the nature of a security interest) under the UCC or comparable law of any jurisdiction.

Lease Documents ” means this Agreement, any Hardware and/or Software Facility Schedules, Summary Schedules, all UCC Financing Statements, and any other documents executed in connection with the Obligations or the transactions contemplated hereby, including those documents described on the Schedule of Documents, as the same may from time to time be amended, modified, supplemented or restated; provided that the Lease Documents shall not include the Warrant Agreement or any equity related agreements between us.

“Material Adverse Effect” means a material adverse effect on (i) Your business, operations, properties, assets or condition (financial or otherwise), (ii) Your ability to perform Your obligations in accordance with the terms of this Agreement, the related Summary Schedules or the related Hardware and/or Software Facility Schedule or Our ability (other than as a result of Our action or inaction) to enforce any of Our rights and remedies with respect to Your obligations in accordance with the terms of this Agreement, the related Summary Schedules or the related Hardware and/or Software Facility Schedule, or (iii) the Equipment.

Merger Event ” means (i) any reorganization, consolidation or merger (or similar transaction or series of transactions) by You or any of Your subsidiaries with or into any other Person (ii) any transaction, including the sale or exchange of outstanding shares of Your capital stock (other than a bona fide venture capital equity financing transaction), in which the holders of Your outstanding capital stock immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain capital stock representing at least 50.0% of the voting power of the surviving corporation of such transaction or series of related transactions (or the parent corporation of such surviving corporation if such surviving corporation is wholly owned by such parent corporation), in each case without regard to whether You are the surviving corporation, or (iii) the sale, license or other disposition of all or substantially all of Your assets.

 

21


Obligations ” means Your obligation to pay to Us all Monthly Payments (whether or not evidenced by any Summary Schedule), together with all rent, fees, costs, professional fees and expenses, or other liabilities or obligations for monetary amounts owed by You to Us pursuant to the Lease Documents, including the indemnity and insurance obligations in Sections 14, 15 and 24 hereof and including such amounts as may accrue or be incurred before or after default or workout or the commencement of any liquidation, dissolution, bankruptcy, receivership or reorganization by or against You, whether due or to become due, matured or un-matured, liquidated or un-liquidated, contingent or non-contingent, and all covenants and duties of any kind or nature, present or future, arising under this Agreement, or any of the other Lease Documents, as the same may from time to time be amended, modified, supplemented or restated, whether or not such obligations are partially or fully secured by the value of Equipment.

Permitted Indebtedness ” means (a) Indebtedness of You in favor of Us; (b) Indebtedness existing at the Closing Date and disclosed on Schedule l; (c) Indebtedness incurred for the acquisition of services, supplies or inventory on normal trade credit in the ordinary course of business; (d) any other Indebtedness not to exceed $550,000,000, during the term of the Lease so long as such Indebtedness is not secured by the Equipment Subject to this Agreement, and (e) extensions, refinancings, modifications, amendments and restatements of any item of Permitted Indebtedness (a) through (d) above, provided that the principal amount thereof is not increased. Notwithstanding the above, You may not enter into any Indebtedness of the type described in subsection (d) without Our prior written consent, until You have issued and sold shares of Your Series B-1 preferred stock for aggregate gross cash proceeds of at least $30,000,000 (excluding any amounts received upon conversion or cancellation of indebtedness).

Person ” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, public benefit corporation, other entity or government (whether federal, state, county, city, municipal, local, foreign, or otherwise, including any instrumentality, division, agency, body or department thereof).

Rent ” has the meaning given to it in Section 10.

UCC ” means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Our Lien on any Equipment is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. Unless otherwise defined herein or in the other Lease Documents terms that are defined in the UCC and used herein or in the other Lease Documents shall have the meanings given to them in the UCC.

Warrant Agreement ” means either the Warrant Agreement dated as of the date hereof between the Parties issued in connection with this Agreement or any other Warrant Agreement between the Parties issued in connection with this Agreement or the Hardware or Software Facility Schedules.

Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. The terms “herein,” “hereof” and “hereunder” and other words of similar import refer to this Agreement as a whole, including all Exhibits, Annexes and Schedules, and not to any particular Section, subsection or other subdivision. Wherever from the context it appears appropriate, each term stated in either the singular or plural shall include the singular and the plural, and pronouns stated in the masculine, feminine or neuter gender shall include the masculine, feminine and neuter genders. The words “including,” “includes” and “include” shall be deemed to be followed by the words “without limitation,” the word “or” is not exclusive; references to Persons include their respective successors and assigns (to the extent and only to the extent permitted by this Agreement and the Lease Documents) or, in the case of governmental Persons, Persons succeeding to the relevant functions of such Persons; and all references to statutes and related regulations shall include any amendments of the same and any successor statutes and regulations. Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Lease Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied.

 

22


(Signature Page to Follow)

 

23


IN WITNESS WHEREOF, The Parties hereto have executed this Agreement on or as of the day and year first above written.

 

AMYRIS BIOTECHNOLOGIES, INC.

as You

   

TRIPLEPOINT CAPITAL LLC

as We

By:

 

/s/ Jeryl Hilleman

   

By:

 

/s/ [signature illegible]

Title:

 

CFO

   

Title:

 

COO

[SIGNATURE PAGE TO PLAIN ENGLISH MASTER LEASE AGREEMENT]

 

24


Schedule of Exhibits

 

Exhibit A

   Form of Hardware Facility Schedule and Software Facility Schedule

Exhibit B

   Form of Purchase-Leaseback Agreement

Exhibit C

   Form of Summary Schedule

Exhibit D

   Company Information

Exhibit E

   Certificate of Compliance

 

25


EXHIBIT A

(Form Hardware and Software Facility Schedules)

 

26


LOGO

 

H ARDWARE /S OFTWARE F ACILITY S CHEDULE D ATED                      , 2008

T O T HE P LAIN E NGLISH M ASTER L EASE A GREEMENT D ATED A S O F M ARCH  14, 2008

     

Facility Number

0534-LE-0_H, 0534-LE-0_S

 

   Commitment Amount               $[            ]               

Equipment         

$[            ]        

Availability Period

[    /    /    ] - [    /    /    ]

  

Lease Term

[    ] Months

  

Lease Rate Factor

TBD on date of each Summary Schedule

 

  

Interest Rate

[    ]%

Facility Fee

[    ]%

  

Advance Rent

$[    ]

  

Interim Rate

Full Daily Equivalent

  

Purchase Option/End of Term Payment

[Not to Exceed] [    ]% of Original Cost

 

O UR C ONTACT I NFORMATION

Name

TriplePoint Capital LLC

  

Address for Notices

2755 Sand Hill Rd., Ste. 150

Menlo Park, CA 94025

  

Address for Equipment Return

2755 Sand Hill Rd., Ste. 150

Menlo Park, CA 94025

     Tel: (650) 854-2090     
     Fax: (650) 854-1850     
     Attn: Sajal Srivastava     
    

Email: legal@triplepointcapital.com

 

    
     Y OUR C ONTACT I NFORMATION     

Customer Name

Amyris Biotechnologies, Inc.

  

Address for Billing/Notices

5980 Horton St., Suite 450

Emeryville, CA 94608

 

Equipment Location

Same As Above

(Unless Noted Differently on the

Summary Schedule)

 

  

Contact Person

Name: Jeryl Hilleman, CFO

Tel: (510) 450-0761 x734

Fax: (510) 450-0794

Email: hilleman@amyris.com

This Hardware Facility Schedule is issued pursuant to the Plain English Master Lease Agreement identified above. All of the terms and conditions of the Plain English Master Lease Agreement are incorporated in and made a part of this Schedule as if they were expressly set forth in this Schedule. The Parties hereby reaffirm all of the terms and conditions of the Plain English Master Lease Agreement except as modified by this Schedule. This Schedule may not be amended or rescinded except by a writing signed by both of The Parties.

 

You:

 

AMYRIS BIOTECHNOLOGIES, INC.

   

Us:

 

TRIPLEPOINT CAPITAL LLC

By:

 

 

   

By:

 

 

Title:

 

 

   

Title:

 

 


EXHIBIT B

(Form Purchase-Leaseback Agreement)


LOGO

P LAIN E NGLISH P URCHASE L EASEBACK A GREEMENT

This is a PLAIN ENGLISH PURCHASE LEASEBACK AGREEMENT dated             , 200 by and between TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES, INC. The words “We”, “Us”, or “Our”, refer to the Buyer, which is TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the Seller, which is AMYRIS BIOTECHNOLOGIES, INC. and not to any individual. The words “The Parties” refers to both TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES, INC.

The Parties agree to the following mutual agreements and conditions listed below:

 

 

PURCHASE INFORMATION

 

 

Purchase Price: $                                                  

 

  

Date of Purchase:                                                  

 

What Do We Purchase : You agree to sell and We agree to purchase from You the Equipment listed in the attached Exhibit A in accordance with the terms and conditions specified in this Plain English Purchase Leaseback Agreement.

What is the Purchase Price : The Purchase Price and the day of purchase will be as set forth above. Prior to giving You the Purchase Price, You will provide Us with copies of the purchase documentation, invoices and/or Bill of Sale and proof of payment to verify Your purchase of the Equipment from the vendor. We will not pay You the Purchase Price until all requested documentation is received by, and is approved by Us.

What is the Leaseback : This Agreement is contingent upon You leasing the Equipment from Us pursuant to the Hardware and Software Facility Schedule Nos. 0534-LE-      H and 0534-LE-      S dated              to the Plain English Master Lease Agreement dated              all between the Parties.

You Make No Warranties : YOU MAKE NO WARRANTIES OTHER THAN THOSE SPECIFICALLY SET OUT IN THIS AGREEMENT (IF ANY), AND SPECIFICALLY DISCLAIM THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

Equipment Will Have Clear Title : Title to the Equipment will be free and clear of all liens, claims and encumbrances of any kind and will vest in Us upon payment of the full Purchase Price stated above. Upon request, You will provide Us with a Bill of Sale to evidence such title.

Tax Issues : We warrant that We are in the business of buying and selling computer, communications and high technology equipment and that the Purchase Price of the Equipment is for the purpose of resale only.


Legal Issues:

 

  ð

This Agreement will be governed by and construed under the laws of California.

 

  ð

This Agreement may be executed in multiple counterparts, each of which will be deemed to be an original and of equal force and effect.

 

  ð

This Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party.

 

AMYRIS BIOTECHNOLOGIES, INC.

   

TRIPLEPOINT CAPITAL LLC

By:

 

 

   

By:

 

 

Title:

 

 

   

Title:

 

 

“SELLER”     “BUYER”

 

2


LOGO

EXHIBIT A - EQUIPMENT


EXHIBIT C

(Form Summary Schedule)


LOGO

PLAIN ENGLISH SUMMARY SCHEDULE

SCHEDULE NUMBER |0534-LE-0_H/S-      |

(Hardware/Software)

This Plain English Summary Schedule dated             , 200   is executed pursuant to the Plain English Master Lease Agreement dated March 14, 2005 between TriplePoint Capital LLC (“Lessor”) and Amyris Biotechnologies, Inc. (“Lessee”). All of the terms, conditions, representations and warranties of the Plain English Master Lease Agreement are incorporated herein and made a part hereof, and this Plain English Monthly Summary Schedule constitutes a Schedule for the Equipment listed below.

 

    SCHEDULE INFORMATION     
     
Facility Number   Schedule Number    Schedule Type

 

0534-LE-0_H/S

 

 

 

0534-LE-0_H/S-__

 

  

 

Hardware/Software

 

     
Schedule Period   Lease Commencement Date    Lease Term

 

[  /  /  ] - [  /  /  ]

 

 

 

[  /  /  ]

 

  

 

[    ] Months

 

     
Total Equipment Cost   Location    Current Use Tax Percentage

 

$[            ]

 

 

 

[                    ]

 

  

 

[            ]%

 

     
Monthly Lease Rate Factor   Daily Interim Rent Rate    One Time Interim Rent

 

[            ]%

 

 

 

Fully Daily Equivalent

 

  

 

$[            ]

 

    
  PAYMENT INFORMATION   
 

 

Monthly Rent

  
 

 

$[            ]

 

  
 

 

Monthly Use Tax

  
 

 

$[            ]

 

  
 

 

Total Monthly Payment

  
 

 

$[            ]

 

  
 

 

[ATTACH EQUIPMENT LIST]

  


EXHIBIT D

YOUR NAME, LOCATIONS, AND OTHER INFORMATION

1.             You hereby represent and warrant and to Us that Your current name and organizational status on the Closing Date is as follows:

 

Name:

  

Amyris Biotechnologies, Inc.

  

Type of Organization:

  

Corporation

  

State of Organization:

  

California

  

Organization File Number:

  

2544865

  

2.             You hereby represent and warrant to Us that for five (5) years prior to the date of this Agreement, You did not do business under any other name or organization or form except the following:

 

Name:

  

N/A

  

Used during dates of:

     

Type of Organization:

     

State of Organization:

     

Organization File Number:

     

3.             Your fiscal year ends on December 31 st .

4.             Your federal employer tax identification number is 55-0856151.

5.             You hereby represent and warrant to Us that the street addresses, cities, states and postal codes of Your current locations and locations where any Equipment may be located as of the Closing Date are:

 

Chief Executive Office:

  

5980 Horton St. Suite 450

Emeryville, CA 94608

  

Principal Place of Business:

  

5980 Horton St. Suite 450

Emeryville, CA 94608

  

Other Locations:

  

5980 Horton St. Suite 450

Emeryville, CA 94608

(Also Suites 350, 360 and 405)

  
  

5885 Hollis Street, Suites 1353 and 1355 Emeryville, CA 94608

  

 


EXHIBIT E

CERTIFICATE OF COMPLIANCE

This Certificate of Compliance shall reference that certain Plain English Master Lease Agreement dated March 14, 2008, by and between TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES, INC. (the “Lease Agreement”). All terms not defined in this Certificate of Compliance shall have the same meanings as in the Lease Agreement. Pursuant to the terms of the Lease Agreement, AMYRIS BIOTECHNOLOGIES, INC. hereby certifies, the following as of [MONTH, DAY, YEAR]”:

 

  ð

We are in compliance as of the date of this Certificate of Compliance with all required covenants unless otherwise noted and attached to this Certificate of Compliance.

 

  ð

As of the date of this Certificate of Compliance all representations and warranties in the Lease Agreement are true and correct in all material respects except to the extent such representations and warranties expressly relate to an earlier date (in which case, those representations and warranties remain true as of such date).

 

  ð

The locations of all Equipment on the attached list and subject to the Lease Agreement are true and correct.

 

 

AMYRIS BIOTECHNOLOGIES, INC.

 
 

Signature:

 

 

 
 

Print Name:

 

 

 
 

Title:

 

 

 
    [ATTACH LIST OF EQUIPMENT]  

 

2


SCHEDULE 1

INDEBTEDNESS

 

Creditor

  

Type of Credit Facility

  

Security Interest Granted

  

Outstanding Amount

Applied Biosystems

(Applera)

  

Lease

  

Equipment Specific

  

$313,061.35

Thermo Electron Corp.

  

Lease

  

Equipment Specific

  

$297,149.73

    

              

 

3


LOGO

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (the “1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THIE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.

PLAIN ENGLISH WARRANT AGREEMENT

This is a PLAIN ENGLISH WARRANT AGREEMENT dated March 14, 2008 by and between AMYRIS BIOTECHNOLOGIES, INC., a California corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company.

The words “We”, “Us”, or “Our” refer to the warrant holder, which is TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the issuer, which is AMYRIS BIOTECHNOLOGIES, INC., and not to any individual. The words “The Parties” refers to both TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES. This Plain English Warrant Agreement may be referred to as the “Warrant Agreement”.

The Parties have entered into a Plain English Master Lease Agreement dated as of March 14, 2008, and related Hardware or Software Facility Schedules and Summary Schedules which are collectively referred to in this Warrant Agreement as the “Lease Agreement”.

In consideration of such Lease Agreement, the Parties agree to the following mutual agreements and conditions set forth below:

 

          W ARRANT  I NFORMATION          

 

Effective Date

  

 

Warrant Number

  

 

Lease Facility Schedules

 

March 14, 2008

 

  

 

0534-W-01

 

  

 

0534-LE-01H; 0534-LE-01S

 

 

Warrant Coverage

 

  

 

Number of Shares

  

 

Price Per Share

  

 

Type of Stock

$250,000 (5% of $5,000,000);

up to an additional $250,000

(5% of any amounts advanced

under the Lease Agreement in

excess of $5,000,000, and

earned based upon

increments of $1,000,000

advanced)

 

  

10,048; up to an additional

10,048 subject to

adjustment per the terms of

this Warrant Agreement

  

$24.88 subject to

adjustment per the terms

of this Warrant Agreement

  

Warrant Stock (as defined

herein) subject to

adjustment per the terms

of this Warrant

Agreement

 

     O UR C ONTACT I NFORMATION     

 

Name

 

TriplePoint Capital LLC

  

 

Address For Notices

 

2755 Sand Hill Rd., Ste. 150

Menlo Park, CA 94025

Tel: (650) 854-2090

Fax: (650) 854-1850

 

  

 

Contact Person

 

Sajal Srivastava, COO

Tel: (650) 233-2102

Fax: (650) 854-1850

email: legal@triplepointcapital.com

 

     Y OUR C ONTACT I NFORMATION     

 

Customer Name

 

Amyris Biotechnologies, Inc.

  

 

Address for Billing/Notices

 

5980 Horton St., Suite 450

Emeryville, CA 94608

  

 

Contact Person

 

Name: Jeryl Hilleman, CFO

Tel: (510) 450-0761 x734

Fax: (510) 450-0794

Email: hilleman@amyris.com

 


 

1.        WHAT YOU AGREE TO GRANT US

 

You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, that number of fully paid and non-assessable shares of Your Warrant Stock equal to Two Hundred Fifty Thousand Dollars ($250,000), divided by the Exercise Price.

In addition, You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from You, at a price per share equal to the Exercise Price, an additional number of fully paid and non-assessable shares of Your Warrant Stock equal to five percent (5%) of any amounts advanced under the Loan Agreement in excess of $5,000,000, divided by the Exercise Price (up to an additional $250,000 in the aggregate of warrant coverage), the additional Warrant Coverage will be earned as follows: (i) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is over $5,000,000 but less than $6,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; (ii) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is $6,000,000 or more but less than $7,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; (iii) immediately upon any Advance in which the total amount advanced under Part I of the Loan Agreement is $7,000,000 or more but less than $8,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; (iv) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is $8,000,000 or more but less than $9,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000; and (v) immediately upon any Advance in which the total amount advanced under Part 1 of the Loan Agreement is $9,000,000 or more but not greater than $10,000,000 We shall have earned additional Warrant Coverage equal to 5% of $1,000,000.

In no event shall the total Warrant Coverage exceed $500,000.

The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are subject to adjustment as provided in Section 4 hereof.

For purposes of this Warrant Agreement, the following capitalized terms have the meanings given below:

“Exercise Price” means the lower of (a) $24.88 and (b) the lowest per share price for which Your preferred stock is sold in the Next Round.

“Next Round” means the next bona fide round of equity financing in which You issue and sell shares of your preferred stock for aggregate gross cash proceeds of at least $1,000,000 (excluding any amounts received upon conversion or cancellation of indebtedness) subsequent to the Effective Date.

“Warrant Stock” means (a) the class and series of Your preferred stock issued in the Next Round, if the lowest per share price for which such preferred stock is sold in the Next Round is less than $24.88, or (b) in all other cases, Your Series B Preferred Stock. For avoidance of doubt, if this Warrant Agreement is exercised prior to the Next Round then this Warrant Agreement shall be exercisable for Your Series B Preferred Stock.

The Parties agree that this Warrant Agreement to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price is included as part of the leased value and will be allocable to the Warrant Agreement and the original issue discount on the Lease Agreement shall be considered to be zero.

 

 

2.        WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK.

 

The term of this Warrant Agreement and our right to purchase Warrant Stock will begin the Effective Date, and shall be available until the earlier of (i) 10 years from the Effective Date or (ii) the effective date of Your initial public offering.

 

2


Notwithstanding the foregoing, Our right to purchase the Warrant Stock shall be automatically and fully exercised via the net issuance method described below (without surrender of the Warrant Agreement) upon the occurrence of a Merger Event, as defined below, with a Person that is not one of Your affiliates, in which Your common stock is exchanged for cash and/or stock that is traded on a recognized public exchange or on the NASDAQ National Market, provided that, upon consummation of the Merger Event, the consideration payable to Us pursuant to such exercise and on account of the Warrant Stock consists of (i) cash or (ii) stock that is traded on a recognized public exchange or on the NASDAQ National Market and the total per share consideration is equal to or greater than five (5) times the aggregate Exercise Price (as adjusted). No less than ten (10) business days prior to any Merger Event, You shall provide Us with written notice of the proposed Merger Event together with a copy of the executed merger agreement, or other definitive documentation (and all schedules and exhibits thereto) and information concerning Your expected capitalization immediately prior to the Merger Event. Upon consummation of the Merger Event, You shall promptly provide Us with (a) a copy of any modifications or amendments to the executed merger agreement, (b) any other documents in connection therewith, (c) updated information, if any, concerning Your capitalization immediately prior to the Merger Event, and, (d) upon request, by Us any other information reasonably necessary to an informed evaluation of Our rights under this Agreement.

 

 

  3.

HOW WE MAY PURCHASE YOUR WARRANT STOCK.

 

We may exercise Our purchase rights, in whole or in part, at any time, or from time to time, prior to the expiration of the term of this Warrant Agreement, by giving You a completed and executed Notice of Exercise in the form attached as Exhibit I . Promptly upon receipt of the Notice of Exercise and in any event no later than twenty-one (21) days after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Warrant Stock that We have purchased and You will execute the Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any.

We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as determined below. If We elect the Net Issuance method, You will issue Warrant Stock using the following formula:

 

     

X =

  

Y(A-B)

     A

 

Where:

 

X =

 

the number of shares of Warrant Stock to be issued to Us.

   

Y =

 

the number of shares of Warrant Stock. We request to be exercised under this Warrant Agreement.

   

A =

 

the fair market value of one share of Warrant Stock.

   

B =

 

the Exercise Price.

For purposes of the above calculation, current fair market value of Warrant Stock shall mean with respect to each share of Warrant Stock:

If the exercise is in connection with the initial public offering of Your Common Stock, and if Your registration statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” specified in the final prospectus of the offering and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise;

If this Warrant Agreement is exercised after, and not in connection with the Your initial public offering, and:

 

  ð

if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; or

 

  ð

if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending

 

3


  three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise.

If this Warrant Agreement is exercised prior to or after Your initial public offering, and:

 

  ð

Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the- counter market, the current fair market value of Warrant Stock shall be the product of (x) the fair market value of a share of Your Common Stock (the highest price per share which You could obtain from a willing buyer (not a current employee or director) for shares of Common Stock sold, from authorized but unissued shares), as determined in good faith by Your Board of Directors and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise, unless You shall become subject to a merger, acquisition or other consolidation pursuant to which You are not the surviving party, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of the Your Warrant Stock on a common equivalent basis pursuant to such merger or acquisition or other consolidation.

During the term of this Warrant Agreement, You will at all times from and after the Effective Date have authorized and reserved a sufficient number of shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and (b) Common Stock to provide for the conversion of the Warrant Stock.

If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an amended Warrant Agreement stating the remaining number of shares that are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement.

If at the end of the term of this Warrant Agreement, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date, then this Warrant Agreement shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of Warrant Stock (or such other securities) for which it shall not previously have been exercised or converted, and You shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion to Us.

 

 

  4.

WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE.

 

 

  ð

If You are Acquired. If at any time: (i) there is a reorganization of Your stock (other than a reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity; (iii) You sell or convey, or grant an exclusive license with respect to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of the outstanding voting power of the capital stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall be made so that We shall thereafter be entitled to receive, upon exercise of Our rights under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that which would have been issuable if We had exercised Our rights under this Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Your Board of Directors) shall be made in the application of the provisions of this Warrant Agreement with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable) shall be applicable to the greatest extent possible.

 

  ð

If You Reclassify Your Stock. If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change any of the securities as-to which purchase rights under this Warrant Agreement exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of

 

4


  such change with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change.

 

  ð

If You Subdivide or Combine Your Shares. If at any time You combine or subdivide Your Series B Preferred Stock, the Exercise Price will be proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination.

 

  ð

If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution (except any distribution specifically provided for in the above paragraphs) of Your Series B Preferred Stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of Your Series B Preferred Stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of which shall be the total number of all shares of Your Series B Preferred Stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares of Warrant Stock (calculated to the nearest whole share) obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.

 

  ð

If You Change the Antidilution Rights of the Warrant Stock or issue New Preferred or Convertible Stock. All antidilution rights applicable to the Warrant Stock purchasable under this Warrant Agreement are as set forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement, amendment, modification of or waiver of any right under Your Certificate of Incorporation. You will provide Us with any written notices relating to such antidilution rights provided to other holders of the Warrant Stock.

 

 

  5.

WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT.

 

Subject to the terms and conditions contained in Section 7, We (or any successor transferee) may transfer in whole or in part this Warrant Agreement and all its rights. You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached hereto as Exhibit III, and Our payment of all transfer taxes and other governmental charges involved in such transfer.

 

 

  6.

REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU.

 

 

  ð

Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of Our rights under this Warrant Agreement will be duly and validly reserved and when issued in accordance with the provisions of this Warrant Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, however, that the Warrant Stock issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer under state and/or Federal securities laws, this Warrant Agreement and any other agreement between Us and You. Upon Our exercise, You will issue to Us certificates for shares of Warrant Stock without charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of shares of Warrant Stock. You will not be required to pay any tax, which may be payable in respect of any transfer involved and the issuance and delivery of any certificate in a name other than TriplePoint Capital EEC.

 

  ð

Due Authority.   Your execution and delivery of this Warrant Agreement and the performance of Your obligations hereunder, including the issuance to Us of the right to acquire the shares of Warrant Stock, have been duly authorized by all necessary corporate action on Your part, other than any amendment of the Company’s articles of incorporation necessary to authorize the Next Round, and this Warrant Agreement is not inconsistent with the Your Certificate of Incorporation or Bylaws, subject to the accuracy of Our representations in Section 7 hereof, does not contravene any law or governmental rule, regulation or order applicable to it, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which You are a party or by which You are bound, and this Warrant Agreement constitutes

 

5


  a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies.

 

  ð

Consents and Approvals.   No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required notices pursuant to Federal and state securities laws, which filings will be effective by the times required thereby and for the filing of any amendment to Your articles of incorporation authorizing Your Next Round.

 

  ð

Issued Securities.   All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other securities have been duly authorized and validly issued and are fully paid and nonassessable. To the extent applicable all outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the Effective Date:

Your authorized capital consists of (A) 23,000,000 shares of Common Stock, of which 4,936,798 shares of Common Stock are issued and outstanding, and (B) 13,087,142 shares of preferred stock, of which 11,171,918 shares are issued and outstanding.

You have reserved 3,863,819 shares of Common Stock for issuance under Your Stock Incentive Plan, under which 2,902,727 options have been granted. Except as otherwise provided in this Warrant Agreement and as noted above, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Your capital stock or other of Your securities.

Except as set forth in Your Investor’s Rights Agreement, a true, correct and complete copy of which has been delivered to Us prior to the issuance of this Warrant, and the Lease Agreement, Your stockholders do not have preemptive rights to purchase new issuances of Your capital stock.

 

  ð

Other Commitments to Register Securities.   As of the Effective Date, except as set forth in this Warrant Agreement and the Investors’ Rights’ Agreement, You are not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued.

 

  ð

Exempt Transaction.   Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Warrant Stock upon exercise of this Warrant Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws.

 

  ð

Compliance with Rule 144.   We may sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and Exchange Commission. Upon exercise of this warrant, we will be obligated to become a party to the Investors’ Rights Agreement and, pursuant thereto, shall be entitled to the benefit of Your covenants with respect to Your compliance with the filing requirements of the Securities and Exchange Commission as set forth in such Rule 144, as may be amended.

 

  ð

No Impairment.     You agree not to, by amendment of Your Articles of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by You, but shall at all times in good faith assist in carrying out of all the provisions of this Warrant and in taking all such action as may be necessary or appropriate to protect Our rights under this Warrant against impairment. However, You shall not be deemed to have impaired Our rights if You amend Your Articles of Incorporation or Your Investor’s Rights Agreement or similar agreements, or the holders of Your equity securities waive their rights thereunder, in a manner that does not (individually or when considered in the context of any other actions being taken in connection with such amendments or waivers)

 

6


  affect Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock.

 

 

  7.

OUR REPRESENTATIONS AND COVENANTS TO YOU.

 

 

  ð

Investment Purpose.   The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of Our rights contained herein and the Common Stock issuable upon conversion will be acquired for investment purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any public distribution of the same in violation of the 1933 Act.

 

  ð

Private Issue.   We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon exercise of this Warrant Agreement and the Common Stock issuable upon conversion of the Warrant Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth in this Section 7.

 

  ð

Disposition of Our Rights.   In no event will We make a disposition of any of Our rights to acquire Warrant Stock or Warrant Stock issuable upon exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to be bound in writing to the applicable terms and conditions of this Warrant Agreement, and (iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that (A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of Our rights to acquire Warrant Stock or Warrant Stock issuable on the exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the beneficial owner of any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Warrant Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You at Our request by the staff of the Securities and Exchange Commission or a ruling shall have been issued to the You at Our request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the holder of a share of Warrant Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without expense to such holder, one or more new certificates for the Warrant or for such shares of Warrant Stock not bearing any restrictive legend referring to 1933 Act registration or exemption.

 

  ð

Financial Risk.   We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and financial condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment.

 

  ð

Risk of No Registration.    We understand that if You do not register with the Securities and Exchange Commission pursuant to Section 12 of the 1934 Act (the “1934 Act”), or file reports pursuant to Section 15(d), of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to purchase Warrant Stock pursuant to this Warrant Agreement, or (ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Warrant Stock, We may be required to hold such securities for an indefinite period. We also understand that any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant Stock, which might be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule.

 

7


  ð

Accredited Investor.  We are an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D of the 1933 Act, as presently in effect.

 

 

  8.

NOTICES YOU AGREE TO PROVIDE US.

 

You agree to give Us at least twenty (20) days prior written notice of the following events:

 

  ð

If You Pay a Dividend or distribution declaration upon your stock.

 

  ð

If You offer for subscription pro-rata to the existing shareholders additional stock or other rights.

 

  ð

If You consummate a Merger Event.

 

  ð

If You have an IPO.

 

  ð

If You dissolve or liquidate.

All notices in this Section must set forth details of the event, and if applicable, how the event adjusts either Our number of shares or Our Exercise Price and the method used for such adjustment.

 

 

  9.

DOCUMENTS YOU WILL PROVIDE US.

 

Upon the Effective Date, copies of

 

  ð

Certified Resolutions

 

  ð

Articles of Incorporation

 

  ð

Investor’s Rights Agreement

 

  ð

Bylaws

 

  ð

Any other documents and other information that We may reasonably request and are necessary to implement the provisions and purposes of this Agreement.

 

 

  10.

REGISTRATION RIGHTS UNDER THE 1933 ACT.

 

The shares of Your common stock into which the Warrant Stock is convertible shall have registration rights as set forth in the Investors’ Rights Agreement, dated as of February 29, 2008, (as amended, restated or otherwise modified in accordance with its terms from time to time, the Investor Rights Agreement”) to the same extent and on the same terms and conditions as possessed by the other Holders thereunder. The provisions set forth in Your Investors’ Rights Agreement relating to such registration rights shall not be amended or modified in a manner that treats Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock. By its receipt of this Warrant, the Holder agrees to be bound by the Investor Rights Agreement in so far as it relates to such registration rights as a Holder pursuant thereto.

 

 

  11.

OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY.

 

Effective Date. This Warrant Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties.

Attorney’s Fees.   In any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant Agreement.

 

8


Governing Law.   This Warrant Agreement shall be governed by and construed for all purposes under and in accordance with the laws of the State of California without giving effect to that body of law pertaining to conflicts of laws.

Consent to Jurisdiction and Venue.   All judicial proceedings arising in or under or related to this Warrant Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Plain English Warrant Agreement. Service of process on any party hereto in any action arising out of or relating to this agreement shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

Mutual Waiver of Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and The Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “ CLAIMS ”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT, NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION, THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Warrant Agreement.

Counterparts.    This Warrant Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Notices.   Any notice required or permitted under this Warrant Agreement shall be given in writing and shall be deemed effectively given upon the earlier of (1) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is sent by overnight mail via nationally recognized courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending Party.

Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement and that in the event of

 

9


any breach of this Agreement, the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this Agreement.

Survival.   The representations, warranties, covenants, and conditions of the Parties contained herein or made pursuant to this Warrant Agreement shall survive the execution and delivery of this Warrant Agreement.

Severability. In the event any one or more of the provisions of this Warrant Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision.

Entire Agreement. This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter.

Amendments. Any provision of this Warrant Agreement may only be amended by a written instrument signed by the Parties.

Lost Warrants or Stork Certificates. You covenant to Us that, upon receipt of evidence reasonably satisfactory to Us of the loss, theft, destruction or mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to You, or in the case of any such mutilation upon surrender and cancellation of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant Agreement or stock certificate.

Rights as Stockholders. We shall not, as a party to this Warrant Agreement, be entitled to vote or receive dividends or be deemed the holder of Series B Preferred Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon Us any of the rights of one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until this Warrant Agreement is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.

Facsimile Signatures. This Warrant Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party.

(Signature Page to Follow)

 

10


IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its officers who are duly authorized as of the Effective Date.

 

 

You:

  AMYRIS BIOTECHNOLOGIES, INC.
 

Signature:

 

 

 
 

Print Name:

 

 

 
 

Title:

 

 

 
 

Us:

 

TRIPLEPOINT CAPITAL LLC

 
 

Signature:

 

 

 
 

Print Name:

 

 

 
 

Title:

 

 

 

[SIGNATURE PAGE TO PLAIN ENGLISH WARRANT AGREEMENT 0534-W-01]

 

11


EXHIBIT I

NOTICE OF EXERCISE

 

  To:

[                                         ]

 

  1.

We hereby elect to purchase [        ] shares of the Series [        ] Preferred Stock of [            ], pursuant to the terms of the Plain English Warrant Agreement dated the [    ] day of [            ], [200    ] (the “Plain English Warrant Agreement”) between You and Us, We hereby tender here payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any.

 

  2.

Method of Exercise (Please initial the applicable blank)

 

  a.

             The undersigned elects to exercise the Plain English Warrant Agreement by means of a cash payment, and gives You full payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any.

 

  b.

             The undersigned elects to exercise the Plain English Warrant Agreement by means of the Net Issuance Exercise method of Section 3 of the Plain English Warrant Agreement.

 

  3.

In exercising Our rights to purchase the Series [        ] Preferred Stock of [                    ], We hereby confirm and acknowledge the investment representations, warranties and covenants made in Section 7 of the Plain English Warrant Agreement.

Please issue a certificate or certificates representing these purchased shares of Series [        ] Preferred Stock in Our name or in such other name as is specified below.

 

 

 

 
 

(Name)

 
 

 

 
 

(Address)

 
 

US:

 

TRIPLEPOINT CAPITAL LLC

 

By:

 

 

 

Title:

 

 

 

Date:

 

 

 

12


EXHIBIT II

ACKNOWLEDGMENT OF EXERCISE

[                                         ], hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase [        ] shares of the Series [        ] Preferred Stock of [                    ], pursuant to the terms of the Plain English Warrant Agreement, and further acknowledges that [        ] shares remain subject to purchase under the terms of the Plain English Warrant Agreement.

 

YOU:

 

 

 
 

By:

 

 

 
 

Title:

 

 

 
 

Date:

 

 

 

 

13


EXHIBIT III

TRANSFER NOTICE

FOR VALUE RECEIVED , the foregoing Plain English Warrant Agreement and all rights evidenced thereby are hereby transferred and assigned to

 

 

 

  
  (Please Print)   
  Whose address is  

 

  
 

 

  
 

Dated:

 

 

  
 

Holder’s Signature:

 

 

  
 

Holder’s Address:

 

 

  
 

Transferee’s Signature:

 

 

  
 

Transferee’s Address:

 

 

  
 

Signature Guaranteed:

 

 

  

NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Plain English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Plain English Warrant Agreement.

 

14


LOGO

 

H ARDWARE F ACILITY S CHEDULE D ATED M ARCH  14, 2008

 

T O T HE P LAIN E NGLISH M ASTER L EASE A GREEMENT D ATED A S O F M ARCH  14, 2008

 

Facility Number

 

Part 1: 0534-LE-01H;

Part 2: 0534-LE-02H

  

 

Commitment Amount

 

Part 1: $10,000,000 (less any amount funded under

Software Facility Schedule 0534-LE-01S);

 

Part 2: $2,000,000 (less any amounts funded under

Software Facility Schedule 0534-LE-02S) Upon

Request and Additional Approval and execution of

a warrant agreement in substantially similar

form to Warrant Agreement 0534-W-01.

 

3/14/08 thru 3/14/09

 

This Availability Period may be extended for a period of 3 months, on such terms as The Parties may mutually agree, We will

conduct any legal and business due diligence deemed necessary by Us in connection with Our attempt to obtain Our requisite

credit approvals. Our agreement to consider providing the extension of the Availability Period is not, and is not to be construed

as, a commitment, offer, or agreement to provide such extension

 

 

Availability Period

 

You grant Us the Right, to

invest up to $500,000 in Your

next round of private equity financing (anticipated to be

Series C) on the same terms

and conditions as other

investors

 

 

Lease Term

 

48 Months

 

(Months 1-12 shall be interest

only)

  

 

Lease Rate Factor

 

Months 1-12: 0.007708%

 

Months 13-48: 3.1672%

 

 

Interest Rate

 

9.25%

 

Facility Fee

 

Part 1: $50,000;

Part 2: $10,000

 

 

Advance Rent

 

The last monthly payment

shall be due in advance

  

 

Interim Rate

 

Full Daily Equivalent

 

 

Purchase Option

 

Not to Exceed 10% of

Original Cost

 

O UR C ONTACT I NFORMATION

 

Name

 

TriplePoint Capital LLC

  

 

Address for Notices

 

2755 Sand Hill Rd., Ste. 150

Menlo Park, CA 94025

Tel: (650) 854-2090

Fax: (650) 854-1850

Attn: Sajal Srivastava

Email: legal@triplepointcapital.com

 

 

 

Address for Equipment Return

 

2755 Sand Hill Rd., Ste. 150

Menlo Park, CA 94025

Y OUR C ONTACT I NFORMATION

 

Customer Name

 

Amyris Biotechnologies, Inc.

  

 

Address for Billing/Notices

 

5980 Horton St., Suite 450

Emeryville, CA 94608

 

Equipment Location

 

Same As Above

(Unless Noted Differently on the

Summary Schedule)

 

 

Contact Person

 

Name: Jeryl Hilleman, CFO

Tel: (510) 450-0761 x734

Fax: (510) 450-0794

Email: hilleman@amyris.com

This Hardware Facility Schedule is issued pursuant to the Plain English Master Lease Agreement identified above. All of the terms and conditions of the Plain English Master Lease Agreement are incorporated in and made a part of this Schedule as if they were expressly set forth in this Schedule. The Parties hereby reaffirm all of the terms and conditions of the Plain English Master Lease Agreement except as modified by this Schedule. This Schedule may not be amended or rescinded except by a writing signed by both of The Parties.

(Signature Page to Follow)


IN WITNESS WHEREOF. The Parties hereto have executed this Hardware Facility Schedule on or as of the day and year first above written.

 

 

You:   AMYRIS BIOTECHNOLOGIES, INC.

 

Us:  TRIPLEPOINT CAPITAL LLC

 

By:

 

 

   

By:

 

 

 

Title:

 

 

   

Title:

 

 

[SIGNATURE PAGE TO HARDWARE FACILITY SCHEDULE 0534-LE-01H/02H]

 

2


LOGO

 

S OFTWARE F ACILITY S CHEDULE D ATED M ARCH  14, 2008

 

T O T HE P LAIN E NGLISH M ASTER L EASE A GREEMENT D ATED A S O F M ARCH  14, 2008

 

Facility Number

 

Part 1: 0534-LE-01S;

 

Part 2: 0534-LE-02S

 

 

Commitment Amount

 

Part 1: Up to $1,000,000 (10% of the

total Commitment Amount under

Hardware Facility

Schedule 0534-LE-01H);

 

Part 2: Up to $200,000 (10% of the total

Commitment Amount under Hardware

Facility Schedule 0534-LE-02H) upon

the availability of Hardware Facility

Schedule 0534-LE-02H.

 

 

 

Equipment

 

Equipment shall include software, and

other “soft costs” including freight

charges, installation, and warranties, but

not taxes

 

Availability Period

 

3/14/08 thru 3/14/09

 

Subject to extension per the

Hardware Facility Schedule

of even date with this

Schedule

 

 

 

Lease Term

 

48 Months

 

(Months 1-12 shall be interest

only)

 

 

Lease Rate Factor

 

Months 1-12: 0.007708%

 

Months 13-48: 3.1672%

 

 

Interest Rate

 

9.25%

 

Facility Fee

 

See Hardware Facility

Schedule of even date with

this Schedule

 

 

 

Advance Rent

 

The last monthly payment

shall be due in advance

 

 

Interim Rate

 

Full Daily Equivalent

 

 

Purchase Option

 

10% of Original Cost

 

O UR C ONTACT I NFORMATION

 

Name

 

TriplePoint Capital LLC

  

 

Address for Notices

 

2755 Sand Hill Rd., Ste. 150

Menlo Park, CA 94025

Tel: (650) 854-2090

Fax: (650) 854-1850

Attn: Sajal Srivastava

Email: legal@triplepointcapital.com

 

 

 

Address for Equipment Return

 

2755 Sand Hill Rd., Ste. 150

Menlo Park, CA 94025

Y OUR C ONTACT I NFORMATION

 

Customer Name

 

Amyris Biotechnologies, Inc.

  

 

Address for Billing/Notices

 

5980 Horton St., Suite 450

Emeryville, CA 94608

 

Equipment Location

 

Same As Above

(Unless Noted Differently on a

Summary Schedule)

 

 

Contact Person

 

Name: Jeryl Hilleman, CFO

Tel: (510) 450-0761 x734

Fax: (510) 450-0794

Email: hilleman@amyris.com

This Software Facility Schedule is issued pursuant to the Plain English Master Lease Agreement identified above. All of the terms and conditions of the Plain English Master Lease Agreement are incorporated in and made a part of this Schedule as if they were expressly set forth in this Schedule. The Parties hereby reaffirm all of the terms and conditions of the Plain English Master Lease Agreement except as modified by this Schedule. This Schedule may not be amended or rescinded except by a writing signed by both of The Parties.

(Signature Page to Follow)


IN WITNESS WHEREOF, The Parties hereto have executed this Hardware Facility Schedule on or as of the day and year first above written.

 

 

You:   AMYRIS BIOTECHNOLOGIES, INC.

 

Us:  TRIPLEPOINT CAPITAL LLC

 

By:

 

 

   

By:

 

 

 

Title:

 

 

   

Title:

 

 

[SIGNATURE PAGE TO SOFTWARE FACILITY SCHEDULE 0534-LE-01S/02S]

 

2


IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be executed by its officers who are duly authorized as of the Effective Date.

 

 

You:

  AMYRIS BIOTECHNOLOGIES, INC.
 

Signature:

 

 

 
 

Print Name:

 

 

 
 

Title:

 

 

 
 

Us:

 

TRIPLEPOINT CAPITAL LLC

 
 

Signature:

 

 

 
 

Print Name:

 

 

 
 

Title:

 

 

 

[SIGNATURE PAGE TO SOFTWARE FACILITY SCHEDULE 0534-LE-01S/02S]

 

3

Exhibit 10.05

LOGO

Via Fed Ex

October 19, 2009

Chris Jaenike,

Amyris Biotechnologies, Inc.

5980 Hollis Street, Suite 100

Emeryville, CA 94608

(510) 740-7465

RE:   Amyris Biotechnologies I TriplePoint Capital — Executed Documents

Dear Chris:

Enclosed, please find the following documents for your files:

 

  1.

First Amendment to Master Lease Agreement (original)

 

  2.

Warrant Agreement, 0534-W-02, (copy)

 

  3.

Amended and Restated Warrant Agreement (copy)

 

  4.

Hardware Facility Schedule - 0534-LE-02H (Original)

 

  5.

Software Facility Schedule — 0534-LE-02S (Original)

 

  6.

Certificate of Secretary of Amyris Biotechnologies (copy)

Should you have any questions or concerns, please do not hesitate to contact me at (650) 233-2161.

 

Sincerely,

/s/ Lonna Eshelman

Lonna Eshelman

Legal Assistant

Enclosures

 

1


LOGO

F IRST A MENDMENT T O P LAIN E NGLISH M ASTER L EASE A GREEMENT

This is a FIRST AMENDMENT TO PLAIN ENGLISH MASTER LEASE AGREEMENT dated as of September 18, 2009 (the “ Amendment ”) by and between AMYRIS BIOTECHNOLOGIES. INC., a California corporation, (“ Lessee ”) and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company, (“ Lessor ”).

RECITALS

A.            Lessee and Lessor are parties to the Plain English Master Lease Agreement dated as of March 14, 2008 (the “Lease Agreement”), pursuant to which Lessor agreed to provide financial accommodations to or for the benefit of Lessee upon the terms and conditions contained in the Lease Agreement. Unless otherwise defined in this Amendment, capitalized terms and matters of construction defined in the Lease Agreement shall have the same meaning given to them in the Lease Agreement.

B.            Lessee has requested an additional Commitment Amount and that certain provisions of the Lease Agreement be amended. Lessor has agreed to do so on the terms and conditions set forth in this Amendment.

AGREEMENT

NOW, THEREFORE, in consideration of the Recitals and of the mutual promises and convenants contained in this Amendment and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged. Lessee and Lessor agree as follows:

 

 

 1.

RATIFICATION; LEASE DOCUMENTS REMAIN IN FULL FORCE AND EFFECT

 

Lessee hereby acknowledges, confirms and ratifies all of the terms and conditions set forth in, and all of its obligations under, the Lease Agreement and the other Lease Documents. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Lessor under the Lease Agreement or any other Lease Document, as in effect prior to the date hereof.

 

 

 2.

AMENDMENTS TO LEASE AGREEMENT

 

 

  A.

Hardware and Software Facility Schedule dated March 14, 2008 : The Part 2 Commitment Amount under the Hardware and Software Facility Schedule dated March 14, 2008 is hereby deleted in its entirety and replaced by Hardware Facility Schedule 0534-LE-02H and Software Facility Schedule 0534-LE-02S dated September 18, 2009.

 

  B.

Section 7, Procedures to Follow When You Purchase the Equipment And We Reimburse You . Section 7 shall be amended by adding the following to subsection Initial Purchase-Leaseback :

 

  ð For Equipment purchased 180 days or less before the date of execution of Hardware Facility Schedule 0534-LE-02H and Software Facility Schedule 0534-LE-02S dated September 18, 2009: 100% of original net Equipment cost for Equipment.

 

  C.

Section 21, Event of Default .  Section 21 shall be amended by adding the following:

 

  ð

Additional Events of Default . (a) , Khosla Ventures II, L.P. (or its affiliate) or KPCB Holdings, Inc. (or its affiliate) no longer retains a seat on Your Board of Directors until such time as You

 

1


  consummate an initial public offering or (b) the individuals holding the offices of Your Chief Executive Officer or Chief Financial Officer as of the Closing Date shall for any reason cease to hold such offices or be actively engaged in Your day-to-day management, unless a successor is appointed within ninety (90) days of such cessation.

 

 

 3.

CONDITIONS TO EFFECTIVENESS

 

As a condition to the effectiveness of this Amendment, Lessor shall have received, in form and substance satisfactory to Lessor, the following:

 

  ð Receipt by Lessor of copies of this Amendment, duly executed by Lessee and Lessor;

 

  ð Receipt by Lessor of the Warrant Agreement of even date and the Amended and Restated Warrant Agreement, duly executed by Lessee and Lessor;

 

  ð Receipt by Lessor of Hardware Facility Schedule 0534-LE-02H and Software Facility Schedule 0534-LE-02S of even date, duly executed by Lessee and Lessor;

 

  ð The Hardware Facility Schedule 0534-LE-02H and Software Facility Schedule 0534-LE-02S Facility Fee;

 

  ð Receipt by Lessor of a Certificate of Secretary regarding resolutions and incumbency; and

 

  ð Certified copy of resolutions of Lessee’s board of directors approving this Agreement, Hardware Facility Schedule 0534-LE-02H and Software Facility Schedule 0534-LE-02S and the associated Warrant Agreement and Amended and Restated Warrant Agreement.

 

 

 4.

REPRESENTATIONS AND WARRANTIES

 

Lessee represents and warrants that the representations and warranties contained in the Lease Agreement were true and correct in all material respects when made and, except to the extent (a) that a particular representation or warranty by its terms expressly applies only to an earlier date or (b) set forth in a Schedule of Exceptions attached hereto, if any, are true and correct in all material respects as of the date of this Amendment. Lessee further represents and warrants that there are no Defaults or Events of Default that have occurred and are continuing as of the date of this Amendment.

 

 

 5.

MISCELLANEOUS

 

 

  ð

Entire Agreement .  The terms and conditions of this Amendment shall be incorporated by reference in the Lease Agreement as though set forth in full in the Lease Agreement. In the event of any inconsistency between the provisions of this Amendment and any other provision of the Lease Agreement, the terms and provisions of this Amendment shall govern and control. Except to the extent specifically amended or superseded by the terms of this Amendment, all of the provisions of the Lease Agreement and the other Lease Documents shall remain in full force and effect to the extent in effect on the date of this Amendment. The Lease Agreement as modified by this Amendment, together with the other Lease Documents, constitutes the complete agreement among the parties and supersedes any prior written or oral agreements, writings, communications or understandings of the parties with respect to the subject matter the Lease Agreement.

 

  ð

Headings .  Section headings used in this Amendment are for convenience of reference only, are not part of this Amendment, and are not to be taken into consideration in interpreting this Amendment.

 

  ð

Recitals .  The recitals set forth at the beginning of this Amendment are true and correct, and such recitals are incorporated into and are a part of this Amendment.

 

2


  ð

Governing, Law .  This Amendment shall be governed by. and construed and enforced in accordance with, the laws of the State of California applicable to contracts made and performed in such state, without regard to the principles thereof regarding conflict of laws.

 

  ð

Effect .    Upon the effectiveness of this Amendment, from and after the date of this Amendment, each reference in the Lease Agreement to “this Agreement,” “hereunder,” “hereof,” or words of like import shall mean and be a reference to the Lease Agreement as amended by this Amendment and each reference in the other Lease Documents to the Lease Agreement, “thereunder,” “thereof,” or words of like import shall mean and be a reference to the Lease Agreement as amended by this Amendment.

 

  ð

No Novation .  Except as expressly provided in Section 2 above, the execution, delivery, and effectiveness of this Amendment shall not (a) limit, impair, constitute a waiver of, or otherwise affect any right, power, or remedy of Lessor under the Lease Agreement or any other Lease Document, (b) constitute a waiver of any provision in the Lease Agreement or in any of the other Lease Documents, or (c) alter, modify, amend, or in any way affect any of the terms, conditions, obligations, covenants, or agreements contained in the Lease Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect.

 

  ð

Counterparts .  This Amendment may be executed in identical counterpart copies, each of which shall be an original, but all of which shall constitute one and the same agreement.

 

  ð

Signatures .  This Amendment may be executed and delivered by facsimile or transmitted electronically in either Tagged Image Format Files (“TIFF”) or Portable Document Format (“PDF”) and, and upon such delivery, the facsimile, TIFF or PDF signature, as applicable, will be deemed to have the same effect as if the original signature had been delivered to the other party.

[SIGNATURE PAGE TO FOLLOW]

 

3


IN WITNESS WHEREOF, The Parties have executed and delivered this Amendment as of the day and year first above written.

 

LESSEE:

   

You:

 

AMYRIS BIOTECHOLOGIES, INC.

   

Signature:

 

 /s/ John G. Melo

   

Print Name:

 

 John G. Melo

   

Title:

 

 CEO

Accepted in Menlo Park, California:      

LESSOR:

   

Us:

 

TRIPLEPOINT CAPITAL LLC

   

Signature:

 

 /s/ Sajal Srivastava

   

Print Name:

 

Sajal Srivastava

   

Title:

 

Chief Operating Officer

[SIGNATURE PAGE TO FIRST AMENDMENT TO PLAIN ENGLISH MASTER LEASE AGREEMENT]

 

4

Exhibit 10.06

REIMBURSEMENT AND SECURITY AGREEMENT

Dated as of November 5, 2009

between

AMYRIS BIOTECHNOLOGIES, INC.

and

BANK OF THE WEST


TABLE OF CONTENTS

 

Section         Page
Article I.      DEFINITIONS, ACCOUNTING AND FINANCIAL TERMS    1
1.01    Defined Terms    1
1.02    Section Headings    1
1.03    Accounting Terms and Financial Terms    1
Article II.      THE LETTERS OF CREDIT    1
2.01    Letters of Credit    1
2.02    Computation of Interest and Fees    3
2.03    Evidence of Debt    3
2.04    Payments Generally    4
Article III.      SECURITY AGREEMENT    4
3.01    Security Interest    4
3.02    No Assumption of Liability    4
3.03    Representations Regarding Collateral    4
3.04    Agreements Regarding Collateral    5
3.05    Remedies upon Default    6
Article IV.      CONDITIONS PRECEDENT TO L/C CREDIT EXTENSIONS    8
4.01    Conditions of Initial L/C Credit Extension    8
4.02    Conditions to all L/C Credit Extensions    9
Article V.      REPRESENTATIONS AND WARRANTIES    9
5.01    Existence, Qualification and Power; Compliance with Laws    9
5.02    Authorization; No Contravention    10
5.03    Governmental Authorization; Other Consents    10
5.04    Binding Effect    10

 

i


5.05      Financial Statements; No Material Adverse Effect    10
5.06      Litigation    11
5.07      No Default    11
5.08      Ownership of Property; Liens    11
5.09      Environmental Compliance    11
5.10      Insurance    11
5.11      Taxes    11
5.12      ERISA Compliance    12
5.13      Subsidiaries    12
5.14      Margin Regulations; Investment Company Act; Public Utility Holding Company Act    12
5.15      Disclosure    13
5.16      Compliance with Laws    13
5.17      Solvency    13
Article VI.        AFFIRMATIVE COVENANTS    13
6.01      Financial Statements    13
6.02      Certificates; Other Information    14
6.03      Notices    14
6.04      Payment of Obligations    15
6.05      Preservation of Existence, Etc.    15
6.06      Maintenance of Properties    15
6.07      Maintenance of Insurance    15
6.08      Compliance with Laws    16
6.09      Books and Records    16
6.10      Inspection Rights    16
6.11      Letters of Credit    16

 

ii


6.12      Support Account    16
Article VII.        NEGATIVE COVENANTS    16
7.01      Liens    17
7.02      Investments    17
7.03      Indebtedness    17
7.04      Fundamental Changes    17
7.05      Dispositions    17
7.06      Restricted Payments    17
7.07      Change in Nature of Business    17
7.08      Transactions with Affiliates    18
7.09      Burdensome Agreements    18
7.10      Use of Proceeds    18
7.11      Liquidity Ratio    18
Article VIII.        EVENTS OF DEFAULT AND REMEDIES    18
8.01      Events of Default    18
8.02      Remedies Upon Event of Default    20
8.03      Application of Funds    20
Article IX.        MISCELLANEOUS    20
9.01      Amendments; Etc.    20
9.02      Notices and Other Communications; Facsimile Copies    21
9.03      No Waiver; Cumulative Remedies    21
9.04      Attorney Fees, Expenses and Taxes    22
9.05      Indemnification by Borrower    22
9.06      Payments Set Aside    23
9.07      Successors and Assigns    23

 

iii


9.08      Confidentiality    25
9.09      Set-off    25
9.10      Counterparts    26
9.11      Integration    26
9.12      Survival of Representations and Warranties    26
9.13      Severability    26
9.14      Governing Law    27
9.15      Waiver of Right to Trial by Jury    27
9.16      Judicial Reference Provision    27
9.17      USA Patriot Act Notice    28
SIGNATURES     

S-1

  
SCHEDULES        
1.01      Definitions   
9.02      Lending Office, Addresses for Notices   

 

iv


REIMBURSEMENT AND SECURITY AGREEMENT

This REIMBURSEMENT AND SECURITY AGREEMENT ( “Agreement” ) is entered into as of November 5, 2009 by and between AMYRIS BIOTECHNOLOGIES, INC., a California corporation (the “Borrower” ) and Bank of the West, a California banking corporation (the “Bank” ).

In consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows:

  ARTICLE I.  DEFINITIONS, ACCOUNTING AND FINANCIAL TERMS

1.01     Defined Terms.

Capitalized terms used, but not otherwise defined, in this Agreement have the meanings given to them in Schedule 1.01.

1.02     Section Headings.

Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document.

1.03     Accounting Terms and Financial Terms.

All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the Complied Financial Statements, except as otherwise specifically prescribed herein. Any financial ratios required to be maintained by Borrower pursuant to this Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number).

ARTICLE II.  THE LETTERS OF CREDIT

2.01     Letters of Credit.

(a)    Subject to the terms and conditions of this Agreement, from time to time on any Business Day until the Letter of Credit Expiration Date, Bank agrees to issue standby Letters of Credit for the account of Borrower; provided that the aggregate amount of outstanding L/C Obligations shall not exceed $3,450,000 or such reduced amount in effect pursuant to Section 2.05 (the “Commitment” ).

(b)    Bank shall be under no obligation to issue, extend or amend any Letter of Credit if:

 

1


(i)      any order or decree of any Governmental Authority, arbitrator or Law shall enjoin, restrain or otherwise inhibit Bank from issuing such Letter of Credit or shall impose on Bank any restriction, reserve or capital requirements (for which Bank is not otherwise compensated under this Agreement) not in effect on the Closing Date, or shall impose on Bank any unreimbursed loss, cost or expense which was not applicable on the Closing Date;

(ii)     the expiry date of such Letter of Credit, as the same may be extended in accordance with this Agreement would occur more than one year after the Letter of Credit Expiration Date;

(iii)    the issuance of such Letter of Credit would violate policies of Bank.

(c)    Each Letter of Credit shall be issued, amended or extended upon receipt by Bank at least two Business Days prior to issuance of a Letter of Credit Application from a Responsible Officer of Borrower that is duly completed.

(d)    Bank will notify Borrower upon receipt of a drawing under a Letter of Credit, and not later than 1:00 p.m. (Pacific Time) on the date of payment, Borrower shall reimburse Bank in an amount equal to such drawing. If Borrower fails to so reimburse Bank, Borrower shall pay interest on the amount drawn in accordance with the Letter of Credit Application for such Letter of Credit.

(e)    The obligation of Borrower to reimburse Bank for drawings under Letters of Credit shall be absolute, unconditional and irrevocable and shall be paid strictly in accordance with this Agreement under all circumstances, including:

(i)      any lack of validity or enforceability of any Letter of Credit, this Agreement or any Loan Document;

(ii)     the existence of any claim, counterclaim, set-off, defense or other right that Borrower may have at any time against any beneficiary or transferee of any Letter of Credit (or any other Person);

(iii)    any draft, demand, certificate or other document presented under such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any loss or delay in the transmission or otherwise of any document required in order to make a drawing under any Letter of Credit;

(iv)    any payment by Bank under any Letter of Credit against presentation of a draft or certificate that does not strictly comply with the terms of such Letter of Credit; or any payment made by Bank under any Letter of Credit to any trustee in bankruptcy, debtor in possession, assignee for the benefit of creditors or other assignee or representative; and

(v)    any other circumstances, including any other circumstance that might otherwise constitute a defense available to, or a discharge of, Borrower.

 

2


Borrower shall promptly examine a copy of each Letter of Credit and each amendment thereto that is delivered to it and, in the event of any claim of noncompliance with Borrower’s instructions or other irregularity, Borrower will immediately notify Bank. Borrower shall be conclusively deemed to have waived any such claim unless notice is so given.

(f)    Borrower agrees that Bank shall not have any responsibility to obtain any document (other than drafts, certificates and documents expressly required by Letters of Credit) or to ascertain or inquire as the validity or accuracy of any such document or the authority of any Person submitting any such document. Borrower assumes all risks of the acts or omissions of any beneficiary of any Letter of Credit. Neither Bank nor any of its Affiliates, officers, directors, employees, agents or attorneys-in-fact, correspondents, participants or assignees shall be liable or responsible for any of the matters described in Section 2.01(e) except to the extent of any direct damages suffered by Borrower that were caused by Bank’s willful misconduct or gross negligence.

(g)    Upon request of Bank after it honors a drawing under a Letter of Credit for which it is not reimbursed by the end of the first Business Day after the date of payment, on the Letter of Credit Expiration Date and as otherwise provided in this Agreement upon an Event of Default, Borrower shall immediately Cash Collateralize all outstanding L/C Obligations. Immediately upon the expiration or other termination of a Letter of Credit, Bank shall return to Borrower the full amount of all cash collateral held by Bank to Cash Collateralize such Letter of Credit.

(h)    Borrower shall pay to Bank a Letter of Credit fee for each Letter of Credit calculated at the rate of 2% per annum on the daily maximum amount available to be drawn under such Letter of Credit. Such fees shall be computed on a quarterly basis in advance and shall be due and payable on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and, thereafter, on demand. Borrower shall pay to Bank on demand, on a nonrefundable basis, the customary issuance, presentation, amendment and other processing fees and other standard costs and charges of Bank relating to letters of credit generally.

(i)    In the event of any conflict between the terms hereof and the terms of any Letter of Credit Application, the terms hereof shall control.

2.02     Computation of Interest and Fees.

All computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year).

2.03     Evidence of Debt.

The L/C Credit Extensions made by Bank shall be evidenced by one or more accounts or records maintained by Bank in the ordinary course of business. The accounts or records maintained by Bank shall be conclusive absent manifest error of the amount of the L/C Credit Extensions made by Bank to Borrower and the interest and payments thereon. Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of Borrower hereunder to pay any amount owing with respect to the Obligations.

 

3


2.04     Payments Generally.

(a)    All payments to be made by Borrower shall be made without condition or deduction for any counterclaim, defense, recoupment or setoff. Except as otherwise expressly provided herein, all payments by Borrower hereunder shall be made to Bank at the applicable Lending Office in Dollars and in immediately available funds not later than 3:00 p.m. on the date specified herein. All payments received by Bank after 3:00 p.m. shall be deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue.

(b)    If any payment to be made by Borrower shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be.

2.05    Termination and Reduction of Commitment. Borrower may, upon notice to the Bank, terminate the Commitment, or from time to time permanently reduce the Commitment; provided that (i) any such notice shall be received by Bank not later than 1:00 p.m., five (5) Business Days prior to the date of termination or reduction, (ii) any such partial reduction shall be in an aggregate amount of $250,000 or any whole multiple of $50,000 in excess thereof, and (iii) Borrower shall not terminate or reduce the Commitment if, after giving effect thereto and to any concurrent prepayments hereunder, the L/C Obligations would exceed the Commitment unless, concurrently with such reduction, Borrower Cash Collateralizes outstanding L/C Obligations by depositing with Bank cash in an amount equal to 110% of such L/C Obligations and grants to Bank a first priority perfected security interest thereon as collateral security for obligations of Borrower to Bank under all related Letter of Credit Applications, each of which remains in full force and effect. Immediately upon the expiration or other termination of a Letter of Credit, Bank shall return to Borrower the full amount of all cash collateral held by Bank to Cash Collateralize such Letter of Credit.

ARTICLE III.          SECURITY AGREEMENT

3.01     Security Interest.

As security for the payment or performance, as the case may be, in full of its Obligations; and any extensions, renewals or modifications of its Obligations, Borrower hereby bargains, sells, conveys, assigns, sets over, mortgages, pledges, hypothecates and transfers to Bank, its successors and assigns, and hereby grants to Bank, its successors and assigns, a security interest in, all of Borrower’s right, title and interest in, to and under the Collateral (the “Security Interest” ).

3.02     No Assumption of Liability.

The Security Interest is granted as security only and shall not subject Bank to, or in any way alter or modify, any obligation or liability of Borrower with respect to or arising out of the Collateral.

3.03     Representations Regarding Collateral.

Borrower represents and warrants to Bank that:

 

4


(a)      The Security Interest constitutes (i) a legal and valid security interest in all the Collateral securing the payment and performance of the Obligations, to the extent a security interest therein can be created under the Uniform Commercial Code and (ii) subject to the filing of financing statements, a perfected security interest in all Collateral in which a security interest may be perfected by filing pursuant to the Uniform Commercial Code.

(b)      The Collateral is owned by Borrower free and clear of any Lien, except for Permitted Liens. Except in favor of Bank, Borrower has not filed or consented to the filing of any financing statement or analogous document under the Uniform Commercial Code or any other applicable laws covering any Collateral.

3.04    Agreements Regarding Collateral.

(a)      Borrower agrees promptly to notify Bank in writing of any change (i) in its official name or in any trade name used to identify it in the conduct of its business or in the ownership of its properties, (ii) in its jurisdiction of organization, the location of its chief executive office, its principal place of business, any office in which it maintains books or records relating to Collateral owned by it or any office or facility at which Collateral owned by it is located (including the establishment of any such new office or facility), (iii) in its identity or corporate structure or (iv) in its organizational identification number. Borrower agrees not to effect or permit any change referred to in the preceding sentence unless all filings have been made under the Uniform Commercial Code that are required in order for Bank to continue at all times following such change to have a valid, legal and perfected first priority security interest in all the Collateral subject only to Permitted Liens. Borrower agrees promptly to notify Bank if any material portion of the Collateral owned or held by Borrower is damaged or destroyed.

(b)      Borrower agrees to maintain, at its own cost and expense, such complete and accurate records with respect to the Collateral owned by it as is consistent with its current practices and in accordance with such prudent and standard practices used in industries that are the same as or similar to those in which Borrower is engaged, but in any event to include complete accounting records indicating all payments and proceeds received with respect to any part of the Collateral, and, at such time or times as Bank may reasonably request, promptly to prepare and deliver to Bank a duly certified schedule or schedules in form and detail reasonably satisfactory to Bank showing the identity, amount and location of any and all material items of Collateral.

(c)      Borrower agrees, at its own cost and expense, to take any and all actions necessary to defend title to the Collateral against all Persons and to defend the Security Interest of Bank in the Collateral and the priority thereof against any Lien not expressly permitted pursuant to this Agreement.

(d)      Borrower agrees, at its own expense, to execute, acknowledge, deliver and cause to be duly filed all such further instruments and documents and take all such actions as Bank may from time to time reasonably request to better assure, preserve, protect and perfect the Security Interest and the rights and remedies created hereby, including the payment of any fees and taxes required in connection with the execution and delivery of this Agreement, the granting of the Security Interest and the filing of any financing statements (including fixture filings) or

 

5


other documents in connection herewith or therewith.

(e)      Bank and its agents may ,at reasonable intervals and upon reasonable prior notice have the right, at Borrower’s own cost and expense, inspect the Collateral, all records related thereto (and to make extracts and copies from such records) and the premises upon which any of the Collateral is located, to discuss Borrower’s affairs with the officers of Borrower and (with the participation of or prior notice to such officers) its independent accountants and to verify under reasonable procedures the validity, amount, quality, quantity, value, condition and status of, or any other matter relating to, the Collateral, including, in the case of accounts or Collateral in the possession of any third Person, by contacting account debtors or the third Person possessing such Collateral for the purpose of making such a verification.

(f)      At its option, upon prior written notice to the Borrower, Bank may, subject to any right that Borrower may have under this Agreement or any other Loan Document to contest the same, discharge past due taxes, assessments, charges, fees, Liens, security interests and other encumbrances at any time levied or placed on the Collateral and may pay for the maintenance and preservation of the Collateral to the extent Borrower fails to do so as required by the Loan Documents, and Borrower agrees to reimburse Bank on demand for any payment made or any expense incurred by Bank pursuant to the foregoing authorization; provided, however, that nothing in this Section shall be interpreted as excusing Borrower from the performance of, or imposing any obligation on Bank to cure or perform, any covenants or other promises of Borrower with respect to taxes, assessments, charges, fees, liens, security interests or other encumbrances and maintenance as set forth herein or in the other Loan Documents.

(g)      Borrower shall not make or permit to be made an assignment, pledge or hypothecation of the Collateral or shall grant any other Lien in respect of the Collateral, except as expressly permitted by this Agreement.

(h)      Borrower, at its own expense, agrees to maintain or cause to be maintained insurance covering physical loss or damage to the Collateral in accordance with this Agreement. Borrower irrevocably makes, constitutes and appoints Bank (and all officers, employees or agents designated by Bank) as Borrower’s true and lawful agent (and attorney-in-fact) for the purpose, during the continuance of an Event of Default, of making, settling and adjusting claims in respect of Collateral under policies of insurance, endorsing the name of Borrower on any check, draft, instrument or other item of payment for the proceeds of such policies of insurance and for making all determinations and decisions with respect thereto. In the event that Borrower at any time or times shall fail to obtain or maintain any of the policies of insurance required hereby or to pay any premium in whole or part relating thereto, Bank may without waiving or releasing any obligation or liability of Borrower hereunder or any Event of Default, in its sole discretion, obtain and maintain such policies of insurance and pay such premium and take any other actions with respect thereto as Bank deems advisable. All sums disbursed by Bank in connection with this Section, including reasonable attorneys’ fees, court costs, expenses and other charges relating thereto, shall be payable, upon demand, by Borrower to Bank and shall be additional Obligations secured hereby.

3.05     Remedies upon Default.

 

6


(a)      Upon the occurrence and during the continuance of an Event of Default, Borrower agrees (a) to deliver each item of Collateral to Bank on demand and (b) that Bank shall have the right to take any of or all the following actions at the same time with or without legal process and with or without prior notice or demand for performance, to take possession of the Collateral and without liability for trespass to enter any premises where the Collateral may be located for the purpose of taking possession of or removing the Collateral, exercise Borrower’s right to bill and receive payment for completed work and, generally, to exercise any and all rights afforded to a secured party under the Uniform Commercial Code or other applicable law. Without limiting the generality of the foregoing, Borrower agrees that Bank shall have the right, subject to the mandatory requirements of applicable law, to sell or otherwise dispose of all or any part of the Collateral, at public or private sale or at any broker’s board or on any securities exchange, for cash, upon credit or for future delivery as Bank shall deem appropriate. Bank shall be authorized at any such sale (if it deems it advisable to do so) to restrict the prospective bidders or purchasers to persons who will represent and agree that they are purchasing the Collateral for their own account for investment and not with a view to the distribution or sale thereof, and upon consummation of any such sale Bank shall have the right to assign, transfer and deliver to the purchaser or purchasers thereof the Collateral so sold. Each such purchaser at any such sale shall hold the property sold absolutely, free from any claim or right on the part of Borrower, and Borrower hereby waives (to the extent permitted by law) all rights of redemption, stay and appraisal which Borrower now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted.

(b)      Except in the case of Collateral that is perishable or threatens to decline speedily in value, is of a type customarily sold on a recognized market or is subject to collection and application against Obligations (including, without limitation, accounts and, to the extent constituting Collateral, the Support Account), Bank shall give Borrower 10 days’ written notice (which Borrower agrees is reasonable notice within the meaning of the Uniform Commercial Code as in effect in California or its equivalent in other jurisdictions) of Bank’s intention to make any sale of Collateral. Such notice, in the case of a public sale, shall state the time and place for such sale and, in the case of a sale at a broker’s board or on a securities exchange, shall state the board or exchange at which such sale is to be made and the day on which the Collateral, or portion thereof, will first be offered for sale at such board or exchange. Any such public sale shall be held at such time or times within ordinary business hours and at such place or places as Bank may fix and state in the notice (if any) of such sale. At any such sale, the Collateral, or portion thereof, to be sold may be sold in one lot as an entirety or in separate parcels, as Bank may (in its sole and absolute discretion) determine. Bank shall not be obligated to make any sale of any Collateral if it shall determine not to do so, regardless of the fact that notice of sale of such Collateral shall have been given. Bank may, without notice or publication, adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed for sale, and such sale may, without further notice, be made at the time and place to which the same was so adjourned. In case any sale of all or any part of the Collateral is made on credit or for future delivery, the Collateral so sold may be retained by Bank until the sale price is paid by the purchaser or purchasers thereof, but Bank shall not incur any liability in case any such purchaser or purchasers shall fail to take up and pay for the Collateral so sold and, in case of any such failure, such Collateral may be sold again upon like notice. At any public (or, to the extent permitted by law, private) sale made pursuant to this Section, Secured Party may bid for or purchase, free (to the extent permitted by law) from any right of

 

7


redemption, stay, valuation or appraisal on the part of Borrower (all said rights being also hereby waived and released to the extent permitted by law), the Collateral or any part thereof offered for sale and may make payment on account thereof by using any Obligation from Borrower as a credit against the purchase price, and Bank may, upon compliance with the terms of sale, hold, retain and dispose of such property without further accountability to Borrower therefor. For purposes hereof, a written agreement to purchase the Collateral or any portion thereof shall be treated as a sale thereof; Bank shall be free to carry out such sale pursuant to such agreement, and Borrower shall not be entitled to the return of the Collateral or any portion thereof subject thereto, notwithstanding the fact that after Bank shall have entered into such an agreement all Events of Default shall have been remedied and the Obligations paid in full. As an alternative to exercising the power of sale herein conferred upon it, Bank may proceed by a suit or suits at law or in equity to foreclose the Security Interest and to sell the Collateral or any portion thereof pursuant to a judgment or decree of a court or courts having competent jurisdiction or pursuant to a proceeding by a court-appointed receiver.

ARTICLE IV.          CONDITIONS PRECEDENT TO L/C Credit Extensions

4.01     Conditions of Initial L/C Credit Extension.

The obligation of Bank to make its initial L/C Credit Extension hereunder is subject to satisfaction of the following conditions precedent:

(a)     Bank’s receipt of the following, each of which shall be originals or facsimiles (followed promptly by originals) unless otherwise specified, each properly executed by a Responsible Officer of Borrower, each dated the Closing Date (or, in the case of certificates of governmental officials, a recent date before the Closing Date) and each in form and substance satisfactory to Bank and its legal counsel:

(i)      executed counterparts of this Agreement and the other Loan Documents sufficient in number for distribution to Bank and Borrower;

(ii)             if requested by Bank, a favorable opinion of counsel to Borrower, addressed to Bank, as to such matters concerning Borrower and the Loan Documents as Bank may reasonably request;

(iii)            one or more certificates of Responsible Officers of Borrower certifying that attached thereto are true, correct and complete copies of the Organization Documents of Borrower, resolutions acceptable to Bank and its counsel and good standing certificates issued by the Secretary of State of the state of Borrower’s incorporation and each other state in which its failure to be in good standing would reasonably be expected to have a Material Adverse Effect;

(iv)            evidence that all insurance required to be maintained pursuant to the Loan Documents has been obtained and is in effect;

(v)             Borrower shall have established the Support Account with Bank;

(vi)            such other assurances, certificates, documents, consents or opinions as

 

8


Bank reasonably may require.

(b)    Any fees required to be paid on or before the Closing Date shall have been paid.

(c)    Borrower shall have paid all fees, expenses and disbursements of any counsel and the allocated cost of internal legal services and all expenses and disbursements of internal counsel to Bank to the extent invoiced prior to or on the Closing Date, plus such additional amounts of fees and expenses as shall constitute its reasonable estimate thereof incurred or to be incurred by it through the closing proceedings (provided that such estimate shall not thereafter preclude a final settling of accounts between Borrower and Bank).

4.02     Conditions to all L/C Credit Extensions.

The obligation of Bank to make any L/C Credit Extension is subject to the following conditions precedent:

(a)    The representations and warranties of Borrower contained in Article V or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct on and as of the date of such L/C Credit Extension, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct as of such earlier date, and except that for purposes of this Section 4.02 , the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 .

(b)    No Event of Default or Potential Default shall exist, or would result from such proposed L/C Credit Extension.

(c)    Bank shall have received a Request for L/C Credit Extension in accordance with the requirements hereof.

Each Request for L/C Credit Extension submitted by Borrower shall be deemed to be a representation and warranty that the conditions specified in Sections 4.02(a) and (b)  have been satisfied on and as of the date of the applicable L/C Credit Extension.

ARTICLE V. REPRESENTATIONS AND WARRANTIES

Borrower represents and warrants to Bank that:

5.01     Existence, Qualification and Power; Compliance with Laws.

Borrower (a) is a corporation duly organized or formed, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own its assets and carry on its business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party, (c) is duly qualified and is licensed and in good standing under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license, and (d) is in

 

9


compliance with all Laws; except in each case referred to in clause (b)(i), (c) or (d), to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect.

5.02     Authorization; No Contravention.

The execution, delivery and performance by Borrower of each Loan Document to which such Person is party, have been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of any of such Person’s Organization Documents; (b) conflict with or result in any breach or contravention of, or the creation of any Lien under, (i) any Contractual Obligation to which such Person is a party or (ii) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject; or (c) violate any Law.

5.03     Governmental Authorization; Other Consents.

No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, Borrower of this Agreement or any other Loan Document except such as have been obtained or made and are in full force and effect and except filings necessary to perfect Liens created under the Loan Documents.

5.04     Binding Effect.

This Agreement has been, and each other Loan Document, when delivered hereunder, will have been, duly executed and delivered by Borrower. This Agreement constitutes, and each other Loan Document when so delivered will constitute, a legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms.

5.05     Financial Statements; No Material Adverse Effect.

(a)    The last audited financial statements of Borrower delivered to Bank (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; (ii) fairly present the financial condition of Borrower and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; and (iii) show all material indebtedness and other liabilities, direct or contingent, of Borrower and its Subsidiaries as of the date thereof, including liabilities for taxes, material loans and Indebtedness.

(b)    Any other financial statements of Borrower and its Subsidiaries delivered to Bank, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for the fiscal quarter ended on that date (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (ii) fairly present the financial condition of Borrower and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby, subject, in the case of clauses (i) and (ii), to the absence of footnotes and to normal year-end audit adjustments.

(c)    Since the date of the last audited financial statements of Borrower delivered to Bank,

 

10


there has been no event or circumstance, either individually or in the aggregate, that has had or could reasonably be expected to have a Material Adverse Effect.

5.06     Litigation.

There are no actions, suits, proceedings, claims or disputes pending or, to the knowledge of Borrower, threatened or contemplated, at law, in equity, in arbitration or before any Governmental Authority, by or against Borrower or any of its Subsidiaries or against any of their properties or revenues that (a) purport to affect or pertain to this Agreement or any other Loan Document, or any of the transactions contemplated hereby, or (b) either individually or in the aggregate, if determined adversely, could reasonably be expected to have a Material Adverse Effect.

5.07     No Default.

Neither Borrower nor any Subsidiary is in default under or with respect to any Contractual Obligation that could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No Potential Default or Event of Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this Agreement or any other Loan Document.

5.08     Ownership of Property; Liens.

Each of Borrower and each Subsidiary has good record and marketable title in fee simple to, or valid leasehold interests in, all real property necessary or used in the ordinary conduct of its business, except for such defects in title as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The property of Borrower and its Subsidiaries is subject to no Liens, other than Liens permitted by Section 7.01 .

5.09     Environmental Compliance.

Borrower and its Subsidiaries conduct in the ordinary course of business a review of the effect of existing Environmental Laws and claims alleging potential liability or responsibility for violation of any Environmental Law on their respective businesses, operations and properties, and as a result thereof Borrower has reasonably concluded that such Environmental Laws and claims could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

5.10     Insurance.

The properties of Borrower and its Subsidiaries are insured with financially sound and reputable insurance companies not Affiliates of Borrower, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where Borrower or the applicable Subsidiary operates.

5.11     Taxes.

 

11


Borrower and its Subsidiaries have filed all Federal, state and other material tax returns and reports required to be filed, and have paid all Federal, state and other material taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP or to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect. There is no proposed tax assessment against Borrower or any Subsidiary that would, if made, have a Material Adverse Effect.

5.12     ERISA Compliance.

(a)    Each Plan is in compliance in all material respects with the applicable provisions of ERISA, the Code and other Federal or state Laws. Each Plan that is intended to qualify under Section 401(a) of the Code has received a favorable determination letter from the IRS or an application for such a letter is currently being processed by the IRS with respect thereto and, to the best knowledge of Borrower, nothing has occurred which would prevent, or cause the loss of, such qualification. Borrower and each ERISA Affiliate have made all required contributions to each Plan subject to Section 412 of the Code, and no application for a funding waiver or an extension of any amortization period pursuant to Section 412 of the Code has been made with respect to any Plan.

(b)    There are no pending or, to the best knowledge of Borrower, threatened claims, actions or lawsuits, or action by any Governmental Authority, with respect to any Plan that could be reasonably be expected to have a Material Adverse Effect. There has been no prohibited transaction or violation of the fiduciary responsibility rules with respect to any Plan that has resulted or could reasonably be expected to result in a Material Adverse Effect.

(c)    (i) No ERISA Event has occurred or is reasonably expected to occur; (ii) no Pension Plan has any Unfunded Pension Liability; (iii) neither Borrower nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability under Title IV of ERISA with respect to any Pension Plan (other than premiums due and not delinquent under Section 4007 of ERISA); (iv) neither Borrower nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability (and no event has occurred which, with the giving of notice under Section 4219 of ERISA, would result in such liability) under Sections 4201 or 4243 of ERISA with respect to a Multiemployer Plan; and (v) neither Borrower nor any ERISA Affiliate has engaged in a transaction that could be subject to Sections 4069 or 4212(c) of ERISA.

5.13     Subsidiaries.

As of the Closing Date, Borrower has no Subsidiaries other than Amyris Fuels, LLC, AB Technologies LLC and Amyris Do Brasil Pesquisa E Desinvolvimento Biocombustiveis Limitada.

5.14     Margin Regulations; Investment Company Act; Public Utility Holding Company Act.

(a)    Borrower is not engaged and will not engage, principally or as one of its important activities, in the business of purchasing or carrying margin stock (within the meaning of

 

12


Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock.

(b)    None of Borrower, any Person Controlling Borrower, or any Subsidiary is or is required to be registered as an “investment company” under the Investment Company Act of 1940.

5.15     Disclosure.

Borrower has disclosed to Bank all agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. No report, financial statement, certificate or other information furnished (whether in writing or orally) by or on behalf of Borrower to Bank in connection with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder (as modified or supplemented by other information so furnished) contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial information, Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time.

5.16     Compliance with Laws.

Each of Borrower and each Subsidiary is in compliance in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its properties, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure to comply therewith, either individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect.

5.17     Solvency.

Borrower is Solvent.

ARTICLE VI.          AFFIRMATIVE COVENANTS

So long as Bank shall have any commitment to issue Letters of Credit hereunder or any L/C Obligations or other Obligation hereunder shall remain unpaid (an L/C Obligation shall be deemed paid if it is Cash Collateralized as provided in Section 2.05), Borrower shall, and shall cause each Subsidiary to:

6.01     Financial Statements.

Deliver to Bank, in form and detail satisfactory to Bank:

(a)    as soon as available, but in any event within 210 days after the end of each fiscal year of Borrower, a consolidated balance sheet of Borrower and its Subsidiaries as at the end of such fiscal year, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal year, setting forth in each case in comparative form the figures for

 

13


the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, such consolidated statements to be audited and accompanied by a report and opinion of an independent certified public accountant firm of nationally recognized standing reasonably acceptable to Bank, which report and opinion shall be prepared in accordance with GAAP and applicable securities laws and shall not be subject to any “going concern” or like qualification or exception or any qualification or exception as to the scope of such audit;

(b)    as soon as available, but in any event within 30 days after the end of each fiscal quarter of Borrower, including, without limitation, each fourth fiscal quarter of Borrower, a consolidated balance sheet of Borrower and its Subsidiaries as at the end of such fiscal quarter, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal quarter and for the portion of Borrower’s fiscal year then ended, setting forth in each case in comparative form the figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year, all in reasonable detail, such consolidated statements to be certified by a Responsible Officer of Borrower as fairly presenting the financial condition, results of operations, shareholders’ equity and cash flows of Borrower and its Subsidiaries in accordance with GAAP, subject only to normal year-end audit adjustments and the absence of footnotes and such consolidating statements to be certified by a Responsible Officer of Borrower to the effect that such statements are fairly stated in all material respects when considered in relation to the consolidated financial statements of Borrower and its Subsidiaries.

6.02     Certificates; Other Information.

Deliver to Bank, in form and detail satisfactory to Bank:

(a)    Within 10 Business Days after the end of each month, a Liquidity Analysis Statement;

(b)    promptly after any request by Bank, copies of any detailed management letters or recommendations submitted to the board of directors (or the audit committee of the board of directors) of Borrower by independent accountants in connection with the accounts or books of Borrower or any Subsidiary; and

(c)    promptly, such additional information regarding the business, financial or corporate affairs of Borrower or any Subsidiary, or compliance with the terms of the Loan Documents, as Bank may from time to time reasonably request.

6.03     Notices.

Promptly notify Bank:

(a)    of the occurrence of any Potential Default or Event of Default;

(b)    any litigation involving Borrower, any of its Subsidiaries or any Guarantor where the aggregate amount in controversy exceeds $100,000;

(c)    of any matter that has resulted or could reasonably be expected to result in a Material Adverse Effect, including (i) breach or non-performance of, or any default under, a Contractual

 

14


Obligation of Borrower or any Subsidiary; (ii) any dispute, litigation, investigation, proceeding or suspension between Borrower or any Subsidiary and any Governmental Authority; or (iii) the commencement of, or any material development in, any litigation or proceeding affecting Borrower or any Subsidiary, including pursuant to any applicable Environmental Laws;

(d)    of the occurrence of any ERISA Event; and

(e)    of any material change in accounting policies or financial reporting practices by Borrower or any Subsidiary.

Each notice pursuant to this Section shall be accompanied by a statement of a Responsible Officer of Borrower setting forth details of the occurrence referred to therein and stating what action Borrower has taken and proposes to take with respect thereto. Each notice pursuant to Section 6.03(a) shall describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached.

6.04     Payment of Obligations.

Pay and discharge as the same shall become due and payable, all its obligations and liabilities, including (a) all tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by Borrower or such Subsidiary; (b) all lawful claims which, if unpaid, would by law become a Lien upon its property; and (c) all Indebtedness, as and when due and payable, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness.

6.05     Preservation of Existence, Etc.

(a)    Preserve, renew and maintain in full force and effect its legal existence and good standing under the Laws of the jurisdiction of its organization except in a transaction permitted by Section 7.04 or 7.05 ; (b) take all reasonable action to maintain all rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business; and (c) preserve or renew all of its registered patents, trademarks, trade names and service marks.

6.06     Maintenance of Properties.

(a)    Maintain, preserve and protect all of its material properties and equipment necessary in the operation of its business in good working order and condition, ordinary wear and tear excepted; (b) make all necessary repairs thereto and renewals and replacements thereof; and (c) use the standard of care typical in the industry in the operation and maintenance of its facilities.

6.07    Maintenance of Insurance.

Maintain with financially sound and reputable insurance companies not Affiliates of Borrower, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as are customarily carried under similar circumstances by such other

 

15


Persons and acceptable to Bank naming Bank as loss payee or additional insured, as applicable, and providing for not less than 30 days’ prior notice to Bank of termination, lapse or cancellation of such insurance, and within 30 days of the Closing Date, deliver to Bank a certificate of insurance or other evidence acceptable to Bank of compliance with this Section.

6.08     Compliance with Laws.

Comply in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except in such instances in which such requirement of Law or order, write, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted and acceptable to Bank.

6.09     Books and Records.

Maintain proper books of record and account, in which full, true and correct entries in conformity with GAAP consistently applied shall be made of all financial transactions and matters involving the assets and business of Borrower or such Subsidiary, as the case may be.

6.10     Inspection Rights.

Permit representatives and independent contractors of Bank to (a) visit and inspect any of its properties, to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants, all at the expense of Borrower and at such reasonable times during normal business hours and as often as may be reasonably desired, upon reasonable advance notice to Borrower; provided , however , that when an Event of Default exists Bank (or any of its representatives or independent contractors) may do any of the foregoing at the expense of Borrower at any time during normal business hours and without advance notice and (b) conduct such audits and implement such account payable and other verification procedures as Bank shall reasonably request.

6.11     Letters of Credit.

Request and utilize Letters of Credit to support operation of its business in the ordinary course as conducted as of the Closing Date.

6.12     Support Account.

At all times, maintain the Support Account with Bank, cause to be held in the Support Account good, collected funds aggregating not less than $3,500,000, and not permit any Lien or other interest of other to be asserted against the Support Account or amounts held therein.

ARTICLE VII.          NEGATIVE COVENANTS

So long as Bank has any commitment to issue Letters of Credit hereunder or any L/C Obligations or other Obligation hereunder shall remain unpaid (an L/C Obligation shall be deemed paid if it is Cash Collateralized as provided in Section 2.05), Borrower shall not directly or indirectly:

 

16


7.01     Liens.

Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, other than Permitted Liens.

7.02     Investments.

Make any Investments, except (a) in the ordinary course of business as presently conducted and (b) Investments in Subsidiaries made by Borrower in its sole discretion, provided, however, that Investments in Subsidiaries that are “controlled foreign corporations” (as defined in the Code) ( “Foreign Subsidiaries” ) shall not at any time exceed, in the aggregate, fifty percent (50%) of the combined net worth of Borrower and all its Affiliates, and, provided further, that in the case of Investments in Subsidiaries that are not Foreign Subsidiaries ( “Domestic Subsidiaries” ), Borrower shall cause each such Domestic Subsidiary to execute all such documents and take all such actions as Bank shall request to grant a security interest in its assets to Bank.

7.03     Indebtedness.

Create, incur, assume or suffer to exist any Indebtedness, except Indebtedness under the Loan Documents and other Indebtedness that is incurred in the ordinary course of business and acceptable to Bank.

7.04     Fundamental Changes.

Merge, dissolve, liquidate, consolidate with or into another Person, or Dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person.

7.05     Dispositions.

Make any Disposition or enter into any agreement to make any Disposition, except (each individually a “Permitted Disposition” and, collectively, “Permitted Dispositions” ): (a) Dispositions of unneeded obsolete or worn out property, whether now owned or hereafter acquired, in the ordinary course of business; (b) Dispositions of inventory in the ordinary course of business; (c) Dispositions of equipment to the extent that (i) such property is exchanged for credit against the purchase price of similar replacement property or (ii) the proceeds of such Disposition are reasonably promptly applied to the purchase price of such replacement property;(d) Dispositions in connection with Permitted Liens; and (e) other Dispositions approved by Bank in writing in its discretion. Upon the prior written request of Borrower, Bank agrees to take such actions and to execute such documents as Borrower shall reasonably request to facilitate Permitted Dispositions fee and clear of Liens of Bank.

7.06     Restricted Payments.

Declare or make, directly or indirectly, any Restricted Payment.

7.07     Change in Nature of Business.

 

17


Engage in any material line of business substantially different from those lines of business conducted by Borrower and its Subsidiaries on the date hereof or any business substantially related or incidental thereto.

7.08     Transactions with Affiliates.

Enter into any transaction of any kind with any Affiliate of Borrower, whether or not in the ordinary course of business, other than on fair and reasonable terms substantially as favorable to Borrower or such Subsidiary as would be obtainable by Borrower or such Subsidiary at the time in a comparable arm’s length transaction with a Person other than an Affiliate. Borrower agrees if it acquires, forms or suffers to exist any Subsidiaries not in effect as of the Closing Date Investments in such Subsidiaries will be governed by Section 7.02.

7.09     Burdensome Agreements.

Enter into any Contractual Obligation that limits the ability of Borrower to create, incur, assume or suffer to exist Liens in favor of Bank on Collateral or the Support Account or assures other Persons of the right to be equally and ratable secured by any Collateral or the Support Account.

7.10     Use of Proceeds.

Use any Letter of Credit, whether directly or indirectly, and whether immediately, incidentally or ultimately, to purchase or carry margin stock (within the meaning of Regulation U of the FRB) or to extend credit to others for the purpose of purchasing or carrying margin stock or to refund indebtedness originally incurred for such purpose.

7.11     Liquidity Ratio.

Permit the Liquidity Ratio at any time to be less than 1.00 to 1.00

ARTICLE VIII.        EVENTS OF DEFAULT AND REMEDIES

8.01     Events of Default.

Any of the following shall constitute an Event of Default:

(a)      Non-Payment . Borrower fails to pay any Obligations when and as required to be paid herein; or

(b)      Specific Covenants . Borrower fails to perform or observe any term, covenant or agreement contained in Sections 3.01 , 3.04 , 3.05 or 6.05 or Article VII ; or

(c)      Other Defaults . Borrower (i) fails to perform or observe any covenant or agreement in Section 6.01 or 6.02 and such failure continues for 10 days after Bank delivers to Borrower written notice thereof or (ii) fails to perform or observe any other covenant or agreement (not specified in subsection (a) or (b) above or in clause (i) of this subsection (c)) contained in any Loan Document on its part to be performed or observed and such failure continues for 30 days; or

 

18


(d)      Representations and Warranties . Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of Borrower herein, in any other Loan Document, or in any document delivered in connection herewith or therewith shall be incorrect or misleading in any material respect when made or deemed made; or

(e)      Cross-Default . Borrower or any of its Subsidiaries (A) fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of any Indebtedness or Guarantee (other than Indebtedness hereunder) having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) in excess of $1,000,000, or (B) fails to observe or perform any other agreement or condition relating to any such Indebtedness or Guarantee or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause the holder or holders of such Indebtedness or the beneficiary or beneficiaries of such Guarantee (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause such Indebtedness to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such Indebtedness to be made, prior to its stated maturity, or such Guarantee to become payable or cash collateral in respect thereof to be demanded; or

(f)      Insolvency Proceedings, Etc . Borrower or any of its Subsidiaries institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its property; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for 60 calendar days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its property is instituted without the consent of such Person and continues undismissed or unstayed for 60 calendar days, or an order for relief is entered in any such proceeding; or

(g)      Inability to Pay Debts; Attachment . (i) Borrower or any of its Subsidiary becomes unable or admits in writing its inability or fails generally to pay its debts as they become due, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the property of any such Person and is not released, vacated or fully bonded within 30 days after its issue or levy; or

(h)      Judgments . There is entered against Borrower or any of its Subsidiary (i) a final judgment or order for the payment of money, or (ii) any one or more non-monetary final judgments and, in either case, (A) enforcement proceedings are commenced by any creditor upon such judgment or order, or (B) there is a period of 30 consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect; or

(i)      ERISA . (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or could reasonably be expected to result in liability of Borrower under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC, or (ii) Borrower or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any

 

19


installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan; or

(j)      Invalidity of Loan Documents . Any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or satisfaction in full of all the Obligations, ceases to be in full force and effect; or Borrower or any other Person contests in any manner the validity or enforceability of any Loan Document; or Borrower denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind any Loan Document; or

(k)      Collateral . Bank shall fail for any reason to have a first priority perfected security interest, subject only to any Permitted Liens, in any Collateral; or.

(l)      Defaults under Other Agreements with Bank . Any default shall occur under any other agreement of Borrower with Bank.

8.02     Remedies Upon Event of Default.

If any Event of Default occurs and is continuing, Bank may take any or all of the following actions:

  (a)   terminate the commitment of Bank to issue Letters of Credit hereunder;

  (b)   require Borrower to Cash Collateralize L/C Obligations;

  (c)   exercise all rights and remedies available to it under the Loan Documents or applicable law;

provided , however , that upon the occurrence of an actual or deemed entry of an order for relief with respect to Borrower under the Bankruptcy Code of the United States, the commitment of Bank shall automatically terminate, the unpaid principal amount of all outstanding Obligations and all interest and other amounts as aforesaid shall automatically become due and payable and the obligations of Borrower to Cash Collateralize L/C Obligations shall automatically become due and payable, in each case without further act of Bank.

8.03     Application of Funds.

After the exercise of remedies provided for in Section 8.02 , any amounts received on account of the Obligations shall be applied by Bank in such order as it elects in its sole discretion.

ARTICLE IX.           MISCELLANEOUS

9.01     Amendments; Etc.

No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by Borrower therefrom, shall be effective unless in writing signed by Bank and Borrower, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

20


9.02     Notices and Other Communications; Facsimile Copies.

(a)      General . Unless otherwise expressly provided herein, all notices and other communications provided for hereunder shall be in writing (including by facsimile transmission). All such written notices shall be mailed, faxed or delivered to the address, facsimile number or (subject to subsection (c) below) electronic mail address specified for notices to the applicable party on Schedule 9.02 ; or to such other address, facsimile number or electronic mail address as shall be designated by such party in a notice to the other party. All notices and other communications expressly permitted hereunder to be given by telephone shall be made to the telephone number specified for notices to the applicable party on Schedule 9.02 , or to such other telephone number as shall be designated by such party in a notice to the other party. All such notices and other communications shall be deemed to be given or made upon the earlier to occur of (i) actual receipt by the relevant party hereto and (ii) (A) if delivered by hand or by courier, when signed for by or on behalf of the relevant party hereto; (B) if delivered by mail, four Business Days after deposit in the mails, postage prepaid; (C) if delivered by facsimile, when sent and receipt has been confirmed by telephone; and (D) if delivered by electronic mail (which form of delivery is subject to the provisions of subsection (c) below), when delivered; provided, however , that notices and other communications to Bank pursuant to Article II shall not be effective until actually received by Bank. In no event shall a voicemail message be effective as a notice, communication or confirmation hereunder.

(b)      Effectiveness of Facsimile Documents and Signatures . Loan Documents may be transmitted and/or signed by facsimile. The effectiveness of any such documents and signatures shall, subject to applicable Law, have the same force and effect as manually-signed originals and shall be binding on Borrower and Bank. Bank may also require that any such documents and signatures be confirmed by a manually-signed original thereof; provided , however , that the failure to request or deliver the same shall not limit the effectiveness of any facsimile document or signature.

(c)      Limited Use of Electronic Mail . Electronic mail and Internet and intranet websites may be used only to distribute routine communications, such as financial statements, and to distribute Loan Documents for execution by the parties thereto, and may not be used for any other purpose.

(d)      Reliance by Bank . Bank shall be entitled to rely and act upon any notices purportedly given by or on behalf of Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. Borrower shall indemnify Bank, its Affiliates, and their respective officers, directors, employees, agents and attorneys-in-fact from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of Borrower. All telephonic notices to and other communications with Bank may be recorded by Bank, and Borrower hereby consents to such recording.

9.03     No Waiver; Cumulative Remedies.

No failure by Bank to exercise, and no delay by Bank in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of

 

21


any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.

9.04     Attorney Fees, Expenses and Taxes.

Borrower agrees (a) to pay or reimburse Bank for all costs and expenses incurred in connection with the development, preparation, negotiation and execution of this Agreement and the other Loan Documents and any amendment, waiver, consent or other modification of the provisions hereof and thereof (whether or not the transactions contemplated hereby or thereby are consummated), and the consummation and administration of the transactions contemplated hereby and thereby, including all fees, expenses and disbursements of any counsel and the allocated cost of internal legal services and all expenses and disbursements of internal counsel, and (b) to pay or reimburse Bank for all costs and expenses incurred in connection with the enforcement, attempted enforcement, or preservation of any rights or remedies under this Agreement or the other Loan Documents (including all such costs and expenses incurred during any “workout” or restructuring in respect of the Obligations and during any legal proceeding, including any proceeding under any Debtor Relief Law), including all fees, expenses and disbursements of any counsel and the allocated cost of internal legal services and all expenses and disbursements of internal counsel. The foregoing costs and expenses shall include all search, filing, recording, title insurance and appraisal charges and fees and taxes related thereto, and other out-of-pocket expenses incurred by Bank and the cost of independent public accountants and other outside experts retained by Bank. All amounts due under this Section 9.04 shall be payable within ten Business Days after demand therefor. The agreements in this Section shall survive the termination of the commitments of Bank and repayment, satisfaction or discharge of all other Obligations.

9.05     Indemnification by Borrower.

Whether or not the transactions contemplated hereby are consummated, Borrower shall indemnify and hold harmless Bank, its Affiliates, and their respective directors, officers, employees, counsel, agents and attorneys-in-fact (collectively the “Indemnitees” ) from and against any and all liabilities, obligations, losses, damages, penalties, claims, demands, actions, judgments, suits, costs, expenses and disbursements (including fees and expenses of counsel) of any kind or nature whatsoever which may at any time be imposed on, incurred by or asserted against any such Indemnitee in any way relating to or arising out of or in connection with (a) the execution, delivery, enforcement, performance or administration of any Loan Document or any other agreement, letter or instrument delivered in connection with the transactions contemplated thereby or the consummation of the transactions contemplated thereby, (b) commitment of Bank hereunder or the use or proposed use of Letters of credit , or (c) any actual or alleged presence or release of Hazardous Materials on or from any property currently or formerly owned or operated by Borrower, any Subsidiary or any Environmental Liability related in any way to Borrower, any Subsidiary, or (d) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory (including any investigation of, preparation for, or defense of any pending or threatened claim, investigation, litigation or proceeding) and regardless of whether any Indemnitee is a party thereto (all the

 

22


foregoing, collectively, the “Indemnified Liabilities” ), in all cases, whether or not caused by or arising, in whole or in part, out of the negligence of the Indemnitees; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such liabilities, obligations, losses, damages, penalties, claims, demands, actions, judgments, suits, costs, expenses or disbursements are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee. No Indemnitee shall have any liability for any indirect or consequential damages relating to this Agreement or any other Loan Document or arising out of its activities in connection herewith or therewith (whether before or after the Closing Date). All amounts due under this Section  9.05 shall be payable within ten Business Days after demand therefor. The agreements in this Section shall survive the termination of the commitment of Bank to issue Letters of Credit and the repayment, satisfaction or discharge of all the other Obligations.

9.06     Payments Set Aside.

To the extent that any payment by or on behalf of Borrower is made to Bank, or Bank exercises its right of set-off, and such payment or the proceeds of such set-off or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by Bank in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then, to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such set-off had not occurred.

9.07     Successors and Assigns.

(a)     The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that Borrower may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of Bank and Bank may not assign or otherwise transfer any of its rights or obligations hereunder except (i) to an Eligible Assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection (c) of this Section, or (iii) by way of pledge or assignment of a security interest subject to the restrictions of subsection (e) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (c) of this Section and, to the extent expressly contemplated hereby, the Indemnitees) any legal or equitable right, remedy or claim under or by reason of this Agreement.

(b)     Bank may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under this Agreement pursuant to documentation acceptable to Bank and the assignee. From and after the effective date specified in such documentation, such Eligible Assignee shall be a party to this Agreement and, to the extent of the interest assigned by Bank, have the rights and obligations of Bank under this Agreement, and Bank shall, to the extent of the interest so assigned, be released from its obligations under this Agreement (and, in the case of an assignment of all of Bank’s rights and obligations under this Agreement, shall cease to be a

 

23


party hereto but shall continue to be entitled to the benefits of Sections 3.01 , 3.04 , 3.05 , 9.04 and 9.05 with respect to facts and circumstances occurring prior to the effective date of such assignment). Upon request, Borrower (at its expense) shall execute and deliver new or replacement Notes to Bank and the assignee, and shall execute and deliver any other documents reasonably necessary or appropriate to give effect to such assignment and to provide for the administration of this Agreement after giving effect thereto.

(c)     Bank may at any time, without the consent of, or notice to, Borrower, sell participations to any Person (other than a natural person or Borrower or any of Borrower’s Affiliates or Subsidiaries) (each, a “ Participant ”) in all or a portion of Bank’s rights and/or obligations under this Agreement; provided that (i) Bank’s obligations under this Agreement shall remain unchanged, (ii) Bank shall remain solely responsible to Borrower for the performance of such obligations and (iii) Borrower shall continue to deal solely and directly with Bank in connection with Bank’s rights and obligations under this Agreement. Any agreement or instrument pursuant to which Bank sells such a participation shall provide that Bank shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that Bank will not, without the consent of the Participant, agree to any amendment, waiver or other modification that would (i) postpone any date upon which any payment of money is scheduled to be made to such Participant or (ii) reduce the principal, interest, fees or other amounts payable to such Participant. Subject to subsection (d) of this Section, Borrower agrees that each Participant shall be entitled to the benefits of Sections 3.01 , 3.04 and 3.05 to the same extent as if it were Bank and had acquired its interest by assignment pursuant to subsection (b) of this Section. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 9.09 as though it were Bank.

(d)     A Participant shall not be entitled to receive any greater payment under Section 3.01 or 3.04 than Bank would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with Borrower’s prior written consent. A Participant that is not a “United States person” within the meaning of Section 7701(a)(30) of the Code shall not be entitled to the benefits of Section 3.01 unless Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of Borrower, to provide to Bank such tax forms prescribed by the IRS as are necessary or desirable to establish an exemption from, or reduction of, U.S. withholding tax.

(e)     Bank may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under the Note, if any) to secure obligations of Bank, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release Bank from any of its obligations hereunder or substitute any such pledgee or assignee for Bank as a party hereto.

(f)     As used herein, the following terms have the following meanings:

Eligible Assignee ” means (a) an Affiliate of Bank; (b) an Approved Fund; and (c) any other Person (other than a natural person) approved by Borrower (such approval not to be unreasonably withheld or delayed); provided that no such approval shall be required if an Event of Default has occurred and is continuing.

 

24


Fund ” means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business.

Approved Fund ” means any Fund that is administered or managed by (a) Bank or (b) an Affiliate of Bank.

9.08     Confidentiality.

Bank agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its and its Affiliates’ directors, officers, employees and agents, including accountants, legal counsel and other advisors (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority, (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to Borrower and its obligations, (g) with the consent of Borrower or (h) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to Bank on a nonconfidential basis from a source other than Borrower. For purposes of this Section, “ Information ” means all information received from Borrower or any of its business, other than any such information that is available to Bank on a nonconfidential basis prior to disclosure by Borrower, provided that, in the case of information received from Borrower after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.

9.09     Set-off.

In addition to any rights and remedies of Bank provided by law, upon the occurrence and during the continuance of any Event of Default, Bank is authorized at any time and from time to time, without prior notice to Borrower or Borrower, any such notice being waived by Borrower to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held by, and other indebtedness at any time owing by, Bank to or for the credit or the account of Borrower against any and all Obligations owing to Bank hereunder or under any other Loan Document, now or hereafter existing, irrespective of whether or not Bank shall have made demand under this Agreement or any other Loan Document and although such Obligations may be contingent or unmatured or denominated in a currency different from that of the applicable deposit or indebtedness. Bank agrees promptly to notify Borrower after any such set-off and application; provided , however , that the failure to give

 

25


such notice shall not affect the validity of such set-off and application.

9.10     Termination. This Agreement and the security interests granted hereby shall terminate when (a) Bank has no further obligations to issue Letters of Credit hereunder and (b) no L/C Obligations or other Obligations remain unpaid (an L/C Obligation shall be deemed paid if it is Cash Collateralized as provided in Section 2.05).

9.11      Discontinuance of Event of Default . Subsequent to the occurrence of a specific Event of Default, in the event that Borrower believes that such specific Event of Default is no longer continuing, it may request that Bank confirm in writing to Borrower that Bank considers that such specific Event of Default has discontinued and that Bank will not seek to claim or to enforce any remedies based thereon. Bank shall make such decision in its sole and unfettered discretion.

9.12     Counterparts.

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

9.13     Integration.

This Agreement, together with the other Loan Documents, comprises the complete and integrated agreement of the parties on the subject matter hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter. In the event of any conflict between the provisions of this Agreement and those of any other Loan Document, the provisions of this Agreement shall control; provided that the inclusion of supplemental rights or remedies in favor of Bank in any other Loan Document shall not be deemed a conflict with this Agreement. Each Loan Document was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor in favor of any party, but rather in accordance with the fair meaning thereof.

9.14     Survival of Representations and Warranties.

All representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by Bank, regardless of any investigation made by Bank or on its behalf and notwithstanding that Bank may have had notice or knowledge of any Potential Default or Event of Default at the time of any L/C Credit Extension, and shall continue in full force and effect as long as any Obligation hereunder shall remain unpaid or unsatisfied.

9.15     Severability.

If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that

 

26


of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

9.16     Governing Law.

(a)     THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, the LAW OF THE STATE OF CALIFORNIA applicable to agreements made and to be performed entirely within such State; PROVIDED THAT BANK SHALL RETAIN ALL RIGHTS ARISING UNDER FEDERAL LAW.

(b)     ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT MAY BE BROUGHT IN THE COURTS OF THE STATE OF CALIFORNIA SITTING IN LOS ANGELES OR OF THE UNITED STATES FOR THE CENTRAL DISTRICT OF SUCH STATE, AND BY EXECUTION AND DELIVERY OF THIS AGREEMENT, BORROWER AND BANK EACH CONSENTS, FOR ITSELF AND IN RESPECT OF ITS PROPERTY, TO THE NON-EXCLUSIVE JURISDICTION OF THOSE COURTS. BORROWER AND BANK EACH IRREVOCABLY WAIVES ANY OBJECTION, INCLUDING ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS , WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY ACTION OR PROCEEDING IN SUCH JURISDICTION IN RESPECT OF ANY LOAN DOCUMENT OR OTHER DOCUMENT RELATED THERETO. BORROWER AND BANK EACH WAIVES PERSONAL SERVICE OF ANY SUMMONS, COMPLAINT OR OTHER PROCESS, WHICH MAY BE MADE BY ANY OTHER MEANS PERMITTED BY THE LAW OF SUCH STATE.

9.17     Waiver of Right to Trial by Jury.

EACH PARTY TO THIS AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER ANY LOAN DOCUMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO ANY LOAN DOCUMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

9.18     Judicial Reference Provision.

In the event the above jury trial waiver is unenforceable, the parties elect to proceed under this Judicial Reference Provision. With the exception of the items specified below, any controversy, dispute or claim between the parties relating to this Agreement or any other document, instrument or transaction between the parties (each, a “Claim”), will be resolved by a reference

 

27


proceeding in California pursuant to Sections 638 et seq. of the California Code of Civil Procedure, or their successor sections, which shall constitute the exclusive remedy for the resolution of any Claim, including whether the Claim is subject to reference. Venue for the reference will be the Superior Court in the County where real property involved in the action, if any, is located, or in a County where venue is otherwise appropriate under law (the Court). The following matters shall not be subject to reference: (i) nonjudicial foreclosure of any security interests in real or personal property, (ii) exercise of self-help remedies (including without limitation set-off), (iii) appointment of a receiver, and (iv) temporary, provisional or ancillary remedies (including without limitation writs of attachment, writs of possession, temporary restraining orders or preliminary injunctions). The exercise of, or opposition to, any of the above does not waive the right to a reference hereunder. The referee shall be selected by agreement of the parties. If the parties do not agree, upon request of any party a referee shall be selected by the Presiding Judge of the Court. The referee shall determine all issues in accordance with existing case law and statutory law of the State of California, including without limitation the rules of evidence applicable to proceedings at law. The referee is empowered to enter equitable and legal relief, and rule on any motion which would be authorized in a court proceeding, including without limitation motions for summary judgment or summary adjudication. The referee shall issue a decision, and pursuant to CCP §644 the referee’s decision shall be entered by the Court as a judgment or order in the same manner as if tried by the Court. The final judgment or order from any decision or order entered by the referee shall be fully appealable as provided by law. The parties reserve the right to findings of fact, conclusions of law, a written statement of decision, and the right to move for a new trial or a different judgment, which new trial if granted will be a reference hereunder. AFTER CONSULTING (OR HAVING THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF ITS CHOICE, EACH PARTY AGREES THAT ALL CLAIMS RESOLVED UNDER THIS REFERENCE PROVISION WILL BE DECIDED BY A REFEREE AND NOT A JURY.

9.19     USA Patriot Act Notice.

Bank hereby notifies Borrower that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “ Act ”), it is required to obtain, verify and record information that identifies Borrower, which information includes the name and address of Borrower and other information that will allow Bank to identify Borrower in accordance with the Act.

 

28


IN WITNESS WHEREOF , the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

AMYRIS BIOTECHNOLOGIES, INC.,  a            

California corporation

By:  

/s/ Jeryl Hilleman

Jeryl Hilleman, Chief Financial Officer

 

29


Bank of the West,  a California banking            

corporation

By:  

/s/ Lebbeus S. Case, Jr.

Lebbeus S. Case, Jr., Vice President & Senior

Relationship Manager

 

30


SCHEDULE 1.01

Affiliate ” means, with respect to any Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. “ Control ” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “ Controlling ” and “ Controlled ” have meanings correlative thereto.

Agreement ” means this Reimbursement and Security Agreement.

Borrower ” has the meaning specified in the introductory paragraph hereto.

Business Day ” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, the state where the Lending Office is located.

Cash Collateralize ” means to pledge and deposit with or deliver to Bank as collateral for L/C Obligations cash or deposit account balances pursuant to documentation in form and substance satisfactory to Bank. Derivatives of such term have corresponding meanings. Borrower hereby grants to Bank a security interest in all such cash, deposit accounts and all balances therein and all proceeds thereof. Cash collateral shall be maintained in blocked deposit accounts at Bank.

Closing Date ” means the first date all the conditions precedent in Section 4.01 are satisfied or waived by Bank.

Code ” means the Internal Revenue Code of 1986.

Collateral ” shall mean all now owned or hereafter acquired right, title and interest of Borrower in (a) Accounts, (b) Documents, (c) Chattel Paper, (d) Deposit Accounts, (e) Equipment, Inventory and other Goods, (f) General Intangibles, (g) Instruments and Promissory Notes, (h) Letter of Credit Rights, (i) Commercial Tort Claims, (j) cash and cash accounts, (k) Investment Property, (l) Fixtures, (m) Supporting Obligations and (n) Proceeds of the foregoing; provided , however , that the following items do not constitute Collateral: (i) any Intellectual Property; (ii) unless and until an Event of Default occurs, the Support Account, (iii) any Equipment which is subject to a purchase money lien permitted under this Agreement in favor of any Person (other than Bank, if the documents relating to such Lien do not permit other Liens, (iv) rights under the TriplePoint Master Lease Agreement and Equipment financed thereunder (v) Subordinated Indebtedness, (vi) the Master Lease Agreement with Applied Biosystems dated June 11, 2007 and Equipment financed thereunder, (vii) the Master Lease Agreement with Thermo Electron Corporation dated June 4, 2007 and Equipment financed thereunder, (viii) the Siemens Equipment Lease dated February 13, 2008 and Equipment financed thereunder, (ix) more than 65% of the presently existing and hereafter issued and outstanding shares of capital stock of any “controlled foreign corporation” (as defined in the Code) which shares entitle the holder thereof to vote for directors or any other matter, (x) any interest of Borrower as a lessee or sublessee under a real property lease or an Equipment lease if Borrower is prohibited by the terms of such lease from granting a security interest therein or under which an assignment or Lien would cause a default to occur (other than to the extent that any such term would be rendered ineffective by


Sections 9406 through 9408 of the Uniform Commercial Code) and (xi) any General Intangible which is the subject of a written agreement which specifically prohibits assignment thereof but only to the extent of such prohibition, and only to the extent that the terms and provisions of a such written agreement, document or instrument creating or evidencing such property or any rights relating thereto expressly prohibit the granting of a security interest therein, making the granting of a security interest therein a breach or event of default or condition the granting of a security interest therein on the consent of a third party whose consent has not been obtained or would cause, or allow a third party to cause, forfeiture of such property upon the granting of a security interest therein or a breach under any written agreement relating thereto. As used in this definition, “ Account Debtor ,” “ Account ,” “ Chattel Paper ,” “ Commercial Tort Claim ,” “ Commodity Account ,” “ Commodity Intermediary ,” “ Deposit Account ,” “ Documents ,” “ Entitlement Holder ,” “ Equipment ,” “ Fixtures ,” “ Financial Asset ,” “ General Intangibles ,” “ Goods ,” “ Inventory ,” “ Investment Property ,” “Instruments,” “ Letter of Credit Rights ,” “ Proceeds ,” “ Promissory Note ,” “ Securities ,” “ Securities Account ,” “ Securities Intermediary ,” “ Securities Entitlement ,” and “ Supporting Obligations ” shall have the meaning assigned to such terms by the Uniform Commercial Code.

Contractual Obligation ” means, as to any Person, any provision of any security issued by such Person or of any material agreement, material instrument or other material undertaking to which such Person is a party or by which it or any of its property is bound.

Control ” has the meaning specified in the definition of “Affiliate.”

Debtor Relief Laws ” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.

Disposition ” or “ Dispose ” means the sale, transfer, license, lease or other disposition (including any sale and leaseback transaction) of any property by any Person, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith.

Dollar ” and “ $ ” mean lawful money of the United States.

Eligible Assignee ” has the meaning specified in Section 9.07(f) .

Environmental Laws ” means any and all Federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.

Environmental Liability ” means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of Borrower or any of its Subsidiaries directly or indirectly resulting from or based upon (a) violation of any


Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.

ERISA ” means the Employee Retirement Income Security Act of 1974.

ERISA Affiliate ” means any trade or business (whether or not incorporated) under common control with Borrower within the meaning of Section 414(b) or (c) of the Code (and Sections 414(m) and (o) of the Code for purposes of provisions relating to Section 412 of the Code).

ERISA Event ” means (a) a Reportable Event with respect to a Pension Plan; (b) a withdrawal by Borrower or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA; (c) a complete or partial withdrawal by Borrower or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization; (d) the filing of a notice of intent to terminate, the treatment of a Plan amendment as a termination under Sections 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer Plan; (e) an event or condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan or Multiemployer Plan; or (f) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon Borrower or any ERISA Affiliate.

Event of Default ” has the meaning specified in Section 8.01 .

FRB ” means the Board of Governors of the Federal Reserve System of the United States.

GAAP ” means generally accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles as may be approved by a significant segment of the accounting profession in the United States, that are applicable to the circumstances as of the date of determination, consistently applied.

Governmental Authority ” means any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, administrative tribunal, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.

Guarantee ” means, as to any Person, any (a) any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the


purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), or (b) any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term “Guarantee” as a verb has a corresponding meaning.

Hazardous Materials ” means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law.

Indebtedness ” means, as to any Person at a particular time, without duplication, all items of indebtedness which, in accordance with GAAP and industry practices, would be included in determining liabilities as shown on the liability side of a balance sheet of such Person as of the date as of which indebtedness is to be determined, including, without limitation, all obligations for money borrowed and capitalized lease obligations, and shall also include all indebtedness and liabilities of any other Person assumed or guaranteed by such Person or in respect of which such Person is secondarily or contingently liable (other than by endorsement of instruments in the course of collection) whether by reason of any agreement to acquire such indebtedness or to supply or advance sums or otherwise.

Indemnified Liabilities ” has the meaning specified in Section 9.05 .

Indemnitees ” has the meaning specified in Section 9.05 .

Intellectual Property ” means all Borrower’s copyrights, trademarks, patents, copyright licenses, trademark licenses, patent licenses, trade secrets, source codes, customer lists, propriety confidential information, inventions (whether or not patented or patentable), technical information, procedures, designs, knowledge, know-how, software, data bases, skill, expertise, experience, processes, models, drawings, materials, records and goodwill associated with the foregoing.

Investment ” means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other acquisition of capital stock or other securities of another Person, (b) a loan, advance or capital contribution to, Guarantee or assumption of debt of, or purchase or other acquisition of any other debt or equity participation or interest in, another Person, including any partnership or joint venture interest in such other


Person, or (c) the purchase or other acquisition (in one transaction or a series of transactions) of assets of another Person that constitute a business unit. For purposes of covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment.

IRS ” means the United States Internal Revenue Service.

Laws ” means, collectively, all international, foreign, Federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.

L/C Credit Extension ” means the issuance, amendment or extension of a Letter of Credit

L/C Obligations ” means, as at any date of determination, the aggregate undrawn amount of all outstanding Letters of Credit plus the aggregate of all unreimbursed drawings under all Letters of Credit.

Lending Office ” means the office or offices of Bank described as such on Schedule 9.02 , or such other office or offices as Bank may from time to time notify Borrower.

Letter of Credit ” means any letter of credit issued or outstanding hereunder.

Letter of Credit Application ” means an application and agreement for the issuance or amendment of a Letter of Credit in the form from time to time used by Bank.

Letter of Credit Expiration Date ” means the day that is Maturity Date or such other date as Bank shall specify.

Lien ” means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement of any kind or nature whatsoever (including any conditional sale or other title retention agreement, and any financing lease having substantially the same economic effect as any of the foregoing).

Liquid Assets ” means the following assets owned by Borrower on an unconsolidated basis (excluding the Support Account) and not owned by any Subsidiary of Borrower which (i) are not the subject of any Lien or other arrangement with any creditor to have his claim satisfied out of the asset (or proceeds thereof) prior to the general creditors of Borrower, and (ii) may be converted to cash within five (5) days: (a) cash and cash equivalents held in the United States; (b) United States Treasury or governmental agency obligations which constitute full faith and credit of the United States of America; (c) Commercial paper rated P-1 or A1 by Moody’s or by S&P, respectively; (d) medium and long-term securities rated investment grade by one of the rating agencies described in (c) above; (e) Eligible Stocks; and (f) mutual funds quoted in The Wall Street Journal which invest primarily in the assets described in (a) through (e) above, where


“Eligible Stocks” means any common or preferred stock which (i) is not subject to statutory or contractual restrictions on sales, (ii) is traded on the New York Stock Exchange, American Stock Exchange or included in the National Market tier of NASDAQ and (iii) has, as of the close of trading on an applicable exchange (excluding after hours trading), a per share price of at least $15.

Liquidity Analysis Statement ” means a certificate executed by a Responsible Officer of Borrower setting forth in form and detail satisfactory to Bank a calculation of the Liquidity Ratio as of the end of the most recently ended month.

Liquidity Ratio ” means, as of any date, the ratio of (a) Borrower’s Liquid Assets as of the end of the month most recently ended to (b) cash expenditures during the six (6) months most recently ended.

Loan Documents ” means this Agreement, any note, any fee letter, Letter of Credit Applications, the Support Account Agreement and each other document and agreement executed or delivered in connection herewith and therewith.

Material Adverse Effect ” means (a) a material adverse change in, or a material adverse effect upon, the operations, business, properties, liabilities (actual or contingent), condition (financial or otherwise) or prospects of Borrower or Borrower and its Subsidiaries taken as a whole; (b) a material impairment of the ability of Borrower to perform its obligations under any Loan Document to which it is a party; or (c) a material adverse effect upon the legality, validity, binding effect or enforceability against Borrower of any Loan Document.

Maturity Date ” means April 30, 2010.

Multiemployer Plan ” means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which Borrower or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years, has made or been obligated to make contributions.

Obligations ” means all advances to, and debts, liabilities, obligations, covenants and duties of, Borrower arising under any Loan Document or otherwise with respect to any Letter of Credit, Swap Contract, card services or other bank products afforded to Borrower by Bank, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against Borrower or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming Borrower as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding.

Organization Documents ” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement; and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or


organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.

Participant ” has the meaning specified in Section 9.07(c) .

PBGC ” means the Pension Benefit Guaranty Corporation.

Pension Plan ” means any “employee pension benefit plan” (as such term is defined in Section 3(2) of ERISA), other than a Multiemployer Plan, that is subject to Title IV of ERISA and is sponsored or maintained by Borrower or any ERISA Affiliate or to which Borrower or any ERISA Affiliate contributes or has an obligation to contribute, or in the case of a multiple employer or other plan described in Section 4064(a) of ERISA, has made contributions at any time during the immediately preceding five plan years.

Permitted Dispositions ” has the meaning specified in Section 7.05 .

Permitted Lien ” means any of the following to the extent not encumbering Collateral or the Support Account (a) Liens pursuant to any Loan Document or otherwise in favor of Bank; (b) Liens existing on the date hereof and reflected on financial statements delivered to Bank prior to the Closing Date and any renewals or extensions thereof; (c) Liens for taxes not yet due or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP; (d) carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than 30 days or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person; (e) pledges or deposits in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other social security legislation, other than any Lien imposed by ERISA; (f) deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety bonds (other than bonds related to judgments or litigation), performance bonds and other obligations of a like nature incurred in the ordinary course of business; (g) easements, rights-of-way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable Person; (h) Liens securing judgments for the payment of money not constituting an Event of Default or securing appeal or other surety bonds related to such judgments; and (i) any other Liens approved in writing by Bank.

Person ” means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.

Plan ” means any “employee benefit plan” (as such term is defined in Section 3(3) of ERISA) established by Borrower or, with respect to any such plan that is subject to Section 412 of the Code or Title IV of ERISA, any ERISA Affiliate.


Potential Default ” means any event or condition that, with the giving of any notice, the passage of time, or both, would be an Event of Default.

Reportable Event ” means any of the events set forth in Section 4043(c) of ERISA, other than events for which the 30 day notice period has been waived.

Request for L/C Credit Extension ” means an application for a Letter of Credit that is in form and substance satisfactory to Bank and any other request relating to a Letter of Credit that Bank may reasonably require in connection with any L/C Credit Extension.

Responsible Officer ” means the chief executive officer, president, chief financial officer, treasurer or assistant treasurer of Borrower. Any document delivered hereunder that is signed by a Responsible Officer of Borrower shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of Borrower and such Responsible Officer shall be conclusively presumed to have acted on behalf of Borrower.

Restricted Payment ” means any dividend or other distribution (whether in cash, securities or other property) with respect to any capital stock or other equity interest of Borrower or any Subsidiary, or any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such capital stock or other equity interest or of any option, warrant or other right to acquire any such capital stock or other equity interest.

Solvent ” means, with respect to any Person on a particular date, that, at fair valuations, the sum of such Person’s assets is greater than all of such Person’s debts.

Subordinated Agreement ” means that certain Subordination Agreement by and between BNP Paribas and Borrower dated December     , 2008 that was acknowledged by Amyris Fuels, Inc.

Subsidiary ” of a Person means a corporation, partnership, joint venture, limited liability company or other business entity of which a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by reason of the happening of a contingency) are at the time beneficially owned, or the management of which is otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person. Unless otherwise specified, all references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or Subsidiaries of Borrower.

Support Account ” has the meaning specified in the Support Account Agreement.

Support Account Agreement ” means an agreement between Bank and Borrower identifying the Support Account and pursuant to which Borrower agrees to maintain the Support Account with Bank on the terms and conditions acceptable to Bank.

Swap Contract ” means any interest rate, credit, commodity or equity swap, cap, floor, collar, forward, foreign exchange transaction, currency swap, cross currency swap, currency option, securities puts, calls, collars, options or forwards or any combination of or option with respect to,


the foregoing or similar transactions now or hereafter entered into between Bank and Borrower.

TriplePoint Master Lease Agreement ” means that certain Plain English Master Lease Agreement dated March 14, 2008 by and between Borrower and TriplePoint Capital, LLC.

Unfunded Pension Liability ” means the excess of a Pension Plan’s benefit liabilities under Section 4001(a)(16) of ERISA, over the current value of that Pension Plan’s assets, determined in accordance with the assumptions used for funding the Pension Plan pursuant to Section 412 of the Code for the applicable plan year.

Uniform Commercial Code ” means the Uniform Commercial Code as in effect in any applicable jurisdiction.

United States ” and “ U.S. ” mean the United States of America.


SCHEDULE 9.02

NOTICE ADDRESSES AND LENDING OFFICE

BORROWER

Amyris Biotechnologies, Inc.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

Attention: Jeryl Hilleman, Chief Financial Officer

BANK

Bank of the West

San Francisco Commercial Banking Office

180 Montgomery St., 3rd Floor

San Francisco, CA 94104

Attention: Lebbeus S. Case, Jr., Vice President & Senior Relationship Manager

 

Schedule 9.02, page 1

Exhibit 10.07

FIRST AMENDMENT TO REIMBURSEMENT AND SECURITY AGREEMENT AND

TO SUPPORT AGREEMENT

THIS FIRST AMENDMENT TO REIMBURSEMENT AND SECURITY AGREEMENT AND TO SUPPORT AGREEMENT (this “ Amendment ”) is entered into as of December 3, 2009 by and between AMYRIS BIOTECHNOLOGIES, INC., California corporation (the “ Borrower ”), and BANK OF THE WEST, a California banking corporation (the “ Bank ”).

Recitals

WHEREAS, the Borrower and the Bank are parties to a Reimbursement Agreement and Security Agreement dated as of November 5, 2009 (the “ Reimbursement Agreement ”) and a Support Agreement dated as of November 5, 2009 (the “ Support Agreement ”).

WHEREAS, the Borrower and the Bank desire to amend the Reimbursement Agreement and the Support Agreement for the purposes hereinafter set forth.

NOW, THEREFORE, for good and valuable consideration, the parties hereto hereby agree as follows:

1.      Amendment to Reimbursement Agreement . Effective as of the First Amendment Effective Date (as hereinafter defined), the Reimbursement Agreement is amended as follows:

(a)    The Commitment amount of $3,450,000 contained in Section 2.01(a) of the Reimbursement Agreement is increased to $4,450,000.

(b)    The amount to be retained in the Support Account in accordance with Section 6.12 of the Reimbursement Agreement is increased to $4,450,000.

(c)    The date in the definition of “Subordinated Agreement” in Schedule 1.01 to the Reimbursement Agreement is completed with the date of “December             2008.”

2.      Support Agreement . Effective as of the First Amendment Effective Date, Section 2 of the Support Agreement is amended and restated to read as follows:

“2. Support Agreement . Bank and Borrower agree that (a) certificate of deposit number 014812230 established by Bank in the name of Borrower, (b) certificate of deposit number 014916080 established by Bank in the name of Borrower and (c) all substitutions, additional and replacement accounts for the foregoing are the collectively, the Support Account (the “ Support Account ”) that, pursuant to the Reimbursement Agreement, Borrower has agreed to maintain with Bank and in which Borrower has agreed to maintain on deposit not less than Four Million Four Hundred and Fifty Thousand Dollars ($4,450,000) (the “ Minimum Amount ”). So long as no Event of Default has occurred under the Reimbursement Agreement, upon request of Borrower made no more frequently than once in any calendar quarter, Bank agrees to release to Borrower any amounts on deposit in the Support Account in excess of the Minimum Amount; provided, that so long as the Support Account is in the form of one or more certificates of deposit or other time deposits, any such release from any such certificate or account shall be available to Borrower only on maturity or roll over dates.

3.      Conditions Precedent . This Amendment shall be effective as of the date (the “ First Amendment Effective Date ”) upon which the following conditions are satisfied:

 

1


(a)    Counterparts of this Amendment shall have been signed and delivered to the Bank by the parties hereto.

(b)    The Bank shall have received such documents and certificates as the Bank or its counsel may reasonably request relating to the organization or formation, existence and good standing of the Borrower, the authorization of this Amendment and any other legal matters relating to the Borrower, the Reimbursement Agreement or this Amendment, all in form and substance satisfactory to the Administrative Agent.

(c)    The Borrower shall have deposited into the Support Account the amounts required to comply with this Amendment.

(d)    The Borrower shall have paid to the Bank all other fees and other amounts due and payable on or prior to the First Amendment Effective Date, including reimbursement or payment of all out-of-pocket expenses required to be reimbursed or paid by the Borrower hereunder.

The Bank shall notify the Borrower of the First Amendment Effective Date, and such notice shall be conclusive and binding.

4.      Representations and Warranties . The Borrower hereby represents and warrants that as of the date hereof, after giving effect to this Amendment, the representations and warranties of the Borrower in the Loan Documents are true and correct in all material respects, and no Potential Default or Event of Default has occurred and is continuing.

5.      Ratification . The Reimbursement Agreement and Support Agreement as amended hereby: are hereby ratified and remain in full force and effect.

6.      Counterparts . This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same agreement and any of the parties hereto may execute this Amendment by signing any such counterpart.

7.      Choice of Law . This Amendment and the other Loan Documents shall be construed in accordance with the internal laws of the State of California applicable to agreements made and to be performed entirely within such State.

[Signature Page Follows]

 

2


IN WITNESS WHEREOF , the parties hereto have caused this Amendment to be duly executed as date first above written.

 

BORROWER:
AMYRIS BIOTECHNOLOGIES, INC.
By:   /s/ Jeryl Hilleman                                  
  Jeryl Hilleman, Chief Financial Officer
BANK:
BANK OF THE WEST
By:   /s/ Lebbeus S. Case                                
  Lebbeus S. Case, Jr., Vice President & Senior
  Relationship Manager

CERTIFICATE OF RESPONSIBLE OFFICER

The undersigned hereby certifies to the Bank that (1) the Borrower has previously delivered to the Bank a true, correct and complete copy of the Borrower’s Organization Documents (collectively, the “ Delivered Organization Documents ”), (2) since such delivery, there has been no changes in the Delivered Organization Documents, and no such document has been repealed, revoked, rescinded or amended in any respect and each remains in full force and effect, (3) the Borrower remains in good standing in the State of California, (4) the resolutions delivered to the Bank by the Borrower on or prior to the date of the Credit Agreement authorize the execution, delivery and performance of the foregoing Amendment and have not been repealed, revoked, rescinded, amended or modified in any respect, (5) such resolutions authorize the Chief Financial Officer (the “ Authorized Executing Officer ”) of the Borrower to execute the foregoing Amendment on behalf of the Borrower, (6) the Person executing the foregoing Amendment on behalf of the Borrower has been duly elected and now holds the Authorized Executing Office set forth below or next to his or her name, and the signature set forth below is his or her true signature, (7) the undersigned is authorized to deliver this Certificate on behalf of the Borrower, and (8) the Bank may conclusively rely on this Certificate unless and until superseding documents shall be delivered to the Bank.

Executed as of this 3 rd day of December, 2009

 

/s/ Tamara L. Tompkins

 
Name:   Tamara Tompkins  
Title:   Secretary  

 

3

Exhibit 10.08

 

LOGO

   UBS FINANCIAL SERVICES INC.

 

  Please complete and sign this form.  
  We must receive it by November 14, 2008.  
  Acceptance of UBS’s offer relating to auction rate securities  
  By signing below and returning this form, I accept UBS’s offer of Rights relating to my Eligible ARS in the account listed below. I understand and acknowledge the following
    All Eligible ARS must remain in my UBS account listed below until I exercise my Rights to sell my Eligible ARS to UBS or they are redeemed by the issuer or purchased or sold on my behalf by UBS;
    I will instruct my UBS Financial Advisor or Branch Manager if and when I want to exercise my Rights and sell my Eligible ARS to UBS during the period of June 30, 2010, through July 2, 2012;
    The acceptance of UBS's offer constitutes consent (to the extent legally required) for UBS, acting as principal, to purchase my Eligible ARS or to sell them on my behalf at any time in its sole discretion and without other prior notice to me, from the date that I accept this offer through July 2, 2012;
    If UBS purchases, sells or otherwise disposes of my Eligible ARS, it will deposit the par value in my account within one business day of settlement of the transaction;
    I release UBS and its employees/agents from all claims except claims for consequential damages directly or indirectly relating to its marketing and sale of ARS and expressly agree that I will not seek any damages or costs (punitive damages, attorney fees, etc.) other than consequential damages. I also will not serve as a class representative or receive benefits under any class action settlement or investor fund;
    If the account named below is in the name of a corporation, partnership, trust or other entity, I represent and warrant that I have the power and authority to accept this offer on behalf of that entity.
 

 

 

 

AMYRIS BIOTECHNOLOGIES, INC.

5885 HOLLIS ST

SUITE 100

EMERYVILLE CA 94608-2015

 

 

Account Number: CP01610

 

 

Please complete and sign this form.

We must receive it by November 14, 2008.

 
   

 

Mail

 

 

UBS Financial Services Inc.

ATTN: ARS Group

1000 Harbor Boulevard

Weehawken, NJ 07086

 
   

 

Fax:

 

 

+1-201-442-7766

 
LOGO   Account owner signature  

/s/ illegible signature

              Date  

11/10/08

 

 

Additional party signature

 

 

 

 

 

            Date

 

 

 

 

 

Daytime telephone number

 

 

 

     
 

 

If you have questions, please contact your UBS Financial Advisor or Branch Manager at +1-312-525-4500.

 

Clients outside the U.S. may call +1-201-352-0105 collect.

 

We kindly request that you do not include comments or questions on this form as it could delay processing of your instructions.

 

UBS AG has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you make an investment decision, you should read the prospectus in that registration statement and other documents that UBS has filed with the SEC for more complete information about UBS and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov or by calling UBS’s ARSClient Service Center at +1-800-253-1974.

 

UBS Financial Services Inc. serves as the clearing firm for UBS International Inc. Accordingly, the information and terms contained in this letter and the accompanying materials are directed to clients of both UBS Financial Services Inc. and UBS International Inc.

 

  ©2008 UBS Financial Services Inc. All rights reserved. Member SIPC   1C-ARSO

LOGO

Exhibit 10.09

NOT SPECIFIED / OTHER

 

 

 

ASSISTANCE AGREEMENT

 

1. Award No.

 

  2. Modification No.   3. Effective Date   4. CFDA No.
DE-EE0002869      

12/28/2009

 

  81.087

5. Awarded To

 

  6. Sponsoring Office   7. Period of Performance

AMYRIS BIOTECHNOLOGIES, INC.

 

Attn: KINKEAD REILING

 

5885 HOLLIS STREET

 

SUITE 100

 

EMERYVILLE CA 94608-2059

 

 

Golden Field Office

 

U.S. Department of Energy

 

Golden Field Office

 

1617 Cole Blvd.

 

Golden CO 80401

 

 

12/28/2009

 

through

 

06/30/2012

8. Type of Agreement

 

  9. Authority   10. Purchase Request or Funding Document No.

¨   Grant

 

x  Cooperative Agreement

 

¨   Other

 

 

109-58 energy Policy Act (2005)

 

111-5 Recovery Act 2009

  10EE001851

11. Remittance Address

 

  12. Total Amount   13. Funds Obligated

AMYRIS BIOTECHNOLOGIES, INC.

 

Attn: KINKEAD REILING

 

5885 HOLLIS STREET

 

SUITE 100

 

EMERYVILLE CA 94608-2059

 

 

Govt. Share:    $24,341,409.00

 

Cost Share :     $10,489,762.00

 

Total :              $34,381,171.00

 

This action : $24,341,409.00

 

Total          : $24,341,409.00

14. Principal Investigator

 

  15. Program Manager   16. Administrator

Todd Pray

 

510-740-7441

 

Renae Viki Binstock

 

Phone: 303-275-6020

 

Golden Field Office

 

U.S. Department of Energy

 

Golden Field Office

 

1617 Cole Blvd.

 

Golden CO 80401-3393

 

17. Submit Payment Requests To

 

  18. Paying Office   19. Submit Reports To

OR for Golden

 

U.S. Department of Energy

 

Oak Ridge Financial Service Center

 

P.O. Box 4517

 

Oak Ridge TN 37831

 

       

20. Accounting and Appropriation Data

 

 

21. Research Title and/or Description of Project

 

RECOVERY ACT: SCALE-UP & MOBILIZATION OF RENEWABLE DIESEL & CHEMICAL PRODUCTION FROM COMMON INTERMEDIATE USING US-BASED FERMENTABLE SUGAR FEEDSTOCKS

 

For the Recipient

 

 

For the United States of America

 

22. Signature of Person Authorized to Sign   25. Signature of Grants/Agreements Officer
   
   

/s/ Michael A. Schledorn

 

 

23. Name and Title

 

 

24. Date Signed

 

 

26. Name of Officer

 

 

27. Date Signed

       
        Michael A. Schledorn  

12/30/2009

 

NOT SPECIFIED / OTHER


NOT SPECIFIED / OTHER
CONTINUATION SHEET            REFERENCE NO. OF DOCUMENT BEING CONTINUED    PAGE    OF     
   DE-EE0002869    2    3
NAME OF OFFEROR OR CONTRACTOR
AMYRIS BIOTECHNOLOGIES, INC.

  ITEM NO.    

  (A)    

 

  

SUPPLIES/SERVICES

(B)

  

  QUANTITY    

  (C)    

  

UNIT  

(D)  

  

  UNIT PRICE    

  (E)    

  

AMOUNT

(F)

    

DUNS Number: 185930182

“Electronic signature or signatures as used in this document means a method of signing an electronic message that—

(A) Identifies and authenticates a particular person as the source of the electronic message;

(B) Indicates such person’s approval of the information contained in the electronic message; and,

(C) Submission via FedConnect constitutes electronically signed documents.”

 

1. This is a conditional award, comprised of this Assistance Agreement and the Special Terms and Conditions. Upon successful completion of negotiations, this award will be modified to lift its conditional status, to revise the Special Terms and Conditions, and to add additional attachments, such as Attachment 1, Intellectual Property Provisions; Attachment 2, Statement of Project Objectives; Attachment 3, Federal Assistance Reporting Requirements; and Attachment 4, Budget Information - Non Construction Program

 

2. The award was prepared using the proposed budget information in the Recipient’s application. The Special Terms and Conditions, Provision 1 of the award states DOE will not release the funding obligated by this award until the Awardee submits a full application and subsequently requested supplemental information, the Contracting Officer reviews and approves the Awardee’s application and supplemental information, and completion of negotiations. Performance against this award is, therefore, at the Recipient’s own risk, and payments for costs incurred for the Recipient’s project will not be made until completion of negotiations.

 

3. The administrative office for this award is 03601. The administrative office (administrative contracting activity) code is needed by the recipient for reporting to FederalReporting.gov concerning awards made with funding from the American Recovery and Reinvestment Act of 2009 (ARRA or Recovery Act). Recipients must report to FederalReporting.gov by the 10th day of each quarter.

 

Continued ...

                   

NOT SPECIFIED / OTHER


NOT SPECIFIED / OTHER
CONTINUATION SHEET            REFERENCE NO. OF DOCUMENT BEING CONTINUED    PAGE    OF     
   DE-EE0002869/001    3    3
NAME OF OFFEROR OR CONTRACTOR
AMYRIS BIOTECHNOLOGIES, INC.

  ITEM NO.    

  (A)    

 

  

SUPPLIES/SERVICES

(B)

  

  QUANTITY    

  (C)    

  

UNIT  

(D)  

  

  UNIT PRICE    

  (E)    

  

AMOUNT

(F)

    

4. A representative of the DOE office will contact the Recipient to request additional and/or revised information needed to supplement and clarify the Recipient’s application, to complete the negotiations of an amended award.

 

DOE Award Administrator: Brenda Dias

             
    

E-mail:

     brenda.dias@go.doe.gov              
    

Phone:

     (303) 275-6043              
           
    

Recipient Business Officer: Karin Walker

             
    

E-mail:

     walker@amyris.com              
    

Phone:

     (510) 597-4734              
           
    

ASAP: NO Extent competed: COMPETED Davis-Bacon

             
    

Act: YES

Delivery Location Code: 03601

Golden Field Office

U.S. Department of Energy

Golden Field Office

1617 Cole Blvd.

Golden CO 80401-3393

 

Payment:

 

OR for Golden

U.S. Department of Energy

Oak Ridge Financial Service Center

P.O. Box 4517

Oak Ridge TN 37831

             
           
    

Fund: 05794 Appr Year: 2009 Allottee: 31 Report

Entity: 200835 Object Class: 41000 Program: 1004173 Project: 2004000 WFO: 0000000 Local Use: 0000000 TAS Agency: 89 TAS Account: 0331

 

 

 

                   
           
                                 
                               

JULY 2004

 

NOT SPECIFIED / OTHER


NOT SPECIFIED / OTHER

 

 

 

ASSISTANCE AGREEMENT

 

1. Award No.

 

  2. Modification No.   3. Effective Date   4. CFDA No.
DE-EE0002869   001  

12/28/2009

 

  81.087

5. Awarded To

 

  6. Sponsoring Office   7. Period of Performance

AMYRIS BIOTECHNOLOGIES, INC.

 

Attn: KINKEAD REILING

 

5885 HOLLIS STREET

 

SUITE 100

 

EMERYVILLE CA 946082059

 

 

Golden Field Office

 

U.S. Department of Energy

 

Golden Field Office

 

1617 Cole Blvd.

 

Golden CO 80401

 

12/28/2009

 

through

 

04/21/2010

8. Type of Agreement

 

  9. Authority   10. Purchase Request or Funding Document No.

¨   Grant

 

x  Cooperative Agreement

 

¨   Other

 

 

109-58 energy Policy Act (2005)

 

111-5 Recovery Act 2009

  10EE003166

11. Remittance Address

 

  12. Total Amount   13. Funds Obligated

AMYRIS BIOTECHNOLOGIES, INC.

 

Attn: KINKEAD REILING

 

SUITE 100

 

EMERYVILLE CA 946082059

 

 

Govt. Share: $24,341,409.00

 

Cost Share : $10,591,590.00

 

Total : $34,932,999.00

 

 

This action: $0.00

 

Total            :

$24,341,409.00

14. Principal Investigator

 

  15. Program Manager   16. Administrator

Neil Renninger

 

Phone: 510-740-7414

 

Renae Viki Binstock

 

Phone: 303-275-6020

 

Golden Field Office

 

U.S. Department of Energy

 

Golden Field Office

 

1617 Cole Blvd.

 

Golden CO 80401-3393

 

17. Submit Payment Requests To

 

  18. Paying Office   19. Submit Reports To

OR for Golden

 

U.S. Department of Energy

 

Oak Ridge Financial Service Center

 

P.O. Box 4517

 

Oak Ridge TN 37831

 

 

OR for Golden

 

U.S. Department of Energy

 

Oak Ridge Financial Service Center

 

P.O. Box 4517

 

Oak Ridge TN 37831

 

  See Attachment 3

20. Accounting and Appropriation Data

 

See Schedule

 

21. Research Title and/or Description of Project

 

RECOVERY ACT: SCALE-UP & MOBILIZATION OF RENEWABLE DIESEL & CHEMICAL PRODUCTION FROM COMMON INTERMEDIATE USING US-BASED FERMENTABLE SUGAR FEEDSTOCKS

 

For the Recipient

 

 

For the United States of America

 

22. Signature of Person Authorized to Sign   25. Signature of Grants/Agreements Officer
   
   

Signature on File

 

 

23. Name and Title

 

 

24. Date Signed

 

 

26. Name of Officer

 

 

27. Date Signed

       
        Michael A. Schledom   3/26/2010


 

NOT SPECIFIED / OTHER

 

CONTINUATION SHEET           

 

REFERENCE NO. OF DOCUMENT BEING CONTINUED

 

   PAGE    OF        
  

DE-EE0002869/001

 

   2    3

 

NAME OF OFFEROR OR CONTRACTOR

 

AMYRIS BIOTECHNOLOGIES, INC.

 

 

  ITEM NO.    

  (A)    

 

 

 

SUPPLIES/SERVICES

(B)

 

 

 

  QUANTITY    

  (C)    

 

 

 

  UNIT    

  (D)    

 

 

 

      UNIT PRICE        

      (E)        

 

 

 

AMOUNT

(F)

 

   

 

DUNS Number: 185930182

 

The administrative office (administrative contracting activity) for this modification is 03601 from STRIPES.

 

The administrative office (administrative contracting activity) code is needed by the contractor/recipient for reporting to FederalReporting.gov concerning awards made with funding from the American Recovery and Reinvestment Act of 2009 (ARRA or Recovery Act).

 

The purposes of this modification are to:

 

1) delete and replace the Special Terms and Conditions;

 

2) add the Intellectual Property Provisions, CDSB-1003 (Attachment 1);

 

3) add the Statement of Project Objectives (Attachment 2);

 

4) add the Federal Assistance Reporting Checklist and Instructions, DOE F 4600.2 (Attachment 3);

 

5) add the Budget Information, SF-424A (Attachment 4);

 

6) add the Requirements For Contingency Funds for Integrated Biorefinery Projects, Appendix (Attachment 5);

 

7) update the Recipient Contacts as shown below and in Block 14 of this Assistance Agreement; and

 

8) this modification approved both Budget Period 1 and Budget Period 2 of the project.

 

All other terms and conditions remain unchanged.

 

In Block 7 of the Assistance Agreement, the Period of Performance reflects the beginning of the Project Period through the end of the current Budget Period, shown as 12/28/2010 through 4/21/2010. For multiple Budget Periods, see Special Terms and Conditions, Provision 4, “Award Project Period and Budget Periods.”

 

DOE Award Administrator: Brenda Dias

E-mail: brenda.dias@go.doe.gov

Continued ...

 

Phone: (303) 275-6043

 

               


NOT SPECIFIED / OTHER


NOT SPECIFIED / OTHER
CONTINUATION SHEET    REFERENCE NO. OF DOCUMENT BEING CONTINUED   PAGE  OF
  

 

DE-EE0002869/001

  3            3
NAME OF OFFEROR OR CONTRACTOR       

 

AMYRIS BIOTECHNOLOGIES, INC.

        

  ITEM NO.    

(A)

  

SUPPLIES/SERVICES

(B)

  

QUANTITY    

(C)    

  

UNIT  

(D)   

  

UNIT PRICE    

(E)   

  

AMOUNT

(F)

    

 

DOE Project Officer: Renae Binstock

 

E-mail: renae.binstock@go.doe.gov

 

Phone: (303) 275-6020

 

Recipient Business Officer: Todd Pray

 

E-mail: pray@amyris.com

 

Phone: (510) 740-7441

 

Recipient Principal Investigator: Neil Renninger

 

E-mail: renninger@amyris.com

 

Phone: (510) 740-7414

 

“Electronic signature or signatures as used in this document means a method of signing an electronic message that —

 

(A) Identifies and authenticates a particular person as the source of the electronic message;

 

(B) Indicates such person’s approval of the information contained in the electronic message; and,

 

(C) Submission via FedConnect constitutes electronically signed documents.”

 

ASAP: NO Extent Competed: COMPETED Davis-Bacon

Act: YES

 

                   
                                               
                        

JULY 2004

 

             

NOT SPECIFIED / OTHER


DE-EE0002869/001

Attachment 1

 

CDSB-1003

Intellectual Property Provisions (CDSB-1003)

Cooperative Agreement - Special Data Statute

Research, Development, or Demonstration

Domestic Small Businesses

 

01. FAR 52.227-1    Authorization and Consent (JUL 1995) – Alternate I (APR 1984)
02. FAR 52.227-2    Notice and Assistance Regarding Patent and Copyright Infringement (AUG 1996)
  

This clause is not applicable if the award is for less than $100,000, in aggregate

03. 10 CFR 600.325

      Appendix A

   Rights in Data - Programs Covered Under Special Data Statutes (OCT 2003)
  

If the contracting officer, in consultation with DOE patent counsel and the DOE program official, determines that delivery of limited rights data or restricted computer software is necessary, Alternates I and II may be inserted into the clause after negotiations with the applicant.

04. FAR 52.227-23    Rights to Proposal Data (Technical) (JUN 1987)

05. 10 CFR 600.325

      Appendix A

   Patent Rights (Small Business Firms and Nonprofit Organizations (OCT 2003)

NOTE: In reading these provisions, any reference to “contractor” shall mean “recipient,” and any reference to “contract” or “subcontract” shall mean “award” or “subaward.”

 

01. FAR 52.227-1 Authorization and Consent (JUL 1995)-Alternate I (APR 1984)

(a)        The Government authorizes and consents to all use and manufacture of any invention described in and covered by a United States patent in the performance of this contract or any subcontract at any tier.

(b)        The Contractor agrees to include, and require inclusion of, this clause, suitably modified to identify the parties, in all subcontracts at any tier for research and development expected to exceed the simplified acquisition threshold; however, omission of this clause from any subcontract, including those at or below the simplified acquisition threshold, does not affect this authorization and consent.

 

1


(End of clause)

 

02. FAR 52.227-2 Notice and Assistance Regarding Patent and Copyright Infringement (AUG 1996)

(a)        The Contractor shall report to the Contracting Officer, promptly and in reasonable written detail, each notice or claim of patent or copyright infringement based on the performance of this contract of which the Contractor has knowledge.

(b)        In the event of any claim or suit against the Government on account of any alleged patent or copyright infringement arising out of the performance of this contract or out of the use of any supplies furnished or work or services performed under this contract, the Contractor shall furnish to the Government, when requested by the Contracting Officer, all evidence and information in possession of the Contractor pertaining to such suit or claim. Such evidence and information shall be furnished at the expense of the Government except where the Contractor has agreed to indemnify the Government.

(c)        The Contractor agrees to include, and require inclusion of, this clause in all subcontracts at any tier for supplies or services (including construction and architect-engineer subcontracts and those for material, supplies, models, samples, or design or testing services) expected to exceed the simplified acquisition threshold at FAR 2.101.

(End of clause)

03.    10 CFR 600.325 Appendix A, Rights in Data - Programs Covered Under Special Data Statutes (OCT 2003)

(a)        Definitions

Computer Data Bases, as used in this clause, means a collection of data in a form capable of, and for the purpose of, being stored in, processed, and operated on by a computer. The term does not include computer software.

Computer software, as used in this clause, means (i) computer programs which are data comprising a series of instructions, rules, routines, or statements, regardless of the media in which recorded, that allow or cause a computer to perform a specific operation or series of operations and (ii) data comprising source code listings, design details, algorithms, processes, flow charts, formulae and related material that would enable the computer program to be produced, created or compiled. The term does not include computer data bases.

Data, as used in this clause, means recorded information, regardless of form or the media on which it may be recorded. The term includes technical data and computer software. The term does not include information incidental to administration, such as financial, administrative, cost or pricing or management information.

Form, fit, and function data, as used in this clause, means data relating to items, components, or processes that are sufficient to enable physical and functional interchangeability

 

2


as well as data identifying source, size, configuration, mating and attachment characteristics, functional characteristics, and performance requirements except that for computer software it means data identifying source, functional characteristics, and performance requirements but specifically excludes the source code, algorithm, process, formulae, and flow charts of the software.

Limited rights data, as used in this clause, means data (other than computer software) developed at private expense that embody trade secrets or are commercial or financial and confidential or privileged.

Restricted computer software, as used in this clause, means computer software developed at private expense and that is a trade secret; is commercial or financial and confidential or privileged; or is published copyrighted computer software; including modifications of such computer software.

Protected data, as used in this clause, means technical data or commercial or financial data first produced in the performance of the award which, if it had been obtained from and first produced by a non-federal party, would be a trade secret or commercial or financial information that is privileged or confidential under the meaning of 5 U.S.C. 552(b)(4) and which data is marked as being protected data by a party to the award.

Protected rights, as used in this clause, mean the rights in protected data set forth in the Protected Rights Notice of paragraph (g) of this clause.

Technical data, as used in this clause, means that data which are of a scientific or technical nature. Technical data does not include computer software, but does include manuals and instructional materials and technical data formatted as a computer data base.

Unlimited rights, as used in this clause, means the right of the Government to use, disclose, reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, in any manner and for any purpose whatsoever, and to have or permit others to do so.

 

  (b) Allocation of Rights

(1)        Except as provided in paragraph (c) of this clause regarding copyright, the Government shall have unlimited rights in—

(i)        Data specifically identified in this agreement as data to be delivered without restriction;

(ii)       Form, fit, and function data delivered under this agreement;

(iii)      Data delivered under this agreement (except for restricted computer software) that constitute manuals or instructional and training material for installation, operation, or routine maintenance and repair of items, components, or processes delivered or furnished for use under this agreement; and

 

3


(iv)      All other data delivered under this agreement unless provided otherwise for protected data in accordance with paragraph (g) of this clause or for limited rights data or restricted computer software in accordance with paragraph (h) of this clause.

(2)        The Recipient shall have the right to—

(i)        Protect rights in protected data delivered under this agreement in the manner and to the extent provided in paragraph (g) of this clause;

(ii)       Withhold from delivery those data which are limited rights data or restricted computer software to the extent provided in paragraph (h) of this clause;

(iii)      Substantiate use of, add, or correct protected rights or copyrights notices and to take other appropriate action, in accordance with paragraph (e) of this clause; and

(iv)      Establish claim to copyright subsisting in data first produced in the performance of this agreement to the extent provided in subparagraph (c)(1) of this clause.

 

  (c) Copyright

(1)        Data first produced in the performance of this agreement. Except as otherwise specifically provided in this agreement, the Recipient may establish, without the prior approval of the Contracting Officer, claim to copyright subsisting in any data first produced in the performance of this agreement. If claim to copyright is made, the Recipient shall affix the applicable copyright notice of 17 U.S.C. 401 or 402 and acknowledgment of Government sponsorship (including agreement number) to the data when such data are delivered to the Government, as well as when the data are published or deposited for registration as a published work in the U.S. Copyright Office. For such copyrighted data, including computer software, the Recipient grants to the Government, and others acting on its behalf, a paid-up nonexclusive, irrevocable, worldwide license to reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, by or on behalf of the Government, for all such data.

(2)        Data not first produced in the performance of this agreement. The Recipient shall not, without prior written permission of the Contracting Officer, incorporate in data delivered under this agreement any data that are not first produced in the performance of this agreement and that contain the copyright notice of 17 U.S.C. 401 or 402, unless the Recipient identifies such data and grants to the Government, or acquires on its behalf, a license of the same scope as set forth in subparagraph (c)(1) of this clause; provided, however, that if such data are computer software, the Government shall acquire a copyright license as set forth in subparagraph (h)(3) of this clause if included in this agreement or as otherwise may be provided in a collateral agreement incorporated or made a part of this agreement.

 

4


(3)        Removal of copyright notices. The Government agrees not to remove any copyright notices placed on data pursuant to this paragraph (c), and to include such notices on all reproductions of the data.

 

  (d) Release, Publication and Use of Data

(1)        The Recipient shall have the right to use, release to others, reproduce, distribute, or publish any data first produced or specifically used by the Recipient in the performance of this contract, except to the extent such data may be subject to the Federal export control or national security laws or regulations, or unless otherwise provided in this paragraph of this clause or expressly set forth in this contract.

(2)        The Recipient agrees that to the extent it receives or is given access to data necessary for the performance of this agreement which contain restrictive markings, the Recipient shall treat the data in accordance with such markings unless otherwise specifically authorized in writing by the Contracting Officer.

 

  (e) Unauthorized Marking of Data

(1)        Notwithstanding any other provisions of this agreement concerning inspection or acceptance, if any data delivered under this agreement bears any restrictive or limiting markings or notices not authorized by this agreement, the Contracting Officer may at any time either return the data to the Recipient or cancel or ignore the markings. However, the following procedures shall apply prior to canceling or ignoring the markings.

(i)        The Contracting Officer shall make written inquiry to the Recipient affording the Recipient 30 days from receipt of the inquiry to provide written justification to substantiate the propriety of the markings;

(ii)       If the Recipient fails to respond or fails to provide written justification to substantiate the propriety of the markings within the 30-day period (or a longer time not exceeding 90 days approval in writing by the Contracting Officer for good cause shown), the Government shall have the right to cancel or ignore the markings at any time after said period and the data will no longer be made subject to any disclosure prohibitions.

(iii)      If the Recipient provides written justification to substantiate the propriety of the markings within the period set in subdivision (e)(1)(i) of this clause, the Contracting Officer shall consider such written justification and determine whether or not the markings are to be cancelled or ignored. If the Contracting Officer determines that the markings are authorized, the Recipient shall be so notified in writing. If the Contracting Officer determines, with concurrence of the head of the contracting activity, that the markings are not authorized, the Contracting Officer shall furnish the Recipient a written determination, which determination shall become the final agency decision regarding the appropriateness of the markings unless the Recipient files suit in a court of competent jurisdiction within 90 days of receipt of the Contracting

 

5


Officer’s decision. The Government shall continue to abide by the markings under this subdivision (e)(1)(iii) until final resolution of the matter either by the Contracting Officer’s determination become final (in which instance the Government shall thereafter have the right to cancel or ignore the markings at any time and the data will no longer be made subject to any disclosure prohibitions), or by final disposition of the matter by court decision if suit is filed.

(2)        The time limits in the procedures set forth in subparagraph (e)(1) of this clause may be modified in accordance with agency regulations implementing the Freedom of Information Act (5 U.S.C. 552) if necessary to respond to a request thereunder.

 

  (f) Omitted or Incorrect Markings

(1)        Data delivered to the Government, without any restrictive or limiting markings or notices authorized by this agreement, shall be deemed to have been furnished with unlimited rights, and the Government assumes no liability for the disclosure, use, or reproduction of such data. However, to the extent the data has not been disclosed without restriction outside the Government, the Recipient may request, within 6 months (or a longer time approved by the Contracting Officer for good cause shown) after delivery of such data, permission to have notices placed on qualifying data at the Recipient’s expense, and the Contracting Officer may agree to do so if the Recipient—

(i)        Identifies the data to which the omitted notice is to be applied;

(ii)       Demonstrates that the omission of the notice was inadvertent;

(iii)      Establishes that the use of the proposed notice is authorized; and

(iv)      Acknowledges that the Government has no liability with respect to the disclosure, use, or reproduction of any such data made prior to the addition of the notice or resulting from the omission of the notice.

(2)        The Contracting Officer may also:

(i)        Permit correction at the Recipient’s expense of incorrect notices if the Recipient identifies the data on which correction of the notice is to be made, and demonstrates that the correct notice is authorized; or

(ii)       Correct any incorrect notices.

 

  (g) Rights to Protected Data:

(1)        The Recipient may, with the concurrence of DOE, claim and mark as protected data, any data first produced in the performance of this award that would have been treated as a trade secret if developed at private expense. Any such claimed “Protected Data” will be clearly marked with the following Protected Rights Notice, and

 

6


will be treated in accordance with such Notice, subject to the provisions of paragraphs (e) and (f) of this clause.

PROTECTED RIGHTS NOTICE

These protected data were produced under Agreement No. DE-EE0002869 with the U.S. Department of Energy and may not be published, disseminated, or disclosed to others outside the Government until unless express written authorization is obtained from the recipient. Upon expiration of the period of protection set forth in this Notice, the Government shall have unlimited rights in this data. This Notice shall be marked on any reproduction of this data, in whole or in part. (End of notice).

(2)        Any such marked Protected Data may be disclosed under obligations of confidentiality for the following purposes:

(a)        For internal DOE evaluation and planning purposes under the restriction that the Protected Data be retained in confidence and not be further disclosed; or

(b)        To DOE staff members or authorized DOE contractors or subcontractors performing work under the Government’s program under the restriction that the Protected Data be retained in confidence and not be further disclosed.

(3)        The obligations of confidentiality and restrictions on publication and dissemination shall end for any Protected Data:

(a)        At the end of the protected period;

(b)        If the data become publicly known or available from other sources without a breach of the obligation of confidentiality with respect to the Protected Data;

(c)        If the same data are independently developed by someone who did not have access to the Protected Data and such data are made available without obligations of confidentiality; or

(d)        If the Recipient disseminates or authorizes another to disseminate such data without obligations of confidentiality.

(4)        However, the Recipient agrees that the following types of data are not considered to be protected and shall be provided to the Government when required by this award without any claim that the data are Protected Data: General test results and data that demonstrate progress toward meeting DOE’s technical goals to design, construct, build, and operate a demonstration- or pilot-scale integrated biorefinery employing lignocellulosic or algal feedstocks, and in certain special cases starch feedstocks, for the production of (i) liquid transportation fuels, (ii) biobased chemicals, products or co-products, or (iii) substitutes for petroleum-based feedstocks and products. These results and data will be made available to the public and included in the final project report, and in other reports and presentations, as appropriate. The parties agree that notwithstanding the data enumerated above, nothing precludes the Government from

 

7


seeking delivery of additional data in accordance with this award, or from making publicly available additional nonprotected data, nor does the preceding enumerated data constitute any admission by the Government that technical data not so enumerated are Protected Data. The general data described above shall not include the following types of data, which Recipient intends, without limitation, to claim and mark as Protected Data:

(a)        Process Flow Diagrams

(b)        Mass & Energy Balances

(c)        Process Performance Parameters and Costs by Unit Operation, including the quality of the data used for those performance parameters, (e.g., scale, replication, degree of integration, range of values, etc.)

(d)        Capital Cost Estimate and Basis thereof: e.g. factored, vendor quotes, actual purchase prices, etc.

(e)        Pro Forma with best reproducible results to date with all assumptions listed and the basis/rationale behind all pro forma input parameters explained, including but not necessarily limited to:

(i)        Production cost parameters: e.g. consumables, utilities, labor, etc.

(ii)       Water consumption requirements and costs

(iii)      Waste disposal requirements and costs

(f)        Any additional financial and technical project information necessary and sufficient to validate the current and actual conversion costs associated with the facility or system as constructed and projected to be operated for converting lignocellulosic or algal feedstocks, and in certain special cases starch feedstocks, into (i) liquid transportation fuels, or (ii) biobased chemicals, products or co-products, or (iii) substitutes for petroleum-based feedstocks and products.

(g)        Technical results based on data collected, to enable the analysis, assessment and evaluation of other areas of interest, including but not necessarily limited to life cycle assessments, green house gas emissions, and sustainability metrics.

(5)        The Government’s sole obligation with respect to any protected data shall be as set forth in this paragraph (g).

(h)        Protection of Limited Rights Data

(1)        When data other than that listed in subparagraphs (b)(1)(i), (ii), and (iii) of this clause are specified to be delivered under this agreement and such data qualify as either limited rights data or restricted computer software, the Recipient, if the Recipient desires to continue protection of such data, shall withhold such data and not furnish them to the Government under this agreement. As a condition to this withholding the

 

8


Recipient shall identify the data being withheld and furnish form, fit, and function data in lieu thereof.

(2)        Notwithstanding subparagraph (h)(1) of this clause, the agreement may identify and specify the delivery of limited rights data, or the Contracting Officer may require by written request the delivery of limited rights data that has been withheld or would otherwise be withholdable. If delivery of such data is so required, the Recipient may affix the following “Limited Rights Notice” to the data and the Government will thereafter treat the data, in accordance with such Notice:

LIMITED RIGHTS NOTICE

(a)        These data are submitted with limited rights under Government Agreement No. DE-EE0002869 (and subaward/contract No.             , if appropriate). These data may be reproduced and used by the Government with the express limitation that they will not, without written permission of the Recipient, be used for purposes of manufacture nor disclosed outside the Government; except that the Government may disclose these data outside the Government for the following purposes, if any, provided that the Government makes such disclosure subject to prohibition against further use and disclosure:

(1)        Use (except for manufacture) by Federal support services contractors within the scope of their contracts;

(2)        These “limited rights data” may be disclosed for evaluation purposes under the restriction that the “limited rights data” be retained in confidence and not be further disclosed;

(3)        These “limited rights data” may be disclosed to other contractors participating in the Government’s program, of which this Recipient is a part, for information or use (except for manufacture) in connection with the work performed under their awards, and under the restriction that the “limited rights data” be retained in confidence and not be further disclosed;

(4)        These “limited rights data” may be used by the Government or others on its behalf for emergency repair or overhaul work under the restriction that the “limited rights data” be retained in confidence and not be further disclosed; and

(5)        Release to a foreign government, or instrumentality thereof, as the interests of the United States Government may require, for information or evaluation, or for emergency repair or overhaul work by such government.

(b)        This Notice shall be marked on any reproduction of these data, in whole or in part.

(End of notice)

(i) Subaward/Contract

 

9


The Recipient has the responsibility to obtain from its subrecipients/contractors all data and rights therein necessary to fulfill the Recipient’s obligations to the Government under this agreement. If a subrecipient/contractor refuses to accept terms affording the Government such rights, the Recipient shall promptly bring such refusal to the attention of the Contracting Officer and not proceed with subaward/contract award without further authorization.

(j)        Additional Data Requirements

In addition to the data specified elsewhere in this agreement to be delivered, the Contracting Officer may, at anytime during agreement performance or within a period of 3 years after acceptance of all items to be delivered under this agreement, order any data first produced or specifically used in the performance of this agreement. This clause is applicable to all data ordered under this subparagraph. Nothing contained in this subparagraph shall require the Recipient to deliver any data the withholding of which is authorized by this clause or data which are specifically identified in this agreement as not subject to this clause. When data are to be delivered under this subparagraph, the Recipient will be compensated for converting the data into the prescribed form, for reproduction, and for delivery.

(k)       The Recipient agrees, except as may be otherwise specified in this agreement for specific data items listed as not subject to this paragraph, that the Contracting Officer or an authorized representative may, up to 3 years after acceptance of all items to be delivered under this contract, inspect at the Recipient’s facility any data withheld pursuant to paragraph (h) of this clause, for purposes of verifying the Recipient’s assertion pertaining to the limited rights or restricted rights status of the data or for evaluating work performance. Where the Recipient whose data are to be inspected demonstrates to the Contracting Officer that there would be a possible conflict of interest if the inspection were made by a particular representative, the Contracting Officer shall designate an alternate inspector.

(End of clause)

 

04. FAR 52.227-23 Rights to Proposal Data (Technical) (JUN 1987)

Except for data contained on pages 1-15 of the Project Narrative, it is agreed that as a condition of award of this contract, and notwithstanding the conditions of any notice appearing thereon, the Government shall have unlimited rights (as defined in the “Rights in Data—General” clause contained in this contract) in and to the technical data contained in the proposal dated June 30, 2009, upon which this contract is based.

05.    10 CFR 600.325 Appendix A, Patent Rights (Small Business Firms and Nonprofit Organizations) (OCT 2003)

(a)        Definitions

Invention means any invention or discovery which is or may be patentable or otherwise protectable under title 35 of the United States Code, or any novel variety of plant which is or may be protected under the Plant Variety Protection Act (7 U.S.C. 2321 et seq.).

 

10


Made when used in relation to any invention means the conception or first actual reduction to practice of such invention.

Nonprofit organization means a university or other institution of higher education or an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 U.S.C. 501(a)) or any nonprofit scientific or educational organization qualified under a State nonprofit organization statute.

Practical application means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system; and, in each case, under such conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or Government regulations available to the public on reasonable terms.

Small business firm means a small business concern as defined at section 2 of Public Law 85-536 (16 U.S.C. 632) and implementing regulations of the Administrator of the Small Business Administration. For the purpose of this clause, the size standards for small business concerns involved in Government procurement and subcontracting at 13 CFR 121.3 through 121.8 and 13 CFR 121.3 through 121.12, respectively, will be used.

Subject invention means any invention of the Recipient conceived or first actually reduced to practice in the performance of work under this award, provided that in the case of a variety of plant, the date of determination (as defined in section 41(d) of the Plant Variety Protection Act, 7 U.S.C. 2401(d) must also occur during the period of award performance.

(b)        Allocation of Principal Rights

The Recipient may retain the entire right, title, and interest throughout the world to each subject invention subject to the provisions of this Patent Rights clause and 35 U.S.C. 203. With respect to any subject invention in which the Recipient retains title, the Federal Government shall have a non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the U.S. the subject invention throughout the world.

(c)        Invention Disclosure, Election of Title and Filing of Patent Applications by Recipient

(1)        The Recipient will disclose each subject invention to DOE within two months after the inventor discloses it in writing to Recipient personnel responsible for the administration of patent matters. The disclosure to DOE shall be in the form of a written report and shall identify the award under which the invention was made and the inventor(s). It shall be sufficiently complete in technical detail to convey a clear understanding to the extent known at the time of disclosure, of the nature, purpose, operation, and the physical, chemical, biological or electrical characteristics of the invention. The disclosure shall also identify any publication, on sale or public use of the invention and whether a manuscript describing the invention has been submitted for publication and, if so, whether it has been accepted for publication at the time of disclosure. In addition, after disclosure to DOE, the Recipient will promptly notify DOE

 

11


of the acceptance of any manuscript describing the invention for publication or of any on sale or public use planned by the Recipient.

(2)        The Recipient will elect in writing whether or not to retain title to any such invention by notifying DOE within two years of disclosure to DOE. However, in any case where publication, on sale, or public use has initiated the one year statutory period wherein valid patent protection can still be obtained in the U.S., the period for election of title may be shortened by the agency to a date that is no more than 60 days prior to the end of the statutory period.

(3)        The Recipient will file its initial patent application on an invention to which it elects to retain title within one year after election of title or, if earlier, prior to the end of any statutory period wherein valid patent protection can be obtained in the U.S. after a publication, on sale, or public use. The Recipient will file patent applications in additional countries or international patent offices within either ten months of the corresponding initial patent application, or six months from the date when permission is granted by the Commissioner of Patents and Trademarks to file foreign patent applications when such filing has been prohibited by a Secrecy Order.

(4)        Requests for extension of the time for disclosure to DOE, election, and filing under subparagraphs (c)(1), (2), and (3) of this clause may, at the discretion of DOE, be granted.

(d)        Conditions When the Government May Obtain Title

The Recipient will convey to DOE, upon written request, title to any subject invention:

(1)        If the Recipient fails to disclose or elect the subject invention within the times specified in paragraph (c) of this patent rights clause, or elects not to retain title; provided that DOE may only request title within 60 days after learning of the failure of the Recipient to disclose or elect within the specified times;

(2)        In those countries in which the Recipient fails to file patent applications within the times specified in paragraph (c) of this Patent Rights clause; provided, however, that if the Recipient has filed a patent application in a country after the times specified in paragraph (c) of this Patent Rights clause, but prior to its receipt of the written request of DOE, the Recipient shall continue to retain title in that country; or

(3)        In any country in which the Recipient decides not to continue the prosecution of any application for, to pay the maintenance fees on, or defend in a reexamination or opposition proceeding on, a patent on a subject invention.

(e)        Minimum Rights to Recipient and Protection of the Recipient Right to File

(1)        The Recipient will retain a non-exclusive royalty-free license throughout the world in each subject invention to which the Government obtains title, except if the Recipient fails to disclose the subject invention within the times specified in paragraph (c) of this Patent Rights clause. The Recipient’s license extends to its

 

12


domestic subsidiaries and affiliates, if any, within the corporate structure of which the Recipient is a party and includes the right to grant sublicenses of the same scope of the extent the Recipient was legally obligated to do so at the time the award was awarded. The license is transferable only with the approval of DOE except when transferred to the successor of that part of the Recipient’s business to which the invention pertains.

(2)        The Recipient’s domestic license may be revoked or modified by DOE to the extent necessary to achieve expeditious practical application of the subject invention pursuant to an application for an exclusive license submitted in accordance with applicable provisions at 37 CFR part 404 and the agency’s licensing regulation, if any. This license will not be revoked in that field of use or the geographical areas in which the Recipient has achieved practical application and continues to make the benefits of the invention reasonably accessible to the public. The license in any foreign country may be revoked or modified at discretion of the funding Federal agency to the extent the Recipient, its licensees, or its domestic subsidiaries or affiliates have failed to achieve practical application in that foreign country.

(3)        Before revocation or modification of the license, the funding Federal agency will furnish the Recipient a written notice of its intention to revoke or modify the license, and the Recipient will be allowed thirty days (or such other time as may be authorized by DOE for good cause shown by the Recipient) after the notice to show cause why the license should not be revoked or modified. The Recipient has the right to appeal, in accordance with applicable regulations in 37 CFR part 404 and the agency’s licensing regulations, if any, concerning the licensing of Government-owned inventions, any decision concerning the revocation or modification of its license.

(f)        Recipient Action to Protect Government’s Interest

(1)        The Recipient agrees to execute or to have executed and promptly deliver to DOE all instruments necessary to:

(i)        Establish or confirm the rights the Government has throughout the world in those subject inventions for which the Recipient retains title; and

(ii)        Convey title to DOE when requested under paragraph (d) of this Patent Rights clause, and to enable the government to obtain patent protection throughout the world in that subject invention.

(2)        The Recipient agrees to require, by written agreement, its employees, other than clerical and non-technical employees, to disclose promptly in writing to personnel identified as responsible for the administration of patent matters and in a format suggested by the Recipient each subject invention made under this award in order that the Recipient can comply with the disclosure provisions of paragraph (c) of this Patent Rights clause, and to execute all papers necessary to file patent applications on subject inventions and to establish the Government’s rights in the subject inventions. The disclosure format should require, as a minimum, the information requested by paragraph (c)(1) of this Patent Rights clause. The Recipient shall instruct such

 

13


employees through the employee agreements or other suitable educational programs on the importance of reporting inventions in sufficient time to permit the filing of patent applications prior to U.S. or foreign statutory bars.

(3)        The Recipient will notify DOE of any decision not to continue prosecution of a patent application, pay maintenance fees, or defend in a reexamination or opposition proceeding on a patent, in any country, not less than 30 days before the expiration of the response period required by the relevant patent office.

(4)        The Recipient agrees to include, within the specification of any U.S. patent application and any patent issuing thereon covering a subject invention, the following statement: “This invention was made with Government support under (identify the award) awarded by (identify DOE). The Government has certain rights in this invention.”

(g)        Subaward/Contract

(1)        The Recipient will include this Patent Rights clause, suitably modified to identify the parties, in all subawards/contracts, regardless of tier, for experimental, developmental or research work to be performed by a small business firm or nonprofit organization. The subrecipient/contractor will retain all rights provided for the Recipient in this Patent Rights clause, and the Recipient will not, as part of the consideration for awarding the subcontract, obtain rights in the subcontractors’ subject inventions.

(2)        The Recipient will include in all other subawards/contracts, regardless of tier, for experimental, developmental or research work, the patent rights clause required by 10 CFR 600.325(c).

(3)        In the case of subawards/contracts at any tier, DOE, the Recipient, and the subrecipient/contractor agree that the mutual obligations of the parties created by this clause constitute a contract between the subrecipient/contractor and DOE with respect to those matters covered by the clause.

(h)        Reporting on Utilization of Subject Inventions

The Recipient agrees to submit on request periodic reports no more frequently than annually on the utilization of a subject invention or on efforts at obtaining such utilization that are being made by the Recipient or its licensees or assignees. Such reports shall include information regarding the status of development, date of first commercial sale or use, gross royalties received by the Recipient and such other data and information as DOE may reasonably specify. The Recipient also agrees to provide additional reports in connection with any march-in proceeding undertaken by DOE in accordance with paragraph (j) of this Patent Rights clause. As required by 35 U.S.C. 202(c)(5), DOE agrees it will not disclose such information to persons outside the Government without the permission of the Recipient.

 

14


(i)        Preference for United States Industry.

Notwithstanding any other provision of this Patent Rights clause, the Recipient agrees that neither it nor any assignee will grant to any person the exclusive right to use or sell any subject invention in the U.S. unless such person agrees that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the U.S. However, in individual cases, the requirement for such an agreement may be waived by DOE upon a showing by the Recipient or its assignee that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible.

(j)        March-in-Rights

The Recipient agrees that with respect to any subject invention in which it has acquired title, DOE has the right in accordance with procedures at 37 CFR 401.6 and any supplemental regulations of the Agency to require the Recipient, an assignee or exclusive licensee of a subject invention to grant a non-exclusive, partially exclusive, or exclusive license in any field of use to a responsible applicant or applicants, upon terms that are reasonable under the circumstances and if the Recipient, assignee, or exclusive licensee refuses such a request, DOE has the right to grant such a license itself if DOE determines that:

(1)        Such action is necessary because the Recipient or assignee has not taken or is not expected to take within a reasonable time, effective steps to achieve practical application of the subject invention in such field of use;

(2)        Such action is necessary to alleviate health or safety needs which are not reasonably satisfied by the Recipient, assignee, or their licensees;

(3)        Such action is necessary to meet requirements for public use specified by Federal regulations and such requirements are not reasonably satisfied by the Recipient, assignee, or licensee; or

(4)        Such action is necessary because the agreement required by paragraph (i) of this Patent Rights clause has not been obtained or waived or because a licensee of the exclusive right to use or sell any subject invention in the U.S. is in breach of such agreement.

(k)        Special Provisions for Awards with Nonprofit Organizations

If the Recipient is a nonprofit organization, it agrees that:

(1)        Rights to a subject invention in the U.S. may not be assigned without the approval of DOE, except where such assignment is made to an organization which has as one of its primary functions the management of inventions, provided that such assignee will be subject to the same provisions as the Recipient;

 

15


(2)        The Recipient will share royalties collected on a subject invention with the inventor, including Federal employee co-inventors (when DOE deems it appropriate) when the subject invention is assigned in accordance with 35 U.S.C. 202(e) and 37 CFR 401.10;

(3)        The balance of any royalties or income earned by the Recipient with respect to subject inventions, after payment of expenses (including payments to inventors) incidental to the administration of subject inventions, will be utilized for the support of scientific or engineering research or education; and

(4)        It will make efforts that are reasonable under the circumstances to attract licensees of subject inventions that are small business firms and that it will give preference to a small business firm if the Recipient determines that the small business firm has a plan or proposal for marketing the invention which, if executed, is equally likely to bring the invention to practical application as any plans or proposals from applicants that are not small business firms; provided that the Recipient is also satisfied that the small business firm has the capability and resources to carry out its plan or proposal.

The decision whether to give a preference in any specific case will be at the discretion of the Recipient. However, the Recipient agrees that the Secretary of Commerce may review the Recipient’s licensing program and decisions regarding small business applicants, and the Recipient will negotiate changes to its licensing policies, procedures or practices with the Secretary when the Secretary’s review discloses that the Recipient could take reasonable steps to implement more effectively the requirements of this paragraph (k)(4).

(l)        Communications

All communications required by this Patent Rights clause should be sent to the DOE Patent Counsel address listed in the Award Document.

(m)      Electronic Filing

Unless otherwise Specified in the award, the information identified in paragraphs (f)(2) and (f)(3) may be electronically filed.

[End of clause]

 

16


DE-EE0002869/001

Attachment 2

STATEMENT OF PROJECT OBJECTIVES

Amyris Biotechnologies, Inc.

Recovery Act: Scale-up and Mobilization of Renewable Diesel and Chemical Production from Common

Intermediate using US-based Fermentable Sugar Feedstocks

A.     PROJECT OBJECTIVES

The Amyris pilot-scale Integrated Biorefinery (IBR) will leverage and upgrade Amyris’s existing Emeryville, California pilot plant and support labs to develop US-based production capabilities for No Compromise ® renewable diesel fuel and petrochemical substitutes such as lubricants and polymers. These products will be derived semi-synthetically from high-impact biomass feedstocks via microbial fermentation to the same 15-carbon isoprenoid intermediate and subsequent chemical finishing. In particular, Amyris will adapt its current sugarcane juice-based processes to instead utilize sweet sorghum juice and lignocellulosic sugars as a domestic feedstock alternative. To this end, the Amyris IBR team will prepare standard operating procedures (SOPs) for diesel and chemical manufacturing from sweet sorghum, and potentially other high-impact feedstocks, at pilot scale. This will enable robust ongoing techno-economic analysis (TEA), regulatory approvals, and a conceptual design for demonstration- and commercial-scale manufacturing facilities at project closure.

B.     PROJECT SCOPE

The primary product of the Amyris IBR is Amyris Renewable Diesel. Secondary products will include lubricants, polymers and other petro-chemical substitutes. Amyris and its project partners will execute on a rapid project to integrate and leverage their collective expertise to enable the conversion of high-impact biomass feedstocks to these advanced, infrastructure-compatible products. Amyris will perform large scale contract manufacturing for process and product testing to support regulatory and end-user acceptance for domestic production and utilization. Amyris will double the fermentation capacity at its pilot plant and add significant functionality to enable more flexible sugar-stream handling and product finishing unit operations.

For Amyris’s IBR project the key feedstock focus will be the utilization of sweet sorghum in collaboration with project partners. The team will plant and harvest sweet sorghum within existing agricultural footprints, concentrate juice to syrup and ship syrup to Amyris and bagasse to Amyris’s pretreatment partner. Sweet sorghum bagasse pretreatment conditions will be developed first at lab scale and then at pilot scale, based on feedback from Amyris regarding fermentation performance using different bagasse-derived sugar streams. Other lignocellulosic sugar streams are options as well, either as risk mitigation for sweet sorghum or as feedstock alternatives once sweet sorghum has been validated. Continuing to use its defined media and cane juice-based fermentation processing as reference points, Amyris will optimize sweet sorghum juice- and lignocellulosic sugar-based C15 production in its pilot plant and support labs using its suite of C6 sugar-utilizing Saccharomyces cerevisiae yeast strains. For downstream integration with product finishing and to utilize unfermented C5 sugars from bagasse, fermentation effluent vinasse will be treated by anaerobic digestion for biogas production.


DE-EE0002869/001

Attachment 2

 

Biogas cleanup procedures will be developed and modeled for production of highly pure methane for conversion to hydrogen – a key component for Amyris product finishing – via steam-methane reformation.

Development of alternative products, in addition to diesel, is a core focus of the Amyris IBR project, with both scale-up efforts relying on a robust TEA. Amyris will leverage a variety of vendors with expertise in large-scale production and fuel and chemical product testing to support product acceptance objectives. Supplementing existing product approvals from 20% Amyris Diesel to higher blend percentages and additional products is a focus area. Finally, readying Amyris from a regulatory standpoint for domestic manufacturing will be a component of this IBR project.

C.      TASKS TO BE PERFORMED

Task A.0  Amyris Pilot Plant Upgrades and Operations

Unit operation upgrades and capacity augmentation for both fermentation and chemical processing at Amyris’s existing Emeryville pilot plant form a core component of this IBR project. During the two budget periods of the project Amyris will leverage its experience in pilot plant design, construction and operation to rapidly execute with minimal incremental permitting required. In particular, Amyris anticipates little or no downtime of ongoing pilot operations during upgrade design and installation.

Subtask A.1  Amyris pilot plant upgrade design and approvals (Budget period 1 (BP1))

Amyris has scoped initial facility design and will rapidly move to complete this effort. Equipment has already been selected and a general contractor has been engaged. Working with the Department of Energy (DOE) Amyris will adapt a risk management plan from the original construction and initial startup of the pilot plant in 2008 and ensure that necessary permitting is completed.

During the design phase Amyris’ pilot plant will continue to operate with current capacity using defined media and real-world feedstocks, such as cane syrup, in order to prototype and develop standard operating procedures (SOPs) and performance metrics for adaptation to sorghum utilization.

Subtask A.2  Amyris pilot plant upgrade installation (BP2)

This subtask will include construction and installation activities. Fermentors have the longest lead time and will most likely require nine months for delivery. Other unit operations for downstream processing and upstream feedstock handling will be installed earlier and as delivered pending construction completion in relevant process areas.

Amyris’s pilot plant will begin handling sweet sorghum-derived feedstreams from a contractor to develop early benchmark data and validate performance targets. During the course of upgrading the pilot plant facility, Amyris will continue ongoing operations and prototyping with defined media and cane-derived feedstreams to simulate and facilitate conversion of sorghum sugars to finished products. This will be accomplished using Amyris’s existing pilot plant capacity and by integrating with additional unit operations as they come online.

 

2


DE-EE0002869/001

Attachment 2

 

Subtask A.3  Post-upgrade Amyris pilot plant operations (BP2)

Following installation and commissioning of pilot plant upgrades, Amyris will operate the pilot plant to produce comprehensive technical, operating and financial data facilitating conceptual design of a demonstration or commercial scale facility acceptable to DOE.

In addition to developing sweet sorghum pilot scale data, this operations phase will include continuing work with simulated sorghum juice (defined media) and cane-derived feedstreams to maintain reference processes in which the Amyris team has demonstrated consistent performance both in terms of communication and reporting. Current in-process controls and SOPs will be expanded upon to ensure continued robust data collection and safe operations, leading to enabling data for the design of a US commercial plant using sweet sorghum or other high-impact feedstocks.

Task B.0  Scale-up and economic analysis of Amyris diesel production from sweet sorghum

To complement the pilot plant upgrades and operations in Task 1, Amyris and partners will focus significant effort on process optimization and integration from feedstock to final diesel product finishing processes and waste treatment.

Subtask B.1  Sweet sorghum development, syrup and bagasse production (BP1-2)

Amyris’s partner will provide both sweet sorghum bagasse and syrup to support integrated processing to Amyris Renewable Diesel. This feedstock partner will manage all aspects of feedstock development and handling including land management, planting within existing agricultural footprints, harvesting, bagasse drying and juice concentration to syrup. They will ship syrup samples to Amyris and will also ship chopped and dried bagasse for lignocellulosic biomass pre-treatment to Amyris’s pre-treatment partner.

Subtask B.2  Lignocellulosic pre-treatment development and scale-up (BP2)

Following receipt of dried, chopped biomass from sweet sorghum or other feedstocks Amyris’s pretreatment partner will undertake three key research and development and scale-up activities. First, they will perform wet chemical compositional analysis of each biomass lot. Second, the partner will undertake parametric pilot-scale pretreatment studies to determine the effect of varying pretreatment conditions on hemi-cellulose conversion yields, enzymatic cellulose digestibility and fermentation performance at Amyris. Third, they will perform pilot-scale pretreatment and enzymatic hydrolysis campaigns to produce concentrated sugar solutions. These sugar streams will be shipped to Amyris for fermentation and downstream process performance testing and scale-up.

Subtask B.3  Fermentation scale-up (BP1-2)

Utilization of sugar streams from such sources as lignocellulosic bagasse and sweet sorghum syrup, as well as other potential feedstocks will result in significant need for medium optimization. This includes optimization of pre-treatment steps to precipitate undesired species, removal of particulates, and sterilization of the medium, as well as supplementation of trace nutrients needed for cost-effective gains in fermentation yield. Additionally, converting current processes to use syrup and lignocellulosic fermentable sugars will likely require significant changes to pre-fermentation handling of sugar streams as well as to operating conditions for fermentation itself.

 

3


DE-EE0002869/001

Attachment 2

 

Initially Amyris will acquire baseline fermentation process data using sweet sorghum syrup and bagasse sugar streams, along with defined and cane-derived media, in its support labs. Later in the project Amyris will develop sweet sorghum SOPs for comparison to cane-based media performance in terms of product yield and sugar utilization rates. Throughout the project Amyris will test S. cerevisiae yeast strains to monitor relative and absolute performance comparing production from defined, cane-derived and sweet sorghum-based media.

Subtask B.4  Anaerobic digestion development and hydrogen production (BP2)

In collaboration with partners, Amyris will develop and optimize an integrated hydrogen production process to utilize residual unfermented C5 sugars from fermentation effluent. This effluent, vinasse, will be exposed to one or two anaerobic digestion conditions for biogas production. Amyris will then lead collaborative efforts to develop and model proper biogas cleanup procedures to ensure effective conversion of methane to hydrogen via steam methane reforming.

Subtask B.5  Recovery, purification and diesel finishing scale-up (BP1-2)

Recovery yield and purity indicators will drive scale-up and process optimization for isolation of the water-immiscible C15 isoprenoid oil phase from fermentation broth aqueous phase and solids components. Various product recovery unit operations will be adapted from defined media and cane syrup-based fermentation recovery processes and tested with sorghum syrup and bagasse sugar-derived media. Amyris will first focus on developing baseline recovery data from sorghum media relative to defined and cane-based fermentations. Later, Amyris will optimize and scale robust recovery processes with sorghum or other feedstocks.

The current base-case chemical finishing process for Amyris Diesel is catalytic hydrogenation of the C15 fermentation intermediate. Product yields are high under current process conditions, and the Amyris team will validate that sweet sorghum utilization in fermentation does not result in degradation of hydrogenation specificity and yield via impurities carried over from recovery. In addition, process engineering expertise will be required to test and ensure that potential impurities identified during biogas clean-up and hydrogen production do not impact final Amyris Diesel quality or cost.

Subtask B.6  TEA and LCA for Amyris Diesel production (BP1-2)

Amyris will lead efforts to merge pre-treatment process models with sugar-to-diesel conversion for an overall TEA of the integrated process for sweet sorghum conversion to Amyris Diesel using Aspen Plus and other software tools. In addition, life cycle analyses (LCA) will be further refined to reflect up-todate process configuration and conceptual designs for commercial scale production.

Task C.  Development and scale-up of value-added products from diesel fermentation intermediate

The third task in this project focuses on the use of the C15 isoprenoid fermentation product used for diesel production as a raw material for the synthesis of a number of large-market, high-value chemicals. The work required in this task will be divided into the following sections:

 

4


DE-EE0002869/001

Attachment 2

 

Subtask C.1  Laboratory-scale development and chemical product synthesis (BP1-2)

High-volume or high-value market needs that are amenable to solutions using the C15 isoprenoid fermentation product will be identified. Scientific literature searches will be continuously performed to determine prior art for candidate product molecules. If patented, Amyris will evaluate whether these patents and patent applications would pose freedom to operate issues to Amyris. Screening experiments on a small (e.g. grams or less) scale will be used to identify an effective (but not necessarily optimum) synthesis and a full characterization of the product. The initial synthesis may have to be scaled up to tens of grams depending on the sample amounts required for any performance testing. Design and initial synthesis of a target product will be followed by comprehensive product and byproduct characterization and application-related product property testing.

Subtask C.2  Mid-scale synthesis and characterization (BP2)

Initial scale-up/optimization will be accomplished by using statistical design of experiments to identify and optimize the important process variables with a minimum number of experiments. This will provide an optimized scaled process for each candidate chemical product that will allow for a preliminary cost assessment, a safety evaluation and a process design that can be the basis of preparing a SOP for technology transfer to the pilot plant. In addition, it will provide large scale samples for more thorough characterization of product properties and sampling to potential customers, for their preliminary application testing, if applicable.

Subtask C.3  Pilot-scale production and chemical process technoeconomics (BP2)

Pre-pilot chemical product scale-up support efforts will comprise determining how the process described performs at scale and the collection of engineering data for plant design and process economics. It will also enable the pilot-scale in-house manufacture of quantities of product suitable for larger scale customer sampling. For any unit operations beyond the capabilities of the pilot plant Amyris IBR will rely on specialized contract research organizations offering custom synthesis and scale-up services. The final phase of new chemical product development would be initiated by a reevaluation of project justification, cost scenarios and market status. These would build upon modeling throughout the project life span that is refined as data becomes available. The final outcome would indicate whether a toll manufacturing option or in-house manufacture would be preferable. Either scenario would require preparation of the appropriate engineering data packages, preliminary commercial scale process design and costing and Capital Expenditure/Operating Expenditure assessments to integrate with the Amyris Diesel TEA and LCA performed in Task B.6.

Task D.0  Regulatory and end-user process and product acceptance

The establishment of market readiness for Amyris Diesel and chemical products is an essential component of the IBR project.

Subtask D.1  Fuel product approval and acceptance (BP1-2)

Under the scope of this project, registration of higher diesel fuel blend ratios (above the current Environmental Protection Agency (EPA) registration at 20% Amyris Diesel) will be pursued. Amyris will perform contract manufacturing and third-party laboratory testing to validate

 

5


DE-EE0002869/001

Attachment 2

 

product properties and determine potential toxicity of chemical substances under EPA test procedures, fuel properties and combustion effects. Additional toxicity data collection will include occupational exposure risk assessment, if necessary.

Subtask D.2  Chemical product approval and acceptance (BP1-2)

Chemical registration dossiers for selected products, either as new products or bio-derived product equivalents will be submitted to EPA for pre-manufacture notice and to fulfill the reporting requirements of EPA under the North American Free Trade Agreement Chemical Assessment and Management Program obligations. Amyris will use contract manufacturing for volume production required for product acceptance testing and validation by potential end-users, contract laboratories, and regulatory agencies.

Subtask D.3  Use approvals for genetically modified microbes (BP1-2)

During the course of the IBR project Amyris will develop the strategy and data required to submit a microbial commercial activity notice (MCAN) for use of genetically modified microorganisms (GMM) in commercial US production.

Subtask D.4  Commercial production process approvals and acceptance (BP1-2)

During the course of the IBR project Amyris will develop and refine the path for commercial process and installation approvals, including any National Environmental Policy Act (NEPA), state or local regulations governing chemical manufacturing. Amyris will focus on states such as Hawaii, Florida, California, Louisiana and Alabama as potential sites for early US production from sweet sorghum and other feedstocks.

Task E.0  Project Management and Reporting (BP1-2)

Management of the timelines and key decision points will be monitored by Amyris using the Earned Value system using percentage completion of each task as a monthly performance-to-plan metric. A detailed baseline plan will be developed with project partners, and progress will be monitored using task start and finish dates to identify variance, major performance issues, key risks to completion, and to enable more accurate forecasting in later quarters. Linkage between task completion and project expenditures will be accomplished using project-based accounting.

 

6


DOE F 4600.2    Attachment 3

 

 

(02/09)   

U.S. Department of Energy

FEDERAL ASSISTANCE REPORTING CHECKLIST

AND INSTRUCTIONS

  
All Other Editions are Obsolete      

 

1. Identification Number:

    DE-EE0002869.001

  

2. Program/Project Title:

    Scale-up and Mobilization of Renewable Diesel and Chemical Production from Common Intermediate using US-based Fermentable Sugar Feedstocks

3. Recipient:

      Amyris Biotechnologies, Inc.

              

4. Reporting Requirements :

   Frequency    No. of Copies    Address

A.  MANAGEMENT REPORTING

þ    Progress Report

þ    Special Status Report (see Special Instructions)

  

A

A

       

https//www.eere-

pmc.energy.gov/SubmitReports.aspx

B.  SCIENTIFIC/TECHNICAL REPORTING

(Reports/Products must be submitted with appropriate

DOE F 241. The 241 forms are available at www.osti.gov/elink )

            

http://www.osti.gov/elink-2413

http://www.osti.gov/elink-2413

http://www.osti.gov/elink-241-

4pre.jsp

 

 

Report/Product

þ    Final Scientific Report

þ    Conference papers/proceedings*

þ    Software/Manual

¨    Other (see special instructions)

* Scientific and technical conferences only

 

 

    Form

DOE F 241.3

DOE F 241.3

DOE F 241.4

DOE F 241.3

  

F

A

A

 

       

C.  FINANCIAL REPORTING

þ    SF-425, Federal Financial Report

       FQ        

https//www.eere-

pmc.energy.gov/SubmitReports.aspx

D.  CLOSEOUT REPORTING

þ    Patent Certification

þ    Property Certification

¨    Other (see Special instructions)

      

F

F

 

       

https//www.eere-

pmc.energy.gov/SubmitReports.aspx

 

E.  OTHER REPORTING

þ    Annual Indirect Cost Proposal

þ    Annual Inventory of Federally Owned Property, If Any

þ    Other (see special instructions)

      

F Y

F Y

A F Q

         

FREQUENCY CODES AND DUE DATES:

A - Within 5 calendar days after events or as specified.

 

F - Final; 90 calendar days after expiration or termination of the award.

 

Y - Yearly; 90 days after the end of the reporting period.

 

S - Semiannually; within 30 days after end of the reporting period.

 

Q - Quarterly; within 30 days after end of the reporting period.

 

5. Special Instructions: The forms identified in the checklist are available at http://management.energy.gov/business doe/business forms.htm .

 

MANAGEMENT REPORTING

 

Special Instructions for the Progress Report: The progress report and financial spreadsheet templates will be forwarded to the Recipient after award. These reports are due monthly within 30 days following the end of each month the project is active.

 

OTHER REPORTING

 

Special Instructions: 1) A Project Management Plan (PMP) is due to the Project Officer 30 days after award and should be revised on a yearly basis. An electronic template will be provided to the Recipient to complete or update as needed. 2) An Annual Technical and Financial Report must be developed and submitted to the DOE Project Officer after award and must be updated annually throughout the duration of the award. Subject to the availability of project funding, the Report will also be due annually for three (3) years after the facility is substantially completed. The schedule for submission will be established by the DOE Project Officer after award. The format for the report with instructions for completion, the electronic template for reporting data, and the schedule will be forwarded to the Recipient after award. 3) Comprehensive Annual Project Review – The Recipient will be required to present the Annual Technical and Financial Report at a Comprehensive Annual Project Review meeting. The schedule for the Comprehensive Annual Project Review will be established by the DOE Project Officer after the award. AMERICAN RECOVERY AND REINVESTMENT ACT REPORTING: See the Special Terms and Conditions for Recovery Act reporting requirements, along with the following website: http://www.federalreporting.gov. The required reports are due no later than ten calendar days after each calendar quarter in which the Recipient receives the assistance award funded in whole or in part by the Recovery Act. Recipients are to report according to ARRA reporting instructions.


Federal Assistance Reporting Instructions (02/09)

 

A. MANAGEMENT REPORTING

Progress Report

The Progress Report must provide a concise narrative assessment of the status of work and include the following information and any other information identified under Special Instructions on the Federal Assistance Reporting Checklist:

 

  1. The DOE award number and name of the recipient.

 

  2. The project title and name of the project director/principal investigator.

 

  3. Date of report and period covered by the report.

 

  4. A comparison of the actual accomplishments with the goals and objectives established for the period and reasons why the established goals were not met.

 

  5. A discussion of what was accomplished under these goals during this reporting period, including major activities, significant results, major findings or conclusions, key outcomes or other achievements. This section should not contain any proprietary data or other information not subject to public release. If such information is important to reporting progress, do not include the information, but include a note in the report advising the reader to contact the Principal Investigator or the Project Director for further information.

 

  6. Cost Status. Show approved budget by budget period and actual costs incurred. If cost sharing is required break out by DOE share, recipient share, and total costs.

 

  7. Schedule Status. List milestones, anticipated completion dates and actual completion dates. If you submitted a project management plan with your application, you must use this plan to report schedule and budget variance. You may use your own project management system to provide this information.

 

  8. Any changes in approach or aims and reasons for change. Remember significant changes to the objectives and scope require prior approval by the contracting officer.

 

  9. Actual or anticipated problems or delays and actions taken or planned to resolve them.

 

  10. Any absence or changes of key personnel or changes in consortium/teaming arrangement.

 

  11. A description of any product produced or technology transfer activities accomplished during this reporting period, such as:


  A. Publications (list journal name, volume, issue); conference papers; or other public releases of results.

 

  B. Web site or other Internet sites that reflect the results of this project.

 

  C. Networks or collaborations fostered.

 

  D. Technologies/Techniques.

 

  E. Inventions/Patent Applications.

 

  F. Other products, such as data or databases, physical collections, audio or video, software or netware, models, educational aid or curricula, instruments or equipment.

Special Status Report

The recipient must report the following events as soon as possible after they occur:

 

  1. Developments that have a significant favorable impact on the project.

 

  2. Problems, delays, or adverse conditions which materially impair the recipient’s ability to meet the objectives of the award or which may require DOE to respond to questions relating to such events from the public. The recipient must report any of the following incidents and include the anticipated impact and remedial action to be taken to correct or resolve the problem/condition:

 

  a. Any single fatality or injuries requiring hospitalization of five or more individuals.

 

  b. Any significant environmental permit violation.

 

  c. Any verbal or written Notice of Violation of any Environmental, Safety, and Health statutes or regulations.

 

  d. Any incident which causes a significant process or hazard control system failure.

 

  e. Any event which is anticipated to cause a significant schedule slippage or cost increase.

 

  f. Any damage to Government-owned equipment valued in excess of $50,000.

 

  g. Any other incident that has the potential for high visibility in the media.


B. SCIENTIFIC/TECHNICAL REPORTS

Final Scientific/Technical Report

Content . The final scientific/technical report must include the following information and any other information identified under Special Instructions on the Federal Assistance Reporting Checklist:

 

  1. Identify the DOE award number; name of recipient; project title; name of project director/principal investigator; and consortium/teaming members.

 

  2. Display prominently on the cover of the report any authorized distribution limitation notices, such as patentable material or protected data. Reports delivered without such notices may be deemed to have been furnished with unlimited rights, and the Government assumes no liability for the disclosure, use or reproduction of such reports.

 

  3. Provide an executive summary, which includes a discussion of 1) how the research adds to the understanding of the area investigated; 2) the technical effectiveness and economic feasibility of the methods or techniques investigated or demonstrated; or 3) how the project is otherwise of benefit to the public. The discussion should be a minimum of one paragraph and written in terms understandable by an educated layman.

 

  4. Provide a comparison of the actual accomplishments with the goals and objectives of the project.

 

  5. Summarize project activities for the entire period of funding, including original hypotheses, approaches used, problems encountered and departure from planned methodology, and an assessment of their impact on the project results. Include, if applicable, facts, figures, analyses, and assumptions used during the life of the project to support the conclusions.

 

  6. Identify products developed under the award and technology transfer activities, such as:

 

  a. Publications (list journal name, volume, issue), conference papers, or other public releases of results;

 

  b. Web site or other Internet sites that reflect the results of this project;

 

  c. Networks or collaborations fostered;

 

  d. Technologies/Techniques;

 

  e. Inventions/Patent Applications, licensing agreements; and


  f. Other products, such as data or databases, physical collections, audio or video, software or netware, models, educational aid or curricula, instruments or equipment.

 

  7. For projects involving computer modeling, provide the following information with the final report:

 

  a. Model description, key assumptions, version, source and intended use;

 

  b. Performance criteria for the model related to the intended use;

 

  c. Test results to demonstrate the model performance criteria were met (e.g., code verification/validation, sensitivity analyses, history matching with lab or field data, as appropriate);

 

  d. Theory behind the model, expressed in non-mathematical terms;

 

  e. Mathematics to be used, including formulas and calculation methods;

 

  f. Whether or not the theory and mathematical algorithms were peer reviewed, and, if so, include a summary of theoretical strengths and weaknesses;

 

  g. Hardware requirements; and

 

  h. Documentation (e.g., users guide, model code).

Electronic Submission . The final scientific/technical report must be submitted electronically via the DOE Energy Link System (E-Link) at http://www.osti.gov/elink-2413 .

Electronic Format . Reports must be submitted in the ADOBE PORTABLE DOCUMENT FORMAT (PDF) and be one integrated PDF file that contains all text, tables, diagrams, photographs, schematic, graphs, and charts.

Submittal Form . The report must be accompanied by a completed electronic version of DOE Form 241.3, “U.S. Department of Energy (DOE), Announcement of Scientific and Technical Information (STI).” You can complete, upload, and submit the DOE F.241.3 online via E-Link. You are encouraged not to submit patentable material or protected data in these reports, but if there is such material or data in the report, you must: (1) clearly identify patentable or protected data on each page of the report; (2) identify such material on the cover of the report; and (3) mark the appropriate block in Section K of the DOE F241.3. Reports must not contain any limited rights data (proprietary data), classified information, information subject to export control classification, or other information not subject to release. Protected data is specific technical data, first produced in the performance of the award that is protected from public release for a period of time by the terms of the award agreement.


Protected Personally Identifiable Information (PII) . Management Reports or Scientific/Technical Reports must not contain any Protected PII. PII is any information about an individual which can be used to distinguish or trace an individual’s identity. Some information that is considered to be PII is available in public sources such as telephone books, public websites, university listings, etc. This type of information is considered to be Public PII and includes, for example, first and last name, address, work telephone number, e-mail address, home telephone number, and general educational credentials. In contrast, Protected PII is defined as an individual’s first name or first initial and last name in combination with any one or more of types of information, including, but not limited to, social security number, passport number, credit card numbers, clearances, bank numbers, biometrics, date and place of birth, mother’s maiden name, criminal, medical and financial records, educational transcripts, etc.

Conference Papers/Proceedings

Content . The recipient must submit a copy of any conference papers/proceedings, with the following information: (1) Name of conference; (2) Location of conference; (3) Date of conference; and (4) Conference sponsor.

Electronic Submission . Scientific/technical conference paper/proceedings must be submitted electronically via the DOE Energy Link System (E-Link) at http://www.osti.gov/elink-2413 . Non-scientific/technical conference papers/proceedings must be sent to the URL listed on the Reporting Checklist.

Electronic Format . Conference papers/proceedings must be submitted in the ADOBE PORTABLE DOCUMENT FORMAT (PDF) and be one integrated PDF file that contains all text, tables, diagrams, photographs, schematic, graphs, and charts.

Submittal Form . Scientific/technical conference papers/proceedings must be accompanied by a completed DOE Form 241.3. The form and instructions are available on E-Link at http://www.osti.gov/elink-2413 . This form is not required for non-scientific or non-technical conference papers or proceedings.

Software/Manual

Content . Unless otherwise specified in the award, the following must be delivered: source code, the executable object code and the minimum support documentation needed by a competent user to understand and use the software and to be able to modify the software in subsequent development efforts.

Electronic Submission . Submissions may be submitted electronically via the DOE Energy Link System (E-Link) at http://www.osti.gov/estsc/241-4pre.jsp They may also be submitted via regular mail to:

Energy Science and Technology Software Center

P.O. Box 1020

Oak Ridge, TN 37831


Submittal Form . Each software deliverable and its manual must be accompanied by a completed DOE Form 241.4 “Announcement of U.S. Department of Energy Computer Software.” The form and instructions are available on E-Link at http://www.osti.gov/estsc//241-4pre.jsp .

 

C. FINANCIAL REPORTING

Recipients must complete the SF-425 as identified on the Reporting Checklist in accordance with the report instructions. A fillable version of the form is available at http://www.whitehouse.gov/omb/grants/grants forms.aspx .

 

D. CLOSEOUT REPORTS

Final Invention and Patent Report

The recipient must provide a DOE Form 2050.11 , “PATENT CERTIFICATION.” This form is available at http://www.directives.doe.gov/pdfs/forms/2050-11.pdf and http://management.energy.gov/business doe/business forms.htm .

Property Certification

The recipient must provide the Property Certification, including the required inventories of non-exempt property, located at http://management.energv.gov/business doe/business forms.htm .

 

E. OTHER REPORTING

Annual Indirect Cost Proposal and Reconciliation

Requirement . In accordance with the applicable cost principles, the recipient must submit an annual indirect cost proposal, reconciled to its financial statements, within six months after the close of the fiscal year, unless the award is based on a predetermined or fixed indirect rate (s), or a fixed amount for indirect facilities and administration (F&A) costs.

Cognizant Agency . The recipient must submit its annual indirect cost proposal directly to the cognizant agency for negotiating and approving indirect costs.

Annual Inventory of Federally Owned Property

Requirement . If at any time during the award the recipient is provided with Government-furnished property or acquires property with project funds and the award specifies that the property vests in the Federal Government (i.e. federally owned property), the recipient must submit an annual inventory of this property to the DOE Award Administrator identified in Block 12 of the Notice of Financial Assistance Award no later then October 30th of each calendar year, to cover an annual reporting period ending on the preceding September 30th.


Content of Inventory . The inventory must include a description of property, tag number, acquisition date, location of property, and acquisition cost, if purchased with project funds. The report must list all federally owned property, including property located at subcontractor’s facilities or other locations.


Applicant Name:  Amyris Biotechnologies, Inc.            Award Number:  DE-EE0002869/001            Attachment 4

Budget Information - Non Construction Programs

OMB Approval No. 0348-0044      

Section A - Budget Summary

              

Grant Program Function or Activity

 

(a)

  

Catalog of Federal
Domestic Assistance
Number

(b)

   Estimated Unobligated Funds    New or Revised Budget
     

Federal

 

(c)

  

Non-Federal

 

(d)

  

Federal

 

(e)

 

Non-Federal

 

(f)

 

Total

 

(g)

1. Budget Period 1

                  $4,207,301   $1,782,480   $5,989,781

2. Budget Period 2

                  $20,134,108   $8,809,110   $28,943,218

3.

                          $0

4.

                          $0

5.                     Totals

        $0    $0    $24,341,409   $10,591,590   $34,932,899
Section B - Budget Categories                            

6. Object Class Categories

   Grant Program, Function or Activity   Total (5)
   Budget Period 1    Budget Period 2    (3)   (4)  

a. Personnel

   $1,389,678    $7,439,335            $8,829,013

b. Fringe Benefits

   $299,893    $1,605,409            $1,905,302

c. Travel

   $12,000    $81,000            $93,000

d. Equipment

   $718,013    $2,207,869            $2,925,882

e. Supplies

   $289,184    $1,454,368            $1,743,552

f. Contractual

   $985,100    $3,988,353            $4,973,453

g. Construction

   $0    $0            $0

h. Other

   $350,363    $1,751,813            $2,102,176

i. Total Direct Charges (sum of 6a-6h)

   $4,044,231    $18,528,147            $22,572,378

j. Indirect Charges

   $1,945,550    $10,415,071            $12,360,621

k. Totals (sum of 6i-6j)

   $5,989,781    $28,943,218            $34,932,399

    

                      

7.           Program Income

                     $0

SF-424A (Rev. 4-92)

Previous Edition Usable

   Presciibed by OMB Circular A-102

Authorized for Local Reproduction

 

Page 1 of 1


DE-EE0002869 / 000

SPECIAL TERMS AND CONDITIONS

Table of Contents

 

Number

  

Subject

  

Page

1.

   CONDITIONAL AVAILABILITY OF FUNDS    2

2.

   RESOLUTION OF CONFLICTING CONDITIONS    2

3.

   AWARD AGREEMENT TERMS AND CONDITIONS    2

4.

   ELECTRONIC AUTHORIZATION OF AWARD DOCUMENTS    3

5.

   AWARD PROJECT PERIOD    3

6.

   INTELLECTUAL PROPERTY PROVISIONS    3

7.

   COST SHARE    3

8.

   REPORTING REQUIREMENTS    4

9.

   PAYMENT PROCEDURES    4

10.

   REBUDGETING AND RECOVERY OF INDIRECT COSTS    5

11.

   INSOLVENCY, BANKRUPTCY OR RECEIVERSHIP    5

12.

   NATIONAL ENVIRONMENTAL POLICY ACT (NEPA) REQUIREMENTS    6

13.

   STATEMENT OF FEDERAL STEWARDSHIP    6

14.

   SITE VISITS    7

15.

   PUBLICATIONS    7

16.

   FEDERAL, STATE, AND MUNICIPAL REQUIREMENTS    7

17.

   LOBBYING RESTRICTIONS    7

18.

   NOTICE REGARDING THE PURCHASE OF AMERICAN-MADE EQUIPMENT AND PRODUCTS — SENSE OF CONGRESS    8

19.

   SPECIAL PROVISIONS RELATING TO WORK FUNDED UNDER AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009 (May 2009)    8

20.

   REPORTING AND REGISTRATION REQUIREMENTS UNDER SECTION 1512 OF THE RECOVERY ACT    12

21.

   REQUIRED USE OF AMERICAN IRON, STEEL, AND MANUFACTURED GOODS SECTION 1605 OF THE AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009    13

22.

   RECOVERY ACT TRANSACTIONS LISTED IN SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND RECIPIENT RESPONSIBILITIES FOR INFORMING SUBRECIPIENTS    16

23.

   WAGE RATE REQUIREMENTS UNDER SECTION 1606 OF THE RECOVERY ACT    16

24.

   DAVIS BACON ACT AND CONTRACT WORK HOURS AND SAFETY STANDARDS ACT    17


DE-EE0002869 / 000

 

SPECIAL TERMS AND CONDITIONS

 

1. CONDITIONAL AVAILABILITY OF FUNDS

 

  a. Notwithstanding the obligation of funds shown on the Assistance Agreement Cover Page, the parties hereby agree that the availability of funds to the Awardee for payment of costs incurred by the Awardee is conditioned upon the Awardee’s submission of a full application and any subsequently requested supplemental information, the Contracting Officer’s review and approval of the Awardee’s application and supplemental information, and completion of negotiations. No funds, therefore, shall be made available to the Awardee for payment, and DOE does not guarantee or assume any obligation to reimburse costs incurred by the Awardee during the negotiation process.

 

  b. When the parties have completed negotiations of all terms and conditions for this award, the Contracting Officer will issue an amendment to this award making available the obligated amount for payment in accordance with the payment provisions contained in the Special Terms and Conditions. The Awardee may then receive payment for allowable costs incurred or recognize costs incurred toward cost share requirements, as applicable, in accordance with the negotiated payment provisions.

 

  c. Failure by the Recipient to provide an application and any subsequently requested supplemental documentation which is acceptable to the Contracting Officer, or failure to complete negotiations will be deemed noncompliance pursuant to 10 CFR 600.24. Based on such noncompliance, the Contracting Officer may unilaterally terminate or suspend this award. In such case, the Awardee shall not be reimbursed for costs incurred at the Awardee’s risk, as described in Paragraph a. above.

 

2. RESOLUTION OF CONFLICTING CONDITIONS

Any apparent inconsistency between Federal statutes and regulations and the terms and conditions contained in this award must be referred to the DOE Award Administrator for guidance.

 

3. AWARD AGREEMENT TERMS AND CONDITIONS

 

  a. This award consists of the Assistance Agreement, plus the following:

 

  1) Special Terms and Conditions.

 

  2) Applicable program regulations.

 

  3) DOE Assistance Regulations, 10 CFR Part 600 at http://ecfr.gpoaccess.gov.

 

  4) If the award is for research and the award is for a university or non-profit, the Research Terms & Conditions and the DOE Agency Specific Requirements at http://www.nsf.gov/bfa/dias/policy/rtc/index.jsp apply.

 

  5) Application/proposal as approved by DOE.

 

2


DE-EE0002869 / 000

 

  6) National Policy Assurances to Be Incorporated as Award Terms in effect on date of award at http://management.energy.gov/business_doe/1374.htm .

 

  b. When the parties have completed negotiations of all final special terms and conditions for this award, the Contracting Officer will issue an amendment and the following documents will be added to the award:

 

  1) Special Terms and Conditions.

 

  2) Attachments:

 

Attachment Number   

Title

1.    Intellectual Property Provisions
2.    Statement of Project Objectives
3.    Federal Assistance Reporting Checklist and Instructions
4.    Budget Pages (SF 424A)

 

4. ELECTRONIC AUTHORIZATION OF AWARD DOCUMENTS

Acknowledgement of award documents by the Recipient’s authorized representative through electronic systems used by the Department of Energy, specifically FedConnect, constitutes the Recipient’s acceptance of the terms and conditions of the award. Acknowledgement via FedConnect by the Recipient’s authorized representative constitutes the Recipient’s electronic signature.

 

5. AWARD PROJECT PERIOD

The Project Period for this award is shown in the Assistance Agreement, Block 7, Period of Performance. The Project Period may be amended upon completion of negotiations.

 

6. INTELLECTUAL PROPERTY PROVISIONS

The intellectual property provisions applicable to this award will be incorporated by reference or included as Attachment 1 to the amended award, upon completion of negotiations.

 

7. COST SHARE

 

  a. The Federal funds currently obligated on this award are shown in the Assistance Agreement, Blocks 12 and 13. The Federal funds and Recipient cost share may be amended upon completion of negotiations.

 

  b. Total Estimated Project Cost is the sum of the Federal Government share and Recipient share of the estimated project costs. The Recipient’s cost share must come from non- Federal sources unless otherwise allowed by law. By accepting Federal funds under this award, you agree that you are liable for your percentage share of total allowable project costs, on a budget period basis, even if the project is terminated early or is not funded to its completion.

 

  c.

If you discover that you may be unable to provide cost sharing that is required upon completion of negotiations, the Recipient should immediately provide written notification

 

3


DE-EE0002869 / 000

 

  to the DOE Award Administrator, indicating whether the Recipient will continue or phase out the project. If the Recipient plans to continue the project, the notification must describe how replacement cost sharing will be secured.

 

  c. The Recipient must maintain records of all project costs that you claim as cost sharing, including in-kind costs, as well as records of costs to be paid by DOE. Such records are subject to audit.

 

  d. Failure to provide the cost sharing required by this Article may result in the subsequent recovery by DOE of some or all the funds provided under the award.

 

8. REPORTING REQUIREMENTS

 

  a. Requirements . The reporting requirements for this award will be identified on the Federal Assistance Reporting Checklist, DOE F 4600.2, and become Attachment 3 to an amended award upon completion of negotiations. (A sample checklist may be found at the following link: http://www.management.energy.gov/documents/DOEF46002PolicyVersion.pdf .)

Failure to comply with the reporting requirements will be considered a material noncompliance with the terms of the award. Noncompliance may result in withholding of future payments, suspension or termination of the current award, and withholding of future awards. A willful failure to perform, a history of failure to perform, or unsatisfactory performance of this and/or other financial assistance awards, may also result in a debarment action to preclude future awards by Federal agencies.

 

  b. Dissemination of scientific/technical reports . Scientific/technical reports submitted under this award will be disseminated on the Internet via the DOE Information Bridge ( www.osti.gov/bridge ), unless the report contains patentable material, protected data or SBIR/STTR data. Citations for journal articles produced under the award will appear on the DOE Energy Citations Database ( www.osti.gov/energycitations ).

 

  c. Restrictions . Reports submitted to the DOE Information Bridge must not contain any Protected Personal Identifiable Information (PII), limited rights data (proprietary data), classified information, information subject to export control classification, or other information not subject to release.

 

9. PAYMENT PROCEDURES

 

  a. Method of Payment . Payment will be made by reimbursement through the Automated Clearinghouse (ACH) method of payment.

 

  b. Requesting Reimbursement . Requests for reimbursements must be made electronically through Department of Energy’s Oak Ridge Financial Service Center (ORFSC) ACH Vendor Inquiry Payment Electronic Reporting System (VIPERS). To access and use VIPERS, you must enroll at https://finweb.oro.doe.gov/vipers.htm . Detailed instructions on how to enroll are provided on the web site.

 

4


DE-EE0002869 / 000

 

For non-construction awards, you must submit a Standard Form (SF) 270, “Request for Advance or Reimbursement,” at https://finweb.oro.doe.gov/vipers.htm and attach a file containing appropriate supporting documentation. The file attachment must show the total Federal share claimed on the SF 270, the non-Federal share claimed for the billing period if cost sharing is required, and cumulative expenditures to date (both Federal and non-Federal) for each of the following categories: salaries/wages and fringe benefits; equipment; travel; participant/training support costs, if any; other direct costs, including subawards/contracts; and indirect costs. For construction awards, you must submit a SF 271, “Outlay Report and Request for Reimbursement for Construction Programs,” through VIPERS.

 

  c. Timing of submittals . Submittal of the SF 270 or SF 271 should coincide with your normal billing pattern, but not more frequently than every two weeks. Requests for reimbursement must be limited to the amount of disbursements made during the billing period for the Federal share of direct project costs and the proportionate share of any allowable indirect costs incurred during that billing period.

 

  d. Adjusting payment requests for available cash . You must disburse any funds that are available from repayments to and interest earned on a revolving fund, program income, rebates, refunds, contract settlements, audit recoveries, credits, discounts, and interest earned on any of those funds before requesting additional cash payments from DOE.

 

  e. Payments . The DOE approving official will approve the invoice as soon as practical, but not later than 30 days after your request is received, unless the billing is improper. Upon receipt of an invoice payment authorization from the DOE approving official, the ORFSC will disburse payment to you. You may check the status of payments at the VIPER web site. All payments are made by electronic funds transfer to the bank account identified on the ACH Vendor/Miscellaneous Payment Enrollment Form (SF 3881) that you filed.

 

10. REBUDGETING AND RECOVERY OF INDIRECT COSTS

 

  a. If actual allowable indirect costs are less than those budgeted and funded under the award, the Awardee may use the difference to pay additional allowable direct costs during the project period. If at the completion of the award the Government’s share of total allowable costs (i.e., direct and indirect), is less than the total costs reimbursed, the Awardee must refund the difference.

 

  b. Awardees are expected to manage their indirect costs. DOE will not amend an award solely to provide additional funds for changes in indirect cost rates. DOE recognizes that the inability to obtain full reimbursement for indirect costs means the Awardee must absorb the underrecovery. Such underrecovery may be allocated as part of the organization’s required cost sharing.

 

11. INSOLVENCY, BANKRUPTCY OR RECEIVERSHIP

 

  a.

The Awardee shall immediately notify the DOE Administrator identified on the Assistance Agreement Cover Page of the occurrence of any of the following events: (i) the Awardee, or the Awardee’s parent’s filing of a voluntary case seeking

 

5


DE-EE0002869 / 000

 

  liquidation or reorganization under the Bankruptcy Act; (ii) the Awardee’s consent to the institution of an involuntary case under the Bankruptcy Act against the Awardee or its parent; (iii) the filing of any similar proceeding for or against the Awardee or its parent, or its consent to, the dissolution, winding-up or readjustment of its debts, appointment of a receiver, conservator, trustee, or other officer with similar powers over the Awardee, under any other applicable state or federal law; or (iv) the Awardee’s insolvency due to its inability to pay its debts generally as they become due.

 

  b. Such notification shall be in writing and shall: (i) specifically set out the details of the occurrence of an event referenced in paragraph (a); (ii) provide the facts surrounding that event; and (iii) provide the impact such event will have on the project being funded by this award.

 

  c. Upon the occurrence of any of the four events described in the first paragraph, DOE reserves the right to conduct a review of the award to determine the Awardee’s compliance with the required elements of the award (including such items as cost share, progress towards technical project objectives, and submission of required reports). If a DOE review determines that there are significant deficiencies or concerns with the Awardee’s performance under the award, DOE reserves the right to impose additional requirements, as needed, including (i) change the Awardee payment method; or (ii) institute payment controls.

 

  d. Failure of the Awardee to comply with this provision may be considered by the Contracting Officer to be a material noncompliance of this financial assistance award.

 

12. NATIONAL ENVIRONMENTAL POLICY ACT (NEPA) REQUIREMENTS

The Awardee and any of its subawardees are restricted from taking any action using Federal funds, which would have an adverse affect on the environment or limit the choice of reasonable alternatives prior to DOE providing either a NEPA clearance or a final NEPA decision regarding this project. If the Awardee moves forward with activities that are not authorized by the Contracting Officer for federal funding by the DOE under this award, in advance of negotiations, to include DOE initiating the NEPA process, the Awardee is doing so at risk of deobligation of federal funding and such costs may not be recognized as allowable cost share.

If this award includes construction activities, the Awardee must submit an environmental evaluation report/evaluation notification form addressing NEPA issues prior to DOE initiating the NEPA process.

 

13. STATEMENT OF FEDERAL STEWARDSHIP

DOE will exercise normal Federal stewardship in overseeing the project activities performed under this award. Stewardship activities include, but are not limited to, conducting site visits; reviewing performance and financial reports; providing technical assistance and/or temporary intervention in unusual circumstances to correct deficiencies which develop during the project; assuring compliance with terms and conditions; and

 

6


DE-EE0002869 / 000

 

reviewing technical performance after project completion to ensure that the award objectives have been accomplished.

 

14. SITE VISITS

DOE’s authorized representatives have the right to make site visits at reasonable times to review project accomplishments and management control systems and to provide technical assistance, if required. The Awardee must provide, and must require its subawardees to provide, reasonable access to facilities, office space, resources, and assistance for the safety and convenience of the DOE and any other government representatives in the performance of their duties. All site visits and evaluations will be performed in a manner that does not unduly interfere with or delay the work.

 

15. PUBLICATIONS

 

  a. The Awardee is encouraged to publish or otherwise make publicly available the results of the work conducted under the award.

 

  b. An acknowledgment of Federal support and a disclaimer must appear in the publication of any material, whether copyrighted or not, based on or developed under this project, as follows:

 

  Acknowledgment : “This material is based upon work supported by the Department of Energy [National Nuclear Security Administration] [add name(s) of other agencies, if applicable] under Award Number(s) [enter the award number(s)].”

 

  Disclaimer : “This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.”

 

16. FEDERAL, STATE, AND MUNICIPAL REQUIREMENTS

The Awardee must obtain any required permits and comply with applicable federal, state, and municipal laws, codes, and regulations for work performed under this award.

 

17. LOBBYING RESTRICTIONS

By accepting funds under this award, the Awardee agrees that none of the funds obligated on the award shall be expended, directly or indirectly, to influence congressional action on any legislation or appropriation matters pending before Congress, other than to

 

7


DE-EE0002869 / 000

 

communicate to Members of Congress as described in 18 U.S.C. 1913. This restriction is in addition to those prescribed elsewhere in statute and regulation.

 

18. NOTICE REGARDING THE PURCHASE OF AMERICAN-MADE EQUIPMENT AND PRODUCTS — SENSE OF CONGRESS

It is the sense of the Congress that, to the greatest extent practicable, all equipment and products purchased with funds made available under this award should be American- made.

 

19. SPECIAL PROVISIONS RELATING TO WORK FUNDED UNDER AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009 (May 2009)

Preamble

The American Recovery and Reinvestment Act of 2009, Pub. L. 111-5, (Recovery Act) was enacted to preserve and create jobs and promote economic recovery, assist those most impacted by the recession, provide investments needed to increase economic efficiency by spurring technological advances in science and health, invest in transportation, environmental protection, and other infrastructure that will provide long-term economic benefits, stabilize State and local government budgets, in order to minimize and avoid reductions in essential services and counterproductive State and local tax increases. Recipients shall use grant funds in a manner that maximizes job creation and economic benefit.

The Recipient shall comply with all terms and conditions in the Recovery Act relating generally to governance, accountability, transparency, data collection and resources as specified in Act itself and as discussed below.

Recipients should begin planning activities for their first tier subrecipients, including obtaining a DUNS number (or updating the existing DUNS record), and registering with the Central Contractor Registration (CCR).

Be advised that Recovery Act funds can be used in conjunction with other funding as necessary to complete projects, but tracking and reporting must be separate to meet the reporting requirements of the Recovery Act and related guidance. For projects funded by sources other than the Recovery Act, Contractors must keep separate records for Recovery Act funds and to ensure those records comply with the requirements of the Act.

The Government has not fully developed the implementing instructions of the Recovery Act, particularly concerning specific procedural requirements for the new reporting requirements. The Recipient will be provided these details as they become available. The Recipient must comply with all requirements of the Act. If the recipient believes there is any inconsistency between ARRA requirements and current award terms and conditions, the issues will be referred to the Contracting Officer for reconciliation.

 

8


DE-EE0002869 / 000

 

Definitions

For purposes of this clause, Covered Funds means funds expended or obligated from appropriations under the American Recovery and Reinvestment Act of 2009, Pub. L. 111-5. Covered Funds will have special accounting codes and will be identified as Recovery Act funds in the grant, cooperative agreement or TIA and/or modification using Recovery Act funds. Covered Funds must be reimbursed by September 30, 2015.

Non-Federal employer means any employer with respect to covered funds — the contractor, subcontractor, grantee, or recipient, as the case may be, if the contractor, subcontractor, grantee, or recipient is an employer; and any professional membership organization, certification of other professional body, any agent or licensee of the Federal government, or any person acting directly or indirectly in the interest of an employer receiving covered funds; or with respect to covered funds received by a State or local government, the State or local government receiving the funds and any contractor or subcontractor receiving the funds and any contractor or subcontractor of the State or local government; and does not mean any department, agency, or other entity of the federal government.

Recipient means any entity that receives Recovery Act funds directly from the Federal government (including Recovery Act funds received through grant, loan, or contract) other than an individual and includes a State that receives Recovery Act Funds.

Special Provisions

A. Flow Down Requirement

Recipients must include these special terms and conditions in any subaward.

B. Segregation of Costs

Recipients must segregate the obligations and expenditures related to funding under the Recovery Act. Financial and accounting systems should be revised as necessary to segregate, track and maintain these funds apart and separate from other revenue streams. No part of the funds from the Recovery Act shall be commingled with any other funds or used for a purpose other than that of making payments for costs allowable for Recovery Act projects.

C. Prohibition on Use of Funds

None of the funds provided under this agreement derived from the American Recovery and Reinvestment Act of 2009, Pub. L. 111-5, may be used by any State or local government, or any private entity, for any casino or other gambling establishment, aquarium, zoo, golf course, or swimming pool.

D. Access to Records

With respect to each financial assistance agreement awarded utilizing at least some of the funds appropriated or otherwise made available by the American Recovery and Reinvestment Act of 2009, Pub. L. 111-5, any representative of an appropriate inspector general appointed under

 

9


DE-EE0002869 / 000

 

section 3 or 8G of the Inspector General Act of 1988 (5 U.S.C. App.) or of the Comptroller General is authorized —

(1) to examine any records of the contractor or grantee, any of its subcontractors or subgrantees, or any State or local agency administering such contract that pertain to, and involve transactions that relate to, the subcontract, subcontract, grant, or subgrant; and

(2) to interview any officer or employee of the contractor, grantee, subgrantee, or agency regarding such transactions.

E. Publication

An application may contain technical data and other data, including trade secrets and/or privileged or confidential information, which the applicant does not want disclosed to the public or used by the Government for any purpose other than the application. To protect such data, the applicant should specifically identify each page including each line or paragraph thereof containing the data to be protected and mark the cover sheet of the application with the following Notice as well as referring to the Notice on each page to which the Notice applies:

Notice of Restriction on Disclosure and Use of Data

The data contained in pages — of this application have been submitted in confidence and contain trade secrets or proprietary information, and such data shall be used or disclosed only for evaluation purposes, provided that if this applicant receives an award as a result of or in connection with the submission of this application, DOE shall have the right to use or disclose the data here to the extent provided in the award. This restriction does not limit the Government’s right to use or disclose data obtained without restriction from any source, including the applicant.

Information about this agreement will be published on the Internet and linked to the website www.recovery.gov, maintained by the Accountability and Transparency Board. The Board may exclude posting contractual or other information on the website on a case-by-case basis when necessary to protect national security or to protect information that is not subject to disclosure under sections 552 and 552a of title 5, United States Code.

F. Protecting State and Local Government and Contractor Whistleblowers .

The requirements of Section 1553 of the Act are summarized below. They include, but are not limited to:

Prohibition on Reprisals: An employee of any non-Federal employer receiving covered funds under the American Recovery and Reinvestment Act of 2009, Pub. L. 111-5, may not be discharged, demoted, or otherwise discriminated against as a reprisal for disclosing, including a disclosure made in the ordinary course of an employee’s duties, to the Accountability and Transparency Board, an inspector general, the Comptroller General, a member of Congress, a State or Federal regulatory or law enforcement agency, a person with supervisory authority over the employee (or other person working for the employer who has the authority to investigate, discover or terminate misconduct), a court or grant jury, the head of a Federal agency, or their representatives information that the employee believes is evidence of:

- gross management of an agency contract or grant relating to covered funds;

 

10


DE-EE0002869 / 000

 

- a gross waste of covered funds;

- a substantial and specific danger to public health or safety related to the implementation or use of covered funds;

- an abuse of authority related to the implementation or use of covered funds; or

- as violation of law, rule, or regulation related to an agency contract (including the competition for or negotiation of a contract) or grant, awarded or issued relating to covered funds.

Agency Action: Not later than 30 days after receiving an inspector general report of an alleged reprisal, the head of the agency shall determine whether there is sufficient basis to conclude that the non-Federal employer has subjected the employee to a prohibited reprisal. The agency shall either issue an order denying relief in whole or in part or shall take one or more of the following actions:

- Order the employer to take affirmative action to abate the reprisal.

- Order the employer to reinstate the person to the position that the person held before the reprisal, together with compensation including back pay, compensatory damages, employment benefits, and other terms and conditions of employment that would apply to the person in that position if the reprisal had not been taken.

- Order the employer to pay the employee an amount equal to the aggregate amount of all costs and expenses (including attorneys’ fees and expert witnesses’ fees) that were reasonably incurred by the employee for or in connection with, bringing the complaint regarding the reprisal, as determined by the head of a court of competent jurisdiction.

Nonenforceablity of Certain Provisions Waiving Rights and remedies or Requiring Arbitration: Except as provided in a collective bargaining agreement, the rights and remedies provided to aggrieved employees by this section may not be waived by any agreement, policy, form, or condition of employment, including any predispute arbitration agreement. No predispute arbitration agreement shall be valid or enforceable if it requires arbitration of a dispute arising out of this section.

Requirement to Post Notice of Rights and Remedies: Any employer receiving covered funds under the American Recovery and Reinvestment Act of 2009, Pub. L. 111-5, shall post notice of the rights and remedies as required therein. (Refer to section 1553 of the American Recovery and Reinvestment Act of 2009, Pub. L. 111-5, www.Recovery.gov, for specific requirements of this section and prescribed language for the notices.).

G. Reserved .

H. False Claims Act

Recipient and sub-recipients shall promptly refer to the DOE or other appropriate Inspector General any credible evidence that a principal, employee, agent, contractor, sub-grantee, subcontractor or other person has submitted a false claim under the False Claims Act or has committed a criminal or civil violation of laws pertaining to fraud, conflict of interest, bribery, gratuity or similar misconduct involving those funds.

 

11


DE-EE0002869 / 000

 

I. Information in Support of Recovery Act Reporting

Recipient may be required to submit backup documentation for expenditures of funds under the Recovery Act including such items as timecards and invoices. Recipient shall provide copies of backup documentation at the request of the Contracting Officer or designee.

J. Availability of Funds

Funds appropriated under the Recovery Act and obligated to this award are available for reimbursement of costs until September 30, 2015.

K. Additional Funding Distribution and Assurance of Appropriate Use of Funds

If the Recipient is a State Government, the following paragraphs apply:

Certification by Governor — Not later than April 3, 2009, for funds provided to any State or agency thereof by the American Reinvestment and Recovery Act of 2009, Pub. L. 111-5, the Governor of the State shall certify that: 1) the state will request and use funds provided by the Act; and 2) the funds will be used to create jobs and promote economic growth.

Acceptance by State Legislature — If funds provided to any State in any division of the Act are not accepted for use by the Governor, then acceptance by the State legislature, by means of the adoption of a concurrent resolution, shall be sufficient to provide funding to such State.

Distribution — After adoption of a State legislature’s concurrent resolution, funding to the State will be for distribution to local governments, councils of government, public entities, and public- private entities within the State either by formula or at the State’s discretion.

L. Certifications

With respect to funds made available to State or local governments for infrastructure investments under the American Recovery and Reinvestment Act of 2009, Pub. L. 111-5, the Governor, mayor, or other chief executive, as appropriate, certified by acceptance of this award that the infrastructure investment has received the full review and vetting required by law and that the chief executive accepts responsibility that the infrastructure investment is an appropriate use of taxpayer dollars. Recipient shall provide an additional certification that includes a description of the investment, the estimated total cost, and the amount of covered funds to be used for posting on the Internet. A State or local agency may not receive infrastructure investment funding from funds made available by the Act unless this certification is made and posted.

 

20. REPORTING AND REGISTRATION REQUIREMENTS UNDER SECTION 1512 OF THE RECOVERY ACT

(a) This award requires the recipient to complete projects or activities which are funded under the American Recovery and Reinvestment Act of 2009 (Recovery Act) and to report on use of Recovery Act funds provided through this award. Information from these reports will be made available to the public.

 

12


DE-EE0002869 / 000

 

(b) The reports are due no later than ten calendar days after each calendar quarter in which the Recipient receives the assistance award funded in whole or in part by the Recovery Act.

(c) Recipients and their first-tier subrecipients must maintain current registrations in the Central Contractor Registration ( http://www.ccr.gov ) at all times during which they have active federal awards funded with Recovery Act funds. A Dun and Bradstreet Data Universal Numbering System (DUNS) Number ( http://www.dnb.com ) is one of the requirements for registration in the Central Contractor Registration.

(d) The recipient shall report the information described in section 1512(c) of the Recovery Act using the reporting instructions and data elements that will be provided online at http://www.FederalReporting.gov and ensure that any information that is pre-filled is corrected or updated as needed.

 

21. REQUIRED USE OF AMERICAN IRON, STEEL, AND MANUFACTURED GOODS SECTION 1605 OF THE AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009

After completion of negotiations, this provision may be revised.

(a) Definitions . As used in this award term and condition—

(1) Manufactured good means a good brought to the construction site for incorporation into the building or work that has been—

(i) Processed into a specific form and shape; or

(ii) Combined with other raw material to create a material that has different properties than the properties of the individual raw materials.

(2) Public building and public work means a public building of, and a public work of, a governmental entity (the United States; the District of Columbia; commonwealths, territories, and minor outlying islands of the United States; State and local governments; and multi-State, regional, or interstate entities which have governmental functions). These buildings and works may include, without limitation, bridges, dams, plants, highways, parkways, streets, subways, tunnels, sewers, mains, power lines, pumping stations, heavy generators, railways, airports, terminals, docks, piers, wharves, ways, lighthouses, buoys, jetties, breakwaters, levees, and canals, and the construction, alteration, maintenance, or repair of such buildings and works.

(3) Steel means an alloy that includes at least 50 percent iron, between .02 and 2 percent carbon, and may include other elements.

(b) Domestic preference . (1) This award term and condition implements Section 1605 of the American Recovery and Reinvestment Act of 2009 (Recovery Act) (Pub. L. 1115), by requiring that all iron, steel, and manufactured goods used in the project are produced in the United States except as provided in paragraph (b)(3) of this section and condition.

 

13


DE-EE0002869 / 000

 

(2) This requirement does not apply to the material listed by the Federal Government as follows:

None.

(3) The award official may add other iron, steel, and/or manufactured goods to the list in paragraph (b)(2) of this section and condition if the Federal Government determines that—

(i) The cost of the domestic iron, steel, and/or manufactured goods would be unreasonable. The cost of domestic iron, steel, or manufactured goods used in the project is unreasonable when the cumulative cost of such material will increase the cost of the overall project by more than 25 percent;

(ii) The iron, steel, and/or manufactured good is not produced, or manufactured in the United States in sufficient and reasonably available quantities and of a satisfactory quality; or

(iii) The application of the restriction of section 1605 of the Recovery Act would be inconsistent with the public interest.

(c) Request for determination of inapplicability of Section 1605 of the Recovery Act . (1)(i) Any recipient request to use foreign iron, steel, and/or manufactured goods in accordance with paragraph (b)(3) of this section shall include adequate information for Federal Government evaluation of the request, including—

(A) A description of the foreign and domestic iron, steel, and/or manufactured goods;

(B) Unit of measure;

(C) Quantity;

(D) Cost;

(E) Time of delivery or availability;

(F) Location of the project;

(G) Name and address of the proposed supplier; and

(H) A detailed justification of the reason for use of foreign iron, steel, and/or manufactured goods cited in accordance with paragraph (b)(3) of this section.

(ii) A request based on unreasonable cost shall include a reasonable survey of the market and a completed cost comparison table in the format in paragraph (d) of this section.

(iii) The cost of iron, steel, and/or manufactured goods material shall include all delivery costs to the construction site and any applicable duty.

(iv) Any recipient request for a determination submitted after Recovery Act funds have been obligated for a project for construction, alteration, maintenance, or repair shall explain why the recipient could not reasonably foresee the need for such determination and could not have

 

14


DE-EE0002869 / 000

 

requested the determination before the funds were obligated. If the recipient does not submit a satisfactory explanation, the award official need not make a determination.

(2) If the Federal Government determines after funds have been obligated for a project for construction, alteration, maintenance, or repair that an exception to section 1605 of the Recovery Act applies, the award official will amend the award to allow use of the foreign iron, steel, and/or relevant manufactured goods. When the basis for the exception is nonavailability or public interest, the amended award shall reflect adjustment of the award amount, redistribution of budgeted funds, and/or other actions taken to cover costs associated with acquiring or using the foreign iron, steel, and/or relevant manufactured goods. When the basis for the exception is the unreasonable cost of the domestic iron, steel, or manufactured goods, the award official shall adjust the award amount or redistribute budgeted funds by at least the differential established in 2 CFR 176.110(a).

(3) Unless the Federal Government determines that an exception to section 1605 of the Recovery Act applies, use of foreign iron, steel, and/or manufactured goods is noncompliant with section 1605 of the American Recovery and Reinvestment Act.

(d) Data . To permit evaluation of requests under paragraph (b) of this section based on unreasonable cost, the Recipient shall include the following information and any applicable supporting data based on the survey of suppliers:

Foreign and Domestic Items Cost Comparison

 

Description    Unit of measure           Quantity          

Cost

(dollars)*

    

Item 1:

                             

Foreign steel, iron, or manufactured good

                       
                               
                               

Domestic steel, iron, or manufactured good

                       
                               
                               

Item 2:

                             

Foreign steel, iron, or manufactured good

                       
                               
                               

Domestic steel, iron, or manufactured good

                       
                               
                               

List name, address, telephone number, email address, and contact for suppliers surveyed. Attach copy of response; if oral, attach summary.

Include other applicable supporting information.

*Include all delivery costs to the construction site.

 

15


DE-EE0002869 / 000

 

22. RECOVERY ACT TRANSACTIONS LISTED IN SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND RECIPIENT RESPONSIBILITIES FOR INFORMING SUBRECIPIENTS

(a) To maximize the transparency and accountability of funds authorized under the American Recovery and Reinvestment Act of 2009 (Pub. L. 1115) (Recovery Act) as required by Congress and in accordance with 2 CFR 215.21 “Uniform Administrative Requirements for Grants and Agreements” and OMB Circular A102 Common Rules provisions, recipients agree to maintain records that identify adequately the source and application of Recovery Act funds. OMB Circular A102 is available at http://www.whitehouse.gov/omb/circulars/a102/a102.html .

(b) For recipients covered by the Single Audit Act Amendments of 1996 and OMB Circular A133, “Audits of States, Local Governments, and Non-Profit Organizations,” recipients agree to separately identify the expenditures for Federal awards under the Recovery Act on the Schedule of Expenditures of Federal Awards (SEFA) and the Data Collection Form (SF SAC) required by OMB Circular A133. OMB Circular A133 is available at http://www.whitehouse.gov/omb/circulars/a133/a133.html . This shall be accomplished by identifying expenditures for Federal awards made under the Recovery Act separately on the SEFA, and as separate rows under Item 9 of Part III on the SFSAC by CFDA number, and inclusion of the prefix “ARRA-” in identifying the name of the Federal program on the SEFA and as the first characters in Item 9d of Part III on the SFSAC.

(c) Recipients agree to separately identify to each subrecipient, and document at the time of subaward and at the time of disbursement of funds, the Federal award number, CFDA number, and amount of Recovery Act funds. When a recipient awards Recovery Act funds for an existing program, the information furnished to subrecipients shall distinguish the subawards of incremental Recovery Act funds from regular subawards under the existing program.

(d) Recipients agree to require their subrecipients to include on their SEFA information to specifically identify Recovery Act funding similar to the requirements for the recipient SEFA described above. This information is needed to allow the recipient to properly monitor subrecipient expenditure of ARRA funds as well as oversight by the Federal awarding agencies, Offices of Inspector General and the Government Accountability Office.

 

23. WAGE RATE REQUIREMENTS UNDER SECTION 1606 OF THE RECOVERY ACT

After completion of negotiations, this provision may be revised.

(a) Section 1606 of the Recovery Act requires that all laborers and mechanics employed by contractors and subcontractors on projects funded directly by or assisted in whole or in part by and through the Federal Government pursuant to the Recovery Act shall be paid wages at rates not less than those prevailing on projects of a character similar in the locality as determined by the Secretary of Labor in accordance with subchapter IV of chapter 31 of title 40, United States Code.

 

16


DE-EE0002869 / 000

 

Pursuant to Reorganization Plan No. 14 and the Copeland Act, 40 U.S.C. 3145, the Department of Labor has issued regulations at 29 CFR parts 1, 3, and 5 to implement the Davis-Bacon and related Acts. Regulations in 29 CFR 5.5 instruct agencies concerning application of the standard Davis-Bacon contract clauses set forth in that section. Federal agencies providing grants, cooperative agreements, and loans under the Recovery Act shall ensure that the standard Davis-Bacon contract clauses found in 29 CFR 5.5(a) are incorporated in any resultant covered contracts that are in excess of $2,000 for construction, alteration or repair (including painting and decorating).

(b) For additional guidance on the wage rate requirements of section 1606, contact your awarding agency. Recipients of grants, cooperative agreements and loans should direct their initial inquiries concerning the application of Davis-Bacon requirements to a particular federally assisted project to the Federal agency funding the project. The Secretary of Labor retains final coverage authority under Reorganization Plan Number 14.

 

24. DAVIS BACON ACT AND CONTRACT WORK HOURS AND SAFETY STANDARDS ACT

After completion of negotiations, this provision may be revised.

Definitions: For purposes of this provision, “Davis Bacon Act and Contract Work Hours and Safety Standards Act,” the following definitions are applicable:

(1) “Award” means any grant, cooperative agreement or technology investment agreement made with Recovery Act funds by the Department of Energy (DOE) to a Recipient. Such Award must require compliance with the labor standards clauses and wage rate requirements of the Davis-Bacon Act (DBA) for work performed by all laborers and mechanics employed by Recipients (other than a unit of State or local government whose own employees perform the construction) Subrecipients, Contractors, and subcontractors.

(2) “Contractor” means an entity that enters into a Contract. For purposes of these clauses, Contractor shall include (as applicable) prime contractors, Recipients, Subrecipients, and Recipients’ or Subrecipients’ contractors, subcontractors, and lower-tier subcontractors. “Contractor” does not mean a unit of State or local government where construction is performed by its own employees.”

(3) “Contract” means a contract executed by a Recipient, Subrecipient, prime contractor, or any tier subcontractor for construction, alteration, or repair. It may also mean (as applicable) (i) financial assistance instruments such as grants, cooperative agreements, technology investment agreements, and loans; and, (ii) Sub awards, contracts and subcontracts issued under financial assistance agreements. “Contract” does not mean a financial assistance instrument with a unit of State or local government where construction is performed by its own employees.

(4) “Contracting Officer” means the DOE official authorized to execute an Award on behalf of DOE and who is responsible for the business management and non-program aspects of the financial assistance process.

 

17


DE-EE0002869 / 000

 

(5) “Recipient” means any entity other than an individual that receives an Award of Federal funds in the form of a grant, cooperative agreement, or technology investment agreement directly from the Federal Government and is financially accountable for the use of any DOE funds or property, and is legally responsible for carrying out the terms and conditions of the program and Award.

(6) “Subaward” means an award of financial assistance in the form of money, or property in lieu of money, made under an award by a Recipient to an eligible Subrecipient or by a Subrecipient to a lower-tier subrecipient. The term includes financial assistance when provided by any legal agreement, even if the agreement is called a contract, but does not include the Recipient’s procurement of goods and services to carry out the program nor does it include any form of assistance which is excluded from the definition of “Award” above.

(7) “Subrecipient” means a non-Federal entity that expends Federal funds received from a Recipient to carry out a Federal program, but does not include an individual that is a beneficiary of such a program.

(a) Davis Bacon Act

(1) Minimum wages.

(i) All laborers and mechanics employed or working upon the site of the work (or under the United States Housing Act of 1937 or under the Housing Act of 1949 in the construction or development of the project), will be paid unconditionally and not less often than once a week, and, without subsequent deduction or rebate on any account (except such payroll deductions as are permitted by regulations issued by the Secretary of Labor under the Copeland Act (29 CFR part 3)), the full amount of wages and bona fide fringe benefits (or cash equivalents thereof) due at time of payment computed at rates not less than those contained in the wage determination of the Secretary of Labor which is attached hereto and made a part hereof, regardless of any contractual relationship which may be alleged to exist between the Contractor and such laborers and mechanics.

Contributions made or costs reasonably anticipated for bona fide fringe benefits under section 1(b)(2) of the Davis-Bacon Act on behalf of laborers or mechanics are considered wages paid to such laborers or mechanics, subject to the provisions of paragraph (a)(1)(iv) of this section; also, regular contributions made or costs incurred for more than a weekly period (but not less often than quarterly) under plans, funds, or programs which cover the particular weekly period, are deemed to be constructively made or incurred during such weekly period. Such laborers and mechanics shall be paid the appropriate wage rate and fringe benefits on the wage determination for the classification of work actually performed, without regard to skill, except as provided in § 5.5(a)(4). Laborers or mechanics performing work in more than one classification may be compensated at the rate specified for each classification for the time actually worked therein, provided that the employer’s payroll records accurately set forth the time spent in each classification in which

 

18


DE-EE0002869 / 000

 

work is performed. The wage determination (including any additional classification and wage rates conformed under paragraph (a)(1)(ii) of this section) and the Davis-Bacon poster (WH-1321) shall be posted at all times by the Contractor and its subcontractors at the site of the work in a prominent and accessible place where it can be easily seen by the workers.

(ii)(A) The Contracting Officer shall require that any class of laborers or mechanics, including helpers, which is not listed in the wage determination and which is to be employed under the Contract shall be classified in conformance with the wage determination. The Contracting Officer shall approve an additional classification and wage rate and fringe benefits therefore only when the following criteria have been met:

(1) The work to be performed by the classification requested is not performed by a classification in the wage determination;

(2) The classification is utilized in the area by the construction industry; and

(3) The proposed wage rate, including any bona fide fringe benefits, bears a reasonable relationship to the wage rates contained in the wage determination.

(B) If the Contractor and the laborers and mechanics to be employed in the classification (if known), or their representatives, and the Contracting Officer agree on the classification and wage rate (including the amount designated for fringe benefits where appropriate), a report of the action taken shall be sent by the Contracting Officer to the Administrator of the Wage and Hour Division, U.S. Department of Labor, Washington, DC 20210. The Administrator, or an authorized representative, will approve, modify, or disapprove every additional classification action within 30 days of receipt and so advise the Contracting Officer or will notify the Contracting Officer within the 30-day period that additional time is necessary.

(C) In the event the Contractor, the laborers or mechanics to be employed in the classification or their representatives, and the Contracting Officer do not agree on the proposed classification and wage rate (including the amount designated for fringe benefits, where appropriate), the Contracting Officer shall refer the questions, including the views of all interested parties and the recommendation of the Contracting Officer, to the Administrator for determination. The Administrator, or an authorized representative, will issue a determination within 30 days of receipt and so advise the Contracting Officer or will notify the Contracting Officer within the 30-day period that additional time is necessary.

(D) The wage rate (including fringe benefits where appropriate) determined pursuant to paragraphs (a)(1)(ii)(B) or (C) of this section, shall be paid to all

 

19


DE-EE0002869 / 000

 

workers performing work in the classification under this Contract from the first day on which work is performed in the classification.

(iii)        Whenever the minimum wage rate prescribed in the Contract for a class of laborers or mechanics includes a fringe benefit which is not expressed as an hourly rate, the Contractor shall either pay the benefit as stated in the wage determination or shall pay another bona fide fringe benefit or an hourly cash equivalent thereof.

(iv)        If the Contractor does not make payments to a trustee or other third person, the Contractor may consider as part of the wages of any laborer or mechanic the amount of any costs reasonably anticipated in providing bona fide fringe benefits under a plan or program, provided that the Secretary of Labor has found, upon the written request of the Contractor, that the applicable standards of the Davis-Bacon Act have been met. The Secretary of Labor may require the Contractor to set aside in a separate account assets for the meeting of obligations under the plan or program.

(2) Withholding. The Department of Energy or the Recipient or Subrecipient shall upon its own action or upon written request of an authorized representative of the Department of Labor withhold or cause to be withheld from the Contractor under this Contract or any other Federal contract with the same prime contractor, or any other federally-assisted contract subject to Davis-Bacon prevailing wage requirements, which is held by the same prime contractor, so much of the accrued payments or advances as may be considered necessary to pay laborers and mechanics, including apprentices, trainees, and helpers, employed by the Contractor or any subcontractor the full amount of wages required by the Contract. In the event of failure to pay any laborer or mechanic, including any apprentice, trainee, or helper, employed or working on the site of the work (or under the United States Housing Act of 1937 or under the Housing Act of 1949 in the construction or development of the project), all or part of the wages required by the Contract, the Department of Energy, Recipient, or Subrecipient, may, after written notice to the Contractor, sponsor, applicant, or owner, take such action as may be necessary to cause the suspension of any further payment, advance, or guarantee of funds until such violations have ceased.

(3) Payrolls and basic records.

(i) Payrolls and basic records relating thereto shall be maintained by the Contractor during the course of the work and preserved for a period of three years thereafter for all laborers and mechanics working at the site of the work (or under the United States Housing Act of 1937, or under the Housing Act of 1949, in the construction or development of the project). Such records shall contain the name, address, and social security number of each such worker, his or her correct classification, hourly rates of wages paid (including rates of contributions or costs anticipated for bona fide fringe benefits or cash equivalents thereof of the types described in section 1(b)(2)(B) of the Davis-Bacon Act), daily and weekly number of hours worked, deductions made, and actual wages paid. Whenever the

 

20


DE-EE0002869 / 000

 

Secretary of Labor has found under 29 CFR 5.5(a)(1)(iv) that the wages of any laborer or mechanic include the amount of any costs reasonably anticipated in providing benefits under a plan or program described in section 1(b)(2)(B) of the Davis-Bacon Act, the Contractor shall maintain records which show that the commitment to provide such benefits is enforceable, that the plan or program is financially responsible, and that the plan or program has been communicated in writing to the laborers or mechanics affected, and records which show the costs anticipated or the actual cost incurred in providing such benefits. Contractors employing apprentices or trainees under approved programs shall maintain written evidence of the registration of apprenticeship programs and certification of trainee programs, the registration of the apprentices and trainees, and the ratios and wage rates prescribed in the applicable programs.

 

  (ii)   (A) The Contractor shall submit weekly for each week in which any Contract work is performed a copy of all payrolls to the Department of Energy if the agency is a party to the Contract, but if the agency is not such a party, the Contractor will submit the payrolls to the Recipient or Subrecipient (as applicable), applicant, sponsor, or owner, as the case may be, for transmission to the Department of Energy. The payrolls submitted shall set out accurately and completely all of the information required to be maintained under 29 CFR 5.5(a)(3)(i), except that full social security numbers and home addresses shall not be included on weekly transmittals. Instead, the payrolls shall only need to include an individually identifying number for each employee (e.g., the last four digits of the employee’s social security number). The required weekly payroll information may be submitted in any form desired. Optional Form WH-347 is available for this purpose from the Wage and Hour Division Web site at http://www.dol.gov/esa/whd/forms/wh347instr.htm or its successor site. The prime Contractor is responsible for the submission of copies of payrolls by all subcontractors. Contractors and subcontractors shall maintain the full social security number and current address of each covered worker, and shall provide them upon request to the Department of Energy if the agency is a party to the Contract, but if the agency is not such a party, the Contractor will submit them to the Recipient or Subrecipient (as applicable), applicant, sponsor, or owner, as the case may be, for transmission to the Department of Energy, the Contractor, or the Wage and Hour Division of the Department of Labor for purposes of an investigation or audit of compliance with prevailing wage requirements. It is not a violation of this section for a prime contractor to require a subcontractor to provide addresses and social security numbers to the prime contractor for its own records, without weekly submission to the sponsoring government agency (or the Recipient or Subrecipient (as applicable), applicant, sponsor, or owner).
    (B) Each payroll submitted shall be accompanied by a “Statement of Compliance,” signed by the Contractor or subcontractor or his or her agent who pays or supervises the payment of the persons employed under the Contract and shall certify the following:

 

21


DE-EE0002869 / 000

 

(1) That the payroll for the payroll period contains the information required to be provided under § 5.5 (a)(3)(ii) of Regulations, 29 CFR part 5, the appropriate information is being maintained under § 5.5 (a)(3)(i) of Regulations, 29 CFR part 5, and that such information is correct and complete;

(2) That each laborer or mechanic (including each helper, apprentice, and trainee) employed on the Contract during the payroll period has been paid the full weekly wages earned, without rebate, either directly or indirectly, and that no deductions have been made either directly or indirectly from the full wages earned, other than permissible deductions as set forth in Regulations, 29 CFR part 3;

(3) That each laborer or mechanic has been paid not less than the applicable wage rates and fringe benefits or cash equivalents for the classification of work performed, as specified in the applicable wage determination incorporated into the Contract.

(C) The weekly submission of a properly executed certification set forth on the reverse side of Optional Form WH-347 shall satisfy the requirement for submission of the “Statement of Compliance” required by paragraph (a)(3)(ii)(B) of this section.

(D) The falsification of any of the above certifications may subject the Contractor or subcontractor to civil or criminal prosecution under section 1001 of title 18 and section 3729 of title 31 of the United States Code.

(iii) The Contractor or subcontractor shall make the records required under paragraph (a)(3)(i) of this section available for inspection, copying, or transcription by authorized representatives of the Department of Energy or the Department of Labor, and shall permit such representatives to interview employees during working hours on the job. If the Contractor or subcontractor fails to submit the required records or to make them available, the Federal agency may, after written notice to the Contractor, sponsor, applicant, or owner, take such action as may be necessary to cause the suspension of any further payment, advance, or guarantee of funds. Furthermore, failure to submit the required records upon request or to make such records available may be grounds for debarment action pursuant to 29 CFR 5.12.

(4) Apprentices and trainees—

(i) Apprentices. Apprentices will be permitted to work at less than the predetermined rate for the work they performed when they are employed pursuant to and individually registered in a bona fide apprenticeship program registered with the U.S. Department of Labor, Employment and Training Administration, Office of Apprenticeship Training, Employer and Labor Services, or with a State Apprenticeship Agency recognized by the Office, or if a person is employed in his

 

22


DE-EE0002869 / 000

 

or her first 90 days of probationary employment as an apprentice in such an apprenticeship program, who is not individually registered in the program, but who has been certified by the Office of Apprenticeship Training, Employer and Labor Services or a State Apprenticeship Agency (where appropriate) to be eligible for probationary employment as an apprentice. The allowable ratio of apprentices to journeymen on the job site in any craft classification shall not be greater than the ratio permitted to the Contractor as to the entire work force under the registered program. Any worker listed on a payroll at an apprentice wage rate, who is not registered or otherwise employed as stated above, shall be paid not less than the applicable wage rate on the wage determination for the classification of work actually performed. In addition, any apprentice performing work on the job site in excess of the ratio permitted under the registered program shall be paid not less than the applicable wage rate on the wage determination for the work actually performed. Where a Contractor is performing construction on a project in a locality other than that in which its program is registered, the ratios and wage rates (expressed in percentages of the journeyman’s hourly rate) specified in the Contractor’s or subcontractor’s registered program shall be observed. Every apprentice must be paid at not less than the rate specified in the registered program for the apprentice’s level of progress, expressed as a percentage of the journeymen hourly rate specified in the applicable wage determination. Apprentices shall be paid fringe benefits in accordance with the provisions of the apprenticeship program. If the apprenticeship program does not specify fringe benefits, apprentices must be paid the full amount of fringe benefits listed on the wage determination for the applicable classification. If the Administrator determines that a different practice prevails for the applicable apprentice classification, fringes shall be paid in accordance with that determination. In the event the Office of Apprenticeship Training, Employer and Labor Services, or a State Apprenticeship Agency recognized by the Office, withdraws approval of an apprenticeship program, the Contractor will no longer be permitted to utilize apprentices at less than the applicable predetermined rate for the work performed until an acceptable program is approved.

(ii) Trainees. Except as provided in 29 CFR 5.16, trainees will not be permitted to work at less than the predetermined rate for the work performed unless they are employed pursuant to and individually registered in a program which has received prior approval, evidenced by formal certification by the U.S. Department of Labor, Employment and Training Administration. The ratio of trainees to journeymen on the job site shall not be greater than permitted under the plan approved by the Employment and Training Administration. Every trainee must be paid at not less than the rate specified in the approved program for the trainee’s level of progress, expressed as a percentage of the journeyman hourly rate specified in the applicable wage determination. Trainees shall be paid fringe benefits in accordance with the provisions of the trainee program. If the trainee program does not mention fringe benefits, trainees shall be paid the full amount of fringe benefits listed on the wage determination unless the Administrator of the Wage and Hour Division determines that there is an apprenticeship program associated with the corresponding journeyman wage rate on the wage

 

23


DE-EE0002869 / 000

 

determination which provides for less than full fringe benefits for apprentices. Any employee listed on the payroll at a trainee rate who is not registered and participating in a training plan approved by the Employment and Training Administration shall be paid not less than the applicable wage rate on the wage determination for the classification of work actually performed. In addition, any trainee performing work on the job site in excess of the ratio permitted under the registered program shall be paid not less than the applicable wage rate on the wage determination for the work actually performed. In the event the Employment and Training Administration withdraws approval of a training program, the Contractor will no longer be permitted to utilize trainees at less than the applicable predetermined rate for the work performed until an acceptable program is approved.

(iii) Equal employment opportunity. The utilization of apprentices, trainees, and journeymen under this part shall be in conformity with the equal employment opportunity requirements of Executive Order 11246, as amended and 29 CFR part 30.

(5) Compliance with Copeland Act requirements. The Contractor shall comply with the requirements of 29 CFR part 3, which are incorporated by reference in this Contract.

(6) Contracts and Subcontracts. The Recipient, Subrecipient, the Recipient’s, and Subrecipient’s contractors and subcontractor shall insert in any Contracts the clauses contained herein in(a)(1) through (10) and such other clauses as the Department of Energy may by appropriate instructions require, and also a clause requiring the subcontractors to include these clauses in any lower tier subcontracts. The Recipient shall be responsible for the compliance by any subcontractor or lower tier subcontractor with all of the paragraphs in this clause.

(7) Contract termination: debarment. A breach of the Contract clauses in 29 CFR 5.5 may be grounds for termination of the Contract, and for debarment as a contractor and a subcontractor as provided in 29 CFR 5.12.

(8) Compliance with Davis-Bacon and Related Act requirements. All rulings and interpretations of the Davis-Bacon and Related Acts contained in 29 CFR parts 1, 3, and 5 are herein incorporated by reference in this Contract.

(9) Disputes concerning labor standards. Disputes arising out of the labor standards provisions of this Contract shall not be subject to the general disputes clause of this Contract. Such disputes shall be resolved in accordance with the procedures of the Department of Labor set forth in 29 CFR parts 5, 6, and 7. Disputes within the meaning of this clause include disputes between the Recipient, Subrecipient, the Contractor (or any of its subcontractors), and the contracting agency, the U.S. Department of Labor, or the employees or their representatives.

 

24


DE-EE0002869 / 000

 

(10) Certification of eligibility.

(i) By entering into this Contract, the Contractor certifies that neither it (nor he or she) nor any person or firm who has an interest in the Contractor’s firm is a person or firm ineligible to be awarded Government contracts by virtue of section 3(a) of the Davis-Bacon Act or 29 CFR 5.12(a)(1).

(ii) No part of this Contract shall be subcontracted to any person or firm ineligible for award of a Government contract by virtue of section 3(a) of the Davis-Bacon Act or 29 CFR 5.12(a)(1).

(iii) The penalty for making false statements is prescribed in the U.S. Criminal Code, 18 U.S.C. 1001.

(b) Contract Work Hours and Safety Standards Act. As used in this paragraph, the terms laborers and mechanics include watchmen and guards.

(1) Overtime requirements. No Contractor or subcontractor contracting for any part of the Contract work which may require or involve the employment of laborers or mechanics shall require or permit any such laborer or mechanic in any workweek in which he or she is employed on such work to work in excess of forty hours in such workweek unless such laborer or mechanic receives compensation at a rate not less than one and one-half times the basic rate of pay for all hours worked in excess of forty hours in such workweek.

(2) Violation; liability for unpaid wages; liquidated damages. In the event of any violation of the clause set forth in paragraph (b)(1) of this section, the Contractor and any subcontractor responsible therefor shall be liable for the unpaid wages. In addition, such Contractor and subcontractor shall be liable to the United States (in the case of work done under contract for the District of Columbia or a territory, to such District or to such territory), for liquidated damages. Such liquidated damages shall be computed with respect to each individual laborer or mechanic, including watchmen and guards, employed in violation of the clause set forth in paragraph (b)(1) of this section, in the sum of $10 for each calendar day on which such individual was required or permitted to work in excess of the standard workweek of forty hours without payment of the overtime wages required by the clause set forth in paragraph (b)(1) of this section.

(3) Withholding for unpaid wages and liquidated damages. The Department of Energy or the Recipient or Subrecipient shall upon its own action or upon written request of an authorized representative of the Department of Labor withhold or cause to be withheld, from any moneys payable on account of work performed by the Contractor or subcontractor under any such contract or any other Federal contract with the same prime Contractor, or any other federally-assisted contract subject to the Contract Work Hours and Safety Standards Act, which is held by the same prime contractor, such sums as may be determined to be necessary to satisfy any liabilities of such Contractor or subcontractor for unpaid wages and liquidated damages as provided in the clause set forth in paragraph (b)(2) of this section.

 

25


DE-EE0002869 / 000

 

(4) Contracts and Subcontracts. The Recipient, Subrecipient, and Recipient’s and Subrecipient’s contractor or subcontractor shall insert in any Contracts, the clauses set forth in paragraph (b)(1) through (4) of this section and also a clause requiring the subcontractors to include these clauses in any lower tier subcontracts. The Recipient shall be responsible for compliance by any subcontractor or lower tier subcontractor with the clauses set forth in paragraphs (b)(1) through (4) of this section.

(5) The Contractor or subcontractor shall maintain payrolls and basic payroll records during the course of the work and shall preserve them for a period of three years from the completion of the Contract for all laborers and mechanics, including guards and watchmen, working on the Contract. Such records shall contain the name and address of each such employee, social security number, correct classifications, hourly rates of wages paid, daily and weekly number of hours worked, deductions made, and actual wages paid. The records to be maintained under this paragraph shall be made available by the Contractor or subcontractor for inspection, copying, or transcription by authorized representatives of the Department of Energy and the Department of Labor, and the Contractor or subcontractor will permit such representatives to interview employees during working hours on the job.

(d) Rates of Wages

After completion of negotiations, this provision may be revised.

The minimum wages to be paid laborers and mechanics under this award involved in performance of work at the project site, as determined by the Secretary of Labor to be prevailing for the corresponding classes of laborers and mechanics employed on projects of a character similar to the contract work in the pertinent locality, are found at http://www.wdol.gov/ , by clicking on “Selecting DBA WDs”. The Wage Determination Number(s) and General Decision Number(s) specific to this award are found below. These wage rates are minimum rates and are not intended to represent the actual wage rates that the Contractor may have to pay.

 

CONSTRUCTION

TYPE

 

  

WAGE DETERMINATION

NUMBER

 

  

GENERAL DECISION NUMBER

 

Building

   TBD    TBD

Highway

   TBD    TBD

Residential

   TBD    TBD

 

26


DE-EE0002869/001

APPENDIX

TO

SPECIAL TERMS AND CONDITIONS

REQUIREMENTS FOR CONTINGENCY FUNDS FOR INTEGRATED BIOREFINERY PROJECTS

 

TO DE-EE0002869-   “ Scale-Up & Mobilization of Renewable Diesel & Chemical Production From Common Intermediate Using US-Based Fermentable Sugar Feedstocks” Biorefinery Project

I.         Background

Recipients of awards selected under Funding Opportunity Announcement DE-FOA-000009 6 are required to provide an initial amount of Contingency funds equal to not less than 25 percent of the Total Project Cost (TPC), subject to the requirements and clarifications provided in this Appendix. TPC includes the approved combined Federal and Recipient cost share funding amounts to accomplish the approved scope in the Statement of Project Objectives that are allowable, reasonable and allocable to the project in accordance with 10 Code of Federal Regulations (CFR) 600.317.

II.         Definition

For the purposes of this award, Contingency is defined as follows:

A provision in the project management plan to mitigate cost and/or schedule risk (Project Management Body of Knowledge, Third Edition).

III.         Requirements

 

A. Purpose

The Recipient may expend Contingency funds solely for the purpose of mitigating risks to the cost and/or schedule associated with the project performance baseline and consistent with the Risk Mitigation or Management Plan (RMP) and Risk Register. Schedule risks ultimately would be reflected as cost overruns. It is expected that those risks will either be: a) performance baseline schedule and/or cost risks that are identified in the RMP and Risk Register (known risks or opportunities); or, b) to mitigate unknown performance baseline risks or uncertainties that become incorporated into the RMP and Risk Register as they are discovered.

 

B. Framework and Criteria

 

  1. The framework that governs the use of Contingency funds on the project authorized under this award relies on the Recipient to manage and control project performance baseline risks, opportunities and uncertainties utilizing the most recent, change-controlled performance baseline, Risk RMP and Risk Register. As risks are successfully mitigated throughout the duration of the project, the need for contingency is anticipated to decline. At the point when the performance test has been completed, the number and magnitude of risks and the available project and Contingency funds will need to be evaluated prior to DOE’s Critical Decision 4 — Approval of Operations.

 

1


DE-EE0002869/001

 

  2. The initial 25 percent minimum Contingency is calculated based on the TPC (DOE share + Recipient cost share) in dollars. The award is divided into two budget periods Budget Periods 1 and 2 (BP1 and BP2). BP1 primarily involves relatively low risk activities associated with design work, permitting, environmental baseline data gathering and analysis, financial close, and other activities that should not require significant contingency to be managed effectively. Therefore, for the purposes of this award, the 25% minimum Contingency requirement will be calculated based on the estimated TPC balance that begins with Budget Period 2 (BP2—construction and operations). The Recipient will need to provide evidence (consistent with evidence standards identified in C. below) of meeting the required 25% minimum Contingency prior to DOE authorizing Critical Decision 3 — Approve Start of Construction. For example, if the BP2 estimate for construction and operations equals a TPC of $100 million, with $50 million DOE funds and $50 million Recipient cost share funds, a minimum of $25 million in initial Contingency funds would be required at the start of BP2. Any increase in the TPC resulting from cost and/or schedule overruns incurred during BP1 will be added to the BP2 TPC before calculating the initial 25% Contingency minimum.

 

  3. Contingency Funds must be: a) liquid, b) immediately available, and c) unrestricted funds that are dedicated to the project.

 

  4. Expenditures of Contingency funds is in addition to the TPC, and cannot count towards cost share. Similarly, expenditures of Contingency cannot result in reimbursement by DOE above the share approved for the project.

 

  5. Contingency is NOT to be included in the project budget estimate.

 

  6. The use of Contingency funds cannot be considered allowable costs under the award unless and until Recipient has actually expended such funds to address cost and/or schedule overruns to the performance baseline.

 

  7. Estimated or projected program income CANNOT count towards contingency up front. However, the Recipient may use program income to reimburse actual expenditures of Contingency funds upon approval by the DOE Contracting Officer.

 

C. Acceptable Evidence of Sufficient Contingency Funds

 

  1. Recipient must provide evidence of Contingency funds that are dedicated to the project and sufficient to meet the 25 percent minimum, which must be documented and reported on a monthly basis consistent with the reporting requirements for this award.

 

  2.

Below is a list of the types of evidence the Contracting Officer may consider. Although this list is not all-inclusive, it represents some of the types of documents the Contracting Officer may consider as evidence of adequate Contingency. DOE will review evidence of adequate Contingency provided by the Recipient on a

 

2


DE-EE0002869/001

 

  case-by-case basis to determine its acceptability. This evidence may include, but is not limited to, one or a combination of the following:

 

  (i) Bank statement of availability of funds

 

  (ii) Letter of credit

 

  (iii) Evidence of sufficient cash funds (e.g., a letter from the bank or investors certifying to the specific amounts and availability of cash contributions)

 

  (iv) EPC Performance Guarantees

 

  (v) Evidence of funds in an escrowed account dedicated to the project

 

  (vi) Performance bond(s) — Terms and conditions must be approved by the Contracting Officer

 

  3. Self-certification of the availability of Contingency funds is generally NOT acceptable evidence. In order for self-certification to be considered acceptable by the Contracting Officer, the following minimum requirements must be met:

 

  a. An executive officer from the Recipient (typically, the Chief Financial Officer) who has control of the disbursement of Contingency funds must:

 

  i. Certify to no less than the minimum required initial specific amount, types and availability of Contingency funds;

 

  ii. Report on the expenditure of those funds monthly to the Contracting Officer; and

 

  iii. Recertify to the specific amount, type and availability of Contingency funds each month.

 

  b. Any Contingency funds expended to address risks and/or opportunities in the performance baseline must be transparent and documented through the most recent approved baseline change control procedure; and

 

  c. The documentation of expenditures of Contingency funds must be transparent such that an independent auditor would be able to easily track the use of such funds through the financial accounting system to the project code of accounts and to the performance baseline cost overruns.

 

D. Control and Management of Contingency Funds

 

  1.

Cost overruns that result in changes to the performance baseline must go through baseline change control. Cost overruns involving the use of Contingency must be documented through the most recent, approved baseline change control procedure. Those cost or schedule overruns that exceed the DOE-approved change control threshold must be approved by DOE. Exception : In the situation where an event occurs

 

3


DE-EE0002869/001

 

  that compromises safety or threatens human health or the environment, the Recipient is expected to expend the appropriate amount of resources and/or Contingency necessary to manage the event and the project to a safe configuration. Changes to the performance baseline and any cost overruns resulting from the event shall be addressed after the Recipient has achieved a safe project configuration.

 

  2. Any month in which the amount of Contingency becomes insufficient to meet the required minimum, it must be reported to the Contracting Officer within five (5) calendar days of discovery.

 

  3. Incorporation of Contingency within the basis of estimates for each activity shall not be allowed. Activity estimates should be consistent with standard Recipient project estimating methods (e.g., activity-based cost estimating, parametric cost estimating, etc.), but shall avoid the embedding and layering of contingency throughout the Work Breakdown Structure (WBS).

 

  4. At the completion of performance test (as described in the performance baseline), DOE will conduct the Critical Decision 4 (CD-4) — Approval of Operations review. This review will also be the point at which DOE will determine the amount of Contingency the Recipient will be required to have available during the operations phase. The criteria for this determination will be as follows:

 

  a. Pilot plants — The amount of the Contingency typically required will be based on a minimum of 10 percent of the initial capital cost (BP2 TPC). Using this as a base, the amount of Contingency will be adjusted taking into account risk mitigation trends through the end of the performance test. For example, if the estimate to complete (ETC) and remaining risks through the end of the performance test reflect successful risk mitigation and cost effective project performance management, DOE would factor that into its decision on what percentage contingency will be required for the operations phase. DOE will withhold a percentage of its funds to assure that the operations phase is completed in accordance with the performance baseline and that DOE receives operations data in the form required.

 

  b. Demonstration plants — The required amount of Contingency typically will be based on a minimum of 10 percent of the initial capital cost (BP2 TPC). Using this as a base, the amount of Contingency will be adjusted using risk mitigation trends through completion of the performance test. For example, if the ETC and risks remaining through the end of the performance test reflect successful risk mitigation and cost effective project performance management, DOE could factor that into its decision on what percentage contingency will be required for the operations phase. Furthermore, if the cost of the core technology exceeds 10 percent of the initial capital cost (BP2 TPC), DOE will factor this into the percentage of DOE funds to be withheld to assure that the operations phase is completed in accordance with the performance baseline.

 

4


Federal Financial Assistance Regulations – 10 CFR 600

3/27/96, Amended 12/05/06

 

10 CFR 600 – Subpart A – General    2

10 CFR 600 – Subpart B – Uniform Administrative Requirements for Grants and

Cooperative Agreements with Institutions of Higher Education, Hospitals, and Other

Non-Profit Organizations.

   27

10 CFR 600 – Subpart C – Uniform Administrative Requirements for Grants and

Cooperative Agreements to State and Local Governments

   76

Subpart D — Administrative Requirements for Grants and Cooperative Agreements With

For-Profit Organizations

   123

10 CFR 600—Subpart F – Eligibility Determination for Certain Financial Assistance

Programs—General Statement of Policy

   189
10 CFR 600— Appendix A to Part 600 – Generally Applicable Requirements    193
10 CFR 600— Appendix B to Part 600 – Audit Report Distributees    195

 

1


10 CFR 600 – Subpart A – General

 

600.1    Purpose.    3
600.2    Applicability.    3
600.3    Definitions.    3
600.4    Deviations.    5
600.5    Selection of award instrument.    6
600.6    Eligibility.    7
600.7    Small and disadvantaged and women-owned business participation.    9
600.8    Program announcements.    9
600.9    [Removed and Reserved].    10
600.10    Form and content of applications.    10
600.11    Intergovernmental review.    11
600.12    Generally applicable requirements.    11
600.13    Merit review.    11
600.14    {Reserved}    12
600.15    Authorized uses of information.    12
600.16    Legal authority and effect of an award.    13
600.17    Contents of award.    13
600.18    Recipient acknowledgement of award.    13
600.19    Notification to unsuccessful applicants.    14
600.20    Maximum DOE obligation.    14
600.21    Access to records.    14
600.22    Disputes and appeals.    15
600.23    Debarment and suspension.    17
600.24    Noncompliance.    17
600.25    Suspension and termination.    18
600.26    Funding.    20
600.27    Reserved.    21
600.28    Restrictions on lobbying.    21
600.29    Fixed obligation awards.    21
600.30    Cost sharing.    22
600.31    Research Misconduct.    23

 

2


Subpart A – General

600.1             Purpose.

This part implements the Federal Grant and Cooperative Agreement Act, Pub. L. 95-224, as amended by Pub. L. 97-258 (31 U.S.C. 6301-6308), and establishes uniform policies and procedures for the award and administration of DOE grants and cooperative agreements. This subpart (Subpart A) sets forth the policies and procedures applicable to the award and administration of grants and cooperative agreements.

600.2             Applicability.

(a) Except as otherwise provided by Federal statute or program rule, this part applies to applications, solicitations, and new, continuation, and renewal awards (and any subsequent subawards).

(b) Any new, continuation, or renewal award (and any subsequent subaward) shall comply with any applicable Federal statute, Federal rule, Office of Management and Budget (OMB) Circular and Governmentwide guidance in effect as of the date of such award.

(c) Financial assistance to foreign entities is governed, to the extent appropriate, by this part and by the administrative requirements and cost principles applicable to their respective recipient type, e.g, governmental, non-profit, commercial.

600.3             Definitions.

Amendment means the written document executed by a DOE contracting officer that changes one or more terms or conditions of an existing financial assistance award.

Award means the written document executed by a DOE Contracting Officer, after an application is approved, which contains the terms and conditions for providing financial assistance to the recipient.

Budget period means the interval of time, specified in the award, into which a project is divided for budgeting and funding purposes.

Continuation award means an award for a succeeding or subsequent budget period after the initial budget period of either an approved project period or renewal thereof.

Contract means a written procurement contract executed by a recipient or subrecipient for the acquisition of property or services under a financial assistance award.

 

3


Contracting Officer means the DOE official authorized to execute awards on behalf of DOE and who is responsible for the business management and non-program aspects of the financial assistance process.

DOE Patent Counsel means the Department of Energy Patent Counsel assisting the Contracting Officer in the review and coordination of patents and data related items.

Financial Assistance means the transfer of money or property to a recipient or subrecipient to accomplish a public purpose of support or stimulation authorized by Federal statute. For purposes of this part, financial assistance instruments are grants and cooperative agreements and subawards.

Head of Contracting Activity or HCA means a DOE official with senior management authority for the award and administration of financial assistance instruments within one or more DOE organizational elements.

Merit review means a thorough, consistent and objective examination of applications based on pre-established criteria by persons who are independent of those submitting the applications and who are knowledgeable in the field of endeavor for which support is requested.

Nonprofit organization means any corporation, trust, foundation, or institution which is entitled to exemption under section 501(c)(3) of the Internal Revenue Code, or which is not organized for profit and no part of the net earnings of which inure to the benefit of any private shareholder or individual (except that the definition of “nonprofit organization” at 48 CFR 27.301 shall apply for patent matters set forth at Sections 600.136 and 600.325).

Program rule means a rule issued by a DOE program office for the award and administration of financial assistance which may describe the program’s purpose or objectives, eligibility requirements for applicants, types of program activities or areas to be supported, evaluation and selection process, cost sharing requirements, etc. These rules usually supplement the generic policies and procedures for financial assistance contained in this part.

Project means the set of activities described in an application, State plan, or other document that is approved by DOE for financial assistance (whether such financial assistance represents all or only a portion of the support necessary to carry out those activities.)

Project period means the total period of time indicated in an award during which DOE expects to provide financial assistance. A project period may consist of one or more budget periods and may be extended by DOE.

Recipient means the organization, individual, or other entity that receives an award from DOE and is financially accountable for the use of any DOE funds or property provided

 

4


for the performance of the project, and is legally responsible for carrying out the terms and conditions of the award.

Renewal award means an award which adds one or more additional budget periods to an existing project period.

Research and development means all research activities, both basic and applied, and all development activities that are supported at universities, colleges, and other non-profit institutions and commercial organizations. “Research” is defined as a systematic study directed toward fuller scientific knowledge or understanding of the subject studied. The term research also includes activities involving the training of individuals in research techniques where such activities utilize the same facilities as other research and development activities and where such activities are not included in the instruction function. “Development” is the systematic use of knowledge and understanding gained from research directed toward the production of useful materials, devices, systems, or methods, including design and development of prototypes and processes.

600.4             Deviations.

(a) General.

(1) A deviation is the use of any policy, procedure, form, standard, term, or condition which varies from a requirement of this part, or the waiver of any such requirement, unless such use or waiver is authorized or precluded by Federal statute. The use of optional or discretionary provisions of this part, including special restrictive conditions used in accordance with Sections 600.114 and 600.212, are not deviations. Awards to foreign entities and the waiver of the cost sharing requirements in Section 600.30 are not subject to this section.

(2) A single-case deviation is a deviation which applies to one financial assistance transaction and one applicant, recipient, or subrecipient only.

(3) A class deviation is a deviation which applies to more than one financial assistance transaction, applicant, recipient, or subrecipient.

(b) The DOE officials specified in paragraph (c) of this section may authorize a deviation only upon a written determination that the deviation is —

(1) Necessary to achieve program objectives;

(2) Necessary to conserve public funds;

(3) Otherwise essential to the public interest; or

(4) Necessary to achieve equity.

 

5


(c) Approval procedures.

(1) A deviation request must be in writing and must be submitted to the responsible DOE Contracting Officer. An applicant for a subaward or a subrecipient shall submit any such request through the recipient.

(2) Except as provided in paragraph (c)(3) of this section —

(i) A single-case deviation may be authorized by the responsible HCA.

(ii) A class deviation may be authorized by the Director, Procurement and Assistance Management or designee.

(3) Whenever the approval of OMB, other Federal agency, or other DOE office is required to authorize a deviation, the proposed deviation must be submitted to the Director, Procurement and Assistance Management or designee for concurrence prior to submission to the authorizing official.

(d) Notice. Whenever a request for a class deviation is approved, DOE shall publish a notice in the Federal Register at least 15 days before the class deviation becomes effective. Whenever a class deviation is contained in a proposed program rule, the preamble to the proposed rule shall describe the purpose and scope of the deviation.

(e) Subawards. A recipient may use a deviation in a subaward only with the prior written approval of a DOE Contracting Officer.

600.5             Selection of award instrument.

(a) If DOE has administrative discretion in the selection of the award instrument, the DOE decision as to whether the relationship is principally one of procurement or financial assistance shall be made pursuant to the Federal Grant and Cooperative Agreement Act as codified at 31 U.S.C. 6301-6306. A grant or cooperative agreement shall be the appropriate instrument, in accordance with this part, when the principal purpose of the relationship is the transfer of money or property to accomplish a public purpose of support or stimulation authorized by Federal statute. In selecting the type of financial assistance instrument, DOE shall limit involvement between itself and the recipient in the performance of a project to the minimum necessary to achieve DOE program objectives.

(b) When it is anticipated that substantial involvement will be necessary between DOE and the recipient during performance of the contemplated activity, the award instrument shall be a cooperative agreement rather than a grant. Every cooperative agreement shall explicitly state the substantial involvement anticipated between DOE and the recipient during the performance of the project. Substantial involvement exists if:

 

6


(1) Responsibility for the management, control, or direction of the project is shared by DOE and the recipient; or

(2) Responsibility for the performance of the project is shared by DOE and the recipient.

(c) Providing technical assistance or guidance of a programmatic nature to a recipient does not constitute substantial involvement if:

(1) the recipient is not required to follow such guidance;

(2) the technical assistance or guidance is not expected to result in continuing DOE involvement in the performance of the project; or

(3) The technical assistance or guidance pertains solely to the administrative requirements of the award.

(d) In cooperative agreements, DOE has the right to intervene in the conduct or performance of project activities for programmatic reasons. Intervention includes the interruption or modification of the conduct or performance of project activities. Suspension or termination of the cooperative agreement under Sections 600.162 and 600.243 does not constitute intervention in the conduct or performance of project activities.

600.6             Eligibility.

(a) General. DOE shall solicit applications for financial assistance in a manner which provides for the maximum amount of competition feasible.

(b) Restricted eligibility. If DOE restricts eligibility, an explanation of why the restriction of eligibility is considered necessary shall be included in the solicitation, program rule, or published notice. Except when authorized by statute or program rule, if the aggregate amount of DOE funds available for award under a solicitation or published notice is $1,000,000 or more, such restriction of eligibility shall be supported by a written determination initiated by the program office and approved by an official no less than two levels above the initiating program official and concurred in by the Contracting Officer and legal counsel. Where the amount of DOE funds is less than $1,000,000, the cognizant HCA and the Contracting Officer may approve the determination.

(c) Noncompetitive financial assistance. DOE may award a grant or cooperative agreement on a noncompetitive basis only if the application satisfies one or more of the following selection criteria:

 

7


(1) The activity to be funded is necessary to the satisfactory completion of, or is a continuation or renewal of, an activity presently being funded by DOE or another Federal agency, and for which competition for support would have a significant adverse effect on continuity or completion of the activity.

(2) The activity is being or would be conducted by the applicant using its own resources or those donated or provided by third parties; however, DOE support of that activity would enhance the public benefits to be derived and DOE knows of no other entity which is conducting or is planning to conduct such an activity.

(3) The applicant is a unit of government and the activity to be supported is related to performance of a governmental function within the subject jurisdiction, thereby precluding DOE provision of support to another entity.

(4) The applicant has exclusive domestic capability to perform the activity successfully, based upon unique equipment, proprietary data, technical expertise, or other such unique qualifications.

(5) The award implements an agreement between the United States Government and a foreign government to fund a foreign applicant.

(6) Time constraints associated with a public health, safety, welfare or national security requirement preclude competition.

(7) The proposed project was submitted as an unsolicited proposal and represents a unique or innovative idea, method, or approach which would not be eligible for financial assistance under a recent, current, or planned solicitation, and if, as determined by DOE, a competitive solicitation would not be appropriate.

(8) The responsible program Assistant Secretary, Deputy Administrator, or other official of equivalent authority determines that a noncompetitive award is in the public interest. This authority may not be delegated.

(d) Approval requirements. Determinations of noncompetitive awards shall be approved, prior to award, by the initiating program official, by the responsible program Assistant Secretary (or official of equivalent authority) or designee, who shall be not less than two organizational levels above that of the project officer, by the Contracting Officer and shall be concurred in by local legal counsel. Where the amount of DOE funds is less than $1,000,000 for a noncompetitive financial assistance award, the determination shall be approved by the cognizant HCA and the Contracting Officer. Concurrence for a particular award or class of awards of $1,000,000 or less may be waived by local legal counsel.

(e) Documentation requirements. A determination of noncompetitive financial assistance (normally prepared by the responsible program official) explaining the basis for the proposed noncompetitive award shall be placed in the award file.

 

8


600.7             Small and disadvantaged and women-owned business participation.

(a) DOE encourages the participation in financial assistance awards of small businesses, including those owned by socially and economically disadvantaged individuals and women, of historically black colleges, and of colleges and universities with substantial minority enrollments.

(b) For definitions of the terms in paragraph (a) of this section, see the Higher Education Act of 1965, and 15 U.S.C. 644, as amended by the Federal Acquisition Streamlining Act (FASA), and implementing regulations under FASA issued by the Office of Federal Procurement Policy.

(c) When entering into contracts under financial assistance awards, recipients and subrecipients shall comply with the requirements of Section 600.144 or Section 600.236, as applicable.

600.8             Program announcements.

(a) General . Program announcements include any issuance used to announce funding opportunities that would result in the award of a discretionary grant or cooperative agreement, whether it is called a program announcement, program notice, solicitation, broad agency announcement, research announcement, notice of program interest, or something else.

(1) A Program Assistant Secretary (or official of equivalent authority) may annually issue a program notice describing research areas in which financial assistance is being made available. Such notice shall also state whether the research areas covered by the notice are to be added to those listed in a previously issued program rule. If they are to be included, then applications received as a result of the notice may be treated as having been in response to that previously published program rule. If they are not to be included, then applications received in response to the notice are to be treated as unsolicited applications. Solicitations may be issued by a DOE Contracting Officer or program office with prior concurrence of the contracting office.

(2) DOE must post synopses of its program announcements and modifications to the announcements at the Grants.gov Internet site, using the standard data elements/format, except for:

(i) Announcements of funding opportunities for awards less than $25,000 for which 100 percent of eligible applicants live outside the United States.

(ii) Single source announcements of funding opportunities which are specifically directed to a known recipient.

 

9


(b) Subawards. In accordance with the provisions of the applicable statute and program rules, if a DOE financial assistance program involves the award of financial assistance by a recipient to a subrecipient, the recipient shall provide sufficient advance notice so that potential subrecipients may prepare timely applications and secure prerequisite reviews and approvals.

(c) Announcement format. DOE must use the government-wide standard format to publish program announcements of funding opportunities.

600.9             [Removed and Reserved].

Section 600.9 is removed and reserved.

600.10           Form and content of applications.

(a) General. Applications shall be required for all financial assistance projects or programs.

(b) Forms. Applications shall be on the form and in the number of copies specified in a program rule, the program announcement or in these regulations. (See also Sections 600.112 and 600.210.) For unsolicited applications, a guide for preparation and submission is available from U.S. Department of Energy, Federal Energy Technology Center, Attn: Unsolicited Proposal Manager, Post Office Box 10940, Pittsburgh, PA, 15236-0940.

(c) Contents of an application. In general, a financial assistance application shall include:

(1) A facesheet containing basic identifying information. The facesheet shall be the Standard Form (SF)424 or other approved DOE application form;

(2) A detailed narrative description of the proposed project, including the objectives of the project and the applicant’s plan for carrying it out;

(3) A budget with supporting justification; and

(4) Any required preaward assurances.

(d) Incomplete applications. DOE may return an application that:

(1) is not signed, either in writing or electronically, by an official authorized to bind the applicant; or

(2) omits any information or documentation required by statute, program rule, or the solicitation, if the nature of the omission precludes review of the application.

 

10


(e) Supplemental information. During the review of a complete application, DOE may request the submission of additional information only if the information is essential to evaluate the application.

600.11           Intergovernmental review.

Intergovernmental review of DOE financial assistance shall be conducted in accordance with 10 CFR Part 1005.

 

600.12           Generally applicable requirements.

(a) Except as expressly exempted by Federal statute or program rule, recipients and subrecipients of DOE financial assistance shall comply with all generally applicable requirements to which they are subject. Generally applicable requirements include, but are not limited to, the requirements of this part, Federal statutes, the OMB Circulars and other Government-wide guidance implemented by this part, Executive Orders, and the requirements identified in Appendix A of this subpart.

(b) Provisions shall be made to design and construct all buildings, in which DOE funds are used, to meet appropriate seismic design and construction standards. Seismic codes and standards meeting or exceeding the provisions of each of the model codes listed in this paragraph are considered to be appropriate for purposes of this part. These codes provide a level of seismic safety that is substantially equivalent to the National Earthquake Hazards Reduction Program (NEHRP) Recommended Provisions for the Development of Seismic Regulations for New Buildings, 1988 Edition (Federal Emergency Management Administration 222 and 223). Revisions of these model codes that are substantially equivalent to or exceed the then current or immediately preceding edition of the NEHRP Recommended Provisions (which are updated triennially) shall be considered to be appropriate standards.

The model codes are as follows:

(1) 1991 Uniform Building Code, of the International Council of Building Officials,

(2) 1992 Supplement to the National Building Code, of the Building Official and Code Administrators International.

(3) 1992 Amendments to the Standard Building Code, of the Southern Building Code Congress International.

600.13           Merit review.

 

11


(a) It is the policy of DOE that discretionary financial assistance be awarded through a merit-based selection process. A merit review means a thorough, consistent, and objective examination of applications based on pre-established criteria by persons who are independent of those submitting the applications and who are knowledgeable in the field of endeavor for which support is requested.

(b) Each program office must establish a merit review system covering the financial assistance programs it administers. Merit review of financial assistance applications is intended to be advisory and is not intended to replace the authority of the project/program official with responsibility for deciding whether an award will be made.

600.14           {Reserved}

600.15           Authorized uses of information.

(a) General. Information contained in applications shall be used only for evaluation purposes unless such information is generally available to the public or is already the property of the Government. The Trade Secrets Act, 18 U.S.C. 1905, prohibits the unauthorized disclosure by Federal employees of trade secret and confidential business information.

(b) Treatment of application information.

(1) An application may include technical data and other data, including trade secrets and/or privileged or confidential commercial or financial information, which the applicant does not want disclosed to the public or used by the Government for any purpose other than application evaluation. To protect such data, the applicant should specifically identify each page including each line or paragraph thereof containing the data to be protected and mark the cover sheet of the application with the following Notice as well as referring to the Notice on each page to which the Notice applies:

Notice of Restriction on Disclosure and Use of Data

The data contained in pages — — of this application have been submitted in confidence and contain trade secrets or proprietary information, and such data shall be used or disclosed only for evaluation purposes, provided that if this applicant receives an award as a result of or in connection with the submission of this application, DOE shall have the right to use or disclose the data herein to the extent provided in the award. This restriction does not limit the Government’s right to use or disclose data obtained without restriction from any source, including the applicant.

(2) Unless a solicitation specifies otherwise, DOE shall not refuse to consider an application solely on the basis that the application is restrictively marked.

 

12


(3) Data (or abstracts of data) marked with the Notice under paragraph (b)(1) of this section shall be retained in confidence and used by DOE or its designated representatives as specified in Section 600.13 solely for the purpose of evaluating the proposal. The data so marked shall not be disclosed or used for any other purpose except to the extent provided in any resulting award, or to the extent required by law, including the Freedom of Information Act (5 U.S.C. 552) (10 CFR Part 1004). The Government shall not be liable for disclosure or use of unmarked data and may use or disclose such data for any purpose.

600.16           Legal authority and effect of an award.

(a) A DOE financial assistance award is valid only if it is in writing and is signed, either in writing or electronically, by a DOE Contracting Officer.

(b) DOE funds awarded under a grant or cooperative agreement shall be obligated as of the date the DOE Contracting Officer signs the award; however, the recipient is not authorized to incur costs under an award prior to the beginning date of the budget period shown in the award except as may be authorized in accordance with Sections 600.125(e) or 600.230 of this part. The duration of the DOE financial obligation shall not extend beyond the expiration date of the budget period shown in the award unless authorized by a DOE Contracting Officer by means of a continuation or renewal award or other extension of the budget period.

600.17           Contents of award.

Each financial assistance award shall be made on a Notice of Financial Assistance Award (DOE F 4600.1) which contains basic identifying and funding information together with attachments including a budget, any special terms and conditions, and any other provisions necessary to establish the respective right, duties, obligation, and responsibilities of DOE and the recipient, consistent with the requirements of this part.

600.18           Recipient acknowledgement of award.

(a) After signature by the DOE Contracting Officer, the award shall be sent to the recipient. The recipient shall acknowledge acceptance by returning a copy signed either in writing or electronically. No DOE funds shall be disbursed until the award document signed by the recipient is received by DOE.

(b) In the event a recipient declines an award, DOE shall deobligate the funds obligated by the award after providing the applicant with at least two weeks written notice of DOE’s intention to deobligate.

 

13


(c) After the recipient acknowledges the award, the terms and conditions of the award may be amended only upon the written request or with the written concurrence of the recipient unless the amendment is one which DOE may make unilaterally in accordance with a program rule or this part.

600.19           Notification to unsuccessful applicants.

DOE shall promptly notify in writing each applicant whose application has not been selected for award or whose application cannot be funded because of the unavailability of appropriated funds. If the application was not selected, the written notice shall briefly explain why the application was not selected and, if for grounds other than unavailability of funds, shall offer the unsuccessful applicant the opportunity for a more detailed explanation upon request.

600.20           Maximum DOE obligation.

(a) The maximum DOE obligation to the recipient is —

(1) For monetary awards, the amount shown in the award as the amount of DOE funds obligated, and

(2) Any designated property.

(b) DOE shall not be obligated to make any additional, supplemental, continuation, renewal, or other award for the same or any other purpose.

600.21            Access to records.

(a) In addition to recipient and subrecipient responsibilities relative to access to records specified in Sections 600.153 and 600.242, for any negotiated contract or subcontract in excess of $10,000 under a grant or cooperative agreement, DOE, the Comptroller General of the United States, the recipient and the subrecipient (if the contract was awarded under a financial assistance subaward), or any of their authorized representatives shall have the right of access to any books, documents, papers, or other records of the contractor or subcontractor which are pertinent to that contract or subcontract, in order to make audit, examination, excerpts, and copies.

(b) The right of access may be exercised for as long as the applicable records are retained by the recipient, subrecipient, contractor, or subcontractor.

 

14


600.22           Disputes and appeals.

(a) Informal dispute resolution. Whenever practicable, DOE shall attempt to resolve informally any dispute over the award or administration of financial assistance. Informal resolution, including resolution through an alternative dispute resolution mechanism, shall be preferred over formal procedures available in 10 CFR Part 1024, to the extent practicable.

(b) Alternative dispute resolution (ADR). Before issuing a final determination in any dispute in which informal resolution has not been achieved, the Contracting Officer shall suggest that the other party consider the use of voluntary consensual methods of dispute resolution, such as mediation. The DOE dispute resolution specialist is available to provide assistance for such disputes, as are trained mediators of other federal agencies. ADR may be used at any stage of a dispute.

(c) Final determination. Whenever a dispute is not resolved informally or through an alternative dispute resolution process, DOE shall mail (by certified mail) a brief written determination signed by a Contracting Officer, setting forth DOE’s final disposition of such dispute. Such determination shall contain the following information:

(1) A summary of the dispute, including a statement of the issues and of the positions taken by the Department and the party or parties to the dispute; and

(2) The factual, legal and, if appropriate, policy reasons for DOE’s disposition of the dispute.

(d) Right of appeal.

(1) Except as provided in paragraph (f)(1) of this section, the final determination under paragraph (c) of this section may be appealed to the Financial Assistance Appeals Board (the Board) in accordance with the procedures set forth in 10 CFR part 1024.

(2) If the final determination under paragraph (c) of this section involves a dispute over which the Board has jurisdiction as provided in paragraph (f)(2) of this section, the Contracting Officer’s determination shall state that, with respect to such dispute, the determination shall be the final decision of the Department unless, within 60 days, a written notice of appeal is filed.

(3) If the final determination under paragraph (c) of this section involves a dispute over which the Board has no jurisdiction as provided in paragraph (f)(1) of this section, the Contracting Officer’s determination shall state that, effective immediately or on a later date specified therein, the determination shall, with respect to such dispute, be the final decision of the Department.

 

15


(e) Effect of appeal. The filing of an appeal with the Board shall not stay any determination or action taken by DOE which is the subject of the appeal. Consistent with its obligation to protect the interests of the Federal Government, DOE may take such authorized actions as may be necessary to preserve the status quo pending decision by the Board, or to preserve its ability to provide relief in the event the Board decides in favor of the appellant.

(f) Review on appeal.

(1) The Board shall have no jurisdiction to review:

(i) Any preaward dispute (except as provided in paragraph (f)(2)(ii) of this section), including use of any special restrictive condition pursuant to Sections 600.114 or 600.212;

(ii) DOE denial of a request for a deviation under Sections 600.4, 600.103, or 600.205 of this part;

(iii) DOE denial of a request for a budget revision or other change in the approved project under Sections 600.125, 600.127, 600.222, or 600.230 of this part or under another term or condition of the award;

(iv) Any DOE action authorized under Sections 600.162(a) (1), (2), (3) or (5); or Sections 600.243 (a)(1), (a)(3) for suspensions only; or Sections 600.162 (a)(4) or Section 600.243(a)(4) for actions disapproving renewal applications or other requests for extension of time or additional funding for the same project when related to recipient noncompliance, or such actions authorized by program rule;

(v) Any DOE decision about an action requiring prior DOE approval under Section 600.144, or Section 600.236 of this part or under another term or condition of the award;

(vi) A DOE decision not to make a continuation award, which decision is based on the insufficiency of available appropriations;

(vii) Any matter which is under the jurisdiction of the Patent Compensation Board (10 CFR 780.3);

(viii) Any matter which may be heard by the Invention Licensing Appeals Board (10 CFR 781.65 and 781.66); and

(ix) Any other dispute not described in paragraph (f)(2) of this section.

(2) In addition to any right of appeal established by program rule, or by the terms and conditions (not inconsistent with paragraph (f)(1) of this section) of an award, the Board shall have jurisdiction to review:

 

16


(i) A DOE determination that the recipient has failed to comply with the applicable requirements of this part, the program statute or rules, or other terms and conditions of the award;

(ii) A DOE decision not to make a continuation award based on any of the determinations described in paragraph (f)(2)(i) of this section;

(iii) Termination of an award for cause, in whole or in part, by DOE;

(iv) A DOE determination that an award is void or invalid;

(v) The application by DOE of an indirect cost rate; and

(vi) DOE disallowance of costs.

(3) In reviewing disputes authorized under paragraph (f)(2) of this section, the Board shall be bound by the applicable law, statutes, and rules, including the requirements of this part, and by the terms and conditions of the award.

(4) The decision of the Board shall be the final decision of the Department.

600.23           Debarment and suspension.

Applicants, recipients, subrecipients, and contractors under financial assistance awards may be debarred and suspended for the causes and in accordance with the procedures set forth in 2 CFR part 901.

600.24           Noncompliance.

(a) Except for noncompliance with nondiscrimination requirements under 10 CFR Part 1040, whenever DOE determines that a recipient has not complied with the applicable requirements of this part, with the requirements of any applicable program statute or rule, or with any other term or condition of the award, a DOE Contracting Officer shall provide to the recipient (by certified mail, return receipt requested) a written notice setting forth:

(1) The factual and legal bases for the determination of noncompliance;

(2) The corrective actions and the date (not less than 30 days after the date of the notice) by which they must be taken.

(3) Which of the actions authorized under Section 600.122(n), Section 600.162(a) or Section 600.243(a) of this part DOE may take if the recipient does not achieve

 

17


compliance within the time specified in the notice, or does not provide satisfactory assurances that actions have been initiated which will achieve compliance in a timely manner.

(b) DOE may take any of the actions set forth in Section 600.122(n), Section 600.162(a), or Section 600.243(a) of this part concurrent with the written notice required under paragraph (a) of this section or with less than 30 days written notice to the recipient whenever:

(1) There is evidence the award was obtained by fraud;

(2) The recipient ceases to exist or becomes legally incapable of performing its responsibilities under the financial assistance award; or

(3) There is a serious mismanagement or misuse of financial assistance award funds necessitating immediate action.

600.25           Suspension and termination.

(a) Suspension and termination for cause. DOE may suspend or terminate an award for cause on the basis of:

(1) a noncompliance determination under Section 600.24, Section 600.122(n), Section 600.162(a), or Section 600.243(a); or

(2) an suspension or debarment of the awardee under Section 600.23.

(b) Notification requirements. Except as provided in Section 600.24, Section 600.162(a), or Section 600.243(a) before suspending or terminating a award for cause, DOE shall mail to the awardee (by certified mail, return receipt requested) a separate written notice in addition to that required by Section 600.24(a), Section 600.162(a), or Section 600.243(a) at least ten days prior to the effective date of the suspension or termination. Such notice shall include, as appropriate:

(1) The factual and legal bases for the suspension or termination;

(2) The effective date or dates of the DOE action;

(3) If the action does not apply to the entire award, a description of the activities affected by the action;

(4) Instructions concerning which costs shall be allowable during the period of suspension, or instructions concerning allowable termination costs, including in either case, instructions concerning any subgrants or contracts;

 

18


(5) Instructions concerning required final reports and other closeout actions for terminated awards (see Sections 600.170 through 600.173 and Sections 600.250 through 600.252);

(6) A statement of the awardee’s right to appeal a termination for cause pursuant to Section 600.22; and

(7) The dated signature of a DOE Contracting Officer.

(c) Suspension.

(1) Unless DOE and the awardee agree otherwise, no period of suspension shall exceed 90 days.

(2) DOE may cancel the suspension at any time, up to and including the date of expiration of the period of suspension, if the awardee takes satisfactory corrective action before the expiration date of the suspension or gives DOE satisfactory evidence that such corrective action will be taken.

(3) If the suspension has not been cancelled by the expiration date of the period of suspension, the awardee shall resume the suspended activities or project unless, prior to the expiration date, DOE notifies the awardee in writing that the period of suspension shall be extended consistent with paragraph (c)(1) of this section or that the award shall be terminated.

(4) As of the effective date of the suspension, DOE shall withhold further payments and shall allow new obligations incurred by the awardee during the period of suspension only if such costs were authorized in the notice of suspension or in a subsequent letter.

(5) If the suspension is cancelled or expires and the award is not terminated, DOE shall reimburse the awardee for any authorized allowable costs incurred during the suspension and, if necessary, may amend the award to extend the period of performance.

(d) Termination by mutual agreement. In addition to any situation where a termination for cause pursuant to Section 600.24, Sections 600.160 through 600.162 or Sections 600.243 through 600.244 is appropriate, either DOE or the awardee may initiate a termination of a award (or portion thereof) as described in this paragraph. If the awardee initiates a termination, the awardee must notify DOE in writing and specify the awardee’s reasons for requesting the termination, the proposed effective date of the termination, and, in the case of a partial termination, a description of the activities to be terminated, and an appropriate budget revision. DOE shall terminate an award or portion thereof under this paragraph only if both parties agree to the termination and the conditions under which it shall occur. If DOE determines that the remaining activities under a partially terminated

 

19


award would not accomplish the purpose for which the award was originally awarded, DOE may terminate the entire award.

(e) Effect of termination. The awardee shall incur no new obligations after the effective date of the termination of a award (or portion thereof), and shall cancel as many outstanding obligations as possible. DOE shall allow full credit to the awardee for the DOE share of noncancellable obligations properly incurred by the awardee prior to the effective date of the termination.

(f) Subgrants. Awardees shall follow the policies and procedures in this section and in Section 600.24, Sections 600.160 through 600.162 or Sections 600.243 through 600.244 for suspending and terminating subgrants.

600.26           Funding.

(a) General. The project period during which DOE expects to provide award support for an approved project shall be specified on the Notice of Financial Assistance Award (DOE Form 4600.1).

(b) Budget period and continuation awards. If the project period is 12 months or less, the budget period and the project period shall be coextensive. Multiyear awards, including formula awards, shall generally be funded annually within the approved project period. Funding for each budget period within the project period shall be contingent on DOE approval of a continuation application submitted in accordance with a schedule specified by DOE. A continuation application shall include:

(1) A statement of technical progress or status of the project to date;

(2) A detailed description of the awardee’s plans for the conduct of the project during the coming year; and

(3) A detailed budget for the upcoming budget period, including an estimate of unobligated balances. A detailed budget need not be submitted if the new or renewal application contained future-year budgets sufficiently detailed to allow DOE to review and approve the categories and elements of cost. Should the award have a change in scope or significant change in the budget, DOE may request a detailed budget.

(4) DOE shall review a continuation application for the adequacy of the awardee’s progress and planned conduct of the project in the subsequent budget period. DOE shall not require a continuation application to compete against any other application. The amount and award of continuation funding is subject to the availability of appropriations.

 

20


(c) Renewal awards. Discretionary renewal awards may be made either on the basis of a solicitation or on a noncompetitive basis. If DOE proposes to restrict eligibility for a discretionary renewal award to the incumbent grantee, the noncompetitive award must be justified in accordance with 600.6(b)(2). Renewal applications must be submitted no later than 6 months prior to the scheduled expiration of the project period unless a program rule or other published instruction establishes a different application deadline.

(d) Extensions. Unless otherwise specified in the award terms and conditions, recipients of financial assistance awards, except recipients of SBIR awards (See Section 600.181), may extend the expiration date of the final budget period of the project (thereby extending the project period) if additional time beyond the established expiration date is needed to assure adequate completion of the original scope of work within the funds already made available. A single extension, which shall not exceed twelve (12) months, may be made for this purpose, and must be made prior to the originally established expiration date. The recipient must notify the cognizant DOE Contracting Officer in the awarding office in writing within ten (10) days of making the extension.

600.27           Reserved.

600.28           Restrictions on lobbying.

Procedures regarding restrictions on lobbying activities of applicants and recipients are contained in 10 CFR 601.110.

600.29           Fixed obligation awards.

(a) General. This section contains provisions applicable to the award of financial assistance instruments on a fixed amount basis. Under a fixed obligation award, funds are issued in support of a project without a requirement for Federal monitoring of actual costs subsequently incurred.

(b) Provisions applicable to fixed obligation awards. Financial assistance awards may be made on a fixed obligation basis subject to the following requirements:

(1) Each fixed obligation award may neither exceed $100,000 nor exceed one year in length.

(2) Programs which require mandatory cost sharing are not eligible.

(3) Proposed costs must be analyzed in detail to ensure consistency with applicable cost principles.

 

21


(4) Budget categories are not stipulated in making an award. However, budgets are submitted by an applicant and reviewed for purposes of establishing the amount to be awarded.

(5) Payments must be made in the same manner as other financial assistance awards, except that when determined appropriate by the cognizant program official and contracting officer a lump sum payment may be made.

(6) Recipients must certify in writing to the contracting officer at the end of the project that the activity was completed or the level of effort was expended, however should the activity or effort not be carried out, the recipient would be expected to make appropriate reimbursements.

(7) Periodic reports may be established for each award so long as they are not more frequently than quarterly.

(8) Changes in principal investigator or project leader, scope of effort, or institution, must receive the prior approval of the Department.

600.30           Cost sharing.

In addition to the requirements of Section 600.123 or Section 600.224, the following requirements apply to research, development, and demonstration projects:

(a) When DOE awards financial assistance for research, development, and demonstration projects where the primary purpose of the project is the ultimate commercialization and utilization of technology by the private sector and when there are reasonable expectations that the recipient will receive significant present or future economic benefits beyond the instant award as a result of the performance of the project, cost sharing shall be required. Unless the cost sharing is required by statute, a waiver of the requirement on a single-case or class basis may be approved by the cognizant Program Assistant Secretary or designee.

(b) Except as provided in section 3002 of the Energy Policy Act of 1992, 42 U.S.C. 13542, or program rule, DOE will decide, on a case-by-case basis, the amount of cost sharing required for a particular project.

(c) Factors in addition to those specified in Section 600.123 or Section 600.224, which may be considered when negotiating cost sharing for research, development, and demonstration projects include the potential benefits to a recipient resulting from the project and the length of time before a project is likely to be commercially successful.

 

22


600.31           Research Misconduct.

(a) A recipient is responsible for maintaining the integrity of research of any kind under an award from DOE including the prevention, detection, and remediation of research misconduct, and the conduct of inquiries, investigations, and adjudication of allegations of research misconduct in accordance with the requirements of this section.

(b) For purposes of this section, the following definitions are applicable:

Adjudication means a formal review of a record of investigation of alleged research misconduct to determine whether and what corrective actions and sanctions should be taken.

Fabrication means making up data or results and recording or reporting them.

Falsification means manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record.

Finding of Research Misconduct means a determination, based on a preponderance of the evidence, that research misconduct has occurred. Such a finding requires a conclusion that there has been a significant departure from accepted practices of the relevant research community and that it be knowingly, intentionally, or recklessly committed.

Inquiry means information gathering and initial fact-finding to determine whether an allegation or apparent instance of misconduct warrants an investigation.

Investigation means the formal examination and evaluation of the relevant facts.

Plagiarism means the appropriation of another person’s ideas, processes, results, or words without giving appropriate credit.

Research means all basic, applied, and demonstration research in all fields of science, medicine, engineering, and mathematics, including, but not limited to, research in economics, education, linguistics, medicine, psychology, social sciences statistics, and research involving human subjects or animals.

Research misconduct means fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results, but does not include honest error or differences of opinion.

Research record means the record of all data or results that embody the facts resulting from scientists’ inquiries, including, but not limited to, research proposals, laboratory

 

23


records, both physical and electronic, progress reports, abstracts, theses, oral presentations, internal reports, and journal articles.

(c) Unless otherwise instructed by the contracting officer, the recipient must conduct an initial inquiry into any allegation of research misconduct. If the recipient determines that there is sufficient evidence to proceed to an investigation, it must notify the contracting officer and, unless otherwise instructed, the recipient must:

(1) Conduct an investigation to develop a complete factual record and an examination of such record leading to either a finding of research misconduct and an identification of appropriate remedies or a determination that no further action is warranted;

(2) Inform the contracting officer if an initial inquiry supports an investigation and, if requested by the contracting officer thereafter, keep the contracting officer informed of the results of the investigation and any subsequent adjudication. When an investigation is complete, the recipient will forward to the contracting officer a copy of the evidentiary record, the investigative report, any recommendations made to the recipient’s adjudicating official, and the adjudicating official’s decision and notification of any corrective action taken or planned, and the subject’s written response to the recommendations (if any).

(3) If the investigation leads to a finding of research misconduct, conduct an adjudication by a responsible official who was not involved in the inquiry or investigation and is separated organizationally from the element which conducted the investigation. The adjudication must include a review of the investigative record and, as warranted, a determination of appropriate corrective actions and sanctions.

(d) The Department may elect to act in lieu of the recipient in conducting an inquiry or investigation into an allegation of research misconduct if the contracting officer finds that:

(1) The research organization is not prepared to handle the allegation in a manner consistent with this section;

(2) The allegation involves an entity of sufficiently small size that it cannot reasonably conduct the inquiry;

(3) DOE involvement is necessary to ensure the public health, safety, and security, or to prevent harm to the public interest; or,

(4) The allegation involves possible criminal misconduct.

(e) DOE reserves the right to pursue such remedies and other actions as it deems appropriate, consistent with the terms and conditions of the award instrument and applicable laws and regulations. However, the recipient’s good faith administration of this section and the effectiveness of its remedial actions and sanctions shall be positive

 

24


considerations and shall be taken into account as mitigating factors in assessing the need for such actions. If DOE pursues any such action, it will inform the subject of the action of the outcome and any applicable appeal procedures.

(f) In conducting the activities in paragraph (c) of this section, the recipient and the Department, if it elects to conduct the inquiry or investigation, shall adhere to the following guidelines:

(1) Safeguards for information and subjects of allegations. The recipient shall provide safeguards to ensure that individuals may bring allegations of research misconduct made in good faith to the attention of the recipient without suffering retribution. Safeguards include: protection against retaliation; fair and objective procedures for examining and resolving allegations; and diligence in protecting positions and reputations. The recipient shall also provide the subjects of allegations confidence that their rights are protected and that the mere filing of an allegation of research misconduct will not result in an adverse action. Safeguards include timely written notice regarding substantive allegations against them, a description of the allegation and reasonable access to any evidence submitted to support the allegation or developed in response to an allegation and notice of any findings of research misconduct.

(2) Objectivity and expertise. The recipient shall select individual(s) to inquire, investigate, and adjudicate allegations of research misconduct who have appropriate expertise and have no unresolved conflict of interest. The individual(s) who conducts an adjudication must not be the same individual(s) who conducted the inquiry or investigation, and must be separate organizationally from the element that conducted the inquiry or investigation.

(3) Timeliness. The recipient shall coordinate, inquire, investigate and adjudicate allegations of research misconduct promptly, but thoroughly. Generally, an investigation should be completed within 120 days of initiation, and adjudication should be complete within 60 days of receipt of the record of investigation.

(4) Confidentiality. To the extent possible, consistent with fair and thorough processing of allegations of research misconduct and applicable law and regulation, knowledge about the identity of the subjects of allegations and informants should be limited to those with a need to know.

(5) Remediation and sanction. If the recipient finds that research misconduct has occurred, it shall assess the seriousness of the misconduct and its impact on the research completed or in process. The recipient must take all necessary corrective actions. Such action may include but are not limited to, correcting the research record and as appropriate imposing restrictions, controls, or other parameters on research in process or to be conducted in the future. The recipient must coordinate remedial actions with the contracting officer. The recipient must also consider whether personnel sanctions are appropriate. Any such sanction must be consistent with any applicable personnel laws, policies, and procedures, and must take into account the seriousness of the misconduct

 

25


and its impact, whether it was done knowingly or intentionally, and whether it was an isolated event or pattern of conduct.

(g) By executing this agreement, the recipient provides its assurance that it has established an administrative process for performing an inquiry, mediating if possible, investigating, and reporting allegations of research misconduct; and that it will comply with its own administrative process and the requirements and definitions of 10 CFR part 733 for performing an inquiry, possible mediation, investigation and reporting of allegations of research misconduct.

(h) The recipient must insert or have inserted the substance of this section, including paragraph (g), in subawards at all tiers that involve research.

 

26


10 CFR 600 – Subpart B – Uniform Administrative

Requirements for Grants and Cooperative Agreements

with Institutions of Higher Education, Hospitals, and

Other Non-Profit Organizations.

 

GENERAL    29
600.100    Purpose.    29
600.101    Definitions.    29
600.102    Effect on other issuances.    34
600.103    Deviations.    34
600.104    Subawards.    34
PRE-AWARD REQUIREMENTS    34
600.110    Purpose.    34
600.111    Pre-award policies.    34
600.112    Forms for applying for Federal assistance.    35
600.113    Debarment and suspension.    36
600.114    Special award conditions.    36
600.115    Metric system of measurement.    36
600.116    Resource Conservation and Recovery Act.    36
600.117    Certifications and representations.    37
POST-AWARD REQUIREMENTS    37
600.120    Purpose of financial and program management.    37
600.121    Standards for financial management systems.    37
600.122    Payment.    39
600.123    Cost sharing or matching.    42
600.124    Program income.    45
600.125    Revision of budget and program plans.    46
600.126    Non-Federal audits.    49
600.127    Allowable costs.    50
600.128    Period of availability of funds.    51
Property Standards    51
600.130    Purpose of property standards.    51
600.131    Insurance coverage.    52
600.132    Real property.    52
600.133    Federally-owned and exempt property.    53
600.134    Equipment.    53
600.135    Supplies and other expendable property.    56
600.136    Intangible property.    57
600.137    Property trust relationship.    58
Procurement Standards    59
600.140    Purpose of procurement standards.    59
600.141    Recipient responsibilities.    59
600.142    Codes of conduct.    59

 

27


600.143    Competition.    59
600.144    Procurement procedures.    60
600.145    Cost and price analysis.    62
600.146    Procurement records.    62
600.147    Contract administration.    63
600.148    Contract provisions.    63
600.149    Resource Conservation and Recovery Act (RCRA).    64
Reports and Records    64
600.150    Purpose of reports and records.    64
600.151    Monitoring and reporting program performance.    64
600.152    Financial reporting.    66
600.153    Retention and access requirements for records.    68
Termination and Enforcement    69
600.160    Purpose of termination and enforcement.    69
600.161    Termination.    70
600.162    Enforcement.    70
After-The-Award Requirements    71
600.170    Purpose.    71
600.171    Closeout procedures.    71
600.172    Subsequent adjustments and continuing responsibilities.    72
600.173    Collection of amounts due.    72
Additional Provisions    73
600.180    Reserved.    73
600.181    Reserved.    73
APPENDIX A TO SUBPART B TO PART 600 – CONTRACT PROVISIONS.    73

 

28


Subpart B -Uniform Administrative Requirements for Grants and Cooperative

Agreements with Institutions of Higher Education, Hospitals, and Other Non-Profit

Organizations.

GENERAL

600.100        Purpose.

This subpart implements OMB Circular A-110 and establishes uniform administrative requirements for grants and agreements awarded to institutions of higher education, hospitals, and other non-profit organizations. It also establishes rules governing subawards to institutions of higher education, hospitals, and non-profit (including grants and cooperative agreements administered by State, local and Indian Tribal governments).

600.101        Definitions.

Accrued expenditures means the charges incurred by the recipient during a given period requiring the provision of funds for:

(1) Goods and other tangible property received;

(2) Services performed by employees, contractors, subrecipients, and other payees; and,

(3) Other amounts becoming owed under programs for which no current services or performance is required.

Accrued income means the sum of:

(1) Earnings during a given period from services performed by the recipient, and goods and other tangible property delivered to purchasers, and

(2) Amounts becoming owed to the recipient for which no current services or performance is required by the recipient.

Acquisition cost of equipment means the net invoice price of the equipment, including the cost of modifications, attachments, accessories, or auxiliary apparatus necessary to make the property usable for the purpose for which it was acquired. Other charges, such as the cost of installation, transportation, taxes, duty or protective in-transit insurance, shall be included or excluded from the unit acquisition cost in accordance with the recipient’s regular accounting practices.

 

29


Advance means a payment made by Treasury check or other appropriate payment mechanism to a recipient upon its request either before outlays are made by the recipient or through the use of predetermined payment schedules.

Award means financial assistance that provides support or stimulation to accomplish a public purpose. Awards include grants and other agreements in the form of money or property in lieu of money, by DOE to an eligible recipient. The terms does not include: technical assistance, which provides services instead of money; other assistance in the form of loans, loan guarantees, interest subsidies, or insurance; direct payments of any kind to individuals; and, contracts which are required to be entered into and administered under procurement laws and regulations.

Cash contributions means the recipient’s cash outlay, including the outlay of money contributed to the recipient by third parties.

Closeout means the process by which DOE determines that all applicable administrative actions and all required work of the award have been completed by the recipient and DOE.

Contract means a procurement contract under an award or subaward, and a procurement subcontract under a recipient’s or subrecipient’s contract.

Cost sharing or matching means that portion of project or program costs not borne by DOE.

Date of completion means the date on which all work under an award is completed or the date on the award document, or any supplement thereto, on which DOE sponsorship ends.

Disallowed costs means those charges to an award that the DOE determines to be unallowable, in accordance with the applicable Federal cost principles or other terms and conditions contained in the award.

Equipment means tangible nonexpendable personal property including exempt property charged directly to the award having a useful life of more than one year and an acquisition cost of $5000 or more per unit. However, consistent with recipient policy, lower limits may be established.

Excess property means property under the control of any Federal awarding agency that, as determined by the head thereof, is no longer required for its needs or the discharge of its responsibilities.

Exempt property means tangible personal property acquired in whole or in part with Federal funds, where the Federal awarding agency has statutory authority to vest title in the recipient without further obligation to the Federal Government. An example of exempt property authority is contained in the Federal Grant and Cooperative Agreement

 

30


Act (31 U.S.C. 6306), for property acquired under an award to conduct basic or applied research by a non-profit institution of higher education or non-profit organization whose principal purpose is conducting scientific research.

Federal awarding agency means the Federal agency that provides an award to the recipient.

Federal funds authorized means the total amount of Federal funds obligated by the Federal Government for use by the recipient. This amount may include any authorized carryover of unobligated funds from prior funding periods when permitted by agency regulations or agency implementing instructions.

Federal share of real property, equipment, or supplies mean that percentage of the property’s acquisition costs and any improvement expenditures paid with Federal funds.

Intangible property and debt instruments means, but is not limited to, trademarks, copyrights, patents and patent applications and such property as loans, notes and other debt instruments, lease agreements, stock and other instruments of property ownership, whether considered tangible or intangible.

Obligations means the amounts of orders places, contracts and grants awarded, services received and similar transactions during a given period that require payment by the recipient during the same or a future period.

Outlays or expenditures means charges made to the project or program. They may be reported on a cash or accrual basis. For reports prepared on a cash basis, outlays are the sum of cash disbursements for direct charges for goods and services, the amount of indirect expense charged, the value of third party in-kind contributions applied and the amount of cash advances and payments made to subrecipients. For reports prepared on an accrual basis, outlays are the sum of cash disbursements for direct charges for goods and services, the amount of indirect expense incurred, the value of in-kind contributions applied, and the net increase (or decrease) in the amounts owed by the recipient for goods and other property received, for services performed by employees, contractors, subrecipients and other payees and other amounts becoming owed under programs for which no current services or performance are required.

Personal property means property of any kind except real property. It may be tangible, having physical existence, or intangible, having no physical existence, such as copyrights, patents, or securities.

Prior approval means written approval by a contracting officer evidencing prior consent.

Program income means gross income earned by the recipient that is directly generated by a supported activity or earned as a result of the award (see exclusions in 600.124(e) and (h)). Program income includes, but is not limited to, income from fees for services performed, the use or rental of real or personal property acquired under federally-funded

 

31


projects, the sale of commodities or items fabricated under an award, license fees and royalties on patents and copyrights, and interest on loans made with award funds. Interest earned on advances of DOE funds is not program income. Except as otherwise provided in this subpart, program regulations, or the terms and conditions of the award, program income does not include the receipt of principal on loans, rebates, credits, discounts, etc., or interest earned on any of them.

Project costs means all allowable costs, as set forth in the applicable Federal cost principles, incurred by a recipient and the value of the contributions made by third parties in accomplishing the objectives of the award during the project period.

Project period means the period established in the award document during which DOE sponsorship begins and ends.

Property means, unless otherwise stated, real property, equipment, intangible property and debt instruments.

Real property means land, including land improvements, structures and appurtenances thereto, but excludes movable machinery and equipment.

Recipient means an organization receiving financial assistance directly from DOE to carry out a project or program. The term includes public and private institutions of higher education, public and private hospitals, and other quasi-public and private non-profit organizations such as, but not limited to, community action agencies, research institutes, educational associations, and health centers. The term shall include commercial organizations which are recipients, subrecipients, or contractors or subcontractors of recipients or subrecipients. The terms does not include government-owned contractor-operated facilities or research centers providing continued support for mission-oriented, large-scale programs that are government-owned or controlled, or are designated as federally-funded research and development centers.

Research and development means all research activities, both basic and applied, and all development activities that are supported at universities, colleges, and other non-profit institutions. “Research” is defined as a systematic study directed toward fuller scientific knowledge or understanding of the subject studied. “Development” is the systematic use of knowledge and understanding gained from research directed toward the production of useful materials, devices, systems, or methods, including design and development of prototypes and processes. The term research also includes activities involving the training of individuals in research techniques where such activities utilize the same facilities as other research and development activities and where such activities are not included in the instruction function.

Small award means a grant or cooperative agreement not exceeding the small purchase threshold fixed at 41 U.S.C. 403(11) (currently $100,000).

 

32


Subaward means an award of financial assistance in the form of money, or property in lieu of money, made under an award by a recipient to an eligible subrecipient or by a subrecipient to a lower tier subrecipient. The term includes financial assistance when provided by any legal agreement, even if the agreement is called a contract, but does not include procurement of goods and services nor does it include any form of assistance which is excluded from the definition of “award” above.

Subrecipient means the legal entity to which a subaward is made and which is accountable to the recipient for the use of the funds provided. The term may include foreign or international organizations (such as agencies of the United Nations).

Supplies means all personal property excluding equipment, intangible property, and debt instruments as defined in this section, and inventions of a contractor conceived or first actually reduced to practice in the performance of work under a funding agreement (“subject inventions”), as defined in 37 CFR Part 401, “Rights to Inventions Made by Nonprofit Organizations and Small Business Firms Under Government Grants, Contracts, and Cooperative Agreements.”

Suspension means an action by DOE that temporarily withdraws DOE sponsorship under an award, pending corrective action by the recipient or pending a decision to terminate the award by the DOE. Suspension of an award is a separate action from suspension under DOE regulations implementing E.O.’s 12549 and 12689, “Debarment and Suspension” (see 10 CFR Part 1036).

Termination means the cancellation of DOE sponsorship, in whole or in part, under an agreement at any time prior to the date of completion.

Third party in-kind contributions means the value of non-cash contributions provided by non-Federal third parties. Third party in-kind contributions may be in the form of real property, equipment, supplies and other expendable property, and the value of goods and services directly benefiting and specifically identifiable to the project or program.

Unliquidated obligations , for financial reports prepared on a cash basis, means the amount of obligations incurred by the recipient that have not been paid. For reports prepared on an accrued expenditure basis, they represent the amount of obligations incurred by the recipient for which an outlay has not been recorded.

Unobligated balance means the portion of the funds authorized by DOE that has not been obligated by the recipient and is determined by deducting the cumulative obligations from the cumulative funds authorized.

Unrecovered indirect cost mans the difference between the amount awarded and the amount which could have been awarded under the recipient’s approved negotiated indirect cost rate.

 

33


Working capital advance means a procedure whereby funds are advanced to the recipient to cover its estimated disbursement needs for a given initial period.

600.102        Effect on other issuances.

For awards subject to this subpart, all administrative requirements of codified program regulations, program manuals, handbooks and other nonregulatory materials which are inconsistent with the requirements of this subpart shall be superseded, except to the extent they are required by statute, or authorized in accordance with the deviations provision in Section 600.4.

600.103        Deviations.

The deviation provisions of 600.4 apply to this subpart.

600.104        Subawards.

Unless sections of this subpart specifically exclude subrecipients from coverage, all DOE recipients, including State, local and Indian tribal governments, shall apply the provisions of this subpart to subrecipients performing work under awards if such subrecipients are institutions of higher education, hospitals, other non-profit organizations. Thus, this subpart is applicable to those types of organizations regardless of the type of recipient receiving the primary award. State and local government subrecipients are subject to the provisions of 10 CFR Part 600, Subpart C, “Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments.” For-profit subrecipients are subject to the provisions of 10 CFR part 600, subpart D, Administrative Requirements for Grants and Cooperative Agreements with For-Profit Organizations.

PRE-AWARD REQUIREMENTS

600.110        Purpose.

Sections 600.111 through 600.117 prescribe forms and instructions and other pre-award matters to be used in applying for DOE awards.

600.111        Pre-award policies.

(a)    Use of Grants and Cooperative Agreements, and Contracts. In each instance, the DOE shall decide on the appropriate award instrument (i.e., grant, cooperative agreement, or contract). The Federal Grant and Cooperative Agreement Act (31 U.S.C. 6301-08)

 

34


governs the use of grants, cooperative agreements and contracts. A grant or cooperative agreement shall be used only when the principal purpose of a transaction is to accomplish a public purpose of support or stimulation authorized by Federal statute. The statutory criterion for choosing between grants and cooperative agreements is that for the latter, “substantial involvement is expected between the executive agency and the State, local government, or other recipient when carrying out the activity contemplated in the agreement.” Contracts shall be used when the principal purpose is acquisition of property or services for the direct benefit or use of the Federal Government.

(b)    Public Notice and Priority Setting. DOE will, whenever practical, notify the public of its intended funding priorities for discretionary grant programs, unless funding priorities are established by Federal statute.

600.112        Forms for applying for Federal assistance.

(a)    General. An application for an award shall be on the form or in the format specified in a program rule, in the solicitation, or in these regulations (see Section 600.10). When the SF-424 form is not used, DOE shall indicate whether the application is subject to review by the State under E.O. 12372. DOE may also require applicants to complete-

(1)    The Notice of Energy RD&D Project (DOE Form 538 (sic)) if the application is for a research, development, or demonstration project; or

(2)    The Federal Assistance Management Summary Report (DOE F 4600.5) or the Federal Assistance Milestone Plan (DOE F 4600.3) as a baseline plan in accordance with the terms and conditions of award if required by program rule or the solicitation. If a solicitation other than a program rule requires the use of one or both of these forms, the solicitation shall contain an explanation of how the information to be provided relates to the objectives of the program.

(b)    Budgetary information. DOE may request and the applicant shall submit the minimum budgetary information necessary to evaluate the costs of the proposed project.

(1)    Applicants for research awards, other than State, local, or Indian tribal governments, will use DOE budget forms ERF 4620.1 and ERF 4620.1A. All other applicants shall use the budget formats established in the solicitation or program regulations.

(2)    DOE may, subsequent to receipt of an application, request additional information from an applicant when necessary for clarification or to make informed preaward determinations.

(c)    Continuation and renewal applications. DOE may require that an application for a continuation or renewal award (see Section 600.26(b) and (c)) be made in the format or on the forms authorized by paragraphs (a) and (b) of this section.

 

35


600.113        Debarment and suspension.

Recipients shall comply with the nonprocurement debarment and suspension common rule implementing E.O.’s 12549 and 12689, “Debarment and Suspension,” 10 CFR Part 1036. This common rule restricts subawards and contracts with certain parties that are debarred, suspended or otherwise excluded from or ineligible for participation in Federal assistance programs or activities.

600.114        Special award conditions.

(a)    If an applicant or recipient has a history of poor performance, is not financially stable, has a management system that does not meet the standards prescribed in this subpart, has not conformed to the terms and conditions of a previous award, or is not otherwise responsible, DOE may impose additional requirements as needed, without regard to the deviation provisions of 600.4. Such applicant or recipient will be notified in writing as to the nature of the additional requirements, the reason why the additional requirements are being imposed, the nature of the corrective action needed, and the time allowed for completing the corrective actions. Reconsideration of the additional requirements may be requested at any time. Any special conditions shall be promptly removed once the conditions that prompted them have been corrected.

(b)    A recipient may place a special restrictive condition, as specified in paragraph (a) of this section, in a subaward. In any such case, the recipient must notify DOE in writing within 15 days of the subaward. DOE shall decide whether to notify OMB and other interested parties.

600.115        Metric system of measurement.

The Metric Conversion Act, as amended by the Omnibus Trade and Competitiveness Act (15 U.S.C. 205) declares that the metric system is the preferred measurement system for U.S. trade and commerce. The Act requires each Federal agency to establish a date or dates in consultation with the Secretary of Commerce, when the metric system of measurement will be used in the agency’s procurements, grants, and other business-related activities. Metric implementation may take longer where the use of the system is initially impractical or likely to cause significant inefficiencies in the accomplishment of federally-funded activities. DOE will follow the provisions of E.O. 12770, “Metric Usage in Federal Government Programs.”

600.116        Resource Conservation and Recovery Act.

 

36


Under the Act (Pub. L. 94-580 codified at 42 U.S.C. 6962), any State agency or agency of a political subdivision of a State which is using appropriated Federal funds must comply with section 6002. Section 6002 requires that preference be given in procurement programs to the purchase of specific products containing recycled materials identified in the guidelines developed by the Environmental Protection Agency (EPA) (40 CFR parts 247-254). Accordingly, State and local institutions of higher education, hospitals, and non-profit organizations that receive direct Federal awards or other Federal funds shall give preference in their procurement programs funded with Federal funds to the purchase of recycled products pursuant to the EPA guidelines.

600.117        Certifications and representations.

Unless prohibited by statute or codified regulation, each Federal awarding agency is authorized and encouraged to allow recipients to submit certifications and representations required by statute, executive order, or regulation on an annual basis, if the recipients have ongoing and continuing relationships with the agency. Annual certifications and representations shall be signed by responsible officials with the authority to ensure recipients’ compliance with the pertinent requirements.

POST-AWARD REQUIREMENTS

Financial and Program Management

600.120        Purpose of financial and program management.

Sections 600.121 through 600.128 prescribe standards for financial management systems, methods for making payments and rules for satisfying cost sharing and matching requirements, accounting for program income, budget revision approvals, making audits, determining allowability of cost, and establishing fund availability.

600.121        Standards for financial management systems.

(a)    Recipients shall relate financial data to performance data and develop unit cost information whenever practical. For awards that support research, it should be noted that it is generally not appropriate to develop unit cost information.

(b)    Except for the provisions of 600.121(f) and 600.181, recipients’ financial management systems shall provide for the following:

(1)    Accurate, current and complete disclosure of the financial results of each federally-sponsored project or program in accordance with the reporting requirements set forth in Section 600.152. If a DOE award requires reporting on an accrual basis from a recipient that maintains its records on other than an accrual basis, the recipient

 

37


shall not be required to establish an accrual accounting system. These recipients may develop such accrual data for their reports on the basis of an analysis of the documentation on hand.

(2)    Records that identify adequately the source and application of funds for federally-sponsored activities. These records shall contain information pertaining to Federal awards, authorizations, obligations, unobligated balances, assets, outlays, income and interest.

(3)    Effective control over and accountability for all funds, property and other assets. Recipients shall adequately safeguard all such assets and assure they are used solely for authorized purposes.

(4)    Comparison of outlays with budget amounts for each award. Whenever appropriate, financial information should be related to performance and unit cost data. As discussed in paragraph (a) of this section, unit cost data is generally not appropriate for awards that support research.

(5)    Written procedures to minimize the time elapsing between the transfer of funds to the recipient from the U.S. Treasury and the issuance or redemption of checks, warrants or payments by other means for program purposes by the recipient. To the extent that the provisions of the Cash Management Improvement Act (CMIA) (Pub. L. 101-453) govern, payment methods of State agencies, instrumentalities, and fiscal agents shall be consistent with CMIA Treasury-State Agreements or the CMIA default procedures codified at 31 CFR Part 205, “Withdrawal of Cash from the Treasury for Advances under Federal Grant and Other Programs.”

(6)    Written procedures for determining the reasonableness, allocability and allowability of costs in accordance with the provisions of the applicable Federal cost principles and the terms and conditions of the award.

(7)    Accounting records including cost accounting records that are supported by source documentation.

(c)    Where the Federal Government guarantees or insures the repayment of money borrowed by the recipient, the Contracting Officer, at his or her discretion may require adequate bonding and insurance if the bonding and insurance requirements of the recipient are not deemed adequate to protect the interest of the Federal Government.

(d)    The Contracting Officer may require adequate fidelity bond coverage where the recipient lacks sufficient coverage to protect the Federal Government’s interest.

(e)    Where bonds are required in the situations described in Sections 600.121(c) and (d), the bonds shall be obtained from companies holding certificates of authority as acceptable sureties, as prescribed in 31 CFR Part 223, “Surety Companies Doing Business with the United States.”

 

38


(f)    Individuals whose financial management systems do not meet the minimum standards of Section 600.121(b) shall maintain a separate bank account for deposit of award or subaward funds. Disbursements by the recipient or subrecipient from this account shall be supported by source documentation such as canceled checks, paid bills, receipts, payrolls, etc.

 

600.122 Payment.

(a)    Payment methods shall minimize the time elapsing between the transfer of funds from the United States Treasury and the issuance or redemption of checks, warrants, or payment by other means by the recipients. Payment methods of State agencies or instrumentalities shall be consistent with Treasury-State CMIA agreements or default procedures codified at 31 CFR Part 205.

(b)    Recipients will be paid in advance, provided they maintain or demonstrate the willingness to maintain:

(1)    Written procedures that minimize the time elapsing between the transfer of funds and disbursement by the recipient, and

(2)    Financial management systems that meet the standards for fund control and accountability as established in Section 600.121. Cash advances to a recipient organization shall be limited to the minimum amounts needed and be timed to be in accordance with the actual, immediate cash requirements of the recipient organization in carrying out the purpose of the approved program or project. The timing and amount of cash advances shall be as close as is administratively feasible to the actual disbursements by the recipient organization for direct program or project costs and the proportionate share of any allowable indirect costs.

(c)    Whenever possible, advances shall be consolidated to cover anticipated cash needs for all awards made by the DOE to the recipient.

(1)    Advance payment mechanisms include, but are not limited to, Treasury check and electronic funds transfer.

(2)    Advance payment mechanisms are subject to 31 CFR Part 205.

(3)    Recipients may submit requests for advances and reimbursements at least monthly when electronic fund transfers are not used.

(d)    Requests for Treasury check advance payment shall be submitted on SF-270, “Request for Advance or Reimbursement,” or other forms as may be authorized by OMB. This form is not to be used when Treasury check advance payments are made to

 

39


the recipient automatically through the use of a predetermined payment schedule or if precluded by special DOE instructions for electronic funds transfer.

(e)    Reimbursement is the preferred method when the requirements in paragraph (b) of this section cannot be met. DOE may also use this method on any construction agreement, or if the major portion of the construction project is accomplished through private market financing or Federal loans, and the Federal assistance constitutes a minor portion of the project.

(1)    When the reimbursement method is used, DOE shall make payment within 30 days after receipt of the billing, unless the billing is improper.

(2)    Recipients are authorized to submit requests for reimbursement at least monthly when electronic funds transfers are not used.

(f)    If a recipient cannot meet the criteria for advance payments and DOE has determined that reimbursement is not feasible because the recipient lacks sufficient working capital, DOE may provide cash on a working capital advance basis. Under this procedure, DOE advances cash to the recipient to cover its estimated disbursement needs for an initial period generally geared to the recipient’s disbursing cycle. Thereafter, DOE reimburses the recipient for its actual cash disbursements. The working capital advance method of payment will not be used for recipients unwilling or unable to provide timely advances to their subrecipient to meet the subrecipient’s actual cash disbursements.

(g)    To the extent available, recipients shall disburse funds available from repayments to and interest earned on a revolving fund, program income, rebates, refunds, contract settlements, audit recoveries and interest earned on such funds before requesting additional cash payments.

(h)    Unless otherwise required by statute, DOE will not withhold payments for proper charges made by recipients at any time during the project period unless paragraph (h)(1) or (h)(2) of this section apply.

(1)    A recipient has failed to comply with the project objectives, the terms and conditions of the award, or DOE reporting requirements.

(2)    The recipient or subrecipient is delinquent in a debt to the United States. Under such conditions, the Federal awarding agency may, upon reasonable notice, inform the recipient that payments shall not be made for obligations incurred after a specified date until the conditions are corrected or the indebtedness to the Federal Government is liquidated. Before withholding any payment, DOE shall notify the recipient that payments shall not be made for obligations incurred after a specified date, which shall ordinarily be no sooner than 30 days from the date of the notice, until the recipient corrects the noncompliance or pays the indebtedness to the Federal government.

 

40


(i)    Standards governing the use of banks and other institutions as depositories of funds advanced under awards are as follows.

(1)    Except for situations described in paragraph (i)(2) of this section, DOE shall not require separate depository accounts for funds provided to a recipient or establish any eligibility requirements for depositories for funds provided to a recipient. However, recipients must be able to account for the receipt, obligation and expenditure of funds.

(2)    Advances of Federal funds shall be deposited and maintained in insured accounts whenever possible.

(j)    Consistent with the national goal of expanding the opportunities for women-owned and minority-owned business enterprises, recipients are encouraged to use women-owned and minority-owned banks (a bank which is owned at least 50 percent by women or minority group members).

(k)    Recipients shall maintain advances of Federal funds in interest bearing accounts, unless paragraph (k) (1), (2) or (3) of this section apply.

(1)    The recipient receives less than $120,000 in Federal awards per year.

(2)    The best reasonably available interest bearing account would not be expected to earn interest in excess of $250 per year on Federal cash balances.

(3)    The depository would require an average or minimum balance so high that it would not be feasible within the expected Federal and non-Federal cash resources.

(l)    For those entities where CMIA and its implementing regulations do not apply, interest earned on Federal advances deposited in interest bearing accounts shall be remitted annually to the HHS Payment Management System through an electronic medium such as the FEDWIRE Deposit system. Recipients which do not have this capability should use a check. The address is the Department of Health and Human Services, Payment Management System, P.O. Box 6021, Rockville, MD 20852. Interest amounts up to $250 per year may be retained by the recipient for administrative expense. State universities and hospitals shall comply with CMIA, as it pertains to interest. If an entity subject to CMIA uses its own funds to pay pre-award costs for discretionary awards without prior written approval from the Federal awarding agency, it waives its right to recover the interest under CMIA.

(m)    Except as noted elsewhere in this subpart, only the following forms shall be authorized for the recipients in requesting advances and reimbursements. Federal agencies shall not require more than an original and two copies of these forms.

(1)    SF-270, Request for Advance or Reimbursement. Each Federal awarding agency shall adopt the SF-270 as a standard form for all nonconstruction programs when electronic funds transfer or predetermined advance methods are not used.

 

41


Federal awarding agencies, however, have the option of using this form for construction programs in lieu of the SF-271, “Outlay Report and Request for Reimbursement for Construction Programs.”

(2)    SF-271, Outlay Report and Request for Reimbursement for Construction Programs. Each Federal awarding agency shall adopt the SF-271 as the standard form to be used for requesting reimbursement for construction programs. However, a Federal awarding agency may substitute the SF-270 when the Federal awarding agency determines that it provides adequate information to meet Federal needs.

(n)    The DOE may convert a recipient from advance payment to reimbursement whenever the recipient no longer meets the criteria for advance payment specified in paragraph (b) of this section. Any such conversion may be accomplished only after the DOE has advised the recipient in writing of the reasons for the proposed action and has provided a period of at least 30 days within which the recipient may take corrective action or provide satisfactory assurances of its intention to take such action.

(o)    With prior DOE approval and in accordance with written DOE instructions, a recipient may assign to a bank, trust company or other financing institution, including any Federal lending agency, reimbursement by Treasury check due from DOE under the following conditions:

(1)    The award provides for reimbursement totaling $1,000 or more;

(2)    The assignment covers all amounts payable under the award that have not already been paid;

(3)    Reassignment is prohibited; and

(4)    The assignee files a written notice of award payment assignment and a true copy of the instrument of assignment with DOE. Any interest costs resulting from a loan obtained on the basis of an assignment are unallowable charges to DOE award funds or any required cost sharing.

(p)    Recipients shall observe the requirements of this section in making or withholding payments to subrecipients except that the forms used by recipients are not required to be used by subrecipients when requesting advances or reimbursement.

600.123         Cost sharing or matching.

(a)    All cost sharing or matching contributions, including cash and third party in-kind, shall meet all of the following criteria.

(1)    Are verifiable from the recipient’s records.

 

42


(2)    Are not included as contributions for any other federally-assisted project or program.

(3)    Are necessary and reasonable for proper and efficient accomplishment of project or program objectives.

(4)    Are allowable under the applicable cost principles.

(5)    Are not paid by the Federal Government under another award, except where authorized by Federal statute to be used for cost sharing or matching.

(6)    Are provided for in the approved budget.

(7)    Conform to other provisions of this subpart, as applicable.

(b)    Unrecovered indirect costs may be included as part of cost sharing or matching.

(c)    Values for recipient contributions of services and property shall be established in accordance with the applicable cost principles. If DOE authorizes recipients to donate buildings or land for construction/facilities acquisition projects or long-term use, the value of the donated property for cost sharing or matching shall be the lesser of either paragraph (c)(1) or (2) of this section.

(1)    The certified value of the remaining life of the property recorded in the recipient’s accounting records at the time of donation.

(2)    The current fair market value. However, when there is sufficient justification, DOE may approve the use of the current fair market value of the donated property, even if it exceeds the certified value at the time of donation to the project.

(d)    Volunteer services furnished by professional and technical personnel, consultants, and other skilled and unskilled labor may be counted as cost sharing or matching if the service is an integral and necessary part of an approved project or program. Rates for volunteer services shall be consistent with those paid for similar work in the recipient’s organization. In those instances in which the required skills are not found in the recipient organization, rates shall be consistent with those paid for similar work in the labor market in which the recipient competes for the kind of services involved. In either case, paid fringe benefits that are reasonable, allowable, and allocable may be included in the valuation.

(e)    When an employer other than the recipient furnishes the services of an employee, these services shall be valued at the employee’s regular rate of pay (plus an amount of fringe benefits that are reasonable, allowable, and allocable, but exclusive of overhead costs), provided these services are in the same skill for which the employee is normally paid.

 

43


(f)    Donated supplies may include such items as office supplies, laboratory supplies or workshop and classroom supplies. Value assessed to donated supplies included in the cost sharing or matching share shall be reasonable and shall not exceed the fair market value of the property at the time of the donation.

(g)    The method used for determining cost sharing or matching for donated equipment, buildings and land for which title passes to the recipient may differ according to the purpose of the award, if either paragraph (g)(1) or (2) of this section apply.

(1)    If the purpose of the award is to assist the recipient in the acquisition of equipment, buildings or land, the total value of the donated property may be claimed as cost sharing or matching.

(2)    If the purpose of the award is to support activities that require the use of equipment, buildings or land, normally only depreciation or use charges for equipment and buildings may be made. However, the full value of equipment or other capital assets and fair rental charges for land may be allowed, provided that DOE has approved the charges.

(h)    The value of donated property shall be determined in accordance with the usual accounting policies of the recipient, with the following qualifications.

(1)    The value of donated land and buildings shall not exceed its fair market value at the time of donation to the recipient as established by an independent appraiser (e.g., certified real property appraiser or General Services Administration representative) and certified by a responsible official of the recipient.

(2)    The value of donated equipment shall not exceed the fair market value of equipment of the same age and condition at the time of donation.

(3)    The value of donated space shall not exceed the fair rental value of comparable space as established by an independent appraisal of comparable space and facilities in a privately-owned building in the same locality.

(4)    The value of loaned equipment shall not exceed its fair rental value.

(i)    The following requirements pertain to the recipient’s supporting records for in-kind contributions from third parties.

(1)    Volunteer services shall be documented and, to the extent feasible, supported by the same methods used by the recipient for its own employees.

(2)    The basis for determining the valuation for personal service, material, equipment, buildings and land shall be documented.

 

44


(j)    DOE shall specify in the solicitation or in the program rule, if any, any cost sharing requirement. The award document shall be specific as to whether the cost sharing is based on a minimum amount for the recipient or on a percentage of total costs.

(k)    If DOE requires that a recipient provide cost sharing which is not required by statute or which exceeds a statutory minimum, DOE shall state in the program rule or solicitation the reasons for requiring such cost sharing, recommended or required levels of cost sharing, and the circumstances under which the requirement for cost sharing may be waived or adjusted during any negotiation.

(l)    Whenever DOE negotiates the amount of cost sharing, DOE may take into account such factors as the use of program income (see Section 600.124), patent rights, and rights in data. Foregone fee or profit shall not be considered in establishing the extent of cost sharing.

600.124         Program income.

(a)    The standards set forth in this section shall be used to account for program income related to projects financed in whole or in part with DOE funds.

(b)    Except as provided in paragraph (h) of this section, program income earned during the project period shall be retained by the recipient and, in accordance with program regulations or the terms and conditions of the award, shall be used in one or more of the following ways.

(1)    Added to funds committed to the project and used to further eligible project objectives.

(2)    Used to finance the non-DOE share of the project.

(3)    Deducted from the total project allowable cost in determining the net allowable costs on which the share of costs is based.

(c)    When DOE authorizes the disposition of program income as described in paragraphs (b)(1) or (b)(2) of this section, program income in excess of any limits stipulated shall be used in accordance with paragraph (b)(3) of this section.

(d)    In the event that the program regulations or the terms and conditions of the award do not specify how program income is to be used, paragraph (b)(3) of this section shall apply automatically to all projects or programs except research. For awards that support research, paragraph (b)(1) of this section shall apply automatically unless the award indicates another alternative in the terms and conditions, the recipient is subject to special award conditions, as indicated in Section 600.114, or the recipient is a commercial organization.

 

45


(e)    Unless program regulations or the terms and conditions of the award provide otherwise, recipients shall have no obligation to the Federal Government regarding program income earned after the end of the project period.

(f)    Unless program regulations or the terms and conditions of the award provide otherwise, costs incident to the generation of program income may be deducted from gross income to determine program income, provided these costs have not been charged to the award.

(g)    Proceeds from the sale of property shall be handled in accordance with the requirements of the Property Standards (See Sections 600.130 through 600.137).

(h)    Unless program regulations or the terms and condition of the award provide otherwise, recipients shall have no obligation to the Federal Government with respect to program income earned from license fees and royalties for copyrighted material, patents, patent applications, trademarks, and inventions produced under an award. However, Patent and Trademark Amendments (35 U.S.C. Chapter 18) apply to inventions made under an experimental, developmental, or research award.

600.125         Revision of budget and program plans.

(a)    The budget plan is the financial expression of the project or program as approved during the award process. It includes the sum of the Federal and non-Federal share when there are cost sharing requirements. It shall be related to performance for program evaluation purposes whenever appropriate.

(b)    Recipients are required to report deviations from budget and program plans, and request prior approvals for budget and program plan revisions, in accordance with this section.

(c)    For nonconstruction awards, recipients shall request prior approvals from the DOE for one or more of the following program or budget related reasons.

(1)    Change in the scope or the objective of the project or program (even if there is no associated budget revision requiring prior written approval).

(2)    Change in a key person specified in the application or award document.

(3)    The absence for more than three months, or a 25 percent reduction in time devoted to the project, by the approved project director or principal investigator.

(4)    The need for additional Federal funding.

(5)    If required by program regulations, the transfer of amounts budgeted for indirect costs to absorb increases in direct costs, or vice versa.

 

46


(6)    The inclusion, unless waived by program regulations or the terms and conditions of award, of costs that require prior approval in accordance with OMB Circular A-21, “Cost Principles for Institutions of Higher Education,” OMB Circular A-122, “Cost Principles for Non-Profit Organizations,” or 45 CFR Part 74 Appendix E, “Principles for Determining Costs Applicable to Research and Development under Grants and Contracts with Hospitals,” or 48 CFR Part 31, “Contract Cost Principles and Procedures,” as applicable.

(7)    The transfer of funds allotted for training allowances (direct payment to trainees) to other categories of expense.

(8)    Unless described in the application and funded in the approved awards, the subaward, transfer or contracting out of any work under an award. This provision does not apply to the purchase of supplies, material, equipment or general support services.

(d)    No other prior approval requirements for specific items may be imposed unless a deviation has been approved in accordance with Section 600.4.

(e)    Except for requirements listed in paragraphs (c)(1) and (c)(4) of this section, program regulations may waive cost-related and administrative prior written approvals required by this Subpart and its Appendices. Such waivers may include authorizing recipients to do any one or more of the following.

(1)    Incur pre-award costs 90 calendar days prior to award without prior approval or more than 90 calendar days with the prior approval of DOE. All pre-award costs are incurred at the recipient’s risk (i.e., DOE is under no obligation to reimburse such costs if for any reason the recipient does not receive an award or if the award is less than anticipated and inadequate to cover such costs).

(2)    Initiate a one-time extension of the expiration date of the final budget period of the project of up to 12 months unless one or more of the following conditions apply.

(i)    The terms and conditions of award prohibit the extension.

(ii)    The extension requires additional Federal funds.

(iii)    The extension involves any change in the approved objectives or scope of the project.

(iv)    The extension is being exercised merely for the purpose of using unobligated balances. For one-time extensions, the recipient must notify the DOE in writing with the supporting reasons and revised expiration date at least 10 days before the expiration date specified in the award.

 

47


(3)    Carry forward unobligated balances to subsequent funding periods.

(4)    For awards that support research, unless the terms and conditions of award provide otherwise, the prior approval requirements described in paragraph (e) of this section are automatically waived (i.e., recipients need not obtain such prior approvals) unless one of the conditions included in Section 600.125(e)(2) applies.

(5)    For continuation awards within a multiple year project in support of research, prior to receipt of continuation funding, preaward expenditures by recipients are not subject to the limitation or approval requirements of Section 600.125(e)(1). Nevertheless, incurrence by the recipient does not impose any obligation on DOE if a continuation award is not subsequently made, or if an award is made for a lesser amount than the recipient expected.

(f)    Program regulations may restrict the transfer of funds among direct cost categories or programs, functions and activities for awards in which DOE’s share of the project exceeds $100,000 and the cumulative amount of such transfers exceeds or is expected to exceed 10 percent of the total budget as last approved by DOE. However, no program regulation shall permit a transfer that would cause any Federal appropriation or part thereof to be used for purposes other than those consistent with the original intent of the appropriation.

(g)    All other changes to nonconstruction budgets, except for the changes described in paragraph (j) of this section, do not require prior approval.

(h)    For construction awards, recipients shall request prior written approval promptly from the Contracting Officer for budget revisions whenever paragraph (h) (1), (2) or (3) of this section apply.

(1)    The revision results from changes in the scope or the objective of the project or program.

(2)    The need arises for additional Federal funds to complete the project.

(3)    A revision is desired which involves specific costs for which prior written approval requirements may be imposed consistent with applicable OMB cost principles listed in Section 600.127.

(i)    Except in accordance with the deviation procedures in 600.4 or as may be provided for in program regulations, no other prior approval requirements for specific items will be imposed by DOE.

(j)    When DOE makes an award that provides support for both construction and nonconstruction work, DOE may require the recipient to request prior approval from DOE before making any fund or budget transfers between the two types of work supported.

 

48


(k)    For both construction and nonconstruction awards, recipients shall notify DOE in writing promptly whenever the amount of Federal authorized funds is expected to exceed the needs of the recipient for the project period by more than $5000 or five percent of the Federal award, whichever is greater. This notification shall not be required if an application for additional funding is submitted for a continuation award.

(l)    Requests for budget revisions may be made by letter.

(m)    Within 30 calendar days from the date of receipt of the request for budget revisions, DOE shall review the request and notify the recipient whether the budget revisions have been approved. If the revision is still under consideration at the end of 30 calendar days, DOE shall inform the recipient in writing of the date when the recipient may expect the decision.

(n)    DOE approval or disapproval of a request for a budget or project revision shall be in writing and signed by a DOE Contracting Officer.

(o)    A request by a subrecipient for prior approval shall be addressed in writing to the recipient. The recipient shall promptly review such request and shall approve or disapprove the request in writing within 30 days from the date of the recipient’s request for the revision. A recipient shall not approve any budget or project revision which is inconsistent with the purpose or terms and conditions of the DOE award. If the revision requested by the subrecipient would result in a change to the recipient’s approved budget or approved project which requires DOE prior approval, the recipient shall obtain DOE approval before approving such revision.

 

600.126 Non-Federal audits.

(a) Recipients and subrecipients that are institutions of higher education or other non-profit organizations (including hospitals) shall be subject to the audit requirements contained in the Single Audit Act Amendments of 1996 (31 U.S.C. 7501-7507) and revised OMB Circular A - 133 , “Audits of States, Local Governments, and Non-Profit Institutions.”

(b) State and local governments shall be subject to the audit requirements contained in the Single Audit Act Amendments of 1996 (31 U.S.C. 7501 - 7507) and revised OMB Circular A-133, “Audits of State, Local Governments, and Non-Profit Organizations.”

(c) For-profit hospitals not covered by the audit provisions of revised OMB Circular A - 133 shall be subject to the audit requirements of the Federal awarding agencies.

(d) The Contracting Officer may audit, or cause to be audited, awards to commercial organizations whenever and in the degree of detail he/she deems necessary. The Contracting Officer shall rely on available audit reports in determining the need for and

 

49


scope of such audits. The commercial organization has similar authority in auditing subrecipients.

(e) The Contracting Officer may audit, or cause to be audited, awards to individuals whenever and in the degree of detail he/she deems necessary. The Contracting Officer shall rely on available audit reports in determining the need for and scope of such audits.

600.127         Allowable costs.

(a) General. For each kind of recipient, there is a set of Federal principles fro determining allowable costs. Allowability of costs shall be determined in accordance with the cost principles applicable to the entity incurring the costs. Thus, allowability of costs incurred by State, local or federally-recognized Indian tribal governments is determined in accordance with the provisions of OMB Circular A-87, “Cost Principles for State and Local Governments.” The allowability of costs incurred by non-profit organizations is determined in accordance with the provisions of OMB Circular A-122, “Cost Principles for Non-Profit Organizations.” The allowability of costs incurred by institutions of higher education is determined in accordance with the provisions of OMB Circular A-21, “Cost Principles for Educational Institutions.” The allowability of costs incurred by hospitals is determined in accordance with the provisions of Appendix E of 45 CFR Part 74, “Principles for Determining Costs Applicable to Research and Development Under Grants and Contracts with Hospitals.” The allowability of costs incurred by commercial organizations and those non-profit organizations listed in Attachment C to Circular A-122 is determined in accordance with the provisions of the Federal Acquisition Regulation (FAR) at 48 CFR Part 31.

(b) Indirect costs. Unless restricted by Federal statute or program rule, DOE shall provide for the reimbursement of appropriate indirect costs.

(1) DOE shall include an amount for indirect costs in an award only if the applicant requests reimbursement of such costs and —

(i) Submits evidence that a cognizant Federal agency has been assigned to establish indirect cost rates for the applicant and indicates or provides evidence that —

(A) A current agreement containing an applicable approved indirect cost rate(s) covering all or part of the budget period for which DOE may provide funding has been established; or

(B) An indirect cost proposal has been submitted to the cognizant agency in order to establish an applicable approved indirect cost rate(s) covering all or part of the budget period for which DOE may provide funding; or

 

50


(C) An indirect cost proposal covering all or part of the budget period and applicable to the activities for which DOE may provide funding will be submitted to the cognizant agency for approval no later than three months after the beginning date of the initial budget period of the DOE award or, for subsequent budget periods, in accordance with any schedule established by the cognizant agency; or

(ii) If not assigned to a cognizant agency, the applicant includes, in the application, data that is current, complete, accurate, and sufficient to allow the Contracting Officer to determine a rate(s) for indirect costs. If the total approved budget will not exceed $100,000 or if the amount requested for indirect costs does not exceed $5,000, DOE may waive the requirement for negotiation of a rate and, in lieu thereof, provide a reasonable allowance for such costs.

(2) Indirect cost proposals shall be prepared and submitted in accordance with the applicable Federal cost principles and instructions from the cognizant agency or from DOE, as appropriate.

(3) If a subaward under an award or subaward provides for the payment of indirect costs, the recipient or subrecipient shall be responsible for negotiating appropriate indirect costs, using the cost principles applicable to the subrecipient or contractor, unless the subrecipient or contractor has negotiated an applicable rate directly with DOE or another Federal department or agency. DOE may review and audit the procedures a recipient or subrecipient uses in conducting indirect cost negotiations.

(c)    Fee or profit. No increment above cost may be paid to a recipient or subrecipient under a DOE award or subaward. A fee or profit may be paid to a contractor providing goods or services under a contract with a recipient or subrecipient.

600.128     Period of availability of funds.

Where a funding period is specified, a recipient may charge to the award only allowable costs resulting from obligations incurred during the funding period and any pre-award costs authorized by DOE.

Property Standards

600.130     Purpose of property standards.

Sections 600.131 through 600.137 set forth uniform standards governing management and disposition of property furnished by the Federal Government or whose cost was charged to a project supported by a Federal award. Recipients shall observe these standards under awards and shall not impose additional requirements, unless specifically required by Federal statute or program regulations. The recipient may use its own

 

51


property management standards and procedures provided it observes the provisions of 600.131 through 600.137.

600.131     Insurance coverage.

Recipients shall, at a minimum, provide the equivalent insurance coverage for real property and equipment acquired with DOE funds as provided to property owned by the recipient. Federally-owned property need not be insured unless required by the terms and conditions of the award.

600.132     Real property.

Unless otherwise provided by statute or program regulations, the requirements concerning the use and disposition of real property acquired in whole or in part under awards are as follows.

(a)    Title to real property shall vest in the recipient subject to the condition that the recipient shall use the real property for the authorized purpose of the project as long as it is needed and shall not encumber the property without approval of DOE.

(b)    The recipient shall obtain written approval by DOE for the use of real property in other federally-sponsored projects when the recipient determines that the property is no longer needed for the purpose of the original project. Use in other projects shall be limited to those under federally-sponsored projects (i.e., awards) or programs that have purposes consistent with those authorized for support by DOE.

(c)    When the real property is no longer needed as provided in paragraphs (a) and (b) of this section, the recipient shall request disposition instructions from DOE or its successor Federal awarding agency. DOE will give one or more of the following disposition instructions.

(1)    The recipient may be permitted to retain title without further obligation to the Federal Government after it compensates the Federal Government for that percentage of the current fair market value of the property attributable to the Federal participation in the project.

(2)    The recipient may be directed to sell the property under guidelines provided by DOE and pay the Federal Government for that percentage of the current fair market value of the property attributable to the Federal participation in the project (after deducting actual and reasonable selling and fix-up expenses, if any, from the sales proceeds). When the recipient is authorized or required to sell the property, proper sales procedures shall be established that provide for competition to the extent practicable and result in the highest possible return.

 

52


(3)    The recipient may be directed to transfer title to the property to the Federal Government or to an eligible third party provided that, in such cases, the recipient shall be entitled to compensation for its attributable percentage of the current fair market value of the property.

600.133     Federally-owned and exempt property.

(a)    Federally-owned property.

(1)    Title to federally-owned property remains vested in the Federal Government. Recipients shall submit annually an inventory listing of federally-owned property in their custody to DOE. Upon completion of the award or when the property is no longer needed, the recipient shall report the property to DOE for further Federal agency utilization.

(2)    If DOE has no further need for the property, it shall be declared excess and reported to the General Services Administration, unless DOE has statutory authority to dispose of the property by alternative methods (e.g., the authority provided by the Federal Technology Transfer Act (15 U.S.C. 3710 (i)) to donate research equipment to educational and non-profit organizations in accordance with E.O. 12821, “Improving Mathematics and Science Education in Support of the National Education Goals.”) Appropriate instructions shall be issued to the recipient by DOE.

(b)    Exempt property. When statutory authority exists, DOE may vest title to property acquired with Federal funds in the recipient without further obligation to the Federal Government and under conditions DOE considers appropriate. For example, under 31 U.S.C. 6306, DOE may so vest title to tangible personal property under a grant or cooperative agreement for basic or applied research in a nonprofit institution of higher education or in a nonprofit organization whose primary purpose is conducting scientific research. Such property is “exempt property” Program regulations or the terms and conditions of award may establish provisions for vesting title to exempt property. Should such conditions not be established and the recipient has no need for the equipment, the recipient shall request disposition instructions from DOE. If DOE does not issue disposition instructions within 120 calendar days of receipt of the request, title to the property shall vest in the recipient without further obligation to the Federal Government. If, at the end of the project, DOE fails to issue disposition instructions within 120 calendar days of the receipt of a final inventory, title to the property shall vest in the recipient without further obligation to the Federal Government.

600.134     Equipment.

(a)    Title to equipment acquired by a recipient with Federal funds shall vest in the recipient, subject to conditions of this section.

 

53


(b)    The recipient shall not use equipment acquired with Federal funds to provide services to non-Federal outside organizations for a fee that is less than private companies charge for equivalent services, unless specifically authorized by Federal statute, for as long as the Federal Government retains an interest in the equipment.

(c)    The recipient shall use the equipment in the project or program for which it was acquired as long as needed, whether or not the project or program continues to be supported by Federal funds and shall not encumber the property without approval of DOE. When no longer needed for the original project or program, the recipient shall use the equipment in connection with its other federally-sponsored activities, in the following order of priority:

(1)    Activities sponsored by DOE, then

(2)    Activities sponsored by other Federal agencies.

(d)    During the time that equipment is used on the project or program for which it was acquired, the recipient shall make it available for use on other projects or programs if such other use will not interfere with the work on the project or program for which the equipment was originally acquired. First preference for such other use shall be given to other projects or programs sponsored by DOE that financed the equipment; second preference shall be given to projects or programs sponsored by other Federal awarding agencies. If the equipment is owned by the Federal Government, use on other activities not sponsored by the Federal Government shall be permissible if authorized by DOE. User charges shall be treated as program income.

(e)    When acquiring replacement equipment, the recipient may use the equipment to be replaced as trade-in or sell the equipment and use the proceeds to offset the costs of the replacement equipment subject to the approval of DOE.

(f)    The recipient’s property management standards for equipment acquired with Federal funds and federally-owned equipment shall include all of the following.

(1)    Equipment records shall be maintained accurately and shall include the following information.

(i)    A description of the equipment.

(ii)    Manufacturer’s serial number, model number, Federal stock number, national stock number, or other identification number.

(iii)    Source of the equipment, including the award number.

(iv)    Whether title vests in the recipient or the Federal Government.

 

54


(v)    Acquisition date (or date received, if the equipment was furnished by the Federal Government) and cost.

(vi)    Information from which one can calculate the percentage of Federal participation in the cost of the equipment (not applicable to equipment furnished by the Federal Government.

(vii)    Location and condition of the equipment and the date the information was reported.

(viii)    Unit acquisition cost.

(ix)    Ultimate disposition data, including date of disposal and sales price or the method used to determine current fair market value where a recipient compensates DOE for its share.

(2)    Equipment owned by the Federal Government shall be identified to indicate Federal ownership.

(3)    A physical inventory of equipment shall be taken and the results reconciled with the equipment records at least once every two years. Any differences between quantities determined by the physical inspection and those shown in the accounting records shall be investigated to determine the causes of the difference. The recipient shall, in connection with the inventory, verify the existence, current utilization, and continued need for the equipment.

(4)    A control system shall be in effect to insure adequate safeguards to prevent loss, damage, or theft of the equipment. Any loss, damage, or theft of equipment shall be investigated and fully documented; if the equipment was owned by the Federal Government, the recipient shall promptly notify DOE.

(5)    Adequate maintenance procedures shall be implemented to keep the equipment in good condition.

(6)    Where the recipient is authorized or required to sell the equipment, proper sales procedures shall be established which provide for competition to the extent practicable and result in the highest possible return.

(g)    When the recipient no longer needs the equipment, the equipment may be used for other activities in accordance with the following standards. Equipment with a current per-unit fair market value of less than $5000 may be retained, sold or otherwise disposed of with no further obligation to the awarding agency. For equipment with a current per unit fair market value of $5000 or more, the recipient may retain the equipment for other uses provided that compensation is made to the original Federal awarding agency or its successor. The amount of compensation shall be computed by applying the percentage of Federal participation in the cost of the original project or program to the current fair

 

55


market value of the equipment. If the recipient has no need for the equipment, the recipient shall request disposition instructions from DOE. DOE shall determine whether the equipment can be used to meet DOE’s requirements. If no requirement exists within DOE, the availability of the equipment shall be reported to the General Services Administration by DOE to determine whether a requirement for the equipment exists in other Federal agencies. DOE will issue instructions to the recipient no later than 120 calendar days after the recipient’s request and the following procedures shall govern.

(1)    If so instructed or if disposition instructions are not issued within 120 calendar days after the recipient’s request, the recipient shall sell the equipment and reimburse DOE an amount computed by applying to the sales proceeds the percentage of Federal participation in the cost of the original project or program. However, the recipient shall be permitted to deduct and retain from the Federal share $500 or ten percent of the proceeds, whichever is less, for the recipient’s selling and handling expenses.

(2)    If the recipient is instructed to ship the equipment elsewhere, the recipient shall be reimbursed by the Federal Government by an amount which is computed by applying the percentage of the recipient’s participation in the cost of the original project or program to the current fair market value of the equipment, plus any reasonable shipping or interim storage costs incurred.

(3)    If the recipient is instructed to otherwise dispose of the equipment, the recipient shall be reimbursed by DOE for such costs incurred in its disposition.

(h)    DOE reserves the right, at the end of a project, to transfer the title to the Federal Government or to a third party named by DOE when such third party is otherwise eligible under existing statutes. Such transfer shall be subject to the following standards.

(1)    The equipment shall be appropriately identified in the award or otherwise made known to the recipient in writing.

(2)    DOE shall issue disposition instructions within 120 calendar days after receipt of a final inventory. The final inventory shall list all equipment acquired with award funds and federally-owned equipment. If DOE fails to issue disposition instructions within the 120 calendar day period, the provisions of Section 600.134(g)(1) apply.

(3)    When DOE exercises its right to take title, the equipment shall be subject to the provisions for federally-owned equipment.

600.135     Supplies and other expendable property.

(a)    Title to supplies and other expendable property shall vest in the recipient upon acquisition. If there is a residual inventory of unused supplies exceeding $5000 in total aggregate value upon termination or completion of the project or program and the

 

56


supplies are not needed for any other federally-sponsored project or program, the recipient shall retain the supplies for use on non-Federal sponsored activities or sell them, but shall, in either case, compensate the Federal Government for its share. The amount of compensation shall be computed in the same manner as for equipment.

(b)    The recipient shall not use supplies acquired with Federal funds to provide services to non-Federal outside organizations for a fee that is less than private companies charge for equivalent services, unless specifically authorized by Federal statute as long as the Federal Government retains an interest in the supplies.

600.136     Intangible property.

(a)    Recipients may copyright any work that is subject to copyright and was developed, or for which ownership was purchased, under an award. DOE reserves a royalty-free, nonexclusive and irrevocable right to reproduce, publish or otherwise use the work for Federal purposes, and to authorize others to do so.

(b)    Recipients are subject to applicable regulations governing patents and inventions, including government-wide regulations issued by the Department of Commerce at 37 CFR part 401, “Rights to Inventions Made by Nonprofit Organizations and Small Business Firms Under Government Grants, Contracts, and Cooperative Agreements.”

(c)    DOE has the right to:

(1)    Obtain, reproduce, publish or otherwise use the data first produced under an award; and

(2)    Authorize others to receive, reproduce, publish, or otherwise use such data for Federal purposes.

 

(d) (1)    In addition, in response to a Freedom of Information act (FOIA) request for research data relating to published research findings produced under an award that were used by the Federal Government in developing an agency action that has the force and effect of law, the DOE shall request, and the recipient shall provide, within a reasonable time, the research data so that they can be made available to the public through the procedures established under the FOIA. If the DOE obtains the research data solely in response to a FOIA request, the agency may charge the requester a reasonable fee equaling the full incremental cost of obtaining the research data. This fee should reflect the costs incurred by the agency, the recipient, and applicable subrecipients. this fee is in addition to any fees the agency may assess under the FOIA (5 U.S.C. 552(a)(4)(A)).

(2)    The following definitions apply for the purposes of this paragraph:

 

57


(i)    Research data is defined as the recorded factual material commonly accepted in the science community as necessary to validate research findings, but not any of the following: preliminary analyses, drafts of scientific papers, plans for future research, peer reviews, or communications with colleagues. This “recorded” material excludes physical objects (e.g., laboratory samples). Research data also do not include:

(A)    Trade secrets, commercial information, materials necessary to be held confidential by a researcher until they are published, or similar information which is protected under the law; and

(B)    Personnel and medical information and similar information the disclosure of which would constitute a clearly unwarranted invasion of personal privacy, such as information that could be used to identify a particular person in a research study.

(ii)    Published is defined as either when:

(A)    Research findings are published in a peer-reviewed scientific or technical journal; or

(B)    DOE publicly and officially cites the research findings in support of an agency action that has the force and effect of law.

(iii)    Used by the Federal Government in developing an agency action that has the force and effect of law is defined as when an agency publicly and officially cites the research findings in support of an agency action that has the force and effect of law.

(e)    Title to intangible property and debt instruments acquired under an award or subaward vests upon acquisition in the recipient. The recipient shall use that property for the originally-authorized purpose, and the recipient shall not encumber the property without approval of DOE. When no longer needed for the originally authorized purpose, disposition of the intangible property shall occur in accordance with the provisions of Section 600.134(g).

600.137     Property trust relationship.

Real property, equipment, intangible property and debt instruments that are acquired or improved with Federal funds shall be held in trust by the recipient as trustee for the beneficiaries of the project or program under which the property was acquired or improved. Recipients shall record liens or other appropriate notices of record to indicate that personal or real property has been acquired or improved with Federal funds and that use and disposition conditions apply to the property.

 

58


Procurement Standards

600.140     Purpose of procurement standards.

Sections 600.141 through 600.148 set forth standards for use by recipients in establishing procedures for the procurement of supplies and other expendable property, equipment, real property and other services with Federal funds. These standards are furnished to ensure that such materials and services are obtained in an effective manner and in compliance with the provisions of applicable Federal statutes and executive orders. No additional procurement standards or requirements shall be imposed by DOE upon recipients, unless specifically required by Federal statute or executive order or in accordance with the deviation procedures of 600.4.

600.141     Recipient responsibilities.

The standards contained in this section do not relieve the recipient of the contractual responsibilities arising under its contract(s). The recipient is the responsible authority, without recourse to DOE regarding the settlement and satisfaction of all contractual and administrative issues arising out of procurements entered into in support of an award or other agreement. This includes disputes, claims, protests of award, source evaluation or other matters of a contractual nature. Matters concerning violation of statute are to be referred to such Federal, State or local authority as may have proper jurisdiction.

600.142     Codes of conduct.

The recipient shall maintain written standards of conduct governing the performance of its employees engaged in the award and administration of contracts. No employee, officer, or agent shall participate in the selection, award, or administration of a contract supported by Federal funds if a real or apparent conflict of interest would be involved. Such a conflict would arise when the employee, officer, or agent, any member of his or her immediate family, his or her partner, or an organization which employs or is about to employ any of the parties indicated herein, has a financial or other interest in the firm selected for an award. The officers, employees, and agents of the recipient shall neither solicit nor accept gratuities, favors, or anything of monetary value from contractors, or parties to subagreements. However, recipients may set standards for situations in which the financial interest is not substantial or the gift is an unsolicited item of nominal value. The standards of conduct shall provide for disciplinary actions to be applied for violations of such standards by officers, employees, or agents of the recipient.

600.143     Competition.

 

59


All procurement transactions shall be conducted in a manner to provide, to the maximum extent practical, open and free competition. The recipient shall be alert to organizational conflicts of interest as well as noncompetitive practices among contractors that may restrict or eliminate competition or otherwise restrain trade. In order to ensure objective contractor performance and eliminate unfair competitive advantage, contractors that develop or draft specifications, requirements, statements of work, invitations for bids and/or requests for proposals shall be excluded from competing for such procurements. Awards shall be made to the bidder or offeror whose bid or offer is responsive to the solicitation and is most advantageous to the recipient, price, quality and other factors considered. Solicitations shall clearly set forth all requirements that the bidder or offeror shall fulfill in order for the bid or offer to be evaluated by the recipient. Any and all bids or offers may be rejected when it is in the recipient’s interest to do so.

600.144     Procurement procedures.

(a)    All recipients shall establish written procurement procedures. These procedures shall provide for, at a minimum, that paragraphs (a)(1), (2) and (3) of this section apply.

(1)    Recipients avoid purchasing unnecessary items.

(2)    Where appropriate, an analysis is made of lease and purchase alternatives to determine which would be the most economical and practical procurement.

(3)    Solicitations for goods and services provide for all of the following.

(i)    A clear and accurate description of the technical requirements for the material, product or service to be procured. In competitive procurements, such a description shall not contain features which unduly restrict competition.

(ii)    Requirements which the bidder/offeror must fulfill and all other factors to be used in evaluating bids or proposals.

(iii)    A description, whenever practicable, of technical requirements in terms of functions to be performed or performance required, including the range of acceptable characteristics or minimum acceptable standards.

(iv)    The specific features of “brand name or equal” descriptions that bidders are required to meet when such items are included in the solicitation.

(v)    The acceptance, to the extent practicable and economically feasible, of products and services dimensioned in the metric system of measurement.

(vi)    Preference, to the extent practicable and economically feasible, for products and services that conserve natural resources and protect the environment and are energy efficient.

 

60


(b)    Positive efforts shall be made by recipients to utilize small businesses, minority-owned firms, and women’s business enterprises, whenever possible. Recipients of DOE awards shall take all of the following steps to further this goal.

(1)    Ensure that small businesses, minority-owned firms, and women’s business enterprises are used to the fullest extent practicable.

(2)    Make information on forthcoming opportunities available and arrange time frames for purchases and contracts to encourage and facilitate participation by small businesses, minority-owned firms, and women’s business enterprises.

(3)    Consider in the contract process whether firms competing for larger contracts intend to subcontract with small businesses, minority-owned firms, and women’s business enterprises.

(4)    Encourage contracting with consortiums of small businesses, minority owned firms and women’s business enterprises when a contract is too large for one of these firms to handle individually.

(5)    Use the services and assistance, as appropriate, of such organizations as the Small Business Administration and the Department of Commerce’s Minority Business Development Agency in the solicitation and utilization of small businesses, minority-owned firms and women’s business enterprises.

(c)    The type of procuring instruments used (e.g., fixed price contracts, cost reimbursable contracts, purchase orders, and incentive contracts) shall be determined by the recipient but shall be appropriate for the particular procurement and for promoting the best interest of the program or project involved. The “cost-plus-a-percentage-of-cost” or “percentage of construction cost” methods of contracting shall not be used.

(d)    Contracts shall be made only with responsible contractors who possess the potential ability to perform successfully under the terms and conditions of the proposed procurement. Consideration shall be given to such matters as contractor integrity, record of past performance, financial and technical resources or accessibility to other necessary resources. In certain circumstances, contracts with certain parties are restricted by DOE’s implementation, in 10 CFR Part 1036, of E.O.’s 12549 and 12689, “Debarment and Suspension.”

(e)    Recipients shall, on request, make available for DOE, pre-award review and procurement documents, such as request for proposals or invitations for bids, independent cost estimates, etc., when any of the following conditions apply.

(1)    A recipient’s procurement procedures or operation fails to comply with the procurement standards in this Subpart.

 

61


(2)    The procurement is expected to exceed the small purchase threshold fixed at 41 U.S.C. 403 (11) (currently $100,000) and is to be awarded without competition or only one bid or offer is received in response to a solicitation.

(3)    The procurement, which is expected to exceed the small purchase threshold, specifies a “brand name” product.

(4)    The proposed award over the small purchase threshold is to be awarded to other than the apparent low bidder under a sealed bid procurement.

(5)    A proposed contract modification changes the scope of a contract or increases the contract amount by more than the amount of the small purchase threshold.

(f)    By agreement of the recipient or subrecipient and the contractor, if consistent with the recipient’s or subrecipient’s usual business practices and applicable state and local law, any contract to which this section applies may provide for the payment of interest penalties on amounts overdue under such contract except that--

(1)    In no case shall any obligation to pay such interest penalties be construed to be an obligation of the Federal government, and

(2)    Any payment of such interest penalties may not be made from DOE funds nor be counted toward meeting a cost sharing requirement of a DOE award.

600.145     Cost and price analysis.

Some form of cost or price analysis shall be made and documented in the procurement files in connection with every procurement action. Price analysis may be accomplished in various ways, including the comparison of price quotations submitted, market prices and similar indicia, together with discounts. Cost analysis is the review and evaluation of each element of cost to determine reasonableness, allocability and allowability.

600.146     Procurement records.

Procurement records and files for purchases in excess of the small purchase threshold shall include the following at a minimum:

(a)    Basis for contractor selection,

(b)    Justification for lack of competition when competitive bids or offers are not obtained, and

(c)    Basis for award cost or price.

 

62


600.147     Contract administration.

A system for contract administration shall be maintained to ensure contractor conformance with the terms, conditions and specifications of the contract and to ensure adequate and timely follow up of all purchases. Recipients shall evaluate contractor performance and document, as appropriate, whether contractors have met the terms, conditions and specifications of the contract.

600.148     Contract provisions.

The recipient shall include, in addition to provisions to define a sound and complete agreement, the following provisions in all contracts. The following provisions shall also be applied to subcontracts.

(a)    Contracts in excess of the small purchase threshold shall contain contractual provisions or conditions that allow for administrative, contractual, or legal remedies in instances in which a contractor violates or breaches the contract terms, and provide for such remedial actions as may be appropriate.

(b)    All contracts in excess of the small purchase threshold shall contain suitable provisions for termination by the recipient, including the manner by which termination shall be effected and the basis for settlement. In addition, such contracts shall describe conditions under which the contract may be terminated for default as well as conditions where the contract may be terminated because of circumstances beyond the control of the contractor.

(c)    Except as otherwise required by statute, an award that requires the contracting (or subcontracting) for construction or facility improvements shall provide for the recipient to follow its own requirements relating to bid guarantees, performance bonds, and payment bonds unless the construction contract or subcontract exceeds $100,000. For those contracts or subcontracts exceeding $100,000, DOE may accept the bonding policy and requirements of the recipient, provided the DOE has made a determination that the Federal Government’s interest is adequately protected. If such a determination has not been made, the minimum requirements shall be as follows.

(1)    A bid guarantee from each bidder equivalent to five percent of the bid price. The “bid guarantee” shall consist of a firm commitment such as a bid bond, certified check, or other negotiable instrument accompanying a bid as assurance that the bidder shall, upon acceptance of his bid, execute such contractual documents as may be required within the time specified.

(2)    A performance bond on the part of the contractor for 100 percent of the contract price. A “performance bond” is one executed in connection with a contract to secure fulfillment of all the contractor’s obligations under such contract.

 

63


(3)    A payment bond on the part of the contractor for 100 percent of the contract price. A “payment bond” is one executed in connection with a contract to assure payment as required by statute of all persons supplying labor and material in the execution of the work provided for in the contract.

(4)    Where bonds are required in the situations described herein, the bonds shall be obtained from companies holding certificates of authority as acceptable sureties pursuant to 31 CFR Part 223, “Surety Companies Doing Business with the United States.”

(d)    All negotiated contracts (except those for less than the small purchase threshold) awarded by recipients shall include a provision to the effect that the recipient, DOE, the Comptroller General of the United States, or any of their duly authorized representatives, shall have access to any books, documents, papers and records of the contractor which are directly pertinent to a specific program for the purpose of making audits, examinations, excerpts and transcriptions.

(e)    All contracts, including small purchases, awarded by recipients and their contractors shall contain the procurement provisions of Appendix A to this Subpart, as applicable.

600.149     Resource Conservation and Recovery Act (RCRA).

Recipients’ procurements shall comply with applicable requirements of RCRA, as described at 600.116 of this subpart.

Reports and Records

600.150     Purpose of reports and records.

Sections 600.151 through 600.153 set forth the procedures for monitoring and reporting on the recipient’s financial and program performance and the necessary standard reporting forms. They also set forth record retention requirements.

600.151     Monitoring and reporting program performance.

(a)    Recipients are responsible for managing and monitoring each project, program, subaward, function or activity supported by the award. Recipients shall monitor subawards to ensure subrecipients have met the audit requirements as delineated in Section 600.126.

(b)    The terms and conditions of the award will prescribe the frequency with which the performance reports shall be submitted. Except as provided in paragraph (f) of this section, performance reports shall not be required more frequently than quarterly or less

 

64


frequently than annually. Annual reports shall be due 90 calendar days after the award year; quarterly or semi-annual reports shall be due 30 days after the reporting period. DOE may require annual reports before the anniversary dates of multiple year awards in lieu of these requirements. The final performance reports are due 90 calendar days after the expiration or termination of the award.

(c)    If inappropriate, a final technical or performance report shall not be required after completion of the project.

(d)    When required, performance reports shall generally contain, for each award, brief information on each of the following.

(1)    A comparison of actual accomplishments with the goals and objectives established for the period, the findings of the investigator, or both. Whenever appropriate and the output of programs or projects can be readily quantified, such quantitative data should be related to cost data for computation of unit costs.

(2)    Reasons why established goals were not met, if appropriate.

(3)    Other pertinent information including, when appropriate, analysis and explanation of cost overruns or high unit costs. DOE may specify in the award that the recipient provide this information on the Federal Assistance Program/Project Status Report (DOE F 4600.6), the technical reporting formats, or the Federal Assistance Management Summary Report. DOE may require that the Federal Assistance Management Summary Report be used as a performance report only when such use is authorized by program rule or the need for this form is explained in the solicitation. The requirements of this section concerning reporting frequency and deadlines shall apply to the Federal Assistance Management Summary Report. (See also Section 600.112 with regard to use of this form as part of the award application.)

(e)    Recipients shall not be required to submit more than the original and two copies of performance reports.

(f)    Recipients shall immediately notify DOE of developments that have a significant impact on the award-supported activities. Also, notification shall be given in the case of problems, delays, or adverse conditions which materially impair the ability to meet the objectives of the award. This notification shall include a statement of the action taken or contemplated, and any assistance needed to resolve the situation.

(g)    DOE may make site visits, as needed.

(h)    DOE shall comply with applicable clearance requirements of 5 CFR Part 1320 when requesting performance data from recipients.

 

65


(i)    Recipients may place performance reporting requirements on subawards consistent with the provisions of this section and shall require interim reporting in accordance with Section 600.151(f).

600.152     Financial reporting.

(a)    The following forms or such other forms as may be approved by OMB are authorized for obtaining financial information from recipients.

(1)    SF-269 or SF-269A, Financial Status Report.

(i)     Recipients shall use the SF-269 or SF-269A to report the status of funds for all nonconstruction projects or programs, except that DOE has the option of not requiring the SF-269 or SF-269A when the SF-270, Request for Advance or Reimbursement, or SF-272, Report of Federal Cash Transactions, is determined to provide adequate information to meet DOE needs. However, a final SF-269 or SF-269A shall be required at the completion of the project when the SF-270 is used only for advances.

(ii)    The terms and conditions of award shall prescribe whether the report shall be on a cash or accrual basis. DOE may require accrual reporting only if such reporting is required by program statute or rule. If the award requires accrual information and the recipient’s accounting records are not normally kept on the accrual basis, the recipient shall not be required to convert its accounting system, but shall develop such accrual information through best estimates based on an analysis of the documentation on hand.

(iii)     DOE shall determine the frequency of the Financial Status Report for each project or program, considering the size and complexity of the particular project or program. However, the report shall not be required more frequently than quarterly or less frequently than annually. A final report shall be required at the completion of the agreement.

(iv)     DOE shall require recipients to submit the SF-269 or SF-269A (an original and no more than two copies) no later than 30 days after the end of each specified reporting period for quarterly and semi-annual reports, and 90 calendar days for annual and final reports. Extensions of reporting due dates may be approved by the DOE upon request of the recipient.

(2)    SF-272, Report of Federal Cash Transactions.

(i)     When funds are advanced, each recipient shall submit the SF-272 and when necessary, its continuation sheet, SF-272a. DOE will use this report to monitor cash advanced to recipients and to obtain disbursement information for each agreement with the recipients.

 

66


(ii)     Recipients shall forecast Federal cash requirements in the “Remarks” section of the report.

(iii)    When practical and deemed necessary, DOE may require recipients to report in the “Remarks” section the amount of cash advances received in excess of three days. Recipients shall provide short narrative explanations of actions taken to reduce the excess balances.

(iv)    Recipients shall be required to submit not more than the original and two copies of the SF-272 15 calendar days following the end of each quarter. DOE may require a monthly report from those recipients receiving advances totaling $1 million or more per year.

(v)     DOE may waive the requirement for submission of the SF-272 for any one of the following reasons:

(A) When monthly advances do not exceed $25,000 per recipient, provided that such advances are monitored through other forms contained in this section;

(B) If, in the Contracting Officer’s opinion, the recipient’s accounting controls are adequate to minimize excessive Federal advances; or,

(C) When electronic payment mechanisms provide adequate data.

(b)    When DOE needs additional information or more frequent reports, the following shall be observed:

(1)    When additional information is needed to comply with legislative requirements, DOE shall issue instructions to require recipients to submit such information under the “Remarks” section of the reports.

(2)    When DOE determines that a recipient’s accounting system does not meet the standards in 600.121, additional pertinent information to further monitor awards may be obtained upon written notice to the recipient until such time as the system is brought up to standard. DOE, in obtaining this information, shall comply with report clearance requirements of 5 CFR Part 1320.

(3)    Contracting officers are encouraged to shade out any line item on any report if not necessary.

(4)    DOE may accept the identical information from the recipients in machine readable format or computer printouts or electronic outputs in lieu of prescribed formats.

 

67


(5)    Computer or electronic outputs may be provided to recipients when that expedites or contributes to the accuracy of reporting.

600.153     Retention and access requirements for records.

(a)    This section sets forth requirements for record retention and access to records for awards to recipients. DOE shall not impose any other record retention or access requirements upon recipients, unless such requirements are established in program regulations.

(b)    Financial records, supporting documents, statistical records, and all other records pertinent to an award shall be retained for a period of three years from the date of submission of the final expenditure report or, for awards that are renewed quarterly or annually, from the date of the submission of the quarterly or annual financial report, as authorized by DOE. The only exceptions are the following:

(1)    If any litigation, claim, or audit is started before the expiration of the 3-year period, the records shall be retained until all litigation, claims or audit findings involving the records have been resolved and final action taken.

(2)    Records for real property and equipment acquired with Federal funds shall be retained for 3 years after final disposition.

(3)    When records are transferred to or maintained by DOE, the 3-year retention requirement is not applicable to the recipient.

(4)    Indirect cost rate proposals, cost allocations plans, and related records, for which retention requirements are specified in Section 600.153(g).

(c)    Copies of original records may be substituted for the original records if authorized by DOE.

(d)    DOE shall request transfer of certain records to its custody from recipients when it determines that the records possess long term retention value. However, in order to avoid duplicate recordkeeping, DOE may make arrangements for recipients to retain any records that are continuously needed for joint use.

(e)    DOE, the Inspector General, Comptroller General of the United States, or any of their duly authorized representatives, have the right of timely and unrestricted access to any books, documents, papers, or other records of recipients that are pertinent to the awards, in order to make audits, examinations, excerpts, transcripts and copies of such documents. This right also includes timely and reasonable access to a recipient’s personnel for the purpose of interview and discussion related to such documents. The rights of access in this paragraph are not limited to the required retention period, but shall last as long as records are retained.

 

68


(f)    Unless required by statute, DOE shall place no restrictions on recipients that limit public access to the records of recipients that are pertinent to an award, except when DOE can demonstrate that such records shall be kept confidential and would have been exempted from disclosure pursuant to the Freedom of Information Act (5 U.S.C. 552) if the records had belonged to DOE.

(g)    Paragraphs (g)(1) and (g)(2) of this section apply to the following types of documents, and their supporting records: indirect cost rate computations or proposals, cost allocation plans, and any similar accounting computations of the rate at which a particular group of costs is chargeable (such as computer usage chargeback rates or composite fringe benefit rates).

(1)    If submitted for negotiation. If the recipient submits to the Federal agency responsible for negotiating the recipient’s indirect cost rate or the subrecipient submits to the recipient the proposal, plan, or other computation to form the basis for negotiation of the rate, then the 3-year retention period for its supporting records starts on the date of such submission.

(2)    If not submitted for negotiation. If the recipient is not required to submit to the cognizant Federal agency or the subrecipient is not required to submit to the recipient the proposal, plan, or other computation for negotiation purposes, then the 3-year retention period for the proposal, plan, or other computation and its supporting records starts at the end of the fiscal year (or other accounting period) covered by the proposal, plan, or other computation.

(h)    If, by the terms and conditions of the award, the recipient or subrecipient-

(1)    Is accountable for program income earned or received after the end of the project period or after the termination of an award or subaward, or

(2)    If program income earned during the project period is required to be applied to costs incurred after the end of the project period or after termination of an award or subaward, the record retention period shall start on the last day of the recipient’s or subrecipient’s fiscal year in which such income was earned or received or such costs were incurred. All other program income records shall be retained in accordance with Section 600.153(b).

Termination and Enforcement

600.160     Purpose of termination and enforcement.

Sections 600.161 and 600.162 set forth uniform suspension, termination and enforcement procedures.

 

69


600.161     Termination.

(a)    Awards may be terminated in whole or in part only if paragraph (a) (1), (2) or (3) of this section apply.

(1)    By DOE, if a recipient materially fails to comply with the terms and conditions of an award.

(2)    By DOE with the consent of the recipient, in which case the two parties shall agree upon the termination conditions, including the effective date and, in the case of partial termination, the portion to be terminated.

(3)    By the recipient upon sending to DOE written notification setting forth the reasons for such termination, the effective date, and, in the case of partial termination, the portion to be terminated. However, if DOE determines in the case of partial termination that the reduced or modified portion of the award will not accomplish the purposes for which the award was made, it may terminate the award in its entirety under either paragraph (a) (1) or (2) of this section.

(b)    If costs are allowed under an award, the responsibilities of the recipient referred to in Section 600.171(a), including those for property management as applicable, shall be considered in the termination of the award, and provision shall be made for continuing responsibilities of the recipient after termination, as appropriate.

600.162     Enforcement.

(a)    Remedies for noncompliance. If a recipient materially fails to comply with the terms and conditions of an award, whether stated in a Federal statute, regulation, assurance, application, or notice of award, DOE may, in addition to imposing any of the special conditions outlined in Section 600.114, take one or more of the following actions, as appropriate in the circumstances.

(1)    Temporarily withhold cash payments pending correction of the deficiency by the recipient or more severe enforcement action by DOE.

(2)    Disallow (that is, deny both use of funds and any applicable matching credit for) all or part of the cost of the activity or action not in compliance.

(3)    Wholly or partly suspend or terminate the current award.

(4)    Withhold further awards for the project or program.

(5)    Take other remedies that may be legally available.

 

70


(b)    Hearings and appeals. In taking an enforcement action, DOE shall provide the recipient an opportunity for hearing, appeal, or other administrative proceeding to which the recipient is entitled under any statute or regulation applicable to the action involved.

(c)    Effects of suspension and termination. Costs of a recipient resulting from obligations incurred by the recipient during a suspension or after termination of an award are not allowable unless the awarding agency expressly authorizes them in the notice of suspension or termination or subsequently. Other recipient costs during suspension or after termination which are necessary and not reasonably avoidable are allowable if paragraph (c) (1) and (2) of this section apply.

(1)    The costs result from obligations which were properly incurred by the recipient before the effective date of suspension or termination, are not in anticipation of it, and in the case of a termination, are noncancellable.

(2)    The costs would be allowable if the award were not suspended or expired normally at the end of the funding period in which the termination takes effect.

(d)    Relationship to debarment and suspension. The enforcement remedies identified in this section, including suspension and termination, do not preclude a recipient from being subject to debarment and suspension under 10 CFR Part 1036.

After-The-Award Requirements

600.170     Purpose.

Sections 600.171 through 600.173 contain closeout procedures and other procedures for subsequent disallowances and adjustments.

600.171     Closeout procedures.

(a)    Recipients shall submit, within 90 calendar days after the date of completion of the award, all financial, performance, and other reports as required by the terms and conditions of the award. DOE may approve extensions when requested by the recipient.

(b)    Unless DOE authorizes an extension, a recipient shall liquidate all obligations incurred under the award not later than 90 calendar days after the funding period or the date of completion as specified in the terms and conditions of the award or in agency implementing instructions.

(c)    DOE shall make prompt payments to a recipient for allowable reimbursable costs under the award being closed out.

 

71


(d)    The recipient shall promptly refund any balances of unobligated cash that DOE has advanced or paid and that is not authorized to be retained by the recipient for use in other projects. OMB Circular A-129 governs unreturned amounts that become delinquent debts.

(e)    When authorized by the terms and conditions of the award, DOE shall make a settlement for any upward or downward adjustments to the Federal share of costs after closeout reports are received.

(f)    The recipient shall account for any real and personal property acquired with Federal funds or received from the Federal Government in accordance with Sections 600.131 through 600.137.

(g)    In the event a final audit has not been performed prior to the closeout of an award, DOE shall retain the right to recover an appropriate amount after fully considering the recommendations on disallowed costs resulting from the final audit.

600.172     Subsequent adjustments and continuing responsibilities.

(a)    The closeout of an award does not affect any of the following.

(1)    The right of DOE to disallow costs and recover funds on the basis of a later audit or other review.

(2)    The obligation of the recipient to return any funds due as a result of later refunds, corrections, or other transactions.

(3)    Audit requirements in 600.126.

(4)    Property management requirements in 600.131 through 600.137.

(5)    Records retention as required in 600.153.

(b)    After closeout of an award, a relationship created under an award may be modified or ended in whole or in part with the consent of DOE and the recipient, provided the responsibilities of the recipient referred to in paragraph 600.173(a), including those for property management as applicable, are considered and provisions made for continuing responsibilities of the recipient, as appropriate.

600.173     Collection of amounts due.

(a)    Any funds paid to a recipient in excess of the amount to which the recipient is finally determined to be entitled under the terms and conditions of the award constitute a debt to

 

72


the Federal Government. If not paid within a reasonable period after the demand for payment, DOE may reduce the debt by paragraph (a) (1), (2) or (3) of this section.

(1)    Making an administrative offset against other requests for reimbursements.

(2)    Withholding advance payments otherwise due to the recipient.

(3)    Taking other action permitted by statute.

(b)    Except as otherwise provided by law, DOE shall charge interest on an overdue debt in accordance with 4 CFR Chapter II, “Federal Claims Collection Standards.”

Additional Provisions

600.180     Reserved.

600.181     Reserved.

APPENDIX A TO SUBPART B TO PART 600 – CONTRACT PROVISIONS.

All contracts, awarded by a recipient, including small purchases, shall contain the following provisions as applicable:

1.        Equal Employment Opportunity – All contracts shall contain a provision requiring compliance with E.O. 11246, “Equal Employment Opportunity,” as amended by E.O. 11375, “Amending Executive Order 11246 Relating to Equal Employment Opportunity,” and as supplemented by regulations at 41 CFR Part 60, “Office of Federal Contract Compliance Programs, Equal Employment Opportunity, Department of Labor.”

2.        Copeland “Anti-Kickback” Act (18 U.S.C. 874 and 40 U.S.C. 276c) – All contracts and subgrants in excess of $2000 for construction or repair awarded by recipients and subrecipients shall include a provision for compliance with the Copeland “Anti-Kickback” Act (18 U.S.C. 874), as supplemented by Department of Labor regulations (29 CFR Part 3, “Contractors and Subcontractors on Public Building or Public Work Financed in Whole or in Part by Loans or Grants from the United States”). The Act provides that each contractor or subrecipient shall be prohibited from inducing, by any means, any person employed in the construction, completion, or repair of public work, to give up any part of the compensation to which he is otherwise entitled. The recipient shall report all suspected or reported violations to the Federal awarding agency.

 

73


3.    Davis-Bacon Act, as amended (40 U.S.C. 276a to a-7) – When required by Federal program legislation, all construction contracts awarded by the recipients and subrecipients of more than $2000 shall include a provision for compliance with the Davis-Bacon Act (40 U.S.C. 276a to a-7) and as supplemented by Department of Labor regulations (29 CFR Part 5, “Labor Standards Provisions Applicable to Contracts Governing Federally Financed and Assisted Construction”). Under this Act, contractors shall be required to pay wages to laborers and mechanics at a rate not less than the minimum wages specified in a wage determination made by the Secretary of Labor. In addition, contractors shall be required to pay wages not less than once a week. The recipient shall place a copy of the current prevailing wage determination issued by the Department of Labor in each solicitation and the award of a contract shall be conditioned upon the acceptance of the wage determination. The recipient shall report all suspected or reported violations to the Federal awarding agency.

4.    Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333) – Where applicable, all contracts awarded by recipients in excess of $2000 for construction contracts and in excess of $2500 for other contracts that involve the employment of mechanics or laborers shall include a provision for compliance with Sections 102 and 107 of the Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333), as supplemented by Department of Labor regulations (29 CFR Part 5). Under Section 102 of the Act, each contractor shall be required to compute the wages of every mechanic and laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work week is permissible provided that the worker is compensated at a rate of not less than 1 1/2 times the basic rate of pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is applicable to construction work and provides that no laborer or mechanic shall be required to work in surroundings or under working conditions which are unsanitary, hazardous or dangerous. These requirements do not apply to the purchases of supplies or materials or articles ordinarily available on the open market, or contracts for transportation or transmission of intelligence.

5.    Rights to Inventions Made Under a Contract or Agreement – Contracts or agreements for the performance of experimental, developmental, or research work shall provide for the rights of the Federal Government and the recipient in any resulting invention in accordance with 37 CFR Part 401, “Rights to Inventions Made by Nonprofit Organizations and Small Business Firms Under Government Grants, Contracts and Cooperative Agreements,” and any implementing regulations issued by the awarding agency.

6.    Clean Air Act (42 U.S.C. 7401 et seq.) and the Federal Water Pollution Control Act (33 U.S.C. 1251 et seq.), as amended – Contracts and subgrants of amounts in excess of $100,000 shall contain a provision that requires the recipient to agree to comply with all applicable standards, orders or regulations issued pursuant to the Clean Air Act (42 U.S.C. 7401 et seq.) and the Federal Water Pollution Control Act as amended (33 U.S.C. 1251 et seq.). Violations shall be reported to the Federal awarding agency and the Regional Office of the Environmental Protection Agency (EPA).

 

74


7.    Byrd Anti-Lobbying Amendment (31 U.S.C. 1352) – Contractors who apply or bid for an award of $100,000 or more shall file the required certification. Each tier certifies to the tier above that it will not and has not used Federal appropriated funds to pay any person or organization for influencing or attempting to influence an officer or employee of any agency, a member of Congress, officer or employee of Congress, or an employee of a member of Congress in connection with obtaining any Federal contract, grant or any other award covered by 31 U.S.C. 1352. Each tier shall also disclose any lobbying with non-Federal funds that takes place in connection with obtaining any Federal award. Such disclosures are forwarded from tier to tier up to the recipient.

8.    Debarment and Suspension (E.O.s 12549 and 12689) – Contract awards that exceed the small purchase threshold and certain other contract awards shall not be made to parties listed on the nonprocurement portion of the General Services Administration’s List of Parties Excluded from Federal Procurement or Nonprocurement Programs in accordance with E.O.s 12549 and 12689, “Debarment and Suspension.” This list contains the names of parties debarred, suspended, or otherwise excluded by agencies, and contractors declared ineligible under statutory or regulatory authority other than E.O. 12549. Contractors with awards that exceed the small purchase threshold shall provide the required certification regarding its exclusion status and that of its principals.

 

75


10 CFR 600 – Subpart C – Uniform Administrative

Requirements for Grants and Cooperative Agreements

to State and Local Governments

 

General    77
600.200      Purpose and scope of this subpart    77
600.201      Scope of 600.200 through 600.205    77
600.202      Definitions    77
600.203      Applicability    81
600.204      Effect on other issuances    82
600.205      Additions and exceptions    83
Pre-Award Requirements    83
600.210      Forms for applying for grants    83
600.211      State plans    84
600.212      Special grant or subgrant conditions for “high-risk” recipients    85
POST-AWARD REQUIREMENTS    86
Financial Administration    86
600.220      Standards for financial management systems    86
600.221      Payment    87
600.222      Allowable costs    89
600.223      Period of availability of funds    90
600.224      Matching or cost sharing    90
600.225      Program income    93
600.226      Non-Federal audit    95
Changes, Property, and Subawards    96
600.230      Changes    96
600.231      Real property    97
600.232      Equipment    98
600.233      Supplies    100
600.234      Copyrights    101
600.235      Subawards to debarred and suspended parties    101
600.236      Procurement    101
600.237      Subgrants    111
Reports, Records, Retention, and Enforcement    112
600.240      Monitoring and reporting program performance    112
600.241      Financial reporting    114
600.242      Retention and access requirements for records    117
600.243      Enforcement    119
600.244      Termination for convenience    120
After-The-Grant Requirements    120
600.250      Closeout    120
600.251      Later disallowances and adjustments    121
600.252      Collection of amounts due    122

 

76


Subpart C — Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments

General

600.200     Purpose and scope of this subpart.

This subpart establishes uniform administrative rules for Federal grants and cooperative agreements and subawards to State, local and Indian tribal governments.

600.201      Scope of 600.200 through 600.205.

This section contains general rules pertaining to this part and procedures for control of exceptions from this subpart.

600.202     Definitions.

As used in this part:

Accrued expenditures mean the charges incurred by the grantee during a given period requiring the provision of funds for: (1) Goods and other tangible property received; (2) services performed by employees, contractors, subgrantees, subcontractors, and other payees; and (3) other amounts becoming owed under programs for which no current services or performance is required, such as annuities, insurance claims, and other benefit payments.

Accrued income means the sum of: (1) Earnings during a given period from services performed by the grantee and goods and other tangible property delivered to purchasers, and (2) amounts becoming owed to the grantee for which no current services or performance is required by the grantee.

Acquisition cost of an item of purchased equipment means the net invoice unit price of the property including the cost of modifications, attachments, accessories, or auxiliary apparatus necessary to make the property usable for the purpose for which it was acquired. Other charges such as the cost of installation, transportation, taxes, duty or protective in-transit insurance, shall be included or excluded from the unit acquisition cost in accordance with the grantee’s regular accounting practices.

Administrative requirements mean those matters common to grants in general, such as financial management, kinds and frequency of reports, and retention of records. These are distinguished from programmatic requirements, which concern matters that can be treated only on a program-by-program or grant-by-grant basis, such as kinds of activities that can be supported by grants under a particular program.

 

77


Awarding agency means (1) with respect to a grant, the Federal agency, and (2) with respect to a subgrant, the party that awarded the subgrant.

Cash contributions means the grantee’s cash outlay, including the outlay of money contributed to the grantee or subgrantee by other public agencies and institutions, and private organizations and individuals. When authorized by Federal legislation, Federal funds received from other assistance agreements may be considered as grantee or subgrantee cash contributions.

Contract means (except as used in the definitions for grant and subgrant in this section and except where qualified by Federal) a procurement contract under a grant or subgrant, and means a procurement subcontract under a contract.

Cost sharing or matching means the value of the third party in-kind contributions and the portion of the costs of a federally assisted project or program not borne by the Federal Government.

Cost-type contract means a contract or subcontract under a grant in which the contractor or subcontractor is paid on the basis of the costs it incurs, with or without a fee.

Equipment means tangible, nonexpendable, personal property having a useful life of more than one year and an acquisition cost of $5,000 or more per unit. A grantee may use its own definition of equipment provided that such definition would at least include all equipment defined above.

Expenditure report means: (1) For nonconstruction grants, the SF269 “Financial Status Report” (or other equivalent report); (2) for construction grants, the SF271 “Outlay Report and Request for Reimbursement” (or other equivalent report).

Federally recognized Indian tribal government means the governing body or a governmental agency of any Indian tribe, band, nation, or other organized group or community (including any Native village as defined in Section 3 of the Alaska Native Claims Settlement Act, 85 Stat 688) certified by the Secretary of the Interior as eligible for the special programs and services provided by him through the Bureau of Indian Affairs.

Government means a State or local government or a federally recognized Indian tribal government.

Grant means an award of financial assistance, including cooperative agreements, in the form of money, or property in lieu of money, by the Federal Government to an eligible grantee. The term does not include technical assistance which provides services instead of money, or other assistance in the form of revenue sharing, loans, loan guarantees, interest subsidies, insurance, or direct appropriations. Also, the term does not include

 

78


assistance, such as a fellowship or other lump sum award, which the grantee is not required to account for.

Grantee means the government to which a grant is awarded and which is accountable for the use of the funds provided. The grantee is the entire legal entity even if only a particular component of the entity is designated in the grant award document.

Local government means a county, municipality, city, town, township, local public authority (including any public and Indian housing agency under the United States Housing Act of 1937) school district, special district, intrastate district, council of governments (whether or not incorporated as a nonprofit corporation under state law), any other regional or interstate government entity, or any agency or instrumentality of a local government.

Obligations means the amounts of orders placed, contracts and subgrants awarded, goods and services received, and similar transactions during a given period that will require payment by the grantee during the same or a future period.

OMB means the United States Office of Management and Budget.

Outlays (expenditures) mean charges made to the project or program. They may be reported on a cash or accrual basis. For reports prepared on a cash basis, outlays are the sum of actual cash disbursement for direct charges for goods and services, the amount of indirect expense incurred, the value of in-kind contributions applied, and the amount of cash advances and payments made to contractors and subgrantees. For reports prepared on an accrued expenditure basis, outlays are the sum of actual cash disbursements, the amount of indirect expense incurred, the value of inkind contributions applied, and the new increase (or decrease) in the amounts owed by the grantee for goods and other property received, for services performed by employees, contractors, subgrantees, subcontractors, and other payees, and other amounts becoming owed under programs for which no current services or performance are required, such as annuities, insurance claims, and other benefit payments.

Percentage of completion method refers to a system under which payments are made for construction work according to the percentage of completion of the work, rather than to the grantee’s cost incurred.

Prior approval means documentation evidencing consent prior to incurring specific cost. For the Department of Energy, this must be signed by a Contracting Officer.

Real property means land, including land improvements, structures and appurtenances thereto, excluding movable machinery and equipment.

Share, when referring to the awarding agency’s portion of real property, equipment or supplies , means the same percentage as the awarding agency’s portion of the acquiring party’s total costs under the grant to which the acquisition costs under the grant to which

 

79


the acquisition cost of the property was charged. Only costs are to be counted — not the value of third-party in-kind contributions.

State means any of the several States of the United States, the District of Columbia, the Commonwealth of Puerto Rico, any territory or possession of the United States, or any agency or instrumentality of a State exclusive of local governments. The term does not include any public and Indian housing agency under United States Housing Act of 1937.

Subgrant means an award of financial assistance in the form of money, or property in lieu of money, made under a grant by a grantee to an eligible subgrantee. The term includes financial assistance when provided by contractual legal agreement, but does not include procurement purchases, nor does it include any form of assistance which is excluded from the definition of grant in this subpart.

Subgrantee means the government or other legal entity to which a subgrant is awarded and which is accountable to the grantee for the use of the funds provided.

Supplies means all tangible personal property other than “equipment” as defined in this subpart.

Suspension means depending on the context, either (1) temporary withdrawal of the authority to obligate grant funds pending corrective action by the grantee or subgrantee or a decision to terminate the grant, or (2) an action taken by a suspending official in accordance with agency regulations implementing E.O. 12549 to immediately exclude a person from participating in grant transactions for a period, pending completion of an investigation and such legal or debarment proceedings as may ensue.

Termination means permanent withdrawal of the authority to obligate previously-awarded grant funds before that authority would otherwise expire. It also means the voluntary relinquishment of that authority by the grantee or subgrantee. Termination does not include: (1) Withdrawal of funds awarded on the basis of the grantee’s underestimate of the unobligated balance in a prior period; (2) withdrawal of the unobligated balance as of the expiration of a grant; (3) refusal to extend a grant or award additional funds, to make a competing or noncompeting continuation, renewal, extension, or supplemental award; or (4) voiding of a grant upon determination that the award was obtained fraudulently, or was otherwise illegal or invalid from inception.

Terms of a grant or subgrant mean all requirements of the grant or subgrant, whether in statute, regulations, or the award document.

Third party in-kind contributions mean property or services which benefit a federally assisted project or program and which are contributed by non-Federal third parties without charge to the grantee, or a cost-type contractor under the grant agreement.

Unliquidated obligations for reports prepared on a cash basis mean the amount of obligations incurred by the grantee that has not been paid. For reports prepared on an

 

80


accrued expenditure basis, they represent the amount of obligations incurred by the grantee for which an outlay has not been recorded.

Unobligated balance means the portion of the funds authorized by the Federal agency that has not been obligated by the grantee and is determined by deducting the cumulative obligations from the cumulative funds authorized.

600.203     Applicability.

(a)    General. Sections 600.200 through 600.252 of this subpart apply to all grants and subgrants to governments, except where inconsistent with Federal statutes or with regulations authorized in accordance with the exception provision of 600.205, or:

(1)    Grants and subgrants to State and local institutions of higher education or State and local hospitals.

(2)    The block grants authorized by the Omnibus Budget Reconciliation Act of 1981 (Community Services; Preventive Health and Health Services; Alcohol, Drug Abuse, and Mental Health Services; Maternal and Child Health Services; Social Services; Low-Income Home Energy Assistance; States’ Program of Community Development Block Grants for Small Cities; and Elementary and Secondary Education other than programs administered by the Secretary of Education under Title V, Subtitle D, Chapter 2, Section 583 — the Secretary’s discretionary grant program) and Titles I - III of the Job Training Partnership Act of 1982 and under the Public Health Services Act (Section 1921), Alcohol and Drug Abuse Treatment and Rehabilitation Block Grant and Part C of Title V, Mental Health Service for the Homeless Block Grant).

(3)    Entitlement grants to carry out the following programs of the Social Security Act:

(i)    Aid to Needy Families with Dependent Children (Title IV - A of the Act, not including the Work Incentive Program (WIN) authorized by section 402(a)19(G); HHS grants for WIN are subject to this subpart);

(ii)   Child Support Enforcement and Establishment of Paternity (Title IV - D of the Act);

(iii)  Foster Care and Adoption Assistance (Title IV - E of the Act);

(iv)  Aid to the Aged, Blind, and Disabled (Titles I, X, XIV, and XVI - AABD of the Act); and

(v)   Medical Assistance (Medicaid) (Title XIX of the Act) not including the State Medicaid Fraud Control program authorized by section 1903(a)(6)(B).

 

81


(4)    Entitlement grants under the following programs of The National School Lunch Act:

(i)    School Lunch (section 4 of the Act),

(ii)   Commodity Assistance (section 6 of the Act),

(iii)  Special Meal Assistance (section 11 of the Act),

(iv)  Summer Food Service for Children (section 13 of the Act), and

(v)   Child Care Food Program (section 17 of the Act).

(5)    Entitlement grants under the following programs of The Child Nutrition Act of 1966:

(i)    Special Milk (section 3 of the Act), and

(ii)   School Breakfast (section 4 of the Act).

(6)    Entitlement grants for State Administrative expenses under The Food Stamp Act of 1977 (section 16 of the Act).

(7)    A grant for an experimental, pilot, or demonstration project that is also supported by a grant listed in paragraph (a)(3) of this section;

(8)    Grant funds awarded under subsection 412(e) of the Immigration and Nationality Act (8 U.S.C. 1522(e)) and subsection 501(a) of the Refugee Education Assistance Act of 1980 (Pub. L. 96 - 422, 94 Stat. 1809), for cash assistance, medical assistance, and supplemental security income benefits to refugees and entrants and the administrative costs of providing the assistance and benefits;

(9)    Grants to local education agencies under 20 U.S.C. 236 through 241 - 1(a), and 242 through 244 (portions of the Impact Aid program), except for 20 U.S.C. 238(d)(2)(c) and 240(f) (Entitlement Increase for Handicapped Children); and

(10)  Payments under the Veterans Administration’s State Home Per Diem Program (38 U.S.C. 641(a)).

(b)    Entitlement programs. Entitlement programs enumerated above in 600.203(a) (3) through (8) are subject to Subpart E.

600.204     Effect on other issuances.

 

82


All other grants administration provisions of codified program regulations, program manuals, handbooks and other nonregulatory materials which are inconsistent with this subpart are superseded, except to the extent they are required by statute, or authorized in accordance with the exception provision in 600.205.

600.205     Additions and exceptions.

(a)    For classes of grants and grantees subject to this subpart, Federal agencies may not impose additional administrative requirements except in codified regulations published in the Federal Register.

(b)    Exceptions for classes of grants or grantees may be authorized only by OMB.

(c)    Exceptions on a case-by-case basis and for subgrantees may be authorized by the affected Federal agencies.

(d)    The DOE procedural requirements for requesting additions and exceptions are specified in 600.4.

Pre-Award Requirements

600.210     Forms for applying for grants.

(a)    Scope.

(1)    This section prescribes forms and instructions to be used by governmental organizations (except hospitals and institutions of higher education operated by a government) in applying for grants. This section is not applicable, however, to formula grant programs which do not require applicants to apply for funds on a project basis.

(2)    This section applies only to applications to Federal agencies for grants, and is not required to be applied by grantees in dealing with applicants for subgrants. However, grantees are encouraged to avoid more detailed or burdensome application requirements for subgrants.

(b)    Authorized forms and instructions for governmental organizations.

(1)    In applying for grants, applicants shall only use standard application forms or those prescribed by the granting agency with the approval of OMB under the Paperwork Reduction Act of 1980.

(2)    Applicants are not required to submit more than the original and two copies of preapplications or applications.

 

83


(3)    Applicants must follow all applicable instructions that bear OMB clearance numbers. Federal agencies may specify and describe the programs, functions, or activities that will be used to plan, budget, and evaluate the work under a grant. Other supplementary instructions may be issued only with the approval of OMB to the extent required under the Paperwork Reduction Act of 1980. For any standard form, except the SF-424 facesheet, Federal agencies may shade out or instruct the applicant to disregard any line item that is not needed.

(4)    When a grantee applies for additional funding (such as a continuation or supplemental award) or amends a previously submitted application, only the affected pages need be submitted. Previously submitted pages with information that is still current need not be resubmitted.

600.211     State plans.

(a)    Scope. The statutes for some programs require States to submit plans before receiving grants. Under regulations implementing Executive Order 12372, “Intergovernmental Review of Federal Programs,” States are allowed to simplify, consolidate and substitute plans. This section contains additional provisions for plans that are subject to regulations implementing the Executive order.

(b)    Requirements. A State need meet only Federal administrative or programmatic requirements for a plan that are in statutes or codified regulations.

(c)    Assurances. In each plan the State will include an assurance that the State shall comply with all applicable Federal statutes and regulations in effect with respect to the periods for which it receives grant funding. For this assurance and other assurances required in the plan, the State may:

(1)    Cite by number the statutory or regulatory provisions requiring the assurances and affirm that it gives the assurances required by those provisions,

(2)    Repeat the assurance language in the statutes or regulations, or

(3)    Develop its own language to the extent permitted by law.

(d)    Amendments. A State will amend a plan whenever necessary to reflect: (1) New or revised Federal statutes or regulations or (2) a material change in any State law, organization, policy, or State agency operation. The State will obtain approval for the amendment and its effective date but need submit for approval only the amended portions of the plan.

 

84


600.212     Special grant or subgrant conditions for “high-risk” recipients.

(a)    A grantee or subgrantee may be considered “high risk” if an awarding agency determines that a grantee or subgrantee:

(1)    Has a history of unsatisfactory performance, or

(2)    Is not financially stable, or

(3)    Has a management system which does not meet the management standards set forth in this subpart, or

(4)    Has not conformed to terms and conditions of previous awards, or

(5)    Is otherwise not responsible; and if the awarding agency determines that an award will be made, special conditions and/or restrictions shall correspond to the high risk condition and shall be included in the award.

(b)    Special conditions or restrictions may include:

(1)    Payment on a reimbursement basis;

(2)    Withholding authority to proceed to the next phase until receipt of evidence of acceptable performance within a given funding period;

(3)    Requiring additional, more detailed financial reports;

(4)    Additional project monitoring;

(5)    Requiring the grantee or subgrantee to obtain technical or management assistance; or

(6)    Establishing additional prior approvals.

(c)    If an awarding agency decides to impose such conditions, the awarding official will notify the grantee or subgrantee as early as possible, in writing, of:

(1)    The nature of the special conditions/restrictions;

(2)    The reason(s) for imposing them;

(3)    The corrective actions which must be taken before they will be removed and the time allowed for completing the corrective actions and

(4)    The method of requesting reconsideration of the conditions/restrictions imposed.

 

85


POST-AWARD REQUIREMENTS

Financial Administration

600.220     Standards for financial management systems.

(a)    A State must expend and account for grant funds in accordance with State laws and procedures for expending and accounting for its own funds. Fiscal control and accounting procedures of the State, as well as its subgrantees and cost-type contractors, must be sufficient to—

(1)    Permit preparation of reports required by this part and the statutes authorizing the grant, and

(2)    Permit the tracing of funds to a level of expenditures adequate to establish that such funds have not been used in violation of the restrictions and prohibitions of applicable statutes.

(b)    The financial management systems of other grantees and subgrantees must meet the following standards:

(1)    Financial reporting. Accurate, current, and complete disclosure of the financial results of financially assisted activities must be made in accordance with the financial reporting requirements of the grant or subgrant.

(2)    Accounting records. Grantees and subgrantees must maintain records which adequately identify the source and application of funds provided for financially-assisted activities. These records must contain information pertaining to grant or subgrant awards and authorizations, obligations, unobligated balances, assets, liabilities, outlays or expenditures, and income.

(3)    Internal control. Effective control and accountability must be maintained for all grant and subgrant cash, real and personal property, and other assets. Grantees and subgrantees must adequately safeguard all such property and must assure that it is used solely for authorized purposes.

(4)    Budget control. Actual expenditures or outlays must be compared with budgeted amounts for each grant or subgrant. Financial information must be related to performance or productivity data, including the development of unit cost information whenever appropriate or specifically required in the grant or subgrant agreement. If unit cost data are required, estimates based on available documentation will be accepted whenever possible.

 

86


(5)    Allowable cost. Applicable OMB cost principles, agency program regulations, and the terms of grant and subgrant agreements will be followed in determining the reasonableness, allowability, and allocability of costs.

(6)    Source documentation. Accounting records must be supported by such source documentation as cancelled checks, paid bills, payrolls, time and attendance records, contract and subgrant award documents, etc.

(7)    Cash management. Procedures for minimizing the time elapsing between the transfer of funds from the U.S. Treasury and disbursement by grantees and subgrantees must be followed whenever advance payment procedures are used. Grantees must establish reasonable procedures to ensure the receipt of reports on subgrantees’ cash balances and cash disbursements in sufficient time to enable them to prepare complete and accurate cash transactions reports to the awarding agency. When advances are made by letter-of-credit or electronic transfer of funds methods, the grantee must make drawdowns as close as possible to the time of making disbursements. Grantees must monitor cash drawdowns by their subgrantees to assure that they conform substantially to the same standards of timing and amount as apply to advances to the grantees.

(c)    An awarding agency may review the adequacy of the financial management system of any applicant for financial assistance as part of a preaward review or at any time subsequent to award.

600.221     Payment.

(a)    Scope. This section prescribes the basic standard and the methods under which a Federal agency will make payments to grantees, and grantees will make payments to subgrantees and contractors.

(b)    Basic standard. Methods and procedures for payment shall minimize the time elapsing between the transfer of funds and disbursement by the grantee or subgrantee, in accordance with Treasury regulations at 31 CFR Part 205.

(c)    Advances. Grantees and subgrantees shall be paid in advance, provided they maintain or demonstrate the willingness and ability to maintain procedures to minimize the time elapsing between the transfer of the funds and their disbursement by the grantee or subgrantee.

(d)    Reimbursement. Reimbursement shall be the preferred method when the requirements in paragraph (c) of this section are not met. Grantees and subgrantees may also be paid by reimbursement for any construction grant. Except as otherwise specified in regulation, Federal agencies shall not use the percentage of completion method to pay construction grants. The grantee or subgrantee may use that method to pay its

 

87


construction contractor, and if it does, the awarding agency’s payments to the grantee or subgrantee will be based on the grantee’s or subgrantee’s actual rate of disbursement.

(e)    Working capital advances. If a grantee cannot meet the criteria for advance payments described in paragraph (c) of this section, and the Federal agency has determined that reimbursement is not feasible because the grantee lacks sufficient working capital, the awarding agency may provide cash or a working capital advance basis. Under this procedure the awarding agency shall advance cash to the grantee to cover its estimated disbursement needs for an initial period generally geared to the grantee’s disbursing cycle. Thereafter, the awarding agency shall reimburse the grantee for its actual cash disbursements. The working capital advance method of payment shall not be used by grantees or subgrantees if the reason for using such method is the unwillingness or inability of the grantee to provide timely advances to the subgrantee to meet the subgrantee’s actual cash disbursements.

(f)    Effect of program income, refunds, and audit recoveries on payment.

(1)    Grantees and subgrantees shall disburse repayments to and interest earned on a revolving fund before requesting additional cash payments for the same activity.

(2)    Except as provided in paragraph (f)(1) of this section, grantees and subgrantees shall disburse program income, rebates, refunds, contract settlements, audit recoveries and interest earned on such funds before requesting additional cash payments.

(g)    Withholding payments.

(1)    Unless otherwise required by Federal statute, awarding agencies shall not withhold payments for proper charges incurred by grantees or subgrantees unless —

(2)    (i)   The grantee or subgrantee has failed to comply with grant award conditions or

     (ii)  The grantee or subgrantee is indebted to the United States.

(2)    Cash withheld for failure to comply with grant award condition, but without suspension of the grant, shall be released to the grantee upon subsequent compliance. When a grant is suspended, payment adjustments will be made in accordance with 600.243(c).

(3)    A Federal agency shall not make payment to grantees for amounts that are withheld by grantees or subgrantees from payment to contractors to assure satisfactory completion of work. Payments shall be made by the Federal agency when the grantees or subgrantees actually disburse the withheld funds to the contractors or to escrow accounts established to assure satisfactory completion of work.

(h)    Cash depositories.

 

88


(1)    Consistent with the national goal of expanding the opportunities for minority business enterprises, grantees and subgrantees are encouraged to use minority banks (a bank which is owned at least 50 percent by minority group members). A list of minority owned banks can be obtained from the Minority Business Development Agency, Department of Commerce, Washington, DC 20230.

(2)    A grantee or subgrantee shall maintain a separate bank account only when required by Federal-State agreement.

(i)    Interest earned on advances. Unless there are statutory provisions to the contrary, grantees and subgrantees shall promptly, but at least quarterly, remit to the Federal agency interest earned on advances. The grantee or subgrantee may keep interest amounts up to $100 per year for administrative expenses.

600.222     Allowable costs.

(a)    Limitation on use of funds. Grant funds may be used only for:

(1)    The allowable costs of the grantees, subgrantees and cost-type contractors, including allowable costs in the form of payments to fixed-price contractors; and

(2)    Reasonable fees or profit to cost-type contractors but not any fee or profit (or other increment above allowable costs) to the grantee or subgrantee.

(b)    Applicable cost principles. For each kind of organization, there is a set of Federal principles for determining allowable costs. Allowable costs will be determined in accordance with the cost principles applicable to the organization incurring the costs. The following chart lists the kinds of organizations and the applicable cost principles.

 

For the costs of a—    Use the principles in —
State, local or Indian tribal government.    OMB Circular A-87.

Private nonprofit organization other than an

(1)institution of higher education,

(2)hospital, or (3) organization named in

OMB Circular A-122 as not subject to that

circular.

   OMB Circular A-122.
Educational institutions.    OMB Circular A-21.

For-profit organization other than a

hospital and an organization named in

OMB Circular A-122 as not subject to that

circular.

  

48 CFR Part 31. Contract Cost Principles

and Procedures, or uniform cost accounting

standards that comply with cost principles

acceptable to the Federal agency.

For-profit organization other than a

hospital and an organization named in

OMB Circular A-122 as not subject to that

   48 CFR 931.2

 

89


circular.   
Hospitals    45 CFR Part 74, Appendix E

600.223     Period of availability of funds.

(a)    General. Where a funding period is specified, a grantee may charge to the award only costs resulting from obligations of the funding period unless carryover of unobligated balances is permitted, in which case the carryover balances may be charged for costs resulting from obligations of the subsequent funding period.

(b)    Liquidation of obligations. A grantee must liquidate all obligations incurred under the award not later than 90 days after the end of the funding period (or as specified in a program regulation) to coincide with the submission of the annual Financial Status Report (SF269). The Federal agency may extend this deadline at the request of the grantee.

600.224     Matching or cost sharing.

(a)    Basic rule: Costs and contributions acceptable. With the qualifications and exceptions listed in paragraph (b) of this section, a matching or cost sharing requirement may be satisfied by either or both of the following:

(1)    Allowable costs incurred by the grantee, subgrantee or a cost-type contractor under the assistance agreement. This includes allowable costs borne by non-Federal grants or by others cash donations from non-Federal third parties.

(2)    The value of third party in-kind contributions applicable to the period to which the cost sharing or matching requirements applies.

(b)    Qualifications and exceptions —

(1)    Costs borne by other Federal grant agreements. Except as provided by Federal statute, a cost sharing or matching requirement may not be met by costs borne by another Federal grant. This prohibition does not apply to income earned by a grantee or subgrantee from a contract awarded under another Federal grant.

(2)    General revenue sharing. For the purpose of this section, general revenue sharing funds distributed under 31 U.S.C. 6702 are not considered Federal grant funds.

(3)    Cost or contributions counted towards other Federal costs-sharing requirements. Neither costs nor the values of third party in-kind contributions may count towards satisfying a cost sharing or matching requirement of a grant agreement if they have been or will be counted towards satisfying a cost sharing or matching requirement of

 

90


another Federal grant agreement, a Federal procurement contract, or any other award of Federal funds.

(4)    Costs financed by program income. Costs financed by program income, as defined in 600.225, shall not count towards satisfying a cost sharing or matching requirement unless they are expressly permitted in the terms of the assistance agreement. (This use of general program income is described in 600.225(g)

(5)    Services or property financed by income earned by contractors. Contractors under a grant may earn income from the activities carried out under the contract in addition to the amounts earned from the party awarding the contract. No costs of services or property supported by this income may count toward satisfying a cost sharing or matching requirement unless other provisions of the grant agreement expressly permit this kind of income to be used to meet the requirement.

(6)    Records. Costs and third party in-kind contributions counting towards satisfying a cost sharing or matching requirement must be verifiable from the records of grantees and subgrantee or cost-type contractors. These records must show how the value placed on third party in-kind contributions was derived. To the extent feasible, volunteer services will be supported by the same methods that the organization uses to support the allocability of regular personnel costs.

(7)    Special standards for third party in-kind contributions.

(i)     Third party in-kind contributions count towards satisfying a cost sharing or matching requirement only where, if the party receiving the contributions were to pay for them, the payments would be allowable costs.

(ii)    Some third party in-kind contributions are goods and services that, if the grantee, subgrantee, or contractor receiving the contribution had to pay for them, the payments would have been an indirect costs. Cost sharing or matching credit for such contributions shall be given only if the grantee, subgrantee, or contractor has established, along with its regular indirect cost rate, a special rate for allocating to individual projects or programs the value of the contributions.

(iii)   A third party in-kind contribution to a fixed-price contract may count towards satisfying a cost sharing or matching requirement only if it results in:

(A)    An increase in the services or property provided under the contract (without additional cost to the grantee or subgrantee) or

(B)    A cost savings to the grantee or subgrantee.

(iv)    The values placed on third party in-kind contributions for cost sharing or matching purposes will conform to the rules in the succeeding sections of this

 

91


subpart. If a third party in-kind contribution is a type not treated in those sections, the value placed upon it shall be fair and reasonable.

(c)    Valuation of donated services —

(1)    Volunteer services. Unpaid services provided to a grantee or subgrantee by individuals will be valued at rates consistent with those ordinarily paid for similar work in the grantee’s or subgrantee’s organization. If the grantee or subgrantee does not have employees performing similar work, the rates will be consistent with those ordinarily paid by other employers for similar work in the same labor market. In either case, a reasonable amount for fringe benefits may be included in the valuation.

(2)    Employees of other organizations. When an employer other than a grantee, subgrantee, or cost-type contractor furnishes free of charge the services of an employee in the employee’s normal line of work, the services will be valued at the employee’s regular rate of pay exclusive of the employee’s fringe benefits and overhead costs. If the services are in a different line of work, paragraph (c)(1) of this section applies.

(d)    Valuation of third party donated supplies and loaned equipment or space.

(1)    If a third party donates supplies, the contribution will be valued at the market value of the supplies at the time of donation.

(2)    If a third party donates the use of equipment or space in a building but retains title, the contribution will be valued at the fair rental rate of the equipment or space.

(e)    Valuation of third party donated equipment, buildings, and land. If a third party donates equipment, buildings, or land, and title passes to a grantee or subgrantee, the treatment of the donated property will depend upon the purpose of the grant or subgrant, as follows:

(1) Awards for capital expenditures. If the purpose of the grant or subgrant is to assist the grantee or subgrantee in the acquisition of property, the market value of that property at the time of donation may be counted as cost sharing or matching,

(2) Other awards. If assisting in the acquisition of property is not the purpose of the grant or subgrant, paragraphs (e)(2) (i) and (ii) of this section apply:

(i) If approval is obtained from the awarding agency, the market value at the time of donation of the donated equipment or buildings and the fair rental rate of the donated land may be counted as cost sharing or matching. In the case of a subgrant, the terms of the grant agreement may require that the approval be obtained from the Federal agency as well as the grantee. In all cases, the approval may be given only if a purchase of the equipment or rental of the land would be approved as an allowable direct cost. If any part of the donated property was

 

92


acquired with Federal funds, only the non-federal share of the property may be counted as cost-sharing or matching.

(ii) If approval is not obtained under paragraph (e)(2)(i) of this section, no amount may be counted for donated land, and only depreciation or use allowances may be counted for donated equipment and buildings. The depreciation or use allowances for this property are not treated as third party in-kind contributions. Instead, they are treated as costs incurred by the grantee or subgrantee. They are computed and allocated (usually as indirect costs) in accordance with the cost principles specified in 600.222, in the same way as depreciation or use allowances for purchased equipment and buildings. The amount of depreciation or use allowances for donated equipment and buildings is based on the property’s market value at the time it was donated.

(f) Valuation of grantee or subgrantee donated real property for construction/acquisition. If a grantee or subgrantee donates real property for a construction or facilities acquisition project, the current market value of that property may be counted as cost sharing or matching. If any part of the donated property was acquired with Federal funds, only the non-federal share of the property may be counted as cost sharing or matching.

(g) Appraisal of real property. In some cases under paragraphs (d), (e) and (f) of this section, it will be necessary to establish the market value of land or a building or the fair rental rate of land or of space in a building. In these cases, the Federal agency may require the market value or fair rental value be set by an independent appraiser, and that the value or rate be certified by the grantee. This requirement will also be imposed by the grantee on subgrantees.

600.225     Program income.

(a) General. Grantees are encouraged to earn income to defray program costs. Program income includes income from fees for services performed, from the use or rental of real or personal property acquired with grant funds, from the sale of commodities or items fabricated under a grant agreement, and from payments of principal and interest on loans made with grant funds. Except as otherwise provided in regulations of the Federal agency, program income does not include interest on grant funds, rebates, credits, discounts, refunds, etc. and interest earned on any of them.

(b) Definition of program income. Program income means gross income received by the grantee or subgrantee directly generated by a grant supported activity, or earned only as a result of the grant agreement during the grant period. “During the grant period” is the time between the effective date of the award and the ending date of the award reflected in the final financial report.

 

93


(c) Cost of generating program income. If authorized by Federal regulations or the grant agreement, costs incident to the generation of program income may be deducted from gross income to determine program income.

(d) Governmental revenues. Taxes, special assessments, levies, fines, and other such revenues raised by a grantee or subgrantee are not program income unless the revenues are specifically identified in the grant agreement or Federal agency regulations as program income.

(e) Royalties. Income from royalties and license fees for copyrighted material, patents, and inventions developed by a grantee or subgrantee is program income only if the revenues are specifically identified in the grant agreement or Federal agency regulations as program income. (See 600.234.)

(f) Property. Proceeds from the sale of real property or equipment will be handled in accordance with the requirements of 600.231 and 600.232.

(g) Use of program income. Program income shall be deducted from outlays which may be both Federal and non-Federal as described below, unless the Federal agency regulations or the grant agreement specify another alternative (or a combination of the alternatives). In specifying alternatives, the Federal agency may distinguish between income earned by the grantee and income earned by subgrantees and between the sources, kinds, or amounts of income. When Federal agencies authorize the alternatives in paragraphs (g) (2) and (3) of this section, program income in excess of any limits stipulated shall also be deducted from outlays.

(1) Deduction. Ordinarily program income shall be deducted from total allowable costs to determine the net allowable costs. Program income shall be used for current costs unless the Federal agency authorizes otherwise. Program income which the grantee did not anticipate at the time of the award shall be used to reduce the Federal agency and grantee contributions rather than to increase the funds committed to the project.

(2) Addition. When authorized, program income may be added to the funds committed to the grant agreement by the Federal agency and the grantee. The program income shall be used for the purposes and under the conditions of the grant agreement.

(3) Cost sharing or matching. When authorized, program income may be used to meet the cost sharing or matching requirement of the grant agreement. The amount of the Federal grant award remains the same.

(h) Income after the award period. There are no Federal requirements governing the disposition of program income earned after the end of the award period (i.e., until the ending date of the final financial report, see paragraph (a) of this section), unless the terms of the agreement or the Federal agency regulations provide otherwise.

 

94


600.226     Non-Federal audit.

(a) Basic rule. Grantees and subgrantees are responsible for obtaining audits in accordance with the Single Audit Act Amendments of 1996 (31 U.S.C. 7501 - 7507) and revised OMB Circular A-133, “Audits of States, Local Governments, and Non-Profit Organizations.” The audits shall be made by an independent auditor in accordance with generally accepted government auditing standards covering financial and compliance audits.

(b) Subgrantees. State or local governments, as those terms are defined for purposes of the Single Audit Act Amendments of 1996, that provide Federal awards to a subgrantee, which expends $300,000 or more (or other amount as specified by OMB) in Federal awards in a fiscal year, shall:

(1) Determine whether State or local subgrantees have met the audit requirements of the Act and whether subgrantees covered by OMB Circular A-110, “Uniform Requirements for Grants and Other Agreements with Institutions of Higher Education, Hospitals and Other Nonprofit Organizations” have met the audit requirement. Commercial contractors (private for profit and private and governmental organizations) providing goods and services to State and local governments are not required to have a single audit performed. State and local governments should use their own procedures to ensure that the contractor has complied with laws and regulations affecting the expenditure of Federal funds;

(2) Determine whether the subgrantee spent Federal assistance funds provided in accordance with applicable laws and regulations. This may be accomplished by reviewing an audit of the subgrantee made in accordance with the Act, OMB Circular A-110, or through other means (e.g., program reviews) if the subgrantee has not had such an audit;

(3) Ensure that appropriate corrective action is taken within six months after receipt of the audit report in instance of noncompliance with Federal laws and regulations;

(4) Consider whether subgrantee audits necessitate adjustment of the grantee’s own records; and

(5) Require each subgrantee to permit independent auditors to have access to the records and financial statements.

(c) Auditor selection. In arranging for audit services, 600.236 shall be followed.

 

95


Changes, Property, and Subawards

600.230     Changes.

(a) General. Grantees and subgrantees are permitted to rebudget within the approved direct cost budget to meet unanticipated requirements and may make limited program changes to the approved project. However, unless waived by the awarding agency, certain types of post-award changes in budgets and projects shall require the prior written approval of the awarding agency.

(b) Relation to cost principles. The applicable cost principles (see 600.222) contain requirements for prior approval of certain types of costs. Except where waived, those requirements apply to all grants and subgrants even if paragraphs (c) through (f) of this section do not.

(c) Budget changes —

(1) Nonconstruction projects. Except as stated in other regulations or an award document, grantees or subgrantees shall obtain the prior approval of the awarding agency whenever any of the following changes is anticipated under a nonconstruction award:

(i) Any revision which would result in the need for additional funding.

(ii) Unless waived by the awarding agency, cumulative transfers among direct cost categories, or, if applicable, among separately budgeted programs, projects, functions, or activities which exceed or are expected to exceed ten percent of the current total approved budget, whenever the awarding agency’s share exceeds $100,000.

(iii) Transfer of funds allotted for training allowances (i.e., from direct payments to trainees to other expense categories).

(2)    Construction projects. Grantees and subgrantees shall obtain prior written approval for any budget revision which would result in the need for additional funds.

(3)    Combined construction and nonconstruction projects. When a grant or subgrant provides funding for both construction and nonconstruction activities, the grantee or subgrantee must obtain prior written approval from the awarding agency before making any fund or budget transfer from nonconstruction to construction or vice versa.

(d)  Programmatic changes. Grantees or subgrantees must obtain the prior approval of the awarding agency whenever any of the following actions is anticipated:

 

96


(1)    Any revision of the scope or objectives of the project (regardless of whether there is an associated budget revision requiring prior approval).

(2) Need to extend the period of availability of funds.

(3) Changes in key persons in cases where specified in an application or a grant award. In research projects, a change in the project director or principal investigator shall always require approval unless waived by the awarding agency.

(4) Under nonconstruction projects, contracting out, subgranting (if authorized by law) or otherwise obtaining the services of a third party to perform activities which are central to the purposes of the award. This approval requirement is in addition to the approval requirements of 600.236 but does not apply to the procurement of equipment, supplies, and general support services.

(e)    Additional prior approval requirements. The awarding agency may not require prior approval for any budget revision which is not described in paragraph (c) of this section.

(f)    Requesting prior approval. (1) A request for prior approval of any budget revision will be in the same budget formal the grantee used in its application and shall be accompanied by a narrative justification for the proposed revision.

(2)    A request for a prior approval under the applicable Federal cost principles (see 600.222) may be made by letter.

(3)    A request by a subgrantee for prior approval will be addressed in writing to the grantee. The grantee will promptly review such request and shall approve or disapprove the request in writing. A grantee will not approve any budget or project revision which is inconsistent with the purpose or terms and conditions of the Federal grant to the grantee. If the revision, requested by the subgrantee would result in a change to the grantee’s approved project which requires Federal prior approval, the grantee will obtain the Federal agency’s approval before approving the subgrantee’s request.

600.231     Real property.

(a)    Title. Subject to the obligations and conditions set forth in this section, title to real property acquired under a grant or subgrant will vest upon acquisition in the grantee or subgrantee respectively.

(b)    Use. Except as otherwise provided by Federal statutes, real property will be used for the originally authorized purposes as long as needed for that purposes, and the grantee or subgrantee shall not dispose of or encumber its title or other interests.

 

97


(c)    Disposition. When real property is no longer needed for the originally authorized purpose, the grantee or subgrantee will request disposition instructions from the awarding agency. The instructions will provide for one of the following alternatives:

(1)    Retention of title. Retain title after compensating the awarding agency. The amount paid to the awarding agency will be computed by applying the awarding agency’s percentage of participation in the cost of the original purchase to the fair market value of the property. However, in those situations where a grantee or subgrantee is disposing of real property acquired with grant funds and acquiring replacement real property under the same program, the net proceeds from the disposition may be used as an offset to the cost of the replacement property.

(2)    Sale of property. Sell the property and compensate the awarding agency. The amount due to the awarding agency will be calculated by applying the awarding agency’s percentage of participation in the cost of the original purchase to the proceeds of the sale after deduction of any actual and reasonable selling and fixing-up expenses. If the grant is still active, the net proceeds from sale may be offset against the original cost of the property. When a grantee or subgrantee is directed to sell property, sales procedures shall be followed that provide for competition to the extent practicable and result in the highest possible return.

(3)    Transfer of title. Transfer title to the awarding agency or to a third-party designated/approved by the awarding agency. The grantee or subgrantee shall be paid an amount calculated by applying the grantee or subgrantee’s percentage of participation in the purchase of the real property to the current fair market value of the property.

 

600.232 Equipment.

(a)    Title. Subject to the obligations and conditions set forth in this section, title to equipment acquired under a grant or subgrant will vest upon acquisition in the grantee or subgrantee respectively.

(b)    States. A State will use, manage, and dispose of equipment acquired under a grant by the State in accordance with State laws and procedures. Other grantees and subgrantees will follow paragraphs (c) through (e) of this section.

(c)    Use.

(1)    Equipment shall be used by the grantee or subgrantee in the program or project for which it was acquired as long as needed, whether or not the project or program continues to be supported by Federal funds. When no longer needed for the original program or project, the equipment may be used in other activities currently or previously supported by a Federal agency.

 

98


(2)    The grantee or subgrantee shall also make equipment available for use on other projects or programs currently or previously supported by the Federal Government, providing such use will not interfere with the work on the projects or program for which it was originally acquired. First preference for other use shall be given to other programs or projects supported by the awarding agency. User fees should be considered if appropriate.

(3)    Notwithstanding the encouragement in 600.225(a) to earn program income, the grantee or subgrantee must not use equipment acquired with grant funds to provide services for a fee to compete unfairly with private companies that provide equivalent services, unless specifically permitted or contemplated by Federal statute.

(4)    When acquiring replacement equipment, the grantee or subgrantee may use the equipment to be replaced as a trade-in or sell the property and use the proceeds to offset the cost of the replacement property, subject to the approval of the awarding agency.

(d)    Management requirements. Procedures for managing equipment (including replacement equipment), whether acquired in whole or in part with grant funds, until disposition takes place will, as a minimum, meet the following requirements:

(1)    Property records must be maintained that include a description of the property, a serial number or other identification number, the source of property, who holds title, the acquisition date, and cost of the property, percentage of Federal participation in the cost of the property, the location, use and condition of the property, and any ultimate disposition data including the date of disposal and sale price of the property.

(2)    A physical inventory of the property must be taken and the results reconciled with the property records at least once every two years.

(3)    A control system must be developed to ensure adequate safeguards to prevent loss, damage, or theft of the property. Any loss, damage, or theft shall be investigated.

(4)    Adequate maintenance procedures must be developed to keep the property in good condition.

(5)    If the grantee or subgrantee is authorized or required to sell the property, proper sales procedures must be established to ensure the highest possible return.

(e)    Disposition. When original or replacement equipment acquired under a grant or subgrant is no longer needed for the original project or program or for other activities currently or previously supported by a Federal agency, disposition of the equipment will be made as follows:

 

99


(1)    Items of equipment with a current per-unit fair market value of less than $5,000 may be retained, sold or otherwise disposed of with no further obligation to the awarding agency.

(2)    Items of equipment with a current per unit fair market value in excess of $5,000 may be retained or sold and the awarding agency shall have a right to an amount calculated by multiplying the current market value or proceeds from sale by the awarding agency’s share of the equipment.

(3)    In cases where a grantee or subgrantee fails to take appropriate disposition actions, the awarding agency may direct the grantee or subgrantee to take excess and disposition actions.

(f)    Federal equipment. In the event a grantee or subgrantee is provided federally-owned equipment:

(1)    Title will remain vested in the Federal Government.

(2)    Grantees or subgrantees will manage the equipment in accordance with Federal agency rules and procedures, and submit an annual inventory listing.

(3)    When the equipment is no longer needed, the grantee or subgrantee will request disposition instructions from the Federal agency.

(g)    Right to transfer title. The Federal awarding agency may reserve the right to transfer title to the Federal Government or a third party named by the awarding agency when such a third party is otherwise eligible under existing statutes. Such transfers shall be subject to the following standards:

(1)    The property shall be identified in the grant or otherwise made known to the grantee in writing.

(2)    The Federal awarding agency shall issue disposition instructions within 120 calendar days after the end of the Federal support of the project for which it was acquired. If the Federal awarding agency fails to issue disposition instructions within the 120 calendar-day period the grantee shall follow 600.232(e).

(3)    When title to equipment is transferred, the grantee shall be paid an amount calculated by applying the percentage of participation in the purchase to the current fair market value of the property.

600.233     Supplies.

(a)    Title. Title to supplies acquired under a grant or subgrant will vest, upon acquisition, in the grantee or subgrantee respectively.

 

100


(b)  Disposition. If there is a residual inventory of unused supplies exceeding $5,000 in total aggregate fair market value upon termination or completion of the award, and if the supplies are not needed for any other federally sponsored programs or projects, the grantee or subgrantee shall compensate the awarding agency for its share.

600.234    Copyrights.

The Federal awarding agency reserves a royalty-free, nonexclusive, and irrevocable license to reproduce, publish or otherwise use, and to authorize others to use, for Federal Government purposes:

(a)  The copyright in any work developed under a grant, subgrant, or contract under a grant or subgrant; and

(b)  Any rights of copyright to which a grantee, subgrantee or a contractor purchases ownership with grant support.

600.235    Subawards to debarred and suspended parties.

Grantees and subgrantees must not make any award or permit any award (subgrant or contract) at any tier to any party which is debarred or suspended or is otherwise excluded from or ineligible for participation in Federal assistance programs under Executive Order 12549, “Debarment and Suspension.”

600.236    Procurement.

(a)  States. When procuring property and services under a grant, a State will follow the same policies and procedures it uses for procurements from its non-Federal funds. The State will ensure that every purchase order or other contract includes any clauses required by Federal statutes and executive orders and their implementing regulations. Other grantees and subgrantees will follow paragraphs (b) through (i) in this section.

(b)  Procurement standards.

(1) Grantees and subgrantees will use their own procurement procedures which reflect applicable State and local laws and regulations, provided that the procurements conform to applicable Federal law and the standards identified in this section.

(2) Grantees and subgrantees will maintain a contract administration system which ensures that contractors perform in accordance with the terms, conditions, and specifications of their contracts or purchase orders.

 

101


(3) Grantees and subgrantees will maintain a written code of standards of conduct governing the performance of their employees engaged in the award and administration of contracts. No employee, officer or agent of the grantee or subgrantee shall participate in selection, or in the award or administration of a contract supported by Federal funds if a conflict of interest, real or apparent, would be involved. Such a conflict would arise when:

(i) The employee, officer or agent,

(ii) Any member of his immediate family,

(iii) His or her partner, or

(iv) An organization which employs, or is about to employ, any of the above, has a financial or other interest in the firm selected for award. The grantee’s or subgrantee’s officers, employees or agents will neither solicit nor accept gratuities, favors or anything of monetary value from contractors, potential contractors, or parties to subagreements. Grantee and subgrantees may set minimum rules where the financial interest is not substantial or the gift is an unsolicited item of nominal intrinsic value. To the extent permitted by State or local law or regulations, such standards or conduct will provide for penalties, sanctions, or other disciplinary actions for violations of such standards by the grantee’s and subgrantee’s officers, employees, or agents, or by contractors or their agents. The awarding agency may in regulation provide additional prohibitions relative to real, apparent, or potential conflicts of interest.

(4) Grantee and subgrantee procedures will provide for a review of proposed procurements to avoid purchase of unnecessary or duplicative items. Consideration should be given to consolidating or breaking out procurements to obtain a more economical purchase. Where appropriate, an analysis will be made of lease versus purchase alternatives, and any other appropriate analysis to determine the most economical approach.

(5) To foster greater economy and efficiency, grantees and subgrantees are encouraged to enter into State and local intergovernmental agreements for procurement or use of common goods and services.

(6) Grantees and subgrantees are encouraged to use Federal excess and surplus property in lieu of purchasing new equipment and property whenever such use is feasible and reduces project costs.

(7) Grantees and subgrantees are encouraged to use value engineering clauses in contracts for construction projects of sufficient size to offer reasonable opportunities for cost reductions. Value engineering is a systematic and creative analysis of each contract item or task to ensure that its essential function is provided at the overall lower cost.

 

102


(8) Grantees and subgrantees will make awards only to responsible contractors possessing the ability to perform successfully under the terms and conditions of a proposed procurement. Consideration will be given to such matters as contractor integrity, compliance with public policy, record of past performance, and financial and technical resources.

(9) Grantees and subgrantees will maintain records sufficient to detail the significant history of a procurement. These records will include, but are not necessarily limited to the following: rationale for the method of procurement, selection of contract type, contractor selection or rejection, and the basis for the contract price.

(10) Grantees and subgrantees will use time and material type contracts only -

(i) After a determination that no other contract is suitable, and

(ii) If the contract includes a ceiling price that the contractor exceeds at its own risk.

(11) Grantees and subgrantees alone will be responsible, in accordance with good administrative practice and sound business judgment, for the settlement of all contractual and administrative issues arising out of procurements. These issues include, but are not limited to source evaluation, protests, disputes, and claims. These standards do not relieve the grantee or subgrantee of any contractual responsibilities under its contracts. Federal agencies will not substitute their judgment for that of the grantee or subgrantee unless the matter is primarily a Federal concern. Violations of law will be referred to the local, State, or Federal authority having proper jurisdiction.

(12) Grantees and subgrantees will have protest procedures to handle and resolve disputes relating to their procurements and shall in all instances disclose information regarding the protest to the awarding agency. A protestor must exhaust all administrative remedies with the grantee and subgrantee before pursuing a protest with the Federal agency. Reviews of protests by the Federal agency will be limited to:

(i) Violations of Federal law or regulations and the standards of this section (violations of State or local law will be under the jurisdiction of State or local authorities) and

(ii) Violations of the grantee’s or subgrantee’s protest procedures for failure to review a complaint or protest. Protests received by the Federal agency other than those specified above will be referred to the grantee or subgrantee.

(c)  Competition.

 

103


(1) All procurement transactions will be conducted in a manner providing full and open competition consistent with the standards of 600.236. Some of the situations considered to be restrictive of competition include but are not limited to:

(i) Placing unreasonable requirements on firms in order for them to qualify to do business, (ii) Requiring unnecessary experience and excessive bonding,

(iii) Noncompetitive pricing practices between firms or between affiliated companies,

(iv) Noncompetitive awards to consultants that are on retainer contracts,

(v) Organizational conflicts of interest,

(vi) Specifying only a “brand name” product instead of allowing “an equal” product to be offered and describing the performance of other relevant requirements of the procurement, and

(vii) Any arbitrary action in the procurement process.

(2) Grantees and subgrantees will conduct procurements in a manner that prohibits the use of statutorily or administratively imposed in-State or local geographical preferences in the evaluation of bids or proposals, except in those cases where applicable Federal statutes expressly mandate or encourage geographic preference. Nothing in this section preempts State licensing laws. When contracting for architectural and engineering (A/E) services, geographic location may be a selection criteria provided its application leaves an appropriate number of qualified firms, given the nature and size of the project, to compete for the contract.

(3) Grantees will have written selection procedures for procurement transactions. These procedures will ensure that all solicitations:

(i) Incorporate a clear and accurate description of the technical requirements for the material, product, or service to be procured. Such description shall not, in competitive procurements, contain features which unduly restrict competition. The description may include a statement of the qualitative nature of the material, product or service to be procured, and when necessary, shall set forth those minimum essential characteristics and standards to which it must conform if it is to satisfy its intended use. Detailed product specifications should be avoided if at all possible. When it is impractical or uneconomical to make a clear and accurate description of the technical requirements, a “brand name or equal” description may be used as a means to define the performance or other salient requirements of a procurement. The specific features of the named brand which must be met by offerors shall be clearly stated; and

 

104


(ii) Identify all requirements which the offerors must fulfill and all other factors to be used in evaluating bids or proposals.

(4) Grantees and subgrantees will ensure that all prequalified lists of persons, firms, or products which are used in acquiring goods and services are current and include enough qualified sources to ensure maximum open and free competition. Also, grantees and subgrantees will not preclude potential bidders from qualifying during the solicitation period.

(d)  Methods of procurement to be followed.

(1) Procurement by small purchase procedures. Small purchase procedures are those relatively simple and informal procurement methods for securing services, supplies, or other property that do not cost more than the simplified acquisition threshold fixed at 41 U.S.C. 403(11) (currently set at $100,000). If small purchase procedures are used, price or rate quotations shall be obtained from an adequate number of qualified sources.

(2) Procurement by sealed bids (formal advertising). Bids are publicly solicited and a firm-fixed-price contract (lump sum or unit price) is awarded to the responsible bidder whose bid, conforming with all the material terms and conditions of the invitation for bids, is the lowest in price. The sealed bid method is the preferred method for procuring construction, if the conditions in 600.236(d)(2)(i) apply.

(i) In order for sealed bidding to be feasible, the following conditions should be present:

(A) A complete, adequate, and realistic specification or purchase description is available;

(B) Two or more responsible bidders are willing and able to compete effectively and for the business; and

(C) The procurement lends itself to a firm fixed price contract and the selection of the successful bidder can be made principally on the basis of price.

(ii) If sealed bids are used, the following requirements apply:

(A) The invitation for bids will be publicly advertised and bids shall be solicited from an adequate number of known suppliers, providing them sufficient time prior to the date set for opening the bids;

(B) The invitation for bids, which will include any specifications and pertinent attachments, shall define the items or services in order for the bidder to properly respond;

 

105


(C) All bids will be publicly opened at the time and place prescribed in the invitation for bids;

(D) A firm fixed-price contract award will be made in writing to the lowest responsive and responsible bidder. Where specified in bidding documents, factors such as discounts, transportation cost, and life cycle costs shall be considered in determining which bid is lowest. Payment discounts will only be used to determine the low bid when prior experience indicates that such discounts are usually taken advantage of; and

(E) Any or all bids may be rejected if there is a sound documented reason.

(3) Procurement by competitive proposals. The technique of competitive proposals is normally conducted with more than one source submitting an offer, and either a fixed-price or cost-reimbursement type contract is awarded. It is generally used when conditions are not appropriate for the use of sealed bids. If this method is used, the following requirements apply:

(i) Requests for proposals will be publicized and identify all evaluation factors and their relative importance. Any response to publicized requests for proposals shall be honored to the maximum extent practical;

(ii) Proposals will be solicited from an adequate number of qualified sources;

(iii) Grantees and subgrantees will have a method for conducting technical evaluations of the proposals received and for selecting awardees;

(iv) Awards will be made to the responsible firm whose proposal is most advantageous to the program, with price and other factors considered; and

(v) Grantees and subgrantees may use competitive proposal procedures for qualifications-based procurement of architectural/engineering (A/E) professional services whereby competitors’ qualifications are evaluated and the most qualified competitor is selected, subject to negotiation of fair and reasonable compensation. The method, where price is not used as a selection factor, can only be used in procurement of A/E professional services. It cannot be used to purchase other types of services though A/E firms are a potential source to perform the proposed effort.

(4) Procurement by noncompetitive proposals is procurement through solicitation of a proposal from only one source, or after solicitation of a number of sources, competition is determined inadequate.

 

106


(i) Procurement by noncompetitive proposals may be used only when the award of a contract is infeasible under small purchase procedures, sealed bids or competitive proposals and one of the following circumstances applies:

(A) The item is available only from a single source;

(B) The public exigency or emergency for the requirement will not permit a delay resulting from competitive solicitation;

(C) The awarding agency authorizes noncompetitive proposals; or

(D) After solicitation of a number of sources, competition is determined inadequate.

(ii) Cost analysis, i.e., verifying the proposed cost data, the projections of the data, and the evaluation of the specific elements of costs and profits, is required.

(iii) Grantees and subgrantees may be required to submit the proposed procurement to the awarding agency for pre-award review in accordance with paragraph (g) of this section.

(e)  Contracting with small and minority firms, women’s business enterprise and labor surplus area firms.

(1) The grantee and subgrantee will take all necessary affirmative steps to assure that minority firms, women’s business enterprises, and labor surplus area firms are used when possible.

(2) Affirmative steps shall include:

(i) Placing qualified small and minority businesses and women’s business enterprises on solicitation lists;

(ii) Assuring that small and minority businesses, and women’s business enterprises are solicited whenever they are potential sources;

(iii) Dividing total requirements, when economically feasible, into smaller tasks or quantities to permit maximum participation by small and minority business, and women’s business enterprises;

(iv) Establishing delivery schedules, where the requirement permits, which encourage participation by small and minority business, and women’s business enterprises;

 

107


(v) Using the services and assistance of the Small Business Administration, and the Minority Business Development Agency of the Department of Commerce; and

(vi) Requiring the prime contractor, if subcontracts are to be let, to take the affirmative steps listed in paragraphs (e)(2) (i) through (v) of this section.

(f)  Contract cost and price.

(1) Grantees and subgrantees must perform a cost or price analysis in connection with every procurement action including contract modifications. The method and degree of analysis is dependent on the facts surrounding the particular procurement situation, but as a starting point, grantees must make independent estimates before receiving bids or proposals. A cost analysis must be performed when the offeror is required to submit the elements of his estimated cost, e.g., under professional, consulting, and architectural engineering services contracts. A cost analysis will be necessary when adequate price competition is lacking, and for sole source procurements, including contract modifications or change orders, unless price reasonableness can be established on the basis of a catalog or market price of a commercial product sold in substantial quantities to the general public or based on prices set by law or regulation. A price analysis will be used in all other instances to determine the reasonableness of the proposed contract price.

(2) Grantees and subgrantees will negotiate profit as a separate element of the price for each contract in which there is no price competition and in all cases where cost analysis is performed. To establish a fair and reasonable profit, consideration will be given to the complexity of the work to be performed, the risk borne by the contractor, the contractor’s investment, the amount of subcontracting, the quality of its record of past performance, and industry profit rates in the surrounding geographical area for similar work.

(3) Costs or prices based on estimated costs for contracts under grants will be allowable only to the extent that costs incurred or cost estimates included in negotiated prices are consistent with Federal cost principles (see 600.222). Grantees may reference their own cost principles that comply with the applicable Federal cost principles.

(4) The cost plus a percentage of cost and percentage of construction cost methods of contracting shall not be used.

(g)  Awarding agency review.

(1) Grantees and subgrantees must make available, upon request of the awarding agency, technical specifications on proposed procurements where the awarding agency believes such review is needed to ensure that the item and/or service specified is the one being proposed for purchase. This review generally will take place prior to

 

108


the time the specification is incorporated into a solicitation document. However, if the grantee or subgrantee desires to have the review accomplished after a solicitation has been developed, the awarding agency may still review the specifications, with such review usually limited to the technical aspects of the proposed purchase.

(2) Grantees and subgrantees must on request make available for awarding agency pre-award review procurement documents, such as requests for proposals or invitations for bids, independent cost estimates, etc. when:

(i) A grantee’s or subgrantee’s procurement procedures or operation fails to comply with the procurement standards in this section; or

(ii) The procurement is expected to exceed the simplified acquisition threshold and is to be awarded without competition or only one bid or offer is received in response to a solicitation; or

(iii) The procurement, which is expected to exceed the simplified acquisition threshold, specifies a “brand name” product; or

(iv) The proposed award is more than the simplified acquisition threshold and is to be awarded to other than the apparent low bidder under a sealed bid procurement; or

(v) A proposed contract modification changes the scope of a contract or increases the contract amount by more than the simplified acquisition threshold.

(3) A grantee or subgrantee will be exempt from the pre-award review in paragraph (g)(2) of this section if the awarding agency determines that its procurement systems comply with the standards of this section.

(i) A grantee or subgrantee may request that its procurement system be reviewed by the awarding agency to determine whether its system meets these standards in order for its system to be certified. Generally, these reviews shall occur where there is a continuous high-dollar funding, and third-party contracts are awarded on a regular basis.

(ii) A grantee or subgrantee may self-certify its procurement system. Such self-certification shall not limit the awarding agency’s right to survey the system. Under a self-certification procedure, awarding agencies may wish to rely on written assurances from the grantee or subgrantee that it is complying with these standards. A grantee or subgrantee will cite specific procedures, regulations, standards, etc., as being in compliance with these requirements and have its system available for review.

(h)  Bonding requirements. For construction or facility improvement contracts or subcontracts exceeding the simplified acquisition threshold, the awarding agency may

 

109


accept the bonding policy and requirements of the grantee or subgrantee provided the awarding agency has made a determination that the awarding agency’s interest is adequately protected. If such a determination has not been made, the minimum requirements shall be as follows:

(1) A bid guarantee from each bidder equivalent to five percent of the bid price. The “bid guarantee” shall consist of a firm commitment such as a bid bond, certified check, or other negotiable instrument accompanying a bid as assurance that the bidder will, upon acceptance of his bid, execute such contractual documents as may be required within the time specified.

(2) A performance bond on the part of the contractor for 100 percent of the contract price. A “performance bond” is one executed in connection with a contract to secure fulfillment of all the contractor’s obligations under such contract.

(3) A payment bond on the part of the contractor for 100 percent of the contract price. A “payment bond” is one executed in connection with a contract to assure payment as required by law of all persons supplying labor and material in the execution of the work provided for in the contract.

(i) Contract provisions. A grantee’s and subgrantee’s contracts must contain provisions in paragraph (i) of this section. Federal agencies are permitted to require changes, remedies, changed conditions, access and records retention, suspension of work, and other clauses approved by the Office of Federal Procurement Policy.

(1) Administrative, contractual, or legal remedies in instances where contractors violate or breach contract terms, and provide for such sanctions and penalties as may be appropriate. (Contracts more than the simplified acquisition threshold)

(2) Termination for cause and for convenience by the grantee or subgrantee including the manner by which it will be effected and the basis for settlement. (All contracts in excess of $10,000)

(3) Compliance with Executive Order 11246 of September 24, 1965, entitled “Equal Employment Opportunity,” as amended by Executive Order 11375 of October 13, 1967, and as supplemented in Department of Labor regulations (41 CFR chapter 60). (All construction contracts awarded in excess of $10,000 by grantees and their contractors or subgrantees)

(4) Compliance with the Copeland “Anti-Kickback” Act (18 U.S.C. 874) as supplemented in Department of Labor regulations (29 CFR Part 3). (All contracts and subgrants for construction or repair)

(5) Compliance with the Davis-Bacon Act (40 U.S.C. 276a to 276a - 7) as supplemented by Department of Labor regulations (29 CFR Part 5). (Construction

 

110


contracts in excess of $2000 awarded by grantees and subgrantees when required by Federal grant program legislation)

(6) Compliance with Sections 103 and 107 of the Contract Work Hours and Safety Standards Act (40 U.S.C. 327 - 330) as supplemented by Department of Labor regulations (29 CFR Part 5). (Construction contracts awarded by grantees and subgrantees in excess of $2000, and in excess of $2500 for other contracts which involve the employment of mechanics or laborers)

(7) Notice of awarding agency requirements and regulations pertaining to reporting.

(8) Notice of awarding agency requirements and regulations pertaining to patent rights with respect to any discovery or invention which arises or is developed in the course of or under such contract.

(9) Awarding agency requirements and regulations pertaining to copyrights and rights in data.

(10) Access by the grantee, the subgrantee, the Federal grantor agency, the Comptroller General of the United States, or any of their duly authorized representatives to any books, documents, papers, and records of the contractor which are directly pertinent to that specific contract for the purpose of making audit, examination, excerpts, and transcriptions.

(11) Retention of all required records for three years after grantees or subgrantees make final payments and all other pending matters are closed.

(12) Compliance with all applicable standards, orders, or requirements issued under section 306 of the Clean Air Act (42 U.S.C. 1857(h)), section 508 of the Clean Water Act (33 U.S.C. 1368), Executive Order 11738, and Environmental Protection Agency regulations (40 CFR part 15). (Contracts, subcontracts, and subgrants of amounts in excess of $100,000).

(13) Mandatory standards and policies relating to energy efficiency which are contained in the state energy conservation plan issued in compliance with the Energy Policy and Conservation Act (Pub. L. 94 - 163, 89 Stat. 871).

600.237         Subgrants.

(a)  States. States shall follow state law and procedures when awarding and administering subgrants (whether on a cost reimbursement or fixed amount basis) of financial assistance to local and Indian tribal governments. States shall:

(1) Ensure that every subgrant includes any clauses required by Federal statute and executive orders and their implementing regulations;

 

111


(2) Ensure that subgrantees are aware of requirements imposed upon them by Federal statute and regulation;

(3) Ensure that a provision for compliance with 600.242 is placed in every cost reimbursement subgrant; and

(4) Conform any advances of grant funds to subgrantees substantially to the same standards of timing and amount that apply to cash advances by Federal agencies.

(b)  All other grantees. All other grantees shall follow the provisions of this subpart which are applicable to awarding agencies when awarding and administering subgrants (whether on a cost reimbursement or fixed amount basis) of financial assistance to local and Indian tribal governments. Grantees shall:

(1) Ensure that every subgrant includes a provision for compliance with this subpart;

(2) Ensure that every subgrant includes any clauses required by Federal statute and executive orders and their implementing regulations; and

(3) Ensure that subgrantees are aware of requirements imposed upon them by Federal statutes and regulations.

(c)  Exceptions. By their own terms, certain provisions of this subpart do not apply to the award and administration of subgrants:

(1) Section 600.210;

(2) Section 600.211;

(3) The letter-of-credit procedures specified in Treasury Regulations at 31 CFR part 205, cited in 600.221; and

(4) Section 600.250.

Reports, Records, Retention, and Enforcement

600.240 Monitoring and reporting program performance.

(a)  Monitoring by grantees. Grantees are responsible for managing the day-to-day operations of grant and subgrant supported activities. Grantees must monitor grant and subgrant supported activities to assure compliance with applicable Federal requirements and that performance goals are being achieved. Grantee monitoring must cover each program, function or activity.

 

112


(b)   Nonconstruction performance reports. The Federal agency may, if it decides that performance information available from subsequent applications contains sufficient information to meet its programmatic needs, require the grantee to submit a performance report only upon expiration or termination of grant support. Unless waived by the Federal agency this report will be due on the same date as the final Financial Status Report.

(1) Grantees shall submit annual performance reports unless the awarding agency requires quarterly or semi-annual reports. However, performance reports will not be required more frequently than quarterly. Annual reports shall be due 90 days after the grant year, quarterly or semi-annual reports shall be due 30 days after the reporting period. The final performance report will be due 90 days after the expiration or termination of grant support. If a justified request is submitted by a grantee, the Federal agency may extend the due date for any performance report. Additionally, requirements for unnecessary performance reports may be waived by the Federal agency.

(2) Performance reports will contain, for each grant, brief information on the following:

(i) A comparison of actual accomplishments to the objectives established for the period. Where the output of the project can be quantified, a computation of the cost per unit of output may be required if that information will be useful.

(ii) The reasons for slippage if established objectives were not met.

(iii) Additional pertinent information including, when appropriate, analysis and explanation of cost overruns or high unit costs.

(3) Grantees will not be required to submit more than the original and two copies of performance reports.

(4) Grantees will adhere to the standards in this section in prescribing performance reporting requirements for subgrantees.

(c)   Construction performance reports. For the most part, on-site technical inspections and certified percentage-of-completion data are relied on heavily by Federal agencies to monitor progress under construction grants and subgrants. The Federal agency will require additional formal performance reports only when considered necessary, and never more frequently than quarterly.

(d)   Significant developments. Events may occur between the scheduled performance reporting dates which have significant impact upon the grant or subgrant supported activity. In such cases, the grantee must inform the Federal agency as soon as the following types of conditions become known:

 

113


(1) Problems, delays, or adverse conditions which will materially impair the ability to meet the objective of the award. This disclosure must include a statement of the action taken, or contemplated, and any assistance needed to resolve the situation.

(2) Favorable developments which enable meeting time schedules and objectives sooner or at less cost than anticipated or producing more beneficial results than originally planned.

(e) Federal agencies may make site visits as warranted by program needs.

(f)   Waivers, extensions.

(1) Federal agencies may waive any performance report required by this part if not needed.

(2) The grantee may waive any performance report from a subgrantee when not needed. The grantee may extend the due date for any performance report from a subgrantee if the grantee will still be able to meet its performance reporting obligations to the Federal agency.

600.241     Financial reporting.

(a)   General.

(1) Except as provided in paragraphs (a) (2) and (5) of this section, grantees will use only the forms specified in paragraphs (a) through (e) of this section, and such supplementary or other forms as may from time to time be authorized by OMB, for:

(i) Submitting financial reports to Federal agencies, or

(ii) Requesting advances or reimbursements when letters of credit are not used.

(2) Grantees need not apply the forms prescribed in this section in dealing with their subgrantees. However, grantees shall not impose more burdensome requirements on subgrantees.

(3) Grantees shall follow all applicable standard and supplemental Federal agency instructions approved by OMB to the extent required under the Paperwork Reduction Act of 1980 for use in connection with forms specified in paragraphs (b) through (e) of this section. Federal agencies may issue substantive supplementary instructions only with the approval of OMB. Federal agencies may shade out or instruct the grantee to disregard any line item that the Federal agency finds unnecessary for its decision making purposes.

 

114


(4) Grantees will not be required to submit more than the original and two copies of forms required under this subpart.

(5) Federal agencies may provide computer outputs to grantees to expedite or contribute to the accuracy of reporting. Federal agencies may accept the required information from grantees in machine usable format or computer printouts instead of prescribed forms.

(6) Federal agencies may waive any report required by this section if not needed.

(7) Federal agencies may extend the due date of any financial report upon receiving a justified request from a grantee.

(b)   Financial Status Report —

(1)   Form. Grantees will use Standard Form 269 or 269A, Financial Status Report, to report the status of funds for all nonconstruction grants and for construction grants when required in accordance with 600.241(e)(2)(iii).

(2)   Accounting basis. Each grantee will report program outlays and program income on a cash or accrual basis as prescribed by the awarding agency. If the Federal agency requires accrual information and the grantee’s accounting records are not normally kept on the accrual basis, the grantee shall not be required to convert its accounting system but shall develop such accrual information through and analysis of the documentation on hand.

(3)   Frequency. The Federal agency may prescribe the frequency of the report for each project or program. However, the report will not be required more frequently than quarterly. If the Federal agency does not specify the frequency of the report, it will be submitted annually. A final report will be required upon expiration or termination of grant support.

(4)   Due date. When reports are required on a quarterly or semiannual basis, they will be due 30 days after the reporting period. When required on an annual basis, they will be due 90 days after the grant year. Final reports will be due 90 days after the expiration or termination of grant support.

(c)   Federal Cash Transactions Report —

(1)   Form.

(i) For grants paid by letter or credit, Treasury check advances or electronic transfer of funds, the grantee will submit the Standard Form 272, Federal Cash Transactions Report, and when necessary, its continuation sheet, Standard Form 272a, unless the terms of the award exempt the grantee from this requirement.

 

115


(ii) These reports will be used by the Federal agency to monitor cash advanced to grantees and to obtain disbursement or outlay information for each grant from grantees. The format of the report may be adapted as appropriate when reporting is to be accomplished with the assistance of automatic data processing equipment provided that the information to be submitted is not changed in substance.

(2)   Forecasts of Federal cash requirements. Forecasts of Federal cash requirements may be required in the “Remarks” section of the report.

(3)   Cash in hands of subgrantees. When considered necessary and feasible by the Federal agency, grantees may be required to report the amount of cash advances in excess of three days’ needs in the hands of their subgrantees or contractors and to provide short narrative explanations of actions taken by the grantee to reduce the excess balances.

(4)   Frequency and due date. Grantees must submit the report no later than 15 working days following the end of each quarter. However, where an advance either by letter of credit or electronic transfer of funds is authorized at an annualized rate of one million dollars or more, the Federal agency may require the report to be submitted within 15 working days following the end of each month.

(d)   Request for advance or reimbursement —

(1)   Advance payments. Requests for Treasury check advance payments will be submitted on Standard Form 270, Request for Advance or Reimbursement. (This form will not be used for drawdowns under a letter of credit, electronic funds transfer or when Treasury check advance payments are made to the grantee automatically on a predetermined basis.)

(2)   Reimbursements. Requests for reimbursement under nonconstruction grants will also be submitted on Standard Form 270. (For reimbursement requests under construction grants, see paragraph (e)(1) of this section.)

(3)   The frequency for submitting payment requests is treated in 600.241(b)(3).

(e)   Outlay report and request for reimbursement for construction programs.

(1) Grants that support construction activities paid by reimbursement method.

(i) Requests for reimbursement under construction grants will be submitted on Standard Form 271, Outlay Report and Request for Reimbursement for Construction Programs. Federal agencies may, however, prescribe the Request for Advance or Reimbursement form, specified in 600.241(d), instead of this form.

(ii) The frequency for submitting reimbursement requests is treated in 600.241(b)(3).

 

116


(2)   Grants that support construction activities paid by letter of credit, electronic funds transfer or Treasury check advance.

(i) When a construction grant is paid by letter of credit, electronic funds transfer or Treasury check advances, the grantee will report its outlays to the Federal agency using Standard Form 271, Outlay Report and Request for Reimbursement for Construction Programs. The Federal agency will provide any necessary special instruction. However, frequency and due date shall be governed by 600.241(b) (3) and (4).

(ii) When a construction grant is paid by Treasury check advances based on periodic requests from the grantee, the advances will be requested on the form specified in 600.241(d).

(iii) The Federal agency may substitute the Financial Status Report specified in 600.241(b) for the Outlay Report and Request for Reimbursement for Construction Programs.

(3)   Accounting basis. The accounting basis for the Outlay Report and Request for Reimbursement for Construction Programs shall be governed by 600.241(b)(2).

600.242     Retention and access requirements for records.

(a)   Applicability.

(1) This section applies to all financial and programmatic records, supporting documents, statistical records, and other records of grantees or subgrantees which are:

(i) Required to be maintained by the terms of this subpart, program regulations or the grant agreement, or

(ii) Otherwise reasonably considered as pertinent to program regulations or the grant agreement.

(2) This section does not apply to records maintained by contractors or subcontractors. For a requirement to place a provision concerning records in certain kinds of contracts, see 600.236(i)(10).

(b)   Length of retention period.

(1) Except as otherwise provided, records must be retained for three years from the starting date specified in paragraph (c) of this section.

 

117


(2) If any litigation, claim, negotiation, audit or other action involving the records has been started before the expiration of the 3-year period, the records must be retained until completion of the action and resolution of all issues which arise from it, or until the end of the regular 3-year period, whichever is later.

(3) To avoid duplicate recordkeeping, awarding agencies may make special arrangements with grantees and subgrantees to retain any records which are continuously needed for joint use. The awarding agency will request transfer of records to its custody when it determines that the records possess long-term retention value. When the records are transferred to or maintained by the Federal agency, the 3-year retention requirement is not applicable to the grantee or subgrantee.

(c)   Starting date of retention period —

(1)   General. When grant support is continued or renewed at annual or other intervals, the retention period for the records of each funding period starts on the day the grantee or subgrantee submits to the awarding agency its single or last expenditure report for that period. However, if grant support is continued or renewed quarterly, the retention period for each year’s records starts on the day the grantee submits its expenditure report for the last quarter of the Federal fiscal year. In all other cases, the retention period starts on the day the grantee submits its final expenditure report. If an expenditure report has been waived, the retention period starts on the day the report would have been due.

(2)   Real property and equipment records. The retention period for real property and equipment records starts from the date of the disposition or replacement or transfer at the direction of the awarding agency.

(3)   Records for income transactions after grant or subgrant support. In some cases grantees must report income after the period of grant support. Where there is such a requirement, the retention period for the records pertaining to the earning of the income starts from the end of the grantee’s fiscal year in which the income is earned.

(4)   Indirect cost rate proposals, cost allocations plans, etc. This paragraph applies to the following types of documents, and their supporting records: indirect cost rate computations or proposals, cost allocation plans, and any similar accounting computations of the rate at which a particular group of costs is chargeable (such as computer usage chargeback rates or composite fringe benefit rates).

(i)   If submitted for negotiation. If the proposal, plan, or other computation is required to be submitted to the Federal Government (or to the grantee) to form the basis for negotiation of the rate, then the 3-year retention period for its supporting records starts from the date of such submission.

(ii)   If not submitted for negotiation. If the proposal, plan, or other computation is not required to be submitted to the Federal Government (or to the grantee) for

 

118


negotiation purposes, then the 3-year retention period for the proposal plan, or computation and its supporting records starts from end of the fiscal year (or other accounting period) covered by the proposal, plan, or other computation.

(d)   Substitution of microfilm. Copies made by microfilming, photocopying, or similar methods may be substituted for the original records.

(e)   Access to records —

(1)   Records of grantees and subgrantees. The awarding agency and the Comptroller General of the United States, or any of their authorized representatives, shall have the right of access to any pertinent books, documents, papers, or other records of grantees and subgrantees which are pertinent to the grant, in order to make audits, examinations, excerpts, and transcripts.

(2)   Expiration of right of access. The rights of access in this section must not be limited to the required retention period but shall last as long as the records are retained.

(f)   Restrictions on public access. The Federal Freedom of Information Act (5 U.S.C. 552) does not apply to records unless required by Federal, State, or local law, grantees and subgrantees are not required to permit public access to their records.

600.243     Enforcement.

(a)   Remedies for noncompliance. If a grantee or subgrantee materially fails to comply with any term of an award, whether stated in a Federal statute or regulation, an assurance, in a State plan or application, a notice of award, or elsewhere, the awarding agency may take one or more of the following actions, as appropriate in the circumstances:

(1) Temporarily withhold cash payments pending correction of the deficiency by the grantee or subgrantee or more severe enforcement action by the awarding agency,

(2) Disallow (that is, deny both use of funds and matching credit for) all or part of the cost of the activity or action not in compliance,

(3) Wholly or partly suspend or terminate the current award for the grantee’s or subgrantee’s program,

(4) Withhold further awards for the program, or

(5) Take other remedies that may be legally available.

(b)   Hearings, appeals. In taking an enforcement action, the awarding agency will provide the grantee or subgrantee an opportunity for such hearing, appeal, or other

 

119


administrative proceeding to which the grantee or subgrantee is entitled under any statute or regulation applicable to the action involved.

(c)   Effects of suspension and termination. Costs of grantee or subgrantee resulting from obligations incurred by the grantee or subgrantee during a suspension or after termination of an award are not allowable unless the awarding agency expressly authorizes them in the notice of suspension or termination or subsequently. Other grantee or subgrantee costs during suspension or after termination which are necessary and not reasonably avoidable are allowable if:

(1) The costs result from obligations which were properly incurred by the grantee or subgrantee before the effective date of suspension or termination, are not in anticipation of it, and, in the case of a termination, are noncancellable, and,

(2) The costs would be allowable if the award were not suspended or expired normally at the end of the funding period in which the termination takes effect.

(d)   Relationship to debarment and suspension. The enforcement remedies identified in this section, including suspension and termination, do not preclude grantee or subgrantee from being subject to “Debarment and Suspension” under E.O. 12549 (see 600.235).

600.244     Termination for convenience.

Except as provided in 600.243 awards may be terminated in whole or in part only as follows:

(a) By the awarding agency with the consent of the grantee or subgrantee in which case the two parties shall agree upon the termination conditions, including the effective date and in the case of partial termination, the portion to be terminated, or

(b) By the grantee or subgrantee upon written notification to the awarding agency, setting forth the reasons for such termination, the effective date, and in the case of partial termination, the portion to be terminated. However, if, in the case of a partial termination, the awarding agency determines that the remaining portion of the award will not accomplish the purposes for which the award was made, the awarding agency may terminate the award in its entirety under either 600.243 or paragraph (a) of this section.

After-The-Grant Requirements

600.250     Closeout.

(a)  General. The Federal agency will close out the award when it determines that all applicable administrative actions and all required work of the grant has been completed.

 

120


(b)  Reports. Within 90 days after the expiration or termination of the grant, the grantee must submit all financial, performance, and other reports required as a condition of the grant. Upon request by the grantee, Federal agencies may extend this timeframe. These may include but are not limited to:

(1)   Final performance or progress report.

(2)   Financial Status Report (SF269) or Outlay Report and Request for Reimbursement for Construction Programs (SF271) (as applicable).

(3)   Final request for payment (SF270) (if applicable).

(4)   Invention disclosure (if applicable).

(5)   Federally-owned property report: In accordance with 600.232 (f), a grantee must submit an inventory of all federally owned property (as distinct from property acquired with grant funds) for which it is accountable and request disposition instructions from the Federal agency of property no longer needed.

(c)   Cost adjustment. The Federal agency will, within 90 days after receipt of reports in paragraph (b) of this section, make upward or downward adjustments to the allowable costs.

(d)   Cash adjustments.

(1) The Federal agency will make prompt payment to the grantee for allowable reimbursable costs.

(2) The grantee must immediately refund to the Federal agency any balance of unobligated (unencumbered) cash advanced that is not authorized to be retained for use on other grants.

600.251     Later disallowances and adjustments.

The closeout of a grant does not affect:

(a) The Federal agency’s right to disallow costs and recover funds on the basis of a later audit or other review;

(b) The grantee’s obligation to return any funds due as a result of later refunds, corrections, or other transactions;

(c) Records retention as required in 600.242;

(d) Property management requirements in 600.231 and 600.232; and

 

121


(e) Audit requirements in 600.226.

600.252     Collection of amounts due.

(a)   Any funds paid to a grantee in excess of the amount to which the grantee is finally determined to be entitled under the terms of the award constitute a debt to the Federal Government. If not paid within a reasonable period after demand, the Federal agency may reduce the debt by:

(b) (1) Making an administrative offset against other requests for reimbursements,

  (2) Withholding advance payments otherwise due to the grantee, or

  (3) Other action permitted by law.

(c)   Except where otherwise provided by statutes or regulations, the Federal agency will charge interest on an overdue debt in accordance with the Federal Claims Collection Standards (4 CFR Ch. II). The date from which interest is computed is not extended by litigation or the filing of any form of appeal.

 

122


Subpart D — Administrative Requirements for Grants and Cooperative Agreements With For-Profit Organizations

 

GENERAL    125
600.301    Purpose    125
600.302    Definitions    125
600.303    Deviations    129
600.304    Special award conditions    129
600.305    Debarment and suspension    130
600.306    Metric system of measurement    130
POST-AWARD REQUIREMENTS    130
Financial and Program Management    130
600.310    Purpose of financial and program management    130
600.311    Standards for financial management systems    131
600.312    Payment    132
600.313    Cost sharing or matching    134
600.314    Program income    135
600.315    Revision of budget and program plans    137
600.316    Audits    138
600.317    Allowable costs    139
600.318    Fee and profit    140
Property Standards    140
600.320    Purpose of property standards    140
600.321    Real property and equipment    140
600.322    Federally owned property    143
600.323    Property management system    144
600.324    Supplies    145
600.325    Intellectual property    145
Procurement Standards    148
600.330    Purpose of procurement standards    148
600.331    Requirements    148
Reports and Records    149
600.340    Purpose of reports and records    149
600.341    Monitoring and reporting program and financial performance    149
600.342    Retention and access requirements for records    150
Termination and Enforcement    151
600.350    Purpose of termination and enforcement    152
600.351    Termination    152
600.352    Enforcement    152
600.353    Disputes and appeals    153
After-the-Award Requirements    153
600.360    Purpose    153
600.361    Closeout procedures    154
600.362    Subsequent adjustments and continuing responsibilities    154
600.363    Collection of amounts due    155

 

123


Additional Provisions    155
600.380    Purpose    155
600.381    Special provisions for Small Business Innovation Research Grants    155
APPENDIX A TO SUBPART D TO PART 600 — PATENT AND DATA   
PROVISIONS    157
Patent Rights (Small Business Firms and Nonprofit Organizations)    157
Patent Rights (Large Business Firms) — No Waiver    163
Rights in Data — General    168
Rights in Data — Programs Covered Under Special Data Statutes    177
APPENDIX B TO SUBPART D TO PART 600 — CONTRACT   
PROVISIONS    186

 

124


Subpart D — Administrative Requirements for Grants and Cooperative Agreements With For-Profit Organizations

GENERAL

600.301   Purpose.

(a)   This subpart prescribes administrative requirements for awards to for-profit organizations.

(b)   Applicability to prime awards and subawards is as follows:

(1)   Prime awards: DOE contracting officers must apply the provisions of this part to awards to for-profit organizations. Contracting officers must not impose requirements that are in addition to, or inconsistent with, the requirements provided in this part, except:

(i)   In accordance with the deviation procedures or special award conditions in Section 600.303 or Section 600.304, respectively; or

(ii) As required by Federal statute, Executive order, or Federal regulation implementing a statute or Executive order.

(2) Subawards. (i) Any legal entity (including any State, local government, university or other nonprofit organization, as well as any for-profit entity) that receives an award from DOE must apply the provisions of this part to subawards with for-profit organizations.

(ii) For-profit organizations that receive prime awards covered by this part must apply to each subaward the administrative requirements that are applicable to the particular type of subrecipient ( e.g., 10 CFR part 600, subpart B, contains requirements for institutions of higher education, hospitals, or other nonprofit organizations and 10 CFR part 600, subpart C, specifies requirements for subrecipients that are States or local governments).

600.302   Definitions.

In addition to the definitions used in subpart A of this part, the following are definitions of terms as used in this subpart:

Advance means a payment made by Treasury check or other appropriate payment mechanism to a recipient upon its request either before outlays are made by the recipient or through the use of predetermined payment schedules.

 

125


Applied research means efforts that seek to determine and exploit the potential of scientific discoveries or improvements in technology, and is directed toward the development of new materials, devices, methods, and processes.

Basic research means efforts directed solely toward increasing knowledge or understanding in science and engineering.

Cash contributions means the recipient’s cash outlay, including the outlay of money contributed to the recipient by third parties.

Closeout means the process by which DOE determines that all applicable administrative actions and all required work of the award have been completed by the recipient and DOE.

Cost sharing or matching means that portion of project or program costs not borne by the Federal Government.

Demonstration means a project designed to determine the technical feasibility and economic potential of a technology on either a pilot plant or a prototype scale.

Development means efforts to create or advance new technology or demonstrate the viability of applying existing technology to new products and processes.

Disallowed costs means those charges to an award that the DOE contracting officer determines to be unallowable, in accordance with the applicable Federal cost principles or other terms and conditions contained in the award.

DOE means the Department of Energy, including the National Nuclear Security Administration (NNSA).

Equipment means tangible, nonexpendable personal property charged directly to the award having a useful life of more than one year and an acquisition cost of $5,000 or more per unit.

Excess property means property under the control of any DOE Headquarters or field office that, as determined by the head thereof, is no longer required for its needs or the discharge of its responsibilities.

Federal funds authorized means the total amount of Federal funds obligated by the Federal Government for use by the recipient. This amount may include any authorized carryover of unobligated funds from prior funding periods.

Federally owned property means property in the possession of, or directly acquired by, the Government and subsequently made available to the recipient.

 

126


Funding period means the period of time when Federal funding is available for obligation by the recipient.

Incremental funding means a method of funding a grant or cooperative agreement where the funds initially obligated to the award are less than the total amount of the award, and DOE anticipates making additional obligations of funds when appropriated funds become available.

Obligations means the amount of orders placed, contracts and grants awarded, services received and similar transactions during a given period that require payment by the recipient during the same or a future period.

Outlays or expenditures means charges made to the project or program. They may be reported on cash or accrual basis. For reports prepared on a cash basis, outlays are the sum of cash disbursements for direct charges for goods and services, the amount of indirect expense charged, the value of third party in-kind contributions applied, and the amount of cash advances and payments made to subrecipients. For reports prepared on an accrual basis, outlays are the sum of cash disbursements for direct charges for goods and services, the amount of indirect expense incurred, the value of in-kind contributions applied, and the net increase (or decrease) in the amounts owed by the recipient for goods and other property received, for services performed by employees, contractors, subrecipients and other payees, and for other amounts becoming owed under programs for which no current services or performance are required.

Personal property means property of any kind except real property. It may be:

(1) Tangible, having physical existence ( i.e., equipment and supplies); or

(2) Intangible, having no physical existence, such as patents, copyrights, data, and software.

Prior approval means written or electronic approval by an authorized official evidencing prior consent.

Program income means gross income earned by the recipient that is directly generated by a supported activity or earned as a result of the award. Program income includes, but is not limited to, income from fees for services performed, the use or rental of real or personal property acquired under federally-funded projects, the sale of commodities or items fabricated under an award, license fees and royalties on patents and copyrights, and interest on loans made with award funds. Interest earned on advances of Federal funds is not program income. Except as otherwise provided in program regulations or the terms and conditions of the award, program income does not include the receipt of principal on loans, rebates, credits, discounts, etc., or interest earned on any of them.

 

127


Project costs means all allowable costs, as set forth in the applicable Federal cost principles, incurred by a recipient and the value of the contributions made by third parties in accomplishing the objectives of the award during the project period.

Property means real property and personal property (equipment, supplies, and intellectual property), unless otherwise stated.

Real property means land, including land improvements, structures and appurtenances thereto, but excludes movable machinery and equipment.

Small award means an award not exceeding the simplified acquisition threshold fixed at 41 U.S.C. 403(11) (currently $100,000).

Small business concern means a small business as defined at section 2 of Pub. L. 85-536 (16 U.S.C. 632) and the implementing regulations of the Administrator of the Small Business Administration. The criteria and size standards for small business concerns are contained in 13 CFR part 121.

Subaward means financial assistance in the form of money, or property in lieu of money, provided under an award by a recipient to an eligible subrecipient or by a subrecipient to a lower tier subrecipient. The term includes financial assistance when provided by an legal agreement, even if the agreement is called a contract, but the term does not include procurement of goods and services or any form of assistance which is not included in the definition of “award” in this part.

Subrecipient means the legal entity to which a subaward is made and which is accountable to the recipient for the use of the funds or property provided.

Supplies means tangible, expendable personal property that is charged directly to the award and that has a useful life of less than one year or an acquisition cost of less than $5,000 per unit.

Suspension means an action by DOE that temporarily withdraws Federal sponsorship under an award, pending corrective action by the recipient or pending a decision to terminate the award by DOE. Suspension of an award is a separate action from suspension of a recipient under 10 CFR part 1036.

Termination means the cancellation of an award, in whole or in part, under an agreement at any time prior to either:

(1) The date on which all work under an award is completed; or

(2) The date on which Federal sponsorship ends, as provided in the award document or any supplement or amendment thereto.

 

128


Third party in-kind contributions means the value of non-cash contributions provided by non-Federal third parties. Third party in-kind contributions may be in the form of real property, equipment, supplies and other expendable property, and the value of goods and services directly benefiting and specifically identifiable to the project or program.

Unobligated balance means the portion of the funds authorized by DOE that has not been obligated by the recipient and is determined by deducting the cumulative obligations from the cumulative funds authorized.

600.303   Deviations.

(a) Individual deviations. Individual deviations affecting only one award are subject to the procedures stated in 10 CFR 600.4.

(b) Class deviations. Class deviations affecting more than one financial assistance transaction are subject to the procedures states in 10 CFR 600.4.

600.304   Special award conditions.

(a) Contracting officers may impose additional requirements as needed, over and above those provided in this subpart, if an applicant or recipient:

(1) Has a history of poor performance;

(2) Is not financially stable;

(3) Has a management system that does not meet the standards prescribed in this subpart;

(4) Has not conformed to the terms and conditions of a previous award; or

(5) Is not otherwise responsible.

(b) Before imposing additional requirements, DOE must notify the applicant or recipient in writing as to:

(1) The nature of the additional requirements;

(2) The reason why the additional requirements are being imposed;

(3) The nature of the corrective action needed;

(4) The time allowed for completing the corrective actions; and

 

129


(5) The method for requesting reconsideration of the additional requirements imposed.

(c) The contracting officer must remove any special conditions if the circumstances that prompted them have been corrected.

600.305   Debarment and suspension.

Recipients must comply with the nonprocurement debarment and suspension common rule implemented in 10 CFR part 1036. This common rule restricts subawards and contracts with certain parties that are debarred, suspended, or otherwise excluded from or ineligible for participation in Federal assistance programs or activities.

600.306   Metric system of measurement.

(a) The Metric Conversion Act of 1975, as amended by the Omnibus Trade and Competitiveness Act of 1988 (15 U.S.C. 205) and implemented by Executive Order 12770, states that:

(1) The metric system is the preferred measurement system for U.S. trade and commerce.

(2) The metric system of measurement will be used, to the extent economically feasible, in Federal agencies’ procurements, grants, and other business-related activities.

(3) Metric implementation is not required if such use is likely to cause significant inefficiencies or loss of markets to United States firms.

(b) Recipients are encouraged to use the metric system to the maximum extent practicable in measurement-sensitive activities and in measurement-sensitive outputs resulting from DOE funded programs.

POST-AWARD REQUIREMENTS

Financial and Program Management

600.310   Purpose of financial and program management.

 

130


Sections 600.311 through 600.318 prescribe standards for financial management systems; methods for making payments; and rules for cost sharing and matching, program income, revisions to budgets and program plans, audits, allowable costs, and fee and profit.

600.311   Standards for financial management systems.

(a) Recipients are encouraged to use existing financial management systems to the extent that the systems comply with Generally Accepted Accounting Principles (GAAP) and the minimum standards in this section. At a minimum, a recipient’s financial management system must provide:

(1) Effective control of all funds. Control systems must be adequate to ensure that costs charged to Federal funds and those counted as the recipient’s cost share or match are consistent with requirements for cost reasonableness, allowability, and allocability in the applicable cost principles ( see 600.317) and in the terms and conditions of the award.

(2) Accurate, current and complete records that document, for each project funded wholly or in part with Federal funds, the source and application of the Federal funds and the recipient’s required cost share or match. These records must:

(i) Contain information about receipts, authorizations, assets, expenditures, program income, and interest.

(ii) Be adequate to make comparisons of outlays with amounts budgeted for each award (as required for programmatic and financial reporting under § 600.341). Where appropriate, financial information should be related to performance and unit cost data.

(3) To the extent that advance payments are authorized under § 600.312, procedures that minimize the time elapsing between the transfer of funds to the recipient from the Government and the recipient’s disbursement of the funds for program purposes.

(4) A system to support charges to Federal awards for salaries and wages, whether treated as direct or indirect costs. If employees work on multiple activities or cost objectives, a distribution of their salaries and wages must be supported by personnel activity reports which:

(i) Reflect an after the fact distribution of the actual activity of each employee.

(ii) Account for the total activity for which each employee is compensated.

(iii) Are prepared at least monthly, and coincide with one or more pay periods.

 

131


(b) If the Federal Government guarantees or insures the repayment of money borrowed by the recipient, DOE, at its discretion, may require adequate bonding and insurance if the bonding and insurance requirements of the recipient are not deemed adequate to protect the interest of the Federal Government.

(c) DOE may require adequate fidelity bond coverage if the recipient lacks sufficient coverage to protect the Federal Government’s interest.

(d) If bonds are required in the situations described in paragraphs (b) and (c) of this section, the bonds must be obtained from companies holding certificates of authority as acceptable sureties, as prescribed in 31 CFR part 223, “Surety Companies Doing Business with the United States.”

600.312 Payment.

(a) Methods available. Payment methods for awards with for-profit organizations are:

(1) Reimbursement. Under this method, the recipient requests reimbursement for costs incurred during a particular time period. In cases where the recipient submits requests for payment to the contracting officer, the DOE payment office reimburses the recipient by electronic funds transfer after approval of the request by the designated contracting officer.

(2) Advance payments. Under this method, DOE makes a payment to a recipient based upon projections of the recipient’s cash needs. The payment generally is made upon the recipient’s request, although predetermined payment schedules may be used when the timing of the recipient’s needs to disburse funds can be predicted in advance with sufficient accuracy to ensure compliance with paragraph (b)(2)(iii) of this section.

(b) Selecting a method. (1) The preferred payment method is the reimbursement method, as described in paragraph (a)(1) of this section.

(2) Advance payments, as described in paragraph (a)(2) of this section, may be used in exceptional circumstances, subject to the following conditions:

(i) The contracting officer, in consultation with the program official, determines in writing that advance payments are necessary or will materially contribute to the probability of success of the project contemplated under the award ( e.g., as startup funds for a project performed by a newly formed company).

(ii) Cash advances must be limited to the minimum amounts needed to carry out the program.

 

132


(iii) Recipients and DOE must maintain procedures to ensure that the timing of cash advances is as close as is administratively feasible to the recipients’ disbursements of the funds for program purposes, including direct program or project costs and the proportionate share of any allowable indirect costs.

(iv) Recipients must maintain advance payments of Federal funds in interest-bearing accounts, and remit annually the interest earned to the contracting officer for return to the Department of Treasury’s miscellaneous receipts account, unless one of the following applies:

(A) The recipient receives less than $120,000 in Federal awards per year.

(B) The best reasonably available interest bearing account would not be expected to earn interest in excess of $250 per year on Federal cash balances.

(C) The depository would require an average or minimum balance so high that establishing an interest bearing account would not be feasible, given the expected Federal and non-Federal cash resources.

(c) Frequency of payments. For either reimbursements or advance payments, recipients may submit requests for payment monthly, or more often if authorized by the contracting officer.

(d) Forms for requesting payment. DOE may authorize recipients to use the SF-270, “Request for Advance or Reimbursement;” the SF-271, “Outlay Report and Request for Reimbursement for Construction Programs;” or prescribe other forms or formats as necessary.

(e) Timeliness of payments. Payments normally will be made within 30 calendar days of the receipt of a recipient’s request for reimbursement or advance by the office designated to receive the request, unless the billing is improper.

(f) Precedence of other available funds. Recipients must disburse funds available from program income, rebates, refunds, contract settlements, audit recoveries, credits, discounts, and interest earned on such funds before requesting additional cash payments.

(g) Withholding of payments. Unless otherwise required by statute, contracting officers may not withhold payments for proper charges made by recipients during the project period for reasons other than the following:

(1) A recipient failed to comply with project objectives, the terms and conditions of the award, or Federal reporting requirements, in which case the contracting officer may suspend payments in accordance with Section 600.352.

(2) The recipient is delinquent on a debt to the United States (see definitions of “debt” and “delinquent debt” in 32 CFR 22.105). In that case, the contracting officer may,

 

133


upon reasonable notice, withhold payments to the recipient until the debt owed is resolved.

600.313   Cost sharing or matching.

(a) Acceptable contributions. All contributions, including cash contributions and third party in-kind contributions, must be accepted as part of the recipient’s cost sharing or matching if such contributions meet all of the following criteria:

(1) They are verifiable from the recipient’s records.

(2) They are not included as contributions for any other federally-assisted project or program.

(3) They are necessary and reasonable for proper and efficient accomplishment of project or program objectives.

(4) They are allowable under Section 600.317.

(5) They are not paid by the Federal Government under another award unless authorized by Federal statute to be used for cost sharing or matching.

(6) They are provided for in the approved budget.

(7) They conform to other provisions of this part, as applicable.

(b) Valuing and documenting contributions — (1) Valuing recipient’s property or services of recipient’s employees. Values are established in accordance with the applicable cost principles in Section 600.317, which means that amounts chargeable to the project are determined on the basis of costs incurred. For real property or equipment used on the project, the cost principles authorize depreciation or use charges. The full value of the item may be applied when the item will be consumed in the performance of the award or fully depreciated by the end of the award. In cases where the full value of a donated capital asset is to be applied as cost sharing or matching, that full value must be the lesser or the following:

(i) The certified value of the remaining life of the property recorded in the recipient’s accounting records at the time of donation; or

(ii) The current fair market value. If there is sufficient justification, the contracting officer may approve the use of the current fair market value of the donated property, even if it exceeds the certified value at the time of donation to the project. The contracting officer may accept the use of any reasonable basis for determining the fair market value of the property.

 

134


(2) Valuing services of others’ employees. If an employer other than the recipient furnishes the services of an employee, those services are valued at the employee’s regular rate of pay plus an amount of fringe benefits and overhead (at an overhead rate appropriate for the location where the services are performed), provided these services are in the same skill for which the employee is normally paid.

(3) Valuing volunteer services. Volunteer services furnished by professional and technical personnel, consultants, and other skilled and unskilled labor may be counted as cost sharing or matching if the service is an integral and necessary part of an approved project or program. Rates for volunteer services must be consistent with those paid for similar work in the recipient’s organization. In those markets in which the required skills are not found in the recipient organization, rates must be consistent with those paid for similar work in the labor market in which the recipient competes for the kind of services involved. In either case, paid fringe benefits that are reasonable, allowable, and allocable may be included in the valuation.

(4) Valuing property donated by third parties. (i) Donated supplies may include such items as office supplies or laboratory supplies. Value assessed to donated supplies included in the cost sharing or matching share must be reasonable and must not exceed the fair market value of the property at the time of the donation.

(ii) Normally only depreciation or use charges for equipment and buildings may be applied. However, the fair rental charges for land and the full value of equipment or other capital assets may be allowed, when they will be consumed in the performance of the award or fully depreciated by the end of the award, provided that the contracting officer has approved the charges. When use charges are applied, values must be determined in accordance with the usual accounting policies of the recipient, with the following qualifications:

(A) The value of donated space must not exceed the fair rental value of comparable space as established by an independent appraisal of comparable space and facilities in a privately-owned building in the same locality.

(B) The value of loaned equipment must not exceed its fair rental value.

(5) Documentation. The following requirements pertain to the recipient’s supporting records for in-kind contributions from third parties:

(i) Volunteer services must be documented and, to the extent feasible, supported by the same methods used by the recipient for its own employees.

(ii) The basis for determining the valuation for personal services and property must be documented.

600.314  Program income.

 

135


(a) DOE must apply the standards in this section to the disposition of program income from projects financed in whole or in part with Federal funds.

(b) Unless program regulations or the terms and conditions of the award provide otherwise, recipients, without any further accounting to DOE, may retain program income earned:

(1) From license fees and royalties for copyrighted material, patents, patent applications, trademarks, and inventions produced under an award.

(2) After the end of the project period.

(c) Unless program regulations or the terms and conditions of the award provide otherwise, costs incident to the generation of program income for which there is some obligation to the Government may be deducted from gross income to determine program income, provided these costs have not been charged to the award.

(d) Other than any program income excluded pursuant to paragraph (b) and (c) of this section, program income earned during the project period must be retained by the recipient and used in one or more of the following ways, as specified in program regulations or the terms and conditions of the award:

(1) Added to funds committed to the project by DOE and recipient and used to further eligible project or program objectives.

(2) Used to finance the non-Federal share of the project or program.

(3) Deducted from the total project or program allowable cost in determining the net allowable costs on which the Federal share of costs is based.

(e) If the program regulation or terms and conditions of an award authorize the disposition of program income as described in paragraph (d)(1) or (d)(2) of this section, and stipulate a limit on the amounts that may be used in those ways, program income in excess of the stipulated limits must be used in accordance with paragraph (d)(3) of this section.

(f) In the event that the program regulation or terms and conditions of the award do not specify how program income is to be used, paragraph (d)(3) of this section applies automatically to all projects or programs except research. For awards that support basic or applied research, paragraph (d)(1) of this section applies automatically unless the terms and conditions specify another alternative or the recipient is subject to special award conditions, as indicated in Section 600.304.

 

136


(g) Proceeds from the sale of property that is acquired, rather than fabricated, under an award are not program income and must be handled in accordance with the requirements of Sections 600.320 through 600.325 of this part.

600.315   Revision of budget and program plans.

(a) The budget plan is the financial expression of the project or program as approved during the award process. It includes the sum of the Federal and non-Federal shares when there are cost sharing requirements. The budget plan must be related to performance for program evaluation purposes, whenever appropriate.

(b) The recipient must obtain the contracting officer’s prior approval if a revision is necessary for either of the following two reasons:

(1) A change in the scope or the objective of the project or program (even if there is no associated budget revision requiring prior written approval).

(2) A need for additional Federal funding.

(c) The recipient must obtain the contracting officer’s prior approval if a revision is necessary for any of the following six reasons, unless the requirement for prior approval is specifically waived in the program regulation or terms and conditions of the award:

(1) A change in the approved project director, principal investigator, or other key person specified in the application or award document.

(2) The absence for more than three months, or a 25 percent reduction in time devoted to the project, by the approved project director or principal investigator.

(3) The inclusion of any additional costs that require prior approval in accordance with the applicable costs principles for Federal funds and the requirements applicable to the recipient’s cost share or match, as provided in Sections 600.313 and 600.317, respectively.

(4) The inclusion of pre-award costs for periods greater than the 90 calendar days immediately preceding the effective date of the award.

(5) A “no-cost” extension of the project period.

(6) Any subaward, transfer, or contracting out of substantive program performance under an award, unless described in the application and funded in the approved awards.

 

137


(d) If specifically required in the program regulation or the terms and conditions of the award, the recipient must obtain the contracting officer’s prior approval for the following revisions:

(1) The transfer of funds among direct cost categories, functions, and activities for awards in which the Federal share of the project exceeds $100,000 and the cumulative amount of such transfers exceeds or is expected to exceed 10 percent of the total budget as last approved by DOE.

(2) For awards that provide support for both construction and nonconstruction work, any fund or budget transfers between the two types of work supported.

(e) Within 30 calendar days from the date of receipt of the recipient’s request for budget revisions, the contracting officer must review the request and notify the recipient whether the budget revisions have been approved. If the revision is still under consideration at the end of 30 calendar days, the contracting officer must inform the recipient in writing of the date when the recipient may expect the decision.

600.316  Audits.

(a) Any recipient that expends $500,000 or more in a year under Federal awards must have an audit made for that year by an independent auditor, in accordance with paragraph (b) of this section. If a recipient is currently performing under a Federal award that requires an audit by its Federal cognizant agency, that auditor must perform the independent audit. The audit generally should be made a part of the regularly scheduled, annual audit of the recipient’s financial statements. However, it may be more economical in some cases to have Federal awards separately audited, and a recipient may elect to do so, unless that option is precluded by award terms and conditions or by Federal laws or regulations applicable to the program(s) under which the awards were made.

(b) The auditor must determine and report on whether:

(1) The recipient has an internal control structure that provides reasonable assurance that it is managing Federal awards in compliance with Federal laws and regulations and the terms and conditions of the awards.

(2) Based on a sampling of Federal award expenditures, the recipient has complied with laws, regulations, and award terms that may have a direct and material effect on Federal awards.

(c) The recipient must make the auditor’s report available to the DOE contracting officers whose awards are affected.

(d) Before requesting an audit in addition to the independent audit, the contracting officer must:

 

138


(1) Consider whether the independent audit satisfies his or her requirements;

(2) Limit the scope of such additional audit to areas not adequately addressed by the independent audit; and

(3) If DOE is not the Federal agency with the predominant fiscal interest in the recipient, coordinate with the agency that has the predominant fiscal interest.

(e) The recipient and its Federal cognizant agency for audit should develop a coordinated audit approach to minimize duplication of audit work.

(f) Audit costs (including a reasonable allocation of the costs of the audit of the recipient’s financial statement, based on the relative benefit to the Government and the recipient) are allowable costs of DOE awards.

600.317  Allowable costs.

(a) DOE determines allowability of costs in accordance with the cost principles applicable to the type of entity incurring the cost as follows:

(1) For-profit organizations. Allowability of costs incurred by for-profit organizations and those nonprofit organizations listed in Attachment C to OMB Circular A-122 is determined in accordance with the for-profit costs principles in 48 CFR part 31 in the Federal Acquisition Regulation, except that patent prosecution costs are not allowable unless specifically authorized in the award document.

(2) Other types of organizations. Allowability of costs incurred by other types of organizations that may be subrecipients under a prime award to a for-profit organization is determined as follows:

(i) Institutions of higher education. Allowability is determined in accordance with OMB Circular A-21, “Cost Principles for Educational Institutions.”

(ii) Other nonprofit organizations. Allowability is determined in accordance with OMB Circular A-122, “Cost Principles for Nonprofit Organizations.”

(iii) Hospitals. Allowability is determined in accordance with the provisions of 45 CFR part 74, Appendix E, “Principles for Determining Costs Applicable to Research and Development Under Grants and Contracts with Hospitals.”

(iv) Governmental organizations. Allowability for State, local, or federally recognized Indian tribal government is determined in accordance with OMB Circular A-87, “Cost Principles for State and Local Governments.”

 

139


(b) Pre-award costs. If a recipient incurs pre-award costs without the prior approval of the contracting officer, DOE may pay those costs incurred within the ninety calendar day period immediately preceding the effective date of the award, if such costs are:

(1) Necessary for the effective and economical conduct of the project;

(2) Otherwise allowable in accordance with the applicable cost principles; and

(3) Less than the total value of the award.

600.318  Fee and profit.

(a) Grants and cooperative agreements may not provide for the payment of fee or profit to recipients or subrecipients, except for awards made pursuant to the Small Business Innovation Research or Small Business Technology Transfer Research programs.

(b) A recipient or subrecipient may pay a fee or profit to a contractor providing goods or services under a contract.

Property Standards

600.320  Purpose of property standards.

Sections 600.321 through 600.325 set forth uniform standards for management, use, and disposition of property. DOE encourages recipients to use existing property-management systems to the extent that the systems meet these minimum requirements.

600.321  Real property and equipment.

(a) Prior approvals for acquisition with Federal funds. Recipients may purchase real property or equipment in whole or in part with Federal funds under an award only with the prior approval of the contracting officer.

(b) Title. Unless a statute specifically authorizes and the award specifies that title to property vests unconditionally in the recipient, title to real property or equipment vests in the recipient subject to the conditions that the recipient:

(1) Use the real property or equipment for the authorized purposes of the project until funding for the project ceases, or until the property is no longer needed for the purposes of the project;

 

140


(2) Not encumber the property without approval of the contracting officer; and

(3) Use and dispose of the property in accordance with paragraphs (d) and (e) of this section.

(c) Federal interest in real property or equipment offered as cost-share. A recipient may offer the full value of real property or equipment that is purchased with recipient’s funds or that is donated by a third party to meet a portion of any required cost sharing or matching, subject to the requirements in Section 600.313. If a resulting award includes such property as a portion of the recipient’s cost share, the Government has a financial interest in the property, ( i.e., a share of the property value equal to the Federal participation in the project). The property is considered as if it had been acquired in part with Federal funds, and is subject to the provisions of paragraphs (b)(1), (b)(2), and (b)(3) of this section and to the provisions of Section 600.323.

(d) Insurance. Recipients must, at a minimum, provide the equivalent insurance coverage for real property and equipment acquired with DOE funds as provided to property owned by the recipient.

(e) Use. If real property or equipment is acquired in whole or in part with Federal funds under an award and the award does not specify that title vests unconditionally in the recipient, the real property or equipment is subject to the following:

(1) During the time that the real property or equipment is used on the project or program for which it was acquired, the recipient must make it available for use on other projects or programs, if such other use does not interfere with the work on the project or program for which the real property or equipment was originally acquired. Use of the real property or equipment on other projects is subject to the following order of priority:

(i) Activities sponsored by DOE grants, cooperative agreements, or other assistance awards;

(ii) Activities sponsored by other Federal agencies’ grants, cooperative agreements, or other assistance awards;

(iii) Activities under Federal procurement contracts or activities not sponsored by any Federal agency. If so used, use charges must be assessed to those activities. For real property or equipment, the use charges must be at rates equivalent to those for which comparable real property or equipment may be leased.

(2) After Federal funding for the project ceases or if the real property or equipment is no longer needed for the purposes of the project, the recipient may use the real property or equipment for other projects, insofar as:

 

141


(i) There are Federally sponsored projects for which the real property or equipment may be used. If the only use for the real property or equipment is for projects that have no Federal sponsorship, the receipt must proceed with disposition of the real property or equipment, in accordance with paragraph (f) of this section.

(ii) The recipient obtains written approval from the contracting officer to do so. The contracting officer must ensure that there is a formal change of accountability for the real property or equipment to a currently funded, Federal award.

(iii) The recipient’s use of the real property or equipment for other projects is in the same order of priority as described in paragraph (e)(1) of this section.

(f) Disposition. (1) If an item of real property or equipment is no longer needed for Federally sponsored projects, the recipient has the following options:

(i) If the property is equipment with a current per unit fair market value of less than $5,000, it may be retained, sold, or otherwise disposed of with no further obligation to DOE.

(ii) If the property that is no longer needed is equipment (rather than real property), the recipient may wish to replace it with an item that is needed currently for the project by trading in or selling to offset the costs of the replacement equipment, subject to the approval of the contracting officer.

(iii) The recipient may elect to retain title, without further obligation to the Federal Government, by compensating the Federal Government for that percentage of the current fair market value of the real property or equipment that is attributable to the Federal participation in the project.

(iv) If the recipient does not elect to retain title to real property or equipment or does not request approval to use equipment as trade-in or offset for replacement equipment, the recipient must request disposition instructions from the responsible agency.

(2) If a recipient requests disposition instructions, the contracting officer must:

(i) For equipment (but not real property), consult with the DOE Project Director to determine whether the condition and nature of the equipment warrant excess screening within DOE. If screening is warranted, the equipment will be made available for reutilization within DOE through the Energy Asset Disposal System (EADS). If no DOE requirement is identified within a 30-day period, EADS automatically reports the availability of the equipment to the General Services Administration, to determine whether a requirement for the equipment exists in other Federal agencies.

 

142


(ii) For either real property or equipment, issue instructions to the recipient for disposition of the property no later than 120 calendar days after the recipient’s request. The contracting officer’s options for disposition are to direct the recipient to:

(A) Transfer title to the real property or equipment to the Federal Government or to an eligible third party provided that, in such cases, the recipient is entitled to compensation for its attributable percentage of the current fair market value of the real property or equipment, plus any reasonable shipping or interim storage costs incurred.

(B) Sell the real property or equipment and pay the Federal Government for that percentage of the current fair market value of the property that is attributable to the Federal participation in the project (after deducting actual and reasonable selling and fix-up expenses, if any, from the sale proceeds). If the recipient is authorized or required to sell the real property or equipment, the recipient must use competitive procedures that result in the highest practicable return.

(3) If the responsible agency fails to issue disposition instructions within 120 calendar days of the recipient’s request, the recipient must dispose of the real property or equipment through the option described in paragraph (f)(2)(ii)(B) of this section.

600.322  Federally owned property.

(a) Annual inventory. The recipient must submit annually to the contracting officer an inventory listing of all Federally owned property in its custody, i.e., property furnished by the Federal Government, rather than acquired by the recipient with Federal funds under the award.

(b) Insurance. The recipient may not insure Federally owned property unless required by the terms and conditions of the award.

(c) Use on other activities. (1) Use of federally owned property on other activities is permissible, if authorized by the contracting officer responsible for administering the award to which the property currently is charged.

(2) Use on other activities must be in the following order of priority:

(i) Activities sponsored by DOE grants, cooperative agreements, or other assistance awards;

(ii) Activities sponsored by other Federal agencies’ grants, cooperative agreements, or other assistance awards;

 

143


(iii) Activities under Federal procurement contracts or activities not sponsored by any Federal agency. If so used, use charges must be assessed to those activities. For real property or equipment, the use charges must be at rates equivalent to those for which comparable real property or equipment may be leased.

(d) Disposition or property. Upon completion of the award, the recipient must submit to the contracting officer a final inventory of Federal owned property. DOE may:

(1) Use the property to meet another Federal Government need ( e.g., by transferring accountability for the property to another Federal award to the same recipient, or by directing the recipient to transfer the property to a Federal agency that needs the property or to another recipient with a currently funded award).

(2) Declare the property to be excess property and either:

(i) Report the property to the General Services Administration through EADS, in accordance with the Federal Property and Administrative Services Act of 1949 (40 U.S.C. 483(b)(2)), as implemented by General Services Administration regulations at 41 CFR 101-47.202; or

(ii) Dispose of the property by alternative methods, if there is authority under law, such as 15 U.S.C. 3710(i).

600.323  Property management system.

The recipient’s property management system must include the following:

(a) Property records must be maintained, to include the following information for property that is Federally owned, equipment that is acquired in whole or in part with Federal funds, or property or equipment that is used as cost sharing or matching:

(1) A description of the property.

(2) Manufacturer’s serial number, model number, Federal stock number, national stock number, or any other identification number.

(3) Source of the property, including the award number.

(4) Whether title vests in the recipient or the Federal Government.

(5) Acquisition date (or date received, if the property was furnished by the Federal Government) and cost.

 

144


(6) Information from which one can calculate the percentage of Federal participation in the cost of the property (not applicable to property furnished by the Federal Government).

(7) The location and condition of the property and the date the information was reported.

(8) Ultimate disposition data, including data of disposal and sales price or the method used to determine current fair market value where a recipient compensates the Federal Government for its share.

(b) Federal owned equipment must be marked to indicate Federal ownership.

(c) A physical inventory must be taken and the results reconciled with the property records at least once every two years. Any differences between quantities determined by the physical inspection and those shown in the accounting records must be investigated to determine the causes of the difference. The recipient must, in connection with the inventory, verify the existence, current utilization, and continued need for the property.

(d) A control system must be in effect to insure adequate safeguards to prevent loss, damage, or theft of the property. Any loss, damage, or theft of property must be investigated and fully documented. If the property is owned by the Federal Government, the recipient must promptly notify the Federal agency responsible for administering the property.

(e) Adequate maintenance procedures must be implemented to keep the property in good condition.

600.324  Supplies.

(a) Title vests in the recipient upon acquisition of supplies acquired with Federal funds under an award.

(b) Upon termination or completion of the project or program, the recipient may retain any unused supplies. If the inventory of unused supplies exceeds $5,000 in total aggregate value and the items are not needed for any other Federally sponsored project or program, the recipient may retain the items for use on non-Federal sponsored activities or sell them, but must, in either case, compensate the Federal Government for its share.

600.325  Intellectual property.

(a) Scope. This section sets forth the policies with regard to disposition of rights to data and to inventions conceived or first actually reduced to practice in the course of, or under, a grant or cooperative agreement with DOE.

 

145


(b) Patents right — small business concerns. In accordance with 35 U.S.C. 202, if the recipient is a small business concern and receives a grant, cooperative agreement, subaward, or contract for research, developmental, or demonstration activities, then, unless there are “exceptional circumstances” as described in 35 U.S.C. 202(e), the award must contain the standard clause in Appendix A to this subpart, entitled “Patents Rights (Small Business Firms and Nonprofit Organizations” which provides to the recipient the right to elect ownership of inventions made under the award.

(c) Patent rights — other than small business concerns, e.g., large businesses — (1) No Patent Waiver. Except as provided by paragraph (c)(2) of this section, if the recipient is a for-profit organization other than a small business concern, as defined in 35 U.S.C. 201(h) and receives an award or a subaward for research, development, and demonstration activities, then, pursuant to statute, the award must contain the standard clause in Appendix A to this subpart, entitled “Patent Rights (Large Business Firms) — No Waiver” which provides that DOE owns the patent rights to inventions made under the award.

(2) Patent Waiver Granted. Paragraph (c)(1) of this section does not apply if:

(i) DOE grants a class waiver for a particular program under 10 CFR part 784;

(ii) The applicant requests and receives an advance patent waiver under 10 CFR part 784; or

(iii) A subaward is covered by a waiver granted under the prime award.

(3) Special Provision. Normally, an award will not include a background patent and data provision. However, under special circumstances, in order to provide heightened assurance of commercialization, a provision providing for a right to require licensing of third parties to background inventions, limited rights data and/or restricted computer software, may be included. Inclusion of a background patent and/or a data provision to assure commercialization will be done only with the written concurrence of the DOE program official setting forth the need for such assurance. An award may include the right to license the Government and third party contractors for special Government purposes when future availability of the technology would also benefit the government, e.g., clean-up of DOE facilities. The scope of any such background patent and/or data licensing provision is subject to negotiation.

(d) Rights in data — general rule.

(1) Subject to paragraphs (d)(2) and (3) of this section, and except as otherwise provided by paragraphs (e) and (f) of this section or other law, any award under this subpart must contain the standard clause in Appendix A to this subpart, entitled “Rights in Data — General”.

 

146


(2) Normally, an award will not require the delivery of limited rights data or restricted computer software. However, if the contracting officer, in consultation with DOE patent counsel and the DOE program official, determines that delivery of limited rights data or restricted computer software is necessary, the contracting officer, after negotiation with the applicant, may insert in the award the standard clause as modified by Alternates I and/or II set forth in Appendix A to this subpart.

(3) If software is specified for delivery to DOE, or if other special circumstances exist, e.g., DOE specifying “open-source” treatment of software, then the contracting officer, after negotiation with the recipient, may include in the award special provisions requiring the recipient to obtain written approval of the contracting officer prior to asserting copyright in the software, modifying the retained Government license, and/or otherwise altering the copyright provisions.

(e) Rights in data — programs covered under special protected data statutes. (1) If a statute, other than those providing for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) programs, provides for a period of time, typically up to five years, during which data produced under an award for research, development, and demonstration may be protected from public disclosure, then the contracting officer must insert in the award the standard clause in Appendix A to this subpart entitled “Rights in Data — Programs Covered Under Special Protected Data Statutes” or, as determined in consultation with DOE patent counsel and the DOE program official, a modified version of such clause which may identify data or categories of data that the recipient must make available to the public.

(2) An award under paragraph (e)(1) of this section is subject to the provisions of paragraphs (d)(2) and (3) of this section.

(f) Rights in data — SBIR/STTR programs. (1) If an applicant receives an award under the SBIR or STTR program, then the contracting officer must insert in the award the standard data clause in the General Terms and Conditions for SBIR Grants, entitled “Rights in Data — SBIR Program”.

(2) The data rights provisions for SBIR/STTR grants are contained in the award terms and conditions for SBIR grants located at http://e-center.doe.gov on the Professionals Homepage under Financial Assistance, Regulations and Guidance.

(g) Authorization and consent. (1) Work performed by a recipient under a grant is not subject to authorization and consent to the use of a patented invention, and the Government assumes no liability for patent infringement by the recipient under 28 U.S.C. 1498.

(2) Work performed by a recipient under a cooperative agreement is subject to authorization and consent to the use of a patented invention consistent with the principles set forth in 48 CFR 27.201-1.

 

147


(3) The contracting officer, in consultation with patent counsel, may also include clauses in the cooperative agreement addressing other patent matters related to authorization and consent, such as patent indemnification of the Government by recipient and notice and assistance regarding patent and copyright infringement. The policies and clauses for these other patent matters will be the same or consistent with those in 48 CFR part 927.

Procurement Standards

600.330  Purpose of procurement standards.

Section 600.331 sets forth requirements necessary to ensure:

(a) Recipients’ procurements that use Federal funds comply with applicable Federal statutes, regulations, and executive orders.

(b) Proper stewardship of Federal funds used in recipients’ procurements.

600.331  Requirements.

The following requirements pertain to recipients’ procurements funded in whole or in part with Federal funds or with recipients’ cost-share or match:

(a) Reasonable cost. Recipients’ procurement procedures must use best commercial practices to ensure reasonable cost for procured goods and services. Recipients are encouraged to buy commercial items, if practicable.

(b) Pre-award review of certain procurements. If the contracting officer determines that there is a compelling need to perform a pre-award review of a specific transaction and the terms of the award identify the specific transaction and provide for such a review, then the recipient must obtain the contracting officer’s approval prior to awarding the transaction and must provide the contracting officer the following documents to review:

(1) Request for proposals or invitation to bid, if any;

(2) Cost estimate;

(3) Proposal/bid;

(4) Proposed award document; and

(5) Summary of negotiations or justification for award.

 

148


(c) Contract provisions. (1) Contracts in excess of the simplified acquisition threshold must contain contractual provisions or conditions that allow for administrative, contractual, or legal remedies in instances in which a contractor violates or breaches the contract terms, and provide for such remedial actions as may be appropriate.

(2) All contracts in excess of the simplified acquisition threshold must contain suitable provisions for termination for default by the recipient and for termination due to circumstances beyond the control of the contractor.

(3) All negotiated contracts in excess of the simplified acquisition threshold must include a provision permitting access of DOE, the Inspector General, the Comptroller General of the United States, or any of their duly authorized representatives, to any books, documents, papers, and records of the contractor that are directly pertinent to a specific programs, for the purpose of making audits, examinations, excerpts, transcriptions, and copies of such documents.

(4) All contracts, including those for amounts less than the simplified acquisition threshold, awarded by recipients and their contractors must contain the procurement provisions of Appendix B to this subpart, as applicable.

(d) Recipient responsibilities. The recipient is the responsible authority, without recourse to DOE, regarding the settlement and satisfaction of all contractual and administrative issues arising out of procurements entered into in support of an award. This includes disputes, claims, protests of award, source evaluation or other matters of a contractual nature. The recipient should refer matters concerning violations of statutes to such Federal, State or local authority as may have proper jurisdiction.

Reports and Records

600.340  Purpose of reports and records.

Sections 600.341 and 600.342 prescribe requirements for monitoring and reporting financial and program performance and for records retention.

600.341  Monitoring and reporting program and financial performance.

(a) The terms and conditions of the award prescribe the reporting requirements, the frequency, and the due dates for reports. At a minimum, requirements must include:

(1) Periodic progress reports (at least annually, but no more frequently than quarterly) addressing both program status and business status, as follows:

 

149


(i) The program portions of the reports must address progress toward achieving program performance goals and milestones, including current issues, problems, or developments.

(ii) The business portions of the reports must provide summarized details on the status of resources (Federal funds and non-Federal cost sharing or matching), including an accounting of expenditures for the period covered by the report. The report should compare the resource status with any payment and expenditure schedules or plans provided in the original award, explain any major deviations from those schedules, and discuss actions that will be taken to address the deviations.

(2) A final technical report if the award is for research and development.

(b) If the contracting officer previously authorized advance payments, pursuant to Section 600.312(a)(2), he/she should consult with the DOE project director and consider whether program progress reported in the periodic progress report, in relation to reported expenditures, is sufficient to justify continued authorization of advance payments.

600.342 Retention and access requirements for records.

(a) This section sets forth requirements for records retention and access to records for awards to recipients and subrecipients.

(b) Financial records, supporting documents, statistical records, and all other records pertinent to an award must be retained for a period of three years from the date of submission of the final expenditure report. The only exceptions are the following.

(1) If any litigation, claim, or audit is started before the expiration of the 3-year period, the records must be retained until all litigation, claims, or audit findings involving the records have been resolved and final action taken.

(2) Records for real property and equipment acquired with Federal funds must be retained for 3 years after final disposition.

(3) If records are transferred to or maintained by DOE, the 3-year retention requirement is not applicable to the recipient.

(4) Indirect cost rate proposals, cost allocation plans, and related records must be retained in accordance with the requirements specified in paragraph (g) of this section.

(c) Copies of original records may be substituted for the original records if authorized by the contracting officer.

 

150


(d) The contracting officer may request that recipients transfer certain records to DOE custody if he or she determines that the records possess long term retention value. However, in order to avoid duplicate recordkeeping, a contracting officer may make arrangements for recipients to retain any records that are continuously needed for joint use.

(e) DOE, the Inspector General, Comptroller General of the United States, or any of their duly authorized representatives, have the right of timely and unrestricted access to any books, documents, papers, or other records of recipients that are pertinent to the awards, in order to make audits, examinations, excerpts, transcripts and copies of such documents. This right also includes timely and reasonable access to a recipient’s personnel for the purpose of interview and discussion related to such documents. The rights of access in this paragraph are not limited to the required retention period, but must last as long as records are retained.

(f) Unless required by statute, DOE must not place restrictions on recipients that limit public access to the records of recipients that are pertinent to an award, except when DOE can demonstrate that such records would be kept confidential and would be exempt from disclosure pursuant to the Freedom of Information Act (5 U.S.C. 552) if the records belonged to DOE.

(g) Indirect cost proposals, cost allocation plans, and other cost accounting documents (such as documents related to computer usage chargeback rates), along with their supporting records, must be retained for a 3-year period, as follows:

(1) If the recipient or the subrecipient is required to submit an indirect-cost proposal, cost allocation plan, or other computation to the cognizant Federal agency for purposes of negotiating an indirect cost rate or other rates, the 3-year retention period starts on the date of the submission.

(2) If the recipient or the subrecipient is not required to submit the documents or supporting records for negotiating an indirect cost rate or other rates, the 3-year retention period for the documents and records starts at the end of the fiscal year (or other accounting period) covered by the proposal, plan, or other computation.

(h) If the information described in this section is maintained on a computer, recipients must retain the computer data on a reliable medium for the time periods prescribed. Recipients may transfer computer data in machine readable form from one reliable computer medium to another. Recipients’ computer data retention and transfer procedures must maintain the integrity, reliability, and security of the original computer data. Recipients must also maintain an audit trail describing the data transfer. For the record retention time periods prescribed in this section, recipients must not destroy, discard, delete, or write over such computer data.

Termination and Enforcement

 

151


600.350 Purpose of termination and enforcement.

Sections 600.351 through 600.353 set forth uniform procedures for suspension, termination, enforcement, and disputes.

600.351 Termination.

(a) Awards may be terminated in whole or in part only in accordance with one of the following:

(1) By the contracting officer, if a recipient materially fails to comply with the terms and conditions of an award.

(2) By the contracting officer with the consent of the recipient, in which case the two parties must agree upon the termination conditions, including the effective date and, in the case of partial termination, the portion to be terminated.

(3) By the recipient upon sending to the contracting officer written notification setting forth the reasons for such termination, the effective date, and, in the case of partial termination, the portion to be terminated. The recipient must provide such notice at least 30 calendar days prior to the effective date of the termination. However, if the contracting officer determines in the case of partial termination that the reduced or modified portion of the award will not accomplish the purposes for which the award was made, he or she may terminate the award in its entirety.

(b) If the recipient incurred allowable costs prior to the termination, the responsibilities of the recipient referred to in § 600.361(b), including those related to property, apply to the termination of the award, and provision must be made for continuing responsibilities of the recipient after termination, as appropriate.

600.352 Enforcement.

(a) Remedies for noncompliance. If a recipient materially fails to comply with the terms and conditions of an award, whether stated in a Federal statute, regulation, assurance, application, or notice of award, the contracting officer may, in addition to imposing any of the special conditions outlined in Section 600.304, take one or more of the following actions, as appropriate:

(1) Temporarily withhold cash payments pending correction of the deficiency by the recipient or more severe enforcement action by the contracting officer.

 

152


(2) Disallow (that is, deny both the use of funds and any applicable matching credit for) all or part of the cost of the activity or action not in compliance.

(3) Wholly or partly suspend or terminate the current award.

(4) Withhold further awards for the project or program.

(5) Apply other remedies that may be legally available.

(b) Hearings and appeals. In taking an enforcement action, DOE must provide the recipient an opportunity for hearing, appeal, or other administrative proceeding to which the recipient is entitled under any statute or regulation applicable to the action involved.

(c) Effects of suspension and termination. Costs resulting from obligations incurred by the recipient during a suspension or after termination of an award are not allowable, unless the contracting officer expressly authorizes them in the notice of suspension or termination or subsequently authorizes such costs. Other recipient costs during suspension or after termination, which are necessary and not reasonably avoidable, are allowable if the costs:

(1) Result from obligations which were properly incurred by the recipient before the effective date of suspension or termination, are not in anticipation of it, and in the case of a termination, are noncancellable; and

(2) Would be allowable if the award expired normally at the end of the funding period.

(d) Relationship to debarment and suspension. The enforcement remedies identified in this section, including suspension and termination, do not preclude a recipient from being subject to debarment and suspension under 10 CFR part 1036.

600.353 Disputes and appeals.

Consistent with 10 CFR 600.22 and part 1024, recipients have the right to appeal certain decisions by contracting officers.

After-the-Award Requirements

600.360 Purpose.

Sections 600.361 through 600.363 contain procedures for closeout and for subsequent disallowances and adjustments.

 

153


600.361 Closeout procedures.

(a) Recipients must submit, within 90 calendar days after the date of completion of the award, all reports required by the terms and conditions of the award. DOE may approve extensions when requested by the recipient.

(b) The following provisions must apply to the closeout:

(1) Unless DOE authorizes an extension, a recipient must liquidate all obligations incurred under the award not later than 90 calendar days after the funding period or the date of completion of the award as specified in the terms and conditions of the award or in agency implementing instructions.

(2) DOE must make prompt, final payments to a recipient for allowable reimbursable costs under the award being closed out.

(3) The recipient must promptly refund any unobligated balances of cash that DOE has advanced or paid and that are not authorized to be retained by the recipient for use in other projects. OMB Circular A-129 governs unreturned amounts that become delinquent debts.

(4) When authorized by the terms and conditions of the award, the contracting officer must make a settlement for any upward or downward adjustments to the Federal share of costs after closeout reports are received.

(5) The recipient must account for any real property and equipment acquired with Federal funds or received from the Federal Government in accordance with Sections 600.321 through 600.325.

(6) If a final audit is required and has not been performed prior to the closeout of an award, DOE retains the right to recover an appropriate amount after fully considering the recommendations on disallowed costs resulting from the final audit.

600.362 Subsequent adjustments and continuing responsibilities.

(a) The closeout of an award does not affect any of the following:

(1) The right of DOE to disallow costs and recover funds on the basis of a later audit or other review.

(2) The obligation of the recipient to return any funds due as a result of later refunds, corrections, or other transactions.

(3) Audit requirements in Section 600.316.

 

154


(4) Property management requirements in Sections 600.321 through 600.325.

(5) Records retention requirements in Section 600.342.

(b) After closeout of an award, the continuing responsibilities under an award may be modified or ended in whole or in part with the consent of the contracting officer and the recipient, provided property management requirements are considered and provisions made for the continuing responsibilities of the recipient, as appropriate.

600.363 Collection of amounts due.

(a) Any funds paid to a recipient in excess of the amount to which the recipient is finally determined to be entitled under the terms and conditions of the award constitute a debt to the Federal Government. If not paid within 30 days after the demand for payment, DOE may reduce the debt in accordance with the procedures and techniques described in 10 CFR part 1015 and OMB Circular A-129, including:

(1) Making an administrative offset against other requests for reimbursements.

(2) Withholding advance payments otherwise due to the recipient.

(3) Taking other action permitted by statute or regulation.

(b) Except as otherwise provided by law, DOE may charge interest and administrative fees on an overdue debt in accordance with 31 CFR Chapter IX, parts 900-904, “Federal Claims Collection Standards.”

Additional Provisions

600.380 Purpose.

The purpose of “Additional Provisions” is to provide alternative requirements for recipients otherwise covered by this subpart D, when they are performing under Small Business Innovation Research grants.

600.381 Special provisions for Small Business Innovation Research Grants.

(a) General. This section contains provisions applicable to the Small Business Innovation Reserach (SBIR) Program.

 

155


(b) Provisions Applicable to Phase I SBIR Awards: Phase I SBIR awards may be made on a fixed obligation basis, subject to the following requirements.

(1) While proposed costs must be analyzed in detail to ensure consistency with applicable cost principles, incurred costs are not subject to review under the standards of cost allowability.

(2) Although detailed budgets are submitted by a recipient and reviewed by DOE for purposes of establishing the amount to be awarded, budget categories are not stipulated in making an award;

(3) Prior approval from the DOE for rebudgeting among categories by the recipient is not required. Prior approval from DOE is required for any variation from the requirement that no more than one-third of Phase I work can be done by subcontractors or consortium partners;

(4) Pre-award expenditure approval is not required;

(5) Payments are to be made in the same manner as other financial assistance (see Section 600.312), except that, when determined appropriate by the cognizant program official and contracting officer, a lump sum payment may be made. If a lump sum payment is made, the award must contain a condition that requires the recipient to return to DOE amounts remaining unexpended at the end of the project if those amounts exceed $500;

(6) Recipients will certify in writing to the Contracting Officer at the end of the project that the activity was completed or the level of effort was expended. Should the activity or effort not be carried out, the recipient would be expected to make appropriate reimbursements;

(7) Requirements for periodic reports may be established for each award so long as they are consistent with Secion 600.341;

(8) Changes in principal investigator or project leader, scope of effort, or institution, require the prior approval of DOE.

(c) Provision Applicable to Phase II SBIR Awards. Phase II SBIR awards may be made for a single budget period of 24 months.

(d) Provisions Applicable to Phase I and Phase II SBIR Awards. (1) The prior approval of the cognizant DOE Contracting Officer is required before the final budget period of the project period may be extended without additional funds.

(2) A fee or profit may be paid to SBIR recipients.

 

156


APPENDIX A TO SUBPART D TO PART 600 -- PATENT AND DATA PROVISIONS

1. Patent Rights (Small Business Firms and Nonprofit Organizations)

2. Patent Rights (Large Business Firms) -- No Waiver

3. Rights in Data -- General

4. Rights in Data -- Programs Covered Under Special Protected Data Statutes

Patent Rights (Small Business Firms and Nonprofit Organizations)

(a) Definitions

Invention means any invention or discovery which is or may be patentable or otherwise protectable under title 35 of the United States Code, or any novel variety of plant which is or may be protected under the Plant Variety Protection Act (7 U.S.C. 2321 et seq.).

Made when used in relation to any invention means the conception or first actual reduction to practice of such invention.

Nonprofit organization means a university or other institution of higher education or an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 U.S.C. 501(a)) or any nonprofit scientific or educational organization qualified under a State nonprofit organization statute.

Practical application means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system; and, in each case, under such conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or Government regulations available to the public on reasonable terms.

Small business firm means a small business concern as defined at section 2 of Public Law 85-536 (16 U.S.C. 632) and implementing regulations of the Administrator of the Small Business Administration. For the purpose of this clause, the size standards for small business concerns involved in Government procurement and subcontracting at 13 CFR 121.3 through 121.8 and 13 CFR 121.3 through 121.12, respectively, will be used.

 

157


Subject invention means any invention of the Recipient conceived or first actually reduced to practice in the performance of work under this award, provided that in the case of a variety of plant, the date of determination (as defined in section 41(d) of the Plant Variety Protection Act, 7 U.S.C. 2401(d) must also occur during the period of award performance.

(b) Allocation of Principal Rights

The Recipient may retain the entire right, title, and interest throughout the world to each subject invention subject to the provisions of this Patent Rights clause and 35 U.S.C. 203. With respect to any subject invention in which the Recipient retains title, the Federal Government shall have a non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the U.S. the subject invention throughout the world.

(c) Invention Disclosure, Election of Title and Filing of Patent Applications by Recipient

(1) The Recipient will disclose each subject invention to DOE within two months after the inventor discloses it in writing to Recipient personnel responsible for the administration of patent matters. The disclosure to DOE shall be in the form of a written report and shall identify the award under which the invention was made and the inventor(s). It shall be sufficiently complete in technical detail to convey a clear understanding to the extent known at the time of disclosure, of the nature, purpose, operation, and the physical, chemical, biological or electrical characteristics of the invention. The disclosure shall also identify any publication, on sale or public use of the invention and whether a manuscript describing the invention has been submitted for publication and, if so, whether it has been accepted for publication at the time of disclosure. In addition, after disclosure to DOE, the Recipient will promptly notify DOE of the acceptance of any manuscript describing the invention for publication or of any on sale or public use planned by the Recipient.

(2) The Recipient will elect in writing whether or not to retain title to any such invention by notifying DOE within two years of disclosure to DOE. However, in any case where publication, on sale, or public use has initiated the one-year statutory period wherein valid patent protection can still be obtained in the U.S., the period for election of title may be shortened by the agency to a date that is no more than 60 days prior to the end of the statutory period.

(3) The Recipient will file its initial patent application on an invention to which it elects to retain title within one year after election of title or, if earlier, prior to the end of any statutory period wherein valid patent protection can be obtained in the U.S. after a publication, on sale, or public use. The Recipient will file patent applications in additional countries or international patent offices within either ten months of the corresponding initial patent application, or six months from the date when permission is granted by the Commissioner of Patents and Trademarks to file foreign patent applications when such filing has been prohibited by a Secrecy Order.

 

158


(4) Requests for extension of the time for disclosure to DOE, election, and filing under subparagraphs (c)(1), (2), and (3) of this clause may, at the discretion of DOE, be granted.

(d) Conditions When the Government May Obtain Title

The Recipient will convey to DOE, upon written request, title to any subject invention:

(1) If the Recipient fails to disclose or elect the subject invention within the times specified in paragraph (c) of this patent rights clause, or elects not to retain title; provided that DOE may only request title within 60 days after learning of the failure of the Recipient to disclose or elect within the specified times;

(2) In those countries in which the Recipient fails to file patent applications within the times specified in paragraph (c) of this Patent Rights clause; provided, however, that if the Recipient has filed a patent application in a country after the times specified in paragraph (c) of this Patent Rights clause, but prior to its receipt of the written request of DOE, the Recipient shall continue to retain title in that country; or

(3) In any country in which the Recipient decides not to continue the prosecution of any application for, to pay the maintenance fees on, or defend in a reexamination or opposition proceeding on, a patent on a subject invention.

(e) Minimum Rights to Recipient and Protection of the Recipient Right To File

(1) The Recipient will retain a non-exclusive royalty-free license throughout the world in each subject invention to which the Government obtains title, except if the Recipient fails to disclose the subject invention within the times specified in paragraph (c) of this Patent Rights clause. The Recipient’s license extends to its domestic subsidiaries and affiliates, if any, within the corporate structure of which the Recipient is a party and includes the right to grant sublicenses of the same scope of the extent the Recipient was legally obligated to do so at the time the award was awarded. The license is transferable only with the approval of DOE except when transferred to the successor of that part of the Recipient’s business to which the invention pertains.

(2) The Recipient’s domestic license may be revoked or modified by DOE to the extent necessary to achieve expeditious practical application of the subject invention pursuant to an application for an exclusive license submitted in accordance with applicable provisions at 37 CFR part 404 and the agency’s licensing regulation, if any. This license will not be revoked in that field of use or the geographical areas in which the Recipient has achieved practical application and continues to make the benefits of the invention reasonably accessible to the public. The license in any foreign country may be revoked or modified at discretion of the funding Federal agency to the extent the Recipient, its licensees, or its domestic subsidiaries or affiliates have failed to achieve practical application in that foreign country.

 

159


(3) Before revocation or modification of the license, the funding Federal agency will furnish the Recipient a written notice of its intention to revoke or modify the license, and the Recipient will be allowed thirty days (or such other time as may be authorized by DOE for good cause shown by the Recipient) after the notice to show cause why the license should not be revoked or modified. The Recipient has the right to appeal, in accordance with applicable regulations in 37 CFR part 404 and the agency’s licensing regulations, if any, concerning the licensing of Government-owned inventions, any decision concerning the revocation or modification of its license.

(f) Recipient Action To Protect Government’s Interest

(1) The Recipient agrees to execute or to have executed and promptly deliver to DOE all instruments necessary to:

(i) Establish or confirm the rights the Government has throughout the world in those subject inventions for which the Recipient retains title; and

(ii) Convey title to DOE when requested under paragraph (d) of this Patent Rights clause, and to enable the government to obtain patent protection throughout the world in that subject invention.

(2) The Recipient agrees to require, by written agreement, its employees, other than clerical and non-technical employees, to disclose promptly in writing to personnel identified as responsible for the administration of patent matters and in a format suggested by the Recipient each subject invention made under this award in order that the Recipient can comply with the disclosure provisions of paragraph (c) of this Patent Rights clause, and to execute all papers necessary to file patent applications on subject inventions and to establish the Government’s rights in the subject inventions. The disclosure format should require, as a minimum, the information requested by paragraph (c)(1) of this Patent Rights clause. The Recipient shall instruct such employees through the employee agreements or other suitable educational programs on the importance of reporting inventions in sufficient time to permit the filing of patent applications prior to U.S. or foreign statutory bars.

(3) The Recipient will notify DOE of any decision not to continue prosecution of a patent application, pay maintenance fees, or defend in a reexamination or opposition proceeding on a patent, in any country, not less than 30 days before the expiration of the response period required by the relevant patent office.

(4) The Recipient agrees to include, within the specification of any U.S. patent application and any patent issuing thereon covering a subject invention, the following statement: “This invention was made with Government support under (identify the award) awarded by (identify DOE). The Government has certain rights in this invention.”

 

160


(g) Subaward/Contract

(1) The Recipient will include this Patent Rights clause, suitably modified to identify the parties, in all subawards/contracts, regardless of tier, for experimental, developmental or research work to be performed by a small business firm or nonprofit organization. The subrecipient/contractor will retain all rights provided for the Recipient in this Patent Rights clause, and the Recipient will not, as part of the consideration for awarding the subcontract, obtain rights in the subcontractors’ subject inventions.

(2) The Recipient will include in all other subawards/contracts, regardless of tier, for experimental, developmental or research work, the patent rights clause required by 10 CFR 600.325(c).

(3) In the case of subawards/contracts at any tier, DOE, the Recipient, and the subrecipient/contractor agree that the mutual obligations of the parties created by this clause constitute a contract between the subrecipient/contractor and DOE with respect to those matters covered by the clause.

(h) Reporting on Utilization of Subject Inventions

The Recipient agrees to submit on request periodic reports no more frequently than annually on the utilization of a subject invention or on efforts at obtaining such utilization that are being made by the Recipient or its licensees or assignees. Such reports shall include information regarding the status of development, date of first commercial sale or use, gross royalties received by the Recipient and such other data and information as DOE may reasonably specify. The Recipient also agrees to provide additional reports in connection with any march-in proceeding undertaken by DOE in accordance with paragraph (j) of this Patent Rights clause. As required by 35 U.S.C. 202(c)(5), DOE agrees it will not disclose such information to persons outside the Government without the permission of the Recipient.

(i) Preference for United States Industry.

Notwithstanding any other provision of this Patent Rights clause, the Recipient agrees that neither it nor any assignee will grant to any person the exclusive right to use or sell any subject invention in the U.S. unless such person agrees that any products embodying the subject invention or produced through the use of the subject invention will be manufactured substantially in the U.S. However, in individual cases, the requirement for such an agreement may be waived by DOE upon a showing by the Recipient or its assignee that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible.

(j) March-in-Rights

The Recipient agrees that with respect to any subject invention in which it has acquired title, DOE has the right in accordance with procedures at 37 CFR 401.6 and any

 

161


supplemental regulations of the Agency to require the Recipient, an assignee or exclusive licensee of a subject invention to grant a non-exclusive, partially exclusive, or exclusive license in any field of use to a responsible applicant or applicants, upon terms that are reasonable under the circumstances and if the Recipient, assignee, or exclusive licensee refuses such a request, DOE has the right to grant such a license itself if DOE determines that:

(1) Such action is necessary because the Recipient or assignee has not taken or is not expected to take within a reasonable time, effective steps to achieve practical application of the subject invention in such field of use;

(2) Such action is necessary to alleviate health or safety needs which are not reasonably satisfied by the Recipient, assignee, or their licensees;

(3) Such action is necessary to meet requirements for public use specified by Federal regulations and such requirements are not reasonably satisfied by the Recipient, assignee, or licensee; or

(4) Such action is necessary because the agreement required by paragraph (i) of this Patent Rights clause has not been obtained or waived or because a licensee of the exclusive right to use or sell any subject invention in the U.S. is in breach of such agreement.

(k) Special Provisions for Awards With Nonprofit Organizations

If the Recipient is a nonprofit organization, it agrees that:

(1) Rights to a subject invention in the U.S. may not be assigned without the approval of DOE, except where such assignment is made to an organization which has as one of its primary functions the management of inventions, provided that such assignee will be subject to the same provisions as the Recipient;

(2) The Recipient will share royalties collected on a subject invention with the inventor, including Federal employee co-inventors (when DOE deems it appropriate) when the subject invention is assigned in accordance with 35 U.S.C. 202(e) and 37 CFR 401.10;

(3) The balance of any royalties or income earned by the Recipient with respect to subject inventions, after payment of expenses (including payments to inventors) incidental to the administration of subject inventions, will be utilized for the support of scientific or engineering research or education; and

(4) It will make efforts that are reasonable under the circumstances to attract licensees of subject inventions that are small business firms and that it will give preference to a small business firm if the Recipient determines that the small business firm has a plan or proposal for marketing the invention which, if executed, is equally likely to bring the invention to practical application as any plans or proposals from applicants that

 

162


are not small business firms; provided that the Recipient is also satisfied that the small business firm has the capability and resources to carry out its plan or proposal. The decision whether to give a preference in any specific case will be at the discretion of the Recipient. However, the Recipient agrees that the Secretary of Commerce may review the Recipient’s licensing program and decisions regarding small business applicants, and the Recipient will negotiate changes to its licensing policies, procedures or practices with the Secretary when the Secretary’s review discloses that the Recipient could take reasonable steps to implement more effectively the requirements of this paragraph (k)(4).

(l) Communications

All communications required by this Patent Rights clause should be sent to the DOE Patent Counsel address listed in the Award Document.

(m) Electronic Filing

Unless otherwise Specified in the award, the information identified in paragraphs (f)(2) and (f)(3) may be electronically filed.

[End of clause]

Patent Rights (Large Business Firms) -- No Waiver

(a) Definitions

DOE patent waiver regulations , as used in this clause, means the Department of Energy patent waiver regulations in effect on the date of award. See 10 CFR part 784.

Invention , as used in this clause, means any invention or discovery which is or may be patentable of otherwise protectable under title 35 of the United States Code or any novel variety of plant that is or may be protectable under the Plant Variety Protection Act (7 U.S.C. 2321, et seq.).

Patent Counsel , as used in this clause, means the Department of Energy Patent Counsel assisting the awarding activity.

Subject invention , as used in this clause, means any invention of the Recipient conceived or first actually reduced to practice in the course of or under this agreement.

(b) Allocations of Principal Rights

(1) Assignment to the Government. The Recipient agrees to assign to the Government the entire right, title, and interest throughout the world in and to each subject invention, except to the extent that rights are retained by the Recipient under subparagraph (b)(2) and paragraph (d) of this clause.

 

163


(2) Greater rights determinations. The Recipient, or an employee-inventor after consultation with the Recipient, may request greater rights than the nonexclusive license an the foreign patent rights provided in paragraph (d) of this clause on identified inventions in accordance with the DOE patent waiver regulation. Each determination of greater rights under this agreement shall be subject to paragraph (c) of this clause, unless otherwise provided in the greater rights determination, and to the reservations and conditions deemed to be appropriate by the Secretary of Energy or designee.

(c) Minimum Rights Acquired by the Government

With respect to each subject invention to which the Department of Energy grants the Recipient principal or exclusive rights, the Recipient agrees to grant to the Government: A nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced each subject invention throughout the world by or on behalf of the Government of the United States (including any Government agency); “march-in rights” as set forth in 37 CFR 401.14(a)(J)); preference for U.S. industry as set forth in 37 CFR 401.14(a)(I); periodic reports upon request, no more frequently than annually, on the utilization or intent of utilization of a subject invention in a manner consistent with 35 U.S.C. 202(c)(50; and such Government rights in any instrument transferring rights in a subject invention.

(d) Minimum Rights to the Recipient

(1) The Recipient is hereby granted a revocable, nonexclusive, royalty-free license in each patent application filed in any country on a subject invention and any resulting patent in which the Government obtains title, unless the Recipient fails to disclose the subject invention within the times specified in subparagraph (e)(2) of this clause. The Recipient’s license extends to its domestic subsidiaries and affiliates, if any, within the corporate structure of which the Recipient is a part and includes the right to grant sublicenses of the same scope to the extent the Recipient was legally obligated to do so at the time the agreement was awarded. The license is transferable only with the approval of DOE except when transferred to the successor of that part of the Recipient’s business to which the invention pertains.

(2) The Recipient may request the right to acquire patent rights to a subject invention in any foreign country where the Government has elected not to secure such rights, subject to the minimum rights acquired by the Government similar to paragraph (c) of this clause. Such request must be made in writhing to the Patent Counsel as part of the disclosure required by subparagraph (e)(2) of this clause, with a copy to the DOE Contracting Officer. DOE approval, if given, will be based on a determination that this would best serve the national interest.

(e) Invention Identification, Disclosures, and Reports

 

164


(1) The Recipient shall establish and maintain active and effective procedures to assure that subject inventions are promptly identified and disclosed to Recipient personnel responsible for patent matters within 6 months of conception and/or first actual reduction to practice, whichever occurs first in the performance of work under this agreement. These procedures shall include the maintenance of laboratory notebooks or equivalent records and other records as are reasonably necessary to document the conception and/or the first actual reduction to practice of subject inventions, and records that show that the procedures for identifying and disclosing the inventions are followed. Upon request, the Recipient shall furnish the Contracting Officer a description of such procedures for evaluation and for determination as to their effectiveness.

(2) The Recipient shall disclose each subject invention to the DOE Patent Counsel with a copy to the Contracting Officer within 2 months after the inventor discloses it in writing to Recipient personnel responsible for patent matters or, if earlier, within 6 months after the Recipient becomes aware that a subject invention has been made, but in any event before any on sale, public use, or publication of such invention known to the Recipient. The disclosure to DOE shall be in the form of a written report and shall identify the agreement under which the invention was made and the inventor(s). It shall be sufficiently complete in technical detail to convey a clear understanding, to the extent known at the time of the disclosure, of the nature, purpose, operation, and physical, chemical, biological, or electrical characteristics of the invention. The disclosure shall also identify any publication, on sale, or public use of the invention and whether a manuscript describing the invention has been submitted for publication and, if so, whether it has been accepted for publication at the time of disclosure. In addition, after disclosure to DOE, the Recipient shall promptly notify Patent Counsel of the acceptance of any manuscript describing the invention for publication or of any on sale or public use planned by the Recipient. The report should also include any request for a greater rights determination in accordance with subparagraph (b)(2) of this clause. When an invention is disclosed to DOE under this paragraph, it shall be deemed to have been made in the manner specified in Sections (a)(1) and (a)(2) of 42 U.S.C. 5908, unless the Recipient contends in writing at the time the invention is disclosed that it was not so made.

(3) The Recipient shall furnish the Contracting Officer a final report, within 3 months after completion of the work listing all subject inventions or containing a statement that there were no such inventions, and listing all subawards/contracts at any tier containing a patent rights clause or containing a statement that there were no such subawards/contracts.

(4) The Recipient agrees to require, by written agreement, its employees, other than clerical and nontechnical employees, to disclose promptly in writing to personnel identified as responsible for the administration of patent matters and in a format suggested by the Recipient each subject invention made under subaward/contract in order that the Recipient can comply with the disclosure provisions of paragraph (c) of this clause, and to execute all papers necessary to file patent applications on subject

 

165


inventions and to establish the Government’s rights in the subject inventions. This disclosure format should require, as a minimum, the information required by subparagraph (e)(2) of this clause.

(5) The Recipient agrees, subject to FAR 27.302(j), that the Government may duplicate and disclose subject invention disclosures and all other reports and papers furnished or required to be furnished pursuant to this clause.

(f) Examination of Records Relating to Inventions

(1) The Contracting Officer or any authorized representative shall, until 3 years after final payment under this agreement, have the right to examine any books (including laboratory notebooks), records, and documents of the Recipient relating to the conception or first actual reduction to practice of inventions in the same field of technology as the work under this agreement to determine whether --

(i) Any such inventions are subject inventions;

(ii) The Recipient has established and maintains the procedures required by subparagraphs (e)(1) and (4) of this clause;

(iii) The Recipient and its inventors have complied with the procedures.

(2) If the Contracting Officer learns of an unreported Recipient invention which the Contracting Officer believes may be a subject invention, the Recipient may be required to disclose the invention to DOE for a determination of ownership rights.

(3) Any examination of records under this paragraph will be subject to appropriate conditions to protect the confidentiality of the information involved.

(g) Subaward/Contract

(1) The recipient shall include the clause PATENT RIGHTS (SMALL BUSINESS FIRMS AND NONPROFIT ORGANIZATIONS) (suitably modified to identify the parties) in all subawards/contracts, regardless of tier, for experimental, developmental, demonstration, or research work to be performed by a small business firm or domestic nonprofit organization, except where the work of the subaward/contract is subject to an Exceptional Circumstances Determination by DOE. In all other subawards/contracts, regardless of tier, for experimental, developmental, demonstration, or research work, the Recipient shall include this clause (suitably modified to identify the parties), or an alternate clause as directed by the contracting officer. The Recipient shall not, as part of the consideration for awarding the subaward/contract, obtain rights in the subrecipient’s/contractor’s subject inventions.

 

166


(2) In the event of a refusal by a prospective subrecipient/contractor to accept such a clause the Recipient:

(i) Shall promptly submit a written notice to the Contracting Officer setting forth the subrecipient/contractor’s reasons for such refusal and other pertinent information that may expedite disposition of the matter; and

(ii) Shall not proceed with such subaward/contract without the written authorization of the Contracting Officer.

(3) In the case of subawards/contracts at any tier, DOE, the subrecipient/contractor, and Recipient agree that the mutual obligations of the parties created by this clause constitute a contract between the subrecipient/contractor and DOE with respect to those matters covered by this clause.

(4) The Recipient shall promptly notify the Contracting Officer in writing upon the award of any subaward/contract at any tier containing a patent rights clause by identifying the subrecipient/contractor, the applicable patent rights clause, the work to be performed under the subaward/contract, and the dates of award and estimated completion. Upon request of the Contracting Officer, the Recipient shall furnish a copy of such subaward/contract, and, no more frequently than annually, a listing of the subawards/contracts that have been awarded.

(5) The Recipient shall identify all subject inventions of a subrecipient/contractor of which it acquires knowledge in the performance of this agreement and shall notify the Patent Counsel, with a copy to the contracting officer, promptly upon identification of the inventions.

(h) Atomic Energy

(1) No claim for pecuniary award of compensation under the provisions of the Atomic Energy Act of 1954, as amended, shall be asserted with respect to any invention or discovery made or conceived in the course of or under this agreement.

(2) Except as otherwise authorized in writing by the Contracting Officer, the Recipient will obtain patent agreements to effectuate the provisions of subparagraph (h)(1) of this clause from all persons who perform any part of the work under this agreement, except nontechnical personnel, such as clerical employees and manual laborers.

(i) Publication

It is recognized that during the course of the work under this agreement, the Recipient or its employees may from time to time desire to release or publish information regarding scientific or technical developments conceived or first actually reduced to practice in the course of or under this agreement. In order that public disclosure of such information will not adversely affect the patent interests of DOE or the Recipient, patent approval for

 

167


release of publication shall be secured from Patent Counsel prior to any such release or publication.

(j) Forfeiture of Rights in Unreported Subject Inventions

(1) The Recipient shall forfeit and assign to the Government, at the request of the Secretary of Energy or designee, all rights in any subject invention which the Recipient fails to report to Patent Counsel within six months after the time the Recipient:

(i) Files or causes to be filed a United States or foreign patent application thereon; or

(ii) Submits the final report required by subparagraph (e)(3) of this clause, whichever is later.

(2) However, the Recipient shall not forfeit rights in a subject invention if, within the time specified in subparagraph (e)(2) of this clause, the Recipient:

(i) Prepares a written decision based upon a review of the record that the invention was neither conceived nor first actually reduced to practice in the course of or under the agreement and delivers the decision to Patent Counsel, with a copy to the Contracting Officer, or

(ii) Contending that the invention is not a subject invention, the Recipient nevertheless discloses the invention and all facts pertinent to this contention to the Patent Counsel, with a copy of the Contracting Officer; or

(iii) Establishes that the failure to disclose did not result from the Recipient’s fault or negligence.

(3) Pending written assignment of the patent application and patents on a subject invention determined by the Secretary of Energy or designee to be forfeited (such determination to be a final decision under the Disputes clause of this agreement), the Recipient shall be deemed to hold the invention and the patent applications and patents pertaining thereto in trust for the Government. The forfeiture provision of this paragraph (j) shall be in addition to and shall not supersede other rights and remedies which the Government may have with respect to subject inventions.

(End of clause)

Rights in Data -- General

(a) Definitions

 

168


Computer Data Bases , as used in this clause, means a collection of data in a form capable of, and for the purpose of, being stored in, processed, and operated on by a computer. The term does not include computer software.

Computer software , as used in this clause, means (i) computer programs which are data comprising a series of instructions, rules, routines or statements, regardless of the media in which recorded, that allow or cause a computer to perform a specific operation or series of operations and (ii) data comprising source code listings, design details, algorithms, processes, flow charts, formulae, and related material that would enable the computer program to be produced, created or compiled. The term does not include computer data bases.

Data , as used in this clause, means recorded information, regardless of form or the media on which it may be recorded. The term includes technical data and computer software. The term does not include information incidental to administration, such as financial, administrative, cost or pricing, or management information.

Form, fit, and function data , as used in this clause, means data relating to items, components, or processes that are sufficient to enable physical and functional interchangeability, as well as data identifying source, size, configuration, mating, and attachment characteristics, functional characteristics, and performance requirements; except that for computer software it means data identifying source, functional characteristics, and performance requirements but specifically excludes the source code, algorithm, process, formulae, and flow charts of the software.

Limited rights , as used in this clause, means the rights of the Government in limited rights data as set forth in the Limited Rights Notice of subparagraph (g)(2) if included in this clause.

Limited rights data , as used in this clause, means data (other than computer software) developed at private expense that embody trade secrets or are commercial or financial and confidential or privileged.

Restricted computer software , as used in this clause, means computer software developed at private expense and that is a trade secret; is commercial or financial and is confidential or privileged; or is published copyrighted computer software; including minor modifications of such computer software.

Restricted rights , as used in this clause, means the rights of the Government in restricted computer software, as set forth in a Restricted Rights Notice of subparagraph (g)(3) if included in this clause, or as otherwise may be provided in a collateral agreement incorporated in and made part of this contract, including minor modifications of such computer software.

 

169


Technical data , as used in this clause, means data (other than computer software) which are of a scientific or technical nature. Technical data does not include computer software, but does include manuals and instructional materials and technical data formatted as a computer data base.

Unlimited rights , as used in this clause, means the right of the Government to use, disclose, reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, in any manner and for any purpose, and to have or permit others to do so.

(b) Allocations of Rights

(1) Except as provided in paragraph (c) of this clause regarding copyright, the Government shall have unlimited rights in --

(i) Data first produced in the performance of this agreement;

(ii) Form, fit, and function data delivered under this agreement;

(iii) Data delivered under this agreement (except for restricted computer software) that constitute manuals or instructional and training material for installation, operation, or routine maintenance and repair of items, components, or processes delivered or furnished for use under this agreement; and

(iv) All other data delivered under this agreement unless provided otherwise for limited rights data or restricted computer software in accordance with paragraph (g) of this clause.

(2) The Recipient shall have the right to --

(i) Use, release to others, reproduce, distribute, or publish any data first produced or specifically used by the Recipient in the performance of this agreement, unless provided otherwise in paragraph (d) of this clause;

(ii) Protect from unauthorized disclosure and use those data which are limited rights data or restricted computer software to the extent provided in paragraph (g) of this clause;

(iii) Substantiate use of, add or correct limited rights, restricted rights, or copyright notices and to take over appropriate action, in accordance with paragraphs (e) and (f) of this clause; and

(iv) Establish claim to copyright subsisting in data first produced in the performance of this agreement to the extent provided in subparagraph (c)(1) of this clause.

 

170


(c) Copyright

(1) Data first produced in the performance of this agreement. Unless provided otherwise in paragraph (d) of this clause, the Recipient may establish, without prior approval of the Contracting Officer, claim to copyright subsisting in data first produced in the performance of this agreement. When claim to copyright is made, the Recipient shall affix the applicable copyright notices of 17 U.S.C. 401 or 402 and acknowledgement of Government sponsorship (including agreement number) to the data when such data are delivered to the Government, as well as when the data are published or deposited for registration as a published work in the U.S. Copyright Office. For such copyrighted data, including computer software, the Recipient grants to the Government, and others acting on its behalf, a paid-up nonexclusive, irrevocable worldwide license in such copyrighted data to reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, by or on behalf of the Government.

(2) Data not first produced in the performance of this agreement. The Recipient shall not, without prior written permission of the Contracting Officer, incorporate in data delivered under this agreement any data not first produced in the performance of this agreement and which contains the copyright notice of 17 U.S.C. 401 or 402, unless the Recipient identifies such data and grants to the Government, or acquires on its behalf, a license of the same scope as set forth in subparagraph (c)(1) of this clause; provided, however, that if such data are computer software the Government shall acquire a copyright license as set forth in subparagraph (g)(3) of this clause if included in this agreement or as otherwise may be provided in a collateral agreement incorporated in or made part of this agreement.

(3) Removal of copyright notices. The Government agrees not to remove any copyright notices placed on data pursuant to this paragraph (c), and to include such notices on all reproductions of the data.

(d) Release, Publication and Use of Data

(1) The Recipient shall have the right to use, release to others, reproduce, distribute, or publish any data first produced or specifically used by the Recipient in the performance of this agreement, except to the extent such data may be subject to the Federal export control or national security laws or regulations, or unless otherwise provided in this paragraph of this clause or expressly set forth in this agreement.

(2) The Recipient agrees that to the extent it receives or is given access to data necessary for the performance of this award, which contain restrictive markings, the Recipient shall treat the data in accordance with such markings unless otherwise specifically authorized in writing by the contracting officer.

(e) Unauthorized Marking of Data

 

171


(1) Notwithstanding any other provisions of this agreement concerning inspection or acceptance, if any data delivered under this agreement are marked with the notices specified in subparagraph (g)(2) or (g)(3) of this clause and use of such is not authorized by this clause, or if such data bears any other restrictive or limiting markings not authorized by this agreement, the Contracting Officer may at any time either return the data to the Recipient or cancel or ignore the markings. However, the following procedures shall apply prior to canceling or ignoring the markings.

(i) The Contracting Officer shall make written inquiry to the Recipient affording the Recipient 30 days from receipt of the inquiry to provide written justification to substantiate the propriety of the markings;

(ii) If the Recipient fails to respond or fails to provide written justification to substantiate the propriety of the markings within the 30-day period (or a longer time not exceeding 90 days approved in writing by the Contracting Officer for good cause shown), the Government shall have the right to cancel or ignore the markings at any time after said period and the data will no longer be made subject to any disclosure prohibitions.

(iii) If the Recipient provides written justification to substantiate the propriety of the markings within the period set in subparagraph (e)(1)(i) of this clause, the Contracting Officer shall consider such written justification and determine whether or not the markings are to be cancelled or ignored. If the Contracting Officer determines that the markings are authorized, the Recipient shall be so notified in writing. If the Contracting Officer determines, with concurrence of the head of the contracting activity, that the markings are not authorized, the Contracting Officer shall furnish the Recipient a written determination, which determination shall become the final agency decision regarding the appropriateness of the markings unless the Recipient files suit in a court of competent jurisdiction within 90 days of receipt of the Contracting Officer’s decision. The Government shall continue to abide by the markings under this subparagraph (e)(1)(iii) until final resolution of the matter either by the Contracting Officer’s determination becoming final (in which instance the Government shall thereafter have the right to cancel or ignore the markings at any time and the data will no longer be made subject to any disclosure prohibitions), or by final disposition of the matter by court decision if suit is filed.

(2) The time limits in the procedures set forth in subparagraph (e)(1) of this clause may be modified in accordance with agency regulations implementing the Freedom of Information Act (5 U.S.C. 552) if necessary to respond to a request thereunder.

(f) Omitted or Incorrect Markings

(1) Data delivered to the Government without either the limited rights or restricted rights notice as authorized by paragraph (g) of this clause, or the copyright notice required by paragraph (c) of this clause, shall be deemed to have been furnished with

 

172


unlimited rights, and the Government assumes no liability for the disclosure, use, or reproduction of such data. However, to the extent the data has not been disclosed without restriction outside the Government, the Recipient may request, within 6 months (or a longer time approved by the Contracting Officer for good cause shown) after delivery or such data, permission to have notices placed on qualifying data at the Recipient’s expense, and the Contracting Officer may agree to do so if the Recipient:

(i) Identifies the data to which the omitted notice is to be applied;

(ii) Demonstrates that the omission of the notice was inadvertent;

(iii) Establishes that the use of the proposed notice is authorized; and

(iv) Acknowledges that the Government has no liability with respect to the disclosure, use, or reproduction of any such data made prior to the addition of the notice or resulting from the omission of the notice.

(2) The Contracting Officer may also:

(i) Permit correction at the Recipient’s expense of incorrect notices if the Recipient identifies the data on which correction of the notice is to be made, and demonstrates that the correct notice is authorized, or

(ii) Correct any incorrect notices.

(g) Protection of Limited Rights Data and Restricted Computer Software

When data other than that listed in subparagraphs (b)(1)(i), (ii), and (iii) of this clause are specified to be delivered under this agreement and qualify as either limited rights data or restricted computer software, if the Recipient desires to continue protection of such data, the Recipient shall withhold such data and not furnish them to the Government under this agreement. As a condition to this withholding, the Recipient shall identify the data being withheld and furnish form, fit, and function data in lieu thereof. Limited rights data that are formatted as a computer data base for delivery to the Government are to be treated as limited rights data and not restricted computer software.

(h) Subaward/Contract

The Recipient has the responsibility to obtain from its subrecipients/contractors all data and rights therein necessary to fulfill the Recipient’s obligations to the Government under this agreement. If a subrecipient/contractor refuses to accept terms affording the Government such rights, the Recipient shall promptly bring such refusal to the attention of the Contracting Officer and not proceed with the subaward/contract award without further authorization.

(i) Additional Data Requirements

In addition to the data specified elsewhere in this agreement to be delivered, the Contracting Officer may, at anytime during agreement performance or within a period of

 

173


3 years after acceptance of all items to be delivered under this agreement, order any data first produced or specifically used in the performance of this agreement. This clause is applicable to all data ordered under this subparagraph. Nothing contained in this subparagraph shall require the Recipient to deliver any data the withholding of which is authorized by this clause, or data which are specifically identified in this agreement as not subject to this clause. When data are to be delivered under this subparagraph, the Recipient will be compensated for converting the data into the prescribed form, for reproduction, and for delivery.

(j) The recipient agrees, except as may be otherwise specified in this award for specific data items listed as not subject to this paragraph, that the Contracting Officer or an authorized representative may, up to three years after acceptance of all items to be delivered under this award, inspect at the Recipient’s facility any data withheld pursuant to paragraph (g) of this clause, for purposes of verifying the Recipient’s assertion pertaining to the limited rights or restricted rights status of the data or for evaluating work performance. Where the Recipient whose data are to be inspected demonstrates to the Contracting Officer that there would be a possible conflict of interest if the inspection were made by a particular representative, the Contracting Officer shall designate an alternate inspector.

As prescribed in 600.325(d)(1), the following Alternate I and/or II may be inserted in the clause in the award instrument.

Alternate I:

(g)(2) Notwithstanding subparagraph (g)(1) of this clause, the agreement may identify and specify the delivery of limited rights data, or the Contracting Officer may require by written request the delivery of limited rights data that has been withheld or would otherwise be withholdable. If delivery of such data is so required, the Recipient may affix the following “Limited Rights Notice” to the data and the Government will thereafter treat the data, in accordance with such Notice:

LIMITED RIGHTS NOTICE

(a) These data are submitted with limited rights under Government agreement No.      (and subaward/contract No.     , if appropriate). These data may be reproduced and used by the Government with the express limitation that they will not, without written permission of the Recipient, be used for purposes of manufacture nor disclosed outside the Government; except that the Government may disclose these data outside the Government for the following purposes, if any, provided that the Government makes such disclosure subject to prohibition against further use and disclosure:

(1) Use (except for manufacture) by Federal support services contractors within the scope of their contracts;

 

174


(2) This “limited rights data” may be disclosed for evaluation purposes under the restriction that the “limited rights data” be retained in confidence and not be further disclosed;

(3) This “limited rights data” may be disclosed to other contractors participating in the Government’s program of which this Recipient is a part for information or use (except for manufacture) in connection with the work performed under their awards and under the restriction that the “limited rights data” be retained in confidence and not be further disclosed;

(4) This “limited rights data” may be used by the Government or others on its behalf for emergency repair or overhaul work under the restriction that the “limited rights data” be retained in confidence and not be further disclosed; and

(5) Release to a foreign government, or instrumentality thereof, as the interests of the United States Government may require, for information or evaluation, or for emergency repair or overhaul work by such government. This Notice shall be marked on any reproduction of this data in whole or in part.

(b) This Notice shall be marked on any reproduction of these data, in whole or in part.

(End of notice)

Alternate II:

(g)(3)(i) Notwithstanding subparagraph (g)(1) of this clause, the agreement may identify and specify the delivery of restricted computer software, or the Contracting Officer may require by written request the delivery of restricted computer software that has been withheld or would otherwise be withholdable. If delivery of such computer software is so required, the Recipient may affix the following “Restricted Rights Notice” to the computer software and the Government will thereafter treat the computer software, subject to paragraphs (e) and (f) of this clause, in accordance with the Notice.

RESTRICTED RIGHTS NOTICE

(a) This computer software is submitted with restricted rights under Government Agreement No.      (and subaward/contract     , if appropriate). It may not be used, reproduced, or disclosed by the Government except as provided in paragraph (b) of this Notice or as otherwise expressly stated in the agreement.

(b) This computer software may be --

(1) Used or copies for use in or with the computer or computers for which it was acquired, including use at any Government installation to which such computer or computers may be transferred;

 

175


(2) Used or copied for use in a backup computer if any computer for which it was acquired is inoperative;

(3) Reproduced for safekeeping (archiv3es) or backup purposes;

(4) Modified, adapted, or combined with other computer software, provided that the modified, combined, or adapted portions of the derivative software are made subject to the same restricted rights;

(5) Disclosed to and reproduced for use by support service Recipients in accordance with subparagraph (b)(1) through (4) of this clause, provided the Government makes such disclosure or reproduction subject to these restricted rights; and

(6) Used or copied for use in or transferred to a replacement computer.

(c) Notwithstanding the foregoing, if this computer software is published copyrighted computer software, it is licensed to the Government, without disclosure prohibitions, with the minimum rights set forth in paragraph (b) of this clause.

(d) Any other rights or limitations regarding the use, duplication, or disclosure of this computer software are to be expressly stated, in, or incorporated in, the agreement.

(e) This Notice shall be marked on any reproduction of this computer software, in whole or in part.

(End of notice)

(ii) Where it is impractical to include the Restricted Rights Notice on restricted computer software, the following short-form Notice may be used in lieu thereof:

RESTRICTED RIGHTS NOTICE

Use, reproduction, or disclosure is subject to restrictions set forth in agreement No.      (and subaward/contract     , If appropriate) with      (name of Recipient and subrecipient/contractor).

(End of notice)

(iii) If restricted computer software is delivered with the copyright notice of 17 U.S.C. 401, it will be presumed to be published copyrighted computer software licensed to the government without disclosure prohibitions, with the minimum rights set forth in paragraph (b) of this clause, unless the Recipient includes the following statement with such copyright notice: ‘Unpublished -- rights reserved under the Copyright Laws of the United States.”

 

176


(End of clause)

Rights in Data -- Programs Covered Under Special Data Statutes

(a) Definitions

Computer Data Bases , as used in this clause, means a collection of data in a form capable of, and for the purpose of, being stored in, processed, and operated on by a computer. The term does not include computer software.

Computer software , as used in this clause, means (i) computer programs which are data comprising a series of instructions, rules, routines, or statements, regardless of the media in which recorded, that allow or cause a computer to perform a specific operation or series of operations and (ii) data comprising source code listings, design details, algorithms, processes, flow charts, formulae and related material that would enable the computer program to be produced, created or compiled. The term does not include computer data bases.

Data , as used in this clause, means recorded information, regardless of form or the media on which it may be recorded. The term includes technical data and computer software. The term does not include information incidental to administration, such as financial, administrative, cost or pricing or management information.

Form, fit, and function data , as used in this clause, means data relating to items, components, or processes that are sufficient to enable physical and functional interchangeability as well as data identifying source, size, configuration, mating and attachment characteristics, functional characteristics, and performance requirements except that for computer software it means data identifying source, functional characteristics, and performance requirements but specifically excludes the source code, algorithm, process, formulae, and flow charts of the software.

Limited rights data , as used in this clause, means data (other than computer software) developed at private expense that embody trade secrets or are commercial or financial and confidential or privileged.

Restricted computer software , as used in this clause, means computer software developed at private expense and that is a trade secret; is commercial or financial and confidential or privileged; or is published copyrighted computer software; including modifications of such computer software.

Protected data , as used in this clause, means technical data or commercial or financial data first produced in the performance of the award which, if it had been obtained from and first produced by a non-federal party, would be a trade secret or commercial or

 

177


financial information that is privileged or confidential under the meaning of 5 U.S.C. 552(b)(4) and which data is marked as being protected data by a party to the award.

Protected rights , as used in this clause, mean the rights in protected data set forth in the Protected Rights Notice of paragraph (g) of this clause.

Technical data , as used in this clause, means that data which are of a scientific or technical nature. Technical data does not include computer software, but does include manuals and instructional materials and technical data formatted as a computer data base.

Unlimited rights , as used in this clause, means the right of the Government to use, disclose, reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, in any manner and for any purpose whatsoever, and to have or permit others to do so.

(b) Allocation of Rights

(1) Except as provided in paragraph (c) of this clause regarding copyright, the Government shall have unlimited rights in --

(i) Data specifically identified in this agreement as data to be delivered without restriction;

(ii) Form, fit, and function data delivered under this agreement;

(iii) Data delivered under this agreement (except for restricted computer software) that constitute manuals or instructional and training material for installation, operation, or routine maintenance and repair of items, components, or processes delivered or furnished for use under this agreement; and

(iv) All other data delivered under this agreement unless provided otherwise for protected data in accordance with paragraph (g) of this clause or for limited rights data or restricted computer software in accordance with paragraph (h) of this clause.

(2) The Recipient shall have the right to --

(i) Protect rights in protected data delivered under this agreement in the manner and to the extent provided in paragraph (g) of this clause;

(ii) Withhold from delivery those data which are limited rights data or restricted computer software to the extent provided in paragraph (h) of this clause;

(iii) Substantiate use of, add, or correct protected rights or copyrights notices and to take other appropriate action, in accordance with paragraph (e) of this clause; and

 

178


(iv) Establish claim to copyright subsisting in data first produced in the performance of this agreement to the extent provided in subparagraph (c)(1) of this clause.

(c) Copyright

(1) Data first produced in the performance of this agreement. Except as otherwise specifically provided in this agreement, the Recipient may establish, without the prior approval of the Contracting Officer, claim to copyright subsisting in any data first produced in the performance of this agreement. If claim to copyright is made, the Recipient shall affix the applicable copyright notice of 17 U.S.C. 401 or 402 and acknowledgment of Government sponsorship (including agreement number) to the data when such data are delivered to the Government, as well as when the data are published or deposited for registration as a published work in the U.S. Copyright Office. For such copyrighted data, including computer software, the Recipient grants to the Government, and others acting on its behalf, a paid-up nonexclusive, irrevocable, worldwide license to reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, by or on behalf of the Government, for all such data.

(2) Data not first produced in the performance of this agreement. The Recipient shall not, without prior written permission of the Contracting Officer, incorporate in data delivered under this agreement any data that are not first produced in the performance of this agreement and that contain the copyright notice of 17 U.S.C. 401 or 402, unless the Recipient identifies such data and grants to the Government, or acquires on its behalf, a license of the same scope as set forth in subparagraph (c)(1) of this clause; provided, however, that if such data are computer software, the Government shall acquire a copyright license as set forth in subparagraph (h)(3) of this clause if included in this agreement or as otherwise may be provided in a collateral agreement incorporated or made a part of this agreement.

(3) Removal of copyright notices. The Government agrees not to remove any copyright notices placed on data pursuant to this paragraph (c), and to include such notices on all reproductions of the data.

(d) Release, Publication and Use of Data

(1) The Receipt shall have the right to use, release to others, reproduce, distribute, or publish any data first produced or specifically used by the Recipient in the performance of this contract, except to the extent such data may be subject to the Federal export control or national security laws or regulations, or unless otherwise provided in this paragraph of this clause or expressly set forth in this contract.

(2) The Recipient agrees that to the extent it receives or is given access to data necessary for the performance of this agreement which contain restrictive markings,

 

179


the Recipient shall treat the data in accordance with such markings unless otherwise specifically authorized in writing by the Contracting Officer.

(e) Unauthorized Marking of Data

(1) Notwithstanding any other provisions of this agreement concerning inspection or acceptance, if any data delivered under this agreement are marked with the notices specified in subparagraph (g)(2) or (g)(3) of this clause and use of such is not authorized by this clause, or if such data bears any other restrictive or limiting markings not authorized by this agreement, the Contracting Officer may at any time either return the data to the Recipient or cancel or ignore the markings. However, the following procedures shall apply prior to canceling or ignoring the markings.

(i) The Contracting Officer shall make written inquiry to the Recipient affording the Recipient 30 days from receipt of the inquiry to provide written justification to substantiate the propriety of the markings;

(ii) If the Recipient fails to respond or fails to provide written justification to substantiate the propriety of the markings within the 30-day period (or a longer time not exceeding 90 days approved in writing by the Contracting Officer for good cause shown), the Government shall have the right to cancel or ignore the markings at any time after said period and the data will no longer be made subject to any disclosure prohibitions.

(iii) If the Recipient provides written justification to substantiate the propriety of the markings within the period set in subdivision (e)(1)(i) of this clause, the Contracting Officer shall consider such written justification and determine whether or not the markings are to be cancelled or ignored. If the Contracting Officer determines that the markings are authorized, the Recipient shall be so notified in writing. If the Contracting Officer determines, with concurrence of the head of the contracting activity, that the markings are not authorized, the Contracting Officer shall furnish the Recipient a written determination, which determination shall become the final agency decision regarding the appropriateness of the markings unless the Recipient files suit in a court of competent jurisdiction within 90 days of receipt of the Contracting Officer’s decision. The Government shall continue to abide by the markings under this subdivision (e)(1)(iii) until final resolution of the matter either by the Contracting Officer’s determination become final (in which instance the Government shall thereafter have the right to cancel or ignore the markings at any time and the data will no longer be made subject to any disclosure prohibitions), or by final disposition of the matter by court decision if suit is filed.

(2) The time limits in the procedures set forth in subparagraph (e)(1) of this clause may be modified in accordance with agency regulations implementing the Freedom of Information Act (5 U.S.C. 552) if necessary to respond to a request thereunder.

 

180


(f) Omitted or Incorrect Markings

(1) Data delivered to the Government without either the limited rights or restricted rights notice as authorized by paragraph ( g) of this clause, or the copyright notice required by paragraph (c) of this clause, shall be deemed to have been furnished with unlimited rights, and the Government assumes no liability for the disclosure, use, or reproduction of such data. However, to the extent the data has not been disclosed without restriction outside the Government, the Recipient may request, within 6 months (or a longer time approved by the Contracting Officer for good cause shown) after delivery of such data, permission to have notices placed on qualifying data at the Recipient’s expense, and the Contracting Officer may agree to do so if the Recipient -

(i) Identifies the data to which the omitted notice is to be applied;

(ii) Demonstrates that the omission of the notice was inadvertent;

(iii) Establishes that the use of the proposed notice is authorized; and

(iv) Acknowledges that the Government has no liability with respect to the disclosure, use, or reproduction of any such data made prior to the addition of the notice or resulting from the omission of the notice.

(2) The Contracting Officer may also:

(i) Permit correction at the Recipient’s expense of incorrect notices if the Recipient identifies the data on which correction of the notice is to be made, and demonstrates that the correct notice is authorized; or

(ii) Correct any incorrect notices.

(g) Rights to Protected Data

(1) The Recipient may, with the concurrence of DOE, claim and mark as protected data, any data first produced in the performance of this award that would have been treated as a trade secret if developed at private expense. Any such claimed “protected data” will be clearly marked with the following Protected Rights Notice, and will be treated in accordance with such Notice, subject to the provisions of paragraphs (e) and (f) of this clause.

PROTECTED RIGHTS NOTICE

These protected data were produced under agreement no.      with the U.S. Department of Energy and may not be published, disseminated, or disclosed to others outside the Government until ( Note:) The period of protection of such data is fully negotiable, but cannot exceed the applicable statutorily authorized maximum), unless express written authorization is obtained from the recipient. Upon expiration of the

 

181


period of protection set forth in this Notice, the Government shall have unlimited rights in this data. This Notice shall be marked on any reproduction of this data, in whole or in part.

(End of notice).

(2) Any such marked Protected Data may be disclosed under obligations of confidentiality for the following purposes:

(a) For evaluation purposes under the restriction that the “Protected Data” be retained in confidence and not be further disclosed; or

(b) To subcontractors or other team members performing work under the Government’s (insert name of program or other applicable activity) program of which this award is a part, for information or use in connection with the work performed under their activity, and under the restriction that the Protected Data be retained in confidence and not be further disclosed.

(3) The obligations of confidentiality and restrictions on publication and dissemination shall end for any Protected Data.

(a) At the end of the protected period;

(b) If the data becomes publicly known or available from other sources without a breach of the obligation of confidentiality with respect to the Protected Data;

(c) If the same data is independently developed by someone who did not have access to the Protected Data and such data is made available without obligations of confidentiality; or

(d) If the Recipient disseminates or authorizes another to disseminate such data without obligations of confidentiality.

(4) However, the Recipient agrees that the following types of data are not considered to be protected and shall be provided to the Government when required by this award without any claim that the data are Protected Data. The parties agree that notwithstanding the following lists of types of data, nothing precludes the Government from seeking delivery of additional data in accordance with this award, or from making publicly available additional non-protected data, nor does the following list constitute any admission by the Government that technical data not on the list is Protected Data. ( Note: It is expected that this paragraph will specify certain types of mutually agreed upon data that will be available to the public and will not be asserted by the recipient/contractor as limited rights or protected data).

(5) The Government’s sole obligation with respect to any protected data shall be as set forth in this paragraph (g).

 

182


(h) Protection of Limited Rights Data

When data other than that listed in subparagraphs (b)(1)(i), (ii), and (iii) of this clause are specified to be delivered under this agreement and such data qualify as either limited rights data or restricted computer software, the Recipient, if the Recipient desires to continue protection of such data, shall withhold such data and not furnish them to the Government under this agreement. As a condition to this withholding the Recipient shall identify the data being withheld and furnish form, fit, and function data in lieu thereof.

(i) Subaward/Contract

The Recipient has the responsibility to obtain from its subrecipients/contractors all data and rights therein necessary to fulfill the Recipient’s obligations to the Government under this agreement. If a subrecipient/contractor refuses to accept terms affording the Government such rights, the Recipient shall promptly bring such refusal to the attention of the Contracting Officer and not proceed with subaward/contract award without further authorization.

(j) Additional Data Requirements

In addition to the data specified elsewhere in this agreement to be delivered, the Contracting Officer may, at anytime during agreement performance or within a period of 3 years after acceptance of all items to be delivered under this agreement, order any data first produced or specifically used in the performance of this agreement. This clause is applicable to all data ordered under this subparagraph. Nothing contained in this subparagraph shall require the Recipient to deliver any data the withholding of which is authorized by this clause or data which are specifically identified in this agreement as not subject to this clause. When data are to be delivered under this subparagraph, the Recipient will be compensated for converting the data into the prescribed form, for reproduction, and for delivery.

(k) The Recipient agrees, except as may be otherwise specified in this agreement for specific data items listed as not subject to this paragraph, that the Contracting Officer or an authorized representative may, up to three years after acceptance of all items to be delivered under this contract, inspect at the Recipient’s facility any data withheld pursuant to paragraph (h) of this clause, for purposes of verifying the Recipient’s assertion pertaining to the limited rights or restricted rights status of the data or for evaluating work performance. Where the Recipient whose data are to be inspected demonstrates to the Contracting Officer that there would be a possible conflict of interest if the inspection were made by a particular representative, the Contracting Officer shall designate an alternate inspector.

As prescribed in 600.325(e)(2), the following Alternate I and/or II may be inserted in the clause in the award instrument.

Alternate I:

 

183


(h)(2) Notwithstanding subparagraph (h)(1) of this clause, the agreement may identify and specify the delivery of limited rights data, or the Contracting Officer may require by written request the delivery of limited rights data that has been withheld or would otherwise be withholdable. If delivery of such data is so required, the Recipient may affix the following “Limited Rights Notice” to the data and the Government will thereafter treat the data, in accordance with such Notice:

LIMITED RIGHTS NOTICE

(a) These data are submitted with limited rights under Government agreement No.      (and subaward/contract No.     , if appropriate). These data may be reproduced and used by the Government with the express limitation that they will not, without written permission of the Recipient, be used for purposes of manufacture nor disclosed outside the Government; except that the Government may disclose these data outside the Government for the following purposes, if any, provided that the Government makes such disclosure subject to prohibition against further use and disclosure:

(1) Use (except for manufacture) by Federal support services contractors within the scope of their contracts;

(2) This “limited rights data” may be disclosed for evaluation purposes under the restriction that the “limited rights data” be retained in confidence and not be further disclosed;

(3) This “limited rights data” may be disclosed to other contractors participating in the Government’s program of which this Recipient is a part for information or use (except for manufacture) in connection with the work performed under their awards and under the restriction that the “limited rights data” be retained in confidence and not be further disclosed;

(4) This “limited rights data” may be used by the Government or others on its behalf for emergency repair or overhaul work under the restriction that the “limited rights data” be retained in confidence and not be further disclosed; and

(5) Release to a foreign government, or instrumentality thereof, as the interests of the United States Government may require, for information or evaluation, or for emergency repair or overhaul work by such government. This Notice shall be marked on any reproduction of this data in whole or in part.

(b) This Notice shall be marked on any reproduction of these data, in whole or in part.

(End of notice)

Alternate II:

 

184


(h)(3)(i) Notwithstanding subparagraph (h)(1) of this clause, the agreement may identify and specify the delivery of restricted computer software, or the Contracting Officer may require by written request the delivery of restricted computer software that has been withheld or would otherwise be withholdable. If delivery of such computer software is so required, the Recipient may affix the following “Restricted Rights Notice” to the computer software and the Government will thereafter treat the computer software, subject to paragraphs (d) and (e) of this clause, in accordance with the Notice:

RESTRICTED RIGHTS NOTICE

(a) This computer software is submitted with restricted rights under Government Agreement No.      (and subaward/contract     , if appropriate). It may not be used, reproduced, or disclosed by the Government except as provided in paragraph (c) of this Notice or as otherwise expressly stated in the agreement.

(b) This computer software may be --

(1) Used or copied for use in or with the computer or computers for which it was acquired, including use at any Government installation to which such computer or computers may be transferred;

(2) Used or copies for use in a backup computer if any computer for which it was acquired is inoperative;

(3) Reproduced for safekeeping (archives) or backup purposes;

(4) Modified, adapted, or combined with other computer software, provided that the modified, combined, or adapted portions of the derivative software are made subject to the same restricted rights;

(5) Disclosed to and reproduced for use by Federal support service Contractors in accordance with subparagraphs (b)(1) through (4) of this clause, provided the Government makes such disclosure or reproduction subject to these restricted rights; and

(6) Used or copies for use in or transferred to a replacement computer.

(c) Notwithstanding the foregoing, if this computer software is published copyrighted computer software, it is licensed to the Government, without disclosure prohibitions, with the minimum rights set forth in paragraph (b) of this clause.

(d) Any other rights or limitations regarding the use, duplication, or disclosure of this computer software are to be expressly stated in, or incorporated in, the agreement.

(e) This Notice shall be marked on any reproduction of this computer software, in whole or in part.

 

185


(End of notice)

(ii) Where it is impractical to include the Restricted Rights Notice on restricted computer software, the following short-form Notice may be used in lieu thereof:

RESTRICTED RIGHTS NOTICE

Use, reproduction, or disclosure is subject to restrictions set forth in Agreement No.      (and subaward/contract     , if appropriate) with      (name of Recipient and subrecipient/contractor).

(End of notice)

(iii) If restricted computer software is delivered with the copyright notice of 17 U.S.C. 401, it will be presumed to be published copyrighted computer software licensed to the Government without disclosure prohibitions, with the minimum rights set forth in paragraph (b) of this clause, unless the Recipient includes the following statement with such copyright notice: “Unpublished -- rights reserved under the Copyright Laws of the United States.”

(End of clause)

APPENDIX B TO SUBPART D TO PART 600 -- CONTRACT PROVISIONS

All contracts awarded by a recipient, including those for amounts less than the simplified acquisition threshold, must contain the following provisions as applicable:

1. Equal Employment Opportunity -- All contracts must contain a provision requiring compliance with E.O. 11246 (3 CFR, 1964-1965 Comp., p. 339), “Equal Employment Opportunity,” as amended by E.O. 11375 (3 CFR, 1966-1970 Comp., p. 684), “Amending Executive Order 11246 Relating to Equal Employment Opportunity,” and as supplemented by regulations at 41 CFR chapter 60, “Office of Federal Contract Compliance Programs, Equal Employment Opportunity, Department of Labor.”

2. Copeland “Anti-Kickback” Act (18 U.S.C. 874 and 40 U.S.C. 276c) -- All contracts and subawards in excess of $2,000 for construction or repair awarded by recipients and subrecipients must include a provision for compliance with the Copeland “Anti-Kickback” Act (18 U.S.C. 874), as supplemented by Department of Labor regulations (29 CFR part 3, “Contractors and Subcontractors on Public Building or Public Work Financed in Whole or in Part by Loans or Grants from the United States”). The Act provides that each contractor or subrecipient must be prohibited from inducing, by any means, any person employed in the construction, completion, or repair of public work, to

 

186


give up any part of the compensation to which he is otherwise entitled. The recipient must report all suspected or reported violations to the responsible DOE contracting officer.

3. Contact Work Hours and Safety Standards Act (40 U.S.C. 327-333) -- Where applicable, all contracts awarded by recipients in excess of $100,000 for construction and other purposes that involve the employment of mechanics or laborers must include a provision for compliance with Sections 102 and 107 of the Contract Work Hours and Safety Standards Act (40 U.S.C. 327-333), as supplemented by Department of Labor regulations (29 CFR part 5). Under Section 102 of the Act, each contractor is required to compute the wages of every mechanic and laborer on the basis of a standard work week of 40 hours. Work in excess of the standard work week is permissible provided that the worker is compensated at a rate of not less than 1 1/2 times the basic rate of pay for all hours worked in excess of 40 hours in the work week. Section 107 of the Act is applicable to construction work and provides that no laborer or mechanic is required to work in surroundings or under working conditions which are unsanitary, hazardous or dangerous. These requirements do not apply to the purchases of supplies or materials or articles ordinarily available on the open market, or contracts for transportation or transmission of intelligence.

4. Rights to Inventions and Data Made Under a Contract or Agreement -- Contracts or agreements for the performance of experimental, development, or research work must provide for the rights of the Federal Government and the recipient in any resulting invention in accordance with 10 CFR 600.325 and Appendix A -- Patent and Data Rights to Subpart D, Part 600.

5. Clean Air Act (42 U.S.C. 7401 et seq.) and the Federal Water Pollution Control Act (33 U.S.C. 1251 et seq.), as amended -- Contracts and subawards of amounts in excess of $100,000 must contain a provision that requires the recipient to agree to comply with all applicable standards, orders or regulations issued pursuant to the Clean Air Act (41 U.S.C. 7401 et seq.) and the Federal Water Pollution control act as amended (33 U.S.C. 1251 et seq.). Violations must be reported to the responsible DOE contracting officer and the Regional Office of the Environmental Protection Agency (EPA).

6. Byrd Anti-Lobbying Amendment (31 U.S.C. 1352) -- Contractors who apply or bid for an award of $100,000 or more must file the required certification. Each tier certifies to the tier above that it will not and has not used Federal appropriated funds to pay any person or organization for influencing or attempting to influence an officer or employee of any agency, a member of Congress, officer or employee of Congress, or an employee of a member of Congress in connection with obtaining any Federal contract, grant or any other award covered by 31 U.S.C.1352. Each tier must also disclose any lobbing with non-Federal funds that takes place in connection with obtaining any Federal award. Such disclosures are forwarded from tier to tier up to the recipient.

7. Debarment and Suspension (E.O.s 12549 and 12689 -- Contract awards that exceed the simplified acquisition threshold and certain other contract awards must not be made to

 

187


parties listed on nonprocurement portion of the General Services Administration’s Lists of Parties Excluded from Federal Procurement and Nonprocurement Programs in accordance with E.O.s 12549 (3 CFR, 1986 Comp., p. 189) and 12689 (3 CFR, 1989 Comp., p. 235), “Debarment and Suspension.” This list contains the names of parties debarred, suspended, or otherwise excluded by agencies, and contractors declared ineligible under statutory or regulatory authority other than E.O. 12549. Contractors with awards that exceed the small purchase threshold must provide the required certification regarding its exclusion status and that of its principals.

8. Davis-Bacon Act (40 U.S.C. 276a) -- As a general rule, it is unlikely that the Davis-Bacon Act, which among other things requires payment of prevailing wages on projects for the construction of public works, would apply to financial assistance awards. However, the presence of certain factors ( e.g., requirement of particular program statues; title to a construction facility resting in the Government) might necessitate a closer analysis of the award, to determine if the Davis-Bacon Act would apply in the particular factual situation presented.

 

188


10 CFR 600--Subpart F – Eligibility Determination for Certain Financial Assistance Programs--General Statement of Policy

 

600.500    Purpose and scope.
600.501    Definitions.
600.502    What must DOE determine.
600.503    Determining the economic interest of the United States.
600.504    Information an applicant must submit.
600.505    Other information DOE may consider.

Subpart F--Eligibility Determination for Certain Financial Assistance Programs--General Statement of Policy

600.500 Purpose and scope.

This subpart implements section 2306 of the Energy Policy Act of 1992, 42 U.S.C. 13525, and sets forth a general statement of policy, including procedures and interpretations, for the guidance of implementing DOE officials in making mandatory pre-award determinations of eligibility for financial assistance under Titles XX through XXIII of that Act.

600.501 Definitions.

The definitions in Sec. 600.3 of this part, including the definition of the term “financial assistance,” are applicable to this subpart. In addition, as used in this subpart:

Act means the Energy Policy Act of 1992.

Company means any business entity other than an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. Sec. 501 (c)(3)).

Covered program means a program under Titles XX through XXIII of the Act. (A list of covered programs, updated periodically as appropriate, is maintained and published by the Department of Energy.)

Parent company means a company that:

(1) Exercises ultimate ownership of the applicant company either directly, by ownership of a majority of that company’s voting securities, or indirectly, by control over a majority of that company’s voting securities through one or more intermediate subsidiary companies or otherwise, and

 

189


(2) Is not itself subject to the ultimate ownership control of another company.

United States means the several States, the District of Columbia, and all commonwealths, territories, and possessions of the United States.

United States-owned company means:

(1) A company that has majority ownership by individuals who are citizens of the United States, or

(2) A company organized under the laws of a State that either has no parent company or has a parent company organized under the laws of a State.

Voting security has the meaning given the term in the Public Utility Holding Company Act (15 U.S.C. 15b(17)).

600.502 What must DOE determine.

A company shall be eligible to receive an award of financial assistance under a covered program only if DOE finds that--

(a) Consistent with Sec. 600.503, the company’s participation in a covered program would be in the economic interest of the United States; and

(b) The company is either--

(1) A United States-owned company; or

(2) Incorporated or organized under the laws of any State and has a parent company which is incorporated or organized under the laws of a country which--

(i) Affords to the United States-owned companies opportunities, comparable to those afforded to any other company, to participate in any joint venture similar to those authorized under the Act;

(ii) Affords to United States-owned companies local investment opportunities comparable to those afforded to any other company; and

(iii) Affords adequate and effective protection for the intellectual property rights of United States-owned companies.

600.503 Determining the economic interest of the United States.

In determining whether participation of an applicant company in a covered program would be in the economic interest of the United States under Sec. 600.502(a), DOE may

 

190


consider any evidence showing that a financial assistance award would be in the economic interest of the United States including, but not limited to--

(a) Investments by the applicant company and its affiliates in the United States in research, development, and manufacturing (including, for example, the manufacture of major components or subassemblies in the United States);

(b) Significant contributions to employment in the United States by the applicant company and its affiliates; and

(c) An agreement by the applicant company, with respect to any technology arising from the financial assistance being sought--

(1) To promote the manufacture within the United States of products resulting from that technology (taking into account the goals of promoting the competitiveness of United States industry); and

(2) To procure parts and materials from competitive suppliers.

600.504 Information an applicant must submit.

(a) Any applicant for financial assistance under a covered program shall submit with the application for financial assistance, or at such later time as may be specified by DOE, evidence for DOE to consider in making findings required under Sec. 600.502(a) and findings concerning ownership status under Sec. 600.502(b).

(b) If an applicant for financial assistance is submitting evidence relating to future undertakings, such as an agreement under Sec. 600.503(c) to promote manufacture in the United States of products resulting from a technology developed with financial assistance or to procure parts and materials from competitive suppliers, the applicant shall submit a representation affirming acceptance of these undertakings. The applicant should also briefly describe its plans, if any, for any manufacturing of products arising from the program-supported research and development, including the location where such manufacturing is expected to occur.

(c) If an applicant for financial assistance is claiming to be a United States-owned company, the applicant must submit a representation affirming that it falls within the definition of that term provided in Sec. 600.501.

(d) DOE may require submission of additional information deemed necessary to make any portion of the determination required by Sec. 600.502.

600.505 Other information DOE may consider.

In making the determination under Sec. 600.502(b)(2), DOE may--

 

191


(a) consider information on the relevant international and domestic law obligations of the country of incorporation of the parent company of an applicant;

(b) consider information relating to the policies and practices of the country of incorporation of the parent company of an applicant with respect to:

(1) The eligibility criteria for, and the experience of United States-owned company participation in, energy-related research and development programs;

(2) Local investment opportunities afforded to United States-owned companies; and

(3) Protection of intellectual property rights of United States-owned companies;

(c) seek and consider advice from other federal agencies, as appropriate; and

(d) consider any publicly available information in addition to the information provided by the applicant.

 

192


10 CFR 600-- Appendix A to Part 600 – Generally Applicable Requirements

Socioeconomic Policy Requirements

Administrative and Fiscal Policy Requirements

Appendix A to Part 600 -- Generally Applicable Requirements

Socioeconomic Policy Requirements

Nondiscrimination in Federally Assisted Programs, 10 CFR Part 1040 (45 FR 40514, June 13, 1980), as proposed to be amended by 46 FR 49546 (October 6, 1981).

Nondiscrimination Provisions in Federally Assisted Construction Contracts, Part III of Executive Order 11246 (September 24, 1965), 3 CFR 1964 -- 65 Comp., p. 345.

Comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment and Rehabilitation Act of 1970, as amended (42 U.S.C. 4581).

Drug Abuse Office and Treatment Act of 1972, as amended (21 U.S.C. 1174).

Architectural Barriers Act of 1968, as amended (42 U.S.C. 4151 et seq.).

National Environmental Policy Act of 1969, as amended (42 U.S.C. 4321 et seq.), 40 CFR Part 1500, as implemented by (45 FR 20694, March 28, 1980).

Sec. 306, Clean Air Act, as amended (42 U.S.C. 7606c).

Sec. 508, Federal Water Pollution Control Act of 1972 (33 U.S.C. 1251 et seq.); Executive Order 11738, September 12, 1973.

Title XIV, Public Health Service Act, as amended (42 U.S.C. 300f -- et seq.).

Sec. 102(a), Flood Disaster Protection Act of 1973 (Pub. L. 93 - 234, 87 Stat. 975).

10 CFR part 1022, “Protection of Wetlands and Floodplains.”

Uniform Relocation Assistance and Land Acquisition Policies Act of 1970 (42 U.S.C. 4601 et seq.).

Coastal Zone Management Act of 1972, as amended (16 U.S.C. 1451 et seq.) (15 CFR Part 930).

 

193


Endangered Species Act of 1973, as amended (16 U.S.C. 1531 et seq.).

Fish and Wildlife Coordination Act (16 U.S.C. 661 et seq.).

Sec. 106, National Historic Preservation Act of 1966, as amended (16 U.S.C. 470f); Executive Order 11593, “Protection and Enhancement of the Cultural Environment,” May 13, 1971, 3 CFR 1971 Comp., p. 154; Archaeological and Historic Preservation Act of 1966 (16 U.S.C. 469 et seq.); Protection of Historic and Cultural Properties, 36 CFR part 800.

Wild and Scenic Rivers Act of 1968, as amended (16 U.S.C. 1271 et seq.).

Protection of Human Subjects, 10 CFR part 745.

Federal Laboratory Animal Welfare Act (7 U.S.C. 2131 et seq.) (9 CFR parts 1, 2, and 3).

Lead-Based Paint Prohibition (42 U.S.C. 4831(b)).

Sec. 7(b), Indian Self-Determination and Education Assistance Act (25 U.S.C. 450e(b)).

Cargo Preference Act of 1954 (46 U.S.C. 1241(b)) (46 CFR 381.7).

International Air Transportation Fair Competitive Practices Act of 1974 (49 U.S.C. 1517).

Executive Order 12138, “Creating a National Women’s Business Enterprise Policy and Prescribing Arrangements for Developing, Coordinating, and Implementing a National Program for Women’s Business Enterprise,” (May 18, 1979) 3 CFR 1979 Comp., p. 393.

Sec. 403(b), Power Plant and Industrial Fuel Use Act of 1978, (42 U.S.C. 8373(b)); Executive Order 12185 (December 17, 1979, 3 CFR 1979 Comp., p. 474).

Administrative and Fiscal Policy Requirements

The Hatch Act (5 U.S.C. 1501 - 1508).

Federal Reports Act, as amended by the Paperwork Reduction Act of 1980, Pub. L. 96 - 511 (44 U.S.C. 3501 et seq.).

OMB Circular A-111, Jointly Funded Assistance to State and Local Governments and Nonprofit Organizations -- Policies and Procedures.

Federal Claims Collection Act of 1966, Pub. L. 89 - 508, 89 Stat. 309 (31 U.S.C. 951 et seq.).

 

194


OMB Circular A-88, Coordinating Indirect Cost Rates and Audit at Educational Institutions.

OMB Circular A-73, Audit of Federal Operations and Programs.

Single Audit Act of 1984, Pub. L. 98 - 502.

OMB Circular A-128, Audits of State and Local Governments.

10 CFR 600-- Appendix B to Part 600 – Audit Report Distributees

Eastern Region

Western Region

Appendix B to Part 600 -- Audit Report Distributees

Distributee: Manager, Eastern Region, Office of Inspector General, U.S. Department of Energy, P.O. Box 1328, Oak Ridge, Tennessee 37831 - 1328.

For recipients in: Alabama, Arkansas, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Hampshire, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, Tennessee, Vermont, Virgin Islands, Virginia, West Virginia, Wisconsin.

Distributee: Manager, Western Region, Office of Inspector General, U.S. Department of Energy, P.O. Box 5400, Albuquerque, New Mexico 87115.

For recipients in: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Kansas, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington, Wyoming.

 

195

Exhibit 10.10

AMYRIS BIOTECHNOLOGIES, INC.

AMENDED AND RESTATED

STRATEGIC ADVISORY SERVICES AGREEMENT

THIS AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT (“ Agreement ”) is made and entered into as of July 31, 2009 (the “ Amendment Date ”), by and between Amyris Biotechnologies, Inc., a California corporation having its principal place of business located at 5885 Hollis Street, Suite 100, Emeryville, CA 94608, USA (“ Amyris ”), and Lit Tele LLC, a Delaware limited liability company, with its registered office at 3411 Silverside Road, Rodney Building #104, in the City of Wilmington, State of Delaware (“ Lit Tele ”). This Agreement amends and restates in its entirety that certain Strategic Advisory Services Agreement by and between Amyris and Lit Tele dated September 15, 2008 (the “ Effective Date ”).

RECITALS

WHEREAS, Amyris is a biotechnology company engaged in the business of developing innovative products using techniques of synthetic biology (the “ Amyris Technology ”); and

WHEREAS, Amyris is currently developing the Amyris Technology for the production and distribution of, among other things, hydrocarbon transportation fuels from sugarcane feedstock in a variety of countries around the world, including Brazil; and

WHEREAS, Amyris, together with Crystalsev Comércio e Representação Ltda., a limited liability company organized and existing under the laws of Brazil, have formed a Brazilian limited liability company called Amyris do Brasil Pesquisa e Desenvolvimento de Biocombustíveis Ltda. (“ ACB ”), for the purpose of (i) using the Amyris Technology to manufacture hydrocarbon transportation fuels from sugarcane feedstock within the country of Brazil, and (ii) trading such hydrocarbon transportation fuels within the country of Brazil and/or abroad; and

WHEREAS, Lit Tele, as a wholly-owned subsidiary of Votorantim Novos Negócios Ltda (“ VNN ”) the venture capital and private equity arm of the Votorantim Group, has extensive knowledge, experience and expertise in advising agricultural-related businesses of the type Amyris and ACB are engaged, and VNN, as the 100% owner of Lit Tele, desires that Lit Tele invest in shares of Series C Preferred Stock of Amyris (the “ Series C Financing ”); and

WHEREAS, as a condition of such investment by Lit Tele, Amyris desires to engage Lit Tele as a consultant to render consultancy services to Amyris and ACB upon the terms and conditions hereinafter set forth; and

WHEREAS, the services provided under this Agreement are intended to be provided and received in a way such that the value of Amyris and ACB are preserved and maximized.

NOW THEREFORE, in consideration of the foregoing recitals and the mutual promises and covenants contained in this Agreement, the parties hereto agree as follows:


AGREEMENT

1. Strategic Advisory Services . Lit Tele agrees to render strategic advisory services to Amyris in connection with Amyris’ business activities in Brazil and other jurisdictions outside the United States (the “ Strategic Advisory Services ”). The parties agree, by way of illustration and not limitation, that such Strategic Advisory Services will include serving as a strategic advisor to ACB. VNN, Lit Tele and Amyris agree that Fernando Reinach, an Executive Director of VNN, will provide such Strategic Advisory Services, unless otherwise agreed by Amyris in writing

2. Compensation and Expenses .

(a) Equity Compensation. During the term of this Agreement, as compensation for the Strategic Advisory Services rendered and other obligations undertaken by Lit Tele hereunder, Lit Tele shall receive:

(i) An initial grant of fifty thousand (50,000) restricted stock units (“ RSUs ”) which shall be issued and shall, except as specified under Sections 6(b) and 6(c) herein, vest in accordance with the terms and conditions set forth in the Restricted Stock Unit Issuance Agreement, as amended, by and between Amyris and Lit Tele and dated September 15, 2008 (the “ Initial RSU Grant ”).

(ii) Immediately following each closing of Amyris’ Series C Financing, an additional grant of that number of RSUs equal to that number of RSUs required to bring Lit Tele (together with any of its affiliates, including the Votorantim Group) to an equity ownership level, including all shares of Amyris preferred stock, common stock, or securities exercisable for or convertible into Amyris preferred or common stock, including RSUs, then held by Lit Tele (together with any of its affiliates) of 5% of the Fully-Diluted Capitalization (as defined below) of Amyris following such closing (the “ Additional RSU Grants ,” and together with the Initial RSU Grant, the “ RSU Grants ”). The Additional RSU Grants shall vest, except as specified under Sections 6(b) and 6(c) herein, in accordance with the terms and conditions set forth in the Restricted Stock Unit Issuance Agreement attached hereto as Exhibit A . “ Fully-Diluted Capitalization ” means the sum of (A) the number of shares of common stock then outstanding, (B) the number of shares of preferred stock then outstanding, (C) the number of shares of capital stock directly issuable upon exercise for cash of warrants then outstanding, (D) the number of shares of common stock issuable upon exercise of then outstanding options, and (E) the number of shares of common stock then available for issuance under the Company’s 2005 Stock Option/Stock Issuance Plan, in each case calculated without duplication with the other clauses in this sentence.

Such RSU Grants shall be inclusive of all fees and expenses and, except as set forth below or otherwise agreed by Amyris in writing, shall be Lit Tele’s sole compensation for rendering the Strategic Advisory Services to Amyris. The parties hereto intend that the RSU Grants shall be without withholding or deduction for any U.S. tax.

(b) Amyris shall reimburse Lit Tele for all travel expenses incurred in connection with travel undertaken by Lit Tele in connection with this Agreement. Such reimbursement shall be made upon receipt and verification by Amyris of customary receipts and vouchers.

3. Lit Tele’s Representations, Warranties and Obligations .

(a) The parties will perform their obligations under this Agreement as independent contractors and nothing contained in this Agreement will be construed to be inconsistent with such relationship or status. This Agreement will not constitute, create or in any way be interpreted as an agency relationship or a joint venture or partnership of any kind. Nothing in this Agreement shall be interpreted or construed

 

2


as creating or establishing an employment relationship between Amyris and VNN’s or Lit Tele’s personnel. Payment of all income taxes due on any amounts paid to Lit Tele hereunder will be the sole responsibility of Lit Tele.

(b) Lit Tele’s performance under this Agreement shall be conducted with due diligence and in full compliance with the highest professional standards of practice in the industry. For performing its duties under the Agreement, Lit Tele shall, to the extent necessary, use its own tools and equipment.

(c) Lit Tele certifies that Lit Tele has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, or that would preclude Lit Tele from complying with the provisions hereof and further certifies that Lit Tele will not enter into any such conflicting agreement during the term of this Agreement. In connection therewith, VNN will not, and will cause its majority-owned subsidiaries not to, without the prior written approval from the Chief Executive Officer of Amyris, engage in any business or activity that is competitive with the business conducted by or known to VNN as demonstrably anticipated by Amyris on the date hereof, and VNN will not, and will cause its majority-owned subsidiaries not to, assist any other person or organization in competing with Amyris, or in preparing to engage in competition with any business conducted by or known to VNN as demonstrably anticipated by Amyris on the date hereof.

4. Confidentiality .

(a) Definition . “ Proprietary Information ” means the Strategic Advisory Services to be provided by Lit Tele hereunder and the results thereof, as well as all information that has been or will be disclosed to Lit Tele by or on behalf of Amyris, directly or indirectly, or is obtained or observed by Lit Tele from Amyris while providing Strategic Advisory Services hereunder, whether in written, oral, visual, graphic, electronic or other form, including, without limitation, the identity, structure, chemical formula and composition of any materials in research or development by Amyris; procedures and formulations for producing any such materials; any related trade secrets, data, reports, analyses, ideas or inventions; information relating to the regulatory status of any such materials; financial or personnel matters relating to Amyris; information relating to Amyris’ sales, marketing, suppliers, clients, customers, investors or business; and all such information of any third party from which Amyris has received such information on a confidential basis. Notwithstanding the foregoing, Proprietary Information does not include any technology, invention, trade secret or know-how and any materials, documents, programs or information owned, controlled by or licensed to Lit Tele, at the date of this Agreement, or developed by Lit Tele independently of this Agreement, without use of or reference to any Proprietary Information, whether patentable or not (hereinafter referred to as “ Lit Tele Technology ”).

(b) Use . Proprietary Information may be used by Lit Tele only to the extent required to perform the Strategic Advisory Services and will not be used for any other purpose without the express prior written consent of Amyris, to be given or withheld in Amyris’ absolute discretion. Proprietary Information will not be used, reproduced or distributed in whole or in part in any form except as required to perform the Strategic Advisory Services.

(c) Nondisclosure . Lit Tele agrees to maintain all Proprietary Information in confidence and not to disclose Proprietary Information to any third party without the express prior written consent of Amyris, to be given or withheld in Amyris’ absolute discretion. In this regard, Lit Tele agrees to disclose Proprietary Information only to those of its employees, agents and consultants who are directly involved in the performance of the Strategic Advisory Services and have a need to see such Proprietary Information to enable Lit Tele to perform the Strategic Advisory Services, and who are bound by written obligations of confidentiality at least as stringent as those set forth herein. Lit Tele will advise its employees, agents and consultants of the confidential nature of the Proprietary Information and agrees

 

3


to be responsible for any breach of the provisions of this Agreement by such employees, agents and consultants.

(d) Protection . Lit Tele agrees to take all reasonable precautions to protect the confidentiality of Proprietary Information and to prevent its disclosure to and use by any unauthorized third party. Lit Tele further agrees to notify Amyris, promptly and in writing, of any actual or suspected misappropriation or unauthorized use or disclosure of the Proprietary Information that may come to Lit Tele’s attention.

(e) Exceptions . Notwithstanding the above, Lit Tele will not have liability to Amyris under this Article 4 with regard to the use or disclosure of any information that Lit Tele can demonstrate by competent written proof: (i) is now, or hereafter becomes, generally known or available to the public through no act or failure to act on the part of Lit Tele; (ii) is known by Lit Tele as a matter of legal right, without restriction on use or disclosure, at the time of receiving such information; (iii) is hereafter furnished to Lit Tele by a third party, as a matter of legal right and without restriction on disclosure, and not on Amyris’ behalf; or (iv) is independently developed by Lit Tele without use of or reference to Proprietary Information. Specific information disclosed as part of the Proprietary Information will not be deemed to fall within the foregoing exclusions merely because certain individual features are published or available to the general public or in the rightful possession of Lit Tele unless the combination as a whole falls within any of the above exceptions.

(f) Return of Materials . All Proprietary Information (including all summaries and whole or partial copies thereof) is and will at all times remain the property of Amyris and will be returned to Amyris by Lit Tele upon the request of Amyris and, in any event, upon the expiration or termination of this Agreement.

(g) Third Party Information . Lit Tele will not disclose or otherwise make available to Amyris in any manner any confidential information of Lit Tele or any confidential information received by Lit Tele from third parties, unless Amyris first agrees in writing to receive such information.

(h) Remedies . Lit Tele acknowledges that its obligations under this Article 4 are necessary and reasonable to protect the Proprietary Information and expressly agrees that monetary damages would be inadequate to compensate Amyris for the breach of any of the terms and conditions of this Article 4. In addition to any other remedies that may be available, in law, in equity, or otherwise, Amyris may be entitled to injunctive relief against any threatened material breach of Article 4 of this Agreement or the continuation of any material breach without the necessity of proving actual damages.

5. Intellectual Property .

(a) Intellectual Property . All information, inventions, discoveries, innovations, suggestions, ideas, communications, correspondence, notes, reports, data, records and results, whether or not copyrightable or patentable, conceived, reduced to practice, made, observed or developed by Lit Tele or its employees or agents, solely or jointly with others, as a result of performing the Strategic Advisory Services relating to Amyris’ Proprietary Information, together with all intellectual property rights related thereto (collectively, the “ Inventions ”) will be and remain at all times the property of Amyris. For the avoidance of doubt, Inventions do not include any Lit Tele IP (as defined in subsection (e) below).

(b) Records . Lit Tele agrees to keep and maintain adequate and current written records of all Inventions made by Lit Tele (solely or jointly with others) during the term of this Agreement. The records will be in the form of notes, sketches, drawings, and any other format that may be specified by Amyris. The records will be available to and remain the sole property of Amyris at all times. Lit Tele will promptly and fully disclose all Inventions to Amyris and will treat all Inventions and records related

 

4


thereto as Proprietary Information of Amyris.

(c) Assignment . Lit Tele hereby assigns to Amyris, without further consideration, all of Lit Tele’s right, title and interest in and to all such Inventions. At Amyris’ request and expense, as Amyris deems necessary or appropriate, Lit Tele will perform, or cause its employees and agents to perform, any and all acts necessary to assist Amyris in perfecting Amyris’ right, title and interest in and to such Inventions. Such acts will include but not be limited to executing all papers, including, without limitation, all documents associated with the filing and prosecution of patent applications, invention assignments and copyright assignments, and providing affidavits or testimony in connection with patent interference, validity or infringement proceedings and participating in other legal proceedings. Reasonable costs related to such assistance, if required, will be paid by Amyris. Lit Tele represents and warrants to Amyris that all of its employees and agents performing Strategic Advisory Services hereunder are required to assign all of their right, title and interest in and to any Inventions to Lit Tele. To the extent that any of the Inventions may not as a matter of law be assigned or transferred to Amyris, or if Lit Tele should, by operation of law or otherwise, hereafter recover, any right, title or interest in or to the Inventions, Lit Tele shall grant to Amyris and its successors and assigns a freely assignable, irrevocable, exclusive, worldwide, royalty-free right and license to all such Inventions with unfettered rights to grant sublicenses.

(d) No Rights Granted . Nothing in this Agreement will be construed as granting Lit Tele, either expressly or by implication, any type of right or license under any intellectual property right or other right of Amyris other than the limited right solely as necessary to enable Lit Tele to perform the Strategic Advisory Services; nor will this Agreement grant Lit Tele any rights in or to the Proprietary Information other than the limited right to use the Proprietary Information solely to perform the Strategic Advisory Services. This Agreement imposes (i) no obligation on Amyris to disclose any Proprietary Information, which will be provided or disclosed, if at all, at Amyris’ sole discretion; and (ii) no obligation for either party to enter into any further agreement with the other party.

(e) Lit Tele IP . Lit Tele shall not, without Amyris’ prior written consent, incorporate into Intellectual Property developed by Lit Tele in the course of performing the Strategic Advisory Services for Amyris (“ Amyris IP ”) any invention, improvement, development, concept, discovery or other proprietary information that is either owned by Lit Tele or in which Lit Tele has an interest (“ Lit Tele IP ”). In the event Lit Tele does knowingly incorporate any Lit Tele IP into Amyris IP without Amyris’ prior written consent, Lit Tele hereby grants Amyris a nonexclusive, fully paid up, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, use, offer for sale, sell or import such Lit Tele IP as part of or in connection with such Amyris IP.

(f) Third Party IP . Lit Tele shall not, without Amyris’ prior written consent, incorporate into Amyris IP any invention, improvement, development, concept, discovery or other proprietary information that Lit Tele knows is owned by any third party (“ Third Party IP ”). To the extent Lit Tele does incorporate any Third Party IP into Amyris IP without Amyris’ prior written consent, Lit Tele shall use its best efforts to cause the third part(y)(ies) who own or have the power to control the disposition of such Third Party IP to grant Amyris a license of the same scope as that set forth in subsection (e) above.

6. Term and Termination .

(a) This Agreement will commence on the Effective Date and will continue for three (3) years unless terminated as provided herein.

(b) Amyris may terminate this Agreement for convenience effective upon thirty (30) days written notice to Lit Tele. In the event that Amyris terminates this Agreement pursuant to this Section 6(b), any

 

5


unvested portion of the RSU Grants shall become immediately vested as of the date of such termination and the Shares (as defined in the Restricted Stock Unit Issuance Agreement attached hereto as Exhibit A) subject to those vested units shall be issued immediately upon such vesting.

(c) In the event that Fernando Reinach ceases to provide the Strategic Advisory Services for any reason, (i) the pro rata portion of the RSU Grants which is unvested at the date of such cessation shall immediately become vested and the Shares (as defined in the Restricted Stock Unit Issuance Agreement attached hereto as Exhibit A) subject to those vested units shall be issued to Lit Tele immediately upon such vesting, (ii) the remainder of the unvested portion of the RSU Grants shall be forfeited and canceled, and (iii) none of the parties to this Agreement shall be liable to any of the other parties for terminating this Agreement in accordance with this provision.

(d) Either party may terminate this Agreement effective immediately upon written notice in the event the other party breaches or defaults under any provision of this Agreement.

(e) Articles 4, 5, 6 and 7 shall survive termination of this Agreement.

7. General Provisions .

(a) This Agreement will be governed by the laws of the State of California, as such laws are applied to contracts entered into and to be performed within such state, without regard to any conflicts of laws provisions. For purposes of Brazilian conflict of law rules, the Parties acknowledge and agree that Amyris is the proponent of the transaction embodied herein.

(b) This Agreement sets forth the entire agreement and understanding between Amyris and Lit Tele relating to the subject matter herein and supersedes all prior discussions between the parties. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless executed in writing and signed by both parties.

(c) All notices required or given herewith shall be addressed to Amyris or Lit Tele at the designated addresses shown below by registered mail, special delivery, or by certified courier service:

If to Lit Tele :

Rua Jeronimo da Vega, 384-12º andar

São Paulo, Brazil

Attn: Fernando Reinach

Fax: +55 (11) 3077-5051

Email: fernando.reinach@vnnegocios.com.br

If to Amyris :

Amyris Biotechnologies, Inc.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

USA

Attn: Legal Department

Fax: (510) 842-1460

Email: tompkins@amyrisbiotech.com

 

6


(d) The headings used in this Agreement are for the convenience of the parties and for reference purposes only and shall not form a part or affect the interpretation of this Agreement.

(e) If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect.

(f) Neither this Agreement nor any right hereunder or interest herein may be assigned or transferred by Lit Tele without the express prior written consent of an officer of Amyris. This Agreement will be binding upon Lit Tele’s heirs, executors, administrators and other legal representatives and will be for the benefit of Amyris, its successors, and its assigns.

(g) If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs, and necessary disbursements, in addition to any other relief to which the party may be entitled.

[Signature Page Follows]

 

7


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

LIT TELE LLC

By:       /s/ Paulo Henrique de Oliveira Santos

Name:  Paulo Henrique de Oliveira Santos

Title:   Authorized Signatory

By:      /s/ Fernando Reinach                        

Name:  Fernando C. Reinach

Title:   Authorized Signatory

Place and Date: _________________________

WITNESSES:

 

1. _____________________________________

Name:

2. ____________________________________

Name:


 

AMYRIS BIOTECHNOLOGIES, INC.

By:       /s/ Tamara L. Tompkins

Name:  Tamara L. Tompkins

Title:    General Counsel

Place and Date: Sao Paulo, Brazil 29 July 2009                    

WITNESSES:

 

1. _____________________________________

Name:

 

2. ____________________________________

Name:


 

S TRATEGIC A DVISORY S ERVICES A GREEMENT

S IGNATURE P AGE


VOTORANTIM NOVOS NEGÓCIOS LTDA,

as a party solely for purposes of Article 1 and Sections 3(c) and 7(a)

By:          /s/ Paulo Henrique de Oliveira Santos         /s/ Fernando Reinach

Name:     Paulo Henrique de Oliveira Santos         Fernando Reinach

Place and Date: _________________________

WITNESSES:

 

1. _____________________________________

Name:

 

2. ____________________________________

Name:


 

 

 

S TRATEGIC A DVISORY S ERVICES A GREEMENT

S IGNATURE P AGE


EXHIBIT A

Form of Restricted Stock Unit Agreement

AMYRIS BIOTECHNOLOGIES, INC.

RESTRICTED STOCK UNIT ISSUANCE AGREEMENT

1.     Grant of Restricted Stock Units .    The Corporation hereby awards to the Participant, as of the Award Date, Restricted Stock Units. Each Restricted Stock Unit which vests pursuant to the vesting schedule set forth below shall entitle Participant to receive one share of Common Stock on the specified issuance date. The number of shares of Common Stock subject to the awarded Restricted Stock Units, the applicable vesting schedule for those shares, the date on which those vested shares shall become issuable to Participant and the remaining terms and conditions governing the award (the “Award”) shall be as set forth in this Agreement. All capitalized terms in this Agreement shall have the meaning assigned to them in the attached Appendix A.

AWARD SUMMARY

 

Participant:

  

Lit Tele LLC

Award Date:

  

[____]

Number of Shares Subject to Award:

  

The maximum number of shares of Common Stock subject to this Award is [_______] (the “Shares”). However, the actual number of shares of Common Stock issuable pursuant to this Award shall be determined in accordance with the Vesting Schedule set forth below.

Vesting Schedule:

  

The Shares shall vest in a series of four (4) successive equal quarterly installments at the end of each fiscal quarter over the one (1)-year period measured from July __, 2009, provided Participant remains in the Corporation’s Service through each such vesting date. However, the Shares may be subject to accelerated vesting in whole or in part in accordance with the provisions of Paragraph 5 of this Agreement.

Issuance

Schedule

  

Each Share in which Participant vests in accordance with the Vesting Schedule shall be issued, subject to Paragraph 8 of this Agreement and the Corporation’s collection of all applicable Withholding Taxes, on the date that particular Share vests (the “Issuance Date”) or as soon after that scheduled Issuance Date as administratively practicable. The Shares which vest pursuant to Paragraph 5 of this Agreement shall be issued in accordance with the provisions of such Paragraph. In addition, any issued Shares shall be subject to the transfer restrictions of this Agreement.


  

In no event shall any fractional shares be issued. Accordingly the total number of Shares to be issued pursuant to the Award shall, to the extent necessary, be rounded down to the next whole Share.

2.     Limited Transferability .    Prior to actual receipt of the Shares which vest and become issuable hereunder, Participant may not transfer any interest in the Award or the underlying Shares; however, the foregoing shall not apply to any transfer of interest in the Award or the underlying shares without consideration to any person or entity, directly or indirectly, controlling, controlled by or under common control with, the Participant, provided that (A) the Participant shall inform the Corporation of such transfer prior to effecting it and (B) the transferee shall enter into a written agreement to be bound by and comply with all provisions of this Agreement, as if it were the original participant hereunder. Any issued Shares shall be subject to the restrictions of Paragraphs 9 and 10 of this Agreement. In addition, Participant shall make no disposition of any issued Shares unless and until there is compliance with all of the following requirements: (i) Participant shall have provided the Corporation with a written summary of the terms and conditions of the proposed disposition; (ii) Participant shall have complied with all requirements of this Agreement applicable to the disposition of the Shares; and (iii) Participant shall have provided the Corporation with written assurances, in form and substance satisfactory to the Corporation, that (a) the proposed disposition does not require registration of the Shares under the 1933 Act or (b) all appropriate action necessary for compliance with the registration requirements of the 1933 Act or any exemption from registration available under the 1933 Act (including Rule 144) has been taken.

3.     Cessation of Service .    Should Participant cease Service for any reason prior to vesting in one or more Shares subject to this Award, then the Award will be immediately cancelled with respect to those unvested Shares, and the number of Restricted Stock Units will be reduced accordingly. Participant shall thereupon cease to have any right or entitlement to receive any Shares under those cancelled units. Should Participant’s Service terminate by reason of Misconduct, then this Award will be immediately cancelled with respect to all the Restricted Stock Units subject to such Award, whether vested or unvested at the time, and Participant shall thereupon cease to have any right or entitlement to receive any Shares under this Award and the cancelled Restricted Stock Units.

4.     Stockholder Rights.      The holder of this Award shall not have any stockholder rights, including voting or dividend rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares following their actual issuance upon the Corporation’s collection of the applicable Withholding Taxes.

5.     Change of Control .

(a) Any Restricted Stock Units subject to this Award at the time of a Change in Control may be assumed by the successor entity or otherwise continued in full force and effect or may be replaced with a cash incentive program of the successor entity which preserves the Fair Market Value of the unvested shares of Common Stock subject to the Award at the time of the Change in Control and provides for subsequent payout of that

 

2


value in accordance with the vesting schedule applicable to the Award. In the event of such assumption or continuation of the Award or such replacement of the Award with a cash incentive program, no accelerated vesting of the Restricted Stock Units shall occur at the time of the Change in Control.

(b) In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award shall be adjusted immediately after the consummation of the Change in Control so as to apply to the number and class of securities into which the Shares subject to those units immediately prior to the Change in Control would have been converted in consummation of that Change in Control had those Shares actually been issued and outstanding at that time. To the extent the actual holders of the outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation (or parent entity) may, in connection with the assumption or continuation of the Restricted Stock Units subject to the Award at that time and with Participant’s prior written consent, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in the Change in Control transaction, provided the substituted common stock is readily tradable on an established U.S. securities exchange or market.

(c) If the Restricted Stock Units subject to this Award at the time of the Change in Control are not assumed or otherwise continued in effect or replaced with a cash incentive program under Section 6(a), then those units will vest immediately prior to the closing of the Change in Control. The Shares subject to those vested units will be issued immediately upon such vesting (or otherwise converted into the right to receive the same consideration per share of Common Stock payable to the other stockholders of the Corporation in consummation of that Change in Control), subject to the Corporation’s collection of the applicable Withholding Taxes.

(d) This Agreement shall not in any way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

6.     Adjustment in Shares .    Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation’s receipt of consideration, appropriate adjustments shall be made to the total number and/or class of securities issuable pursuant to this Award in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.

 

3


7.     Compliance with Laws and Regulations .    The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Corporation and Participant with all applicable requirements of law relating thereto and with all applicable regulations of any Stock Exchange on which the Common Stock may be listed for trading at the time of such issuance.

8.     Representations .     the time of issuance of the Shares, Participant shall, if required by the Corporation, deliver to the Corporation Participant’s Investment Representation Statement in the form attached hereto as Exhibit A.

9.     Market Stand-Off .

(a) In connection with any underwritten public offering by the Corporation of its equity securities pursuant to an effective registration statement filed under the 1933 Act, including the Corporation’s initial public offering, Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to, any issued Shares without the prior written consent of the Corporation or its underwriters. Such restriction (the “Market Stand-Off”) shall be in effect for such period of time from and after the effective date of the final prospectus for the offering as may be requested by the Corporation or such underwriters. In no event, however, shall such period exceed one hundred eighty (180) days, and the Market Stand-Off shall in no event be applicable to any underwritten public offering effected more than two (2) years after the effective date of the Corporation’s initial public offering.

(b) Participant shall be subject to the Market Stand-Off provided and only if the officers and directors of the Corporation are also subject to similar restrictions.

(c) Any new, substituted or additional securities which are by reason of any Recapitalization or Reorganization distributed with respect to the issued Shares shall be immediately subject to the Market Stand-Off, to the same extent the issued Shares are at such time covered by such provisions.

(d) In order to enforce the Market Stand-Off, the Corporation may impose stop-transfer instructions with respect to the issued Shares until the end of the applicable stand-off period.

10.     Right of First Refusal

(a) Grant .    The Corporation is hereby granted the right of first refusal (the “First Refusal Right”), exercisable in connection with any proposed transfer of the Shares. For purposes of this Section 10, the term “transfer” shall include any sale, assignment, pledge, encumbrance or other disposition of the Shares intended to be made by Participant.

 

4


(b) Notice of Intended Disposition .    In the event Participant desires to accept a bona fide third-party offer for the transfer of any or all of such shares (the Shares subject to such offer to be hereinafter referred to as the “Target Shares”), Participant shall promptly (i) deliver to the Corporation written notice (the “Disposition Notice”) of the terms of the offer, including the purchase price and the identity of the third-party offeror, and (ii) provide satisfactory proof that the disposition of the Target Shares to such third-party offeror would not be in contravention of the provisions of this Agreement.

(c) Exercise of the First Refusal Right .     The Corporation shall, for a period of twenty-five (25) days following receipt of the Disposition Notice, have the right to repurchase any or all of the Target Shares subject to the Disposition Notice upon the same terms as those specified therein or upon such other terms (not materially different from those specified in the Disposition Notice) to which Participant consents. Such right shall be exercisable by delivery of written notice (the “Exercise Notice”) to Participant prior to the expiration of the twenty-five (25)-day exercise period. If such right is exercised with respect to all the Target Shares, then the Corporation shall effect the repurchase of such shares, including payment of the purchase price, not more than five (5) business days after delivery of the Exercise Notice; and at such time the certificates representing the Target Shares shall be delivered to the Corporation.

Should the purchase price specified in the Disposition Notice be payable in property other than cash or evidences of indebtedness, the Corporation shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property. If Participant and the Corporation cannot agree on such cash value within ten (10) days after the Corporation’s receipt of the Disposition Notice, the valuation shall be made by an appraiser of recognized standing selected by Participant and the Corporation or, if they cannot agree on an appraiser within twenty (20) days after the Corporation’s receipt of the Disposition Notice, each shall select an appraiser of recognized standing and the two (2) appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by Participant and the Corporation. The closing shall then be held on the later of (i) the fifth (5th) business day following delivery of the Exercise Notice or (ii) the fifth (5th) business day after such valuation shall have been made.

(d) Non-Exercise of the First Refusal Right .     In the event the Exercise Notice is not given to Participant prior to the expiration of the twenty-five (25)-day exercise period, Participant shall have a period of thirty (30) days thereafter in which to sell or otherwise dispose of the Target Shares to the third-party offeror identified in the Disposition Notice upon terms (including the purchase price) no more favorable to such third-party offeror than those specified in the Disposition Notice; provided , however, that any such sale or disposition must not be effected in contravention of the provisions of Paragraphs 2, 9 and 11 of this Agreement. The third-party offeror shall acquire the Target Shares subject to the First Refusal Right and the provisions and restrictions of Paragraphs 2, 9 and 11, and any subsequent disposition of the acquired shares must be effected in compliance with the terms and conditions of such First Refusal Right and the provisions and restrictions of Paragraphs 2, 9 and 11. In the event Participant does not effect such sale or disposition of the Target Shares within the specified thirty (30)-day period, the First Refusal Right shall

 

5


continue to be applicable to any subsequent disposition of the Target Shares by Participant until such right lapses.

(e) Partial Exercise of the First Refusal Right . In the event the Corporation makes a timely exercise of the First Refusal Right with respect to a portion, but not all, of the Target Shares specified in the Disposition Notice, Participant shall have the option, exercisable by written notice to the Corporation delivered within five (5) business days after Participant’s receipt of the Exercise Notice, to effect the sale of the Target Shares pursuant to either of the following alternatives:

(i)        sale or other disposition of all the Target Shares to the third-party offeror identified in the Disposition Notice, but in full compliance with the requirements of Section 10(d), as if the Corporation did not exercise the First Refusal Right; or

(ii)        sale to the Corporation of the portion of the Target Shares which the Corporation has elected to purchase, such sale to be effected in substantial conformity with the provisions of Section 10(c). The First Refusal Right shall continue to be applicable to any subsequent disposition of the remaining Target Shares until such right lapses.

Participant’s failure to deliver timely notification to the Corporation shall be deemed to be an election by Participant to sell the Target Shares pursuant to alternative (i) above.

(f) Recapitalization/Reorganization .

(i)        Any new, substituted or additional securities or other property which is by reason of any Recapitalization distributed with respect to the issued Shares shall be immediately subject to the First Refusal Right, but only to the extent the issued Shares are at the time covered by such right.

(ii)        In the event of a Reorganization, the First Refusal Right shall remain in full force and effect and shall apply to the new capital stock or other property received in exchange for the issued Shares in consummation of the Reorganization, but only to the extent the issued Shares are at the time covered by such right.

(g) Lapse . The First Refusal Right shall lapse upon the earliest to occur of (i) the first date on which shares of the Common Stock are held of record by more than five hundred (500) persons, (ii) a determination made by the Board that a public market exists for the outstanding shares of Common Stock or (iii) a firm commitment underwritten public offering, pursuant to an effective registration statement under the 1933 Act, covering the offer and sale of the Common Stock in the aggregate amount of at least twenty million dollars ($20,000,000). However, the Market Stand-Off shall continue to remain in full force and effect following the lapse of the First Refusal Right.

 

6


(h) No Waiver .     The failure of the Corporation in any instance to exercise the First Refusal Right shall not constitute a waiver of any other repurchase rights and/or rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Corporation and Participant. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

(i) Cancellation of Shares .     If the Corporation shall make available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased in accordance with the provisions of this Agreement, then from and after such time, the person from whom such shares are to be repurchased shall no longer have any rights as a holder of such shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such shares shall be deemed purchased in accordance with the applicable provisions hereof, and the Corporation shall be deemed the owner and holder of such shares, whether or not the certificates therefor have been delivered as required by this Agreement.

(j) Exempted Transfers .      Notwithstanding the foregoing, the First Refusal Right of the Corporation set forth in this Section 10 shall not apply to any transfer without consideration to any person or entity, directly or indirectly, controlling, controlled by or under common control with the Participant; provided that (A) the Participant shall inform the Corporation of such transfer prior to effecting it and (B) the transferee shall enter into a written agreement to be bound by and comply with all provisions of this Agreement, as if it were the original participant hereunder. Such transferred Shares shall remain “Shares” hereunder, and such transferee shall be treated as the “Participant” for purposes of this Agreement.

11. Restrictive Legends and Refusal to Transfer .

(a) The stock certificates for the Shares shall be endorsed with one or more of the following restrictive legends:

“The shares represented by this certificate have not been registered under the Securities Act of 1933. The shares may not be sold or offered for sale in the absence of (a) an effective registration statement for the shares under such Act, (b) a ‘no action’ letter of the Securities and Exchange Commission with respect to such sale or offer or (c) satisfactory assurances to the Corporation that registration under such Act is not required with respect to such sale or offer.”

 

7


“The shares represented by this certificate are subject to certain rights of first refusal granted to the Corporation and accordingly may not be sold, assigned, transferred, encumbered, or in any manner disposed of except in conformity with the terms of a written agreement dated September [ ], 2008, between the Corporation and the registered holder of the shares (or the predecessor in interest to the shares). A copy of such agreement is maintained at the Corporation’s principal corporate offices.”

(b) The Corporation shall not be required (i) to transfer on its books any Shares which have been sold or transferred in violation of the provisions of this Agreement or (ii) to treat as the owner of the Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom the Shares have been transferred in contravention of this Agreement.

12. Notices .    Any notice required to be given or delivered to the Corporation under the terms of this Agreement shall be in writing and addressed to the Corporation at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated below Participant’s signature line on this Agreement. All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.

13. Successors and Assigns .    Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and Participant and Participant’s assigns.

14. Governing Law .    The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of California without resort to that State’s conflict-of-laws rules.

15. Employment at Will .    Nothing in this Agreement shall confer upon Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining Participant) or of Participant, which rights are hereby expressly reserved by each, to terminate Participant’s Service at any time for any reason, with or without cause.

16. Participant Undertaking .    Participant hereby agrees to take whatever additional action and execute whatever additional documents the Corporation may deem necessary or advisable in order to carry out or effect one or more of the obligations or

 

8


restrictions imposed on either Participant or the issued Shares pursuant to the provisions of this Agreement.

IN WITNESS WHEREOF , the parties have executed this Agreement on the day and year first indicated above.

 

AMYRIS BIOTECHNOLOGIES, INC.

 

By:            

   

Title:

   

 

LIT TELE LLC, PARTICIPANT

Signature:

Title:

Signature:  

   

Title:

   

Address:

   

 

8


APPENDIX A

DEFINITIONS

The following definitions shall be in effect under the Agreement:

A. Agreement shall mean this Restricted Stock Unit Issuance Agreement.

B. Award shall mean the award of Restricted Stock Units made to Participant pursuant to the terms of this Agreement.

C. Award Date shall mean the date the Restricted Stock Units are awarded to Participant pursuant to the Agreement and shall be the date indicated in Section 1 of the Agreement.

D. Board shall mean the Corporation’s Board of Directors.

E. Change in Control shall mean a change in ownership or control of the Corporation effected through any of the following transactions:

(i)        a merger, consolidation or other reorganization approved by the Corporation’s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction, or

(ii)        a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution of the Corporation, or

(iii)        the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders.

In no event shall any public offering of the Corporation’s securities be deemed to constitute a Change in Control.

F. Code shall mean the Internal Revenue Code of 1986, as amended.

G. Common Stock shall mean shares of the Corporation’s common stock.

 

A-1


H. Corporation shall mean Amyris Biotechnologies, Inc., a California corporation, and any successor corporation to all or substantially all of the assets or voting stock of Amyris Biotechnologies, Inc.

I. Disposition Notice shall have the meaning assigned to such term in Section 10(b).

J. Exercise Notice shall have the meaning assigned to such term in Section 10(c).

K. Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

(i)         If the Common Stock is at the time traded on the Nasdaq Global or Global Select Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers for that particular Stock Exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(ii)    If the Common Stock is at the time listed on any other Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Board to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(iii)        If the Common Stock is not at the time neither listed on any Stock Exchange, then the Fair Market Value shall be determined by the Board after taking into account such factors as the Board shall deem appropriate.

L. First Refusal Right shall have the meaning assigned to such term in Section 10.

M. Market Stand-Off shall mean the market stand-off restriction specified in Section 9.

N. Misconduct shall mean the commission of any act of fraud, embezzlement or dishonesty by Participant or Participant’s agents, any unauthorized use or disclosure by such person of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by Participant or its agents adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in

 

A-2


a material manner. The foregoing definition shall not be deemed to be inclusive of all the acts or omissions which the Corporation (or any Parent or Subsidiary) may consider as grounds for the dismissal or discharge of any optionee, participant or other person in the service of the Corporation (or any Parent or Subsidiary).

O. 1934 Act shall mean the Securities Exchange Act of 1934, as amended from time to time.

P. Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

Q. Recapitalization shall mean any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the Corporation’s outstanding Common Stock as a class without the Corporation’s receipt of consideration.

R. Reorganization shall mean any of the following transactions:

(i)        a merger or consolidation in which the Corporation is not the surviving entity,

(ii)       a sale, transfer or other disposition of all or substantially all of the Corporation’s assets,

(iii)      a reverse merger in which the Corporation is the surviving entity but in which the Corporation’s outstanding voting securities are transferred in whole or in part to a person or persons different from the persons holding those securities immediately prior to the merger, or

(iv)      any transaction effected primarily to change the state in which the Corporation is incorporated or to create a holding company structure.

S. Restricted Stock Unit shall mean each unit subject to this Award which shall entitle Participant to receive one share of Common Stock at a designated time following the vesting of that unit.

T. Service shall mean Participant’s performance of services for the Corporation (or any Parent or Subsidiary) pursuant to the Advisory Service Agreement between the Corporation and Participant dated September [    ], 2008. For purposes of this Agreement, Participant shall be deemed to cease Service immediately upon the occurrence of the either of the following events: (i) Participant no longer performs services in the foregoing capacity for the Corporation (or any Parent or Subsidiary) or (ii) the entity for which Participant performs such services ceases to remain a Parent or Subsidiary of the

 

A-3


Corporation, even though Participant may subsequently continue to perform services for that entity.

U. Stock Exchange shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.

V. Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

W. Target Shares shall have the meaning assigned to such term in Section 10(b).

X. Withholding Taxes shall mean the employment taxes, social security taxes, social insurance, payroll taxes, contributions, payment on account obligations, national taxes and other applicable taxes and payments required to be withheld by the Corporation in connection with the vesting of the shares of Common Stock under the Award or the issuance of shares of Common Stock under the Award.

 

A-4


EXHIBIT A

INVESTMENT REPRESENTATION STATEMENT

 

Participant:

  

 

  

Corporation:

  

 

  

Security:

  

_______________ shares of Common Stock (“Shares”)

Date:

  

 

  

Representations : In connection with the issuance of the Shares, Participant hereby represents to the Corporation as follows:

(i)        The Shares have not been registered under the 1933 Act and are being issued to Participant in reliance upon the exemption from such registration provided by Section 4(2) of the 1933 Act. Participant hereby confirms that Participant has been informed that the Shares are restricted securities under the 1933 Act and may not be resold or transferred unless the Shares are first registered under the Federal securities laws or unless an exemption from such registration is available.

(ii)        Participant is acquiring the Shares solely for investment purposes for Participant’s own account, and not as a nominee or agent and with no present intention of distributing, reselling, granting any participation in or otherwise distributing any of the Shares or any interest therein other than pursuant to the 1933 Act. Participant does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant a participating interest in, any of the Shares.

(iii)        Participant is aware of the Corporation’s business affairs and financial condition and has been furnished with, and has had access to, such information as Participant considers necessary or appropriate for deciding whether to invest in the Shares. Participant has had an opportunity to ask questions and receive answers from the Corporation regarding the terms and conditions of the issuance of the Shares.

(iv)        Participant understands that the Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, Participant must hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or unless an exemption from such registration and qualification requirements is available. Participant acknowledges that the Corporation has no obligation to register or qualify the Shares for resale. Participant further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and requirements relating to the Corporation which are outside of Participant’s control, and which the Corporation is under no obligation to and may not be able to satisfy.

 

A-5


(v)        Participant understands that there is no public market for the Shares, that no market may ever develop for them, and that the Shares have not been approved or disapproved by the Securities and Exchange Commission or any governmental agency.

(vi)        Participant understands that the Shares are subject to certain restrictions on transfer set forth in the Restricted Stock Unit Agreement between the Corporation and Participant dated as of September [    ], 2008 (the “Agreement”).

(vii)        Participant is able to fend for itself in the transactions contemplated by the Agreement, can bear the economic risk of investment in the Shares and has such knowledge and experience in financial or business matters to be capable of evaluating the merits and risks of the investment in the Shares.

(viii)        If Participant is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code), Participant represents that it has satisfied itself to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares, including the legal requirements within its jurisdiction for the purchase of the Shares, any foreign exchange restrictions applicable to such purchase, any governmental or other consents that may need to be obtained and any income tax and other tax consequences, if any, that may be relevant to the purchase, holding, sale or transfer of the Shares. Participant’s subscription and payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of Participant’s jurisdiction.

(ix)        Participant has read the following definition of “Accredited Investor” from Rule 501 of Regulation D and certifies that Participant is an “Accredited Investor:”

Accredited Investor . “Accredited investor” shall mean any person who comes within any of the following categories, or who the issuer reasonably believes comes within any of the following categories, at the time of the sale of the securities to that person:

•        Any natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000

•        Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year

•        Any bank as defined in section 3(a)(2) of the Securities Act of 1933, as amended, (the “Act”) or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; any broker dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; any insurance company as defined in Section 2(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small

 

A-6


Business Investment Act of 1958; any employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000; or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors

•        Any private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 (a U.S. venture capital fund which invests primarily through private placements in non-publicly traded securities and makes available (either directly or through co-investors) to the portfolio companies significant guidance concerning management, operations or business objectives)

•        Any organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000

•        Any director, executive officer or general partner of the issuer of the securities being offered or sold, or any director, executive officer or general partner of a general partner of that issuer

•        Any trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii)

•        Any entity in which all of the equity owners are accredited investors

 

A-7

Exhibit 10.11

AMYRIS BIOTECHNOLOGIES, INC.

AMENDMENT NO. 1 TO

AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT

THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT, by and between Amyris Biotechnologies, Inc., a California corporation (the “ Company ”), and Lit Tele LLC, a Delaware limited liability company (“ Lit Tele ”), is dated as of February 11, 2010 (this “ Amendment ”), and amends that certain Amended and Restated Strategic Advisory Services Agreement, by and between the Company and Lit Tele, dated as of July 31, 2009 (the “ Agreement ”). Capitalized terms used and not defined herein shall have those meanings given to them in the Agreement.

WHEREAS, the Company and Lit Tele entered into the Agreement in connection with the sale and issuance of shares of the Company’s Series C Preferred Stock pursuant to that certain Series C Preferred Stock Purchase Agreement dated as of July 31, 2009 (the “ Purchase Agreement ”);

WHEREAS, in consideration of Lit Tele entering into the Purchase Agreement and in order to clarify the number of warrants Lit Tele is eligible to receive under the Agreement, the parties have agreed to enter into this Amendment; and

WHEREAS, this Amendment has been signed and delivered by the Company and Lit Tele as set forth in Section 7(b) of the Agreement.

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

1.         Amendment to Section 2(a)(ii) .  Section 2(a)(ii) of the Agreement is hereby amended and restated to read in its entirety as follows:

“An additional grant of 126,272 RSUs (the “ Additional RSU Grant, ” and together with the Initial RSU Grant, the “ RSU Grants ”). The Additional RSU Grant shall vest, except as specified under Sections 6(b) and 6(c) herein, in accordance with the terms and conditions set forth in the Restricted Stock Unit Issuance Agreement attached hereto as Exhibit A.

Such RSU Grants shall be inclusive of all fees and expenses and, except as set forth below or otherwise agreed by Amyris in writing, shall be Lit Tele’s sole compensation for rendering the Strategic Advisory Services to Amyris. The parties hereto intend that the RSU Grants shall be without withholding or deduction for any U.S. tax.”

2.         Full Force and Effect .  Except as expressly modified by this Amendment, the terms of the Agreement remain in full force and effect.

3.         Consent to this Amendment .  The execution of this Amendment by the Company and Lit Tele shall be deemed, for purposes of Section 7(b) of the Agreement, to be their mutual written consent to amend the Agreement as set forth therein.


4.         Governing Law .  This Amendment shall be governed by the laws of the State of California, as such laws are applied to contracts entered into and to be performed within such state, without regard to any conflicts of laws provisions. For purposes of Brazilian conflict of law rules, the Parties acknowledge and agree that the Company is the proponent of the transaction embodied herein.

5.         Counterparts .  This Amendment may be executed in two or more counterparts, including counterparts transmitted by facsimile, other electronic transmission or otherwise, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

6.         Successors and Assigns .  Neither this Amendment nor any right hereunder or interest herein may be assigned or transferred by Lit Tele without the express prior written consent of an officer of the Company. This Amendment will be binding upon Lit Tele’s heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns.

7.         Prevailing Party .  If any action at law or in equity is necessary to enforce or interpret the terms of this Amendment, the prevailing party shall be entitled to reasonable attorneys’ fees, costs, and necessary disbursements, in addition to any other relief to which the party may be entitled

8.         Entire Agreement .  This Amendment and the Agreement, along with the Purchase Agreement and the other documents delivered pursuant thereto, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants or agreements except as specifically set forth herein and therein.

[Signature Pages Follow]

 

2


IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 to Amended and Restated Strategic Advisory Services Agreement as of the date first above written.

 

COMPANY:

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

 

/s/ John G. Melo

 

John G. Melo

Chief Executive Officer

 

Address:

 

5885 Hollis Street, Ste. 100

Emeryville, CA 94608

 

 

 

 

 

AMENDMENT NO. 1 TO AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT

SIGNATURE PAGE


IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 to Amended and Restated Strategic Advisory Services Agreement as of the date first above written.

 

LIT TELE:

 

LIT TELE LLC

By:

 

/s/ Fernando Reinach

 

Fernando C. Reinach

Authorized Signatory

 

Address:

 

3411 Silverside Road

Rodney Building #104

Wilmington, DE 19810

 

 

 

 

 

AMENDMENT NO. 1 TO AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT

SIGNATURE PAGE


EXHIBIT A

Form of Restricted Stock Unit Agreement

AMYRIS BIOTECHNOLOGIES, INC.

RESTRICTED STOCK UNIT ISSUANCE AGREEMENT

1.   Grant of Restricted Stock Units .   The Corporation hereby awards to the Participant, as of the Award Date, Restricted Stock Units. Each Restricted Stock Unit which vests pursuant to the vesting schedule set forth below shall entitle Participant to receive one share of Common Stock on the specified issuance date. The number of shares of Common Stock subject to the awarded Restricted Stock Units, the applicable vesting schedule for those shares, the date on which those vested shares shall become issuable to Participant and the remaining terms and conditions governing the award (the “Award”) shall be as set forth in this Agreement. All capitalized terms in this Agreement shall have the meaning assigned to them in the attached Appendix A.

AWARD SUMMARY

 

Participant:

  

Lit Tele LLC

Award Date:

  

February 11, 2010

Number of Shares Subject to Award:

  

The maximum number of shares of Common Stock subject to this Award is 126,272 (the “Shares”). However, the actual number of shares of Common Stock issuable pursuant to this Award shall be determined in accordance with the Vesting Schedule set forth below.

Vesting Schedule:

  

31,568 of the Shares shall vest on the following dates, provided Participant remains in the Corporation’s Service through each such vesting date: December 31, 2009; March 31, 2010; June 30, 2010; and September 30, 2010. However, the Shares may be subject to accelerated vesting in whole or in part in accordance with the provisions of Paragraph 5 of this Agreement.

Issuance Schedule

  

Each Share in which Participant vests in accordance with the Vesting Schedule shall be issued, subject to Paragraph 8 of this Agreement and the Corporation’s collection of all applicable Withholding Taxes, on the date that particular Share vests (the “Issuance Date”) or as soon after that


  

scheduled Issuance Date as administratively practicable. The Shares which vest pursuant to Paragraph 5 of this Agreement shall be issued in accordance with the provisions of such Paragraph. In addition, any issued Shares shall be subject to the transfer restrictions of this Agreement.

 

In no event shall any fractional shares be issued. Accordingly the total number of Shares to be issued pursuant to the Award shall, to the extent necessary, be rounded down to the next whole Share.

2.   Limited Transferability .   Prior to actual receipt of the Shares which vest and become issuable hereunder, Participant may not transfer any interest in the Award or the underlying Shares; however, the foregoing shall not apply to any transfer of interest in the Award or the underlying shares without consideration to any person or entity, directly or indirectly, controlling, controlled by or under common control with, the Participant, provided that (A) the Participant shall inform the Corporation of such transfer prior to effecting it and (B) the transferee shall enter into a written agreement to be bound by and comply with all provisions of this Agreement, as if it were the original participant hereunder. Any issued Shares shall be subject to the restrictions of Paragraphs 9 and 10 of this Agreement. In addition, Participant shall make no disposition of any issued Shares unless and until there is compliance with all of the following requirements: (i) Participant shall have provided the Corporation with a written summary of the terms and conditions of the proposed disposition; (ii) Participant shall have complied with all requirements of this Agreement applicable to the disposition of the Shares; and (iii) Participant shall have provided the Corporation with written assurances, in form and substance satisfactory to the Corporation, that (a) the proposed disposition does not require registration of the Shares under the 1933 Act or (b) all appropriate action necessary for compliance with the registration requirements of the 1933 Act or any exemption from registration available under the 1933 Act (including Rule 144) has been taken.

3.   Cessation of Service .   Should Participant cease Service for any reason prior to vesting in one or more Shares subject to this Award, then the Award will be immediately cancelled with respect to those unvested Shares, and the number of Restricted Stock Units will be reduced accordingly. Participant shall thereupon cease to have any right or entitlement to receive any Shares under those cancelled units. Should Participant’s Service terminate by reason of Misconduct, then this Award will be immediately cancelled with respect to all the Restricted Stock Units subject to such Award, whether vested or unvested at the time, and Participant shall thereupon cease to have any right or entitlement to receive any Shares under this Award and the cancelled Restricted Stock Units.

4.   Stockholder Rights.    The holder of this Award shall not have any stockholder rights, including voting or dividend rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares following their actual issuance upon the Corporation’s collection of the applicable Withholding Taxes.

 

2


5.   Change of Control .

(a) Any Restricted Stock Units subject to this Award at the time of a Change in Control may be assumed by the successor entity or otherwise continued in full force and effect or may be replaced with a cash incentive program of the successor entity which preserves the Fair Market Value of the unvested shares of Common Stock subject to the Award at the time of the Change in Control and provides for subsequent payout of that value in accordance with the vesting schedule applicable to the Award. In the event of such assumption or continuation of the Award or such replacement of the Award with a cash incentive program, no accelerated vesting of the Restricted Stock Units shall occur at the time of the Change in Control.

(b) In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award shall be adjusted immediately after the consummation of the Change in Control so as to apply to the number and class of securities into which the Shares subject to those units immediately prior to the Change in Control would have been converted in consummation of that Change in Control had those Shares actually been issued and outstanding at that time. To the extent the actual holders of the outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation (or parent entity) may, in connection with the assumption or continuation of the Restricted Stock Units subject to the Award at that time and with Participant’s prior written consent, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in the Change in Control transaction, provided the substituted common stock is readily tradable on an established U.S. securities exchange or market.

(c) If the Restricted Stock Units subject to this Award at the time of the Change in Control are not assumed or otherwise continued in effect or replaced with a cash incentive program under Section 6(a), then those units will vest immediately prior to the closing of the Change in Control. The Shares subject to those vested units will be issued immediately upon such vesting (or otherwise converted into the right to receive the same consideration per share of Common Stock payable to the other stockholders of the Corporation in consummation of that Change in Control), subject to the Corporation’s collection of the applicable Withholding Taxes.

(d) This Agreement shall not in any way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

6.   Adjustment in Shares .   Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation’s receipt of consideration, appropriate adjustments shall be made to the total number and/or class of securities issuable pursuant to this Award in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.

 

3


7.   Compliance with Laws and Regulations .   The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Corporation and Participant with all applicable requirements of law relating thereto and with all applicable regulations of any Stock Exchange on which the Common Stock may be listed for trading at the time of such issuance.

8.   Representations .   At the time of issuance of the Shares, Participant shall, if required by the Corporation, deliver to the Corporation Participant’s Investment Representation Statement in the form attached hereto as Exhibit A.

9.   Market Stand-Off .

(a) In connection with any underwritten public offering by the Corporation of its equity securities pursuant to an effective registration statement filed under the 1933 Act, including the Corporation’s initial public offering, Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to, any issued Shares without the prior written consent of the Corporation or its underwriters. Such restriction (the “Market Stand-Off”) shall be in effect for such period of time from and after the effective date of the final prospectus for the offering as may be requested by the Corporation or such underwriters. In no event, however, shall such period exceed one hundred eighty (180) days, and the Market Stand-Off shall in no event be applicable to any underwritten public offering effected more than two (2) years after the effective date of the Corporation’s initial public offering.

(b) Participant shall be subject to the Market Stand-Off provided and only if the officers and directors of the Corporation are also subject to similar restrictions.

(c) Any new, substituted or additional securities which are by reason of any Recapitalization or Reorganization distributed with respect to the issued Shares shall be immediately subject to the Market Stand-Off, to the same extent the issued Shares are at such time covered by such provisions.

(d) In order to enforce the Market Stand-Off, the Corporation may impose stop-transfer instructions with respect to the issued Shares until the end of the applicable stand-off period.

10.   Right of First Refusal

(a)   Grant .     The Corporation is hereby granted the right of first refusal (the “First Refusal Right”), exercisable in connection with any proposed transfer of the Shares. For purposes of this Section 10, the term “transfer” shall include any sale, assignment, pledge, encumbrance or other disposition of the Shares intended to be made by Participant.

 

4


(b)   Notice of Intended Disposition .     In the event Participant desires to accept a bona fide third-party offer for the transfer of any or all of such shares (the Shares subject to such offer to be hereinafter referred to as the “Target Shares”), Participant shall promptly (i) deliver to the Corporation written notice (the “Disposition Notice”) of the terms of the offer, including the purchase price and the identity of the third-party offeror, and (ii) provide satisfactory proof that the disposition of the Target Shares to such third-party offeror would not be in contravention of the provisions of this Agreement.

(c)   Exercise of the First Refusal Right .     The Corporation shall, for a period of twenty-five (25) days following receipt of the Disposition Notice, have the right to repurchase any or all of the Target Shares subject to the Disposition Notice upon the same terms as those specified therein or upon such other terms (not materially different from those specified in the Disposition Notice) to which Participant consents. Such right shall be exercisable by delivery of written notice (the “Exercise Notice”) to Participant prior to the expiration of the twenty-five (25)-day exercise period. If such right is exercised with respect to all the Target Shares, then the Corporation shall effect the repurchase of such shares, including payment of the purchase price, not more than five (5) business days after delivery of the Exercise Notice; and at such time the certificates representing the Target Shares shall be delivered to the Corporation.

Should the purchase price specified in the Disposition Notice be payable in property other than cash or evidences of indebtedness, the Corporation shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property. If Participant and the Corporation cannot agree on such cash value within ten (10) days after the Corporation’s receipt of the Disposition Notice, the valuation shall be made by an appraiser of recognized standing selected by Participant and the Corporation or, if they cannot agree on an appraiser within twenty (20) days after the Corporation’s receipt of the Disposition Notice, each shall select an appraiser of recognized standing and the two (2) appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by Participant and the Corporation. The closing shall then be held on the later of (i) the fifth (5th) business day following delivery of the Exercise Notice or (ii) the fifth (5th) business day after such valuation shall have been made.

(d)   Non-Exercise of the First Refusal Right .     In the event the Exercise Notice is not given to Participant prior to the expiration of the twenty-five (25)-day exercise period, Participant shall have a period of thirty (30) days thereafter in which to sell or otherwise dispose of the Target Shares to the third-party offeror identified in the Disposition Notice upon terms (including the purchase price) no more favorable to such third-party offeror than those specified in the Disposition Notice; provided, however, that any such sale or disposition must not be effected in contravention of the provisions of Paragraphs 2, 9 and 11 of this Agreement. The third-party offeror shall acquire the Target Shares subject to the First Refusal Right and the provisions and restrictions of Paragraphs 2, 9 and 11, and any subsequent disposition of the acquired shares must be effected in compliance with the terms and conditions of such First Refusal Right and the provisions and restrictions of Paragraphs 2, 9 and 11. In the event Participant does not effect such sale or disposition of the Target Shares within the specified thirty (30)-day period, the First Refusal Right shall

 

5


continue to be applicable to any subsequent disposition of the Target Shares by Participant until such right lapses.

(e) Partial Exercise of the First Refusal Right . In the event the Corporation makes a timely exercise of the First Refusal Right with respect to a portion, but not all, of the Target Shares specified in the Disposition Notice, Participant shall have the option, exercisable by written notice to the Corporation delivered within five (5) business days after Participant’s receipt of the Exercise Notice, to effect the sale of the Target Shares pursuant to either of the following alternatives:

(i)        sale or other disposition of all the Target Shares to the third-party offeror identified in the Disposition Notice, but in full compliance with the requirements of Section 10(d), as if the Corporation did not exercise the First Refusal Right; or

(ii) sale to the Corporation of the portion of the Target Shares which the Corporation has elected to purchase, such sale to be effected in substantial conformity with the provisions of Section 10(c). The First Refusal Right shall continue to be applicable to any subsequent disposition of the remaining Target Shares until such right lapses.

Participant’s failure to deliver timely notification to the Corporation shall be deemed to be an election by Participant to sell the Target Shares pursuant to alternative (i) above.

(f) Recapitalization/Reorganization .

(i)        Any new, substituted or additional securities or other property which is by reason of any Recapitalization distributed with respect to the issued Shares shall be immediately subject to the First Refusal Right, but only to the extent the issued Shares are at the time covered by such right.

(ii)        In the event of a Reorganization, the First Refusal Right shall remain in full force and effect and shall apply to the new capital stock or other property received in exchange for the issued Shares in consummation of the Reorganization, but only to the extent the issued Shares are at the time covered by such right.

(g) Lapse . The First Refusal Right shall lapse upon the earliest to occur of (i) the first date on which shares of the Common Stock are held of record by more than five hundred (500) persons, (ii) a determination made by the Board that a public market exists for the outstanding shares of Common Stock or (iii) a firm commitment underwritten public offering, pursuant to an effective registration statement under the 1933 Act, covering the offer and sale of the Common Stock in the aggregate amount of at least twenty million dollars ($20,000,000). However, the Market Stand-Off shall continue to remain in full force and effect following the lapse of the First Refusal Right.

 

6


(h)   No Waiver .     The failure of the Corporation in any instance to exercise the First Refusal Right shall not constitute a waiver of any other repurchase rights and/or rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Corporation and Participant. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

(i)   Cancellation of Shares .    If the Corporation shall make available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased in accordance with the provisions of this Agreement, then from and after such time, the person from whom such shares are to be repurchased shall no longer have any rights as a holder of such shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such shares shall be deemed purchased in accordance with the applicable provisions hereof, and the Corporation shall be deemed the owner and holder of such shares, whether or not the certificates therefor have been delivered as required by this Agreement.

(j)     Exempted Transfers .      Notwithstanding the foregoing, the First Refusal Right of the Corporation set forth in this Section 10 shall not apply to any transfer without consideration to any person or entity, directly or indirectly, controlling, controlled by or under common control with the Participant; provided that (A) the Participant shall inform the Corporation of such transfer prior to effecting it and (B) the transferee shall enter into a written agreement to be bound by and comply with all provisions of this Agreement, as if it were the original participant hereunder. Such transferred Shares shall remain “Shares” hereunder, and such transferee shall be treated as the “Participant” for purposes of this Agreement.

11.   Restrictive Legends and Refusal to Transfer .

(a) The stock certificates for the Shares shall be endorsed with one or more of the following restrictive legends:

“The shares represented by this certificate have not been registered under the Securities Act of 1933. The shares may not be sold or offered for sale in the absence of (a) an effective registration statement for the shares under such Act, (b) a ‘no action’ letter of the Securities and Exchange Commission with respect to such sale or offer or (c) satisfactory assurances to the Corporation that registration under such Act is not required with respect to such sale or offer.”

 

7


“The shares represented by this certificate are subject to certain rights of first refusal granted to the Corporation and accordingly may not be sold, assigned, transferred, encumbered, or in any manner disposed of except in conformity with the terms of a written agreement dated July 31, 2009, between the Corporation and the registered holder of the shares (or the predecessor in interest to the shares). A copy of such agreement is maintained at the Corporation’s principal corporate offices.”

(b) The Corporation shall not be required (i) to transfer on its books any Shares which have been sold or transferred in violation of the provisions of this Agreement or (ii) to treat as the owner of the Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom the Shares have been transferred in contravention of this Agreement.

12. Notices .   Any notice required to be given or delivered to the Corporation under the terms of this Agreement shall be in writing and addressed to the Corporation at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated below Participant’s signature line on this Agreement. All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.

13. Successors and Assigns .   Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and Participant and Participant’s assigns.

14. Governing Law .   The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of California without resort to that State’s conflict-of-laws rules.

15. Employment at Will .   Nothing in this Agreement shall confer upon Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining Participant) or of Participant, which rights are hereby expressly reserved by each, to terminate Participant’s Service at any time for any reason, with or without cause.

16. Participant Undertaking .   Participant hereby agrees to take whatever additional action and execute whatever additional documents the Corporation may deem necessary or advisable in order to carry out or effect one or more of the obligations or

 

8


restrictions imposed on either Participant or the issued Shares pursuant to the provisions of this Agreement.

IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first indicated above.

 

AMYRIS BIOTECHNOLOGIES, INC.

 

By:            

   

Title:

   

 

LIT TELE LLC, PARTICIPANT

Signature:

Title:

Signature:

   

Title:

   

Address:

   
   

 

9


APPENDIX A

DEFINITIONS

The following definitions shall be in effect under the Agreement:

A. Agreement shall mean this Restricted Stock Unit Issuance Agreement.

B. Award shall mean the award of Restricted Stock Units made to Participant pursuant to the terms of this Agreement.

C. Award Date shall mean the date the Restricted Stock Units are awarded to Participant pursuant to the Agreement and shall be the date indicated in Section 1 of the Agreement.

D. Board shall mean the Corporation’s Board of Directors.

E. Change in Control shall mean a change in ownership or control of the Corporation effected through any of the following transactions:

(i)        a merger, consolidation or other reorganization approved by the Corporation’s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction, or

(ii)        a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution of the Corporation, or

(iii)        the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders.

In no event shall any public offering of the Corporation’s securities be deemed to constitute a Change in Control.

F. Code shall mean the Internal Revenue Code of 1986, as amended.

G. Common Stock shall mean shares of the Corporation’s common stock.


H. Corporation shall mean Amyris Biotechnologies, Inc., a California corporation, and any successor corporation to all or substantially all of the assets or voting stock of Amyris Biotechnologies, Inc.

I. Disposition Notice shall have the meaning assigned to such term in Section 10(b).

J. Exercise Notice shall have the meaning assigned to such term in Section 10(c).

K. Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

(i)        If the Common Stock is at the time traded on the Nasdaq Global or Global Select Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers for that particular Stock Exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(ii)        If the Common Stock is at the time listed on any other Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Board to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(iii)        If the Common Stock is not at the time neither listed on any Stock Exchange, then the Fair Market Value shall be determined by the Board after taking into account such factors as the Board shall deem appropriate.

L. First Refusal Right shall have the meaning assigned to such term in Section 10.

M. Market Stand-Off shall mean the market stand-off restriction specified in Section 9.

N. Misconduct shall mean the commission of any act of fraud, embezzlement or dishonesty by Participant or Participant’s agents, any unauthorized use or disclosure by such person of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by Participant or its agents adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in

 

A-2


a material manner. The foregoing definition shall not be deemed to be inclusive of all the acts or omissions which the Corporation (or any Parent or Subsidiary) may consider as grounds for the dismissal or discharge of any optionee, participant or other person in the service of the Corporation (or any Parent or Subsidiary).

O. 1934 Act shall mean the Securities Exchange Act of 1934, as amended from time to time.

P. Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

Q. Recapitalization shall mean any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the Corporation’s outstanding Common Stock as a class without the Corporation’s receipt of consideration.

R. Reorganization shall mean any of the following transactions:

(i)        a merger or consolidation in which the Corporation is not the surviving entity,

(ii)        a sale, transfer or other disposition of all or substantially all of the Corporation’s assets,

(iii)        a reverse merger in which the Corporation is the surviving entity but in which the Corporation’s outstanding voting securities are transferred in whole or in part to a person or persons different from the persons holding those securities immediately prior to the merger, or

(iv)        any transaction effected primarily to change the state in which the Corporation is incorporated or to create a holding company structure.

S. Restricted Stock Unit shall mean each unit subject to this Award which shall entitle Participant to receive one share of Common Stock at a designated time following the vesting of that unit.

T. Service shall mean Participant’s performance of services for the Corporation (or any Parent or Subsidiary) pursuant to the Amended and Restated Advisory Services Agreement between the Corporation and Participant dated July 31, 2009. For purposes of this Agreement, Participant shall be deemed to cease Service immediately upon the occurrence of the either of the following events: (i) Participant no longer performs services in the foregoing capacity for the Corporation (or any Parent or Subsidiary) or (ii) the entity for which Participant performs such services ceases to remain a Parent or Subsidiary of

 

A-3


the Corporation, even though Participant may subsequently continue to perform services for that entity.

U. Stock Exchange shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.

V. Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

W. Target Shares shall have the meaning assigned to such term in Section 10(b).

X. Withholding Taxes shall mean the employment taxes, social security taxes, social insurance, payroll taxes, contributions, payment on account obligations, national taxes and other applicable taxes and payments required to be withheld by the Corporation in connection with the vesting of the shares of Common Stock under the Award or the issuance of shares of Common Stock under the Award.

 

A-4


EXHIBIT A

INVESTMENT REPRESENTATION STATEMENT

 

Participant:

       

Corporation:

       

Security:

  

_______________ shares of Common Stock (“Shares”)

Date:

       

Representations : In connection with the issuance of the Shares, Participant hereby represents to the Corporation as follows:

(i)        The Shares have not been registered under the 1933 Act and are being issued to Participant in reliance upon the exemption from such registration provided by Section 4(2) of the 1933 Act. Participant hereby confirms that Participant has been informed that the Shares are restricted securities under the 1933 Act and may not be resold or transferred unless the Shares are first registered under the Federal securities laws or unless an exemption from such registration is available.

(ii)        Participant is acquiring the Shares solely for investment purposes for Participant’s own account, and not as a nominee or agent and with no present intention of distributing, reselling, granting any participation in or otherwise distributing any of the Shares or any interest therein other than pursuant to the 1933 Act. Participant does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant a participating interest in, any of the Shares.

(iii)        Participant is aware of the Corporation’s business affairs and financial condition and has been furnished with, and has had access to, such information as Participant considers necessary or appropriate for deciding whether to invest in the Shares. Participant has had an opportunity to ask questions and receive answers from the Corporation regarding the terms and conditions of the issuance of the Shares.

(iv)        Participant understands that the Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, Participant must hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or unless an exemption from such registration and qualification requirements is available. Participant acknowledges that the Corporation has no obligation to register or qualify the Shares for resale. Participant further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and requirements relating to the Corporation which are outside of Participant’s control, and which the Corporation is under no obligation to and may not be able to satisfy.


(v)        Participant understands that there is no public market for the Shares, that no market may ever develop for them, and that the Shares have not been approved or disapproved by the Securities and Exchange Commission or any governmental agency.

(vi)        Participant understands that the Shares are subject to certain restrictions on transfer set forth in the Restricted Stock Unit Agreement between the Corporation and Participant dated as of [                          ], 20[    ] (the “Agreement”).

(vii)        Participant is able to fend for itself in the transactions contemplated by the Agreement, can bear the economic risk of investment in the Shares and has such knowledge and experience in financial or business matters to be capable of evaluating the merits and risks of the investment in the Shares.

(viii)        If Participant is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code), Participant represents that it has satisfied itself to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares, including the legal requirements within its jurisdiction for the purchase of the Shares, any foreign exchange restrictions applicable to such purchase, any governmental or other consents that may need to be obtained and any income tax and other tax consequences, if any, that may be relevant to the purchase, holding, sale or transfer of the Shares. Participant’s subscription and payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of Participant’s jurisdiction.

(ix)        Participant has read the following definition of “Accredited Investor” from Rule 501 of Regulation D and certifies that Participant is an “Accredited Investor:”

Accredited Investor . “Accredited investor” shall mean any person who comes within any of the following categories, or who the issuer reasonably believes comes within any of the following categories, at the time of the sale of the securities to that person:

•        Any natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000

•        Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year

•         Any bank as defined in section 3(a)(2) of the Securities Act of 1933, as amended, (the “Act”) or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; any broker dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; any insurance company as defined in Section 2(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small

 

A-2


Business Investment Act of 1958; any employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000; or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors

•        any private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 (a U.S. venture capital fund which invests primarily through private placements in non-publicly traded securities and makes available (either directly or through co-investors) to the portfolio companies significant guidance concerning management, operations or business objectives)

•        Any organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000

•        Any director, executive officer or general partner of the issuer of the securities being offered or sold, or any director, executive officer or general partner of a general partner of that issuer

•        Any trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii)

•        Any entity in which all of the equity owners are accredited investors

 

A-3

Exhibit 10.17

 

 

 

LEASE

BETWEEN

ES EAST ASSOCIATES, LLC (LANDLORD)

AND

AMYRIS BIOTECHNOLOGIES, INC. (TENANT)

EMERYSTATION EAST

Emeryville, California


TABLE OF CONTENTS

 

            Page(s)

ARTICLE 1

  

BASIC LEASE PROVISIONS

   1

1.1

  

BASIC LEASE PROVISIONS

   1

1.2

  

ENUMERATION OF EXHIBITS AND RIDER

   6

1.3

  

DEFINITIONS

   6

ARTICLE 2

  

PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING

   12

2.1

  

LEASE OF PREMISES

   12

2.2

  

TEMPORARY PREMISES

   12

2.3

  

PILOT PLANT

   13

2.4

  

TERM

   14

2.5

  

FAILURE TO GIVE POSSESSION

   15

2.6

  

CONDITION OF PREMISES

   16

2.7

  

PARKING

   16

2.8

  

RENEWAL OPTION

   17

2.9

  

LEASE AT 5980 HORTON STREET (“EXISTING LEASE”) AND SUBLEASE AT 5915 HOLLIS STREET (“EXISTING SUBLEASE”)

   19

2.10

  

EXPANSION RIGHT

   20

2.11

  

SECOND FLOOR RIGHT OF FIRST REFUSAL

   22

2.12

  

FIRST FLOOR RIGHT OF FIRST OFFER

   23

2.13

  

OPTION TO TERMINATE

   24

ARTICLE 3

  

RENT

   25

3.1

  

PAYMENT OF RENT

   25

3.2

  

SERIES B FINANCING

   25

ARTICLE 4

  

RENT ADJUSTMENTS AND PAYMENTS

   25

4.1

  

RENT ADJUSTMENTS

   25

4.2

  

STATEMENT OF LANDLORD

   26

4.3

  

BOOKS AND RECORDS

   26

4.4

  

TENANT OR LEASE SPECIFIC TAXES

   27

ARTICLE 5

  

SECURITY DEPOSIT

   27

ARTICLE 6

  

SERVICES

   28

6.1

  

LANDLORD’S GENERAL SERVICES

   28

 

-i-


TABLE OF CONTENTS

(continued)

 

            Page(s)

6.2

  

ELECTRICAL SERVICES

   29

6.3

  

ADDITIONAL AND AFTER HOUR SERVICES

   30

6.4

  

TELEPHONE SERVICES

   30

6.5

  

DELAYS IN FURNISHING SERVICES

   31

6.6

  

CHOICE OF SERVICE PROVIDER

   32

6.7

  

SIGNAGE

   32

6.8

  

GARAGE STORAGE

   33

6.9

  

ROOF TOP COMMUNICATIONS EQUIPMENT

   33

ARTICLE 7

  

POSSESSION, USE AND CONDITION OF PREMISES

   34

7.1

  

POSSESSION AND USE OF PREMISES

   34

7.2

  

LANDLORD ACCESS TO PREMISES; APPROVALS

   44

7.3

  

QUIET ENJOYMENT

   45

ARTICLE 8

  

MAINTENANCE

   45

8.1

  

LANDLORD’S MAINTENANCE

   45

8.2

  

TENANT’S MAINTENANCE

   46

ARTICLE 9

  

ALTERATIONS AND IMPROVEMENTS

   46

9.1

  

TENANT ALTERATIONS

   46

9.2

  

LIENS

   48

9.3

  

EQUIPMENT LEASING AND FINANCING

   48

ARTICLE 10

  

ASSIGNMENT AND SUBLETTING

   49

10.1

  

ASSIGNMENT AND SUBLETTING

   49

10.2

  

RECAPTURE

   50

10.3

  

EXCESS RENT

   51

10.4

  

TENANT LIABILITY

   51

10.5

  

ASSUMPTION AND ATTORNMENT

   52

10.6

  

PROCESSING EXPENSES

   52

ARTICLE 11

  

DEFAULT AND REMEDIES

   52

11.1

  

EVENTS OF DEFAULT

   52

11.2

  

LANDLORD’S REMEDIES

   53

11.3

  

ATTORNEY’S FEES

   55

 

-ii-


TABLE OF CONTENTS

(continued)

 

            Page(s)

11.4

  

BANKRUPTCY

   56

11.5

  

LANDLORD’S DEFAULT

   57

ARTICLE 12

  

SURRENDER OF PREMISES

   57

12.1

  

IN GENERAL

   57

12.2

  

LANDLORD’S RIGHTS

   58

ARTICLE 13

  

HOLDING OVER

   58

ARTICLE 14

  

DAMAGE BY FIRE OR OTHER CASUALTY

   58

14.1

  

SUBSTANTIAL UNTENANTABILITY

   58

14.2

  

INSUBSTANTIAL UNTENANTABILITY

   59

14.3

  

RENT ABATEMENT

   59

14.4

  

WAIVER OF STATUTORY REMEDIES

   60

ARTICLE 15

  

EMINENT DOMAIN

   60

15.1

  

TAKING OF WHOLE OR SUBSTANTIAL PART

   60

15.2

  

TAKING OF PART

   60

15.3

  

COMPENSATION

   61

ARTICLE 16

  

INSURANCE

   61

16.1

  

TENANT’S INSURANCE

   61

16.2

  

FORM OF POLICIES

   61

16.3

  

LANDLORD’S INSURANCE

   62

16.4

  

WAIVER OF SUBROGATION

   62

16.5

  

NOTICE OF CASUALTY

   63

ARTICLE 17

  

WAIVER OF CLAIMS AND INDEMNITY

   63

17.1

  

WAIVER OF CLAIMS

   63

17.2

  

INDEMNITY BY TENANT

   64

17.3

  

INDEMNITY BY LANDLORD

   64

ARTICLE 18

  

RULES AND REGULATIONS

   65

18.1

  

RULES

   65

18.2

  

ENFORCEMENT

   65

ARTICLE 19

  

LANDLORD’S RESERVED RIGHTS

   65

ARTICLE 20

  

ESTOPPEL CERTIFICATES AND FINANCIAL STATEMENTS

   66

 

-iii-


TABLE OF CONTENTS

(continued)

 

            Page(s)

20.1

  

IN GENERAL

   66

20.2

  

ENFORCEMENT

   66

ARTICLE 21

  

RESERVED

   67

ARTICLE 22

  

REAL ESTATE BROKERS

   67

ARTICLE 23

  

MORTGAGEE PROTECTION

   67

23.1

  

SUBORDINATION AND ATTORNMENT

   67

23.2

  

MORTGAGEE PROTECTION

   68

ARTICLE 24

  

NOTICES

   68

ARTICLE 25

  

MISCELLANEOUS

   69

25.1

  

LATE CHARGES

   69

25.2

  

NO JURY TRIAL; VENUE: JURISDICTION

   70

25.3

  

DISCRIMINATION

   70

25.4

  

OPTION

   70

25.5

  

AUTHORITY

   70

25.6

  

ENTIRE AGREEMENT

   71

25.7

  

MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE

   71

25.8

  

EXCULPATION

   71

25.9

  

ACCORD AND SATISFACTION

   71

25.10

  

LANDLORD’S OBLIGATIONS ON SALE OF BUILDING

   71

25.11

  

BINDING EFFECT

   72

25.12

  

CAPTIONS

   72

25.13

  

TIME; APPLICABLE LAW; CONSTRUCTION

   72

25.14

  

ABANDONMENT

   72

25.15

  

LANDLORD’S RIGHT TO PERFORM TENANT’S DUTIES

   73

25.16

  

SECURITY SYSTEM

   73

25.17

  

NO LIGHT, AIR OR VIEW EASEMENTS

   73

25.18

  

RECORDATION

   73

25.19

  

SURVIVAL

   73

25.20

  

RIDERS

   73

 

-iv-


LEASE

ARTICLE 1

BASIC LEASE PROVISIONS

 

1.1

BASIC LEASE PROVISIONS

In the event of any conflict between these Basic Lease Provisions and any other Lease provision, such other Lease provision shall control.

 

 

  (1)

BUILDING AND ADDRESS:

 

 

 

EmeryStation East

 

 

5885 Hollis Street

 

 

Emeryville, California 94608

 

 

  (2)

LANDLORD AND ADDRESS:

 

 

 

ES East Associates, LLC

 

 

1120 Nye Street, Suite 400

 

 

San Rafael, California 94901

 

 

  (3)

TENANT AND CURRENT ADDRESS:

 

 

(a)

Name: Amyris Biotechnologies, Inc.

 

(b)

State of incorporation: California

 

 

 

Notices to Tenant shall be addressed:

 

 

 

Prior to the Commencement Date:

 

 

 

Amyris Biotechnologies, Inc.

 

 

5980 Horton Street

 

 

Emeryville, California 94608

 

 

Attention: President

 

 

 

with a copy to:

 

 

 

Amyris Biotechnologies, Inc.

 

 

5980 Horton Street

 

 

Emeryville, California 94608

 

 

Attention: General Counsel

 

 

 

On and after the Commencement Date:

 

 

 

At the Premises Attention: President

 

1


 

 

  with a copy to:

 

 

 

  At the Premises

 

 

  Attention: General Counsel

(4)         DATE OF LEASE: as of August 22, 2007

(5)        LEASE TERM:     Ten (10) years, subject to extension or early termination as provided herein.

(6)        PROJECTED COMMENCEMENT DATE:   April 23, 2008; provided, however, that such date is based upon certain assumptions specified in the Project Schedule set forth as Schedule 2 to Exhibit C ( i.e. , the period for the issuance of permits and the anticipated construction period for the Tenant Improvements), and such date shall be adjusted to the extent such Project Schedule is adjusted to reflect the actual period for issuance, of permits and the Contractor’s actual anticipated construction period for the Tenant Improvements (but not for delays in the preparation of Design Documents or Construction Drawings resulting from the failure of either Landlord or Tenant to provide information or review documents in accordance with the Project Schedule, but the Project Schedule shall be adjusted in the event the Design Group does not meet the timeframes set forth in the Project Schedule for the preparation of the Design Documents or the Construction Drawings through no fault of Landlord or Tenant) and shall also be adjusted to reflect the actual time for receipt and evaluation of bids, such adjustment to be confirmed by Landlord and Tenant in writing following the determination thereof, which determination shall be made at the time the Contractor for the Tenant Improvements is selected pursuant to the terms of the Workletter.

(7)        EXPIRATION DATE:   The last day of the 120th calendar month following the Commencement Date.

(8)        MONTHY BASE RENT:

 

PERIOD

  MONTHLY BASE RENT    RATE/RSF

Months 1 -9   1 / 2 *

  $110,384.17    —  

Months 9  1 / 2  -12

  $220,768.34    —  

Months 13-24

  $252,656.70    $3.57

Months 25-36

  $260,236.40    $3.68

Months 37-48

  $268,043.50    $3.79

Months 49-60

  $276,084.80    $3.90

Months 61-72

  $284,367.35    $4.02

Months 73-84

  $292,898.37    $4.14

Months 85-96

  $301,685.32    $4.26

Months 97-108

  $310,735.88    $4.39

Months 109-120

  $320,057.95    $4.53

The foregoing Monthly Base Rent shall be subject to increase to the extent and as provided for in Section 1.1(17) with respect to the amortization of the Additional Tenant Improvement Allowance. *See the definition of “Lease Year” below and Section 3.1 regarding the proration of Monthly Base Rent for any partial calendar month at the beginning of the first Lease Year.

 

2


Commencing on the Commencement Date, Tenant shall pay Tenant’s Share of all Operating Expenses and Taxes, in addition to the Monthly Base Rent.

Deferred Base Rent; Landlord Loan :   Notwithstanding the foregoing, at any time prior to the Commencement Date, Tenant may elect by written notice to Landlord to defer a portion of the Monthly Base Rent due under this Lease during the first thirty-six (36) months of the Term (the “Monthly Base Rent Deferral Period”), such portion being $0.60 per square foot of the Premises per month ( i.e. , $42,414.60 per month) (the “Monthly Deferral Amount”).

Such deferral of Monthly Base Rent shall be deemed to be a loan from Landlord to Tenant (the “Deferred Rent Loan”), with each Monthly Deferral Amount being deemed an advance under the Deferred Rent Loan made as of the first day of the month in which such Monthly Deferral Amount would otherwise be due and payable by Tenant as Monthly Base Rent owing hereunder. Except as otherwise provided below, no payment under the Deferred Rent Loan shall be due during the Monthly Base Rent Deferral Period.

Commencing on the first day of the thirty-seventh (37th) month of the Term, and continuing on the first day of each month thereafter to and including the first day of the sixtieth (60th) month of the Term (the “Deferred Rent Loan Final Payment Date”), the Deferred Rent Loan shall be due and payable in twenty-four (24) equal monthly installments in the amount of $65,035.72 (each a “Deferred Rent Loan Payment”) (Landlord and Tenant hereby acknowledge that the amount of each such Deferred Rent Loan Payment includes an “interest” factor of $0.02 per square foot), each of which Deferred Rent Loan Payments shall be an obligation of Tenant to Landlord separate and apart from, and in addition to, the Monthly Base Rent amount payable hereunder by Tenant for such month. The Deferred Rent Loan may be prepaid by Tenant in whole or in part (in one or more increments of $65,035.72), at any time and from time to time prior to the Deferred Rent Loan Final Payment Date. Any partial prepayment of the Deferred Rent Loan shall be applied to the last installment payment(s) of the Deferred Rent Loan. In the event of any monetary Default by Tenant under this Lease, there shall be no further deferral of Monthly Base Rent allowed hereunder (in the event that such monetary Default occurs during the Monthly Base Rent Deferral Period); and in any case in the event of a monetary Default by Tenant under this Lease, the outstanding balance of the Deferred Rent Loan shall become immediately due and payable without notice or demand by Landlord. In the event Tenant fails to make any Deferred Rent Loan Payment when due under the Deferred Rent Loan, such unpaid amount shall bear interest at the Default Rate until paid. In addition, the then outstanding balance of the Deferred Rent Loan shall be due and payable upon the termination of this Lease, if this Lease terminates for any reason prior to the Deferred Rent Loan Final Payment Date. For purposes hereof, if at any time the outstanding balance of the Deferred Rent Loan becomes due and payable pursuant to any of the foregoing provisions, such outstanding balance shall be determined by including therein the $0.02 per square foot interest factor noted above ( i.e. , for each three (3) Monthly Deferral Amounts that remain outstanding at such time, such outstanding principal balance shall be deemed to equal the amount of two (2) Deferred Rent Loan Payments, with appropriate proration for that portion of the outstanding Monthly Deferral Amounts equal to less than three (3) Monthly Deferral Amounts) together with any accrued but unpaid interest at the Default Rate, as provided for above; provided, however, that in no event shall Landlord be entitled to any such interest to the extent that the amount thereof would be in violation of any applicable usury law.

 

3


In the event Tenant elects such deferral of Monthly Base Rent as provided for above, Tenant shall deliver to Landlord, on or before the Commencement Date and on or before the first day of each quarterly (3-month) period thereafter during the Monthly Base Rent Deferral Period, a Letter of Credit as security for the payment of the Deferred Rent Loan (each such Letter of Credit being referred to as a “Deferred Rent Letter of Credit”). The amount of each such Deferred Rent Letter of Credit shall be equal to the amount of $130,071.44 ( i.e. , two (2) monthly Deferred Rent Loan Payments), based upon the assumption that the Monthly Deferral Amount will be deferred each month during the Monthly Base Rent Deferral Period and the Deferred Rent Loan will be repaid in twenty-four (24) equal monthly installments as provided for above. In the event Tenant fails to deliver any Deferred Rent Letter of Credit within five (5) days after written notice from Landlord of such failure, such failure shall constitute a monetary Default by Tenant with respect to the Deferred Rent Loan, in which case (a) no further deferral of Monthly Base Rent shall be allowed hereunder, and (b) the outstanding balance of the Deferred Rent Loan shall become immediately due and payable without notice or demand by Landlord. In the event that Tenant fails to make a Deferred Rent Loan Payment, or otherwise fails to pay the Deferred Rent Loan at any time the same shall become due and payable hereunder, within five (5) days after written notice from Landlord of such failure, such failure by Tenant shall constitute a monetary Default by Tenant under this Lease; and in such case Landlord may draw upon the Deferred Rent Letters of Credit up to the total amount due under the Deferred Rent Loan. One Deferred Rent Letter of Credit shall be released to Tenant immediately following Tenant’s (i) payment of the second Deferred Rent Loan Payment, and (ii) payment of every second Deferred Rent Loan Payment thereafter.

(9) RENTABLE AREA OF THE PREMISES:   70,691 rentable square feet, comprised of 36,031 rentable square feet on the first floor (Suite 100) and 34,660 rentable square feet on the second floor of the Building (Suite 200)

 

 

(10)

SUITE NUMBERS:     100 and 200

 

 

(11)

SECURITY DEPOSIT:     $735,893.31

 

 

 

The Security Deposit shall be paid by Tenant to Landlord within two (2) business days after the Date of Lease by cash or a Letter of Credit.

 

 

(12)

TENANT’S USE OF PREMISES:   General office and administration, and all legally permitted functions of a life science or research and development company, including chemistry labs, biology labs, fuel development and related uses.

 

 

(13)

PARKING:

(A)        Two (2) spaces per 1,000 rentable square feet of the Premises ( i.e. , 142 spaces based on 70,691 rentable square feet) consisting of 132 unreserved parking spaces and 10 reserved parking spaces in the Building garage.

(B)        One (1) space per 1,000 rentable square feet of the Premises ( i.e. , 71 spaces based on 70,691 rentable square feet) of unreserved parking spaces in the Terraces garage (5855 Horton Street), the Heritage Square surface lot (6121 Hollis Street) and/or other

 

4


lots or structures in the vicinity of the Building owned or controlled by Landlord or its affiliates (the “Offsite Parking”).

The total number of parking spaces shall not exceed 3 spaces per 1,000 square feet of the Premises.

In addition, Tenant may purchase guest parking validation for its visitors using the parking facilities serving the Project at the same discount rates available to Tenant for its parking in the Building, as set forth in Section 2.7.

(14)    GARAGE STORAGE FEE (if applicable pursuant to Section 6.8(e)): $1.00 industrial gross per month per usable square foot of the Garage Storage Area made available by Landlord to Tenant pursuant to Section 6.8(e), increased annually by 3%. Without limitation of the foregoing, no Operating Expenses or Taxes shall be payable in connection with Tenant’s use of the Garage Storage Area.

 

 

(15)

BROKERS:

 

 

 

Landlord’s Broker:

 

 

 

Cornish & Carey Commercial

 

 

5980 Horton Street

 

 

Emeryville, California 94608

 

 

 

Tenant’s Broker:

 

 

 

Aegis Realty Partners

 

 

130 Webster Street

 

 

Oakland, California 94607

(16)     BASIC TENANT IMPROVEMENT ALLOWANCE: $8,836,375.00 ($125.00 per rentable square foot of the Premises).

(17)     ADDITIONAL TENANT IMPROVEMENT ALLOWANCE:

In addition to the Basic Tenant Improvement Allowance specified in Section 1.1(16) above, Landlord shall provide an additional tenant improvement allowance to Tenant (the “Additional Tenant Improvement Allowance”) in an amount equal to fifty percent (50%) of the Additional Tenant Improvement Allowance Applicable Portion, as determined in accordance with Section 4 of the Workletter. In no event shall the Additional Tenant Improvement Allowance exceed a maximum of $1,767,275.00 ( i.e. , $25.00 per rentable square foot of the Premises).

The amount of the Additional Tenant Improvement Allowance funded by Landlord shall be amortized in equal monthly installments payable by Tenant over the initial ten (10) year Term of the Lease, at an annual interest rate of 9.5%, compounded monthly, with such monthly payments to commence on the Commencement Date and continuing on the first day of each month thereafter during the initial ten (10) year Term of the Lease; and the Monthly Base

 

5


Rent owing hereunder shall be increased by the amount of such monthly amortization payments due hereunder (such monthly amortization payments being referred to herein as the “Additional Tenant Improvement Allowance Monthly Payments”). For example, if the Additional Tenant Improvement Allowance funded by Landlord is $1,767,275.00, then, in addition to the Monthly Base Rent amount specified in Section 1.1(8) above, Tenant would owe an Additional Tenant Improvement Allowance Monthly Payment equal to $22,868.11 per month during the initial ten (10) year Term of the Lease.

 

1.2

ENUMERATION OF EXHIBITS AND RIDER

The Exhibits and Rider set forth below and attached to this Lease are incorporated in this Lease by this reference:

EXHIBIT A:   Plan of Premises

EXHIBIT A-1:   Garage Storage Area

EXHIBIT B:   Workletter Agreement

EXHIBIT C-1:   Laboratory Rules and Regulations

EXHIBIT C-2:   Rules and Regulations

EXHIBIT D:   Base Building Description

RIDER 1:   Commencement Date Agreement

RIDER 2:   Form of Letter of Credit

SCHEDULE 1:   Summary of Existing Tenants Rights to Available Premises

 

1.3

DEFINITIONS

For purposes hereof, the following terms shall have the following meanings:

AFFILIATE:   Any corporation or other business entity that is owned or controlled by, owns or controls, or is under common ownership or control with Tenant.

BUILDING:   The building located at the address specified in Section 1.1(1). The Building may include office, lab, retail and other uses.

COMMENCEMENT DATE:   The date specified in Section 2.4.

COMMON AREAS:   All areas of the Project made available by Landlord from time to time for the general common use or benefit of the tenants of the Building, and their employees and invitees, or the public, as such areas currently exist and as they may be changed from time to time.

DECORATION WORK:   Tenant Alterations which do not require a building permit and which do not involve any of the structural elements of the Building, or any of the Building’s systems, including its electrical, mechanical, plumbing, security, heating, ventilating, air-conditioning, communication, and fire and life safety systems.

DEFAULT RATE:   Two (2) percentage points above the rate then most recently announced by Bank of America N.T.&S.A. at its San Francisco main office as its base lending

 

6


reference rate, from time to time announced, but in no event higher than the maximum rate permitted by Law.

EXPIRATION DATE:   The date specified in Section 1.1(7).

FORCE MAJEURE:   Any accident, casualty, act of God, war or civil commotion, strike or labor troubles, or any cause whatsoever beyond the reasonable control of Landlord, including water shortages, energy shortages or governmental preemption in connection with an act of God, a national emergency, or by reason of Law, or by reason of the conditions of supply and demand which have been or are affected by act of God, war or other emergency.

INDEMNITEES:   Collectively, Landlord, any Mortgagee or ground lessor of the Property, the property manager and the leasing manager for the Property and their respective partners, members, directors, officers and employees.

LAND:   The parcel(s) of real estate on which the Building and Project are located.

LANDLORD WORK:   The construction and installation of improvements to the Premises to be furnished by Landlord, as specifically described in the Workletter or exhibits attached hereto.

LAWS OR LAW:   All laws, ordinances, rules, regulations, other requirements, orders, rulings or decisions adopted or made by any governmental body, agency, department or judicial authority having jurisdiction over the Property, the Premises or Tenant’s activities at the Premises and any covenants, conditions or restrictions of record which affect the Property.

LEASE:   This instrument and all exhibits and riders attached hereto.

LEASE YEAR:   The twelve month period beginning on the Commencement Date and each subsequent twelve month, or shorter (if applicable), period until the Expiration Date; provided that, if the Commencement Date occurs on a date other than the first day of a calendar month, the first Lease Year shall be deemed to include such partial calendar month and the twelve full calendar months thereafter. The proration of Monthly Base Rent for any such partial calendar month during which the Commencement Date occurs shall be as set forth in Section 3.1.

LETTER OF CREDIT:   An unconditional, irrevocable sight draft letter of credit, drawable in the San Francisco Bay Area, issued by a national bank reasonably satisfactory to Landlord (provided that Landlord hereby approves Silicon Valley Bank as an acceptable issuer of a Letter of Credit), naming Landlord as beneficiary and otherwise in form and substance reasonably satisfactory to Landlord. The Letter of Credit shall be for a one (1) year term and shall provide: (i) that Landlord may make partial and multiple draws thereunder; (ii) that if Tenant fails to pay any Rent due under the Lease (or a Deferred Rent Loan Payment pursuant to Section 1.1(8)) after applicable notice and cure periods, if any, with respect to any provision of the Lease, Landlord may at its sole option draw upon the Letter of Credit in an amount sufficient to cure such failure by Tenant, and the bank will honor a sight draft of Landlord accompanied only by a statement of Landlord that it has the right to draw upon the Letter of Credit pursuant to the terms of the Lease or the Tenant has filed a petition of bankruptcy; (iii) that notwithstanding

 

7


such statement, the bank shall honor such draw without inquiry and the bank shall not have the authority, ability, right or discretion to inquire as to the basis for such statement; (iv) that in the event of Landlord’s assignment or other transfer of its interest in the Lease, the Letter of Credit shall be freely transferable by Landlord, one or more times, without charge and without recourse to the Landlord or the assignee or transferee of such interest; (v) that the Letter of Credit is governed by the Uniform Customs and Practice for Documentary Credits (2007 revisions), International Chamber of Commerce Publication No. 600; (vi) that the Letter of Credit will be automatically renewed upon the expiration of its term for additional one (1) year periods, not to extend beyond sixty (60) days after the Expiration Date of the Lease; and (vii) that if the bank does not confirm the extension of the Letter of Credit at least thirty (30) days prior to the relevant annual expiration date or if Tenant does not substitute a replacement Letter of Credit by such date, or if a monetary Default occurs under the Lease, Landlord shall be entitled to draw on the Letter of Credit and to hold and apply such funds as an additional Security Deposit in accordance with the terms of the Lease. A Letter of Credit substantially in the form of Rider 2 attached hereto shall be deemed to satisfy the foregoing requirements.

MONTHLY BASE RENT:   The monthly rent specified in Section 1.1(8), as such amount may be increased pursuant to the terms of Section 1.1(17) hereof.

MORTGAGEE:   Any holder of a mortgage, deed of trust or other security instrument encumbering the Property.

NATIONAL HOLIDAYS:   New Year’s Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and Christmas Day and other holidays recognized by the Landlord and the janitorial and other unions servicing the Building in accordance with their contracts.

OPERATING EXPENSES:   All reasonable costs, expenses and disbursements of every kind and nature which Landlord incurs in connection with the ownership, management, operation, maintenance, replacement and repair of the Building and the Property (including, without limitation, (1) property management fees not to exceed an amount equal to 3.5% of gross revenues of the Property (“Management Fee Cap”); (2) costs and expenses of any capital expenditure or improvement, amortized over the useful life of the applicable capital expenditure or improvement, as reasonably determined by Landlord, together with interest thereon on the unamortized costs at the lower of the rate incurred by Landlord to finance such capital expenditure or improvement or the Default Rate, which capital expenditure or improvement (a) is made to the Property after the Commencement Date in order to comply with Laws enacted after the Commencement Date and which was not required to be made prior to such enactment, or (b) is installed for the purpose of reducing or controlling Operating Expenses; (3) the costs of changing utility service providers); and (4) the cost of operating a fitness center (currently such fitness center is located in the EmeryStation I building) for the benefit of the Project, as reasonably determined by Landlord. Operating Expenses shall not include, (i) costs of alterations of the premises of tenants of the Project, (ii) costs of capital improvements to the Project (except as expressly permitted above in the definition of “Operating Expenses”), (iii) depreciation charges, (iv) interest and principal payments on loans (except for loans for capital improvements which Landlord is allowed to include in Operating Expenses as provided above), (v) ground rental payments, (vi) real estate brokerage and leasing commissions, (vii) advertising and marketing expenses, (viii) costs of Landlord reimbursed by insurance

 

8


proceeds, (ix) expenses incurred in negotiating leases of tenants in the Project or enforcing lease obligations of tenants in the Project, (x) management fees in excess of the Management Fee Cap, (xi) Landlord’s general corporate overhead, (xii) reserves, (xiii) except for routine monitoring, costs associated with mold or any Hazardous Materials which are not the responsibility of Tenant hereunder, (xiv) any costs, fines or penalties incurred due to violations by Landlord of this Lease or any other lease of the Property, or due to the gross negligence or willful misconduct of Landlord or any Indemnitee, (xv) overhead profit increments paid to Landlord’s subsidiaries or affiliates for services on or to the Building or the Property or for supplies or other materials to the extent the cost of the services, supplies or materials exceeds the cost that would have been paid had the services, supplies or materials been provided by unaffiliated parties on a competitive basis (excluding, however, the property management fee, which is subject to the Management Fee Cap), (xvi) the cost of correcting any defect in the design or construction of the Building or the Common Areas, (xvii) costs of repairs (including capital repairs) necessary as a result of a casualty, except for commercially reasonable deductible amounts (if such deductible amounts pertain to capital expenditures, they shall be amortized over the useful life of the item(s) being repaired with interest at the rate specified in clause (2) above, and such amortization amount shall be included as an Operating Expense hereunder), (xviii) damage and repairs covered under any insurance policy carried by, or required to be carried pursuant to this Lease by, Landlord in connection with the Building or the Property, (xix) the cost of any service provided to any tenant (including Tenant) for which Landlord is entitled to reimbursement from such tenant directly and not as an Operating Expense, and (xx) the cost of any services provided to other tenants and not provided to Tenant. If any Operating Expense, though paid in one year, relates to more than one calendar year, at the option of Landlord such expense may be proportionately allocated among such related calendar years. Operating Expenses for the Building that are not, in Landlord’s reasonable discretion, allocable solely to either the lab, office or retail portion of the Building shall be equitably allocated by Landlord between such uses.

PREMISES:   The space located in the Building at the Suite Numbers listed in Section 1.1(10) and depicted on Exhibit A attached hereto (as the same may be increased by Tenant’s exercise of the Expansion Right provided for in Section 2.10 below).

PROJECT or PROPERTY:   The Project consists of the office and lab/research building with ground floor retail space located at the street address specified in Section 1.1(1) in Emeryville, California, the parking garage in the Building, such associated surface parking as designated by Landlord from time to time, landscaping and improvements, together with the Land, any associated interests in real property, and the personal property, fixtures, machinery, equipment, systems and apparatus located in or used in conjunction with any of the foregoing. The Project may also be referred to as the Property.

REAL PROPERTY:   The Property excluding any personal property.

RENT:   Collectively, Monthly Base Rent, Rent Adjustments, Rent Adjustment Deposits, Additional Tenant Improvement Allowance Monthly Payments, if applicable, Garage Storage Fee, if applicable, and all other charges, payments, late fees or other amounts required to be paid by Tenant under this Lease.

 

9


RENT ADJUSTMENT:   Any amounts owed by Tenant for payment of Operating Expenses or Taxes. The Rent Adjustments shall be determined and paid as provided in Article Four.

RENT ADJUSTMENT DEPOSIT:   An amount equal to Landlord’s estimate of the Rent Adjustment attributable to each month of the applicable calendar year (or partial calendar year) during the Term. On or before the Commencement Date and with each Landlord’s Statement (defined in Article Four), Landlord may estimate and notify Tenant in writing of its estimate of the Operating Expenses and of Taxes for such calendar year (or partial calendar year). Prior to the first determination by Landlord of the amount of Operating Expenses and of Taxes for the first calendar year (or partial calendar year), Landlord may estimate such amounts in the foregoing calculation. The last estimate by Landlord shall remain in effect as the applicable Rent Adjustment Deposit unless and until Landlord notifies Tenant in writing of a change, which notice may be given by Landlord from time to time during each year throughout the Term.

RENTABLE AREA OF THE PREMISES:   The amount of square footage set forth in Section 1.1(9). The Rentable Area of the Premises and the Building or Project shall not be revised during the Term except to reflect a physical expansion or reduction of the Premises, Building and/or Project, as the case may be. The Rentable Area of the Building as of the Date of Lease is 247,615 rentable square feet (comprised of 243,841 rentable square feet of laboratory/office space and 3,774 rentable square feet of retail space).

SECURITY DEPOSIT:   The amount specified in Section 1.1(11) to be deposited by Tenant with Landlord as security for Tenant’s performance of its obligations under this Lease.

STANDARD OPERATING HOURS:   Monday through Friday from 8:00 A.M. to 6:00 P.M. and Saturdays from 9:00 A.M. to 1:00 P.M., excluding National Holidays.

SUBSTANTIALLY COMPLETE or SUBSTANTIAL COMPLETION:   The substantial completion of the Landlord Work, except for minor insubstantial details of construction, decoration or mechanical adjustments which remain to be done, as evidenced by (i) Landlord’s delivery to Tenant of the written final inspection of the Landlord Work by the City of Emeryville which confirms that Tenant is permitted to occupy the Premises (as improved by the Landlord Work), and (ii) the issuance of a certificate of substantial completion by the Architect (as identified in the Workletter),

TAXES:   All federal, state and local governmental taxes, assessments and charges of every kind or nature, whether general, special, ordinary or extraordinary, which Landlord shall pay or become obligated to pay because of or in connection with the ownership, leasing, management, control or operation of the Property or any of its components (including any personal property used in connection therewith), which may also include any rental or similar taxes levied in lieu of or in addition to general real and/or personal property taxes. For purposes hereof, Taxes for any year shall be Taxes which are assessed for any period of such year, whether or not such Taxes are billed and payable in a subsequent calendar year. There shall be included in Taxes for any year the amount of all reasonable, out-of-pocket fees, costs and expenses (including reasonable attorneys’ fees) paid by Landlord during such year in seeking or obtaining any refund or reduction of Taxes (but not to exceed the amount of such refund or

 

10


reduction reasonably estimated to be realized therefrom). Taxes for any year shall be reduced by the net amount of any tax refund received by Landlord attributable to such year. If a special assessment payable in installments is levied against any part of the Property, Taxes for any year shall include only the installment of such assessment and any interest payable or paid during such year. Taxes shall not include (i) any federal or state inheritance, general income, gift or estate taxes, except that if a change occurs in the method of taxation resulting in whole or in part in the substitution of any such taxes, or any other assessment, for any Taxes as above defined, such substituted taxes or assessments shall be included in the Taxes, (ii) any documentary transfer taxes, or (iii) interest or penalties resulting from Landlord’s failure to pay Taxes in a timely manner.

TENANT ALTERATIONS:   Any alterations, improvements, additions, installations or construction by or on behalf of Tenant in or to the Premises or to any Building systems serving the Premises (excluding the Landlord Work). Tenant Alterations shall not include any of Tenant’s trade fixtures, equipment, inventory and/or personal property.

TENANT DELAY:   Any delay in the Substantial Completion of the Landlord Work by the Projected Commencement Date to the extent caused by:

(1)        any Change Order (as defined in the Workletter) requested or made by Tenant;

(2)        Tenant’s failure to submit plans, supply information, approve plans, specifications or estimates, or give authorizations within the applicable time periods specified in the Workletter;

(3)        Tenant’s failure to approve and pay for such Tenant Work as Landlord undertakes to complete at Tenant’s expense, pursuant to the terms of, and within the applicable time periods specified in, the Workletter;

(4)        the performance or completion by Tenant or any person engaged by Tenant of any work in or about the Premises; or

(5)        any other event expressly identified as a Tenant Delay in the Workletter.

TENANT’S SHARE:   The percentage that represents the ratio of the Rentable Area of the Premises to the Rentable Area of the Building, as determined by Landlord from time to time. Tenant acknowledges that the Rentable Area of the Premises and/or Rentable Area of the Building may change during the Term; provided, however, that the determination of Tenant’s Share at any time shall be subject to the limitation specified in the definition of the term “Rentable Area of the Premises,” as specified above.

TERM:   The term of this Lease commencing on the Commencement Date and expiring on the Expiration Date (as the same may be accelerated by the Option to Terminate pursuant to Section 2.13 or extended by the First Renewal Term pursuant to Section 2.8).

TERMINATION DATE:   The Expiration Date (subject to acceleration pursuant to Section 2.13 or extension pursuant to Section 2.8) or such earlier date as this Lease terminates or Tenant’s right to possession of the Premises terminates.

 

11


WORKLETTER:   The Agreement regarding the manner of completion of Landlord Work set forth on Exhibit B attached hereto.

ARTICLE 2

PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING

 

2.1

LEASE OF PREMISES

(a)        Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises for the Term and upon the terms, covenants and conditions provided in this Lease.

(b)        In addition to Tenant’s non-exclusive right to use the Common Areas, Tenant shall have the non-exclusive right to use of the conference room currently located on the second floor of EmeryStation I and the fitness center currently located in EmeryStation I in accordance with the standard policy regulating such usage, and at the hourly or monthly rates for the use thereof, established by Landlord (or the owner or operator of the building in which any such facility is located) from time to time; provided, however, that during the two (2) year period commencing on the Date of Lease, Tenant may use the conference center for up to 10 hours per month at no hourly cost for such usage. Landlord reserves the right, in its sole discretion, to relocate the conference room and/or fitness center to the Building, EmeryStation North, Heritage Square or any other building in the vicinity of the Building that is owned or operated by Landlord or an affiliate of Landlord, or to discontinue the provision of a conference room and/or fitness center as an amenity of the Project.

 

2.2

TEMPORARY PREMISES

(a)        Prior to the Commencement Date, Landlord shall use commercially reasonable efforts to make available to Tenant up to 12,000 rentable square feet of temporary premises (the “Temporary Premises”). The Temporary Premises shall be located either in the Building and/or in other buildings located in Emeryville or Berkeley owned by entities affiliated with Landlord and may be located in one or more of such buildings. Notwithstanding the foregoing or any other provision of this Section 2.2, Landlord makes no representation or promise that any such Temporary Premises will be available at any time for Tenant’s use.

(b)        Within thirty (30) days after the Date of Lease, Tenant shall notify Landlord as to the amount of any laboratory Temporary Premises which it believes it will require, and thereafter Landlord and Tenant shall cooperate reasonably with each other and in good faith to address, within ten (10) days after Landlord’s receipt of such notice from Tenant, Tenant’s needs for laboratory Temporary Premises (including, without limitation, identifying the location of the laboratory Temporary Premises, the delivery date for the laboratory Temporary Premises, and the Base Rent for the laboratory Temporary Premises (subject to Section 2.2(d) below)). Landlord shall have no obligation hereunder to provide, and Tenant shall have no obligation hereunder to lease, any Temporary Premises (either laboratory space or Office Space) unless any such Temporary Premises are available and the terms thereof are mutually acceptable to Landlord and Tenant.

(c)        As part of the Temporary Premises, a suite of office space with cubicle office furniture in place may be available for lease in EmeryStation North, Emery Station or Heritage

 

12


Square (the “Office Space”). If available, such Office Space may be leased by Tenant at the rate of $2.75 fully serviced per rentable square foot per month. Landlord will notify Tenant from time to time during the period from the Date of Lease until January 31, 2008, of any then-available Office Space containing a minimum of 2,000 rentable square feet, and Tenant shall have ten (10) business days after receipt of such notice to elect to lease such Office Space at the rental rate set forth in this Section 2.2(c) and on the other terms of this Section 2.2 applicable to Office Space.

(d)        The Monthly Base Rent for any laboratory Temporary Premises shall be equal to the lesser of (i) an amount equal to $3.47 per rentable square foot of such laboratory Temporary Premises, or (ii) the fair market rental value of such laboratory Temporary Premises, as reasonably determined by Landlord and Tenant prior to the occupancy of such laboratory Temporary Premises. In addition to Monthly Base Rent, Tenant shall pay Tenant’s Share of Operating Expenses and Taxes for the applicable building(s) in which the laboratory Temporary Premises are located, based on the ratio of the rentable square feet of the laboratory Temporary Premises in the applicable building to the total rentable square feet in the applicable building.

(e)        The Temporary Premises (as built out for laboratory use or office space, as applicable) shall be delivered to Tenant in its “as is” condition and Landlord shall have no obligation to perform any tenant improvements or other alterations in the Temporary Premises.

(f)        The Temporary Premises shall be solely for use by Tenant, and Tenant’s occupancy of the Temporary Premises shall be subject to all of the terms and conditions of this Lease (to the extent applicable), and Tenant shall provide evidence of the insurance coverage required hereunder prior to occupying any portion of the Temporary Premises.

(g)        Within thirty (30) days after the Commencement Date, Tenant shall surrender and vacate the Temporary Premises in substantially the same condition in which the Temporary Premises were delivered to Tenant, subject to ordinary wear and tear, casualty, condemnation and Landlord’s repair obligations. If Tenant shall not so vacate, Tenant shall be a holdover tenant with respect to the Temporary Premises and shall be subject to Article 13 of this Lease.

(h)        Notwithstanding anything to the contrary in this Section 2.2, if, despite Landlord’s commercially reasonable efforts to deliver such space, Landlord fails to deliver exclusive possession of an increment of the Temporary Premises (including any laboratory space or Office Space) which Tenant has elected to lease pursuant to this Section 2.2 by the delivery date therefor agreed to by Landlord and Tenant, Tenant shall have the right to rescind its election to lease such increment of Temporary Premises and shall have no further obligation with respect thereto.

 

2.3

PILOT PLANT

Tenant is currently defining specifications for its Pilot Plant and will explore potential locations in Premises, Building and Project once the requirements have been defined. If Tenant decides it does not wish to locate the Pilot Plant in the Premises, Landlord and Tenant shall cooperate in good faith to explore possibilities for locating the Pilot Plant in properties owned by Landlord or its affiliates in the vicinity of the Project, including, without limitation, the Project’s

 

13


south yard. In connection therewith, Landlord is willing to explore the potential acquisition of the adjacent gas station property; provided that Landlord shall not have any obligation to acquire such property and neither party shall have any obligation hereunder to enter into a lease with respect to such Pilot Plant.

 

2.4

TERM

(a)        The Commencement Date shall be the date determined as follows:

  (1)        If the Landlord Work is Substantially Complete on or before the Projected Commencement Date, then on the date which is the earlier to occur of: (a) the Projected Commencement Date (provided Landlord has delivered exclusive possession of the Premises to Tenant by such date), or (b) the date Tenant first occupies all or part of the Premises for the conduct of business; or

  (2)        If the Landlord Work is not Substantially Complete by the Projected Commencement Date, then on the date on which Landlord delivers exclusive possession of the Premises to Tenant with the Landlord Work Substantially Complete.

(b)        If Landlord is delayed in Substantially Completing the Landlord Work by the Projected Commencement Date as a result of any Tenant Delay, then the Commencement Date shall be accelerated by one (1) day for each day of such Tenant Delay. If Landlord believes a Tenant Delay has occurred, Landlord shall notify Tenant in writing within two (2) business days after the occurrence of the event, action or inaction which constitutes the Tenant Delay and the known or anticipated extent of the Tenant Delay, and Tenant shall have the right within two (2) business days after receipt of such notice to cure the event, action or inaction before such event, action or inaction shall constitute a Tenant Delay; provided, however, that ten (10) business days shall be the maximum number of cure days available to Tenant for the cure of any such event(s), action(s) or inaction(s) constituting a Tenant Delay, after which Tenant shall not be entitled to any further cure periods with respect to Tenant Delays (provided, however, that Landlord shall continue to notify Tenant of the occurrence of any Tenant Delays).

(c)        Landlord shall provide Tenant with written notice of the date that is twenty-one (21) days prior to the date that Landlord reasonably anticipates that the Landlord Work will be Substantially Complete. Tenant shall be allowed access into the Premises from and after such date specified by Landlord in such notice for installation of furniture, fixtures, phone and cabling, provided that such early access shall not interfere with the completion of Landlord Work. Such early entry shall be subject to all the terms and provisions of this Lease, except that Tenant shall have no obligation to pay Base Rent, Additional Rent or other charges during such early entry period unless Tenant commences business operations in the Premises during such early entry period.

(d)        Within thirty (30) days following the occurrence of the Commencement Date, Landlord and Tenant shall enter into an agreement (the form of which is attached hereto as Rider 1) confirming the Commencement Date and the Expiration Date. If Tenant fails to enter into such agreement (provided the same is accurate), then the Commencement Date and the Expiration Date shall be the dates designated by Landlord in such agreement.

 

14


2.5

FAILURE TO GIVE POSSESSION

If Landlord shall be unable to give possession of the Premises on the Projected Commencement Date by reason of the following: (i) despite Landlord’s commercially reasonable efforts in pursuing the same, the Landlord Work is not Substantially Complete, or (ii) for any other reason beyond Landlord’s reasonable control, then Landlord shall not be subject to any liability for the failure to give possession on said date. Under such circumstances the rent reserved and covenanted to be paid herein shall not commence until the Premises are made available to Tenant by Landlord in the condition required under this Lease, and no such failure to give possession on the Projected Commencement Date shall affect the validity of this Lease or the obligations of the Tenant hereunder. In the event of any dispute as to whether the Landlord Work is Substantially Complete, such dispute will be subject to resolution pursuant to the arbitration provision of Section 6 of the Workletter.

Notwithstanding the foregoing, if the Commencement Date (as determined pursuant to Section 2.4) has not occurred on or before the date that is thirty (30) days after the Projected Commencement Date (as such Projected Commencement Date is determined following the resolution of the assumptions specified in the Project Schedule set forth as Schedule 2 to Exhibit C hereto, as described in Section 1.1(6) above, and as such Projected Commencement Date shall be extended on a day-for-day basis for each day that the Commencement Date is delayed as a consequence of any events of Force Majeure ), Tenant, except as otherwise set forth in the next succeeding paragraph, as its sole remedy for such late delivery of the Premises (so long as Landlord has continued to use commercially reasonable efforts to pursue completion of the Tenant Improvements in the Premises), shall receive one (1) day of abatement of Monthly Base Rent for each day between such thirtieth (30th) day after such Projected Commencement Date (subject to the extension specified above) and the actual Commencement Date of this Lease, such Monthly Base Rent abatement to be applied to the first month(s) of Monthly Base Rent payable under this Lease, as specified in Section 1.1(8) above.

Notwithstanding the foregoing, if the Commencement Date (as determined pursuant to Section 2.4) has not occurred on or before the date that is one hundred eighty (180) days after the Projected Commencement Date (as such Projected Commencement Date is determined following the resolution of the assumptions specified in the Project Schedule set forth as Schedule 2 to Exhibit C hereto, as described in Section 1.1(6) above, and as such Projected Commencement Date shall be extended on a day-for-day basis for each day that the Commencement Date is delayed as a consequence of any events of Force Majeure ), then, in addition to the remedy set forth in the immediately preceding paragraph, Tenant shall have the right to terminate this Lease at any time thereafter upon ten (10) days’ notice to Landlord, in which case this Lease shall terminate as of the tenth (10th) after Landlord’s receipt of such notice from Tenant (including, if applicable, this Lease as it pertains to any Expansion Premises) unless the Commencement Date has occurred on or before such tenth (10th) day after Landlord’s receipt thereof; and in the event this Lease so terminates, any monies or deposits previously paid or delivered by Tenant to Landlord shall be promptly returned to Tenant, and neither party shall have any further obligations or liabilities hereunder. Further, in the event this Lease is so terminated, then any ROFR Space Lease entered into pursuant to Section 2.11, if any, and any lease of Available Premises entered into pursuant to Section 2.12, if any, shall also terminate as of the effective date of the termination of this Lease.

 

15


2.6

CONDITION OF PREMISES

Tenant shall notify Landlord in writing within thirty (30) days after the later of Substantial Completion of the Landlord Work or Landlord’s delivery of possession of the Premises of any “punch list items” with respect to the Landlord Work or any patent defects claimed by Tenant or in the materials or workmanship furnished by Landlord in completing the Landlord Work. Landlord shall proceed diligently to correct the items stated in such notice (and shall use commercially reasonable efforts to complete the correction of such items within thirty (30) days, to the extent such work can reasonably be accomplished within thirty (30) days). If Landlord disputes the existence of any such items, the decision of the Architect shall be final and binding on the parties, and Landlord shall proceed promptly after the decision of the Architect to correct such items in accordance with the immediately preceding sentence. No agreement of Landlord to alter, remodel, decorate, clean or improve the Premises or the Real Property and no representation regarding the condition of the Premises or the Real Property in connection with Tenant’s occupancy has been made by or on behalf of Landlord to Tenant, except as may be specifically stated in this Lease or in the Workletter. Notwithstanding the foregoing, Landlord shall deliver the Premises to Tenant in “broom clean” condition and with all Building systems in good working order.

 

2.7

PARKING

During the Term, Tenant may use up to the number of spaces specified in Section 1.1(13) for parking at the standard prevailing monthly rates being charged from time to time by Landlord or its parking operator without regard to discounts provided to any other occupants of the Building (as of the Date of Lease, such prevailing rates in the Building garage are $100.00 per stall per month for unreserved parking and $135.00 per stall per month for reserved parking in the Building garage). Notwithstanding anything herein to the contrary, with respect to the parking spaces in the Building garage, (i) Tenant shall not be obligated to pay any charges for such parking during the first year of the Term, (ii) Tenant shall be obligated to pay 50% of the prevailing monthly rates for such parking during the second year of the Term, and (iii) Tenant shall be obligated to pay 100% of the prevailing monthly rates for such parking thereafter. In the event Tenant fails at any time to pay the full amount of such parking charges, and such failure continues for a period of ten (10) days after written notice thereof from Landlord to Tenant, Tenant’s parking rights shall be reduced to the extent of Tenant’s failure to pay for any such parking. The locations and type of parking shall be designated by Landlord or Landlord’s parking operator from time to time. Tenant acknowledges and agrees that the parking spaces serving the Project may include tandem parking and a mixture of spaces for compact vehicles as well as full-size passenger automobiles, and that Tenant shall not use parking spaces for vehicles larger than the striped size of the parking spaces. All vehicles utilizing Tenant’s parking privileges shall prominently display identification stickers or other markers, and/or have passes or keycards for ingress and egress, as may be required and provided by Landlord or its parking operator from time to time. Tenant shall comply with any and all reasonable parking rules and regulations from time to time established by Landlord or Landlord’s parking operator, including a requirement that Tenant pay to Landlord or Landlord’s parking operator a reasonable charge for loss and replacement of passes, keycards, identification stickers or markers, and for any and all loss or other damage to the extent caused by persons or vehicles related to use of Tenant’s parking privileges. Tenant shall not allow any vehicles using Tenant’s parking privileges to be

 

16


parked, loaded or unloaded except in accordance with this Section, including in the areas and in the manner designated by Landlord or its parking operator for such activities. If any vehicle is using the parking or loading areas contrary to any provision of this Section 2.7, Landlord or its parking operator shall have the right, in addition to all other rights and remedies of Landlord under this Lease, to remove or tow away the vehicle without prior notice to Tenant, and the cost thereof shall be paid to Landlord within thirty (30) days after notice from Landlord to Tenant.

 

2.8

RENEWAL OPTION

(a)        Tenant shall have the option to renew this Lease with respect to either (i) the initial Premises as depicted on Exhibit A attached hereto, or (ii) such initial Premises, plus (A) the Expansion Premises, if any, incorporated into the Premises pursuant to Section 2.10, and/or (B) any ROFR Space, if any, with respect to which the expiration of the term of the applicable ROFR Space Lease coincides with the Expiration Date of this Lease, for one (1) additional term of five (5) years (“Renewal Option”), commencing upon expiration of the Term (“Renewal Term”). The Renewal Option must be exercised, if at all, by written notice given by Tenant to Landlord not earlier than twelve (12) months nor later than nine (9) months prior to expiration of the Term, which notice shall specify whether the Renewal Option is being exercised with respect to the area described in clause (i) or clause (ii) of the preceding sentence. If Tenant properly exercises the Renewal Option, references in the Lease to the Term shall be deemed to mean the Renewal Term, unless the context clearly provides otherwise. The Renewal Option shall be null and void and Tenant shall have no right to renew this Lease if on the date Tenant exercises the Renewal Option or on the date immediately preceding the commencement date of the Renewal Term a Default beyond the applicable cure period shall have occurred and be continuing hereunder.

(b)        If Tenant properly exercises the Renewal Option, then during the Renewal Term all of the terms and conditions set forth in this Lease as applicable to the Premises during the initial Term shall apply during the Renewal Term, including without limitation the obligation to pay Operating Expenses and Taxes, except that (i) Tenant shall take the Premises in their then “as-is” state and condition and Landlord shall have no obligation to make or pay for any improvements to the Premises, and (ii) during the Renewal Term the Monthly Base Rent payable by Tenant shall be 95% of the monthly Fair Market Rent during the Renewal Term as hereinafter set forth.

(c)        For purposes of this Section, the term “Fair Market Rent” shall mean the rental rate, additional rent adjustment and other charges and increases, if any, for space comparable in size, location and quality of the Premises under primary lease (and not sublease) to new or renewing tenants, for a comparable term with a tenant improvement allowance, if applicable and taking into consideration such amenities as existing improvements, view, floor on which the Premises are situated and the like, situated in comparable buildings in Emeryville or Berkeley. The Fair Market Rent shall not take into account any Tenant Alterations paid for by Tenant.

(d)        If Tenant properly exercises the Renewal Option to extend the term of the Lease, Landlord, by notice to Tenant not more than thirty (30) days after Tenant’s exercise of the Renewal Option, shall indicate Landlord’s determination of 95% of the Fair Market Rent. Tenant, within thirty (30) days after date on which Landlord provides such notice of 95% of the

 

17


Fair Market Rent shall either (i) give Landlord final binding written notice (“Binding Notice”) of Tenant’s acceptance of Landlord’s determination of 95% of the Fair Market Rent, or (ii) if Tenant disagrees with Landlords’ determination, provide Landlord with written notice of Tenant’s election to submit the Fair Market Rent to binding arbitration (the “Arbitration Notice”). If Tenant fails to provide Landlord with either a Binding Notice or Arbitration Notice within such thirty (30) day period, Tenant shall have been deemed to have given the Binding Notice. If Tenant provides Landlord with a Binding Notice, Landlord and Tenant shall enter into the Renewal Amendment (as defined below) upon the terms and conditions set forth herein.

(e)        If the parties are unable to agree upon the Fair Market Rent for the Premises within ten (10) days after Landlord’s receipt of the Arbitration Notice, Fair Market Rent as of commencement of the , Renewal Term shall be determined as follows:

  (1)        Within twenty (20) days after receipt of Landlord’s notice specifying Fair Market Rent, Tenant, at its sole expense, shall obtain and deliver in writing to Landlord a determination of the Fair Market Rent for the Premises for a term equal to the , Renewal Term from a broker or appraiser (“Tenant’s broker”) licensed in the State of California and engaged in the office and lab markets in Emeryville and Berkeley, California, for at least the immediately preceding five (5) years. If Landlord accepts such determination, Landlord shall provide written notice thereof within ten (10) days after Landlord’s receipt of such determination and the Base Rent for the , Renewal Term shall be adjusted to an amount equal to 95% of the Fair Market Rent determined by Tenant’s broker. Landlord shall be deemed to have accepted Tenant’s determination if Landlord fails to respond within the ten (10) day period.

  (2)        If Landlord provides notice that it does not accept such determination, within twenty (20) days after receipt of the determination of Tenant’s broker, Landlord shall designate a broker or appraiser (“Landlord’s broker”) licensed in the State of California and possessing the qualifications set forth in (1) above. Landlord’s broker and Tenant’s broker shall name a third broker, similarly qualified and who is not then or has not previously acted for either party, within five (5) days after the appointment of Landlord’s broker (“Neutral Broker”).

  (3)        The Neutral Broker shall determine the Fair Market Rent for the Premises as of the commencement of the Renewal Term within fifteen (15) days after the appointment of the Neutral Broker by choosing the determination of the Landlord’s broker or the Tenant’s broker which is closest to its own determination of Fair Market Rent. The decision of the Neutral Broker shall be binding on Landlord and Tenant.

(f)        Landlord shall pay the costs and fees of Landlord’s broker in connection with any determination hereunder, and Tenant shall pay the costs and fees of Tenant’s broker in connection with such determination. The costs and fees of the Neutral Broker shall be paid one-half by Landlord and one-half by Tenant.

(g)        If the amount of the Fair Market Rent has not been determined pursuant to this Section 2.8 as of the commencement of the Renewal Term, then Tenant shall continue to pay the Base Rent in effect at the expiration of the initial Term until the amount of the Fair Market Rent is determined. When such determination is made, Tenant shall pay any deficiency to Landlord upon demand or Landlord shall credit any overage to Tenant.

 

18


(h)        If Tenant is entitled to and properly exercises its Renewal Option, upon determination of Fair Market Rent pursuant to this Section 2.8, Landlord shall prepare an amendment (the “Renewal Amendment”) to reflect changes in the Base Rent, Term, Expiration Date and other appropriate terms. The Renewal Amendment shall be sent to Tenant within a reasonable time after determination of Fair Market Rent and, provided the same is accurate, Tenant shall execute and return the Renewal Amendment to Landlord within ten (10) days after Tenant’s receipt of same, but an otherwise valid exercise of the Renewal Option shall be fully effective whether or not the Renewal Amendment is executed.

 

2.9

LEASE AT 5980 HORTON STREET (“EXISTING LEASE”) AND SUBLEASE AT 5915 HOLLIS STREET (“EXISTING SUBLEASE”)

(a)         Existing Lease Early Termination Date .   Tenant shall have until December 31, 2007 (“Notification Date”) to notify Landlord in writing whether it elects to modify the termination date of the Existing Lease as to Suite 405 and/or Suite 450 thereof to be the date that is (i) in the case of Suite 405, ten (10) days after the Commencement Date of this Lease, and (ii) in the case of Suite 450, thirty (30) days after the Commencement Date of this Lease (in each case, as applicable, the “Early Termination Date”).

  (1)         Terms and Conditions of Early Termination .   If Tenant elects the Early Termination Date with respect to the Existing Lease as to Suite 405 and/or Suite 450 thereof, the following terms and conditions shall apply:

(i)         Delivery to Landlord .   Tenant shall remove the following furniture, fixtures and equipment from the premises described in the Existing Lease: (A) Suite 405 -all furniture, office equipment and the glass café tables, and (B) Suite 450 - all furniture, office equipment and fermentation equipment, including all support structures and equipment, piping, floor mounts and other accessories related thereto (and Tenant shall repair any holes in and other damage to the floor or flooring in Suite 405 and Suite 450); and Tenant shall otherwise surrender each such Suite in its as-is condition and broom - clean on or before the applicable Early Termination Date.

(ii)         Prorations and Adjustments .   Tenant shall pay Monthly Base Rent and Tenant’s Share of Operating Expenses and Taxes with respect to the Existing Lease pursuant to the terms of the Existing Lease through the Commencement Date of this Lease. Tenant shall have no obligation for Monthly Base Rent and Tenant’s Share of Operating Expenses and Taxes from and after the Commencement Date of this Lease; provided that, if Tenant shall not vacate Suite 405 or Suite 450 on or before the applicable Early Termination Date, Tenant shall be a holdover tenant with respect to such Suite from and after the applicable Early Termination Date and shall be subject to Article 13 of the Existing Lease.

(iii)         No Release of Accrued Obligations .   Except as otherwise expressly provided herein, the Early Termination Date shall not: (a) be deemed to excuse or release either party from any obligation or liability, including, without limitation, any obligation or liability under provisions of the Existing Lease to indemnify, defend and hold harmless the other party, or with respect to any breach or breaches of the Existing Lease, which obligation or liability (i) first arises prior to the Early Termination Date or (ii) arises out of or is incurred in connection with

 

19


events or other matters which took place prior to the Early Termination Date, or (b) affect any obligation under the Existing Lease which by its terms is intended to survive the expiration or sooner termination of the Existing Lease.

  (2)         Amendment of Existing Lease .   If Tenant exercises its right under this Section 2.9 to terminate the Existing Lease as to Suite 405 and/or Suite 450 thereof, the landlord under the Existing Lease and Tenant shall promptly execute an amendment of the Existing Lease incorporating the terms of this Section 2.9. The amendment to the Existing Lease shall provide that in the event Tenant exercises its termination right under Section 2.5 above, Tenant shall have the right to terminate the amendment to the Existing Lease and to restate the Existing Lease to its terms (including the original termination date) existing prior to the amendment.

(b)         Extension of Tenant’s Existing Sublease for 5915 Hollis Street

  (1)        Tenant presently sublets space in 5915 Hollis Street from Rocket Software (“Rocket”) pursuant to the Existing Sublease. The termination date of Rocket’s lease of space at 5915 Hollis Street and of the Existing Sublease is September 30, 2007.

  (2)        Notwithstanding the foregoing, Landlord and Tenant hereby agree to extend the term of the Existing Sublease as a direct lease between the landlord at 5915 Hollis Street (Landlord’s affiliate) and Tenant to the date ten (10) days after the Commencement Date of this Lease on the same terms and conditions and at the same Base Rent as is then being paid by Tenant pursuant to the Existing Sublease, except that no security deposit shall be due from Tenant pursuant to such direct lease between the landlord at 5915 Hollis Street and Tenant.

  (3)        Concurrent with the execution of this Lease, the landlord at 5915 Hollis Street and Tenant shall execute an amendment of the Existing Sublease incorporating the terms of this Section 2.9(b) and making such Existing Sublease a direct lease between such landlord and Tenant, effective as of October 1, 2007.

 

2.10

EXPANSION RIGHT

(a)        At any time prior to December 31, 2007, but not thereafter, Tenant shall have the right to notify Landlord (“Expansion Right”) that Tenant elects to incorporate the entire remaining portion of the second floor of the Building comprised of 20,880 rentable square feet (the “Expansion Premises”) into the Premises.

(b)        The Expansion Premises shall be incorporated into the Premises under the terms of this Lease, subject to the following:

(i)        The Monthly Base Rent for the Expansion Premises shall be the per square foot rate applicable to the initial Premises during the Term as specified in Section 1.1(8), except that (A) during the period from the commencement date of the Lease with respect to the Expansion Premises (the “Expansion Premises Commencement Date”) until the end of the Reduced Base Rent Proration Period (as defined below), the Monthly Base Rent for the Expansion Premises shall be $1.74 per rentable square foot of the Expansion Premises, and (B) if the Reduced Base Rent Proration Period ends prior to the end of the first Lease Year, the Monthly Base Rent for the Expansion Premises for the balance of the first Lease Year shall be

 

20


$3.47 per rentable square foot. As used herein, the “Reduced Base Rent Proration Period” shall be 0.079 times the number of months (including the fractional portion of a partial month) from the Expansion Premises Commencement Date to the stated Expiration Date of this Lease. Further, the terms of Section 1.1(8) regarding Deferred Base Rent shall not be applicable to the Expansion Premises.

(ii)        With respect to the Expansion Premises, the Basic Tenant Improvement Allowance provided for in Section 1.1(16) and the Additional Tenant Improvement Allowance provided for in Section 1.1(17) shall in each case be adjusted, as applied to the Expansion Premises, by multiplying the applicable Allowance by a fraction, the numerator of which is the number of months (including the fractional portion of a partial month) from the Expansion Premises Commencement Date to the stated Expiration Date of this Lease and the denominator of which is 120. Further, to the extent that Tenant does not utilize the full amount of the Basic Tenant Improvement Allowance applicable to the Expansion Premises, the remainder of such Allowance shall first be applied against (i.e., in reduction of) the amount of the Additional Tenant Improvement Allowance utilized by Tenant for the initial Premises (and the Additional Tenant Improvement Allowance Monthly Payments shall be reduced accordingly) and the balance of such unused amount, if any, shall be credited, in equal monthly installments (without interest) over the three (3) year period following the Expansion Premises Commencement Date, against the Monthly Base Rent owing hereunder. Further, the Security Deposit shall be increased by the amount of $217,360.80, and such additional amount of the Security Deposit shall be delivered by Tenant to Landlord at the time Tenant exercises the Expansion Right.

(iii)        With respect to the Expansion Premises, two (2) unreserved parking spaces per 1,000 rentable square feet of the Expansion Premises shall be provided in the Building garage and one (1) unreserved parking space per 1,000 rentable square feet of the Expansion Premises shall be provided in the Offsite Parking, at the same discounted rates set forth in Section 2.7.

(iv)        The Expansion Premises Projected Commencement Date shall be determined by Landlord and Tenant, each acting reasonably and in good faith and utilizing a process similar to the process for determining the Projected Commencement Date under this Lease for the initial Premises. Regardless of the actual Expansion Premises Commencement Date, the Lease shall expire with respect to the Expansion Premises on the Expiration Date applicable to the initial Premises.

(c)        Notwithstanding anything to the contrary contained herein, all rights of Tenant pursuant to this Section 2.10 shall, at Landlord’s election upon notice to Tenant, be of no further force and effect with respect to the Expansion Premises, whether or not Tenant has timely exercised the Expansion Right granted herein, if a Default (as hereinafter defined) exists at the time of exercise of the Expansion Right or at the time of commencement of the term for the Expansion Premises.

(d)        If Tenant is entitled to and properly exercises its Expansion Right, Landlord shall promptly prepare an amendment to this Lease to reflect the Base Rent, Tenant Improvement Allowance, Projected Commencement Date and other appropriate terms applicable in connection

 

21


with the addition of the Expansion Premises to the Premises covered by this Lease (including a Workletter providing for Landlord’s construction of the tenant improvements within the Expansion Premises reflecting terms agreed to by Landlord and Tenant pursuant to Section 2.10(b)(iv) and otherwise consistent with the terms of the Workletter attached hereto). If accurate, Tenant shall execute and return the amendment to Landlord within ten (10) days after Tenant’s receipt of same.

 

2.11      

SECOND FLOOR RIGHT OF FIRST REFUSAL

(a)        If Tenant does not exercise the Expansion Right, then through December 31, 2008, but not thereafter, Tenant shall have a continuing right of first refusal to lease space on the balance of the second floor of the Building constituting a total of 20,880 rentable square feet (“ROFR Space”) with respect to the ROFR Space or any portion thereof that Landlord proposes to lease to a third party (the “Right of First Refusal”).

(b)        Prior to entering into a letter of intent with a prospective tenant with regard to the ROFR Space or any portion thereof, Landlord shall give Tenant written notice (“Refusal Offer Notice”) describing the portion of the ROFR Space which is the subject of such proposed letter of intent, the proposed delivery date of such space, rental rate, parking terms, the term of the proposed lease (including any extension terms), and any tenant improvement allowances or improvements, alterations, or monetary concessions to be provided by Landlord, and any other material terms proposed by Landlord for the applicable ROFR Space (“Material Terms”).

(c)        Tenant shall have a period of ten (10) business days in which to notify Landlord (“Response Notice”) whether it will lease the ROFR Space described in the Refusal Offer Notice on the Material Terms. If Tenant does not provide a Response Notice within such period, Landlord shall be free for a period of six (6) months after the expiration of such ten (10) business days period to enter into a lease for the ROFR Space described in the Refusal Offer Notice on terms that are not materially more favorable to a tenant the Material Terms specified in the Refusal Offer Notice; provided that this Right of First Refusal shall continue to exist for other ROFR Space which was not the subject of the Refusal Offer Notice.

(d)        If Tenant provides a Response Notice agreeing to lease the ROFR Space described in the Refusal Offer Notice on the Material Terms, Landlord shall promptly prepare a lease (“ROFR Space Lease”), which shall incorporate the Material Terms and shall otherwise generally be on the same terms and conditions of this Lease (excluding, however, the business terms of this Lease applicable to the Premises, including, without limitation, Sections 1.1, 2.2, 2.3, 2.4, 2.7, 2.8 (unless otherwise applicable pursuant thereto), 2.9, 2.10, 2.11, 2.12 and 2.13, and with appropriate adjustments to the terms of Section 10.2 to reflect Landlord’s recapture rights applicable to the ROFR Space). Tenant agrees to sign the ROFR Space Lease (if accurate) within ten (10) days after delivery of the same.

(e)        If the term for any such ROFR Space stated in the Material Terms applicable with respect thereto (including any extension option(s) provided for therein) is shorter than the Term provided for herein, then and in such event, Tenant may elect in the Response Notice to make the term of the ROFR Space described in the Refusal Offer Notice the same as the Term provided for herein (“Additional ROFR Term”) in which case the Monthly Base Rent for such ROFR

 

22


Space during the Additional ROFR Term shall be equal on a per square foot basis to the Monthly Base Rent applicable to the initial Premises (exclusive of the ROFR Space) from time to time during the Additional ROFR Term.

(f)        Notwithstanding anything to the contrary contained herein, all rights of Tenant pursuant to this Section 2.11 shall, at Landlord’s election upon notice to Tenant, be of no further force and effect with respect to the ROFR Space or any portion thereof, whether or not Tenant has timely exercised the Right of First Refusal granted herein with respect thereto, if a Default (as hereinafter defined) exists at the time of exercise of the Right of First Refusal or at the time of commencement of the term for the ROFR Space or any portion thereof.

 

2.12      

FIRST FLOOR RIGHT OF FIRST OFFER

(a)        Subject to the rights of other tenants pursuant to leases in effect as of the Date of Lease (as summarized in Schedule 1 attached hereto), through December 31, 2007, but not thereafter (the “Offer Period”), Tenant shall have a continuous right of first offer to lease Available Premises (as hereinafter defined) on the first floor of the Building as it becomes available (the “Right of First Offer”).

(b)        As used in this Section 2.12, Available Premises shall mean space which is located on the first (1st) floor of the Building which becomes available for leasing. Tenant acknowledges that such space may be built out as spec office/lab suites. Space shall not be deemed to be Available Premises if an existing tenant occupying the Available Premises renews or extends its term pursuant to the terms of an extension right in effect on the Date of Lease and shown on Schedule 1 attached hereto.

(c)        In the event that Landlord proposes to negotiate with a prospective tenant, or if Landlord otherwise intends to market the Available Premises or any portion thereof, Landlord shall give written notice thereof to Tenant (the “ROFO Offer Notice”), which notice shall include the estimated delivery date of such space to Tenant. For a period of fifteen (15) business days after receipt of Landlord’s notice, Landlord and Tenant shall negotiate in good faith concerning the leasing of such space but neither party shall be obligated to enter into a lease of such space unless the parties mutually agree on the terms and conditions of such lease. Such lease shall be upon market terms, taking into account, among other criteria, the then creditworthiness of Tenant, and Tenant acknowledges that the term for such space may be different from the Term for the Premises and that the rent and tenant improvement package for such space may be different than the rent and tenant improvement package for the Premises. This Right of First Offer shall continue to exist during the Offer Period for other Available Premises.

(d)        Notwithstanding anything to the contrary contained herein, all rights of Tenant pursuant to this Section 2.12 with respect to the subject Available Premises shall, at Landlord’s election upon notice to Tenant, be of no further force and effect with respect to such Available Premises, whether or not Tenant has timely exercised the Right of First Offer granted herein with respect thereto, and Landlord shall have no obligation to deliver any ROFO Offer Notice to Tenant with respect to such Available Premises, if a Default (as hereinafter defined) exists at the time of exercise of the Right of First Offer, or at the time that Landlord would otherwise be

 

23


required to deliver such ROFO Offer Notice, or at the time of commencement of the term for the applicable Available Premises.

(e)        If Landlord and Tenant reach agreement upon the terms of a lease of the Available Premises or any portion thereof pursuant to Section 2.12(c), Landlord promptly shall prepare such lease setting forth the agreed terms and conditions for the Available Premises or applicable portion thereof and shall otherwise generally be on the same terms and conditions of this Lease (excluding, however, the business terms of this Lease applicable to the Premises, including, without limitation, Sections 1.1, 2.2, 2.3, 2.4, 2.7, 2.8, 2.9, 2.10, 2.11, 2.12 and 2.13, and with appropriate adjustments to the terms of Section 10.2 to reflect Landlord’s recapture rights applicable to the Available Premises). If accurate, Tenant shall execute and return such lease to Landlord within ten (10) days after Tenant’s receipt of same.

 

2.13      

OPTION TO TERMINATE

(a)        Tenant shall have the option of terminating this Lease as of the last day of the sixtieth (60 th ) month after the Commencement Date (“Termination Option”) with respect to the entirety of the original Premises and the Expansion Premises (if leased by Tenant pursuant to Section 2.10 above).

(b)        Tenant shall exercise its Termination Option by written notice (“Termination Notice”) which must be sent, if at all, no later than the last day of the forty-seventh (47 th ) month of the Term. The effective date of such termination shall be the last day of the sixtieth (60 th ) month of the Term (“Termination Effective Date”).

(c)        In the event Tenant exercises the Termination Option, Tenant shall pay Landlord an agreed upon termination fee equal to $127.00 per rentable square foot of the Premises (including, if applicable, the Expansion Premises) (the “Termination Fee”). Tenant shall pay fifty percent (50%) of the Termination Fee concurrent with delivery of the Termination Notice, and the remaining fifty percent (50%) of the Termination Fee upon the Termination Effective Date.

(d)        If Tenant properly exercises the Termination Option, Tenant shall remain liable for all Monthly Base Rent, Rent Adjustments and other sums due under this Lease up to and including the Termination Effective Date even though billings for such may occur subsequent to the Termination Effective Date; provided, however, in no event shall Tenant have any obligation to pay to Landlord the unamortized balance of the Additional Tenant Improvement Allowance, if any.

(e)        Notwithstanding anything to the contrary contained in this Section 2.13, all rights of Tenant to terminate this Lease pursuant to this Section 2.13 shall, at Landlord’s election upon notice to Tenant, be of no further force and effect, whether or not Tenant has timely exercised the Termination Option granted herein, if a Default (as hereinafter defined) exists at the time of exercise of the Termination Option or on the Termination Effective Date.

 

24


ARTICLE 3

RENT

3.1         PAYMENT OF RENT . Tenant agrees to pay to Landlord at the address specified in Section 1.1(2), or to such other persons, or at such other places designated by Landlord, without any prior demand therefor in immediately available funds and without any deduction or offset whatsoever, Rent, including Monthly Base Rent and Rent Adjustments in accordance with Article Four, during the Term. Monthly Base Rent shall be paid monthly in advance on the first day of each month of the Term. Monthly Base Rent shall be prorated for partial months within the Term (provided, however, that if the Commencement Date occurs on a date other than the first day of a calendar month, (i) the Monthly Base Rent for such initial partial calendar month shall be prorated using a monthly rental rate of $220,768.34 per month), and (ii) Tenant thereafter shall be entitled to a full nine and one-half (9  1 / 2 ) months of Monthly Base Rent using the monthly rental rate of $110,384.17. Unpaid Rent shall bear interest at the Default Rate from the date due until paid. Tenant’s covenant to pay Rent shall be independent of every other covenant in this Lease.

3.2         SERIES B FINANCING . In addition to the obligation to pay Monthly Base Rent and Rent Adjustments when and as required herein, simultaneously with the closing of Tenant’s anticipated Series B Financing (or a similar equity or debt, to the extent convertible to equity, financing), Tenant shall provide Landlord, at no cost to Landlord, Series B Preferred Stock (or its equivalent) in an amount equal to $245,297.00.

ARTICLE 4

RENT ADJUSTMENTS AND PAYMENTS

 

4.1

RENT ADJUSTMENTS

From and after the Commencement Date, Tenant shall pay to Landlord Rent Adjustments with respect to each calendar year (or partial calendar year in the case of the year in which the Commencement Date and the Termination Date occur) as follows:

(1)        The Rent Adjustment Deposit representing Tenant’s Share of Operating Expenses for the applicable calendar year (or partial calendar year), monthly during the Term with the payment of Monthly Base Rent; and

(2)        The Rent Adjustment Deposit representing Tenant’s Share of Taxes for the applicable calendar year (or partial calendar year), monthly during the Term with the payment of Monthly Base Rent; and

(3)        Any Rent Adjustments due in excess of the Rent Adjustment Deposits in accordance with Section 4.2. Rent Adjustments due from Tenant to Landlord for any calendar year (or partial calendar year) shall be Tenant’s Share of Operating Expenses for such calendar year (or partial calendar year) and Tenant’s Share of Taxes for such calendar year (or partial calendar year).

(4)        For purposes of determining Rent Adjustments, if the Building or Property is not fully occupied during all or a portion of any calendar year during the Term, Landlord shall make

 

25


appropriate adjustments to the variable components of Operating Expenses for such calendar year (or partial calendar year), employing sound accounting and management principles consistently applied, to determine the amount of Operating Expenses that would have been paid or incurred by Landlord had the Building or Property been ninety-five percent (95%) occupied, and the amount so determined shall be deemed to have been the amount of Operating Expenses for such calendar year (or partial calendar year). In the event that the Property is not fully assessed for all or a portion of any calendar year (or partial calendar year) during the Term, then Taxes shall be adjusted to an amount which would have been payable in such calendar year (or partial calendar year) if the Property had been fully assessed.

 

4.2

STATEMENT OF LANDLORD

As soon as feasible after the expiration of each calendar year, Landlord will furnish Tenant a statement (“Landlord’s Statement”) showing the following:

(1)        Operating Expenses and Taxes for the calendar year;

(2)        The amount of Rent Adjustments due Landlord for the last calendar year, less credit for Rent Adjustment Deposits paid, if any; and

(3)        Any change in the Rent Adjustment Deposit due monthly in the current calendar year, including the amount or revised amount due for months preceding any such change pursuant to Landlord’s Statement.

Tenant shall pay to Landlord within thirty (30) days after receipt of such statement any amounts for Rent Adjustments then due in accordance with Landlord’s Statement. Any amounts due from Landlord to Tenant pursuant to this Section shall be credited to the Rent Adjustment Deposit next coming due, or refunded to Tenant if the Term has already expired. No interest or penalties shall accrue on any amounts that Landlord is obligated to credit or refund to Tenant by reason of this Section 4.2. Landlord’s failure to deliver Landlord’s Statement or to compute the amount of the Rent Adjustments shall not constitute a waiver by Landlord of its right to deliver such items nor constitute a waiver or release of Tenant’s obligations to pay such amounts. The Rent Adjustment Deposit shall be credited against Rent Adjustments due for the applicable calendar year (or partial calendar year). During the last complete calendar year or during any partial calendar year in which the Lease terminates, Landlord may include in the Rent Adjustment Deposit its estimate of Rent Adjustments which may not be finally determined until after the termination of this Lease. Tenant’s obligation to pay Rent Adjustments survives the expiration or termination of the Lease. Notwithstanding the foregoing, in no event shall the sum of Monthly Base Rent and the Rent Adjustments be less than the Monthly Base Rent payable.

 

4.3

BOOKS AND RECORDS

Landlord shall maintain books and records showing Operating Expenses and Taxes in accordance with sound accounting and management practices, consistently applied. Tenant or its representative (which representative shall be a certified public accountant licensed to do business in the state in which the Property is located and whose primary business is certified public accounting and who shall not be paid on a contingency basis) shall have the right, for a period of ninety (90) days following the date upon which Landlord’s Statement is delivered to Tenant, to

 

26


examine the Landlord’s books and records with respect to the items in the foregoing statement of Operating Expenses and Taxes during normal business hours, upon written notice, delivered at least three (3) business days in advance. If Tenant does not object in writing to Landlord’s Statement within ninety (90) days of Tenant’s receipt thereof, specifying the nature of the item in dispute and the reasons therefor, then Landlord’s Statement shall be considered final and accepted by Tenant and Tenant shall be deemed to have waived its right to dispute Landlord’s Statement. If Tenant does dispute any Landlord’s Statement, Tenant shall deliver a copy of any such audit to Landlord within 120 days after the date upon which Landlord’s Statement was delivered to Tenant. Any amount due to the Landlord as shown on Landlord’s Statement, whether or not disputed by Tenant as provided herein shall be paid by Tenant when due as provided above, without prejudice to any such written exception. In no event shall Tenant be permitted to examine Landlord’s records or to dispute any statement of Operating Expenses and Taxes unless Tenant has paid and continues to pay all Rent when due. Upon resolution of any dispute with respect to Operating Expenses and Taxes, Tenant shall either pay Landlord any shortfall or Landlord shall credit Tenant against the Rent Adjustment Deposit next coming due with respect to any overages paid by Tenant. The records obtained by Tenant shall be treated as confidential and neither Tenant nor any of its representatives or agents shall disclose or discuss the information set forth in the audit to or with any other person or entity (“Confidentiality Requirement”). Tenant shall indemnify and hold Landlord harmless for any losses or damages to the extent arising out of the breach of the Confidentiality Requirement. Landlord shall pay for the reasonable third party costs of Tenant’s audit if the final determination of the dispute shows a disparity of 5% or more in Operating Expenses and Taxes over the Operating Expenses and Taxes as shown on Landlord’s Statement.

 

4.4

TENANT OR LEASE SPECIFIC TAXES

In addition to Monthly Base Rent, Rent Adjustments, Rent Adjustment Deposits and other charges to be paid by Tenant, Tenant shall pay to Landlord, upon demand, any and all taxes payable by Landlord (other than federal or state inheritance, general income, gift or estate taxes) whether or not now customary or within the contemplation of the parties hereto: (a) upon, allocable to, or measured by the Rent payable hereunder, including any gross receipts tax or excise tax levied by any governmental or taxing body with respect to the receipt of such rent; or (b) upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion thereof; or (c) upon the measured value of Tenant’s personal property located in the Premises or in any storeroom or any other place in the Premises or the Property, or the areas used in connection with the operation of the Property, it being the intention of Landlord and Tenant that, to the extent possible, such personal property taxes shall be billed to and paid directly by Tenant; (d) resulting from any Tenant Alterations to the Premises; or (e) upon this transaction. Taxes paid by Tenant pursuant to this Section 4.5 shall not be included in any computation of Taxes payable pursuant to Sections 4.1 and 4.2.

ARTICLE 5

SECURITY DEPOSIT

(a)        Within two (2) business days after the Date of Lease, Tenant shall deliver to Landlord the Security Deposit in cash or a Letter of Credit. In the event that Tenant delivers the

 

27


Security Deposit in the form of a Letter of Credit, such Letter of Credit may initially show an outside expiration date of June 21, 2018; provided, however, that promptly following the occurrence of the Commencement Date of this Lease, the Letter of Credit shall be amended such that the outside expiration date of the Letter of Credit is the date that is sixty (60) days after the Expiration Date of this Lease (as determined based upon the actual Commencement Date of this Lease).

(b)        The Security Deposit may be applied by Landlord to cure, in whole or part, any Default of Tenant under this Lease, and upon notice by Landlord of such application, Tenant shall replenish the Security Deposit in full by paying to Landlord within thirty (30) days of demand the amount so applied. Landlord’s application of the Security Deposit shall not constitute a waiver of Tenant’s Default to the extent that the Security Deposit does not fully compensate Landlord for all losses, damages, costs and expenses incurred by Landlord in connection with such Default and shall not prejudice any other rights or remedies available to Landlord under this Lease or by Law. Landlord shall not pay any interest on the Security Deposit. Landlord shall not be required to keep the Security Deposit separate from its general accounts. The Security Deposit shall not be deemed an advance payment of Rent or a measure of damages for any Default by Tenant under this Lease, nor shall it be a bar or defense of any action that Landlord may at any time commence against Tenant. In the absence of evidence satisfactory to Landlord of an assignment of the right to receive the Security Deposit or the remaining balance thereof, Landlord may return the Security Deposit to the original Tenant, regardless of one or more assignments of this Lease. Upon the transfer of Landlord’s interest under this Lease, Landlord’s obligation to Tenant with respect to the Security Deposit shall terminate upon transfer to the transferee of the Security Deposit, or any balance thereof. Except as otherwise expressly set forth herein, the Security Deposit, or any balance thereof, shall be returned to Tenant within thirty (30) days after Landlord recovers possession of the Premises. To the fullest extent permitted by law, Landlord may hold and apply the Security Deposit to post termination damages and, to the extent inconsistent, Tenant hereby waives any and all rights of Tenant under the provisions of Section 1950.7 of the California Civil Code or other Law regarding security deposits.

(c)        If Landlord draws upon the Letter of Credit in accordance with the terms of this Lease, Tenant shall, within thirty (30) days after Landlord’s draw, restore the amount available under the Letter of Credit to its original amount by providing Landlord with an amendment to the Letter of Credit evidencing that the amount available under the Letter of Credit has been restored to its original amount. In the alternative, at Tenant’s election, Tenant may deposit with Landlord a cash sum in an amount which when added to the amount available to be drawn under the Letter of Credit equals the face amount of the Letter of Credit. Tenant’s failure to do so shall be a material breach of this Lease.

ARTICLE 6

SERVICES

 

6.1

LANDLORD’S GENERAL SERVICES

(a)        Tenant shall have access to the Building and the Premises 24 hours a day, 365 days a year.

 

28


(b)        Throughout the Term, Landlord shall furnish the following services, the cost of which services shall be included in Operating Expenses or paid directly by Tenant to Landlord or the utility or service provider, as applicable, if such services are segregated from the other services provided to the Building:

(1)        heat, ventilation and air-conditioning (“HVAC”) in the Premises and the Common Areas available twenty-four hours per day, seven days per week, subject to compliance with all applicable voluntary and mandatory regulations and Laws (see Exhibit D attached hereto for HVAC capacities). Tenant will have certain limited ability to adjust directly temperatures (potentially within a range of 4 - 7 degrees) and possibly air flows (potentially within a range of increases or decreases of 10% - 15%) within the Premises, to the extent feasible;

(2)        water for use in the Premises and Common Areas from the regular supply of the Building;

(3)        customary cleaning and janitorial services in the Common Areas five (5) days per week, excluding National Holidays;

(4)        washing of the outside windows in the Premises weather permitting at intervals determined by Landlord;

(5)        automatic passenger and swing/freight elevator service in common with other tenants of the Building. Freight elevator service will be subject to reasonable scheduling by Landlord; and

(6)        security personnel.

(c)        If Tenant uses heat generating machines or equipment in the Premises to an extent which adversely affects the temperature otherwise maintained by the air-cooling system or whenever the occupancy or electrical load adversely affects the temperature otherwise maintained by the air-cooling system, Landlord reserves the right to install or to require Tenant to install supplementary air-conditioning units in the Premises. Tenant shall bear all costs and expenses related to the installation, maintenance and operation of such units.

(d)        Tenant shall pay directly for all janitorial expenses incurred by Tenant if Tenant elects to contract for janitorial service. If Landlord provides janitorial services to the Premises, Tenant shall pay the costs thereof to Landlord on a monthly basis.

 

6.2

ELECTRICAL SERVICES

(a)        Landlord shall furnish to the Premises electric current and natural gas service for general office and laboratory use, including normal lighting, normal business office machines; and Tenant shall pay for such utilities in accordance with Landlord’s customary practice with respect thereto ( i.e. , monthly billings on an estimated basis with annual reconciliations based upon Tenant’s actual usage). Notwithstanding any provision of the Lease to the contrary, without, in each instance, the prior written approval of Landlord, in Landlord’s prudent business judgment, Tenant shall not make any alterations or additions to the electric equipment or systems. Tenant’s use of electric current shall at no time exceed the capacity of the wiring,

 

29


feeders and risers providing electric current to the Premises or the Building. The consent of Landlord to the installation of electric equipment shall not relieve Tenant from the obligation to limit usage of electricity to no more than such capacity.

(b)        As part of the Landlord Work, Landlord will install one or more meters to measure electric current furnished to the Premises.

(c)        Landlord shall furnish to the Premises replacement lamps, bulbs, ballasts and starters used in any normal Building lighting installed in the Premises, except that if the replacement or repair of such items is a result of negligence of Tenant, its employees, agents, servants, licensees, subtenants, contractors or invitees, such cost shall be paid by Tenant within ten days after notice from Landlord and shall not be included as part of Operating Expenses.

 

6.3

ADDITIONAL AND AFTER HOUR SERVICES

(a)        At Tenant’s written request, Landlord shall furnish additional quantities of any of the services or utilities specified in Section 6.1, if Landlord can reasonably do so, on the terms set forth herein. For services or utilities requested by Tenant and furnished by Landlord, Tenant shall pay to Landlord as a charge therefor Landlord’s prevailing rates charged from time to time for such services and utilities.

 

6.4

TELEPHONE SERVICES

All telephone, and communication connections which Tenant may desire shall be subject to Landlord’s prior written approval, in Landlord’s reasonable discretion, and the location of all wires and the work in connection therewith shall be performed by contractors approved by Landlord and shall be subject to the direction of Landlord, except that such approval is not required as to Tenant’s telephone equipment and Tenant’s internet connectivity (including cabling) within the Premises and from the Premises in a route designated by Landlord to any telephone cabinet or panel provided (as existing or as installed as part of Landlord’s Work, if any) on Tenant’s floors for Tenant’s connection to the telephone cable serving the Building so long as Tenant’s equipment does not require connections different than or additional to those to the telephone cabinet or panel provided. Except to the extent of such cabling within the Premises or from the Premises to such telephone cabinet or panel, Landlord reserves the right to designate and control the entity or entities providing telephone or other communication cable installation, removal, repair and maintenance in the Building and to restrict and control access to telephone cabinets or panels, so long as such entity is competitively priced with other similar vendors. In the event Landlord designates a particular vendor or vendors to provide such cable installation, removal, repair and maintenance for the Building pursuant to the immediately preceding sentence, Tenant agrees to abide by and participate in such program. Tenant shall be responsible for and shall pay all costs incurred in connection with the installation of telephone cables and communication wiring in the Premises, including any hook-up, access and maintenance fees related to the installation of such wires and cables in the Premises and the commencement of service therein, and the maintenance thereafter of such wire and cables; and there shall be included in Operating Expenses for the Building all installation, removal, hook-up or maintenance costs incurred by Landlord in connection with telephone cables and communication wiring serving the Building which are not allocable to any individual users of

 

30


such service but are allocable to the Building generally. If Tenant fails to maintain all telephone cables and communication wiring in the Premises and such failure affects or interferes with the operation or maintenance of any other telephone cables or communication wiring serving the Building and is not repaired by Tenant within three (3) business days after written notice from Landlord of such failure, Landlord or any vendor hired by Landlord, subject to compliance with the terms of Section 7.2, may enter into and upon the Premises forthwith and perform such repairs, restorations or alterations as Landlord reasonably deems necessary in order to eliminate any such interference (and Landlord may recover from Tenant all of Landlord’s out-of-pocket costs in connection therewith). If required by Landlord, no later than the Termination Date Tenant shall remove all telephone cables and communication wiring installed by Tenant for and during Tenant’s occupancy. Except as otherwise provided in Section 6.5, Tenant agrees that neither Landlord nor any of its agents or employees shall be liable to Tenant, or any of Tenant’s employees, agents, customers or invitees or anyone claiming through, by or under Tenant, for any damages, injuries, losses, expenses, claims or causes of action because of any interruption, diminution, delay or discontinuance at any time for any reason in the furnishing of any telephone or other communication service to the Premises and the Building.

 

6.5

DELAYS IN FURNISHING SERVICES

Tenant agrees that Landlord shall not be in breach of this Lease nor be liable to Tenant for damages or otherwise, for any failure to furnish, or a delay in furnishing, or a change in the quantity or character of any service when such failure, delay or change is occasioned, in whole or in part, by repairs, improvements or mechanical breakdowns by the act or default of Tenant or other parties or by an event of Force Majeure. No such failure, delay or change shall be deemed to be an eviction or disturbance of Tenant’s use and possession of the Premises, or relieve Tenant from paying Rent or from performing any other obligations of Tenant under this Lease, without any deduction or offset. Failure to any extent to make available, or any slowdown, stoppage, or interruption of, the specified utility services resulting from any cause, including changes in service provider or Landlord’s compliance with any voluntary or similar governmental or business guidelines now or hereafter published or any requirements now or hereafter established by any governmental agency, board, or bureau having jurisdiction over the operation of the Property shall not render Landlord liable in any respect for damages to either persons, property, or business, nor be construed as an eviction of Tenant or work an abatement of Rent, nor relieve Tenant of Tenant’s obligations for fulfillment of any covenant or agreement hereof. Should any equipment or machinery furnished by Landlord break down or for any cause cease to function properly, Landlord shall use reasonable diligence to repair same promptly, but Tenant shall have no claim for abatement of Rent or damages on account of any interruption of service occasioned thereby or resulting therefrom. Notwithstanding anything in this Section 6.5 to the contrary, if the Premises, or a material portion of the Premises, are made untenantable and are not actually used by Tenant for a period in excess of three (3) consecutive business days as a result of a failure, delay or change in any service due to Landlord’s negligence or willful misconduct, and Tenant has given Landlord notice of such failure, delay or change, then Tenant shall be entitled to receive an abatement of Monthly Base Rent payable hereunder (excluding, however, any Deferred Rent Loan Payments and any Additional Tenant Improvement Allowance Monthly Payments, which shall continue to be due and payable regardless of any such rent abatement) during the period beginning on the fourth (4th) consecutive business day after such notice and ending on the day the service has been restored. If the entire Premises have not been rendered

 

31


untenantable by such failure, delay or change, the amount of abatement shall be equitably prorated.

 

6.6

CHOICE OF SERVICE PROVIDER

Tenant acknowledges that Landlord may, at Landlord’s sole option, to the extent permitted by applicable law, elect to change, from time to time, the company or companies which provide services (including electrical service, gas service and water, but not the telephone service provider) to the Building, the Premises and/or its occupants. Notwithstanding anything to the contrary set forth in this Lease, Tenant acknowledges that Landlord has not and does not make any representations or warranties concerning the identity or identities of the company or companies which provide services to the Building and the Premises or its occupants and Tenant acknowledges that the choice of service providers and matters concerning the engagement and termination thereof shall be solely that of Landlord. The foregoing provision is not intended to modify, amend, change or otherwise derogate any provision of this Lease concerning the nature or type of service to be provided or any specific information concerning the amount thereof to be provided. Tenant agrees to cooperate with Landlord and each of its service providers in connection with any change in service or provider.

 

6.7

SIGNAGE

(a)        Landlord, at its cost and not part of the Tenant Improvement Allowance, shall list Tenant in the electronic directory for the Building in the main lobby of the Building and shall install Building standard identification signage for Tenant in the listing of tenants in the second floor elevator lobby (if any) and at Tenant’s main entry door to the Premises on each multi-tenant floor. Any change in such initial signage shall be only with Landlord’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, shall conform to Building standard signage and shall be at Tenant’s sole cost and expense. In addition to the foregoing Building standard signage, Tenant, at its cost, shall have the right to install its logo in the second floor elevator lobby and/or at the main entry door to the Premises on each floor, provided such logo has been approved in advance in writing by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed. Landlord shall provide its response to Tenant’s submittal of logo under this subsection with seven (7) business days after Landlord’s receipt of such information. Landlord’s approval shall be deemed given if Landlord fails to respond within the seven (7) business day period. Landlord hereby confirms its approval of Tenant’s logo consistent with Tenant’s logo on its suite entry at 5915 Hollis Street; provided, however, that the size of such logo proposed by Tenant remains subject to Landlord’s approval as provided for above.

(b)        In addition to Tenant’s rights under Section 6.7(a), Tenant shall have the right to install and maintain, at Tenant’s sole cost and expense, for Tenant’s exclusive use, (i) a monument sign in the plaza area of the Project at a location mutually agreed upon by Landlord and Tenant, or (ii) signage on the Building in a location mutually agreed upon by Landlord and Tenant. Tenant shall comply with any and all Laws applicable to such monument or Building signage, and Tenant shall not install any monument or Building signage without having obtained all necessary permits and licenses. Such monument or Building signage shall be subject to Landlord’s prior approval as to size (provided that, to the extent that the Project is subject to a

 

32


maximum amount or area of such signage, Tenant shall be entitled to utilize up to Tenant’s Share of such maximum amount for Tenant’s signage), lettering, materials, color, lighting and content of the sign, which approval shall not be unreasonably withheld, conditioned or delayed. Landlord shall provide its response to Tenant’s submittals of monument or Building signage design and content under this subsection within seven (7) business days after Landlord’s receipt of such information. Landlord’s approval shall be deemed given if Landlord fails to respond within such seven (7) business day period. Tenant, at Tenant’s sole cost and expense, shall maintain such monument or Building signage in good condition and repair throughout the Term of this Lease and shall, prior to the Expiration Date or sooner termination of this Lease, remove such monument or Building signage and repair any damage to the Property resulting therefrom.

 

6.8

GARAGE STORAGE

(a)        Landlord will provide, at no cost to Tenant, a 10’ x 10’ area on the grounds of the Project in a location to be determined by Landlord for Tenant to construct, at Tenant’s sole cost and expense, a storage facility for Hazardous Materials and/or other items.

(b)        Tenant will be responsible for obtaining all permits for the construction, operation and closure of such storage facility, and throughout the Term Tenant shall maintain such storage facility and the materials stored therein in a neat and orderly condition and in accordance with applicable Laws.

(c)        Tenant shall be responsible for all costs of design, permit, construction and maintenance of the storage facility and for its removal upon the Expiration Date or sooner termination of this Lease; and Tenant shall repair any damage to the Property resulting from the removal of such storage facility.

(d)        Landlord will have the right to approve, which approval shall not be unreasonably withheld, conditioned or delayed, the location and design of the storage facility as well as to receive from Tenant from time to time upon Landlord’s request disclosure of all materials stored therein.

(e)        As an alternative to the 10’ x 10’ area described in Section 6.8(a), Tenant may elect, by notice delivered to Landlord no later than thirteen (13) weeks after the Date of Lease, to use 411 usable square feet of storage space in the Building garage in the location shown on Exhibit A-1 attached hereto for Tenant’s storage of Hazardous Materials and/or other items (the “Garage Storage Area”), in which case Tenant shall pay the Garage Storage Fee set forth in Section 1.1(14).

 

6.9

ROOF TOP COMMUNICATIONS EQUIPMENT

(a)        At Tenant’s sole cost and expense, Tenant shall have the non-exclusive right to install, use, maintain, repair and remove a satellite dish, television antennas, and related equipment on the roof of the Building (“Telecommunications Equipment”) within an area of the roof of approximately fifty (50) square feet. The location of the Telecommunication Equipment on the roof, its size, dimension and capacity and the plans for its construction and installation shall be subject to Landlord’s prior written approval, which shall not be unreasonably withheld, conditioned or delayed.

 

33


(b)        Prior to installing the Telecommunication Equipment, Tenant shall obtain the approval of all governmental authorities having jurisdiction over the Telecommunications Equipment and all permits required for its use and operation. Tenant shall provide copies of all such approvals and permits to Landlord as a condition to obtaining Landlord’s consent for such installation. Tenant’s use and operation of the satellite dish shall conform to all applicable Laws and such usage shall not interfere with the operations of Telecommunications Equipment of other tenants in the Project.

(c)        Upon expiration of the Lease, Tenant shall be responsible for all costs and expenses associated with the removal of the Telecommunications Equipment and the restoration of the area where such equipment is located to the condition it was in prior to such installation, casualties and condemnation excepted.

(d)        Tenant agrees to indemnify and hold Landlord harmless from and against any losses, costs or damages incurred by Landlord, to the extent arising or resulting from Tenant’s use of the Telecommunications Equipment.

ARTICLE 7

POSSESSION, USE AND CONDITION OF PREMISES

 

7.1

POSSESSION AND USE OF PREMISES

(a)        Tenant shall occupy and use the Premises only for the uses specified in Section 1.1 to conduct Tenant’s business. Tenant shall not occupy or use the Premises (or permit the use or occupancy of the Premises) for any purpose or in any manner which: (1) is unlawful or in violation of any Law or Hazardous Materials Law; (2) may increase the cost of, or invalidate, any policy of insurance carried on the Building or covering its operations; (3) is contrary to or prohibited by the terms and conditions of this Lease or the rules of the Building set forth in Article Eighteen; or (4) would create or continue a nuisance.

(b)        Landlord, at its cost and not part of the Tenant Improvement Allowance, shall provide Tenant with Access Card Keys in number sufficient for all occupants of the Premises; and, when delivered to Tenant, Tenant shall place a deposit for such cards with Landlord to cover lost cards or cards which are not returned at the end of the Term.

(c)        Landlord and Tenant acknowledge that the Americans With Disabilities Act of 1990 (42 U.S.C. §12101 et seq.) and regulations and guidelines promulgated thereunder, as all of the same may be amended and supplemented from time to time (collectively referred to herein as the “ADA”) establish requirements for business operations, accessibility and barrier removal, and that such requirements may or may not apply to the Premises, the Building and the Project depending on, among other things: (1) whether Tenant’s business is deemed a “public accommodation” or “commercial facility”, (2) whether such requirements are “readily achievable”, and (3) whether a given alteration affects a “primary function area” or triggers “path of travel” requirements. The parties hereby agree that: (a) Landlord shall be responsible for ADA Title III compliance in the Common Areas and “path of travel” requirements to the Premises and the rest-rooms, as of the Commencement Date, (b) Landlord shall be responsible for ADA Title III compliance (including within the Premises) with respect to the Landlord Work,

 

34


(c) Landlord may perform, or require that Tenant perform, and Tenant shall be responsible for the cost of, ADA Title III “path of travel” requirements triggered by Tenant Alterations in the Premises, and (d) Landlord may perform, or require Tenant to perform, and Tenant shall be responsible for the cost of, ADA Title III compliance in the Common Areas necessitated by the Building being deemed to be a “public accommodation” instead of a “commercial facility” as a result of Tenant’s particular use of the Premises. Tenant shall be solely responsible for requirements under Title I of the ADA relating to Tenant’s employees.

(d)         Hazardous Materials .

(1)         Definitions . The following terms shall have the following meanings for purposes of this Lease:

(i)        “Biohazardous Materials” means any and all substances and materials defined or referred to as a “medical waste,” “biological waste,” “biohazardous waste,” “biohazardous material” or any other term of similar import under any Hazardous Materials Laws, including (but not limited to) California Health & Safety Code Sections 25105 et seq., and any regulations promulgated thereunder, as amended from time to time.

(ii)        “Environmental Condition” means the Release of any Hazardous Materials in, over, on, under, from or about the Project (including, but not limited to, the Premises).

(iii)        “Environmental Damages” means all claims, suits, judgments, damages, losses, penalties, fines, liabilities, encumbrances, liens, costs and expenses of whatever kind or nature, contingent or otherwise, matured or unmatured, foreseeable or unforeseeable, arising out of or in connection with any Environmental Condition, including, to the extent arising out of an Environmental Condition, without limitation: (A) damages for personal injury, or for injury to the Project or natural resources occurring on or off the Project, including without limitation (1) any claims brought by or on behalf of any person, (2) any damage to the Project or natural resource, and (3) costs of any investigation, remediation, removal, abatement, containment, closure, restoration or monitoring work required by any federal, state or local governmental agency or political subdivision, or Hazardous Materials Law; (B) reasonable fees incurred for the services of attorneys, consultants, contractors, experts and laboratories in connection with the preparation of any feasibility studies, investigations or reports or the performance of any work described above; and (C) any liability to any third person or governmental agency to indemnify such person or agency for costs expended or liabilities incurred in connection with any items described in clause (A) or (B) above.

(iv)        “Handling,” when used with reference to any Hazardous Material, means any receipt, storage, use, generation, Release, transportation, treatment or disposal of such Hazardous Material.

(v)        “Hazardous Materials” means any and all explosive, biohazardous, radioactive or otherwise toxic or hazardous materials or hazardous wastes, including, without limitation, any asbestos-containing materials, PCB’s, CFCs, petroleum and derivatives thereof, Radioactive Materials, Biohazardous Materials, Hazardous Wastes, any other substances defined

 

35


or listed as or meeting the characteristics of a hazardous substance, hazardous material, hazardous waste, extremely hazardous waste, restricted hazardous waste, toxic substance, toxic waste, biohazardous material, biohazardous waste, biological waste, medical waste, radiation, radioactive substance, radioactive waste, or other similar term, as applicable, under any Hazardous Materials Laws, and/or any mixed materials, substances or wastes containing more than one of the foregoing categories of materials, substances or wastes.

(vi)        “Hazardous Materials Laws” means, collectively, (A) the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. Sections 9601-9657, (B) the Hazardous Materials Transportation Act of 1975, 49 U.S.C. Sections 1801-1812, (C) the Resource Conservation and Recovery Act of 1976, 42 U.S.C. Sections 6901-6987 (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, “RCRA”), (D) the California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health & Safety Code Sections 25300 et seq., (E) the Hazardous Materials Release Response Plans and Inventory Act, California Health & Safety Code Sections 25500 et seq., (F) the California Hazardous Waste Control Law, California Health & Safety Code Sections 25100 et seq. (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, the “CHWCL”), (G) California Health & Safety Code Sections 25015-25027.8, (H) any amendments to or successor statutes to any of the foregoing, as adopted or enacted from time to time, (I) any regulations or amendments thereto promulgated pursuant to any of the foregoing from time to time, (J) any statutes, laws, ordinances, codes, rules or regulations relating to Biohazardous Materials, including (but not limited to) any regulations or requirements with respect to the shipping, use, decontamination and disposal thereof, and (K) any other Laws now or at any time hereafter in effect regulating, relating to or imposing liability or standards of conduct concerning any Hazardous Materials, including (but not limited to) any requirements or conditions imposed pursuant to the terms of any orders, permits, licenses, registrations or operating plans issued or approved by any governmental or quasi-governmental authority from time to time either on a Project-wide basis or in connection with any Handling of Hazardous Materials in, on or about the Premises or the Project.

(vii)        “Hazardous Wastes” means (A) any waste listed as or meeting the identified characteristics of a “hazardous waste” or terms of similar import under RCRA, (B) any waste meeting the identified characteristics of a “hazardous waste,” “extremely hazardous waste” or “restricted hazardous waste” under the CHWCL, and/or (C) any and all other substances and materials defined or referred to as a “hazardous waste” or other term of similar import under any Hazardous Materials Laws.

(viii)        “Radioactive Materials” means (A) any and all substances and materials the Handling of which requires an approval, consent, permit or license from the Nuclear Regulatory Commission, (B) any and all substances and materials the Handling of which requires a Radioactive Material License or other similar approval, consent, permit or license from the State of California, and (C) any and all other substances and materials defined or referred to as “radiation,” a “radioactive material” or “radioactive waste,” or any other term of similar import under any Hazardous Materials Laws, including (but not limited to) Title 26, California Code of Regulations Section 17-30100, and any statutes, regulations or other laws administered, enforced or promulgated by the Nuclear Regulatory Commission.

 

36


(ix)        “Release” means any accidental or intentional spilling, leaking, pumping, pouring, emitting, discharging, injecting, escaping, leaching, migrating, dumping or disposing into the air, land, surface water, groundwater or the environment (including without limitation the abandonment or discarding of receptacles containing any Hazardous Materials).

(x)        “Tenant Contamination” means any Hazardous Material Release in violation of any Hazardous Materials Laws on or about the Property by Tenant and/or any agents, employees, contractors, vendors, suppliers, licensees, subtenants, and invitees of Tenant (a “Tenant Party”).

(xi)        “Landlord Contamination” means any hazardous materials which exist in, on, under, at or in the vicinity of the Project as of the date of this Lease or which migrate onto or beneath the Project from off-site sources during the term of the Lease or after termination of the Lease. Tenant shall not be required to pay any costs with respect to the remediation or abatement of Landlord Contamination.

(2)         Handling of Hazardous Materials . The parties acknowledge that Tenant wishes and intends to use all or a portion of the Premises as a radio/bio-pharmaceutical, research, development, preparation and dispensing facility and otherwise for the conduct by Tenant of its business in accordance with the use specified in Section 1.1, that such use, as conducted or proposed to be conducted by Tenant, would customarily include the Handling of Hazardous Materials, and that Tenant shall therefore be permitted to engage in the Handling in the Premises of necessary and reasonable quantities of Hazardous Materials customarily used in or incidental to the operation of a radio/bio pharmaceutical research, preparation and dispensing facility and the other business operations of Tenant in the manner conducted or proposed to be conducted by Tenant hereunder (“Permitted Hazardous Materials”), provided that the Handling of such Permitted Hazardous Materials by all Tenant Parties shall at all times comply with and be subject to all provisions of this Lease and all applicable requirements of Hazardous Materials Laws. Without limiting the generality of the foregoing, Tenant shall comply at all times with all Hazardous Materials Laws applicable to any aspect of Tenant’s use of the Premises and the Project and of Tenant’s operations and activities in, on and about the Premises and the Project, and shall ensure at all times that Tenant’s Handling of Hazardous Materials on and about the Premises does not violate the terms of any governmental licenses or permits applicable to the Building (including, but not limited to, the Building Discharge Permit as defined below) or Premises or to Tenant’s Handling of any Hazardous Materials therein.

(3)         Disposition or Emission of Hazardous Materials . Tenant shall not Release or dispose of any Hazardous Wastes or Hazardous Materials, except to the extent authorized by permit or in compliance with applicable Hazardous Materials Laws, at the Premises or on the Project, but instead shall arrange for off-site disposal, under Tenant’s own name and EPA waste generator number (or other similar identifying information issued or prescribed by any other governmental authority with respect to Radioactive Materials, Biohazardous Materials or any other Hazardous Materials) and at Tenant’s sole expense, in compliance with all applicable Hazardous Materials Laws, with Landlord’s Rules and with all other applicable legal and regulatory requirements.

 

37


(4)         Information Regarding Hazardous Materials . Tenant shall provide the following information and/or documentation to Landlord in writing prior to the Commencement Date, and thereafter shall update such information and/or documentation as specifically described in subsections (i)-(x) below, which updates shall reflect any material changes in such information and/or documentation:

(i)        An inventory of all Hazardous Materials that Tenant receives, uses, handles, generates, transports, stores, treats or disposes of from time to time, or at the time of preparation of such inventory proposes or expects to use, handle, generate, transport, store, treat or dispose of from time to time, in connection with its operations at the Premises. Such inventory shall include, but shall separately identify, any Hazardous Wastes, Biohazardous Materials and Radioactive Materials covered by the foregoing description. If such inventory includes any Biohazardous Materials, Tenant shall also disclose in writing to Landlord the Biosafety Level designation associated with the use of such materials. Such inventory shall be updated annually, in January of each calendar year.

(ii)        Copies of all then existing permits, licenses, registrations and other similar documents issued by any governmental or quasi-governmental authority that authorize any Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party. Such information shall be updated annually, in January of each calendar year.

(iii)        All Material Safety Data Sheets (“MSDSs”), if any, required to be completed with respect to operations of Tenant at the Premises from time to time in accordance with Title 26, California Code of Regulations Section 8-5194 or 42 U.S.C. Section 11021, or any amendments thereto, and any Hazardous Materials Inventory Sheets that detail the MSDSs. Such information shall be updated from time to time upon Landlord’s written request.

(iv)        All hazardous waste manifests (as defined in Title 26, California Code of Regulations Section 22-66481), if any, that Tenant is required to complete from time to time in connection with its operations at the Premises. Such information shall be updated from time to time upon Landlord’s written request.

(v)        A copy of any Hazardous Materials Business Plan required from time to time with respect to Tenant’s operations at the Premises pursuant to California Health & Safety Code Sections 25500 et seq., and any regulations promulgated thereunder, as amended from time to time, or in connection with Tenant’s application for a business license from the City of Emeryville. If applicable law does not require Tenant to prepare a Hazardous Materials Business Plan, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Hazardous Materials Business Plan, including (but not limited to) information regarding Tenant’s Hazardous Materials inventories. The parties acknowledge that a Hazardous Materials Business Plan would ordinarily include an emergency response plan, and that regardless of whether applicable law requires Tenant or other tenants in the Building to prepare Hazardous Materials Business Plans, Landlord in its discretion may elect to prepare a coordinated emergency response plan for the entire Building and/or for multiple Buildings on the Project. Such information shall be updated from time to time upon Landlord’s written request.

 

38


(vi)        Any Contingency Plans and Emergency Procedures required of Tenant from time to time, in connection with its operations at the Premises, pursuant to applicable law, Title 26, California Code of Regulations Sections 22-67140 et seq., and any amendments thereto, and any Training Programs and Records required under Title 26, California Code of Regulations Section 22-66493, and any amendments thereto from time to time. Landlord in its discretion may elect to prepare a Contingency Plan and Emergency Procedures for the entire Building and/or for multiple Buildings on the Project, in which event, if applicable law does not require Tenant to prepare a Contingency Plan and Emergency Procedures for its operations at the Premises, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Contingency Plan and Emergency Procedures. Such information shall be updated from time to time upon Landlord’s written request.

(vii)        Copies of any biennial or other periodic reports furnished or required to be furnished to the California Department of Health Services from time to time, under applicable law, pursuant to Title 26, California Code of Regulations Section 22-66493 and any amendments thereto, relating to any Hazardous Materials.

(viii)        Copies of any industrial wastewater discharge permits issued to or held by Tenant from time to time in connection with its operations at the Premises (the parties presently anticipate, however, that because of the existence of the Building Discharge Permit in Landlord’s name as described above. Tenant will not be required to maintain a separate, individual discharge permit).

(ix)        Copies of any other lists, reports, studies, or inventories of Hazardous Materials or of any subcategories of materials included in Hazardous Materials that Tenant is otherwise required to prepare and file from time to time with any governmental or quasi-governmental authority in connection with Tenant’s operations at the Premises, including (but not limited to) reports filed by Tenant with the Federal Food & Drug Administration or any other regulatory authorities primarily in connection with the presence (or lack thereof) of any “select agents” or other Biohazardous Materials on the Premises, together with proof of filing thereof.

(x)        Any other information reasonably requested by Landlord in writing from time to time in connection with (A) Landlord’s monitoring (in Landlord’s reasonable discretion) and enforcement of Tenant’s obligations under this Section and of compliance with applicable Legal Requirements in connection with any Handling or Release of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, (B) any inspections or enforcement actions by any governmental authority pursuant to any Hazardous Materials Laws or any other Legal Requirements relating to the presence or Handling of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, and/or (C) Landlord’s preparation (in Landlord’s discretion) and enforcement of any reasonable rules and procedures relating to the presence or Handling by Tenant or any Tenant Party of Hazardous Materials in the Premises or Building or on or about the Project, including (but not limited to) any contingency plans or emergency response plans as described above. Except as otherwise required by Law, Landlord shall keep confidential any information supplied to Landlord by Tenant pursuant to the foregoing, provided, however, that the foregoing shall not

 

39


apply to any information filed by Tenant with any governmental authority or available to the public at large. Landlord may provide such information to its lenders, consultants, purchasers or investors on a need to know basis provided (i) such entities agree in writing to keep such information confidential; (ii) Landlord uses diligent efforts to limit the scope of any such disclosure to only those portions of the information which are necessary for the intended purpose; and (iii) no less than ten (10) days prior to making any such disclosure, Landlord provides Tenant with written notice of the identity of the receiving party and the scope and purpose of the disclosure, and permits Tenant to redact those portions of the information which Tenant believes are reasonably necessary to protect its proprietary and/or confidential information.

(5)         Indemnification; Notice of Release . Tenant shall be responsible for and shall indemnify, defend and hold Landlord harmless from and against all Environmental Damages to the extent arising out of or in connection with, or otherwise relating to, (i) any Handling of Hazardous Materials by any Tenant Party in, on or about the Premises or the Project in violation of this Section 7.1(d), (ii) any breach of Tenant’s obligations under this Section or of any Hazardous Materials Laws by any Tenant Party, or (iii) the existence of any Tenant Contamination in, on or about the Premises or the Project to the extent caused by any Tenant Party, including without limitation any removal, cleanup or restoration work and materials necessary to return the Project or any improvements of whatever nature located on the Project to the condition existing prior to the Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party. In the event of any Tenant Contamination in, on or about the Premises or any other portion of the Project or any adjacent lands, Tenant shall promptly remedy the problem in accordance with all applicable Hazardous Materials Laws, shall give Landlord oral notice of any such non-standard or non.-customary Release promptly after Tenant becomes aware of such Release, followed by written notice to Landlord within five (5) days after Tenant becomes aware of such Release, and shall furnish Landlord with concurrent copies of any and all notices, reports and other written materials filed by any Tenant Party with any governmental authority in connection with such Release. Landlord shall be responsible for and shall indemnify and hold Tenant harmless from and against all Environmental Damages which arise prior to, during or after the Term of this Lease, as a result of the presence of, any Release of or the Handling of any Hazardous Material in, on, about, to, from or under the Premises, Building or Property, except to the extent provided for as Tenant’s responsibility in this Section 7.1(d); provided that, if the Hazardous Materials that are the subject of such Release are Hazardous Materials that Tenant uses, handles, generates, transports, stores, treats or disposes of at or from the Premises (as such Hazardous Materials are specified on the inventory or other information to be provided by Tenant pursuant to Section 7.1(d)(4) above), Tenant shall have the burden of reasonably demonstrating that such Hazardous Materials were not Released by Tenant, otherwise Landlord shall have the burden of reasonably demonstrating that Tenant was responsible for the Release of such Hazardous Materials. Tenant shall have no obligation to remedy any Hazardous Materials contamination which was not caused or Released by a Tenant Party. Notwithstanding anything to the contrary herein, neither Landlord nor Tenant shall be responsible for or be required to indemnify the other for lost profits, or other consequential, punitive or special damages incurred by the other.

(6)         Governmental Notices . Tenant shall promptly provide Landlord with copies of all written notices received by Tenant relating to any actual or alleged presence or

 

40


Handling by any Tenant Party of Hazardous Materials in, on or about the Premises or any other portion of the Project, including, without limitation, any notice of violation, notice of responsibility or demand for action from any federal, state or local governmental authority or official in connection with any actual or alleged presence or Handling by any Tenant Party of Hazardous Materials in or about the Premises or any other portion of the Project.

(7)         Inspection by Landlord . In addition to, and not in limitation of, Landlord’s rights under this Lease, upon reasonable prior request by Landlord (provided, however, not more than twice a year absent a material breach of this Section 7.1(d) by Tenant), Tenant shall grant Landlord and its consultants, as well as any governmental authorities having jurisdiction over the Premises or over any aspect of Tenant’s use thereof, reasonable access to the Premises at reasonable times, with reasonable prior notice, to inspect Tenant’s Handling of Hazardous Materials in, on and about the Premises, and Landlord shall not thereby incur any liability to Tenant or be deemed guilty of any disturbance of Tenant’s use or possession of the Premises by reason of such entry; provided, however that Landlord shall use reasonable efforts to minimize interference with Tenant’s use of the Premises caused by such entry. Landlord shall comply with any security precaution reasonably imposed by Tenant during any entry onto the Premises and shall minimizes to the extent reasonably possible any interference with Tenant’s use of the Premises caused by such entry. Notwithstanding Landlord’s rights of inspection and review of documents, materials and physical conditions under this Section with respect to Tenant’s Handling of Hazardous Materials, Landlord shall have no duty or obligation to perform any such inspection or review or to monitor in any way any documents, materials, physical conditions or compliance with Legal Requirements in connection with Tenant’s Handling of Hazardous Materials, and no third Party shall be entitled to rely on Landlord to conduct any such inspection, review or monitoring by reason of the provisions of this Section.

(8)         Monitoring by Landlord . Landlord reserves the absolute right to monitor, in Landlord’s reasonable discretion and at Landlord’s cost (the reasonable cost of which shall be recoverable as an Operating Expense hereunder (except in the case of a breach of any of Tenant’s obligations under this Section, in which event such monitoring costs may be charged back entirely to Tenant and shall be reimbursed by Tenant to Landlord within ten (10) days after written demand by Landlord from time to time, accompanied by supporting documentation reasonably evidencing the costs for which such reimbursement is claimed)), at such times and from time to time as Landlord in its reasonable discretion may determine, through consultants engaged by Landlord or otherwise as Landlord in its reasonable discretion may determine, (x) all aqueous and atmospheric discharges and emissions from the Premises during the Term by a Tenant Party, (y) Tenant’s compliance and the collective compliance of all tenants in the Building with requirements and restrictions relating to the occupancy classification of the Building (including, but not limited to, Hazardous Materials inventory levels of Tenant and all other tenants in the Building), and (z) Tenant’s compliance with all other requirements of this Section.

(9)         Discovery of Discharge . If Landlord, Tenant or any governmental or quasi-governmental authority discovers any Release from the Premises during the Term by a Tenant Party in violation of this Section 7.1(d) that, in Landlord’s reasonable determination, jeopardizes the ability of the Building or the Project to comply with applicable Hazardous Materials Laws, or if Landlord discovers any other breach of Tenant’s obligations under this

 

41


Section 7.1(d), then upon receipt of written notice from Landlord or at such earlier time as Tenant obtains actual knowledge of such Release, Tenant at its sole expense shall within a reasonable time (x) in the case of a Release in violation of this Lease, cease the applicable discharge or emission and remediate any continuing effects of the discharge or emission until such time, if any, as Tenant demonstrates to Landlord’s reasonable satisfaction that the applicable discharge or emission is in compliance with all applicable Hazardous Materials Laws and any other applicable regulatory commitments and obligations to the satisfaction of the appropriate governmental agency with jurisdiction over the Release, and (y) in the case of any other breach of Tenant’s obligations under this Section 7.1(d), take such corrective measures consistent with applicable Hazardous Materials Laws as Landlord may reasonably request in writing in order to cure or eliminate the breach as promptly as practicable and to remediate any continuing effects of the breach.

(10)         Post-Occupancy Study . If Tenant or any Tenant Party Handles any Hazardous Materials in, on or about the Premises or the Project during the Term of this Lease, then no later than fifteen (15) days prior to the termination or expiration of this Lease, Tenant at its sole cost and expense shall obtain and deliver to Landlord an environmental study, performed by an expert reasonably satisfactory to Landlord, evaluating, the presence or absence of any Tenant Contamination in, on and about the Premises and the Property. Such study shall be based on a reasonable and prudent level of tests and investigations of the Premises and surrounding portions of the Project (if appropriate) which tests shall be conducted no earlier than the date of termination or expiration of this Lease. Liability for any remedial actions required or recommended on the basis of such study shall be allocated in accordance with the applicable provisions of this Lease. To the extent any such remedial actions are the responsibility of Tenant, Tenant at its sole expense shall promptly commence and diligently pursue to completion the required remedial actions.

(11)         Emergency Response Plans . If Landlord in its reasonable discretion adopts any emergency response plan and/or any Contingency Plan and Emergency Procedures for the Building or for multiple Buildings on the Project as contemplated above, Landlord shall provide copies of any such plans and procedures to Tenant and, so long as such plans and procedures are reasonable and do not unreasonably interfere with Tenant’s use of or access to the Premises or materially increase the cost incurred by Tenant with respect to the Premises, Tenant shall comply with all of the requirements of such plans and procedures to the extent applicable to Tenant and/or the Premises. If Landlord elects to adopt or materially modify any such plans or procedures that apply to the Building during the Term of this Lease, Landlord shall consult with Tenant in the course of preparing such plans, procedures or modifications in order to try to ensure that they will accurately reflect and be consistent with Tenant’s operations in the Premises, but Landlord alone shall determine, in its good faith reasonable discretion, the appropriate scope of such consultation and nothing in this paragraph shall be construed to give Tenant any right of approval or disapproval over Landlord’s adoption or modification of any such plans or procedures so long as such plans and procedures are reasonable and do not unreasonably interfere with Tenant’s Use at or access to the Premises or materially increase the cost incurred by Tenant with respect to the Premises.

(12)         Radioactive Materials . Without limiting any other applicable provisions of this Section, if Tenant Handles or proposes to Handle any Radioactive Materials in or about

 

42


the Premises, Tenant shall provide Landlord with copies of Tenant’s licenses or permits for such Radioactive Materials and with copies of all radiation protection programs and procedures required under applicable Legal Requirements or otherwise adopted by Tenant from time to time in connection with Tenant’s Handling of such Radioactive Materials. In addition, Tenant shall comply with any and all rules and procedures issued by Landlord in its good faith discretion from time to time with respect to the Handling of Radioactive Materials on the Project (such as, by way of example but not limitation, rules implementing a label defacement program for decayed waste destined for common trash and/or rules relating to transportation and storage of Radioactive Materials on the Project), provided that such rules and procedures shall be reasonable and not in conflict with any applicable Legal Requirements.

(13)         Deemed Holdover Occupancy . Notwithstanding any other provisions of this Lease, Tenant expressly agrees as follows:

(i)        If Tenant Handles any Radioactive Materials in or about the Premises during the Term of this Lease, then for so long as any license or permit relating to such Radioactive Materials remains open following any otherwise applicable termination or expiration of the Term of this Lease and another entity handling Radioactive Materials which is a bona fide prospective tenant of Landlord as demonstrated by a current signed lease proposal or letter of intent is legally prohibited from occupying a portion of the Premises for a use similar to the Use while such license or permit remains open, then and in such event, Tenant shall be deemed to be occupying that portion of the Premises on a holdover basis without Landlord’s consent (notwithstanding such otherwise applicable termination or expiration of the Term of this Lease) and shall be required to continue to pay Rent in accordance with the holdover provisions of this Lease solely for that portion of the Premises which is covered by the radioactive materials license or permit, until such time as all such Radioactive Materials licenses and permits have been fully closed out in accordance with the requirements of all applicable Hazardous Materials Laws.

(ii)        If Tenant Handles any Hazardous Materials in or about the Premises during the Term of this Lease and, at the otherwise applicable termination or expiration of the Term of this Lease Tenant has failed to remove from the Premises and the Building all known Hazardous Materials Handled by a Tenant Party or has failed to complete any remediation or removal of Tenant’s Contamination and/or to have fully remediated, in compliance with the requirements of all applicable Hazardous Materials Laws, the Tenant’s Handling and/or Release (if applicable) of any such Hazardous Materials during the Term of this Lease, then for so long as such circumstances continue to exist, Tenant shall be deemed to be occupying the Premises on a holdover basis without Landlord’s consent (notwithstanding such otherwise applicable termination or expiration of the Term of this Lease) and shall be required to continue pay Rent in accordance with the holdover provisions of this Lease until such time as all such circumstances have been fully resolved in accordance with the requirements of this Lease and with all applicable Hazardous Materials Laws and other Legal Requirements.

(14)         Survival of Obligations . Each party’s obligations under this Section 7.1(d) shall survive the expiration or other termination of this Lease and shall survive any conveyance by Landlord of its interest in the Premises. The provisions of this Section 7.1(d) and any exercise by either party of any of the rights and remedies contained herein shall be without

 

43


prejudice to any other rights and remedies that such party may have under this Lease or under applicable law with respect to any Environmental Conditions and/or any Hazardous Materials with respect to any breach of the other party’s obligations under this Section 7.1(d). Either party’s exercise or failure to exercise, at any time or from time to time, any or all of the rights granted in this Section 7.1(d) shall not in any way impose any liability on such party or shift from the other party to such party any responsibility or obligation imposed upon the other party under this Lease or under applicable law with respect to Hazardous Materials, Environmental Conditions and/or compliance with Hazardous Materials Laws.

(15)         Laboratory Rules and Regulations . Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the laboratory rules and regulations (“Laboratory Rules and Regulations”) attached to this Lease as Exhibit C-1 and with all reasonable modifications and additions thereto which Landlord may make from time to time.

(16)         Copies of Environmental Documents . Landlord represents it has provided to Tenant copies of all environmental reports (including Phase 1 Environmental Assessments and invasive soil and groundwater investigation and remediation reports) within its possession or control as of the Date of Lease.

 

7.2

LANDLORD ACCESS TO PREMISES; APPROVALS

(a)        Tenant shall permit Landlord to erect, use and maintain pipes, ducts, wiring and conduits in and through the Premises, so long as Tenant’s use, layout or design of the Premises is not materially affected or altered. Landlord or Landlord’s agents shall have the right to enter upon the Premises in the event of an emergency, or to inspect the Premises, to perform janitorial and other services, to conduct safety and other testing in the Premises and to make such repairs, alterations, improvements or additions to the Premises or the Building or other parts of the Property as Landlord may deem necessary or desirable (including all alterations, improvements and additions in connection with a change in service provider or providers). Landlord shall provide not less than one (1) business days’ written notice prior to entry into the Premises except for the ongoing provision of Landlord services and for emergencies. Janitorial and cleaning services shall be performed after normal business hours. Any entry or work by Landlord may be during normal business hours provided Landlord uses reasonable efforts to ensure that any entry or work shall not materially interfere with Tenant’s use or occupancy of the Premises.

(b)        If Tenant shall not be personally present to permit an entry into the Premises when for any reason an entry therein shall be necessary or permissible, Landlord (or Landlord’s agents), after attempting to notify Tenant (unless Landlord believes an emergency situation exists), may enter the Premises without rendering Landlord or its agents liable therefor, and without relieving Tenant of any obligations under this Lease.

(c)        Subject to the notice requirement and other terms of Landlord’s entry set forth in Section 7.2(a), Landlord may enter the Premises for the purpose of conducting such inspections, tests and studies as Landlord may reasonably deem necessary to confirm Tenant’s compliance with all Laws and Hazardous Materials Laws or for other purposes necessary in Landlord’s reasonable judgment to ensure the sound condition of the Property and the systems serving the Property. Landlord’s rights under this Section 7.2(c) are for Landlord’s own protection only, and

 

44


Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party as a result of the exercise or non-exercise of such rights, for compliance with Laws or Hazardous Materials Laws or for the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.

(d)        Subject to the notice requirement and other terms of Landlord’s entry set forth in Section 7.2(a), Landlord may do any of the foregoing, or undertake any of the inspection or work described in the preceding paragraphs without such action constituting an actual or constructive eviction of Tenant, in whole or in part, or giving rise to an abatement of Rent by reason of loss or interruption of business of the Tenant, or otherwise.

(e)        The review, approval or consent of Landlord with respect to any item required or permitted under this Lease is for Landlord’s own protection only, and Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party, as a result of the exercise or non-exercise of such rights, for compliance with Laws or Environmental Laws or for the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.

 

7.3

QUIET ENJOYMENT

Landlord covenants, in lieu of any implied covenant of quiet possession or quiet enjoyment, that so long as Tenant is in compliance with the covenants and conditions set forth in this Lease, Tenant shall have the right to quiet enjoyment of the Premises without hindrance or interference from Landlord or those claiming through Landlord, and subject to the covenants and conditions set forth in the Lease and to the rights of any Mortgagee or ground lessor.

ARTICLE 8

MAINTENANCE

 

8.1

LANDLORD’S MAINTENANCE

Subject to the provisions of Article Fourteen, Landlord shall maintain in good condition and make necessary repairs to the foundations, roofs, exterior walls, and the structural elements of the Building, the electrical, plumbing, heating, ventilating, air-conditioning, mechanical, communication, security and the fire and life safety systems of the Building and those corridors, washrooms and lobbies which are Common Areas of the Building (which shall be deemed to include the restrooms in the Premises and elsewhere in the Building), except that: (a) Landlord shall not be responsible for the maintenance or repair of any floor or wall coverings in the Premises or any of such systems which are located within the Premises, serve only the Premises and are supplemental or special to the Building’s standard systems; and (b) the cost of performing any of said maintenance or repairs whether to the Premises or to the Building caused by the negligence of Tenant, its employees, agents, servants, licensees, subtenants, contractors or invitees, shall be paid by Tenant, subject to the waivers set forth in Section 16.4. Landlord shall not be liable to Tenant for any expense, injury, loss or damage resulting from work done in or upon, or in connection with the use of, any adjacent or nearby building, land, street or alley.

 

45


8.2

TENANT’S MAINTENANCE

Tenant shall periodically inspect the Premises to identify any conditions that are dangerous or in need of maintenance or repair. Tenant shall promptly provide Landlord with notice of any such conditions. Tenant shall, at its sole cost and expense, perform all maintenance and repairs to the Premises that are not Landlord’s express responsibility under this Lease, and keep the Premises in good condition and repair, reasonable wear and tear excepted. Tenant’s repair and maintenance obligations include, without limitation, repairs to: (a) floor covering; (b) interior partitions; (c) doors; (d) the interior side of demising walls; (e) electronic, phone and data cabling and related equipment that is installed by or for the exclusive benefit of Tenant (collectively, “Cable”); (f) supplemental air conditioning units, kitchens, including hot water heaters, plumbing, and similar facilities exclusively serving Tenant; and (g) Alterations. To the extent Landlord is not reimbursed by insurance proceeds, Tenant shall reimburse Landlord for the cost of repairing damage to the Building caused by the acts of Tenant, Tenant Related Parties and their respective contractors and vendors. If Tenant fails to make any repairs to the Premises for more than 15 days after notice from Landlord (although notice shall not be required in an emergency), Landlord may make the repairs, and Tenant shall pay the reasonable out-of-pocket cost of the repairs, together with an administrative charge in an amount equal to 10% of the cost of the repairs. Tenant hereby waives all right to make repairs at the expense of Landlord or in lieu thereof to vacate the Premises and its other similar rights as provided in California Civil Code Sections 1932(1), 1941 and 1942 or any other Legal Requirement (whether now or hereafter in effect). In addition to the foregoing, Tenant shall be responsible for repairing all special tenant fixtures and improvements, including garbage disposals, showers, plumbing, and appliances.

ARTICLE 9

ALTERATIONS AND IMPROVEMENTS

 

9.1

TENANT ALTERATIONS

(a)        The following provisions shall apply to the completion of any Tenant Alterations:

(1)        Tenant shall not, except as provided herein, without the prior written consent of Landlord, which consent shall not be unreasonably withheld, make or cause to be made any Tenant Alterations in or to the Premises or any Property systems serving the Premises. Prior to making any Tenant Alterations, Tenant shall give Landlord ten (10) days prior written notice (or such earlier notice as would be necessary pursuant to applicable Law) to permit Landlord sufficient time to post appropriate notices of non-responsibility. Subject to all other requirements of this Article Nine, Tenant may undertake Decoration Work and may install and remove Cable (“Cabling Work”) without Landlord’s prior written consent. For Tenant Alterations other than Decoration Work and Cabling Work, Tenant shall furnish Landlord with the names and addresses of all contractors and subcontractors and copies of all contracts. All Tenant Alterations (other than Decoration Work and Cabling Work) shall be performed only by contractors or mechanics approved by Landlord, which approval shall not be unreasonably withheld, provided, however, that Landlord may, in its sole discretion, specify the engineers and contractors to perform all work relating to the Building systems (including the mechanical, heating, plumbing, security, ventilating, air-conditioning, electrical, communication and the fire

 

46


and life safety systems in the Building) provided that the rates of such contractors are competitive with the rates of other contractors qualified (in Landlord’s reasonable judgment) to perform such work. The contractors, mechanics and engineers who may be used are further limited to those whose work will not cause or threaten to cause disharmony or interference with Landlord or other tenants in the Building and their respective agents and contractors performing work in or about the Building. Landlord may further condition its consent to Tenant Alterations (other than Decoration Work and Cabling Work) upon Tenant furnishing to Landlord and Landlord approving prior to the commencement of any work or delivery of materials to the Premises related to the Tenant Alterations such of the following as specified by Landlord: architectural plans and specifications, opinions from Landlord’s engineers stating that the Tenant Alterations will not in any way adversely affect the Building’s systems, necessary permits and licenses, certificates of insurance (which, notwithstanding anything to the contrary herein, must be delivered to and reasonably approved by Landlord in the case of Decoration Work and Cabling as well as Tenant Alterations requiring Landlord’s consent), and such other documents in such form reasonably requested by Landlord. Landlord may, in the exercise of reasonable judgment, require that Tenant provide Landlord with appropriate evidence of Tenant’s ability to complete and pay for the completion of the Tenant Alterations, which may include, in the case of Tenant Alterations costing in excess of $100,000 in the aggregate for a particular Tenant Alteration or a series of related Tenant Alterations, a performance bond or letter of credit. Upon completion of the Tenant Alterations, Tenant shall deliver to Landlord an as-built mylar and digitized (if available) set of plans and specifications for the Tenant Alterations. Landlord shall review and provide its approval or comments on any submittals made by Tenant for Tenant Alterations requiring Landlord’s approval hereunder within ten (10) business days after such submittal. At the time of Landlord’s written approval of any Tenant Alteration requiring Landlord’s written approval hereunder, Landlord shall notify Tenant if such Tenant Alteration is a Required Removable (as defined in Article Twelve). Landlord’s failure to designate a Tenant Alteration as a Required Removable at the time of such approval shall be deemed Landlord’s determination that such Tenant Alteration is not a Required Removable.

(2)        Tenant shall pay the cost of all Tenant Alterations. Upon completion of Tenant Alterations, Tenant shall furnish Landlord with contractors’ affidavits and full and final waivers of lien and receipted bills covering all labor and materials expended and used in connection therewith and such other documentation reasonably requested by Landlord or Mortgagee.

(3)        Tenant agrees to complete all Tenant Alterations (i) in accordance with all applicable Laws, including Hazardous Materials Laws, all requirements of applicable insurance companies and in accordance with Landlord’s standard construction rules and regulations, and (ii) in a good and workmanlike manner with the use of good grades of materials. Tenant shall notify Landlord promptly if Tenant receives any notice of violation of any Law in connection with completion of any Tenant Alterations and shall promptly take such steps as are necessary to remedy such violation. In no event shall such supervision or right to supervise by Landlord nor shall any approvals given by Landlord under this Lease constitute any warranty by Landlord to Tenant of the adequacy of the design, workmanship or quality of such work or materials for Tenant’s intended use or of compliance with the requirements of Section 9.1(a)(3)(i) and (ii) above or impose any liability upon Landlord in connection with the performance of such work. With respect to any Tenant Alterations requiring Landlord’s consent and costing in excess

 

47


of $50,000 in the aggregate for a particular Tenant Alteration or a series of related Tenant Alterations, Landlord shall charge an administration fee of five percent (5%) of the cost of such Tenant Alterations; provided that, if Tenant requests that Landlord perform such work for Tenant and Landlord elects to do so, Landlord’s administration fee in connection therewith shall be fifteen percent (15%).

(b)        All Landlord Work and Tenant Alterations whether installed by Landlord or Tenant, shall without compensation or credit to Tenant, become part of the Premises and the property of Landlord at the time of their installation and shall remain in the Premises, unless pursuant to Article Twelve, Tenant may remove them or is required to remove them at Landlord’s request (subject to Landlord’s prior approval notice referenced in Section 9(a)(1) above).

 

9.2

LIENS

Tenant shall not permit any lien or claim for lien of any mechanic, laborer or supplier or any other lien to be filed against the Building, the Land, the Premises, or any other part of the Property arising out of work performed, or alleged to have been performed by, or at the direction of, or on behalf of Tenant. If any such lien or claim for lien is filed, Tenant shall within twenty (20) days of receiving notice of such lien or claim (a) have such lien or claim for lien released of record or (b) deliver to Landlord a bond in form, content, amount, and issued by surety, satisfactory to Landlord, indemnifying, protecting, defending and holding harmless the Indemnitees against all costs and liabilities resulting from such lien or claim for lien and the foreclosure or attempted foreclosure thereof. If Tenant fails to take any of the above actions, Landlord, in addition to its rights and remedies under Article Eleven, without investigating the validity of such lien or claim for lien, may pay or discharge the same and Tenant shall, as payment of additional Rent hereunder, reimburse Landlord upon demand for the amount so paid by Landlord, including Landlord’s reasonable out-of-pocket expenses and attorneys’ fees. Tenant shall not be responsible for liens arising out of the performance by Landlord of the Landlord Work, so long as Tenant has paid all sums due or owing by Tenant for costs of the Landlord Work in excess of the allowances to be provided by Landlord.

 

9.3

EQUIPMENT LEASING AND FINANCING

Notwithstanding any provision of this Lease to the contrary, Tenant may enter into leases for, and/or grant security interests in, Tenant’s trade fixtures, equipment, inventory and personal property in the Premises pursuant to one or more equipment leases and/or security agreements. Landlord shall (i) subordinate any landlord lien rights that it may have in and to such items to the interest of the lessor and lenders therein, and, in the case of trade fixtures, waive any claim that the same are part of the Building or the Property by virtue of being affixed thereto, and (ii) so long as this Lease is still in effect, permit the lessor and lenders under any such leases and security agreements to remove the leased or encumbered property, upon default by Tenant under such leases and security agreements, pursuant to customary, commercially reasonable lien waiver agreement(s) between Landlord and any such lessor or lender. Tenant shall be responsible for Landlord’s reasonable out-of-pocket costs in connection with the preparation and/or review of any such agreement, including reasonable attorneys’ fees.

 

48


ARTICLE 10

ASSIGNMENT AND SUBLETTING

 

10.1

ASSIGNMENT AND SUBLETTING

(a)        Subject to Landlord’s Recapture Right in Section 10.2, if applicable, without the prior written consent of Landlord, which consent of Landlord shall not be unreasonably withheld, conditioned or delayed, Tenant may not sublease, assign, mortgage, pledge, hypothecate or otherwise transfer or permit the transfer of this Lease or the encumbering of Tenant’s interest therein in whole or in part, by operation of Law or otherwise or permit the use or occupancy of the Premises, or any part thereof, by anyone other than Tenant and its employees. Tenant agrees that the provisions governing sublease and assignment set forth in this Article Ten shall be deemed to be reasonable. If Tenant desires to enter into any sublease of the Premises or assignment of this Lease, Tenant shall deliver written notice thereof to Landlord (“Tenant’s Notice”), together with the identity of the proposed subtenant or assignee and the proposed principal terms thereof and current financial and other information reasonably requested by Landlord in order for Landlord to make an informed judgment with respect to such proposed subtenant or assignee at least thirty (30) days prior to the commencement date of the term of the proposed sublease or assignment. If Tenant proposes to sublease less than all of the Rentable Area of the Premises, the space proposed to be sublet and the space retained by Tenant must each be a marketable unit as reasonably determined by Landlord (provided that without limitation, each of the following shall be deemed to be a marketable unit for purposes of subleasing: (i) all of the space on a particular floor in the Building that constitutes a portion of the Premises, (ii) Suite 100, (iii) Suite 200, or (iv) the Expansion Premises) and otherwise in compliance with all Laws. Landlord shall notify Tenant in writing of its approval or disapproval of the proposed sublease or assignment or, if applicable, its decision to exercise its Recapture Right under Section 10.2, within twenty (20) days after receipt of Tenant’s Notice (and all required information). Tenant shall submit for Landlord’s approval (which approval shall not be unreasonably withheld) any advertising which Tenant or its agents intend to use with respect to the space proposed to be sublet.

(b)        With respect to Landlord’s consent to an assignment or sublease, the parties agree it shall be reasonable for Landlord to withhold its consent where, without limitation of other reasonable grounds:

(1)        the business reputation of the proposed subtenant or assignee is not consistent with the quality of the occupants of the Building; or

(2)        the proposed assignee’s or sublessee’s use of the Premises would violate Section 7.1 of this Lease; or

(3)        the proposed sublessee or assignee is a bona fide prospective tenant of Landlord for comparable available space in the Project as demonstrated by a written proposal signed by Landlord and such prospective tenant within ninety (90) days prior to the date of Tenant’s request; provided that, if Tenant delivered a Tenant’s Advance Recapture Notice (defined below) with respect to the proposed sublease or assignment and Landlord did not identify such proposed sublessee or assignee as a Landlord Current

 

49


Prospect (defined below) in response thereto, it shall not be deemed to be reasonable for Landlord to withhold its consent to such sublease or assignment on the basis that the proposed sublessee or assignee is a prospective tenant of Landlord.

(c)        Any sublease or assignment shall be expressly subject to the terms and conditions of this Lease. Any subtenant or assignee shall execute such documents as Landlord may reasonably require to evidence such subtenant or assignee’s assumption of the obligations and liabilities of Tenant under this Lease. Tenant shall deliver to Landlord a copy of all agreements executed by Tenant and the proposed subtenant and assignee with respect to the Premises. Landlord’s approval of a sublease, assignment, hypothecation, transfer or third party use or occupancy shall not constitute a waiver of Tenant’s obligation to obtain Landlord’s consent to further assignments or subleases, hypothecations, transfers or third party use or occupancy. In the case of an assignment of this Lease (other than an assignment permitted pursuant to Section 10.1(d) below). Tenant shall pay to Landlord the outstanding balance of the Deferred Rent Loan, if any, on or before the effective date of such assignment.

(d)        So long as Tenant is not entering into a transaction described herein for the purpose of avoiding or otherwise circumventing the remaining terms of this Article, Tenant may, subject to Section 10.5, assign its entire interest under this Lease or sublease all or a portion of the Premises, without the consent of Landlord and without any right of recapture and without any obligation to pay Excess Rent, to (i) an Affiliate, or (ii) a successor to Tenant by purchase or other acquisition of Tenant’s capital stock or substantially all of Tenant’s assets, merger, consolidation or reorganization, provided that all of the following conditions are satisfied: (1) Tenant shall give Landlord written notice at least five (5) business days prior to the effective date of the proposed transfer and such entity shall expressly assume Tenant’s obligations hereunder; (2) with respect to an assignment to an Affiliate, Tenant continues to have a net worth equal to or greater than Tenant’s net worth at the date immediately prior to such transfer; and (3) with respect to a purchase, merger, consolidation or reorganization which results in Tenant ceasing to exist as a separate legal entity, Tenant’s successor shall have a net worth equal to or greater than Tenant’s net worth at the date immediately prior to such transfer.

 

10.2

RECAPTURE

Excluding any assignment or sublease contemplated in Section 10.1(d), in the event Tenant intends to (i) assign this Lease, (ii) sublet all of Suite 100, or all of Suite 200, or all of the Expansion Premises, in each case for a term of 3 years or more, or (iii) sublet any portion of the Premises for the remaining Term, Landlord shall have the option to terminate this Lease with respect to, and exclude from the Premises covered by this Lease (the “Recapture Right”), the space proposed to be assigned or sublet effective as of the proposed commencement date of such sublease or assignment. If Landlord is entitled to and properly exercises its Recapture Right, Tenant shall surrender possession of the space proposed to be subleased or subject to the assignment to Landlord on the effective date of recapture of such space from the Premises, and the Monthly Base Rent, Rentable Area of the Premises, Tenant’s Share, Additional Tenant Improvement Allowance Monthly Payments, and other applicable terms of this Lease shall be adjusted accordingly as of such effective date; and, in addition, Tenant shall pay to Landlord on such effective date that percentage of the outstanding balance of the Deferred Rent Loan, if any,

 

50


that is outstanding as of such effective date equal to the percentage of the area of the Premises that is then being recaptured by Landlord.

Notwithstanding anything to the contrary in Section 10.1(a), Tenant may provide notice to Landlord of Tenant’s intent to assign or sublease as contemplated in clauses (i), (ii) and (iii) of this Section 10.2 above and the contemplated effective date of such assignment or sublease (“Tenant’s Advance Recapture Notice”), and within fifteen (15) business days after receipt of Tenant’s Advance Recapture Notice from Tenant, (i) Landlord will indicate in writing to Tenant whether or not Landlord exercises its Recapture Right with respect to such contemplated assignment or sublease, and (ii) in the event that Landlord does not elect to exercise its Recapture Right, Landlord may disclose the identity of any bona fide prospective tenant with whom Landlord is then in active negotiations for the lease of space in the Project comparable to the space contemplated to be assigned or sublet by Tenant (a “Landlord Current Prospect”). If Landlord elects to exercise its Recapture Right, Landlord’s election shall be deemed final and binding on Tenant unless Tenant, within five (5) business days after Landlord’s notice, rescinds Tenant’s Advance Recapture Notice to Landlord of Tenant’s intent to enter into such contemplated assignment or subletting transaction. If Landlord does not elect to exercise its Recapture Right within fifteen (15) business days after receipt of Tenant’s Advance Recapture Notice, Landlord shall be deemed to have waived its right to elect the Recapture Right as to any assignment or subletting transaction for which Tenant, during the six (6) month period after Landlord’s election or deemed election not to exercise its Recapture Right in accordance with this Section 10.2, seeks Landlord’s prior consent under Section 10.1, and Landlord’s rights with respect to any such proposed transaction shall be limited to Landlord’s rights under this Article Ten without giving effect to the terms of this Section 10.2.

 

10.3

EXCESS RENT

Tenant shall pay Landlord on the first day of each month during the term of the sublease or assignment, fifty percent (50%) of the amount by which the sum of all rent and other consideration (direct or indirect) due from the subtenant or assignee for such month exceeds: (i) that portion of the Monthly Base Rent, Rent Adjustments and Additional Tenant Improvement Allowance Monthly Payments due under this Lease for said month which is allocable to the space sublet or assigned (excluding, however, any Deferred Rent Loan Payments); and (ii) the following costs and expenses for the subletting or assignment of such space: (1) brokerage commissions and attorneys’ fees and expenses, (2) the actual costs paid in making any improvements or substitutions in the Premises required by any sublease or assignment; and (3) “free rent” periods, costs of any inducements or concessions given to subtenant or assignee, moving costs, and other amounts in respect of such subtenant’s or assignee’s other leases or occupancy arrangements. All such costs and expenses shall be amortized over the term of the sublease or assignment pursuant to sound accounting principles.

 

10.4

TENANT LIABILITY

In the event of any sublease or assignment, whether or not with Landlord’s consent, Tenant shall not be released or discharged from any liability, whether past, present or future, under this Lease, including any liability arising from the exercise of any renewal or expansion option, to the extent such exercise is expressly permitted by Landlord. Tenant’s liability shall

 

51


remain primary, and in the event of default by any subtenant, assignee or successor of Tenant in performance or observance of any of the covenants or conditions of this Lease, Landlord may proceed directly against Tenant without the necessity of exhausting remedies against said subtenant, assignee or successor. After any assignment, Landlord may consent to subsequent assignments or subletting of this Lease, or amendments or modifications of this Lease with assignees of Tenant, without notifying Tenant, or any successor of Tenant, and without obtaining its or their consent thereto, and such action shall not relieve Tenant or any successor of Tenant of liability under this Lease. In addition, if Tenant has any options to extend the Term or to add other space to the Premises, such options shall not be available to any subtenant or assignee (other than an assignee pursuant to an assignment described in Section 10.1(d)), directly or indirectly without Landlord’s express written consent, which may be withheld in Landlord’s sole discretion.

 

10.5

ASSUMPTION AND ATTORNMENT

If Tenant shall assign this Lease as permitted herein, the assignee shall expressly assume all of the obligations of Tenant hereunder in a written instrument satisfactory to Landlord and furnished to Landlord not later than fifteen (15) days prior to the effective date of the assignment. If Tenant shall sublease the Premises as permitted herein, Tenant shall, at Landlord’s option, within fifteen (15) days following any request by Landlord, obtain and furnish to Landlord the written agreement of such subtenant to the effect that the subtenant will attorn to Landlord and will pay all subrent directly to Landlord.

 

10.6

PROCESSING EXPENSES

Tenant shall pay to Landlord, as Landlord’s cost of processing each proposed assignment or subletting (whether or not the same is ultimately approved by Landlord or consummated by Tenant), an amount equal to the sum of (i) all reasonable attorneys’ fees and expenses incurred by Landlord with respect to such assignment or sublease, plus (ii) the sum of $750.00 for the cost of Landlord’s administrative, accounting and clerical time (collectively, “Processing Costs”).

ARTICLE 11

DEFAULT AND REMEDIES

 

11.1

EVENTS OF DEFAULT

The occurrence or existence of any one or more of the following shall constitute a “Default” by Tenant under this Lease:

(1)        Tenant fails to pay any installment or other payment of Rent including Rent Adjustment Deposits or Rent Adjustments within five (5) days after written notice from Landlord of such failure;

(2)        Tenant fails to observe or perform any of the other covenants, conditions or provisions of this Lease or the Workletter and fails to cure such default within thirty (30) days after written notice thereof to Tenant, provided, however, that if such failure cannot reasonably be cured within thirty (30) days, it shall not be a default if Tenant has begun such cure within the thirty (30)-day period and thereafter diligently and continuously pursues the same to completion;

 

52


(3)        the interest of Tenant in this Lease is levied upon under execution or other legal process;

(4)        a petition is filed by or against Tenant to declare Tenant bankrupt or seeking a plan of reorganization or arrangement under any Chapter of the Bankruptcy Act, or any amendment, replacement or substitution therefor, or to delay payment of, reduce or modify Tenant’s debts, which in the case of an involuntary action is not discharged within thirty (30) days;

(5)        Tenant is declared insolvent by Law or any assignment of Tenant’s property is made for the benefit of creditors;

(6)        a receiver is appointed for Tenant or Tenant’s property, which appointment is not discharged within thirty (30) days; or

(7)        upon the dissolution of Tenant.

 

11.2

LANDLORD’S REMEDIES

(a)        A Default shall constitute a breach of the Lease for which Landlord shall have the rights and remedies set forth in this Section 11.2 and all other rights and remedies set forth in this Lease or now or hereafter allowed by Law, whether legal or equitable, and all rights and remedies of Landlord shall be cumulative and none shall exclude any other right or remedy now or hereafter allowed by applicable Law.

(b)        With respect to a Default, at any time Landlord may terminate Tenant’s right to possession by written notice to Tenant stating such election. Any written notice required pursuant to Section 11.1 shall constitute notice of unlawful detainer pursuant to California Code of Civil Procedure Section 1161 if, at Landlord’s sole discretion, it states Landlord’s election that Tenant’s right to possession is terminated after expiration of any period required by Law or any longer period required by Section 11.1. Upon the expiration of the period stated in Landlord’s written notice of termination (and unless such notice provides an option to cure within such period and Tenant cures the Default within such period), Tenant’s right to possession shall terminate and this Lease shall terminate, and Tenant shall remain liable as hereinafter provided. Upon such termination in writing of Tenant’s right to possession, Landlord shall have the right, subject to applicable Law, to re-enter the Premises and dispossess Tenant and the legal representatives of Tenant and all other occupants of the Premises by unlawful detainer or other summary proceedings, or as otherwise permitted by Law, regain possession of the Premises and remove their property (including their trade fixtures, personal property and those Tenant Alterations which Tenant is required or permitted to remove under Article Twelve), but Landlord shall not be obligated to effect such removal, and such property may, at Landlord’s option, be stored elsewhere, sold or otherwise dealt with as permitted by Law, at the risk of, expense of and for the account of Tenant, and the proceeds of any sale shall be applied pursuant to Law. Landlord shall in no event be responsible for the value, preservation or safekeeping of any such property. Tenant hereby waives all claims for damages that may be caused by Landlord’s removing or storing Tenant’s personal property pursuant to this Section or Section 12.1, and Tenant hereby indemnifies, and agrees to defend, protect and hold harmless, the Indemnitees

 

53


from any and all loss, claims, demands, actions, expenses, liability and cost (including attorneys’ fees and expenses) to the extent arising out of or in any way related to such removal or storage. Upon such written termination of Tenant’s right to possession and this Lease, Landlord shall have the right to recover damages for Tenant’s Default as provided herein or by Law, including the following damages provided by California Civil Code Section 1951.2:

(1)        the worth at the time of award of the unpaid Rent which had been earned at the time of termination;

(2)        the worth at the time of award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such Rent loss that Tenant proves could reasonably have been avoided;

(3)        the worth at the time of award of the amount by which the unpaid Rent for the balance of the term of this Lease after the time of award exceeds the amount of such Rent loss that Tenant proves could be reasonably avoided; and

(4)        any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant’s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including, without limitation, Landlord’s unamortized costs of tenant improvements, leasing commissions and legal fees incurred in connection with entering into this Lease. The word “rent” as used in this Section 11.2 shall have the same meaning as the defined term Rent in this Lease. The “worth at the time of award” of the amount referred to in clauses (1) and (2) above is computed by allowing interest at the Default Rate. The worth at the time of award of the amount referred to in clause (3) above is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%). For the purpose of determining unpaid Rent under clause (3) above, the monthly Rent reserved in this Lease shall be deemed to be the sum of the Monthly Base Rent, monthly storage space rent, if any, and the amounts last payable by Tenant as Rent Adjustments for the calendar year in which Landlord terminated this Lease as provided hereinabove.

(c)        Even if Tenant is in Default and/or has abandoned the Premises, this Lease shall continue in effect for so long as Landlord does not terminate Tenant’s right to possession by written notice as provided in Section 11.2(b) above, and Landlord may enforce all its rights and remedies under this Lease, including the right to recover Rent as it becomes due under this Lease. In such event, Landlord shall have all of the rights and remedies of a landlord under California Civil Code Section 1951.4 (lessor may continue Lease in effect after Tenant’s Default and abandonment and recover Rent as it becomes due, if Tenant has the right to sublet or assign, subject only to reasonable limitations), or any successor statute. During such time as Tenant is in Default, if Landlord has not terminated this Lease by written notice and if Tenant requests Landlord’s consent to an assignment of this Lease or a sublease of the Premises, subject to Landlord’s Recapture Right pursuant to Section 10.2, Landlord shall not unreasonably withhold its consent to such assignment or sublease. Tenant acknowledges and agrees that the provisions of Article Ten shall be deemed to constitute reasonable limitations of Tenant’s right to assign or sublet. Tenant acknowledges and agrees that in the absence of written notice pursuant to Section 11.2(b) above terminating Tenant’s right to possession, no other act of Landlord shall

 

54


constitute a termination of Tenant’s right to possession or an acceptance of Tenant’s surrender of the Premises, including acts of maintenance or preservation or efforts to relet the Premises or the appointment of a receiver upon initiative of Landlord to protect Landlord’s interest under this Lease or the withholding of consent to a subletting or assignment, or terminating a subletting or assignment, if in accordance with other provisions of this Lease.

(d)        In the event that Landlord seeks an injunction with respect to a breach or threatened breach by Tenant of any of the covenants, conditions or provisions of this Lease, Tenant agrees to pay the premium for any bond required in connection with such injunction.

(e)        Tenant hereby waives any and all rights to relief from forfeiture, redemption or reinstatement granted by Law (including California Civil Code of Procedure Sections 1174 and 1179) in the event of Tenant being evicted or dispossessed for any cause or in the event of Landlord obtaining possession of the Premises by reason of Tenant’s Default or otherwise;

(f)        Notwithstanding any other provision of this Lease, a notice to Tenant given under this Article and Article Twenty-four of this Lease or given pursuant to California Code of Civil Procedure Section 1161, and any notice served by mail shall be deemed served, and the requisite waiting period deemed to begin under said Code of Civil Procedure Section upon mailing, without any additional waiting requirement under Code of Civil Procedure Section 1011 et seq. or by other Law. For purposes of Code of Civil Procedure Section 1162, Tenant’s “place of residence”, “usual place of business”, “the property” and “the place where the property is situated” shall mean and be the Premises, whether or not Tenant has vacated same at the time of service.

(g)        The voluntary or other surrender or termination of this Lease, or a mutual termination or cancellation thereof, shall not work a merger and shall terminate all or any existing assignments, subleases, subtenancies or occupancies permitted by Tenant, except if and as otherwise specified in writing by Landlord.

(h)        No delay or omission in the exercise of any right or remedy of Landlord upon any default by Tenant, and no exercise by Landlord of its rights pursuant to Section 25.15 to perform any duty which Tenant fails timely to perform, shall impair any right or remedy or be construed as a waiver. No provision of this Lease shall be deemed waived by Landlord unless such waiver is in writing signed by Landlord. The waiver by Landlord of any breach of any provision of this Lease shall not be deemed a waiver of any subsequent breach of the same or any other provision of this Lease.

 

11.3

ATTORNEY’S FEES

In the event any party brings any suit or other proceeding with respect to the subject matter or enforcement of this Lease, the prevailing party (as determined by the court, agency or other authority before which such suit or proceeding is commenced) shall, in addition to such other relief as may be awarded, be entitled to recover attorneys’ fees, expenses and costs of investigation as actually incurred, including court costs, expert witness fees, costs and expenses of investigation, and all attorneys’ fees, costs and expenses in any such suit or proceeding (including in any action or participation in or in connection with any case or proceeding under

 

55


the Bankruptcy Code, 11 United States Code Sections 101 et seq., or any successor statutes, in establishing or enforcing the right to indemnification, in appellate proceedings, or in connection with the enforcement or collection of any judgment obtained in any such suit or proceeding).

 

11.4

BANKRUPTCY

To the extent permitted by Law, the following provisions shall apply in the event of the bankruptcy or insolvency of Tenant:

(a)        In connection with any proceeding under Chapter 7 of the Bankruptcy Code where the trustee of Tenant elects to assume this Lease for the purposes of assigning it, such election or assignment, may only be made upon compliance with the provisions of (b) and (c) below, which conditions Landlord and Tenant acknowledge to be commercially reasonable. In the event the trustee elects to reject this Lease then Landlord shall immediately be entitled to possession of the Premises without further obligation to Tenant or the trustee.

(b)        Any election to assume this Lease under Chapter 11 or 13 of the Bankruptcy Code by Tenant as debtor-in-possession or by Tenant’s trustee (the “Electing Party”) must provide for:

The Electing Party to cure or provide to Landlord adequate assurance that it will cure all monetary defaults under this Lease within fifteen (15) days from the date of assumption and it will cure all nonmonetaty defaults under this Lease within thirty (30) days from the date of assumption. Landlord and Tenant acknowledge such condition to be commercially reasonable.

(c)        If the Electing Party has assumed this Lease or elects to assign Tenant’s interest under this Lease to any other person, such interest may be assigned only if the intended assignee has provided adequate assurance of future performance (as herein defined), of all of the obligations imposed on Tenant under this Lease.

For the purposes hereof, “adequate assurance of future performance” means that Landlord has ascertained that each of the following conditions has been satisfied:

(1)        The assignee has submitted a current financial statement, certified by its chief financial officer, which shows a net worth and working capital in amounts sufficient to assure the future performance by the assignee of Tenant’s obligations under this Lease; and

(2)        Landlord has obtained consents or waivers from any third parties that may be required under a lease, mortgage, financing arrangement, or other agreement by which Landlord is bound, to enable Landlord to permit such assignment.

(d)        Landlord’s acceptance of rent or any other payment from any trustee, receiver, assignee, person, or other entity will not be deemed to have waived, or waive, the requirement of Landlord’s consent, Landlord’s right to terminate this Lease for any transfer of Tenant’s interest under this Lease without such consent, or Landlord’s claim for any amount of Rent due from Tenant.

 

56


11.5

LANDLORD’S DEFAULT

Landlord shall be in default hereunder if Landlord fails to perform any obligation of Landlord hereunder and such failure continues for a period of thirty (30) days after written notice thereof by Tenant to Landlord; provided, however, that if such failure to perform such obligation cannot reasonably be cured within such thirty (30) day period, it shall not be a default if Landlord has begun such cure within such thirty (30) day period and thereafter diligently pursues the same to completion. In no event shall Tenant have the right to terminate or rescind this Lease as a result of Landlord’s default as to any covenant or agreement contained in this Lease. Tenant hereby waives such remedies of termination and rescission and hereby agrees that Tenant’s remedies for default hereunder shall be limited to a suit for damages and/or injunction. In addition, Tenant hereby covenants that, it will provide the Mortgagee with a copy of any notice of default provided to Landlord.

ARTICLE 12

SURRENDER OF PREMISES

 

12.1

IN GENERAL

Upon the Termination Date, Tenant shall surrender and vacate the Premises immediately and deliver possession thereof to Landlord in good condition and repair, ordinary wear and tear, casualty damage, condemnation, Landlord’s repair obligations and damage caused by Landlord excepted. Tenant shall deliver to Landlord all keys to the Premises. All improvements in and to the Premises, including any Tenant Alterations (collectively, “Leasehold Improvements”) shall remain upon the Premises at the end of the Term without compensation to Tenant Without limitation of the foregoing, Tenant shall have no obligation to remove any Landlord Work (including the Tenant Improvements) or Decoration Work installed by or for Tenant. Landlord, however, may require Tenant, at its expense, (a) by written notice to Tenant at least 30 days prior to the Termination Date, to remove any Cable installed by or for the benefit of Tenant, and (b) pursuant to Section 9.1(a), to remove any Tenant Alterations that, in Landlord’s reasonable judgment, are of a nature that would require removal and repair costs that are materially in excess of the removal and repair costs associated with standard office and lab improvements (collectively referred to as “Required Removables”). Required Removables shall include, without limitation, internal stairways, raised floors, personal baths and showers, vaults, rolling file systems and structural alterations and modifications. Landlord’s failure to designate any Tenant Alteration as a Required Removable at the time of Landlord’s approval pursuant to Section 9.1(a) shall be deemed Landlord’s confirmation that such Tenant Alteration is not a Required Removable. The designated Required Removables shall be removed by Tenant before the Termination Date. Tenant shall repair damage caused by the installation or removal of Required Removables. If Tenant fails to perform its obligations in a timely manner, Landlord may perform such work at Tenant’s expense. If any of the Tenant Alterations which were installed by Tenant involved the lowering of ceilings, raising of floors or the installation of specialized wall or floor coverings or lights, then , unless otherwise approved by Landlord in writing, Tenant shall also be obligated to return such surfaces to their condition prior to the commencement of this Lease. Tenant shall also be required to close any staircases or other openings between floors. In the event possession of the Premises is not delivered to Landlord when required hereunder, or if Tenant shall fail to remove those items described above, Landlord

 

57


may (but shall not be obligated to), at Tenant’s expense, remove any of such property and store, sell or otherwise deal with such property, and undertake, at Tenant’s expense, such restoration work as Landlord deems necessary or advisable.

 

12.2

LANDLORD’S RIGHTS

All property which may be removed from the Premises by Landlord pursuant to Section 12.1 shall be conclusively presumed to have been abandoned by Tenant and Landlord may deal with such property as provided in Section 11.2(b), including the waiver and indemnity obligations provided in that Section. Tenant shall also reimburse Landlord for all costs and expenses incurred by Landlord in removing any of Tenant Alterations and in restoring the Premises to the condition required by this Article 12 Lease at the Termination Date.

ARTICLE 13

HOLDING OVER

In the event that Tenant holds over in possession of the Premises after the Termination Date, Tenant shall pay Landlord 125% of the Monthly Base Rent payable for the month immediately preceding the holding over plus Rent Adjustments for such holdover period, which Landlord may reasonably estimate. Tenant shall also pay all damages sustained by Landlord by reason of claims made by any succeeding tenant (as demonstrated by a signed proposal or letter of intent or lease), as a result of such retention of possession. The provisions of this Article shall not constitute a waiver by Landlord of any re-entry rights of Landlord and Tenant’s continued occupancy of the Premises shall be as a tenancy in sufferance.

ARTICLE 14

DAMAGE BY FIRE OR OTHER CASUALTY

 

14.1

SUBSTANTIAL UNTENANTABILITY

(a)        If any fire or other casualty (whether insured or uninsured) renders all or a substantial portion of the Premises or the Building untenantable, Landlord shall, with reasonable promptness after the occurrence of such damage, estimate the length of time that will be required to substantially complete the repair and restoration and shall by notice advise Tenant of such estimate (“Landlord’s Notice”). If Landlord estimates that the amount of time required to substantially complete such repair and restoration will exceed two hundred seventy (270) days from the date such damage occurred, then Landlord, or Tenant if all or a substantial portion of the Premises is rendered untenantable, shall have the right to terminate this Lease as of the date of such damage upon giving written notice to the other at any time within twenty (20) days after delivery of Landlord’s Notice, provided that if Landlord so chooses, Landlord’s Notice may also constitute such notice of termination.

(b)        Unless this Lease is terminated as provided in the preceding subparagraph, Landlord shall proceed with reasonable promptness to repair and restore the Premises to its condition as existed prior to such casualty (including the Landlord Work, but exclusive of any Tenant Alterations), subject to reasonable delays for insurance adjustments and Force Majeure delays, and also subject to zoning Laws and building codes then in effect. Landlord shall have no liability to Tenant, and Tenant shall not be entitled to terminate this Lease if such repairs and

 

58


restoration are not in fact completed within the time period estimated by Landlord so long as Landlord shall proceed with reasonable diligence to complete such repairs and restoration.

(c)        Tenant acknowledges that Landlord shall be entitled to the full proceeds of any insurance coverage, whether carried by Landlord or Tenant, for damages to the Premises, except for those proceeds of Tenant’s insurance of its own personal property and equipment which would be removable by Tenant at the Termination Date. All such insurance proceeds shall be payable to Landlord whether or not the Premises are to be repaired and restored, provided, however, if this Lease is not terminated and the parties proceed to repair and restore Tenant Alterations at Tenant’s cost, to the extent Landlord received proceeds of Tenant’s insurance covering Tenant Alterations, such proceeds shall be applied to reimburse Tenant for its cost of repairing and restoring Tenant Alterations.

(d)        Notwithstanding anything to the contrary herein set forth: (i) Landlord shall have no duty pursuant to this Section to repair or restore any portion of any Tenant Alterations or to expend for any repair or restoration of the Premises or Building amounts in excess of insurance proceeds paid to Landlord and available for repair or restoration; and (ii) Tenant shall not have the right to terminate this Lease pursuant to this Section if any damage or destruction was caused by the act or neglect of Tenant, its agent or employees. Whether or not the Lease is terminated pursuant to this Article Fourteen, in no event shall Tenant be entitled to any compensation or damages for loss of the use of the whole or any part of the Premises or for any inconvenience or annoyance occasioned by any such damage, destruction, rebuilding or restoration of the Premises or the Building or access thereto.

(e)        Any repair or restoration of the Premises performed by Tenant shall be in accordance with the provisions of Article Nine hereof.

 

14.2

INSUBSTANTIAL UNTENANTABILITY

If the Premises or the Building is damaged by a casualty but neither is rendered substantially untenantable (and Tenant’s access thereto is not materially impaired) and Landlord estimates that the time to substantially complete the repair or restoration will not exceed two hundred seventy (270) days from the date such damage occurred, then Landlord shall proceed to repair and restore the Building or the Premises, other than Tenant Alterations, with reasonable promptness, unless such damage is to the Premises and occurs during the last six (6) months of the Term (and Tenant has not exercised the Renewal Option), in which event either Tenant or Landlord shall have the right to terminate this Lease as of the date of such casualty by giving written notice thereof to the other within twenty (20) days after the date of such casualty. Notwithstanding the aforesaid, Landlord’s obligation to repair shall be limited in accordance with the provisions of Section 14.1 above.

 

14.3

RENT ABATEMENT

If all or any part of the Premises are rendered untenantable by fire or other casualty and this Lease is not terminated, Monthly Base Rent and Rent Adjustments (but not any Deferred Rent Loan Payments and any Additional Tenant Improvement Allowance Monthly Payments, which shall continue to be due and payable regardless of any such Rent abatement) shall abate

 

59


for that part of the Premises which is untenantable on a per diem basis from the date of the casualty until Landlord has Substantially Completed the repair and restoration work in the Premises which it is required to perform, provided, that as a result of such casualty, Tenant does not occupy the portion of the Premises which is untenantable during such period.

 

14.4

WAIVER OF STATUTORY REMEDIES

The provisions of this Lease, including this Article Fourteen, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, the Premises or the Property or any part of either, and any Law, including Sections 1932(2), 1933(4), 1941 and 1942 of the California Civil Code, with respect to any rights or obligations concerning damage or destruction shall have no application to this Lease or to any damage to or destruction of all or any part of the Premises or the Property or any part of either, and are hereby waived.

ARTICLE 15

EMINENT DOMAIN

 

15.1

TAKING OF WHOLE OR SUBSTANTIAL PART

In the event the whole or any substantial part of the Building or of the Premises is taken or condemned by any competent authority for any public use or purpose (including a deed given in lieu of condemnation) and is thereby rendered untenantable, this Lease shall terminate as of the date title vests in such authority, and Monthly Base Rent and Rent Adjustments shall be apportioned as of the Termination Date. In the event of a partial taking of the Premises, Tenant may terminate this Lease if Tenant reasonably determines it cannot conduct its business in the portion of the Premises that was not taken. Notwithstanding anything to the contrary herein set forth, in the event the taking is temporary (for less than the remaining Term of the Lease), Landlord may elect either (i) to terminate this Lease or (ii) permit Tenant to receive the entire award attributable to the Premises in which case Tenant shall continue to pay Rent and this Lease shall not terminate.

 

15.2

TAKING OF PART

In the event a part of the Building or the Premises is taken or condemned by any competent authority (or a deed is delivered in lieu of condemnation) and this Lease is not terminated, the Lease shall be amended to reduce or increase, as the case may be, the Monthly Base Rent and Tenant’s Share to reflect the Rentable Area of the Premises or Building, as the case may be, remaining after any such taking or condemnation. Landlord, upon receipt and to the extent of the award in condemnation (or proceeds of sale) shall make necessary repairs and restorations to the Premises (exclusive of Tenant Alterations) and to the Building to the extent necessary to constitute the portion of the Building not so taken or condemned as a complete architectural and economically efficient unit. Notwithstanding the foregoing, if as a result of any taking, or a governmental order that the grade of any street or alley adjacent to the Building is to be changed and such taking or change of grade makes it necessary or desirable to substantially remodel or restore the Building or prevents the economical operation of the Building, Landlord shall have the right to terminate this Lease upon ninety (90) days prior written notice to Tenant.

 

60


15.3

COMPENSATION

Landlord shall be entitled to receive the entire award (or sale proceeds) from any such taking, condemnation or sale without any payment to Tenant, and Tenant hereby assigns to Landlord Tenant’s interest, if any, in such award; provided, however, Tenant shall have the right separately to pursue against the condemning authority a separate award in respect of the loss, if any, to Tenant Alterations paid for by Tenant without any credit or allowance from Landlord, and Tenant’s furniture, fixtures and equipment, so long as there is no diminution of Landlord’s award as a result.

ARTICLE 16

INSURANCE

 

16.1

TENANT’S INSURANCE

Tenant, at Tenant’s expense, agrees to maintain in force, with a company or companies acceptable to Landlord, during the Term: (a) Commercial General Liability Insurance on a primary basis and without any right of contribution from any insurance carried by Landlord covering the Premises on an occurrence basis against all claims for personal injury, bodily injury, death and property damage, including contractual liability covering the indemnification provisions in this Lease, and such insurance shall be for such limits that are reasonably required by Landlord from time to time but not less than a combined single limit of Five Million and No/100 Dollars ($5,000,000.00) (provided, however, that prior to the earlier of the Commencement Date or Tenant’s entry onto the Premises pursuant to Section 2.4(c), such liability insurance shall be in an amount not less than Three Million Dollars ($3,000,000)); (b) Workers’ Compensation and Employers’ Liability Insurance to the extent required by and in accordance with the Laws of the State of California; (c) “All Risks” property insurance in an amount adequate to cover the full replacement cost of all Tenant Alterations, equipment, installations, fixtures and contents of the Premises in the event of loss; (d) in the event a motor vehicle is to be used by Tenant in connection with its business operation from the Premises, Comprehensive Automobile Liability Insurance coverage with limits of not less than One Million and No/100 Dollars ($1,000,000.00) combined single limit coverage against bodily injury liability and property damage liability arising out of the use by or on behalf of Tenant, its agents and employees in connection with this Lease, of any owned, non-owned or hired motor vehicles; and (e) such other insurance or coverages as Landlord reasonably requires.

 

16.2

FORM OF POLICIES

Each policy referred to in 16.1 shall satisfy the following requirements. Each policy shall (i) name Landlord and the Indemnitees as additional insureds (except Workers’ Compensation and Employers’ Liability Insurance), (ii) be issued by one or more responsible insurance companies licensed to do business in the State of California reasonably satisfactory to Landlord, (iii) where applicable, provide for deductible amounts satisfactory to Landlord and not permit co-insurance, (iv) shall provide that such insurance may not be canceled or amended without thirty (30) days’ prior written notice to the Landlord, and (v) each policy of “All-Risks” property insurance shall provide that the policy shall not be invalidated should the insured waive in writing prior to a loss, any or all rights of recover), against any other party for losses covered by

 

61


such policies. Tenant may satisfy its obligations with respect to liability insurance coverage in excess of Three Million Dollars ($3,000,000) by virtue of an excess or umbrella liability policy so long as the coverage afforded thereby is not reduced or diminished in any way. Tenant shall deliver to Landlord, certificates of insurance and at Landlord’s request, copies of all policies and renewals thereof to be maintained by Tenant hereunder, not less than ten (10) days prior to the Commencement Date and not less than ten (10) days prior to the expiration date of each policy.

 

16.3

LANDLORD’S INSURANCE

Landlord agrees to purchase and keep in full force and effect during the Term hereof, including any extensions or renewals thereof, insurance under policies issued by insurers of recognized responsibility, qualified to do business in the State of California on the Building in amounts not less than the greater of eighty (80%) percent of the then full replacement cost (without depreciation) of the Building (above foundations, and including the Landlord Work) or an amount sufficient to prevent Landlord from becoming a co-insurer under the terms of the applicable policies, against fire and such other risks as may be included in standard forms of all risk coverage insurance reasonably available from time to time. Landlord agrees to maintain in force during the Term, Commercial General Liability Insurance covering the Building on an occurrence basis against all claims for personal injury, bodily injury, death, and property damage. Such insurance shall be for a combined single limit of not less than Five Million and No/100 Dollars ($5,000,000.00). Neither Landlord’s obligation to carry such insurance nor the carrying of such insurance shall be deemed to be an indemnity by Landlord with respect to any claim, liability, loss, cost or expense due, in whole or in part, to Tenant’s negligent acts or omissions or willful misconduct. Without obligation to do so, Landlord may, in its sole discretion from time to time, carry insurance in amounts greater and/or for coverage additional to the coverage and amounts set forth above.

 

16.4

WAIVER OF SUBROGATION

(a)        Landlord agrees that, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, it will include in its “All Risks” policies appropriate clauses pursuant to which the insurance companies (i) waive all right of subrogation against Tenant with respect to losses payable under such policies and/or (ii) agree that such policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policies.

(b)        Tenant agrees to include, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, in its “All Risks” insurance policy or policies on Tenant Alterations, whether or not removable, and on Tenant’s furniture, furnishings, fixtures and other property removable by Tenant under the provisions of this Lease appropriate clauses pursuant to which the insurance company or companies (i) waive the right of subrogation against Landlord and/or any tenant of space in the Building with respect to losses payable under such policy or policies and/or (ii) agree that such policy or policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policy or policies. If Tenant is unable to obtain in such policy or policies either of the clauses described in the preceding sentence, Tenant shall, if legally possible and without necessitating a change in insurance carriers, have Landlord named

 

62


in such policy or policies as an additional insured. If Landlord shall be named as an additional insured in accordance with the foregoing, Landlord agrees to endorse promptly to the order of Tenant, without recourse, any check, draft, or order for the payment of money representing the proceeds of any such policy or representing any other payment growing out of or connected with said policies, and Landlord does hereby irrevocably waive any and all rights in and to such proceeds and payments.

(c)        Landlord hereby waives any and all right of recovery which it might otherwise have against Tenant, its servants, agents and employees, for loss or damage occurring to the Real Property and the fixtures, appurtenances and equipment therein, to the extent the same arises from a risk or peril that is required to be insured against under a property insurance policy or policies that Landlord is required to maintain pursuant to this Lease, notwithstanding that such loss or damage may result from the negligence or fault of Tenant, its servants, agents or employees. Tenant hereby waives any and all right of recovery which it might otherwise have against Landlord, its servants, and employees for loss or damage to Tenant Alterations, whether or not removable, and to Tenant’s furniture, furnishings, fixtures and other property removable by Tenant under the provisions hereof to the extent the same arises from a risk or peril that is required to be insured against under a property insurance policy or policies Tenant is required to maintain pursuant to this Lease, notwithstanding that such loss or damage may result from the negligence or fault of Landlord, its servants, agents or employees.

(d)        Landlord and Tenant hereby agree to advise the other promptly if the clauses to be included in their respective insurance policies pursuant to subparagraphs (a) and (b) above cannot be obtained on the terms hereinbefore provided and thereafter to furnish the other with a certificate of insurance or copy of such policies showing the naming of the other as an additional insured, as aforesaid. Landlord and Tenant hereby also agree to notify the other promptly of any cancellation or change of the terms of any such policy that would affect such clauses or naming. All such policies which name both Landlord and Tenant as additional insureds shall, to the extent obtainable, contain agreements by the insurers to the effect that no act or omission of any additional insured will invalidate the policy as to the other additional insureds.

 

16.5

NOTICE OF CASUALTY

Tenant shall give Landlord notice in case of a fire or other casualty in the Premises promptly after Tenant is aware of such event.

ARTICLE 17

WAIVER OF CLAIMS AND INDEMNITY

 

17.1

WAIVER OF CLAIMS

To the extent permitted by Law, and except as expressly provided in Article Seven pertaining to Hazardous Materials, Tenant releases the Indemnitees from, and waives all claims for, damage to person or property sustained by the Tenant or any occupant of the Premises or the Property to the extent resulting directly or indirectly from any existing or future condition, defect, matter or thing in and about the Premises or the Property or any part of either or any equipment or appurtenance therein, or resulting from any accident in or about the Premises or the

 

63


Property, or resulting directly or indirectly from any act or neglect of any tenant or occupant of the Property or of any other person, including Landlord’s agents and servants, except to the extent caused by the gross negligence or willful and wrongful act of any of the Indemnitees. To the extent permitted by Law, Tenant hereby waives any consequential damages, compensation or claims for inconvenience or loss of business, rents, or profits as a result of such injury or damage, whether or not caused by the gross negligence or willful and wrongful act of any of the Indemnitees. If any such damage, whether to the Premises or the Property or any part of either, or whether to Landlord or to other tenants in the Property, results from any act or neglect of Tenant, its employees, servants, agents, contractors, invitees or customers, Tenant shall be liable therefor and Landlord may, at Landlord’s option, repair such damage and Tenant shall, upon demand by Landlord, as payment of additional Rent hereunder, reimburse Landlord within ten (10) days of demand for the total cost of such repairs, in excess of amounts, if any, paid to Landlord under insurance covering such damages. Tenant shall not be liable for any such damage caused by its acts or neglect if Landlord or a tenant has recovered the full amount of the damage from proceeds of insurance policies and the insurance company has waived its right of subrogation against Tenant.

 

17.2

INDEMNITY BY TENANT

To the extent permitted by Law, Tenant hereby indemnifies, and agrees to protect, defend and hold the Indemnitees harmless, against any and all actions, claims, demands, liability, costs and expenses, including reasonable attorneys’ fees and expenses for the defense thereof, to the extent arising from Tenant’s occupancy of the Premises, from the undertaking by Tenant of any Tenant Alterations or repairs to the Premises, from the conduct of Tenant’s business on the Premises, or from any breach or default on the part of Tenant in the performance of any covenant or agreement on the part of Tenant to be performed pursuant to the terms of this Lease, or from any willful act or negligence of Tenant, its agents, contractors, servants, employees, customers or invitees, in or about the Premises or the Property or any part of either. In case of any action or proceeding brought against the Indemnitees by reason of any such claim, upon notice from Landlord, Tenant covenants to defend such action or proceeding by counsel chosen by Landlord, in Landlord’s reasonable discretion. Landlord reserves the right to settle, compromise or dispose of any and all actions, claims and demands related to the foregoing indemnity. The foregoing indemnity shall not operate to relieve Indemnitees of liability to the extent such liability is caused by the willful and wrongful act of Indemnitees. Further, the foregoing indemnity is subject to and shall not diminish any waivers in effect in accordance with Section 16.4 by Landlord or its insurers to the extent of amounts, if any, paid to Landlord under its “All-Risks” property insurance.

 

17.3

INDEMNITY BY LANDLORD

To the extent permitted by Law, Landlord hereby indemnifies, and agrees to protect, defend and hold Tenant and its directors, officers and employees (the “Tenant Indemnitees”) harmless, against any and all actions, claims, demands, liability, costs and expenses, including reasonable attorneys’ fees and expenses for the defense thereof, to the extent arising from the undertaking by Landlord of the Landlord Work or repairs to the Premises or the Building, or from any breach or default on the part of Landlord in the performance of any covenant or agreement on the part of Landlord to be performed pursuant to the terms of this Lease, or from

 

64


any willful act or the active negligence of Landlord, its agents, contractors and employees, in or about the Premises or the Property or any part of either. In case of any action or proceeding brought against the Tenant Indemnitees by reason of any such claim, upon notice from Tenant, Landlord covenants to defend such action or proceeding by counsel chosen by Landlord. The foregoing indemnity shall not operate to relieve Tenant Indemnitees of liability to the extent such liability is caused by the willful and wrongful act of Tenant Indemnitees. Further, the foregoing indemnity is subject to and shall not diminish any waivers in effect in accordance with Section 16.4 by Tenant or its insurers to the extent of amounts, if any, paid to Tenant under its “All-Risks” property insurance.

ARTICLE 18

RULES AND REGULATIONS

 

18.1

RULES

Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the rules and regulations listed on Exhibit C-2 attached hereto and with all reasonable modifications and additions thereto which Landlord may make from time to time.

 

18.2

ENFORCEMENT

Nothing in this Lease shall be construed to impose upon the Landlord any duty or obligation to enforce the rules and regulations as set forth on Exhibit C or as hereafter adopted, or the terms, covenants or conditions of any other lease as against any other tenant, and the Landlord shall not be liable to the Tenant for violation of the same by any other tenant, its servants, employees, agents, visitors or licensees. Landlord shall use reasonable efforts to enforce the rules and regulations of the Project in a uniform and non-discriminatory manner. In the event of any inconsistency between the rules and regulations and the Lease, the Lease shall control.

ARTICLE 19

LANDLORD’S RESERVED RIGHTS

Landlord shall have the following rights exercisable without notice to Tenant and without liability to Tenant for damage or injury to persons, property or business and without being deemed an eviction or disturbance of Tenant’s use or possession of the Premises or giving rise to any claim for offset or abatement of Rent: (1) to change the Building’s name or street address upon thirty (30) days’ prior written notice to Tenant; (2) to install, affix and maintain all signs on the exterior and/or interior of the Building; (3) to designate and/or approve prior to installation, all types of signs, window shades, blinds, drapes, awnings or other similar items, and all internal lighting that may be visible from the exterior of the Premises; (4) upon reasonable prior written notice to Tenant, to display the Premises to prospective purchasers and lenders at reasonable business hours at any time during the Term and to prospective tenants at reasonable business hours during the last twelve (12) months of the Term; (5) to grant to any party the exclusive right to conduct any business or render any service in or to the Building, provided such exclusive right shall not operate to prohibit Tenant from using the Premises for the purpose permitted hereunder; (6) to change the arrangement and/or location of entrances or passageways, doors and doorways,

 

65


corridors, elevators, stairs, washrooms or public portions of the Building, and to close entrances, doors, corridors, elevators or other facilities, provided that such action shall not materially and adversely interfere with Tenant’s access to or use of the Premises or the Building; (7) to have access for Landlord and other tenants of the Building to any mail chutes and boxes located in or on the Premises as required by any applicable rules of the United States Post Office; and (8) to close the Building after Standard Operating Hours, except that Tenant and its employees and invitees shall be entitled to admission at all times, under such regulations as Landlord prescribes for security purposes.

ARTICLE 20

ESTOPPEL CERTIFICATES AND FINANCIAL STATEMENTS

 

20.1

IN GENERAL

(a)        Within ten (10) days after request therefor by Landlord or Tenant, the other party agrees to execute an Estoppel Certificate, binding upon such party, certifying any factual information pertaining to this Lease reasonably requested by the requesting party or by any existing or prospective lender, mortgagee or purchaser. With respect to an Estoppel Certificate requested by Landlord, the following certifications requested of Tenant shall be deemed reasonable: (i) that this Lease is unmodified and in full force and effect (or if there have been modifications, a description of such modifications and that this Lease as modified is in full force and effect); (ii) the dates to which Rent has been paid; (iii) that Tenant is in the possession of the Premises if that is the case; (iv) that Landlord is not in default under this Lease, or, if Tenant believes Landlord is in default, the nature thereof in detail; (v) that Tenant has no offsets or defenses to the performance of its obligations under this Lease (or if Tenant believes there are any offsets or defenses, a full and complete explanation thereof); (vi) that the Premises have been completed in accordance with the terms and provisions hereof or the Workletter, that Tenant has accepted the Premises and the condition thereof and of all improvements thereto and has no claims against Landlord or any other party with respect thereto; and (vii) any other factual information relating to the Lease reasonably requested.

(b)        Within ten (10) days after written request from Landlord from time to time during the Term, Tenant shall provide Landlord with current financial statements setting forth Tenant’s financial condition and net worth for the most recent quarter, including balance sheets and statements of profits and losses. Such statements shall be prepared by an independent accountant or certified by Tenant’s president, chief executive officer or chief financial officer. Landlord shall keep such financial information confidential and shall only disclose such information to Landlord’s lenders, consultants, purchasers or investors (who shall be subject to the same confidentiality obligations) on a need to know basis in connection with the administration of this Lease.

 

20.2

ENFORCEMENT

In the event that Tenant fails to deliver an Estoppel Certificate, and such default continues for two (2) days after a second notice to Tenant, then such failure shall be a Default for which there shall be no cure or grace period. In addition to any other remedy available to Landlord, Landlord may impose a charge equal to $500.00 for each day that Tenant fails to

 

66


deliver an Estoppel Certificate and Tenant shall be deemed to have irrevocably appointed Landlord as Tenant’s attorney-in-fact to execute and deliver such Estoppel Certificate.

ARTICLE 21

RESERVED

ARTICLE 22

REAL ESTATE BROKERS

Each of Landlord and Tenant represents that, except for the brokers it listed in Section 1.1(15), it has not dealt with any real estate broker, sales person, or finder in connection with this Lease, and no such person initiated or participated in the negotiation of this Lease. Each of Landlord and Tenant hereby agrees to indemnify, protect, defend and hold the other harmless from and against any and all liabilities and claims for commissions and fees arising out of a breach of the foregoing representation. Landlord agrees to pay any commission to which the brokers listed in Section 1.1(15) are entitled in connection with this Lease pursuant to Landlord’s written agreement with such brokers.

ARTICLE 23

MORTGAGEE PROTECTION

 

23.1

SUBORDINATION AND ATTORNMENT

(a)        Subject to Section 23.1(b), this Lease is and shall be expressly subject and subordinate at all times to (i) any ground or underlying lease of the Real Property, now or hereafter existing, and all amendments, extensions, renewals and modifications to any such lease, and (ii) the lien of any mortgage or trust deed now or hereafter encumbering fee title to the Real Property and/or the leasehold estate under any such lease, and all amendments, extensions, renewals, replacements and modifications of such mortgage or trust deed and/or the obligation secured thereby, unless such ground lease or ground lessor, or mortgage, trust deed or Mortgagee, expressly provides or elects that the Lease shall be superior to such lease or mortgage or trust deed. If any such mortgage or trust deed is foreclosed (including any sale of the Real Property pursuant to a power of sale), or if any such lease is terminated, upon request of the Mortgagee or ground lessor, as the case may be, Tenant shall attorn to the purchaser at the foreclosure sale or to the ground lessor under such lease, as the case may be, provided, however, that such purchaser or ground lessor shall not be (i) bound by any payment of Rent for more than one month in advance except payments in the nature of security for the performance by Tenant of its obligations under this Lease; (ii) subject to any offset, defense or damages arising out of a default of any obligations of any preceding Landlord; or (iii) bound by any amendment or modification of this Lease made without the written consent of the Mortgagee or ground lessor; which consent shall not be unreasonably withheld; provided, however, that such consent shall not be required in the case of any amendment or modification made or entered into to evidence the exercise by Tenant of any specific right or option provided for herein in favor of Tenant (such as the exercise of the Renewal Option, the Expansion Right, the Right of First Refusal, the Right of First Offer or the Termination Option) or (iv) liable for any security deposits not

 

67


actually received in cash by such purchaser or ground lessor. This subordination shall be self-operative and no further certificate or instrument of subordination need be required by any such Mortgagee or ground lessor. In confirmation of such subordination, however, Tenant shall execute promptly any reasonable certificate or instrument consistent with this Article 23 that Landlord, Mortgagee or ground lessor may request. Upon request by such successor in interest, Tenant shall execute and deliver reasonable instruments confirming the attornment and non-disturbance provided for herein.

(b)        Notwithstanding the foregoing, (i) as a condition precedent to Tenant’s obligations under this Lease, Tenant and Landlord’s current Mortgagee shall have entered into a mutually acceptable subordination, non-disturbance and attornment agreement within thirty (30) days following mutual execution of this Lease, and (ii) as a condition to the subordination of this Lease to any future ground lease or mortgage, Tenant and such future ground lessor or mortgagee shall have entered into a mutually acceptable subordination, non-disturbance and attornment agreement which recognizes Tenant’s rights under this Lease. Landlord hereby represents and warrants to Tenant that there is currently no ground or underlying lease of the Real Property.

 

23.2

MORTGAGEE PROTECTION

Tenant agrees to give any Mortgagee or ground lessor, by registered or certified mail, a copy of any notice of default served upon the Landlord by Tenant, provided that prior to such notice Tenant has received notice (by way of service on Tenant of a copy of an assignment of rents and leases, or otherwise) of the address of such Mortgagee or ground lessor. Tenant further agrees that any such Mortgagee or ground lessor shall have the same cure period as Landlord under this Lease with respect to such default (provided that such cure period shall not commence until thirty (30) days after receipt of such notice from Tenant) and in addition shall include, if necessary to effect such cure, the period to commence and consummate foreclosure proceedings or other proceedings to acquire possession of the Real Property, so long as such proceedings are promptly commenced and diligently pursued to completion. Such period of time shall be extended by any period within which such Mortgagee or ground lessor is prevented from commencing or pursuing such foreclosure proceedings or other proceedings to acquire possession of the Real Property by reason of Landlord’s bankruptcy.

ARTICLE 24

NOTICES

(a)        All notices, demands or requests provided for or permitted to be given pursuant to this Lease must be in writing and shall be personally delivered, sent by Federal Express or other reputable overnight courier service, or mailed by first class, registered or certified United States mail, return receipt requested, postage prepaid.

(b)        All notices, demands or requests to be sent pursuant to this Lease shall be deemed to have been properly given or served by delivering or sending the same in accordance with this Section, addressed to the parties hereto at their respective addresses listed in Section 1.1.

 

68


(c)        Notices, demands or requests sent by mail or overnight courier service as described above shall be effective upon deposit in the mail or with such courier service. However, the time period in which a response to any such notice, demand or request must be given shall commence to run from (i) in the case of delivery by mail, the date of receipt on the return receipt of the notice, demand or request by the addressee thereof, or (ii) in the case of delivery by Federal Express or other overnight courier service, the date of acceptance of delivery by an employee, officer, director or partner of Landlord or Tenant. Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given, as indicated by advice from Federal Express or other overnight courier service or by mail return receipt, shall be deemed to be receipt of notice, demand or request sent. Notices may also be served by personal service upon any officer, director or partner of Landlord or Tenant, and shall be effective upon such service.

(d)        By giving to the other party at least thirty (30) days written notice thereof, either party shall have the right from time to time during the term of this Lease to change their respective addresses for notices, statements, demands and requests, provided such new address shall be within the United States of America.

ARTICLE 25

MISCELLANEOUS

 

25.1

LATE CHARGES

(a)        All payments required hereunder (other than the Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits, which shall be due as hereinbefore provided) to Landlord shall be paid within thirty (30) days after Landlord’s written demand therefor. All such amounts (including Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits) not paid when due shall bear interest from the date due until the date paid at the Default Rate in effect on the date such payment was due.

(b)        In the event Tenant is more than five (5) days late in paying any installment of Rent due under this Lease, Tenant shall pay Landlord a late charge equal to five percent (5%) of the delinquent installment of Rent. The parties agree that (i) such delinquency will cause Landlord to incur costs and expenses not contemplated herein, the exact amount of which will be difficult to calculate, including the cost and expense that will be incurred by Landlord in processing each delinquent payment of rent by Tenant, (b) the amount of such late charge represents a reasonable estimate of such costs and expenses and that such late charge shall be paid to Landlord for each delinquent payment in addition to all Rent otherwise due hereunder. The parties further agree that the payment of late charges and the payment of interest provided for in subparagraph (a) above are distinct and separate from one another in that the payment of interest is to compensate Landlord for its inability to use the money improperly withheld by Tenant, while the payment of late charges is to compensate Landlord for its additional administrative expenses in handling and processing delinquent payments.

(c)        Payment of interest at the Default Rate and/or of late charges shall not excuse or cure any Default by Tenant under this Lease, nor shall the foregoing provisions of this Article or any such payments prevent Landlord from exercising any right or remedy available to Landlord

 

69


under this Lease upon a Default due to Tenant’s failure to pay Rent when due, including the right to terminate this Lease.

 

25.2

NO JURY TRIAL; VENUE: JURISDICTION

To the fullest extent permitted by law, including laws enacted after the Commencement Date, each party hereto (which includes any assignee, successor, heir or personal representative of a party) shall not seek a jury trial, hereby waives trial by jury, and hereby further waives any objection to venue in the County in which the Project is located, and agrees and consents to personal jurisdiction of the courts of the State of California, in any action or proceeding or counterclaim brought by any party hereto against the other on any matter whatsoever arising out of or in any way connected with this Lease, the relationship of Landlord and Tenant, Tenant’s use or occupancy of the Premises, or any claim of injury or damage, or the enforcement of any remedy under any statute, emergency or otherwise, whether any of the foregoing is based on this Lease or on tort law. No party will seek to consolidate any such action in which a jury has been waived with any other action in which a jury trial cannot or has not been waived. It is the intention of the parties that these provisions shall be subject to no exceptions. The provisions of this Section shall survive the expiration or earlier termination of this Lease.

 

25.3

DISCRIMINATION

Tenant agrees for Tenant and Tenant’s heirs, executors, administrators, successors and assigns and all persons claiming under or through Tenant, and this Lease is made and accepted upon and subject to the following conditions: that there shall be no discrimination against or segregation of any person or group of persons on account of race, color, creed, religion, sex, marital status, national origin or ancestry (whether in the leasing, subleasing, transferring, use, occupancy, tenure or enjoyment of the Premises or otherwise) nor shall Tenant or any person claiming under or through Tenant establish or permit any such practice or practices of discrimination or segregation with reference to the use or occupancy of the Premises by Tenant or any person claiming through or under Tenant.

 

25.4

OPTION

This Lease shall not become effective as a lease or otherwise until executed and delivered by both Landlord and Tenant, and the submission of the Lease to Tenant does not constitute a reservation of or option for the Premises.

 

25.5

AUTHORITY

Each of Landlord and Tenant represents and warrants to the other that it has full authority and power to enter into and perform its obligations under this Lease, that the person executing this Lease is fully empowered to do so, and that no consent or authorization is necessary from any third party. Landlord may request that Tenant provide Landlord evidence of Tenant’s authority.

 

70


25.6

ENTIRE AGREEMENT

This Lease, the Exhibits attached hereto (including the Workletter) contain the entire agreement between Landlord and Tenant concerning the Premises and there are no other agreements, either oral or written, and no other representations or statements, either oral or written, on which either Landlord or Tenant has relied. This Lease shall not be modified except by a writing executed by Landlord and Tenant.

 

25.7

MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE

If Mortgagee of Landlord requires a modification of this Lease which shall not result in any increased cost or expense to Tenant or in any adverse change in the rights and obligations of Tenant hereunder, then Tenant agrees that the Lease may be so modified.

 

25.8

EXCULPATION

Tenant agrees, on its behalf and on behalf of its successors and assigns, that any liability or obligation of Landlord under this Lease shall only be enforced against Landlord’s equity interest in the Property up to a maximum of Five Million Dollars ($5,000,000.00) and in no event against any other assets of the Landlord, or Landlord’s officers or directors or partners, and that any liability of Landlord with respect to this Lease shall be so limited and Tenant shall not be entitled to any judgment in excess of such amount; provided, however, that the foregoing dollar amount limitation (i) shall not limit the amounts payable under any insurance policies maintained by Landlord, and (ii) shall not be applicable with respect to Landlord’s obligation (a) to perform the Landlord Work and provide the Basic Tenant Improvement Allowance and Additional Tenant Improvement Allowance specified in Sections 1.1(16) and 1.1(17) above, or (b) with respect to Environmental Damages for which Landlord is responsible under Section 7.1(d)(5).

 

25.9

ACCORD AND SATISFACTION

No payment by Tenant or receipt by Landlord of a lesser amount than any installment or payment of Rent due shall be deemed to be other than on account of the amount due, and no endorsement or statement on any check or any letter accompanying any check or payment of Rent shall be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord’s right to recover the balance of such installment or payment of Rent or pursue any other remedies available to Landlord. No receipt of money by Landlord from Tenant after the termination of this Lease or Tenant’s right of possession of the Premises shall reinstate, continue or extend the Term. Receipt or acceptance of payment from anyone other than Tenant, including an assignee of Tenant, is not a waiver of any breach of Article Ten, and Landlord may accept such payment on account of the amount due without prejudice to Landlord’s right to pursue any remedies available to Landlord.

 

25.10

LANDLORD’S OBLIGATIONS ON SALE OF BUILDING

In the event of any sale or other transfer of the Building, and upon the transferee’s assumption in writing of Landlord’s obligations under this Lease arising from and after the date of such sale or transfer, Landlord shall be entirely freed and relieved of all agreements and

 

71


obligations of Landlord hereunder accruing or to be performed after the date of such sale or transfer, and any remaining liability of Landlord with respect to this Lease shall be limited to the dollar amount specified in Section 25.8 (except as otherwise provided in Section 25.8) and Tenant shall not be entitled to any judgment in excess of such amount. Landlord shall have the right to assign this Lease to an entity comprised of the principals of Landlord or affiliates of such entities. Upon such assignment and assumption of the obligations of Landlord hereunder, Landlord shall be entirely freed and relieved of all obligations hereunder.

 

25.11

BINDING EFFECT

Subject to the provisions of Article Ten, this Lease shall be binding upon and inure to the benefit of Landlord and Tenant and their respective heirs, legal representatives, successors and permitted assigns.

 

25.12

CAPTIONS

The Article and Section captions in this Lease are inserted only as a matter of convenience and in no way define, limit, construe, or describe the scope or intent of such Articles and Sections.

 

25.13

TIME; APPLICABLE LAW; CONSTRUCTION

Time is of the essence of this Lease and each and all of its provisions. This Lease shall be construed in accordance with the Laws of the State of California. If more than one person signs this Lease as Tenant, the obligations hereunder imposed shall be joint and several. If any term, covenant or condition of this Lease or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, covenant or condition to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each item, covenant or condition of this Lease shall be valid and be enforced to the fullest extent permitted by Law. Wherever the term “including” or “includes” is used in this Lease, it shall have the same meaning as if followed by the phrase “but not limited to”. The language in all parts of this Lease shall be construed according to its normal and usual meaning and not strictly for or against either Landlord or Tenant.

 

25.14

ABANDONMENT

In the event Tenant abandons the Premises but is otherwise in compliance with all the terms, covenants and conditions of this Lease, Landlord shall (i) have the right to enter into the Premises in order to show the space to prospective tenants, (ii) have the right to reduce the services provided to Tenant pursuant to the terms of this Lease to such levels as Landlord reasonably determines to be adequate services for an unoccupied premises, and (iii) during the last six (6) months of the Term, have the right to prepare the Premises for occupancy by another tenant upon the end of the Term. Tenant expressly acknowledges that in the absence of written notice pursuant to Section 11.2(b) or pursuant to California Civil Code Section 1951.3 terminating Tenant’s right to possession, none of the foregoing acts of Landlord or any other act of Landlord shall constitute a termination of Tenant’s right to possession or an acceptance of Tenant’s surrender of the Premises, and the Lease shall continue in effect.

 

72


25.15

LANDLORD’S RIGHT TO PERFORM TENANT’S DUTIES

If Tenant fails timely to perform any of its duties under this Lease or the Workletter, Landlord shall have the right (but not the obligation), to perform such duty on behalf and at the expense of Tenant without prior notice to Tenant, and all sums expended or expenses incurred by Landlord in performing such duty shall be deemed to be additional Rent under this Lease and shall be due and payable upon demand by Landlord. Except where a Tenant Default has occurred and is continuing, or an emergency affecting the security or safety of the Building or persons, Landlord shall provide Tenant with fifteen (15) days written notice prior to exercising the rights in this Section 25.15.

 

25.16

SECURITY SYSTEM

Landlord shall not be obligated to provide or maintain any security patrol or security system. Landlord shall not be responsible for the quality of any such patrol or system which may be provided hereunder or for damage or injury to Tenant, its employees, invitees or others due to the failure, action or inaction of such patrol or system.

 

25.17

NO LIGHT, AIR OR VIEW EASEMENTS

Any diminution or shutting off of light, air or view by any structure which may be erected on lands of or adjacent to the Project shall in no way affect this Lease or impose any liability on Landlord.

 

25.18

RECORDATION

Neither this Lease, nor any notice nor memorandum regarding the terms hereof, shall be recorded by Tenant. Any such unauthorized recording shall be a Default for which there shall be no cure or grace period. Tenant agrees to execute and acknowledge, at the request of Landlord, a memorandum of this Lease, in recordable form.

 

25.19

SURVIVAL

The waivers of the right of jury trial, the other waivers of claims or rights, the releases, and the obligations of Landlord and Tenant under this Lease to indemnify, protect, defend and hold harmless the other (and/or any other indemnitee) shall survive the expiration or termination of this Lease, and so shall all other obligations or agreements which by their terms survive expiration or termination of the Lease.

 

25.20

RIDERS

All Riders attached hereto and executed both by Landlord and Tenant shall be deemed to be a part hereof and hereby incorporated herein.

[Signatures on Following Page]

 

73


IN WITNESS WHEREOF, this Lease has been executed as of the date set forth in Section 1.1(4) hereof.

 

TENANT:

   

LANDLORD:

AMYRIS BIOTECHNOLOGIES, INC.,
a California corporation

   

ES EAST ASSOCIATES, LLC,
a California limited liability company

By:

 

/s/ John G. Melo

   

By:    

 

/s/ Richard Robbins

Print Name:

 

John G. Melo

   

Richard K. Robbins

Its:  

 

CEO

     

    Managing Member

By:

 

/s/ Tamara L. Tompkins

     

Print Name:

 

Tamara L. Tompkins

     

Its:  

 

General Counsel and Secretary

     

 

74


LOGO


LOGO


Exhibit A-1

GARAGE STORAGE AREA


LOGO


EXHIBIT B

WORK LETTER AGREEMENT

(Allowance)

1.         Defined Terms . Capitalized Terms used in this Workletter shall have the same meanings set forth in the Lease except as otherwise specified herein and except for Terms capitalized in the ordinary course of punctuation. For purposes of this Workletter, the following capitalized terms have the following meanings:

1.1        “Landlord Work” means the construction and installation of the Tenant Improvements. In addition to such Landlord Work, Landlord has constructed, and will complete the construction of, the Building as described in the Base Building Description attached as Exhibit D to the Lease, at Landlord’s sole cost and expense.

1.2        “Design Documents” means the layout plans and specifications for the real property improvements to be constructed by Landlord in the Premises which are the final product of the preliminary space planning and which (i) will be based upon, among other things, the preliminary space plan, attached to this Workletter as Schedule 1 (the “Space Plan”); and (ii) comply with all Law as applicable and as interpreted at the time of construction of the Tenant Improvements, including, all building codes and the ADA.

1.3        “Construction Drawings” means the final architectural plans and specifications, and engineering plans and specifications, for the real property improvements to be constructed by Landlord in the Premises in sufficient detail to be submitted for governmental approvals and building permits and to serve as the detailed construction drawings and specifications for the contractor, and shall be based upon and consistent with the Design Documents.

1.4        “Tenant Improvements” means all real property improvements to be constructed by Landlord as shown on the Construction Drawings, as they may be modified as provided herein.

1.5        “Tenant Improvement Allowance” means the Basic Tenant Improvement Allowance specified in Section 1.1(16) of the Lease.

2.         Design Matters .

2.1        Landlord and Tenant have approved Dowler Grumman Architects, as architect (“Architect”). Within three (3) weeks after the Date of Lease, Landlord and Tenant shall approve a mechanical, electrical and plumbing engineer (“Engineer”), based on proposals prepared by Tenant, approved by Landlord, and submitted to (i) Flack & Kurtz, and (ii) Randall Lamb Associates no later than two (2) weeks after the Date of Lease. The Architect and Engineer shall be referred to collectively herein as the “Design Group”.

2.2        Tenant shall work with the Design Group to complete Design Documents and Construction Drawings in accordance with the schedule set forth in the Project Schedule attached to this Workletter as Schedule 2 (the “Project Schedule”), but in no event later than

 

1


thirteen (13) weeks after the Date of Lease. Any failure by Tenant to supply information and/or to provide authorizations or to otherwise comply with the time periods for Tenant’s performance set forth in the Project Schedule which causes the Design Group to fail to complete and deliver to Landlord the Design Documents and Construction Drawings by such date shall constitute a Tenant Delay. Also, Tenant shall attempt to avoid inclusion (but shall not be prohibited from including) in the Construction Drawings of materials or equipment that require unusually long fabrication or delivery times (“Long Lead Time Items”) and Landlord shall attempt to identify to Tenant any such Long Lead Time Items that may be included in the Construction Drawings that Tenant might otherwise not be aware of but in any event, to the extent that any such Long Lead Time Items are included in the Construction Drawings and cause a delay in Substantial Completion of the Landlord Work, such delay shall constitute a Tenant Delay. Landlord shall undertake its review of the Design Documents and Construction Drawings in accordance with the schedule set forth in the Project Schedule, and any delay in such review by Landlord shall not constitute a Tenant Delay and shall not otherwise affect the Projected Commencement Date, The Construction Drawings submitted by the Design Group to Landlord and approved by Tenant shall be referred to herein as the “Approved Construction Drawings.”

2.3        Tenant shall be responsible for the suitability for the Tenant’s needs and business of the design and function of all Tenant Improvements.

3.         Construction; Landlord’s Contribution; Tenant Improvement Costs .

3.1         Construction; Landlord’s Contribution . Promptly following delivery of the Approved Construction Drawings to Landlord pursuant to Section 2.2, Landlord will obtain bids from (i) DPR, (ii) BCCI, and (iii) two (2) other reputable general contractors mutually agreed to by Landlord and Tenant within two (2) weeks after the Date of Lease, as general contractors for construction of the Tenant Improvements in accordance with the Approved Construction Drawings. Promptly following receipt of such bids, Landlord and Tenant will review the bids and agree upon the contractor for the Tenant Improvements (“Contractor”). Promptly following selection of the Contractor, Landlord will also prepare and deliver to Tenant a nonbinding preliminary estimate (“Landlord’s Estimate”) of the Tenant Improvement Costs based upon the Contractor’s bid and including the cost elements described in Section 3.2 below. Tenant shall review and provide written approval of Landlord’s Estimate within five (5) business days after receipt thereof. Landlord shall use commercially reasonable efforts to cause Contractor to complete the construction of the Tenant Improvements in a good and workmanlike manner and in accordance with the Approved Construction Drawings, up to a maximum cost to Landlord of the Tenant Improvement Allowance (subject to Sections 4(a) and 4(c) below).

3.2         Tenant Improvement Costs . The cost of the Tenant Improvements (“Tenant Improvement Costs”) to be paid by Landlord from, but not in excess of, the Tenant Improvement Allowance shall include:

(a)        The costs of the Design Group and any other consultants retained by Landlord and approved in writing by Tenant in connection with the preparation of Design Documents and Constructions Drawings, and engineering costs associated with completion of the State of California energy utilization calculations under Title 24 legislation;

 

2


(b)        All costs of obtaining from the City of Emeryville and any other governmental authority, approvals, building permits and occupancy permits with respect to the Tenant Improvements;

(c)        All costs of interior design and finish schedule plans and specifications including as-built drawings with respect to the Tenant Improvements;

(d)        All costs of procuring, installing and constructing the Tenant Improvements, including: (i) the cost of all on-site supervisory and administrative staff, office, equipment and temporary services rendered or provided by Contractor in connection with construction of the Tenant Improvements; and (ii) the cost of any services or utilities made available by Landlord;

(e)        Without limiting the generality of the foregoing, the Tenant Improvement Costs include all costs of designing, procuring, constructing and installing Tenant Improvements in compliance with Law as applicable and as interpreted at the time of construction of the Tenant Improvements, including with all building codes and the ADA;

(f)        All fees payable to the Design Group if it is required by Tenant to redesign any portion of the Tenant Improvements following Tenant’s delivery to Landlord of the Approved Construction Drawings, and all costs in connection with any approved Change Order in accordance with the provisions of this Workletter;

(g)        The costs and expenses of the construction manager retained by Tenant;

(h)        The cost of any supplementary air cooling systems or units installed in or to serve the Premises; and

(i)        The cost of any solar panels installed in connection with the Tenant Improvements.

In no event shall the Tenant Improvement Costs include, (i), except as set forth in Sections 3.2(h) and 3.2(i) above, any costs of procuring or installing in the Premises any trade fixtures, equipment, furniture, furnishings, telephone equipment, cabling for any of the foregoing, or other personal property (“Personal Property”) to be used in the Premises by Tenant, and the cost of such Personal Property shall be paid by Tenant, (ii) any costs or expenses of any consultants retained by Tenant with respect to design, procurement, installation or construction of improvements or installations, whether real or personal property, for the Premises, other than those of Tenant’s construction manager, or (iii) any construction management, administration or supervision fee to Landlord, with Landlord hereby acknowledging that it shall not be entitled to any such fee in connection with the Landlord Work.

3.3         Limitations of Landlord’s Obligations . Upon Substantial Completion of the Tenant Improvements, Landlord shall have no further obligation to construct improvements or construct modifications to or changes in the Tenant Improvements, except to complete the punchlist of Landlord Work remaining to be completed or correct any part thereof not in compliance with the Approved Construction Drawings and any approved modifications thereof,

 

3


as provided in Section 2.6 of the Lease. Except as otherwise provided in Section 2.10 of the Lease with respect to the Expansion Premises, if applicable, if the Tenant Improvement Allowance exceeds the Tenant Improvement Costs, then Landlord shall retain such excess and shall have no obligation or liability to Tenant with respect to such excess.

4.         Costs of Tenant Improvements in Excess of Tenant Improvement Allowance .

(a)        The positive difference, if any, between (i) the Landlord’s Estimate approved by Tenant, and (ii) the Tenant Improvement Allowance (the “Tenant TI Contribution”) shall be paid in accordance with this Section 4. With respect to the amount of the Tenant TI Contribution up to a maximum of $3,534,550 (the “Additional Tenant Improvement Allowance Applicable Portion”), Tenant hereby elects to have Landlord fund 50% of the Additional Tenant Improvement Allowance Applicable Portion as the Additional Tenant Improvement Allowance pursuant to Section 1.1(17) of the Lease, and as a result the amount of the Tenant TI Contribution shall be reduced by the amount of the Additional Tenant Improvement Allowance to be so funded by Landlord (the Tenant TI Contribution as so reduced by the amount of Landlord’s Additional Tenant Improvement Allowance shall be referred to as the “Remaining Balance of the Tenant TI Contribution”). Further, Tenant may defer payment of the Remaining Balance of the Tenant TI Contribution pursuant to Section 4(c) below. In the event the Tenant TI Contribution exceeds the Additional Tenant Improvement Allowance Applicable Portion, Tenant shall accompany its approval of the Landlord’s Estimate with a good check made payable to the order of Landlord in the amount of the positive difference between (i) the Tenant TI Contribution, and (ii) the Additional Tenant Improvement Allowance Applicable Portion, and such funds shall be applied to the Tenant Improvements Costs before Landlord’s Tenant Improvement Allowance or Landlord’s Additional Tenant Improvement Allowance.

(b)        Tenant may, pursuant to the provisions of this Workletter, request a Change Order (defined below) to the Approved Construction Drawings to reduce or delete all or part of the anticipated Tenant TI Contribution.

(c)        Commencing upon Tenant’s approval of the Landlord’s Estimate, Tenant shall pay, on a monthly basis, the Remaining Balance of the Tenant TI Contribution pro-rata as the Tenant Improvement Costs are incurred in connection with construction of the Tenant Improvements ( i.e. , payments of the Remaining Balance of the Tenant TI Contribution shall be made in proportion to the Remaining Balance of the Tenant TI Contribution divided by the overall Tenant improvement Costs). By way of illustration of the foregoing, if (A) the Landlord’s Estimate approved by Tenant for the Tenant Improvements is $175.00 per rentable square foot of the Premises, the Remaining Balance of the Tenant TI Contribution will be $25.00 per rentable square foot of the Premises (assuming that Landlord funds the maximum amount of the Additional Tenant Improvement Allowance specified in Section 1.1(17) of the Lease; i.e. , $25.00 per rentable square foot); then (B) Tenant shall pay 14.29% ( i.e. , 25/175) of the Tenant Improvement Costs incurred on a monthly basis, beginning upon Tenant’s approval of the Landlord’s Estimate.

(d)        Upon Substantial Completion of the Tenant Improvements and completion of the items, if any, described in Section 2.6 of the Lease, Landlord will determine the actual costs of the Tenant Improvements (excluding any costs covered under contractor

 

4


warranty to correct defects in materials or workmanship in the Tenant Improvements) and shall reconcile the actual costs of the Tenant Improvements with the Landlord’s Estimate. If the Tenant TI Contribution (or, if applicable, the Remaining Balance of the Tenant TI Contribution) is less than the amount owed by Tenant pursuant to such reconciliation, Tenant shall promptly pay the difference to Landlord. If the Tenant TI Contribution (or, if applicable, the Remaining Balance of the Tenant TI Contribution) is more than the amount owed by Tenant pursuant to such reconciliation, Landlord shall immediately remit 50% of the difference to Tenant and shall apply the other 50% in reduction of the Landlord’s Additional Tenant Improvement Allowance.

5.         Changes . If Tenant shall request any change, addition or alteration in the Approved Construction Drawings, Landlord shall promptly give Tenant a written estimate of (a) the cost of engineering and design services and the construction contractor services to prepare a change order (the “Change Order”) in accordance with such request, (b) the cost of work to be performed pursuant to such Change Order, and (c) the time delay expected because of such requested Change Order. Within three (3) business days following Tenant’s receipt of the foregoing written estimate, Tenant shall notify Landlord in writing whether it approves such written estimate. If Tenant approves such written estimate and if such cost would cause the Tenant Improvement Costs to exceed the Tenant Improvement Allowance, then the amount of the estimated cost so approved by Tenant shall be paid in accordance with Sections 4(a) and 4(c) above. If such written authorization, and check if required pursuant to Section 4(a), are not received by Landlord within such three (3) business day period, Landlord shall not be obligated to prepare the Change Order or perform any work in connection therewith. Upon completion of the work of the Change Order and submission of the final cost thereof by Landlord to Tenant, any such additional amounts in excess of Tenant Improvement Allowance shall be paid in accordance with Sections 4(a) and 4(c) above. Any delay in Substantial Completion of the Tenant Improvements resulting from such request for a Change Order or from the changes so made or necessitated shall be chargeable as Tenant Delay.

6.         Tenant Delay . If the Substantial Completion of the Tenant Improvements in the Premises is delayed beyond the Projected Commencement Date due to Tenant Delay (defined in the Lease or otherwise expressly identified as such herein), the provisions of Section 2.4(b) of the Lease shall apply.

In the event of any dispute between Landlord and Tenant regarding (i) the occurrence or alleged occurrence, or the duration, of any Tenant Delay or Force Majeure, (ii) the determination of the Projected Commencement Date pursuant to Section 1.1(6), or (iii) Substantial Completion of the Tenant Improvements, the parties agree to attempt to resolve such dispute promptly and in good faith; provided, however, that if the parties are unable to resolve such dispute within ten (10) days after such dispute arises, the parties shall retain an independent third party architect familiar with construction in the vicinity of the Project of tenant improvements similar in nature to the Tenant Improvements to arbitrate such dispute, which third party arbitrator shall have the authority to make a final and binding resolution of such dispute, and the parties shall share equally the fees and charges of such arbitrator.

7.         Entry by Tenant . Tenant may enter the Premises during construction of the Tenant Improvements and prior to the Commencement Date in accordance with Section 2.4(e) of the Lease.

 

5


8.         Force and Effect . The terms and conditions of this Workletter supplement the Lease and shall be construed to be a part of the Lease and are incorporated in the Lease. Without limiting the generality of the foregoing, any default by any party hereunder shall have the same force and effect as a default under the Lease. Should any inconsistency arise between this Workletter and the Lease as to the specific matters that are the subject of this Workletter, the terms and conditions of this Workletter shall control.

9.         Representatives of Parties .

(a)        Landlord has designated Geoffrey Sears as its sole representative with respect to the matters set forth in this Workletter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of Landlord as required in this Workletter.

(b)        Tenant has designated Rob Middleton as its sole representative with respect to the matters set forth in this Workletter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of Tenant as required in this Workletter.

 

6


SCHEDULE 1 to Exhibit B

SPACE PLAN


LOGO


LOGO


SCHEDULE 2 to Exhibit B

PROJECT SCHEDULE

 

Wk

  

MILESTONE

  

DESCRIPTION

  

ATTENDEES

  

ANTICIPATED

OUTCOME

Wk

  

VISIONING

              
    

 

Visioning Session

  

 

Establish Goals, Objectives
and Imaging for the project

  

Wareham
Amyris
Cole Project Mgmt
DGA

  

 

•  Establish Amyris goals

•  Set Priorities for project

 

Wk 1-2

08-20-07

through

08-31-07

  

DETAILED

PROGRAMMIG

              
    

Project

Start/Lease

Signing

  

Written authorization to proceed

  

Wareham/Amyris/Arch

  

Assumed will be received authorization to proceed once floor plan is approved

    

Program

Validation

  

Meeting with science team Representatives to:

 

•  Validated floor plan

•  Layout equipment

•  Layout Utilities

•  Discuss Preliminary
Casework requirements

 

Assume 1.5 hours per meeting per group

  

Amyris

Cole Project Mgmt

DGA

  

Receive the data to
complete the detailed design

    

Program

Validation

  

Meeting with administration
team Representatives to:

 

•  Validated floor plan

•  Layout equipment

•  Discuss conference room requirements

•  Discuss copy and break
room requirements

 

Assume 1.5 hours meeting

  

Amyris

Cole Project Mgmt

DGA

  

Receive the data to
complete the detailed design

    

Select Engineer

       

Wareham

Cole Project Mgmt

DGA

    

Wk 3-4

09-03-07

through

09-14-07

  

DETAILED

PROGRAMMIG

              
    

Layout Review

  

Meeting with science team Representatives to:

 

•  Review and finalize
equipment/utility plans

•  Tour labs to look at any unique existing equipment

 

Assume 1.5 hours per meeting per group

  

Amyris

Cole Project Mgmt

DGA

MEP Engineers (if selected)

  

Finalize equipment layouts and give the Engineers a chance to
ask questions about
utility requirements

    

Layout Review

  

Meeting with other project
team stakeholders including EH&S, Safety, FM&E an IT to review their detailed program needs

 

Assume 1 hour per meeting

  

Amyris

Cole Project Mgmt

DGA

MEP Engineers (if selected)

  

Finalize detailed program
needs for project stakeholders

 

1


Wk

  

MILESTONE

  

DESCRIPTION

  

ATTENDEES

  

ANTICIPATED

OUTCOME

    

Reflecting Ceiling

Plan

  

DGA will prepare a preliminary RCP for the team

  

DGA

  

For distribution to the MEP Engineers

    

Code Review

  

Preliminary meeting with
the City of Emeryville

  

DGA

  

Review exiting and get
preliminary feedback of
permit timelines

    

Complete Detailed

Programming

  

Provide Detailed Program packages for final sign-off

  

Wareham

Amyris

Cole Project Mgmt

DGA

  

Participants will have one week to review the design and provide any comments

Wk 5

09-17-07

through

09-21-07

  

 

DESIGN

DEVELOPMENT

              
    

Layout Review

  

Present preliminary casework layouts with science team Representatives

  

Amyris

Cole Project Mgmt

DGA

  

Get feedback on layouts t finalize the casework design

    

Complete Detailed

Programming

  

Participants to provide comment
for final sign-off on the detailed design

  

Wareham

Amyris

Cole Project Mgmt

DGA

  

Sign-off for detailed design

Wk 6

09-24-07

through

09-28-07

  

DESIGN

DEVELOPMENT

              
    

Look and Feel

  

 

Present preliminary look and
feel for the project

  

Wareham

Amyris

Cole Project Mgmt

DGA

  

Get preliminary feedback on the look an feel for the project

    

Layout Review

  

Present final casework layouts with science team Representatives

 

Assume 1 hour per group

  

Amyris

Cole Project Mgmt

DGA

  

Finalize casework design

    

Design Team

Meeting

  

Desig coordination meeting

  

Wareham

Amyris Representative

Cole Project Mgmt

DGA

MEP Engineers

  

Weekly meeting

    

Schedule Meeting

  

Review project

Construction schedule – potential input from Contractors

  

Wareham

Amyris

Cole Project Mgmt

DGA

    

Wk 7

10-01-07

through

10-05-07

  

DESIGN

DEVELOPMENT

              
    

Look and Feel

  

 

Present final look and feel for the project

  

Wareham

Amyris

Cole Project Mgmt

DGA

  

Finalize the look and feel
for the project

    

Design Team

Meeting

  

Design coordination meeting

  

Warehom

Amyris Representative
Cole Project Mgmt

MEP Engineers

  

Weekly meeting

    

Pre-bid Package

  

Discuss Pre-bid requirements

  

Wareham

Amyris Representative

Cole Project Mgmt

MEP Engineers

  

Verify pre-bid package needs

 

2


Wk

  

MILESTONE

  

DESCRIPTION

  

ATTENDEES

  

ANTICIPATED

OUTCOME

Wk 8

10-08-07

through

10-12-07

  

CONSTRUCTION

DOCUMENTS

              
    

Complete Design

Development

  

Provide Design

Development packages for

final sign-off

  

Wareham

Amyris

Cole Project Mgmt

DGA

  

Participants will have one week
to review the documents and provide comments

    

Deisgn Team

Meeting

  

Design coordination meeting

  

Wareham

Amyris Representative

Cole Project Mgmt

MEP Engineers

  

Weekly meeting

Wk 9

10-15-07

through

10-19-07

  

CONSTRUCTION

DOCUMENTS

              
    

Complete Design

Development

  

Participants to provide comment
for final sign-off on the detailed design

  

Wareham

Amyris

Cole Project Mgmt

DGA

  

Sign-off for Design

Development

    

Design Team

Meeting

  

Design coordination

  

Wareham

Amyris Representative

Cole Project Mgmt

MEP Engineer

  

Weekly meeting

Wk 10

10-22-07

through

10-26-07

  

CONSTRUCTION

DOCUMENTS

              
    

Pre-bid Package

  

Submit pre-bid package for
review and approval

  

Wareham

Amyris Representative

Cole Project Mgmt

MEP Engineers

  

Participants will have one

week to review and approve

    

Design Team

Meeting

  

Design coordination

  

Wareham

Amyris Representative

Cole Project Mgmt

MEP Engineers

  

Weekly meeting

    

Preliminary Cost

Estimate

  

Review preliminary cost estimate

  

Wareham

Amyris Representative

Cole Project Mgmt

MEP Engineers

  

Determine if Value

Engineering is required

Wk 11

10-29-07

through

11-02-07

  

CONSTRUCTION

DOCUMENTS

              
    

Pre-bid Package

  

Submit the Pre-bid Package

  

DGA

MEP Engineers

    
    

90% Construction

Documents

  

Present 90% Construction Documents

  

Wareham

Amyris

Cole Project Mgmt

MEP Engineers

  

Participants will have one

week to review and comment

    

Design Team

Meeting

  

Design coordination

  

Wareham

Amyris Representative

Cole Project Mgmt

MEP Engineers

  

Weekly meeting

    

Permit Submission

  

Submit to City for Review

  

Wareham

DGA

  

4 week permit review

    

Bid Package to

GC’s

  

Submit Bid Package to

GC’s

  

Wareham

DGA

  

2 week bid duration for GC’s will have some allowances the will have to be leveled to select a GC, but it will allow construction to commence on week 13

 

3


Wk

  

MILESTONE

  

DESCRIPTION

  

ATTENDEES

  

ANTICIPATED

OUTCOME

Wk 12

11-05-07

through

11-09-07

  

CONSTRUCTION

DOCUMENTS

              
    

90% Construction

Documents

  

Receive final comments

  

Wareham

Amyris

Cole Project Mgmt

MEP Engineers

  

Design to incorporate final

comments

    

Final Documents

  

Design Team will submit

final bid documents

  

Design Team

    

Wk 13-33

11-12-07

through

03-28-08

  

POST

CONSTRUCTION

DOCUMENTS

              
    

Final Bid to

Selected GC and

outstanding trades

  

Submit 100% CD’s to

selected General Contractor

for final bidding of all

remaining subcontractors

  

Wareham

DGA

  

Final Pricing and Final

Schedule submitted to Team

on week 15

    

Construction

  

Construction begins with

pre-bid trades and as Permit

Documents are being

reviewed

  

Wareham

DGA

General Contractor

Cole Project Mgmt

Amyris

  

Anticipated 20 week

construction starting on week

13 and ending on week 33

Wk 15

11-26-07

through

11-30-07

  

Construction

              
    

Final Bids received

for outstanding sub

trades

  

All remaining

subcontractors are released

  

Wareham

DGA

Cole Project Mgmt

Amyris

  

Construction continues

uninterrupted

    

Permit

  

Receive permit from the

City of Emeryville

  

Wareham

DGA

  

Construction continues

uninterrputed

Wk 32-34

03-31-08

through

04-11-08

  

Furniture and

Commissioning

              
    

Install Furn. And

Commission

equipment

  

Complete furniture

installation and commission

all equipment

  

Wareham

DGA

Cole Project Mgmt

Amyris

Furniture Dealer

  

Move In on week 35

Wk 35

04-14-08

through

04-18-08

  

Completion

              
    

Project Complete

  

All work is complete and

Amyris moves in

  

Wareham

DGA

Cole Project Mgmt

Amyris

Furniture Dealer

  

MOVE IN /

Rent Commencement

 

************         Yellow shading denotes key milestones that need to be met to maintain schedule

 

4


EXHIBIT C-1

LABORATORY RULES AND REGULATIONS

1.        Any laboratory equipment (glass and cage washers, sterilizers, centrifuges, etc.) being used during normal business hours must be properly insulated for noise to prevent interruption of other tenants’ business. Landlord reserves the right to request all equipment be insulated prior to occupancy. Should other tenants complain of noise, lab tenant will be responsible for abating any noise issues, at their sole cost.

2.        Any damages to property due to leaks from lab equipment will be the sole responsibility of the Tenant. Should damage occur in other Tenant spaces, any and all damages and clean up will be the responsibility of equipment owner (lab tenant).

3.        Animal activities are a recognized and necessary process in the biotech industry. It can only be conducted by lab tenants pursuant to all the requirements of their respective lease (including the “Use” clause) and requires specific, written approval by Landlord in advance. We also expect any animal operations to be conducted pursuant to all regulations, standards and best industry practices relating to them.

4.        The EmeryStation Campus is a mixed-use facility and lab tenants share space with office tenants. To reduce the potential interaction with office tenants and their employees and visitors with any biotech animal operations; animal testing performed; deliveries of animals and any equipment, foods, cleaners, etc. associated with animal activities must be coordinated through the Loading Dock after hours and with the cooperation of the building management and security personnel. Tenant should make every effort to handle any deliveries relating to animal activities outside of Building Standard Hours. The freight elevator must be used at all times, and delivery trucks should not be visible to the other tenants in the campus area. No cartons, containers or cardboard boxes bearing the nature of contents may be stored or left in common area spaces, to include any garage/freight areas. Feed bags, animal carriers, and any and all containers must be disposed of properly and with discretion.

5.        All exterior signage relating to laboratory operations (i.e., visible to common areas including corridors) must be kept to the minimum required by law. All signs must have Landlord’s approval prior to installation.

 

1


EXHIBIT C-2

RULES AND REGULATIONS

1.        No sidewalks, entrance, passages, courts, elevators, vestibules, stairways, corridors or halls shall be obstructed or encumbered by Tenant or used for any purpose other than ingress and egress to and from the Premises.

2.        No awning or other projection shall be attached to the outside walls or windows of the Project without the prior written consent of Landlord. No curtains, blinds, shades, drapes or screens shall be attached to or hung in, or used in connection with, any window within the Premises which faces the street, without the prior written consent of Landlord. Such awnings, projections, curtains, blinds, shades, drapes, screens and other fixtures must be of a quality, type, design, color, material and general appearance approved by Landlord, and shall be attached in the manner approved by Landlord. All lighting fixtures hung in offices or spaces along the perimeter of the Premises must be of a quality, type, design, bulb color, size and general appearance approved by Landlord.

3.        Except as expressly otherwise permitted herein or in the Lease, no sign, advertisement, notice, lettering, decoration or other thing shall be exhibited, inscribed, painted or affixed by Tenant on any part of the Project outside of the Premises or any part of the Premises which faces outward toward public portions of the Project, without the prior written consent of Landlord. For the avoidance of doubt, Landlord and Tenant agree that the restrictions in this Section 3 shall not apply to any portion of the Premises which is entirely inside the Premises. In the event of the violation of the foregoing by Tenant, Landlord may remove same without any liability, and may charge the expense incurred by such removal to Tenant.

4.        Intentionally Omitted.

5.        No showcases or similar articles shall be put in front of or affixed to any part of the exterior of the Project, nor placed in public portions thereof without the prior written consent of Landlord.

6.        The water and wash closets and other plumbing fixtures shall not be used for any purposes other than those for which they were constructed, and no sweepings, rubbish, rags or other substances shall be thrown therein. All damages resulting from any misuse of the fixtures shall be borne by Tenant to the extent that Tenant or Tenant’s agents, servants, employees, contractors, visitors or licensees shall have caused the same.

7.        Intentionally Omitted.

8.        No animal or bird of any kind shall be brought into or kept in or about the Premises or the Project, except seeing-eye dogs or other service animals.

9.        Intentionally Omitted.

10.        Tenant shall not make, or permit to be made, any unseemly or disturbing noises or disturb or interfere with occupants of the Project, or neighboring buildings or premises, or those

 

1


having business with them. Tenant shall not throw anything out of the doors, windows or skylights or down the passageways.

11.        Intentionally Omitted,

12.        No additional mail slots of any kind shall be placed upon any of the exterior doors of the Premises by Tenant. Tenant must, upon the termination of the tenancy, restore to Landlord all keys of offices and toilet rooms, either furnished to, or otherwise procured by Tenant, and in the event of the loss of any keys so furnished, Tenant shall pay to Landlord the cost thereof.

13.        All removals, or the carrying in or out of any safes, freight, furniture, construction material, bulky matter or heavy equipment of any description must take place during the hours which Landlord or its agent may determine from time to time. Landlord reserves the right to prescribe the weight and position of all safes, which must be placed upon two-inch thick plank strips to distribute the weight. The moving of safes, freight, furniture, fixtures, bulky matter or heavy equipment of any kind must be made upon previous notice to the Building Manager and in a manner and at times prescribed by him, and the persons employed by Tenant for such work are subject to Landlord’s prior approval. Landlord reserves the right to inspect all safes, freight or other bulky articles to be brought into the Project and to exclude from the Project all safes, freight or other bulky articles which violate any of these Rules and Regulations or the Lease of which these Rules and Regulations are a part.

14.        Intentionally Omitted.

15.        Landlord shall have the right to prohibit any advertising or business conducted by Tenant referring to the Project which, in Landlord’s opinion, tends to impair the reputation of the Project or its desirability as a first class building for offices and/or commercial services and upon notice from Landlord, Tenant shall refrain from or discontinue such advertising.

16.        Landlord reserves the right to exclude from the Project between the hours of 6:00 p.m. and 8:00 a.m. Monday through Friday, after 1:00 p.m. on Saturdays and at all hours Sundays and legal holidays, all persons who do not present a pass to the Project issued by Landlord. Landlord may furnish passes to Tenant so that Tenant may validate and issue same. Tenant shall safeguard said passes and shall be responsible for all acts of persons in or about the Project who possess a pass issued to Tenant.

17.        Tenant’s contractors shall, while in the Premises or elsewhere in the Project, be subject to and under the control and direction of the Building Manager (but not as agent or servant of said Building Manager or of Landlord).

18.        If the Premises is or becomes infested with vermin as a result of the use or any misuse or neglect of the Premises by Tenant, its agents, servants, employees, contractors, visitors or licensees, Tenant shall forthwith at Tenant’s expense cause the same to be exterminated from time to time to the satisfaction of Landlord and shall employ such licensed exterminators as shall be approved in writing in advance by Landlord.

 

2


19.        The requirements of Tenant will be attended to only upon application at the office of the Project. Project personnel shall not perform any work or do anything outside of their regular duties unless under special instructions from the office of the Landlord.

20.        Canvassing, soliciting and peddling in the Project are prohibited and Tenant shall cooperate to prevent the same.

21.        Intentionally Omitted.

22.        There shall not be used in any premises, or in the public halls, plaza areas, lobbies, or elsewhere in the Project, either by Tenant or by jobbers or others, in the delivery or receipt of merchandise, any hand trucks or dollies, except those equipped with rubber tires and sideguards.

23.        Tenant, Tenant’s agents, employees, contractors, licensees, or visitors shall not park any vehicles in any driveways, service entrances, or areas posted “No Parking” and shall comply with any other parking restrictions imposed by Landlord from time to time.

24.        Tenant shall install and maintain, at Tenant’s sole cost and expense, an adequate visibly marked (at all times properly operational) fire extinguisher next to any duplicating or photocopying machine or similar heat producing equipment, which may or may not contain combustible material, in the Premises.

25.        Intentionally Omitted.

26.        Tenant shall not use the name of the Project for any purpose other than as the address of the business to be conducted by Tenant in the Premises, nor shall Tenant use any picture of the Project in its advertising, stationery or in any other manner without the prior written permission of Landlord. Landlord expressly reserves the right at any time to change said name without in any manner being liable to Tenant therefor.

27.        Tenant shall not operate or conduct any restaurant, luncheonette or cafeteria for the sale or service of food or beverages to its employees or to others, except that food and beverage preparation by Tenant’s employees using microwave ovens, toasters, toaster ovens or coffee makers shall be permitted provided no odors of cooking or other processes emanate from the Premises. Tenant shall not install or permit the installation or use of any commercial vending machine except by such persons and in such manner as are approved in advance in writing by Landlord.

28.        The Premises shall not be used as an employment agency, a public stenographer or typist, a labor union office, a physician’s or dentist’s office, a dance or music studio, a school, a beauty salon, or barber shop, the business of photographic, multilith or multigraph reproductions or offset printing (not precluding using any part of the Premises for photographic, multilith or multigraph reproductions solely in connection with Tenant’s own business and/or activities), a restaurant or bar, an establishment for the sale of confectionery, soda, beverages, sandwiches, ice cream or baked goods, an establishment for preparing, dispensing or consumption of food or beverages of any kind in any manner whatsoever (except as permitted by Section 27 above), or news or cigar stand, or a radio, television or recording studio, theatre or

 

3


exhibition hall, or manufacturing, or the storage or sale of merchandise, goods, services or property of any kind at wholesale, retail or auction, or for lodging or sleeping (provided Landlord acknowledges and agrees that the foregoing shall not be deemed to prohibit Tenant from producing chemical compounds and/or intermediaries as part of the ordinary course of research and development activities).

29.        Business machines and mechanical equipment shall be placed and maintained by Tenant at Tenant’s expense in settings sufficient in Landlord’s judgment to absorb and prevent vibration, noise and annoyance. Tenant shall not install any machine or equipment which causes noise, heat, cold or vibration to be transmitted to the structure of the building in which the Premises are located without Landlord’s prior written consent, which consent may be conditioned on such tenns as Landlord may require. Tenant shall not place a load upon any floor of the Premises exceeding the floor load per square foot that such floor was designed to carry and which is allowed by Law (provided Landlord shall provide Tenant with notice of each such floor load).

30.        Intentionally Omitted.

31.        Tenant shall not store any vehicle within the parking area. Tenant’s parking rights are limited to the use of parking spaces for short-term parking, of up to twenty-four (24) hours, of vehicles utilized in the normal and regular daily travel to and from the Project. Tenants who wish to park a vehicle for longer than a 24-hour period shall notify the Building Manager for the Project; and such parking shall be permitted for up to five (5) days to accommodate the business travel of an employee of Tenant, but otherwise any parking for longer than a 24-hour period shall require the consent of Landlord and in any case may not be longer than two (2) weeks. Any motor vehicles parked without the prior written consent of the Building Manager for the Project for longer than a 24-hour period shall be deemed stored in violation of this rule and regulation and shall be towed away and stored at the owner’s expense or disposed of as provided by Law.

32.        Smoking is prohibited in the Premises, the Building and all enclosed Common Areas of the Project, including all lobbies, all hallways, all elevators and all lavatories.

 

4


EXHIBIT D

BASE BUILDING DESCRIPTION

ARCHITECTURE

Summary: EmeryStation East is organized around a nearly 20,000 square foot landscaped urban garden. Stunning sculpture and fountains at the grand portal to this approximately 245,000 square-foot Class A science research building invites employees, visitors and the public to enjoy the verdant raised landscaped plaza. This central courtyard provides attractive views from the occupiable spaces in the building and an area of congregation and repose. It also provides a convenient pedestrian link from Hollis Street through EmeryStation East to EmeryStation 1 and the Amtrak Transit Center beyond.

The base building was designed by American Institute of Architects award-winning SmithGroup, which has particular expertise in quality lab design. The architecture is bright, translucent, high-tech and elegant–reflecting the sophistication of the functions inside the building. Window walls control the transparency where appropriate. Tenant’s may elect to install standard mini-blinds as part of their build-outs. Exterior lighting enhances the building’s architecture and landscaping at grade and the plaza level.

Wareham is delivering the base building shell with common areas, main lobby, elevators, stairways, bathrooms, landscaping and security already in place. This gives tenants maximum utility and the best economies in creating their workplaces, as well as allowing maximum speed in completing their tenant improvements.

Floor Plans: Floors ranging in size from 23,000 square feet up to over 65,000 square feet and three complete stair towers give both small and large tenants the maximum efficiency and flexibility in design and space planning. Predominant 32 foot by 32 foot bays provide the opportunity for 10 foot 8 inch lab bench modules in both directions. Each floor features amply-sized usable outdoor terraces that provide areas of congregation, meeting, eating or relaxation.

Parking: The project includes two levels of lighted, structured parking for tenants’ employees plus required accessible handicapped / van parking. The garage levels are exhausted both naturally and mechanically. Visitor parking is available as part of the overall EmeryStation campus: presently it is available both at the surface lot just north of the Amtrak Transit Center and well as at the Terraces Garage.

Main Lobby: Accessible via stone-clad monumental entry stairs at the grand portal off Hollis Street to the east and at the large, raised landscaped plaza off Peladeau Street to the west, the building’s main lobby is a two-story glass cube with elegant stone flooring, landscaping, monumental artwork and a security desk providing visitor information and controlling access to the core elevators.

Elevators: The four main project elevators are state-of-the-art “Gen2” machine-room-less (MRL) elevators. The central core includes three passenger elevators, each with 4,000 lb. capacity, 350 feet per minute speed and a 9’7” tall architecturally-designed custom cab. The


central core also includes the building freight elevator with a 5,000 lb. capacity and its own vestibules on each tenant floor. All core elevators, including the freight elevator, serve the project’s two parking levels and the four occupiable floors above. In addition to the four core elevators, the project has two hydraulic shuttle elevators that provide tenant, visitor, public and ADA access from both Hollis and Peladeau Streets up to the landscaped plaza and main lobby level.

Bathrooms: Four complete bathrooms per floor (two each Mens’ and Womens’) with stone vanities and tile floors and accents.

Elevator Lobbies and Corridors: Finished as part of the base building on all multi-tenant floors.

Loading Dock: The base building includes a grade-level loading dock/area at the south end of the property. The loading dock accesses the freight elevator via the secure garage.

Interior Walls / Drywall: All core areas are drywalled and fire-taped as part of the base building. Drywall walls are fully finished in all finished areas such as bathrooms, main lobby, stair towers, garage areas, etc. Z-clips to allow easy connection of drywall at the exterior beams are already in place as part of the base building, as are stick pins in the underside of the roof slab to allow for easy installation of batt insulation.

Security: Card-reader-based security is distributed into garage and main doors at grade and to the plaza / lobby level. Exterior and garage areas feature security cameras reporting to the main lobby desk. Doors in the stair towers are prepped for future security hardware to allow tenants the opportunity to utilize the stairs as secure means of intra-floor travel in addition to the elevators. The elevators are pre-wired for security card readers as well. Tenants can extend off the main building system (at their cost) if they wish.

Landscaping: Wareham prides itself on the quality of its project’s landscaping, as evident in many of its surrounding buildings. The base building includes an extensive landscaped environment both at the elevated plaza garden and around the perimeter at grade. Certain of those planting areas at grade function as organic “bioswales” that filter stormwater before it is released into the public sewer system.

STRUCTURAL SYSTEM

Summary: The project features a state-of-the-art structural system designed by renowned engineering firm Rutherford and Chekene. It includes a large concrete mat foundation with two levels of reinforced concrete parking above and four levels of steel-framed occupiable space above the garage.

The reinforced concrete mat foundation system is designed to provide a rigid base that will limit foundation deflections and allow the building to maintain important stability on the site. The seismic-force-resisting system includes both buckling-restrained-braced (BRB) frames and moment frames. BRB frames are now being used in the design of new institutional-quality labs and hospitals such as those of the new UCSF Mission Bay campus. The building’s steel frame

 

2


supports reinforced concrete floors on metal decking. The tenant spaces measure 16 feet from floor to floor.

The live load is generally 130 lbs. per square foot. The low vibration areas of the building have the added effect of having greater load carrying capabilities. Drawing S0.03 in the base building construction document set more fully and accurately describes the capacities of the various areas of the building.

Vibration: The building is designed to meet an overall vibration criteria of 8000 micro-inches per second velocity (MIPS). The base building also features special low-vibration areas such as those required by most major research institutions; these areas have been designed to limit walker-induced vibration to a stringent 2000 MIPS.

Rooftop Equipment Platform: A large galvanized steel platform has been provided on the rooftop for building MEP infrastructure needs. It is designed to allow for ease of layout of units and has capacity to support equipment such as air handling units, exhaust stacks, fans, switchgear, micro-turbines, cooling towers, etc.

MECHANICAL, ELECTRICAL AND PLUMBING SYSTEMS

Summary: Reliability, flexibility and energy efficiency are the basis of the building’s mechanical, electrical and plumbing systems design by Flack & Kurz. The generous 16 foot floor-to-floor heights provide area for the vital and complicated infrastructure needed in today’s labs.

HEATING, VENTILATION AND AIR CONDITIONING (HVAC)

Supply: The base building HVAC system includes six complete vertical shafts located along the building’s central spine for optimal flexibility and serviceability on each floor. Multiple shafts are provided to minimize duct lengths and sizes and allow additional flexibility for the tenants. Each shaft is accessible on each floor by a door which accesses an internal platform to allow easier addition of vertical extra ducts, pipes, etc. Each shaft has a galvanized supply duct inside which feed into a galvanized horizontal supply manifolds on the roof. This design allows tenants to “plug in” the correct amount of shared supply and exhaust units, sized to their needs, on the large, raised base building steel equipment platform at the roof to serve their specific needs.

The air conditioning system(s) for the tenant spaces are intended to include shared air handling units sized based on tenant-specific needs and with variable speed drives sized to provide cooling for:

Lighting at 1.5 watts per sq ft

People based on 100 sq ft per person

Equipment at 1.2 watts per sq ft (of heat output)

(There is capacity in the chilled water system to cool an additional 6.2 watts per square foot of equipment on average, as more fully discussed below.)

The combination of dedicated outside air system(s) and supplemental cooling and variable volume laboratory controls provided by the tenant is intended to use less energy than a

 

3


traditional lab exhaust system and will provide a high level of reliability and flexibility for all tenants.

Chilled Water: The base building includes a piped distribution system to accommodate up to 950 tons of total cooling. Chilled water can run from the complete, enclosed base building chiller room down to four vertical risers (three risers serve all four floors and the fourth provides extra service to the larger top two floors). The chilled water design is intended to provide cooling for an additional 6.2 watts per square foot for biotech lab loads or equipment cooling on average. Cooling would be provided via fan coil units or chilled beams provided by the tenant. This approach allows tenants to add the cooling where needed. Energy is saved by providing additional cooling only where needed and minimizing the need for additional reheating. Like with the air side, the base building is designed to allow tenants to appropriately size their chilled water needs and to “plug in” the right chiller and chilled water pump capacity into the existing system. Piping and valves for tenant-supplied shared chillers and pumps are provided as part of the base building.

Cooling Towers: The base building features a main condenser water loop and pre-installed valves to allow for connection of the required pumps and as many as three cooling towers totaling at least 950 tons, depending on the specific needs of tenants, again in a “plug-in” scenario by each tenant. The cooling tower area is already architecturally screened as part of the base building.

Hot Water: As with chilled water, the base building has an enclosed boiler room where tenant-supplied pumps can push hot water down four separate risers (three risers serving all floors and a fourth providing additional service to the larger top two floors). The system was designed to handle at least 12 million BTU’s of hot water. Heating water created by the co-gen system will be available to supplement tenant-supplied boilers.

Exhaust: Each shaft on each floor is served by two independent stainless steel exhaust ducts that tie into stainless steel duct manifolds at the roof. As with supply, tenants will size the exhaust needed by their use and “plug in” the appropriate units and stacks on the roof platform, connecting to one of the base building exhaust manifolds.

VFDs: The supply, exhaust and chiller equipment to be added as tenant build-outs proceed and specific tenant needs are determined are intended to feature energy-efficient VFDs.

Controls: The base building features a computer-controlled Building Management System (BMS) backbone to which tenants will connect.

Specialty Exhaust and Piping: There is roof and shaft space negotiable for specialty systems that might be required by a tenant. As noted above, each shaft has an internal work platform inside of it, accessible by a man-door on each floor, to allow tenants to easily add specialty exhaust ducts or piping systems.

Rooftop Equipment Platform: As noted in the discussion regarding Structure, the project’s roof includes a very large steel dunnage support deck that provides room for contemplated HVAC and electrical equipment, leaving extra room negotiable for additional, special needs that tenants might have.

 

4


For Ventilation and Exhaust air, the duct infrastructure has been sized for capacity of 0.85 cfm per USF, deemed adequate by the building engineers to provide the greater of: a) six foot fume hoods at a density of one hood per 1,075 USF, and b) 6 air changes per hour in all lab spaces. Office ventilation rates of 20 cfm per person can be accommodated. The assumption was for no more than 60/40 lab/office mix. Necessary supply and exhaust units will be sized and supplied by tenants. It is possible that any one tenant may only need “a part” of a fan, etc., in which case Landlord is willing to consider “buying” the excess capacity at the direct cost of the purchased unit to make this capacity available for other tenants. The sizing of the Emergency generator assumes fume hoods and fans are connected thereto.

For Cooling, base building infrastructure assumes averaging as much as one ton per 275 USF to cool 6 watts per USF. The chilled water piping can meet the need for up to 0.0017 gpm per USF within a tenant space. Chiller/chiller pump and cooling tower/cooling tower pump sizing and purchase to by be tenants. Landlord may participate in the “right-sizing” of this sort of equipment purchases as was discussed above with supply and exhaust fans.

PLUMBING

Water: Water service has been secured from EBMUD as part of the base building. Potable domestic cold water and hot water are provided to all the toilet rooms and to the janitor closets. Additionally, the base building features four separate domestic cold water risers (two on each end of the building) available for tenant use. Tenants will meet their own identified domestic and industrial hot water needs as part of their build-outs (other than at existing base building bathrooms, where Landlord has provided the hot water heater). There is a capped water connection each floor for tenants to share. Each tenant shall be entitles to its pro-rata share of the total building supply. Earlier tenants must leave valve connections for future tenants.

Waste: Sewer connection and capacity has been secured from EBMUD as part of the base building. Sanitary waste and vent lines are provided at multiple locations for tie-in by the tenants. There are four 3” capped connections serving each floor on the north side of the building and two such connections serving each floor on the south side.

Natural Gas: The base building has secured natural gas services from PG&E. There are two taps in a horizontal line just below the first floor (accessible from the garage) where tenants can tap if they wish to bring natural gas to their premises. These taps are sized to allow service of 7 inches / one-half psi. Each floor has a stub; earlier tenants must leave a stub for future tenants. Tenants may have their pro-rata share of the total 1200 CFH supply to the building.

Specialty Piping: Air, vacuum and/or specialty gas systems are to be determined per specific tenant need as part of the tenant improvement design. However, as noted above, provisions have been made in the shafts for specialty piping risers if needed, and there is extra room on the roof and in the lower garage levels for tenant specialty equipment needs (as negotiated).

FIRE PROTECTION

Sprinklers: Fire water service has been secured from EBMUD as part of the base building. The base building features a fire pump on emergency power serving two main vertical risers and full horizontal line distribution to provide shell coverage. The system has been designed for

 

5


“ordinary hazard” levels appropriate to a lab building; the base building upturned heads provide the necessary code shell coverage. The concrete on metal slab floors provide two-hour fire rating between floors.

Life Safety System: The base building includes the backbone (in two risers) for an addressable fire/strobe/annunciation system. Each riser has a terminal cabinet on each of the four occupiable floors at which tenants can connect. The base building includes devices at all completed areas such as bathrooms, lobby, garage, etc.

ELECTRICAL

Main PG&E Services: Two 4000 amp services from PG&E have been secured as part of the base building. These provide 277/480 3-phase power. In addition to these, the base building has a 1,000 KW gas-fired electrical co-generation system, more fully described below. The PG&E services have been sized to allow for tenant capacities as follows:

 

Lighting:

  

1.5 watts per USF

Office power and receptacles

  

3.5 watts per USF

Lab equipment power

  

12 watts per USF

All main electrical switchgear is provided as part of the base building, as are two 2000 amp /480V tapable bus risers that run up vertically on each side of the building. Each riser has an enclosed and ventilated electrical room on each of the four occupiable floors (i.e., two electrical rooms per floor). Each electrical room includes a 600 amp / 480V distribution board with space for multiple tenant service breakers where tenants can tap in to run power to their specific suites and step down the 277/480V 3-phase power if and as needed. Tenants will install E-Mon D-Mon measuring devices at this point, connected to the BMS system, to allow the energy usage inside their specific suites to be accurately measured and billed.

Grounding: There are two risers for electrical grounding and two risers for telecom grounding available on each floor.

Emergency Power: A 1250 KW standby diesel emergency generator and two vertical emergency power rises running up the building are provided as part of the base building to support building life safety and essential exhaust loads. This diesel emergency generator has been oversized to allow Landlord the ability to offer certain amounts of emergency power to tenants on a separately-negotiable basis. The co-generation system (more fully described below), provides a possible additional source of non-grid-based power to tenants in the building during times when the PG&E power grid might be interrupted.

Co-Gen: The base building will be supported by a co-generation system consisting of four 250 KW natural gas-fired engine generators. The co-gen system will reduce the reliance on the utility company and can allow for certain tenant operations while utility power is unavailable, as separately negotiated. The two PG&E services described above have been sized as if the co-gen system is not present, so the co-gen capacity represents redundancy based on the design assumptions. The co-gen also provides the opportunity for power cost savings relative to the municipal utility provider. The heat generated by the engines will be captured and used to

 

6


provide hot water for the buildings heating water needs. Excess may be available for tenants’ industrial hot water needs.

Lighting: The lighting systems chosen for the base building utilize high-efficiency lamping and ballast to maximize energy efficiency and lamp life. The lighting design provides dramatic accent lighting while keeping the light levels to a minimum. Again, lighting is kept efficient yet effective. Base building includes lighting in all completed areas such as bathrooms, main lobby, garage, etc.

In Amyris’ case, each floor of the Initial Premises (i.e., the north side of Floors 1 and 2) capture the entirety of one base building electrical closet. Each such closet contains:

 

 

1)

a lighting panel with 1.5 watts per USF for Tenant lighting at 277/480 volts (the south wing closets are the same)

 

 

2)

a distribution panel with 12 watts per USF at 600 amps at 277/480 volts, 3-phase 4-wire (the south wing closets are at 400 amps)

 

 

3)

a transformer providing 2.4 watts per USF at 120/208 3-phase 4-wire feeding 42 pole panels (the south wing closets are the same), which feed receptacles in the base building bathrooms but in balance are available.

TELECOM

Telecommunication riser closets stack vertically and are centrally positioned at two locations on each tenant floor. Each closet provides a clear route to the main telco room located in the first garage level (the MPOE). The MPOE has access to phone, cable and fiber services of several different providers. The riser closets are designed to maximize tenant cabling space and provide future flexibility for the fiber and cabling needs for the building tenants.

 

7


RIDER 1

COMMENCEMENT DATE AGREEMENT

ES EAST ASSOCIATES, LLC, a California limited liability company (“Landlord”), and                          (“Tenant”), have entered into a certain Lease dated as of              , 2007 (the “Lease”).

WHEREAS, Landlord and Tenant wish to confirm and memorialize the Commencement Date and Expiration Date of the Lease as provided for in Section 2.2(b) of the Lease;

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein and in the Lease, Landlord and Tenant agree as follows:

1. Unless otherwise defined herein, all capitalized terms shall have the same meaning ascribed to them in the Lease.

2. The Commencement Date (as defined in the Lease) of the Lease is                  .

3. The Expiration Date (as defined in the Lease) of the Lease is                      .

4. Tenant hereby confirms the following:

(a) That it has accepted possession of the premises pursuant to the terms of the Lease;

(b) That the Landlord Work is Substantially Complete; and

(c) That the Lease is in full force and effect.

5. Except as expressly modified hereby, all terms and provisions of the Lease are hereby ratified and confirmed and shall remain in full force and effect and binding on the parties hereto.

6. The Lease and this Commencement Date Agreement contain all of the terms, covenants, conditions and agreements between the Landlord and the Tenant relating to the subject matter herein. No prior other agreements or understandings pertaining to such matters are valid or of any force and effect.

 

TENANT:

   

LANDLORD:

   

ES EAST ASSOCIATES, LLC,
a California limited liability company

By:

       

By:

   

Its:

         

Richard K. Robbins

       

Managing Member

Date:

         


RIDER 2

FORM OF LETTER OF CREDIT


THIS IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF             

DATED:                       , 20__

BENEFICIARY:

ES EAST ASSOCIATES, LLC

1120 NYE STREET, SUITE 400

SAN RAFAEL, CA 94901

AS “ LANDLORD

APPLICANT:

AMYRIS BIOTECHNOLOGIES, INC.

5980 HORTON STREET, SUITE 450

EMERYVILLE, CA 94608

AS “ TENANT

 

AMOUNT:

  

USS735,893.31 (SEVEN HUNDRED THIRTY-FIVE THOUSAND EIGHT HUNDRED NINETY-THREE AND 31/100 U.S. DOLLARS)

EXPIRATION DATE:

  

                 , 2008

LOCATION:

  

SANTA CLARA, CALIFORNIA

LADIES AND GENTLEMEN:

WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF              IN YOUR FAVOR. THIS LETTER OF CREDIT IS AVAILABLE BY SIGHT PAYMENT WITH OURSELVES ONLY AGAINST PRESENTATION AT THIS OFFICE OF THE FOLLOWING DOCUMENTS:

 

 

1.

THE ORIGINAL OF THIS LETTER OF CREDIT AND ALL AMENDMENT(S), IF ANY.

 

2.

YOUR SIGHT DRAFT DRAWN ON US IN THE FORM ATTACHED HERETO AS EXHIBIT “A” .

 

3.

A DATED CERTIFICATION PURPORTEDLY SIGNED BY AN AUTHORIZED OFFICER OR REPRESENTATIVE OF THE BENEFICIARY, FOLLOWED BY HIS/HER PRINTED NAME AND DESIGNATED TITLE, STATING EITHER OF THE FOLLOWING:

 

(A.)

“THE UNDERSIGNED, AS LANDLORD UNDER THE LEASE BETWEEN ES EAST ASSOCIATES, LLC AS LANDLORD AND AMYRIS BIOTECHNOLOGIES, INC. AS TENANT (AS THE SAME MAY BE AMENDED OR ASSIGNED FROM TIME TO TIME) HAS THE RIGHT TO DRAW UPON SILICON VALLEY BANK IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF              UPON THE TERMS OF THE LEASE OR THE TENANT HAS FILED A PETITION OF BANKRUPTCY.”

OR

 

(B.)

“WITHIN THIRTY (30) DAYS PRIOR TO THE EXPIRATION DATE OF THIS LETTER OF CREDIT BENEFICIARY HAS NOT RECEIVED AN EXTENSION AT LEAST FOR ONE YEAR TO THE EXISTING LETTER OF

DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECHNOLOGIES, INC.

 

            
CLIENT’S SIGNATURE(S)       DATE   

 

1


THIS IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF             

DATED:                       , 20__

CREDIT OR A REPLACEMENT LETTER OF CREDIT SATISFACTORY TO THE BENEFICIARY.”

THE LEASE AGREEMENT MENTIONED ABOVE IS FOR IDENTIFICATION PURPOSES ONLY AND IT IS NOT INTENDED THAT SAID LEASE AGREEMENT BE INCORPORATED HEREIN OR FORM PART OF THIS LETTER OF CREDIT.

PARTIAL AND MULTIPLE DRAWINGS ARE ALLOWED. THIS LETTER OF CREDIT MUST ACCOMPANY ANY DRAWINGS HEREUNDER FOR ENDORSEMENT OF THE DRAWING AMOUNT AND WILL BE RETURNED TO THE BENEFICIARY UNLESS IT IS FULLY UTILIZED.

WE AGREE THAT WE SHALL HAVE NO AUTHORITY, DUTY, DISCRETION OR RIGHT TO INQUIRE AS TO THE BASIS UPON WHICH BENEFICIARY HAS DETERMINED THAT THE AMOUNT IS DUE AND OWING OR HAS DETERMINED TO PRESENT TO US ANY DRAFT UNDER THIS LETTER OF CREDIT, AND THE PRESENTATION OF SUCH DRAFT IN STRICT COMPLIANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT, SHALL AUTOMATICALLY RESULT IN PAYMENT TO TIIE BENEFICIARY.

THIS LETTER OF CREDIT SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT, FROM THE PRESENT OR EACII FUTURE EXPIRATION DATE UNLESS AT LEAST SIXTY (60)  DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE NOTIFY YOU BY REGISTERED MAIL/OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESS THAT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND THE CURRENT EXPIRATION DATE, BUT IN ANY EVENT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND JULY 21, 2018 , WHICH SHALL BE THE FINAL EXPIRATION DATE OF THIS LETTER OF CREDIT.

THE DATE THIS LETTER OF CREDIT EXPIRES IN ACCORDANCE WITH THE ABOVE PROVISION IS THE “FINAL EXPIRATION DATE”. UPON THE OCCURRENCE OF THE FINAL EXPIRATION DATE THIS LETTER OF CREDIT SHALL FULLY AND FINALLY EXPIRE AND NO PRESENTATIONS MADE UNDER THIS LETTER OF CREDIT AFTER SUCH DATE WILL BE HONORED.

THIS LETTER OF CREDIT MAY ALSO BE CANCELED PRIOR TO ANY PRESENT OR FUTURE EXPIRATION DATE ONLY UPON RECEIPT BY SILICON VALLEY BANK BY OVERNIGHT COURIER OR REGISTERED MAIL (RETURN RECEIPT REQUESTED) OF THE ORIGINAL LETTER OF CREDIT AND ALL AMENDMENTS (IF ANY) FROM THE BENEFICIARY TOGETHER WITH A STATEMENT PURPORTEDLY SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE BENEFICIARY ON COMPANY LETTERHEAD STATING THAT THE LETTER OF CREDIT IS NO LONGER REQUIRED AND IS BEING RETURNED FOR CANCELLATION.

THIS LETTER OF CREDIT IS TRANSFERABLE ONE OR MORE TIMES, BUT IN EACH INSTANCE ONLY TO A SINGLE BENEFICIARY AS TRANSFEREE AND ONLY UP TO THE THEN AVAILABLE AMOUNT IN FAVOR OF ANY NOMINATED TRANSFEREE THAT IS THE SUCCESSOR IN INTEREST TO BENEFICIARY (“TRANSFEREE”), ASSUMING SUCH TRANSFER

DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECHNOLOGIES, INC.

 

            
CLIENT’S SIGNATURE(S)       DATE   

 

2


THIS IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF             

DATED:                       , 20__

TO SUCH TRANSFEREE WOULD BE IN COMPLIANCE WITH THEN APPLICABLE LAW AND REGULATION, INCLUDING BUT NOT LIMITED TO THE REGULATIONS OF THE U. S. DEPARTMENT’ OF TREASURY AND U. S. DEPARTMENT OF COMMERCE. AT THE TIME OF TRANSFER, THE ORIGINAL LETTER OF CREDIT AND ORIGINAL AMENDMENT(S), IF ANY, MUST BE SURRENDERED TO US AT OUR ADDRESS INDICATED IN THIS LETTER OF CREDIT TOGETHER WITH OUR LETTER OF TRANSFER DOCUMENTATION AS PER ATTACHED EXHIBIT “B” DULY EXECUTED AND ACCOMPANIED BY THE ORIGINAL LETTER OF CREDIT AND ALL AMENDMENT(S), IF ANY. THE CORRECTNESS OF THE SIGNATURE AND TITLE OF THE PERSON SIGNING THE TRANSFER FORM MUST BE VERIFIED BY BENEFICIARY’S BANK. APPLICANT SHALL PAY OUR TRANSFER FEE OF 1/4 OF 1% OF THE TRANSFER AMOUNT US$250.00) UNDER THIS LETTER OF CREDIT. ANY REQUEST FOR TRANSFER WILL BE EFFECTED BY US SUBJECT TO THE ABOVE CONDITIONS. HOWEVER, ANY REQUEST FOR TRANSFER AND OUR OBLIGATION TO EFFECI”THE TRANSFER OF THIS LETTER OF CREDIT IS NOT CONTINGENT UPON APPLICANT’S ABILITY TO PAY OR ACTUAL PAYMENT OF OUR TRANSFER FEE. ANY TRANSFER OF THIS LETTER OF CREDIT MAY NOT CHANGE THE PLACE OR DATE OF EXPIRATION OF THE LETTER OF CREDIT FROM OUR ABOVE SPECIFIED OFFICE. EACH TRANSFER SHALL BE EVIDENCED BY OUR ENDORSEMENT ON THE REVERSE OF THE LETTER OF CREDIT AND WE SHALL FORWARD THE ORIGINAL OF THE LETTER OF CREDIT SO ENDORSED TO THE TRANSFEREE.

DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT.

DOCUMENTS MUST BE DELIVERED TO US DURING REGULAR BUSINESS HOURS ON A BUSINESS DAY OR FORWARDED TO US BY OVERNIGHT DELIVERY SERVICE TO: SILICON VALLEY BANK, 3003 TASMAN DRIVE, 2 ND FLOOR, MAIL SORT HF210, SANTA CLARA, CALIFORNIA 95054, ATTENTION: GLOBAL FINANCIAL SERVICES - STANDBY LETTER OF CREDIT DEPARTMENT (THE “BANK’S OFFICE”).

AS USED HEREIN, THE TERM “BUSINESS DAY” MEANS A DAY ON WHICH WE ARE OPEN AT OUR ABOVE ADDRESS IN SANTA CLARA, CALIFORNIA TO CONDUCT OUR LETTER OF CREDIT BUSINESS. NOTWITHSTANDING ANY PROVISION TO THE CONTRARY IN THE UCP (AS HEREINAFTER DEFINED), IF THE EXPIRATION DATE OR THE FINAL EXPIRATION DATE IS NOT A BUSINESS DAY THEN SUCH DATE SHALL BE AUTOMATICALLY EXTENDED TO THE NEXT SUCCEEDING DATE WHICH IS A BUSINESS DAY.

WE HEREBY ENGAGE WITH YOU THAT DRAFT(S) DRAWN AND/OR DOCUMENTS PRESENTED UNDER AND IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON PRESENTATION TO SILICON VALLEY BANK, IF PRESENTED ON OR BEFORE THE EXPIRATION DATE OF THIS LETTER OF CREDIT, REGARDLESS OF WHETHER THE APPLICANT DISPUTES ANY SUCH PRESENTATION.

IF ANY INSTRUCTIONS ACCOMPANYING A DRAWING UNDER THIS LETTER OF CREDIT REQUEST THAT PAYMENT IS TO BE MADE BY TRANSFER TO YOUR ACCOUNT WITH ANOTHER BANK, WE WILL ONLY EFFECT SUCH PAYMENT BY FED WIRE TO A U.S.

DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECHNOLOGIES, INC.

 

            
CLIENT’S SIGNATURE(S)       DATE   

 

3


THIS IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF             

DATED:                       , 20__

REGULATED BANK, AND WE AND/OR SUCH OTHER BANK MAY RELY ON AN ACCOUNT NUMBER SPECIFIED IN SUCH INSTRUCTIONS EVEN IF THE NUMBER IDENTIFIES A PERSON OR ENTITY DIFFERENT FROM THE INTENDED PAYEE.

THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS (2007 REVISION), INTERNATIONAL, CHAMBER OF COMMERCE, PUBLICATION NO. 600 (THE “UCP”).

SILICON VALLEY BANK,

 

(FOR BANK USE ONLY)

     

(FOR BANK USE ONLY)

  

AUTHORIZED SIGNATURE

     

AUTHORIZED SIGNATURE

  

 

 

DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECHNOLOGIES, INC.

 

            
CLIENT’S SIGNATURE(S)       DATE   

 

4


THIS IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF             

DATED:                       , 20__

EXHIBIT “A”

 

 

SIGHT DRAFT/BILL OF EXCHANGE

   

DATE:                             

  

REF. NO.                     

   

AT SIGHT OF THIS DRAFT

    
 

PAY TO THE ORDER OF                                                                                                                                     US$                     

U.S. DOLLARS                                                                                                                                                                                   

 

“DRAWN UNDER SILICON VALLEY BANK , SANTA CLARA, CALIFORNIA, IRREVOCABLE STANDBY LETTER OF CREDIT NUMBER NO. SVBSF              DATED                      , 20__”

   

TO:

  

  SILICON VALLEY BANK

    
    

  3003 TASMAN DRIVE

  

[INSERT NAME OF BENEFICIARY]

    

  SANTA CLARA, CA 95054

    
         
         

Authorized Signature

 

GUIDELINES TO PREPARE THE SIGHT DRAFT OR BILL OF EXCHANGE:

 

1.

DATE             INSERT ISSUANCE DATE OF DRAFT.

2.

REF. NO.             INSERT YOUR REFERENCE NUMBER IF ANY.

3.

PAY TO THE ORDER OF:             INSERT NAME OF BENEFICIARY

4.

US$             INSERT AMOUNT OF DRAWING IN NUMERALS/FIGURES.

5.

U.S DOLLARS             INSERT AMOUNT OF DRAWING IN WORDS.

6.

LETTER OF CREDIT NUMB ER INSERT THE LAST DIGITS OF OUR STANDBY L/C NUMBER THAT PERTAINS TO THE DRAWING.

7.

DATED             INSERT THE ISSUANCE DATE OF OUR STANDBY L/C.

 

NOTE:    

BENEFICIARY SHOULD ENDORSE THE BACK OF THE SIGHT DRAFT AS YOU WOULD A CHECK.

IF YOU NEED FURTI IER ASSISTANCE IN COMPLETING THIS SIGHT DRAFT, PLEASE CALL OUR L/C PAYMENT SECTION AND ASK FOR: EFRAIN TUVILLA AT (408) 654-6349 OR ALICE DALUZ AT (408) 654-7120.

DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECHNOLOGIES, INC.

 

            
CLIENT’S SIGNATURE(S)       DATE   

 

5


THIS IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF             

DATED:                       , 20__

EXHIBIT “B”

DATE

 

TO:

  SILICON VALLEY BANK

    

  3003 TASMAN DRIVE

    

  SANTA CLARA, CA 95054

 

 

ATTN:    

GLOBAL FINANCIAL SERVICES

 

    

    STANDBY LETTERS OF CREDIT

 

 

RE:

SILICON VALLEY BANK IRREVOCABLE STANDBY LETTER OF CREDIT NO.                

GENTLEMEN:

FOR VALUE RECEIVED, THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO:

 

       

(NAME OF TRANSFEREE)

 

       

(ADDRESS)

ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS TRANSFER.

BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE. TRANSFEREE SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF, INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECT TO THE TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY.

DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECHNOLOGIES, INC.

 

            
CLIENT’S SIGNATURE(S)       DATE   

 

6


THIS IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF             

DATED:                           , 20__

THE ORIGINAL OF SUCH LETTER OF CREDIT IS RETURNED HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER ON THE REVERSE THEREOF, AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER.

 

       
      SIGNATURE AUTHENTICATED
         

(BENEFICIARY’S NAME)

 

     

THE NAME(S) TITLE(S), AND SIGNATURE(S) CONFORM TO THAT/THOSE ON FILE WITH US FOR THE COMPANY AND THE SIGNATURE(S) IS/ARE AUTHORIZED TO EXECUTE THIS INSTRUMENT.

WE FURTHER CONFIRM THAT THE COMPANY HAS BEEN IDENTIFIED APPLYING THE APPROPRIATE DUE DILIGENCE AND ENHANCED DUE DILIGENCE AS REQUIRED BY THE BANK SECRECY ACT AND ALL ITS SUBSEQUENT AMENDMENTS.

(SIGNATURE OF BENEFICIARY)      
       
(PRINTED NAME AND TITLE)      
 
     

_________________________________

      (NAME OF BANK)
 
     

_________________________________

      (ADDRESS OF BANK)
 
     

_________________________________

      (CITY, STATE, ZIP CODE)
 
     

_________________________________

      (AUTHORIZED SIGNATURE)
 
     

_________________________________

      (PRINTED NAME AND TITLE)
 
     

_________________________________

     

(TELEPHONE NUMBER)

 

DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECHNOLOGIES, INC.

 

            
CLIENT’S SIGNATURE (S)       DATE   

 

7


SCHEDULE 1 to Lease

SUMMARY OF EXISTING TENANTS RIGHTS TO AVAILABLE PREMISES

NONE

Exhibit 10.18

FIRST AMENDMENT TO LEASE

THIS FIRST AMENDMENT TO LEASE (the “ First Amendment ”), dated as of March 10, 2008 (the “ Effective Date ”), is entered into by and between ES EAST ASSOCIATES, LLC, a California limited liability company (“ Landlord ”), and AMYRIS BIOTECHNOLOGIES, INC., a California corporation (“ Tenant ”), with reference to the following facts:

A.        Landlord and Tenant entered into that certain Lease dated as of August 22, 2007 (the “ Lease ”), pursuant to which Landlord leases to Tenant space currently containing approximately 70,691 rentable square feet (the “ Original Premises ”) described as Suite Number 100 on the first (1st) floor and Suite Number 200 on second (2nd) floor of the building commonly known as EmeryStation East, located at 5885 Hollis Street, Emeryville, California (the “ Building ”).

B.        Landlord and Tenant desire to add to the Premises that certain space containing approximately 20,880 rentable square feet located on the second (2nd) floor of the Building, as more particularly shown in Exhibit A hereto (the “ Expansion Space ”).

NOW, THEREFORE, in consideration of the mutual covenants set forth herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:

1.         Incorporation of Recitals; Defined Terms .    Recitals A and B set forth above are incorporated herein by this reference. Capitalized terms used in this First Amendment and not otherwise defined herein shall have the respective meanings set forth in the Lease.

2.         Expansion .

(a)         Addition of Expansion Space .    Effective as of the Expansion Space Commencement Date (as defined below), the Original Premises is increased by the addition of the Expansion Space, and the Original Premises and the Expansion Space, collectively, shall be deemed the “Premises,” as defined in the Lease. The term for the Expansion Space (the “ Expansion Term ”) shall commence on the Expansion Space Commencement Date (as defined below) and end on the Expiration Date (as the same may be accelerated by the Option to Terminate pursuant to Section 2.13 of the Lease or extended by the First Renewal Term pursuant to Section 2.8 of the Lease). The Expansion Space is subject to all the terms and conditions of the Lease as expressly modified herein.

(b)         Expansion Space Commencement Date .    The “ Expansion Space Commencement Date ” shall be the date on which Landlord delivers exclusive possession of the Expansion Space to Tenant with the Landlord Expansion Work Substantially Complete. Landlord and Tenant hereby agree that the “ Projected Expansion Space Commencement Date ” is September 16, 2008. If, on or before March 10, 2008, Tenant authorizes Landlord to apply funds from the Allowances (as defined in Section 2(e)(ii) below) to procure the items listed on Exhibit C hereto, which items Tenant has been advised by the Contractor (as defined in


the Expansion Workletter) are all those required for the Tenant Expansion Improvements (based on the latest in-process drawings provided by Tenant) that would not otherwise be available in a timely fashion, and if Tenant authorizes Landlord to commence construction of the Expansion Space on or before April 1, 2008, even though subcontractor bids from the Contractor and Landlord’s Estimate (as defined in the Expansion Workletter) will not be in place at that time, then the Projected Expansion Space Commencement Date shall be August 5, 2008.

(i)        If Landlord is delayed in Substantially Completing the Landlord Expansion Work by the Projected Expansion Space Commencement Date as a result of any Tenant Delay, then the Expansion Space Commencement Date shall be accelerated by one (1) day for each day of such Tenant Delay. If Landlord believes a Tenant Delay has occurred, Landlord shall notify Tenant in writing within two (2) business days after the occurrence of the event, action or inaction which constitutes the Tenant Delay and the known or anticipated extent of the Tenant Delay, and Tenant shall have the right within two (2) business days after receipt of such notice to cure the event, action or inaction before such event, action or inaction shall constitute a Tenant Delay; provided, however, that ten (10) business days shall be the maximum number of cure days available to Tenant for the cure of any such event(s), action(s) or inaction(s) constituting a Tenant Delay, after which Tenant shall not be entitled to any further cure periods with respect to Tenant Delays (provided, however, that Landlord shall continue to notify Tenant of the occurrence of any Tenant Delays).

(ii)        Landlord shall provide Tenant with written notice of the date that is twenty-one (21) days prior to the date that Landlord reasonably anticipates that the Landlord Expansion Work will be Substantially Complete. Tenant shall be allowed access into the Expansion Space from and after such date specified by Landlord in such notice for installation of furniture, fixtures, phone and cabling, provided that such early access shall not interfere with the completion of Landlord Expansion Work. Such early entry shall be subject to all the terms and provisions of the Lease, as amended by this First Amendment, except that Tenant shall have no obligation to pay Base Rent, Additional Rent or other charges with respite to the Expansion Space during such early entry period unless Tenant commences business operations in the Expansion Space during such early entry period.

(iii)        Within thirty (30) days following the occurrence of the Expansion Space Commencement Date, Landlord and Tenant shall enter into an agreement (the form of which shall be substantially the same as Rider 1 attached to the Lease) confirming the Expansion Space Commencement Date. If Tenant fails to enter into such agreement (provided the same is accurate), then the Expansion Space Commencement Date shall be the date designated by Landlord in such agreement.

(iv)        For purposes of incorporation from the Lease into this First Amendment, in the term “Substantially Complete” or “Substantial Completion”, and in the term “Tenant Delay”, (1) “Landlord Expansion Work” shall be substituted for “Landlord Work”, (2) “Expansion Space” shall be substituted for “Premises”, (3) “Expansion Workletter” shall be substituted for “Workletter”, and (4) “Projected Expansion Space Commencement Date” shall be substituted for “Projected Commencement Date.”

(c)         Condition of Expansion Space .    Tenant shall notify Landlord in writing within thirty (30) days after the later of Substantial Completion of the Landlord Expansion Work or Landlord’s delivery of possession of the Expansion Space of any “punch list items” with

 

2


respect to the Landlord Expansion Work or any patent defects claimed by Tenant in the materials or workmanship furnished by Landlord in completing the Landlord Expansion Work. Landlord shall proceed diligently to correct the items stated in such notice (and shall use commercially reasonable efforts to complete the correction of such items within thirty (30) days, to the extent such work can reasonably be accomplished within thirty (30) days). If Landlord disputes the existence of any such items, the decision of the Architect (as defined in the Expansion Workletter) shall be final and binding on the premises, and Landlord shall proceed promptly after the decision of the Architect to correct such items in accordance with the immediately preceding sentence. No agreement of Landlord to alter, remodel, decorate, clean or improve the Expansion Space or the Real Property and no representation regarding the condition of the Expansion Space or the Real Property in connection with Tenant’s occupancy of the Expansion Space has been made by or on behalf of Landlord to Tenant, except as may be specifically stated in this First Amendment or in the Expansion Workletter. Notwithstanding the foregoing, Landlord shall deliver the Expansion Space to Tenant in “broom clean” condition and with all Building systems in good working order.

(d)          Failure to Give Possession of Expansion Space .

(i)        If Landlord is unable to deliver possession of the Expansion Space by the Projected Expansion Space Commencement Date by reason of the following: (A) despite Landlord’s commercially reasonable efforts in pursuing the same, the Landlord Expansion Work is not Substantially Complete, or (B) for any other reason beyond Landlord’s reasonable control, then Landlord shall not be subject to any liability for the failure to give possession by the Projected Expansion Space Commencement Date, and such failure to deliver possession by the Projected Expansion Space Commencement Date shall not affect the validity of this First Amendment or the obligations of Tenant hereunder. In the event of any dispute as to whether the Landlord Expansion Work is Substantially Complete, such dispute will be subject to resolution pursuant to the arbitration provision of Section 6 of the Expansion Workletter.

(ii)        Notwithstanding the foregoing, if the Expansion Space Commencement Date (as determined pursuant to Section 2(b) above) has not occurred on or before the date that is thirty (30) days after the Projected Expansion Space Commencement Date (as such Projected Expansion Space Commencement Date shall be extended on a day-for-day basis for each day that the Expansion Space Commencement Date is delayed as a consequence of any events of Force Majeure [including delay in securing all necessary permits and building inspections within normal time frames for projects comparable to the Tenant Expansion Improvements, provided Landlord uses commercially reasonable efforts to expedite such matters] or Tenant Delay), except as otherwise set forth in the next succeeding paragraph, as its sole remedy for such late delivery of the Expansion Space (so long as Landlord has continued to use commercially reasonable efforts to pursue completion of the Tenant Expansion Improvements in the Expansion Space), shall receive one (1) day of abatement of Monthly Base Rent with respect to the Expansion Space for each day between such thirtieth (30th) day after such Projected Expansion Space Commencement Date (subject to the extension specified above) and the actual Expansion Space Commencement Date, such Monthly Base Rent abatement to be applied to the first month(s) of Monthly Base Rent with respect to the Expansion Space payable under this First Amendment, as specified in Section 2(f) below.

 

3


(iii)        Notwithstanding the foregoing, if the Expansion Space Commencement Date (as determined pursuant to Section 2(b) above) has not occurred on or before the date that is one hundred eighty (180) days after the Projected Expansion Space Commencement Date (as such Projected Expansion Space Commencement Date is extended on a day-for-day basis for each day that the Expansion Space Commencement Date is delayed as a consequence of any events of Force Majeure or Tenant Delay), then Tenant shall have the right to terminate this First Amendment at any time thereafter upon ten (10) days’ written notice to Landlord, in which case this First Amendment shall terminate as of the tenth (10th) after Landlord’s receipt of such written notice from Tenant unless the Expansion Space Commencement Date has occurred on or before such tenth (10th) day after Landlord’s receipt thereof; and in the event this First Amendment so terminates, any monies or deposits previously paid or delivered by Tenant to Landlord with respect to the Expansion Space shall be promptly returned to Tenant, and neither party shall have any further obligations or liabilities hereunder.

(e)          Landlord Expansion Work .    Landlord’s construction of improvements in the Expansion Space (the “ Landlord Expansion Work ”) shall be governed by the “ Expansion Workletter ” attached hereto as Exhibit B . Landlord’s insurance, indemnity, ADA and restoration obligations under the Lease with respect to the “Landlord Work” are hereby modified to mean and include the Landlord Expansion Work, in addition to the Landlord Work. In addition, Section 25.8(ii)(a) of the Lease is hereby modified to include the Landlord Expansion Work, the Expansion Allowance and the Additional Expansion Allowance, in addition to the Landlord Work, the Basic Tenant Improvement Allowance and the Additional Tenant Improvement Allowance.

(i)         Expansion Allowance .    Landlord shall provide an “ Expansion Allowance ” with respect to the Expansion Space that will be an amount to be determined by multiplying the Basic Tenant Improvement Allowance ($125.00 per rentable square foot) by a fraction, the numerator of which is the number of months (including the financial portion of a month) from the Expansion Space Commencement Date to the stated Expiration Date of the Lease, and the denominator of which is 120. For example, if the Commencement Date for the Lease is May 1, 2008, and the Expansion Space Commencement Date is August 1, 2008 (three months later), the Expansion Allowance would be determined by multiplying $125.00 by 117/120, which would result in the Expansion Allowance being $121.87 per rentable square foot of the Expansion Space.

(ii)         Additional Expansion Allowance .    In addition to the Expansion Allowance specified in Section 2(e)(i) above, Landlord shall provide an additional allowance (the “ Additional Expansion Allowance ”) to Tenant for the construction of Tenant Expansion Improvements (as defined in the Expansion Workletter) in an amount equal to (A) $522,000.00 ( i.e. , $25.00 per rentable square foot of the Expansion Space), multiplied by (B) a fraction, the numerator of which is the number of months (including the financial option of a partial month) from the Expansion Space Commencement Date to the stated Expiration Date of the Lease, and the numerator of which is 120. The Expansion Allowance and the Additional Expansion Allowance are sometimes referred to collectively herein as the “ Allowances ”.

(iii)        The amount of the Additional Expansion Allowance funded by Landlord pursuant to Section 2(e)(ii) above shall be amortized in equal monthly installments

 

4


payable by Tenant over the Expansion Term in the same manner, and at the same annual interest rate, as set forth in Section l.l(17) of the Lease with respect to the Additional Tenant Improvement Allowance, with such monthly payments to commence on the Expansion Space Commencement Date.

(iv)        To the extent that Tenant does not utilize the full amount of the Allowances on construction of the Tenant Expansion Improvements, the remainder of the Allowances shall be applied, at Tenant’s option (A) to the Tenant Improvement Costs with respect to the Original Premises, or (B) against ( i.e. , in reduction of) the amount of the Additional Tenant Improvement Allowance utilized by Tenant for the Original Premises (and the Additional Tenant Improvement Allowance Monthly Payments shall be reduced accordingly), with the balance of such unused amount of the Allowances, if any, to be credited, in equal monthly installments (without interest) over the three (3) year period following the Expansion Space Commencement Date, against the Monthly Base Rent owing under the Lease.

(v)        Section 2.13(d) of the Lease is hereby modified to add that in the event Tenant properly exercises the Termination Option, Tenant shall have no obligation to pay to Landlord the unamortized balance of the Additional Expansion Allowance, if any.

(f)          Rent .

(i)        The Monthly Base Rent for the Expansion Space shall be the per square foot rate applicable to the Original Premises during the Term as specified in Section 1.1(8) of the Lease, except that: (A) during the period from Expansion Space Commencement Date until the end of the Reduced Base Rent Proration Period (as defined in Section 2.10(b)(i) of the Lease), the Monthly Base Rent for the Expansion Space shall be $1.74 per rentable square foot of the Expansion Space, and (B) if the Reduced Base Rent Proration Period ends prior to the end of the first Lease Year, the Monthly Base Rent for the Expansion Space for the balance of the first Lease Year shall be $3.47 per rentable square foot of the Expansion Space.

(ii)        The terms of Section l.l(8) of the Lease regarding Deferred Base Rent shall not apply to the Expansion Space.

(g)         Additional Security Deposit .    Tenant has delivered to Landlord the sum of $217,360.80 in cash or a Letter of Credit, which has been added to and become part of the Security Deposit held by Landlord under the terms of the Lease. Accordingly, the Security Deposit has been increased to $953,254.11.

(h)         Parking .    Section l.l(13) of the Lease is hereby amended to reflect the addition of the Expansion Space (the Premises therefore consisting of 91,571 rentable square feet as of the Effective Date), so that Tenant may use: (i) up to an additional two (2) spaces per 1,000 rentable square feet of the Expansion Space ( i.e. , 42 spaces based on 20,880 rentable square feet), for a total, combined with the 142 spaces based on the Original Premises, of 184 parking spaces in the Building garage (174 unreserved, 10 reserved), and (ii) up to an additional one (1) space per 1,000 rentable square feet of the Expansion Space ( i.e. , 21 spaces based on 20,880 rentable square feet), for a total, combined with the 71 spaces based on the Original Premises, of 92 unreserved parking spaces at the Offsite Parking, all under the same terms and conditions set

 

5


forth in the Lease with respect to the parking spaces for the Original Premises (including, without limitation, the same discounted rates set forth in Section 2.7 of the Lease).

(i)         Tenant Alterations; Surrender .    “Tenant Alterations”, as defined in the Lease, is hereby modified to exclude therefrom the Landlord Expansion Work, in addition to the Landlord Work. In addition, the fourth sentence of Section 12.1 of the Lease is hereby modified to add that Tenant shall have no obligation to remove any Landlord Expansion Work (including the Tenant Expansion Improvements).

3.         Authority .    This First Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns. Each party hereto and the persons signing below warrant that the person signing below on such party’s behalf is authorized to do so and to bind such party to the terms of this First Amendment.

4.         Intentionally Omitted .

5.         Entire Agreement; No Amendment .    This First Amendment and the exhibits attached hereto constitute the entire agreement and understanding between the parties with respect to the subject of this First Amendment and shall supersede all prior written and oral agreements concerning this subject matter. This First Amendment may not be amended, modified or otherwise exchanged in any respect whatsoever except by a writing duly executed by authorized representatives of Landlord and Tenant.

6.         Status of Lease .    Except as amended by this First Amendment, the Lease remains unchanged and, as amended by this First Amendment, the Lease is in full force and effect.

7.         No Lender Consent Required .    Landlord and Tenant hereby acknowledge and agree that, pursuant to the terms of that certain Subordination, Attornment and Non-Disturbance Agreement dated as of August 28, 2007 between Landlord, Tenant and Comerica Bank, as agent for the lenders (“ Beneficiary ”), and recorded on September 13, 2007, as Instrument No. 2007-329927 in the Official Records of Alameda County, California, Beneficiary’s consent is not required for this First Amendment. Landlord hereby represents and warrants to Tenant that as of the Effective Date: (i) Beneficiary is the only Mortgagee, and (ii) there is no ground or underlying lease of the Real Property.

(signatures appear on following page)

 

6


IN WITNESS WHEREOF, the undersigned have duly executed this First Amendment as of the date first above written.

 

TENANT:

   

LANDLORD:

AMYRIS BIOTECHNOLOGIES, INC.

a California corporation

   

ES EAST ASSOCIATES, LLC.

a California limited liability company

By:

 

/s/ Tamara L. Tompkins

   

By:    

 

/s/ Richard Robbins

Print Name:

 

Tamara L. Tompkins                                

   

Richard K. Robbins

Its:    

 

General Counsel                                                 

     

  Managing Member

By:

 

/s/ John Melo

     

Print Name:

 

_ John Melo                                                     

     

Its:    

 

Chief Executive Officer

     

 

7


EXHIBIT A

EXPANSION SPACE

(see attached)


LOGO


EXHIBIT B

EXPANSION WORKLETTER

1.         Defined Terms .    Capitalized Terms used in this Expansion Workletter (this “ Workletter ”) shall have the same meanings set forth in the Lease (as amended by the First Amendment to Lease) except as otherwise specified herein and except for terms capitalized in the ordinary course of punctuation. For purposes of this Workletter, the following capitalized terms have the following meanings:

1.1.        “ Landlord Expansion Work ” means the construction and installation of the Tenant Expansion Improvements.

1.2        “ Design Documents ” means the layout plans and specifications for the real property improvements to be constructed by Landlord in the Expansion Space which are the final product of the preliminary space planning and which (i) will be based upon, among other things, the preliminary space plan, attached to this Workletter as Schedule 1 (the “ Space Plan ”); and (ii) comply with all Law as applicable and as interpreted at the time of construction of the Tenant Expansion Improvements, including, all building codes and the ADA.

1.3        “ Construction Drawings ” means the final architectural plans and specifications, and engineering plans and specifications, for the real property improvements to be constructed by Landlord in the Expansion Space in sufficient detail to be submitted for governmental approvals and building permits and to serve as the detailed construction drawings and specifications for the contractor, and shall be based upon and consistent with the Design Documents.

1.4        “ Tenant Expansion Improvements ” means all real property improvements to be constructed by Landlord in the Expansion Space as shown on the Construction Drawings, as they may be modified as provided herein.

1.5        “ Allowances ” means, collectively, the Expansion Allowance specified in Section 2(e)(i) of the First Amendment and the Additional Expansion Allowance specified in Section 2(e)(ii) of the First Amendment.

2          Design Matters .

2.1.        Landlord and Tenant have approved Dowler Grumman Architects, as architect (“ Architect ”), and Randall Lamb Associates as the mechanical, electrical and plumbing engineer (“ Engineer ”). The Architect and Engineer shall be referred to collectively herein as the “ Design Group ”.

2.2        Tenant shall work with the Design Group to complete and deliver the Design Documents and Construction Drawings to Landlord by no later than March 24, 2008. Failure by Tenant to deliver to Landlord the Design Documents and Construction Drawings by such date shall constitute a Tenant Delay. Within ten (10) business days after receipt of the Design Documents and the Construction Drawings, Landlord shall deliver written notice Tenant of either Landlord’s approval of the Design Documents and the Construction Drawings or


Landlord’s reasonable disapproval thereof (including the possibility that such drawings are incomplete and therefore not sufficient from which to construct the Tenant Expansion Improvements), in which event Landlord’s notice shall specify the reasonable changes that must be made to the Design Documents or the Construction Drawings as a condition of Landlord’s approval. If Landlord delivers notice of disapproval, within five (5) business days after Tenant’s receipt thereof Tenant shall deliver a revised set of Design Documents and Construction Drawings to Landlord which shall incorporate the changes specified in Landlord’s notice of disapproval. Landlord shall provide final written approval of the revised Design Documents and Construction Drawings within five (5) business days after receipt thereof The final Construction Drawings submitted by Tenant to Landlord and approved by Landlord pursuant to this Section 2.2 shall be referred to herein as the “ Approved Construction Drawings .”

2.3        Tenant shall be responsible for the suitability for the Tenant’s needs and business of the design and function of all Tenant Expansion Improvements.

3.         Construction; Landlord’s Contribution; Tenant Expansion Improvement Costs .

3.1.         Construction; Landlord’s Contribution .    Landlord and Tenant hereby agree that Landlord shall engage DPR Construction Inc. (“ Contractor ”) as the general contractor for the construction of the Tenant Expansion Improvements. Within five (5) days after Landlord and Tenant have agreed upon the Approved Construction Drawings pursuant to Section 2.2 above, Landlord shall cause the Contractor to obtain bids for the construction of the Tenant Expansion Improvements from subcontractors under the supervision of Landlord. Within five (5) days following receipt of such bids from the subcontractors, Landlord and Tenant shall review the bids and agree upon the subcontractors for the Tenant Expansion Improvements. Within five (5) days following selection of the subcontractors, Landlord shall also prepare and deliver to Tenant a nonbinding preliminary estimate (“ Landlord’s Estimate ”) of the Tenant Expansion Improvement Costs (defined below) based upon the foregoing bids and including the cost elements described in Section 3.2 below. Tenant shall review and provide written approval of Landlord’s Estimate within five (5) business days after receipt thereof. Landlord shall use commercially reasonable efforts to cause Contractor to complete the construction of the Tenant Expansion Improvements in a good and workmanlike manner and in accordance with the Approved Construction Drawings, up to a maximum cost to Landlord of the Allowances (subject to Sections 4(a) and 4(c) below).

3.2.         Tenant Expansion Improvement Costs .    The cost of the Tenant Expansion Improvements (“ Tenant Expansion Improvement Costs ”) which Landlord is obligated to pay shall not exceed the cumulative amount of the Allowances. The Allowances shall include:

(a)        The costs of the Design Group and any other consultants retained by Landlord and approved in writing by Tenant in connection with the preparation of Design Documents and Constructions Drawings, and engineering costs associated with completion of the State of California energy utilization calculations under Title 24 legislation;

(b)        All costs of obtaining from the City of Emeryville and any other governmental authority, approvals, building permits and occupancy permits with respect to the Tenant Expansion Improvements;

 

2


(c)        All costs of interior design and finish schedule plans and specifications including as-built drawings with respect to the Tenant Expansion Improvements;

(d)        All costs of procuring, installing and constructing the Tenant Expansion Improvements, including: (i) the cost of all on-site supervisory and administrative staff, office, equipment and temporary services rendered or provided by Contractor in connection with construction of the Tenant Expansion Improvements; and (ii) the cost of any services or utilities made available by Landlord;

(e)        Without limiting the generality of the foregoing, the Tenant Expansion Improvement Costs include all costs of designing, procuring, constructing and installing Tenant Expansion Improvements in compliance with Law as applicable and as interpreted at the time of construction of the Tenant Expansion Improvements, including with all building codes and the ADA;

(f)        All fees payable to the Design Group if it is required by Tenant to redesign any portion of the Tenant Expansion Improvements following Tenant’s delivery to Landlord of the Approved Construction Drawings, and all costs in connection with any approved Change Order in accordance with the provisions of this Workletter;

(g)        The costs and expenses of the construction manager retained by Tenant;

(h)        The cost of any supplementary air cooling systems or units installed in or to serve the Expansion Space; and

(i)        The cost of any solar panels installed in connection with the Tenant Expansion Improvements.

In no event shall the Tenant Expansion Improvement Costs include, (i), except as set forth in Sections 3.2(h) and 3.2(i) above, any costs of procuring or installing in the Expansion Space any trade fixtures, equipment, furniture, furnishings, telephone equipment, cabling for any of the foregoing, or other personal property (“ Personal Property ”) to be used in the Expansion Space by Tenant, and the cost of such Personal Property shall be paid by Tenant, (ii) any costs or expenses of any consultants retained by Tenant with respect to design, procurement, installation or construction of improvements or installations, whether real or personal property, for the Expansion Space, other than those of Tenant’s construction manager, or (iii) any construction management, administration or supervision fee to Landlord, with Landlord hereby acknowledging that it shall not be entitled to any such fee in connection with the Landlord Expansion Work.

3.3.         Limitations of Landlord’s Obligations .    Upon Substantial Completion of the Tenant Expansion Improvements, Landlord shall have no further obligation to construct improvements or construct modifications to or changes in the Tenant Expansion Improvements, except to complete the punchlist of Landlord Expansion Work remaining to be completed or correct any part not in compliance with the Approved Construction Drawings and any approved modifications thereof, as provided in Section 2(c) of the First Amendment.

 

3


4.         Costs of Tenant Expansion Improvements in Excess of Allowances .

(a) The positive difference, if any, between (i) the Landlord’s Estimate approved by Tenant, and (ii) the cumulative total of the Allowances (the “ Tenant Expansion TI Contribution ”) shall be paid in accordance with this Section 4. Tenant may defer payment of the Tenant Expansion TI Contribution pursuant to Section 4(c) below. In the event the Landlord’s Estimate approved by Tenant exceeds the cumulative total of the Allowances, Tenant shall accompany its approval of the Landlord’s Estimate with a good check made payable to the order of Landlord in the amount of such positive difference, and such funds shall be applied to the Tenant Expansion Improvements Costs before the Expansion Allowance or the Additional Expansion Allowance.

(b)        Tenant may, pursuant to the provisions of this Workletter, request a Change Order (defined below) to the Approved Construction Drawings to reduce or delete all or part of the anticipated Tenant Expansion TI Contribution.

(c)        At the option of Tenant, instead of paying the Tenant Expansion TI Contribution pursuant to Section 4(a) above, commencing upon Tenant’s approval of the Landlord’s Estimate, Tenant shall pay, on a monthly basis, the Tenant Expansion TI Contribution pro-rata as the Tenant Expansion Improvement Costs are incurred in connection with construction of the Tenant Expansion Improvements ( i.e. , payments of the Tenant Expansion TI Contribution shall be made in proportion to the Tenant Expansion TI Contribution divided by the overall Tenant Expansion Improvement Costs). By way of illustration of the foregoing, if (A) the Landlord’s Estimate approved by Tenant for the Tenant Expansion Improvements is $175.00 per rentable square foot of the Expansion Space, then after subtracting the Expansion Allowance (assume $125.00 per rentable square foot for purposes of this example), and subtracting the Additional Expansion Allowance (assume $25.00 per rentable square foot for purposes of this example), the Tenant Expansion TI Contribution will be $25.00 per rentable square foot of the Expansion Space; then (B) Tenant shall pay 14.29% ( i.e. , 25/175) of the Tenant Expansion Improvement Costs incurred on a monthly basis, beginning upon Tenant’s approval of the Landlord’s Estimate.

(d)        Upon Substantial Completion of the Tenant Expansion Improvements and completion of the items, if any, described in Section 2(c) of the First Amendment, Landlord will determine the actual costs of the Tenant Expansion Improvements (excluding any costs covered under contractor warranty to correct defects in materials or workmanship in the Tenant Expansion Improvements) and shall reconcile the actual costs of the Tenant Expansion Improvements with Landlord’s Estimate. If the Tenant Expansion TI Contribution is less than the amount owed by Tenant pursuant to such reconciliation, Tenant shall promptly pay the difference to Landlord. If the Tenant Expansion TI Contribution is more than the amount owed by Tenant pursuant to such reconciliation, Landlord shall immediately remit 100% of the difference to Tenant.

5.         Changes .    If Tenant shall request any change, addition or alteration in the Approved Construction Drawings, Landlord, within five (5) business days after receipt of such request, shall give Tenant a written estimate of (a) the cost of engineering and design services and the construction contractor services to prepare a change order (the “ Change Order ”) in

 

4


accordance with such request, (b) the cost of work to be performed pursuant to such Change Order, and (c) the time delay expected because of such requested Change Order. Within three (3) business days following Tenant’s receipt of the foregoing written estimate, Tenant shall notify Landlord in writing whether it approves such written estimate. If Tenant approves such written estimate and if such cost would cause the Tenant Expansion Improvement Costs to exceed the cumulative total of the Allowances, then the amount of the estimated cost so approved by Tenant shall be paid in accordance with Sections 4(a) and 4(c) above. If such written authorization, and check if required pursuant to Section 4(a), are not received by Landlord within such three (3) business day period, Landlord shall not be obligated to prepare the Change Order or perform any work in connection therewith. Upon completion of the work of the Change Order and submission of the final cost thereof by Landlord to Tenant, any such additional amounts in excess of the cumulative total of the Allowances shall be paid in accordance with Sections 4(a) and 4(c) above.

6.         Dispute Resolution .    If Substantial Completion of the Tenant Expansion Improvements in the Expansion Space is delayed beyond the Projected Expansion Space Commencement Date due to Tenant Delay (defined in the Lease, as incorporated into the First Amendment with respect to the Expansion Space pursuant to Section 2(b)(iv) of the First Amendment), the provisions of Section 2(b) of the First Amendment shall apply. Landlord’s failure to supply information, estimates, authorizations or approvals within the applicable time periods specified in this Workletter shall not constitute a Tenant Delay and shall not otherwise affect the Projected Expansion Space Commencement Date. In the event of any dispute between Landlord and Tenant regarding (i) the occurrence or alleged occurrence, or the duration, of any Tenant Delay or Force Majeure, (ii) the determination of the Expansion Space Commencement Date pursuant to Section 2(b) of the First Amendment, or (iii) Substantial Completion of the Tenant Expansion Improvements, the parties agree to attempt to resolve such dispute promptly and in good faith; provided, however, that if the parties are unable to resolve such dispute within ten (10) days after such dispute arises, the parties shall retain an independent third party architect familiar with the construction in the vicinity of the Project of tenant improvements similar in nature to the Tenant Expansion Improvements, to arbitrate such dispute. Such third party arbitrator shall have the authority to make a final and binding resolution of such dispute, and the parties shall share equally the fees and charges of such arbitrator.

7.         Entry by Tenant .    Tenant may enter the Expansion Space during construction of the Tenant Expansion Improvements and prior to the Expansion Space Commencement Date in accordance with Section 2(b) of the First Amendment.

8.         Force and Effect .    The terms and conditions of this Workletter supplement the First Amendment and shall be construed to be a part of the First Amendment and are incorporated in the First Amendment. Without limiting the generality of the foregoing, any default by any party hereunder shall have the same force and effect as a default under the Lease. Should any inconsistency arise between this Workletter and the Lease (as amended by the First Amendment), as to the specific matters that are the subject of this Workletter, the terms and conditions of this Workletter shall control.

 

5


9.         Representatives of Parties .

(a)        Landlord has designated Geoffrey Sears as its sole representative with respect to the matters set forth in this Workletter, who, until further written notice to Tenant shall have full authority and responsibility to act on behalf of Landlord as required in this Workletter.

(b)        Tenant has designated Rick Campbell as its sole representative with respect to the matters set forth in this Workletter, who, until further written notice to Landlord, shall have full authority and responsibility to act on behalf of Tenant as required in this Workletter.

 

6


SCHEDULE 1 to Exhibit B

SPACE PLAN

(see attached)


LOGO


EXHIBIT C

EARLY PROCUREMENT ITEMS

Critical Milestones to make 4/1/08 start of construction

 

 

1.

100% CD document issued by 3/20/08

 

2.

City inspection by 4/21/08

 

3.

Long lead procurement starting 3/10/08 - long lead material/equipment specified for Phase II that is also used for Phase I will be released without submittal approval. Submittal will be issued for record.

 

 

Light fixtures - finalize quantity, fixture types by 3/7/08

 

 

Fan coil units - finalize mechanical equipment schedule by 3/7/08

 

 

VAV/EAV boxes - finalize mechanical equipment schedule by 3/7/08

 

 

Any welded HM frames - finalize door schedule, hardware specification by 3/7/08

 

 

Electrical panels - finalize electrical panel count by 3/7/08

 

 

FSD - finalize quantity, size by 3/7/08

Exhibit 10.19

SECOND AMENDMENT TO LEASE

THIS SECOND AMENDMENT TO LEASE (the “ Second Amendment ”), dated as of April 25, 2008 (the “ Effective Date ”), is entered into by and between ES EAST ASSOCIATES, LLC, a California limited liability company (“ Landlord ”), and AMYRIS BIOTECHNOLOGIES, INC., a California corporation (“ Tenant ”), with reference to the following facts:

A.        Landlord and Tenant entered into that certain Lease dated as of August 22, 2007 (the “ Original Lease ”), with respect to those certain premises described therein containing a total of 70,691 rentable square feet (the “ Original Premises ”), consisting of Suite 100 on the first (1st) floor and Suite 200 on the second (2nd) floor of the building commonly known as EmeryStation East, located at 5885 Hollis Street, Emeryville, California (the “ Building ”).

B.        Landlord and Tenant entered into that certain First Amendment to Lease dated as of March 10, 2008 (the “ First Amendment ”), pursuant to which the Original Premises was expanded to add that certain space containing 20,880 rentable square feet located on the second (2nd) floor of the Building (the “ Expansion Space ”), on the terms and conditions set forth in the First Amendment.

C.        The Original Premises, as expanded by the Expansion Space, is referred to collectively herein as the “ Premises ”. The Original Lease, as amended by the First Amendment, is referred to collectively herein as the “ Lease ”.

D.        Concurrent with the execution of this Second Amendment, Landlord’s affiliate (EmeryStation Triangle, LLC) and Tenant are entering into that certain Lease of even date herewith (the “ Triangle Lease ”), with respect to those certain premises containing 16,638 rentable square feet, located across the street from the Building and the Premises, and having the address of 5850 Hollis Street, Emeryville, California.

E.        As a condition of Tenant and Landlord’s affiliate entering into the Triangle Lease, Landlord and Tenant shall amend the Lease as provided for hereinbelow.

NOW, THEREFORE, in consideration of the mutual covenants set forth herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:

1.         Incorporation of Recitals; Defined Terms . Recitals A, B, C, D and E set forth above are incorporated herein by this reference. Capitalized terms used in this Second Amendment and not otherwise defined herein shall have the respective meanings set forth in the Lease.

2.         Cross Default . Section 11.1 of the Lease shall be amended as follows:

(a)        In Section 11.1(7), the period shall be replaced with a semicolon. The word “or” shall be deleted from the end of Section 11.1(6) of the Lease, and reinserted at the end of Section 11.1(7) after the semicolon.

 

1


(b)        The following provision shall be inserted following Section 11.1(7) of the Lease:

(8)        So long as the then-landlord under the Lease dated as of April 25, 2008 between Tenant and EmeryStation Triangle, LLC, an affiliate of Landlord, for premises containing 16,638 rentable square feet (as such premises may change over time) located at 5850 Hollis Street in Emeryville, CA, the building across the street from the Premises (the “Triangle Lease”), is an affiliate of the then-Landlord under this Lease, Tenant is in Default (beyond any applicable cure period set forth therein) under the Triangle Lease.

3.         Authority . This Second Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns. Each party hereto and the persons signing below warrant that the person signing below on such party’s behalf is authorized to do so and to bind such party to the terms of this Second Amendment.

4.         Entire Agreement; No Amendment . This Second Amendment constitutes the entire agreement and understanding between the parties with respect to the subject of this Second Amendment and shall supersede all prior written and oral agreements concerning this subject matter. This Second Amendment may not be amended, modified or otherwise changed in any respect whatsoever except by a writing duly executed by authorized representatives of Landlord and Tenant.

5.         Status of Lease . Except as amended by this Second Amendment, the Lease remains unchanged and, as amended by this Second Amendment, the Lease is in full force and effect.

(signatures on following page)

 

2


IN WITNESS WHEREOF, the undersigned have duly executed this Second Amendment as of the date first above written.

 

TENANT:     LANDLORD:

AMYRIS BIOTECHNOLOGIES, INC.,

a California corporation

   

ES EAST ASSOCIATES, LLC,

a California limited liability company

By:   /s/ John G. Melo     By:       /s/ Richard Robbins
Print Name: John G. Melo       Richard K. Robbins
Its: Chief Executive Officer       Managing Member
By:   /s/ Tamara L. Tompkins      
Print Name: Tamara L. Tompkins      
Its: Secretary and General Counsel      

 

3

Exhibit 10.20

THIRD AMENDMENT TO LEASE

THIS THIRD AMENDMENT TO LEASE (the “ Third Amendment ”), dated as of July 31, 2008 (the “ Effective Date ”), is entered into by and between ES EAST ASSOCIATES, LLC, a California limited liability company (“ Landlord ”), and AMYRIS BIOTECHNOLOGIES, INC., a California corporation (“ Tenant ”), with reference to the following facts:

A.        Landlord and Tenant entered into that certain Lease dated as of August 22, 2007 (the “ Original Lease ”), as amended by that certain First Amendment to Lease dated as of March 10, 2008 (the “ First Amendment ”) and that certain Second Amendment to Lease dated as of April 25, 2008 (the “ Second Amendment ”) (the Original Lease, as amended by the First Amendment and Second Amendment is referred to herein as the “ Lease ”), pursuant to which Landlord leases to Tenant space currently containing approximately 91,571 rentable square feet comprised of the Original Premises and the Expansion Space (the Original Premises and the Expansion Space are collectively referred to herein as the “ Premises ”) comprised of Suite Number 100 on the first (1st) floor and Suite Number(s) 200 and 250 on second (2nd) floor of the building commonly known as EmeryStation East, located at 5885 Hollis Street, Emeryville, California (the “ Building ”).

B.        Pursuant to the terms and conditions set forth in the Lease (including the Workletter attached as Exhibit B to the Original Lease, and the Expansion Workletter attached as Exhibit B to the First Amendment), Landlord has made available or is obligated to make available o Tenant the Tenant Improvement Allowance, Additional Tenant Improvement Allowance, Expansion Allowance, and Additional Expansion Allowance (collectively, the “ Build-Out Allowance ”) in connection with the construction of the Tenant Improvements (as defined in the Original Lease) and the Tenant Expansion Improvements (as defined in the First Amendment) in the Premises (collectively, the “ Tenant Improvements ”).

C.        Tenant has requested additional funding from Landlord to finance the costs to construct Tenant Improvements in the Premises, and Landlord agrees to provide such additional funding, pursuant to the terms and conditions set forth in this Third Amendment.

NOW, THEREFORE, in consideration of the mutual covenants set forth herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:

1.         Incorporation of Recitals; Defined Terms . Recitals A, B, and C set forth above are incorporated herein by this reference. Capitalized terms used in this Third Amendment and not otherwise defined herein shall have the respective meanings set forth in the Lease.

2.         Third Amendment Allowance . Landlord shall provide to Tenant the additional amount of up to One Million Dollars ($1,000,000) (the “ Third Amendment Allowance ”) to pay for the Tenant Improvements in the Premises, which Third Amendment Allowance shall be disbursed by Landlord in accordance with the terms of the Lease.

(a)         Repayment . The amount of the Third Amendment Allowance funded by Landlord shall be amortized in equal monthly installments payable by Tenant over the number of

 

1


months in the period commencing on the first day of the first full calendar month after the Expansion Space Commencement Date and ending on the last day of the last full calendar month prior to the date that would be the Termination Effective Date if Tenant were to exercise the Termination Option pursuant to Section 2.13 of the Original Lease (as subsequently amended in the First Amendment) (the “ Third Amendment Allowance Amortization Period ”), at an annual interest rate of 9.5%, compounded monthly, with such monthly payments to commence on the first day of the first calendar month following the Expansion Space Commencement Date and continuing on the first day of each month thereafter during the Third Amendment Allowance Amoritzation Period (such monthly amortization payments being referred to herein as the “ Third Amendment Allowance Monthly Amortization Payments ”). The Monthly Base Rent owing under the Lease shall be increased by such Third Amendment Allowance Monthly Amortization Payments.

(b)         Other Lease Modifications .

(i)        References to “Monthly Base Rent” and “Rent” in Sections 1.1(8) and 1.3 of the Original Lease shall be amended to include the Third Amendment Allowance Monthly Amortization Payments. The terms of Section 1.1(8) of the Original Lease with respect to the Deferred Base Rent shall not apply to the Third Amendment Allowance Monthly Amortization Payments.

(ii)        In the “Excess Rent” provision contained in Section 10.3 of the Original Lease, subsection (i) of such Section 10.3 is hereby deleted in its entirety and replaced with the following: “(i) that portion of the Monthly Base Rent, Rent Adjustments, Additional Tenant Improvement Allowance Monthly Payments, and monthly payments with respect to the Additional Expansion Allowance pursuant to Section 2(e)(iii) of the First Amendment to Lease due under this Lease for said month which is allocable to the space sublet or assigned (excluding, however, any Deferred Rent Loan Payments and Third Amendment Allowance Monthly Amortization Payments);”.

(iii)        Sections 14.3, 15.1, and 15.2 of the Original Lease with respect to the abatement and/or reduction of Rent shall not apply to the Third Amendment Allowance Monthly Amortization Payments.

(iv)        If (x) for any reason, including but not limited to Landlord’s exercise of its Recapture Right set forth in Section 10.2 of the Original Lease, the Termination Date occurs earlier than the scheduled Expiration Date set forth in Section 1.1(7) of the Original Lease, and (y) Tenant has not yet paid in full the Third Amendment Allowance, then the unamortized balance of the Third Amendment Allowance shall immediately become due and payable as of the Termination Date.

(v)        Section 25.8(ii)(a) of the Original Lease, as previously modified by the First Amendment, is further modified to mean and include the Third Amendment Allowance.

3.         Stock and Stock Warrants . As soon as practicable after the execution of this Third Amendment:

 

2


(a)        Tenant shall offer to Landlord (or its qualified affiliates and/or designees approved by Tenant) the right to purchase, in its sole and absolute discretion, anytime before August 15, 2008, up to 9,897 shares of Series B-1 Preferred Stock of Tenant (“ Stock Shares ”) at the Series B-1 offering price (namely $25.26 per share); and

(b)        Subject to and conditioned upon Landlord’s delivery to Tenant of (i) a copy of the Consent executed by Beneficiary, or (ii) the Evidence of No Mortgages, as appropriate, as provided in Section 7 hereto, Tenant shall deliver to Landlord stock warrants (“ Warrants ”) granting Landlord the right to purchase, in its sole and absolute discretion, any time before an Initial Public Offering (“ IPO ”) of stock shares of Tenant (the timing of such IPO Tenant will provide Landlord, its permitted assignees or transferees reasonable advance notice of) up to 2,009 shares of Tenant’s Series B-1 Preferred Stock at the Series B-1 offering price. The right to purchase such Stock Shares, or the Stock Shares and/or Warrants themselves, shall be, subject to customary restrictions including securities laws and restrictions to which other shareholders of Tenant are similarly bound, transferable by Landlord to one or more individuals and/or entities designated by Landlord from time to time. Landlord shall notify Tenant of such transfer, and Tenant shall cooperate to effect any such permitted transfer and record such transfer in Tenant’s books and records.

4.         Authority . This Third Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns. Each party hereto and the persons signing below warrant that the person signing below on such party’s behalf is authorized to do so and to bind such party to the terms of this Third Amendment.

5.         Entire Agreement; No Amendment . This Third Amendment constitutes the entire agreement and understanding between the parties with respect to the subject of this Third Amendment and shall supersede all prior written and oral agreements concerning this subject matter. This Third Amendment may not be amended, modified or otherwise changed in any respect whatsoever except by a writing duly executed by authorized representatives of Landlord and Tenant.

6.         Status of Lease . Except as amended by this Third Amendment, the Lease remains unchanged and, as amended by this Third Amendment, the Lease is in full force and effect.

7.         Consent of Lender . The effectiveness of this Third Amendment is conditioned upon (i) Comerica Bank (“ Beneficiary ”) consenting in writing to this Third Amendment by executing the Consent, in the form attached hereto or such other form as is reasonably acceptable to Tenant (“the “ Consent ”), in accordance with the terms of that certain Subordination, Attornment and Non-Disturbance Agreement dated as of August 28, 2007 by and among Beneficiary, Landlord and Tenant and recorded on September 13, 2007 as Instrument No. 2009-329927 in the Official Records of Alameda County, California (the “ SNDA ”), or (ii) Landlord delivering to Tenant: (a) a conformed copy of the full reconveyance of the Deed of Trust described in the SNDA, as recorded in the Official Records of Alameda County, California, (b) a current title commitment for the Real Property issued by Chicago Title Company or another reputable title company evidencing that there are no deeds of trust or mortgages encumbering the Real Property, and (e) a written representation and warranty from Landlord that there is currently no ground or underlying lease or mortgage or deed of trust encumbering the Real Property

 

3


(collectively, the “ Evidence of No Mortgages ”). Landlord shall use commercially reasonable efforts to obtain the Consent or to deliver the Evidence of No Mortgages, as appropriate, as soon as possible after the mutual execution of this Third Amendment.

IN WITNESS WHEREOF, the undersigned have duly executed this Third Amendment as of the date first above written.

 

TENANT:

   

LANDLORD:

AMYRIS BIOTECHNOLOGIES, INC.,

a California corporation

   

ES EAST ASSOCIATES, LLC,

a California limited liability company

By:

 

/s/ Tamara L. Tompkins

   

By:    

 

/s/ Richard Robbins

Print Name: Tamara L. Tompkins

     

Richard K. Robbins

Its:        General Counsel

     

Managing Member

By:

 

/s/ Kinkead Reiling

     

Print Name: Kinkead Reiling

     

Its:        SVP Corp Devel

     

 

4


CONSENT OF BENEFICIARY

In accordance with the terms of that certain Subordination, Attornment and Non-Disturbance Agreement dated as of August 28, 2007 by and among the undersigned, as beneficiary (“Beneficiary”), ES East Associates, LLC, as owner (“Landlord”), and Amyris Biotechnologies, Inc., as tenant (“Tenant”), and recorded on September 13, 2007 as Instrument No. 2009-329927 in the Official Records of Alameda County, California (the “SNDA”), Beneficiary hereby consents to the entering into of the foregoing Third Amendment to Lease dated as of July              , 2008 between Landlord and Tenant. Beneficiary agrees that nothing set forth in the SNDA shall alter or reduce the rights of Tenant to receive any undisbursed portion of the Third Amendment Allowance (as defined in the foregoing Third Amendment to Lease).

 

BENEFICIARY:

 

COMERICA BANK,

as Agent

By:

   

Name:

   

Title:

   

Date:                                               , 2008

Exhibit 10.21

FOURTH AMENDMENT TO LEASE

THIS FOURTH AMENDMENT TO LEASE (this “ Fourth Amendment ”), dated as of November 14, 2009 (the “ Effective Date ”), is entered into by and between ES EAST, LLC, a California limited liability company (“ Landlord ”), and AMYRIS BIOTECHNOLOGIES, INC., a California corporation (“ Tenant ”), with reference to the following facts:

A.        Landlord (as successor in interest to ES East Associates, LLC) and Tenant are parties to that certain Lease dated as of August 22, 2007 (the “ Original Lease ”), as amended by that certain First Amendment to Lease dated as of March 10, 2008 (the “ First Amendment ”), that certain Second Amendment to Lease dated as of April 25, 2008 (the “ Second Amendment ”), that certain Third Amendment to Lease dated as of July 31, 2008 (the “ Third Amendment ”), and that certain Commencement Date Agreement dated October 14, 2008 (the “ Commencement Date Agreement ”) (the Original Lease, as amended by the First Amendment, the Second Amendment, the Third Amendment and the Commencement Date Agreement, is referred to herein as the “ Lease ”).

B.        Pursuant to the Original Lease, Landlord leased to Tenant space containing approximately 70,691 rentable square feet (the “ Original Premises ”) described as Suite Number 100 on the first (1st) floor and Suite Number 200 on second (2nd) floor of the building commonly known as EmeryStation East, located at 5885 Hollis Street, Emeryville, California (the “ Building ”). Pursuant to the First Amendment, Landlord leased to Tenant certain additional space containing approximately 20,880 rentable square feet (the “ Expansion Space ”) described as Suite Number 250 on the second (2nd) floor of the Building. The Expansion Space has been built out for use as general office and administrative space.

C.        The Commencement Date of the Term of the Lease with respect to the Original Premises was May 5, 2008, and the Commencement Date of the Term of the Lease with respect to the Expansion Space was September 16, 2008. The initial ten (10) year Term of the Lease is scheduled to expire on May 31, 2018 (with respect to both the Original Premises and the Expansion Space). Tenant has a Renewal Option to renew the Lease for one (1), five (5) year Renewal Term, as provided for in Section 2.8 of the Original Lease. Tenant also has a Termination Option to terminate the Lease effective as of May 31, 2013 (the “ Termination Effective Date ”), as provided for in Section 2.13 of the Original Lease.

D.        Tenant does not currently need the Expansion Space and is willing to give Landlord the right to recapture the Expansion Space and remove the Expansion Space from the Premises covered by the Lease for one or more periods described herein on the terms and conditions described herein. In connection therewith, the parties desire to amend various other provisions of the Lease, including, without limitation, making certain adjustments to the Monthly Base Rent owing by Tenant to Landlord under the Lease.

NOW, THEREFORE, in consideration of the above recitals, which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant agree as follows:


1.         Incorporation of Recitals; Defined Terms . Recitals A, B, C and D set forth above are incorporated herein by this reference. Capitalized terms used in this Fourth Amendment and not otherwise defined herein shall have the respective meanings set forth in the Lease.

2.         Landlord’s Recapture of Expansion Space . Landlord shall have the right to recapture the Expansion Space and remove the Expansion Space from the Premises covered by the Lease for the period(s) and on the terms and conditions specified hereinbelow (“ Landlord’s Recapture Right ”). In the event that Landlord elects to exercise such Landlord’s Recapture Right, Landlord shall notify Tenant in writing of such election on or before December 31, 2009 (“ Landlord’s Recapture Election Notice ”). If Landlord so notifies Tenant of Landlord’s exercise of Landlord’s Recapture Right, the terms and conditions specified hereinbelow shall apply. If Landlord fails to so notify Tenant of Landlord’s exercise of Landlord’s Recapture Right, such right shall expire, in which case this Fourth Amendment and the terms and conditions provided for herein shall be of no further force and effect.

(a)         Recapture Periods . In the event that Landlord timely exercises Landlord’s Recapture Right, the Expansion Space shall be recaptured by Landlord and removed from the Premises covered by the Lease for the following period(s) (each, a “ Recapture Period ,” and collectively, the “ Recapture Periods ”):

(i)         First Recapture Period . The first Recapture Period (“ First Recapture Period ”) shall be the period commencing upon delivery of Landlord’s Recapture Election Notice (provided that Tenant shall have a period of twenty (20) days after Tenant’s receipt of Landlord’s Recapture Election Notice to deliver the Expansion Space to Landlord as provided for in Section 2(c)) and ending on March 31, 2015; provided, however, that Landlord shall have the right to specify a later date for the end of the First Recapture Period by written notice given to Tenant on or before December 31, 2010, which later date for the end of the First Recapture Period shall be the last day of a calendar month in 2015 (after March of 2015), as so specified by Landlord; provided, further, however, that in the event Tenant, in its sole and absolute discretion, exercises the Termination Option provided for in Section 2.13 of the Original Lease, the First Recapture Period shall end on the Termination Effective Date, notwithstanding anything to the contrary set forth in this Section 2(a)(i) or elsewhere in this Fourth Amendment.

(ii)         Second Recapture Period . The second Recapture Period (“ Second Recapture Period ”) shall be the period commencing immediately following the last day of the First Recapture Period and ending on May 31, 2018; provided, however, that the Second Recapture Period shall commence and be in effect only if (1) Landlord timely exercised Landlord’s Recapture Right for the First Recapture Period pursuant to Section 2(a)(i), (2) Tenant did not exercise the Termination Option provided for in Section 2.13 of the Original Lease, and (3) Landlord notifies Tenant in writing not less than one hundred fifty (150) days prior to the expiration of the First Recapture Period that Landlord elects to extend Landlord’s recapture of the Expansion Space for the Second Recapture Period.

(b)         Effect of Landlord’s Recapture . In the event that Landlord timely elects to exercise Landlord’s Recapture Right as provided for above, then, during the First Recapture Period and the Second Recapture Period, if applicable, the Expansion Space shall not be part of

 

2


the Premises covered by the Lease and, except as otherwise expressly provided for in this Section 2(b), Tenant shall not have any obligation or liability under the Lease with respect to the Expansion Space, including, without limitation, the obligation to pay any Monthly Base Rent or Rent Adjustments or any parking charges for or attributable to the Expansion Space for any such Recapture Period. In furtherance of the foregoing, during each Recapture Period that takes effect, Tenant’s Share for purposes of determining Tenant’s Rent Adjustment payments under the Lease and any other applicable terms of the Lease shall be attributable to and determined with respect to the Original Premises only, and shall not include the Expansion Space. Notwithstanding the foregoing, however, (1) Tenant shall continue to be obligated to pay the Monthly Base Rent and Rent Adjustments for or attributable to the Expansion Space through December 31, 2009, regardless of whether the First Recapture Period commences prior to January 1, 2010, and (2) Tenant shall not be relieved of the obligation to pay on a monthly basis the amortization payments owing with respect to the Additional Expansion Allowance as provided for in Section 2(e)(ii) of the First Amendment, which monthly amortization payments are in the amount of $6,693.64, and such obligation shall remain in full force and effect until such obligation has been fully satisfied (subject to the terms of Section 2.13(d) of the Original Lease, as the same was modified in the First Amendment); and, further, nothing herein is intended to or shall affect in any way any of Tenant’s payment obligations arising under the Original Lease with respect to the Original Premises (including, without limitation, Monthly Base Rent, Rent Adjustments, the Deferred Rent Loan or the Additional Tenant Improvement Allowance), or arising under the Third Amendment with respect to the Third Amendment Allowance.

(c)         Tenant’s Delivery of Expansion Space . In the event that Landlord timely exercises Landlord’s Recapture Right, not later than twenty (20) days after Tenant’s receipt of Landlord’s Recapture Election Notice, Tenant shall deliver vacant possession of the Expansion Space to Landlord with all of Tenant’s furniture, fixtures and equipment removed therefrom, broom clean and in good condition and repair, ordinary wear and tear, casualty damage, condemnation, Landlord’s repair obligations and damage caused by Landlord excepted.

(d)         Possession of Expansion Space During Recapture Period(s) . During each Recapture Period, Landlord shall have the right to lease the Expansion Space to one or more third parties. During the Recapture Period(s), Landlord or any such lessee shall have the right to make alterations or modifications to the Expansion Space or portions thereof from time to time that are consistent with general office uses. If during the First Recapture Period Landlord or any such lessee proposes to make alterations or modifications to any portion of the Expansion Space for any use other than general office use, Landlord shall notify Tenant in advance of the nature and extent of such proposed alterations or modifications; and, within ten (10) business days after Tenant’s receipt of such notice, Tenant shall notify Landlord as to whether or not Tenant will require the removal of such non-office use alterations or modifications, and the Expansion Space restored to its condition existing immediately prior to such alterations or modifications, prior to Landlord’s redelivery of the Expansion Space to Tenant upon the expiration of the First Recapture Period in the event that Landlord does not elect to exercise Landlord’s Recapture Right for the Second Recapture Period (with Landlord to have no obligation to remove or restore any such non-office alterations or modifications that Tenant did not designate for removal and restoration at the time of Landlord’s original notice thereof to Tenant). Landlord shall indemnify, protect, defend and hold the Tenant Indemnitees harmless against any and all actions,

 

3


claims, demands, liability, costs and expenses, including reasonable attorneys’ fees and expenses for the defense thereof, to the extent arising from Landlord’s or any lessee’s occupancy of the Expansion Space during any Recapture Period, from the undertaking by Landlord or any lessee of any alterations, modifications or repairs to the Expansion Space during any Recapture Period, from the conduct of any lessee’s business in the Expansion Space, or from any willful act or negligence of Landlord or any lessee, or their respective agents, contractors or employees, in, on or about the Expansion Space.

(e)        Expiration of First Recapture Period; Termination of Renewal Option .

(i)         First Recapture Period . In the event that Landlord timely exercises Landlord’s Recapture Right as provided for above, and if Landlord has the right, but does not thereafter elect, to extend Landlord’s recapture of the Expansion Space for the Second Recapture Period, then upon the expiration of the First Recapture Period, the Expansion Space shall be delivered to Tenant in accordance with the terms of Section 2(e)(iii) and shall again become part of the Premises covered by the Lease, and Tenant shall again be entitled to the use and occupancy thereof (including, without limitation, the parking rights set forth in Section 2(h) of the First Amendment) subject to and in accordance with the terms and conditions of the Lease for the balance of the Term (and the Renewal Term, if applicable); provided, however, notwithstanding anything to the contrary set forth in the Lease or this Fourth Amendment, upon the expiration or earlier termination of the Lease, Tenant’s restoration obligations under the Lease shall not include removal of, and Tenant shall not have the obligation to remove, any alterations or modifications made by Landlord or any lessee to the Expansion Space or portions thereof, nor shall Tenant have any obligation to restore the Expansion Space to its condition existing prior to any such alterations or modifications. In such case, the Monthly Base Rent for the Expansion Space shall again be the per square foot rate applicable to the Original Premises for the balance of the Term as specified in Section 1.1(8) of the Original Lease; and Tenant shall again be liable for Rent Adjustment payments attributable to the Expansion Space for the balance of the Term (and the Renewal Term, if applicable). In the event that Landlord timely exercises Landlord’s Recapture Right as provided for above, and the First Recapture Period ends on the Termination Effective Date, then, notwithstanding anything to the contrary set forth in the Lease or this Fourth Amendment, Tenant shall have no surrender obligations whatsoever with respect to the Expansion Space upon the Termination Effective Date.

(ii)         Second Recapture Period . In the event that Landlord has the right, and timely elects, to extend Landlord’s recapture of the Expansion Space for the Second Recapture Period, then, notwithstanding anything to the contrary set forth in the Lease or this Fourth Amendment, Tenant shall have no surrender obligations whatsoever with respect to the Expansion Space.

(iii)         Landlord’s Delivery of Expansion Space . In the event that the Expansion Space is to be delivered to Tenant upon the expiration of the First Recapture Period in accordance with the terms of Section 2(e)(i), Landlord shall deliver vacant possession of the Expansion Space, including any alterations or modifications thereto made by Landlord or any lessee thereof during the First Recapture Period that Landlord was not required to remove pursuant to the terms of Section 2(d), to Tenant broom clean and in good condition and repair, ordinary wear and tear excepted, and with all alterations or modifications thereto made by

 

4


Landlord or any lessee thereof during the First Recapture Period that Landlord was required to remove pursuant to the terms of Section 2(d) removed and the Expansion Space restored to its condition existing immediately prior to such alterations or modifications; provided, however, that if Landlord is unable to deliver possession of the Expansion Space upon the expiration of the First Recapture Period for any reason, then Landlord shall not be subject to any liability for the failure to so deliver the Expansion Space to Tenant, and in such case, the First Recapture Period shall be deemed to be extended until such time as Landlord is able to deliver vacant possession of the Expansion Space to Tenant in accordance with this Section 2(e)(iii); provided further, however, (i) in no event shall Tenant have any obligation to pay any increases in Monthly Base Rent pursuant to Section 2(f) below during any such extended First Recapture Period, and (ii) in the event Landlord fails to deliver the Expansion Space to Tenant within sixty (60) days after the expiration of the First Recapture Period, Tenant shall thereafter have the right to terminate the Lease with respect to the Expansion Space by written notice thereof to Landlord.

(iv)         Termination of Renewal Option re Expansion Space . If Landlord has the right, and timely elects, to extend Landlord’s recapture of the Expansion Space for the Second Recapture Period, then upon Landlord’s exercise of Landlord’s Recapture Right for the Second Recapture Period, the Renewal Option shall no longer include the Expansion Space and the Expansion Space shall be deleted therefrom and shall not be part of the Premises that is included in or subject to the Renewal Option.

(f)         Original Premises — Monthly Base Rent Increases During Recapture Periods . Landlord and Tenant acknowledge that the annual periods for the increases in Monthly Base Rent provided for in Section 1.1(8) of the Original Lease commence June 1 of each Lease Year and terminate May 31. In consideration of the fact that Tenant shall be relieved of the obligation to pay Monthly Base Rent for the Expansion Space during each Recapture Period that takes effect hereunder (subject to clause (1) of the last sentence of Section 2(b) with regard to the First Recapture Period), Monthly Base Rent owing under the Lease for the Original Premises shall be increased as provided below for each such Recapture Period.

(i)         First Recapture Period . Starting January 1, 2010, and thereafter throughout the First Recapture Period, Monthly Base Rent for the Original Premises shall be increased by the following amounts for the following time periods (and the schedule of Monthly Base Rent set forth in Section 1.1(8) of the Original Lease is hereby amended accordingly):

 

Period

   Amount of Monthly Base Rent
Increase for Original Premises*

1/1/2010 - 5/31/2010

   $64,414.80

6/1/2010 - 5/31/2011

   $66,711.60

6/1/2011 - 5/31/2012

   $69,008.40

6/1/2012 - 5/31/2013

   $71,305.20

6/1/2013 - 5/31/2014 (if applicable)

   $73,810.80

6/1/2014 - End of First Recapture Period

   $76,316.40

(if applicable)

  

* For each of the above periods, the amount of the Monthly Base Rent increase for the Original Premises reflects the difference between (a) the per rentable square foot Monthly Base Rent rate

 

5


for the Expansion Space that would otherwise have been payable under Section 1.1(8) of the Lease with respect to the Expansion Space during such period, less (b) $0.485 per rentable square foot, with $0.485 per rentable square foot being the difference between (1) $2.25 per rentable square foot ( i.e. , Landlord’s and Tenant’s good faith estimate of the full service market rental rate per rentable square foot of the Expansion Space for the Expansion Space during such period), less (2) $1.765 per rentable square foot ( i.e. , the sum of (A) $1.54 per rentable square foot ( i.e. , Landlord’s and Tenant’s good faith estimate of the per rentable square foot Rent Adjustment rate for the Expansion Space during such period), plus (B) $0.225 per rentable square foot ( i.e. , Landlord’s and Tenant’s good faith estimate of the aggregate per rentable square foot rate for janitorial expenses and individually-measured and billed electricity expenses that would have been payable by Tenant under the Lease for the Expansion Space during such period).

For example: For the month of May 2010, the Monthly Base Rent for the Original Premises pursuant to the schedule of Monthly Base Rent set forth in Section 1.1(8) of the Original Lease is $252,656.70. In the event that Landlord timely exercises Landlord’s Recapture Right as provided for above, the Monthly Base Rent for the Original Premises for the month of May 2010, would increase by the amount of $64,414.80 ( i.e. , $3.085 per rentable square foot [$3.57 per rentable square foot less $0.485 per rentable square foot] times 20,880 rentable square feet) from $252,656.70 (as provided in Section 1.1(8) of the Original Lease) to a total amount of $317,071.50.

(ii)         Second Recapture Period — Defined Terms . For purposes of determining the amount by which the Monthly Base Rent for the Original Premises will be increased during the Second Recapture Period (if applicable), the following terms shall have the meanings set forth below:

(A)         Fair Market Rent - Full Service . The term “ Monthly Fair Market Rent - Full Service ” shall mean the per square foot per month rental rate determined on a “full service” basis (as opposed to a “NNN” rental rate) for office space (and without regard to any non-office use alterations or modifications to the Expansion Space or any portions thereof made by Landlord or any lessee thereof in accordance with Section 2(d)) comparable in size, location and quality of the Expansion Space under primary lease (and not sublease) to new or renewing tenants, for a term comparable to the Second Recapture Period, in comparable buildings in Emeryville or Berkeley, California; provided, however, that the Fair Market Rent -Full Service for the Expansion Space for the Second Recapture Period shall not be less than $2.25 or greater than $3.23 per square foot per month. The procedure for determining the Monthly Fair Market Rent - Full Service shall be consistent with the procedures for determining Fair Market Rent for the Premises for the Renewal Term as provided for in Section 2.8 of the Original Lease, except that (x) Landlord’s notice to Tenant of Landlord’s determination of the Monthly Fair Market Rent - Full Service shall be given to Tenant not less than sixty (60) days prior to the commencement of the Second Recapture Period and Tenant shall have ten (10) days within which to provide Landlord with the Binding Notice or the Arbitration Notice, (y) if the parties are unable to agree upon the Monthly Fair Market Rent - Full Service within five (5) days after Landlord’s receipt of an Arbitration Notice, the Monthly Fair Market Rent - Full Service shall be determined pursuant to the arbitration process provided for in Section 2.8(e) of the Original Lease, and (z) the overall time period for the conduct of such arbitration process shall

 

6


be reduced to a total of thirty (30) days and the interim time periods for each step provided in Section 2.8(e) shall be correspondingly reduced to fit within such 30 day period.

(B)         Monthly NNN Expense Factor . The term “ Monthly NNN Expense Factor ” shall mean the per square foot per month cost of Operating Expenses and Taxes for the Building as reasonably determined by Landlord based upon Landlord’s good faith estimate of the annual Operating Expenses and Taxes for the Building for the twelve month period following the date of determination thereof.

(C)         Monthly Base Rent Increase Amount . The term “ Monthly Base Rent Increase Amount ” shall mean (y) the per square foot amount equal to the Monthly Fair Market Rent - Full Service minus the Monthly NNN Expense Factor, multiplied by (z) 20,880 ( i.e. , the rentable square footage of the Expansion Space).

(iii)         Second Recapture Period Monthly Base Rent Increase . In the event that Landlord has the right, and timely elects, to extend Landlord’s recapture of the Expansion Space for the Second Recapture Period, then during the Second Recapture Period, the Monthly Base Rent for the Original Premises shall be increased by the Monthly Base Rent Increase Amount determined on the basis of the Fair Market Rent - Full Service for the Expansion Space for the Second Recapture Period as provided for in Section 2(1)(ii)(A) above and the Monthly NNN Expense Factor determined as of the commencement of the Second Recapture Period as provided for in Section 2(f)(ii)(B) above.

(g)         Parking . During any Recapture Period, the number of parking spaces that Tenant may use shall be as specified in Section 1.1(13) of the Original Lease; and the terms of Section 2(h) of the First Amendment regarding Parking (including, without limitation, any parking charges associated with the parking spaces allocated to the Expansion Space thereunder) shall not apply during any Recapture Period.

(h)         Tenant’s Exercise of Termination Option . Nothing set forth in this Fourth Amendment shall restrict, or is intended to restrict, Tenant’s exercise, in its sole and absolute discretion, of the Termination Option provided for in Section 2.13 of the Original Lease. In the event Tenant exercises the Termination Option provided for in Section 2.13 of the Original Lease, then, regardless of whether the Expansion Space is then subject to recapture pursuant to the terms of this Fourth Amendment, such termination shall be effective as to both the Original Premises and the Expansion Space on the Termination Effective Date ( i.e. , May 31, 2013), and the Termination Fee shall be a total amount of $11,629,517 ( i.e. , $127 per rentable square foot times 91,571 rentable square feet), which Termination Fee shall be payable as provided in said Section 2.13 of the Original Lease.

3.         Authority . This Fourth Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns. Each party hereto and the persons signing below warrant that the person signing below on such party’s behalf is authorized to do so and to bind such party to the terms of this Fourth Amendment.

4.         Entire Agreement; No Amendment . This Fourth Amendment constitutes the entire agreement and understanding between the parties with respect to the subject of this Fourth

 

7


Amendment and shall supersede all prior written and oral agreements concerning this subject matter. This Fourth Amendment may not be amended, modified or otherwise changed in any respect whatsoever except by a writing duly executed by authorized representatives of Landlord and Tenant.

5.         Status of Lease . Except as amended by this Fourth Amendment, the Lease remains unchanged and, as amended by this Fourth Amendment, the Lease is in full force and effect.

6.         No Ground or Underlying Lease; Consent of Lender . Landlord hereby represents and warrants to Tenant that as of the Effective Date there is no ground or underlying lease of the Real Property. The effectiveness of this Fourth Amendment is conditioned upon Principal Life Insurance Company (“ Lender ”), as Lender under that certain Subordination, Non-Disturbance and Attornment Agreement dated as of October 31, 2008 executed by and among Landlord, Tenant and Lender, and recorded on October 31, 2008 as Instrument No. 2008-320952 in the Official Records of Alameda County, California (the “SNDA”), consenting in writing to this Fourth Amendment by executing the Consent of Lender in the form attached hereto, or such other form as is reasonably acceptable to Tenant, or alternatively, an email or letter from Lender to Landlord to the effect that Lender’s consent is not required for this Fourth Amendment and that Lender will be bound by this Fourth Amendment in the event of foreclosure of the Mortgage described in the SNDA or conveyance in lieu thereof (the “ Consent ”). Landlord shall use commercially reasonable efforts to obtain the Consent as soon as reasonably possible after the Effective Date. In the event that, despite such commercially reasonable efforts by Landlord, Landlord has not obtained the Consent by the date that Landlord would otherwise deliver Landlord’s Recapture Election Notice, Landlord shall nevertheless have the right to deliver Landlord’s Recapture Election Notice, and the Expansion Space shall be recaptured by Landlord in accordance with the terms of this Fourth Amendment; provided, however, that notwithstanding anything to the contrary set forth in this Fourth Amendment, Tenant shall have no obligation to pay any increase in Monthly Base Rent as contemplated in Section 2(f) of this Fourth Amendment unless and until the Consent has been obtained.

(signatures on following page)

 

8


IN WITNESS WHEREOF, the undersigned have duly executed this Fourth Amendment, on the date(s) set forth below, effective as of the Effective Date.

 

TENANT:

   

LANDLORD:

AMYRIS BIOTECHNOLOGIES, INC.,

a California corporation

   

ES EAST, LLC,

a California limited liability company

   

By:  

 

ES EAST ASSOCIATES, LLC,

By:  

 

/s/ John G. Melo

     

a California limited liability company

Print Name:_ John G. Melo                                         

   

Its:

 

Managing Member

Its:

 

_ Chief Executive Officer                                      

     

By:  

 

/s/ Tamara L. Tompkins

     

By:

 

/s/ Richard Robbins

Print Name: Tamara L. Tompkins                            

        Richard K. Robbins

Its:     General Counsel and Secretary                    

     

Its:

  Managing Member

Date:

         

      Date:

   

 

9


CONSENT OF LENDER

The undersigned, Principal Life Insurance Company (“Lender”), the Lender under that certain Subordination, Non-Disturbance and Attornment Agreement dated as of October 31, 2008 executed by and among ES East, LLC (“Landlord”), Amyris Biotechnologies, Inc. (“Tenant”), and Lender, and recorded on October 31, 2008 as Instrument No. 2008-320952 in the Official Records of Alameda County, California, hereby consents to the entering into of the foregoing Fourth Amendment to Lease dated as of November          , 2009 between Landlord and Tenant.

 

LENDER:

PRINCIPAL LIFE INSURANCE COMPANY,

an Iowa corporation

By:

 

Principal Real Estate Investors, LLC,
a Delaware limited liability company,
its authorized signatory

 

By:

   
 

Name:

   
 

Its:

   

Date:                                                   , 2009

Exhibit 10.22

LEASE

BETWEEN

EMERYSTATION TRIANGLE, LLC (LANDLORD)

AND

AMYRIS BIOTECHNOLOGIES, INC. (TENANT)

5850 HOLLIS STREET

Emeryville, California


TABLE OF CONTENTS

 

          Page

ARTICLE 1

  

BASIC LEASE PROVISIONS

   1

1.1  

  

BASIC LEASE PROVISIONS

   1

1.2  

  

ENUMERATION OF EXHIBITS AND RIDER

   4

1.3  

  

DEFINITIONS

   4

ARTICLE 2

  

PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING

   9

2.1  

  

LEASE OF PREMISES

   9

2.2  

  

TERM

   10

2.3  

  

FAILURE TO GIVE POSSESSION

   11

2.4  

  

CONDITION OF PREMISES

   11

2.5  

  

PARKING

   11

2.6  

  

RENEWAL OPTION

   12

2.7  

  

EXPANSION RIGHT

   14

2.8  

  

EXPANSION PREMISES RIGHT OF FIRST OFFER

   17

ARTICLE 3

  

RENT

   18

3.1  

  

PAYMENT OF RENT

   18

ARTICLE 4

  

RENT ADJUSTMENTS AND PAYMENTS

   18

4.1  

  

RENT ADJUSTMENTS

   18

4.2  

  

STATEMENT OF LANDLORD

   19

4.3  

  

BOOKS AND RECORDS

   20

4.4  

  

TENANT OR LEASE SPECIFIC TAXES

   20

ARTICLE 5

  

SECURITY DEPOSIT

   21

ARTICLE 6

  

SERVICES

   22

6.1  

  

LANDLORD’S GENERAL SERVICES

   22

6.2  

  

SERVICES

   23

6.3  

  

TELEPHONE SERVICES

   23

6.4  

  

DELAYS IN FURNISHING SERVICES

   24

6.5  

  

CHOICE OF SERVICE PROVIDER

   25

6.6  

  

SIGNAGE

   25

ARTICLE 7

  

POSSESSION, USE AND CONDITION OF PREMISES

   25

7.1  

  

POSSESSION AND USE OF PREMISES

   25


TABLE OF CONTENTS

 

          Page

7.2    

  

LANDLORD ACCESS TO PREMISES; APPROVALS

   36

7.3    

  

QUIET ENJOYMENT

   37

ARTICLE 8

  

MAINTENANCE

   37

8.1    

  

LANDLORD’S MAINTENANCE

   37

8.2    

  

TENANT’S MAINTENANCE

   37

ARTICLE 9

  

ALTERATIONS AND IMPROVEMENTS

   38

9.1    

  

TENANT ALTERATIONS

   38

9.2    

  

LIENS

   40

9.3    

  

EQUIPMENT LEASING AND FINANCING

   40

ARTICLE 10

  

ASSIGNMENT AND SUBLETTING

   40

10.1    

  

ASSIGNMENT AND SUBLETTING

   40

10.2    

  

[INTENTIONALLY OMITTED]

   42

10.3    

  

EXCESS RENT

   42

10.4    

  

TENANT LIABILITY

   42

10.5    

  

ASSUMPTION AND ATTORNMENT

   43

10.6    

  

PROCESSING EXPENSES

   43

ARTICLE 11

  

DEFAULT AND REMEDIES

   43

11.1    

  

EVENTS OF DEFAULT

   43

11.2    

  

LANDLORD’S REMEDIES

   44

11.3    

  

ATTORNEY’S FEES

   46

11.4    

  

BANKRUPTCY

   47

11.5    

  

LANDLORD’S DEFAULT

   47

ARTICLE 12

  

SURRENDER OF PREMISES

   48

12.1    

  

IN GENERAL

   48

12.2    

  

LANDLORD’S RIGHTS

   49

ARTICLE 13

  

HOLDING OVER

   49

ARTICLE 14

  

DAMAGE BY FIRE OR OTHER CASUALTY

   49

14.1    

  

SUBSTANTIAL UNTENANTABILITY

   49

14.2    

  

INSUBSTANTIAL UNTENANTABILITY

   50

14.3    

  

RENT ABATEMENT

   51

 

ii


TABLE OF CONTENTS

 

         

Page

14.4    

  

WAIVER OF STATUTORY REMEDIES

   51

ARTICLE 15

  

EMINENT DOMAIN

   51

15.1    

  

TAKING OF WHOLE OR SUBSTANTIAL PART

   51

15.2    

  

TAKING OF PART

   51

15.3    

  

COMPENSATION

   52

ARTICLE 16

  

INSURANCE

   52

16.1    

  

TENANT’S INSURANCE

   52

16.2    

  

FORM OF POLICIES

   53

16.3    

  

LANDLORD’S INSURANCE

   53

16.4    

  

WAIVER OF SUBROGATION

   53

16.5    

  

NOTICE OF CASUALTY

   54

ARTICLE 17

  

WAIVER OF CLAIMS AND INDEMNITY

   55

17.1    

  

WAIVER OF CLAIMS

   55

17.2    

  

INDEMNITY BY TENANT

   55

17.3    

  

INDEMNITY BY LANDLORD

   56

ARTICLE 18

  

RULES AND REGULATIONS

   56

18.1    

  

RULES

   56

18.2    

  

ENFORCEMENT

   56

ARTICLE 19

  

LANDLORD’S RESERVED RIGHTS

   56

ARTICLE 20

  

ESTOPPEL CERTIFICATES AND FINANCIAL STATEMENTS

   57

20.1    

  

IN GENERAL

   57

20.2    

  

ENFORCEMENT

   58

ARTICLE 21

  

RELOCATION OF TENANT

   58

ARTICLE 22

  

REAL ESTATE BROKERS

   58

ARTICLE 23

  

MORTGAGEE PROTECTION

   59

23.1    

  

SUBORDINATION AND AT’TORNMENT

   59

23.2    

  

MORTGAGEE PROTECTION

   60

ARTICLE 24

  

NOTICES

   60

ARTICLE 25

  

MISCELLANEOUS

   61

25.1    

  

LATE CHARGES

   61

 

iii


TABLE OF CONTENTS

 

          Page

25.2

  

NO JURY TRIAL; VENUE; JURISDICTION

   61

25.3

  

DISCRIMINATION

   62

25.4

  

OPTION

   62

25.5

  

AUTHORITY

   62

25.6

  

ENTIRE AGREEMENT

   62

25.7

  

MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE

   62

25.8

  

EXCULPATION

   62

25.9

  

ACCORD AND SATISFACTION

   63

25.10

  

LANDLORD’S OBLIGATIONS ON SALE OF BUILDING

   63

25.11

  

BINDING EFFECT

   63

25.12

  

CAPTIONS

   63

25.13

  

TIME; APPLICABLE LAW; CONSTRUCTION

   64

2514

  

ABANDONMENT

   64

25.15

  

LANDLORD’S RIGHT TO PERFORM TENANT’S DUTIES

   64

25.16

  

SECURITY SYSTEM

   64

25.17

  

NO LIGHT, AIR OR VIEW EASEMENTS

   65

25.18

  

RECORDATION

   65

25.19

  

SURVIVAL

   65

25.20

  

RIDERS

   65

 

iv


LEASE

ARTICLE 1

BASIC LEASE PROVISIONS

 

1.1

BASIC LEASE PROVISIONS

In the event of any conflict between these Basic Lease Provisions and any other Lease provision, such other Lease provision shall control.

(1)      BUILDING AND ADDRESS:

5850 Hollis Street

Emeryville, California 94608

(2)      LANDLORD AND ADDRESS:

EmeryStation Triangle, LLC

1120 Nye Street, Suite 400

San Rafael, California 94901

(3)      TENANT AND CURRENT ADDRESS:

 

 

(a)

Name: Amyris Biotechnologies, Inc.

 

 

(b)

State of incorporation: California

Notices to Tenant shall be addressed:

Prior to the Commencement Date:

Amyris Biotechnologies, Inc.

5980 Horton Street, Suite 350

Emeryville, California 94608

Attention: General Counsel

On and after the Commencement Date:

Amyris Biotechnologies, Inc.

Suite 100, EmeryStation East

5885 Hollis Street

Emeryville, California 94608

Attention: General Counsel

(4)      DATE OF LEASE:     as of April 25, 2008

(5)      LEASE TERM: Approximately ten (10) years, subject to extension as provided herein, and subject to the definition of “Expiration Date” below.

 

1


(6)        PROJECTED COMMENCEMENT DATE:   No later than May 16, 2008

(7)        EXPIRATION DATE:   The last day of the 120th full calendar month following the Commencement Date (as defined in Section 2.2(a)).

(8)        MONTHLY BASE RENT:   (Based on 16,638 RSF)

 

PERIOD

 

  

MONTHLY BASE RENT            

 

  

RATE/RSF

 

Months 1 - 12*

   $20,464.74    $1.23

Months 13-24

   $21,795.78    $1.31

Months 25-36

   $23,126.82    $1.39

Months 37-48

   $24,457.86    $1.47

Months 49-60

   $25,788.90    $1.55

Months 61-72

   $27,119.94    $1.63

Months 73-84

   $28,450.98    $1.71

Months 85-96

   $29,782.02    $1.79

Months 97-108

   $31,113.06    $1.87

Month 109 -

Expiration Date        

 

   $32,444.10    $1.95

In addition to the Monthly Base Rent amounts indicated above, commencing on the Commencement Date (as defined in Section 2.2(a)) Tenant shall pay an additional fixed amount of $2,000.20 per month each month during the initial Term of the Lease until such time, if any, that Tenant both: a) exercises its Expansion Right described in Section 2.7 hereof, and b) has waived its Expansion Premises Termination Right described in Section 2.7(f) hereof, after which time Tenant shall no longer have any obligation to pay such additional fixed monthly amount.

* These 12-month periods commence on the Commencement Date (as defined in Section 2.2(a)). If the Commencement Date occurs on a date other than the first day of a calendar month, the first 12-month period shall be deemed to include such partial calendar month and the twelve full calendar months thereafter.

The foregoing Monthly Base Rent shall be subject to increase to the extent and as provided for in Section 1.1(16) with respect to the amortization of the Tenant Improvement Allowance.

Commencing on the Commencement Date (as defined in Section 2.2(a)), Tenant shall pay the Monthly Base Rent under the terms set forth in Article 3 and Tenant’s Share of all Operating Expenses and Taxes under the terms set forth in Article 4.

(9)        RENTABLE AREA OF THE PREMISES:   16,638 rentable square feet, on the first (1st) floor of the Building

 

2


(10)        SUITE NUMBERS:   1353 and 1355 (59th Street)

(11)        SECURITY DEPOSIT:   $79,363.26, subject to the provisions of Article 5

(12)        TENANT’S USE OF PREMISES:   General office, warehouse, laboratory and research and development, with associated administration, including but not limited to, operation and administration of a fermentation research pilot plant. In no event shall Tenant’s use of the Premises violate the Conditions of Approval contained in any Conditional Use Permit (“CUP”) granted by the City of Emeryville to Tenant. Any and all costs associated with Tenant complying with the conditions of such a CUP shall be Tenant’s sole expense.

(13)        PARKING:

(A)     Subject to Section 2.7 below, sixteen (16) unreserved parking spaces in the EmeryStation East project (5885 Hollis Street).

(14)        [INTENTIONALLY DELETED]

(15)        BROKERS:

Tenant’s Broker:

Aegis Realty Partners

130 Webster Street

Oakland, California 94607

(16)        TENANT IMPROVEMENT ALLOWANCE:   Landlord shall provide a tenant improvement allowance to Tenant (the “Tenant Improvement Allowance”) pursuant to Section 4.2 of the Workletter. In no event shall the Tenant Improvement Allowance exceed a maximum of $249,570.00 ( i.e. , $15.00 per rentable square foot of the Premises).

The amount of the Tenant Improvement Allowance funded by Landlord shall be amortized in equal monthly installments payable by Tenant over the initial Term of the Lease, at an annual interest rate of 9.5%, compounded monthly, with such monthly payments to commence on the date the Tenant Improvement Allowance is funded by Landlord and continuing on the first day of each month thereafter during the initial Term of the Lease; and the Monthly Base Rent owing hereunder shall be increased by the amount of such monthly amortization payments due hereunder (such monthly amortization payments being referred to herein as the “Tenant Improvement Allowance Monthly Payments”). For example, if the Tenant Improvement Allowance funded by Landlord is $249,570.00, and the date of said funding is four months after the Commencement Date such that the remaining length under the initial Term is 116 months, then, in addition to the Monthly Base Rent amount specified in Section 1.1(8) above, Tenant would owe a Tenant Improvement Allowance Monthly Payment equal to $3,298.29 per month during the initial Term of the Lease.

 

3


1.2

ENUMERATION OF EXHIBITS AND RIDER

The Exhibits and Rider set forth below and attached to this Lease are incorporated in this Lease by this reference:

 

EXHIBIT A:

  

Plan of Premises

EXHIBIT A-1:

  

Plan of Expansion Premises

EXHIBIT B:

  

Workletter Agreement

EXHIBIT C-1:

  

Laboratory Rules and Regulations

EXHIBIT C-2:

  

Rules and Regulations

RIDER 1:

  

Commencement Date Agreement

RIDER 2:

  

Form of Letter of Credit

 

1.3

DEFINITIONS

For purposes hereof, the following terms shall have the following meanings:

AFFILIATE:   Any corporation or other business entity that is owned or controlled by, owns or controls, or is under common ownership or control with Tenant.

BUILDING:   The building located at the address specified in Section 1.1(1). The Building may include warehouse, laboratory, office, and research and development uses.

COMMENCEMENT DATE:   The date specified in Section 2.2.

COMMON AREAS:   All areas of the Project made available by Landlord from time to time for the general common use or benefit of the tenants of the Building, and their employees and invitees, or the public, as such areas currently exist and as they may be changed from time to time.

DECORATION WORK:   Tenant Alterations which do not require a building permit and which do not involve any of the structural elements of the Building, or any of the Building’s systems, including its electrical, mechanical, plumbing, security, heating, ventilating, air-conditioning, communication, and fire and life safety systems.

DEFAULT RATE:   Two (2) percentage points above the rate then most recently announced by Bank of America N.T.&S.A. at its San Francisco main office as its base lending reference rate, from time to time announced, but in no event higher than the maximum rate permitted by Law.

EXPIRATION DATE:   The date specified in Section 1.1(7).

FORCE MAJEURE:   Any accident, casualty, act of God, war or civil commotion, strike or labor troubles, or any cause whatsoever beyond the reasonable control of Landlord, including water shortages, energy shortages or governmental preemption in connection with an act of God, a national emergency, or by reason of Law, or by reason of the conditions of supply and demand which have been or are affected by act of God, war or other emergency.

 

4


INDEMNITEES:   Collectively, Landlord, any Mortgagee or ground lessor of the Property, the property manager and the leasing manager for the Property and their respective partners, members, directors, officers and employees.

LAND:   The parcel(s) of real estate on which the Building and Project are located.

LANDLORD DELAY:   Any delay in the design, permitting or construction of the Tenant Improvements or move into the Premises by Tenant which is due solely to (i) Landlord’s failure to furnish information, within Landlord’s possession or control, in accordance with the terms of the Workletter; (ii) unreasonable changes in the Design Documents, Construction Drawings, Construction Contract or Schedule of Values (as such terms are defined in the Workletter) requested by Landlord; (iii) undue interference with the work of the Tenant Improvements by Landlord or Landlord’s agents, contractors, employees, representatives, or consultants, including without limitation, as a result of the performance by Landlord of any work within the Building or the Property; (iv) Landlord’s failure to provide Tenant with access to and/or utilities for the Premises from and after the Commencement Date to which Landlord has the ability to provide such access; and (v) Landlord’s failure to reasonably cooperate with Tenant in connection with obtaining from the City of Emeryville and any other governmental authority, approvals, building permits and occupancy permits.

LAWS OR LAW:   All laws, ordinances, rules, regulations, other requirements, orders, rulings or decisions adopted or made by any governmental body, agency, department or judicial authority having jurisdiction over the Property, the Premises or Tenant’s activities at the Premises and any covenants, conditions or restrictions of record which affect the Property.

LEASE:   This instrument and all exhibits and riders attached hereto.

LEASE YEAR:   The twelve month period beginning on the Commencement Date and each subsequent twelve month, or shorter (if applicable), period until the Expiration Date. The proration of Monthly Base Rent for any such partial calendar month during which the Commencement Date occurs shall be as set forth in Section 3.1.

LETTER OF CREDIT:   An unconditional, irrevocable sight draft letter of credit, drawable in the San Francisco Bay Area, issued by a national bank reasonably satisfactory to Landlord (provided that Landlord hereby approves each of Silicon Valley Bank, Comerica Bank, and UBS as an acceptable issuer of a Letter of Credit), naming Landlord as beneficiary and otherwise in form and substance reasonably satisfactory to Landlord. The Letter of Credit shall be for a one (1) year term and shall provide: (i) that Landlord may make partial and multiple draws thereunder; (ii) that if Tenant fails to pay any Rent due under the Lease after applicable notice and cure periods, if any, with respect to any provision of the Lease, Landlord may at its sole option draw upon the Letter of Credit in an amount sufficient to cure such failure by Tenant, and the bank will honor a sight draft of Landlord accompanied only by a statement of Landlord that it has the right to draw upon the Letter of Credit pursuant to the terms of the Lease or the Tenant has filed a petition of bankruptcy; (iii) that notwithstanding such statement, the bank shall honor such draw without inquiry and the bank shall not have the authority, ability, right or discretion to inquire as to the basis for such statement; (iv) that in the event of Landlord’s assignment or other transfer of its interest in the Lease, the Letter of Credit shall be freely

 

5


transferable by Landlord, one or more times, without charge and without recourse to the Landlord or the assignee or transferee of such interest; (v) that the Letter of Credit is governed by the Uniform Customs and Practice for Documentary Credits (2007 revisions), International Chamber of Commerce Publication No. 600; (vi) that the Letter of Credit will be automatically renewed upon the expiration of its term for additional one (1) year periods, not to extend beyond sixty (60) days after the Expiration Date of the Lease; and (vii) that if the bank does not confirm the extension of the Letter of Credit at least thirty (30) days prior to the relevant annual expiration date or if Tenant does not substitute a replacement Letter of Credit by such date, or if a monetary Default occurs under the Lease, Landlord shall be entitled to draw on the Letter of Credit and to hold and apply such funds as an additional Security Deposit in accordance with the terms of the Lease. A Letter of Credit substantially in the form of Rider 2 attached hereto shall be deemed to satisfy the foregoing requirements.

MONTHLY BASE RENT:   The monthly rent specified in Section 1.1(8), as such amount may be increased pursuant to the terms of Section 1.1(16) hereof.

MORTGAGEE:   Any holder of a mortgage, deed of trust or other security instrument encumbering the Property.

NATIONAL HOLIDAYS:   New Year’s Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and Christmas Day and other holidays recognized by the Landlord and the janitorial and other unions servicing the Building in accordance with their contracts.

OPERATING EXPENSES:   All reasonable costs, expenses and disbursements of every kind and nature which Landlord incurs in connection with the ownership, management, operation, maintenance, replacement and repair of the Building and the Property (including, without limitation, (1) property management fees not to exceed an amount equal to 3.5% of gross revenues of the Property (“Management Fee Cap”); (2) costs and expenses of any capital expenditure or improvement, amortized over the useful life of the applicable capital expenditure or improvement, as reasonably determined by Landlord, together with interest thereon on the unamortized costs at the lower of the rate incurred by Landlord to finance such capital expenditure or improvement or the Default Rate, which capital expenditure or improvement (a) is made to the Property after the Commencement Date in order to comply with Laws enacted after the Commencement Date and which was not required to be made prior to such enactment, or (b) is installed for the purpose of reducing or controlling Operating Expenses; (3) the costs of changing utility service providers; and (4) the cost of operating a fitness center (currently such fitness center is located in the EmeryStation I building) for the benefit of the Project, as reasonably determined by Landlord, Operating Expenses shall not include, (i) costs of alterations of the premises of tenants of the Project, (ii) costs of capital improvements to the Project (except as expressly permitted above in the definition of “Operating Expenses”), (iii) depreciation charges, (iv) interest and principal payments on loans (except for loans for capital improvements which Landlord is allowed to include in Operating Expenses as provided above), (v) ground rental payments, (vi) real estate brokerage and leasing commissions, (vii) advertising and marketing expenses, (viii) costs of Landlord reimbursed by insurance proceeds, (ix) expenses incurred in negotiating leases of tenants in the Project or enforcing lease obligations of tenants in the Project, (x) management fees in excess of the Management Fee Cap, (xi) Landlord’s general corporate overhead, (xii) reserves, (xiii) except for routine monitoring, costs associated with

 

6


mold or any Hazardous Materials which are not the responsibility of Tenant hereunder, (xiv) any costs, fines or penalties incurred due to violations by Landlord of this Lease or any other lease of the Property, or due to the gross negligence or willful misconduct of Landlord or any Indemnitee, (xv) overhead profit increments paid to Landlord’s subsidiaries or affiliates for services on or to the Building or the Property or for supplies or other materials to the extent the cost of the services, supplies or materials exceeds the cost that would have been paid had the services, supplies or materials been provided by unaffiliated parties on a competitive basis (excluding, however, the property management fee, which is subject to the Management Fee Cap), (xvi) the cost of correcting any defect in the design or construction of the Building or the Common Areas, (xvii) costs of repairs (including capital repairs) necessary as a result of a casualty, except for commercially reasonable deductible amounts (if such deductible amounts pertain to capital expenditures, they shall be amortized over the useful life of the item(s) being repaired with interest at the rate specified in clause (2) above, and such amortization amount shall be included as an Operating Expense hereunder), (xviii) damage and repairs covered under any insurance policy carried by, or required to be carried pursuant to this Lease by, Landlord in connection with the Building or the Property, (xix) the cost of any service provided to any tenant (including Tenant) for which Landlord is entitled to reimbursement from such tenant directly and not as an Operating Expense, (xx) the cost of any services provided to other tenants and not provided to Tenant, (xxi) the costs of removal of any or all of the existing parking spaces along Hollis Street and replacement thereof with new streetscape and/or landscape improvements, if Landlord elects to do so in its sole and absolute discretion, and (xxii) the costs of any manor capital improvements to the landscaped area immediately in front of (i.e., north of, along 591 Street) the Premises. If any Operating Expense, though paid in one year, relates to more than one calendar year, at the option of Landlord such expense may be proportionately allocated among such related calendar years. Operating Expenses for the Building that are not, in Landlord’s reasonable discretion, allocable solely to individual tenants of the Building shall be equitably allocated by Landlord among the Building’s tenants.

PREMISES:   The space located in the Building listed in Section 1.1(10) and depicted on Exhibit A attached hereto (as the same may be increased by Tenant’s exercise of the Expansion Right provided for in Section 2.10 below).

PROJECT or PROPERTY:   The Project consists of the warehouse building located at the street address specified in Section 1.1(1) in Emeryville, California, landscaping and improvements, together with the Land, any associated interests in real property, and the personal property, fixtures, machinery, equipment, systems and apparatus located in or used in conjunction with any of the foregoing. The Project may also be referred to as the Property.

REAL PROPERTY:   The Property excluding any personal property.

RENT:   Collectively, Monthly Base Rent, Rent Adjustments, Rent Adjustment Deposits, Tenant Improvement Allowance Monthly Payments, and all other charges, payments, late fees or other amounts required to be paid by Tenant under this Lease.

RENT ADJUSTMENT:   Any amounts owed by Tenant for payment of Operating Expenses or Taxes. The Rent Adjustments shall be determined and paid as provided in Article Four.

 

7


RENT ADJUSTMENT DEPOSIT:   An amount equal to Landlord’s estimate of the Rent Adjustment attributable to each month of the applicable calendar year (or partial calendar year) during the Term. On or before the Commencement Date (as defined in Section 2.2(a)) and with each Landlord’s Statement (defined in Article Four), Landlord may estimate and notify Tenant in writing of its estimate of the Operating Expenses and of Taxes for such calendar year (or partial calendar year). Prior to the first determination by Landlord of the amount of Operating Expenses and of Taxes for the first calendar year (or partial calendar year), Landlord may estimate such amounts in the foregoing calculation. The last estimate by Landlord shall remain in effect as the applicable Rent Adjustment Deposit unless and until Landlord notifies Tenant in writing of a change, which notice may be given by Landlord from time to time during each year throughout the Term.

RENTABLE AREA OF THE PREMISES:   The amount of square footage set forth in Section 1.1(9). The Rentable Area of the Premises and the Building shall not be revised during the Term except to reflect a physical expansion or reduction of the Premises or the Building, as the case may be. The Rentable Area of the Building as of the Date of Lease is 38,701 rentable square feet.

SECURITY DEPOSIT:   The amount specified in Section 1.1(11) to be deposited by Tenant with Landlord as security for Tenant’s performance of its obligations under this Lease.

SUBSTANTIAL COMPLETION:   The substantial completion of the Tenant Improvements, except for minor insubstantial details of construction, decoration or mechanical adjustments which remain to be done and do not interfere with Tenant’s ability to use and occupy the Premises, as evidenced by Tenant’s receipt of a certificate of occupancy or an equivalent written permit or approval from the City of Emeryville permitting the occupancy of the Premises as improved by the Tenant Improvements.

TAXES:   All federal, state and local governmental taxes, assessments and charges of every kind or nature, whether general, special, ordinary or extraordinary, which Landlord shall pay or become obligated to pay because of or in connection with the ownership, leasing, management, control or operation of the Property or any of its components (including any personal property used in connection therewith), which may also include any rental or similar taxes levied in lieu of or in addition to general real and/or personal property taxes. For purposes hereof, Taxes for any year shall be Taxes which are assessed for any period of such year, whether or not such Taxes are billed and payable in a subsequent calendar year. There shall be included in Taxes for any year the amount of all reasonable, out-of-pocket fees, costs and expenses (including reasonable attorneys’ fees) paid by Landlord during such year in seeking or obtaining any refund or reduction of Taxes (but not to exceed the amount of such refund or reduction reasonably estimated to be realized therefrom). Taxes for any year shall be reduced by the net amount of any tax refund received by Landlord attributable to such year. If a special assessment payable in installments is levied against any part of the Property, Taxes for any year shall include only the installment of such assessment and any interest payable or paid during such year. Taxes shall not include (i) any federal or state inheritance, general income, gift or estate taxes, except that if a change occurs in the method of taxation resulting in whole or in part in the substitution of any such taxes, or any other assessment, for any Taxes as above defined, such substituted taxes or assessments shall be included in the Taxes, (ii) any documentary

 

8


transfer taxes, or (iii) interest or penalties resulting from Landlord’s failure to pay Taxes in a timely manner.

TENANT ALTERATIONS:   Any alterations, improvements, additions, installations or construction by or on behalf of Tenant in or to the Premises or to any Building systems serving the Premises. Tenant Alterations shall include the Tenant Improvements, but shall not include any of Tenant’s trade fixtures, equipment ( e.g. , laboratory and process equipment), inventory and/or personal property.

TENANT’S SHARE:   The percentage that represents the ratio of the Rentable Area of the Premises to the Rentable Area of the Building, as determined by Landlord from time to time. Based on the rentable areas as of the date of this Lease, Tenant’s Share for the initial Premises is 16,638/38,701 = 42.99% and Tenant’s Share for the Expansion Premises is 5,927/38,701 15.31%. Tenant acknowledges that the Rentable Area of the Premises and/or Rentable Area of the Building may change during the Term; provided, however, that the determination of Tenant’s Share at any time shall be subject to the limitation specified in the definition of the term “Rentable Area of the Premises,” as specified above.

TERM:   The term of this Lease commencing on the Commencement Date and expiring on the Expiration Date (as the same may be extended by the Renewal Term pursuant to Section 2.8).

TERMINATION DATE:   The Expiration Date (subject to extension pursuant to Section 2.8) or such earlier date as this Lease terminates or Tenant’s right to possession of the Premises terminates.

WORKLETTER:   The Agreement regarding the manner of completion of the Tenant Improvements set forth on Exhibit B attached hereto.

ARTICLE 2

PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING

 

2.1

LEASE OF PREMISES

(a)        Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises for the Term and upon the terms, covenants and conditions provided in this Lease.

(b)        Tenant shall have the non-exclusive right to use the fitness center currently located in EmeryStation 1 in accordance with the standard policy regulating usage established by Landlord (or the owner or operator of the building in which such fitness center is located) from time to time. Landlord reserves the right, in its sole discretion, to relocate the fitness center to EmeryStation East, EmeryStation North, Heritage Square or any other building in the vicinity of the Building that is owned or operated by Landlord or an affiliate of Landlord, or to discontinue the provision of a fitness center as an amenity of the Project. So long as a fitness center is provided as an amenity of the Project, Tenant shall pay its pro-rata share of the costs of operation thereof as an Operating Expense. Tenant shall also have non-exclusive use of the Common Areas and of the open area at the Building’s southeast corner so as to be able to install, if required by the City as a condition of Tenant’s CUP, building permit or other approval granted

 

9


by the City to Tenant, an exit pathway accessing the public greenway. Once installed, Landlord shall maintain the exit pathway in good condition and repair, the cost of which shall be an Operating Expense.

 

2.2

TERM

(a)      The “Commencement Date” shall be the date Landlord delivers exclusive possession of the Premises to Tenant in the condition required under Section 2.4, which date shall be as soon as practicable following the PH Lease Termination Effective Date (as defined below), with Landlord making every commercially-reasonable effort for said date to be the date immediately following the PH Lease Termination Effective Date, and shall not be later than the Projected Commencement Date ( e.g. , May 16, 2008), subject to the following:

(1)        By no later than April 21, 2008, Landlord shall deliver to Tenant an executed agreement (“Termination Agreement”) entered into between Landlord and PH Productions (the “Current Premises Tenant”) for the early termination of the current lease of the Premises between Landlord and Current Premises Tenant (the “PH Lease) providing for an effective termination date of the PH Lease (the “PH Lease Termination Effective Date”) no later than May 15, 2008. Landlord shall use commercially reasonable efforts to enter into a commercially reasonable Termination Agreement with the Current Premises Tenant as soon as possible after the Date of Lease. In the event that despite such commercially reasonable efforts, Landlord is unable to deliver such Termination Agreement to Tenant by April 21, 2008, Tenant, in its sole discretion, may elect to: (i) terminate this Lease by delivering written notice to Landlord at least ten (10) days prior to the date Tenant designated in such notice for termination, which designated date shall be the effective termination date, or (ii) have Landlord continue negotiations with the Current Premises Tenant to enter into a commercially reasonable Termination Agreement by no later than thirty (30) days after April 21, 2008; which process Tenant, in its sole discretion, may elect to continue for no more than an two (2) additional 30-day periods after the expiration of the initial 30-day negotiation period. However, Landlord shall not be required to continue negotiations with the Current Premises Tenant under the process set forth in (ii) above if Landlord, in Landlord’s reasonable discretion, determines that the Current Premises Tenant will not execute a commercially reasonable Termination Agreement for the early termination of the PH Lease. Notwithstanding the foregoing, if despite Landlord’s commercially reasonable efforts, Landlord and the Current Premises Tenant do not execute a Termination Agreement by May 31, 2008, this Lease shall immediately terminate and any monies or deposits previously paid or delivered by Tenant to Landlord shall be promptly returned to Tenant.

Within thirty (30) days following the occurrence of the Commencement Date, Landlord and Tenant shall enter into an agreement (the form of which is attached hereto as Rider 1) confirming the Commencement Date and the Expiration Date). If Tenant fails to enter into such agreement (provided the same is accurate), then the Commencement Date and the Expiration Date shall be the dates designated by Landlord in such agreement.

 

10


2.3

FAILURE TO GIVE POSSESSION

Landlord shall use commercially reasonable efforts to cause the Current Premises Tenant to surrender the Premises by no later than the PH Lease Termination Effective Date. If Landlord shall be unable to give possession of the Premises by the Projected Commencement Date by reason of the following: (i) the holding over or retention of possession by the Current Premises Tenant, or (ii) for any other reason beyond Landlord’s reasonable control, then Landlord shall not be subject to any liability for the failure to give possession on said date and, except as otherwise set forth in Section 2.2(a) above and this Section 2.3, no such failure to give possession on the Projected Commencement Date shall affect the validity of this Lease or the obligations of the Tenant hereunder. Notwithstanding the foregoing, if the Current Premises Tenant fails to surrender possession of the Premises by the PH Lease Termination Effective Date, Landlord, at its sole cost, shall use commercially reasonable efforts (including commencing eviction proceedings) to obtain possession of the Premises as soon as possible. In addition, notwithstanding anything to the contrary in Section 2.2 or this Section 2.3, if for any reason the Commencement Date has not occurred on or before June 15, 2008, Tenant shall have the right to terminate this Lease for a period not exceed fifteen (15) days after June 15, 2008, by delivering ten (10) days’ written notice to Landlord. In the event this Lease so terminates, any monies or deposits previously paid or delivered by Tenant to Landlord shall be promptly returned to Tenant, and neither party shall have any further obligations or liabilities hereunder.

 

2.4

CONDITION OF PREMISES

Landlord shall deliver the Premises to Tenant in broom clean condition, with all Building systems, including electrical, mechanical, plumbing, heating, ventilation, air conditioning (if any), communication, and fire and life safety, in good working order, with all furniture, fixtures and equipment (but not including storage racks, which Landlord may leave in the Premises at its sole discretion) of the Current Premises Tenant and any other tenant or occupant removed, and otherwise in “As Is, Where Is” condition (including existing walls and improvements therein) as of the Date of Lease.

 

2.5

PARKING

Tenant may use up to the number of spaces specified in Section 1.1(13) for parking at the standard prevailing monthly rates being charged from time to time by Landlord or any Landlord designated parking operator without regard to discounts provided to any other users of the EmeryStation East garage (as of the Date of Lease, such prevailing rates in the EmeryStation East garage are $100.00 per stall per month for unreserved parking and $135.00 per stall per month for reserved parking).

In the event Tenant fails at any time to pay the full amount of such parking charges, and such failure continues for a period of ten (10) days after written notice thereof from Landlord to Tenant, Tenant’s parking rights shall be reduced to the extent of Tenant’s failure to pay for any such parking. Subject to the terms of this Section 2.5, the locations and type of parking shall be designated by Landlord, a Landlord affiliate, or any Landlord designated parking operator from time to time. Tenant acknowledges and agrees that the parking spaces serving the Project may include tandem parking and a mixture of spaces for compact vehicles as well as full-size

 

11


passenger automobiles, and that Tenant shall not use parking spaces for vehicles larger than the striped size of the parking spaces. All vehicles utilizing Tenant’s parking privileges shall prominently display identification stickers or other markers, and/or have passes or keycards for ingress and egress, as may be required and provided by Landlord, a Landlord affiliate, or any Landlord designated parking operator from time to time. Tenant shall comply with any and all reasonable parking rules and regulations from time to time established by Landlord, a Landlord affiliate, or any parking operator, including a requirement that Tenant pay to Landlord, a Landlord affiliate, or any Landlord designated parking operator a reasonable charge for loss and replacement of passes, keycards, identification stickers or markers, and for any and all loss or other damage to the extent caused by persons or vehicles related to use of Tenant’s parking privileges. Tenant shall not allow any vehicles using Tenant’s parking privileges to be parked, loaded or unloaded except in accordance with this Section 2.5, including in the areas and in the manner designated by Landlord, a Landlord affiliate, or any Landlord designated parking operator for such activities. If any vehicle is using the parking or loading areas contrary to any provision of this Section 2.5, Landlord, a Landlord affiliate, or any Landlord designated parking operator shall have the right, in addition to all other rights and remedies of Landlord under this Lease, to remove or tow away the vehicle without prior notice to Tenant, and the cost thereof shall be paid to Landlord within thirty (30) days after notice from Landlord to Tenant.

 

2.6

RENEWAL OPTION

(a)        Tenant shall have the option to renew this Lease (“Renewal Option”) with respect to either (i) the initial Premises as depicted on Exhibit A attached hereto or (ii) the initial Premises, plus the Expansion Premises, if the Expansion Premises have been incorporated into the Premises pursuant to Section 2.7, for one (1) additional term of five (5) years (“Renewal Term”), commencing upon expiration of the initial Term. The Renewal Option must be exercised, if at all, by written notice given by Tenant to Landlord not earlier than fifteen (15) months nor later than twelve (12) months prior to expiration of the initial Term, which notice shall specify whether the Renewal Option is being exercised with respect to the area described in clause (i) or clause (ii) of the preceding sentence. If Tenant properly exercises the Renewal Option, references in the Lease to the Term shall be deemed to mean the Renewal Term, unless the context clearly provides otherwise. The Renewal Option shall be null and void and there shall be no right to renew this Lease if on the date the Tenant exercises the Renewal Option, or on the date immediately preceding the commencement date of the Renewal Term, a Default beyond the applicable cure period shall have occurred and be continuing hereunder.

(b)        If Tenant properly exercises the Renewal Option, then during the Renewal Term all of the terms and conditions set forth in this Lease as applicable to the Premises during the initial Term shall apply during the Renewal Term, including without limitation the obligation to pay Operating Expenses and Taxes, except that (i) Tenant shall take the Premises in their then “as-is” state and condition and Landlord shall have no obligation to make or pay for any improvements to the Premises, and (ii) during the Renewal Term the Monthly Base Rent payable by Tenant shall be the monthly Fair Market Rent during the Renewal Term as hereinafter set forth, except that in no event shall the Monthly Base Rent during the Renewal Term be less than Monthly Base Rent during the last month of the initial Term immediately prior to the commencement of the Renewal Term.

 

12


(c)        For purposes of this Section, the term “Fair Market Rent” shall mean the rental rate, additional rent adjustment and other charges and increases, if any, for space comparable in size, location and quality of the Premises under primary lease (and not sublease) to new or renewing tenants, for a comparable term with a tenant improvement allowance, if applicable and taking into consideration such amenities as existing improvements, view, floor on which the Premises are situated and the like, situated in comparable buildings in Emeryville or Berkeley. The Fair Market Rent shall not take into account any Tenant Alterations paid for by Tenant.

(d)        If Tenant properly exercises the Renewal Option to extend the term of the Lease, Landlord, by notice to Tenant not more than thirty (30) days after Tenant’s exercise of the Renewal Option, shall indicate Landlord’s determination of the Fair Market Rent. Tenant, within thirty (30) days after date on which Landlord provides such notice of the Fair Market Rent shall either (i) give Landlord final binding written notice (“Binding Notice”) of Tenant’s acceptance of Landlord’s determination of the Fair Market Rent, or (ii) if Tenant disagrees with Landlords’ determination, provide Landlord with written notice of Tenant’s election to submit the Fair Market Rent to binding arbitration (the “Arbitration Notice”). If Tenant fails to provide Landlord with either a Binding Notice or Arbitration Notice within such thirty (30) day period, Tenant shall have been deemed to have given the Binding Notice. If Tenant provides Landlord with a Binding Notice, Landlord and Tenant shall enter into the Renewal Amendment (as defined below) upon the terms and conditions set forth herein.

(e)        If the parties are unable to agree upon the Fair Market Rent for the Premises within ten (10) days after Landlord’s receipt of the Arbitration Notice, Fair Market Rent as of commencement of the Renewal Term shall be determined as follows:

(1)        Within twenty (20) days after receipt of Landlord’s notice specifying Fair Market Rent, Tenant, at its sole expense, shall obtain and deliver in writing to Landlord a determination of the Fair Market Rent for the Premises for a term equal to the Renewal Term from a broker or appraiser (“Tenant’s broker”) licensed in the State of California and engaged in the office and lab markets in Emeryville and Berkeley, California, for at least the immediately preceding five (5) years. If Landlord accepts such determination, Landlord shall provide written notice thereof within ten (10) days after Landlord’s receipt of such determination and the Base Rent for the Renewal Term shall be adjusted to an amount equal to the Fair Market Rent determined by Tenant’s broker. Landlord shall be deemed to have accepted Tenant’s determination if Landlord fails to respond within the ten (10) day period.

(2)        If Landlord provides notice that it does not accept such determination, within twenty (20) days after receipt of the determination of Tenant’s broker, Landlord shall designate a broker or appraiser (“Landlord’s broker”) licensed in the State of California and possessing the qualifications set forth in (1) above. Landlord’s broker and Tenant’s broker shall name a third broker, similarly qualified and who is not then or has not previously acted for either party, within five (5) days after the appointment of Landlord’s broker (“Neutral Broker”).

(3)        The Neutral Broker shall determine the Fair Market Rent for the Premises as of the commencement of the Renewal Term within fifteen (15) days after the appointment of the Neutral Broker by choosing the determination of the Landlord’s broker or the Tenant’s

 

13


broker which is closest to its own determination of Fair Market Rent. The decision of the Neutral Broker shall be binding on Landlord and Tenant.

(f)        Landlord shall pay the costs and fees of Landlord’s broker in connection with any determination hereunder, and Tenant shall pay the costs and fees of Tenant’s broker in connection with such determination. The costs and fees of the Neutral Broker shall be paid one- half by Landlord and one-half by Tenant.

(g)        If the amount of the Fair Market Rent has not been determined pursuant to this Section 2.6 as of the commencement of the Renewal Term, then Tenant shall continue to pay the Base Rent in effect at the expiration of the initial Term until the amount of the Fair Market Rent is determined. When such determination is made, Tenant shall pay any deficiency to Landlord upon demand.

(h)        If Tenant is entitled to and properly exercises its Renewal Option, upon determination of Fair Market Rent pursuant to this Section 2.6, Landlord shall prepare an amendment (the “Renewal Amendment”) to reflect changes in the Base Rent, Term, Expiration Date and other appropriate terms. The Renewal Amendment shall be sent to Tenant within a reasonable time after determination of Fair Market Rent and, provided the same is accurate, Tenant shall execute and return the Renewal Amendment to Landlord within ten (10) days after Tenant’s receipt of same, but an otherwise valid exercise of the Renewal Option shall be fully effective whether or not the Renewal Amendment is executed.

 

2.7

EXPANSION RIGHT

(a)        The space adjacent to the Premises, consisting of approximately 5,927 rentable square feet (the “Expansion Premises”) as set forth in Exhibit A-1 , is currently subject to a lease (the “Current Expansion Premises Lease”) between Landlord and the current tenant of the Expansion Premises (the “Current Expansion Premises Tenant”) which is scheduled to expire per its terms on October 31, 2008. Landlord hereby confirms that the Current Expansion Premises Tenant has no renewal or extension right under the Current Expansion Premises Lease. If Landlord becomes aware that the Expansion Premises will become available at any time prior to October 31, 2008 as a result of the early termination of the Current Expansion Premises Lease, and/or Landlord has a bonafide offer from a third-party tenant, which may include the Current Expansion Premises Tenant, such offer evidenced by a term sheet or letter of intent signed by Landlord and such third party, Landlord shall promptly notify Tenant of such availability or of such signed third-party term sheet or letter of intent (the “Expansion Availability Notice”). The Expansion Availability Notice shall specify the effective date of the early termination of the Current Expansion Premises Lease (the “Current Expansion Premises Lease Termination Effective Date”) or the identity of the interested third-party tenant, as the case may be. Notwithstanding the foregoing, regardless of the date of the Expansion Premises actually becoming available prior October 31, 2008, or of the timing of any third-party tenant’s agreement to terms, as the case may be, Landlord shall not deliver an Expansion Availability Notice to Tenant prior to July 1, 2008. Tenant shall have the right (the “Expansion Right”) to incorporate the Expansion Premises into, and cause the Expansion Premises to become a part of, the Premises by delivering written notice to Landlord (“Tenant’s Expansion Notice”) upon the earlier to occur of (1) within five (5) business days after the date Landlord delivers the

 

14


Expansion Availability Notice to Tenant, and (ii) December 31, 2008 (if Landlord has not delivered an Expansion Availability Notice to Tenant). If Tenant fails to deliver Tenant’s Expansion Notice by the applicable outside date, Tenant shall be deemed to have elected not to exercise the Expansion Right and Landlord shall be free to enter into a lease of the Expansion Premises with a third party. Notwithstanding the above, in no event does Tenant’s Expansion Right pursuant to this Section 2.7 exist beyond December 31, 2008.

(b)        Intentionally omitted.

(c)        If Tenant properly exercises its Expansion Right under the terms set forth herein, the Expansion Premises shall be incorporated into the Premises under the same terms and conditions of this Lease, subject to the following:

(i)        The “Expansion Premises Commencement Date” shall be the date Landlord delivers exclusive possession of the Expansion Premises to Tenant, in broom clean condition, with all existing Building systems, including electrical, mechanical, plumbing, heating, ventilation, air conditioning (if any), communication, and fire and life safety, in good working order, with all furniture, fixtures and equipment (including any storage racks,) of the Current Expansion Premises Tenant and any other tenant or occupant removed, and otherwise in “As Is, Where Is” condition (including existing walls and improvements therein) as of the Date of this Lease. Landlord shall use commercially reasonable efforts to cause the Current Expansion Premises Tenant to surrender the Expansion Premises by the earlier of: a) October 31, 2008 and b) the Current Expansion Premises Lease Termination Effective Date, as applicable. If the Current Expansion Premises Tenant fails to surrender possession of the Expansion Premises by such applicable expiration date, Landlord, at its sole cost, shall use commercially reasonable efforts (including commencing eviction proceedings) to obtain possession of the Expansion Premises as soon as practicable. If, despite such commercially reasonable efforts, the Expansion Premises Commencement Date has not occurred by the date which is sixty (60) days after the existing expiration date of the Current Expansion Premises Lease, for no more than fifteen (15) days following such 60-day period, Tenant, as its sole remedy as a result of such failure to deliver the Expansion Premises, shall have the right to terminate this Lease only with respect to the Expansion Premises by delivering written notice to Landlord (the “Expansion Termination Notice”), in which case this Lease with respect to the Expansion Premises only, shall terminate as of the tenth (10th) day after Landlord’s receipt of the Expansion Termination Notice unless Landlord has delivered exclusive possession of the Expansion Premises to Tenant in the required condition on or before such tenth (10th) day after Landlord’s receipt thereof. If Tenant does not terminate this Lease with respect to the Expansion Premises, the “Expansion Premises Rent Commencement Date” shall be either:

(1)        the same date as the “Expansion Premises Commencement Date” if Tenant has not yet waived its termination right under Section 2.7(f); or

(2)        if and when Tenant waives its termination right under Section 2.7(f), the earlier of (i) ninety (90) days after the Expansion Premises Commencement Date (as the same may be extended as a consequence of any Landlord Delay or by act of god such as earthquake or flood or casualty not caused by Tenant or Tenant’s agents, contractors, employees

 

15


or invitees), or (ii) the date Tenant commences its business operations in the Expansion Premises.

From and after the Expansion Premises Rent Commencement Date and continuing until the Expiration Date, the Monthly Base Rent for the Expansion Premises shall be the per square foot rate applicable to the initial Premises for such applicable period during the initial Term, as specified in Section 1.1(8).

(ii)        With respect to the Expansion Premises, Tenant shall receive (A) a tenant improvement allowance in the amount of Seven and 50/100 Dollars ($7.50) per rentable square foot of the Expansion Premises (the “Basic Tenant Improvement Allowance for Expansion Premises”), and (B) the Tenant Improvement Allowance provided for in Section 1.1(16) (calculated on a rentable square foot basis). In each case, the allowances shall be adjusted, as applied to the Expansion Premises, by multiplying the applicable Allowance by a fraction, the numerator of which is the number of months (including the fractional portion of a partial month) from the Expansion Premises Commencement Date to the stated Expiration Date of this Lease and the denominator of which is the total number of months in the initial Term of this Lease. Further, to the extent that Tenant does not utilize the full amount of the Basic Tenant Improvement Allowance for Expansion Premises, the remainder of such Allowance shall be applied against (i.e., in reduction of) the amount of the Tenant Improvement Allowance utilized by Tenant for the initial Premises (and the Tenant Improvement Allowance Monthly Payments shall be reduced accordingly). Notwithstanding any Security Deposit adjustment or reduction rights Tenant may have under Article 5, if Tenant properly exercises its Expansion Right, then concurrently with the delivery of Tenant’s Expansion Notice, Tenant shall be required to deposit with Landlord an additional $28,271.79 to increase the amount of the Security Deposit held by Landlord as of the date of Tenant’s Expansion Notice, so that at no time during the Term after the delivery of Tenant’s Expansion Option shall the Security Deposit be less than $28,271.79. Notwithstanding the terms of Article 5 of the Lease that address the potential return to Tenant of all or a portion of the Security Deposit for the initial Premises, the Security Deposit for the Expansion Premises is not subject to such potential reduction or return.

(iii)        With respect to the Expansion Premises, one (1) unreserved parking space per 1,000 rentable square feet of the Expansion Premises shall be provided in the EmeryStation East garage at the same rates set forth in Section 2.5. In addition, in the event any parking in addition to the number of spaces specified in this Section 2.7(c)(iii) is required by the City of Emeryville as a condition to the City’s issuance of any use permit with respect to the Expansion Premises, then Landlord shall use commercially reasonable efforts to provide to Tenant the use of additional spaces of up to the number required by the City of Emeryville for parking at the standard prevailing monthly rates being charged from time to time by Landlord, a Landlord affiliate or any Landlord designated parking operator without regard to discounts provided to any other users of such parking facilities. Such additional parking spaces shall be located in the EmeryStation and/or Heritage Square parking facilities (as reasonably determined by Landlord) and shall otherwise be subject to the terms of Section 2.5. Notwithstanding the foregoing, if, despite Landlord’s commercially-reasonable efforts, Landlord is unable to obtain City of Emeryville approval for Tenant’s use of such additional parking spaces required by any use permit within thirty (30) days following receipt of Tenant’s use permits, Landlord or Tenant may terminate this Lease only with respect to the Expansion Premises by delivering written notice to

 

16


the other, within ten (10) days thereafter, of its election to terminate under this Section 2 .7(c)(iii).

(d)        Notwithstanding anything to the contrary contained herein, all rights of Tenant pursuant to this Section 2.7 shall, at Landlord’s election upon notice to Tenant, be of no further force and effect with respect to the Expansion Premises, whether or not Tenant has properly exercised the Expansion Right granted herein, if on the date Tenant delivers Tenant’s Expansion Notice a Default beyond the applicable cure period shall have occurred and be continuing hereunder.

(e)        If Tenant is entitled to and properly exercises its Expansion Right, Landlord shall promptly prepare an amendment to this Lease (the “Expansion Amendment”) to reflect the Monthly Base Rent, Tenant Improvement Allowance, and other appropriate terms applicable in connection with the addition of the Expansion Premises to the Premises covered by this Lease. If accurate, Tenant shall execute and return the Expansion Amendment to Landlord within ten (10) days after Tenant’s receipt of same; however, if Tenant delivers Tenant’s Expansion Notice, Tenant shall be irrevocably obligated to lease the Expansion Premises (subject to any termination rights set forth in this Section 2.7) regardless of Tenant’s failure to timely execute and deliver the Expansion Amendment.

(f)        Landlord shall reasonably cooperate with Tenant and promptly execute any reasonable documents requested by Tenant in connection with Tenant obtaining the necessary use permits from the City of Emeryville for Tenant’s intended use of the Expansion Premises. Notwithstanding the foregoing, if Tenant has not obtained such use permits within one hundred twenty (120) days after Tenant’s delivery of Tenant’s Expansion Notice, then Tenant shall have the right to terminate the lease of the Expansion Premises by delivering written notice to Landlord within ten (10) days after the expiration of such one hundred twenty (120) day period, in which case the lease of the Expansion Premises shall terminate as of the tenth (10th) day after Landlord’s receipt of such notice from Tenant. In the event Tenant terminates this Lease with respect to the Expansion Premises under this Section 2.7(f), Tenant shall have no right to recover any Rent previously paid or delivered by Tenant to Landlord with respect to the Expansion Premises; however, Landlord shall return to Tenant any monies previously paid by Tenant to increase the Security Deposit pursuant to Section 2.7(c)(ii).

 

2.8

EXPANSION PREMISES RIGHT OF FIRST OFFER

(a)        During the period commencing on January 1, 2009 and up to and including December 31, 2009 (the “Offer Period”), Tenant shall have a continuous right of first offer to lease the Expansion Premises if and when it becomes available during the Offer Period (the “Right of First Offer”).

(b)        Subject to the terms and conditions set forth in this Section 2.8, in the event that Landlord proposes to negotiate with a prospective tenant during the Offer Period, or if Landlord otherwise intends to market the Expansion Premises or any portion thereof during the Offer Period, Landlord shall give written notice thereof to Tenant (the “ROFO Offer Notice”), which ROFO Offer Notice shall include the estimated delivery date of such space to Tenant. For a period of fifteen (15) business days after Landlord’s delivery of the ROFO Offer Notice, at the

 

17


election of Tenant, Landlord and Tenant shall negotiate in good faith concerning the leasing of such space but neither party shall be obligated to enter into a lease or amendment for such space unless the parties mutually agree on the terms and conditions of such lease or amendment.

(c)        Notwithstanding anything to the contrary contained herein, all rights of tenant pursuant to this Section 2.8 with respect to the Expansion Premises shall, at Landlord’s election upon notice to Tenant, be of no further force and effect with respect to such Expansion Premises, whether or not Tenant has properly exercised the Right of First Offer granted herein with respect thereto, and Landlord shall have no obligation to deliver any ROFO Offer Notice to Tenant with respect to such Expansion Premises, if a Default of the Lease beyond the applicable cure period has occurred and is continuing at the time of exercise of the Right of First Offer or at the time that Landlord would otherwise be required to deliver such ROFO Offer Notice.

(d)        If Landlord and Tenant reach an agreement upon the terms of a new lease or amendment for the Expansion Premises or any portion thereof pursuant to Section 2.8(c), Landlord promptly shall prepare such lease or amendment setting forth the agreed terms and conditions for the lease of the Expansion Premises or applicable portion thereof, and shall otherwise generally be on the same terms and conditions of this Lease (excluding, however, the business terms of this Lease applicable to the Premises). If accurate, Tenant shall execute and return such lease or amendment to Landlord within ten (10) days after Tenant’s receipt of same.

ARTICLE 3

RENT

3.1         PAYMENT OF RENT .   From and after the Commencement Date, Tenant agrees to pay to Landlord at the address specified in Section 1.1(2), or to such other persons, or at such other places designated by Landlord, without any prior demand therefor in immediately available funds and without any deduction or offset whatsoever, Monthly Base Rent during the Term. Notwithstanding the foregoing, Tenant shall be entitled to an abatement of Monthly Base Rent on a day-for-day basis for each day that Substantial Completion of the Tenant Improvements is delayed as a consequence of any Landlord Delay or by act of god such as earthquake or flood or casualty not caused by Tenant or Tenant’s agents, contractors, employees or invitees, which abatement shall be taken as such delay(s) occur. Monthly Base Rent shall be paid monthly in advance on the first day of each month of the Term, except that the first installment of Monthly Base Rent shall be paid by Tenant to Landlord concurrently with the execution of this Lease. Monthly Base Rent shall be daily prorated for partial months within the Term. Unpaid Rent shall bear interest at the Default Rate from the date due until paid. Tenant’s covenant to pay Rent shall be independent of every other covenant in this Lease.

ARTICLE 4

RENT ADJUSTMENTS AND PAYMENTS

 

4.1

RENT ADJUSTMENTS

Commencing on the Commencement Date, Tenant shall pay to Landlord Rent Adjustments with respect to each calendar year (or partial calendar year in the case of the year in which the Commencement Date and the Termination Date occur) as follows:

 

18


(1)        The Rent Adjustment Deposit representing Tenant’s Share of Operating Expenses for the applicable calendar year (or partial calendar year), monthly during the Term with the payment of Monthly Base Rent; and

(2)        The Rent Adjustment Deposit representing Tenant’s Share of Taxes for the applicable calendar year (or partial calendar year), monthly during the Term with the payment of Monthly Base Rent; and

(3)        Any Rent Adjustments due in excess of the Rent Adjustment Deposits in accordance with Section 4.2. Rent Adjustments due from Tenant to Landlord for any calendar year (or partial calendar year) shall be Tenant’s Share of Operating Expenses for such calendar year (or partial calendar year) and Tenant’s Share of Taxes for such calendar year (or partial calendar year).

(4)        For purposes of determining Rent Adjustments, if the Building or Property is not fully occupied during all or a portion of any calendar year during the Term, Landlord shall make appropriate adjustments to the variable components of Operating Expenses for such calendar year (or partial calendar year), employing sound accounting and management principles consistently applied, to determine the amount of Operating Expenses that would have been paid or incurred by Landlord had the Building or Property been one hundred percent (100%) occupied, and the amount so determined shall be deemed to have been the amount of Operating Expenses for such calendar year (or partial calendar year). In the event that the Property is not fully assessed for all or a portion of any calendar year (or partial calendar year) during the Term, then Taxes shall be adjusted to an amount which would have been payable in such calendar year (or partial calendar year) if the Property had been fully assessed.

 

4.2

STATEMENT OF LANDLORD

As soon as feasible after the expiration of each calendar year, Landlord will furnish Tenant a statement (“Landlord’s Statement”) showing the following:

(1)        Operating Expenses and Taxes for the calendar year;

(2)        The amount of Rent Adjustments due Landlord for the last calendar year, less credit for Rent Adjustment Deposits paid, if any; and

(3)        Any change in the Rent Adjustment Deposit due monthly in the current calendar year, including the amount or revised amount due for months preceding any such change pursuant to Landlord’s Statement.

Tenant shall pay to Landlord within thirty (30) days after receipt of such statement any amounts for Rent Adjustments then due in accordance with Landlord’s Statement. Any amounts due from Landlord to Tenant pursuant to this Section shall be credited to the Rent Adjustment Deposit next coming due, or refunded to Tenant if the Term has already expired. No interest or penalties shall accrue on any amounts that Landlord is obligated to credit or refund to Tenant by reason of this Section 4.2. Landlord’s failure to deliver Landlord’s Statement or to compute the amount of the Rent Adjustments shall not constitute a waiver by Landlord of its right to deliver such items nor constitute a waiver or release of Tenant’s obligations to pay such amounts. The

 

19


Rent Adjustment Deposit shall be credited against Rent Adjustments due for the applicable calendar year (or partial calendar year). During the last complete calendar year or during any partial calendar year in which the Lease terminates, Landlord may include in the Rent Adjustment Deposit its estimate of Rent Adjustments which may not be finally determined until after the termination of this Lease. Tenant’s obligation to pay Rent Adjustments survives the expiration or termination of the Lease. Notwithstanding the foregoing, in no event shall the sum of Monthly Base Rent and the Rent Adjustments be less than the Monthly Base Rent payable.

 

4.3

BOOKS AND RECORDS

Landlord shall maintain books and records showing Operating Expenses and Taxes in accordance with sound accounting and management practices, consistently applied. Tenant or its representative (which representative shall be a certified public accountant licensed to do business in the state in which the Property is located and whose primary business is certified public accounting and who shall not be paid on a contingency basis) shall have the right, for a period of ninety (90) days following the date upon which Landlord’s Statement is delivered to Tenant, to examine the Landlord’s books and records with respect to the items in the foregoing statement of Operating Expenses and Taxes during normal business hours, upon written notice, delivered at least three (3) business days in advance. If Tenant does not object in writing to Landlord’s Statement within ninety (90) days of Tenant’s receipt thereof, specifying the nature of the item in dispute and the reasons therefor, then Landlord’s Statement shall be considered final and accepted by Tenant and Tenant shall be deemed to have waived its right to dispute Landlord’s Statement. If Tenant does dispute any Landlord’s Statement, Tenant shall deliver a copy of any such audit to Landlord within 120 days after the date upon which Landlord’s Statement was delivered to Tenant. Any amount due to the Landlord as shown on Landlord’s Statement, whether or not disputed by Tenant as provided herein shall be paid by Tenant when due as provided above, without prejudice to any such written exception. In no event shall Tenant be permitted to examine Landlord’s records or to dispute any statement of Operating Expenses and Taxes unless Tenant has paid and continues to pay all Rent when due. Upon resolution of any dispute with respect to Operating Expenses and Taxes, Tenant shall either pay Landlord any shortfall or Landlord shall credit Tenant against the Rent Adjustment Deposit next coming due with respect to any overages paid by Tenant. The records obtained by Tenant shall be treated as confidential and neither Tenant nor any of its representatives or agents shall disclose or discuss the information set forth in the audit to or with any other person or entity (“Confidentiality Requirement”). Tenant shall indemnify and hold Landlord harmless for any losses or damages to the extent arising out of the breach of the Confidentiality Requirement. Landlord shall pay for the reasonable third party costs of Tenant’s audit if the final determination of the dispute shows a disparity of 5% or more in Operating Expenses and Taxes over the Operating Expenses and Taxes as shown on Landlord’s Statement.

 

4.4

TENANT OR LEASE SPECIFIC TAXES

In addition to Monthly Base Rent, Rent Adjustments, Rent Adjustment Deposits and other charges to be paid by Tenant, Tenant shall pay to Landlord, upon demand, any and all taxes payable by Landlord (other than federal or state inheritance, general income, gift or estate taxes) whether or not now customary or within the contemplation of the parties hereto: (a) upon, allocable to, or measured by the Rent payable hereunder, including any gross receipts tax or

 

20


excise tax levied by any governmental or taxing body with respect to the receipt of such rent; or (b) upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion thereof; or (c) upon the measured value of Tenant’s personal property located in the Premises or in any storeroom or any other place in the Premises or the Property, or the areas used in connection with the operation of the Property, it being the intention of Landlord and Tenant that, to the extent possible, such personal property taxes shall be billed to and paid directly by Tenant; (d) resulting from any Tenant Alterations to the Premises; or (e) upon this transaction. Taxes paid by Tenant pursuant to this Section 4.5 shall not be included in any computation of Taxes payable pursuant to Sections 4.1 and 4.2.

ARTICLE 5

SECURITY DEPOSIT

(a)        Within two (2) business days after the Date of Lease, Tenant shall deliver to Landlord the Security Deposit in the amount set forth in Section 1.1(11) of this Lease in the form of cash or a Letter of Credit. In the event that Tenant delivers the Security Deposit in the form of a Letter of Credit, such Letter of Credit shall show an expiration date that is no less than sixty (60) days after the Expiration Date of this Lease.

(b)        If and only if Tenant provides satisfactory (in Landlord’s reasonable discretion) evidence (including but not limited to invoices marked “paid”) to Landlord that Tenant has incurred an amount in excess of Four Million Dollars ($4,000,000.00) for hard costs and commercially reasonable soft costs at the Premises (not including costs incurred for any personal property which are not permanently affixed to the Premises, or improvements constructed at the Expansion Space, if any) during the first (1st) twelve (12) months of the Term, then Landlord shall return the Security Deposit to Tenant within thirty (30) days after receipt of such evidence. Notwithstanding the provisions on this Section, in no event shall the amount of the Security Deposit applicable to the Expansion Premises be returned to Tenant as a result of Tenant’s expenditures on improvements to either the Initial or Expansion Premises.

(c)        The Security Deposit may be applied by Landlord to cure, in whole or part, any Default of Tenant under this Lease, and upon notice by Landlord of such application, Tenant shall replenish the Security Deposit in full by paying to Landlord within thirty (30) days of demand the amount so applied. Landlord’s application of the Security Deposit shall not constitute a waiver of Tenant’s Default to the extent that the Security Deposit does not fully compensate Landlord for all losses, damages, costs and expenses incurred by Landlord in connection with such Default and shall not prejudice any other rights or remedies available to Landlord under this Lease or by Law. Landlord shall not pay any interest on the Security Deposit. Landlord shall not be required to keep the Security Deposit separate from its general accounts. The Security Deposit shall not be deemed an advance payment of Rent or a measure of damages for any Default by Tenant under this Lease, nor shall it be a bar or defense of any action that Landlord may at any time commence against Tenant. In the absence of evidence satisfactory to Landlord of an assignment of the right to receive the Security Deposit or the remaining balance thereof, Landlord may return the Security Deposit to the original Tenant, regardless of one or more assignments of this Lease. Upon the transfer of Landlord’s interest under this Lease, Landlord’s obligation to Tenant with respect to the Security Deposit shall

 

21


terminate upon transfer to the transferee of the Security Deposit, or any balance thereof. Except as otherwise expressly set forth herein, the Security Deposit, or any balance thereof, shall be returned to Tenant within thirty (30) days after Landlord recovers possession of the Premises. To the fullest extent permitted by law, Landlord may hold and apply the Security Deposit to post termination damages and, to the extent inconsistent, Tenant hereby waives any and all rights of Tenant under the provisions of Section 1950.7 of the California Civil Code or other Law regarding security deposits.

(d)        If Landlord draws upon the Letter of Credit in accordance with the terms of this Lease, Tenant shall, within thirty (30) days after Landlord’s draw, restore the amount available under the Letter of Credit to its original amount by providing Landlord with an amendment to the Letter of Credit evidencing that the amount available under the Letter of Credit has been restored to its original amount. In the alternative, at Tenant’s election, Tenant may deposit with Landlord a cash sum in an amount which when added to the amount available to be drawn under the Letter of Credit equals the face amount of the Letter of Credit. Tenant’s failure to do so shall be a material breach of this Lease.

ARTICLE 6

SERVICES

 

6.1

LANDLORD’S GENERAL SERVICES

(a)        Tenant shall have access to the Building and the Premises twenty-four (24) hours a day, 365 days a year.

(b)        Tenant shall pay directly for all janitorial expenses incurred by Tenant if Tenant elects to contract for janitorial service. If Landlord, upon Tenant’s written request, provides janitorial services to the Premises, Tenant shall pay the costs thereof to Landlord on a monthly basis.

(c)        Throughout the Term, Landlord shall furnish the following services, the cost of which services shall be included in Operating Expenses or paid directly by Tenant to Landlord or the utility or service provider, as applicable, if such services are segregated from the other services provided to the Building:

(1)        heat, ventilation and air conditioning (“HVAC”) (but only to that portion of the Premises with air conditioning existing as of the Date of Lease) in the Premises available twenty four hours per day, seven days per week, subject to compliance with all applicable voluntary and mandatory regulations and Laws; provided, however, in the event Tenant installs its own HVAC system with respect to the Premises as part of the Tenant Improvements or subsequent Tenant Alterations, the cost of such HVAC services to the Premises shall be paid directly by Tenant to the utility or service provider and Tenant shall have no obligation to pay Landlord for any such services to the Premises;

(2)        water for use in the Premises and the Common Areas from the regular supply of the Building unless Tenant installs its own water service for the Premises, in which case Tenant shall be responsible for the cost of such water services; and

 

22


(3)        washing of the outside windows in the Premises weather permitting at intervals determined by Landlord.

 

6.2

SERVICES

(a)        Landlord shall furnish to the Premises electric current, water, sewer, and natural gas service in the quantities existing in the Premises as of the Date of Lease, and Tenant shall pay for such utilities in accordance with Landlord’s customary practice with respect thereto ( i.e. , monthly billings on an estimated basis with annual reconciliations based upon Tenant’s actual usage). Notwithstanding any provision of the Lease to the contrary, without, in each instance, the prior written approval of Landlord, in Landlord’s prudent business judgment, Tenant shall not make any alterations or additions to the existing electric equipment or systems serving the Premises. Tenant’s use of electric current provided by the existing electric equipment or systems shall at no time exceed the capacity of the existing wiring, feeders and risers providing electric current to the Premises or the Building. In the event Tenant installs its own electricity, water, sewer, and/or natural gas systems with respect to the Premises as part of the Tenant Improvements or subsequent Tenant Alterations (the quantities of which new systems shall not be limited to the quantities of the systems existing in the Premises as of the Date of Lease or the capacities of the existing wiring, feeders and risers providing electric current to the Building), then (i) the cost of such utility services to the Premises shall be paid directly by Tenant to the utility or service provider and Tenant shall have no obligation to pay Landlord for any such utility services to the Premises, (ii) Tenant shall promptly furnish copies of any and all utility bills related to the Premises upon request by Landlord, and (iii) by no later than the Termination Date, Tenant shall assign any utilities services agreement and/or service account with respect to the Premises to Landlord (but Tenant shall retain all liabilities and obligations accruing prior to the Termination Date, and shall defend, indemnify, and hold Landlord harmless against any claims, damages, penalties, interest, fees, and/or costs incurred by Landlord arising out of such Tenant liabilities and obligations, except to the extent caused by the willful act or the active negligence of Landlord or its agents, contractors or employees, which indemnity shall survive the Termination Date of this Lease).

 

6.3

TELEPHONE SERVICES

All telephone, and communication connections which Tenant may desire shall be subject to Landlord’s prior written approval, in Landlord’s reasonable discretion, and the location of all wires and the work in connection therewith shall be performed by contractors approved by Landlord and shall be subject to the direction of Landlord, except that such approval is not required as to Tenant’s telephone equipment and Tenant’s internet connectivity (including cabling) within the Premises and from the Premises in a route designated by Landlord to any telephone cabinet or panel provided (as existing) on Tenant’s floors for Tenant’s connection to the telephone cable serving the Building so long as Tenant’s equipment does not require connections different than or additional to those to the telephone cabinet or panel provided. Except to the extent of such cabling within the Premises or from the Premises to such telephone cabinet or panel, Landlord reserves the right to designate and control the entity or entities providing telephone or other communication cable installation, removal, repair and maintenance in the Building and to restrict and control access to telephone cabinets or panels, so long as such entity is competitively priced with other similar vendors. In the event Landlord designates a

 

23


particular vendor or vendors to provide such cable installation, removal, repair and maintenance for the Building pursuant to the immediately preceding sentence, Tenant agrees to abide by and participate in such program. Tenant shall be responsible for and shall pay all costs incurred in connection with the installation of telephone cables and communication wiring in the Premises, including any hook-up, access and maintenance fees related to the installation of such wires and cables in the Premises and the commencement of service therein, and the maintenance thereafter of such wire and cables; and there shall be included in Operating Expenses for the Building all installation, removal, hook-up or maintenance costs incurred by Landlord in connection with telephone cables and communication wiring serving the Building which are not allocable to any individual users of such service but are allocable to the Building generally. If Tenant fails to maintain all telephone cables and communication wiring in the Premises and such failure affects or interferes with the operation or maintenance of any other telephone cables or communication wiring serving the Building and is not repaired by Tenant within three (3) business days after written notice from Landlord of such failure, Landlord or any vendor hired by Landlord, subject to compliance with the terms of Section 7.2, may enter into and upon the Premises forthwith and perform such repairs, restorations or alterations as Landlord reasonably deems necessary in order to eliminate any such interference (and Landlord may recover from Tenant all of Landlord’s out- of-pocket costs in connection therewith). If required by Landlord, no later than the Termination Date Tenant shall remove all telephone cables and communication wiring installed by Tenant for and during Tenant’s occupancy. Except as otherwise provided in Section 6.5, Tenant agrees that neither Landlord nor any of its agents or employees shall be liable to Tenant, or any of Tenant’s employees, agents, customers or invitees or anyone claiming through, by or under Tenant, for any damages, injuries, losses, expenses, claims or causes of action because of any interruption, diminution, delay or discontinuance at any time for any reason in the furnishing of any telephone or other communication service to the Premises and the Building.

 

6.4

DELAYS IN FURNISHING SERVICES

Tenant agrees that Landlord shall not be in breach of this Lease nor be liable to Tenant for damages or otherwise, for any failure to furnish, or a delay in furnishing, or a change in the quantity or character of any service when such failure, delay or change is occasioned, in whole or in part, by repairs, improvements or mechanical breakdowns by the act or default of Tenant or other parties or by an event of Force Majeure. No such failure, delay or change shall be deemed to be an eviction or disturbance of Tenant’s use and possession of the Premises, or relieve Tenant from paying Rent or from performing any other obligations of Tenant under this Lease, without any deduction or offset. Failure to any extent to make available, or any slowdown, stoppage, or interruption of, the specified utility services resulting from any cause, including changes in service provider or Landlord’s compliance with any voluntary or similar governmental or business guidelines now or hereafter published or any requirements now or hereafter established by any governmental agency, board, or bureau having jurisdiction over the operation of the Property shall not render Landlord liable in any respect for damages to either persons, property, or business, nor be construed as an eviction of Tenant or work an abatement of Rent, nor relieve Tenant of Tenant’s obligations for fulfillment of any covenant or agreement hereof. Should any equipment or machinery furnished by Landlord break down or for any cause cease to function properly, Landlord shall use reasonable diligence to repair same promptly, but Tenant shall have no claim for abatement of Rent or damages on account of any interruption of service occasioned thereby or resulting therefrom. Notwithstanding anything in this Section 6.5 to the contrary, if

 

24


the Premises, or a material portion of the Premises, are made untenantable and are not actually used by Tenant for a period in excess of three (3) consecutive business days as a result of a failure, delay or change in any service due to Landlord’s negligence or willful misconduct, and Tenant has given Landlord notice of such failure, delay or change, then Tenant shall be entitled to receive an abatement of Monthly Base Rent payable hereunder (excluding, however, any Tenant Improvement Allowance Monthly Payments, which shall continue to be due and payable regardless of any such rent abatement) during the period beginning on the fourth (4th) consecutive business day after such notice and ending on the day the service has been restored. If the entire Premises have not been rendered untenantable by such failure, delay or change, the amount of abatement shall be equitably prorated.

 

6.5

CHOICE OF SERVICE PROVIDER

Tenant acknowledges that Landlord may, at Landlord’s sole option, to the extent permitted by applicable law, elect to change, from time to time, the company or companies which provide services (including electrical service, gas service and water, but not the telephone service provider) to the Building, the Premises and/or its occupants. Notwithstanding anything to the contrary set forth in this Lease, Tenant acknowledges that Landlord has not and does not make any representations or warranties concerning the identity or identities of the company or companies which provide services to the Building and the Premises or its occupants and Tenant acknowledges that the choice of service providers and matters concerning the engagement and termination thereof shall be solely that of Landlord. The foregoing provision is not intended to modify, amend, change or otherwise derogate any provision of this Lease concerning the nature or type of service to be provided or any specific information concerning the amount thereof to be provided. Tenant agrees to cooperate with Landlord and each of its service providers in connection with any change in service or provider.

 

6.6

SIGNAGE

If, at any time during the Term, Landlord installs any common, non-exclusive monument signage for the Project featuring tenant names, Tenant shall have the right to display its name on the most prominent position thereon at Tenant’s sole cost and expense, subject to Landlord’s reasonable approval of the design and location of such signage. Once installed, Landlord shall maintain any monument sign in good condition and repair, the cost of which shall be an Operating Expense. Subject to the rights of any existing tenants of the Building as of the Date of Lease, Landlord shall not grant more prominent on-building signage to other tenants of the Building than it will grant to Tenant. Tenant shall also have the right to install signage at its main entry door at its sole cost and expense, subject to Landlord’s reasonable approval of the design of such signage.

ARTICLE 7

POSSESSION, USE AND CONDITION OF PREMISES

 

7.1

POSSESSION AND USE OF PREMISES

(a)        Tenant shall occupy and use the Premises only for the uses specified in Section 1.1 to conduct Tenant’s business. Tenant shall not occupy or use the Premises (or permit the use

 

25


or occupancy of the Premises) for any purpose or in any manner which: (1) is unlawful or in violation of any Law or Hazardous Materials Law; (2) may increase the cost of, or invalidate, any policy of insurance carried on the Building or covering its operations; (3) is contrary to or prohibited by the terms and conditions of this Lease or the rules of the Building set forth in Article Eighteen; or (4) would create or continue a nuisance.

(b)        Landlord, at its cost and not part of the Tenant Improvement Allowance, shall provide Tenant with keys in number sufficient for all occupants of the Premises; and, when delivered to Tenant, Tenant shall place a deposit for such keys with Landlord to cover lost keys or keys which are not returned at the end of the Term.

(c)        Landlord and Tenant acknowledge that the Americans With Disabilities Act of 1990 (42 U.S.C. §12101 et seq.) and regulations and guidelines promulgated thereunder, as all of the same may be amended and supplemented from time to time (collectively referred to herein as the “ADA”) establish requirements for business operations, accessibility and barrier removal, and that such requirements may or may not apply to the Premises, the Building and the Project depending on, among other things: (1) whether Tenant’s business is deemed a “public accommodation” or “commercial facility”, (2) whether such requirements are “readily achievable”, and (3) whether a given alteration affects a “primary function area” or triggers “path of travel” requirements. The parties hereby agree that: (a) Landlord shall be responsible for ADA Title III compliance in the Common Areas and “path of travel” requirements to the Premises and the restrooms, as of the Commencement Date, and, except as set forth in subsection (b) of this Section 7.1(c), for any “path of travel” requirements or other improvements to any portion of the Building or the Project outside of the Premises triggered by Tenant Alterations, (b) Landlord may perform, or require that Tenant perform, and Tenant shall be responsible for the cost of, ADA Title III “path of travel” requirements triggered by Tenant Alterations which change the entrances to the Building as they exist as of the Date of Lease, and (c) Landlord may perform, or require Tenant to perform, and Tenant shall be responsible for the cost of, ADA Title III compliance in the Common Areas necessitated by the Building being deemed to be a “public accommodation” instead of a “commercial facility” as a result of Tenant’s particular use of the Premises which change the entrances to the Building as they exist as of the Date of Lease. Tenant shall be solely responsible for requirements under Title I of the ADA relating to Tenant’s employees.

(d)         Hazardous Materials .

(1)         Definitions. The following terms shall have the following meanings for purposes of this Lease:

(i)        “Biohazardous Materials” means any and all substances and materials defined or referred to as a “medical waste,” “biological waste,” “biohazardous waste,” “biohazardous material” or any other term of similar import under any Hazardous Materials Laws, including (but not limited to) California Health & Safety Code Sections 25105 et seq., and any regulations promulgated thereunder, as amended from time to time.

 

26


(ii)        “Environmental Condition” means the Release of any Hazardous Materials in, over, on, under, from or about the Project (including, but not limited to, the Premises).

(iii)        “Environmental Damages” means all claims, suits, judgments, damages, losses, penalties, fines, liabilities, encumbrances, liens, costs and expenses of whatever kind or nature, contingent or otherwise, matured or unmatured, foreseeable or unforeseeable, arising out of or in connection with any Environmental Condition, including, to the extent arising out of an Environmental Condition, without limitation: (A) damages for personal injury, or for injury to the Project or natural resources occurring on or off the Project, including without limitation (1) any claims brought by or on behalf of any person, (2) any damage to the Project or natural resource, and (3) costs of any investigation, remediation, removal, abatement, containment, closure, restoration or monitoring work required by any federal, state or local governmental agency or political subdivision, or Hazardous Materials Law; (B) reasonable fees incurred for the services of attorneys, consultants, contractors, experts and laboratories in connection with the preparation of any feasibility studies, investigations or reports or the performance of any work described above; and (C) any liability to any third person or governmental agency to indemnify such person or agency for costs expended or liabilities incurred in connection with any items described in clause (A) or (B) above.

(iv)        “Handling,” when used with reference to any Hazardous Material, means any receipt, storage, use, generation, Release, transportation, treatment or disposal of such Hazardous Material.

(v)        “Hazardous Materials” means any and all explosive, biohazardous, radioactive or otherwise toxic or hazardous materials or hazardous wastes, including, without limitation, any asbestos-containing materials, PCB’s, CFCs, petroleum and derivatives thereof, Radioactive Materials, Biohazardous Materials, Hazardous Wastes, any other substances defined or listed as or meeting the characteristics of a hazardous substance, hazardous material, hazardous waste, extremely hazardous waste, restricted hazardous waste, toxic substance, toxic waste, biohazardous material, biohazardous waste, biological waste, medical waste, radiation, radioactive substance, radioactive waste, or other similar term, as applicable, under any Hazardous Materials Laws, and/or any mixed materials, substances or wastes containing more than one of the foregoing categories of materials, substances or wastes.

(vi)        “Hazardous Materials Laws” means, collectively, (A) the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. Sections 9601-9657, (B) the Hazardous Materials Transportation Act of 1975, 49 U.S.C. Sections 1801-1812, (C) the Resource Conservation and Recovery Act of 1976, 42 U.S.C. Sections 6901-6987 (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, “RCRA”), (D) the California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health & Safety Code Sections 25300 et seq., (E) the Hazardous Materials Release Response Plans and Inventory Act, California Health & Safety Code Sections 25500 et seq., (F) the California Hazardous Waste Control Law, California Health & Safety Code Sections 25100 et seq. (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, the “CHWCL”), (G) California Health & Safety Code Sections

 

27


25015-25027.8, (H) any amendments to or successor statutes to any of the foregoing, as adopted or enacted from time to time, (I) any regulations or amendments thereto promulgated pursuant to any of the foregoing from time to time, (J) any statutes, laws, ordinances, codes, rules or regulations relating to Biohazardous Materials, including (but not limited to) any regulations or requirements with respect to the shipping, use, decontamination and disposal thereof, and (K) any other Laws now or at any time hereafter in effect regulating, relating to or imposing liability or standards of conduct concerning any Hazardous Materials, including (but not limited to) any requirements or conditions imposed pursuant to the terms of any orders, permits, licenses, registrations or operating plans issued or approved by any governmental or quasi- governmental authority from time to time either on a Project-wide basis or in connection with any Handling of Hazardous Materials in, on or about the Premises or the Project.

(vii)        “Hazardous Wastes” means (A) any waste listed as or meeting the identified characteristics of a “hazardous waste” or terms of similar import under RCRA, (B) any waste meeting the identified characteristics of a “hazardous waste,” “extremely hazardous waste” or “restricted hazardous waste” under the CHWCL, and/or (C) any and all other substances and materials defined or referred to as a “hazardous waste” or other term of similar import under any Hazardous Materials Laws.

(viii)        “Radioactive Materials” means (A) any and all substances and materials the Handling of which requires an approval, consent, permit or license from the Nuclear Regulatory Commission, (B) any and all substances and materials the Handling of which requires a Radioactive Material License or other similar approval, consent, permit or license from the State of California, and (C) any and all other substances and materials defined or referred to as “radiation,” a “radioactive material” or “radioactive waste,” or any other term of similar import under any Hazardous Materials Laws, including (but not limited to) Title 26, California Code of Regulations Section 17-30100, and any statutes, regulations or other laws administered, enforced or promulgated by the Nuclear Regulatory Commission.

(ix)        “Release” means any accidental or intentional spilling, leaking, pumping, pouring, emitting, discharging, injecting, escaping, leaching, migrating, dumping or disposing into the air, land, surface water, groundwater or the environment (including without limitation the abandonment or discarding of receptacles containing any Hazardous Materials).

(x)        “Tenant Contamination” means any Hazardous Material Release in violation of any Hazardous Materials Laws on or about the Property by Tenant and/or any agents, employees, contractors, vendors, suppliers, licensees, subtenants, and invitees of Tenant (a “Tenant Party”).

(xi)        “Landlord Contamination” means any hazardous materials which exist in, on, under, at or in the vicinity of the Project as of the date of this Lease or which migrate onto or beneath the Project from off-site sources during the term of the Lease or after termination of the Lease. Tenant shall not be required to pay any costs with respect to the remediation or abatement of Landlord Contamination.

(2)          Handling of Hazardous Materials .   The parties acknowledge that Tenant wishes and intends to use all or a portion of the Premises as a fermentation research pilot plant

 

28


and otherwise for the conduct by Tenant of its business in accordance with the use specified in Section 1.1, that such use, as conducted or proposed to be conducted by Tenant, would customarily include the Handling of Hazardous Materials, and that Tenant shall therefore be permitted to engage in the Handling in the Premises of necessary and reasonable quantities of Hazardous Materials customarily used in or incidental to the operation of a fermentation research pilot plant and the other business operations of Tenant in the manner conducted or proposed to be conducted by Tenant hereunder (“Permitted Hazardous Materials”), provided that the Handling of such Permitted Hazardous Materials by all Tenant Parties shall at all times comply with and be subject to all provisions of this Lease and all applicable requirements of Hazardous Materials Laws. Without limiting the generality of the foregoing, Tenant shall comply at all times with all Hazardous Materials Laws applicable to any aspect of Tenant’s use of the Premises and the Project and of Tenant’s operations and activities in, on and about the Premises and the Project, and shall ensure at all times that Tenant’s Handling of Hazardous Materials on and about the Premises does not violate the terms of any governmental licenses or permits applicable to the Building or Premises or to Tenant’s Handling of any Hazardous Materials therein.

(3)         Disposition or Emission of Hazardous Materials .  Tenant shall not Release or dispose of any Hazardous Wastes or Hazardous Materials, except to the extent authorized by permit or in compliance with applicable Hazardous Materials Laws, at the Premises or on the Project, but instead shall arrange for off-site disposal, under Tenant’s own name and EPA waste generator number (or other similar identifying information issued or prescribed by any other governmental authority with respect to Radioactive Materials, Biohazardous Materials or any other Hazardous Materials) and at Tenant’s sole expense, in compliance with all applicable Hazardous Materials Laws, with the rules and regulations listed in Exhibit C-1 and Exhibit C-2 attached hereto and with all other applicable legal and regulatory requirements.

(4)         Information Regarding Hazardous Materials .  Tenant shall provide the following information and/or documentation to Landlord in writing prior to the Commencement Date, and thereafter shall update such information and/or documentation as specifically described in subsections (i)-(x) below, which updates shall reflect any material changes in such information and/or documentation:

(i)        An inventory of all Hazardous Materials that Tenant receives, uses, handles, generates, transports, stores, treats or disposes of from time to time, or at the time of preparation of such inventory proposes or expects to use, handle, generate, transport, store, treat or dispose of from time to time, in connection with its operations at the Premises. Such inventory shall include, but shall separately identify, any Hazardous Wastes, Biohazardous Materials and Radioactive Materials covered by the foregoing description. If such inventory includes any Biohazardous Materials, Tenant shall also disclose in writing to Landlord the Biosafety Level designation associated with the use of such materials. Such inventory shall be updated annually, in January of each calendar year.

(ii)        Copies of all then existing permits, licenses, registrations and other similar documents issued by any governmental or quasi-governmental authority that authorize any Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party. Such information shall be updated annually, in January of each calendar year.

 

29


(iii)        All Material Safety Data Sheets (“MSDSs”), if any, required to be completed with respect to operations of Tenant at the Premises from time to time in accordance with Title 26, California Code of Regulations Section 8-5194 or 42 U.S.C. Section 11021, or any amendments thereto, and any Hazardous Materials Inventory Sheets that detail the MSDSs. Such information shall be updated from time to time upon Landlord’s written request.

(iv)        All hazardous waste manifests (as defined in Title 26, California Code of Regulations Section 22-66481), if any, that Tenant is required to complete from time to time in connection with its operations at the Premises. Such information shall be updated from time to time upon Landlord’s written request.

(v)        A copy of any Hazardous Materials Business Plan required from time to time with respect to Tenant’s operations at the Premises pursuant to California Health & Safety Code Sections 25500 et seq., and any regulations promulgated thereunder, as amended from time to time, or in connection with Tenant’s application for a business license from the City of Emeryville. If applicable law does not require Tenant to prepare a Hazardous Materials Business Plan, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Hazardous Materials Business Plan, including (but not limited to) information regarding Tenant’s Hazardous Materials inventories. The parties acknowledge that a Hazardous Materials Business Plan would ordinarily include an emergency response plan, and that regardless of whether applicable law requires Tenant or other tenants in the Building to prepare Hazardous Materials Business Plans, Landlord in its discretion may elect to prepare a coordinated emergency response plan for the entire Building and/or for multiple Buildings on the Project. Such information shall be updated from time to time upon Landlord’s written request.

(vi)        Any Contingency Plans and Emergency Procedures required of Tenant from time to time, in connection with its operations at the Premises, pursuant to applicable law, Title 26, California Code of Regulations Sections 22-67140 et seq., and any amendments thereto, and any Training Programs and Records required under Title 26, California Code of Regulations Section 22-66493, and any amendments thereto from time to time, Landlord in its discretion may elect to prepare a Contingency Plan and Emergency Procedures for the entire Building and/or for multiple Buildings on the Project, in which event, if applicable law does not require Tenant to prepare a Contingency Plan and Emergency Procedures for its operations at the Premises, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Contingency Plan and Emergency Procedures. Such information shall be updated from time to time upon Landlord’s written request.

(vii)        Copies of any biennial or other periodic reports furnished or required to be furnished to the California Department of Health Services from time to time, under applicable law, pursuant to Title 26, California Code of Regulations Section 22-66493 and any amendments thereto, relating to any Hazardous Materials.

(viii)        Copies of any industrial wastewater discharge permits issued to or held by Tenant from time to time in connection with its operations at the Premises (to the extent

 

30


Tenant is required to maintain a separate, individual discharge permit in addition to any discharge permit for the Building maintained by Landlord in Landlord’s name).

(ix)        Copies of any other lists, reports, studies, or inventories of Hazardous Materials or of any subcategories of materials included in Hazardous Materials that Tenant is otherwise required to prepare and file from time to time with any governmental or quasi-governmental authority in connection with Tenant’s operations at the Premises, including (but not limited to) reports filed by Tenant with the Federal Food & Drug Administration or any other regulatory authorities primarily in connection with the presence (or lack thereof) of any “select agents” or other Biohazardous Materials on the Premises, together with proof of filing thereof.

(x)        Any other information reasonably requested by Landlord in writing from time to time in connection with (A) Landlord’s monitoring (in Landlord’s reasonable discretion) and enforcement of Tenant’s obligations under this Section and of compliance with applicable Hazardous Materials Laws in connection with any Handling or Release of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, (B) any inspections or enforcement actions by any governmental authority pursuant to any Hazardous Materials Laws relating to the presence or Handling of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, and/or (C) Landlord’s preparation (in Landlord’s discretion) and enforcement of any reasonable rules and procedures relating to the presence or ‘Handling by Tenant or any Tenant Party of Hazardous Materials in the Premises or Building or on or about the Project, including (but not limited to) any contingency plans or emergency response plans as described above. Except as otherwise required by Law, Landlord shall keep confidential any information supplied to Landlord by Tenant pursuant to the foregoing, provided, however, that the foregoing shall not apply to any information filed by Tenant with any governmental authority or available to the public at large. Landlord may provide such information to its lenders, consultants, purchasers or investors on a need to know basis provided (i) such entities agree in writing to keep such information confidential; (ii) Landlord uses diligent efforts to limit the scope of any such disclosure to only those portions of the information which are necessary for the intended purpose; and (iii) no less than ten (10) days prior to making any such disclosure, Landlord provides Tenant with written notice of the identity of the receiving party and the scope and purpose of the disclosure, and permits Tenant to redact those portions of the information which Tenant believes are reasonably necessary to protect its proprietary and/or confidential information.

(5)         Indemnification; Notice of Release .   Tenant shall be responsible for and shall indemnify, defend and hold Landlord harmless from and against all Environmental Damages to the extent arising out of or in connection with, or otherwise relating to, (i) any Handling of Hazardous Materials by any Tenant Party in, on or about the Premises or the Project in violation of this Section 7.1(d), (ii) any breach of Tenant’s obligations under this Section or of any Hazardous Materials Laws by any Tenant Party, or (iii) the existence of any Tenant Contamination in, on or about the Premises or the Project to the extent caused by any Tenant Party, including without limitation any removal, cleanup or restoration work and materials necessary to return the Project or any improvements of whatever nature located on the Project to the condition existing prior to the Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party. In the event of any Tenant Contamination in, on or about the

 

31


Premises or any other portion of the Project or any adjacent lands, Tenant shall promptly remedy the problem in accordance with all applicable Hazardous Materials Laws, shall give Landlord oral notice of any such non-standard or non-customary Release promptly after Tenant becomes aware of such Release, followed by written notice to Landlord within five (5) days after Tenant becomes aware of such Release, and shall furnish Landlord with concurrent copies of any and all notices, reports and other written materials filed by any Tenant Party with any governmental authority in connection with such Release. Landlord shall be responsible for and shall indemnify and hold Tenant harmless from and against all Environmental Damages which arise prior to, during or after the Term of this Lease, as a result of the presence of, any Release of or the Handling of any Hazardous Material in, on, about, to, from or under the Premises, Building or Property, except to the extent provided for as Tenant’s responsibility in this Section 7.1(d); provided that, if the Hazardous Materials that are the subject of such Release are Hazardous Materials that Tenant uses, handles, generates, transports, stores, treats or disposes of at or from the Premises (as such Hazardous Materials are specified on the inventory or other information to be provided by Tenant pursuant to Section 7.1(d)(4) above), Tenant shall have the burden of reasonably demonstrating that such Hazardous Materials were not Released by Tenant, otherwise Landlord shall have the burden of reasonably demonstrating that Tenant was responsible for the Release of such Hazardous Materials. Tenant shall have no obligation to remedy any Hazardous Materials contamination which was not caused or Released by a Tenant Party. Notwithstanding anything to the contrary herein, neither Landlord nor Tenant shall be responsible for or be required to indemnify the other for lost profits, or other consequential, punitive or special damages incurred by the other.

(6)         Governmental Notices .   Tenant shall promptly provide Landlord with copies of all written notices received by Tenant relating to any actual or alleged presence or Handling by any Tenant Party of Hazardous Materials in, on or about the Premises or any other portion of the Project, including, without limitation, any notice of violation, notice of responsibility or demand for action from any federal, state or local governmental authority or official in connection with any actual or alleged presence or Handling by any Tenant Party of Hazardous Materials in or about the Premises or any other portion of the Project.

(7)         Inspection by Landlord .   In addition to, and not in limitation of, Landlord’s rights under this Lease, upon reasonable prior request by Landlord (provided, however, not more than twice a year absent a material breach of this Section 7.1(d) by Tenant), Tenant shall grant Landlord and its consultants, as well as any governmental authorities having jurisdiction over the Premises or over any aspect of Tenant’s use thereof, reasonable access to the Premises at reasonable times, with reasonable prior notice, to inspect Tenant’s Handling of Hazardous Materials in, on and about the Premises, and Landlord shall not thereby incur any liability to Tenant or be deemed guilty of any disturbance of Tenant’s use or possession of the Premises by reason of such entry; provided, however that Landlord shall use reasonable efforts to minimize interference with Tenant’s use of the Premises caused by such entry. Landlord shall comply with any security precaution reasonably imposed by Tenant during any entry onto the Premises and shall minimizes to the extent reasonably possible any interference with Tenant’s use of the Premises caused by such entry. Notwithstanding Landlord’s rights of inspection and review of documents, materials and physical conditions under this Section with respect to Tenant’s Handling of Hazardous Materials, Landlord shall have no duty or obligation to perform any such inspection or review or to monitor in any way any documents, materials, physical

 

32


conditions or compliance with Hazardous Materials Laws in connection with Tenant’s Handling of Hazardous Materials, and no third Party shall be entitled to rely on Landlord to conduct any such inspection, review or monitoring by reason of the provisions of this Section.

(8)         Monitoring by Landlord .   Landlord reserves the absolute right to monitor, in Landlord’s reasonable discretion and at Landlord’s cost (the reasonable cost of which shall be recoverable as an Operating Expense hereunder (except in the case of a breach of any of Tenant’s obligations under this Section, in which event such monitoring costs may be charged back entirely to Tenant and shall be reimbursed by Tenant to Landlord within ten (10) days after written demand by Landlord from time to time, accompanied by supporting documentation reasonably evidencing the costs for which such reimbursement is claimed)), at such times and from time to time as Landlord in its reasonable discretion may determine, through consultants engaged by Landlord or otherwise as Landlord in its reasonable discretion may determine, (x) all aqueous and atmospheric discharges and emissions from the Premises during the Term by a Tenant Party, (y) Tenant’s compliance and the collective compliance of all tenants in the Building with requirements and restrictions relating to the occupancy classification of the Building (including, but not limited to, Hazardous Materials inventory levels of Tenant and all other tenants in the Building), and (z) Tenant’s compliance with all other requirements of this Section.

(9)         Discovery of Discharge .   If Landlord, Tenant or any governmental or quasi-governmental authority discovers any Release from the Premises during the Term by a Tenant Party in violation of this Section 7.1(d) that, in Landlord’s reasonable determination, jeopardizes the ability of the Building or the Project to comply with applicable Hazardous Materials Laws, or if Landlord discovers any other breach of Tenant’s obligations under this Section 7.1(d), then upon receipt of written notice from Landlord or at such earlier time as Tenant obtains actual knowledge of such Release, Tenant at its sole expense shall within a reasonable time (x) in the case of a Release in violation of this Lease, cease the applicable discharge or emission and remediate any continuing effects of the discharge or emission until such time, if any, as Tenant demonstrates to Landlord’s reasonable satisfaction that the applicable discharge or emission is in compliance with all applicable Hazardous Materials Laws and any other applicable regulatory commitments and obligations to the satisfaction of the appropriate governmental agency with jurisdiction over the Release, and (y) in the case of any other breach of Tenant’s obligations under this Section 7.1(d), take such corrective measures consistent with applicable Hazardous Materials Laws as Landlord may reasonably request in writing in order to cure or eliminate the breach as promptly as practicable and to remediate any continuing effects of the breach.

(10)         Post-Occupancy Study .   If Tenant or any Tenant Party Handles any Hazardous Materials in, on or about the Premises or the Project during the Term of this Lease, then no later than fifteen (15) days prior to the termination or expiration of this Lease, Tenant at its sole cost and expense shall obtain and deliver to Landlord an environmental study, performed by an expert reasonably satisfactory to Landlord, evaluating, the presence or absence of any Tenant Contamination in, on and about the Premises and the Property. Such study shall be based on a reasonable and prudent level of tests and investigations of the Premises and surrounding portions of the Project (if appropriate) which tests shall be conducted no earlier than the date of termination or expiration of this Lease. Liability for any remedial actions required or

 

33


recommended on the basis of such study shall be allocated in accordance with the applicable provisions of this Lease. To the extent any such remedial actions are the responsibility of Tenant, Tenant at its sole expense shall promptly commence and diligently pursue to completion the required remedial actions.

(11)         Emergency Response Plans .   If Landlord in its reasonable discretion adopts any emergency response plan and/or any Contingency Plan and Emergency Procedures for the Building or for multiple Buildings on the Project as contemplated above, Landlord shall provide copies of any such plans and procedures to Tenant and, so long as such plans and procedures are reasonable and do not unreasonably interfere with Tenant’s use of or access to the Premises or materially increase the cost incurred by Tenant with respect to the Premises, Tenant shall comply with all of the requirements of such plans and procedures to the extent applicable to Tenant and/or the Premises. If Landlord elects to adopt or materially modify any such plans or procedures that apply to the Building during the Term of this Lease, Landlord shall consult with Tenant in the course of preparing such plans, procedures or modifications in order to try to ensure that they will accurately reflect and be consistent with Tenant’s operations in the Premises, but Landlord alone shall determine, in its good faith reasonable discretion, the appropriate scope of such consultation and nothing in this paragraph shall be construed to give Tenant any right of approval or disapproval over Landlord’s adoption or modification of any such plans or procedures so long as such plans and procedures are reasonable and do not unreasonably interfere with Tenant’s Use at or access to the Premises or materially increase the cost incurred by Tenant with respect to the Premises.

(12)         Radioactive Materials .   Without limiting any other applicable provisions of this Section, if Tenant Handles or proposes to Handle any Radioactive Materials in or about the Premises, Tenant shall provide Landlord with copies of Tenant’s licenses or permits for such Radioactive Materials and with copies of all radiation protection programs and procedures required under applicable Hazardous Materials Laws or otherwise adopted by Tenant from time to time in connection with Tenant’s Handling of such Radioactive Materials. In addition, Tenant shall comply with any and all rules and procedures issued by Landlord in its good faith discretion from time to time with respect to the Handling of Radioactive Materials on the Project (such as, by way of example but not limitation, rules implementing a label defacement program for decayed waste destined for common trash and/or rules relating to transportation and storage of Radioactive Materials on the Project), provided that such rules and procedures shall be reasonable and not in conflict with any applicable Hazardous Materials Laws.

(13)         Deemed Holdover Occupancy .   Notwithstanding any other provisions of this Lease, Tenant expressly agrees as follows:

(i)        If Tenant Handles any Radioactive Materials in or about the Premises during the Term of this Lease, then for so long as any license or permit relating to such Radioactive Materials remains open following any otherwise applicable termination or expiration of the Term of this Lease and another entity handling Radioactive Materials which is a bona fide prospective tenant of Landlord as demonstrated by a current signed lease proposal or letter of intent is legally prohibited from occupying a portion of the Premises for a use similar to the Use while such license or permit remains open, then and in such event, Tenant shall be deemed to be occupying that portion of the Premises on a holdover basis without Landlord’s consent

 

34


(notwithstanding such otherwise applicable termination or expiration of the Term of this Lease) and shall be required to continue to pay Rent in accordance with the holdover provisions of this Lease solely for that portion of the Premises which is covered by the radioactive materials license or permit, until such time as all such Radioactive Materials licenses and permits have been fully closed out in accordance with the requirements of all applicable Hazardous Materials Laws.

(ii)        If Tenant Handles any Hazardous Materials in or about the Premises during the Term of this Lease and, at the otherwise applicable termination or expiration of the Term of this Lease Tenant has failed to remove from the Premises and the Building all known Hazardous Materials Handled by a Tenant Party or has failed to complete any remediation or removal of Tenant’s Contamination and/or to have fully remediated, in compliance with the requirements of all applicable Hazardous Materials Laws, the Tenant’s Handling and/or Release (if applicable) of any such Hazardous Materials during the Term of this Lease, then for so long as such circumstances continue to exist, and a bona fide prospective tenant of Landlord as demonstrated by a current signed lease proposal or letter of intent is prohibited under applicable Hazardous Materials Laws from occupying a portion of the Premises for its valid business purposes otherwise permitted by the City of Emeryville as a result of Tenant’s failure to complete any such required remediation or removal, Tenant shall be deemed to be occupying the Premises on a holdover basis without Landlord’s consent (notwithstanding such otherwise applicable termination or expiration of the Term of this Lease) and shall be required to continue pay Rent in accordance with the holdover provisions of this Lease until such time as all such circumstances have been fully resolved in accordance with the requirements of this Lease and with all applicable Hazardous Materials Laws.

(14)         Survival of Obligations .   Each party’s obligations under this Section 7.1(d) shall survive the expiration or other termination of this Lease and shall survive any conveyance by Landlord of its interest in the Premises. The provisions of this Section 7.1(d) and any exercise by either party of any of the rights and remedies contained herein shall be without prejudice to any other rights and remedies that such party may have under this Lease or under applicable law with respect to any Environmental Conditions and/or any Hazardous Materials with respect to any breach of the other party’s obligations under this Section 7.1(d). Either party’s exercise or failure to exercise, at any time or from time to time, any or all of the rights granted in this Section 7.1(d) shall not in any way impose any liability on such party or shift from the other party to such party any responsibility or obligation imposed upon the other party under this Lease or under applicable law with respect to Hazardous Materials, Environmental Conditions and/or compliance with Hazardous Materials Laws.

(15)         Laboratory Rules and Regulations .   Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the laboratory rules and regulations (“Laboratory Rules and Regulations”) attached to this Lease as Exhibit C-1 and with all reasonable modifications and additions thereto which Landlord may make from time to time.

(16)         Copies of Environmental Documents .   Landlord represents it has provided to Tenant copies of all environmental reports (including Phase 1 Environmental Assessments and invasive soil and groundwater investigation and remediation reports) within its possession or control as of the Date of Lease.

 

35


7.2

LANDLORD ACCESS TO PREMISES; APPROVALS

(a)        Tenant shall permit Landlord to erect, use and maintain pipes, ducts, wiring and conduits in and through the Premises, so long as Tenant’s use, layout or design of the Premises is not materially affected or altered. Landlord or Landlord’s agents shall have the right to enter upon the Premises in the event of an emergency, or to inspect the Premises, to perform janitorial and other services, to conduct safety and other testing in the Premises and to make such repairs, alterations, improvements or additions to the Premises or the Building or other parts of the Property as Landlord may deem necessary or desirable (including all alterations, improvements and additions in connection with a change in service provider or providers). Landlord shall provide not less than one (1) business days’ written notice prior to entry into the Premises except for the ongoing provision of Landlord services and for emergencies. Any janitorial and cleaning services pursuant to this Lease shall be performed after normal business hours. Any entry or work by Landlord may be during normal business hours provided Landlord uses reasonable efforts to ensure that any entry or work shall not materially interfere with Tenant’s use or occupancy of the Premises. Except in connection with any ongoing provision by Landlord of janitorial and cleaning services or in an emergency, Landlord shall be accompanied by an authorized representative of Tenant upon each entry by Landlord into the Premises.

(b)        If Tenant shall not be personally present to permit an entry into the Premises when for any reason an entry therein shall be necessary or permissible, Landlord (or Landlord’s agents), after attempting to notify Tenant (unless Landlord believes an emergency situation exists), may enter the Premises without rendering Landlord or its agents liable therefor, and without relieving Tenant of any obligations under this Lease.

(c)        Subject to the notice requirement and other terms of Landlord’s entry set forth in Section 7.2(a), Landlord may enter the Premises for the purpose of conducting such inspections, tests and studies as Landlord may reasonably deem necessary to confirm Tenant’s compliance with all Laws and Hazardous Materials Laws or for other purposes necessary in Landlord’s reasonable judgment to ensure the sound condition of the Property and the systems serving the Property. Landlord’s rights under this Section 7.2(c) are for Landlord’s own protection only, and Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party as a result of the exercise or non-exercise of such rights, for compliance with Laws or Hazardous Materials Laws or for the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.

(d)        Subject to the notice requirement and other terms of Landlord’s entry set forth in Section 7.2(a), Landlord may do any of the foregoing, or undertake any of the inspection or work described in the preceding paragraphs without such action constituting an actual or constructive eviction of Tenant, in whole or in part, or giving rise to an abatement of Rent by reason of loss or interruption of business of the Tenant, or otherwise.

(e)        The review, approval or consent of Landlord with respect to any item required or permitted under this Lease is for Landlord’s own protection only, and Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party, as a result of the exercise or non-exercise of such rights, for compliance with Laws or Environmental Laws or for

 

36


the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.

 

7.3

QUIET ENJOYMENT

Landlord covenants, in lieu of any implied covenant of quiet possession or quiet enjoyment, that so long as Tenant is in compliance with the covenants and conditions set forth in this Lease, Tenant shall have the right to quiet enjoyment of the Premises without hindrance or interference from Landlord or those claiming through Landlord, and subject to the covenants and conditions set forth in the Lease and to the rights of any Mortgagee or ground lessor.

ARTICLE 8

MAINTENANCE

 

8.1

LANDLORD’S MAINTENANCE

Subject to the provisions of Article 4 and Article 14, and any costs of which that are recoverable by Landlord under this Lease as part of its Operating Expenses, Landlord shall maintain in good condition and make necessary repairs to the foundations, roofs, exterior walls, entrances, exterior windows, and the structural elements of the Building, the electrical, plumbing, heating, ventilating, air conditioning, mechanical, communication, security and fire and life safety systems of the Building, and the Common Areas, except that: (a) Landlord shall not be responsible for the maintenance or repair of anything in the Premises other than “structural” elements, or any of such systems which are located within the Premises, serve only the Premises and are supplemental or special to the Building’s standard systems; and (b) the cost of performing any of said maintenance or repairs whether to the Premises or to the Building caused by the negligence of Tenant, its employees, agents, servants, licensees, subtenants, contractors or invitees, shall be paid solely by Tenant, subject to the waivers set forth in Section 16.4. Landlord shall not be liable to Tenant for any expense, injury, loss or damage resulting from work done in or upon, or in connection with the use of, any adjacent or nearby building, land, street or alley.

 

8.2

TENANT’S MAINTENANCE

Tenant shall periodically inspect the Premises to identify any conditions that are dangerous or in need of maintenance or repair. Tenant shall promptly provide Landlord with notice of any such conditions. Tenant shall, at its sole cost and expense, perform all maintenance and repairs to the Premises that are not Landlord’s express responsibility under this Lease, and keep the Premises in good condition and repair, reasonable wear and tear excepted. Tenant’s repair and maintenance obligations include, without limitation, repairs to: (a) floor covering; (b) interior partitions; (c) doors; (d) the interior side of demising walls; (e) electronic, phone and data cabling and related equipment that is installed by or for the exclusive benefit of Tenant (collectively, “Cable”); (f) supplemental air conditioning units, kitchens, including hot water heaters, plumbing, and similar facilities exclusively serving Tenant; and (g) Alterations. To the extent Landlord is not reimbursed by insurance proceeds, Tenant shall reimburse Landlord for the cost of repairing damage to the Building caused by the acts of Tenant, Tenant Related Parties and their respective contractors and vendors. If Tenant fails to make any repairs to the Premises

 

37


for more than 15 days after notice from Landlord (although notice shall not be required in an emergency), Landlord may make the repairs, and Tenant shall pay the reasonable out-of-pocket cost of the repairs, together with an administrative charge in an amount equal to 10% of the cost of the repairs. Tenant hereby waives all right to make repairs at the expense of Landlord or in lieu thereof to vacate the Premises and its other similar rights as provided in California Civil Code Sections 1932(1), 1941 and 1942 or any other Legal Requirement (whether now or hereafter in effect). In addition to the foregoing, Tenant shall be responsible for repairing all special tenant fixtures and improvements, including garbage disposals, showers, plumbing, and appliances.

ARTICLE 9

ALTERATIONS AND IMPROVEMENTS

 

9.1

TENANT ALTERATIONS

(a)        The following provisions shall apply to the completion of any Tenant Alterations (other than the Tenant Improvements, the design, construction and completion of which are instead addressed in the Workletter):

(1)        Tenant shall not, except as provided herein, without the prior written consent of Landlord, which consent shall not be unreasonably withheld, make or cause to be made any Tenant Alterations in or to the Premises or any Property systems serving the Premises. Prior to making any Tenant Alterations, Tenant shall give Landlord ten (10) days prior written notice (or such earlier notice as would be necessary pursuant to applicable Law) to permit Landlord sufficient time to post appropriate notices of non-responsibility. Subject to all other requirements of this Article Nine, Tenant may undertake Decoration Work and may install and remove Cable (“Cabling Work”) without Landlord’s prior written consent. For Tenant Alterations other than Decoration Work and Cabling Work, Tenant shall furnish Landlord with the names and addresses of all contractors and subcontractors and copies of all contracts. All Tenant Alterations (other than Decoration Work and Cabling Work) shall be performed only by contractors or mechanics approved by Landlord, which approval shall not be unreasonably withheld, provided, however, that Landlord may, in its sole discretion, specify the engineers and contractors to perform all work relating to the Building systems (including the mechanical, heating, plumbing, security, ventilating, air-conditioning, electrical, communication and the fire and life safety systems in the Building) provided that the rates of such contractors are competitive with the rates of other contractors qualified (in Landlord’s reasonable judgment) to perform such work, The contractors, mechanics and engineers who may be used are further limited to those whose work will not cause or threaten to cause disharmony or interference with Landlord or other tenants in the Building and their respective agents and contractors performing work in or about the Building. Landlord may further condition its consent to Tenant Alterations (other than Decoration Work and Cabling Work) upon Tenant furnishing to Landlord and Landlord approving prior to the commencement of any work or delivery of materials to the Premises related to the Tenant Alterations such of the following as specified by Landlord: architectural plans and specifications, opinions from Landlord’s engineers stating that the Tenant Alterations will not in any way adversely affect the Building’s systems, necessary permits and licenses, certificates of insurance (which, notwithstanding anything to the contrary herein, must be delivered to and reasonably approved by Landlord in the case of Decoration Work and

 

38


Cabling as well as Tenant Alterations requiring Landlord’s consent), and such other documents in such form reasonably requested by Landlord. Landlord may, in the exercise of reasonable judgment, require that Tenant provide Landlord with appropriate evidence of Tenant’s ability to complete and pay for the completion of the Tenant Alterations, which may include, in the case of non-standard and non-exterior Tenant Alterations costing in excess of $250,000 in the aggregate for a particular Tenant Alteration or a series of related Tenant Alterations, a performance bond or letter of credit. Upon completion of the Tenant Alterations, Tenant shall deliver to Landlord an as-built mylar and digitized (if available) set of plans and specifications for the Tenant Alterations. Landlord shall review and provide its approval or comments on any submittals made by Tenant for Tenant Alterations requiring Landlord’s approval hereunder within ten (10) business days after such submittal. At the time of Landlord’s written approval of any Tenant Alteration requiring Landlord’s written approval hereunder, Landlord shall notify Tenant if such Tenant Alteration is a Required Removable (as defined in Article Twelve). Landlord’s failure to designate a Tenant Alteration as a Required Removable at the time of such approval shall be deemed Landlord’s determination that such Tenant Alteration is not a Required Removable.

(2)        Tenant shall pay the cost of all Tenant Alterations. Upon completion of Tenant Alterations, Tenant shall furnish Landlord with contractors’ affidavits and full and final waivers of lien and receipted bills covering all labor and materials expended and used in connection therewith and such other documentation reasonably requested by Landlord or Mortgagee.

(3)        Tenant agrees to complete all Tenant Alterations (i) in accordance with all applicable Laws, including Hazardous Materials Laws, all requirements of applicable insurance companies and in accordance with Landlord’s standard construction rules and regulations, and (ii) in a good and workmanlike manner with the use of good grades of materials. Tenant shall notify Landlord promptly if Tenant receives any notice of violation of any Law in connection with completion of any Tenant Alterations and shall promptly take such steps as are necessary to remedy such violation. In no event shall such supervision or right to supervise by Landlord nor shall any approvals given by Landlord under this Lease constitute any warranty by Landlord to Tenant of the adequacy of the design, workmanship or quality of such work or materials for Tenant’s intended use or of compliance with the requirements of Section 9.1(a)(3)(i) and (ii) above or impose any liability upon Landlord in connection with the performance of such work. With respect to any Tenant Alterations requiring Landlord’s consent and costing in excess of $50,000 in the aggregate for a particular Tenant Alteration or a series of related Tenant Alterations, Landlord shall charge an administration fee of five percent (5%) of the cost of such Tenant Alterations; provided that, if Tenant requests that Landlord perform such work for Tenant and Landlord elects to do so, Landlord’s administration fee in connection therewith shall be fifteen percent (15%).

(b)        All Tenant Alterations (including the Tenant Improvements) shall remain the property of Tenant during the Term and shall, without compensation or credit to Tenant, become the property of Landlord upon the Termination Date and shall remain in the Premises, unless pursuant to Article 12, Tenant may remove them or is required to remove them at Landlord’s request (subject to Landlord’s prior approval notice referenced in Section 9.1(a)(1) above).

 

39


9.2

LIENS

Tenant shall not permit any lien or claim for lien of any mechanic, laborer or supplier or any other lien to be filed against the Building, the Land, the Premises, or any other part of the Property arising out of work performed, or alleged to have been performed by, or at the direction of, or on behalf of Tenant. If any such lien or claim for lien is filed, Tenant shall within twenty (20) days of receiving notice of such lien or claim (a) have such lien or claim for lien released of record or (b) deliver to Landlord a bond in form, content, amount, and issued by surety, satisfactory to Landlord, indemnifying, protecting, defending and holding harmless the Indemnitees against all costs and liabilities resulting from such lien or claim for lien and the foreclosure or attempted foreclosure thereof. If Tenant fails to take any of the above actions, Landlord, in addition to its rights and remedies under Article 11, without investigating the validity of such lien or claim for lien, may pay or discharge the same and Tenant shall, as payment of additional Rent hereunder, reimburse Landlord upon demand for the amount so paid by Landlord, including Landlord’s reasonable out-of-pocket expenses and attorneys’ fees.

 

9.3

EQUIPMENT LEASING AND FINANCING

Notwithstanding any provision of this Lease to the contrary, Tenant may enter into leases for, and/or grant security interests in, Tenant’s trade fixtures, equipment, inventory and personal property in the Premises pursuant to one or more equipment leases and/or security agreements. Landlord shall (i) subordinate any landlord lien rights that it may have in and to such items to the interest of the lessor and lenders therein, and, in the case of trade fixtures, waive any claim that the same are part of the Building or the Property by virtue of being affixed thereto, and (ii) so long as this Lease is still in effect, permit the lessor and lenders under any such leases and security agreements to remove the leased or encumbered property, upon default by Tenant under such leases and security agreements, pursuant to customary, commercially reasonable lien waiver agreement(s) between Landlord and any such lessor or lender, Tenant shall be responsible for Landlord’s reasonable out-of-pocket costs in connection with the preparation and/or review of any such agreement, including reasonable attorneys’ fees.

ARTICLE 10

ASSIGNMENT AND SUBLETTING

 

10.1

ASSIGNMENT AND SUBLETTING

(a)        Without the prior written consent of Landlord, which consent of Landlord shall not be unreasonably withheld, conditioned or delayed, Tenant may not sublease, assign, mortgage, pledge, hypothecate or otherwise transfer or permit the transfer of this Lease or the encumbering of Tenant’s interest therein in whole or in part, by operation of Law or otherwise or permit the use or occupancy of the Premises, or any part thereof, by anyone other than Tenant and its employees. Tenant agrees that the provisions governing sublease and assignment set forth in this Article Ten shall be deemed to be reasonable. If Tenant desires to enter into any sublease of the Premises or assignment of this Lease, Tenant shall deliver written notice thereof to Landlord (“Tenant’s Notice”), together with the identity of the proposed subtenant or assignee and the proposed principal terms thereof and current financial and other information reasonably requested by Landlord in order for Landlord to make an informed judgment with respect to such

 

40


proposed subtenant or assignee at least thirty (30) days prior to the commencement date of the term of the proposed sublease or assignment. If Tenant proposes to sublease less than all of the Rentable Area of the Premises, the space proposed to be sublet and the space retained by Tenant must each be a marketable unit as reasonably determined by Landlord (provided that, without limitation, the Expansion Premises shall be considered a marketable unit) and otherwise in compliance with all Laws. Landlord shall notify Tenant in writing of its approval or disapproval of the proposed sublease or assignment within twenty (20) days after receipt of Tenant’s Notice (and all required information). Tenant shall submit for Landlord’s approval (which approval shall not be unreasonably withheld) any advertising which Tenant or its agents intend to use with respect to the space proposed to be sublet.

(b)        With respect to Landlord’s consent to an assignment or sublease, the parties agree it shall be reasonable for Landlord to withhold its consent where, without limitation of other reasonable grounds:

(1)        the business reputation of the proposed subtenant or assignee is not consistent with the quality of the occupants of the Building; or

(2)        the proposed assignee’s or sublessee’s use of the Premises would violate Section 7.1 of this Lease; or

(3)        the proposed sublessee or assignee is a bona fide prospective tenant of Landlord for comparable available space in the Building as demonstrated by a written proposal signed by Landlord and such prospective tenant within ninety (90) days prior to the date of Tenant’s request.

(c)        Any sublease or assignment shall be expressly subject to the terms and conditions of this Lease. Any subtenant or assignee shall execute such documents as Landlord may reasonably require to evidence such subtenant or assignee’s assumption of the obligations and liabilities of Tenant under this Lease. Tenant shall deliver to Landlord a copy of all agreements executed by Tenant and the proposed subtenant and assignee with respect to the Premises. Landlord’s approval of a sublease, assignment, hypothecation, transfer or third party use or occupancy shall not constitute a waiver of Tenant’s obligation to obtain Landlord’s consent to further assignments or subleases, hypothecations, transfers or third party use or occupancy.

(d)        So long as Tenant is not entering into a transaction described herein for the purpose of avoiding or otherwise circumventing the remaining terms of this Article, Tenant may, subject to Section 10.5, assign its entire interest under this Lease or sublease all or a portion of the Premises, without the consent of Landlord and without any right of recapture and without any obligation to pay Excess Rent, to (i) an Affiliate, or (ii) a successor to Tenant by purchase or other acquisition of Tenant’s capital stock or substantially all of Tenant’s assets, merger, consolidation or reorganization, provided that all of the following conditions are satisfied: (1) Tenant shall give Landlord written notice at least five (5) business days prior to the effective date of the proposed transfer and such entity shall expressly assume Tenant’s obligations hereunder; (2) with respect to an assignment to an Affiliate, Tenant continues to have a net worth equal to or greater than Tenant’s net worth at the date immediately prior to such transfer; and (3) with respect to a purchase, merger, consolidation or reorganization which results in Tenant

 

41


ceasing to exist as a separate legal entity, Tenant’s successor shall have a net worth equal to or greater than Tenant’s net worth at the date immediately prior to such transfer.

 

10.2

[INTENTIONALLY OMITTED]

 

10.3

EXCESS RENT

Tenant shall pay Landlord on the first day of each month during the term of the sublease or assignment, fifty percent (50%) of the amount by which the sum of all rent and other consideration (direct or indirect) due from the subtenant or assignee for such month exceeds: (i) that portion of the Monthly Base Rent, Rent Adjustments and Tenant Improvement Allowance Monthly Payments due under this Lease for said month which is allocable to the space sublet or assigned; and (ii) the following costs and expenses for the subletting or assignment of such space: (1) brokerage commissions and attorneys’ fees and expenses, (2) the actual costs paid in making any improvements or substitutions in the Premises required by any sublease or assignment; (3) “free rent” periods, costs of any inducements or concessions given to subtenant or assignee, moving costs, and other amounts in respect of such subtenant’s or assignee’s other leases or occupancy arrangements; (4) the unamortized portions of any Tenant Improvements and/or Tenant Alterations made in the Premises (or portion thereof to be sublet) which were paid for solely by Tenant, calculated on a straight-line basis without interest over the remaining term of the Lease (but not including any extension options thereto), and (5) any rent or other consideration due from the subtenant or assignee with respect to the sale or lease of any of Tenant’s trade fixtures, equipment, inventory or personal property in the Premises (or portion thereof to be sublet). All such costs and expenses shall be amortized over the term of the sublease or assignment pursuant to sound accounting principles.

 

10.4

TENANT LIABILITY

In the event of any sublease or assignment, whether or not with Landlord’s consent, Tenant shall not be released or discharged from any liability, whether past, present or future, under this Lease, including any liability arising from the exercise of any renewal or expansion option, to the extent such exercise is expressly permitted by Landlord. Tenant’s liability shall remain primary, and in the event of default by any subtenant, assignee or successor of Tenant in performance or observance of any of the covenants or conditions of this Lease, Landlord may proceed directly against Tenant without the necessity of exhausting remedies against said subtenant, assignee or successor. After any assignment, Landlord may consent to subsequent assignments or subletting of this Lease, or amendments or modifications of this Lease with assignees of Tenant, without notifying Tenant, or any successor of Tenant, and without obtaining its or their consent thereto, and such action shall not relieve Tenant or any successor of Tenant of liability under this Lease. In addition, if Tenant has any options to extend the Term or to add other space to the Premises, such options shall not be available to any subtenant or assignee (other than an assignee pursuant to an assignment described in Section 10.1(d)), directly or indirectly without Landlord’s express written consent, which may be withheld in Landlord’s sole discretion.

 

42


10.5

ASSUMPTION AND ATTORNMENT

If Tenant shall assign this Lease as permitted herein, the assignee shall expressly assume all of the obligations of Tenant hereunder in a written instrument satisfactory to Landlord and furnished to Landlord not later than fifteen (15) days prior to the effective date of the assignment. If Tenant shall sublease the Premises as permitted herein, Tenant shall, at Landlord’s option, within fifteen (15) days following any request by Landlord, obtain and furnish to Landlord the written agreement of such subtenant to the effect that the subtenant will attorn to Landlord and will pay all subrent directly to Landlord.

 

10.6

PROCESSING EXPENSES

Tenant shall pay to Landlord, as Landlord’s cost of processing each proposed assignment or subletting (whether or not the same is ultimately approved by Landlord or consummated by Tenant), an amount equal to the sum of (i) all reasonable attorneys’ fees and expenses incurred by Landlord with respect to such assignment or sublease, plus (ii) the sum of $750.00 for the cost of Landlord’s administrative, accounting and clerical time (collectively, “Processing Costs”).

ARTICLE 11

DEFAULT AND REMEDIES

 

11.1

EVENTS OF DEFAULT

The occurrence or existence of any one or more of the following shall constitute a “Default” by Tenant under this Lease:

(1)        Tenant fails to pay any installment or other payment of Rent including Rent Adjustment Deposits or Rent Adjustments within five (5) days after written notice from Landlord of such failure;

(2)        Tenant fails to observe or perform any of the other covenants, conditions or provisions of this Lease or the Workletter and fails to cure such default within thirty (30) days after written notice thereof to Tenant, provided, however, that if such failure cannot reasonably be cured within thirty (30) days, it shall not be a default if Tenant has begun such cure within the thirty (30)-day period and thereafter diligently and continuously pursues the same to completion;

(3)        the interest of Tenant in this Lease is levied upon under execution or other legal process;

(4)        a petition is filed by or against Tenant to declare Tenant bankrupt or seeking a plan of reorganization or arrangement under any Chapter of the Bankruptcy Act, or any amendment, replacement or substitution therefor, or to delay payment of, reduce or modify Tenant’s debts, which in the case of an involuntary action is not discharged within thirty (30) days;

(5)        Tenant is declared insolvent by Law or any assignment of Tenant’s property is made for the benefit of creditors;

 

43


(6)        a receiver is appointed for Tenant or Tenant’s property, which appointment is not discharged within thirty (30) days;

(7)        upon the dissolution of Tenant; or

(8)        So long as the then-landlord under the Lease dated August 22, 2007 between Tenant and ES East Associates, LLC, an affiliate of Landlord, for the premises commonly known as Suites 100 and 200 (as such premises may change over time), located at 5885 Hollis Street, Emeryville, California (the “EmeryStation East Lease”), is an affiliate of the then- Landlord under this Lease, Tenant is in Default (beyond any applicable cure period set forth therein) under the EmeryStation East Lease.

 

11.2

LANDLORD’S REMEDIES

(a)        A Default shall constitute a breach of the Lease for which Landlord shall have the rights and remedies set forth in this Section 11.2 and all other rights and remedies set forth in this Lease or now or hereafter allowed by Law, whether legal or equitable, and all rights and remedies of Landlord shall be cumulative and none shall exclude any other right or remedy now or hereafter allowed by applicable Law.

(b)        With respect to a Default, at any time Landlord may terminate Tenant’s right to possession by written notice to Tenant stating such election. Any written notice required pursuant to Section 11.1 shall constitute notice of unlawful detainer pursuant to California Code of Civil Procedure Section 1161 if at Landlord’s sole discretion, it states Landlord’s election that Tenant’s right to possession is terminated after expiration of any period required by Law or any longer period required by Section 11.1. Upon the expiration of the period stated in Landlord’s written notice of termination (and unless such notice provides an option to cure within such period and Tenant cures the Default within such period), Tenant’s right to possession shall terminate and this Lease shall terminate, and Tenant shall remain liable as hereinafter provided. Upon such termination in writing of Tenant’s right to possession, Landlord shall have the right, subject to applicable Law, to re-enter the Premises and dispossess Tenant and the legal representatives of Tenant and all other occupants of the Premises by unlawful detainer or other summary proceedings, or as otherwise permitted by Law, regain possession of the Premises and remove their property (including their trade fixtures, personal property and those Tenant Alterations which Tenant is required or permitted to remove under Article Twelve), but Landlord shall not be obligated to effect such removal, and such property may, at Landlord’s option, be stored elsewhere, sold or otherwise dealt with as permitted by Law, at the risk of, expense of and for the account of Tenant, and the proceeds of any sale shall be applied pursuant to Law. Landlord shall in no event be responsible for the value, preservation or safekeeping of any such property. Tenant hereby waives all claims for damages that may be caused by Landlord’s removing or storing Tenant’s personal property pursuant to this Section or Section 12.1, and Tenant hereby indemnifies, and agrees to defend, protect and hold harmless, the Indemnitees from any and all loss, claims, demands, actions, expenses, liability and cost (including attorneys’ fees and expenses) to the extent arising out of or in any way related to such removal or storage. Upon such written termination of Tenant’s right to possession and this Lease, Landlord shall have the right to recover damages for Tenant’s Default as provided herein or by Law, including the following damages provided by California Civil Code Section 1951.2:

 

44


(1)        the worth at the time of award of the unpaid Rent which had been earned at the time of termination;

(2)        the worth at the time of award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such Rent loss that Tenant proves could reasonably have been avoided;

(3)        the worth at the time of award of the amount by which the unpaid Rent for the balance of the term of this Lease after the time of award exceeds the amount of such Rent loss that Tenant proves could be reasonably avoided; and

(4)        any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant’s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including, without limitation, Landlord’s unamortized costs of tenant improvements, leasing commissions and legal fees incurred in connection with entering into this Lease. The word “rent” as used in this Section 11.2 shall have the same meaning as the defined term Rent in this Lease. The “worth at the time of award” of the amount referred to in clauses (1) and (2) above is computed by allowing interest at the Default Rate. The worth at the time of award of the amount referred to in clause (3) above is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%). For the purpose of determining unpaid Rent under clause (3) above, the monthly Rent reserved in this Lease shall be deemed to be the sum of the Monthly Base Rent, monthly storage space rent, if any, and the amounts last payable by Tenant as Rent Adjustments for the calendar year in which Landlord terminated this Lease as provided hereinabove.

(c)        Even if Tenant is in Default and/or has abandoned the Premises, this Lease shall continue in effect for so long as Landlord does not terminate Tenant’s right to possession by written notice as provided in Section 11.2(b) above, and Landlord may enforce all its rights and remedies under this Lease, including the right to recover Rent as it becomes due under this Lease. In such event, Landlord shall have all of the rights and remedies of a landlord under California Civil Code Section 1951.4 (lessor may continue Lease in effect after Tenant’s Default and abandonment and recover Rent as it becomes due, if Tenant has the right to sublet or assign, subject only to reasonable limitations), or any successor statute. During such time as Tenant is in Default, if Landlord has not terminated this Lease by written notice and if Tenant requests Landlord’s consent to an assignment of this Lease or a sublease of the Premises, Landlord shall not unreasonably withhold its consent to such assignment or sublease. Tenant acknowledges and agrees that the provisions of Article Ten shall be deemed to constitute reasonable limitations of Tenant’s right to assign or sublet. Tenant acknowledges and agrees that in the absence of written notice pursuant to Section 11.2(b) above terminating Tenant’s right to possession, no other act of Landlord shall constitute a termination of Tenant’s right to possession or an acceptance of Tenant’s surrender of the Premises, including acts of maintenance or preservation or efforts to relet the Premises or the appointment of a receiver upon initiative of Landlord to protect Landlord’s interest under this Lease or the withholding of consent to a subletting or assignment, or terminating a subletting or assignment, if in accordance with other provisions of this Lease.

 

45


(d)        In the event that Landlord seeks an injunction with respect to a breach or threatened breach by Tenant of any of the covenants, conditions or provisions of this Lease, Tenant agrees to pay the premium for any bond required in connection with such injunction.

(e)        Tenant hereby waives any and all rights to relief from forfeiture, redemption or reinstatement granted by Law (including California Civil Code of Procedure Sections 1174 and 1179) in the event of Tenant being evicted or dispossessed for any cause or in the event of Landlord obtaining possession of the Premises by reason of Tenant’s Default or otherwise;

(f)        Notwithstanding any other provision of this Lease, a notice to Tenant given under this Article and Article Twenty-four of this Lease or given pursuant to California Code of Civil Procedure Section 1161, and any notice served by mail shall be deemed served, and the requisite waiting period deemed to begin under said Code of Civil Procedure Section upon mailing, without any additional waiting requirement under Code of Civil Procedure Section 1011 et seq. or by other Law. For purposes of Code of Civil Procedure Section 1162, Tenant’s “place of residence”, “usual place of business”, “the property” and “the place where the property is situated” shall mean and be the Premises, whether or not Tenant has vacated same at the time of service.

(g)        The voluntary or other surrender or termination of this Lease, or a mutual termination or cancellation thereof, shall not work a merger and shall terminate all or any existing assignments, subleases, subtenancies or occupancies permitted by Tenant, except if and as otherwise specified in writing by Landlord.

(h)        No delay or omission in the exercise of any right or remedy of Landlord upon any default by Tenant, and no exercise by Landlord of its rights pursuant to Section 25.15 to perform any duty which Tenant fails timely to perform, shall impair any right or remedy or be construed as a waiver. No provision of this Lease shall be deemed waived by Landlord unless such waiver is in writing signed by Landlord. The waiver by Landlord of any breach of any provision of this Lease shall not be deemed a waiver of any subsequent breach of the same or any other provision of this Lease.

 

11.3

ATTORNEY’S FEES

In the event any party brings any suit or other proceeding with respect to the subject matter or enforcement of this Lease, the prevailing party (as determined by the court, agency or other authority before which such suit or proceeding is commenced) shall, in addition to such other relief as may be awarded, be entitled to recover attorneys’ fees, expenses and costs of investigation as actually incurred, including court costs, expert witness fees, costs and expenses of investigation, and all attorneys’ fees, costs and expenses in any such suit or proceeding (including in any action or participation in or in connection with any case or proceeding under the Bankruptcy Code, 11 United States Code Sections 101 et seq., or any successor statutes, in establishing or enforcing the right to indemnification, in appellate proceedings, or in connection with the enforcement or collection of any judgment obtained in any such suit or proceeding).

 

46


11.4

BANKRUPTCY

To the extent permitted by Law, the following provisions shall apply in the event of the bankruptcy or insolvency of Tenant:

(a)        In connection with any proceeding under Chapter 7 of the Bankruptcy Code where the trustee of Tenant elects to assume this Lease for the purposes of assigning it, such election or assignment, may only be made upon compliance with the provisions of (b) and (c) below, which conditions Landlord and Tenant acknowledge to be commercially reasonable. In the event the trustee elects to reject this Lease then Landlord shall immediately be entitled to possession of the Premises without further obligation to Tenant or the trustee.

(b)        Any election to assume this Lease under Chapter 11 or 13 of the Bankruptcy Code by Tenant as debtor-in-possession or by Tenant’s trustee (the “Electing Party”) must provide for:

The Electing Party to cure or provide to Landlord adequate assurance that it will cure all monetary defaults under this Lease within fifteen (15) days from the date of assumption and it will cure all nonmonetary defaults under this Lease within thirty (30) days from the date of assumption. Landlord and Tenant acknowledge such condition to be commercially reasonable.

(c)        If the Electing Party has assumed this Lease or elects to assign Tenant’s interest under this Lease to any other person, such interest may be assigned only if the intended assignee has provided adequate assurance of future performance (as herein defined), of all of the obligations imposed on Tenant under this Lease.

For the purposes hereof, “adequate assurance of future performance” means that Landlord has ascertained that each of the following conditions has been satisfied:

(1)        The assignee has submitted a current financial statement, certified by its chief financial officer, which shows a net worth and working capital in amounts sufficient to assure the future performance by the assignee of Tenant’s obligations under this Lease; and

(2)        Landlord has obtained consents or waivers from any third parties that may be required under a lease, mortgage, financing arrangement, or other agreement by which Landlord is bound, to enable Landlord to permit such assignment.

(d)        Landlord’s acceptance of rent or any other payment from any trustee, receiver, assignee, person, or other entity will not be deemed to have waived, or waive, the requirement of Landlord’s consent, Landlord’s right to terminate this Lease for any transfer of Tenant’s interest under this Lease without such consent, or Landlord’s claim for any amount of Rent due from Tenant.

 

11.5

LANDLORD’S DEFAULT

Landlord shall be in default hereunder if Landlord fails to perform any obligation of Landlord hereunder and such failure continues for a period of thirty (30) days after written notice thereof by Tenant to Landlord; provided, however, that if such failure to perform such obligation cannot reasonably be cured within such thirty (30) day period, it shall not be a default if

 

47


Landlord has begun such cure within such thirty (30) day period and thereafter diligently pursues the same to completion. In no event shall Tenant have the right to terminate or rescind this Lease as a result of Landlord’s default as to any covenant or agreement contained in this Lease. Tenant hereby waives such remedies of termination and rescission and hereby agrees that Tenant’s remedies for default hereunder shall be limited to a suit for damages and/or injunction. In addition, Tenant hereby covenants that, it will provide the Mortgagee with a copy of any notice of default provided to Landlord.

ARTICLE 12

SURRENDER OF PREMISES

 

12.1

IN GENERAL

Upon the Termination Date, Tenant shall surrender and vacate the Premises immediately and deliver possession thereof to Landlord in good condition and repair, ordinary wear and tear, casualty damage, condemnation, Landlord’s repair obligations and damage caused by Landlord excepted. Tenant shall deliver to Landlord all keys to the Premises. Except as otherwise set forth in this Section 12.1 or pursuant to written notice from Landlord to Tenant pursuant to Section 9.1(a)(1) of this Lease, all Tenant Alterations shall remain upon the Premises at the end of the Term without compensation to Tenant. Without limitation of the foregoing, Tenant shall have no obligation to remove any Decoration Work installed by or for Tenant. Landlord, however, may require Tenant, at its expense, (a) by written notice to Tenant at least 30 days prior to the Termination Date, to remove any Cable installed by or for the benefit of Tenant, and (b) pursuant to Section 9.1(a)(1), to remove any Tenant Alterations made subsequent to the Tenant Improvements that, in Landlord’s reasonable judgment, are of a nature that would require removal and repair costs that are materially in excess of the removal and repair costs associated with standard office and lab improvements (collectively referred to as “Required Removables”). Required Removables shall include, without limitation, internal stairways, raised floors, personal baths and showers, vaults, rolling file systems and structural alterations and modifications. Landlord’s failure to designate any Tenant Alteration as a Required Removable at the time of Landlord’s approval pursuant to Section 9.1(a) shall be deemed Landlord’s confirmation that such Tenant Alteration is not a Required Removable. The designated Required Removables shall be removed by Tenant by the Termination Date. Tenant shall repair damage caused by the removal of Required Removables. Upon the Termination Date, Tenant shall remove Tenant’s trade fixtures, equipment, inventory and personal property from the Premises.

With respect to the Tenant Improvements, by no later than the Termination Date, Tenant shall remove those components of the Tenant Improvements that have been specifically and reasonably designated for removal by Landlord based on Landlord’s review of the final Construction Drawings (as such term is defined in the Workletter) (collectively referred to as the “Pilot Plant Removables”). Within ten (10) days after Landlord’s receipt of the final Construction Drawings, Landlord shall deliver the list of Pilot Plant Removables to Tenant. Landlord’s failure to deliver the list of Pilot Plant Removables within such ten (10)-day period shall be deemed Landlord’s acknowledgment that there are no Pilot Plant Removables. If Landlord delivers such list, Landlord and Tenant shall promptly thereafter enter into an amendment to this Lease attaching the list of Pilot Plant Removables. Tenant shall repair any damage caused by the removal of the Pilot Plant Removables. Notwithstanding anything to the

 

48


contrary in this Section 12.1, Tenant shall have no obligation to remove any component of the Tenant Improvements other than the Pilot Plant Removables.

If Tenant fails to perform its obligations in a timely manner, Landlord may perform such work at Tenant’s expense. If any of the Tenant Alterations which were installed by Tenant subsequent to the Tenant Improvements involved the lowering of ceilings, raising of floors or the installation of specialized wall or floor coverings or lights, then, unless otherwise approved by Landlord in writing, Tenant shall also be obligated to return such surfaces to their condition prior to the installation of such Tenant Alterations. Tenant shall also be required to close any staircases or other openings between floors. In the event possession of the Premises is not delivered to Landlord when required hereunder, or if Tenant shall fail to remove those items described above, Landlord may (but shall not be obligated to), at Tenant’s expense, remove any of such property and store, sell or otherwise deal with such property, and undertake, at Tenant’s expense, such restoration work as Landlord deems necessary or advisable.

 

12.2

LANDLORD’S RIGHTS

All property which may be removed from the Premises by Landlord pursuant to Section 12.1 shall be conclusively presumed to have been abandoned by Tenant and Landlord may deal with such property as provided in Section 11.2(b), including the waiver and indemnity obligations provided in that Section. Tenant shall also reimburse Landlord for all costs and expenses incurred by Landlord in removing any of Tenant Alterations and in restoring the Premises to the condition required by this Article 12 Lease at the Termination Date.

ARTICLE 13

HOLDING OVER

In the event that Tenant holds over in possession of the Premises after the Termination Date, Tenant shall pay Landlord 125% of the Monthly Base Rent payable for the month immediately preceding the holding over plus Rent Adjustments for such holdover period, which Landlord may reasonably estimate. Tenant shall also pay all damages sustained by Landlord by reason of claims made by any succeeding tenant (as demonstrated by a signed proposal or letter of intent or lease), as a result of such retention of possession. The provisions of this Article shall not constitute a waiver by Landlord of any re-entry rights of Landlord and Tenant’s continued occupancy of the Premises shall be as a tenancy in sufferance.

ARTICLE 14

DAMAGE BY FIRE OR OTHER CASUALTY

 

14.1

SUBSTANTIAL UNTENANTABILITY

(a)        If any fire or other casualty (whether insured or uninsured) renders all or a substantial portion of the Premises or the Building untenantable, Landlord shall, with reasonable promptness after the occurrence of such damage, estimate the length of time that will be required to substantially complete the repair and restoration and shall by notice advise Tenant of such estimate (“Landlord’s Notice”). If Landlord estimates that the amount of time required to substantially complete such repair and restoration will exceed one hundred eighty (180) days from the date such damage occurred, then Landlord, or Tenant if all or a substantial portion of

 

49


the Premises is rendered untenantable, shall have the right to terminate this Lease as of the date of such damage upon giving written notice to the other at any time within twenty (20) days after delivery of Landlord’s Notice, provided that if Landlord so chooses, Landlord’s Notice may also constitute such notice of termination.

(b)        Unless this Lease is terminated as provided in the preceding subparagraph, Landlord shall proceed with reasonable promptness to repair and restore the Premises to its condition as existed prior to such casualty (exclusive of any Tenant Alterations), subject to reasonable delays for insurance adjustments and Force Majeure delays, and also subject to zoning Laws and building codes then in effect. Landlord shall have no liability to Tenant, and Tenant shall not be entitled to terminate this Lease if such repairs and restoration are not in fact completed within the time period estimated by Landlord so long as Landlord shall proceed with reasonable diligence to complete such repairs and restoration.

(c)        Tenant acknowledges that Landlord shall be entitled to the full proceeds of any insurance coverage, whether carried by Landlord or Tenant, for damages to the Premises, except for those proceeds of Tenant’s insurance of its own personal property and equipment which would be removable by Tenant at the Termination Date. All such insurance proceeds shall be payable to Landlord whether or not the Premises are to be repaired and restored, provided, however, if this Lease is not terminated and the parties proceed to repair and restore Tenant Alterations at Tenant’s cost, to the extent Landlord received proceeds of Tenant’s insurance covering Tenant Alterations, such proceeds shall be applied to reimburse Tenant for its cost of repairing and restoring Tenant Alterations.

(d)        Notwithstanding anything to the contrary herein set forth: (i) Landlord shall have no duty pursuant to this Section to repair or restore any portion of any Tenant Alterations or to expend for any repair or restoration of the Premises or Building amounts in excess of insurance proceeds paid to Landlord and available for repair or restoration; and (ii) Tenant shall not have the right to terminate this Lease pursuant to this Section if any damage or destruction was caused by the act or neglect of Tenant, its agent or employees. Whether or not the Lease is terminated pursuant to this Article Fourteen, in no event shall Tenant be entitled to any compensation or damages for loss of the use of the whole or any part of the Premises or for any inconvenience or annoyance occasioned by any such damage, destruction, rebuilding or restoration of the Premises or the Building or access thereto.

(e)        Any repair or restoration of the Premises performed by Tenant shall be in accordance with the provisions of Article Nine hereof.

 

14.2

INSUBSTANTIAL UNTENANTABILITY

If the Premises or the Building is damaged by a casualty but neither is rendered substantially untenantable (and Tenant’s access thereto is not materially impaired) and Landlord estimates that the time to substantially complete the repair or restoration will not exceed one hundred eighty (180) days from the date such damage occurred, then Landlord shall proceed to repair and restore the Building or the Premises, other than Tenant Alterations, with reasonable promptness, unless such damage is to the Premises and occurs during the last six (6) months of the Term (and Tenant has not exercised the Renewal Option), in which event either Tenant or

 

50


Landlord shall have the right to terminate this Lease as of the date of such casualty by giving written notice thereof to the other within twenty (20) days after the date of such casualty. Notwithstanding the aforesaid, Landlord’s obligation to repair shall be limited in accordance with the provisions of Section 14.1 above.

 

14.3

RENT ABATEMENT

If all or any part of the Premises are rendered untenantable by fire or other casualty and this Lease is not terminated, Monthly Base Rent and Rent Adjustments (but not any Tenant Improvement Allowance Monthly Payments, which shall continue to be due and payable regardless of any such Rent abatement) shall abate for that part of the Premises which is untenantable on a per diem basis from the date of the casualty until Landlord has Substantially Completed the repair and restoration work in the Premises which it is required to perform, provided, that as a result of such casualty, Tenant does not occupy the portion of the Premises which is untenantable during such period.

 

14.4

WAIVER OF STATUTORY REMEDIES

The provisions of this Lease, including this Article Fourteen, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, the Premises or the Property or any part of either, and any Law, including Sections 1932(2), 1933(4), 1941 and 1942 of the California Civil Code, with respect to any rights or obligations concerning damage or destruction shall have no application to this Lease or to any damage to or destruction of all or any part of the Premises or the Property or any part of either, and are hereby waived.

ARTICLE 15

EMINENT DOMAIN

 

15.1

TAKING OF WHOLE OR SUBSTANTIAL PART

In the event the whole or any substantial part of the Building or of the Premises is taken or condemned by any competent authority for any public use or purpose (including a deed given in lieu of condemnation) and is thereby rendered untenantable, this Lease shall terminate as of the date title vests in such authority, and Monthly Base Rent and Rent Adjustments shall be apportioned as of the Termination Date. In the event of a partial taking of the Premises, Tenant may terminate this Lease if Tenant reasonably determines it cannot conduct its business in the portion of the Premises that was not taken. Notwithstanding anything to the contrary herein set forth, in the event the taking is temporary (for less than the remaining Term of the Lease), Landlord may elect either (i) to terminate this Lease or (ii) permit Tenant to receive the entire award attributable to the Premises in which case Tenant shall continue to pay Rent and this Lease shall not terminate.

 

15.2

TAKING OF PART

In the event a part of the Building or the Premises is taken or condemned by any competent authority (or a deed is delivered in lieu of condemnation) and this Lease is not terminated, the Lease shall be amended to reduce or increase, as the case may be, the Monthly

 

51


Base Rent and Tenant’s Share to reflect the Rentable Area of the Premises or Building, as the case may be, remaining after any such taking or condemnation. Landlord, upon receipt and to the extent of the award in condemnation (or proceeds of sale) shall make necessary repairs and restorations to the Premises (exclusive of Tenant Alterations) and to the Building to the extent necessary to constitute the portion of the Building not so taken or condemned as a complete architectural and economically efficient unit. Notwithstanding the foregoing, if as a result of any taking, or a governmental order that the grade of any street or alley adjacent to the Building is to be changed and such taking or change of grade makes it necessary or desirable to substantially remodel or restore the Building or prevents the economical operation of the Building, Landlord shall have the right to terminate this Lease upon ninety (90) days prior written notice to Tenant.

 

15.3

COMPENSATION

Landlord shall be entitled to receive the entire award (or sale proceeds) from any such taking, condemnation or sale without any payment to Tenant, and Tenant hereby assigns to Landlord Tenant’s interest, if any, in such award; provided, however, Tenant shall have the right separately to pursue against the condemning authority a separate award in respect of the loss, if any, to Tenant Alterations paid for by Tenant without any credit or allowance from Landlord, and Tenant’s furniture, fixtures and equipment, so long as there is no diminution of Landlord’s award as a result.

ARTICLE 16

INSURANCE

 

16.1

TENANT’S INSURANCE

Tenant, at Tenant’s expense, agrees to maintain in force, with a company or companies acceptable to Landlord, during the Term: (a) Commercial General Liability Insurance on a primary basis and without any right of contribution from any insurance carried by Landlord covering the Premises on an occurrence basis against all claims for personal injury, bodily injury, death and property damage, including contractual liability covering the indemnification provisions in this Lease, and such insurance shall be for such limits that are reasonably required by Landlord from time to time but not less than a combined single limit of Five Million and No/100 Dollars ($5,000,000.00); (b) Workers’ Compensation and Employers’ Liability Insurance to the extent required by and in accordance with the Laws of the State of California; (c) “All Risks” property insurance in an amount adequate to cover the full replacement cost of all Tenant Alterations, equipment, installations, fixtures and contents of the Premises in the event of loss; (d) in the event a motor vehicle is to be used by Tenant in connection with its business operation from the Premises, Comprehensive Automobile Liability Insurance coverage with limits of not less than One Million and No/100 Dollars ($1,000,000.00) combined single limit coverage against bodily injury liability and property damage liability arising out of the use by or on behalf of Tenant, its agents and employees in connection with this Lease, of any owned, non-owned or hired motor vehicles; and (e) such other insurance or coverages as Landlord reasonably requires.

 

52


16.2

FORM OF POLICIES

Each policy referred to in 16.1 shall satisfy the following requirements. Each policy shall (i) name Landlord and the Indemnitees as additional insureds (except Workers’ Compensation and Employers’ Liability Insurance), (ii) be issued by one or more responsible insurance companies licensed to do business in the State of California reasonably satisfactory to Landlord, (iii) where applicable, provide for deductible amounts satisfactory to Landlord and not permit co-insurance, (iv) shall provide that such insurance may not be canceled or amended without thirty (30) days’ prior written notice to the Landlord, and (v) each policy of “All-Risks” property insurance shall provide that the policy shall not be invalidated should the insured waive in writing prior to a loss, any or all rights of recovery against any other party for losses covered by such policies. Tenant may satisfy its obligations with respect to liability insurance coverage in excess of Three Million Dollars ($3,000,000) by virtue of an excess or umbrella liability policy so long as the coverage afforded thereby is not reduced or diminished in any way. Tenant shall deliver to Landlord, certificates of insurance and at Landlord’s request, copies of all policies and renewals thereof to be maintained by Tenant hereunder, not less than ten (10) days prior to the Commencement Date and not less than ten (10) days prior to the expiration date of each policy.

 

16.3

LANDLORD’S INSURANCE

Landlord agrees to purchase and keep in full force and effect during the Term hereof, including any extensions or renewals thereof, insurance under policies issued by insurers of recognized responsibility, qualified to do business in the State of California on the Building in amounts not less than the greater of eighty (80%) percent of the then full replacement cost (without depreciation) of the Building (above foundations) or an amount sufficient to prevent Landlord from becoming a co-insurer under the terms of the applicable policies, against fire and such other risks as may be included in standard forms of all risk coverage insurance reasonably available from time to time. Landlord agrees to maintain in force during the Term, Commercial General Liability Insurance covering the Building on an occurrence basis against all claims for personal injury, bodily injury, death, and property damage. Such insurance shall be for a combined single limit of not less than Five Million and No/100 Dollars ($5,000,000.00). Neither Landlord’s obligation to carry such insurance nor the carrying of such insurance shall be deemed to be an indemnity by Landlord with respect to any claim, liability, loss, cost or expense due, in whole or in part, to Tenant’s negligent acts or omissions or willful misconduct. Without obligation to do so, Landlord may, in its sole discretion from time to time, carry insurance in amounts greater and/or for coverage additional to the coverage and amounts set forth above.

 

16.4

WAIVER OF SUBROGATION

(a)        Landlord agrees that, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, it will include in its “All Risks” policies appropriate clauses pursuant to which the insurance companies (i) waive all right of subrogation against Tenant with respect to losses payable under such policies and/or (ii) agree that such policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policies.

 

53


(b)        Tenant agrees to include, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, in its “All Risks” insurance policy or policies on Tenant Alterations, whether or not removable, and on Tenant’s furniture, furnishings, fixtures and other property removable by Tenant under the provisions of this Lease appropriate clauses pursuant to which the insurance company or companies (i) waive the right of subrogation against Landlord and/or any tenant of space in the Building with respect to losses payable under such policy or policies and/or (ii) agree that such policy or policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policy or policies. If Tenant is unable to obtain in such policy or policies either of the clauses described in the preceding sentence, Tenant shall, if legally possible and without necessitating a change in insurance carriers, have Landlord named in such policy or policies as an additional insured. If Landlord shall be named as an additional insured in accordance with the foregoing, Landlord agrees to endorse promptly to the order of Tenant, without recourse, any check, draft, or order for the payment of money representing the proceeds of any such policy or representing any other payment growing out of or connected with said policies, and Landlord does hereby irrevocably waive any and all rights in and to such proceeds and payments.

(c)        Landlord hereby waives any and all right of recovery which it might otherwise have against Tenant, its servants, agents and employees, for loss or damage occurring to the Real Property and the fixtures, appurtenances and equipment therein, to the extent the same arises from a risk or peril that is required to be insured against under a property insurance policy or policies that Landlord is required to maintain pursuant to this Lease, notwithstanding that such loss or damage may result from the negligence or fault of Tenant, its servants, agents or employees. Tenant hereby waives any and all right of recovery which it might otherwise have against Landlord, its servants, and employees for loss or damage to Tenant Alterations, whether or not removable, and to Tenant’s furniture, furnishings, fixtures and other property removable by Tenant under the provisions hereof to the extent the same arises from a risk or peril that is required to be insured against under a property insurance policy or policies Tenant is required to maintain pursuant to this Lease, notwithstanding that such loss or damage may result from the negligence or fault of Landlord, its servants, agents or employees.

(d)        Landlord and Tenant hereby agree to advise the other promptly if the clauses to be included in their respective insurance policies pursuant to subparagraphs (a) and (b) above cannot be obtained on the terms hereinbefore provided and thereafter to furnish the other with a certificate of insurance or copy of such policies showing the naming of the other as an additional insured, as aforesaid. Landlord and Tenant hereby also agree to notify the other promptly of any cancellation or change of the terms of any such policy that would affect such clauses or naming. All such policies which name both Landlord and Tenant as additional insureds shall, to the extent obtainable, contain agreements by the insurers to the effect that no act or omission of any additional insured will invalidate the policy as to the other additional insureds.

 

16.5

NOTICE OF CASUALTY

Tenant shall give Landlord notice in case of a fire or other casualty in the Premises promptly after Tenant is aware of such event.

 

54


ARTICLE 17

WAIVER OF CLAIMS AND INDEMNITY

 

17.1

WAIVER OF CLAIMS

To the extent permitted by Law, and except as expressly provided in Article Seven pertaining to Hazardous Materials, Tenant releases the Indemnitees from, and waives all claims for, damage to person or property sustained by the Tenant or any occupant of the Premises or the Property to the extent resulting directly or indirectly from any existing or future condition, defect, matter or thing in and about the Premises or the Property or any part of either or any equipment or appurtenance therein, or resulting from any accident in or about the Premises or the Property, or resulting directly or indirectly from any act or neglect of any tenant or occupant of the Property or of any other person, including Landlord’s agents and servants, except to the extent caused by the gross negligence or willful and wrongful act of any of the Indemnitees. To the extent permitted by Law, Tenant hereby waives any consequential damages, compensation or claims for inconvenience or loss of business, rents, or profits as a result of such injury or damage, whether or not caused by the gross negligence or willful and wrongful act of any of the Indemnitees. If any such damage, whether to the Premises or the Property or any part of either, or whether to Landlord or to other tenants in the Property, results from any act or neglect of Tenant, its employees, servants, agents, contractors, invitees or customers, Tenant shall be liable therefor and Landlord may, at Landlord’s option, repair such damage and Tenant shall, upon demand by Landlord, as payment of additional Rent hereunder, reimburse Landlord within ten (10) days of demand for the total cost of such repairs, in excess of amounts, if any, paid to Landlord under insurance covering such damages. Tenant shall not be liable for any such damage caused by its acts or neglect if Landlord or a tenant has recovered the full amount of the damage from proceeds of insurance policies and the insurance company has waived its right of subrogation against Tenant.

 

17.2

INDEMNITY BY TENANT

To the extent permitted by Law, Tenant hereby indemnifies, and agrees to protect, defend and hold the Indemnitees harmless, against any and all actions, claims, demands, liability, costs and expenses, including reasonable attorneys’ fees and expenses for the defense thereof, to the extent arising from Tenant’s occupancy of the Premises, from the undertaking by Tenant of any Tenant Alterations or repairs to the Premises, from the conduct of Tenant’s business on the Premises, or from any breach or default on the part of Tenant in the performance of any covenant or agreement on the part of Tenant to be performed pursuant to the terms of this Lease, or from any willful act or negligence of Tenant, its agents, contractors, servants, employees, customers or invitees, in or about the Premises or the Property or any part of either. In case of any action or proceeding brought against the Indemnitees by reason of any such claim, upon notice from Landlord, Tenant covenants to defend such action or proceeding by counsel chosen by Landlord, in Landlord’s reasonable discretion. Landlord reserves the right to settle, compromise or dispose of any and all actions, claims and demands related to the foregoing indemnity. The foregoing indemnity shall not operate to relieve Indemnitees of liability to the extent such liability is caused by the willful and wrongful act of Indemnitees. Further, the foregoing indemnity is subject to and shall not diminish any waivers in effect in accordance with Section 16.4 by

 

55


Landlord or its insurers to the extent of amounts, if any, paid to Landlord under its “All-Risks” property insurance.

 

17.3

INDEMNITY BY LANDLORD

To the extent permitted by Law, Landlord hereby indemnifies, and agrees to protect, defend and hold Tenant and its directors, officers and employees (the “Tenant Indemnitees”) harmless, against any and all actions, claims, demands, liability, costs and expenses, including reasonable attorneys’ fees and expenses for the defense thereof, to the extent arising from any work or repairs by Landlord to the Premises or the Building, or from any breach or default on the part of Landlord in the performance of any covenant or agreement on the part of Landlord to be performed pursuant to the terms of this Lease, or from any willful act or the active negligence of Landlord, its agents, contractors and employees, in or about the Premises or the Property or any part of either. In case of any action or proceeding brought against the Tenant Indemnitees by reason of any such claim, upon notice from Tenant, Landlord covenants to defend such action or proceeding by counsel chosen by Landlord. The foregoing indemnity shall not operate to relieve Tenant Indemnitees of liability to the extent such liability is caused by the willful and wrongful act of Tenant Indemnitees. Further, the foregoing indemnity is subject to and shall not diminish any waivers in effect in accordance with Section 16.4 by Tenant or its insurers to the extent of amounts, if any, paid to Tenant under its “All-Risks” property insurance.

ARTICLE 18

RULES AND REGULATIONS

 

18.1

RULES

Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the rules and regulations listed in Exhibit C-1 and Exhibit C-2 attached hereto and with all reasonable modifications and additions thereto which Landlord may make from time to time.

 

18.2

ENFORCEMENT

Nothing in this Lease shall be construed to impose upon the Landlord any duty or obligation to enforce the rules and regulations as set forth in Exhibit C-1 and Exhibit C-2, or as hereafter adopted, or the terms, covenants or conditions of any other lease as against any other tenant, and the Landlord shall not be liable to the Tenant for violation of the same by any other tenant, its servants, employees, agents, visitors or licensees. Landlord shall use reasonable efforts to enforce the rules and regulations of the Project in a uniform and non-discriminatory manner. In the event of any inconsistency between the rules and regulations and this Lease, this Lease shall control.

ARTICLE 19

LANDLORD’S RESERVED RIGHTS

Landlord shall have the following rights exercisable without notice to Tenant and without liability to Tenant for damage or injury to persons, property or business and without being deemed an eviction or disturbance of Tenant’s use or possession of the Premises or giving rise to any claim for offset or abatement of Rent: (1) to change the Building’s name or street address

 

56


upon thirty (30) days’ prior written notice to Tenant; (2) to install, affix and maintain all signs on the exterior and/or interior of the Building; (3) to designate and/or approve prior to installation, all types of signs, window shades, blinds, drapes, awnings or other similar items, and all internal lighting that may be visible from the exterior of the Premises; (4) upon reasonable prior written notice to Tenant, to display the Premises to prospective purchasers and lenders at reasonable business hours at any time during the Term and to prospective tenants at reasonable business hours during the last twelve (12) months of the Term; (5) to grant to any party the exclusive right to conduct any business or render any service in or to the Building, provided such exclusive right shall not operate to prohibit Tenant from using the Premises for the purpose permitted hereunder; (6) to change the arrangement and/or location of entrances or passageways, doors and doorways, corridors, elevators, stairs, washrooms or public portions of the Building, and to close entrances, doors, corridors, elevators or other facilities, provided that such action shall not materially and adversely interfere with Tenant’s access to or use of the Premises or the Building; and (7) to have access for Landlord and other tenants of the Building to any mail chutes and boxes located in or on the Premises as required by any applicable rules of the United States Post Office.

ARTICLE 20

ESTOPPEL CERTIFICATES AND FINANCIAL STATEMENTS

 

20.1

IN GENERAL

(a)        Within ten (10) days after request therefor by Landlord or Tenant, the other party agrees to execute an Estoppel Certificate, binding upon such party, certifying any factual information pertaining to this Lease reasonably requested by the requesting party or by any existing or prospective lender, mortgagee or purchaser. With respect to an Estoppel Certificate requested by Landlord, the following certifications requested of Tenant shall be deemed reasonable: (i) that this Lease is unmodified and in full force and effect (or if there have been modifications, a description of such modifications and that this Lease as modified is in full force and effect); (ii) the dates to which Rent has been paid; (iii) that Tenant is in the possession of the Premises if that is the case; (iv) that Landlord is not in default under this Lease, or, if Tenant believes Landlord is in default, the nature thereof in detail; (v) that Tenant has no offsets or defenses to the performance of its obligations under this Lease (or if Tenant believes there are any offsets or defenses, a full and complete explanation thereof); (vi) that the Premises have been completed in accordance with the terms and provisions hereof or the Workletter, that Tenant has accepted the Premises and the condition thereof and of all improvements thereto and has no claims against Landlord or any other party with respect thereto; and (vii) any other factual information relating to the Lease reasonably requested.

(b)        Within ten (10) days after written request from Landlord from time to time during the Term, Tenant shall provide Landlord with current financial statements setting forth Tenant’s financial condition and net worth for the most recent quarter, including balance sheets and statements of profits and losses. Such statements shall be prepared by an independent accountant or certified by Tenant’s president, chief executive officer or chief financial officer. Landlord shall keep such financial information confidential and shall only disclose such information to Landlord’s lenders, consultants, purchasers or investors (who shall be subject to the same confidentiality obligations) on a need to know basis in connection with the administration of this Lease.

 

57


20.2

ENFORCEMENT

In the event that Tenant fails to deliver an Estoppel Certificate, and such default continues for two (2) days after a second notice to Tenant, then such failure shall be a Default for which there shall be no cure or grace period. In addition to any other remedy available to Landlord, Landlord may impose a charge equal to $500.00 for each day that Tenant fails to deliver an Estoppel Certificate and Tenant shall be deemed to have irrevocably appointed Landlord as Tenant’s attorney-in-fact to execute and deliver such Estoppel Certificate.

ARTICLE 21

RELOCATION OF TENANT

Landlord shall have a one-time right at any time after the seventh (7th) anniversary of the Commencement Date to substitute for the Premises other premises in the Project, or any other comparable building owned by Landlord or any Landlord affiliate in Emeryville (the “New Premises”), in which event the New Premises shall be deemed to be the Premises for all purposes under this Lease, provided that (i) the New Premises shall be substantially the same as the Premises in area and interior functionality; (ii) Landlord shall pay all costs and expenses of physically moving Tenant, its property and equipment to the New Premises; (iii) Landlord shall give Tenant not less than one hundred twenty (120) days’ prior written notice of such substitution; (iv) Landlord, at its expense, shall improve the New Premises with improvements substantially the same as those in the Premises at the time of such substitution; (v) there shall be no downtime in the operation of Tenant’s business as a result of the substitution, with the result that the existing Premises (including all of the improvements, and Tenant’s property and equipment therein) must remain in place and fully functional until such time as Landlord, at its expense, has caused the New Premises to be fully functional with like property and equipment); (vi) notwithstanding anything to the contrary in this Lease, in the event of relocation, Tenant shall have no restoration obligations with respect to the Premises as they existed before the relocation or with respect to the New Premises; (vii) Tenant shall not be obligated to incur or pay any costs or expenses of the relocation, including without limitation, any increased Rent; (viii) Tenant shall have the right to approve the size and location of the New Premises, which approval shall not be unreasonably withheld; (ix) if the New Premises are smaller than the Premises as they existed before the relocation, Monthly Base Rent, Rent Adjustments and Rent Adjustment Deposits shall be proportionately reduced; (x) Landlord shall be responsible for obtaining all necessary use permits from the City of Emeryville with respect to Tenant’s operations in the New Premises, and Tenant shall reasonably cooperate with Landlord in Landlord’s efforts to obtain such permits; and (xi) Tenant shall have parking and signage rights with respect to the New Premises reasonably comparable to the parking and signage rights outlined in this Lease.

ARTICLE 22

REAL ESTATE BROKERS

Each of Landlord and Tenant represents that, except for the brokers it listed in Section 1.1(15), it has not dealt with any real estate broker, sales person, or finder in connection with this Lease, and no such person initiated or participated in the negotiation of this Lease. Each of Landlord and Tenant hereby agrees to indemnify, protect, defend and hold the other harmless from and against any and all liabilities and claims for commissions and fees arising out of a

 

58


breach of the foregoing representation. Landlord agrees to pay any commission to which the brokers listed in Section 1.1(15) are entitled in connection with this Lease pursuant to Landlord’s written agreement with such brokers.

ARTICLE 23

MORTGAGEE PROTECTION

 

23.1

SUBORDINATION AND ATTORNMENT

(a)        Subject to Section 23.1(b), this Lease is and shall be expressly subject and subordinate at all times to (i) any ground or underlying lease of the Real Property, now or hereafter existing, and all amendments, extensions, renewals and modifications to any such lease, and (ii) the lien of any mortgage or trust deed now or hereafter encumbering fee title to the Real Property and/or the leasehold estate under any such lease, and all amendments, extensions, renewals, replacements and modifications of such mortgage or trust deed and/or the obligation secured thereby, unless such ground lease or ground lessor, or mortgage, trust deed or Mortgagee, expressly provides or elects that the Lease shall be superior to such lease or mortgage or trust deed. If any such mortgage or trust deed is foreclosed (including any sale of the Real Property pursuant to a power of sale), or if any such lease is terminated, upon request of the Mortgagee or ground lessor, as the case may be, Tenant shall attorn to the purchaser at the foreclosure sale or to the ground lessor under such lease, as the case may be, provided, however, that such purchaser or ground lessor shall not be (i) bound by any payment of Rent for more than one month in advance except payments in the nature of security for the performance by Tenant of its obligations under this Lease; (ii) subject to any offset, defense or damages arising out of a default of any obligations of any preceding Landlord; or (iii) bound by any amendment or modification of this Lease made without the written consent of the Mortgagee or ground lessor; which consent shall not be unreasonably withheld; provided, however, that such consent shall not be required in the case of any amendment or modification made or entered into to evidence the exercise by Tenant of any specific right or option provided for herein in favor of Tenant (such as the exercise of the Renewal Option or the Expansion Right) or (iv) liable for any security deposits not actually received in cash by such purchaser or ground lessor. This subordination shall be self-operative and no further certificate or instrument of subordination need be required by any such Mortgagee or ground lessor. In confirmation of such subordination, however, Tenant shall execute promptly any reasonable certificate or instrument consistent with this Article 23 that Landlord, Mortgagee or ground lessor may request. Upon request by such successor in interest, Tenant shall execute and deliver reasonable instruments confirming the attornment and non-disturbance provided for herein.

(b)        Notwithstanding the foregoing, (i) as a condition precedent to the subordination of this Lease to any future ground lease, mortgage, or deed of trust, Tenant and such future ground lessor or mortgagee shall have entered into a commercially-reasonable form subordination, non- disturbance and attornment agreement which recognizes Tenant’s rights under this Lease. Landlord hereby represents and warrants to Tenant that, as of the Date of Lease, (1) there is no ground or underlying lease of the Property, and (ii) there is no deed of trust or mortgage encumbering the Property.

 

59


23.2

MORTGAGEE PROTECTION

Tenant agrees to give any Mortgagee or ground lessor, by registered or certified mail, a copy of any notice of default served upon the Landlord by Tenant, provided that prior to such notice Tenant has received notice (by way of service on Tenant of a copy of an assignment of rents and leases, or otherwise) of the address of such Mortgagee or ground lessor. Tenant further agrees that any such Mortgagee or ground lessor shall have the same cure period as Landlord under this Lease with respect to such default (provided that such cure period shall not commence until thirty (30) days after receipt of such notice from Tenant) and in addition shall include, if necessary to effect such cure, the period to commence and consummate foreclosure proceedings or other proceedings to acquire possession of the Real Property, so long as such proceedings are promptly commenced and diligently pursued to completion. Such period of time shall be extended by any period within which such Mortgagee or ground lessor is prevented from commencing or pursuing such foreclosure proceedings or other proceedings to acquire possession of the Real Property by reason of Landlord’s bankruptcy.

ARTICLE 24

NOTICES

(a)        All notices, demands or requests provided for or permitted to be given pursuant to this Lease must be in writing and shall be personally delivered, sent by Federal Express or other reputable overnight courier service, or mailed by first class, registered or certified United States mail, return receipt requested, postage prepaid.

(b)        All notices, demands or requests to be sent pursuant to this Lease shall be deemed to have been properly given or served by delivering or sending the same in accordance with this Section, addressed to the parties hereto at their respective addresses listed in Section 1.1.

(c)        Notices, demands or requests sent by mail or overnight courier service as described above shall be effective upon deposit in the mail or with such courier service. However, the time period in which a response to any such notice, demand or request must be given shall commence to run from (i) in the case of delivery by mail, the date of receipt on the return receipt of the notice, demand or request by the addressee thereof, or (ii) in the case of delivery by Federal Express or other overnight courier service, the date of acceptance of delivery by an employee, officer, director or partner of Landlord or Tenant. Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given, as indicated by advice from Federal Express or other overnight courier service or by mail return receipt, shall be deemed to be receipt of notice, demand or request sent. Notices may also be served by personal service upon any officer, director or partner of Landlord or Tenant, and shall be effective upon such service.

(d)        By giving to the other party at least thirty (30) days written notice thereof, either party shall have the right from time to time during the term of this Lease to change their respective addresses for notices, statements, demands and requests, provided such new address shall be within the United States of America.

 

60


ARTICLE 25

MISCELLANEOUS

 

25.1

LATE CHARGES

(a)        All payments required hereunder (other than the Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits, which shall be due as hereinbefore provided) to Landlord shall be paid within thirty (30) days after Landlord’s written demand therefor. All such amounts (including Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits) not paid when due shall bear interest from the date due until the date paid at the Default Rate in effect on the date such payment was due.

(b)        In the event Tenant is more than five (5) days late in paying any installment of Rent due under this Lease, Tenant shall pay Landlord a late charge equal to five percent (5%) of the delinquent installment of Rent. The parties agree that (i) such delinquency will cause Landlord to incur costs and expenses not contemplated herein, the exact amount of which will be difficult to calculate, including the cost and expense that will be incurred by Landlord in processing each delinquent payment of rent by Tenant, (ii) the amount of such late charge represents a reasonable estimate of such costs and expenses and that such late charge shall be paid to Landlord for each delinquent payment in addition to all Rent otherwise due hereunder. The parties further agree that the payment of late charges and the payment of interest provided for in subparagraph (a) above are distinct and separate from one another in that the payment of interest is to compensate Landlord for its inability to use the money improperly withheld by Tenant, while the payment of late charges is to compensate Landlord for its additional administrative expenses in handling and processing delinquent payments.

(c)        Payment of interest at the Default Rate and/or of late charges shall not excuse or cure any Default by Tenant under this Lease, nor shall the foregoing provisions of this Article or any such payments prevent Landlord from exercising any right or remedy available to Landlord under this Lease upon a Default due to Tenant’s failure to pay Rent when due, including the right to terminate this Lease.

 

25.2

NO JURY TRIAL; VENUE; JURISDICTION

To the fullest extent permitted by law, including laws enacted after the Commencement Date, each party hereto (which includes any assignee, successor, heir or personal representative of a party) shall not seek a jury trial, hereby waives trial by jury, and hereby further waives any objection to venue in the County in which the Project is located, and agrees and consents to personal jurisdiction of the courts of the State of California, in any action or proceeding or counterclaim brought by any party hereto against the other on any matter whatsoever arising out of or in any way connected with this Lease, the relationship of Landlord and Tenant, Tenant’s use or occupancy of the Premises, or any claim of injury or damage, or the enforcement of any remedy under any statute, emergency or otherwise, whether any of the foregoing is based on this Lease or on tort law. No party will seek to consolidate any such action in which a jury has been waived with any other action in which a jury trial cannot or has not been waived. It is the intention of the parties that these provisions shall be subject to no exceptions. The provisions of this Section shall survive the expiration or earlier termination of this Lease.

 

61


25.3

DISCRIMINATION

Tenant, agrees for Tenant and Tenant’s heirs, executors, administrators, successors and assigns and all persons claiming under or through Tenant, and this Lease is made and accepted upon and subject to the following conditions: that there shall be no discrimination against or segregation of any person or group of persons on account of race, color, creed, religion, sex, marital status, national origin or ancestry (whether in the leasing, subleasing, transferring, use, occupancy, tenure or enjoyment of the Premises or otherwise) nor shall Tenant or any person claiming under or through Tenant establish or permit any such practice or practices of discrimination or segregation with reference to the use or occupancy of the Premises by Tenant or any person claiming through or under Tenant.

 

25.4

OPTION

This Lease shall not become effective as a lease or otherwise until executed and delivered by both Landlord and Tenant, and the submission of the Lease to Tenant does not constitute a reservation of or option for the Premises.

 

25.5

AUTHORITY

Each of Landlord and Tenant represents and warrants to the other that it has full authority and power to enter into and perform its obligations under this Lease, that the person executing this Lease is fully empowered to do so, and that no consent or authorization is necessary from any third party. Landlord may request that Tenant provide Landlord evidence of Tenant’s authority.

 

25.6

ENTIRE AGREEMENT

This Lease, the Exhibits attached hereto (including the Workletter) contain the entire agreement between Landlord and Tenant concerning the Premises and there are no other agreements, either oral or written, and no other representations or statements, either oral or written, on which either Landlord or Tenant has relied. This Lease shall not be modified except by a writing executed by Landlord and Tenant.

 

25.7

MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE

If Mortgagee of Landlord requires a modification of this Lease which shall not result in any increased cost or expense to Tenant or in any adverse change in the rights and obligations of Tenant hereunder, then Tenant agrees that the Lease may be so modified.

 

25.8

EXCULPATION

Tenant agrees, on its behalf and on behalf of its successors and assigns, that any liability or obligation of Landlord under this Lease shall only be enforced against Landlord’s equity interest in the Property up to a maximum of Five Million Dollars ($5,000,000.00) and in no event against any other assets of the Landlord, or Landlord’s officers or directors or partners, and that any liability of Landlord with respect to this Lease shall be so limited and Tenant shall not be entitled to any judgment in excess of such amount; provided, however, that the foregoing

 

62


dollar amount limitation (i) shall not limit the amounts payable under any insurance policies maintained by Landlord, and (ii) shall not be applicable with respect to Landlord’s obligation (a) to provide the Basic Tenant Improvement Allowance for Expansion Premises specified in Section 2.7(c)(ii) above and the Tenant Improvement Allowance specified in Section 1.1(16) above, or (b) with respect to Environmental Damages for which Landlord is responsible under Section 7.1(d)(5).

 

25.9

ACCORD AND SATISFACTION

No payment by Tenant or receipt by Landlord of a lesser amount than any installment or payment of Rent due shall be deemed to be other than on account of the amount due, and no endorsement or statement on any check or any letter accompanying any check or payment of Rent shall be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord’s right to recover the balance of such installment or payment of Rent or pursue any other remedies available to Landlord. No receipt of money by Landlord from Tenant after the termination of this Lease or Tenant’s right of possession of the Premises shall reinstate, continue or extend the Term. Receipt or acceptance of payment from anyone other than Tenant, including an assignee of Tenant, is not a waiver of any breach of Article Ten, and Landlord may accept such payment on account of the amount due without prejudice to Landlord’s right to pursue any remedies available to Landlord.

 

25.10

LANDLORD’S OBLIGATIONS ON SALE OF BUILDING

In the event of any sale or other transfer of the Building, and upon the transferee’s assumption in writing of Landlord’s obligations under this Lease arising from and after the date of such sale or transfer, Landlord shall be entirely freed and relieved of all agreements and obligations of Landlord hereunder accruing or to be performed after the date of such sale or transfer, and any remaining liability of Landlord with respect to this Lease shall be limited to the dollar amount specified in Section 25.8 (except as otherwise provided in Section 25.8) and Tenant shall not be entitled to any judgment in excess of such amount. Landlord shall have the right to assign this Lease to an entity comprised of the principals of Landlord or affiliates of such entities. Upon such assignment and assumption of the obligations of Landlord hereunder, Landlord shall be entirely freed and relieved of all obligations hereunder.

 

25.11

BINDING EFFECT

Subject to the provisions of Article Ten, this Lease shall be binding upon and inure to the benefit of Landlord and Tenant and their respective heirs, legal representatives, successors and permitted assigns.

 

25.12

CAPTIONS

The Article and Section captions in this Lease are inserted only as a matter of convenience and in no way define, limit, construe, or describe the scope or intent of such Articles and Sections.

 

63


25.13

TIME; APPLICABLE LAW; CONSTRUCTION

Time is of the essence of this Lease and each and all of its provisions. This Lease shall be construed in accordance with the Laws of the State of California. If more than one person signs this Lease as Tenant, the obligations hereunder imposed shall be joint and several. If any term, covenant or condition of this Lease or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, covenant or condition to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each item, covenant or condition of this Lease shall be valid and be enforced to the fullest extent permitted by Law. Wherever the term “including” or “includes” is used in this Lease, it shall have the same meaning as if followed by the phrase “but not limited to”. The language in all parts of this Lease shall be construed according to its normal and usual meaning and not strictly for or against either Landlord or Tenant.

 

25.14

ABANDONMENT

In the event Tenant abandons the Premises but is otherwise in compliance with all the terms, covenants and conditions of this Lease, Landlord shall (i) have the right to enter into the Premises in order to show the space to prospective tenants, (ii) have the right to reduce the services provided to Tenant pursuant to the terms of this Lease to such levels as Landlord reasonably determines to be adequate services for an unoccupied premises, and (iii) during the last six (6) months of the Term, have the right to prepare the Premises for occupancy by another tenant upon the end of the Term. Tenant expressly acknowledges that in the absence of written notice pursuant to Section 11.2(b) or pursuant to California Civil Code Section 1951.3 terminating Tenant’s right to possession, none of the foregoing acts of Landlord or any other act of Landlord shall constitute a termination of Tenant’s right to possession or an acceptance of Tenant’s surrender of the Premises, and the Lease shall continue in effect.

 

25.15

LANDLORD’S RIGHT TO PERFORM TENANT’S DUTIES

If Tenant fails timely to perform any of its duties under this Lease or the Workletter, Landlord shall have the right (but not the obligation), to perform such duty on behalf and at the expense of Tenant without prior notice to Tenant, and all sums expended or expenses incurred by Landlord in performing such duty shall be deemed to be additional Rent under this Lease and shall be due and payable upon demand by Landlord. Except where a Tenant Default has occurred and is continuing, or an emergency affecting the security or safety of the Building or persons, Landlord shall provide Tenant with fifteen (15) days written notice prior to exercising the rights in this Section 25.15.

 

25.16

SECURITY SYSTEM

Landlord shall not be obligated to provide or maintain any security patrol or security system. Landlord shall not be responsible for the quality of any such patrol or system which may be provided hereunder or for damage or injury to Tenant, its employees, invitees or others due to the failure, action or inaction of such patrol or system.

 

64


25.17

NO LIGHT, AIR OR VIEW EASEMENTS

Any diminution or shutting off of light, air or view by any structure which may be erected on lands of or adjacent to the Project shall in no way affect this Lease or impose any liability on Landlord.

 

25.18

RECORDATION

Neither this Lease, nor any notice nor memorandum regarding the terms hereof, shall be recorded by Tenant. Any such unauthorized recording shall be a Default for which there shall be no cure or grace period. Tenant agrees to execute and acknowledge, at the request of Landlord, a memorandum of this Lease, in recordable form.

 

25.19

SURVIVAL

The waivers of the right of jury trial, the other waivers of claims or rights, the releases, and the obligations of Landlord and Tenant under this Lease to indemnify, protect, defend and hold harmless the other (and/or any other indemnitee) shall survive the expiration or termination of this Lease, and so shall all other obligations or agreements which by their terms survive expiration or termination of the Lease.

 

25.20

RIDERS

All Riders attached hereto and executed both by Landlord and Tenant shall be deemed to be a part hereof and hereby incorporated herein.

[Signatures on Following Page]

 

65


IN WITNESS WHEREOF, this Lease has been executed as of the date set forth in Section 1.1(4) hereof.

 

TENANT:

   

LANDLORD:

AMYRIS BIOTECHNOLOGIES, INC.,

a California corporation

   

EMERYSTATION TRIANGLE, LLC,

a California limited liability company

By:

 

/s/ John G. Melo

   

By:    

 

/s/ Richard Robbins

Print Name: John G. Melo

     

Richard K. Robbins

Its: Chief Executive Officer

     

Managing Member

By:

 

/s/ Tamara L. Tompkins

     

Print Name: Tamara L. Tompkins

     

Its: General Counsel and Secretary

     

The individuals signing on behalf of the California corporation above hereby represent and warrant that at least one of the individuals signing above is one of the following: (x) the chairman of the board, the president, or a vice president of the tenant entity; and that the other individual is one of the following: (y) the secretary, assistant secretary, the chief financial officer, or assistant treasurer of the tenant entity; provided, however, that a single individual signing alone for such corporate entity represents and warrants that such individual holds at least two corporate offices with one office in each of the two categories listed above (i.e., clauses (x) and (y) above).

 

66


EXHIBIT A

PLAN OF PREMISES


LOGO


EXHIBIT A-1

PLAN OF EXPANSION PREMISES


LOGO


EXHIBIT B

WORKLETTER AGREEMENT

(TENANT BUILD)

1.         Defined Terms .   Capitalized terms used in this Workletter shall have the same meanings set forth in the Lease except as otherwise specified herein and except for terms capitalized in the ordinary course of punctuation. For purposes of this Workletter the following capitalized terms have the following meanings:

1.1        “Design Documents” means the layout plans and specifications for the real property improvements to be constructed by Tenant in the Premises which are the final product of the preliminary space plan attached as Schedule 1 to this Workletter and which include, among other things, all partitions, doors, windows, the exit pathway accessing the public greenway, HVAC (heating, ventilating and air conditioning systems) distribution, ceiling systems, light fixtures, plumbing installations, process piping, electrical installations and outlets, office and laboratory improvements, telephone and data installations and outlets, any other installations required by Tenant, fire and life-safety systems, wall finishes and floor coverings, whether to be newly installed or requiring changes from the as-is condition of the Premises as of the Date of Lease, all in sufficient detail for Landlord’s review.

1.2        “Construction Contract” means the proposed construction contract for the Tenant Improvements.

1.3        “Construction Drawings” means the final architectural plans and specifications, and engineering plans and specifications, for the real property improvements to be constructed by Tenant in the Premises in sufficient detail to be submitted for governmental approvals and building permits and to serve as the detailed construction drawings and specifications for the contractor.

1.4        “Schedule of Values” means the estimated allocation of costs to the various portions of the work involved in the construction and installation of the Tenant Improvements.

1.5        “Tenant Improvements” means all real property improvements to be constructed by Tenant as shown on the Construction Drawings, as they may be modified as provided herein.

1.6        “Tenant Improvement Allowance” means the amount to be provided by Landlord (not to exceed $249,750) and payable by Tenant pursuant to Section 1.1(16) of the Lease on account of hard and soft costs incurred by Tenant in connection with the design, permitting and construction of the Tenant Improvements, including but not limited to, construction costs, space planning and design fees, architecture and engineering fees, and permit fees incurred by Tenant in the design and construction of the Tenant Improvements.

 

1


2.         Development of Plans .

2.1         Approval of Architect and Contractor .   Tenant’s architect (“Architect”), contractor, major suppliers and major subcontractors shall each be subject to the reasonable approval of Landlord, which approval shall not be unreasonably withheld or conditioned and shall be given or withheld within five (5) business days after Tenant’s written request therefor. Landlord’s failure to respond within the five (5) business day period shall be deemed Landlord’s approval of the Architect, contractor, major supplier or major subcontractor designated by Tenant. Landlord may request reasonable information about these entities, including financial statements and a summary of representative projects. If Landlord reasonably disapproves the Architect, contractor, any major subcontractor or major supplier within the five (5) business day period, the parties shall negotiate in good faith to select another Architect, contractor, subcontractor or materials supplier mutually and reasonably acceptable to the parties. Landlord shall be entitled to withhold its approval of any entity or person who, in Landlord’s reasonable determination, is financially or otherwise professionally unqualified to design or construct the Tenant Improvements. Landlord hereby approves Gicklhorn Lazzarotto as an acceptable Architect, and Dome Construction Corporation as an acceptable contractor. Notwithstanding the foregoing, Landlord’s approval of any Architect, contractor, subcontractor or materials supplier shall not constitute Landlord’s representation or warranty that any such architect, contractor, subcontractor or supplier is in fact qualified to perform the Tenant Improvements.

2.2         Design Documents .   Prior to Tenant’s commencement of the construction of the Tenant Improvements, Tenant shall prepare the Design Documents and deliver them to Landlord. Landlord agrees that Tenant, at Tenant’s option, may deliver the Design Documents to Landlord in increments (not to exceed three (3) increments) with respect to one or more components of the Tenant Improvements ( e.g. , schematic design drawings, use permit design drawings, 50% detailed design drawings), instead of providing the Design Documents for the entire Tenant Improvements at one time, and in such event, Landlord shall review and approve (or disapprove) each incremental submission of the Design Documents in accordance with the time periods set forth in this Section 2.2. Within five (5) business days following delivery of the Design Documents, Landlord shall deliver written notice to Tenant of either Landlord’s approval of the Design Documents or Landlord’s reasonable disapproval thereof, in which event the notice shall specify the reasonable changes that must be made to the Design Documents as a condition of Landlord’s approval. Landlord’s failure to approve or disapprove the Design Documents within such five (5) business day period shall be deemed Landlord’s approval of the Design Documents, as submitted. Notwithstanding the foregoing, Landlord shall only disapprove the Design Documents if the same (i) will cause an adverse effect on the structural integrity of the Building; (ii) is not in compliance with applicable Law, (iii) will cause an adverse effect on the Building’s systems, or (iv) negatively impacts any portion of the Building’s exterior envelope, Common Areas or mechanical, electrical and/or plumbing systems (individually and collectively, a “Design Problem”). If Landlord timely delivers notice of disapproval, Tenant shall deliver a revised set of Design Documents to Landlord which shall incorporate the changes specified in Landlord’s notice of disapproval, and the foregoing submittal and approval process shall be repeated in accordance with the procedures set forth in this Section 2.2 until Landlord reasonably approves the entire Design Documents.

 

2


2.3         Construction Drawings .   Promptly after the entire Design Documents are approved by Landlord pursuant to Section 2.2, Tenant shall cause to be prepared the Construction Drawings that are consistent with the Design Documents. The Construction Drawings shall be delivered to Landlord for approval, which approval of Landlord shall not be unreasonably withheld, conditioned or delayed. Landlord shall deliver to Tenant, as soon as reasonably practicable, but within five (5) business days following receipt thereof, written notice of approval or reasonable disapproval of the Construction Drawings, in which event the notice shall specify the changes that must be made to the Construction Drawings as a condition for obtaining Landlord’s approval. Landlord’s failure to approve or disapprove the Construction Drawings within the five (5) business day period shall be deemed Landlord’s approval of the Construction Drawings, as submitted. Notwithstanding the foregoing, Landlord shall only disapprove the Construction Drawings if the same (i) do not comply in any material respect with the Design Documents, or (ii) contain a Design Problem. If Landlord timely delivers notice of disapproval, Tenant shall deliver a revised set of Construction Drawings to Landlord, which incorporate the required changes specified in Landlord’s notice of disapproval, and the foregoing submittal and approval process shall be repeated in accordance with the procedures set forth in this Section 2.3 until Landlord reasonably approves the entire Construction Drawings. Upon approval by Landlord, Landlord and Tenant shall each sign a copy of the approved Construction Drawings.

2.4         Landlord’s Approval .   Landlord’s approval of the Design Drawings and Construction Drawings shall not be unreasonably withheld, conditioned or delayed. Landlord may, at Landlord’s option, have the Design Documents or the Construction Drawings reviewed by Landlord’s architect, engineer and/or construction manager; provided, however, that any such review shall be performed within the time periods set forth above for Landlord’s review of the Design Documents and the Construction Drawings. Landlord shall be entitled to deduct the reasonable, out-of-pocket, documented cost (not to exceed $5,000.00) of any such review from the Tenant Improvement Allowance. In no event shall the approval by Landlord (or Landlord’s architect, engineer or construction manager) of the Design Documents or the Construction Drawings constitute a representation or warranty by Landlord (or Landlord’s architect, engineer or construction manager) of: (i) their accuracy, sufficiency or completeness for their intended purpose; (ii) the absence of design defects or construction flaws; or (iii) their compliance with applicable laws.

2.5         Compliance with Laws .   The Design Documents and Construction Drawings (i) shall be in a form satisfactory for filing with appropriate governmental authorities and (ii) shall conform to all applicable Laws as interpreted at the time of construction.

2.6         Changes .   No material changes shall be made to the Design Documents or the Construction Drawings in excess of $200,000 (except for changes to the Building’s structure or exterior, or to the Building’s utility systems which shall require Landlord’s consent) without the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed. All change orders requested by Tenant under this Section 2.6 shall be made in writing and shall specify any estimated added or reduced cost resulting therefrom. Any change proposed by Tenant shall be reasonably approved or disapproved by Landlord in writing within five (5) business days following Landlord’s receipt of reasonably detailed information

 

3


pertaining to the proposed change. Landlord’s failure to approve any proposed change within five (5) business days shall be deemed Landlord’s approval thereof.

3.         Construction of Tenant Improvements

3.1         Permits and Approvals .   Tenant shall promptly submit the Construction Drawings to all appropriate governmental agencies for approval, and shall not commence construction or installation of the Tenant Improvements unless and until Tenant has obtained all necessary permits and approvals and has delivered copies of these documents to Landlord. Landlord shall reasonably cooperate with Tenant and promptly execute any documents requested by Tenant, subject to Landlord’s review and reasonable approval, in connection with Tenant obtaining such permits and approvals.

3.2         Construction Contract .   Prior to the commencement of construction and installation of the Tenant Improvements, Tenant shall submit to Landlord for Landlord’s reasonable approval, which approval shall not be unreasonably withheld, conditioned or delayed, the Construction Contract and the Schedule of Values. Within five (5) business days following the delivery of the Construction Contract and the Schedule of Values, Landlord shall deliver written notice to Tenant either approving or reasonably disapproving the same, in which event Landlord shall specify the changes that must be made to these documents as a condition of Landlord’s approval. Landlord’s failure to approve or disapprove the Construction Contract and the Schedule of Values within the five (5) business day period shall be deemed Landlord’s approval of the same, as submitted. If Landlord timely delivers notice of disapproval of the Construction Contract or the Schedule of Values, Tenant shall deliver to Landlord revised copies of the Construction Contract or the Schedule of Values, as appropriate, which incorporate the specified changes. Following approval of the Construction Contract by Landlord, Tenant shall not materially amend, materially modify or terminate the Construction Contract without Landlord’s prior written approval, which consent shall not be unreasonably withheld, conditioned or delayed and shall be given or withheld in accordance with the terms of this Section 3.2.

3.3         Commencement and Completion of Construction .   Following Tenant’s satisfaction of all of the requirements of Section 2 above and this Section 3, Tenant shall commence construction and installation of the Tenant Improvements in accordance with the Construction Drawings and shall pursue the same diligently to completion. Tenant covenants to give Landlord at least ten (10) days’ prior written notice of its commencement of construction or delivery of materials to the Premises to enable Landlord to post a notice of nonresponsibility respecting the Tenant Improvements.

3.4         Building Systems .   If Tenant performs work as part of the Tenant Improvements that pertains to the structure of the Building or the Building’s systems, Landlord may require Tenant to engage Landlord’s structural engineer to design, supervise and monitor any construction work affecting either the Building systems or the structure of the Building, provided that such engineer is then available to perform such services without unreasonable delay and the rates of such engineer are competitive (but not necessarily equal to or less than) with the rates of other engineers in the Emeryville/Berkeley vicinity, similarly qualified to perform such services.

 

4


3.5         Inspections .   Landlord and its officers, agents or employees shall have the right at all reasonable times during construction to enter upon the Premises and inspect the Tenant Improvements and to determine that the same are in conformity with the Construction Drawings and all of the requirements of this Workletter. Tenant acknowledges, however, that Landlord is under no obligation to supervise, inspect or inform Tenant of the progress of construction and Tenant agrees that it shall not rely upon Landlord to perform any of these activities. Neither the inspection rights granted to Landlord in this Workletter, nor the making of such inspections by Landlord, shall operate as a waiver of any rights of Landlord to require that the construction and installation of the Tenant Improvements conform with this Workletter, the Construction Drawings and all requirements of applicable Law as interpreted at the time of construction.

3.6         Walk-Through of Tenant Improvements .   Within five (5) business days following the Substantial Completion of the Tenant Improvements, Tenant shall notify Landlord and shall provide Landlord an opportunity to inspect the Tenant Improvements. Within ten (10) business days following Tenant’s notice, (i) Landlord (or its representative) and Tenant (or its representative) shall walk-through and inspect the Tenant Improvements, and (ii) Landlord shall deliver written notice to Tenant either approving the Tenant Improvements or advising Tenant of any material defects or material uncompleted items in the Tenant Improvements based on the Construction Drawings, except that Landlord shall have no liability or obligation to advise Tenant of any such defects or uncompleted items. Landlord’s failure to notify Tenant of any defects or uncompleted items within such ten (10) day period shall be deemed Landlord’s approval of the Tenant Improvements as constructed. Tenant shall promptly repair such defects or uncompleted items to Landlord’s reasonable satisfaction in substantial accordance with the Construction Drawings. Landlord’s approval of the Tenant Improvements, or Landlord’s failure to advise Tenant of any defects or uncompleted items in the Tenant Improvements, shall not relieve Tenant of responsibility for constructing and installing the Tenant Improvements in accordance with the Construction Drawings, this Workletter, and all applicable Laws as interpreted at the time of construction. Notwithstanding the generality of the foregoing, Landlord’s approval of the Tenant Improvements shall not be deemed a representation by Landlord that the Tenant Improvements constructed are in accordance with the Construction Drawings or applicable Laws (including without limitation, functionality of design, the configuration of the Premises, and the placement of Tenant’s furniture, appliances and equipment).

3.7         Final Documents .   Following Substantial Completion of the Tenant Improvements, Tenant shall (a) deliver to Landlord a copy of the certificate of occupancy or an equivalent written permit or approval from the City of Emeryville permitting the occupancy of the Premises as improved by the Tenant Improvements; (b) promptly cause a notice of completion to be validly recorded for the Tenant Improvements; (c) furnish Landlord with unconditional waivers of lien in statutory form from the contractor and all material subcontractors and material suppliers in connection with the Tenant Improvements, and the Architect; (d) deliver to Landlord a certificate of the Architect certifying substantial completion of the Tenant Improvements in substantial accordance with the Construction Drawings; (e) deliver to Landlord a full set of reproducible as-built drawings (signed and dated by the contractor and each responsible subcontractor) for the Tenant Improvements; and (f) deliver to

 

5


Landlord copies of all written construction and equipment warranties and manuals related to the Tenant Improvements.

4.         Payment of Costs of Tenant Improvements .

4.1         Tenant’s Cost .   Except as otherwise set forth herein, any costs incurred in the design or construction of the Tenant Improvements in excess of the Tenant Improvement Allowance shall be borne by Tenant in accordance with the terms and conditions set forth below. The costs of the Tenant Improvements shall include all hard and soft costs of designing, permitting and constructing the Tenant Improvements, including without limitation the following items:

(a)        The costs of the Architect, contractor, suppliers and subcontractors and any other consultants retained by Tenant in connection with the preparation of Design Documents and Constructions Drawings related to the construction of the Tenant Improvements in the Premises;

(b)        All costs of obtaining from the City of Emeryville and any other governmental authority, approvals, building permits and occupancy permits, if any;

(c)        All costs installing and constructing the Tenant Improvements;

(d)        All costs of designing, constructing and installing the Tenant Improvements in compliance with all applicable Laws, including with all building codes and the ADA, as interpreted at the time of construction; and

(e)        All reasonable, out-of-pocket fees (not to exceed $5,000.00) payable to Landlord’s architectural or engineering firm pursuant to Section 2.4 above if they are required to review, monitor or design any portion of the Tenant Improvements in accordance with this Workletter. Except as expressly set forth in this Section 4.1, Landlord shall receive no fee for coordination, supervision, profit, overhead or general conditions in connection with the Tenant Improvements.

The costs of the Tenant Improvements shall not include any moving costs, legal or accounting costs, furniture, laboratory and process equipment, or other personal property which is not permanently affixed to the Premises, which costs shall be borne solely by Tenant without the benefit of any portion of the Tenant Improvement Allowance.

4.2         Disbursement of the Tenant Improvement Allowances .   Within thirty (30) days after Tenant’s delivery to Landlord of (i) evidence, as Landlord may reasonably require (including but not limited to invoices marked “paid”), that Tenant has incurred an amount in excess of Two Million Dollars ($2,000,000.00) for the cost of the Tenant Improvements, (ii) if requested by Landlord, a certification reasonably satisfactory to Landlord delivered by Tenant and/or Tenant’s Architect that the work covered by such costs has been completed in substantial accordance with the Construction Drawings; and (iii) unconditional partial lien releases from the general contractor and each subcontractor who performed such work, Landlord shall pay to Tenant the full amount of the Tenant Improvement Allowance. In the event Landlord fails to make timely disbursement of the Tenant Improvement Allowance upon Tenant’s satisfaction of

 

6


the terms of this Section 4.2, Tenant, at its option, and without any other rights or remedies as a result of Landlord’s failure to disburse the Tenant Improvement Allowance, may offset the amount of the Tenant Improvement Allowance from the payment of Rent next due under the Lease until such undisbursed amount is fully exhausted.

5.         Intentionally Omitted .

6.         General Requirements for Construction .

6.1         Tenant’s Obligation to Construct .   Tenant shall cause the Tenant Improvements to be constructed and installed in a good and workmanlike manner in accordance with the Construction Drawings, this Workletter and all applicable Laws as interpreted at the time of construction. Tenant shall be solely responsible for the payment of all cost and expenses related to the construction and installation of the Tenant Improvements, subject to reimbursement by Landlord as provided for in this Workletter.

6.2         Tenant’s Access to the Premises .   Tenant shall coordinate with the Building’s project manager for access to the Premises and the scheduling of construction work. Tenant shall exercise due diligence and commercially reasonable efforts to ensure that Tenant’s construction and installation of the Tenant Improvements does not unreasonably interfere with the use and enjoyment of other tenants of the Building or the Project. Landlord shall use commercially reasonable efforts to accommodate Tenant’s scheduling of deliveries and construction activities.

6.3         Coordination of Construction Activities .   If any shutdown of plumbing, electrical or air conditioning equipment of the Building becomes necessary during the course of construction of the Tenant Improvements, Tenant shall notify Landlord and Landlord and Tenant shall agree upon when, and upon what conditions, such shutdown may be made in order to cause the least disruption to other tenants in the Building. Subject to the terms of Section 16.4 of the Lease, any damage to the Building or the Project to the extent caused solely by Tenant or its contractor or subcontractors in connection with the construction of the Tenant Improvements shall be promptly repaired at Tenant’s sole cost and expense.

6.4         Protection against Lien Claims .   Tenant shall file or cause to be filed a valid notice of completion within ten (10) days following completion of construction of the Tenant Improvements, file or cause to be filed a notice of cessation upon any cessation of labor on the Tenant Improvements for a continuous period of thirty (30) days or more, and take all reasonable steps to forestall the assertion of claims of lien against the Premises, the Building or the Project arising out of the Tenant Improvements. Upon the request of Landlord, Tenant shall provide Landlord with satisfactory evidence of the release or removal (including removal by appropriate surety bond) of all liens recorded against the Premises, the Project, or any portion thereof, and/or all stop notices received by Tenant. Section 9.2 of the Lease shall apply with respect to any lien or claim of lien filed with respect to Tenant’s construction of the Tenant Improvements.

6.5         Indemnification .   Tenant’s indemnity as set forth in Section 17.2 of the Lease shall also apply, to the extent permitted by Law, with respect to any and all claims,

 

7


liabilities, demands, losses, expenses, damages or causes of actions (whether legal or equitable in nature) asserted by any person, firm, corporation, governmental body or agency or entity to the extent and in any manner arising out of the construction of the Tenant Improvements, and except to the extent caused by the gross negligence or willful misconduct of Landlord or of its agents, employees or contractors. This indemnification shall be in addition to the insurance requirements set forth in the Lease and this Workletter and the obligations hereunder shall survive the expiration or termination of the Lease.

7.         Insurance .

7.1         Tenant’s Required Insurance Coverage .   At least five (5) days prior to the date Tenant commences construction of the Tenant Improvements, Tenant shall submit to Landlord evidence (including endorsements with respect to named additional insureds) of (i) the insurance coverage required under Article 16 of the Lease; and (ii) broad form “Builder’s Risk” property damage insurance with limits of not less than one hundred percent (100%) of the estimated value of the Tenant Improvements. All such policies shall provide that thirty (30) days’ written notice must be given to Landlord prior to expiration, termination, or cancellation. The insurance policies shall name Landlord and Landlord’s property manager as additional insureds and shall provide that Landlord, although an additional insured, may recover for any loss suffered by Landlord or Landlord’s agents by reason of the negligence of Tenant or Tenant’s contractors, subcontractors and/or employees.

7.2         Other Insurance Coverage .   At least five (5) business days prior to the date Tenant commences construction of the Tenant Improvements, Tenant shall deliver to Landlord certificates of insurance from the carrier(s) providing insurance to Tenant’s contractor and Tenant’s Architect evidencing the following types of coverage in such amounts as are reasonably determined by Landlord to be necessary for the construction of the Tenant Improvements: (i) professional liability insurance; (ii) commercial general liability insurance; (iii) business automobile liability insurance; (iv) workers’ compensation insurance; and (v) umbrella liability insurance. The insurance specified in (i), (ii), (iii) and (v) above shall name Landlord and Landlord’s property manager as additional insureds, and all such policies shall provide that thirty (30) days’ written notice must be given to Landlord prior to termination or cancellation.

7.3         Waivers of Claims against Landlord .   Each of Landlord and Tenant waives, and Tenant shall use commercially reasonable efforts to cause each of its architects and contractors to waive, all rights to recover against Landlord and its agents, contractors and employees for any loss or damage arising from a cause covered by insurance required to be carried by Landlord or Tenant or such architect or contractor, as applicable, hereunder and shall cause each respective insurer to waive all rights of subrogation against Landlord and its agents, contractors, and employees in connection therewith to the same extent.

8.         Default and Remedies .

8.1         Defaults .   Each of the following events shall constitute an event of default (“Default”) under this Workletter:

 

8


(a)        Failure by Tenant to comply with any of the covenants, provisions or conditions of this Workletter which is not corrected within thirty (30) days after the giving of written notice by Landlord to Tenant, provided, however, that if such failure cannot reasonably be cured within thirty (30) days, it shall not be a Default if Tenant has begun such cure within the thirty (30) day period and thereafter diligently and continuously pursued the same to completion;

(b)        Substantial and material deviations of the construction of the Tenant Improvements from the Construction Drawings, including any modifications made to the Construction Drawings by change orders issued during the course of construction, without the approval of Landlord, including material defects in workmanship or materials in the construction of the Tenant Improvements, that have been verified as such by an independent third party architect familiar with construction in the Bay Area and with tenant improvements similar in nature to the Tenant Improvements, and which are not corrected by Tenant (or its contractor) within thirty (30) days after written notice from Landlord (or if the defect is such that it cannot reasonably be corrected within said thirty (30) day period, the correction of such defect is not initiated by Tenant or the Contractor within said thirty (30) day period and thereafter prosecuted diligently to completion);

(c)        The Default by Tenant of any provision of the Lease after the expiration of applicable notice and cure periods, if any; and

(d)        Failure by Tenant, within one (1) year of the Commencement Date (as such one (1) year period shall be extended for any Landlord Delay or any delay caused by act of god such as earthquake or flood or casualty not caused by Tenant or Tenant’s agents, contractors, employees or invitees), to do all of the following: (i) Substantially Complete construction of the Tenant Improvements in accordance with the Construction Drawings, this Workletter, and applicable Laws, (ii) secure a certificate of occupancy from the City of Emeryville, and (iii) record a notice of completion, where such failure is not corrected by Tenant within thirty (30) days after written notice from Landlord (or if such failure is such that it cannot be reasonably corrected within said thirty (30) day period, the correction of such failure is not initiated by Tenant within said thirty (30) day period and thereafter prosecuted diligently to completion.

8.2         Remedies .   In the event of a Default by Tenant under this Workletter, Landlord shall thereafter have no obligation to disburse the Tenant Improvement Allowance unless and until such Default is cured. Any such Default shall be a default under the Lease and shall entitle Landlord to exercise all remedies set forth in the Lease.

9.         Force and Effect .   The terms and conditions of this Workletter supplement the Lease and shall be construed to be a part of the Lease and are incorporated in the Lease. Without limiting the generality of the foregoing, any default by any party hereunder shall have the same force and effect as a default under the Lease. Should any inconsistency arise between this Workletter and the Lease as to the specific matters that are the subject of this Workletter, the terms and conditions of this Workletter shall control.

 

9


10.         Representatives of Parties .

(a)        Landlord has designated Geoffrey Sears as its sole representative with respect to the matters set forth in this Workletter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of Landlord as required in this Workletter.

(b)        Tenant has designated Jeff Lievense as its sole representative with respect to the matters set forth in this Workletter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of Tenant as required in this Workletter.

11.         Resolution of Disputes .   In the event of any dispute between Landlord and Tenant regarding (i) the occurrence or alleged occurrence, or the duration, of any Landlord Delay or delay in Substantial Completion caused by act of god such as earthquake or flood or casualty not caused by Tenant or Tenant’s agents, contractors, employees or invitees, or (ii) Substantial Completion of the Tenant Improvements, the parties agree to attempt to resolve such dispute promptly and in good faith; provided, however, that if the parties are unable to resolve such dispute within ten (10) days after such dispute arises, the parties shall retain an independent third party architect familiar with construction in the vicinity of the Project of tenant improvements similar in nature to the Tenant Improvements to arbitrate such dispute, which third party arbitrator shall have the authority to make a final and binding resolution of such dispute, and the parties shall share equally the fees and charges of such arbitrator.

 

10


SCHEDULE 1 to Exhibit B

PRELIMINARY SPACE PLAN

(see attached)

 

1


LOGO


EXHIBIT C-1

LABORATORY RULES AND REGULATIONS

1.        Any laboratory equipment (glass and cage washers, sterilizers, centrifuges, etc.) being used during normal business hours must be properly insulated for noise to prevent interruption of other tenants’ business. Landlord reserves the right to request all equipment be insulated prior to occupancy. Should other tenants complain of noise, lab tenant will be responsible for abating any noise issues, at their sole cost.

2.        Any damages to property due to leaks from lab equipment will be the sole responsibility of the Tenant. Should damage occur in other Tenant spaces, any and all damages and clean up will be the responsibility of equipment owner (lab tenant).

3.        Animal activities are a recognized and necessary process in the biotech industry. It can only be conducted by lab tenants pursuant to all the requirements of their respective lease (including the “Use” clause) and requires specific, written approval by Landlord in advance. We also expect any animal operations to be conducted pursuant to all regulations, standards and best industry practices relating to them.

4.        The EmeryStation Campus is a mixed-use facility and lab tenants share space with office tenants. To reduce the potential interaction with office tenants and their employees and visitors with any biotech animal operations; animal testing performed; deliveries of animals and any equipment, foods, cleaners, etc. associated with animal activities must be coordinated through the Loading Dock after hours and with the cooperation of the building management and security personnel. Tenant should make every effort to handle any deliveries relating to animal activities outside of Building Standard Hours. The freight elevator must be used at all times, and delivery trucks should not be visible to the other tenants in the campus area. No cartons, containers or cardboard boxes bearing the nature of contents may be stored or left in common area spaces, to include any garage/freight areas. Feed bags, animal carriers, and any and all containers must be disposed of properly and with discretion.

5.        All exterior signage relating to laboratory operations ( i.e. , visible to common areas including corridors) must be kept to the minimum required by law. All signs must have Landlord’s approval prior to installation.


EXHIBIT C-2

RULES AND REGULATIONS

1.        No sidewalks, entrance, passages, courts, elevators, vestibules, stairways, corridors or halls shall be obstructed or encumbered by Tenant or used for any purpose other than ingress and egress to and from the Premises.

2.        No awning or other projection shall be attached to the outside walls or windows of the Project without the prior written consent of Landlord. No curtains, blinds, shades, drapes or screens shall be attached to or hung in, or used in connection with, any window within the Premises which faces the street, without the prior written consent of Landlord. Such awnings, projections, curtains, blinds, shades, drapes, screens and other fixtures must be of a quality, type, design, color, material and general appearance approved by Landlord, and shall be attached in the manner approved by Landlord. All lighting fixtures hung in offices or spaces along the perimeter of the Premises must be of a quality, type, design, bulb color, size and general appearance approved by Landlord.

3.        Except as expressly otherwise permitted herein or in the Lease, no sign, advertisement, notice, lettering, decoration or other thing shall be exhibited, inscribed, painted or affixed by Tenant on any part of the Project outside of the Premises or any part of the Premises which faces outward toward public portions of the Project, without the prior written consent of Landlord. For the avoidance of doubt, Landlord and Tenant agree that the restrictions in this Section 3 shall not apply to any portion of the Premises which is entirely inside the Premises. In the event of the violation of the foregoing by Tenant, Landlord may remove same without any liability, and may charge the expense incurred by such removal to Tenant.

4.        Intentionally Omitted.

5.        No showcases or similar articles shall be put in front of or affixed to any part of the exterior of the Project, nor placed in public portions thereof without the prior written consent of Landlord.

6.        The water and wash closets and other plumbing fixtures shall not be used for any purposes other than those for which they were constructed, and no sweepings, rubbish, rags or other substances shall be thrown therein. All damages resulting from any misuse of the fixtures shall be borne by Tenant to the extent that Tenant or Tenant’s agents, servants, employees, contractors, visitors or licensees shall have caused the same.

7.        Intentionally Omitted.

8.        No animal or bird of any kind shall be brought into or kept in or about the Premises or the Project, except seeing-eye dogs or other service animals.

9.        Intentionally Omitted.

 

1


10.        Tenant shall not make, or permit to be made, any unseemly or disturbing noises or disturb or interfere with occupants of the Project, or neighboring buildings or premises, or those having business with them. Tenant shall not throw anything out of the doors, windows or skylights or down the passageways.

11.        Intentionally Omitted.

12.        No additional mail slots of any kind shall be placed upon any of the exterior doors of the Premises by Tenant. Tenant must, upon the termination of the tenancy, restore to Landlord all keys of offices and toilet rooms, either furnished to, or otherwise procured by Tenant, and in the event of the loss of any keys so furnished, Tenant shall pay to Landlord the cost thereof.

13.        All removals, or the carrying in or out of any safes, freight, furniture, construction material, bulky matter or heavy equipment of any description must take place during the hours which Landlord or its agent may determine from time to time. Landlord reserves the right to prescribe the weight and position of all safes, which must be placed upon two-inch thick plank strips to distribute the weight. The moving of safes, freight, furniture, fixtures, bulky matter or heavy equipment of any kind must be made upon previous notice to the Building Manager and in a manner and at times prescribed by him, and the persons employed by Tenant for such work are subject to Landlord’s prior approval. Landlord reserves the right to inspect all safes, freight or other bulky articles to be brought into the Project and to exclude from the Project all safes, freight or other bulky articles which violate any of these Rules and Regulations or the Lease of which these Rules and Regulations are a part.

14.        Intentionally Omitted.

15.        Landlord shall have the right to prohibit any advertising or business conducted by Tenant referring to the Project which, in Landlord’s opinion, tends to impair the reputation of the Project or its desirability as a first class building for offices and/or commercial services and upon notice from Landlord, Tenant shall refrain from or discontinue such advertising.

16.        Landlord reserves the right to exclude from the Project between the hours of 6:00 p.m. and 8:00 a.m. Monday through Friday, after 1:00 p.m. on Saturdays and at all hours Sundays and legal holidays, all persons who do not present a pass to the Project issued by Landlord. Landlord may furnish passes to Tenant so that Tenant may validate and issue same. Tenant shall safeguard said passes and shall be responsible for all acts of persons in or about the Project who possess a pass issued to Tenant.

17.        Tenant’s contractors shall, while in the Premises or elsewhere in the Project, be subject to and under the control and direction of the Building Manager (but not as agent or servant of said Building Manager or of Landlord).

18.        If the Premises is or becomes infested with vermin as a result of the use or any misuse or neglect of the Premises by Tenant, its agents, servants, employees, contractors, visitors or licensees, Tenant shall forthwith at Tenant’s expense cause the same to be exterminated from time to time to the satisfaction of Landlord and shall employ such licensed exterminators as shall be approved in writing in advance by Landlord.

 

2


19.        The requirements of Tenant will be attended to only upon application at the office of the Project. Project personnel shall not perform any work or do anything outside of their regular duties unless under special instructions from the office of the Landlord.

20.        Canvassing, soliciting and peddling in the Project are prohibited and Tenant shall cooperate to prevent the same.

21.        Intentionally Omitted.

22.        There shall not be used in any premises, or in the public halls, plaza areas, lobbies, or elsewhere in the Project, either by Tenant or by jobbers or others, in the delivery or receipt of merchandise, any hand trucks or dollies, except those equipped with rubber tires and sideguards.

23.        Tenant, Tenant’s agents, employees, contractors, licensees, or visitors shall not park any vehicles in any driveways, service entrances, or areas posted “No Parking” and shall comply with any other parking restrictions imposed by Landlord from time to time.

24.        Tenant shall install and maintain, at Tenant’s sole cost and expense, an adequate visibly marked (at all times properly operational) fire extinguisher next to any duplicating or photocopying machine or similar heat producing equipment, which may or may not contain combustible material, in the Premises.

25.        Intentionally Omitted.

26.        Tenant shall not use the name of the Project for any purpose other than as the address of the business to be conducted by Tenant in the Premises, nor shall Tenant use any picture of the Project in its advertising, stationery or in any other manner without the prior written permission of Landlord. Landlord expressly reserves the right at any time to change said name without in any manner being liable to Tenant therefor.

27.        Tenant shall not operate or conduct any restaurant, luncheonette or cafeteria for the sale or service of food or beverages to its employees or to others, except that food and beverage preparation by Tenant’s employees using microwave ovens, toasters, toaster ovens or coffee makers shall be permitted provided no odors of cooking or other processes emanate from the Premises. Tenant shall not install or permit the installation or use of any commercial vending machine except by such persons and in such manner as are approved in advance in writing by Landlord.

28.        The Premises shall not be used as an employment agency, a public stenographer or typist, a labor union office, a physician’s or dentist’s office, a dance or music studio, a school, a beauty salon, or barber shop, the business of photographic, multilith or multigraph reproductions or offset printing (not precluding using any part of the Premises for photographic, multilith or multigraph reproductions solely in connection with Tenant’s own business and/or activities), a restaurant or bar, an establishment for the sale of confectionery, soda, beverages, sandwiches, ice cream or baked goods, an establishment for preparing, dispensing or consumption of food or beverages of any kind in any manner whatsoever (except as permitted by Section 27 above), or news or cigar stand, or a radio, television or recording studio, theatre or

 

3


exhibition hall, or manufacturing, or the storage or sale of merchandise, goods, services or property of any kind at wholesale, retail or auction, or for lodging or sleeping (provided Landlord acknowledges and agrees that the foregoing shall not be deemed to prohibit Tenant from producing chemical compounds and/or intermediaries as part of the ordinary course of research and development activities).

29.        Business machines and mechanical equipment shall be placed and maintained by Tenant at Tenant’s expense in settings sufficient in Landlord’s judgment to absorb and prevent vibration, noise and annoyance. Tenant shall not install any machine or equipment which causes noise, heat, cold or vibration to be transmitted to the structure of the building in which the Premises are located without Landlord’s prior written consent, which consent may be conditioned on such terms as Landlord may require. Tenant shall not place a load upon any floor of the Premises exceeding the floor load per square foot that such floor was designed to carry and which is allowed by Law (provided Landlord shall provide Tenant with notice of each such floor load).

30.        Intentionally Omitted.

31.        Tenant shall not store any vehicle within the parking area. Tenant’s parking rights are limited to the use of parking spaces for short-term parking, of up to twenty-four (24) hours, of vehicles utilized in the normal and regular daily travel to and from the Project. Tenants who wish to park a vehicle for longer than a 24-hour period shall notify the Building Manager for the Project; and such parking shall be permitted for up to five (5) days to accommodate the business travel of an employee of Tenant, but otherwise any parking for longer than a 24-hour period shall require the consent of Landlord and in any case may not be longer than two (2) weeks. Any motor vehicles parked without the prior written consent of the Building Manager for the Project for longer than a 24-hour period shall be deemed stored in violation of this rule and regulation and shall be towed away and stored at the owner’s expense or disposed of as provided by Law.

32.        Smoking is prohibited in the Premises, the Building and all enclosed Common Areas of the Project, including all lobbies, all hallways, all elevators and all lavatories.

 

4


RIDER 1

COMMENCEMENT DATE AGREEMENT

EMERYSTATION TRIANGLE, LLC, a California limited liability company (“Landlord”), and __________________(“Tenant”), have entered into a certain Lease dated as of ________________, 2008 (the “Lease”).

WHEREAS, Landlord and Tenant wish to confirm and memorialize the Commencement Date and Expiration Date of the Lease as provided for in Section 2.2(a), Section 3.1, and Section 1.1(7), respectively, of the Lease;

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein and in the Lease, Landlord and Tenant agree as follows:

1.        Unless otherwise defined herein, all capitalized terms shall have the same meaning ascribed to them in the Lease.

2.        The Commencement Date (as defined in the Lease) of the Lease is ___________.

3.        The Expiration Date (as defined in the Lease) of the Lease is ________________.

4.        Tenant hereby confirms the following:

(a)        That it has accepted possession of the Premises pursuant to the terms of the Lease; and

(b)        That the Lease is in full force and effect.

5.        Except as expressly modified hereby, all terms and provisions of the Lease are hereby ratified and confirmed and shall remain in full force and effect and binding on the parties hereto.

6.        The Lease and this Commencement Date Agreement contain all of the terms, covenants, conditions and agreements between the Landlord and the Tenant relating to the subject matter herein. No prior other agreements or understandings pertaining to such matters are valid or of any force and effect.

 

TENANT:

   

LANDLORD:

   

EMERYSTATION TRIANGLE, LLC,

   

a California limited liability company

By:

       

By:    

   

Its:

         

Richard K. Robbins

       

Managing Member

Date:  

         


RIDER 2

FORM OF LETTER OF CREDIT

(see attached)


THIS DRAFT IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

CLIENT/APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

 

 

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF ______

(THE ABOVE LC NUMBER AND THE ISSUANCE DATE BELOW, WILL BE INSERTED AT TIME OF LC ISSUANCE)

DATED: ____________ __, 20___

BENEFICIARY:

EMERY STATION TRIANGLE, LLC

1120 NYE STREET, SUITE 400

SAN RAFAEL, CA 94901

AS “ LANDLORD

APPLICANT:

AMYRIS BIOTECHNOLOGIES, INC.

5980 HORTON STREET, SUITE 450

EMERYVILLE, CA 94608

AS “ TENANT

 

AMOUNT:

  

US$79,363,26 (SEVENTY-NINE THOUSAND THREE-HUNDRED SIXTY-THREE AND 26/100 U.S. DOLLARS)

EXPIRATION DATE:

  

_____________ __, 20___

LOCATION:

  

SANTA CLARA, CALIFORNIA

LADIES AND GENTLEMEN:

WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF ____ IN YOUR FAVOR. THIS LETTER OF CREDIT IS AVAILABLE BY SIGHT PAYMENT WITH OURSELVES ONLY AGAINST PRESENTATION AT THIS OFFICE OF THE FOLLOWING DOCUMENTS:

 

1.

THE ORIGINAL OF THIS LETTER OF CREDIT AND ALL AMENDMENT (S), IF ANY.

 

2.

YOUR SIGHT DRAFT DRAWN ON US IN THE FORM ATTACHED HERETO AS EXHIBIT “A” .

 

3.

A DATED CERTIFICATION PURPORTEDLY SIGNED BY AN AUTHORIZED OFFICER OR REPRESENTATIVE OF THE BENEFICIARY, FOLLOWED BY HIS/HER PRINTED NAME AND DESIGNATED TITLE, STATING EITHER OF THE FOLLOWING:

 

(A.)

“A DEFAULT (AS DEFINED IN THE LEASE) HAS OCCURRED BY AMYRIS BIOTECHNOLOGIES, INC. AS TENANT UNDER THAT CERTAIN LEASE AGREEMENT BY AND BETWEEN TENANT, AND BENEFICIARY, AS LANDLORD. FURTHERMORE THIS IS TO CERTIFY THAT: (I) LANDLORD HAS GIVEN WRITTEN NOTICE TO TENANT TO CURE THE DEFAULT AND SUCH DEFAULT HAS NOT BEEN CURED UP TO THIS DATE OF DRAWING UNDER THIS LETTER OF CREDIT AND ALL APPLICABLE CURE PERIOD (IF ANY) HAS EXPIRED; AND (II) THE TERMS AND CONDITIONS OF THE LEASE AUTHORIZE LANDLORD TO NOW DRAW DOWN ON THE LETTER OF CREDIT.”

OR

 

 

PAGE 1 OF 6

LC DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECIINOLOGIES, INC.

 

            
CLIENT/APPLICANT’S SIGNATURE(S)       DATE   

(NOTE: AN AUTHORIZED SIGNATORY FOR THE CLIENT MUST AFFIX HIS/HER SIGNATURE AND DATE EACH PAGE OF THIS DRAFT. IT MUST THEN BE ATTACHED TO AND FORM PART OF THE LC APPLICATION TO SIGNIFY THEIR AND BENEIFICIARY’S AGREEMENT TO THIS DRAFT.)

FILE NAME: \AMYRIS_LEASE_V3_04APR08


THIS DRAFT IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

CLIENT/APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

 

 

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF ______

(THE ABOVE LC NUMBER AND THE ISSUANCE DATE BELOW, WILL BE INSERTED AT TIME OF LC ISSUANCE)

DATED: ____________ __, 20___

 

 

(B.)

“WITHIN THIRTY (30) DAYS PRIOR TO THE EXPIRATION DATE OF THIS LETTER OF CREDIT BENEFICIARY HAS NOT RECEIVED AN EXTENSION AT LEAST FOR ONE YEAR TO THE EXISTING LETTER OF CREDIT OR A REPLACEMENT LETTER OF CREDIT SATISFACTORY TO THE BENEFICIARY.”

THE LEASE AGREEMENT MENTIONED ABOVE IS FOR IDENTIFICATION PURPOSES ONLY AND IT IS NOT INTENDED THAT SAID LEASE AGREEMENT BE INCORPORATED HEREIN OR FORM PART OF THIS LETTER OF CREDIT.

PARTIAL DRAWINGS ARE ALLOWED. THIS LETTER OF CREDIT MUST ACCOMPANY ANY DRAWINGS HEREUNDER FOR ENDORSEMENT OF THE DRAWING AMOUNT AND WILL BE RETURNED TO THE BENEFICIARY UNLESS IT IS FULLY UTILIZED.

WE AGREE THAT WE SHALL HAVE NO DUTY OR RIGHT TO INQUIRE AS TO THE BASIS UPON WHICH BENEFICIARY HAS DETERMINED THAT THE AMOUNT IS DUE AND OWING OR HAS DETERMINED TO PRESENT TO US ANY DRAFT UNDER THIS LETTER OF CREDIT, AND THE PRESENTATION OF SUCH DRAFT IN STRICT COMPLIANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT, SHALL AUTOMATICALLY RESULT IN PAYMENT TO THE BENEFICIARY.

THIS LETTER OF CREDIT SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT, FROM THE PRESENT OR EACH FUTURE EXPIRATION DATE UNLESS AT LEAST SIXTY (60) DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE NOTIFY YOU BY REGISTERED MAIL/OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESS THAT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND THE CURRENT EXPIRATION DATE. BUT IN ANY EVENT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND JUNE 1, 2018, WHICH SHALL BE THE FINAL EXPIRATION DATE OF THIS LETTER OF CREDIT.

THE DATE THIS LETTER OF CREDIT EXPIRES IN ACCORDANCE WITH THE ABOVE PROVISION IS THE “FINAL EXPIRATION DATE”. UPON THE OCCURRENCE OF THE FINAL EXPIRATION DATE THIS LETTER OF CREDIT SHALL FULLY AND FINALLY EXPIRE AND NO PRESENTATIONS MADE UNDER THIS LETTER OF CREDIT AFTER SUCH DATE WILL BE HONORED.

THIS LETTER OF CREDIT MAY ALSO BE CANCELED PRIOR TO ANY PRESENT OR FUTURE EXPIRATION DATE, UPON RECEIPT BY SILICON VALLEY BANK BY OVERNIGHT COURIER OR REGISTERED MAIL (RETURN RECEIPT REQUESTED) OF THE ORIGINAL LETTER OF CREDIT AND ALL AMENDMENTS (IF ANY) FROM THE BENEFICIARY TOGETHER WITH A STATEMENT SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE BENEFICIARY ON COMPANY LETTERHEAD STATING THAT THE LETTER OF CREDIT IS NO LONGER REQUIRED AND IS BEING RETURNED FOR CANCELLATION.

 

 

PAGE 2 OF 6

LC DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECIINOLOGIES, INC.

 

            
C LIENT / APPLICANT S S IGNATURE ( S )       D ATE   

(NOTE: AN AUTHORIZED SIGNATORY FOR THE CLIENT MUST AFFIX HIS/HER SIGNATURE AND DATE EACH PAGE OF THIS DRAFT. IT MUST THEN BE ATTACHED TO AND FORM PART OF THE LC APPLICATION TO SIGNIFY THEIR AND BENEIFICIARY’S AGREEMENT TO THIS DRAFT.)

FILE NAME: \AMYRIS_LEASE_V3_04APR08

 

2


THIS DRAFT IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

CLIENT/APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

 

 

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF ______

(THE ABOVE LC NUMBER AND THE ISSUANCE DATE BELOW, WILL BE INSERTED AT TIME OF LC ISSUANCE)

DATED: ____________ __, 20___

THIS LETTER OF CREDIT IS TRANSFERABLE ONE OR MORE TIMES. BUT IN EACH INSTANCE ONLY TO A SINGLE BENEFICIARY AS TRANSFEREE AND ONLY UP TO THE THEN AVAILABLE AMOUNT IN FAVOR OF ANY NOMINATED TRANSFEREE THAT IS THE SUCCESSOR IN INTEREST TO BENEFICIARY (“TRANSFEREE”), ASSUMING SUCH TRANSFER TO SUCH TRANSFEREE WOULD BE IN COMPLIANCE WITH THEN APPLICABLE LAW AND REGULATION, INCLUDING BUT NOT LIMITED TO THE REGULATIONS OF THE U.S. DEPARTMENT OF TREASURY AND U.S. DEPARTMENT OF COMMERCE. AT THE TIME OF TRANSFER, THE ORIGINAL LETTER OF CREDIT AND ORIGINAL AMENDMENT(S), IF ANY, MUST BE SURRENDERED TO US AT OUR ADDRESS INDICATED IN THIS LETTER OF CREDIT TOGETHER WITH OUR LETTER OF TRANSFER DOCUMENTATION AS PER ATTACHED EXHIBIT “B” DULY EXECUTED AND ACCOMPANIED BY THE ORIGINAL LETTER OF CREDIT AND ALL AMENDMENT(S), IF ANY. THE CORRECTNESS OF THE SIGNATURE AND TITLE OF THE PERSON SIGNING THE TRANSFER FORM MUST BE VERIFIED BY BENEFICIARY’S BANK. APPLICANT SHALL PAY OUR TRANSFER FEE OF 1/4 OF 1% OF THE TRANSFER AMOUNT (MINIMUM US$250.00) UNDER THIS LETTER OF CREDIT. ANY REQUEST FOR TRANSFER WILL BE EFFECTED BY US SUBJECT TO THE ABOVE CONDITIONS. HOWEVER, ANY REQUEST FOR TRANSFER IS NOT CONTINGENT UPON APPLICANT’S ABILITY TO PAY OUR TRANSFER FEE. ANY TRANSFER OF THIS LETTER OF CREDIT MAY NOT CHANGE THE PLACE OR DATE OF EXPIRATION OF THE LETTER OF CREDIT FROM OUR ABOVE SPECIFIED OFFICE. EACH TRANSFER SHALL BE EVIDENCED BY OUR ENDORSEMENT ON THE REVERSE OF THE LETTER OF CREDIT AND WE SHALL FORWARD THE ORIGINAL OF THE LETTER OF CREDIT SO ENDORSED TO THE TRANSFEREE.

DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT.

DOCUMENTS MUST BE DELIVERED TO US DURING REGULAR BUSINESS HOURS ON A BUSINESS DAY OR FORWARDED TO US BY OVERNIGHT DELIVERY SERVICE TO: SILICON VALLEY BANK, 3003 TASMAN DRIVE, 2ND FLOOR, MAIL SORT HF210, SANTA CLARA, CALIFORNIA 95054. ATTENTION: GLOBAL FINANCIAL SERVICES -STANDBY LETTER OF CREDIT DEPARTMENT (THE “BANK’S OFFICE”).

AS USED HEREIN, THE TERM “BUSINESS DAY” MEANS A DAY ON WHICH WE ARE OPEN AT OUR ABOVE ADDRESS IN SANTA CLARA, CALIFORNIA TO CONDUCT OUR LETTER OF CREDIT BUSINESS. NOTWITHSTANDING ANY PROVISION TO THE CONTRARY IN THE UCP (AS HEREINAFTER DEFINED), IF THE EXPIRATION DATE OR THE FINAL EXPIRATION DATE IS NOT A BUSINESS DAY THEN SUCH DATE SHALL BE AUTOMATICALLY EXTENDED TO THE NEXT SUCCEEDING DATE WHICH IS A BUSINESS DAY.

WE HEREBY ENGAGE WITH YOU THAT DRAFT(S) DRAWN AND/OR DOCUMENTS PRESENTED UNDER AND IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON PRESENTATION TO SILICON VALLEY BANK, IF PRESENTED ON OR BEFORE THE EXPIRATION DATE OF THIS CREDIT.

 

 

PAGE 3 OF 6

LC DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECIINOLOGIES, INC.

 

            
C LIENT / APPLICANT S S IGNATURE ( S )       D ATE   

(NOTE: AN AUTHORIZED SIGNATORY FOR THE CLIENT MUST AFFIX HIS/HER SIGNATURE AND DATE EACH PAGE OF THIS DRAFT. IT MUST THEN BE ATTACHED TO AND FORM PART OF THE LC APPLICATION TO SIGNIFY THEIR AND BENEIFICIARY’S AGREEMENT TO THIS DRAFT.)

FILE NAME: \AMYRIS_LEASE_V3_04APR08

 

3


THIS DRAFT IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

CLIENT/APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

 

 

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF ______

(THE ABOVE LC NUMBER AND THE ISSUANCE DATE BELOW, WILL BE INSERTED AT TIME OF LC ISSUANCE)

DATED: ____________ __, 20___

IF ANY INSTRUCTIONS ACCOMPANYING A DRAWING UNDER THIS LETTER OF CREDIT REQUEST THAT PAYMENT IS TO BE MADE BY TRANSFER TO YOUR ACCOUNT WITH ANOTHER BANK, WE WILL ONLY EFFECT SUCH PAYMENT BY FED WIRE TO A U.S. REGULATED BANK, AND WE AND/OR SUCH OTHER BANK MAY RELY ON AN ACCOUNT NUMBER SPECIFIED IN SUCH INSTRUCTIONS EVEN IF THE NUMBER IDENTIFIES A PERSON OR ENTITY DIFFERENT FROM THE INTENDED PAYEE.

THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS (2007 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 600 (THE “UCP”).

 

SILICON VALLEY BANK,

  

(FOR BANK USE ONLY)

  

(FOR BANK USE ONLY)

AUTHORIZED SIGNATURE

  

AUTHORIZED SIGNATURE

 

 

 

 

PAGE 4 OF 6

LC DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECIINOLOGIES, INC.

 

            
C LIENT / APPLICANT S S IGNATURE ( S )       D ATE   

(NOTE: AN AUTHORIZED SIGNATORY FOR THE CLIENT MUST AFFIX HIS/HER SIGNATURE AND DATE EACH PAGE OF THIS DRAFT. IT MUST THEN BE ATTACHED TO AND FORM PART OF THE LC APPLICATION TO SIGNIFY THEIR AND BENEIFICIARY’S AGREEMENT TO THIS DRAFT.)

FILE NAME: \AMYRIS_LEASE_V3_04APR08

 

4


THIS DRAFT IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

CLIENT/APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

 

 

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF ______

(THE ABOVE LC NUMBER AND THE ISSUANCE DATE BELOW, WILL BE INSERTED AT TIME OF LC ISSUANCE)

DATED: ____________ __, 20___

EXHIBIT “A”

 

    

SIGHT DRAFT/BILL OF

EXCHANGE

         
   

DATE: ________________________

     

REF. NO. ___________________________

    
   

AT SIGHT OF THIS BILL OF EXCHANGE

       
 

PAY TO THE ORDER OF______________________________________________US$______________________________

U.S. DOLLARS _______________________________________________________________________________________

 

“DRAWN UNDER SILICON VALLEY BANK , SANTA CLARA, CALIFORNIA,

IRREVOCABLE STANDBY LETTER OF CREDIT NUMBER NO. SVBSF ______ DATED

______________ __, 20___”

   

TO:   SILICON VALLEY BANK

         

         3003 TASMAN DRIVE

      [INSERT NAME OF BENEFICIARY]     

         SANTA CLARA, CA 95054

          
   
           
    

Authorized Signature

 

GUIDELINES TO PREPARE THE SIGHT DRAFT OR BILL OF EXCHANGE:

 

1.

DATE            INSERT ISSUANCE DATE OF DRAFT OR BILL OF EXCHANGE.

2.

REF. NO.       INSERT YOUR REFERENCE NUMBER IF ANY.

3.

PAY TO THE ORDER OF:           INSERT NAME OF BENEFICIARY

4.

US$                INSERT AMOUNT OF DRAWING IN NUMERALS/FIGURES.

5.

U.S. DOLLARS           INSERT AMOUNT OF DRAWING IN WORDS.

6.

LETTER OF CREDIT NUMBER INSERT THE LAST DIGITS OF OUR STANDBY L/C NUMBER THAT PERTAINS TO THE DRAWING.

7.

DATED         INSERT THE ISSUANCE DATE OF OUR STANDBY L/C.

 

NOTE:

BENEFICIARY SHOULD ENDORSE THE BACK OF THE SIGHT DRAFT OR BILL OF EXCHANGE AS YOU WOULD A CHECK.

IF YOU NEED FURTHER ASSISTANCE IN COMPLETING THIS SIGHT DRAFT OR BILL OF EXCHANGE, PLEASE CALL OUR L/C PAYMENT SECTION AND ASK FOR:   EFRAIN TUVILLA AT (408) 654-6349 OR ALICE DALUZ AT (408) 654-7120.

 

 

PAGE 5 OF 6

LC DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECIINOLOGIES, INC.

 

            
C LIENT / APPLICANT S S IGNATURE ( S )       D ATE   

(NOTE: AN AUTHORIZED SIGNATORY FOR THE CLIENT MUST AFFIX HIS/HER SIGNATURE AND DATE EACH PAGE OF THIS DRAFT. IT MUST THEN BE ATTACHED TO AND FORM PART OF THE LC APPLICATION TO SIGNIFY THEIR AND BENEIFICIARY’S AGREEMENT TO THIS DRAFT.)

FILE NAME: \AMYRIS_LEASE_V3_04APR08

 

5


THIS DRAFT IS FOR DISCUSSION PURPOSES ONLY.

IT WILL BECOME AN INTEGRAL PART OF AND MUST BE ATTACHED TO

SILICON VALLEY BANK APPLICATION FOR STANDBY LETTER OF CREDIT WHEN APPROVED FOR ISSUANCE BY

CLIENT/APPLICANT: AMYRIS BIOTECHNOLOGIES, INC.

 

 

IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF ______

(THE ABOVE LC NUMBER AND THE ISSUANCE DATE BELOW, WILL BE INSERTED AT TIME OF LC ISSUANCE)

DATED: ____________ __, 20___

EXHIBIT “B”

DATE:

 

TO:

SILICON VALLEY BANK

 

3003 TASMAN DRIVE

 

SANTA CLARA, CA 95054

 

 

ATTN:

GLOBAL FINANCIAL SERVICES

 

 

STANDBY LETTERS OF CREDIT

RE: SILICON VALLEY BANK IRREVOCABLE STANDBY LETTER OF CREDIT NO.                 

GENTLEMEN:

FOR VALUE RECEIVED. THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO:

__________________________________________________________________________________

(NAME OF TRANSFEREE)                                                                         

__________________________________________________________________________________

(ADDRESS)                                                                          

ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS TRANSFER.

BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE. TRANSFEREE SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF, INCLUDING SOLE RIGHT’S RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECT TO THE TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY.

THE ORIGINAL OF SUCH LETTER OF CREDIT IS RETURNED HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER ON THE REVERSE THEREOF, AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER.

 

SINCERELY.

          
         SIGNATURE AUTHENTICATED   
               
  

(BENEFICIARY’S NAME)

 

     

THE NAME(S) TITLE(S), AND SIGNATURE(S) CONFORM TO THAT/THOSE ON FILE WITH US FOR THE COMPANY AND THE SIGNATURE(S) IS/ARE AUTHORIZED TO EXECUTE THIS INSTRUMENT.

WE FURTHER CONFIRM THAT THE COMPANY HAS BEEN IDENTIFIED APPLYING THE APPROPRIATE DUE DILIGENCE AND ENHANCED DUE DILIGENCE AS REQUIRED BY THE BANK SECRECY ACT AND ALL ITS SUBSEQUENT AMENDMENTS.

  
   (SIGNATURE OF BENEFICIARY)         
             
   (PRINTED NAME AND TITLE)         
 
         _________________________________________   
         (NAME OF BANK)   
         _________________________________________   
         (ADDRESS OF BANK)   
         _________________________________________   
         (CITY, STATE, ZIP CODE)   
         _________________________________________   
         (AUTHORIZED SIGNATURE)   
         _________________________________________   
         (PRINTED NAME AND TITLE)   
         _________________________________________   
        

(TELEPHONE NUMBER)

 

  

 

 

PAGE 6 OF 6

LC DRAFT LANGUAGE APPROVED FOR ISSUANCE BY: AMYRIS BIOTECIINOLOGIES, INC.

 

            
C LIENT / APPLICANT S S IGNATURE ( S )       D ATE   

(NOTE: AN AUTHORIZED SIGNATORY FOR THE CLIENT MUST AFFIX HIS/HER SIGNATURE AND DATE EACH PAGE OF THIS DRAFT. IT MUST THEN BE ATTACHED TO AND FORM PART OF THE LC APPLICATION TO SIGNIFY THEIR AND BENEIFICIARY’S AGREEMENT TO THIS DRAFT.)

FILE NAME: \AMYRIS_LEASE_V3_04APR08

 

6

Exhibit 10.23

April 25, 2008

Mr. Geoff Sears

WAREHAM DEVELOPMENT

1120 Nye Street, Suite 40

San Rafael, CA 94901

 

Re: Lease Between Emerystation Triangle, LLC and Amyris Biotechnologies,
     Inc. for Space Located at 5850 Hollis Street, Emeryville, CA

Dear Geoff,

Reference is made to that certain Lease being executed concurrently herewith (the “Lease”) between Emerystation Triangle, LLC, as Landlord, and Amyris Biotechnologies, Inc., as Tenant, for certain space within the building located at 5850 Hollis Street, Emeryville, California, as more particularly described in the Lease (the “Premises”). Capitalized terms used in this letter agreement and not defined herein will have the meanings given to them in the Lease.

Landlord and Tenant hereby agree the Lease is amended as follows:

1.        In Section 2.2(a)(1) of the Lease, the three references to the date “April 21, 2008” are hereby deleted and replaced with the date “April 25, 2008”.

2.        Notwithstanding anything to the contrary set forth in the Lease, Landlord and Tenant hereby agree that the Premises will be delivered to Tenant in the following phases (and the Termination Agreement with the Current Premises Tenant to be delivered by Landlord to Tenant pursuant to Section 2.2(a)(1) of the Lease, as such Section 2.2(a)(1) has been amended by this letter agreement, shall reflect the following termination effective dates):

 

   

Warehouse Portion of Premises : The PH Lease Termination Effective Date with respect to the warehouse portion of the Premises shall be no later than May 18, 2008. The Commencement Date of the Lease with respect to the warehouse portion of the Premises shall therefore be no later than May 19, 2008. The warehouse portion of the Premises shall be delivered by Landlord to Tenant in the condition required under Section 2.4 of the Lease, except that Landlord shall also be obligated to remove the storage racks from the warehouse portion of the Premises prior to delivery thereof by Landlord to Tenant.

 

   

Office Portion of Premises : The PH Lease Termination Effective Date with respect to the office portion of the Premises (including the “dance studio” portion thereof) shall be no later than June 30, 2008. The Commencement Date of the Lease with respect to the office portion of the Premises shall therefore be no later than July 1, 2008. Landlord agrees to use commercially reasonable efforts to accelerate the PH Lease Termination Effective Date with respect to the office portion of the Premises but is under no obligation to effect a termination effective date earlier than June 30, 2008. The office portion of the Premises shall be delivered by Landlord to Tenant in the condition required under Section 2.4 of the Lease.

 

1


3.        Section 2.3 of the Lease (Failure to Give Possession) is hereby amended and restated in its entirety as follows:

“Landlord shall use commercially reasonable efforts to cause the Current Premises Tenant (i) to surrender the warehouse portion of the Premises by no later the PH Lease Termination Effective Date with respect to the warehouse portion of the Premises ( i.e. , May 18, 2008), and (ii) to surrender the office portion of the Premises (including the “dance studio” portion thereof) by no later than the PH Lease Termination Effective Date with respect to the office portion of the Premises ( i.e. , June 30, 2008). If Landlord shall be unable to give possession of the warehouse portion of the Premises by May 19, 2008 or the office portion of the Premises by July 1, 2008, by reason of the following: (i) the holding over or retention of possession by the Current Premises Tenant, or (ii) for any other reason beyond Landlord’s reasonable control, then Landlord shall not be subject to any liability for the failure to give possession on said applicable date and, except as otherwise set forth in Section 2.2(a) of this Lease (as amended by side letter) and this Section 2.3, no such failure to give possession on said applicable date shall affect the validity of this Lease or the obligations of the Tenant hereunder. Notwithstanding the foregoing, if the Current Premises Tenant fails to surrender possession of the warehouse portion of the Premises by May 18, 2008 or fails to surrender possession of the office portion of the Premises by June 30, 2008, in each such case Landlord, at its sole cost, shall use commercially reasonable efforts (including commencing eviction proceedings) to obtain possession of the applicable portion of the Premises as soon as possible. In addition, notwithstanding anything to the contrary in Section 2.2 of this Lease (as amended by side letter) or this Section 2.3, if for any reason the Commencement Date with respect to the entire Premises has not occurred on or before July 31, 2008, Tenant shall have the right to terminate this Lease for a period not exceeding fifteen (15) days after July 31, 2008, by delivering ten (10) days’ written notice to Landlord. In the event this Lease so terminates, (i) any monies or deposits previously paid or delivered by Tenant to Landlord shall be promptly returned to Tenant, (ii) neither party shall have any further obligations or liabilities hereunder, and (iii) Tenant shall restore the portion of the Premises, if any, that had been delivered by Landlord to Tenant as of such termination to its condition as of the date of delivery thereof by Landlord to Tenant (subject to reasonable wear and tear).”

4.        For purposes of Section 1.1(7), Section 1.1(8), the definition of “Operating Expenses” in Section 1.3, Section 4.1 and Section 21 of the Lease and Section 8.1(d) of the Workletter Agreement (Exhibit B to the Lease), the Commencement Date shall be deemed to be the Commencement Date of the Lease with respect to the warehouse portion of the Premises.

Except as set forth in this letter agreement, the Lease remains unmodified and in full force and effect.

By their signatures below, the parties are in agreement with the terms set forth above.

 

 

 

AGREED AND ACCEPTED:    
EMERYSTATION TRIANGLE, LLC     AMYRIS BIOTECHNOLOGIES, INC.
By:   /s/ Richard K. Robbins                                             By:   /s/ Tamara L. Tompkins                                 
Its:   Manager                                                                  Its:   Secretary & General Counsel                          
Date: April 25, 2008     Date: April 25, 2008

 

2

Exhibit 10.24

SECOND AMENDMENT TO LEASE

THIS SECOND AMENDMENT TO LEASE (the “ Second Amendment ”), dated as of February 5, 2010 (the “ Effective Date ”), is entered into by and between EMERYSTATION TRIANGLE, LLC, a California limited liability company (“ Landlord ”), and AMYRIS BIOTECHNOLOGIES, INC., a California corporation (“ Tenant ”), with reference to the following facts:

A.        Landlord and Tenant are parties to that certain Lease dated as of April 25, 2008, as amended by that certain letter dated as of April 25, 2008 (the “ Lease ”), pursuant to which Landlord leases to Tenant space containing approximately 16,638 rentable square feet (the “ Original Premises ”) on the first (1st) floor of the building located at 5850 Hollis Street, Emeryville, California (the “ Building ”).

B.        Per the terms of the Lease, the Lease Term expires April 30, 2018, subject to the Tenant’s right to renew the Lease pursuant to Section 2.6 thereof. Landlord has provided Tenant with the Tenant Improvement Allowance contemplated in Section 1.1(16) of the Lease.

C.        Pursuant to the terms and conditions set forth in the Lease, Section 2.7 (Expansion Right) and Section 2.8 (Expansion Premises Right of First Offer) expired without exercise by Tenant and thus are no longer valid and, as a result, the additional $2,000.20 fixed amount of Monthly Base Rent referenced in Section 1.1(8) of the Lease is due and payable in conjunction with the Original Premises for the balance of the Lease Term.

D.        Tenant has now determined it has a need for the “ Expansion Premises ” (as defined in Section 2.7 of the Lease and Exhibit A-1 hereof), and Tenant has requested, and Landlord has agreed, to expand the Lease to include the Expansion Premises pursuant to the terms of this Second Amendment.

NOW, THEREFORE , in consideration of the above recitals, which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant agree as follows:

1.         Premises : The Expansion Premises, measuring 5,927 rentable square feet, shall be added to the Premises upon the “ Expansion Premises Commencement Date ,” which is hereby defined as the date on which Landlord delivers exclusive possession of the Expansion Premises to Tenant. Tenant agrees to accept the Expansion Premises in their current as-is condition. From the Expansion Premises Commencement Date onward, the Expansion Premises and the Original Premises shall be considered the Premises for all purposes under the Lease, the “ Rentable Area ” of the Premises shall be 22,565 square feet, and “ Tenant’s Share ” shall be 64.53%.

2.         Monthly Base Rent : Commencing upon the Expansion Premises Commencement Date, in addition to the Monthly Base Rent for the Original Premises, Tenant shall pay Monthly Base Rent for the Expansion Premises (“ Expansion Premises Monthly Base Rent ”) as follows:

 

1


PERIOD

   MONTHLY BASE RENT

Expansion Space Commencement Date - April 30, 2011

   $4,750.42

Effective May 1, 2011 and annually thereafter, the Expansion Premises Monthly Base Rent shall increase three percent (3%),

3.         Rent Adjustments : Effective on the Expansion Premises Commencement Date, Tenant’s obligations regarding Rent Adjustment and Rent Adjustment Deposits, more specifically defined in Section 4.1 of the Lease, shall be calculated using the revised Tenant’s Share noted in paragraph 1 above.

4.         Security Deposit : Pursuant to Section 1.1(11) and Article 5 of the Lease, Landlord currently holds a Letter of Credit in the amount of $79,363.26 as Security Deposit (the “ Original Security Deposit ”). Upon the Effective Date, the Security Deposit shall be increased by $28,271.79 (the “ Additional Security Deposit ”), which shall be satisfied pursuant to such Letter of Credit, as modified. Within five (5) business days after Landlord’s receipt of information regarding Tenant’s expenditure of at least Four Million Dollars ($4,000,000.00) on improvements to the Original Premises, as described in Section 5(b) of the Lease, Landlord will return the Original Security Deposit to Tenant. The Additional Security Deposit shall not be subject to the terms of Section 5(b) of the Lease and shall be retained by Landlord as the Security Deposit pursuant to the Lease terms.

5.         Tenant Improvement Allowance : Landlord shall provide Tenant with a tenant improvement allowance for the Expansion Premises of $44,452.50 (the “ Expansion Premises T I Allowance ”). This Expansion Premises T I Allowance shall be applied to the cost of improvements by Tenant in accordance with the terms set forth in Workletter Agreement attached as Exhibit B to the Lease.

6.         Proposed Developments : Tenant hereby acknowledges that Landlord has disclosed to Tenant the proposed development of the parcel immediately adjacent to and south of the Building (the “ EmeryStation Greenway Parcel ”), on which is contemplated construction of a five-level (one subterranean and four above-ground levels) commercial building. This development is more commonly referred to as the “ EmeryStation Greenway Building ”. Landlord has also disclosed that the site of the Building has been identified as a possible future second phase of the EmeryStation Greenway project. Further, as part of the EmeryStation Greenway Building or as a separate project, Landlord has disclosed that it may, in its sole discretion, elect to reconfigure the parking field and vehicle access area west of the Building and east of Hollis Street, substantially as contemplated in the drawings attached hereto as Exhibit A-2 (the “ Hollis Street Frontage Improvements ”). In the event Landlord elects to proceed with the Hollis Street Frontage Improvements, Landlord agrees to cooperate with Tenant and to make commercially-reasonable efforts to accomplish the work in a manner that is not materially disruptive to Tenant’s operations.

7.         Relocation Assistance Waiver : Tenant has been informed that Landlord has entered into an Owner Participation Agreement (“ OPA ”) with the Emeryville Redevelopment Agency (“ Agency ”) and that the OPA contemplates demolition and/or redevelopment of the

 

2


building in which the premises are located following the expiration or earlier termination of this Lease. Tenant understands that by virtue of the OPA or other agreements between Landlord and the Agency and/or the City of Emeryville (“City”), Tenant may be eligible for relocation payments and other relocation assistance under Government Code Sections 7260 et seq. or other State, Federal or local laws and regulations (“ Relocation Assistance Law ”). Tenant understands that the Relocation Assistance Law provides, among other things, for: a) advisory assistance including referral to comparable facilities; b) payment of actual, reasonable moving and related expenses or for a fixed expense and dislocation allowance, at the displaced tenant’s election; c) payment of certain business reestablishment expenses; and d) ninety (90) days written notice before being required to move.

As material consideration for Landlord’s obligations under this Lease, Tenant fully waives, releases and discharges Landlord, Agency, City and its and their respective officers, employees, volunteers, agents and representatives, from and against any and all manner of rights, demands, liabilities, obligations, claims, damages, fines, penalties, expenses (including attorneys’ fees and costs), and causes of action, in law or equity, of any kind or nature, known or unknown, now existing or hereinafter arising, which arise from or relate in any manner to the expiration or termination of Tenant’s leasehold interest as provided for herein, or the discontinuance or relocation of tenant’s business operations, or the relocation of any person, business, or other occupant located on or within the premises, including the waiver and release of all business goodwill claims (if any) and all relocation rights and benefits available under Relocation Assistance Law. Tenant acknowledges and agrees that the waiver and release set forth herein is material consideration for Landlord’s agreements hereunder, that City and Agency are third-party beneficiaries of the waivers and releases set forth herein, and that, but for this waiver and release, Landlord would not have entered into this Lease with Tenant. By releasing and forever discharging all of the claims and rights described above, Tenant expressly waives any rights under California Civil Code Section 1542, which provides:

“A general release does not extend to claims for which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.”

As such relates to this paragraph 7, Tenant hereby waives and relinquishes all rights and benefits which it may have under Section 1542 of the California Civil Code.

/s/ J.H.

Tenant Initials

The obligations of Tenant under this paragraph 7 shall survive the termination or expiration of the Lease.

8.         Brokerage : Tenant represents and warrants that it has represented itself in entering into this Second Amendment and that no brokerage, consulting or finders fee shall be due and payable to a representative of Tenant as a result hereof.

9.         Authority . This Second Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns. Each

 

3


party hereto and the persons signing below warrant that the person signing below on such party’s behalf is authorized to do so and to bind such party to the terms of this Second Amendment.

10.         Entire Agreement; No Amendment . This Second Amendment constitutes the entire agreement and understanding between the parties with respect to the subject of this Second Amendment and shall supersede all prior written and oral agreements concerning this subject matter. This Second Amendment may not be amended, modified or otherwise changed in any respect whatsoever except by a writing duly executed by authorized representatives of Landlord and Tenant.

11.         Status of Lease . Except as amended by this Second Amendment, the Lease remains unchanged and, as amended by this Second Amendment, the Lease is in full force and effect. Any capitalized term used but not defined herein shall have the meaning ascribed to such term in the Lease.

IN WITNESS WHEREOF, the undersigned have duly executed this Second Amendment as of the date first above written.

 

TENANT:     LANDLORD:

AMYRIS BIOTECHNOLOGIES, INC.,

a California corporation

   

EMERYSTATION TRIANGLE, LLC,

a California limited liability company

By:   /s/ Jeryl Hilleman                                             By:   /s/ Richard Robbins                                        
Print Name:   Jeryl Hilleman                                   Its:     Managing Member
Its:   CFO                                                                     

 

By:   /s/ Tamara L. Tompkins                                     By:   /s/ Richard Robbins                                        
Print Name:   Tamara L. Tompkins                                           Richard K. Robbins
Its:   General Counsel & Corporate Secretary             Its:                     Managing Member

 

4


 

 

EXHIBIT A-1

Expansion Premises


LOGO


LOGO


 

 

 

EXHIBIT A-2

Hollis Street Frontage Improvements


LOGO


LOGO

Exhibit 10.25

December 22, 2008

Mr. Geoffrey Sears

EmeryStation Triangle, LLC

1120 Nye Street, Suite 400

San Rafael, CA 94901

Re: Pilot Plant Expansion Right

Dear Geoff:

We have elected not to lease the Expansion Premises, as defined in that certain Lease dated April 25, 2008 between EmeryStation Triangle, LLC and Amyris Biotechnologies, Inc. (the “Lease”). This letter serves as notice of the waiver of our Expansion Premises Termination Right under Section 2.7(f) of the Lease.

Best Regards,

 

/s/ Chris Jaenike

Chris Jaenike

Assistant General Counsel

Exhibit 10.26

[free translation]

PRIVATE INSTRUMENT OF NON RESIDENTIAL

REAL ESTATE LEASE AGREEMENT

By means of the present Private Instrument of Non Residential Real Estate Lease Agreement (“Agreement”):

LESSORS: LUCIO TOMASIELLO , Brazilian, single, of age, businessman, bearer of identity card RG N. 20.790.427 SSP-SP, enrolled with CPF/MF under N. 137.566.718-10, resident and domiciled in the city of Campinas, State of São Paulo, at Rua XI de Agosto, 411, ap. 103; and MAURICIO TOMASIELLO , Brazilian, single, of age, businessman, bearer of identity card RG N. 23.019.084-4 SSP-SP, enrolled with CPF/MF under N. 128.654.298-73, resident and domiciled in the city of Jundiaí, State of São Paulo, at Rua Antonio Lopes de Oliveira, 600.

LESSEE: AMYRIS PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTÍVEIS LTDA ., headquartered in the City of São Paulo, State of São Paulo, at Rua Capitão Antonio Rosa, 376, Jardim Paulistano, CEP 01443-900, enrolled with CNPJ under N. 09.379.224/0001-20, hereby represented pursuant to its Articles of Association.

REAL ESTATE: STORAGE SHED for commercial use, still under construction in lot N. 5, square I, of the commercial/industrial allotment named Techno Park Campinas, described and characterized as follows: “corner lot, front to Rua 4 (four), measuring 102,10m (one hundred and two meters and 10 centimeters) with curve in the front; 65,00m (sixty five meters) in the left lateral looking to the lot from the street, facing with lot 4 (four) and 65,00m (sixty five meters) in the right lateral, facing with lot 6 (six), comprising an area of 3,318.31m2”. The mentioned storage shed shall have 1,368.09m2 of total constructed area and will be located in this city at Rua James Clerk Maxwell N. 315, CEP 13069-380, object of enrollment N. 100068 filed before the 2 nd Real Estate Registry of the City of Campinas – SP, registered in the municipality of Campinas under the cartographic code N. 3162.44.26.0285.00000 (“Real Estate”).

WHEREAS the terrain lot where the commercial storage shed is currently being constructed object of the present instrument was purchased by Lessors by means of the Deed of Purchase and Sale drafted on October 19, 2007, Book 206, page 249 of the 6 th Notary Public of Campinas, still pending registry in the Real Estate’s enrollment;

WHEREAS the construction of the commercial storage shed is being conducted by the LESSORS and its conclusion is foreseen to May 31 st , 2008;

WHEREAS before the conclusion of the construction and start of lease of the Real Estate, LESEE may adequate it to its activities, promoting changes in the original project;

NOW THEREFORE , the parties resolve to execute the present Agreement which shall be ruled pursuant to the clauses and conditions below:

 

1


[free translation]

 

1 st ) LESSORS represent that: (i) they are the lawful owners and holders of the Real Estate object of the lease, pursuant to the Deed of Purchase and Sale drafted on October 19, 2007 before the 6 th Notary Public of Campinas, duly registered in the enrollment of the Real Estate; (ii) the Real Estate is free and clear of any encumbrances, charges, burden, inclusively related to tax obligations, and there are no judicial or extrajudicial disputes incident upon such Real Estate; (iii) they have the lawfull title of the Real Estate and may freely dispose of it; (iv) the region where the Real Estate is located allows the LESSEE to develop activities foreseen in clause 7 th below under the city urban regulations; and (v) the commercial storage shed herein leased is being constructed pursuant to and observing the municipal rules regarding the occupation of soil in the municipality of Campinas, as well as pursuant to the technical rules applicable.

2 nd ) The term of the lease is 36 ( thirty-six ) months, starting on 06/01/2008 , provided the obligations foreseen in clauses 3 rd and 4 th below are complied with, and ending on 05/31/2011 , date when the LESSEE undertakes to return the Real Estate leased herein, free and unoccupied, in the same conditions as received, with exception to the wear and tear resulting from the regular use of the Real Estate and the provisions set forth in clause 8 th , paragraph 4.

Paragraph 1 – Nevertheless the term of the lease herein agreed, the parties agree that this Agreement shall be effective as of the date of its execution, and shall be effective and produce all effects resulting from its existence and validity, taking into account the rights and obligations adjusted by the parties before the start of the Real Estate lease term.

Paragraph 2 – The present agreement may be renewed, by equal period of time, by means of written communication from the LESSEE within no longer than 120 (one hundred and twenty) days before its final term, and the LESSORS shall respond to such request within no longer than 5 (five) business days.

3 rd ) LESSORS undertake to deliver the Real Estate to the LESSEE on 06/01/2008, free and clear of people and goods, with the works currently in progress duly concluded and pursuant to the Works Project and potential modifications approved by the City Hall of Campinas annexed hereto (“Annex I”), with exception to those adequacies to be incorporated by the LESSEE , pursuant to annex II (“Annex II”), which is henceforth agreed by the LESSORS . The return of the Real Estate is also subject to the verification by the LESSEE of the conformity of works performed with the projects contained in Annexes I and II.

Paragraph 1 – The parties henceforth agree that LESSEE or the representative appointed by it shall have access to the constructions in progress for the exclusive purpose of promoting the adequacies provided for in Annex II.

Paragraph 2 – Upon the return of the Real Estate and start of the lease term, LESSORS shall still present to LESSEE the following documents:

 

2


[free translation]

 

 

(a)

Updated certificate of enrollment N. 100068 of the 2 nd Real Estate Registry of Campinas, containing the acquisition title of the Real Estate by the LESSORS duly registered, as well as the annotation of the Inspection Performance Certification [Alvará de Execução] of the work currently in progress and the Certificate issued by the City Hall of Campinas attesting the construction currently in progress, pursuant to Annex I;

 

(b)

Final plan approved by the City Hall of Campinas for the construction established;

 

(c)

Copy of the IPTU [Annual Urban Real Estate Municipal Tax] ;

 

(d)

Request of Inspection Certificate from the Fire Department;

 

(e)

Approval of the project by the Fire Department;

 

(f)

Technical Report on Stability and Safety, pursuant to the standards of the City Hall of Campinas, signed by an engineer enrolled with the Department of Soil Use and Occupation of the municipality of Campinas; and

 

(g)

Term of Declaration of SANASA (Waste & Water incumbent), approving the working conditions related to the water and sewerage system of the Real Estate.

Paragraph 3 – In case of default by the LESSORS to return the Real Estate to the LESSEE within the term and conditions set forth above, LESSEE has the option to grant a term extension for the compliance with the obligations foreseen in this clause within 7 (seven) days.

Paragraph 4 – After the end of the additional term of 7 (seven) days, LESSEE , under its sole discretion, may demand from LESSORS the payment of a daily fine equivalent to 1/30 of the monthly rent agreed for in the present Agreement until the effective compliance with the provisions of the head and paragraphs one and two of this clause, in case the Real Estate cannot be delivered due to reasons that hinder LESSEE’S exercise of full possession, especially considering the activity to be developed, pursuant to clause 7 th below.

Paragraph 5 – As of 06/16/2008 LESSEE may, under its sole discretion, opt to: (i) terminate this Agreement without incurring any fine or indemnity; or (ii) assume the conduction and conclude the works on its own account, contracting third parties at its own choice, and the expenses resulting from the works shall be discounted from the value of the subsequent monthly rents.

Paragraph 6 – Taking into consideration that the responsibility for installing the air conditioning in the Real Estate is undertaken by LESSEE , the delay of LESSORS in delivering the Real Estate, pursuant to this clause, as a consequence of delay or omission of LESSEE in supplying the items related to the air conditioning installation shall not be subject to the fines foreseen in Paragraphs 3, 4 and 5 above.

4 th ) Once the commercial storage shed construction is concluded, the delivery of the Real Estate shall be preceded of an inspection by the parties, on a date and hour previously agreed, and on such event it shall be drafted the corresponding term of receipt of keys and annotations necessary regarding the status of the Real Estate (“Initial Inspection Term”), in special the appointment of improvements and works made by LESSEE which may be raised by the end of the lease.

 

3


[free translation]

 

5 th ) As of the date of the Initial Inspection Term, LESSEE shall pay to LESSORS the amount of R$22,440.00 (twenty two thousand four hundred and forty Reais) as monthly rent, with restatements as allowed by law. The due date shall be the day five following the payable month, and the amount shall be deposited in bank account of Bank 341, agency 0166, account N. 03900-8, and the deposit ticket shall be valid as receipt and release. The monthly rent shall be annually restated by the IGP-M variation, measured by Fundação Getúlio Vargas or, in case of suppression by its legal substitute, which better reflects the inflation of the period, under the discretion of the LESSORS , adopting as data-base the day 06/01/2008.

Paragraph 1 – In case of rent payment delay within the term agreed, LESSEE shall be considered in default, irrespective of notification or judicial or extrajudicial summons, and a fine of 2% (two percent) shall apply upon the delayed amount since the due date, plus a monetary restatement pursuant to the index set forth in this clause, per day of delay plus an interest in arrears of 1% (one percent) per month.

Paragraph 2 – During the whole term of lease agreed herein, LESSEE undertakes to comply with the obligations listed below, which shall be timely paid, directly to the relevant collecting entity:

 

 

(a)

IPTU [Annual Urban Real Estate Municipal Tax] and other municipal taxes currently levied or to be levied upon the plot and the building, as well as any other taxes charges by the public authorities or public services concessionaires related to the building object of this lease;

 

 

(b)

Quota on the Monthly Contribution Tax payable by Condomínio Tech Point to Associação dos Proprietários do Techno Park Campinas – ASSOCITECH, related to the expenses with maintenance, administration, safety and payment of taxes, charges and tariffs related to the private development of Techno Park Campinas;

 

 

(c)

Water (Sanasa) and electricity (CPFL) consumptions and expenses with telephone; and

 

 

(d)

Individual consumptions of any nature.

Paragraph 3 – During the whole lease term, LESSEE shall be solely responsible for the payment of the municipal taxes and duties due, even though proportionally, upon the Real Estate herein leased, and shall not be responsible for former obligations, which shall remain under LESSORS’ responsibility, even though they are verified in the future. LESSORS undertake to deliver to LESSEE the IPTU installments bills related to the current fiscal year, as well as all other bills in their hands, always within the due terms, under penalty of responding for the fines and burdens of the corresponding default.

 

4


[free translation]

 

Paragraph 4 – Whenever requested by LESSORS , LESSEE shall present all payment receipts of taxes levied upon the Real Estate, water, electricity and sewerage charges related to the period.

Paragraph 5 LESSORS shall refund LESSEE of eventual fines enforced against it by the public power, by virtue of irregularities resulting from acts or omissions ascribed exclusively to LESSORS . In case the penalty implies the privation of use of the Real Estate, LESSORS shall indemnify LESSEE of the damages and costs incurred, including lawyers’ fees, provided that LESSEE : (i) notifies LESSORS in writing and timely for them to contest or present defense and (ii) supplies LESSORS with all information related to the event.

Paragraph 6 LESSEE still undertakes to promptly communicate to LESSORS about the receipt from any public authority of any summons, subpoena or notification related to the Real Estate.

6 th ) It is herein understood that, pursuant to the Brazilian Civil Code, LESSEE annually responds for the insurance against fire, explosions, gales, electric damages and disasters of any nature, starting on the 1 st rent payable, and the others on the same date of the subsequent years, until the effective return of keys of the building, having as insured value the amount equivalent to 80 (eighty) times the monthly rent value in force by the time of the respective engagements, which values shall contain a beneficiary clause on behalf of LESSORS . The civil liability insurance coverage shall take into account the sort of activity developed in the plant by the LESSEE .

Paragraph 1 LESSEE undertakes to send to LESSORS within no longer than 20 (twenty) days as of the start of effectiveness of the lease, the insurance policy and a copy of the insurance premium payment receipt.

7 th ) LESSEE designates the Real Estate presently leased exclusively for COMMERCIAL purposes, with the following destination: biofuels research and development laboratory, rendering of services and office, and it shall be used solely for this purpose. The change of such destination without previous consent of LESSORS is forbidden.

Paragraph 1 LESSEE on its own account and risk shall obtain all authorizations, licenses and permits necessary for the performance of commercial activities it intends to perform in the leased real estate, being liable for all consequences resulting from the performance of such business activities. However, considering that such licenses and permits depend on the Certificate of Work Conclusion which will be only requested to the City Hall of Campinas upon the termination of the construction currently in progress in the Real Estate and, still, the term taken by the relevant local authorities to issue the mentioned Certificate, LESSORS undertake to sign and supply LESSEE with any and all document and declarations necessary to obtain the Provisory Use Permit [Alvará de Uso Provisório] before said authorities, so LESSEE may start its activities in the Real Estate. In case LESSEE does not obtain the Provisory Use Permit, it may, under its sole discretion, terminate the present Agreement, without the payment of any fine or

 

5


[free translation]

 

indemnity, except if the lack of procurement of the Provisory Use Permit results from LESSEE’S exclusive action or omission.

Paragraph 2 – Taking into account the Provisory Use Permit has a validity term of 1 (one) year, LESSORS undertake to obtain the Certificate of Work Conclusion, as well as the protocol of request of the Debt Clearance Certificate of INSS within no longer than 30 (thirty) days as of the issue of the Certificate of Work Conclusion, before the Provisory Use Certificate expires, under penalty of termination of this Agreement by LESSEE , under its own discretion, without payment of any fine or indemnity.

8 th ) The good operating condition, structure and division of the Real Estate, as well as the accessories therein shall be described in detail in the Initial Inspection Term subscribed by the parties, which shall be a part of this instrument for all purposes of law.

Paragraph 1 – The necessary improvements introduced by LESSEE , although not authorized by LESSORS shall be incorporated to the Real Estate and reimbursed by LESSORS . The helpful improvements shall be reimbursed the same way, provided they have been previously authorized by LESSORS .

Paragraph 2 – In case LESSEE performs works or adds ornamentation improvements, such improvements shall be incorporated to the Real Estate and no reimbursement and/or indemnity of any monies spent shall be due to LESSEE , except those improvements of any nature indicated in the Initial Inspection Term, as foreseen in clause 4 th .

Paragraph 3 LESSORS henceforth authorize LESSEE to install lights and other identification plates in the front side of the Real Estate, under its expenses and exclusive liability for the payment of the fees due to and licenses required by the public authorities.

Paragraph 4 – By the end of the lease, the Real Estate shall be returned in the same use good operating conditions specified in the term of inspection already mentioned, except to the wear and tear resulting from the regular use of the Real Estate, and LESSEE may raise all improvements that may be indicated in the Initial Inspection Term.

Paragraph 5 LESSEE undertakes to communicate, in writing, with 45 (forty-five) days in advance, the effective date of delivery of the Real Estate, so LESSORS or the person appointed by them performs the inspection, within such term, with date and hour previously arranged, and receive the keys, once all obligations contained in this Agreement are fulfilled.

Paragraph 6 LESSEE shall receive the release of the obligations assumed by means of delivery of the Real Estate keys to LESSORS .

Paragraph 7 – In case LESSORS request repair in the Real Estate to return it to the conditions foreseen for its delivery, the respective works shall be made under LESSEE’S expenses. While such works are not finished, LESSEE shall remain liable

 

6


[free translation]

 

for the payment of rents and charges due, even though it is not occupying the Real Estate.

9 th ) Under penalty of termination by operation of law, irrespective of any judicial or extrajudicial summons, without right to indemnity or retention, besides paying the fine set forth in clause 12 th , LESSEE undertakes to:

 

 

(a)

Not sublease, assign, lend in whole or in part, the leased Real Estate, even though this Agreement is on behalf of LESSEE , without previous consent in writing by LESSORS , except the sublease, assignment or loan for companies of its economic group;

 

 

(b)

Comply, at its own expenses, without any right to indemnity by LESSORS , with all requirements and summons of municipal, state or federal public health it gives cause to, paying all fines on the due dates; and

 

 

(c)

Give option to LESSORS , when they understand convenient and on a date and hour previously agreed with LESSEE , to verify or inspect the leased Real Estate, personally or by authorized people, in order to certify its good operating condition.

10 th ) The present Agreement shall also be considered rescinded, by operation of law, irrespective of any judicial or extrajudicial summons, without right to any of the parties to any indemnity, in case of expropriation in whole or in part of the Real Estate, and the parties shall be released of all clauses related to charges agreed in this Agreement, provided that LESSEE shall be entitled to receive from the competent authority the indemnity it may have right to.

11 th ) In case of loss which demands the total reconstruction of the Real Estate, the lease shall be terminated, and the parties shall be released of any fine or value between each other related to such rescission. In case of partial loss, and provided that the competent authority allows the safe use of a portion of the Real Estate, the lease may be maintained, provided that: (i) this is the interest of both parties; (ii)  LESSORS and LESSEE agree the conditions for its maintenance, including potential need of reconstruction of the damaged portion, value of rents during the reconstruction period and responsibilities of each party, and the parties henceforth agree that lessors shall be responsible for the reconstruction and expenses resulting from it once it is the beneficiary of the insurance policy, pursuant to clause 6 th above.

12 th ) In case of legal and/or contractual default by any of the parties, the damaged party shall notify the violator party to comply with its obligations within 30 (thirty) days as of the notification receipt. After the term of 30 (thirty) days without the compliance with the obligation, the damaged party may request the termination of the Agreement, and the violator party shall be subject to the payment of a fine corresponding to 3 (three) times the value of monthly rent in force by the time of the infraction, monetarily restated pursuant to the index set forth in clause 5 th , plus interests of 1% (one percent) per month, until the effective payment, not excluding other liabilities, rights and claims.

 

7


[free translation]

 

In case of suit, the violator party shall be responsible for the judicial expenses and lawyers’ fees, herein set forth in 20% (twenty percent).

Paragraph 1 – In case of early return of the Real Estate, LESSEE shall bear the payment of the fine above defined, observing the proportionality foreseen in article 4 of Law 8,245/91.

Paragraph 2 – The specific cases ruled by clauses 3 rd , paragraphs 4, 5, and 5 th , paragraph 1, of this Agreement shall be subject to the fines mentioned in such provisions.

13 th ) LESSEE has the option to terminate the present Agreement, at anytime, irrespective of the payment of fine or indemnity, in case the performance of its activities in the Real Estate becomes impracticable, due to restrictions of use provenly imposed by state and municipal authorities, or other relevant authorities and resulting from restrictions of region and/or from irregularities in the construction which makes the procurement of the necessary licenses for the regular performance of activities by LESSEE impracticable in the Real Estate.

14 th ) As a guarantee to the payment of rents, taxes, and all other monies due by LESSEE and compliance with all obligations herein foreseen, LESSEE henceforth agrees to deposit as a guarantee of this rent an escrow in the amount of R$63,320.00 (sixty three thousand, three hundred twenty Reais) equivalent to 3 (three) monthly rents.

Paragraph 1 – In case LESSEE demands from LESSORS the payment of the fine foreseen in paragraph 4 of clause 3 rd above, due to the delay in the delivery of the Real Estate, LESSEE may, at its sole discretion, claim the payment of such fine or discount from the escrow the value of the mentioned fine.

Paragraph 2 – The deposit shall occur in a savings account on behalf of LESSORS , to be opened in the first business day subsequent to the signature of the Initial Inspection Term.

Paragraph 3 – The value of the escrow may be used by LESSORS in case of proven default by LESSEE .

Paragraph 4 – By the end of the lease with the delivery of keys and observed the requirements of this Agreement for its effectiveness, LESSEE shall withdraw the amount deposited and the profits related to it, without prejudice of the proper Judicial Suit.

Paragraph 5 – Besides the rent, the guarantee herein offered shall also guarantee the accessories of the rent, as foreseen in this Agreement, until the effective delivery of the keys and termination of this Agreement.

15 th ) LESSORS assume before LESSEE , its relatives, clients, employees, agents or any other people frequently visiting the Real Estate any liability for defects in the Real Estate, pursuant to the provisions of item IV of article 22 of Law N. 8,245/91.

 

8


[free translation]

 

16 th ) In case of eventual need of LESSORS to provide regularizations in the documents of the Real Estate or in the Real Estate itself to make the construction currently in progress feasible, LESSORS henceforth undertake to make it under their own expenses, under penalty of having this Agreement terminated by LESSEE .

17 th ) In case it is necessary to file an action to force the compliance with the rules of this Agreement, the parties agree that the notification, the main action and the summons shall take place by means of a letter with proof of receipt [Aviso de Recebimento – AR] , telex or fac-símile, or still by other forms provided by the Civil Procedure Code, as the case may be.

18 th ) In case the Real Estate is unoccupied and abandoned, LESSORS are henceforth authorized to vest in its possession.

19 th ) The parties agree that, in case LESSORS are interested in disposing of the Real Estate object of this lease to third parties, LESSEE shall be entitled to the right of first refusal on the purchase, pursuant to article 27 of Law 8,245/91.

Paragraph 1 LESSORS shall communicate their intention to sell the Real Estate to LESSEE , providing the conditions and rules of negotiation, in special the price and form of payment.

Paragraph 2 LESSEE shall manifest on the offer within 30 (thirty) days as of the receipt of the communication. In case LESSEE fails to do so, LESSORS are released to dispose the Real Estate to third parties. LESSEE’ silence shall be deemed as lack of interest.

Paragraph 3 – The present lease shall remain in force even in case of disposal of the leased Real Estate, and LESSORS undertake to give knowledge to the purchaser and provide the annotation in the instrument of disposal or commitment to disposal about the obligation of the purchaser or the promise to respect the present Agreement and keep it in force until its termination, henceforth authorizing the registry of this agreement before the competent Real Estate Registry, under LESSEE’S expenses.

Paragraph 4 LESSORS undertake to answer for potential demands under their responsibility or addressed to it, within the legal time frame, made by the Real Estate Registry and requested by LESSEE , in order to provide the registry and annotation above mentioned.

20 th ) The waiver or forbearance of any of the parties regarding their rights or the compliance with any obligation resulting from the present Agreement, or the imposition of any penalty or fine shall neither be considered a novation, nor implicit derogation of the terms of this Agreement, nor shall serve as a precedent, and consequently does not imply in any contractual modification, only mere concession of the party.

 

9


[free translation]

 

21 st ) The present instrument substitutes any other agreement, whether verbal or written, that may have been entered into by the parties until this date, with the purposes of agreeing on the rental of the Real Estate at stake.

22 nd ) The present Agreement constrains the Parties themselves, their heirs and successors under any title.

23 rd ) Besides the clauses and conditions herein agreed for, the rights and obligations of the parties shall be ruled by the provisions of the Civil Code, of Law N. 8,245/91 and other legal provisions applicable to the case.

24 th ) The parties elect the jurisdiction where the Real Estate is located, for the solution of any doubt or dispute which may eventually rise from this instrument, waiving any other, the most privileged it may be.

IN WITNESS WHEREOF, the parties hereto execute the present agreement in 3 (three) counterparts of the same contents and form, and for the same purpose.

Campinas, March 31 st , 2008.

 

       
   

LESSORS:

 

/s/ Lucio Tomasiello

   

 

/s/ Mauricio Tomasiello

   
  LUCIO TOMASIELLO     MAURICIO TOMASIELLO  
   

LESSEE:

 

/s/ Roel Collier

         
 

AMYRIS PESQUISA E

DESENVOLVIMENTO DE

BIOCOMBUSTÍVEIS LTDA.

     
 

WITNESSES:

 

    1. [signature illegible]

    Name: José Luiz Guazzelli

    RG: 3797611 SSPSP

    CPF: 262.761.948-91

   

 

2. [signature illegible]

Name: Alfredo Henrique Soares

RG: 3797611 SSPSP

CPF: 262.761.948-91

 

 

10


[free translation]

 

Annex I

 

11


[free translation]

 

Annex 2

 

12


[free translation]

 

AMENDMENT TO THE PRIVATE INSTRUMENT OF NON RESIDENTIAL

REAL ESTATE LEASE AGREEMENT

By means of the present Amendment to the Private Instrument of Non Residential Real Estate Lease Agreement (“Amendment”):

LESSORS: LUCIO TOMASIELLO , Brazilian, single, of age, businessman, bearer of identity card RG N. 20.790.427 SSP-SP, enrolled with CPF/MF under N. 137.566.718-10, resident and domiciled in the city of Campinas, State of São Paulo, at Rua XI de Agosto, 411, ap. 103; and MAURICIO TOMASIELLO, Brazilian, single, of age, businessman, bearer of identity card RG N. 23.019.084-4 SSP-SP, enrolled with CPF/MF under N. 128.654.298-73, resident and domiciled in the city of Jundiaí, State of São Paulo, at Rua Antonio Lopes de Oliveira, 600.

LESSEE: AMYRIS PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTÍVEIS LTDA ., headquartered in the City of São Paulo, State of São Paulo, at Rua Capitão Antonio Rosa, 376, Jardim Paulistano, CEP 01443-900, enrolled with CNPJ under N. 09.379.224/0001-20, hereby represented pursuant to its Articles of Association.

WHEREAS the Parties executed on March 31 st , 2008 the Private Instrument of Non Residential Real Estate Lease Agreement (“Agreement”), intending to rent the real estate located in the city of Campinas, at Rua Rui James Clerk Maxwell, 315, CEP 13069-380 (“Real Estate”);

WHEREAS the mentioned Agreement set forth the start of lease as of the conclusion of the construction or the commercial storage shed conducted by LESSORS , formalized by means of the term of receipt of keys and annotations applicable regarding the good operating condition of the Real Estate (“Initial Inspection Term”), pursuant to clauses 2 nd and 4 th of the Agreement;

WHEREAS the construction of the storage shed was concluded by LESSORS on May 31 st and delivered to LESSEE pursuant to the documents listed in paragraph 2 of clause 3 rd of the Agreement;

WHEREAS , the Parties intend to modify the conditions of guarantee set forth in clause 14 th of the Agreement.

NOW THEREFORE, the parties decide to execute the present Amendment which shall be ruled pursuant to the clauses and conditions below:

1 st ) The Parties declare the term of 36 (thirty six) months of lease started on June 1 st , 2008, and will end on May 31 st , 2011, date when LESSEE imperatively undertakes to return the Real Estate leased, free and unoccupied, in the same conditions it has received it, pursuant to the Initial Inspection Term attached hereto (Annex I), except for the natural wear and tear resulting from the regular use of the Real Estate and the provisions of clause 8 th , paragraph 4 of the Agreement.

 

13


[free translation]

 

2 nd ) Taking into account the start of the lease, the first rental payment due by LESSEE to LESSORS shall take place on July/5/2008 and the subsequent monthly payments shall be paid on the day five of the subsequent months.

3 rd ) The Parties decide to modify the guarantee conditions of the rental established in clause 14 th of the Agreement, which shall be read as follows:

14 th ) As a guarantee to the payment of rents, taxes, and all other monies due by LESSEE and compliance with all obligations herein foreseen, LESSEE henceforth agrees to deposit as a guarantee of this rent an escrow in the amount of R$22,440.00 (twenty two thousand, four hundred forty Reais) equivalent to 1 (one) monthly rent.

Paragraph 1 – The deposit shall occur in Bank         , Agency         , account N.             , on behalf of LESSORS , together with the payment of the first rental payment.

Paragraph 2 – The value of the escrow may be used by LESSORS in case of proven default by LESSEE .

Paragraph 3 – By the end of the lease with the delivery of keys and observed the requirements of this Agreement for its effectiveness, LESSEE shall withdraw the amount deposited and the profits related to it, without prejudice of the proper Judicial Suit.

Paragraph 4 – Besides the rent, the guarantee herein offered shall also guarantee the accessories of the rent, as foreseen in this Agreement, until the effective delivery of the keys and termination of this Agreement.”

4 th ) The Parties ratify all other provisions of the Agreement not modified by this instrument.

IN WITNESS WHEREOF, the parties hereto execute the present agreement in 3 (three) counterparts of the same contents and form, and for the same purpose.

Campinas, July 5 th , 2008.

 

       
   

LESSORS:

 

/s/ Lucio Tomasiello

   

 

/s/ Mauricio Tomasiello

   
  LUCIO TOMASIELLO     MAURICIO TOMASIELLO  
   

LESSEE:

 

/s/ Roel Collier

         
  AMYRIS PESQUISA E      

 

14


[free translation]

 

 

DESENVOLVIMENTO DE

BIOCOMBUSTÍVEIS LTDA.

     
 

WITNESSES:

 

    1.

    Name:

    RG:

    CPF:

   

 

2.

Name:

RG:

CPF:

 

 

15


[free translation]

 

SECOND AMENDMENT TO THE PRIVATE INSTRUMENT OF NON RESIDENTIAL REAL ESTATE LEASE AGREEMENT

By means of the present Second Amendment to the Private Instrument of Non Residential Real Estate Lease Agreement (the “ Amendment ”), and in the best terms of law, the parties identified below (jointly referred to as “ Parties ”):

LESSORS: LUCIO TOMASIELLO , Brazilian, single, of age, businessman, bearer of identity card RG N. 20.790.427 SSP-SP, enrolled with CPF/MF under N. 137.566.718-10, resident and domiciled in the city of Campinas, State of São Paulo, at Rua XI de Agosto, 411, ap. 103; and MAURICIO TOMASIELLO, Brazilian, single, of age, businessman, bearer of identity card RG N. 23.019.084-4 SSP-SP, enrolled with CPF/MF under N. 128.654.298-73, resident and domiciled in the city of Jundiaí, State of São Paulo, at Rua Antonio Lopes de Oliveira, 600.

LESSEE: AMYRIS-CRYSTALSEV PESQUISA E DESENVOLVIMENTO DE BIOCOMBUSTÍVEIS LTDA ., headquartered in the City of São Paulo, State of São Paulo, at Rua Capitão Antonio Rosa, 376, Jardim Paulistano, CEP 01443-900, enrolled with CNPJ under N. 09.379.224/0001-20, hereby represented pursuant to its Articles of Association.

REAL ESTATE: STORAGE SHED for commercial use, still under construction, located at lot N. 5, square I, of the commercial/industrial allotment named Techno Park Campinas, described and characterized as follows: “corner lot, front to Rua 4 (four), measuring 102,10m (one hundred and two meters and 10 centimeters) with curve in the front; 65,00m (sixty five meters) in the left lateral looking to the lot from the street, facing with lot 4 (four) and 65,00m (sixty five meters) in the right lateral, facing with lot 6 (six), comprising an area of 3,318.31m2”. The mentioned storage shed shall have 1,368.09m2 of total constructed area and will be located in this city at Rua James Clerk Maxwell N. 315, CEP 13069-380, object of enrollment N. 100068 filed before the 2 nd Real Estate Registry of the City of Campinas – SP, registered in the municipality of Campinas under the cartographic code N. 3162.44.26.0285.00000 (the “ Real Estate ”).

WHEREAS on March 30 th , 2008, the Parties executed the Private Instrument of Non Residential Real Estate Lease Agreement (the “ Agreement ”), related to the lease of the Real Estate, subsequently amended on July 5 th , 2008; and

WHEREAS the Parties have interest in extending the term of lease, currently from 36 (thirty six) months to 60 (sixty) months.

NOW THEREFORE, the Parties decide to execute the present Amendment which shall be ruled pursuant to the terms and conditions below:

CLAUSE 1

 

16


[free translation]

 

The Parties decide to extend the term of lease, currently of 36 (thirty six) months, to 60 (sixty) months. In this sense, the final term of the Agreement shall be May 31 st , 2013. Due to such modification, Clause 2 nd of the Agreement shall be read as follows:

2 nd ) The term of the lease is 60 ( sixty ) months, starting on 06/01/2008 , provided the obligations foreseen in clauses 3 rd and 4 th below are complied with, and ending on 05/31/2013 , date when the LESSEE undertakes to return the Real Estate leased herein, free and unoccupied, in the same conditions as received, with exception to the wear and tear resulting from the regular use of the Real Estate and the provisions set forth in clause 8 th , paragraph 4.

Paragraph 1 – Nevertheless the term of the lease herein agreed, the parties agree that this Agreement shall be effective as of the date of its execution, and shall be effective and produce all effects resulting from its existence and validity, taking into account the rights and obligations adjusted by the parties before the start of the Real Estate lease term.

Paragraph 2 – The present agreement may be renewed, by equal period of time, by means of written communication from the LESSEE within no longer than 120 (one hundred and twenty) days before its final term, and the LESSORS shall respond to such request within no longer than 5 (five) business days.”

CLAUSE 2

All other provisions of the Agreement not expressly modified by this instrument shall remain in force and effective.

IN WITNESS WHEREOF, the parties hereto execute the present Amendment in 3 (three) counterparts of the same contents and form, and in the presence of the 2 (two) witnesses undersigned, for all purposes of law.

Campinas, October 30 th , 2008.

 

       
   

LESSORS:

 

/s/ Lucio Tomasiello

   

 

/s/ Mauricio Tomasiello

   
  LUCIO TOMASIELLO     MAURICIO TOMASIELLO  
   

LESSEE:

 

/s/ Roel Collier

         
  AMYRIS-CRYSTALSEV PESQUISA E
DESENVOLVIMENTO DE
BIOCOMBUSTÍVEIS LTDA.
     
 

            WITNESSES:

 

    1.                                 

   

 

2.                                           

 

 

17


[free translation]

 

 

    Name:

    RG:

    CPF:

   

    Name:

    RG:

    CPF:

 

 

18

Exhibit 10.27

 

5980 HORTON STR SUITE 450    LOGO

 

EMERYVILLE, CA 94608

  

 

PHONE: 510.450.0761

  

 

FAX: 510.450.0794

  

September 27, 2006

John G. Melo

663 Greenwood Avenue

Glencoe, IL 60022

Dear John,

On behalf of Amyris (the “Company”), I am very excited to offer you the position of Chief Executive Officer. Speaking for ourselves, as well as the Company’s Board of Directors (the “Board”), and the other members of the Company’s management team, we are all very impressed with you and what you will bring to the Company. We believe that with your background, you will make significant contributions to the success of the Company.

The terms of your new position with the Company are as set forth below:

1.      Position; Board Membership. The Board of Directors will appoint you to the Board sometime during the month of October 2006, provided it does not create a conflict with your current employer. If it does create a conflict, then a mutually agreeable Board Appointment date will be decided by you and the Amyris Board of Directors. On or before November 15, you will become the Chief Executive Officer of the Company. As CEO you will have responsibility for the Company’s operations and strategic direction, as well as other tasks assigned to you by the Board. You will report directly to the Board. While employed by the Company, except with the written approval of the Board, you will not actively engage in any other employment, occupation or consulting activity.

2.       Start Date. You will commence this new position with the Company on or before November 15, 2006.

3.       Compensation.

a.      Base Salary. You will be paid a monthly salary of $25,833.33 minus applicable withholdings, which is equivalent to $310,000 on an annualized basis. Your salary will be payable pursuant to the Company’s regular payroll policy (or in the same manner as other officers of the Company).

b.      Bonus Program. The Board would like to work with you to create a mutually agreeable bonus program for yourself and other members of the management team of the Company that will allow you and the team to participate in upside success of the Company’s performance.

S YNTHETIC B IOLOGY , R EAL S OLUTIONS

www.amyrisbiotech.com


Your targeted annual bonus will be $75,000, based on milestones set forth by the Board of Directors. This bonus is payable by the end of CY 2007. The Board will discuss with you the creation of this program within your first 90 days of employment. The bonus program for your second year of employment will be targeted at $100,000.00, based upon milestones set forth by the Board of Directors. This bonus payable by the end of CY 2008.

4.      Stock Options.

a.      Initial Grant. In connection with the commencement of your employment, the Company will grant you an option to purchase 1,000,000 shares of Common Stock, with an exercise price equal to the fair market value of the Common Stock of the Company on the date of the grant. The proposed award represents approximately 6.5% of the fully diluted outstanding capitalization of the Company following the installment of the second tranche of the most recent round of financing. The option will vest and become exercisable, contingent on your continued employment with the Company on each respective vesting date, over a period of 5 years as follows: one year after your start date, 20% of the option will vest; thereafter, the remaining shares will vest on a monthly schedule of 1/48 of the total number of shares subject to the grant upon the completion of each month of employment. The option will be an incentive stock option to the maximum extent allowed by the tax code and will be subject to the terms of the Company’s Stock Option Plan and the Stock Option Agreement between you and the Company, which you will be required to execute as a condition of the grant.

5.      Benefits.

a.      Insurance Benefits. The Company will provide you with the standard medical and dental insurance benefits available to other employees of the Company.

b.      Vacation. You will earn vacation consistent with the Company’s vacation policy offered to other employees of the Company.

6.       Relocation and commuting reimbursement:

a.      Amyris will fund up to $50,000.00 in costs directly associated with your commute between Chicago and Emeryville, until June of 2007.

b.      Amyris will reimburse you up to $100,000.00 in relocation costs associated with your move to the San Francisco Bay Area.

7.      At-Will Employment. Your employment with the Company shall be for no specified period or term and may be terminated by you or by the Company at any time for any or no reason, with or without Cause, as long as written notice is provided the Company that you provide thirty (30) days written notice of your intention to resign. The “at-will” nature of your employment shall remain unchanged during your tenure as an employee of the Company, and may only be changed by an express written agreement that is signed by you and by the Chairman of the Board.

8.      Termination of Employment. If you resign your employment with the Company or if the Company terminates your employment for Cause, at any time, you will receive your base salary, as well as any accrued but unused vacation (if applicable), earned through the effective

 

2

S YNTHETIC B IOLOGY , R EAL S OLUTIONS

www.amyrisbiotech.com


resignation or termination date, and no additional compensation. If the Company terminates your employment for any reason other than Cause, it will give you written notice of termination, any base salary and accrued but unused vacation that is earned through the effective termination date, and, conditioned on your (a) signing and not revoking a release of any and all claims, in a form prescribed by the Company, (b) resigning from the Board (if applicable) on the date that your employment terminates, and (c) returning to the Company all of its property and confidential information that is in your possession, you will receive the following: (i) continuation of your base salary for 12 months beyond the effective termination date, payable in accordance with the regular payroll practices of the Company, provided that these payments will be terminated as of the date you commence employment with another employer; and (ii) if you elect to continue your health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) following the termination of your employment, then the Company shall pay your monthly premium under COBRA until the earlier of (x) 12 months following the effective termination date, or (y) the date upon which you commence employment with an entity other than the Company and (iii) if you are terminated within your first year of employment, your option granted under Paragraph 4 will vest on a monthly basis commensurate with the number of months that you were employed by the Company. You will notify the Company in writing within 5 days of your receipt of an offer of employment with any entity other than the Company, and will accordingly identify the date upon which you will commence employment in such writing. This salary continuance is meant to be provided to you as you actively seek future employment and as noted will cease once you have secured such employment. 1

For all purposes under this Agreement, a termination for “Cause” shall mean a determination by the Board that your employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Company; (ii) a violation of a federal or state law or regulation applicable to the business of the Company; (iii) conviction or plea of no contest to a felony under the laws of the United States or any State; (iv) fraud or misappropriation of property belonging to the Company or its affiliates; (v) non-performance, non-compliance or interference with the other party’s performance of the terms of any confidentiality, invention assignment or proprietary information agreement with the Company or with a former employer, (vi) your failure to satisfactorily perform your duties after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) your misconduct or gross negligence in connection with the performance of your duties.

9.      Change of Control. If, during your employment with the Company, there is a Change of Control event, and the Company terminates your employment without Cause or you are Constructively Terminated within 6 months of that event, then you will be eligible to receive the benefits provided in Section 8, as well as immediate accelerated vesting of 50% of any of the unvested shares under your outstanding options as of the date of termination (in this scenario, a minimum of 75% of your options will be vested), conditioned on your complying with the

 

1 NB: If the executive terminates when the Company is publicly traded, and payments extend into the next calendar year, in order to avoid IRC Section 409A no severance payments may be made for 6 months following termination. If the requirements of IRC Section 409A are not satisfied, the executive will be taxed on the severance amount at termination with a 20% tax penalty.

 

3

S YNTHETIC B IOLOGY , R EAL S OLUTIONS

www.amyrisbiotech.com


requirements of Sections 8(a), (b), and (c) of this Agreement. These benefits will be subject to the terms and requirements of Section 8. 2

“Constructive Termination” shall mean a resignation of your employment within 30 days of the occurrence of any of the following events which occurs within 5 months following a Change of Control: (i) a material reduction in your responsibilities; (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of the Company; or (iii) a relocation of your principal office to a location more than 50 miles from the location of your principal office immediately preceding a Change of Control.

“Change of Control” shall be defined as (i) merger, reorganization, consolidation or other acquisition (or series of related transactions of such nature) pursuant to which more than fifty percent (50%) of the voting power of all equity of the Company would be transferred by the holders of the Company’s outstanding shares (excluding a reincorporation to effect a change in domicile); (ii) a sale of all or substantially all of the assets of the Company; or (iii) any other transaction or series of transactions, in which the Company’s stockholders immediately prior to such transaction or transactions own immediately after such transaction less than 50% of the voting equity securities of the surviving corporation or its parent

10.      Confidential Information and Invention Assignment Agreement. As an employee of the Company, you will have access to certain Company confidential information and you may during the course of your employment develop certain information or inventions, which will be the property of the Company. To protect the interest of the Company you will need to sign the Company’s standard “Employee Confidentiality Agreement” as a condition of your employment, a copy of which is enclosed.

11.      No Inconsistent Obligations. By accepting this offer of employment, you represent and warrant to the Company that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this letter. You also represent and warrant that you will not use or disclose, in connection with your employment by the Company, any trade secrets or other proprietary information or intellectual property in which you or any other person has any right, title or interest, and that your employment by the Company will not infringe upon or violate the rights of any other person or entity. You represent and warrant to the Company that you have returned all property and confidential information relating to any prior employers.

12.      Arbitration. Any dispute or claim arising out of or in connection with this letter agreement will be finally settled by binding arbitration in an independent jurisdiction in accordance with the rules of the American Arbitration Association by one arbitrator appointed in accordance with said rules. The arbitrator shall apply California law, without reference to rules of conflicts of law or rules of statutory arbitration, to the resolution of any dispute. Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.

 

2 NB: Depending on the size of the option grant and the value of the shares at termination, the severance payments may become subject to IRC Section 280G.

 

4

S YNTHETIC B IOLOGY , R EAL S OLUTIONS

www.amyrisbiotech.com


Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance with this paragraph, without breach of this arbitration provision.

This offer is subject to final agreement on a mutually acceptable start date and transition plan, which will be negotiated during the first part of the week of September 25, 2006.

We are all delighted to be able to extend this offer and look forward to working with you. To indicate your acceptance of the Company’s offer, please sign and date this letter the space provided below, and also sign the enclosed Employee Confidentiality Agreement, and return both to me. A duplicate original is enclosed for your records. This letter agreement, together with the Employee Confidentiality Agreement and any stock option and purchase agreements, sets forth our entire agreement and understanding regarding the terms of your employment with Company and supersedes any prior representations or agreements, whether written or oral (including that certain offer letter also dated as of the date hereof). This letter agreement may not be modified or amended except by a written agreement, signed by the Chairman of the Board of the Company and by you.

This offer, if not accepted, will expire at close of business on September 29, 2006.

Sincerely,

On Behalf of the Board of Directors

 

/s/ John Doerr
John Doerr
Kleiner Perkins Caufield & Byers

 

/s/ Samir Kaul
Samir Kaul
Khosla Ventures

 

5

S YNTHETIC B IOLOGY , R EAL S OLUTIONS

www.amyrisbiotech.com

Exhibit 10.28

LOGO

AMENDMENT TO OFFER LETTER AGREEMENT

This Amendment to the Offer Letter Agreement (this “ Amendment ”) is made and entered into as of December 18, 2008, by and among John G. Melo (“ Executive ”) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ”).

RECITALS

A.        The Company and Executive are parties to that certain Offer Letter Agreement between the Company and the Executive dated September 27, 2006 (the “ Agreement ”). All capitalized terms set forth herein shall (unless otherwise defined herein) have the meanings given to them in the Agreement.

B.        The Company and Executive wish to clarify the terms of the Agreement by means of this Amendment to the Agreement.

AMENDMENT

NOW THEREFORE, the parties hereby agree as follows:

1.         FIRST AMENDMENT TO AGREEMENT . The following language shall be added to the end of Section 3(b):

Any bonus described in this section shall be paid no later than March 15 of the year following the year with respect to which the bonus is earned.

2.         SECOND AMENDMENT . Section 8 shall be deleted in its entirety and replaced with the following language:

8.        Termination of Employment. If you resign your employment with the Company or if the Company terminates your employment for Cause, at any time, you will receive your base salary, as well as any accrued but unused vacation (if applicable), earned through the effective resignation or termination date, and no additional compensation. If the Company terminates your employment for any reason other than Cause, it will give you written notice of termination, any base salary and accrued but unused vacation that is earned through the effective termination date, and, conditioned on your (a) signing and not revoking a release of any and all claims, in a form prescribed by the Company, (b) resigning from the Board (if applicable) on the date that your employment terminates, and (c) returning to the Company all of its property and confidential information that is in your possession, you will receive the following: (i) continuation of your base salary for 12 months beyond the effective termination date, payable in accordance with the regular payroll practices of the Company, provided that these payments will be terminated as of the date you commence employment with another employer; and (ii) if you elect to continue your health insurance coverage under the Consolidated Omnibus Budget


Reconciliation Act of 1985, as amended (“COBRA”) following the termination of your employment, then the Company shall pay your monthly premium under COBRA until the earlier of (x) 12 months following the effective termination date, or (y) the date upon which you commence employment with an entity other than the Company and (iii) if you are terminated within your first year of employment, your option granted under Paragraph 4 will vest on a monthly basis commensurate with the number of months that you were employed by the Company. The Company will commence payment of the salary continuation and COBRA described in this Section 8 on the first regular payroll date that is 30 days (or where determined necessary by the Company to make the release described above effective, 60 days) following your termination of employment, provided that prior to such date the release described above becomes effective. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date of the application of this provision, and the balance of the installments will be payable in accordance with their original schedule . You will notify the Company in writing within 5 days of your receipt of an offer of employment with any entity other than the Company, and will accordingly identify the date upon which you will commence employment in such writing. This salary continuance is meant to be provided to you as you actively seek future employment and as noted will cease once you have secured such employment.

For all purposes under this Agreement, a termination for “Cause” shall mean a determination by the Board that your employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Company; (ii) a violation of a federal or state law or regulation applicable to the business of the Company; (iii) conviction or plea of no contest to a felony under the laws of the United States or any State; (iv) fraud or misrepresentation of property belonging to the Company or its affiliates; (v) non-performance, non-compliance or interference with the other party’s performance of the terms of any confidentiality, invention assignment or proprietary information agreement with the Company or with a former employer, (vi) your failure to satisfactorily perform your duties after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) your misconduct or gross negligence in connection with the performance of your duties.

For purposes of this Agreement a termination of employment will be determined consistent with relating “separation from service” as defined in Section 409A of the Code and the regulations thereunder (“Section 409A”). Notwithstanding anything else provided herein, to the extent any payments provided under this Agreement in connection with your termination of employment constitute compensation subject to Section 409A, and you are deemed at the time of such termination of employment to be a “specified employee” under Section 409A, then such payment shall not be made or commence until the earlier of (i) the expiration of the 6-month period measured from your separation from service from the Company or (ii) the of your death following such a separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to you including, without limitation, the additional tax for which you would otherwise be liable under Section

 

2


409A(a)(1)(B) in the absence of such a deferral. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date but for the application of this provision, and the balance of the installments (if any) will be payable in accordance with their original schedule. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision will be read in such a manner so that all payments hereunder comply with Section 409A. To the extent any payment under this Agreement may be classified as a “short-term deferral” within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this Section 8 are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

3.         THIRD AMENDMENT TO AGREEMENT . Footnote 1 in Section 8 shall be deleted in its entirety.

4.         FOURTH AMENDMENT TO AGREEMENT . The second paragraph of Section 8 (defining “Constructive Termination”) shall be deleted in its entirety and replaced with the following language:

“Constructive Termination” shall mean a resignation of your employment within 30 120 days of the occurrence of any of the following events which occurs within 5 months following a Change of Control: (i) a material reduction in your responsibilities; (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of the Company; or (iii) a relocation of your principal office to a location more than 50 miles from the location of your principal office immediately preceding a Change in Control; provided, however, that you shall provide notice to the Company, within 90 days of occurrence of a condition listed above constituting a Constructive Termination and allow the Company 30 days in which to cure such condition.

5.         NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Agreement remain in full force and effect.

6.         COUNTERPARTS . This Amendment may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same instrument.

 

    COMPANY

   

EXECUTIVE

LOGO

   

LOGO

    By:

 

Tamara L. Tompkins

   

    John G. Melo

    Its:

 

General Counsel and Secretary

   

 

3

Exhibit 10.29

 

5505 HOLLIS STR SUITE 100

EMERYVILLE, CA 94608

PHONE: 510.740.7440

FAX: 510.225.2401

  

LOGO

  
     
     
     

September 30, 2008

Joel R. Cherry

1445 Drew Avenue

Davis, CA 95616

Re: Offer of Employment with Amyris Biotechnologies, Inc.

Dear Joel:

On behalf of Amyris Biotechnologies, Inc. (“Amyris”), I am delighted to offer to you employment with Amyris. If you accept this offer and satisfy the conditions of acceptance set forth herein, your employment with Amyris will commence on November 1, 2008, under the following terms:

Position

You will be employed full-time by Amyris as the Senior Vice President of Research Program Management and Operations reporting to me, John Melo, CEO. This position is responsible for research resource allocation and integrated fuels program management.

Salary

Your base salary will be $310,000 per year ($25833.33 per month) payable in accordance with Amyris’ regular payroll schedule which is currently semi-monthly. Your salary will be subject to adjustment from time to time pursuant to Amyris’ employee compensation policies then in effect.

Signing Bonus

You will also receive a one-time signing bonus in the amount of $40,000 which will be payable at the time you received your first regular pay check. This entire amount will be repayable by you to Amyris in full in the event you voluntarily terminate your employment prior to the completion of one (1) year of service with Amyris.

Bonus

You will be eligible for an annual performance-based bonus of up to $75,000. Such bonus will be payable provided that (i) you achieve certain performance objectives which shall be established during the first month of your employment with Amyris, (ii) you are still employed by Amyris at year-end and when the bonus is paid out.

Equity

Amyris will recommend to its Board of Directors that you be granted an option to purchase 210,000 shares of common stock of Amyris at the fair market value of the common stock on the date of Board approval (which represents approximately 1% of Amyris’ current, fully diluted outstanding capital stock). Such shares would vest as follows: (i) twenty percent (20%) upon completion of your twelfth (12 th ) month of employment, and (ii) the balance in a series of forty-eight (48) equal monthly installments upon completion of each additional month of employment with Amyris thereafter. Any option(s) granted to


you will be subject to the then-current terms and conditions of Amyris’ employee stock option plan and agreement.

Relocation Expenses

Amyris will reimburse you for and/or directly pay up to $100,000 in total relocation costs associated with your move from Davis, California to the San Francisco Bay Area. We request that you work with us to solicit several bids for the movement of your household goods from experienced moving companies. Amyris will directly retain one of the companies, the choice of which would be mutually acceptable to you and Amyris. Subject to the limitations set out above, the expenses relating to the movement of your household goods will be paid directly by Amyris to the moving company. All other amounts received by you for relocation expense reimbursement will be reported as taxable income to you in the year received as required by applicable tax law. In the event that you terminate your employment with Amyris before the completion of twelve (12) months of employment, you agree to promptly repay Amyris one hundred percent (100%) of the relocation expenses by personal check or other negotiable instrument. All relocation expenses need to be approved by Amyris before the costs are incurred and must be documented by reasonably detailed receipts.

Benefits

You will be eligible to participate in the employee benefits and benefit plans that are available to full-time employees of Amyris. Currently, these include (i) 12 paid holidays, (ii) 3 weeks of paid vacation (pro-rated by hiring date), (iii) up to 6 days of paid sick leave per year (pro-rated by hiring date), (iv) medical insurance, (v) dental insurance, (vi) supplemental health and flexible spending accounts, (vii) group term life insurance, (viii) accidental death & disability insurance, (ix) long-term disability insurance, and (x) 401K plan. You will also be eligible to receive paid access to gym facilities. The terms of your benefits will be governed by the applicable plan documents and Amyris’ policies. Enclosed is an Employee Benefit Overview. For the last two years, at Amyris’ discretion, the company has closed for approximately one week between December 24 and the first work day of January of the following year. Amyris may continue closing for the holidays in the future but if the company decides not to close, you will be entitled to an additional 5 personal days of time off that you may take with proper planning.

Termination of Employment

If you resign your employment with Amyris or if Amyris terminates your employment for Cause (as defined below) at any time, you will receive your base salary as well as any accrued but unused vacation (if applicable) earned through the effective resignation or termination date and no additional compensation. If Amyris terminates your employment for any reason other than Cause, it will give you written notice of termination, any base salary and accrued but unused vacation that is earned through the effective termination date and, conditioned on your (i) signing and not revoking a release of any and all claims, in a form prescribed by Amyris, and (ii) returning to Amyris all of its property and confidential information that is in your possession, you will receive the following:

(A) Continuation of your base salary for twelve (12) months beyond the effective termination date, payable in accordance with the regular payroll practices of Amyris, provided that these payments will be terminated as of the date you commence employment with another employer or engage or participate in any consulting or advisory arrangement or any other arrangement that involves any form of remuneration, including remuneration for services performed by you as an officer, director, employee, representative or agent of, or in any other capacity for, any other person or entity (each, an “Engagement”);

(B) If you elect to continue your health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) following the termination of your employment, then Amyris shall pay your monthly premium under COBRA until the earlier of (x)

 

Page 2 of 5


twelve (12) months following the effective termination date, or (y) the date upon which you commence employment with an entity other than Amyris or any other Engagement; and

(C) If your employment is terminated by Amyris for any reason other than for Cause within your first year of employment, a portion of your options granted under Section 4 above will vest as follows: the number of shares that shall vest shall be equal to the number obtained by multiplying the number of shares of common stock subject to the option granted pursuant to Section 4 by a fraction, the numerator of which shall be the number of complete months you have been employed by Amyris up to the date of termination and the denominator of which shall be 60.

You will notify Amyris in writing within five (5) days of your receipt of an offer of employment with any entity other than Amyris or for any other type of Engagement, and will accordingly identify the date upon which you will commence such employment or Engagement in such writing. These salary and benefits continuance benefits are intended to be provided to you as you actively seek future employment or another Engagement, and therefore, as noted, will cease once you have secured such employment or Engagement. 1

For all purposes under this Agreement, a termination for “Cause” shall mean a determination that your employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Amyris, (ii) a violation of a federal or state law or regulation applicable to the business of Amyris, (iii) conviction or plea of no contest to a felony or to a misdemeanour involving moral turpitude under the laws of the United States or any State, (iv) fraud or misappropriation of property belonging to Amyris or its affiliates, (v) non-performance, non-compliance or interference with any third party’s performance of the terms of any confidentiality, invention assignment or proprietary information agreement with Amyris or with a former employer, (vi) your failure to satisfactorily perform your duties as assigned from time to time by Amyris after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) your misconduct or gross negligence in connection with the performance of your duties.

Change of Control

If, during your employment with Amyris, there is a Change of Control event (as defined below), and Amyris terminates your employment without Cause or you are Constructively Terminated (as defined below) within, six (6) months of that event, then you will be eligible to receive the benefits provided in Section 8, as well as immediate accelerated vesting of fifty percent (50%) of any of the unvested shares under your outstanding options as of the date of termination, conditioned on your complying with the requirements of Section 8 above.

“Change of Control” shall mean (i) a merger, reorganization, consolidation or other transaction (or series of related transactions of such nature) pursuant to which more than fifty percent (50%) of the voting power of all outstanding equity securities of Amyris is transferred by the holders of Amyris’s outstanding shares (excluding a reincorporation to effect a change in domicile), (ii) a sale of all or substantially all of the assets of Amyris, or (iii) any other transaction or series of related transactions, in which Amyris’ stockholders immediately prior to such transaction or transactions own immediately after such transaction less than fifty (50%) of the voting equity securities of the surviving corporation or its parent.

“Constructive Termination” shall mean a resignation of your employment within thirty (30) days of the occurrence of any of the following events which occurs within six (6) months following a Change of

 

 

1 Depending on the size of the option grant and the value of the shares at termination, the severance payments may become subject to IRC Section 280G.

 

Page 3 of 5


Control: (i) a material reduction in your responsibilities, (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all or substantially all executive officers of Amyris, or (iii) a relocation of your principal office to a location more than fifty (50) miles from the location of your principal office immediately preceding a Change of Control.

Amyris’ Policies

As an employee of Amyris, you will be subject to, and expected to comply with its policies and procedures, personnel and otherwise, as such policies are developed and communicated to you.

“At-Will” Employment

Employment with Amyris is “at-will”. This means that it is not for any specified period of time and can be terminated by you or by Amyris at any time, with or without advance notice, and for any or no particular reason or cause. It also means that your job duties, title and responsibility and reporting level, compensation and benefits, as well as Amyris’ personnel policies and procedures, may be changed at any time in the sole discretion of Amyris. However, the “at-will” nature of your employment shall remain unchanged during your tenure as an employee of Amyris and may not be changed, except in an express writing signed by you and by Amyris’ Chief Executive Officer.

Full-Time Service to Amyris

Amyris requires that, as a full-time employee, you devote your full business time, attention, skills and efforts to the tasks and duties of your position as assigned by Amyris. If you wish to request consent to provide services (for any or no form of compensation) to any other person or business entity while employed by Amyris, you must first receive permission from the Chief Executive Officer of Amyris.

Conditions of Offer

In order to accept this offer, and for your acceptance to be effective, you must satisfy the following conditions:

 

 

You must provide satisfactory documentary proof of your identity and right to work in the United States of America on your first day of employment.

 

 

You must agree in writing to the terms of the enclosed Proprietary Information and Inventions Agreement (“PHA”) without modification.

 

 

You must consent to, and Amyris must obtain satisfactory results from, reference and background checks. Until you have been informed in writing by Amyris that such checks have been completed and the results satisfactory, you may wish to defer reliance on this offer.

 

 

You must agree in writing to the terms of the enclosed Mutual Agreement to Binding Arbitration (“ Arbitration Agreement ”) without modification.

By signing and accepting this offer, you represent and warrant that: (i) you are not subject to any pre-existing contractual or other legal obligation with any person or entity that may be an impediment to your employment with, or your providing services to, Amyris as its employee; and (ii) you have not and shall not bring onto Amyris’ premises, or use in the course of your employment with Amyris, any confidential or proprietary information of another person or entity to whom you previously provided services.

Entire Agreement

Provided that the conditions of this offer and your acceptance are satisfied, this letter together with the enclosed PIIA and Arbitration Agreement (collectively, the “ Offer Documents ”) shall constitute the full

 

Page 4 of 5


and complete agreement between you and Amyris regarding the terms and conditions of your employment. The Offer Documents cancel, supersede and replace any and all prior negotiations, representations or agreements, written and oral, between you and Amyris or any representative or agent of Amyris regarding any aspect of your employment. Any change to the terms of your employment with Amyris, as set forth in this letter, must be in an individualized writing to you, signed by the Chief Executive Officer of Amyris to be effective.

Please confirm your acceptance of this offer by signing and returning the enclosed copy of this letter as well as the PIIA and Arbitration Agreement to me by October 3, 2008. If not accepted by you as of that date, this offer will expire. We look forward to having you join Amyris. If you have any questions, please do not hesitate to contact me at (510) 740-7440.

 

Sincerely,

/s/ John G. Melo

John G. Melo

Chief Executive Officer

I HAVE READ AND ACCEPT THIS EMPLOYMENT OFFER:

 

/s/ Joel R. Cherry

   

1 October , 2008

Joel R. Cherry

   

Date

Enclosures

 

Page 5 of 5

Exhibit 10.30

LOGO

AMENDMENT TO OFFER LETTER AGREEMENT

This Amendment to the Offer Letter Agreement (this “ Amendment ”) is made and entered into as of December 19, 2008, by and among Joel R. Cherry (“ Executive ”) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ”).

RECITALS

A.        The Company and Executive are parties to that certain Offer Letter Agreement between the Company and the Executive dated September 30, 2008 (the “ Agreement ”). All capitalized terms set forth herein shall (unless otherwise defined herein) have the meanings given to them in the Agreement.

B.        The Company and Executive wish to clarify the terms of the Agreement by means of this Amendment to the Agreement.

AMENDMENT

NOW THEREFORE, the parties hereby agree as follows:

1.         FIRST AMENDMENT TO AGREEMENT . The following language shall be added to the end of the fifth paragraph of the Agreement (entitled “ Bonus ”):

Such bonus shall be paid no later than March 15 of the year following the year with respect to which the bonus is earned.

2.         SECOND AMENDMENT . The following language shall be added to the end of subparagraph (A) of the ninth paragraph of the Agreement (entitled “ Termination of Employment ”):

Amyris will commence payment of the salary continuation described in this subparagraph (A) and the COBRA benefits described below in subparagraph (B) on the first regular payroll date that is 30 days (or where determined necessary by Amyris to make the release described above effective, 60 days) following your termination of employment, provided that prior to such date the release described above becomes effective. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date but for the application of this provision, and the balance of the installments will be payable in accordance with their original schedule;

3.         THIRD AMENDMENT TO AGREEMENT . The following language shall be added to the end of the Section entitled “ Termination of Employment ” as a new paragraph:

For purposes of this Agreement, a termination of employment will be determined consistent with the rules relating to a “separation from service “as defined in Section 409A of the Code and the regulations thereunder (“Section 409A’). Notwithstanding anything else provided herein, to the extent any payments provided under


this Agreement in connection with your termination of employment constitute deferred compensation subject to Section 409A, and you are deemed at the time of such termination of employment to be a “specified employee” under Section 409A, then such payment shall not be made or commence until the earlier of (i) the expiration of the 6-month period measured from your separation from service from Amyris or (ii) the date of your death following such a separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to you including, without limitation, the additional tax for which you would otherwise be liable under Section 409A(a)(1)(B) in the absence of such a deferral. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date but for the application of this provision, and the balance of the installments (if any) will be payable in accordance with their original schedule. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision will be read in such a manner so that all payments hereunder comply with Section 409A. To the extent any payment under this Agreement may be classified as a “short-term deferral” within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this Section 8 are intended to constitute separate payments for purposes of this Section 1.409A-2(b)(2) of the Treasury Regulations.

4.         FOURTH AMENDMENT TO AGREEMENT . The third paragraph of the Section entitled “ Change of Control ” (defining “Constructive Termination”) shall be deleted in its entirety and replaced with the following language:

“Constructive Termination” shall mean a resignation of your employment within 30 120 days of the occurrence of any of the following events which occurs within 6 months following a Change of Control: (i) a material reduction in your responsibilities; (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of Amyris; or (iii) a relocation of your principal office to a location more than fifty (50) miles from the location of your principal office immediately preceding a Change in Control; provided, however, that you shall provide notice to the Amyris, within 90 days of occurrence of a condition listed above constituting a Constructive Termination and allow Amyris 30 days in which to cure such condition.

5.         NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Agreement remain in full force and effect.

6.         COUNTERPARTS . This Amendment may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same instrument.

 

    COMPANY:     EXECUTIVE:

LOGO

   

LOGO

    By:   John G. Melo         Joel R. Cherry
    Its:   Chief Executive Officer    

 

2

Exhibit 10.31

 

5980 HORTON STR SUITE 450 EMERYVILLE, CA 94608

PHONE: 510.740.7440

FAX: 510-496-8244

   LOGO

Jeryl L. Hilleman

1398 Dana Avenue

Palo Alto, CA 94301

January 17, 2008

Re: Offer of Employment with Amyris Biotechnologies, Inc.

Dear Jeryl:

On behalf of Amyris Biotechnologies, (“Amyris”), I am delighted to offer to you employment with Amyris. If you accept this offer and satisfy the conditions of acceptance set forth herein, your employment with Amyris will commence no later than January 28, 2008, under the following terms:

 

1.

Position

You will he employed full-time by Amyris as the Chief Financial Officer reporting to me, John Melo.

 

2.

Salary

Your base salary will be $300,000 per year ($25,000 per month) payable in accordance with Amyris’ regular payroll schedule which is currently semi-monthly. Your salary will be subject to adjustment from time to time pursuant to Amyris’ employee compensation policies then in effect.

 

3.

Bonus

You will be eligible for an annual performance based bonus of up to $100,000. Such bonus will be payable provided that (i) you achieve certain performance objectives which shall be established during the first month of your employment with Amyris, (ii) you are still employed by Amyris at year-end and when the bonus is paid out.

 

4.

Equity

Amyris will recommend to its Board of Directors that you be granted an option to purchase 210,000 shares of common stock of Amyris at the fair market value of the common stock on the date of Board approval (which represents approximately 1% of Amyris’ current, fully diluted outstanding capital stock). Such shares would vest as follows: (i) twenty percent (20%) upon completion of your twelfth (12 th ) month of employment, and (ii) the balance in a series of forty-eight (48) equal monthly instalments upon completion of each additional month of employment

S Y N T H E T I C    B I O L O G Y ,    R E A L    S O L U T I O N S

www.amyrisbiotech.com


with Amyris thereafter. Any option(s) granted to you will be subject to the then-current terms and conditions of Amyris’ employee stock option plan and agreement.

 

5.

Benefits

You will be eligible to participate in the employee benefits and benefit plans that are available to full-time employees of Amyris. Currently, these include (i) 12 paid holidays, (ii) 3 weeks of paid vacation (pro-rated by hiring date), (iii) up to 6 days of paid sick leave per year (pro-rated by hiring date), (iv) medical insurance, (v) dental insurance, (vi) supplemental health and flexible spending accounts, (vii) group term life insurance, (viii) accidental death & disability insurance, (ix) long-term disability insurance, and (x) 401 K plan. You will also be eligible to receive paid access to gym facilities. The terms of your benefits will be governed by the applicable plan documents and Amyris’ Amyris policies. Enclosed is an Employee Benefit Overview.

 

6.

Termination of Employment

If you resign your employment with Amyris or if Amyris terminates your employment for Cause (as defined below) at any time, you will receive your base salary as well as any accrued but unused vacation (if applicable) earned through the effective resignation or termination date and no additional compensation. If Amyris terminates your employment for any reason other than Cause, it will give you written notice of termination, any base salary and accrued but unused vacation that is earned through the effective termination date and, conditioned on your (i) signing and not revoking a release of any and all claims, in a form prescribed by Amyris, and (ii) returning to Amyris all of its property and confidential information that is in your possession, you will receive the following:

(A) Continuation of your base salary for twelve (12) months beyond the effective termination date, payable in accordance with the regular payroll practices of Amyris, provided that these payments will be terminated as of the date you commence employment with another employer;

(B) If you elect to continue your health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) following the termination of your employment, then Amyris shall pay your monthly premium under COBRA until the earlier of (x) twelve (12) months following the effective termination date, or (y) the date upon which you commence employment with an entity other than Amyris; and

(C) If you are terminated within your first year of employment, your option granted under Section 4 above will vest on a monthly basis commensurate with the number of months that you were employed by Amyris.

You will notify Amyris in writing within five (5) days of your receipt of an offer of employment with any entity other than Amyris, and will accordingly identify the date upon which you will commence employment in such writing. These salary and benefits continuance benefits are

 

Page 2 of 5

Rev 9/06


intended to be provided to you as you actively seek future employment and therefore, as noted, will cease once you have secured such employment.1 1

For all purposes under this Agreement, a termination for “Cause” shall mean a determination that your employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Amyris, (ii) a violation of a federal or state law or regulation applicable to the business of Amyris, (iii) conviction or plea of no contest to a felony under the laws of the United States or any State, (iv) fraud or misappropriation of property belonging to Amyris or its affiliates, (v) non-performance, noncompliance or interference with the other party’s performance of the terms of any confidentiality, invention assignment or proprietary information agreement with Amyris or with a former employer, (vi) your failure to satisfactorily perform your duties after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) your misconduct or gross negligence in connection with the performance of your duties.

 

7.

Change of Control

If, during your employment with Amyris, there is a Change of Control event (as defined below), and Amyris terminates your employment without Cause or you are Constructively Terminated (as defined below) within six (6) months of that event, then you will be eligible to receive the benefits provided in Section 6, as well as immediate accelerated vesting of fifty percent (50%) of any of the unvested shares under your outstanding options as of the date of termination, conditioned on your complying with the requirements of Sections 6 above.

“Change of Control” shall be defined as (i) merger, reorganization, consolidation or other acquisition (or series of related transactions of such nature) pursuant to which more than fifty percent (50%) of the voting power of all equity of Amyris would be transferred by the holders of Amyris’s outstanding shares (excluding a reincorporation to effect a change in domicile), (ii) a sale of all or substantially all of the assets of Amyris, or (iii) any other transaction or series of transactions, in which Amyris’ stockholders immediately prior to such transaction or transactions own immediately after such transaction less than fifty (50%) of the voting equity securities of the surviving corporation or its parent.

“Constructive Termination” shall mean a resignation of your employment within thirty (30) days of the occurrence of any of the following events which occurs within five (5) months following a Change of Control: (i) a material reduction in your responsibilities, (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of Amyris, or (iii) a relocation of your principal office to a location more than fifty (50) miles from the location of your principal office immediately preceding a Change of Control.

 

8.

Amyris’ Amyris Policies

As an employee of Amyris, you will be subject to, and expected to comply with its policies and procedures, personnel and otherwise, as such policies are developed and communicated to you.

 

Page 3 of 5

Rev 9/06

 

 

1 Depending on the size of the option grant and the value of the shares at termination, the severance payments may become subject to IRC Section 280G.


9.

“At-Will” Employment

Employment with Amyris is “at-will”. This means that it is not for any specified period of time and can be terminated by you or by Amyris at any time, with or without advance notice, and for any or no particular reason or cause. It also means that your job duties, title and responsibility and reporting level, compensation and benefits, as well as Amyris’ personnel policies and procedures, may be changed at any time in the sole discretion of Amyris. However, the “at-will” nature of your employment shall remain unchanged during your tenure as an employee of Amyris and may not be changed, except in an express writing signed by you and by Amyris’ President.

 

10.

Full-Time Service to Amyris

Amyris requires that, as a full-time employee, you devote your full business time, attention, skills and efforts to the tasks and duties of your position as assigned by Amyris. If you wish to request consent to provide services (for any or no form of compensation) to any other person or business entity while employed by Amyris, you must first receive permission from the President of Amyris.

 

11.

Conditions of Offer

In order to accept this offer, and for your acceptance to be effective, you must satisfy the following conditions:

 

 

You must provide satisfactory documentary proof of your identity and right to work in the United States of America on your first day of employment.

 

 

You must agree in writing to the terms of the enclosed Proprietary Information and Inventions Agreement (“PIIA”) without modification.

 

 

You must consent to, and Amyris must obtain satisfactory results from, reference and background checks. Until you have been informed in writing by Amyris that such checks have been completed and the results satisfactory, you may wish to defer reliance on this offer.

 

 

You must agree in writing to the terms of the enclosed Mutual Agreement to Binding Arbitration (“Arbitration Agreement”) without modification.

By signing and accepting this offer, you represent and warrant that: (i) you are not subject to any pre-existing contractual or other legal obligation with any person, Amyris or business enterprise which may be an impediment to your employment with, or your providing services to, Amyris as its employee; and (ii) you have not and shall not bring onto Amyris’ premises, or use in the course of your employment with Amyris, any confidential or proprietary information of another person, Amyris or business enterprise to whom you previously provided services.

 

12.

Entire Agreement

Provided that the conditions of this offer and your acceptance are satisfied, this letter together with the enclosed PIIA and Arbitration Agreement (collectively, the “Offer Documents”) shall constitute the full and complete agreement between you and Amyris regarding the terms and

 

Page 4 of 5

Rev 9/06


conditions of your employment. The Offer Documents cancel, supersede and replace any and all prior negotiations, representations or agreements, written and oral, between you and Amyris or any representative or agent of Amyris regarding any aspect of your employment. Any change to the terms of your employment with Amyris, as set forth in this letter, must be in an individualized writing to you, signed by Amyris to be effective.

Please confirm your acceptance of this offer, by signing and returning the enclosed copy of this letter as well as the PIIA and Arbitration Agreement to me by January 21, 2008. If not accepted by you as of that date, this offer will expire. We look forward to having you join Amyris. If you have any questions, please do not hesitate to co tact me at (510) 740-7440.

 

Sincerely,

LOGO

John G. Melo

Chief Executive Officer

I HAVE READ AND ACCEPT THIS EMPLOYMENT OFFER:

 

LOGO

   

January 17, 2008

Jeryl L. Hilleman

   

Date

 

Page 5 of 5

Rev 9/06

Exhibit 10.32

LOGO

AMENDMENT TO OFFER LETTER AGREEMENT

This Amendment to the Offer Letter Agreement (this “ Amendment ”) is made and entered into as of December 18, 2008, by and among Jeryl L. Hilleman (“ Executive ”) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ”).

RECITALS

A.        The Company and Executive are parties to that certain Offer Letter Agreement between the Company and the Executive dated January 17, 2008 (the “ Agreement ”). All capitalized terms set forth herein shall (unless otherwise defined herein) have the meanings given to them in the Agreement.

B.        The Company and Executive wish to clarify the terms of the Agreement by means of this Amendment to the Agreement.

AMENDMENT

NOW THEREFORE, the parties hereby agree as follows:

1.         FIRST AMENDMENT TO AGREEMENT . The following language shall be added to the end of Section 3:

Such bonus shall be paid no later than March 15 the year following the year with respect to which the bonus is earned.

2.         SECOND AMENDMENT TO AGREEMENT . The following language shall be added to the end of subparagraph (A) of Section 6:

Antyris will commence payment of the salary continuation described in this subparagraph (A) of Section 6 and the COBRA benefits described below in subparagraph (B) of Section 6 on the first regular payroll date that is thirty (30) days (or where determined necessary by Amyris to make the release described above effective, sixty (60) days following your termination of employment, provided that prior to such date the release described above becomes effective. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date but for the application of this provision, and the balance of the installments will be payable in accordance with their original schedule.

3.         THIRD AMENDMENT TO AGREEMENT . The following language shall be added to the end of Section 6 as a new paragraph:

For purposes of this Agreement, a termination of employment will be determined consistent with the rules relating to a “separation from service” as defined in


Section 409A of the Code and the regulations thereunder (“Section 409A”). Notwithstanding anything else provided herein, to the extent any payments provided under this Agreement in connection with your termination of employment constitute deferred compensation subject to Section 409A, and you are deemed at the time of such termination of employment to be a “specified employee” under Section 409A, then such payment shall not be made or commence until the earlier of (i) the expiration of the 6-month period measured from your separation from service from Amyris or (ii) the date of your death following such a separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to you including, without limitation, the additional tax for which you would otherwise be liable under Section 409A(a)(1)(B) in the absence of such a deferral. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date but for the application of this provision, and the balance of the installments (if any) will be payable in accordance with their original schedule. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision will be read in such a manner so that all payments hereunder comply with Section 409A. To the extent any payment under this Agreement may be classified as a “short-term deferral” within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this Section 6 are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

4.         FOURTH AMENDMENT TO AGREEMENT . The third paragraph of Section 7 (defining “Constructive Termination”) shall be deleted in its entirety and replaced with the following language:

“Constructive Termination” shall mean a resignation of your employment within 30 120 days of the occurrence of any of the following events which occurs within 6 months following a Change of Control: (i) a material reduction in your responsibilities; (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of Amyris; or (iii) a relocation of your principal office to a location more than fitly (50) miles from the location of your principal office immediately preceding a Change in Control; provided, however, that you shall provide notice to Amyris, within ninety_(90) days of occurrence of a condition listed above constituting a Constructive Termination and allow Amyris thirty (30) days in which to cure such condition .

5.         NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Agreement remain in full force and effect.

6.         COUNTERPARTS . This Amendment may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same instrument.

 

2


    COMPANY     EXECUTIVE

LOGO

   

LOGO

    By:   John G. Melo         Jeryl L. Hilleman
    Its;   Chief Executive Officer    

 

3

Exhibit 10.33

 

5980 HORTON STR SUITE 450

EMERYVILLE, CA 94608

PHONE: 510.740.7440

FAX: 510.496.8244

   LOGO
  
  
  

Jeff Lievense

916 Stevens Creek Cir

Forsyth, IL 62535

October 22, 2007

Re: Offer of Employment with Amyris Biotechnologies, Inc.

Dear Jeff:

On behalf of Amyris Biotechnologies, Inc. (“Amyris”), I am delighted to offer to you employment with Amyris. If you accept this offer and satisfy the conditions of acceptance set forth herein, your employment with Amyris will commence on January 2, 2008, under the following terms:

1.      Position

You will be employed full-time by Amyris as the Senior Vice President, Process Development and Manufacturing reporting to me, John Melo, CEO.

2.      Salary

Your base salary will be $300,000 per year ($25,000.00 per month) payable in accordance with Amyris’ regular payroll schedule which is currently semi-monthly. Your salary will be subject to adjustment from time to time pursuant to Amyris’ employee compensation policies then in effect.

3.      Bonus

You will be eligible for an annual performance-based bonus of up to $75,000. Such bonus will be payable provided that (i) you achieve certain performance objectives which shall be established during the first month of your employment with Amyris, (ii) you are still employed by Amyris at year-end and when the bonus is paid out.

4.      Equity

Amyris will recommend to its Board of Directors that you be granted an option to purchase 200,000 shares of common stock of Amyris at the fair market value of the common stock on the date of Board approval (which represents approximately 1% of Amyris’ current, fully diluted outstanding capital stock). Such shares would vest as follows: (i) twenty percent (20%) upon completion of your twelfth (12 th ) month of employment, and (ii) the balance in a series of forty- eight (48) equal monthly installments upon completion of each additional month of employment with Amyris thereafter. Any option(s) granted to you will be subject to the then-current terms and conditions of Amyris’ employee stock option plan and agreement.

5.      Relocation Expenses

S YNTHETIC B IOLOGY , R EAL S OLUTIONS

www.amyrisbiotech.com


Amyris will reimburse you for and/or directly pay up to $100,000 in total relocation costs associated with your move from Illinois to the San Francisco Bay Area. We request that you work with us to solicit several bids for the movement of your household goods from experienced moving companies. Amyris will directly retain one of the companies, the choice of which would be mutually acceptable to you and Amyris. Subject to the limitations set out above, the expenses relating to the movement of your household goods will be paid directly by Amyris to the moving company. All other amounts received by you for relocation expense reimbursement will be reported as taxable income to you in the year received as required by applicable tax law. In the event that you terminate your employment with Amyris before the completion of twelve (12) months of employment, you agree to promptly repay Amyris one hundred percent (100%) of the relocation expenses by personal check or other negotiable instrument. All relocation expenses need to be approved by Amyris before the costs are incurred and must be documented by reasonably detailed receipts.

6.      Travel Expenses

Amyris will reimburse you for travel and lodging expenses from the date on which your employment with Amyris commences up to and including August 31, 2008, as follows. Amyris will reimburse you for up to two (2) roundtrip flights between Illinois and the San Francisco Bay Area per month. Unless otherwise agreed by Amyris in writing in advance, such flights shall be economy class. Amyris will also reimburse you for reasonable and customary lodging expenses (e.g. a customary studio or one-bedroom apartment or a standard hotel room) in or near Emeryville, California. All travel and lodging expenses to be reimbursed by Amyris must be documented by reasonably detailed receipts. Reimbursed expenses shall be reported on your Form W-2 to the extent required by applicable tax law.

7.      Benefits

You will be eligible to participate in the employee benefits and benefit plans that are available to full-time employees of Amyris. Currently, these include (i) 12 paid holidays, (ii) 3 weeks of paid vacation (pro-rated by hiring date), (iii) up to 6 days of paid sick leave per year (pro-rated by hiring date), (iv) medical insurance, (v) dental insurance, (vi) supplemental health and flexible spending accounts, (vii) group term life insurance, (viii) accidental death & disability insurance, (ix) long-term disability insurance, and (x) 401(K) plan. You will also be eligible to receive paid access to gym facilities. The terms of your benefits will be governed by the applicable plan documents and Amyris’ policies. Enclosed is an Employee Benefit Overview.

8.      Termination of Employment

If you resign your employment with Amyris or if Amyris terminates your employment for Cause (as defined below) at any time, you will receive your base salary as well as any accrued but unused vacation (if applicable) earned through the effective resignation or termination date and no additional compensation. If Amyris terminates your employment for any reason other than Cause, it will give you written notice of termination, any base salary and accrued but unused vacation that is earned through the effective termination date and, conditioned on your (i) signing and not revoking a release of any and all claims, in a form prescribed by Amyris, and (ii) returning to Amyris all of its property and confidential information that is in your possession, you will receive the following:

 

Page 2 of 6


(A)   Continuation of your base salary for twelve (12) months beyond the effective termination date, payable in accordance with the regular payroll practices of Amyris, provided that these payments will be terminated as of the date you commence employment with another employer or engage or participate in any consulting or advisory arrangement or any other arrangement that involves any form of remuneration, including remuneration for services performed by you as an officer, director, employee, representative or agent of, or in any other capacity for, any other person or entity (each, an “Engagement”);

(B)   If you elect to continue your health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) following the termination of your employment, then Amyris shall pay your monthly premium under COBRA until the earlier of (x) twelve (12) months following the effective termination date, or (y) the date upon which you commence employment with an entity other than Amyris or any other Engagement; and

(C)   If your employment is terminated by Amyris for any reason other than for Cause within your first year of employment, a portion of your option granted under Section 4 above will vest as follows: the number of shares that shall vest shall be equal to the number obtained by multiplying the number of shares of common stock subject to the option granted pursuant to Section 4 by a fraction, the numerator of which shall be the number of complete months you have been employed by Amyris up to the date of termination and the denominator of which shall be 60.

You will notify Amyris in writing within five (5) days of your receipt of an offer of employment with any entity other than Amyris or for any other type of Engagement, and will accordingly identify the date upon which you will commence such employment or Engagement in such writing. These salary and benefits continuance benefits are intended to be provided to you as you actively seek future employment or another Engagement, and therefore, as noted, will cease once you have secured such employment or Engagement. 1

For all purposes under this Agreement, a termination for “Cause” shall mean a determination that your employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Amyris, (ii) a violation of a federal or state law or regulation applicable to the business of Amyris, (iii) conviction or plea of no contest to a felony or to a misdemeanour involving moral turpitude under the laws of the United States or any State, (iv) fraud or misappropriation of property belonging to Amyris or its affiliates, (v) non-performance, non-compliance or interference with any third party’s performance of the terms of any confidentiality, invention assignment or proprietary information agreement with Amyris or with a former employer, (vi) your failure to satisfactorily perform your duties as assigned from time to time by Amyris after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) your misconduct or gross negligence in connection with the performance of your duties.

9.      Change of Control

 

 

1 Depending on the size of the option grant and the value of the shares at termination, the severance payments may become subject to IRC Section 280G.

 

Page 3 of 6


If, during your employment with Amyris, there is a Change of Control event (as defined below), and Amyris terminates your employment without Cause or you are Constructively Terminated (as defined below) within six (6) months of that event, then you will be eligible to receive the benefits provided in Section 8, as well as immediate accelerated vesting of fifty percent (50%) of any of the unvested shares under your outstanding options as of the date of termination, conditioned on your complying with the requirements of Section 8 above.

“Change of Control” shall mean (i) a merger, reorganization, consolidation or other transaction (or series of related transactions of such nature) pursuant to which more than fifty percent (50%) of the voting power of all outstanding equity securities of Amyris is transferred by the holders of Amyris’ outstanding shares (excluding a reincorporation to effect a change in domicile), (ii) a sale of all or substantially all of the assets of Amyris, or (iii) any other transaction or series of related transactions, in which Amyris’ stockholders immediately prior to such transaction or transactions own immediately after such transaction less than fifty (50%) of the voting equity securities of the surviving corporation or its parent.

“Constructive Termination” shall mean a resignation of your employment within thirty (30) days of the occurrence of any of the following events which occurs within six (6) months following a Change of Control: (i) a material reduction in your responsibilities, (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all or substantially all executive officers of Amyris, or (iii) a relocation of your principal office to a location more than fifty (50) miles from the location of your principal office immediately preceding a Change of Control.

10.      Amyris’ Policies

As an employee of Amyris, you will be subject to, and expected to comply with its policies and procedures, personnel and otherwise, as such policies are developed and communicated to you.

11.      “At-Will” Employment

Employment with Amyris is “at-will”. This means that it is not for any specified period of time and can be terminated by you or by Amyris at any time, with or without advance notice, and for any or no particular reason or cause. It also means that your job duties, title and responsibility and reporting level, compensation and benefits, as well as Amyris’ personnel policies and procedures, may be changed at any time in the sole discretion of Amyris. However, the “at-will” nature of your employment shall remain unchanged during your tenure as an employee of Amyris and may not be changed, except in an express writing signed by you and by Amyris’ Chief Executive Officer.

12.      Full-Time Service to Amyris

Amyris requires that, as a full-time employee, you devote your full business time, attention, skills and efforts to the tasks and duties of your position as assigned by Amyris. If you wish to request consent to provide services (for any or no form of compensation) to any other person or business entity while employed by Amyris, you must first receive permission from the Chief Executive Officer of Amyris.

 

Page 4 of 6


13.      Conditions of Offer

In order to accept this offer, and for your acceptance to be effective, you must satisfy the following conditions:

 

 

You must provide satisfactory documentary proof of your identity and right to work in the United States of America on your first day of employment.

 

 

You must agree in writing to the terms of the enclosed Proprietary Information and Inventions Agreement (“ PIIA ”) without modification.

 

 

You must consent to, and Amyris must obtain satisfactory results from, reference and background checks. Until you have been informed in writing by Amyris that such checks have been completed and the results satisfactory, you may wish to defer reliance on this offer.

 

 

You must agree in writing to the terms of the enclosed Mutual Agreement to Binding Arbitration (“ Arbitration Agreement ”) without modification.

By signing and accepting this offer, you represent and warrant that: (i) you are not subject to any pre-existing contractual or other legal obligation with any person or entity that may be an impediment to your employment with, or your providing services to, Amyris as its employee; and (ii) you have not and shall not bring onto Amyris’ premises, or use in the course of your employment with Amyris, any confidential or proprietary information of another person or entity to whom you previously provided services.

14.      Entire Agreement

Provided that the conditions of this offer and your acceptance are satisfied, this letter together with the enclosed PIIA and Arbitration Agreement (collectively, the “ Offer Documents ”) shall constitute the full and complete agreement between you and Amyris regarding the terms and conditions of your employment. The Offer Documents cancel, supersede and replace any and all prior negotiations, representations or agreements, written and oral, between you and Amyris or any representative or agent of Amyris regarding any aspect of your employment. Any change to the terms of your employment with Amyris, as set forth in this letter, must be in an individualized writing to you, signed by the Chief Executive Officer of Amyris to be effective.

Please confirm your acceptance of this offer by signing and returning the enclosed copy of this letter as well as the PIIA and Arbitration Agreement to me by October 26, 2007. If not accepted by you as of that date, this offer will expire. We look forward to having you join Amyris. If you have any questions, please do not hesitate to contact me at (510) 740-7440.

 

Sincerely,

/s/ John G. Melo

John G. Melo

Chief Executive Officer

 

Page 5 of 6


I HAVE READ AND ACCEPT THIS EMPLOYMENT OFFER:

 

/s/ Jeff C. Lievense

   

October 28, 2007

Jeff C. Lievense

   

Date

Enclosures

 

Page 6 of 6

Exhibit 10.34

LOGO

AMENDMENT TO OFFER LETTER AGREEMENT

This Amendment to the Offer Letter Agreement (this “ Amendment ”) is made and entered into as of December 18, 2008, by and among Jeff Lievense (“ Executive ”) and Amyris Biotechnologies, Inc., a California corporation (the “ Company ”).

RECITALS

A.        The Company and Executive are parties to that certain Offer Letter Agreement between the Company and the Executive dated October 22, 2007 (the “ Agreement ”). All capitalized terms set forth herein shall (unless otherwise defined herein) have the meanings given to them in the Agreement.

B.        The Company and Executive wish to clarify the terms of the Agreement by means of this Amendment to the Agreement.

AMENDMENT

NOW THEREFORE, the parties hereby agree as follows:

1.         FIRST AMENDMENT TO AGREEMENT . The following language shall be added to the end of Section 3:

Such bonus shall be paid no later than March 15 the year following the year with respect to which the bonus is earned.

2.         SECOND AMENDMENT TO AGREEMENT . The following language shall be added to the end of subparagraph (A) of Section 8:

Antyris will commence payment of the salary continuation described in this subparagraph (A) of Section 8 and the COBRA benefits described below in subparagraph (B) of Section 8 on the first regular payroll date that is thirty (30) days (or where determined necessary by Amyris to make the release described above effective, sixty (60) days following your termination of employment, provided that prior to such date the release described above becomes effective. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date but for the application of this provision, and the balance of the installments will be payable in accordance with their original schedule.

3.         THIRD AMENDMENT TO AGREEMENT . The following language shall be added to the end of Section 8 as a new paragraph:

For purposes of this Agreement, a termination of employment will be determined


consistent with the rules relating to a “separation from service” as defined in Section 409A of the Code and the regulations thereunder (“Section 409A”). Notwithstanding anything else provided herein, to the extent any payments provided under this Agreement in connection with your termination of employment constitute deferred compensation subject to Section 409A, and you are deemed at the time of such termination of employment to be a “specified employee” under Section 409A, then such payment shall not be made or commence until the earlier of (i) the expiration of the 6-month period measured from your separation from service from Amyris or (ii) the date of your death following such a separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to you including, without limitation, the additional tax for which you would otherwise be liable under Section 409A(a)(1)(B) in the absence of such a deferral. The first payment thereof will include a catch-up payment covering the amount that would have otherwise been paid during the period between your termination of employment and the first payment date but for the application of this provision, and the balance of the installments (if any) will be payable in accordance with their original schedule. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A, the provision will be read in such a manner so that all payments hereunder comply with Section 409A. To the extent any payment under this Agreement may be classified as a “short-term deferral” within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this Section 8 are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

4.         FOURTH AMENDMENT TO AGREEMENT . The third paragraph of Section 9 (defining “Constructive Termination”) shall be deleted in its entirety and replaced with the following language:

“Constructive Termination” shall mean a resignation of your employment within 30 120 days of the occurrence of any of the following events which occurs within 6 months following a Change of Control: (i) a material reduction in your responsibilities; (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of Amyris; or (iii) a relocation of your principal office to a location more than fitly (50) miles from the location of your principal office immediately preceding a Change in Control; provided, however, that you shall provide notice to Amyris, within ninety (90) days of occurrence of a condition listed above constituting a Constructive Termination and allow Amyris thirty (30) days in which to cure such condition .

5.         NO OTHER AMENDMENTS . Except as expressly set forth above, all of the terms and conditions of the Agreement remain in full force and effect.


6.         COUNTERPARTS . This Amendment may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same instrument.

 

    COMPANY     EXECUTIVE

LOGO

   

LOGO

    By:   John G. Melo         Jeff Lievense
    Its:   Chief Executive Officer    

Exhibit 10.35

LOGO

AMYRIS BIOTECHNOLOGIES, INC.

January  24 th , 2005

Re: Offer of Employment with Amyris Biotechnologies, Inc.

Dear Tamara Tompkins

On behalf of Amyris Biotechnologies, Inc. (“ Amyris ”), I am delighted to offer to you employment with Amyris. If you accept this offer and satisfy the conditions of acceptance set forth herein, your employment with Amyris will commence on February 7, 2005, under the following terms:

Position .

You will be employed full-time by Amyris initially as its Vice President of Operations and Legal Affairs, reporting to Kinkead Reiling, Ph.D.

Cash Compensation.

You will initially earn a monthly base salary of $8333.33 annualized at $100,000, which shall be paid in accordance with Amyris’ regular payroll schedule. Upon Amyris’ first equity funding event or corporate partnership to which you contribute materially and which is worth at least $4,000,000 your annualized salary will be increased by $50,000 to $150,000. Further, this pay raise will be retroactive to your initial date of employment. For funding events of less than $4,000,000 and more than $1,000,000, the aforementioned raise will be a based on the following formula: $50,000*(Funding-1,000,000)/3,000,000.

Benefits.

You will be eligible to participate in the employee benefits plans, including paid time off, that are generally made available to the employees of Amyris, as those benefits become available. At this time, Amyris can offer you three (3) weeks of vacation and the payment of your California Bar Dues. Further, Amyris will contribute to you MCLE fees in accordance with our standard budget for employee attendance of conferences (currently estimated at $1500/year). Because Amyris is newly-formed, we are working diligently to put in place a full range of benefits as soon as possible.

Equity.

You will be recommended to Amyris’ Board of Directors (the “Board”) to be granted a stock option to purchase 75,000 shares of common stock of Amyris (the “Option Shares”) at the strike price of $0.10 per share, which will vest as follows: (i) except as provided below, twenty-five percent (25%) of the Option Shares will vest upon completion of your twelfth (12th) month of employment with Amyris, and (ii) the balance of the Option Shares will vest in a series of thirty- six (36) successive equal monthly instalments upon your completion of each additional month of employment with Amyris thereafter.

Notwithstanding clause (i) of the preceding paragraph, if, at any time during the initial twelve (12) months of your employment with Amyris, there is an Involuntary Termination of your


LOGO

employment, a number of Option Shares equal to (x) 1/48 of the Option Shares, multiplied by (y) the number of months you were employed by Amyris prior to the effective date of such Involuntary Termination (pro-rated for any month(s) of partial employment) shall accelerate and become immediately vested. For purposes of this offer letter, an “Involuntary Termination” shall mean the termination of your employment with Amyris for one or more of the following reasons:

(1) You are involuntary dismissed or discharged by Amyris for reasons other than: (a) an act of fraud, embezzlement, or dishonesty, (b) the unauthorized use or disclosure by you of confidential information or trade secrets of Amyris, (c) any misconduct by you that has a material adverse affect on the business or affairs of Amyris, or (d) one or more unsatisfactory performance reviews; or

(2) You voluntarily resign following: (a) a change in your position with Amyris which materially reduces your duties and responsibilities or the level of management of Amyris to which you report, or (b) a reduction in your level of compensation by more than fifteen percent (15%).

Company Policy.

As an employee of Amyris, you will be subject to, and will be expected to comply with its policies and procedures, personnel and otherwise, as those policies are developed and communicated to you.

“At-Will” Employment.

Employment with Amyris is “at-will”. This means that it is not for any specified period of time and can be terminated by you or by Amyris at any time, with or without advance notice, and for any or no particular reason or cause. It also means that your job duties, title and responsibility and reporting level, compensation and benefits, as well as Amyris’ personnel policies and procedures, may be changed at any time in the sole discretion of Amyris. However, the “at-will” nature of your employment shall remain unchanged during your tenure as an employee of Amyris and may not be changed, except in an express writing signed by you and by Amyris’ President.

Full-time Services to The Company

The Company requires that, as a full-time employee, you devote your full business time, attention, skills and efforts to the tasks and duties of your position as assigned by the Company. If you wish to request consent to provide services (for any or no form of compensation) to any other person or business entity while employed by the Company, please contact Kinkead Reiling.

Conditions of Offer.

In order to accept this offer, and for your acceptance to be effective, you must satisfy the following conditions:

 

 

Your ability to provide satisfactory documentary proof of your identity and right to work in the United States of America on your first day of employment.


LOGO

 

 

Your signed agreement to, and ongoing compliance with, the terms of the enclosed Proprietary Information and Inventions Agreement without modification,

 

 

Your consent to, and results satisfactory to the Company of, reference and background checks. Until you have been informed in writing by the Company that such checks have been completed and the results satisfactory, you may wish to defer reliance on this offer.

 

 

Your signed agreement to the terms of the enclosed Mutual Agreement to Arbitrate Employment Disputes without modification.

 

 

Your return of the enclosed copy of this letter, after being signed by you without modification, to the Company no later than February 5, 2005, after which time this offer will expire. By signing and accepting this offer, you represent and warrant that: (i) you are not subject to any pre- existing contractual or other legal obligation with any person, company or business enterprise which may be an impediment to your employment with, or your providing services to, the Company as its employee; and (ii) you have not and shall not bring onto Company premises, or use in the course of your employment with the Company, any confidential or proprietary information of another person, company or business enterprise to whom you previously provided services.

Entire Agreement.

Provided that the conditions of this offer and your acceptance are satisfied, this letter and the enclosed PIIA shall constitute the full and complete agreement between you and Amyris regarding the terms and conditions of your employment. This letter and the enclosed PIIA cancel supersede and replace any and all prior negotiations, representations or agreements, written and oral, between you and Amyris or any representative or agent of Amyris regarding any aspect of your employment. Any change to the terms of your employment with Amyris, as set forth in this letter, must be in an individualized writing to you, signed by Amyris to be effective.

Please confirm your acceptance of this offer, by signing and returning the enclosed copy of this letter and the PIIA to Kinkead Reiling by February 5, 2005. If not accepted by you as of that date, this offer will expire. We look forward to having you join Amyris. If you have any questions, please do not hesitate to contact Kinkead at (415) 640-9742.

Sincerely,

 

/s/ Kinkead Reiling

Kinkead Reiling

President, Amyris Biotechnologies, Inc.

I ACCEPT AMYRIS’S OFFER OF EMPLOYMENT, ABOVE.

 

/s/ Tamara Tompkins

   

February 7, 2005

Tammy Tompkins

   

Date

Exhibit 10.36

LOGO

Tamara L. Tompkins

1040 Continentals Way #13

Belmont, CA 94002

January 15, 2009

Re: Amendment to Offer Letter

Dear Tammy:

This letter amends the offer letter between you and Amyris Biotechnologies, Inc. (“Amyris”) dated January 25, 2005 (the “Original Offer Letter”). The Original Offer Letter shall be amended by adding the following provisions:

 

 

1.

Termination of Employment. If you resign your employment with Amyris or if Amyris terminates your employment for Cause (as defined below) at any time, you will receive your base salary as well as any accrued but unused vacation (if applicable) earned through the effective resignation or termination date and no additional compensation. If Amyris terminates your employment for any reason other than Cause, it will give you written notice of termination, any base salary and accrued but unused vacation that is earned through the effective termination date and, conditioned on your (i) signing and not revoking a release of any and all claims, in a form prescribed by Amyris, and (ii) returning to Amyris all of its property and confidential information that is in your possession, you will receive the following:

 

 

(A)

Continuation of your base salary for twelve (12) months beyond the effective termination date, payable in accordance with the regular payroll practices of Amyris, provided that these payments will be terminated as of the date you commence employment with another employer or engage or participate in any consulting or advisory arrangement or any other arrangement that involves any form of remuneration, including remuneration for services performed by you as an officer, director, employee, representative or agent of, or in any other capacity for, any other person or entity (each, an “Engagement”);

 

 

(B)

If you elect to continue your health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) following the termination of your employment, then Amyris shall pay your monthly premium under COBRA until the earlier of (x) twelve (12) months following the effective termination date, or (y) the date upon which you commence employment with an entity other than Amyris or any other Engagement; and

 

 

(C)

If your employment is terminated by Amyris for any reason other than for Cause within your first year of employment, a portion of your options granted under

5885 Hollis Street Suite 100, Emeryville California 94608

P. 510 450 0781 F: 510 225 284 8


Section 4 above will vest as follows: the number of shares that shall vest shall be equal to the number obtained by multiplying the number of shares of common stock subject to the option granted pursuant to Section 4 by a fraction, the numerator of which shall be the number of complete months you have been employed by Amyris up to the date of termination and the denominator of which shall be 60.

You will notify Amyris in writing within five (5) days of your receipt of an offer of employment with any entity other than Amyris or for any other type of Engagement, and will accordingly identify the date upon which you will commence such employment or Engagement in such writing. These salary and benefits continuance benefits are intended to be provided to you as you actively seek future employment or another Engagement, and therefore, as noted, will cease once you have secured such employment or Engagement.

For all purposes under this Agreement, a termination for “Cause” shall mean a determination that your employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Amyris, (ii) a violation of a federal or state law or regulation applicable to the business of Amyris, (iii) conviction or plea of no contest to a felony or to a misdemeanor involving moral turpitude under the laws of the United States or any State, (iv) fraud or misappropriation of property belonging to Amyris or its affiliates, (v) nonperformance, non-compliance or interference with any third party’s performance of the terms of any confidentiality, invention assignment or proprietary information agreement with Amyris or with a former employer, (vi) your failure to satisfactorily perform your duties as assigned from time to time by Amyris after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) your misconduct or gross negligence in connection with the performance of your duties.

 

 

2.

Change of Control. If, during your employment with Amyris, there is a Change of Control event (as defined below), and Amyris terminates your employment without Cause or you are Constructively Terminated (as defined below) within six (6) months of that event, then you will be eligible to receive the benefits provided in Section 8, as well as immediate accelerated vesting of fifty percent (50%) of any of the unvested shares under your outstanding options as of the date of termination, conditioned on your complying with the requirements of Section 8 above.

“Change of Control” shall mean (i) a merger, reorganization, consolidation or other transaction (or series of related transactions of such nature) pursuant to which more than fifty percent (50%) of the voting power of all outstanding equity securities of Amyris is transferred by the holders of Amyris’ outstanding shares (excluding a reincorporation to effect a change in domicile), (ii) a sale of all or substantially all of the assets of Amyris, or (iii) any other transaction or series of related transactions, in which Amyris’ stockholders immediately prior to such transaction or transactions own immediately after such transaction less than fifty (50%) of the voting equity securities of the surviving corporation or its parent.


“Constructive Termination” shall mean a resignation of your employment within thirty (30) days of the occurrence of any of the following events which occurs within six (6) months following a Change of Control: (i) a material reduction in your responsibilities, (ii) a material reduction in your base salary, unless such reduction in your base salary is comparable in percentage to, and is part of, a reduction in the base salary of all or substantially all executive officers of Amyris, or (iii) a relocation of your principal office to a location more than fifty (50) miles from the location of your principal office immediately preceding a Change of Control.

Please confirm your acceptance of this amendment by signing and returning the enclosed copy of this letter.

 

Sincerely,

LOGO

John G. Melo

Chief Executive Officer

I HAVE READ AND ACCEPT THIS AMENDMENT:

 

LOGO

   

January 15, 2009

Tamara L. Tompkins

   

Date

Exhibit 10.37

AMYRIS BIOTECHNOLOGIES, INC.

2005 STOCK OPTION/STOCK ISSUANCE PLAN

ARTICLE ONE

GENERAL PROVISIONS

 

 

I.

PURPOSE OF THE PLAN

This 2005 Stock Option/Stock Issuance Plan is intended to promote the interests of Amyris Biotechnologies, Inc., a California corporation, by providing eligible persons in the Corporation’s employ or service with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Corporation as an incentive for them to continue in such employ or service.

Capitalized terms herein shall have the meanings assigned to such terms in the attached Appendix.

 

 

II.

STRUCTURE OF THE PLAN

A.        The Plan shall be divided into two (2) separate equity programs:

(i)        the Option Grant Program under which eligible persons may, at the discretion of the Plan Administrator, be granted options to purchase shares of Common Stock, and

(ii)        the Stock Issuance Program under which eligible persons may, at the discretion of the Plan Administrator, be issued shares of Common Stock directly, either through the immediate purchase of such shares or as a bonus for services rendered the Corporation (or any Parent or Subsidiary) or pursuant to restricted stock units or other share right awards which vest upon the completion of a designated service period or the attainment of pre-established performance milestones.

B.        The provisions of Articles One and Four shall apply to both equity programs under the Plan and shall accordingly govern the interests of all persons under the Plan.

 

 

III.

ADMINISTRATION OF THE PLAN

A.        The Plan shall be administered by the Board. However, any or all administrative functions otherwise exercisable by the Board may be delegated to the Committee. Members of the Committee shall serve for such period of time as the Board may determine and shall be subject to removal by the Board at any time. The Board may also at any time terminate the functions of the Committee and reassume all powers and authority previously delegated to the Committee.

B.        The Plan Administrator shall have full power and authority (subject to the provisions of the Plan) to establish such rules and regulations as it may deem appropriate for

 

1


proper administration of the Plan and to make such determinations under, and issue such interpretations of, the Plan and any outstanding options or stock issuances thereunder as it may deem necessary or advisable. Decisions of the Plan Administrator shall be final and binding on all parties who have an interest in the Plan or any option grant or stock issuance thereunder.

 

 

IV.

ELIGIBILITY

A.        The persons eligible to participate in the Plan are as follows:

(i)        Employees,

(ii)        non-employee members of the Board or the non-employee members of the board of directors of any Parent or Subsidiary, and

(iii)        consultants and other independent advisors who provide services to the Corporation (or any Parent or Subsidiary).

B.        The Plan Administrator shall have full authority to determine, (i) with respect to the grants made under the Option Grant Program, which eligible persons are to receive such grants, the time or times when those grants are to be made, the number of shares to be covered by each such grant, the status of the granted option as either an Incentive Option or a Non-Statutory Option, the time or times when each option is to become exercisable, the vesting schedule (if any) applicable to the option shares and the maximum term for which the option is to remain outstanding, and (ii) with respect to stock issuances or other stock-based awards under the Stock Issuance Program, which eligible persons are to receive such issuances or awards, the time or times when those issuances or awards are to be made, the number of shares subject to such issuance or award to each Participant, the vesting schedule (if any) applicable to the issued shares and the consideration to be paid by the Participant for such shares.

C.        The Plan Administrator shall have the absolute discretion either to grant options in accordance with the Option Grant Program or to effect stock issuances in accordance with the Stock Issuance Program.

 

 

V.

STOCK SUBJECT TO THE PLAN

A.        The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock. The maximum number of shares of Common Stock which may be issued over the term of the Plan shall not exceed Five Million Nine Hundred Forty-Two Thousand Seven Hundred (5,942,700) shares.

B.        Shares of Common Stock subject to outstanding options shall be available for subsequent issuance under the Plan to the extent (i) the options expire or terminate for any reason prior to exercise in full or (ii) the options are cancelled in accordance with the cancellation-regrant provisions of Article Two. Unvested shares issued under the Plan and subsequently repurchased by the Corporation, at a price per share not greater than the option exercise or direct issue price paid per share, pursuant to the Corporation’s repurchase rights under the Plan shall be added back to the number of shares of Common Stock reserved for

 

2


issuance under the Plan and shall accordingly be available for reissuance through one or more subsequent option grants or direct stock issuances under the Plan.

C.        Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation’s receipt of consideration, appropriate adjustments shall be made to (i) the maximum number and/or class of securities issuable under the Plan and (ii) the number and/or class of securities and the exercise price per share in effect under each outstanding option in order to prevent the dilution or enlargement of benefits thereunder. The adjustments determined by the Plan Administrator shall be final, binding and conclusive. In no event shall any such adjustments be made in connection with the conversion of one or more outstanding shares of the Corporation’s preferred stock into shares of Common Stock.

 

3


ARTICLE TWO

OPTION GRANT PROGRAM

 

 

I.

OPTION TERMS

Each option shall be evidenced by one or more documents in the form approved by the Plan Administrator; provided, however, that each such document shall comply with the terms specified below. Each document evidencing an Incentive Option shall, in addition, be subject to the provisions of the Plan applicable to such options.

A.         Exercise Price .

1.        The exercise price per share shall be fixed by the Plan Administrator in accordance with the following provisions:

(i)        The exercise price per share shall not be less than one hundred percent (100%) of the Fair Market Value per share of Common Stock on the option grant date.

(ii)        If the person to whom the option is granted is a 10% Stockholder, then the exercise price per share shall not be less than one hundred ten percent (110%) of the Fair Market Value per share of Common Stock on the option grant date.

2.        The exercise price shall become immediately due upon exercise of the option and shall, subject to the provisions of Section I of Article Four and the documents evidencing the option, be payable in cash or check made payable to the Corporation. Should the Common Stock be registered under Section 12 of the 1934 Act at the time the option is exercised, then the exercise price may also be paid as follows:

(i)        in shares of Common Stock held for the requisite period necessary to avoid a charge to the Corporation’s earnings for financial reporting purposes and valued at Fair Market Value on the Exercise Date, or

(ii)        to the extent the option is exercised for vested shares, through a special sale and remittance procedure pursuant to which the Optionee shall concurrently provide irrevocable instructions (A) to a brokerage firm (reasonably satisfactory to the Corporation for purposes of administering such procedure in compliance with any applicable pre-clearance or pre-notification requirements) to effect the immediate sale of the purchased shares and remit to the Corporation, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable for the purchased shares plus all applicable income and employment taxes required to be withheld by the Corporation by reason of such exercise and (B) to the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm on the settlement date in order to complete the sale.

 

4


Except to the extent such sale and remittance procedure is utilized, payment of the exercise price for the purchased shares must be made on the Exercise Date.

B.         Exercise and Term of Options .    Each option shall be exercisable at such time or times, during such period and for such number of shares as shall be determined by the Plan Administrator and set forth in the documents evidencing the option grant. However, no option shall have a term in excess of ten (10) years measured from the option grant date.

C.         Effect of Termination of Service .

1.        The following provisions shall govern the exercise of any options held by the Optionee at the time of cessation of Service or death:

(i)        Should the Optionee cease to remain in Service for any reason other than death, Disability or Misconduct, then the Optionee shall have a period of three (3) months following the date of such cessation of Service during which to exercise each outstanding option held by such Optionee.

(ii)        Should Optionee’s Service terminate by reason of Disability, then the Optionee shall have a period of twelve (12) months following the date of such cessation of Service during which to exercise each outstanding option held by such Optionee.

(iii)        If the Optionee dies while holding an outstanding option, then the personal representative of his or her estate or the person or persons to whom the option is transferred pursuant to the Optionee’s will or the laws of inheritance or the Optionee’s designated beneficiary or beneficiaries of that option shall have a twelve (12)-month period following the date of the Optionee’s death to exercise such option.

(iv)        Under no circumstances, however, shall any such option be exercisable after the specified expiration of the option term.

(v)        During the applicable post-Service exercise period, the option may not be exercised in the aggregate for more than the number of vested shares for which the option is exercisable on the date of the Optionee’s cessation of Service. No additional shares shall vest under the option following the Optionee’s cessation of Service, except to the extent (if any) specifically authorized by the Plan Administrator in its sole discretion pursuant to an express written agreement with Optionee. Upon the expiration of the applicable exercise period or (if earlier) upon the expiration of the option term, the option shall terminate and cease to be outstanding for any vested shares for which the option has not been exercised.

(vi)        Should Optionee’s Service be terminated for Misconduct or should Optionee otherwise engage in Misconduct while holding one or more outstanding options under the Plan, then all those options shall terminate immediately and cease to remain outstanding.

 

5


2.        The Plan Administrator shall have the discretion, exercisable either at the time an option is granted or at any time while the option remains outstanding, to:

(i)        extend the period of time for which the option is to remain exercisable following Optionee’s cessation of Service or death from the limited period otherwise in effect for that option to such greater period of time as the Plan Administrator shall deem appropriate, but in no event beyond the expiration of the option term, and/or

(ii)        permit the option to be exercised, during the applicable post-Service exercise period, not only with respect to the number of vested shares of Common Stock for which such option is exercisable at the time of the Optionee’s cessation of Service but also with respect to one or more additional installments in which the Optionee would have vested under the option had the Optionee continued in Service.

D.         Stockholder Rights .    The holder of an option shall have no stockholder rights with respect to the shares subject to the option until such person shall have exercised the option, paid the exercise price and become the recordholder of the purchased shares.

E.         Unvested Shares .    The Plan Administrator shall have the discretion to grant options which are exercisable for unvested shares of Common Stock. Should the Optionee cease Service while holding such unvested shares, the Corporation shall have the right to repurchase any or all of those unvested shares at a price per share equal to the lower of (i) the exercise price paid per share or (ii) the Fair Market Value per share of Common Stock at the time of Optionee’s cessation of Service. The terms upon which such repurchase right shall be exercisable (including the period and procedure for exercise and the appropriate vesting schedule for the purchased shares) shall be established by the Plan Administrator and set forth in the document evidencing such repurchase right. The Plan Administrator may not impose a vesting schedule upon any option grant or the shares of Common Stock subject to that option which is more restrictive than twenty percent (20%) vesting per year of Service, with the initial vesting to occur not later than one (1) year after the option grant date. However, such limitation shall not be applicable to any option grants made to individuals who are officers of the Corporation, non- employee Board members or independent consultants.

F.         First Refusal Rights .    Until such time as the Common Stock is first registered under Section 12 of the 1934 Act, the Corporation shall have the right of first refusal with respect to any proposed disposition by the Optionee (or any successor in interest) of any shares of Common Stock issued under the Plan. Such right of first refusal shall be exercisable in accordance with the terms established by the Plan Administrator and set forth in the document evidencing such right.

G.         Limited Transferability of Options .    An Incentive Stock Option shall be exercisable only by the Optionee during his or her lifetime and shall not be assignable or transferable other than by will or by the laws of inheritance following the Optionee’s death. A Non-Statutory Option may be assigned in whole or in part during the Optionee’s lifetime to one or more members of the Optionee’s family or to a trust established exclusively for the Optionee and/or one or more such family members or to Optionee’s former spouse, to the extent such assignment is in connection with the Optionee’s estate plan or pursuant to a domestic relations

 

6


order. The assigned portion may only be exercised by the person or persons who acquire a proprietary interest in the Non-Statutory Option pursuant to the assignment. The terms applicable to the assigned portion shall be the same as those in effect for the option immediately prior to such assignment and shall be set forth in such documents issued to the assignee as the Plan Administrator may deem appropriate. Notwithstanding the foregoing, the Optionee may also designate one or more persons as the beneficiary or beneficiaries of his or her outstanding options under the Plan, and those options shall, in accordance with such designation, automatically be transferred to such beneficiary or beneficiaries upon the Optionee’s death while holding those options. Such beneficiary or beneficiaries shall take the transferred options subject to all the terms and conditions of the applicable agreement evidencing each such transferred option, including (without limitation) the limited time period during which the option may be exercised following the Optionee’s death.

 

 

II.

INCENTIVE OPTIONS

The terms specified below shall be applicable to all Incentive Options. Except as modified by the provisions of this Section II, all the provisions of Articles One, Two and Four shall be applicable to Incentive Options. Options which are specifically designated as Non- Statutory Options shall not be subject to the terms of this Section II.

A.         Eligibility .    Incentive Options may only be granted to Employees.

B.         Dollar Limitation .    The aggregate Fair Market Value of the shares of Common Stock (determined as of the respective date or dates of grant) for which one or more options granted to any Employee under the Plan (or any other option plan of the Corporation or any Parent or Subsidiary) may for the first time become exercisable as Incentive Options during any one (1) calendar year shall not exceed the sum of One Hundred Thousand Dollars ($100,000). To the extent the Employee holds two (2) or more such options which become exercisable for the first time in the same calendar year, the foregoing limitation on the exercisability of such options as Incentive Options shall be applied on the basis of the order in which such options are granted, except to the extent otherwise provided under applicable law or regulation.

C.         10% Stockholder .    If any Employee to whom an Incentive Option is granted is a 10% Stockholder, then the option term shall not exceed five (5) years measured from the option grant date.

 

 

III.

CHANGE IN CONTROL

A.        The shares subject to each option outstanding under the Plan at the time of a Change in Control shall automatically vest in full so that each such option shall, immediately prior to the effective date of the Change in Control, become exercisable for all of the shares of Common Stock at the time subject to that option and may be exercised for any or all of those shares as fully-vested shares of Common Stock. However, the shares subject to an outstanding option shall not vest on such an accelerated basis if and to the extent: (i) such option is assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction and any repurchase rights of the

 

7


Corporation with respect to the unvested option shares are concurrently assigned to such successor corporation (or parent thereof) or otherwise continued in effect or (ii) such option is to be replaced with a cash incentive program of the Corporation or any successor corporation which preserves the spread existing on the unvested option shares at the time of the Change in Control (the excess of the Fair Market Value of those shares over the aggregate exercise price payable for such shares) and provides for subsequent payout of that spread in accordance with the same vesting schedule applicable to those unvested option shares or (iii) the acceleration of such option is subject to other limitations imposed by the Plan Administrator at the time of the option grant.

B.        All outstanding repurchase rights shall also terminate automatically, and the shares of Common Stock subject to those terminated rights shall immediately vest in full, in the event of any Change in Control, except to the extent: (i) those repurchase rights are assigned to the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such accelerated vesting is precluded by other limitations imposed by the Plan Administrator at the time the repurchase right is issued.

C.        Immediately following the consummation of the Change in Control, all outstanding options shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in effect pursuant to the terms of the Change in Control transaction.

D.        Each option which is assumed in connection with a Change in Control or otherwise continued in effect shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to the Optionee in consummation of such Change in Control, had the option been exercised immediately prior to such Change in Control. Appropriate adjustments shall also be made to (i) the number and class of securities available for issuance under the Plan following the consummation of such Change in Control and (ii) the exercise price payable per share under each outstanding option, provided the aggregate exercise price payable for such securities shall remain the same. To the extent the actual holders of the Corporation’s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption or continuation of the outstanding options under this Plan, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control.

E.        The Plan Administrator shall have the discretion, exercisable either at the time the option is granted or at any time while the option remains outstanding, to structure one or more options so that those options shall automatically accelerate and vest in full (and any repurchase rights of the Corporation with respect to the unvested shares subject to those options shall immediately terminate) upon the occurrence of a Change in Control, whether or not those options are to be assumed in the Change in Control or otherwise continued in effect.

F.        The Plan Administrator shall also have full power and authority, exercisable either at the time the option is granted or at any time while the option remains

 

8


outstanding, to structure such option so that the shares subject to that option will automatically vest on an accelerated basis should the Optionee’s Service terminate by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of any Change in Control in which the option is assumed or otherwise continued in effect and the repurchase rights applicable to those shares do not otherwise terminate. Any option so accelerated shall remain exercisable for the fully-vested option shares until the expiration or sooner termination of the option term. In addition, the Plan Administrator may provide that one or more of the Corporation’s outstanding repurchase rights with respect to shares held by the Optionee at the time of such Involuntary Termination shall immediately terminate on an accelerated basis, and the shares subject to those terminated rights shall accordingly vest at that time.

G.        The portion of any Incentive Option accelerated in connection with a Change in Control shall remain exercisable as an Incentive Option only to the extent the applicable One Hundred Thousand Dollar ($100,000) limitation is not exceeded. To the extent such dollar limitation is exceeded, the accelerated portion of such option shall be exercisable as a Non-Statutory Option under the Federal tax laws.

H.        The grant of options under the Plan shall in no way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

 

 

IV.

CANCELLATION AND REGRANT OF OPTIONS

The Plan Administrator shall have the authority to effect, at any time and from time to time, with the consent of the affected option holders, the cancellation of any or all outstanding options under the Plan and to grant in substitution therefor new options covering the same or different number of shares of Common Stock but with an exercise price per share based on the Fair Market Value per share of Common Stock on the new option grant date.

 

9


ARTICLE THREE

STOCK ISSUANCE PROGRAM

 

 

I.

STOCK ISSUANCE TERMS

Shares of Common Stock may be issued under the Stock Issuance Program through direct and immediate issuances without any intervening option grants. Each such stock issuance shall be evidenced by a Stock Issuance Agreement which complies with the terms specified below. Shares of Common Stock may also be issued under the Stock Issuance Program pursuant to share right awards or restricted stock units which entitle the recipients to receive the shares underlying those awards or units upon the attainment of designated performance goals or the satisfaction of specified Service requirements or upon the expiration of a designated time period following the vesting of those awards or units.

A.         Issue Price .

1.        The issue price per share shall be fixed by the Plan Administrator but shall not be less than one hundred percent (100%) of the Fair Market Value per share of Common Stock on the issue date.

2.        Subject to the provisions of Section I of Article Four, shares of Common Stock may be issued under the Stock Issuance Program for any of the following items of consideration which the Plan Administrator may deem appropriate in each individual instance:

(i)        cash or check made payable to the Corporation,

(ii)        past services rendered to the Corporation (or any Parent or Subsidiary), or

(iii)        any other valid consideration under the California Corporations Code.

B.         Vesting Provisions .

1.        Shares of Common Stock issued under the Stock Issuance Program may, in the discretion of the Plan Administrator, be fully and immediately vested upon issuance or may vest in one or more installments over the Participant’s period of Service or upon attainment of specified performance objectives. Shares of Common Stock may also be issued under the Stock Issuance Program pursuant to share right awards or restricted stock units which entitle the recipients to receive the shares underlying those awards or units upon the attainment of designated performance goals or the satisfaction of specified Service requirements or upon the expiration of a designated time period following the vesting of those awards or units, including (without limitation) a deferred distribution date following the termination of the Participant’s Service. However, the Plan Administrator may not impose a vesting schedule upon any stock issuance or other stock-based award made under the Stock Issuance Program which is more restrictive than twenty percent (20%) vesting per year of Service, with initial vesting to occur not later than the completion of one (1) year of Service measured from the date of such issuance or

 

10


award. Such limitation shall not apply to any Common Stock issuances made to the officers of the Corporation, non-employee Board members or independent consultants.

2.        Any new, substituted or additional securities or other property (including money paid other than as a regular cash dividend) which the Participant may have the right to receive with respect to the Participant’s unvested shares of Common Stock by reason of any stock dividend, stock split, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation’s receipt of consideration shall be issued subject to (i) the same vesting requirements applicable to the Participant’s unvested shares of Common Stock and (ii) such escrow arrangements as the Plan Administrator shall deem appropriate.

3.        The Participant shall have full stockholder rights with respect to any shares of Common Stock issued to the Participant under the Stock Issuance Program, whether or not the Participant’s interest in those shares is vested. Accordingly, the Participant shall have the right to vote such shares and to receive any regular cash dividends paid on such shares. However, dividend-equivalent units may be paid or credited, either in cash or in actual or phantom shares of Common Stock, on outstanding restricted stock unit or share right awards, subject to such terms and conditions as the Plan Administrator may deem appropriate.

4.        Should the Participant cease to remain in Service while holding one or more unvested shares of Common Stock issued under the Stock Issuance Program or should the performance objectives not be attained with respect to one or more such unvested shares of Common Stock, then those shares shall be immediately surrendered to the Corporation for cancellation, and the Participant shall have no further stockholder rights with respect to those shares. To the extent the surrendered shares were previously issued to the Participant for consideration paid in cash or cash equivalent (including the Participant’s purchase-money indebtedness), the Corporation shall repay to the Participant the lower of (i) the cash consideration paid for the surrendered shares or (ii) the Fair Market Value of those shares at the time of Participant’s cessation of Service and shall cancel the unpaid principal balance of any outstanding purchase-money note of the Participant attributable to such surrendered shares by the applicable clause (i) or (ii) amount.

5.        The Plan Administrator may in its discretion waive the surrender and cancellation of one or more unvested shares of Common Stock (or other assets attributable thereto) which would otherwise occur upon the non-completion of the vesting schedule applicable to those shares. Such waiver shall result in the immediate vesting of the Participant’s interest in the shares of Common Stock as to which the waiver applies. Such waiver may be effected at any time, whether before or after the Participant’s cessation of Service or the attainment or non-attainment of the applicable performance objectives.

6.        Outstanding share right awards or restricted stock units under the Stock Issuance Program shall automatically terminate, and no shares of Common Stock shall actually be issued in satisfaction of those awards or units, if the performance goals or Service requirements established for such awards or units are not attained or satisfied. The Plan Administrator, however, shall have the discretionary authority to issue vested shares of Common

 

11


Stock under one or more outstanding share right awards or restricted stock units as to which the designated performance goals or Service requirements have not been attained or satisfied.

C.         First Refusal Rights . Until such time as the Common Stock is first registered under Section 12 of the 1934 Act, the Corporation shall have the right of first refusal with respect to any proposed disposition by the Participant (or any successor in interest) of any shares of Common Stock issued under the Stock Issuance Program. Such right of first refusal shall be exercisable in accordance with the terms established by the Plan Administrator and set forth in the document evidencing such right.

 

 

II.

CHANGE IN CONTROL

A.        Upon the occurrence of a Change in Control, all outstanding repurchase rights under the Stock Issuance Program shall terminate automatically, and the shares of Common Stock subject to those terminated rights shall immediately vest in full, except to the extent: (i) those repurchase rights are assigned to the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction or (ii) such accelerated vesting is precluded by other limitations imposed by the Plan Administrator at the time the repurchase right is issued.

B.        Each outstanding restricted stock unit or share right award assumed in connection with a Change in Control or otherwise continued in effect shall be adjusted immediately after the consummation of that Change in Control so as to apply to the number and class of securities into which the shares of Common Stock subject to the award immediately prior to the Change in Control would have been converted in consummation of such Change in Control had those shares actually been outstanding at that time. To the extent the actual holders of the Corporation’s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption or continuation of the outstanding restricted stock units or share right awards, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control transaction. If any such restricted stock unit or share right award is not so assumed or otherwise continued in effect, or if such unit or award is not replaced with a cash incentive award which preserves the Fair Market Value of the Common Stock underlying that unit or award at the time of the Change in Control and provides for subsequent payout of the dollar amount in accordance with the vesting schedule in effect for such unit or award at the time of the Change in Control, then such unit or award shall vest, and the shares of Common Stock subject to such unit or award shall become issuable immediately prior to the consummation of the Change in Control.

C.        The Plan Administrator shall have the discretionary authority to structure one or more unvested stock issuances or one or more restricted stock unit or other share right awards under the Stock Issuance Program so that the shares of Common Stock subject to those issuances or awards shall automatically vest (or vest and become issuable) in whole or in part immediately upon the occurrence of a Change in Control or upon the subsequent termination of the Participant’s Service by reason of an Involuntary Termination within a designated period (not to exceed eighteen (18) months) following the effective date of that Change in Control transaction.

 

12


 

III.

SHARE ESCROW/LEGENDS

Unvested shares may, in the Plan Administrator’s discretion, be held in escrow by the Corporation until the Participant’s interest in such shares vests or may be issued directly to the Participant with restrictive legends on the certificates evidencing those unvested shares.

 

13


ARTICLE FOUR

MISCELLANEOUS

 

 

I.

FINANCING

The Plan Administrator may permit any Optionee or Participant to pay the option exercise price under the Option Grant Program or the purchase price for shares issued under the Stock Issuance Program by delivering a full-recourse promissory note payable in one or more installments which bears interest at a market rate and is secured by the purchased shares. In no event, however, may the maximum credit available to the Optionee or Participant exceed the sum of (i) the aggregate option exercise price or purchase price payable for the purchased shares plus (ii) any applicable income and employment tax liability incurred by the Optionee or the Participant in connection with the option exercise or share purchase.

 

 

II.

EFFECTIVE DATE AND TERM OF PLAN

A.        The Plan shall become effective when adopted by the Board, but no option granted under the Plan may be exercised, and no shares shall be issued under the Plan, until the Plan is approved by the Corporation’s stockholders. If such stockholder approval is not obtained within twelve (12) months after the date of the Board’s adoption of the Plan, then all options previously granted under the Plan shall terminate and cease to be outstanding, and no further options shall be granted and no shares shall be issued under the Plan. Subject to such limitation, the Plan Administrator may grant options and issue shares under the Plan at any time after the effective date of the Plan and before the date fixed herein for termination of the Plan.

B.        The Plan shall terminate upon the earliest of (i) the expiration of the ten (10)-year period measured from the date the Plan is adopted by the Board, (ii) the date on which all shares available for issuance under the Plan shall have been issued as vested shares or (iii) the termination of all outstanding options in connection with a Change in Control. All options and unvested stock issuances outstanding at the time of a clause (i) termination event shall continue to have full force and effect in accordance with the provisions of the documents evidencing those options or issuances.

 

 

III.

AMENDMENT OF THE PLAN

A.        The Board shall have complete and exclusive power and authority to amend or modify the Plan in any or all respects. However, no such amendment or modification shall adversely affect the rights and obligations with respect to options or unvested stock issuances at the time outstanding under the Plan unless the Optionee or the Participant consents to such amendment or modification. In addition, certain amendments may require stockholder approval pursuant to applicable laws and regulations.

B.        Options may be granted under the Option Grant Program and shares may be issued under the Stock Issuance Program which are in each instance in excess of the number of shares of Common Stock then available for issuance under the Plan, provided any excess shares actually issued under those programs shall be held in escrow until there is obtained stockholder approval of an amendment sufficiently increasing the number of shares of Common

 

14


Stock available for issuance under the Plan. If such stockholder approval is not obtained within twelve (12) months after the date the first such excess grants or issuances are made, then (i) any unexercised options granted on the basis of such excess shares shall terminate and cease to be outstanding and (ii) the Corporation shall promptly refund to the Optionees and the Participants the exercise or purchase price paid for any excess shares issued under the Plan and held in escrow, together with interest (at the applicable Short Term Federal Rate) for the period the shares were held in escrow, and such shares shall thereupon be automatically cancelled and cease to be outstanding.

 

 

IV.

USE OF PROCEEDS

Any cash proceeds received by the Corporation from the sale of shares of Common Stock under the Plan shall be used for general corporate purposes.

 

 

V.

WITHHOLDING

The Corporation’s obligation to deliver shares of Common Stock upon the exercise of any options granted under the Plan or upon the issuance or vesting of any shares issued under the Plan shall be subject to the satisfaction of all applicable income and employment tax withholding requirements.

 

 

VI.

REGULATORY APPROVALS

The implementation of the Plan, the granting of any options under the Plan and the issuance of any shares of Common Stock (i) upon the exercise of any option or (ii) under the Stock Issuance Program shall be subject to the Corporation’s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the options granted under it and the shares of Common Stock issued pursuant to it.

 

 

VII.

NO EMPLOYMENT OR SERVICE RIGHTS

Nothing in the Plan shall confer upon the Optionee or the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining such person) or of the Optionee or the Participant, which rights are hereby expressly reserved by each, to terminate such person’s Service at any time for any reason, with or without cause.

 

 

VIII.

FINANCIAL REPORTS

The Corporation shall deliver a balance sheet and an income statement at least annually to each individual holding an outstanding option under the Plan, unless such individual is a key Employee whose duties in connection with the Corporation (or any Parent or Subsidiary) assure such individual access to equivalent information.

 

15


APPENDIX

The following definitions shall be in effect under the Plan:

A.         Board shall mean the Corporation’s Board of Directors.

B.         Change in Control shall mean a change in ownership or control of the Corporation effected through any of the following transactions:

(i)        a merger, consolidation or other reorganization approved by the Corporation’s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction, or

(ii)        a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution of the Corporation, or

(iii)        the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders.

In no event shall any public offering of the Corporation’s securities be deemed to constitute a Change in Control.

C.         Code shall mean the Internal Revenue Code of 1986, as amended.

D.         Committee shall mean a committee of one (1) or more Board members appointed by the Board to exercise one or more administrative functions under the Plan.

E.         Common Stock shall mean the Corporation’s common stock.

F.         Corporation shall mean Amyris Biotechnologies, Inc., a California corporation, and any successor corporation to all or substantially all of the assets or voting stock of Amyris Biotechnologies, Inc. which shall by appropriate action adopt the Plan.

G.         Disability shall mean the inability of the Optionee or the Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment and shall be determined by the Plan Administrator on the basis of such medical evidence as the Plan Administrator deems warranted under the circumstances.

 

1


H.         Employee shall mean an individual who is in the employ of the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.

I.         Exercise Date shall mean the date on which the Corporation shall have received written notice of the option exercise.

J.         Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

(i)        If the Common Stock is at the time traded on the Nasdaq National Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers on the Nasdaq National Market and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(ii)        If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(iii)        If the Common Stock is at the time neither listed on any Stock Exchange nor traded on the Nasdaq National Market, then the Fair Market Value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate.

K.         Incentive Option shall mean an option which satisfies the requirements of Code Section 422.

L.         Involuntary Termination shall mean the termination of the Service of any individual which occurs by reason of:

(i)        such individual’s involuntary dismissal or discharge by the Corporation for reasons other than Misconduct, or

(ii)        such individual’s voluntary resignation following (A) a change in his or her position with the Corporation which materially reduces his or her duties and responsibilities or the level of management to which he or she reports, (B) a reduction in his or her level of compensation (including base salary, fringe benefits and target bonus under any corporate-performance based bonus or incentive programs) by more than fifteen percent (15%) or (C) a relocation of such individual’s place of employment by

 

A-2


more than fifty (50) miles, provided and only if such change, reduction or relocation is effected without the individual’s consent.

M.     Misconduct shall mean the commission of any act of fraud, embezzlement or dishonesty by the Optionee or Participant, any unauthorized use or disclosure by such person of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by such person adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in a material manner. The foregoing definition shall not in any way preclude or restrict the right of the Corporation (or any Parent or Subsidiary) to discharge or dismiss any Optionee, Participant or other person in the Service of the Corporation (or any Parent or Subsidiary) for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of the Plan, to constitute grounds for termination for Misconduct.

N.         1934 Act shall mean the Securities Exchange Act of 1934, as amended.

O.         Non-Statutory Option shall mean an option not intended to satisfy the requirements of Code Section 422.

P.         Option Grant Program shall mean the option grant program in effect under the Plan.

Q.         Optionee shall mean any person to whom an option is granted under the Plan.

R.         Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

S.         Participant shall mean any person who is issued shares of Common Stock under the Stock Issuance Program.

T.         Plan shall mean the Corporation’s 2005 Stock Option/Stock Issuance Plan, as set forth in this document.

U.         Plan Administrator shall mean either the Board or the Committee acting in its capacity as administrator of the Plan.

V.         Service shall mean the performance of services for the Corporation (or any Parent or Subsidiary, whether now existing or subsequently established) by a person in the capacity of an Employee, a non-employee member of the board of directors or a consultant or independent advisor, except to the extent otherwise specifically provided in the documents evidencing the option grant or stock issuance. For purposes of the Plan, an Optionee or Participant shall be deemed to cease Service immediately upon the occurrence of the either of the following events: (i) Optionee or Participant no longer performs services in any of the foregoing capacities for the Corporation or any Parent or Subsidiary or (ii) the entity for which Optionee or

 

A-3


Participant is performing such services ceases to remain a Parent or Subsidiary of the Corporation, even though the Optionee or Participant may subsequently continue to perform services for that entity. Service shall not be deemed to cease during a period of military leave, sick leave or other personal leave approved by the Corporation; provided, however , that for a leave which exceeds three (3) months, Service shall be deemed, for purposes of determining the period within which any outstanding option held by the Optionee in question may be exercised as an Incentive Option, to cease on the first day immediately following the expiration of such three (3)-month period, unless that Optionee is provided with the right to return to Service following such leave either by statute or by written contract. Except to the extent otherwise required by law or expressly authorized by the Plan Administrator, no Service credit shall be given for vesting purposes for any period the Optionee or Participant is on a leave of absence.

W.         Stock Exchange shall mean either the American Stock Exchange or the New York Stock Exchange.

X.         Stock Issuance Agreement shall mean the agreement entered into by the Corporation and the Participant at the time of issuance of shares of Common Stock under the Stock Issuance Program.

Y.         Stock Issuance Program shall mean the stock issuance program in effect under the Plan.

Z.         Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

AA.     10% Stockholder shall mean the owner of stock (as determined under Code Section 424(d)) possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Corporation (or any Parent or Subsidiary).

 

A-4

Exhibit 10.38

AMYRIS BIOTECHNOLOGIES, INC.

NOTICE OF GRANT OF STOCK OPTION

Notice is hereby given of the following option grant (the “Option”) to purchase shares of the Common Stock of Amyris Biotechnologies, Inc. (the “Corporation”):

Optionee : _______________________________________________________________________

Grant Date : ______________________________________________________________________

Vesting Commencement Date : ______________________________________________________

Exercise Price : $________________________ per share

Number of Option Shares : ________________ shares of Common Stock

Expiration Date : __________________________________________________________________

 

Type of Option :

  

_______   Incentive Stock Option

  

_______   Non-Statutory Stock Option

Date Exercisable : Immediately Exercisable

Vesting Schedule : The Option Shares shall initially be unvested and subject to repurchase by the Corporation at the lower of (i) the Exercise Price paid per share or (ii) the Fair Market Value per share at the time of Optionee’s cessation of Service. Optionee shall acquire a vested interest in, and the Corporation’s repurchase right shall accordingly lapse with respect to, (i) twenty percent (20%) of the Option Shares upon Optionee’s completion of one (1) year of Service measured from the Vesting Commencement Date and (ii) the balance of the Option Shares in a series of forty-eight (48) successive equal monthly installments upon Optionee’s completion of each additional month of Service over the forty-eight (48)-month period measured from the first anniversary of the Vesting Commencement Date. The Option shall not become exercisable for any additional Option Shares following the Optionee’s cessation of Service, except to the extent (if any) specifically authorized by the Plan Administrator in its sole discretion pursuant to an express written agreement with Optionee.

Optionee understands and agrees that the Option is granted subject to and in accordance with the terms of the Amyris Biotechnologies, Inc. 2005 Stock Option/Stock Issuance Plan (the “Plan”). Optionee further agrees to be bound by the terms of the Plan and the terms of the Option as set forth in the Stock Option Agreement attached hereto as Exhibit A. Optionee understands that any Option Shares purchased under the Option will be subject to the


terms set forth in the Stock Purchase Agreement attached hereto as Exhibit B. Optionee hereby acknowledges receipt of a copy of the Plan in the form attached hereto as Exhibit C.

REPURCHASE RIGHTS . OPTIONEE HEREBY AGREES THAT ALL OPTION SHARES ACQUIRED UPON THE EXERCISE OF THE OPTION SHALL BE SUBJECT TO CERTAIN REPURCHASE RIGHTS AND RIGHTS OF FIRST REFUSAL EXERCISABLE BY THE CORPORATION AND ITS ASSIGNS. THE TERMS OF SUCH RIGHTS ARE SPECIFIED IN THE ATTACHED STOCK PURCHASE AGREEMENT.

At Will Employment . Nothing in this Notice or in the attached Stock Option Agreement or Plan shall confer upon Optionee any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to terminate Optionee’s Service at any time for any reason, with or without cause.

Definitions . All capitalized terms in this Notice shall have the meaning assigned to them in this Notice or in the attached Stock Option Agreement.

DATED:                               ,             

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

   

Name:

   

Title:

   
   
  , OPTIONEE        

Address:  

   
   

Attachments :

Exhibit A - Stock Option Agreement

Exhibit B - Stock Purchase Agreement

Exhibit C - 2005 Stock Option/Stock Issuance Plan

 

2


EXHIBIT A

STOCK OPTION AGREEMENT


EXHIBIT B

STOCK PURCHASE AGREEMENT


EXHIBIT C

2005 STOCK OPTION/STOCK ISSUANCE PLAN

Exhibit 10.39

NON-EXEMPT EMPLOYEE

UNDER FAIR LABOR STANDARDS ACT

AMYRIS BIOTECHNOLOGIES, INC.

NOTICE OF GRANT OF STOCK OPTION

Notice is hereby given of the following option grant (the “Option”) to purchase shares of the Common Stock of Amyris Biotechnologies, Inc. (the “Corporation”):

Optionee :                                                                                                                                                                

Grant Date :                                                                                                                                                             

Vesting Commencement Date :                                                                                                                          

Exercise Price : $                                                           per share

Number of Option Shares :                                          shares of Common Stock

Expiration Date :                                                                                                                                                     

Type of Option:                  Incentive Stock Option

                 Non-Statutory Stock Option

Date Exercisable : The Option shall become exercisable for all the Option Shares upon the Optionee’s completion of six (6) months of Service measured from the Grant Date.

Vesting Schedule : The Option Shares shall initially be unvested and subject to repurchase by the Corporation at the lower of (i) the Exercise Price paid per share or (ii) the Fair Market Value per share at the time of Optionee’s cessation of Service. Optionee shall acquire a vested interest in, and the Corporation’s repurchase right shall accordingly lapse with respect to, (i) twenty percent (20%) of the Option Shares upon Optionee’s completion of one (1) year of Service measured from the Vesting Commencement Date and (ii) the balance of the Option Shares in a series of forty-eight (48) successive equal monthly installments upon Optionee’s completion of each additional month of Service over the forty-eight (48)-month period measured from the first anniversary of the Vesting Commencement Date. The Option shall not become exercisable for any additional Option Shares following the Optionee’s cessation of Service, except to the extent (if any) specifically authorized by the Plan Administrator in its sole discretion pursuant to an express written agreement with Optionee.


Optionee understands and agrees that the Option is granted subject to and in accordance with the terms of the Amyris Biotechnologies, Inc. 2005 Stock Option/Stock Issuance Plan (the “Plan”). Optionee further agrees to be bound by the terms of the Plan and the terms of the Option as set forth in the Stock Option Agreement attached hereto as Exhibit A. Optionee understands that any Option Shares purchased under the Option will be subject to the terms set forth in the Stock Purchase Agreement attached hereto as Exhibit B. Optionee hereby acknowledges receipt of a copy of the Plan in the form attached hereto as Exhibit C.

REPURCHASE RIGHTS . OPTIONEE HEREBY AGREES THAT ALL OPTION SHARES ACQUIRED UPON THE EXERCISE OF THE OPTION SHALL BE SUBJECT TO CERTAIN REPURCHASE RIGHTS AND RIGHTS OF FIRST REFUSAL EXERCISABLE BY THE CORPORATION AND ITS ASSIGNS. THE TERMS OF SUCH RIGHTS ARE SPECIFIED IN THE ATTACHED STOCK PURCHASE AGREEMENT.

At Will Employment . Nothing in this Notice or in the attached Stock Option Agreement or Plan shall confer upon Optionee any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to terminate Optionee’s Service at any time for any reason, with or without cause.

Definitions . All capitalized terms in this Notice shall have the meaning assigned to them in this Notice or in the attached Stock Option Agreement.

DATED :                              ,             

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

   

Name:

   

Title:

   
   
  , OPTIONEE        

Address:

   
   

Attachments :

Exhibit A - Stock Option Agreement

Exhibit B - Stock Purchase Agreement

Exhibit C - 2005 Stock Option/Stock Issuance Plan

 

2


EXHIBIT A

STOCK OPTION AGREEMENT


EXHIBIT B

STOCK PURCHASE AGREEMENT


EXHIBIT C

2005 STOCK OPTION/STOCK ISSUANCE PLAN

Exhibit 10.40

AMYRIS BIOTECHNOLOGIES, INC.

NOTICE OF GRANT OF STOCK OPTION

(FOR NON-U.S. EMPLOYEES)

Notice is hereby given of the following option grant (the “Option”) to purchase shares of the Common Stock of Amyris Biotechnologies, Inc. (the “Corporation”):

Optionee : [Insert]

Grant Date : [Insert]

Vesting Commencement Date : [Insert]

Exercise Price : US$[Insert] per share

Number of Option Shares : [Insert] shares of Common Stock

Expiration Date : [Insert]

Type of Option :                  Incentive Stock Option

          X       Non-Statutory Stock Option

Vesting Schedule : [Insert]. The Option shall not become exercisable for any additional Option Shares following the Optionee’s cessation of Service, except to the extent (if any) specifically authorized by the Plan Administrator in its sole discretion pursuant to an express written agreement with Optionee.

Optionee understands and agrees that the Option is granted subject to and in accordance with the terms of the Amyris Biotechnologies, Inc. 2005 Stock Option/Stock Issuance Plan (the “Plan”). Optionee further agrees to be bound by the terms of the Plan and the terms of the Option as set forth in the Stock Option Agreement, including the Appendices, attached hereto as Exhibit A. Optionee understands that any Option Shares purchased under the Option will be subject to the terms set forth in the Stock Purchase Agreement attached hereto as Exhibit B. Optionee hereby acknowledges receipt of a copy of the Plan in the form attached hereto as Exhibit C.

Employment . Nothing in this Notice or in the attached Stock Option Agreement or Plan shall confer upon Optionee any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to terminate Optionee’s Service at any time for any reason, with or without cause.


Definitions. All capitalized terms in this Notice shall have the meaning assigned to them in this Notice or in the attached Stock Option Agreement.

DATED : [Insert]

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

   

Name:

 

Tamara L. Tompkins

Title:

 

General Counsel & Secretary

   
 

[Insert], OPTIONEE

Address:  

   
   

Attachments :

Exhibit A - Stock Option Agreement, including the Appendices

Exhibit B - Stock Purchase Agreement

Exhibit C - 2005 Stock Option/Stock Issuance Plan

Exhibit 10.41

AMYRIS BIOTECHNOLOGIES, INC.

STOCK OPTION AGREEMENT

RECITALS

A.        The Board has adopted the Plan for the purpose of retaining the services of selected Employees, non-employee members of the Board or the board of directors of any Parent or Subsidiary and consultants and other independent advisors in the service of the Corporation (or any Parent or Subsidiary).

B.        Optionee is to render valuable services to the Corporation (or a Parent or Subsidiary), and this Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Corporation’s grant of an option to Optionee.

C.        All capitalized terms in this Agreement shall have the meaning assigned to them in the attached Appendix.

NOW, THEREFORE, it is hereby agreed as follows:

1.         Grant of Option .    The Corporation hereby grants to Optionee, as of the Grant Date, an option to purchase up to the number of Option Shares specified in the Grant Notice. The Option Shares shall be purchasable from time to time during the option term specified in Paragraph 2 at the Exercise Price.

2.         Option Term .    This option shall have a term of ten (10) years measured from the Grant Date and shall accordingly expire at the close of business on the Expiration Date, unless sooner terminated in accordance with Paragraph 5 or 6.

3.         Limited Transferability .

(a)        This option shall be neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee’s death and may be exercised, during Optionee’s lifetime, only by Optionee. However, Optionee may designate one or more persons as the beneficiary or beneficiaries of this option, and this option shall, in accordance with such designation, automatically be transferred to such beneficiary or beneficiaries upon the Optionee’s death while holding this option. Such beneficiary or beneficiaries shall take the transferred option subject to all the terms and conditions of this Agreement, including (without limitation) the limited time period during which this option may, pursuant to Paragraph 5, be exercised following Optionee’s death.

(b)        If this option is designated a Non-Statutory Option in the Grant Notice, then this option may be assigned in whole or in part during Optionee’s lifetime to one or more members of Optionee’s family or to a trust established for the exclusive benefit of Optionee and/or one or more such family members or to Optionee’s former spouse, to the extent such assignment is in connection with the Optionee’s estate plan or pursuant to a domestic


relations order. The assigned portion shall be exercisable only by the person or persons who acquire a proprietary interest in the option pursuant to such assignment. The terms applicable to the assigned portion shall be the same as those in effect for this option immediately prior to such assignment.

4.         Dates of Exercise .    This option shall become exercisable for the Option Shares in one or more installments as specified in the Grant Notice. As the option becomes exercisable for such installments, those installments shall accumulate, and the option shall remain exercisable for the accumulated installments until the Expiration Date or sooner termination of the option term under Paragraph 5 or 6.

5.         Cessation of Service .    The option term specified in Paragraph 2 shall terminate (and this option shall cease to be outstanding) prior to the Expiration Date should any of the following provisions become applicable:

(a)        Should Optionee cease to remain in Service for any reason (other than death, Disability or Misconduct) while this option is outstanding, then Optionee (or any person or persons to whom this option is transferred pursuant to a permitted transfer under Paragraph 3) shall have a period of three (3) months (commencing with the date of such cessation of Service) during which to exercise this option, but in no event shall this option be exercisable at any time after the Expiration Date.

(b)        Should Optionee die while this option is outstanding, then the personal representative of Optionee’s estate or the person or persons to whom the option is transferred pursuant to Optionee’s will or the laws of inheritance following Optionee’s death or to whom the option is transferred during Optionee’s lifetime pursuant to a permitted transfer under Paragraph 3 shall have the right to exercise this option. However, if Optionee dies while holding this option and has an effective beneficiary designation in effect for this option at the time of his or her death, then the designated beneficiary or beneficiaries shall have the exclusive right to exercise this option following Optionee’s death. Any such right to exercise this option shall lapse, and this option shall cease to be outstanding, upon the earlier of (i) the expiration of the twelve (12)-month period measured from the date of Optionee’s death or (ii) the Expiration Date.

(c) Should Optionee cease Service by reason of Disability while this option is outstanding, then Optionee (or any person or persons to whom this option is transferred pursuant to a permitted transfer under Paragraph 3) shall have a period of twelve (12) months (commencing with the date of such cessation of Service) during which to exercise this option. In no event shall this option be exercisable at any time after the Expiration Date.

Note :   Exercise of this option on a date later than three (3) months following cessation of Service due to Disability will result in loss of favorable Incentive Option treatment, unless such Disability constitutes Permanent Disability. In the event that Incentive Option treatment is not available, this option will be taxed as a Non-Statutory Option upon exercise.

 

2


(d)        During the limited period of post-Service exercisability, this option may not be exercised in the aggregate for more than the number of Option Shares in which Optionee is, at the time of Optionee’s cessation of Service, vested pursuant to the Vesting Schedule specified in the Grant Notice or the special vesting acceleration provisions of Paragraph 6. No additional Option Shares shall vest, whether pursuant to the normal Vesting Schedule specified in the Grant Notice or the special vesting acceleration provisions of Paragraph 6, following the Optionee’s cessation of Service, except to the extent (if any) specifically authorized by the Plan Administrator pursuant to an express written agreement with the Optionee. Upon the expiration of such limited exercise period or (if earlier) upon the Expiration Date, this option shall terminate and cease to be outstanding for any vested Option Shares for which the option has not been exercised.

(e)        Should Optionee’s Service be terminated for Misconduct or should Optionee otherwise engage in Misconduct while this option is outstanding, then this option shall terminate immediately and cease to remain outstanding.

6.         Change in Control .

(a)        Should a Change in Control occur during the Optionee’s period of Service, then the Option Shares at the time subject to this option but not otherwise vested shall automatically vest in full so that this option shall, immediately prior to the effective date of the Change in Control, become exercisable for all of the Option Shares as fully vested shares and may be exercised for any or all of those Option Shares as vested shares. However, the Option Shares shall not vest on such an accelerated basis if and to the extent: (i) this option is assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction and the Corporation’s repurchase rights with respect to the unvested Option Shares are assigned to such successor corporation (or parent thereof) or otherwise continued in effect or (ii) this option is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing on the unvested Option Shares at the time of the Change in Control (the excess of the Fair Market Value of those Option Shares over the Exercise Price payable for such shares) and provides for subsequent payout of that spread in accordance with the same Vesting Schedule applicable to those unvested Option Shares as set forth in the Grant Notice or (iii) such accelerated vesting is otherwise precluded pursuant to the provisions of Paragraph 5(d) above.

(b)        Immediately following the Change in Control, this option shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction.

(c)        If this option is assumed in connection with a Change in Control or otherwise continued in effect, then this option shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to Optionee in consummation of such Change in Control had the option been exercised immediately prior to such Change in Control, and appropriate adjustments shall also be made to the Exercise Price, provided the aggregate Exercise Price shall remain the same. To the extent

 

3


that the actual holders of the Corporation’s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption or continuation of this option, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control.

(d)        This Agreement shall not in any way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

7.         Adjustment in Option Shares .    Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation’s receipt of consideration, appropriate adjustments shall be made to (i) the total number and/or class of securities subject to this option and (ii) the Exercise Price in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.

8.         Stockholder Rights .    The holder of this option shall not have any stockholder rights with respect to the Option Shares until such person shall have exercised the option, paid the Exercise Price and become the record holder of the purchased shares.

9.         Manner of Exercising Option .

(a)        In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable, Optionee (or any other person or persons exercising the option) must take the following actions:

(i)        Execute and deliver to the Corporation a Purchase Agreement for the Option Shares for which the option is exercised.

(ii)        Pay the aggregate Exercise Price for the purchased shares in one or more of the following forms:

(A)        cash or check made payable to the Corporation; or

(B)        a promissory note payable to the Corporation, but only to the extent authorized by the Plan Administrator in accordance with Paragraph 14.

Should the Common Stock be registered under Section 12 of the 1934 Act at the time the option is exercised, then the Exercise Price may also be paid as follows:

 

4


(C)        in shares of Common Stock held by Optionee (or any other person or persons exercising the option) for the requisite period necessary to avoid a charge to the Corporation’s earnings for financial reporting purposes and valued at Fair Market Value on the Exercise Date; or

(D)        to the extent the option is exercised for vested Option Shares, through a special sale and remittance procedure pursuant to which Optionee (or any other person or persons exercising the option) shall concurrently provide irrevocable instructions (a) to a brokerage firm (reasonably satisfactory to the Corporation for purposes of administering such procedure in compliance with any applicable pre-clearance or pre-notification requirements) to effect the immediate sale of the purchased shares and remit to the Corporation, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate Exercise Price payable for the purchased shares plus all applicable income and employment taxes required to be withheld by the Corporation by reason of such exercise and (b) to the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm on such settlement date in order to complete the sale.

Except to the extent the sale and remittance procedure is utilized in connection with the option exercise, payment of the Exercise Price must accompany the Purchase Agreement delivered to the Corporation in connection with the option exercise.

(iii)        Furnish to the Corporation appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option.

(iv)        Execute and deliver to the Corporation such written representations as may be requested by the Corporation in order for it to comply with the applicable requirements of applicable securities laws.

(v)        Make appropriate arrangements with the Corporation (or Parent or Subsidiary employing or retaining Optionee) for the satisfaction of all applicable income and employment tax withholding requirements applicable to the option exercise.

(b)        As soon as practical after the Exercise Date, the Corporation shall issue to or on behalf of Optionee (or any other person or persons exercising this option) a certificate for the purchased Option Shares, with the appropriate legends affixed thereto.

(c)        In no event may this option be exercised for any fractional shares.

 

5


10.         REPURCHASE RIGHTS .    ALL OPTION SHARES ACQUIRED UPON THE EXERCISE OF THIS OPTION SHALL BE SUBJECT TO CERTAIN RIGHTS OF THE CORPORATION AND ITS ASSIGNS TO REPURCHASE THOSE SHARES IN ACCORDANCE WITH THE TERMS SPECIFIED IN THE PURCHASE AGREEMENT.

11.         Compliance with Laws and Regulations .

(a)        The exercise of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Corporation and Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange (or the Nasdaq National Market, if applicable) on which the Common Stock may be listed for trading at the time of such exercise and issuance.

(b)        The inability of the Corporation to obtain approval from any regulatory body having authority deemed by the Corporation to be necessary to the lawful issuance and sale of any Common Stock pursuant to this option shall relieve the Corporation of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Corporation, however, shall use its best efforts to obtain all such approvals.

12.         Successors and Assigns .    Except to the extent otherwise provided in Paragraphs 3 and 6, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and Optionee, Optionee’s assigns and the legal representatives, heirs and legatees of Optionee’s estate.

13.         Notices .    Any notice required to be given or delivered to the Corporation under the terms of this Agreement shall be in writing and addressed to the Corporation at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed to Optionee at the address indicated below Optionee’s signature line on the Grant Notice. All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.

14.         Financing .    The Plan Administrator may, in its absolute discretion and without any obligation to do so, permit Optionee to pay the Exercise Price for the purchased Option Shares by delivering a full-recourse promissory note bearing interest at a market rate and secured by those Option Shares. The payment schedule in effect for any such promissory note shall be established by the Plan Administrator in its sole discretion.

15.         Construction .    This Agreement and the option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. All decisions of the Plan Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in this option.

 

6


16.         Governing Law . The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of California without resort to that State’s conflict-of-laws rules.

17.         Stockholder Approval . If the Option Shares covered by this Agreement exceed, as of the Grant Date, the number of shares of Common Stock which may be issued under the Plan as last approved by the stockholders, then this option shall be void with respect to such excess shares, unless stockholder approval of an amendment sufficiently increasing the number of shares of Common Stock issuable under the Plan is obtained in accordance with the provisions of the Plan.

18.         Additional Terms Applicable to an Incentive Option . In the event this option is designated an Incentive Option in the Grant Notice, the following terms and conditions shall also apply to the grant:

(a)        This option shall cease to qualify for favorable tax treatment as an Incentive Option if (and to the extent) this option is exercised for one or more Option Shares: (i) more than three (3) months after the date Optionee ceases to be an Employee for any reason other than death or Permanent Disability or (ii) more than twelve (12) months after the date Optionee ceases to be an Employee by reason of Permanent Disability.

(b)        This option shall not become exercisable in the calendar year in which granted if (and to the extent) the aggregate Fair Market Value (determined at the Grant Date) of the Common Stock for which this option would otherwise first become exercisable in such calendar year would, when added to the aggregate value (determined as of the respective date or dates of grant) of the Common Stock and any other securities for which one or more other Incentive Options granted to Optionee prior to the Grant Date (whether under the Plan or any other option plan of the Corporation or any Parent or Subsidiary) first become exercisable during the same calendar year, exceed One Hundred Thousand Dollars ($100,000) in the aggregate. To the extent the exercisability of this option is deferred by reason of the foregoing limitation, the deferred portion shall become exercisable in the first calendar year or years thereafter in which the One Hundred Thousand Dollar ($100,000) limitation of this Paragraph 18(b) would not be contravened, but such deferral shall in all events end immediately prior to the effective date of a Change in Control in which this option is not to be assumed or otherwise continued in effect, whereupon the option shall become immediately exercisable as a Non-Statutory Option for the deferred portion of the Option Shares.

(c)        Should Optionee hold, in addition to this option, one or more other options to purchase Common Stock which become exercisable for the first time in the same calendar year as this option, then for purposes of the foregoing limitations on the exercisability of such options as Incentive Options, this option and each of those other options shall be deemed to become first exercisable in that calendar year on the basis of the chronological order in which they were granted, except to the extent otherwise provided under applicable law or regulation.

 

7


APPENDIX

The following definitions shall be in effect under the Agreement:

A.         Agreement shall mean this Stock Option Agreement.

B.         Board shall mean the Corporation’s Board of Directors.

C.         Change in Control shall mean a change in ownership or control of the Corporation effected through any of the following transactions:

(i)        a merger, consolidation or other reorganization approved by the Corporation’s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction, or

(ii)        a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution of the Corporation, or

(iii)        the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders.

In no event shall any public offering of the Corporation’s securities be deemed to constitute a Change in Control.

D.         Code shall mean the Internal Revenue Code of 1986, as amended.

E.         Common Stock shall mean the Corporation’s common stock.

F.         Corporation shall mean Amyris Biotechnologies, Inc., a California corporation, and any successor corporation to all or substantially all of the assets or voting stock of Amyris Biotechnologies, Inc. which shall by appropriate action assume this option.

 

A-1


G.         Disability shall mean the inability of Optionee to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment and shall be determined by the Plan Administrator on the basis of such medical evidence as the Plan Administrator deems warranted under the circumstances. Disability shall be deemed to constitute Permanent Disability in the event that such Disability is expected to result in death or has lasted or can be expected to last for a continuous period of twelve (12) months or more.

H.     Employee shall mean an individual who is in the employ of the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.

I.     Exercise Date shall mean the date on which the option shall have been exercised in accordance with Paragraph 9 of the Agreement.

J.     Exercise Price shall mean the exercise price payable per Option Share as specified in the Grant Notice.

K.     Expiration Date shall mean the date on which the option expires as specified in the Grant Notice.

L.     Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

(i)        If the Common Stock is at the time traded on the Nasdaq National Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as the price is reported by the National Association of Securities Dealers on the Nasdaq National Market and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(ii)        If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(iii)        If the Common Stock is at the time neither listed on any Stock Exchange nor traded on the Nasdaq National Market, then the Fair Market Value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate.

 

A-2


M.         Grant Date shall mean the date of grant of the option as specified in the Grant Notice.

N.         Grant Notice shall mean the Notice of Grant of Stock Option accompanying the Agreement, pursuant to which Optionee has been informed of the basic terms of the option evidenced hereby.

O.         Incentive Option shall mean an option which satisfies the requirements of Code Section 422.

P.         Misconduct shall mean the commission of any act of fraud, embezzlement or dishonesty by Optionee, any unauthorized use or disclosure by Optionee of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by Optionee adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in a material manner. The foregoing definition shall not in any way preclude or restrict the right of the Corporation (or any Parent or Subsidiary) to discharge or dismiss Optionee or any other person in the Service of the Corporation (or any Parent or Subsidiary) for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of the Plan or this Agreement, to constitute grounds for termination for Misconduct.

Q.         1934 Act shall mean the Securities Exchange Act of 1934, as amended.

R.         Non-Statutory Option shall mean an option not intended to satisfy the requirements of Code Section 422.

S.         Option Shares shall mean the number of shares of Common Stock subject to the option.

T.         Optionee shall mean the person to whom the option is granted as specified in the Grant Notice.

U.         Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

V.         Plan shall mean the Corporation’s 2005 Stock Option/Stock Issuance Plan.

W.         Plan Administrator shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan.

X.         Purchase Agreement shall mean the stock purchase agreement in substantially the form of Exhibit B to the Grant Notice.

 

A-3


Y.         Service shall mean the Optionee’s performance of services for the Corporation (or any Parent or Subsidiary, whether now existing or subsequently established) in the capacity of an Employee, a non-employee member of the board of directors or a consultant or independent advisor. For purposes of this Agreement, Optionee shall be deemed to cease Service immediately upon the occurrence of the either of the following events: (i) Optionee no longer performs services in any of the foregoing capacities for the Corporation or any Parent or Subsidiary or (ii) the entity for which Optionee is performing such services ceases to remain a Parent or Subsidiary of the Corporation, even though the Optionee may subsequently continue to perform services for that entity. Service shall not be deemed to cease during a period of military leave, sick leave or other personal leave approved by the Corporation; provided, however , that should such leave of absence exceed three (3) months, then for purposes of determining the period within which the Option (if designated as an Incentive Option in the Grant Notice) may be exercised as such an Incentive Option under the federal tax laws, the Optionee’s Service shall be deemed to cease on the first day immediately following the expiration of such three (3)-month period, unless Optionee is provided with the right to return to Service following such leave either by statute or by written contract. Except to the extent otherwise required by law or expressly authorized by the Plan Administrator, no Service credit shall be given for vesting purposes for any period the Optionee is on a leave of absence.

Z.         Stock Exchange shall mean the American Stock Exchange or the New York Stock Exchange.

AA.         Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

BB.         Vesting Schedule shall mean the vesting schedule specified in the Grant Notice pursuant to which the Optionee is to vest in the Option Shares in a series of installments over his or her period of Service.

 

A-4

Exhibit 10.42

AMYRIS BIOTECHNOLOGIES, INC.

STOCK OPTION AGREEMENT

(FOR NON-U.S. EMPLOYEES)

RECITALS

A.        The Board has adopted the Plan for the purpose of rewarding selected Employees, non-employee members of the Board or the board of directors of any Parent or Subsidiary and consultants and other independent advisors in the service of the Corporation (or any Parent or Subsidiary).

B.        This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Corporation’s grant of an option to Optionee.

C.        All capitalized terms in this Agreement shall have the meaning assigned to them in the attached Appendix A.

NOW, THEREFORE , it is hereby agreed as follows:

1.         Grant of Option . The Corporation hereby grants to Optionee, as of the Grant Date, an option to purchase up to the number of Option Shares specified in the Grant Notice. The Option Shares shall be purchasable from time to time during the option term specified in Paragraph 2 at the Exercise Price and as set forth in the Grant Notice.

2.         Option Term . This option shall have a term of ten (10) years measured from the Grant Date and shall accordingly expire at the close of business on the Expiration Date, unless sooner terminated in accordance with Paragraph 5 or 6.

3.         Limited Transferability . This option shall be neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee’s death and may be exercised, during Optionee’s lifetime, only by Optionee.

4.         Dates of Exercise . This option shall become exercisable for the Option Shares in one or more installments as specified in the Grant Notice. As the option becomes exercisable for such installments, those installments shall accumulate, and the option shall remain exercisable for the accumulated installments until the Expiration Date or sooner termination of the option term under Paragraph 5 or 6.

5.         Cessation of Service . The option term specified in Paragraph 2 shall terminate (and this option shall cease to be outstanding) prior to the Expiration Date should any of the following provisions become applicable:


(a)        Should Optionee cease to remain in Service for any reason (other than death, Disability or Misconduct) while this option is outstanding, then Optionee shall have a period of three (3) months (commencing with the date of such cessation of Service) during which to exercise this option, but in no event shall this option be exercisable at any time after the Expiration Date.

(b)        Should Optionee die while this option is outstanding, then the personal representative of Optionee’s estate or the person or persons to whom the option is transferred pursuant to Optionee’s will or the laws of inheritance following Optionee’s death shall have the right to exercise this option. Any such right to exercise this option shall lapse, and this option shall cease to be outstanding, upon the earlier of (i) the expiration of the twelve (12)-month period measured from the date of Optionee’s death or (ii) the Expiration Date.

(c)        Should Optionee cease Service by reason of Disability while this option is outstanding, then Optionee shall have a period of twelve (12) months (commencing with the date of such cessation of Service) during which to exercise this option. In no event shall this option be exercisable at any time after the Expiration Date.

   Note : Exercise of this option on a date later than three (3) months following cessation of Service due to Disability will result in loss of favorable Incentive Option treatment, unless such Disability constitutes Permanent Disability. In the event that Incentive Option treatment is not available, this option will be taxed as a Non-Statutory Option upon exercise.

(d)        During the limited period of post-Service exercisability, this option may not be exercised in the aggregate for more than the number of Option Shares in which Optionee is, at the time of Optionee’s cessation of Service, vested pursuant to the Vesting Schedule specified in the Grant Notice or the special vesting acceleration provisions of Paragraph 6. No additional Option Shares shall vest, whether pursuant to the normal Vesting Schedule specified in the Grant Notice or the special vesting acceleration provisions of Paragraph 6, following the Optionee’s cessation of Service, except to the extent (if any) specifically authorized by the Plan Administrator pursuant to an express written agreement with the Optionee. Upon the expiration of such limited exercise period or (if earlier) upon the Expiration Date, this option shall terminate and cease to be outstanding for any vested Option Shares for which the option has not been exercised.

(e)        Should Optionee’s Service be terminated for Misconduct or should Optionee otherwise engage in Misconduct while this option is outstanding, then this option shall terminate immediately and cease to remain outstanding.

6.           Change in Control .

(a)        Should a Change in Control occur during the Optionee’s period of Service, then the Option Shares at the time subject to this option but not otherwise vested shall automatically vest in full so that this option shall, immediately prior to the effective date of the

 

2


Change in Control, become exercisable for all of the Option Shares as fully vested shares and may be exercised for any or all of those Option Shares as vested shares. However, the Option Shares shall not vest on such an accelerated basis if and to the extent: (i) this option is assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction and the Corporation’s repurchase rights with respect to the unvested Option Shares are assigned to such successor corporation (or parent thereof) or otherwise continued in effect or (ii) this option is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing on the unvested Option Shares at the time of the Change in Control (the excess of the Fair Market Value of those Option Shares over the Exercise Price payable for such shares) and provides for subsequent payout of that spread in accordance with the same Vesting Schedule applicable to those unvested Option Shares as set forth in the Grant Notice or (iii) such accelerated vesting is otherwise precluded pursuant to the provisions of Paragraph 5(d) above.

(b)        Immediately following the Change in Control, this option shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction.

(c)        If this option is assumed in connection with a Change in Control or otherwise continued in effect, then this option shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to Optionee in consummation of such Change in Control had the option been exercised immediately prior to such Change in Control, and appropriate adjustments shall also be made to the Exercise Price, provided the aggregate Exercise Price shall remain the same. To the extent that the actual holders of the Corporation’s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption or continuation of this option, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control.

(d)        This Agreement shall not in any way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

7.           Adjustment in Option Shares . Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation’s receipt of consideration, appropriate adjustments shall be made to (i) the total number and/or class of securities subject to this option and (ii) the Exercise Price in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.

 

3


8.           Stockholder Rights . The holder of this option shall not have any stockholder rights with respect to the Option Shares until such person shall have exercised the option, paid the Exercise Price and become the record holder of the purchased shares.

9.           Manner of Exercising Option .

(a)      In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable, Optionee (or any other person or persons exercising the option) must take the following actions:

(i)        Execute and deliver to the Corporation a Purchase Agreement for the Option Shares for which the option is exercised.

(ii)        Pay the aggregate Exercise Price for the purchased shares in one or more of the following forms:

(A)        cash or check made payable to the Corporation; or

(B)        a promissory note payable to the Corporation, but only to the extent authorized by the Plan Administrator in accordance with Paragraph 24.

Should the Common Stock be registered under Section 12 of the 1934 Act at the time the option is exercised, then the Exercise Price may also be paid as follows:

(C)        to the extent the option is exercised for vested Option Shares, through a special sale and remittance procedure pursuant to which Optionee (or any other person or persons exercising the option) shall concurrently provide irrevocable instructions (a) to a brokerage firm (reasonably satisfactory to the Corporation for purposes of administering such procedure in compliance with any applicable pre-clearance or pre-notification requirements) to effect the immediate sale of the purchased shares and remit to the Corporation, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate Exercise Price payable for the purchased shares plus all Tax-Related Items, and (b) to the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm on such settlement date in order to complete the sale.

Except to the extent the sale and remittance procedure is utilized in connection with the option exercise, payment of the Exercise Price must accompany the Purchase Agreement delivered to the Corporation in connection with the option exercise.

 

4


(iii)        Furnish to the Corporation appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option.

(iv)        Execute and deliver to the Corporation such written representations as may be requested by the Corporation in order for it to comply with the applicable requirements of applicable securities laws.

(v)        Make appropriate arrangements with the Corporation (or Parent or Subsidiary employing or retaining Optionee) for the satisfaction of all Tax-Related Items (as defined below).

(b)      As soon as practical after the Exercise Date, the Corporation shall issue to or on behalf of Optionee (or any other person or persons exercising this option) a certificate for the purchased Option Shares, with the appropriate legends affixed thereto.

(c)      In no event may this option be exercised for any fractional shares.

10.           Responsibility for Taxes . Regardless of any action the Corporation or Optionee’s Employer takes with respect to any or all Tax-Related Items, Optionee acknowledges that the ultimate liability for all Tax-Related Items is and remains Optionee’s responsibility and may exceed the amount actually withheld by the Corporation or the Employer. Optionee further acknowledges that the Corporation and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the option, including, but not limited to, the grant, vesting or exercise of the option, the subsequent sale of shares of Option Shares acquired pursuant to such exercise and the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the option to reduce or eliminate Optionee’s liability for Tax-Related Items or achieve any particular tax result. Further, if Optionee has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, Optionee acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

Prior to the relevant taxable or tax withholding event, as applicable, Optionee will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer to satisfy all Tax-Related Items. In this regard, Optionee authorizes the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (i) withholding from Optionee’s wages or other cash compensation paid to Optionee by the Corporation and/or the Employer; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at exercise of the Option either through a voluntary sale or through a mandatory sale arranged by the Corporation (on Optionee’s behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued at exercise of the Option.

To avoid any negative accounting treatment, the Corporation may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or

 

5


other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, Optionee is deemed to have been issued the full number of shares of Common Stock subject to the exercised Options, notwithstanding that a number of the shares of Common Stock are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of Optionee’s participation in the Plan.

Finally, Optionee shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of Optionee’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the shares or the proceeds of the sale of shares of Common Stock if Optionee fails to comply with Optionee’s obligations in connection with the Tax-Related Items.

11.           Nature of Grant . In accepting the option, Optionee acknowledges, understands and agrees that:

(a)        the Plan is established voluntarily by the Corporation, it is discretionary in nature, and may be amended, suspended or terminated by the Corporation at any time;

(b)        the grant of the option is voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted repeatedly in the past;

(c)        all decisions with respect to future option grants, if any, will be at the sole discretion of the Corporation;

(d)        Optionee is voluntarily participating in the Plan;

(e)        the option and any Option Shares are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Corporation or the Employer, and are outside the scope of Optionee’s employment contract, if any;

(f)        the option and any Option Shares are not intended to replace any pension rights or compensation;

(g)        the option and Option Shares are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Corporation, the Employer, or any Subsidiary of the Corporation;

 

6


(h)        the option grant and Optionee’s participation in the Plan will not be interpreted to form an employment contract or relationship with the Corporation or any Subsidiary of the Corporation;

(i)        the future value of the shares of Common Stock underlying the option is unknown and cannot be predicted with certainty;

(j)        if the underlying shares of Common Stock do not increase in value, the option will have no value;

(k)        if Optionee exercises the option and acquires Option Shares, the value of such Option Shares may increase or decrease in value, even below the Exercise Price;

(l)        no claim or entitlement to compensation or damages shall arise from forfeiture of the option resulting from termination of Optionee’s employment by the Corporation or the Employer (for any reason whatsoever and whether or not in breach of local labor laws) and in consideration of the grant of the option to which Optionee is otherwise not entitled, Optionee irrevocably agrees never to institute any claim against the Corporation or the Employer, waives his or her ability, if any, to bring any such claim, and releases the Corporation and the Employer from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Optionee shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claims;

(m)        if Optionee is an Employee, in the event of termination of Optionee’s employment (whether or not in breach of local labor laws), Optionee’s right to vest in the option under the Plan, if any, will terminate effective as of the date that Optionee is no longer actively providing Services and will not be extended by any notice period mandated under local law ( e.g. , active employment would not include a period of “garden leave” or similar period pursuant to local law); the Board shall have the exclusive discretion to determine when Optionee is no longer actively providing Services for purposes of Optionee’s option grant; and

(n)        the option and the benefits under the Plan, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability.

12.           No Advice Regarding Grant . The Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding Optionee’s participation in the Plan or Optionee’s acquisition or sale of the Option Shares. Optionee is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.

13.           Data Privacy . Optionee hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Optionee’s personal data as described in this Agreement and any other option grant materials by and among, as applicable,

 

7


the Employer, the Corporation and its Subsidiaries for the exclusive purpose of implementing, administering and managing Optionee’s participation in the Plan.

Optionee understands that the Corporation and the Employer may hold certain personal information about Optionee, including, but not limited to, Optionee’s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Corporation, details of all options or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in Optionee’s favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”).

Optionee understands that Data will be transferred to a stock plan service provider as may be selected by the Corporation in the future to assist the Corporation with the implementation, administration and management of the Plan. Optionee understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipient’s country (e.g., the United States) may have different data privacy laws and protections than Optionee’s country. Optionee understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting Optionee’s local human resources representative. Optionee authorizes the Employer, Corporation, any such stock plan service provider and any other possible recipients which may assist the Corporation (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purpose of implementing, administering and managing his or her participation in the Plan. Optionee understands that Data will be held only as long as is necessary to implement, administer and manage Optionee’s participation in the Plan. Optionee understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative. Optionee understands, however, that refusing or withdrawing his or her consent may affect Optionee’s ability to participate in the Plan. For more information on the consequences of Optionee’s refusal to consent or withdrawal of consent, Optionee understands that he or she may contact his or her local human resources representative.

14.         Governing Law . The option grant and the interpretation, performance and enforcement of this Agreement, the Grant Notice, the Purchase Agreement and any other document related to the Option and/or the Plan are governed by, and subject to, the laws of the State of California, without regard to the conflict of law provisions, as provided in the Plan. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or the Agreement, the Grant Notice, the Purchase Agreement or any other document related to the Option and/or the Plan, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of Alameda County , California, or the federal courts for the United States for the Northern District of California, and no other courts, where this grant is made and/or to be performed.

 

8


15.           Electronic Delivery . The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Optionee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.

16.           Language . If Optionee has received this Agreement, or any other document related to the option and/or the Plan translated into a language other than English and if the translated version is different than the English version, the English version will control.

17.           Severability . The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

18.           Appendix B . The option shall be subject to any special provisions set forth in the attached Appendix B for Optionee’s country of residence, if any. If Optionee relocates to one of the countries included in Appendix B during the life of the option, the special provisions for such country shall apply to Optionee, to the extent the Corporation determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan. Appendix B constitutes part of this Agreement.

19.           Imposition of Other Requirements . The Corporation reserves the right to impose other requirements on the option and the Option Shares to the extent the Corporation determines it is necessary or advisable in order to comply with local laws or facilitate the administration of the Plan, and to require Optionee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

20.           REPURCHASE RIGHTS . ALL OPTION SHARES ACQUIRED UPON THE EXERCISE OF THIS OPTION SHALL BE SUBJECT TO CERTAIN RIGHTS OF THE CORPORATION AND ITS ASSIGNS TO REPURCHASE THOSE SHARES IN ACCORDANCE WITH THE TERMS SPECIFIED IN THE PURCHASE AGREEMENT.

21.           Compliance with Laws and Regulations .

(a)        The exercise of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Corporation and Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange (or the Nasdaq National Market, if applicable) on which the Common Stock may be listed for trading at the time of such exercise and issuance.

(b)        The inability of the Corporation to obtain approval from any regulatory body having authority deemed by the Corporation to be necessary to the lawful issuance and sale of any Common Stock pursuant to this option shall relieve the Corporation of any liability with respect to the non-issuance or sale of the Common Stock as to which such

 

9


approval shall not have been obtained. The Corporation, however, shall use its best efforts to obtain all such approvals.

22.           Successors and Assigns . Except to the extent otherwise provided in Paragraph 6, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and Optionee, Optionee’s legal representatives, and heirs and legatees of Optionee’s estate.

23.           Notices . Any notice required to be given or delivered to the Corporation under the terms of this Agreement shall be in writing and addressed to the Corporation at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed to Optionee at the address indicated below Optionee’s signature line on the Grant Notice. All notices shall be deemed effective upon personal delivery or upon deposit in the post office, postage prepaid and properly addressed to the party to be notified.

24.           Financing . The Plan Administrator may, in its absolute discretion and without any obligation to do so, permit Optionee to pay the Exercise Price for the purchased Option Shares by delivering a full-recourse promissory note bearing interest at a market rate and secured by those Option Shares. The payment schedule in effect for any such promissory note shall be established by the Plan Administrator in its sole discretion.

25.           Construction . This Agreement and the option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. All decisions of the Plan Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in this option.

26.           Stockholder Approval . If the Option Shares covered by this Agreement exceed, as of the Grant Date, the number of shares of Common Stock which may be issued under the Plan as last approved by the stockholders, then this option shall be void with respect to such excess shares, unless stockholder approval of an amendment sufficiently increasing the number of shares of Common Stock issuable under the Plan is obtained in accordance with the provisions of the Plan.

27.           Additional Terms Applicable to an Incentive Option (For U.S. Taxpayers) . In the event this option is designated an Incentive Option in the Grant Notice, the following terms and conditions shall also apply to the grant:

(a)        This option shall cease to qualify for favorable tax treatment as an Incentive Option if (and to the extent) this option is exercised for one or more Option Shares: (i) more than three (3) months after the date Optionee ceases to be an Employee for any reason other than death or Permanent Disability or (ii) more than twelve (12) months after the date Optionee ceases to be an Employee by reason of Permanent Disability.

(b)        This option shall not become exercisable in the calendar year in which granted if (and to the extent) the aggregate Fair Market Value (determined at the Grant

 

10


Date) of the Common Stock for which this option would otherwise first become exercisable in such calendar year would, when added to the aggregate value (determined as of the respective date or dates of grant) of the Common Stock and any other securities for which one or more other Incentive Options granted to Optionee prior to the Grant Date (whether under the Plan or any other option plan of the Corporation or any Parent or Subsidiary) first become exercisable during the same calendar year, exceed One Hundred Thousand Dollars ($100,000) in the aggregate. To the extent the exercisability of this option is deferred by reason of the foregoing limitation, the deferred portion shall become exercisable in the first calendar year or years thereafter in which the One Hundred Thousand Dollar ($100,000) limitation of this Paragraph 27(b) would not be contravened, but such deferral shall in all events end immediately prior to the effective date of a Change in Control in which this option is not to be assumed or otherwise continued in effect, whereupon the option shall become immediately exercisable as a Non-Statutory Option for the deferred portion of the Option Shares.

(c)        Should Optionee hold, in addition to this option, one or more other options to purchase Common Stock which become exercisable for the first time in the same calendar year as this option, then for purposes of the foregoing limitations on the exercisability of such options as Incentive Options, this option and each of those other options shall be deemed to become first exercisable in that calendar year on the basis of the chronological order in which they were granted, except to the extent otherwise provided under applicable law or regulation.

 

11


APPENDIX A

The following definitions shall be in effect under the Agreement:

A.         Agreement shall mean this Stock Option Agreement.

B.         Board shall mean the Corporation’s Board of Directors.

C.         Change in Control shall mean a change in ownership or control of the Corporation effected through any of the following transactions:

(i)        a merger, consolidation or other reorganization approved by the Corporation’s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction, or

(ii)        a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution of the Corporation, or

(iii)        the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders.

In no event shall any public offering of the Corporation’s securities be deemed to constitute a Change in Control.

D.         Code shall mean the U.S. Internal Revenue Code of 1986, as amended.

E.         Common Stock shall mean the Corporation’s common stock.

F.         Corporation shall mean Amyris Biotechnologies, Inc., a California corporation, and any successor corporation to all or substantially all of the assets or voting stock of Amyris Biotechnologies, Inc. which shall by appropriate action assume this option.

G.         Disability shall mean the inability of Optionee to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment and shall be determined by the Plan Administrator on the basis of such medical evidence as the Plan Administrator deems warranted under the circumstances. Disability shall be

 

A-1


deemed to constitute Permanent Disability in the event that such Disability is expected to result in death or has lasted or can be expected to last for a continuous period of tw.elve (12) months or more.

H.         Employee shall mean an individual who is in the employ of the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.

I.         Employer shall mean Optionee’s employer.

J.         Exercise Date shall mean the date on which the option shall have been exercised in accordance with Paragraph 9 of the Agreement.

K.         Exercise Price shall mean the exercise price payable per Option Share as specified in the Grant Notice.

L.         Expiration Date shall mean the date on which the option expires as specified in the Grant Notice.

M.         Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

(i)        If the Common Stock is at the time traded on the Nasdaq National Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as the price is reported by the National Association of Securities Dealers on the Nasdaq National Market and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(ii)        If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(iii)        If the Common Stock is at the time neither listed on any Stock Exchange nor traded on the Nasdaq National Market, then the Fair Market Value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate.

N.         Grant Date shall mean the date of grant of the option as specified in the Grant Notice.

 

A-2


O.         Grant Notice shall mean the Notice of Grant of Stock Option accompanying the Agreement, pursuant to which Optionee has been informed of the basic terms of the option evidenced hereby.

P.         Incentive Option shall mean an option which satisfies the requirements of Code Section 422.

Q.         Misconduct shall mean the commission of any act of fraud, embezzlement or dishonesty by Optionee, any unauthorized use or disclosure by Optionee of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by Optionee adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in a material manner. The foregoing definition shall not in any way preclude or restrict the right of the Corporation (or any Parent or Subsidiary) to discharge or dismiss Optionee or any other person in the Service of the Corporation (or any Parent or Subsidiary) for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of the Plan or this Agreement, to constitute grounds for termination for Misconduct.

R.         1934 Act shall mean the U.S. Securities Exchange Act of 1934, as amended.

S.         Non-Statutory Option shall mean an option not intended to satisfy the requirements of Code Section 422.

T.         Option Shares shall mean the number of shares of Common Stock subject to the option.

U.         Optionee shall mean the person to whom the option is granted as specified in the Grant Notice.

V.         Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

W.         Plan shall mean the Corporation’s 2005 Stock Option/Stock Issuance Plan.

X.         Plan Administrator shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan.

Y.         Purchase Agreement shall mean the stock purchase agreement in substantially the form of Exhibit B to the Grant Notice.

Z.         Service shall mean the Optionee’s performance of services for the Corporation (or any Parent or Subsidiary, whether now existing or subsequently established) in

 

A-3


the capacity of an Employee, a non-employee member of the board of directors or a consultant or independent advisor. For purposes of this Agreement, Optionee shall be deemed to cease Service immediately upon the occurrence of either of the following events: (i) Optionee no longer actively performs services in any of the foregoing capacities for the Corporation or any Parent or Subsidiary or (ii) the entity for which Optionee is performing such services ceases to remain a Parent or Subsidiary of the Corporation, even though the Optionee may subsequently continue to perform services for that entity. Service shall not be deemed to cease during a period of military leave, sick leave or other personal leave approved by the Corporation; provided, however , that should such leave of absence exceed three (3) months, then for purposes of determining the period within which the Option (if designated as an Incentive Option in the Grant Notice) may be exercised as such an Incentive Option under the federal tax laws, the Optionee’s Service shall be deemed to cease on the first day immediately following the expiration of such three (3)-month period, unless Optionee is provided with the right to return to Service following such leave either by statute or by written contract. Except to the extent otherwise required by law or expressly authorized by the Plan Administrator, no Service credit shall be given for vesting purposes for any period the Optionee is on a leave of absence.

AA.         Stock Exchange shall mean the American Stock Exchange or the New York Stock Exchange.

BB.         Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

CC.         Tax-Related Items shall mean any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to Optionee’s participation in the Plan and legally applicable to Optionee.

DD.         Vesting Schedule shall mean the vesting schedule specified in the Grant Notice pursuant to which the Optionee is to vest in the Option Shares in a series of installments over his or her period of Service.

 

A-4


APPENDIX B TO

AMYRIS BIOTECHNOLOGIES, INC.

STOCK OPTION AGREEMENT

(FOR NON-U.S. EMPLOYEES)

Terms and Conditions

This Appendix B includes additional terms and conditions that govern the options granted to Optionee under the Plan if Optionee resides in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix B have the meanings set forth in the Plan and/or the Agreement.

Notifications

This Appendix B also includes information regarding exchange controls and certain other issues of which Optionee should be aware with respect to Optionee’s participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of December 2009. Such laws are often complex and change frequently. As a result, the Corporation strongly recommends that Optionee not rely on the information in this Appendix B as the only source of information relating to the consequences of Optionee’s participation in the Plan because the information may be out of date at the time that Optionee exercises the Option or sells Option Shares acquired under the Plan.

In addition, the information contained herein is general in nature and may not apply to Optionee’s particular situation and the Corporation is not in a position to assure Optionee of any particular result. Accordingly, Optionee is advised to seek appropriate professional advice as to how the relevant laws in Optionee’s country may apply to Optionee’s situation.

Finally, if Optionee is a citizen or resident of a country other than the one in which Optionee is currently working, the information contained herein may not be applicable to Optionee.

BRAZIL

Terms and Conditions

Compliance with Law.  By accepting the option, Optionee acknowledges his or her agreement to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the exercise of the option, the receipt of any dividends, and the sale of Option Shares acquired under the Plan.

Exhibit 10.43

AMYRIS BIOTECHNOLOGIES, INC.

STOCK PURCHASE AGREEMENT

AGREEMENT made this              day of                                      ,              by and between Amyris Biotechnologies, Inc., a California corporation, and                                               , Optionee under the Corporation’s 2005 Stock Option/Stock Issuance Plan.

All capitalized terms in this Agreement shall have the meaning assigned to them in this Agreement or in the attached Appendix.

 

 

A.

EXERCISE OF OPTION

1.         Exercise .   Optionee hereby purchases              shares of Common Stock (the “Purchased Shares”) pursuant to that certain option (the “Option”) granted Optionee on                                  ,              (the “Grant Date”) to purchase up to                      shares of Common Stock (the “Option Shares”) under the Plan at the exercise price of $                      per share (the “Exercise Price”).

2.         Payment . Concurrently with the delivery of this Agreement to the Corporation, Optionee shall pay the Exercise Price for the Purchased Shares in accordance with the provisions of the Option Agreement and shall deliver whatever additional documents may be required by the Option Agreement as a condition for exercise, together with a duly-executed blank Assignment Separate from Certificate (in the form attached hereto as Exhibit I) with respect to the Purchased Shares.

3.         Stockholder Rights .   Until such time as the Corporation exercises the Repurchase Right or the First Refusal Right, Optionee (or any successor in interest) shall have all the rights of a stockholder (including voting, dividend and liquidation rights) with respect to the Purchased Shares, subject, however, to the transfer restrictions of Articles B and C.

 

 

B.

SECURITIES LAW COMPLIANCE

1.         Restricted Securities .   The Purchased Shares have not been registered under the 1933 Act and are being issued to Optionee in reliance upon the exemption from such registration provided by SEC Rule 701 for stock issuances under compensatory benefit plans such as the Plan. Optionee hereby confirms that Optionee has been informed that the Purchased Shares are restricted securities under the 1933 Act and may not be resold or transferred unless the Purchased Shares are first registered under the Federal securities laws or unless an exemption from such registration is available. Accordingly, Optionee hereby acknowledges that Optionee is acquiring the Purchased Shares for investment purposes only and not with a view to resale and is prepared to hold the Purchased Shares for an indefinite period and that Optionee is aware that SEC Rule 144 issued under the 1933 Act which exempts certain resales of unrestricted securities is not presently available to exempt the resale of the Purchased Shares from the registration requirements of the 1933 Act.


2.       Restrictions on Disposition of Purchased Shares .   Optionee shall make no disposition of the Purchased Shares (other than a Permitted Transfer) unless and until there is compliance with all of the following requirements:

(i)        Optionee shall have provided the Corporation with a written summary of the terms and conditions of the proposed disposition.

(ii)       Optionee shall have complied with all requirements of this Agreement applicable to the disposition of the Purchased Shares.

(iii)      Optionee shall have provided the Corporation with written assurances, in form and substance satisfactory to the Corporation, that (a) the proposed disposition does not require registration of the Purchased Shares under the 1933 Act or (b) all appropriate action necessary for compliance with the registration requirements of the 1933 Act or any exemption from registration available under the 1933 Act (including Rule 144) has been taken.

The Corporation shall not be required (i) to transfer on its books any Purchased Shares which have been sold or transferred in violation of the provisions of this Agreement or (ii) to treat as the owner of the Purchased Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom the Purchased Shares have been transferred in contravention of this Agreement.

3.       Restrictive Legends .   The stock certificates for the Purchased Shares shall be endorsed with one or more of the following restrictive legends:

“The shares represented by this certificate have not been registered under the Securities Act of 1933. The shares may not be sold or offered for sale in the absence of (a) an effective registration statement for the shares under such Act, (b) a ‘no action’ letter of the Securities and Exchange Commission with respect to such sale or offer or (c) satisfactory assurances to the Corporation that registration under such Act is not required with respect to such sale or offer.”

“The shares represented by this certificate are subject to certain repurchase rights and rights of first refusal granted to the Corporation and accordingly may not be sold, assigned, transferred, encumbered, or in any manner disposed of except in conformity with the terms of a written agreement dated                      , 20      between the Corporation and the registered holder of the shares (or the predecessor in interest to the shares). A copy of such agreement is maintained at the Corporation’s principal corporate offices.”

 

2


 

C.

TRANSFER RESTRICTIONS

1.       Restriction on Transfer .   Except for any Permitted Transfer, Optionee shall not transfer, assign, encumber or otherwise dispose of any of the Purchased Shares which are subject to the Repurchase Right. In addition, Purchased Shares which are released from the Repurchase Right shall not be transferred, assigned, encumbered or otherwise disposed of in contravention of the First Refusal Right or the Market Stand-Off.

2.       Transferee Obligations .   Each person (other than the Corporation) to whom the Purchased Shares are transferred by means of a Permitted Transfer must, as a condition precedent to the validity of such transfer, acknowledge in writing to the Corporation that such person is bound by the provisions of this Agreement and that the transferred shares are subject to (i) the Repurchase Right, (ii) the First Refusal Right and (iii) the Market Stand-Off, to the same extent such shares would be so subject if retained by Optionee.

3.       Market Stand-Off .

(a)        In connection with any underwritten public offering by the Corporation of its equity securities pursuant to an effective registration statement filed under the 1933 Act, including the Corporation’s initial public offering, Owner shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to, any Purchased Shares without the prior written consent of the Corporation or its underwriters. Such restriction (the “Market Stand-Off”) shall be in effect for such period of time from and after the effective date of the final prospectus for the offering as may be requested by the Corporation or such underwriters. In no event, however, shall such period exceed one hundred eighty (180) days, and the Market Stand-Off shall in no event be applicable to any underwritten public offering effected more than two (2) years after the effective date of the Corporation’s initial public offering.

(b)        Owner shall be subject to the Market Stand-Off provided and only if the officers and directors of the Corporation are also subject to similar restrictions.

(c)        Any new, substituted or additional securities which are by reason of any Recapitalization or Reorganization distributed with respect to the Purchased Shares shall be immediately subject to the Market Stand-Off, to the same extent the Purchased Shares are at such time covered by such provisions.

(d)        In order to enforce the Market Stand-Off, the Corporation may impose stop-transfer instructions with respect to the Purchased Shares until the end of the applicable stand-off period.

 

3


 

D.

REPURCHASE RIGHT

1.       Grant .   The Corporation is hereby granted the right (the “Repurchase Right”), exercisable at any time during the sixty (60)-day period following the date Optionee ceases for any reason to remain in Service or (if later) during the sixty (60)-day period following the execution date of this Agreement, to repurchase at the Repurchase Price any or all of the Purchased Shares in which Optionee is not, at the time of his or her cessation of Service, vested in accordance with the Vesting Schedule applicable to those shares or the special vesting acceleration provisions of Paragraph D.6 of this Agreement (such shares to be hereinafter referred to as the “Unvested Shares”).

2.       Exercise of the Repurchase Right .   The Repurchase Right shall be exercisable by written notice delivered to each Owner of the Unvested Shares prior to the expiration of the sixty (60)-day exercise period. The notice shall indicate the number of Unvested Shares to be repurchased, the Repurchase Price to be paid per share and the date on which the repurchase is to be effected, such date to be not more than thirty (30) days after the date of such notice. The certificates representing the Unvested Shares to be repurchased shall be delivered to the Corporation on the closing date specified for the repurchase. Concurrently with the receipt of such stock certificates, the Corporation shall pay to Owner, in cash or cash equivalents (including the cancellation of any purchase-money indebtedness), an amount equal to the Repurchase Price for the Unvested Shares which are to be repurchased from Owner.

3.       Termination of the Repurchase Right .   The Repurchase Right shall terminate with respect to any Unvested Shares for which it is not timely exercised under Paragraph D.2. In addition, the Repurchase Right shall terminate and cease to be exercisable with respect to any and all Purchased Shares in which Optionee vests in accordance with the Vesting Schedule. All Purchased Shares as to which the Repurchase Right lapses shall, however, remain subject to (i) the First Refusal Right and (ii) the Market Stand-Off.

4.       Aggregate Vesting Limitation .   If the Option is exercised in more than one increment so that Optionee is a party to one or more other Stock Purchase Agreements (the “Prior Purchase Agreements”) which are executed prior to the date of this Agreement, then the total number of Purchased Shares as to which Optionee shall be deemed to have a fully-vested interest under this Agreement and all Prior Purchase Agreements shall not exceed in the aggregate the number of Purchased Shares in which Optionee would otherwise at the time be vested, in accordance with the Vesting Schedule, had all the Purchased Shares (including those acquired under the Prior Purchase Agreements) been acquired exclusively under this Agreement.

5.       Recapitalization .   Any new, substituted or additional securities or other property (including cash paid other than as a regular cash dividend) which is by reason of any Recapitalization distributed with respect to the Purchased Shares shall be immediately subject to the Repurchase Right and any escrow requirements hereunder, but only to the extent the Purchased Shares are at the time covered by such right or escrow requirements. Appropriate adjustments to reflect such distribution shall be made to the number and/or class of Purchased

 

4


Shares subject to this Agreement and to the Repurchase Price per share to be paid upon the exercise of the Repurchase Right in order to reflect the effect of any such Recapitalization upon the Corporation’s capital structure; provided, however, that the aggregate Repurchase Price shall remain the same.

6.       Change in Control .

(a)        The Repurchase Right shall automatically terminate in its entirety, and all the Purchased Shares shall vest in full, immediately prior to the consummation of any Change in Control, except to the extent the Repurchase Right is to be assigned to the successor entity in such Change in Control or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction.

(b)        To the extent the Repurchase Right remains in effect following a Change in Control, such right shall apply to any new securities or other property (including any cash payments) received in exchange for the Purchased Shares in consummation of the Change in Control, but only to the extent the Purchased Shares are at the time covered by such right. Appropriate adjustments shall be made to the Repurchase Price per share payable upon exercise of the Repurchase Right to reflect the effect (if any) of the Change in Control upon the Corporation’s capital structure; provided , however, that the aggregate Repurchase Price shall remain the same. The new securities or other property (including any cash payments) issued or distributed with respect to the Purchased Shares in consummation of the Change in Control shall be immediately deposited in escrow with the Corporation (or the successor entity) and shall not be released from escrow until Optionee vests in such securities or other property in accordance with the same Vesting Schedule in effect for the Purchased Shares.

 

 

E.

RIGHT OF FIRST REFUSAL

1.       Grant .   The Corporation is hereby granted the right of first refusal (the “First Refusal Right”), exercisable in connection with any proposed transfer of the Purchased Shares in which Optionee has vested in accordance with the provisions of Article D. For purposes of this Article E, the term “transfer” shall include any sale, assignment, pledge, encumbrance or other disposition of the Purchased Shares intended to be made by Owner, but shall not include any Permitted Transfer.

2.       Notice of Intended Disposition .   In the event any Owner of Purchased Shares in which Optionee has vested desires to accept a bona fide third-party offer for the transfer of any or all of such shares (the Purchased Shares subject to such offer to be hereinafter referred to as the “Target Shares”), Owner shall promptly (i) deliver to the Corporation written notice (the “Disposition Notice”) of the terms of the offer, including the purchase price and the identity of the third-party offeror, and (ii) provide satisfactory proof that the disposition of the Target Shares to such third-party offeror would not be in contravention of the provisions set forth in Articles B and C.

 

5


3.       Exercise of the First Refusal Right .   The Corporation shall, for a period of twenty-five (25) days following receipt of the Disposition Notice, have the right to repurchase any or all of the Target Shares subject to the Disposition Notice upon the same terms as those specified therein or upon such other terms (not materially different from those specified in the Disposition Notice) to which Owner consents. Such right shall be exercisable by delivery of written notice (the “Exercise Notice”) to Owner prior to the expiration of the twenty-five (25)-day exercise period. If such right is exercised with respect to all the Target Shares, then the Corporation shall effect the repurchase of such shares, including payment of the purchase price, not more than five (5) business days after delivery of the Exercise Notice; and at such time the certificates representing the Target Shares shall be delivered to the Corporation.

Should the purchase price specified in the Disposition Notice be payable in property other than cash or evidences of indebtedness, the Corporation shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property. If Owner and the Corporation cannot agree on such cash value within ten (10) days after the Corporation’s receipt of the Disposition Notice, the valuation shall be made by an appraiser of recognized standing selected by Owner and the Corporation or, if they cannot agree on an appraiser within twenty (20) days after the Corporation’s receipt of the Disposition Notice, each shall select an appraiser of recognized standing and the two (2) appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by Owner and the Corporation. The closing shall then be held on the later of (i) the fifth (5th) business day following delivery of the Exercise Notice or (ii) the fifth (5th) business day after such valuation shall have been made.

4.       Non-Exercise of the First Refusal Right .   In the event the Exercise Notice is not given to Owner prior to the expiration of the twenty-five (25)-day exercise period, Owner shall have a period of thirty (30) days thereafter in which to sell or otherwise dispose of the Target Shares to the third-party offeror identified in the Disposition Notice upon terms (including the purchase price) no more favorable to such third-party offeror than those specified in the Disposition Notice; provided, however, that any such sale or disposition must not be effected in contravention of the provisions of Articles B and C. The third-party offeror shall acquire the Target Shares subject to the First Refusal Right and the provisions and restrictions of Article B and Paragraph C.3, and any subsequent disposition of the acquired shares must be effected in compliance with the terms and conditions of such First Refusal Right and the provisions and restrictions of Article B and Paragraph C.3. In the event Owner does not effect such sale or disposition of the Target Shares within the specified thirty (30)-day period, the First Refusal Right shall continue to be applicable to any subsequent disposition of the Target Shares by Owner until such right lapses.

5.       Partial Exercise of the First Refusal Right .   In the event the Corporation makes a timely exercise of the First Refusal Right with respect to a portion, but not all, of the Target Shares specified in the Disposition Notice, Owner shall have the option, exercisable by written notice to the Corporation delivered within five (5) business days after Owner’s receipt of the Exercise Notice, to effect the sale of the Target Shares pursuant to either of the following alternatives:

 

6


(i)        sale or other disposition of all the Target Shares to the third-party offeror identified in the Disposition Notice, but in full compliance with the requirements of Paragraph E.4, as if the Corporation did not exercise the First Refusal Right; or

(ii)        sale to the Corporation of the portion of the Target Shares which the Corporation has elected to purchase, such sale to be effected in substantial conformity with the provisions of Paragraph E.3. The First Refusal Right shall continue to be applicable to any subsequent disposition of the remaining Target Shares until such right lapses.

Owner’s failure to deliver timely notification to the Corporation shall be deemed to be an election by Owner to sell the Target Shares pursuant to alternative (i) above.

6.       Recapitalization/Reorganization .

(a)        Any new, substituted or additional securities or other property which is by reason of any Recapitalization distributed with respect to the Purchased Shares shall be immediately subject to the First Refusal Right, but only to the extent the Purchased Shares are at the time covered by such right.

(b)        In the event of a Reorganization, the First Refusal Right shall remain in full force and effect and shall apply to the new capital stock or other property received in exchange for the Purchased Shares in consummation of the Reorganization, but only to the extent the Purchased Shares are at the time covered by such right.

7.       Lapse .   The First Refusal Right shall lapse upon the earliest to occur of (i) the first date on which shares of the Common Stock are held of record by more than five hundred (500) persons, (ii) a determination made by the Board that a public market exists for the outstanding shares of Common Stock or (iii) a firm commitment underwritten public offering, pursuant to an effective registration statement under the 1933 Act, covering the offer and sale of the Common Stock in the aggregate amount of at least twenty million dollars ($20,000,000). However, the Market Stand-Off shall continue to remain in full force and effect following the lapse of the First Refusal Right.

 

 

F.

SPECIAL TAX ELECTION

The acquisition of the Purchased Shares may result in adverse tax consequences which may be avoided or mitigated by filing an election under Code Section 83(b). Such election must be filed within thirty (30) days after the date of this Agreement. A description of the tax consequences applicable to the acquisition of the Purchased Shares and the form for making the Code Section 83(b) election are set forth in Exhibit II. OPTIONEE SHOULD CONSULT WITH HIS OR HER TAX ADVISOR TO DETERMINE THE TAX CONSEQUENCES OF ACQUIRING THE PURCHASED SHARES AND THE ADVANTAGES AND DISADVANTAGES OF FILING THE CODE SECTION 83(b) ELECTION. OPTIONEE ACKNOWLEDGES THAT IT IS OPTIONEE’S SOLE

 

7


RESPONSIBILITY, AND NOT THE CORPORATION’S, TO FILE A TIMELY ELECTION UNDER CODE SECTION 83(b), EVEN IF OPTIONEE REQUESTS THE CORPORATION OR ITS REPRESENTATIVES TO MAKE THIS FILING ON HIS OR HER BEHALF.

 

 

G.

GENERAL PROVISIONS

1.       Assignment .   The Corporation may assign the Repurchase Right and/or the First Refusal Right to any person or entity selected by the Board, including (without limitation) one or more stockholders of the Corporation.

2.       At Will Employment .   Nothing in this Agreement or in the Plan shall confer upon Optionee any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to terminate Optionee’s Service at any time for any reason, with or without cause.

3.       Notices .   Any notice required to be given under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, registered or certified, postage prepaid and properly addressed to the party entitled to such notice at the address indicated below such party’s signature line on this Agreement or at such other address as such party may designate by ten (10) days advance written notice under this paragraph to all other parties to this Agreement.

4.       No Waiver .   The failure of the Corporation in any instance to exercise the Repurchase Right or the First Refusal Right shall not constitute a waiver of any other repurchase rights and/or rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Corporation and Optionee. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

5.       Cancellation of Shares .   If the Corporation shall make available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Purchased Shares to be repurchased in accordance with the provisions of this Agreement, then from and after such time, the person from whom such shares are to be repurchased shall no longer have any rights as a holder of such shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such shares shall be deemed purchased in accordance with the applicable provisions hereof, and the Corporation shall be deemed the owner and holder of such shares, whether or not the certificates therefor have been delivered as required by this Agreement.

 

8


 

H.

MISCELLANEOUS PROVISIONS

1.       Optionee Undertaking .   Optionee hereby agrees to take whatever additional action and execute whatever additional documents the Corporation may deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on either Optionee or the Purchased Shares pursuant to the provisions of this Agreement.

2.       Agreement is Entire Contract .   This Agreement constitutes the entire contract between the parties hereto with regard to the subject matter hereof. This Agreement is made pursuant to the provisions of the Plan and shall in all respects be construed in conformity with the terms of the Plan.

3.       Governing Law .   This Agreement shall be governed by, and construed in accordance with, the laws of the State of California without resort to that State’s conflict-of-laws rules.

4.       Counterparts .   This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

5.       Successors and Assigns .   The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and upon Optionee, Optionee’s permitted assigns and the legal representatives, heirs and legatees of Optionee’s estate, whether or not any such person shall have become a party to this Agreement and have agreed in writing to join herein and be bound by the terms hereof.

 

9


IN WITNESS WHEREOF , the parties have executed this Agreement on the day and year first indicated above.

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

   

Name:

   

Title:

   

Address:

   
   
   
          , OPTIONEE

Address:

   
   
 

 

10


SPOUSAL ACKNOWLEDGMENT

The undersigned spouse of Optionee has read and hereby approves the foregoing Stock Purchase Agreement. In consideration of the Corporation’s granting Optionee the right to acquire the Purchased Shares in accordance with the terms of such Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of such Agreement, including (without limitation) the right of the Corporation (or its assigns) to purchase any Purchased Shares in which Optionee is not vested at time of his or her cessation of Service.

 

   
 

OPTIONEE’S SPOUSE

Address:

   
   
 


EXHIBIT I

ASSIGNMENT SEPARATE FROM CERTIFICATE

FOR VALUE RECEIVED                              hereby sell(s), assign(s) and transfer(s) unto Amyris Biotechnologies, Inc. (the “Corporation”),                      (              ) shares of the Common Stock of the Corporation standing in his or her name on the books of the Corporation represented by Certificate No.                      herewith and do(es) hereby irrevocably constitute and appoint                              Attorney to transfer the said stock on the books of the Corporation with full power of substitution in the premises.

Dated:                             

Signature                                                              

Instruction : Please do not fill in any blanks other than the signature line. Please sign exactly as you would like your name to appear on the issued stock certificate. The purpose of this assignment is to enable the Corporation to exercise the Repurchase Right without requiring additional signatures on the part of Optionee.


EXHIBIT II

FEDERAL INCOME TAX CONSEQUENCES AND

SECTION 83(b) TAX ELECTION

I.         Federal Income Tax Consequences and Section 83(b) Election For Exercise of Non-Statutory Option . If the Purchased Shares are acquired pursuant to the exercise of a Non-Statutory Option, as specified in the Grant Notice, then under Code Section 83, the excess of the Fair Market Value of the Purchased Shares on the date any forfeiture restrictions applicable to such shares lapse over the Exercise Price paid for those shares will be reportable as ordinary income on the lapse date. For this purpose, the term “forfeiture restrictions” includes the right of the Corporation to repurchase the Purchased Shares pursuant to the Repurchase Right. However, Optionee may elect under Code Section 83(b) to be taxed at the time the Purchased Shares are acquired, rather than when and as such Purchased Shares cease to be subject to such forfeiture restrictions. Such election must be filed with the Internal Revenue Service within thirty (30) days after the date of the Agreement. Even if the Fair Market Value of the Purchased Shares on the date of the Agreement equals the Exercise Price paid (and thus no tax is payable), the election must be made to avoid adverse tax consequences in the future. The form for making this election is attached as part of this exhibit. FAILURE TO MAKE THIS FILING WITHIN THE APPLICABLE THIRTY (30)-DAY PERIOD WILL RESULT IN THE RECOGNITION OF ORDINARY INCOME BY OPTIONEE AS THE FORFEITURE RESTRICTIONS LAPSE.

II.         Federal Income Tax Consequences and Conditional Section 83(b) Election For Exercise of Incentive Option . If the Purchased Shares are acquired pursuant to the exercise of an Incentive Option, as specified in the Grant Notice, then the following tax principles shall be applicable to the Purchased Shares:

(i)        For regular tax purposes, no taxable income will be recognized at the time the Option is exercised.

(ii)       The excess of (a) the Fair Market Value of the Purchased Shares on the date the Option is exercised or (if later) on the date any forfeiture restrictions applicable to the Purchased Shares lapse over (b) the Exercise Price paid for the Purchased Shares will be includible in Optionee’s taxable income for alternative minimum tax purposes.

(iii)      If Optionee makes a disqualifying disposition of the Purchased Shares, then Optionee will recognize ordinary income in the year of such disposition equal in amount to the excess of (a) the Fair Market Value of the Purchased Shares on the date the Option is exercised or (if later) on the date any forfeiture restrictions applicable to the Purchased Shares lapse over (b) the Exercise Price paid for the Purchased Shares. Any additional gain recognized upon the disqualifying disposition will be either short-term or long-term capital gain depending upon the period for which the Purchased Shares are held prior to the disposition.


(iv)        For purposes of the foregoing, the term “forfeiture restrictions” will include the right of the Corporation to repurchase the Purchased Shares pursuant to the Repurchase Right. The term “disqualifying disposition” means any sale or other disposition 1 of the Purchased Shares within two (2) years after the Grant Date or within one (1) year after the exercise date of the Option.

(v)        The Code Section 83(b) election will be effective in limiting the Optionee’s alternative minimum taxable income to the excess of the Fair Market Value of the Purchased Shares at the time the Option is exercised over the Exercise Price paid for those shares.

Page 2 of the attached form for making the election should be filed with any election made in connection with the exercise of an Incentive Option.

 

 

1 Generally, a disposition of shares purchased under an Incentive Option includes any transfer of legal title, including a transfer by sale, exchange or gift, but does not include a transfer to the Optionee’s spouse, a transfer into joint ownership with right of survivorship if Optionee remains one of the joint owners, a pledge, a transfer by bequest or inheritance or certain tax-free exchanges permitted under the Code.

 

2


SECTION 83(b) ELECTION

This statement is being made under Section 83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section 1.83-2.

 

(1)

The taxpayer who performed the services is:

Name:

Address:

Taxpayer Ident. No.:

 

(2)

The property with respect to which the election is being made is                      shares of the common stock of Amyris Biotechnologies, Inc.

 

(3)

The property was issued on                      ,              .

 

(4)

The taxable year in which the election is being made is the calendar year              .

 

(5)

The property is subject to a repurchase right pursuant to which the issuer has the right to acquire the property at the lower of the purchase price paid per share or the fair market value per share, if for any reason taxpayer’s service with the issuer terminates. The issuer’s repurchase right will lapse in a series of annual and monthly installments over a five (5)-year period ending on                      , 20__.

 

(6)

The fair market value at the time of transfer (determined without regard to any restriction other than a restriction which by its terms will never lapse) is $                      per share.

 

(7)

The amount paid for such property is $                      per share.

 

(8)

A copy of this statement was furnished to Amyris Biotechnologies, Inc. for whom taxpayer rendered the services underlying the transfer of property.

 

(9)

This statement is executed on                              ,              .

 

           

Spouse (if any)

   

Taxpayer

This election must be filed with the Internal Revenue Service Center with which taxpayer files his or her Federal income tax returns and must be made within thirty (30) days after the execution date of the Stock Purchase Agreement. This filing should be made by registered or certified mail, return receipt requested. Optionee must retain two (2) copies of the completed form for filing with his or her Federal and state tax returns for the current tax year and an additional copy for his or her records.


The property described in the above Section 83(b) election is comprised of shares of common stock acquired pursuant to the exercise of an incentive stock option under Section 422 of the Internal Revenue Code (the “Code”). Accordingly, the purpose of this election is to have the alternative minimum taxable income attributable to the purchased shares measured by the amount by which the fair market value of such shares at the time of their transfer to the Taxpayer exceeds the purchase price paid for the shares. In the absence of this election, such alternative minimum taxable income would be measured by the spread between the fair market value of the purchased shares and the purchase price which exists on the various lapse dates in effect for the forfeiture restrictions applicable to such shares.

THIS PAGE 2 IS TO BE ATTACHED TO ANY SECTION 83(b) ELECTION FILED IN CONNECTION WITH THE EXERCISE OF AN INCENTIVE STOCK OPTION UNDER THE FEDERAL TAX LAWS.

 

2


APPENDIX

The following definitions shall be in effect under the Agreement:

A.         Agreement shall mean this Stock Purchase Agreement.

B.         Board shall mean the Corporation’s Board of Directors.

C.         Change in Control shall mean a change in ownership or control of the Corporation effected through any of the following transactions:

  (i)        a merger, consolidation or other reorganization approved by the Corporation’s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction, or

  (ii)      a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution of the Corporation, or

  (iii)     the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders.

In no event shall any public offering of the Corporation’s securities be deemed to constitute a Change in Control.

D.         Code shall mean the Internal Revenue Code of 1986, as amended.

E.         Common Stock shall mean the Corporation’s common stock.

F.         Corporation shall mean Amyris Biotechnologies, Inc., a California corporation, and any successor corporation to all or substantially all of the assets or voting stock of Amyris Biotechnologies, Inc. which shall by appropriate action adopt the Plan.

G.         Disposition Notice shall have the meaning assigned to such term in Paragraph E.2.

 

A-1


H.       Exercise Price shall have the meaning assigned to such term in Paragraph A.1.

I.         Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

(i)        If the Common Stock is at the time traded on the Nasdaq National Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers on the Nasdaq National Market and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(ii)      If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(iii)     If the Common Stock is at the time neither listed on any Stock Exchange nor traded on the Nasdaq National Market, then the Fair Market Value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate.

J.         First Refusal Right shall mean the right granted to the Corporation in accordance with Article E.

K.         Grant Date shall have the meaning assigned to such term in Paragraph A.1.

L.         Grant Notice shall mean the Notice of Grant of Stock Option pursuant to which Optionee has been informed of the basic terms of the Option.

M.        Incentive Option shall mean an option which satisfies the requirements of Code Section 422.

N.         Market Stand-Off shall mean the market stand-off restriction specified in Paragraph C.3.

O.         1933 Act shall mean the Securities Act of 1933, as amended.

P.         1934 Act shall mean the Securities Exchange Act of 1934, as amended.

 

A-2


Q.         Non-Statutory Option shall mean an option not intended to satisfy the requirements of Code Section 422.

R.         Option shall have the meaning assigned to such term in Paragraph A.1.

S.         Option Agreement shall mean all agreements and other documents evidencing the Option.

T.         Optionee shall mean the person to whom the Option is granted under the Plan.

U.         Owner shall mean Optionee and all subsequent holders of the Purchased Shares who derive their chain of ownership through a Permitted Transfer from Optionee.

V.         Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

W.         Permitted Transfer shall mean (i) a gratuitous transfer of the Purchased Shares, provided and only if Optionee obtains the Corporation’s prior written consent to such transfer, (ii) a transfer of title to the Purchased Shares effected pursuant to Optionee’s will or the laws of inheritance following Optionee’s death or (iii) a transfer to the Corporation in pledge as security for any purchase-money indebtedness incurred by Optionee in connection with the acquisition of the Purchased Shares.

X.         Plan shall mean the Corporation’s 2005 Stock Option/Stock Issuance Plan.

Y.         Plan Administrator shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan.

Z.         Prior Purchase Agreement shall have the meaning assigned to such term in Paragraph D.4.

AA.       Purchased Shares shall have the meaning assigned to such term in Paragraph A.1.

BB.      Recapitalization shall mean any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the Corporation’s outstanding Common Stock as a class without the Corporation’s receipt of consideration.

 

A-3


CC.         Reorganization shall mean any of the following transactions:

    (i)       a merger or consolidation in which the Corporation is not the surviving entity,

    (ii)      a sale, transfer or other disposition of all or substantially all of the Corporation’s assets,

    (iii)     a reverse merger in which the Corporation is the surviving entity but in which the Corporation’s outstanding voting securities are transferred in whole or in part to a person or persons different from the persons holding those securities immediately prior to the merger, or

    (iv)      any transaction effected primarily to change the state in which the Corporation is incorporated or to create a holding company structure.

DD.       Repurchase Price shall mean the lower of (i) the Exercise Price or (ii) the Fair Market Value per share of Common Stock on the date of Optionee’s cessation of Service.

EE.        Repurchase Right shall mean the right granted to the Corporation in accordance with Article D.

FF.        SEC shall mean the Securities and Exchange Commission.

GG.       Service shall mean the Optionee’s performance of services for the Corporation (or any Parent or Subsidiary, whether now existing or subsequently established) in the capacity of an Employee, a non-employee member of the board of directors or a consultant or independent advisor. For purposes of this Agreement, Optionee shall be deemed to cease Service immediately upon the occurrence of the either of the following events: (i) Optionee no longer performs services in any of the foregoing capacities for the Corporation or any Parent or Subsidiary or (ii) the entity for which Optionee is performing such services ceases to remain a Parent or Subsidiary of the Corporation, even though the Optionee may subsequently continue to perform services for that entity. Service shall not be deemed to cease during a period of military leave, sick leave or other personal leave approved by the Corporation. However, except to the extent otherwise required by law or expressly authorized by the Plan Administrator, no Service credit shall be given for vesting purposes for any period the Optionee is on a leave of absence.

HH.       Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

II.          Target Shares shall have the meaning assigned to such term in Paragraph E.2.

 

A-4


JJ.         Unvested Shares shall have the meaning assigned to such term in Paragraph D.1.

KK.       Vesting Schedule shall mean the vesting schedule specified in the Grant Notice pursuant to which the Optionee is to vest in the Option Shares in a series of installments over his or her period of Service.

 

A-5

Exhibit 10.44

AMYRIS BIOTECHNOLOGIES, INC.

STOCK PURCHASE AGREEMENT

(FOR NON-U.S. EMPLOYEES)

AGREEMENT made this              day of                          ,              by and between Amyris Biotechnologies, Inc., a California corporation, and «First» «Last», Optionee under the Corporation’s 2005 Stock Option/Stock Issuance Plan.

All capitalized terms in this Agreement shall have the meaning assigned to them in this Agreement or in the attached Appendix.

A.         EXERCISE OF OPTION

1.         Exercise . Optionee hereby purchases              shares of Common Stock (the “Purchased Shares”) pursuant to that certain option (the “Option”) granted Optionee on              (the “Grant Date”) to purchase up to «M__Option_Shares» shares of Common Stock (the “Option Shares”) under the Plan at the exercise price of $US              per share (the “Exercise Price”).

2.         Payment . Concurrently with the delivery of this Agreement to the Corporation, Optionee shall pay the Exercise Price for the Purchased Shares in accordance with the provisions of the Option Agreement and shall deliver whatever additional documents may be required by the Option Agreement as a condition for exercise.

3.         Responsibility for Taxes . Current with the delivery of this Agreement, Optionee will pay or make adequate arrangements satisfactory to the Corporation and/or the Optionee’s Employer to satisfy all Tax-Related Items. In this regard, Optionee authorizes the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (i) withholding from Optionee’s wages or other cash compensation paid to Optionee by the Corporation, and/or the Employer; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at exercise of the Option either through a voluntary sale or through a mandatory sale arranged by the Corporation (on Optionee’s behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued at exercise of the Option.

Finally, Optionee shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of Optionee’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the shares or the proceeds of the sale of shares of Common Stock if Optionee fails to comply with Optionee’s obligations in connection with the Tax-Related Items.


4.         Stockholder Rights . Until such time as the Corporation exercises the Repurchase Right or the First Refusal Right, Optionee (or any successor in interest) shall have all the rights of a stockholder (including voting, dividend and liquidation rights) with respect to the Purchased Shares, subject, however, to the transfer restrictions of Articles B and C.

B.         SECURITIES LAW COMPLIANCE

1.         Restricted Securities . The Purchased Shares have not been registered under the 1933 Act and are being issued to Optionee in reliance upon the exemption from such registration provided by SEC Rule 701 for stock issuances under compensatory benefit plans such as the Plan. Optionee hereby confirms that Optionee has been informed that the Purchased Shares are restricted securities under the 1933 Act and may not be resold or transferred unless the Purchased Shares are first registered under the Federal securities laws or unless an exemption from such registration is available. Accordingly, Optionee hereby acknowledges that Optionee is acquiring the Purchased Shares for investment purposes only and not with a view to resale and is prepared to hold the Purchased Shares for an indefinite period and that Optionee is aware that SEC Rule 144 issued under the 1933 Act which exempts certain resales of unrestricted securities is not presently available to exempt the resale of the Purchased Shares from the registration requirements of the 1933 Act.

2.         Restrictions on Disposition of Purchased Shares . Optionee shall make no disposition of the Purchased Shares (other than a Permitted Transfer) unless and until there is compliance with all of the following requirements:

(i)        Optionee shall have provided the Corporation with a written summary of the terms and conditions of the proposed disposition.

(ii)        Optionee shall have complied with all requirements of this Agreement applicable to the disposition of the Purchased Shares.

(iii)        Optionee shall have provided the Corporation with written assurances, in form and substance satisfactory to the Corporation, that (a) the proposed disposition does not require registration of the Purchased Shares under the 1933 Act or (b) all appropriate action necessary for compliance with the registration requirements of the 1933 Act or any exemption from registration available under the 1933 Act (including Rule 144) has been taken.

The Corporation shall not be required (i) to transfer on its books any Purchased Shares which have been sold or transferred in violation of the provisions of this Agreement or (ii) to treat as the owner of the Purchased Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom the Purchased Shares have been transferred in contravention of this Agreement.

3.         Restrictive Legends . The stock certificates for the Purchased Shares shall be endorsed with one or more of the following restrictive legends:

 

2


“The shares represented by this certificate have not been registered under the Securities Act of 1933. The shares may not be sold or offered for sale in the absence of (a) an effective registration statement for the shares under such Act, (b) a ‘no action’ letter of the Securities and Exchange Commission with respect to such sale or offer or (c) satisfactory assurances to the Corporation that registration under such Act is not required with respect to such sale or offer.”

C.         TRANSFER RESTRICTIONS

1.         Restriction on Transfer . Except for any Permitted Transfer, Optionee shall not transfer, assign, encumber or otherwise dispose of any of the Purchased Shares in contravention of the First Refusal Right or the Market Stand-Off.

2.         Transferee Obligations . Each person (other than the Corporation) to whom the Purchased Shares are transferred by means of a Permitted Transfer must, as a condition precedent to the validity of such transfer, acknowledge in writing to the Corporation that such person is bound by the provisions of this Agreement and that the transferred shares are subject to (i) the First Refusal Right and (ii) the Market Stand-Off, to the same extent such shares would be so subject if retained by Optionee.

3.         Market Stand-Off .

(a)        In connection with any underwritten public offering by the Corporation of its equity securities pursuant to an effective registration statement filed under the 1933 Act, including the Corporation’s initial public offering, Owner shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to, any Purchased Shares without the prior written consent of the Corporation or its underwriters. Such restriction (the “Market Stand-Off”) shall be in effect for such period of time from and after the effective date of the final prospectus for the offering as may be requested by the Corporation or such underwriters. In no event, however, shall such period exceed one hundred eighty (180) days, and the Market Stand-Off shall in no event be applicable to any underwritten public offering effected more than two (2) years after the effective date of the Corporation’s initial public offering.

(b)        Owner shall be subject to the Market Stand-Off provided and only if the officers and directors of the Corporation are also subject to similar restrictions.

(c)        Any new, substituted or additional securities which are by reason of any Recapitalization or Reorganization distributed with respect to the Purchased Shares shall be immediately subject to the Market Stand-Off, to the same extent the Purchased Shares are at such time covered by such provisions.

(d)        In order to enforce the Market Stand-Off, the Corporation may impose stop-transfer instructions with respect to the Purchased Shares until the end of the applicable stand-off period.

 

3


D.         RIGHT OF FIRST REFUSAL

1.         Grant . The Corporation is hereby granted the right of first refusal (the “First Refusal Right”), exercisable in connection with any proposed transfer of the Purchased Shares in which Optionee has vested. For purposes of this Article D, the term “transfer” shall include any sale, assignment, pledge, encumbrance or other disposition of the Purchased Shares intended to be made by Owner, but shall not include any Permitted Transfer.

2.         Notice of Intended Disposition . In the event any Owner of Purchased Shares in which Optionee has vested desires to accept a bona fide third-party offer for the transfer of any or all of such shares (the Purchased Shares subject to such offer to be hereinafter referred to as the “Target Shares”), Owner shall promptly (i) deliver to the Corporation written notice (the “Disposition Notice”) of the terms of the offer, including the purchase price and the identity of the third-party offeror, and (ii) provide satisfactory proof that the disposition of the Target Shares to such third-party offeror would not be in contravention of the provisions set forth in Articles B and C.

3.         Exercise of the First Refusal Right . The Corporation shall, for a period of twenty-five (25) days following receipt of the Disposition Notice, have the right to repurchase any or all of the Target Shares subject to the Disposition Notice upon the same terms as those specified therein or upon such other terms (not materially different from those specified in the Disposition Notice) to which Owner consents. Such right shall be exercisable by delivery of written notice (the “Exercise Notice”) to Owner prior to the expiration of the twenty-five (25)-day exercise period. If such right is exercised with respect to all the Target Shares, then the Corporation shall effect the repurchase of such shares, including payment of the purchase price, not more than five (5) business days after delivery of the Exercise Notice; and at such time the certificates representing the Target Shares shall be delivered to the Corporation.

Should the purchase price specified in the Disposition Notice be payable in property other than cash or evidences of indebtedness, the Corporation shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property. If Owner and the Corporation cannot agree on such cash value within ten (10) days after the Corporation’s receipt of the Disposition Notice, the valuation shall be made by an appraiser of recognized standing selected by Owner and the Corporation or, if they cannot agree on an appraiser within twenty (20) days after the Corporation’s receipt of the Disposition Notice, each shall select an appraiser of recognized standing and the two (2) appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by Owner and the Corporation. The closing shall then be held on the later of (i) the fifth (5th) business day following delivery of the Exercise Notice or (ii) the fifth (5th) business day after such valuation shall have been made.

4.         Non-Exercise of the First Refusal Right . In the event the Exercise Notice is not given to Owner prior to the expiration of the twenty-five (25)-day exercise period, Owner shall have a period of thirty (30) days thereafter in which to sell or otherwise dispose of

 

4


the Target Shares to the third-party offeror identified in the Disposition Notice upon terms (including the purchase price) no more favorable to such third-party offeror than those specified in the Disposition Notice; provided , however, that any such sale or disposition must not be effected in contravention of the provisions of Articles B and C. The third-party offeror shall acquire the Target Shares subject to the First Refusal Right and the provisions and restrictions of Article B and Paragraph C.3, and any subsequent disposition of the acquired shares must be effected in compliance with the terms and conditions of such First Refusal Right and the provisions and restrictions of Article B and Paragraph C.3. In the event Owner does not effect such sale or disposition of the Target Shares within the specified thirty (30)-day period, the First Refusal Right shall continue to be applicable to any subsequent disposition of the Target Shares by Owner until such right lapses.

5.         Partial Exercise of the First Refusal Right . In the event the Corporation makes a timely exercise of the First Refusal Right with respect to a portion, but not all, of the Target Shares specified in the Disposition Notice, Owner shall have the option, exercisable by written notice to the Corporation delivered within five (5) business days after Owner’s receipt of the Exercise Notice, to effect the sale of the Target Shares pursuant to either of the following alternatives:

(i)        sale or other disposition of all the Target Shares to the third-party offeror identified in the Disposition Notice, but in full compliance with the requirements of Paragraph D.4, as if the Corporation did not exercise the First Refusal Right; or

(ii)        sale to the Corporation of the portion of the Target Shares which the Corporation has elected to purchase, such sale to be effected in substantial conformity with the provisions of Paragraph D.3. The First Refusal Right shall continue to be applicable to any subsequent disposition of the remaining Target Shares until such right lapses.

Owner’s failure to deliver timely notification to the Corporation shall be deemed to be an election by Owner to sell the Target Shares pursuant to alternative (i) above.

6.         Recapitalization/Reorganization .

(a)        Any new, substituted or additional securities or other property which is by reason of any Recapitalization distributed with respect to the Purchased Shares shall be immediately subject to the First Refusal Right, but only to the extent the Purchased Shares are at the time covered by such right.

(b)        In the event of a Reorganization, the First Refusal Right shall remain in full force and effect and shall apply to the new capital stock or other property received in exchange for the Purchased Shares in consummation of the Reorganization, but only to the extent the Purchased Shares are at the time covered by such right.

7.         Lapse . The First Refusal Right shall lapse upon the earliest to occur of (i) the first date on which shares of the Common Stock are held of record by more than five

 

5


hundred (500) persons, (ii) a determination made by the Board that a public market exists for the outstanding shares of Common Stock or (iii) a firm commitment underwritten public offering, pursuant to an effective registration statement under the 1933 Act, covering the offer and sale of the Common Stock in the aggregate amount of at least twenty million dollars ($20,000,000). However, the Market Stand-Off shall continue to remain in full force and effect following the lapse of the First Refusal Right.

E.         GENERAL PROVISIONS

1.         Assignment . The Corporation may assign the First Refusal Right to any person or entity selected by the Board, including (without limitation) one or more stockholders of the Corporation.

2.         Employment . Nothing in this Agreement or in the Plan shall confer upon Optionee any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to terminate Optionee’s Service at any time for any reason, with or without cause.

3.         Notices . Any notice required to be given under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the post office, registered or certified, postage prepaid and properly addressed to the party entitled to such notice at the address indicated below such party’s signature line on this Agreement or at such other address as such party may designate by ten (10) days advance written notice under this paragraph to all other parties to this Agreement.

4.         No Waiver . The failure of the Corporation in any instance to exercise the First Refusal Right shall not constitute a waiver of any other rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Corporation and Optionee. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

5.         Cancellation of Shares . If the Corporation shall make available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Purchased Shares to be purchased in accordance with the provisions of this Agreement, then from and after such time, the person from whom such shares are to be purchased shall no longer have any rights as a holder of such shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such shares shall be deemed purchased in accordance with the applicable provisions hereof, and the Corporation shall be deemed the owner and holder of such shares, whether or not the certificates therefor have been delivered as required by this Agreement.

 

6


F.         MISCELLANEOUS PROVISIONS

1.         Optionee Undertaking . Optionee hereby agrees to take whatever additional action and execute whatever additional documents the Corporation may deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on either Optionee or the Purchased Shares pursuant to the provisions of this Agreement.

2.         Agreement is Entire Contract . This Agreement constitutes the entire contract between the parties hereto with regard to the subject matter hereof. This Agreement is made pursuant to the provisions of the Plan and shall in all respects be construed in conformity with the terms of the Plan.

3.         Governing Law . This Agreement shall be governed by, and construed in accordance with, the laws of the State of California, without resort to that State’s conflict of laws rules, as provided in the Plan. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of Alameda County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this Agreement is made and/or to be performed.

4.         Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

5.         Successors and Assigns . The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and upon Optionee, Optionee’s permitted assigns and the legal representatives, heirs and legatees of Optionee’s estate, whether or not any such person shall have become a party to this Agreement and have agreed in writing to join herein and be bound by the terms hereof.

 

7


IN WITNESS WHEREOF , the parties have executed this Agreement on the day and year first indicated above.

 

AMYRIS BIOTECHNOLOGIES, INC.

By:

   

Name:

   

Title:

   

Address:

   
   
   
   

«First» «Last», OPTIONEE

Address:  

   
   

 

8


SPOUSAL ACKNOWLEDGMENT

The undersigned spouse of Optionee has read and hereby approves the foregoing Stock Purchase Agreement. In consideration of the Corporation’s granting Optionee the right to acquire the Purchased Shares in accordance with the terms of such Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of such Agreement.

 

   
 

OPTIONEE’S SPOUSE

Address:  

   
   


APPENDIX

The following definitions shall be in effect under the Agreement:

A.         Agreement shall mean this Stock Purchase Agreement.

B.         Board shall mean the Corporation’s Board of Directors.

C.         Change in Control shall mean a change in ownership or control of the Corporation effected through any of the following transactions:

(i)        a merger, consolidation or other reorganization approved by the Corporation’s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction, or

(ii)        a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution of the Corporation, or

(iii)        the acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders.

In no event shall any public offering of the Corporation’s securities be deemed to constitute a Change in Control.

D.         Code shall mean the U.S. Internal Revenue Code of 1986, as amended.

E.         Common Stock shall mean the Corporation’s common stock.

F.         Corporation shall mean Amyris Biotechnologies, Inc., a California corporation, and any successor corporation to all or substantially all of the assets or voting stock of Amyris Biotechnologies, Inc. which shall by appropriate action adopt the Plan.

G.         Disposition Notice shall have the meaning assigned to such term in Paragraph D.2.

H.         Employer shall mean Optionee’s employer.

 

A-1


I.         Exercise Price shall have the meaning assigned to such term in Paragraph A.1.

J.         Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

(i)        If the Common Stock is at the time traded on the Nasdaq National Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers on the Nasdaq National Market and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(ii)        If the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal . If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

(iii)        If the Common Stock is at the time neither listed on any Stock Exchange nor traded on the Nasdaq National Market, then the Fair Market Value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate.

K.         First Refusal Right shall mean the right granted to the Corporation in accordance with Article E.

L.         Grant Date shall have the meaning assigned to such term in Paragraph A.1.

M.         Grant Notice shall mean the Notice of Grant of Stock Option pursuant to which Optionee has been informed of the basic terms of the Option.

N.         Incentive Option shall mean an option which satisfies the requirements of Code Section 422.

O.         Market Stand-Off shall mean the market stand-off restriction specified in Paragraph C.3.

P.         1933 Act shall mean the U.S. Securities Act of 1933, as amended.

Q.         1934 Act shall mean the U.S. Securities Exchange Act of 1934, as amended.

 

A-2


R.         Non-Statutory Option shall mean an option not intended to satisfy the requirements of Code Section 422.

S.         Option shall have the meaning assigned to such term in Paragraph A.1.

T.         Option Agreement shall mean all agreements and other documents evidencing the Option.

U.         Optionee shall mean the person to whom the Option is granted under the Plan.

V.         Owner shall mean Optionee and all subsequent holders of the Purchased Shares who derive their chain of ownership through a Permitted Transfer from Optionee.

W.         Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

X.         Permitted Transfer shall mean (i) a gratuitous transfer of the Purchased Shares, provided and only if Optionee obtains the Corporation’s prior written consent to such transfer, (ii) a transfer of title to the Purchased Shares effected pursuant to Optionee’s will or the laws of inheritance following Optionee’s death or (iii) a transfer to the Corporation in pledge as security for any purchase-money indebtedness incurred by Optionee in connection with the acquisition of the Purchased Shares.

Y.         Plan shall mean the Corporation’s 2005 Stock Option/Stock Issuance Plan.

Z.         Plan Administrator shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan.

AA.         Purchased Shares shall have the meaning assigned to such term in Paragraph A.1.

BB.         Recapitalization shall mean any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the Corporation’s outstanding Common Stock as a class without the Corporation’s receipt of consideration.

CC.         Reorganization shall mean any of the following transactions:

(i)        a merger or consolidation in which the Corporation is not the surviving entity,

 

A-3


(ii)        a sale, transfer or other disposition of all or substantially all of the Corporation’s assets,

(iii)        a reverse merger in which the Corporation is the surviving entity but in which the Corporation’s outstanding voting securities are transferred in whole or in part to a person or persons different from the persons holding those securities immediately prior to the merger, or

(iv)        any transaction effected primarily to change the state in which the Corporation is incorporated or to create a holding company structure.

DD.         SEC shall mean the Securities and Exchange Commission.

EE.         Service shall mean the Optionee’s performance of services for the Corporation (or any Parent or Subsidiary, whether now existing or subsequently established) in the capacity of an Employee, a non-employee member of the board of directors or a consultant or independent advisor. For purposes of this Agreement, Optionee shall be deemed to cease Service immediately upon the occurrence of either of the following events: (i) Optionee no longer performs services in any of the foregoing capacities for the Corporation or any Parent or Subsidiary or (ii) the entity for which Optionee is performing such services ceases to remain a Parent or Subsidiary of the Corporation, even though the Optionee may subsequently continue to perform services for that entity. Service shall not be deemed to cease during a period of military leave, sick leave or other personal leave approved by the Corporation. However, except to the extent otherwise required by law or expressly authorized by the Plan Administrator, no Service credit shall be given for vesting purposes for any period the Optionee is on a leave of absence.

FF.         Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

GG.         Target Shares shall have the meaning assigned to such term in Paragraph D.2.

HH.         Tax-Related Items shall mean any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to Optionee’s participation in the Plan and legally applicable to Optionee.

 

A-4

Exhibit 21.01

Subsidiaries of Amyris Biotechnologies, Inc.

 

Name of Subsidiary      Jurisdiction
AB Technologies LLC      Delaware
Amyris Fuels, LLC      Delaware
Amyris Brasil S.A.      Brazil
SMA Indústria Química S.A.      Brazil

Exhibit 23.01

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use in this Registration Statement on Form S-1 of our report dated April 16, 2010 relating to the consolidated financial statements of Amyris Biotechnologies, Inc., which appears in such Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

 

/s/ PricewaterhouseCoopers LLP

San Jose, California

April 16, 2010